intravenous	O
azithromycin-induced	B-Drug
ototoxicity	B-ADR
0	O
<EOS>	O
immobilization	O
,	O
while	O
paget	O
bone	O
disease	O
wa	O
present	O
,	O
and	O
perhaps	O
enhanced	O
activation	O
of	O
dihydrotachysterol	B-Drug
by	O
rifampicin	O
,	O
could	O
have	O
led	O
to	O
increased	B-ADR
calcium-release	I-ADR
into	O
the	O
circulation	O
0	O
<EOS>	O
unaccountable	O
severe	O
hypercalcemia	B-ADR
in	O
a	O
patient	O
treated	O
for	O
hypoparathyroidism	O
with	O
dihydrotachysterol	B-Drug
0	O
<EOS>	O
method	O
:	O
we	O
report	O
two	O
case	O
of	O
pseudoporphyria	B-ADR
caused	O
by	O
naproxen	B-Drug
and	O
oxaprozin	O
0	O
<EOS>	O
method	O
:	O
we	O
report	O
two	O
case	O
of	O
pseudoporphyria	B-ADR
caused	O
by	O
naproxen	O
and	O
oxaprozin	B-Drug
0	O
<EOS>	O
naproxen	B-Drug
,	O
the	O
most	O
common	O
offender	O
,	O
ha	O
been	O
associated	O
with	O
a	O
dimorphic	O
clinical	O
pattern	O
:	O
a	O
pct-like	O
presentation	O
and	O
one	O
simulating	O
erythropoietic	B-ADR
protoporphyria	I-ADR
in	O
the	O
pediatric	O
population	O
0	O
<EOS>	O
result	O
:	O
a	O
44-year-old	O
man	O
taking	O
naproxen	B-Drug
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year-old	O
woman	O
on	O
oxaprozin	O
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	O
bulla	O
and	O
cutaneous	B-ADR
fragility	I-ADR
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hand	O
0	O
<EOS>	O
result	O
:	O
a	O
44-year-old	O
man	O
taking	O
naproxen	O
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year-old	O
woman	O
on	O
oxaprozin	B-Drug
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	O
bulla	O
and	O
cutaneous	B-ADR
fragility	I-ADR
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hand	O
0	O
<EOS>	O
result	O
:	O
a	O
44-year-old	O
man	O
taking	O
naproxen	B-Drug
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year-old	O
woman	O
on	O
oxaprozin	O
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADR
bulla	I-ADR
and	O
cutaneous	O
fragility	O
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hand	O
0	O
<EOS>	O
result	O
:	O
a	O
44-year-old	O
man	O
taking	O
naproxen	O
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year-old	O
woman	O
on	O
oxaprozin	B-Drug
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADR
bulla	I-ADR
and	O
cutaneous	O
fragility	O
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hand	O
0	O
<EOS>	O
background	O
:	O
how	O
to	O
best	O
treat	O
psychotic	O
patient	O
who	O
have	O
had	O
past	O
clozapine-induced	B-Drug
agranulocytosis	O
or	O
granulocytopenia	B-ADR
remains	O
a	O
problem	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
result	O
suggest	O
that	O
olanzapine	O
may	O
be	O
useful	O
in	O
treating	O
patient	O
with	O
clozapine-induced	B-Drug
granulocytopenia	B-ADR
without	O
the	O
risk	O
of	O
recurrence	O
of	O
hematologic	O
side	O
effect	O
0	O
<EOS>	O
prolonged	O
severe	O
5-fluorouracil-associated	B-Drug
neurotoxicity	B-ADR
in	O
a	O
patient	O
with	O
dihydropyrimidine	O
dehydrogenase	O
deficiency	O
0	O
<EOS>	O
we	O
describe	O
the	O
side	O
effect	O
of	O
5-fu	B-Drug
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	O
mucositis	O
,	O
desquamating	O
dermatitis	O
,	O
prolonged	O
myelosuppression	O
,	O
and	O
neurologic	B-ADR
toxicity	I-ADR
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
we	O
describe	O
the	O
side	O
effect	O
of	O
5-fu	B-Drug
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	O
mucositis	O
,	O
desquamating	O
dermatitis	O
,	O
prolonged	B-ADR
myelosuppression	I-ADR
,	O
and	O
neurologic	O
toxicity	O
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
we	O
describe	O
the	O
side	O
effect	O
of	O
5-fu	B-Drug
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	B-ADR
mucositis	I-ADR
,	O
desquamating	O
dermatitis	O
,	O
prolonged	O
myelosuppression	O
,	O
and	O
neurologic	O
toxicity	O
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
this	O
case	O
suggests	O
that	O
bh-ac	B-Drug
,	O
a	O
derivative	O
of	O
cytosine	O
arabinoside	O
(	O
1-beta-d-arabinofuranosylcytosine	O
)	O
could	O
be	O
a	O
cause	O
of	O
reversible	O
encephalopathy	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
reversible	O
encephalopathy	B-ADR
syndrome	I-ADR
in	O
a	O
16-year-old	O
girl	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
aml	O
)	O
,	O
who	O
is	O
undergoing	O
during	O
consolidation	O
chemotherapy	O
composed	O
of	O
bh-ac	B-Drug
(	O
n4-behenoyl-1-beta-d-arabinofuranosyl	O
cytosine	O
)	O
and	O
idarubicin	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
reversible	O
encephalopathy	B-ADR
syndrome	I-ADR
in	O
a	O
16-year-old	O
girl	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
aml	O
)	O
,	O
who	O
is	O
undergoing	O
during	O
consolidation	O
chemotherapy	O
composed	O
of	O
bh-ac	O
(	O
n4-behenoyl-1-beta-d-arabinofuranosyl	O
cytosine	O
)	O
and	O
idarubicin	B-Drug
0	O
<EOS>	O
in	O
one	O
case	O
,	O
the	O
readministration	O
of	O
riluzole	B-Drug
wa	O
followed	O
by	O
the	O
relapse	O
of	O
hepatitis	B-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
two	O
patient	O
who	O
developed	O
acute	O
hepatitis	B-ADR
after	O
taking	O
riluzole	B-Drug
at	O
the	O
recommended	O
dose	O
(	O
100	O
mg	O
daily	O
)	O
for	O
7	O
and	O
4	O
week	O
,	O
respectively	O
0	O
<EOS>	O
lupus-like	B-ADR
syndrome	I-ADR
caused	O
by	O
5-aminosalicylic	B-Drug
acid	I-Drug
in	O
patient	O
with	O
inflammatory	O
bowel	O
disease	O
0	O
<EOS>	O
although	O
the	O
two	O
local	O
anesthetic	O
usually	O
do	O
not	O
cause	O
methemoglobinemia	B-ADR
,	O
we	O
suspect	O
that	O
the	O
displacement	O
of	O
lidocaine	B-Drug
from	O
protein	O
binding	O
by	O
bupivacaine	O
,	O
in	O
combination	O
with	O
metabolic	O
acidosis	O
and	O
treatment	O
with	O
other	O
oxidant	O
,	O
wa	O
the	O
reason	O
for	O
the	O
development	O
of	O
methemoglobinemia	O
0	O
<EOS>	O
methemoglobinemia	B-ADR
after	O
axillary	O
block	O
with	O
bupivacaine	B-Drug
and	O
additional	O
injection	O
of	O
lidocaine	O
in	O
the	O
operative	O
field	O
0	O
<EOS>	O
methemoglobinemia	B-ADR
after	O
axillary	O
block	O
with	O
bupivacaine	O
and	O
additional	O
injection	O
of	O
lidocaine	B-Drug
in	O
the	O
operative	O
field	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
and	O
ischemic	O
heart	O
disease	O
who	O
developed	O
clinically	O
significant	O
methemoglobinemia	B-ADR
after	O
an	O
axillary	O
block	O
with	O
bupivacaine	B-Drug
and	O
additional	O
injection	O
of	O
lidocaine	O
in	O
the	O
operative	O
field	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
and	O
ischemic	O
heart	O
disease	O
who	O
developed	O
clinically	O
significant	O
methemoglobinemia	B-ADR
after	O
an	O
axillary	O
block	O
with	O
bupivacaine	O
and	O
additional	O
injection	O
of	O
lidocaine	B-Drug
in	O
the	O
operative	O
field	O
0	O
<EOS>	O
detection	O
of	O
activated	O
eosinophil	O
in	O
nasal	O
polyp	O
of	O
an	O
aspirin-induced	B-Drug
asthma	B-ADR
patient	O
0	O
<EOS>	O
an	O
episode	O
of	O
subacute	O
encephalopathy	B-ADR
after	O
the	O
infusion	O
of	O
a	O
moderate	O
dose	O
of	O
methotrexate	B-Drug
(	O
1500	O
mg	O
/	O
m2	O
)	O
(	O
mtx	O
)	O
is	O
reported	O
in	O
a	O
young	O
adult	O
with	O
metastastic	O
gastric	O
cancer	O
0	O
<EOS>	O
we	O
believe	O
that	O
this	O
represents	O
an	O
unusual	O
case	O
of	O
moderate-dose	O
mtx-induced	B-Drug
neurotoxicity	B-ADR
in	O
a	O
patient	O
with	O
gastric	O
cancer	O
,	O
which	O
ha	O
not	O
previously	O
been	O
reported	O
0	O
<EOS>	O
we	O
describe	O
a	O
life	O
threatening	O
side	O
effect	O
of	O
acute	O
epoprostenol	B-Drug
infusion	O
(	O
pulmonary	B-ADR
edema	I-ADR
)	O
in	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
associated	O
with	O
limited	O
scleroderma	O
and	O
discus	O
it	O
management	O
and	O
potential	O
etiology	O
0	O
<EOS>	O
a	O
14-year-old	O
girl	O
with	O
newly	O
diagnosed	O
sle	O
developed	O
a	O
pruritic	B-ADR
bullous	I-ADR
eruption	I-ADR
while	O
on	O
prednisone	B-Drug
0	O
<EOS>	O
hydroxyurea-induced	B-Drug
acute	B-ADR
interstitial	I-ADR
pneumonitis	I-ADR
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggests	O
that	O
the	O
interstitial	B-ADR
pneumonitis	I-ADR
wa	O
induced	O
by	O
hydroxyurea	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
first	O
case	O
of	O
hydroxyurea-induced	B-Drug
acute	B-ADR
interstitial	I-ADR
pneumonitis	I-ADR
reported	O
in	O
the	O
literature	O
0	O
<EOS>	O
allergic	O
and	O
irritant	B-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
calcipotriol	B-Drug
0	O
<EOS>	O
calcipotriol	B-Drug
(	O
daivonex	O
r	O
;	O
leo	O
pharmaceutical	O
,	O
zurich	O
,	O
switzerland	O
)	O
may	O
cause	O
irritation	O
of	O
the	O
skin	O
,	O
whereas	O
allergic	B-ADR
reaction	I-ADR
are	O
le	O
common	O
0	O
<EOS>	O
calcipotriol	B-Drug
(	O
daivonex	O
r	O
;	O
leo	O
pharmaceutical	O
,	O
zurich	O
,	O
switzerland	O
)	O
may	O
cause	O
irritation	B-ADR
of	I-ADR
the	I-ADR
skin	I-ADR
,	O
whereas	O
allergic	O
reaction	O
are	O
le	O
common	O
0	O
<EOS>	O
the	O
present	O
observation	O
suggests	O
,	O
that	O
a	O
batch	O
of	O
different	O
testing	O
dos	O
,	O
including	O
lower	O
testing	O
dos	O
may	O
help	O
to	O
differentiate	O
between	O
an	O
allergic	O
type	O
of	O
contact	O
dermatitis	O
and	O
an	O
irritant	B-ADR
type	I-ADR
of	I-ADR
reaction	I-ADR
after	O
treatment	O
with	O
calcipotriol	B-Drug
0	O
<EOS>	O
myotonia	B-ADR
associated	O
with	O
sarcoidosis	O
:	O
marked	O
exacerbation	O
with	O
pravastatin	B-Drug
0	O
<EOS>	O
pravastatin	B-Drug
is	O
associated	O
with	O
myotonia	B-ADR
in	O
animal	O
0	O
<EOS>	O
this	O
case	O
suggests	O
that	O
sarcoidosis	O
and	O
pravastatin	B-Drug
,	O
two	O
entity	O
not	O
frequently	O
associated	O
with	O
myotonia	B-ADR
,	O
may	O
interact	O
in	O
a	O
synergistic	O
manner	O
to	O
produce	O
severe	O
clinical	O
myotonia	O
in	O
human	O
0	O
<EOS>	O
hypersensitivity	O
to	O
aspirin	B-Drug
can	O
be	O
manifested	O
a	O
acute	O
asthma	O
,	O
urticaria	O
and	O
/	O
or	O
angioedema	B-ADR
,	O
or	O
a	O
systemic	O
anaphylactoid	O
reaction	O
0	O
<EOS>	O
hypersensitivity	O
to	O
aspirin	B-Drug
can	O
be	O
manifested	O
a	O
acute	O
asthma	O
,	O
urticaria	O
and	O
/	O
or	O
angioedema	O
,	O
or	O
a	O
systemic	B-ADR
anaphylactoid	I-ADR
reaction	I-ADR
0	O
<EOS>	O
hypersensitivity	O
to	O
aspirin	B-Drug
can	O
be	O
manifested	O
a	O
acute	O
asthma	O
,	O
urticaria	B-ADR
and	O
/	O
or	O
angioedema	O
,	O
or	O
a	O
systemic	O
anaphylactoid	O
reaction	O
0	O
<EOS>	O
conclusion	O
:	O
fixed	O
drug	O
eruption	B-ADR
is	O
associated	O
with	O
many	O
drug	O
but	O
this	O
is	O
the	O
first	O
such	O
report	O
with	O
omeprazole	B-Drug
0	O
<EOS>	O
fixed	O
drug	O
eruption	B-ADR
in	O
hand	O
caused	O
by	O
omeprazole	B-Drug
0	O
<EOS>	O
the	O
objective	O
of	O
this	O
report	O
is	O
to	O
describe	O
a	O
case	O
of	O
fixed	O
drug	O
eruption	B-ADR
that	O
occurred	O
during	O
omeprazole	B-Drug
treatment	O
0	O
<EOS>	O
a	O
26-year-old	O
japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	B-ADR
erythema	I-ADR
and	O
pustule	O
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	O
,	O
and	O
fever	O
up	O
to	O
39	O
degree	O
c	O
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-Drug
0	O
<EOS>	O
a	O
26-year-old	O
japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	O
erythema	O
and	O
pustule	O
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	O
,	O
and	O
fever	B-ADR
up	I-ADR
to	I-ADR
39	I-ADR
degree	I-ADR
c	I-ADR
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-Drug
0	O
<EOS>	O
a	O
26-year-old	O
japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	O
erythema	O
and	O
pustule	O
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	B-ADR
,	O
and	O
fever	O
up	O
to	O
39	O
degree	O
c	O
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-Drug
0	O
<EOS>	O
a	O
26-year-old	O
japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	O
erythema	O
and	O
pustule	B-ADR
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	O
,	O
and	O
fever	O
up	O
to	O
39	O
degree	O
c	O
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-Drug
0	O
<EOS>	O
acute	B-ADR
generalized	I-ADR
exanthematous	I-ADR
pustulosis	I-ADR
induced	O
by	O
salazosulfapyridine	B-Drug
in	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acute	B-ADR
generalized	I-ADR
exanthematous	I-ADR
pustulosis	I-ADR
(	O
agep	O
)	O
induced	O
by	O
salazosulfapyridine	B-Drug
in	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
39-year-old	O
white	O
jewish	O
schizophrenic	O
man	O
treated	O
with	O
olanzapine	B-Drug
developed	O
an	O
elevated	B-ADR
serum	I-ADR
ck	I-ADR
concentration	I-ADR
with	O
a	O
peak	O
concentration	O
of	O
4000	O
iu	O
/	O
l	O
(	O
normal	O
<	O
230	O
)	O
0	O
<EOS>	O
discussion	O
:	O
olanzapine	B-Drug
,	O
like	O
other	O
atypical	O
antipsychotic	O
drug	O
,	O
may	O
cause	O
muscle	B-ADR
injury	I-ADR
with	I-ADR
concomitant	I-ADR
elevation	I-ADR
of	I-ADR
serum	I-ADR
ck	I-ADR
of	O
muscle	O
origin	O
0	O
<EOS>	O
marked	O
elevation	B-ADR
of	I-ADR
serum	I-ADR
creatine	I-ADR
kinase	I-ADR
associated	O
with	O
olanzapine	B-Drug
therapy	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
marked	O
elevation	B-ADR
of	I-ADR
serum	I-ADR
creatine	I-ADR
kinase	I-ADR
(	O
ck	O
)	O
associated	O
with	O
olanzapine	B-Drug
therapy	O
0	O
<EOS>	O
diclofenac-associated	B-Drug
hepatitis	B-ADR
0	O
<EOS>	O
this	O
patient	O
,	O
who	O
had	O
a	O
history	O
of	O
osteoarthritis	O
,	O
had	O
severe	O
hepatitis	B-ADR
5	O
week	O
after	O
being	O
started	O
on	O
diclofenac	B-Drug
for	O
increasing	O
pain	O
in	O
the	O
joint	O
0	O
<EOS>	O
2-cda	B-Drug
induces	O
lymphocytopenia	B-ADR
,	O
which	O
may	O
explain	O
the	O
improvement	O
in	O
this	O
patient	O
psoriasis	O
0	O
<EOS>	O
one	O
case	O
of	O
priapism	B-ADR
occurred	O
during	O
heparin	B-Drug
therapy	O
for	O
a	O
previous	O
surgical	O
operation	O
to	O
the	O
knee	O
is	O
reported	O
0	O
<EOS>	O
priapism	B-ADR
a	O
a	O
complication	O
of	O
heparin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
association	O
between	O
heparin	B-Drug
and	O
priapism	O
is	O
often	O
recognized	O
;	O
abnormal	B-ADR
platelet	I-ADR
aggregation	I-ADR
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
0	O
<EOS>	O
the	O
association	O
between	O
heparin	B-Drug
and	O
priapism	B-ADR
is	O
often	O
recognized	O
;	O
abnormal	O
platelet	O
aggregation	O
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
0	O
<EOS>	O
it	O
carry	O
a	O
well-known	O
risk	O
of	O
neutropenia	O
and	O
agranulocytosis	B-ADR
,	O
which	O
necessitates	O
the	O
immediate	O
discontinuation	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
it	O
carry	O
a	O
well-known	O
risk	O
of	O
neutropenia	B-ADR
and	O
agranulocytosis	O
,	O
which	O
necessitates	O
the	O
immediate	O
discontinuation	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
objective	O
:	O
we	O
report	O
a	O
patient	O
who	O
developed	O
neutropenia	O
on	O
clozapine	B-Drug
,	O
but	O
behind	O
the	O
cell	O
count	O
decrease	O
showed	O
to	O
be	O
a	O
diurnal	B-ADR
variation	I-ADR
of	I-ADR
the	I-ADR
white	I-ADR
blood	I-ADR
cell	I-ADR
(	O
wbc	O
)	O
0	O
<EOS>	O
acute	B-ADR
neutrophilic	I-ADR
dermatosis	I-ADR
induced	O
by	O
all-trans-retinoic	B-Drug
acid	I-Drug
treatment	O
for	O
acute	O
promyelocytic	O
leukemia	O
0	O
<EOS>	O
finding	O
on	O
discontinuation	O
and	O
rechallenge	O
supported	O
the	O
assumption	O
that	O
the	O
hair	B-ADR
loss	I-ADR
wa	O
a	O
side	O
effect	O
of	O
the	O
paroxetine	B-Drug
0	O
<EOS>	O
hair	B-ADR
loss	I-ADR
associated	O
with	O
paroxetine	B-Drug
treatment	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
37-year-old	O
female	O
who	O
complained	O
of	O
moderate	O
hair	B-ADR
loss	I-ADR
during	O
paroxetine	B-Drug
treatment	O
0	O
<EOS>	O
conclusion	O
:	O
patient	O
with	O
insulin	B-Drug
allergy	O
may	O
not	O
have	O
complete	O
resolution	O
of	O
their	O
symptom	O
after	O
standard	O
desensitization	O
,	O
particularly	O
those	O
patient	O
with	O
concomitant	O
protamine	B-ADR
allergy	I-ADR
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	O
urticaria	O
,	O
angioedema	B-ADR
,	O
and	O
occasional	O
wheezing	O
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	O
urticaria	O
,	O
angioedema	B-ADR
,	O
and	O
occasional	O
wheezing	O
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	B-ADR
urticaria	I-ADR
,	O
angioedema	O
,	O
and	O
occasional	O
wheezing	O
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	B-ADR
urticaria	I-ADR
,	O
angioedema	O
,	O
and	O
occasional	O
wheezing	O
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	O
urticaria	O
,	O
angioedema	O
,	O
and	O
occasional	O
wheezing	B-ADR
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
method	O
:	O
the	O
patient	O
required	O
insulin	B-Drug
desensitization	O
for	O
severe	O
urticaria	O
,	O
angioedema	O
,	O
and	O
occasional	O
wheezing	B-ADR
resulting	O
from	O
her	O
insulin	O
dose	O
0	O
<EOS>	O
objective	O
:	O
the	O
purpose	O
of	O
this	O
study	O
wa	O
to	O
determine	O
whether	O
desensitization	O
to	O
nph	O
insulin	B-Drug
,	O
a	O
well	O
a	O
standard	O
insulin	O
desensitization	O
,	O
could	O
control	O
allergic	B-ADR
symptom	I-ADR
in	O
a	O
patient	O
allergic	O
to	O
both	O
nph	O
and	O
regular	O
insulin	O
0	O
<EOS>	O
objective	O
:	O
the	O
purpose	O
of	O
this	O
study	O
wa	O
to	O
determine	O
whether	O
desensitization	O
to	O
nph	B-Drug
insulin	I-Drug
,	O
a	O
well	O
a	O
standard	O
insulin	O
desensitization	O
,	O
could	O
control	O
allergic	B-ADR
symptom	I-ADR
in	O
a	O
patient	O
allergic	O
to	O
both	O
nph	O
and	O
regular	O
insulin	O
0	O
<EOS>	O
patient	O
receiving	O
neutral	B-Drug
protamine	I-Drug
hagedorn	I-Drug
(	I-Drug
nph	I-Drug
)	I-Drug
insulin	I-Drug
are	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
protamine	B-ADR
hypersensitivity	I-ADR
0	O
<EOS>	O
protamine	B-ADR
allergy	I-ADR
a	O
a	O
complication	O
of	O
insulin	B-Drug
hypersensitivity	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
she	O
continued	O
to	O
receive	O
regular	O
insulin	B-Drug
4	O
time	O
per	O
day	O
over	O
the	O
following	O
3	O
year	O
with	O
only	O
occasional	O
hive	B-ADR
0	O
<EOS>	O
the	O
patient	O
had	O
recurrence	O
of	O
urticaria	O
and	O
angioedema	B-ADR
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
nph	O
wa	O
stopped	O
and	O
she	O
wa	O
desensitized	O
to	O
regular	O
insulin	B-Drug
0	O
<EOS>	O
the	O
patient	O
had	O
recurrence	O
of	O
urticaria	O
and	O
angioedema	B-ADR
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
nph	B-Drug
wa	O
stopped	O
and	O
she	O
wa	O
desensitized	O
to	O
regular	O
insulin	O
0	O
<EOS>	O
the	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADR
and	O
angioedema	O
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
nph	O
wa	O
stopped	O
and	O
she	O
wa	O
desensitized	O
to	O
regular	O
insulin	B-Drug
0	O
<EOS>	O
the	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADR
and	O
angioedema	O
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
nph	B-Drug
wa	O
stopped	O
and	O
she	O
wa	O
desensitized	O
to	O
regular	O
insulin	O
0	O
<EOS>	O
a	O
5-month-old	O
infant	O
became	O
lethargic	B-ADR
and	O
poorly	O
responsive	O
after	O
receiving	O
1	O
drop	O
of	O
brimonidine	B-Drug
in	O
each	O
eye	O
0	O
<EOS>	O
a	O
5-month-old	O
infant	O
became	O
lethargic	O
and	O
poorly	B-ADR
responsive	I-ADR
after	O
receiving	O
1	O
drop	O
of	O
brimonidine	B-Drug
in	O
each	O
eye	O
0	O
<EOS>	O
an	O
11-day-old	O
infant	O
became	O
lethargic	O
and	O
apneic	B-ADR
after	O
a	O
single	O
drop	O
of	O
brimonidine	B-Drug
0	O
<EOS>	O
an	O
11-day-old	O
infant	O
became	O
lethargic	B-ADR
and	O
apneic	O
after	O
a	O
single	O
drop	O
of	O
brimonidine	B-Drug
0	O
<EOS>	O
apparent	O
central	B-ADR
nervous	I-ADR
system	I-ADR
depression	I-ADR
in	O
infant	O
after	O
the	O
use	O
of	O
topical	O
brimonidine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
topical	O
brimonidine	B-Drug
may	O
be	O
associated	O
with	O
central	B-ADR
nervous	I-ADR
system	I-ADR
depression	I-ADR
in	O
infant	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
two	O
case	O
in	O
which	O
topical	O
brimonidine	B-Drug
resulted	O
in	O
apparent	O
central	B-ADR
nervous	I-ADR
system	I-ADR
depression	I-ADR
and	O
unresponsiveness	O
in	O
an	O
infant	O
0	O
<EOS>	O
ceftriaxone	B-Drug
wa	O
approved	O
in	O
1997	O
for	O
the	O
treatment	O
of	O
otitis	O
medium	O
despite	O
previous	O
study	O
that	O
documented	O
an	O
association	O
of	O
ceftriaxone	O
with	O
elevated	B-ADR
hepato-biliary	I-ADR
enzyme	I-ADR
and	O
transient	O
biliary	O
stasis	O
0	O
<EOS>	O
ceftriaxone	B-Drug
wa	O
approved	O
in	O
1997	O
for	O
the	O
treatment	O
of	O
otitis	O
medium	O
despite	O
previous	O
study	O
that	O
documented	O
an	O
association	O
of	O
ceftriaxone	O
with	O
elevated	O
hepato-biliary	O
enzyme	O
and	O
transient	B-ADR
biliary	I-ADR
stasis	I-ADR
0	O
<EOS>	O
hepato-biliary	B-ADR
abnormality	I-ADR
secondary	O
to	O
ceftriaxone	B-Drug
use	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
anterior	B-ADR
lumbosacral	I-ADR
radiculopathy	I-ADR
after	O
intrathecal	O
methotrexate	B-Drug
treatment	O
0	O
<EOS>	O
reported	O
are	O
three	O
child	O
who	O
developed	O
progressive	B-ADR
paraparesis	I-ADR
after	O
intrathecal	O
methotrexate	B-Drug
administration	O
followed	O
by	O
complete	O
or	O
partial	O
recovery	O
0	O
<EOS>	O
during	O
the	O
first	O
day	O
of	O
arsenic	B-Drug
trioxide	I-Drug
treatment	O
a	O
rapid	O
decrease	B-ADR
in	I-ADR
the	I-ADR
d-dimers	I-ADR
wa	O
seen	O
(	O
normal	O
value	O
reached	O
until	O
day	O
7	O
)	O
,	O
together	O
with	O
a	O
slight	O
decrease	O
in	O
peripheral	O
blood	O
leukocyte	O
0	O
<EOS>	O
during	O
the	O
first	O
day	O
of	O
arsenic	B-Drug
trioxide	I-Drug
treatment	O
a	O
rapid	O
decrease	O
in	O
the	O
d-dimers	O
wa	O
seen	O
(	O
normal	O
value	O
reached	O
until	O
day	O
7	O
)	O
,	O
together	O
with	O
a	O
slight	B-ADR
decrease	I-ADR
in	I-ADR
peripheral	I-ADR
blood	I-ADR
leukocyte	I-ADR
0	O
<EOS>	O
a	O
22-year-old	O
black	O
man	O
developed	O
fever	O
,	O
chill	B-ADR
,	O
fatigue	O
,	O
night	O
sweat	O
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	O
,	O
pruritic	O
,	O
macular	O
eruption	O
3	O
week	O
after	O
starting	O
minocycline	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
a	O
22-year-old	O
black	O
man	O
developed	O
fever	O
,	O
chill	O
,	O
fatigue	B-ADR
,	O
night	O
sweat	O
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	O
,	O
pruritic	O
,	O
macular	O
eruption	O
3	O
week	O
after	O
starting	O
minocycline	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
a	O
22-year-old	O
black	O
man	O
developed	O
fever	B-ADR
,	O
chill	O
,	O
fatigue	O
,	O
night	O
sweat	O
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	O
,	O
pruritic	O
,	O
macular	O
eruption	O
3	O
week	O
after	O
starting	O
minocycline	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
a	O
22-year-old	O
black	O
man	O
developed	O
fever	O
,	O
chill	O
,	O
fatigue	O
,	O
night	O
sweat	O
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADR
,	I-ADR
pruritic	I-ADR
,	I-ADR
macular	I-ADR
eruption	I-ADR
3	O
week	O
after	O
starting	O
minocycline	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
a	O
22-year-old	O
black	O
man	O
developed	O
fever	O
,	O
chill	O
,	O
fatigue	O
,	O
night	B-ADR
sweat	I-ADR
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	O
,	O
pruritic	O
,	O
macular	O
eruption	O
3	O
week	O
after	O
starting	O
minocycline	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
with	O
the	O
negative	O
viral	O
serology	O
,	O
the	O
clinical	O
picture	O
wa	O
most	O
consistent	O
with	O
an	O
infectious	O
mononucleosis-like	B-ADR
syndrome	I-ADR
produced	O
by	O
the	O
minocycline	B-Drug
ingestion	O
0	O
<EOS>	O
we	O
conclude	O
that	O
the	O
presence	O
of	O
this	O
metabolic	O
defect	O
combined	O
with	O
topical	O
5-fu	B-Drug
(	O
a	O
drug	O
demonstrating	O
a	O
narrow	O
therapeutic	O
index	O
)	O
result	O
in	O
the	O
unusual	O
presentation	O
of	O
life-threatening	B-ADR
toxicity	I-ADR
after	O
treatment	O
with	O
a	O
topical	O
drug	O
0	O
<EOS>	O
we	O
now	O
report	O
the	O
first	O
known	O
cancer	O
patient	O
who	O
developed	O
life-threatening	B-ADR
complication	I-ADR
after	O
treatment	O
with	O
topical	O
5-fu	B-Drug
and	O
wa	O
shown	O
subsequently	O
to	O
have	O
profound	O
dpd	O
deficiency	O
0	O
<EOS>	O
an	O
acute	B-ADR
ischaemic	I-ADR
event	I-ADR
associated	O
with	O
the	O
use	O
of	O
venlafaxine	B-Drug
:	O
a	O
case	O
report	O
and	O
proposed	O
pathophysiological	O
mechanism	O
0	O
<EOS>	O
the	O
association	O
of	O
venlafaxine	B-Drug
treatment	O
with	O
ischaemic	B-ADR
event	I-ADR
could	O
be	O
explained	O
by	O
it	O
unique	O
pharmacological	O
and	O
haemodynamic	O
property	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
association	O
between	O
an	O
acute	B-ADR
cardiovascular	I-ADR
event	I-ADR
and	O
venlafaxine	B-Drug
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
an	O
elderly	O
woman	O
with	O
a	O
pre-existing	O
history	O
of	O
ischaemic	O
heart	O
disease	O
,	O
who	O
wa	O
treated	O
with	O
venlafaxine	B-Drug
,	O
and	O
developed	O
acute	B-ADR
myocardial	I-ADR
ischaemia	I-ADR
within	O
the	O
first	O
week	O
of	O
treatment	O
0	O
<EOS>	O
apparent	O
cyclophosphamide	B-Drug
(	O
cytoxan	O
)	O
embryopathy	B-ADR
:	O
a	O
distinct	O
phenotype	O
?	O
<EOS>	O
the	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
cp	B-Drug
exposure	O
with	O
multiple	O
congenital	O
anomaly	O
and	O
to	O
establish	O
an	O
apparent	O
cp	O
embryopathy	B-ADR
phenotype	O
0	O
<EOS>	O
the	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
cp	B-Drug
exposure	O
with	O
multiple	B-ADR
congenital	I-ADR
anomaly	I-ADR
and	O
to	O
establish	O
an	O
apparent	O
cp	O
embryopathy	O
phenotype	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	O
,	O
blepharophimosis	B-ADR
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	B-ADR
,	O
blepharophimosis	O
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADR
delay	I-ADR
,	O
craniosynostosis	O
,	O
blepharophimosis	O
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	O
,	O
blepharophimosis	O
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	B-ADR
limb	I-ADR
defect	I-ADR
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	O
,	O
blepharophimosis	O
,	O
flat	B-ADR
nasal	I-ADR
bridge	I-ADR
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	O
,	O
blepharophimosis	O
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	B-ADR
thumb	I-ADR
and	O
oligodactyly	O
0	O
<EOS>	O
the	O
reported	O
case	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-Drug
shared	O
the	O
following	O
manifestation	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	O
delay	O
,	O
craniosynostosis	O
,	O
blepharophimosis	O
,	O
flat	O
nasal	O
bridge	O
,	O
abnormal	O
ear	O
,	O
and	O
distal	O
limb	O
defect	O
including	O
hypoplastic	O
thumb	O
and	O
oligodactyly	B-ADR
0	O
<EOS>	O
we	O
conclude	O
that	O
(	O
a	O
)	O
cyclophosphamide	B-Drug
is	O
a	O
human	B-ADR
teratogen	I-ADR
,	O
(	O
b	O
)	O
a	O
distinct	O
phenotype	O
exists	O
,	O
and	O
(	O
c	O
)	O
the	O
safety	O
of	O
cp	O
in	O
pregnancy	O
is	O
in	O
serious	O
question	O
0	O
<EOS>	O
in	O
all	O
case	O
,	O
seizure	B-ADR
were	O
controlled	O
by	O
withdrawal	O
of	O
phenytoin	B-Drug
and	O
reduction	O
of	O
drug	O
level	O
0	O
<EOS>	O
paradoxical	O
seizure	B-ADR
in	O
phenytoin	B-Drug
toxicity	O
0	O
<EOS>	O
we	O
present	O
three	O
patient	O
with	O
paradoxical	O
seizure	B-ADR
;	O
their	O
serum	O
phenytoin	B-Drug
level	O
were	O
43.5	O
mcg	O
/	O
ml	O
,	O
46.5	O
mcg	O
/	O
ml	O
and	O
38.3	O
mcg	O
/	O
ml	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
suggests	O
that	O
losartan	B-Drug
can	O
induce	O
late-onset	O
angioedema	B-ADR
in	O
patient	O
with	O
normal	O
renal	O
function	O
and	O
that	O
the	O
reaction	O
can	O
recur	O
after	O
initial	O
resolution	O
of	O
the	O
symptom	O
0	O
<EOS>	O
losartan-induced	B-Drug
angioedema	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
angioedema	B-ADR
associated	O
with	O
losartan	B-Drug
administration	O
0	O
<EOS>	O
the	O
incidence	O
of	O
angioedema	B-ADR
secondary	O
to	O
losartan	B-Drug
,	O
an	O
angiotensin	O
ii	O
receptor	O
antagonist	O
,	O
is	O
unknown	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
female	O
acromegalic	O
patient	O
in	O
whom	O
multiple	O
hepatic	B-ADR
adenoma	I-ADR
appeared	O
soon	O
after	O
danazol	B-Drug
treatment	O
for	O
uterine	O
fibromatosis	O
0	O
<EOS>	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
is	O
a	O
rare	O
and	O
serious	O
complication	O
of	O
anticoagulation	O
therapy	O
0	O
<EOS>	O
pediatric	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
:	O
management	O
with	O
danaparoid	O
(	O
orgaran	O
)	O
0	O
<EOS>	O
there	O
remains	O
a	O
paucity	O
of	O
information	O
pertaining	O
to	O
alternative	O
anticoagulation	O
strategy	O
for	O
use	O
during	O
cardiopulmonary	O
bypass	O
concomitant	O
with	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
,	O
especially	O
in	O
child	O
0	O
<EOS>	O
we	O
report	O
the	O
successful	O
treatment	O
of	O
heparin-induced	B-Drug
thrombocytopenia	O
and	O
subsequent	O
hemorrhagic	B-ADR
complication	I-ADR
postoperatively	O
in	O
a	O
2-year-old	O
child	O
with	O
danaparoid	O
(	O
orgaran	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
successful	O
treatment	O
of	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
and	O
subsequent	O
hemorrhagic	O
complication	O
postoperatively	O
in	O
a	O
2-year-old	O
child	O
with	O
danaparoid	O
(	O
orgaran	O
)	O
0	O
<EOS>	O
taxane-induced	B-Drug
glaucoma	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
glaucoma	B-ADR
induced	O
by	O
doxetaxel	B-Drug
therapy	O
for	O
metastatic	O
breast	O
cancer	O
0	O
<EOS>	O
acute	O
hyperphosphatemia	B-ADR
caused	O
by	O
sodium	B-Drug
phosphate	I-Drug
enema	O
in	O
a	O
patient	O
with	O
liver	O
dysfunction	O
and	O
chronic	O
renal	O
failure	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acute	O
hyperphosphatemia	B-ADR
secondary	O
to	O
rectal	O
administration	O
of	O
sodium	B-Drug
phosphate	O
and	O
sodium	O
biphosphate	B-Drug
(	O
fleet	O
enema	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acute	O
hyperphosphatemia	B-ADR
secondary	O
to	O
rectal	O
administration	O
of	O
sodium	B-Drug
phosphate	I-Drug
and	O
sodium	O
biphosphate	O
(	O
fleet	O
enema	O
)	O
0	O
<EOS>	O
prolongation	B-ADR
of	I-ADR
the	I-ADR
qt	I-ADR
interval	I-ADR
and	O
ventricular	O
tachyarrhymias	O
have	O
been	O
described	O
in	O
patient	O
on	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
prolongation	O
of	O
the	O
qt	O
interval	O
and	O
ventricular	B-ADR
tachyarrhymias	I-ADR
have	O
been	O
described	O
in	O
patient	O
on	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
recurrent	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
following	O
treatment	O
with	O
pentavalent	O
antimonial	O
drug	O
and	O
amiodarone	B-Drug
0	O
<EOS>	O
emphasis	O
is	O
given	O
to	O
the	O
differentiation	O
of	O
diphenylhydantoin	B-Drug
induced	O
gingival	B-ADR
hyperplasia	I-ADR
from	O
the	O
angiomatous	O
enlargement	O
of	O
the	O
gingiva	O
before	O
any	O
treatment	O
is	O
planned	O
0	O
<EOS>	O
a	O
66-year-old	O
japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADR
and	O
thrombocytopenia	O
due	O
to	O
d-penicillamine	O
(	O
d-pen	B-Drug
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
wa	O
not	O
markedly	O
severe	O
0	O
<EOS>	O
a	O
66-year-old	O
japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADR
and	O
thrombocytopenia	O
due	O
to	O
d-penicillamine	B-Drug
(	O
d-pen	O
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
wa	O
not	O
markedly	O
severe	O
0	O
<EOS>	O
a	O
66-year-old	O
japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	O
and	O
thrombocytopenia	B-ADR
due	O
to	O
d-penicillamine	O
(	O
d-pen	B-Drug
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
wa	O
not	O
markedly	O
severe	O
0	O
<EOS>	O
a	O
66-year-old	O
japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	O
and	O
thrombocytopenia	B-ADR
due	O
to	O
d-penicillamine	B-Drug
(	O
d-pen	O
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
wa	O
not	O
markedly	O
severe	O
0	O
<EOS>	O
cessation	O
of	O
d-pen	B-Drug
and	O
the	O
start	O
of	O
corticosteroid	O
therapy	O
were	O
followed	O
by	O
recovery	O
from	O
bicytopenia	B-ADR
0	O
<EOS>	O
in	O
vitro	O
inhibition	B-ADR
of	I-ADR
hematopoiesis	I-ADR
in	O
a	O
patient	O
with	O
systemic	O
sclerosis	O
treated	O
with	O
d-penicillamine	B-Drug
0	O
<EOS>	O
these	O
finding	O
suggest	O
that	O
bicytopenia	B-ADR
in	O
this	O
patient	O
wa	O
caused	O
by	O
d-pen	B-Drug
and	O
may	O
be	O
due	O
to	O
different	O
sensitivity	O
in	O
the	O
hematopoietic	O
lineage	O
0	O
<EOS>	O
a	O
48-year-old	O
woman	O
who	O
wa	O
treated	O
for	O
thyrotoxicosis	O
with	O
methimazole	B-Drug
developed	O
agranulocytosis	B-ADR
0	O
<EOS>	O
postoperative	O
hypocalcemic	B-ADR
tetany	I-ADR
caused	O
by	O
fleet	O
phospho-soda	O
preparation	O
in	O
a	O
patient	O
taking	O
alendronate	B-Drug
sodium	I-Drug
:	O
report	O
of	O
a	O
case	O
0	O
<EOS>	O
postoperative	O
hypocalcemic	B-ADR
tetany	I-ADR
caused	O
by	O
fleet	B-Drug
phospho-soda	I-Drug
preparation	O
in	O
a	O
patient	O
taking	O
alendronate	O
sodium	O
:	O
report	O
of	O
a	O
case	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	B-Drug
(	O
fosamax	O
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	O
and	O
hypocalcemic	B-ADR
tetany	I-ADR
after	O
bowel	O
preparation	O
with	O
fleet	O
phospho-soda	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	O
(	O
fosamax	O
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	O
and	O
hypocalcemic	B-ADR
tetany	I-ADR
after	O
bowel	O
preparation	O
with	O
fleet	B-Drug
phospho-soda	I-Drug
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	O
(	O
fosamax	B-Drug
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	O
and	O
hypocalcemic	B-ADR
tetany	I-ADR
after	O
bowel	O
preparation	O
with	O
fleet	O
phospho-soda	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	B-Drug
(	O
fosamax	O
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADR
and	O
hypocalcemic	O
tetany	O
after	O
bowel	O
preparation	O
with	O
fleet	O
phospho-soda	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	O
(	O
fosamax	O
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADR
and	O
hypocalcemic	O
tetany	O
after	O
bowel	O
preparation	O
with	O
fleet	B-Drug
phospho-soda	I-Drug
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
patient	O
who	O
wa	O
previously	O
prescribed	O
alendronate	O
(	O
fosamax	B-Drug
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADR
and	O
hypocalcemic	O
tetany	O
after	O
bowel	O
preparation	O
with	O
fleet	O
phospho-soda	O
0	O
<EOS>	O
described	O
here	O
are	O
2	O
patient	O
who	O
developed	O
thrombotic	B-ADR
microangiopathy	I-ADR
of	O
the	O
kidney	O
after	O
receiving	O
high	O
cumulative	O
dos	O
of	O
the	O
new	O
anticancer	O
drug	O
gemcitabine	B-Drug
0	O
<EOS>	O
thrombotic	O
microangiopathy	O
with	O
renal	B-ADR
failure	I-ADR
in	O
two	O
patient	O
undergoing	O
gemcitabine	B-Drug
chemotherapy	O
0	O
<EOS>	O
thrombotic	B-ADR
microangiopathy	I-ADR
with	O
renal	O
failure	O
in	O
two	O
patient	O
undergoing	O
gemcitabine	B-Drug
chemotherapy	O
0	O
<EOS>	O
the	O
first	O
patient	O
wa	O
a	O
61-year-old	O
man	O
with	O
a	O
30-year	O
history	O
of	O
fistulizing	O
cd	O
in	O
whom	O
b-cell	B-ADR
non-hodgkin	I-ADR
lymphoma	I-ADR
wa	O
diagnosed	O
9	O
month	O
after	O
treatment	O
with	O
infliximab	B-Drug
0	O
<EOS>	O
the	O
relationship	O
between	O
infliximab	B-Drug
treatment	O
and	O
lymphoma	B-ADR
in	O
crohn	O
disease	O
0	O
<EOS>	O
the	O
second	O
is	O
a	O
29-year-old	O
man	O
with	O
cd	O
in	O
whom	O
nodular	B-ADR
sclerosing	I-ADR
hodgkin	I-ADR
lymphoma	I-ADR
wa	O
diagnosed	O
3	O
week	O
after	O
infusion	O
with	O
infliximab	B-Drug
0	O
<EOS>	O
we	O
describe	O
the	O
clinical	O
course	O
of	O
2	O
patient	O
with	O
crohn	O
disease	O
(	O
cd	O
)	O
in	O
whom	O
lymphoma	B-ADR
wa	O
diagnosed	O
after	O
treatment	O
with	O
infliximab	B-Drug
0	O
<EOS>	O
codeine	B-Drug
intoxication	I-ADR
in	O
the	O
neonate	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
codeine	B-Drug
intoxication	I-ADR
in	O
the	O
neonate	O
,	O
in	O
which	O
the	O
drug	O
wa	O
prescribed	O
for	O
cough	O
control	O
during	O
an	O
emergency	O
department	O
visit	O
0	O
<EOS>	O
hydroxyurea	B-Drug
(	O
hu	O
)	O
and	O
sodium	O
phenylbutyrate	O
(	O
spb	O
)	O
have	O
been	O
shown	O
to	O
increase	B-ADR
fetal	I-ADR
hemoglobin	I-ADR
(	O
hb	O
f	O
)	O
level	O
in	O
patient	O
with	O
thalassemia	O
intermedia	O
0	O
<EOS>	O
hydroxyurea	O
(	O
hu	O
)	O
and	O
sodium	B-Drug
phenylbutyrate	I-Drug
(	O
spb	O
)	O
have	O
been	O
shown	O
to	O
increase	B-ADR
fetal	I-ADR
hemoglobin	I-ADR
(	O
hb	O
f	O
)	O
level	O
in	O
patient	O
with	O
thalassemia	O
intermedia	O
0	O
<EOS>	O
of	O
the	O
four	O
patient	O
who	O
responded	O
to	O
hu	B-Drug
with	O
an	O
increase	B-ADR
in	I-ADR
total	I-ADR
hb	I-ADR
,	O
all	O
reported	O
symptomatic	O
improvement	O
and	O
three	O
have	O
not	O
required	O
further	O
transfusion	O
0	O
<EOS>	O
prolonged	O
response	O
were	O
achieved	O
with	O
low	O
dos	O
of	O
hu	B-Drug
(	O
3-10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
higher	O
dos	O
were	O
associated	O
with	O
mild	O
reversible	O
hematologic	O
or	O
hepatic	B-ADR
toxicity	I-ADR
and	O
no	O
further	O
increase	O
in	O
hb	O
0	O
<EOS>	O
prolonged	O
response	O
were	O
achieved	O
with	O
low	O
dos	O
of	O
hu	B-Drug
(	O
3-10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
higher	O
dos	O
were	O
associated	O
with	O
mild	B-ADR
reversible	I-ADR
hematologic	I-ADR
or	O
hepatic	O
toxicity	O
and	O
no	O
further	O
increase	O
in	O
hb	O
0	O
<EOS>	O
sodium	O
phenylbutyrate	O
wa	O
added	O
to	O
treatment	O
with	O
hu	B-Drug
in	O
two	O
patient	O
,	O
but	O
failed	O
to	O
produce	O
an	O
increase	O
in	O
total	O
hb	O
despite	O
increasing	B-ADR
hb	I-ADR
f	I-ADR
level	O
0	O
<EOS>	O
sodium	B-Drug
phenylbutyrate	I-Drug
wa	O
added	O
to	O
treatment	O
with	O
hu	O
in	O
two	O
patient	O
,	O
but	O
failed	O
to	O
produce	O
an	O
increase	O
in	O
total	O
hb	O
despite	O
increasing	B-ADR
hb	I-ADR
f	I-ADR
level	O
0	O
<EOS>	O
we	O
conclude	O
that	O
low-dose	O
hu	B-Drug
therapy	O
in	O
patient	O
with	O
thalassemia	O
intermedia	O
may	O
increase	B-ADR
total	I-ADR
hb	I-ADR
level	O
sufficiently	O
to	O
eliminate	O
the	O
need	O
for	O
transfusion	O
0	O
<EOS>	O
we	O
describe	O
the	O
clinical	O
response	O
,	O
a	O
determined	O
by	O
increase	B-ADR
in	I-ADR
total	I-ADR
hb	I-ADR
and	O
decreased	O
transfusion	O
need	O
,	O
in	O
five	O
patient	O
with	O
thalassemia	O
intermedia	O
treated	O
with	O
hu	B-Drug
alone	O
or	O
in	O
combination	O
with	O
spb	O
0	O
<EOS>	O
we	O
describe	O
the	O
clinical	O
response	O
,	O
a	O
determined	O
by	O
increase	B-ADR
in	I-ADR
total	I-ADR
hb	I-ADR
and	O
decreased	O
transfusion	O
need	O
,	O
in	O
five	O
patient	O
with	O
thalassemia	O
intermedia	O
treated	O
with	O
hu	O
alone	O
or	O
in	O
combination	O
with	O
spb	B-Drug
0	O
<EOS>	O
a	O
36-y-o	O
patient	O
with	O
schizophrenia	O
,	O
who	O
had	O
consumed	O
gradually	O
increasing	O
quantity	O
of	O
oolong	B-Drug
tea	I-Drug
that	O
eventually	O
reached	O
15	O
l	O
each	O
day	O
,	O
became	O
delirious	B-ADR
and	O
wa	O
admitted	O
to	O
a	O
psychiatric	O
hospital	O
0	O
<EOS>	O
after	O
abstinence	O
from	O
oolong	B-Drug
tea	I-Drug
his	O
delirium	B-ADR
resolved	O
0	O
<EOS>	O
severe	O
rhabdomyolysis	O
following	O
massive	O
ingestion	O
of	O
oolong	O
tea	O
:	O
caffeine	B-Drug
intoxication	I-ADR
with	O
coexisting	O
hyponatremia	O
0	O
<EOS>	O
severe	O
rhabdomyolysis	O
following	O
massive	O
ingestion	O
of	O
oolong	B-Drug
tea	I-Drug
:	O
caffeine	B-ADR
intoxication	I-ADR
with	O
coexisting	O
hyponatremia	O
0	O
<EOS>	O
severe	O
rhabdomyolysis	B-ADR
following	O
massive	O
ingestion	O
of	O
oolong	O
tea	O
:	O
caffeine	B-Drug
intoxication	O
with	O
coexisting	O
hyponatremia	O
0	O
<EOS>	O
severe	O
rhabdomyolysis	B-ADR
following	O
massive	O
ingestion	O
of	O
oolong	B-Drug
tea	I-Drug
:	O
caffeine	O
intoxication	O
with	O
coexisting	O
hyponatremia	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-Drug
,	O
which	O
is	O
present	O
in	O
oolong	O
tea	O
,	O
wa	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	O
a	O
well	O
a	O
the	O
delirium	B-ADR
,	O
although	O
severe	O
hyponatremia	O
ha	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	O
on	O
rare	O
occasion	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-Drug
,	O
which	O
is	O
present	O
in	O
oolong	O
tea	O
,	O
wa	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	O
a	O
well	O
a	O
the	O
delirium	O
,	O
although	O
severe	O
hyponatremia	B-ADR
ha	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	O
on	O
rare	O
occasion	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-Drug
,	O
which	O
is	O
present	O
in	O
oolong	O
tea	O
,	O
wa	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADR
a	O
well	O
a	O
the	O
delirium	O
,	O
although	O
severe	O
hyponatremia	O
ha	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	O
on	O
rare	O
occasion	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-Drug
,	O
which	O
is	O
present	O
in	O
oolong	O
tea	O
,	O
wa	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADR
a	O
well	O
a	O
the	O
delirium	O
,	O
although	O
severe	O
hyponatremia	O
ha	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	O
on	O
rare	O
occasion	O
0	O
<EOS>	O
the	O
possibility	O
of	O
severe	O
rhabdomyolysis	B-ADR
should	O
be	O
considered	O
in	O
a	O
patient	O
with	O
water	O
intoxication	O
due	O
to	O
massive	O
ingestion	O
of	O
caffeine-containing	B-Drug
beverage	O
0	O
<EOS>	O
the	O
possibility	O
of	O
severe	O
rhabdomyolysis	O
should	O
be	O
considered	O
in	O
a	O
patient	O
with	O
water	B-ADR
intoxication	I-ADR
due	O
to	O
massive	O
ingestion	O
of	O
caffeine-containing	B-Drug
beverage	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
caffeine	B-Drug
toxicity	I-ADR
injured	O
the	O
muscle	O
cell	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	O
depletion	O
induced	O
by	O
the	O
coexisting	O
hyponatremia	O
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
caffeine	B-Drug
toxicity	O
injured	O
the	O
muscle	O
cell	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	O
depletion	O
induced	O
by	O
the	O
coexisting	B-ADR
hyponatremia	I-ADR
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
caffeine	B-Drug
toxicity	O
injured	B-ADR
the	I-ADR
muscle	I-ADR
cell	I-ADR
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	O
depletion	O
induced	O
by	O
the	O
coexisting	O
hyponatremia	O
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
caffeine	B-Drug
toxicity	O
injured	O
the	O
muscle	O
cell	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADR
depletion	I-ADR
induced	O
by	O
the	O
coexisting	O
hyponatremia	O
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
caffeine	B-Drug
toxicity	O
injured	O
the	O
muscle	O
cell	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	O
depletion	O
induced	O
by	O
the	O
coexisting	O
hyponatremia	O
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADR
0	O
<EOS>	O
after	O
the	O
addition	O
of	O
citalopram	B-Drug
,	O
a	O
desmethylclomipramine	O
plasma	O
level	O
increase	O
and	O
an	O
8-hydroacy-desmethylclomipramine	B-ADR
plasma	I-ADR
level	I-ADR
decrease	I-ADR
were	O
observed	O
0	O
<EOS>	O
after	O
the	O
addition	O
of	O
citalopram	B-Drug
,	O
a	O
desmethylclomipramine	B-ADR
plasma	I-ADR
level	I-ADR
increase	I-ADR
and	O
an	O
8-hydroacy-desmethylclomipramine	O
plasma	O
level	O
decrease	O
were	O
observed	O
0	O
<EOS>	O
we	O
report	O
3	O
case	O
of	O
hiv-1	O
infected	O
patient	O
who	O
experienced	O
symptomatic	O
angiolipomas	B-ADR
shortly	O
after	O
starting	O
antiretroviral	O
therapy	O
including	O
the	O
protease	O
inhibitor	O
indinavir	B-Drug
0	O
<EOS>	O
elevated	B-ADR
serum	I-ADR
triglyceride	I-ADR
with	O
clozapine	B-Drug
resolved	O
with	O
risperidone	O
in	O
four	O
patient	O
0	O
<EOS>	O
in	O
two	O
patient	O
clozapine	B-Drug
wa	O
reinstated	O
after	O
risperidone	O
wa	O
discontinued	O
;	O
serum	B-ADR
triglyceride	I-ADR
level	I-ADR
increased	I-ADR
0	O
<EOS>	O
this	O
increase	O
when	O
clozapine	O
wa	O
switched	O
to	O
risperidone	O
and	O
vice	O
versa	O
is	O
consistent	O
with	O
our	O
previous	O
report	O
of	O
elevated	B-ADR
serum	I-ADR
triglyceride	I-ADR
level	I-ADR
in	O
clozapine-treated	B-Drug
patient	O
0	O
<EOS>	O
intravenous	O
valproate	B-Drug
associated	O
with	O
significant	O
hypotension	B-ADR
in	O
the	O
treatment	O
of	O
status	O
epilepticus	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
significant	O
hypotension	B-ADR
associated	O
with	O
intravenous	O
valproate	B-Drug
in	O
the	O
treatment	O
of	O
status	O
epilepticus	O
in	O
the	O
pediatric	O
population	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
severe	O
hypotension	B-ADR
associated	O
with	O
intravenous	O
valproate	B-Drug
used	O
to	O
treat	O
status	O
epilepticus	O
in	O
an	O
11-year-old	O
girl	O
0	O
<EOS>	O
in	O
both	O
patient	O
the	O
rippling	B-ADR
phenomenon	I-ADR
worsened	I-ADR
with	O
pyridostigmine	B-Drug
treatment	O
but	O
markedly	O
improved	O
after	O
immunosuppression	O
with	O
azathioprine	O
0	O
<EOS>	O
a	O
diagnosis	O
of	O
masked	O
theophylline	B-Drug
poisoning	I-ADR
should	O
be	O
considered	O
in	O
similar	O
situation	O
involving	O
a	O
rapid	O
decrease	O
of	O
insulin	O
requirement	O
0	O
<EOS>	O
salicylate	O
intoxication	B-ADR
wa	O
excluded	O
,	O
and	O
theophylline	B-Drug
wa	O
finally	O
incriminated	O
0	O
<EOS>	O
theophylline	B-Drug
intoxication	I-ADR
mimicking	O
diabetic	O
ketoacidosis	O
in	O
a	O
child	O
0	O
<EOS>	O
this	O
compound	O
,	O
used	O
by	O
adult	O
in	O
the	O
child	O
home	O
,	O
had	O
caused	O
accidental	O
theophylline	B-Drug
poisoning	I-ADR
,	O
mimicking	O
diabetic	O
ketoacidosis	O
0	O
<EOS>	O
methylene	O
blue	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
ifosfamide-induced	B-Drug
encephalopathy	I-ADR
:	O
report	O
of	O
12	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
ten	O
to	O
15	O
%	O
of	O
patient	O
treated	O
with	O
ifosfamide	B-Drug
develop	O
an	O
encephalopathy	B-ADR
0	O
<EOS>	O
we	O
conclude	O
that	O
mb	O
is	O
an	O
effective	O
treatment	O
for	O
ifosfamide-induced	B-Drug
encephalopathy	I-ADR
0	O
<EOS>	O
portal	B-ADR
vein	I-ADR
thrombosis	I-ADR
in	O
a	O
patient	O
with	O
severe	O
haemophilia	O
a	O
and	O
f	B-Drug
v	O
g1691a	O
mutation	O
during	O
continuous	O
infusion	O
of	O
f	O
viii	B-Drug
after	O
intramural	O
jejunal	O
bleeding	O
--	O
successful	O
thrombolysis	O
under	O
heparin	O
therapy	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
14-year-old	O
boy	O
with	O
severe	O
haemophilia	O
a	O
who	O
developed	O
a	O
portal	B-ADR
vein	I-ADR
thrombosis	I-ADR
during	O
continuous	O
infusion	O
of	O
f	B-Drug
viii	I-Drug
0	O
<EOS>	O
a	O
60-year-old	O
woman	O
with	O
diabetes	O
mellitus	O
(	O
type	O
2	O
)	O
developed	O
an	O
acute	B-ADR
icteric	I-ADR
hepatitis-like	I-ADR
illness	I-ADR
6	O
week	O
after	O
the	O
initiation	O
of	O
gliclazide	B-Drug
therapy	O
0	O
<EOS>	O
gliclazide-induced	B-Drug
acute	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
in	O
conclusion	O
,	O
this	O
case	O
strongly	O
suggests	O
that	O
gliclazide	B-Drug
can	O
induce	O
acute	B-ADR
icteric	I-ADR
liver	I-ADR
necro-inflammation	I-ADR
which	O
may	O
be	O
misdiagnosed	O
clinically	O
a	O
acute	O
viral	O
hepatitis	O
0	O
<EOS>	O
we	O
believe	O
that	O
this	O
is	O
the	O
first	O
description	O
of	O
acute	B-ADR
hepatitis	I-ADR
caused	O
by	O
an	O
idiosyncratic	O
adverse	O
reaction	O
to	O
gliclazide	B-Drug
or	O
to	O
one	O
of	O
it	O
metabolite	O
0	O
<EOS>	O
we	O
describe	O
the	O
case	O
of	O
acute	B-ADR
hepatitis	I-ADR
induced	O
by	O
gliclazide	B-Drug
,	O
a	O
second	O
generation	O
sulfonylurea	O
0	O
<EOS>	O
caution	O
is	O
,	O
therefore	O
,	O
needed	O
to	O
prevent	O
undesired	O
accumulation	O
of	O
tca	B-Drug
that	O
may	O
lead	O
to	O
protracted	O
cushing	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
cushing	B-ADR
syndrome	I-ADR
persisted	O
more	O
than	O
6	O
month	O
while	O
tca	B-Drug
concentration	O
remained	O
detectable	O
for	O
at	O
least	O
80	O
day	O
0	O
<EOS>	O
the	O
presented	O
patient	O
wa	O
treated	O
with	O
200	O
mg	O
tca	B-Drug
and	O
developed	O
cushing	B-ADR
syndrome	I-ADR
6	O
week	O
later	O
(	O
cortisol	O
and	O
acth	O
concentration	O
were	O
below	O
limit	O
of	O
detection	O
,	O
tca	O
concentration	O
were	O
>	O
3	O
microgram	O
/	O
l	O
)	O
0	O
<EOS>	O
both	O
had	O
impaired	O
lung	O
function	O
and	O
abnormal	B-ADR
computed	I-ADR
tomographic	I-ADR
scan	I-ADR
,	O
and	O
their	O
condition	O
improved	O
when	O
nitrofurantoin	B-Drug
wa	O
withdrawn	O
and	O
corticosteroid	O
treatment	O
commenced	O
0	O
<EOS>	O
both	O
had	O
impaired	B-ADR
lung	I-ADR
function	I-ADR
and	O
abnormal	O
computed	O
tomographic	O
scan	O
,	O
and	O
their	O
condition	O
improved	O
when	O
nitrofurantoin	B-Drug
wa	O
withdrawn	O
and	O
corticosteroid	O
treatment	O
commenced	O
0	O
<EOS>	O
bronchiolitis	B-ADR
obliterans	I-ADR
organising	I-ADR
pneumonia	I-ADR
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
0	O
<EOS>	O
the	O
case	O
history	O
are	O
presented	O
of	O
two	O
patient	O
who	O
developed	O
lung	O
disease	O
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
with	O
histological	O
feature	O
of	O
bronchiolitis	O
obliterans	O
organising	O
pneumonia	O
(	O
boop	B-ADR
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
0	O
<EOS>	O
the	O
case	O
history	O
are	O
presented	O
of	O
two	O
patient	O
who	O
developed	O
lung	O
disease	O
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
with	O
histological	O
feature	O
of	O
bronchiolitis	B-ADR
obliterans	I-ADR
organising	I-ADR
pneumonia	I-ADR
(	O
boop	O
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
0	O
<EOS>	O
the	O
case	O
history	O
are	O
presented	O
of	O
two	O
patient	O
who	O
developed	O
lung	B-ADR
disease	I-ADR
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
with	O
histological	O
feature	O
of	O
bronchiolitis	O
obliterans	O
organising	O
pneumonia	O
(	O
boop	O
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
0	O
<EOS>	O
the	O
favourable	O
outcome	O
in	O
these	O
two	O
patient	O
contrast	O
with	O
the	O
fatal	B-ADR
outcome	I-ADR
of	O
the	O
two	O
other	O
reported	O
case	O
of	O
nitrofurantoin	B-Drug
induced	O
boop	O
0	O
<EOS>	O
the	O
favourable	O
outcome	O
in	O
these	O
two	O
patient	O
contrast	O
with	O
the	O
fatal	O
outcome	O
of	O
the	O
two	O
other	O
reported	O
case	O
of	O
nitrofurantoin	B-Drug
induced	I-ADR
boop	I-ADR
0	O
<EOS>	O
the	O
spectrum	O
of	O
nitrofurantoin	B-Drug
lung	B-ADR
injury	I-ADR
continues	O
to	O
widen	O
0	O
<EOS>	O
the	O
two	O
middle	O
aged	O
woman	O
presented	O
with	O
respiratory	B-ADR
symptom	I-ADR
after	O
prolonged	O
treatment	O
with	O
nitrofurantoin	B-Drug
0	O
<EOS>	O
we	O
suggest	O
that	O
the	O
previous	O
classification	O
of	O
nitrofurantoin	B-Drug
induced	I-ADR
lung	I-ADR
injury	I-ADR
into	O
``	O
acute	O
'	O
and	O
``	O
chronic	O
'	O
injury	O
is	O
an	O
oversimplification	O
in	O
view	O
of	O
the	O
wide	O
variety	O
of	O
pathological	O
entity	O
that	O
have	O
subsequently	O
emerged	O
0	O
<EOS>	O
intravenous	O
administration	O
of	O
levodopa	O
ameliorated	O
a	O
refractory	O
akathisia	B-ADR
case	O
induced	O
by	O
interferon-alpha	B-Drug
0	O
<EOS>	O
the	O
present	O
report	O
illustrates	O
a	O
rare	O
case	O
of	O
refractory	O
akathisia	B-ADR
after	O
interferon-alpha	B-Drug
treatment	O
and	O
also	O
that	O
levodopa	O
treatment	O
would	O
be	O
theoretically	O
and	O
practically	O
useful	O
in	O
reducing	O
the	O
neurotoxicity	O
associated	O
with	O
interferon-alpha	O
0	O
<EOS>	O
the	O
present	O
report	O
illustrates	O
a	O
rare	O
case	O
of	O
refractory	O
akathisia	O
after	O
interferon-alpha	B-Drug
treatment	O
and	O
also	O
that	O
levodopa	O
treatment	O
would	O
be	O
theoretically	O
and	O
practically	O
useful	O
in	O
reducing	O
the	O
neurotoxicity	B-ADR
associated	O
with	O
interferon-alpha	O
0	O
<EOS>	O
acute	B-ADR
erythroid	I-ADR
leukemia	I-ADR
after	O
cyclophosphamide	B-Drug
therapy	O
for	O
multiple	O
myeloma	O
:	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
the	O
development	O
of	O
erythroid	O
leukemia	O
plus	O
carcinoma	B-ADR
in	O
these	O
two	O
men	O
suggests	O
mutagenic	O
change	O
secondary	O
to	O
cyclophosphamide	B-Drug
therapy	O
0	O
<EOS>	O
scleroderma-like	B-ADR
reaction	I-ADR
induced	O
by	O
uracil-tegafur	O
(	O
uft	B-Drug
)	O
,	O
a	O
second-generation	O
anticancer	O
agent	O
0	O
<EOS>	O
scleroderma-like	B-ADR
reaction	I-ADR
induced	O
by	O
uracil-tegafur	B-Drug
(	O
uft	O
)	O
,	O
a	O
second-generation	O
anticancer	O
agent	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
uft-induced	B-Drug
scleroderma-like	I-ADR
reaction	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
scleroderma-like	B-ADR
reaction	I-ADR
induced	O
by	O
long-term	O
administration	O
of	O
uft	B-Drug
0	O
<EOS>	O
central	B-ADR
nervous	I-ADR
system	I-ADR
manifestation	I-ADR
of	O
an	O
ibuprofen	B-Drug
overdose	O
reversed	O
by	O
naloxone	O
0	O
<EOS>	O
ibuprofen	B-Drug
overdose	O
is	O
usually	O
characterized	O
by	O
gi	O
upset	O
,	O
dizziness	B-ADR
,	O
and	O
mild	O
sedation	O
0	O
<EOS>	O
ibuprofen	B-Drug
overdose	O
is	O
usually	O
characterized	O
by	O
gi	B-ADR
upset	I-ADR
,	O
dizziness	O
,	O
and	O
mild	O
sedation	O
0	O
<EOS>	O
ibuprofen	B-Drug
overdose	O
is	O
usually	O
characterized	O
by	O
gi	O
upset	O
,	O
dizziness	O
,	O
and	O
mild	B-ADR
sedation	I-ADR
0	O
<EOS>	O
presently	O
,	O
treatment	O
of	O
acute	O
ibuprofen	B-Drug
intoxication	I-ADR
with	O
complication	O
requires	O
supportive	O
therapy	O
until	O
the	O
symptom	O
resolve	O
over	O
24	O
to	O
48	O
hour	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
11-month-old	O
female	O
infant	O
with	O
a	O
depressed	B-ADR
level	I-ADR
of	I-ADR
consciousness	I-ADR
after	O
ingestion	O
of	O
ibuprofen	B-Drug
whose	O
mental	O
status	O
markedly	O
improved	O
with	O
administration	O
of	O
naloxone	O
0	O
<EOS>	O
flecainide-associated	B-Drug
pneumonitis	O
with	O
acute	B-ADR
respiratory	I-ADR
failure	I-ADR
in	O
a	O
patient	O
with	O
the	O
leopard	O
syndrome	O
0	O
<EOS>	O
flecainide-associated	B-Drug
pneumonitis	B-ADR
with	O
acute	O
respiratory	O
failure	O
in	O
a	O
patient	O
with	O
the	O
leopard	O
syndrome	O
0	O
<EOS>	O
flecainide	B-Drug
is	O
a	O
rare	O
cause	O
of	O
hypersensitivity	B-ADR
pneumonitis	I-ADR
,	O
and	O
few	O
case	O
have	O
been	O
reported	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
interstitial	B-ADR
hypoxaemiant	I-ADR
pneumonitis	I-ADR
probably	O
related	O
to	O
flecainide	B-Drug
in	O
a	O
patient	O
with	O
the	O
leopard	O
syndrome	O
,	O
a	O
rare	O
congenital	O
disorder	O
0	O
<EOS>	O
sagittal	B-ADR
sinus	I-ADR
thrombosis	I-ADR
associated	O
with	O
transient	O
free	O
protein	O
s	O
deficiency	O
after	O
l-asparaginase	B-Drug
treatment	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
sagittal	O
sinus	O
thrombosis	O
associated	O
with	O
transient	B-ADR
free	I-ADR
protein	I-ADR
s	I-ADR
deficiency	I-ADR
after	O
l-asparaginase	B-Drug
treatment	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
adult	O
patient	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
presented	O
with	O
repeated	O
transient	O
ischemic	O
attack	O
followed	O
by	O
a	O
seizure	B-ADR
during	O
consolidation	O
treatment	O
with	O
l-asparaginase	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
adult	O
patient	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
presented	O
with	O
repeated	O
transient	B-ADR
ischemic	I-ADR
attack	I-ADR
followed	O
by	O
a	O
seizure	O
during	O
consolidation	O
treatment	O
with	O
l-asparaginase	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
young	O
adolescent	O
with	O
benign	B-ADR
intracranial	I-ADR
hypertension	I-ADR
which	O
we	O
attribute	O
to	O
the	O
use	O
of	O
minocycline	B-Drug
for	O
acne	O
0	O
<EOS>	O
we	O
report	O
2	O
patient	O
who	O
developed	O
polyarteritis	B-ADR
nodosa	I-ADR
following	O
vaccination	B-Drug
against	I-Drug
hepatitis	I-Drug
b	I-Drug
0	O
<EOS>	O
in	O
this	O
case	O
,	O
it	O
wa	O
suspected	O
that	O
a	O
combination	O
of	O
cigarette	O
smoking	O
,	O
pulmonary	O
fibrosis	O
,	O
and	O
low-dose	O
methotrexate	B-Drug
therapy	O
might	O
have	O
promoted	O
the	O
development	O
of	O
lung	B-ADR
cancer	I-ADR
0	O
<EOS>	O
this	O
case	O
report	O
illustrates	O
the	O
use	O
of	O
continuous	O
high-dose	O
intracoronary	O
nitroglycerin	O
infusion	O
through	O
a	O
6	O
french	O
coronary	O
guiding	O
catheter	O
in	O
the	O
treatment	O
of	O
a	O
patient	O
with	O
cocaine-induced	B-Drug
refractory	B-ADR
coronary	I-ADR
vasospasm	I-ADR
0	O
<EOS>	O
however	O
,	O
a	O
illustrated	O
by	O
these	O
and	O
other	O
case	O
reported	O
to	O
date	O
,	O
the	O
onset	O
of	O
troglitazone-induced	B-Drug
liver	B-ADR
injury	I-ADR
is	O
insidious	O
and	O
temporally	O
variable	O
0	O
<EOS>	O
it	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	B-ADR
associated	O
with	O
troglitazone	B-Drug
is	O
a	O
drug-class	O
effect	O
or	O
specific	O
to	O
troglitazone	O
0	O
<EOS>	O
it	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	B-ADR
associated	O
with	O
troglitazone	B-Drug
is	O
a	O
drug-class	O
effect	O
or	O
specific	O
to	O
troglitazone	O
0	O
<EOS>	O
other	O
thiazolidinediones	O
currently	O
in	O
clinical	O
trial	O
may	O
be	O
able	O
to	O
provide	O
the	O
therapeutic	O
benefit	O
of	O
troglitazone	B-Drug
without	O
significant	O
hepatotoxicity	B-ADR
0	O
<EOS>	O
the	O
three	O
reported	O
case	O
demonstrate	O
that	O
troglitazone	B-Drug
is	O
an	O
idiosyncratic	O
hepatotoxin	O
that	O
can	O
lead	O
to	O
irreversible	B-ADR
liver	I-ADR
injury	I-ADR
0	O
<EOS>	O
troglitazone-induced	B-Drug
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
0	O
<EOS>	O
nitrofurantoin-induced	B-Drug
lung	B-ADR
disease	I-ADR
:	O
two	O
case	O
demonstrating	O
resolution	O
of	O
apparently	O
irreversible	O
ct	O
abnormality	O
0	O
<EOS>	O
we	O
present	O
two	O
case	O
of	O
nitrofurantoin-induced	B-Drug
pulmonary	O
toxicity	O
in	O
which	O
the	O
initial	O
hrct	O
showed	O
a	O
widespread	O
reticular	O
pattern	O
and	O
associated	O
distortion	B-ADR
of	I-ADR
the	I-ADR
lung	I-ADR
parenchyma	I-ADR
,	O
thought	O
to	O
represent	O
established	O
fibrosis	O
0	O
<EOS>	O
we	O
present	O
two	O
case	O
of	O
nitrofurantoin-induced	B-Drug
pulmonary	O
toxicity	O
in	O
which	O
the	O
initial	O
hrct	O
showed	O
a	O
widespread	O
reticular	O
pattern	O
and	O
associated	O
distortion	O
of	O
the	O
lung	O
parenchyma	O
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADR
0	O
<EOS>	O
we	O
present	O
two	O
case	O
of	O
nitrofurantoin-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
in	O
which	O
the	O
initial	O
hrct	O
showed	O
a	O
widespread	O
reticular	O
pattern	O
and	O
associated	O
distortion	O
of	O
the	O
lung	O
parenchyma	O
,	O
thought	O
to	O
represent	O
established	O
fibrosis	O
0	O
<EOS>	O
we	O
present	O
two	O
case	O
of	O
nitrofurantoin-induced	B-Drug
pulmonary	O
toxicity	O
in	O
which	O
the	O
initial	O
hrct	O
showed	O
a	O
widespread	B-ADR
reticular	I-ADR
pattern	I-ADR
and	O
associated	O
distortion	O
of	O
the	O
lung	O
parenchyma	O
,	O
thought	O
to	O
represent	O
established	O
fibrosis	O
0	O
<EOS>	O
fluoxetine-related	B-Drug
death	B-ADR
in	O
a	O
child	O
with	O
cytochrome	O
p-450	O
2d6	O
genetic	O
deficiency	O
0	O
<EOS>	O
the	O
medical	O
examiner	O
report	O
indicated	O
death	B-ADR
caused	O
by	O
fluoxetine	B-Drug
toxicity	O
0	O
<EOS>	O
the	O
medical	O
examiner	O
report	O
indicated	O
death	O
caused	O
by	O
fluoxetine	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
fluoxetine-related	B-Drug
death	B-ADR
in	O
a	O
child	O
with	O
a	O
confirmed	O
genetic	O
polymorphism	O
of	O
the	O
cyp2d6	O
gene	O
that	O
result	O
in	O
impaired	O
drug	O
metabolism	O
0	O
<EOS>	O
a	O
50-year-old	O
woman	O
with	O
a	O
history	O
of	O
migraine	O
without	O
aura	O
,	O
predominantly	O
occurring	O
around	O
her	O
menstrual	O
period	O
,	O
developed	O
a	O
spinal	B-ADR
cord	I-ADR
lesion	I-ADR
following	O
the	O
use	O
of	O
zolmitriptan	B-Drug
0	O
<EOS>	O
spinal	B-ADR
cord	I-ADR
infarction	I-ADR
during	O
use	O
of	O
zolmitriptan	B-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
temporal	O
relationship	O
suggests	O
that	O
the	O
spinal	B-ADR
cord	I-ADR
infarction	I-ADR
may	O
be	O
related	O
to	O
the	O
use	O
of	O
zolmitriptan	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
10-year-old	O
white	O
girl	O
with	O
bilateral	O
optic	O
glioma	O
developed	O
a	O
hypersensitivity	B-ADR
reaction	O
to	O
carboplatin	B-Drug
after	O
nine	O
course	O
0	O
<EOS>	O
this	O
regimen	O
could	O
prove	O
useful	O
for	O
other	O
patient	O
who	O
develop	O
hypersensitivity	B-ADR
reaction	O
to	O
carboplatin	B-Drug
and	O
allow	O
therapy	O
to	O
continue	O
0	O
<EOS>	O
perinatal	O
vasoconstrictive	O
renal	B-ADR
insufficiency	I-ADR
associated	O
with	O
maternal	O
nimesulide	B-Drug
use	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
adverse	B-ADR
effect	I-ADR
of	I-ADR
fetal	I-ADR
renal	I-ADR
circulation	I-ADR
by	O
maternal	O
ingestion	O
of	O
nimesulide	B-Drug
0	O
<EOS>	O
although	O
the	O
t-aml	B-ADR
developed	O
following	O
oral	O
etoposide	B-Drug
therapy	O
,	O
the	O
child	O
had	O
previously	O
received	O
high-dose	O
,	O
multiagent	O
chemotherapy	O
,	O
and	O
rearrangement	O
of	O
the	O
mll	O
gene	O
wa	O
not	O
demonstrated	O
0	O
<EOS>	O
secondary	B-ADR
leukemia	I-ADR
in	O
a	O
child	O
with	O
neuroblastoma	O
while	O
on	O
oral	O
etoposide	B-Drug
:	O
what	O
is	O
the	O
cause	O
?	O
<EOS>	O
the	O
author	O
present	O
a	O
case	O
of	O
t-aml	B-ADR
that	O
developed	O
in	O
a	O
child	O
with	O
metastatic	O
neuroblastoma	O
18	O
month	O
after	O
he	O
received	O
oral	O
etoposide	B-Drug
,	O
given	O
for	O
palliation	O
purpose	O
0	O
<EOS>	O
background	O
:	O
cyanamide	B-Drug
,	O
an	O
aversive	O
agent	O
widely	O
used	O
in	O
japan	O
,	O
is	O
known	O
to	O
induce	O
various	O
degree	O
of	O
hepatic	B-ADR
lesion	I-ADR
with	I-ADR
ground-glass	I-ADR
inclusion	I-ADR
body	I-ADR
0	O
<EOS>	O
case	O
2	O
:	O
a	O
43-year-old	O
male	O
alcoholic	O
remained	O
completely	O
abstinent	O
with	O
cyanamide	B-Drug
treatment	O
for	O
5	O
year	O
and	O
complained	O
of	O
general	B-ADR
fatigue	I-ADR
0	O
<EOS>	O
case	O
3	O
:	O
a	O
29-year-old	O
female	O
alcoholic	O
complained	O
of	O
general	O
fatigue	B-ADR
and	O
a	O
slight	O
fever	O
after	O
1.5	O
year	O
of	O
abstinence	O
with	O
cyanamide	B-Drug
treatment	O
0	O
<EOS>	O
case	O
3	O
:	O
a	O
29-year-old	O
female	O
alcoholic	O
complained	O
of	O
general	O
fatigue	O
and	O
a	O
slight	O
fever	B-ADR
after	O
1.5	O
year	O
of	O
abstinence	O
with	O
cyanamide	B-Drug
treatment	O
0	O
<EOS>	O
case	O
4	O
:	O
a	O
61-year-old	O
male	O
alcoholic	O
who	O
remained	O
completely	O
abstinent	O
while	O
taking	O
cyanamide	B-Drug
for	O
3	O
year	O
showed	O
slight	O
elevation	B-ADR
of	I-ADR
serum	I-ADR
transaminase	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
in	O
some	O
abstainer	O
who	O
take	O
cyanamide	B-Drug
for	O
several	O
year	O
,	O
thin	O
septum-like	O
liver	O
fibrosis	O
progress	O
along	O
with	O
the	O
emergence	O
of	O
ground-glass	B-ADR
hepatocytes	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
in	O
some	O
abstainer	O
who	O
take	O
cyanamide	B-Drug
for	O
several	O
year	O
,	O
thin	O
septum-like	B-ADR
liver	I-ADR
fibrosis	I-ADR
progress	O
along	O
with	O
the	O
emergence	O
of	O
ground-glass	O
hepatocytes	O
0	O
<EOS>	O
cyanamide-induced	B-Drug
liver	B-ADR
dysfunction	I-ADR
after	O
abstinence	O
in	O
alcoholic	O
:	O
a	O
long-term	O
follow-up	O
study	O
on	O
four	O
case	O
0	O
<EOS>	O
when	O
cyanamide-treated	B-Drug
alcoholic	O
relapse	O
into	O
drinking	O
,	O
more	O
severe	O
inflammation	B-ADR
develops	O
in	O
the	O
liver	O
0	O
<EOS>	O
a	O
patient	O
with	O
an	O
allergy	O
to	O
a	O
macrolide	O
antibiotic	O
wa	O
given	O
tacrolimus	B-Drug
and	O
developed	O
a	O
sudden	B-ADR
cutaneous	I-ADR
reaction	I-ADR
0	O
<EOS>	O
a	O
77-year-old	O
woman	O
with	O
no	O
history	O
of	O
epilepsy	O
presented	O
a	O
probable	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
while	O
receiving	O
continuous	O
intravenous	O
morphine	B-Drug
for	O
back	O
pain	O
relating	O
to	O
vertebral	O
metastasis	O
of	O
a	O
malignant	O
lymphoma	O
0	O
<EOS>	O
a	O
generalized	B-ADR
tonic-clonic	I-ADR
seizure	I-ADR
occurred	O
a	O
few	O
minute	O
after	O
injection	O
of	O
the	O
morphine	O
antagonist	O
naloxone	B-Drug
0	O
<EOS>	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
:	O
the	O
role	O
of	O
morphine	B-Drug
and	O
it	O
antagonist	O
0	O
<EOS>	O
spontaneous	O
bacterial	B-ADR
peritonitis	I-ADR
induced	O
by	O
intraarterial	O
vasopressin	B-Drug
therapy	O
0	O
<EOS>	O
although	O
the	O
literature	O
on	O
the	O
use	O
of	O
risperidone	B-Drug
in	O
elderly	O
patient	O
with	O
dementia	O
consists	O
largely	O
of	O
uncontrolled	O
trial	O
,	O
case	O
report	O
,	O
and	O
chart	O
review	O
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
doe	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	O
symptom	O
(	O
eps	B-ADR
)	O
0	O
<EOS>	O
although	O
the	O
literature	O
on	O
the	O
use	O
of	O
risperidone	B-Drug
in	O
elderly	O
patient	O
with	O
dementia	O
consists	O
largely	O
of	O
uncontrolled	O
trial	O
,	O
case	O
report	O
,	O
and	O
chart	O
review	O
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
doe	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	B-ADR
symptom	I-ADR
(	O
eps	O
)	O
0	O
<EOS>	O
three	O
month	O
following	O
splenectomy	O
,	O
multiple	B-ADR
abscess	I-ADR
occurred	O
in	O
the	O
muscle	O
of	O
both	O
thigh	O
while	O
the	O
patient	O
wa	O
receiving	O
the	O
third	O
course	O
of	O
the	O
chop	B-Drug
regimen	O
0	O
<EOS>	O
after	O
seven	O
month	O
	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	O
and	O
ethambutol	B-Drug
a	O
nine-year-old	O
boy	O
developed	O
polyarthritis	O
,	O
rash	O
and	O
hepatitis	O
in	O
association	O
with	O
anti-native	B-ADR
dna	I-ADR
antibody	I-ADR
and	O
positive	O
antinuclear	O
factor	O
0	O
<EOS>	O
after	O
seven	O
month	O
	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	O
and	O
ethambutol	B-Drug
a	O
nine-year-old	O
boy	O
developed	O
polyarthritis	O
,	O
rash	O
and	O
hepatitis	B-ADR
in	O
association	O
with	O
anti-native	O
dna	O
antibody	O
and	O
positive	O
antinuclear	O
factor	O
0	O
<EOS>	O
after	O
seven	O
month	O
	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	O
and	O
ethambutol	B-Drug
a	O
nine-year-old	O
boy	O
developed	O
polyarthritis	B-ADR
,	O
rash	O
and	O
hepatitis	O
in	O
association	O
with	O
anti-native	O
dna	O
antibody	O
and	O
positive	O
antinuclear	O
factor	O
0	O
<EOS>	O
after	O
seven	O
month	O
	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	O
and	O
ethambutol	B-Drug
a	O
nine-year-old	O
boy	O
developed	O
polyarthritis	O
,	O
rash	B-ADR
and	O
hepatitis	O
in	O
association	O
with	O
anti-native	O
dna	O
antibody	O
and	O
positive	O
antinuclear	O
factor	O
0	O
<EOS>	O
polyarthritis	O
,	O
hepatitis	O
and	O
anti-native	B-ADR
dna	I-ADR
antibody	I-ADR
after	O
treatment	O
with	O
ethambutol	B-Drug
and	O
rifampicin	O
0	O
<EOS>	O
polyarthritis	O
,	O
hepatitis	O
and	O
anti-native	B-ADR
dna	I-ADR
antibody	I-ADR
after	O
treatment	O
with	O
ethambutol	O
and	O
rifampicin	B-Drug
0	O
<EOS>	O
polyarthritis	O
,	O
hepatitis	B-ADR
and	O
anti-native	O
dna	O
antibody	O
after	O
treatment	O
with	O
ethambutol	B-Drug
and	O
rifampicin	O
0	O
<EOS>	O
polyarthritis	O
,	O
hepatitis	B-ADR
and	O
anti-native	O
dna	O
antibody	O
after	O
treatment	O
with	O
ethambutol	O
and	O
rifampicin	B-Drug
0	O
<EOS>	O
polyarthritis	B-ADR
,	O
hepatitis	O
and	O
anti-native	O
dna	O
antibody	O
after	O
treatment	O
with	O
ethambutol	B-Drug
and	O
rifampicin	O
0	O
<EOS>	O
polyarthritis	B-ADR
,	O
hepatitis	O
and	O
anti-native	O
dna	O
antibody	O
after	O
treatment	O
with	O
ethambutol	O
and	O
rifampicin	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
normotensive	B-ADR
scleroderma	I-ADR
renal	I-ADR
crisis	I-ADR
after	O
high-dose	O
methylprednisolone	B-Drug
treatment	O
0	O
<EOS>	O
hus	B-ADR
ha	O
been	O
reported	O
after	O
several	O
anticancer	O
chemotherapy	O
and	O
most	O
often	O
after	O
mitomycin	B-Drug
c-based	I-Drug
chemotherapy	O
regimen	O
0	O
<EOS>	O
severe	B-ADR
hemolytic	I-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-Drug
and	O
gemcitabine	O
0	O
<EOS>	O
severe	B-ADR
hemolytic	I-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	O
and	O
gemcitabine	B-Drug
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hus	B-ADR
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-Drug
and	O
gemcitabine	O
,	O
and	O
described	O
it	O
favorable	O
outcome	O
after	O
chemotherapy	O
interruption	O
and	O
supportive	O
care	O
with	O
a	O
1	O
year	O
follow-up	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hus	B-ADR
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	O
and	O
gemcitabine	B-Drug
,	O
and	O
described	O
it	O
favorable	O
outcome	O
after	O
chemotherapy	O
interruption	O
and	O
supportive	O
care	O
with	O
a	O
1	O
year	O
follow-up	O
0	O
<EOS>	O
an	O
evaluation	O
of	O
ovarian	O
structure	O
and	O
function	O
should	O
be	O
considered	O
in	O
woman	O
of	O
reproductive	O
age	O
being	O
treated	O
with	O
valproate	B-Drug
for	O
epilepsy	O
,	O
especially	O
if	O
they	O
develop	O
menstrual	B-ADR
cycle	I-ADR
disturbance	I-ADR
during	O
treatment	O
0	O
<EOS>	O
background	O
:	O
reproductive	O
endocrine	O
disorder	O
characterized	O
by	O
menstrual	O
disorder	O
,	O
polycystic	O
ovary	O
,	O
and	O
hyperandrogenism	B-ADR
seem	O
to	O
be	O
common	O
among	O
woman	O
treated	O
with	O
sodium	B-Drug
valproate	I-Drug
for	O
epilepsy	O
0	O
<EOS>	O
background	O
:	O
reproductive	O
endocrine	O
disorder	O
characterized	O
by	O
menstrual	B-ADR
disorder	I-ADR
,	O
polycystic	O
ovary	O
,	O
and	O
hyperandrogenism	O
seem	O
to	O
be	O
common	O
among	O
woman	O
treated	O
with	O
sodium	B-Drug
valproate	I-Drug
for	O
epilepsy	O
0	O
<EOS>	O
background	O
:	O
reproductive	O
endocrine	O
disorder	O
characterized	O
by	O
menstrual	O
disorder	O
,	O
polycystic	B-ADR
ovary	I-ADR
,	O
and	O
hyperandrogenism	O
seem	O
to	O
be	O
common	O
among	O
woman	O
treated	O
with	O
sodium	B-Drug
valproate	I-Drug
for	O
epilepsy	O
0	O
<EOS>	O
background	O
:	O
reproductive	B-ADR
endocrine	I-ADR
disorder	I-ADR
characterized	O
by	O
menstrual	O
disorder	O
,	O
polycystic	O
ovary	O
,	O
and	O
hyperandrogenism	O
seem	O
to	O
be	O
common	O
among	O
woman	O
treated	O
with	O
sodium	B-Drug
valproate	I-Drug
for	O
epilepsy	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
3	O
case	O
presented	O
here	O
illustrate	O
the	O
development	O
of	O
reproductive	B-ADR
endocrine	I-ADR
disorder	I-ADR
after	O
the	O
initiation	O
of	O
valproate	B-Drug
therapy	O
in	O
woman	O
with	O
epilepsy	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
the	O
development	O
of	O
valproate-related	B-Drug
reproductive	B-ADR
endocrine	I-ADR
disorder	I-ADR
in	O
woman	O
with	O
epilepsy	O
0	O
<EOS>	O
patient	O
:	O
three	O
patient	O
developed	O
a	O
reproductive	B-ADR
endocrine	I-ADR
disorder	I-ADR
during	O
treatment	O
with	O
valproate	B-Drug
0	O
<EOS>	O
result	O
:	O
replacing	O
valproate	B-Drug
with	O
lamotrigine	O
resulted	O
in	O
a	O
decrease	O
in	O
serum	B-ADR
testosterone	I-ADR
concentration	O
in	O
all	O
3	O
woman	O
0	O
<EOS>	O
the	O
polycystic	O
change	O
disappeared	O
from	O
the	O
ovary	O
in	O
2	O
of	O
the	O
woman	O
after	O
valproate	B-Drug
therapy	O
wa	O
discontinued	O
,	O
and	O
the	O
2	O
woman	O
who	O
had	O
gained	O
weight	O
and	O
developed	O
amenorrhea	B-ADR
while	O
being	O
treated	O
with	O
valproate	O
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
0	O
<EOS>	O
the	O
polycystic	O
change	O
disappeared	O
from	O
the	O
ovary	O
in	O
2	O
of	O
the	O
woman	O
after	O
valproate	B-Drug
therapy	O
wa	O
discontinued	O
,	O
and	O
the	O
2	O
woman	O
who	O
had	O
gained	B-ADR
weight	I-ADR
and	O
developed	O
amenorrhea	O
while	O
being	O
treated	O
with	O
valproate	O
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
0	O
<EOS>	O
the	O
polycystic	B-ADR
change	I-ADR
disappeared	O
from	O
the	O
ovary	O
in	O
2	O
of	O
the	O
woman	O
after	O
valproate	B-Drug
therapy	O
wa	O
discontinued	O
,	O
and	O
the	O
2	O
woman	O
who	O
had	O
gained	O
weight	O
and	O
developed	O
amenorrhea	O
while	O
being	O
treated	O
with	O
valproate	O
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
0	O
<EOS>	O
however	O
,	O
recurrent	O
staphylococcus	B-ADR
aureus	I-ADR
sepsis	I-ADR
developed	O
during	O
cya	B-Drug
therapy	O
0	O
<EOS>	O
recurrent	O
septicemia	O
with	O
lethal	B-ADR
outcome	O
during	O
and	O
after	O
cyclosporine	B-Drug
therapy	O
in	O
severe	O
ulcerative	O
colitis	O
0	O
<EOS>	O
recurrent	O
septicemia	B-ADR
with	O
lethal	O
outcome	O
during	O
and	O
after	O
cyclosporine	B-Drug
therapy	O
in	O
severe	O
ulcerative	O
colitis	O
0	O
<EOS>	O
a	O
60	O
year-old	O
woman	O
with	O
chronic	O
renal	O
failure	O
developed	O
acute	O
proximal	B-ADR
muscle	I-ADR
weakness	I-ADR
after	O
receiving	O
a	O
regular	O
dosage	O
of	O
colchicine	B-Drug
0	O
<EOS>	O
colchicine-induced	B-Drug
myopathy	B-ADR
in	O
renal	O
failure	O
0	O
<EOS>	O
muscle	O
biopsy	O
revealed	O
variation	O
in	O
muscle	O
fiber	O
size	O
and	O
few	O
vacuolated	O
fiber	O
which	O
were	O
feature	O
of	O
colchicine-induced	B-Drug
myopathy	B-ADR
0	O
<EOS>	O
muscle	O
biopsy	O
revealed	O
variation	O
in	O
muscle	O
fiber	O
size	O
and	O
few	O
vacuolated	B-ADR
fiber	I-ADR
which	O
were	O
feature	O
of	O
colchicine-induced	B-Drug
myopathy	O
0	O
<EOS>	O
muscle	O
biopsy	O
revealed	O
variation	B-ADR
in	I-ADR
muscle	I-ADR
fiber	I-ADR
size	I-ADR
and	O
few	O
vacuolated	O
fiber	O
which	O
were	O
feature	O
of	O
colchicine-induced	B-Drug
myopathy	O
0	O
<EOS>	O
a	O
third	O
patient	O
experienced	O
disabling	B-ADR
neurotoxicity	I-ADR
in	O
the	O
extremity	O
of	O
a	O
prior	O
ulnar	O
nerve	O
and	O
tendon	O
transposition	O
after	O
receiving	O
paclitaxel	B-Drug
0	O
<EOS>	O
phantom	O
limb	O
pain	O
a	O
a	O
manifestation	O
of	O
paclitaxel	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
phantom	B-ADR
limb	I-ADR
pain	I-ADR
a	O
a	O
manifestation	O
of	O
paclitaxel	B-Drug
neurotoxicity	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
that	O
plp	B-ADR
can	O
occur	O
after	O
initiation	O
of	O
paclitaxel	B-Drug
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
prior	O
amputation	O
who	O
experienced	O
phantom	B-ADR
limb	I-ADR
pain	I-ADR
(	O
plp	O
)	O
after	O
receiving	O
paclitaxel	B-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
prior	O
amputation	O
who	O
experienced	O
phantom	O
limb	O
pain	O
(	O
plp	B-ADR
)	O
after	O
receiving	O
paclitaxel	B-Drug
therapy	O
0	O
<EOS>	O
skin	O
manifestation	O
of	O
a	O
case	O
of	O
phenylbutazone-induced	B-Drug
serum	B-ADR
sickness-like	I-ADR
reaction	I-ADR
0	O
<EOS>	O
skin	B-ADR
manifestation	I-ADR
of	O
a	O
case	O
of	O
phenylbutazone-induced	B-Drug
serum	O
sickness-like	O
reaction	O
0	O
<EOS>	O
our	O
experience	O
support	O
hemodialysis	O
for	O
esrf	O
patient	O
with	O
atenolol	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
allergic	O
reaction	O
to	O
gemfibrozil	B-Drug
manifesting	O
a	O
eosinophilic	B-ADR
gastroenteritis	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
ege	B-ADR
manifested	O
a	O
an	O
allergy	O
to	O
gemfibrozil	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
second	O
report	O
of	O
lactic	B-ADR
acidosis	I-ADR
in	O
a	O
patient	O
on	O
stavudine	O
and	O
lamivudine	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
second	O
report	O
of	O
lactic	B-ADR
acidosis	I-ADR
in	O
a	O
patient	O
on	O
stavudine	B-Drug
and	O
lamivudine	O
0	O
<EOS>	O
we	O
present	O
an	O
aid	O
patient	O
with	O
severe	O
and	O
prolonged	O
lactic	B-ADR
acidosis	I-ADR
on	O
stavudine	O
and	O
lamivudine	B-Drug
0	O
<EOS>	O
we	O
present	O
an	O
aid	O
patient	O
with	O
severe	O
and	O
prolonged	O
lactic	B-ADR
acidosis	I-ADR
on	O
stavudine	B-Drug
and	O
lamivudine	O
0	O
<EOS>	O
ataxia	B-ADR
caused	O
by	O
propafenone	B-Drug
ha	O
been	O
reported	O
to	O
the	O
pharmaceutical	O
company	O
and	O
drug	O
monitoring	O
agency	O
,	O
but	O
ha	O
not	O
been	O
well	O
described	O
or	O
emphasized	O
in	O
the	O
medical	O
literature	O
0	O
<EOS>	O
a	O
wide	O
variety	O
of	O
adverse	B-ADR
central	I-ADR
nervous	I-ADR
system	I-ADR
effect	I-ADR
have	O
been	O
reported	O
in	O
association	O
with	O
propafenone	B-Drug
;	O
dizziness	O
is	O
the	O
most	O
common	O
0	O
<EOS>	O
a	O
wide	O
variety	O
of	O
adverse	O
central	O
nervous	O
system	O
effect	O
have	O
been	O
reported	O
in	O
association	O
with	O
propafenone	B-Drug
;	O
dizziness	B-ADR
is	O
the	O
most	O
common	O
0	O
<EOS>	O
propafenone-induced	B-Drug
ataxia	B-ADR
:	O
report	O
of	O
three	O
case	O
0	O
<EOS>	O
we	O
describe	O
3	O
elderly	O
patient	O
with	O
moderate	O
to	O
severe	O
ataxia	B-ADR
that	O
occurred	O
while	O
they	O
were	O
taking	O
propafenone	B-Drug
0	O
<EOS>	O
a	O
74-year-old	O
man	O
received	O
oral	O
administration	O
of	O
pilsicainide	B-Drug
,	O
a	O
pure	O
sodium	O
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
paroxysmal	O
atrial	O
fibrillation	O
to	O
sinus	O
rhythm	O
and	O
developed	O
loss	B-ADR
of	I-ADR
consciousness	I-ADR
two	O
day	O
later	O
0	O
<EOS>	O
when	O
pilsicainide	B-Drug
is	O
prescribed	O
in	O
patient	O
with	O
coronary	O
artery	O
disease	O
or	O
renal	O
dysfunction	O
,	O
close	O
attention	O
must	O
be	O
paid	O
to	O
avoid	O
life-threatening	B-ADR
arrhythmia	I-ADR
due	O
to	O
high	O
plasma	O
concentration	O
of	O
the	O
drug	O
0	O
<EOS>	O
the	O
case	O
are	O
important	O
in	O
documenting	O
that	O
drug-induced	O
dystonias	O
do	O
occur	O
in	O
patient	O
with	O
dementia	O
,	O
that	O
risperidone	B-Drug
appears	O
to	O
have	O
contributed	O
to	O
dystonia	B-ADR
among	O
elderly	O
patient	O
,	O
and	O
that	O
the	O
categorization	O
of	O
dystonic	O
reaction	O
need	O
further	O
clarification	O
0	O
<EOS>	O
provocation	O
of	O
non-convulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
by	O
tiagabine	B-Drug
in	O
three	O
adolescent	O
patient	O
0	O
<EOS>	O
the	O
event	O
of	O
non-convulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
subsided	O
following	O
reduction	O
in	O
tiagabine	B-Drug
dosage	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
non-convulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
provoked	O
by	O
tiagabine	B-Drug
in	O
adolescent	O
patient	O
0	O
<EOS>	O
there	O
have	O
been	O
many	O
report	O
of	O
probable	O
lithium-induced	B-Drug
organic	B-ADR
brain	I-ADR
syndrome	I-ADR
occurring	O
when	O
serum	O
lithium	O
level	O
are	O
within	O
or	O
close	O
to	O
the	O
therapeutic	O
range	O
0	O
<EOS>	O
when	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	O
symptom	O
and	O
intense	B-ADR
anxiety	I-ADR
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-Drug
neurotoxicity	O
0	O
<EOS>	O
when	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	O
symptom	O
and	O
intense	O
anxiety	O
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
when	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	B-ADR
symptom	I-ADR
and	O
intense	O
anxiety	O
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-Drug
neurotoxicity	O
0	O
<EOS>	O
protease	O
inhibitor-induced	O
carbamazepine	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	O
and	O
saquinavir	O
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	B-Drug
and	O
saquinavir	O
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	O
and	O
saquinavir	B-Drug
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	O
and	O
saquinavir	O
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADR
ataxia	I-ADR
related	O
to	O
carbamazepine	B-Drug
toxicity	O
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	B-Drug
and	O
saquinavir	O
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADR
ataxia	I-ADR
related	O
to	O
carbamazepine	O
toxicity	O
0	O
<EOS>	O
protease	O
inhibitor	O
(	O
ritonavir	O
and	O
saquinavir	B-Drug
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADR
ataxia	I-ADR
related	O
to	O
carbamazepine	O
toxicity	O
0	O
<EOS>	O
ritonavir	B-Drug
acted	O
a	O
a	O
cyp3a4	O
inhibitor	O
,	O
diminishing	O
carbamazepine	O
metabolism	O
and	O
provoking	O
an	O
increase	O
in	O
serum	O
level	O
and	O
clinical	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
ritonavir	B-Drug
acted	O
a	O
a	O
cyp3a4	O
inhibitor	O
,	O
diminishing	B-ADR
carbamazepine	I-ADR
metabolism	I-ADR
and	O
provoking	O
an	O
increase	O
in	O
serum	O
level	O
and	O
clinical	O
toxicity	O
0	O
<EOS>	O
ritonavir	B-Drug
acted	O
a	O
a	O
cyp3a4	O
inhibitor	O
,	O
diminishing	O
carbamazepine	O
metabolism	O
and	O
provoking	O
an	O
increase	B-ADR
in	I-ADR
serum	I-ADR
level	I-ADR
and	O
clinical	O
toxicity	O
0	O
<EOS>	O
the	O
patient	O
wa	O
diagnosed	O
with	O
carbamazepine	B-Drug
toxicity	I-ADR
related	O
to	O
the	O
introduction	O
of	O
ritonavir	O
0	O
<EOS>	O
the	O
patient	O
wa	O
diagnosed	O
with	O
carbamazepine	B-ADR
toxicity	I-ADR
related	O
to	O
the	O
introduction	O
of	O
ritonavir	B-Drug
0	O
<EOS>	O
anaphylaxis	B-ADR
to	O
calcitonin	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
we	O
have	O
introduced	O
a	O
case	O
of	O
anaphylaxis	B-ADR
by	O
calcitonin	B-Drug
that	O
suggest	O
an	O
ige	O
mediated	O
hypersensitivity	O
reaction	O
0	O
<EOS>	O
the	O
intramuscular	O
challenge	O
test	O
with	O
25	O
ui	O
of	O
miacalcic	B-Drug
wa	O
positive	O
with	O
an	O
immediate	O
anaphylactic	B-ADR
reaction	I-ADR
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	O
,	O
conjunctivitis	B-ADR
and	O
perspiration	O
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-Drug
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	O
)	O
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	O
,	O
conjunctivitis	B-ADR
and	O
perspiration	O
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	O
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	B-Drug
)	O
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	O
,	O
conjunctivitis	O
and	O
perspiration	B-ADR
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-Drug
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	O
)	O
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	O
,	O
conjunctivitis	O
and	O
perspiration	B-ADR
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	O
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	B-Drug
)	O
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	B-ADR
,	O
conjunctivitis	O
and	O
perspiration	O
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-Drug
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	O
)	O
0	O
<EOS>	O
we	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
year	O
old	O
woman	O
with	O
several	O
previous	O
episode	O
of	O
rhinitis	B-ADR
,	O
conjunctivitis	O
and	O
perspiration	O
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	O
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
calsynar	B-Drug
)	O
0	O
<EOS>	O
minocycline	B-Drug
a	O
a	O
cause	O
of	O
drug-induced	O
autoimmune	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
minocycline-induced	B-Drug
autoimmune	B-ADR
hepatitis	I-ADR
is	O
usually	O
identical	O
to	O
sporadic	O
autoimmune	O
hepatitis	O
0	O
<EOS>	O
we	O
describe	O
the	O
clinical	O
and	O
liver	O
biopsy	O
morphologic	O
feature	O
for	O
4	O
patient	O
with	O
minocycline-induced	B-Drug
autoimmune	B-ADR
hepatitis	I-ADR
(	O
group	O
1	O
)	O
0	O
<EOS>	O
l-asparaginase-provoked	B-Drug
seizure	O
a	O
singular	O
expression	O
of	O
central	B-ADR
nervous	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
l-asparaginase-provoked	B-Drug
seizure	B-ADR
a	O
singular	O
expression	O
of	O
central	O
nervous	O
toxicity	O
0	O
<EOS>	O
patient	O
treated	O
with	O
l-asparaginase	B-Drug
may	O
present	O
with	O
hemorrhagic	B-ADR
and	O
thrombotic	O
cerebrovascular	O
event	O
0	O
<EOS>	O
patient	O
treated	O
with	O
l-asparaginase	B-Drug
may	O
present	O
with	O
hemorrhagic	O
and	O
thrombotic	B-ADR
cerebrovascular	I-ADR
event	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
seizure	B-ADR
associated	O
with	O
l-asparaginase	B-Drug
therapy	O
but	O
no	O
evidence	O
of	O
hemorrhagic	O
or	O
thrombotic	O
cerebrovascular	O
event	O
0	O
<EOS>	O
eighty-two	O
patient	O
with	O
various	O
malignancy	O
who	O
received	O
imipenem	O
/	O
cilastatin	B-Drug
143	O
time	O
for	O
neutropenic	B-ADR
fever	I-ADR
between	O
march	O
1994	O
and	O
october	O
1999	O
in	O
department	O
of	O
pediatric	O
oncology	O
,	O
gazi	O
university	O
,	O
were	O
identified	O
0	O
<EOS>	O
eighty-two	O
patient	O
with	O
various	O
malignancy	O
who	O
received	O
imipenem	B-Drug
/	O
cilastatin	O
143	O
time	O
for	O
neutropenic	B-ADR
fever	I-ADR
between	O
march	O
1994	O
and	O
october	O
1999	O
in	O
department	O
of	O
pediatric	O
oncology	O
,	O
gazi	O
university	O
,	O
were	O
identified	O
0	O
<EOS>	O
incidence	O
of	O
seizure	B-ADR
in	O
pediatric	O
cancer	O
patient	O
treated	O
with	O
imipenem	O
/	O
cilastatin	B-Drug
0	O
<EOS>	O
incidence	O
of	O
seizure	B-ADR
in	O
pediatric	O
cancer	O
patient	O
treated	O
with	O
imipenem	B-Drug
/	O
cilastatin	O
0	O
<EOS>	O
proconvulsive	B-ADR
tendency	O
of	O
imipenem	O
/	O
cilastatin	B-Drug
is	O
one	O
of	O
it	O
well-known	O
side	O
effect	O
0	O
<EOS>	O
proconvulsive	B-ADR
tendency	O
of	O
imipenem	B-Drug
/	O
cilastatin	O
is	O
one	O
of	O
it	O
well-known	O
side	O
effect	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	B-ADR
attributed	O
to	O
imipenem	O
/	O
cilastatin	B-Drug
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	O
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	B-ADR
attributed	O
to	O
imipenem	B-Drug
/	O
cilastatin	O
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	O
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	O
attributed	O
to	O
imipenem	O
/	O
cilastatin	B-Drug
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	B-ADR
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	O
attributed	O
to	O
imipenem	B-Drug
/	O
cilastatin	O
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	B-ADR
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	O
attributed	O
to	O
imipenem	O
/	O
cilastatin	B-Drug
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	B-ADR
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
three	O
of	O
these	O
patient	O
had	O
convulsion	O
attributed	O
to	O
imipenem	B-Drug
/	O
cilastatin	O
;	O
3.6	O
%	O
of	O
the	O
patient	O
had	O
seizure	B-ADR
,	O
or	O
2	O
%	O
of	O
imipenem	O
/	O
cilastatin	O
administration	O
wa	O
followed	O
by	O
a	O
seizure	O
attack	O
0	O
<EOS>	O
gabapentin-induced	B-Drug
mood	O
change	O
with	O
hypomanic	B-ADR
feature	O
in	O
adult	O
0	O
<EOS>	O
gabapentin-induced	B-Drug
mood	B-ADR
change	I-ADR
with	O
hypomanic	O
feature	O
in	O
adult	O
0	O
<EOS>	O
we	O
report	O
two	O
adult	O
who	O
received	O
gabapentin	B-Drug
(	O
gbp	O
)	O
and	O
subsequently	O
developed	O
behavioural	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
we	O
report	O
two	O
adult	O
who	O
received	O
gabapentin	O
(	O
gbp	B-Drug
)	O
and	O
subsequently	O
developed	O
behavioural	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
acute	B-ADR
pancreatitis	I-ADR
in	O
a	O
child	O
with	O
idiopathic	O
ulcerative	O
colitis	O
on	O
long-term	O
5-aminosalicylic	B-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
a	O
10-year-old	O
boy	O
with	O
ulcerative	O
colitis	O
who	O
developed	O
acute	B-ADR
pancreatitis	I-ADR
while	O
on	O
long-term	O
treatment	O
with	O
5-aminosalicylic	B-Drug
acid	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
marked	O
visual	B-ADR
field	I-ADR
constriction	I-ADR
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	B-Drug
therapy	O
0	O
<EOS>	O
electro-oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potential	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patient	O
with	O
vigabatrin-attributed	B-Drug
visual	B-ADR
field	I-ADR
constriction	I-ADR
0	O
<EOS>	O
purpose	O
:	O
symptomatic	O
visual	B-ADR
field	I-ADR
constriction	I-ADR
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	B-Drug
ha	O
been	O
reported	O
0	O
<EOS>	O
the	O
current	O
study	O
investigated	O
the	O
visual	O
field	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patient	O
with	O
known	O
vigabatrin-attributed	B-Drug
visual	B-ADR
field	I-ADR
loss	I-ADR
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
0	O
<EOS>	O
the	O
field	B-ADR
defect	I-ADR
and	O
some	O
electrophysiological	O
abnormality	O
persist	O
when	O
vigabatrin	B-Drug
therapy	O
is	O
withdrawn	O
0	O
<EOS>	O
depressive	B-ADR
symptom	I-ADR
disappeared	O
after	O
interferon	B-Drug
therapy	O
wa	O
stopped	O
0	O
<EOS>	O
treatment	O
of	O
chronic	O
hepatitis	O
c	O
with	O
interferon	O
alpha	O
(	O
ifn-alpha	B-Drug
)	O
is	O
relatively	O
contraindicated	O
in	O
patient	O
with	O
psychiatric	O
disorder	O
because	O
of	O
possible	O
severe	O
psychiatric	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
treatment	O
of	O
chronic	O
hepatitis	O
c	O
with	O
interferon	B-Drug
alpha	I-Drug
(	O
ifn-alpha	O
)	O
is	O
relatively	O
contraindicated	O
in	O
patient	O
with	O
psychiatric	O
disorder	O
because	O
of	O
possible	O
severe	O
psychiatric	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
while	O
for	O
ribavirin	O
antidepressant	O
effect	O
are	O
not	O
known	O
,	O
we	O
suppose	O
that	O
antidepressant	O
may	O
prevent	O
change	B-ADR
in	I-ADR
serotonergic	I-ADR
or	I-ADR
noradrenergic	I-ADR
neurotransmission	I-ADR
caused	O
by	O
ifn-alpha	B-Drug
0	O
<EOS>	O
intensive	O
high-flux	O
hemodiafiltration	O
is	O
often	O
used	O
in	O
the	O
management	O
of	O
vancomycin	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
management	O
of	O
hypophosphatemia	O
induced	O
by	O
high-flux	O
hemodiafiltration	O
for	O
the	O
treatment	O
of	O
vancomycin	B-Drug
toxicity	I-ADR
:	O
intravenous	O
phosphorus	O
therapy	O
versus	O
use	O
of	O
a	O
phosphorus-enriched	O
dialysate	O
0	O
<EOS>	O
we	O
describe	O
2	O
child	O
with	O
cerebral	O
palsy	O
who	O
suffered	O
significant	O
morbidity	B-ADR
immediately	O
after	O
treatment	O
with	O
hyperbaric	B-Drug
oxygen	I-Drug
0	O
<EOS>	O
a	O
33-year-old	O
male	O
presented	O
with	O
brown	B-ADR
discolouration	I-ADR
of	I-ADR
the	I-ADR
fingernail	I-ADR
following	O
the	O
application	O
of	O
4	O
%	O
hydroquinone	O
in	O
sorbolene	O
cream	O
and	O
0.1	B-Drug
%	I-Drug
tretinoin	I-Drug
cream	I-Drug
to	O
the	O
face	O
intermittently	O
for	O
9	O
month	O
0	O
<EOS>	O
a	O
33-year-old	O
male	O
presented	O
with	O
brown	B-ADR
discolouration	I-ADR
of	I-ADR
the	I-ADR
fingernail	I-ADR
following	O
the	O
application	O
of	O
4	B-Drug
%	I-Drug
hydroquinone	I-Drug
in	I-Drug
sorbolene	I-Drug
cream	I-Drug
and	O
0.1	O
%	O
tretinoin	O
cream	O
to	O
the	O
face	O
intermittently	O
for	O
9	O
month	O
0	O
<EOS>	O
nail	B-ADR
staining	I-ADR
from	O
hydroquinone	B-Drug
cream	O
0	O
<EOS>	O
gangrene	B-ADR
of	O
the	O
fingertip	O
after	O
bleomycin	B-Drug
and	O
methotrexate	O
0	O
<EOS>	O
gangrene	B-ADR
of	O
the	O
fingertip	O
after	O
bleomycin	O
and	O
methotrexate	B-Drug
0	O
<EOS>	O
this	O
support	O
the	O
well-reported	O
potential	O
of	O
bleomycin	B-Drug
to	O
trigger	O
acral	B-ADR
vascular	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
57-year-old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADR
digital	I-ADR
ischemia	I-ADR
and	O
gangrene	O
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-Drug
and	O
methotrexate	O
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
0	O
<EOS>	O
we	O
describe	O
a	O
57-year-old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADR
digital	I-ADR
ischemia	I-ADR
and	O
gangrene	O
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	O
and	O
methotrexate	B-Drug
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
0	O
<EOS>	O
we	O
describe	O
a	O
57-year-old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	O
digital	O
ischemia	O
and	O
gangrene	B-ADR
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-Drug
and	O
methotrexate	O
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
0	O
<EOS>	O
we	O
describe	O
a	O
57-year-old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	O
digital	O
ischemia	O
and	O
gangrene	B-ADR
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	O
and	O
methotrexate	B-Drug
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
0	O
<EOS>	O
diarrhea-associated	B-ADR
over-anticoagulation	I-ADR
in	O
a	O
patient	O
taking	O
warfarin	B-Drug
:	O
therapeutic	O
role	O
of	O
cholestyramine	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
significant	O
over-anticoagulation	O
temporally	O
associated	O
with	O
a	O
bout	O
of	O
protracted	O
diarrhea	B-ADR
in	O
a	O
patient	O
on	O
warfarin	B-Drug
therapy	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
significant	O
over-anticoagulation	B-ADR
temporally	O
associated	O
with	O
a	O
bout	O
of	O
protracted	O
diarrhea	O
in	O
a	O
patient	O
on	O
warfarin	B-Drug
therapy	O
0	O
<EOS>	O
mi	B-ADR
related	O
to	O
the	O
use	O
of	O
activated	O
and	O
non-activated	O
pccs	B-Drug
predominantly	O
affect	O
young	O
patient	O
who	O
often	O
have	O
no	O
preceding	O
history	O
of	O
,	O
or	O
risk	O
factor	O
for	O
,	O
mi	O
and	O
tends	O
to	O
be	O
associated	O
with	O
large	O
cumulative	O
dos	O
of	O
concentrate	O
0	O
<EOS>	O
recombinant	O
viia	O
concentrate	O
in	O
the	O
management	O
of	O
bleeding	O
following	O
prothrombin	B-Drug
complex	I-Drug
concentrate-related	I-Drug
myocardial	B-ADR
infarction	I-ADR
in	O
patient	O
with	O
haemophilia	O
and	O
inhibitor	O
0	O
<EOS>	O
we	O
have	O
safely	O
used	O
recombinant	O
factor	O
viia	O
to	O
treat	O
bleeding	O
in	O
the	O
immediate	O
and	O
long-term	O
period	O
following	O
pcc-related	B-Drug
mi	B-ADR
0	O
<EOS>	O
even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADR
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine-induced	B-Drug
thrombocytopenia	O
0	O
<EOS>	O
even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADR
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine-induced	B-Drug
thrombocytopenia	O
0	O
<EOS>	O
even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADR
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine-induced	B-Drug
thrombocytopenia	O
0	O
<EOS>	O
occult	O
quinine-induced	B-Drug
thrombocytopenia	B-ADR
0	O
<EOS>	O
only	O
after	O
three	O
subsequent	O
episode	O
of	O
severe	O
,	O
symptomatic	O
thrombocytopenia	B-ADR
over	O
the	O
next	O
four	O
week	O
did	O
he	O
say	O
,	O
upon	O
repeat	O
questioning	O
,	O
that	O
he	O
had	O
continued	O
to	O
take	O
quinine	B-Drug
for	O
night	O
leg	O
cramp	O
0	O
<EOS>	O
an	O
8-year-old	O
child	O
with	O
familial	O
mediterranean	O
fever	O
exhibited	O
sign	O
of	O
colchicine	B-Drug
intoxication	I-ADR
while	O
receiving	O
prophylactic	O
dos	O
of	O
the	O
drug	O
0	O
<EOS>	O
conclusion	O
:	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
colchicine	B-Drug
intoxication	I-ADR
in	O
this	O
age	O
group	O
ha	O
been	O
described	O
in	O
the	O
english	O
literature	O
0	O
<EOS>	O
near	O
fatal	O
acute	O
colchicine	B-Drug
intoxication	I-ADR
in	O
a	O
child	O
0	O
<EOS>	O
near	B-ADR
fatal	I-ADR
acute	O
colchicine	B-Drug
intoxication	O
in	O
a	O
child	O
0	O
<EOS>	O
acute	B-ADR
myeloid	I-ADR
leukemia	I-ADR
and	O
lung	O
cancer	O
occurring	O
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
fludarabine	B-Drug
and	O
autologous	O
peripheral	O
blood	O
stem-cell	O
transplantation	O
0	O
<EOS>	O
acute	O
myeloid	O
leukemia	O
and	O
lung	B-ADR
cancer	I-ADR
occurring	O
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
fludarabine	B-Drug
and	O
autologous	O
peripheral	O
blood	O
stem-cell	O
transplantation	O
0	O
<EOS>	O
we	O
describe	O
the	O
exceptional	O
development	O
of	O
aml	B-ADR
and	O
lung	O
cancer	O
in	O
a	O
patient	O
with	O
previously	O
diagnosed	O
cll	O
in	O
minimal	O
residual	O
disease	O
status	O
after	O
fludarabine	B-Drug
treatment	O
followed	O
by	O
autologous	O
peripheral	O
blood	O
stem-cell	O
transplantation	O
0	O
<EOS>	O
we	O
describe	O
the	O
exceptional	O
development	O
of	O
aml	O
and	O
lung	B-ADR
cancer	I-ADR
in	O
a	O
patient	O
with	O
previously	O
diagnosed	O
cll	O
in	O
minimal	O
residual	O
disease	O
status	O
after	O
fludarabine	B-Drug
treatment	O
followed	O
by	O
autologous	O
peripheral	O
blood	O
stem-cell	O
transplantation	O
0	O
<EOS>	O
in	O
2	O
of	O
the	O
3	O
case	O
the	O
patient	O
were	O
also	O
taking	O
lithium	B-Drug
carbonate	I-Drug
and	O
beta-blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-ADR
0	O
<EOS>	O
in	O
the	O
present	O
paper	O
the	O
author	O
describe	O
2	O
female	O
patient	O
who	O
developed	O
incontinence	B-ADR
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
paroxetine	B-Drug
and	O
sertraline	O
,	O
a	O
well	O
a	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
0	O
<EOS>	O
in	O
the	O
present	O
paper	O
the	O
author	O
describe	O
2	O
female	O
patient	O
who	O
developed	O
incontinence	B-ADR
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
paroxetine	O
and	O
sertraline	B-Drug
,	O
a	O
well	O
a	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
0	O
<EOS>	O
in	O
the	O
present	O
paper	O
the	O
author	O
describe	O
2	O
female	O
patient	O
who	O
developed	O
incontinence	B-ADR
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
paroxetine	O
and	O
sertraline	O
,	O
a	O
well	O
a	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-Drug
0	O
<EOS>	O
this	O
concern	O
2	O
male	O
patient	O
who	O
experienced	O
incontinence	B-ADR
while	O
taking	O
venlafaxine	B-Drug
0	O
<EOS>	O
case	O
study	O
in	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
0	O
<EOS>	O
major	O
point	O
illustrated	O
are	O
,	O
(	O
1	O
)	O
occurrence	O
of	O
hit	B-ADR
with	O
any	O
dose	O
or	O
form	O
of	O
heparin	B-Drug
;	O
(	O
2	O
)	O
misperceptions	O
on	O
the	O
diagnostic	O
criterion	O
;	O
(	O
3	O
)	O
correct	O
(	O
thrombin	O
inhibitor	O
)	O
and	O
incorrect	O
(	O
platelet	O
transfusion	O
and	O
warfarin	O
)	O
management	O
;	O
(	O
4	O
)	O
influence	O
of	O
management	O
strategy	O
on	O
clinical	O
outcome	O
;	O
(	O
5	O
)	O
severity	O
of	O
the	O
syndrome	O
;	O
and	O
(	O
6	O
)	O
potential	O
for	O
both	O
anamnestic	O
response	O
to	O
heparin	O
and	O
disappearance	O
of	O
hit	O
antibody	O
over	O
time	O
0	O
<EOS>	O
type	O
ii	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
(	O
hit	O
)	O
is	O
an	O
immunological	O
disorder	O
characterized	O
by	O
antibody	O
to	O
heparin-platelet	O
factor	O
4	O
complex	O
and	O
a	O
high	O
risk	O
of	O
thrombotic	O
complication	O
0	O
<EOS>	O
after	O
several	O
unrevealing	O
medical	O
work-ups	O
,	O
he	O
wa	O
found	O
to	O
have	O
a	O
high	B-ADR
blood	I-ADR
lead	B-Drug
level	I-ADR
(	O
122	O
microg	O
/	O
dl	O
)	O
;	O
he	O
ha	O
a	O
history	O
of	O
scraping	O
and	O
sanding	O
lead	O
paint	O
without	O
adequate	O
protective	O
measure	O
0	O
<EOS>	O
it	O
also	O
highlight	O
a	O
current	O
major	O
etiologic	O
question	O
,	O
that	O
is	O
,	O
whether	O
and	O
to	O
what	O
degree	O
lead	O
exposure	O
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-ADR
,	O
and	O
raise	O
the	O
issue	O
of	O
whether	O
lead-induced	B-Drug
hypertension	O
constitutes	O
a	O
subset	O
of	O
hypertension	O
that	O
is	O
especially	O
amenable	O
to	O
therapy	O
with	O
dietary	O
calcium	O
0	O
<EOS>	O
it	O
also	O
highlight	O
a	O
current	O
major	O
etiologic	O
question	O
,	O
that	O
is	O
,	O
whether	O
and	O
to	O
what	O
degree	O
lead	O
exposure	O
contributes	O
to	O
the	O
development	O
of	O
hypertension	O
,	O
and	O
raise	O
the	O
issue	O
of	O
whether	O
lead-induced	B-Drug
hypertension	I-ADR
constitutes	O
a	O
subset	O
of	O
hypertension	O
that	O
is	O
especially	O
amenable	O
to	O
therapy	O
with	O
dietary	O
calcium	O
0	O
<EOS>	O
poorly	O
controlled	O
hypertension	O
in	O
a	O
painter	O
with	O
chronic	O
lead	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
this	O
case	O
demonstrates	O
an	O
occupational	O
activity	O
(	O
construction	O
)	O
that	O
ha	O
now	O
become	O
the	O
dominant	O
source	O
of	O
lead	B-Drug
exposure	O
for	O
u.s.	O
adult	O
,	O
the	O
importance	O
of	O
a	O
good	O
occupational	O
history	O
to	O
suspecting	O
and	O
making	O
a	O
diagnosis	O
,	O
the	O
possible	O
outcome	O
of	O
chronic	O
lead	B-ADR
toxicity	I-ADR
,	O
and	O
the	O
importance	O
of	O
preventing	O
further	O
exposure	O
and	O
using	O
proper	O
method	O
to	O
treat	O
acute	O
toxicity	O
0	O
<EOS>	O
severe	B-ADR
rash	I-ADR
,	O
including	O
the	O
stevens-johnson	O
syndrome	O
(	O
sjs	O
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-Drug
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
0	O
<EOS>	O
severe	O
rash	O
,	O
including	O
the	O
stevens-johnson	O
syndrome	O
(	O
sjs	B-ADR
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-Drug
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
0	O
<EOS>	O
severe	O
rash	O
,	O
including	O
the	O
stevens-johnson	B-ADR
syndrome	I-ADR
(	O
sjs	O
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-Drug
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
0	O
<EOS>	O
stevens-johnson	B-ADR
syndrome	I-ADR
caused	O
by	O
the	O
antiretroviral	O
drug	O
nevirapine	B-Drug
0	O
<EOS>	O
though	O
physician	O
treating	O
large	O
population	O
of	O
patient	O
with	O
hiv	O
are	O
well	O
aware	O
of	O
this	O
complication	O
,	O
only	O
one	O
other	O
report	O
of	O
nevirapine-associated	B-Drug
sjs	B-ADR
ha	O
been	O
documented	O
in	O
the	O
dermatology	O
literature	O
0	O
<EOS>	O
we	O
describe	O
2	O
case	O
of	O
sjs	B-ADR
related	O
to	O
nevirapine	B-Drug
use	O
and	O
review	O
the	O
literature	O
on	O
this	O
newly	O
recognized	O
association	O
0	O
<EOS>	O
oral	O
intake	O
and	O
acarbose	B-Drug
were	O
withheld	O
and	O
the	O
ileus	B-ADR
spontaneously	O
resolved	O
after	O
2	O
day	O
0	O
<EOS>	O
there	O
is	O
evidence	O
that	O
the	O
angiotensin	O
ii	O
receptor	O
antagonist	O
,	O
losartan	B-Drug
,	O
increase	B-ADR
urate	I-ADR
excretion	I-ADR
by	O
reducing	O
reabsorption	O
of	O
urate	O
in	O
the	O
renal	O
proximal	O
tubule	O
0	O
<EOS>	O
atrial	B-ADR
fibrillation	I-ADR
occurring	O
in	O
a	O
patient	O
taking	O
etanercept	B-Drug
plus	O
methotrexate	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
atrial	B-ADR
fibrillation	I-ADR
occurring	O
in	O
a	O
patient	O
taking	O
etanercept	O
plus	O
methotrexate	B-Drug
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
review	O
of	O
the	O
literature	O
revealed	O
two	O
other	O
case	O
of	O
hepatic	B-ADR
angiosarcoma	I-ADR
in	O
patient	O
after	O
long-term	O
cyclophosphamide	B-Drug
treatment	O
0	O
<EOS>	O
hepatic	B-ADR
angiosarcoma	I-ADR
occurring	O
after	O
cyclophosphamide	B-Drug
therapy	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
propose	O
that	O
cyclophosphamide	B-Drug
be	O
added	O
to	O
the	O
list	O
of	O
exposure	O
potentially	O
associated	O
with	O
hepatic	B-ADR
angiosarcoma	I-ADR
0	O
<EOS>	O
ara-c	B-Drug
is	O
frequently	O
associated	O
with	O
dermatologic	B-ADR
toxicity	I-ADR
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	O
epidermal	O
necrolysis	O
described	O
in	O
connection	O
with	O
this	O
drug	O
0	O
<EOS>	O
ara-c	B-Drug
is	O
frequently	O
associated	O
with	O
dermatologic	O
toxicity	O
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
described	O
in	O
connection	O
with	O
this	O
drug	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ara-c	B-Drug
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hour	O
)	O
,	O
she	O
developed	O
bullous	B-ADR
lesion	I-ADR
on	I-ADR
the	I-ADR
hand	I-ADR
and	I-ADR
sol	I-ADR
that	I-ADR
disseminated	I-ADR
,	I-ADR
evolving	I-ADR
to	I-ADR
necrosis	I-ADR
,	O
sepsis	O
,	O
and	O
death	O
on	O
the	O
22nd	O
day	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ara-c	B-Drug
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hour	O
)	O
,	O
she	O
developed	O
bullous	O
lesion	O
on	O
the	O
hand	O
and	O
sol	O
that	O
disseminated	O
,	O
evolving	O
to	O
necrosis	O
,	O
sepsis	O
,	O
and	O
death	B-ADR
on	O
the	O
22nd	O
day	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ara-c	B-Drug
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hour	O
)	O
,	O
she	O
developed	O
bullous	O
lesion	O
on	O
the	O
hand	O
and	O
sol	O
that	O
disseminated	O
,	O
evolving	O
to	O
necrosis	O
,	O
sepsis	B-ADR
,	O
and	O
death	O
on	O
the	O
22nd	O
day	O
0	O
<EOS>	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
after	O
the	O
use	O
of	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
we	O
report	O
a	O
fatal	O
case	O
of	O
toxic	O
epidermal	O
necrolysis	O
(	O
ten	B-ADR
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
a	O
fatal	O
case	O
of	O
toxic	O
epidermal	O
necrolysis	O
(	O
ten	B-ADR
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
(	O
ten	O
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
(	O
ten	O
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
0	O
<EOS>	O
quetiapine	B-Drug
and	O
obsessive-compulsive	B-ADR
symptom	I-ADR
(	O
ocs	O
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic-induced	O
ocs	O
0	O
<EOS>	O
quetiapine	B-Drug
and	O
obsessive-compulsive	O
symptom	O
(	O
ocs	B-ADR
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic-induced	O
ocs	O
0	O
<EOS>	O
quetiapine	B-Drug
and	O
obsessive-compulsive	O
symptom	O
(	O
ocs	B-ADR
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic-induced	O
ocs	O
0	O
<EOS>	O
the	O
first	O
known	O
report	O
of	O
quetiapine	B-Drug
exacerbating	B-ADR
ocs	I-ADR
in	O
a	O
43-year-old	O
man	O
with	O
obsessive-compulsive	O
disorder	O
(	O
ocd	O
)	O
,	O
trichotillomania	O
,	O
delusional	O
disorder	O
and	O
bipolar	O
ii	O
disorder	O
is	O
presented	O
0	O
<EOS>	O
he	O
wa	O
diagnosed	O
with	O
possible	O
serotonin	B-ADR
syndrome	I-ADR
;	O
his	O
symptom	O
resolved	O
after	O
clomipramine	B-Drug
wa	O
stopped	O
but	O
before	O
clozapine	O
wa	O
restarted	O
eight	O
day	O
later	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	B-ADR
syndrome	I-ADR
in	O
a	O
patient	O
receiving	O
clomipramine	B-Drug
after	O
clozapine	O
wa	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	B-ADR
syndrome	I-ADR
in	O
a	O
patient	O
receiving	O
clomipramine	O
after	O
clozapine	B-Drug
wa	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
0	O
<EOS>	O
possible	O
serotonin	B-ADR
syndrome	I-ADR
associated	O
with	O
clomipramine	B-Drug
after	O
withdrawal	O
of	O
clozapine	O
0	O
<EOS>	O
possible	O
serotonin	B-ADR
syndrome	I-ADR
associated	O
with	O
clomipramine	O
after	O
withdrawal	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	B-ADR
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	B-ADR
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADR
oddly	I-ADR
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADR
oddly	I-ADR
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	B-ADR
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	B-ADR
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	B-ADR
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	B-ADR
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	B-ADR
profusely	I-ADR
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	B-ADR
profusely	I-ADR
,	O
shivering	O
,	O
and	O
became	O
tremulous	O
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	O
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	B-ADR
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
the	O
day	O
after	O
clozapine	B-Drug
wa	O
stopped	O
,	O
while	O
he	O
wa	O
still	O
receiving	O
clomipramine	O
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	O
oddly	O
,	O
started	O
sweating	O
profusely	O
,	O
shivering	O
,	O
and	O
became	O
tremulous	B-ADR
,	O
agitated	O
,	O
and	O
confused	O
0	O
<EOS>	O
quinine	B-Drug
induced	O
coagulopathy	B-ADR
--	O
a	O
near	O
fatal	O
experience	O
0	O
<EOS>	O
the	O
cause	O
of	O
his	O
bleeding	O
wa	O
a	O
severe	B-ADR
thrombocytopoaenia	I-ADR
,	O
induced	O
by	O
chronic	O
ingestion	O
of	O
quinine	B-Drug
0	O
<EOS>	O
dose-dependent	O
olanzapine-associated	B-Drug
leukopenia	B-ADR
:	O
three	O
case	O
report	O
0	O
<EOS>	O
these	O
case	O
suggest	O
the	O
possibility	O
that	O
,	O
in	O
some	O
patient	O
,	O
leukopenia	O
or	O
agranulocytosis	B-ADR
during	O
olanzapine	B-Drug
treatment	O
might	O
be	O
dose-related	O
0	O
<EOS>	O
these	O
case	O
suggest	O
the	O
possibility	O
that	O
,	O
in	O
some	O
patient	O
,	O
leukopenia	B-ADR
or	O
agranulocytosis	O
during	O
olanzapine	B-Drug
treatment	O
might	O
be	O
dose-related	O
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
patient	O
who	O
developed	O
leukopenia	B-ADR
during	O
olanzapine	B-Drug
treatment	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
illustrates	O
a	O
potential	O
link	O
between	O
dermatologic	B-ADR
and	I-ADR
ocular	I-ADR
5-fu	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
differential	O
diagnosis	O
included	O
ocular	O
rosacea	O
with	O
cicatrizing	O
conjunctivitis	O
and	O
5-fu-induced	B-Drug
ectropion	B-ADR
0	O
<EOS>	O
discussion	O
:	O
patient	O
with	O
5-fu-induced	B-Drug
ectropion	B-ADR
experience	O
tender	O
,	O
red	O
,	O
scaled	O
lid	O
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
0	O
<EOS>	O
discussion	O
:	O
patient	O
with	O
5-fu-induced	B-Drug
ectropion	O
experience	O
tender	B-ADR
,	I-ADR
red	I-ADR
,	I-ADR
scaled	I-ADR
lid	I-ADR
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
0	O
<EOS>	O
ectropion	B-ADR
secondary	O
to	O
bolus	O
injection	O
of	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
exacerbation	O
of	O
5-fu	B-Drug
dermatologic	B-ADR
toxicity	I-ADR
in	O
patient	O
with	O
preexisting	O
condition	O
suggests	O
the	O
importance	O
of	O
aggressive	O
ocular	O
prophylaxis	O
,	O
using	O
frequent	O
ocular	O
lubrication	O
and	O
topical	O
steroid	O
preparation	O
with	O
concurrent	O
medical	O
management	O
of	O
pre-existing	O
dermatologic	O
condition	O
0	O
<EOS>	O
presented	O
is	O
a	O
case	O
of	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
induced	O
by	O
acetazolamide	B-Drug
therapy	O
for	O
glaucoma	O
0	O
<EOS>	O
renal	B-ADR
failure	I-ADR
associated	O
with	O
acetazolamide	B-Drug
therapy	O
for	O
glaucoma	O
0	O
<EOS>	O
this	O
sulfonamide	O
like	O
nephropathy	O
should	O
be	O
differentiated	O
from	O
acetazolamide-related	B-Drug
calcium	B-ADR
phosphate	I-ADR
nephrolithiasis	I-ADR
0	O
<EOS>	O
ischaemic	B-ADR
colitis	I-ADR
in	O
a	O
patient	O
taking	O
meloxicam	B-Drug
0	O
<EOS>	O
symptom	O
and	O
endoscopic	B-ADR
lesion	I-ADR
quickly	O
regressed	O
within	O
1	O
week	O
of	O
meloxicam	B-Drug
withdrawal	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
presented	O
with	O
bloody	B-ADR
diarrhoea	I-ADR
after	O
15	O
mg	O
meloxicam	B-Drug
daily	O
for	O
10	O
day	O
for	O
osteoarthritis	O
0	O
<EOS>	O
we	O
suggest	O
that	O
meloxicam	B-Drug
might	O
have	O
intestinal	B-ADR
toxic	I-ADR
effect	I-ADR
when	O
taken	O
in	O
high	O
dos	O
,	O
because	O
of	O
reduced	O
cox-2	O
selectivity	O
0	O
<EOS>	O
a	O
these	O
case	O
revealed	O
,	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
is	O
mandatory	O
after	O
starting	O
spironolactone	B-Drug
,	O
and	O
patient	O
should	O
be	O
advised	O
to	O
stop	O
spironolactone	O
immediately	O
if	O
diarrhoea	B-ADR
develops	O
0	O
<EOS>	O
in	O
patient	O
with	O
chronic	O
heart	O
failure	O
,	O
spironolactone	B-Drug
added	O
to	O
conventional	O
treatment	O
may	O
lead	O
to	O
serious	B-ADR
and	I-ADR
,	I-ADR
occasionally	I-ADR
,	I-ADR
fatal	I-ADR
hyperkalaemia	I-ADR
0	O
<EOS>	O
in	O
some	O
case	O
this	O
seems	O
to	O
happen	O
because	O
spironolactone	B-Drug
cause	O
diarrhoea	B-ADR
0	O
<EOS>	O
serious	B-ADR
adverse	I-ADR
event	I-ADR
experienced	O
by	O
patient	O
with	O
chronic	O
heart	O
failure	O
taking	O
spironolactone	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
advanced	O
colonic	O
carcinoma	O
who	O
wa	O
treated	O
with	O
concomitant	O
chemoirradiation	O
with	O
oxaliplatin	B-Drug
and	O
developed	O
a	O
peculiar	O
dermnatitis	B-ADR
in	O
the	O
irradiated	O
field	O
after	O
being	O
exposed	O
to	O
subsequent	O
chemotherapy	O
with	O
oxaliplatin	O
0	O
<EOS>	O
an	O
11-year-old	O
boy	O
developed	O
a	O
severe	B-ADR
enteropathy	I-ADR
2	O
year	O
after	O
initiation	O
of	O
clofazimine	B-Drug
treatment	O
for	O
graft-versus-host	O
disease	O
0	O
<EOS>	O
clofazimine	B-Drug
enteropathy	B-ADR
caused	O
by	O
crystal	O
deposition	O
can	O
be	O
life-threatening	O
0	O
<EOS>	O
clofazimine	B-Drug
enteropathy	O
caused	O
by	O
crystal	O
deposition	O
can	O
be	O
life-threatening	B-ADR
0	O
<EOS>	O
clofazimine	B-Drug
enteropathy	B-ADR
in	O
a	O
pediatric	O
bone	O
marrow	O
transplant	O
recipient	O
0	O
<EOS>	O
she	O
developed	O
a	O
severe	B-ADR
urticarial	I-ADR
rash	I-ADR
3	O
week	O
following	O
initiation	O
of	O
therapy	O
with	O
enoxaparin	B-Drug
0	O
<EOS>	O
we	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	B-ADR
vision	I-ADR
,	O
qrs	O
broadening	O
and	O
cardiac	O
failure	O
due	O
to	O
chronic	O
cibenzoline	B-Drug
intoxication	O
0	O
<EOS>	O
we	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	O
vision	O
,	O
qrs	O
broadening	O
and	O
cardiac	B-ADR
failure	I-ADR
due	O
to	O
chronic	O
cibenzoline	B-Drug
intoxication	O
0	O
<EOS>	O
we	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	O
vision	O
,	O
qrs	O
broadening	O
and	O
cardiac	O
failure	O
due	O
to	O
chronic	O
cibenzoline	B-Drug
intoxication	I-ADR
0	O
<EOS>	O
we	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	O
vision	O
,	O
qrs	B-ADR
broadening	I-ADR
and	O
cardiac	O
failure	O
due	O
to	O
chronic	O
cibenzoline	B-Drug
intoxication	O
0	O
<EOS>	O
indolent	O
aspergillus	B-ADR
arthritis	I-ADR
complicating	O
fludarabine-based	B-Drug
non-myeloablative	O
stem	O
cell	O
transplantation	O
0	O
<EOS>	O
we	O
describe	O
two	O
patient	O
with	O
aspergillus	B-ADR
arthritis	I-ADR
of	I-ADR
the	I-ADR
knee	I-ADR
joint	I-ADR
following	O
fludarabine-based	B-Drug
non-myeloablative	O
stem	O
cell	O
transplantation	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
present	O
finding	O
suggest	O
that	O
fluvoxamine	B-Drug
can	O
cause	O
increased	B-ADR
libido	I-ADR
in	O
some	O
patient	O
0	O
<EOS>	O
increased	B-ADR
libido	I-ADR
in	O
a	O
woman	O
treated	O
with	O
fluvoxamine	B-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
objective	O
:	O
the	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
a	O
case	O
of	O
increased	B-ADR
libido	I-ADR
during	O
fluvoxamine	B-Drug
therapy	O
0	O
<EOS>	O
result	O
:	O
the	O
patient	O
,	O
a	O
27-year-old	O
married	O
japanese	O
woman	O
with	O
borderline	O
personality	O
disorder	O
,	O
developed	O
an	O
increased	B-ADR
libido	I-ADR
with	O
the	O
administration	O
of	O
fluvoxamine	B-Drug
0	O
<EOS>	O
the	O
increased	B-ADR
libido	I-ADR
disappeared	O
after	O
fluvoxamine	B-Drug
wa	O
discontinued	O
0	O
<EOS>	O
an	O
infant	O
who	O
developed	O
pancreatitis	B-ADR
during	O
meglumine	B-Drug
antimoniate	I-Drug
treatment	O
for	O
visceral	O
leishmaniasis	O
and	O
who	O
wa	O
successfully	O
treated	O
with	O
a	O
combination	O
of	O
allopurinol	O
and	O
ketoconazole	O
is	O
reported	O
0	O
<EOS>	O
successful	O
treatment	O
of	O
visceral	O
leishmaniasis	O
with	O
allopurinol	O
plus	O
ketoconazole	O
in	O
an	O
infant	O
who	O
developed	O
pancreatitis	B-ADR
caused	O
by	O
meglumine	B-Drug
antimoniate	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
report	O
showed	O
that	O
the	O
clinical	O
appearance	O
of	O
hashimoto	B-ADR
disease	I-ADR
after	O
ifn-alpha	B-Drug
therapy	O
for	O
chronic	O
c	O
hepatitis	O
in	O
our	O
patient	O
wa	O
associated	O
with	O
a	O
specific	O
genetic	O
predisposition	O
(	O
dr5	O
)	O
for	O
this	O
pathology	O
0	O
<EOS>	O
further	O
study	O
are	O
necessary	O
to	O
evaluate	O
whether	O
the	O
study	O
of	O
hla	O
antigen	O
may	O
be	O
a	O
very	O
useful	O
tool	O
to	O
detect	O
the	O
patient	O
with	O
a	O
predisposition	O
to	O
develop	O
autoimmune	B-ADR
thyroiditis	I-ADR
,	O
in	O
order	O
to	O
make	O
a	O
early	O
diagnosis	O
of	O
thyroid	O
disorder	O
during	O
the	O
ifn-alpha	B-Drug
treatment	O
0	O
<EOS>	O
further	O
study	O
are	O
necessary	O
to	O
evaluate	O
whether	O
the	O
study	O
of	O
hla	O
antigen	O
may	O
be	O
a	O
very	O
useful	O
tool	O
to	O
detect	O
the	O
patient	O
with	O
a	O
predisposition	O
to	O
develop	O
autoimmune	O
thyroiditis	O
,	O
in	O
order	O
to	O
make	O
a	O
early	O
diagnosis	O
of	O
thyroid	B-ADR
disorder	I-ADR
during	O
the	O
ifn-alpha	B-Drug
treatment	O
0	O
<EOS>	O
hashimoto	B-ADR
disease	I-ADR
during	O
interferon-alpha	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
pre-treatment	O
negative	O
anti-thyroid	O
autoantibody	O
and	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
to	O
the	O
thyroid	O
disease	O
0	O
<EOS>	O
objective	O
:	O
the	O
author	O
described	O
a	O
case	O
of	O
hashimoto	B-ADR
disease	I-ADR
during	O
interferon-alpha	O
(	O
ifn-alpha	B-Drug
)	O
treatment	O
for	O
chronic	O
viral	O
c	O
hepatitis	O
in	O
a	O
patient	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
associated	O
with	O
the	O
thyroid	O
disease	O
0	O
<EOS>	O
objective	O
:	O
the	O
author	O
described	O
a	O
case	O
of	O
hashimoto	B-ADR
disease	I-ADR
during	O
interferon-alpha	B-Drug
(	O
ifn-alpha	O
)	O
treatment	O
for	O
chronic	O
viral	O
c	O
hepatitis	O
in	O
a	O
patient	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
associated	O
with	O
the	O
thyroid	O
disease	O
0	O
<EOS>	O
during	O
dose-finding	O
study	O
for	O
intravenous	O
proton	O
pump	O
inhibitor	O
omeprazole	B-Drug
and	O
pantoprazole	O
,	O
three	O
of	O
six	O
young	O
female	O
volunteer	O
receiving	O
omeprazole	O
and	O
two	O
young	O
female	O
volunteer	O
receiving	O
pantoprazole	O
developed	O
peripheral	B-ADR
edema	I-ADR
within	O
8	O
hr	O
when	O
high	O
dos	O
of	O
the	O
proton	O
pump	O
inhibitor	O
were	O
applied	O
by	O
continuous	O
infusion	O
together	O
with	O
large	O
volume	O
of	O
fluid	O
0	O
<EOS>	O
during	O
dose-finding	O
study	O
for	O
intravenous	O
proton	O
pump	O
inhibitor	O
omeprazole	O
and	O
pantoprazole	B-Drug
,	O
three	O
of	O
six	O
young	O
female	O
volunteer	O
receiving	O
omeprazole	O
and	O
two	O
young	O
female	O
volunteer	O
receiving	O
pantoprazole	O
developed	O
peripheral	B-ADR
edema	I-ADR
within	O
8	O
hr	O
when	O
high	O
dos	O
of	O
the	O
proton	O
pump	O
inhibitor	O
were	O
applied	O
by	O
continuous	O
infusion	O
together	O
with	O
large	O
volume	O
of	O
fluid	O
0	O
<EOS>	O
pheripheral	B-ADR
edema	I-ADR
wa	O
observed	O
in	O
five	O
female	O
patient	O
after	O
taking	O
proton	O
pump	O
inhibitor	O
omeprazole	O
,	O
lansoprazole	B-Drug
,	O
or	O
pantoprazole	O
for	O
7-15	O
day	O
for	O
peptic	O
acid	O
disease	O
in	O
recommended	O
standard	O
dos	O
0	O
<EOS>	O
pheripheral	B-ADR
edema	I-ADR
wa	O
observed	O
in	O
five	O
female	O
patient	O
after	O
taking	O
proton	O
pump	O
inhibitor	O
omeprazole	B-Drug
,	O
lansoprazole	O
,	O
or	O
pantoprazole	O
for	O
7-15	O
day	O
for	O
peptic	O
acid	O
disease	O
in	O
recommended	O
standard	O
dos	O
0	O
<EOS>	O
pheripheral	B-ADR
edema	I-ADR
wa	O
observed	O
in	O
five	O
female	O
patient	O
after	O
taking	O
proton	O
pump	O
inhibitor	O
omeprazole	O
,	O
lansoprazole	O
,	O
or	O
pantoprazole	B-Drug
for	O
7-15	O
day	O
for	O
peptic	O
acid	O
disease	O
in	O
recommended	O
standard	O
dos	O
0	O
<EOS>	O
motor	B-ADR
fluctuation	I-ADR
appear	O
after	O
2-3	O
year	O
of	O
levodopa	B-Drug
treatment	O
,	O
and	O
affect	O
at	O
least	O
50	O
%	O
of	O
patient	O
after	O
five	O
year	O
0	O
<EOS>	O
conclusion	O
:	O
significant	O
weight	B-ADR
loss	I-ADR
is	O
a	O
potential	O
adverse	O
event	O
in	O
patient	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
leflunomide	B-Drug
0	O
<EOS>	O
leflunomide-associated	B-Drug
weight	B-ADR
loss	I-ADR
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
method	O
:	O
we	O
queried	O
35	O
rheumatologist	O
at	O
the	O
robert	O
breck	O
brigham	O
arthritis	O
center	O
to	O
determine	O
if	O
weight	B-ADR
loss	I-ADR
had	O
occurred	O
a	O
an	O
adverse	O
event	O
in	O
patient	O
treated	O
with	O
leflunomide	B-Drug
between	O
november	O
1998	O
and	O
january	O
2000	O
0	O
<EOS>	O
objective	O
:	O
to	O
determine	O
the	O
frequency	O
of	O
weight	B-ADR
loss	I-ADR
in	O
patient	O
treated	O
with	O
leflunomide	B-Drug
for	O
rheumatoid	O
arthritis	O
at	O
an	O
arthritis	O
referral	O
center	O
0	O
<EOS>	O
result	O
:	O
five	O
of	O
70	O
patient	O
who	O
had	O
begun	O
leflunomide	B-Drug
therapy	O
had	O
significant	O
weight	B-ADR
loss	I-ADR
that	O
could	O
not	O
be	O
linked	O
to	O
other	O
identifiable	O
etiology	O
0	O
<EOS>	O
it	O
is	O
increasingly	O
recognized	O
that	O
dose	O
adjustment	O
of	O
oral	O
valacyclovir	B-Drug
in	O
renal	O
failure	O
is	O
necessary	O
to	O
avoid	O
neurotoxicity	B-ADR
0	O
<EOS>	O
neurotoxicity	B-ADR
of	O
valacyclovir	B-Drug
in	O
peritoneal	O
dialysis	O
:	O
a	O
pharmacokinetic	O
study	O
0	O
<EOS>	O
she	O
developed	O
neurotoxicity	B-ADR
with	O
an	O
adjustment	O
dosage	O
of	O
valacyclovir	B-Drug
for	O
a	O
cutaneous	O
zoster	O
infection	O
0	O
<EOS>	O
avascular	B-ADR
necrosis	I-ADR
of	I-ADR
the	I-ADR
femoral	I-ADR
head	I-ADR
in	O
patient	O
with	O
prostate	O
cancer	O
treated	O
with	O
cyproterone	B-Drug
acetate	I-Drug
and	O
radiotherapy	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
history	O
of	O
two	O
patient	O
with	O
histologically	O
confirmed	O
adenocarcinoma	O
of	O
the	O
prostate	O
,	O
both	O
of	O
whom	O
had	O
been	O
treated	O
with	O
steroidal	O
anti-androgen	O
therapy	O
in	O
the	O
form	O
of	O
cyproterone	B-Drug
acetate	I-Drug
prior	O
to	O
radical	O
or	O
palliative	O
pelvic	O
irradiation	O
,	O
and	O
who	O
subsequently	O
developed	O
femoral	B-ADR
head	I-ADR
avascular	I-ADR
necrosis	I-ADR
0	O
<EOS>	O
levofloxacin	B-Drug
induced	O
polymorphic	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
with	O
normal	O
qt	O
interval	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
polymorphic	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
with	O
normal	O
qt	O
interval	O
associated	O
with	O
the	O
oral	O
use	O
of	O
levofloxacin	B-Drug
in	O
the	O
absence	O
of	O
other	O
etiology	O
known	O
to	O
cause	O
these	O
arrhythmia	O
0	O
<EOS>	O
so	O
far	O
,	O
few	O
case	O
of	O
pulmonary	B-ADR
side	I-ADR
effect	I-ADR
caused	O
by	O
ticlopidine	B-Drug
have	O
been	O
reported	O
0	O
<EOS>	O
special	O
care	O
should	O
be	O
taken	O
when	O
pulmonary	B-ADR
symptom	I-ADR
appear	O
in	O
association	O
with	O
ticlopidine	B-Drug
treatment	O
0	O
<EOS>	O
ticlopidine-induced	B-Drug
interstitial	B-ADR
pulmonary	I-ADR
disease	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
interstitial	B-ADR
pulmonary	I-ADR
disease	I-ADR
that	O
occurred	O
together	O
with	O
lymphocytic	O
colitis	O
during	O
treatment	O
with	O
ticlopidine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
interstitial	O
pulmonary	O
disease	O
that	O
occurred	O
together	O
with	O
lymphocytic	B-ADR
colitis	I-ADR
during	O
treatment	O
with	O
ticlopidine	B-Drug
0	O
<EOS>	O
a	O
patient	O
that	O
received	O
methadone	B-Drug
for	O
cancer-associated	O
pain	O
developed	O
myoclonus	B-ADR
a	O
a	O
side	O
effect	O
0	O
<EOS>	O
methadone-induced	B-Drug
myoclonus	B-ADR
in	O
advanced	O
cancer	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
fatal	B-ADR
hyperkalemia	I-ADR
owing	O
to	O
succinylcholine	B-Drug
administration	O
in	O
a	O
patient	O
with	O
mucositis	O
secondary	O
to	O
chemotherapy	O
0	O
<EOS>	O
succinylcholine-induced	B-Drug
hyperkalemia	B-ADR
in	O
a	O
patient	O
with	O
mucositis	O
secondary	O
to	O
chemotherapy	O
0	O
<EOS>	O
we	O
believe	O
that	O
mucositis	O
wa	O
a	O
contributing	O
factor	O
to	O
this	O
case	O
of	O
fatal	B-ADR
hyperkalemia	I-ADR
after	O
administration	O
of	O
succinylcholine	B-Drug
,	O
with	O
a	O
mechanism	O
similar	O
to	O
that	O
reported	O
with	O
thermal	O
injury	O
0	O
<EOS>	O
cutaneous	B-ADR
seeding	I-ADR
after	O
ultrasound-guided	O
percutaneous	O
ethanol	B-Drug
injection	I-Drug
for	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
needle-track	O
cutaneous	B-ADR
seeding	I-ADR
of	O
hepatocellular	O
carcinoma	O
(	O
hcc	O
)	O
after	O
sonographically	O
guided	O
percutaneous	O
ethanol	B-Drug
injection	I-Drug
(	O
pei	O
)	O
0	O
<EOS>	O
adenosine-induced	B-Drug
ventricular	B-ADR
fibrillation	I-ADR
0	O
<EOS>	O
however	O
,	O
adenosine	B-Drug
shortens	O
the	O
antegrade	O
refractoriness	O
of	O
accessory	O
atrioventricular	O
connection	O
and	O
may	O
cause	O
acceleration	B-ADR
of	I-ADR
the	I-ADR
ventricular	I-ADR
rate	I-ADR
during	O
atrial	O
fibrillation	O
0	O
<EOS>	O
we	O
observed	O
ventricular	B-ADR
fibrillation	I-ADR
in	O
2	O
patient	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
pre-excited	O
atrial	O
fibrillation	O
and	O
were	O
given	O
12	O
mg	O
of	O
adenosine	B-Drug
0	O
<EOS>	O
after	O
the	O
dose	O
of	O
methylprednisolone	B-Drug
wa	O
reduced	O
from	O
40	O
mg	O
to	O
20	O
mg	O
i.v	O
0	O
q6h	O
and	O
shifted	O
to	O
other	O
anti-asthma	O
treatment	O
by	O
procaterol	O
metered	O
dose	O
inhaler	O
via	O
spacer	O
,	O
the	O
psychotic	B-ADR
reaction	I-ADR
disappeared	O
a	O
few	O
hour	O
later	O
0	O
<EOS>	O
continuous	O
eeg	O
monitoring	O
is	O
helpful	O
in	O
managing	O
seizure	B-ADR
that	O
occur	O
a	O
a	O
complication	O
of	O
cbz	B-Drug
od	O
,	O
after	O
the	O
course	O
of	O
recovery	O
or	O
worsening	O
,	O
and	O
in	O
providing	O
assistance	O
with	O
prognosis	O
0	O
<EOS>	O
massive	O
cbz	B-Drug
od	O
may	O
produce	O
a	O
reversible	O
encephalopathy	O
that	O
includes	O
cortical	B-ADR
hyperexcitability	I-ADR
,	O
a	O
profound	O
burst-suppression	O
eeg	O
pattern	O
,	O
and	O
cranial	O
nerve	O
areflexia	O
0	O
<EOS>	O
massive	O
cbz	B-Drug
od	O
may	O
produce	O
a	O
reversible	O
encephalopathy	O
that	O
includes	O
cortical	O
hyperexcitability	O
,	O
a	O
profound	O
burst-suppression	O
eeg	O
pattern	O
,	O
and	O
cranial	B-ADR
nerve	I-ADR
areflexia	I-ADR
0	O
<EOS>	O
massive	O
cbz	B-Drug
od	O
may	O
produce	O
a	O
reversible	O
encephalopathy	O
that	O
includes	O
cortical	O
hyperexcitability	O
,	O
a	O
profound	B-ADR
burst-suppression	I-ADR
eeg	I-ADR
pattern	I-ADR
,	O
and	O
cranial	O
nerve	O
areflexia	O
0	O
<EOS>	O
massive	O
cbz	B-Drug
od	O
may	O
produce	O
a	O
reversible	B-ADR
encephalopathy	I-ADR
that	O
includes	O
cortical	O
hyperexcitability	O
,	O
a	O
profound	O
burst-suppression	O
eeg	O
pattern	O
,	O
and	O
cranial	O
nerve	O
areflexia	O
0	O
<EOS>	O
massive	O
plasmocytosis	O
due	O
to	O
methimazole-induced	B-Drug
bone	B-ADR
marrow	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
massive	B-ADR
plasmocytosis	I-ADR
due	O
to	O
methimazole-induced	B-Drug
bone	O
marrow	O
toxicity	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	O
due	O
to	O
mmi	B-Drug
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	B-ADR
plasmocytosis	I-ADR
0	O
<EOS>	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	B-ADR
due	O
to	O
mmi	B-Drug
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	O
plasmocytosis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
associated	O
with	O
didanosine	B-Drug
and	O
masquerading	O
a	O
a	O
surgical	O
abdomen	O
and	O
compare	O
the	O
clinical	O
,	O
biologic	O
,	O
histologic	O
,	O
and	O
ultrastructural	O
finding	O
with	O
report	O
described	O
previously	O
0	O
<EOS>	O
this	O
report	O
detail	O
a	O
case	O
of	O
bilateral	B-ADR
avascular	I-ADR
necrosis	I-ADR
of	I-ADR
the	I-ADR
femoral	I-ADR
head	I-ADR
in	O
a	O
patient	O
receiving	O
standard	O
	O
dos	O
of	O
dexamethasone	B-Drug
a	O
part	O
of	O
the	O
antiemetic	O
regimen	O
used	O
in	O
cisplatin-based	O
combination	O
chemotherapy	O
0	O
<EOS>	O
although	O
no	O
coagulation	O
study	O
wa	O
done	O
and	O
the	O
meckel	O
diverticulum	O
is	O
normally	O
associated	O
with	O
bleeding	O
,	O
the	O
particular	O
intensity	O
of	O
the	O
following	O
hemorrhage	B-ADR
may	O
have	O
been	O
favored	O
by	O
metformin	B-Drug
0	O
<EOS>	O
an	O
obese	O
patient	O
,	O
not	O
diabetic	O
,	O
treated	O
with	O
metformin	B-Drug
for	O
some	O
week	O
,	O
wa	O
referred	O
to	O
u	O
with	O
severe	B-ADR
inferior	I-ADR
digestive	I-ADR
hemorrhage	I-ADR
,	O
diagnosed	O
with	O
meckel	O
diverticulum	O
0	O
<EOS>	O
digestive	B-ADR
hemorrhage	I-ADR
caused	O
by	O
a	O
meckel	O
diverticulum	O
in	O
a	O
metformin-treated	B-Drug
patient	O
:	O
is	O
there	O
any	O
connection	O
?	O
<EOS>	O
ulcer	B-ADR
became	I-ADR
worse	I-ADR
after	O
tobramycin	O
and	O
gentamycin	B-Drug
treatment	O
for	O
2	O
day	O
0	O
<EOS>	O
ulcer	B-ADR
became	I-ADR
worse	I-ADR
after	O
tobramycin	B-Drug
and	O
gentamycin	O
treatment	O
for	O
2	O
day	O
0	O
<EOS>	O
possible	O
linkage	O
of	O
amprenavir	B-Drug
with	O
intracranial	B-ADR
bleeding	I-ADR
in	O
an	O
hiv-infected	O
hemophiliac	O
0	O
<EOS>	O
the	O
bleeding	B-ADR
resolved	O
on	O
discontinuation	O
of	O
apv	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
occurrence	O
of	O
spontaneous	O
intracranial	B-ADR
bleeding	I-ADR
in	O
an	O
human	O
immunodeficiency	O
virus	O
(	O
hiv	O
)	O
-infected	O
adolescent	O
with	O
hemophilia	O
a	O
who	O
wa	O
receiving	O
amprenavir	B-Drug
(	O
apv	O
)	O
0	O
<EOS>	O
according	O
to	O
the	O
naranjo	O
probability	O
scale	O
,	O
the	O
relationship	O
of	O
gemcitabine	B-Drug
treatment	O
with	O
cutaneous	B-ADR
eruption	I-ADR
in	O
our	O
patient	O
is	O
possible	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
the	O
first	O
case	O
of	O
gemcitabine-induced	B-Drug
labd	B-ADR
0	O
<EOS>	O
linear	B-ADR
immunoglobulin	I-ADR
a	I-ADR
bullous	I-ADR
dermatosis	I-ADR
induced	O
by	O
gemcitabine	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
linear	O
immunoglobulin	O
(	O
ig	O
)	O
a	O
bullous	O
dermatosis	O
(	O
labd	B-ADR
)	O
induced	O
by	O
gemcitabine	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
linear	B-ADR
immunoglobulin	I-ADR
(	I-ADR
ig	I-ADR
)	I-ADR
a	I-ADR
bullous	I-ADR
dermatosis	I-ADR
(	O
labd	O
)	O
induced	O
by	O
gemcitabine	B-Drug
0	O
<EOS>	O
twenty-four	O
hour	O
after	O
the	O
administration	O
of	O
gemcitabine	B-Drug
,	O
a	O
symmetric	B-ADR
,	I-ADR
bullous	I-ADR
,	I-ADR
herpetiform	I-ADR
eruption	I-ADR
appeared	O
on	O
his	O
trunk	O
and	O
upper	O
limb	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
the	O
most	O
frequently	O
implicated	O
drug	O
,	O
but	O
other	O
agent	O
have	O
been	O
reported	O
to	O
cause	O
labd	B-ADR
0	O
<EOS>	O
although	O
taxol	B-Drug
ha	O
shown	O
significant	O
activity	O
in	O
advanced	O
ovarian	O
cancer	O
,	O
peripheral	B-ADR
neuropathy	I-ADR
is	O
likely	O
to	O
become	O
the	O
major	O
dose-limiting	O
toxicity	O
0	O
<EOS>	O
a	O
rare	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADR
walking	I-ADR
25	O
day	O
after	O
treatment	O
with	O
weekly	O
paclitaxel	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADR
walking	I-ADR
because	O
of	O
marked	O
pain	O
in	O
the	O
lower	O
extremity	O
and	O
loss	O
of	O
proprioception	O
25	O
day	O
after	O
treatment	O
with	O
weekly	O
taxol	B-Drug
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
x3	O
)	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	O
walking	O
because	O
of	O
marked	O
pain	O
in	O
the	O
lower	O
extremity	O
and	O
loss	B-ADR
of	I-ADR
proprioception	I-ADR
25	O
day	O
after	O
treatment	O
with	O
weekly	O
taxol	B-Drug
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
x3	O
)	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	O
walking	O
because	O
of	O
marked	B-ADR
pain	I-ADR
in	O
the	O
lower	O
extremity	O
and	O
loss	O
of	O
proprioception	O
25	O
day	O
after	O
treatment	O
with	O
weekly	O
taxol	B-Drug
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
x3	O
)	O
0	O
<EOS>	O
relief	O
by	O
naloxone	O
of	O
morphine-induced	B-Drug
spasm	B-ADR
of	O
the	O
sphincter	O
of	O
oddi	O
in	O
a	O
post-cholecystectomy	O
patient	O
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
had	O
undergone	O
cholecystectomy	O
previously	O
,	O
but	O
in	O
whom	O
morphine	B-Drug
given	O
in	O
the	O
emergency	O
department	O
precipitated	O
pain	O
consistent	O
with	O
biliary	B-ADR
colic	I-ADR
;	O
the	O
pain	O
resolved	O
promptly	O
after	O
administration	O
of	O
naloxone	O
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
had	O
undergone	O
cholecystectomy	O
previously	O
,	O
but	O
in	O
whom	O
morphine	B-Drug
given	O
in	O
the	O
emergency	O
department	O
precipitated	O
pain	B-ADR
consistent	O
with	O
biliary	O
colic	O
;	O
the	O
pain	O
resolved	O
promptly	O
after	O
administration	O
of	O
naloxone	O
0	O
<EOS>	O
myasthenia	B-ADR
gravis	I-ADR
during	O
low-dose	O
ifn-alpha	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
developed	O
an	O
acute	O
intrahepatic	B-ADR
cholestasis	I-ADR
after	O
100	O
mg	O
of	O
sodium	B-Drug
aurothiomalate	I-Drug
0	O
<EOS>	O
acute	B-ADR
lung	I-ADR
injury	I-ADR
associated	O
with	O
5-fluorouracil	B-Drug
and	O
oxaliplatinum	O
combined	O
chemotherapy	O
0	O
<EOS>	O
acute	B-ADR
lung	I-ADR
injury	I-ADR
associated	O
with	O
5-fluorouracil	O
and	O
oxaliplatinum	B-Drug
combined	O
chemotherapy	O
0	O
<EOS>	O
diarrhoea	O
,	O
t-cd4+	O
lymphopenia	O
and	O
bilateral	B-ADR
patchy	I-ADR
pulmonary	I-ADR
infiltrates	I-ADR
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	O
and	O
5-fluorouracil	B-Drug
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
diarrhoea	O
,	O
t-cd4+	O
lymphopenia	O
and	O
bilateral	B-ADR
patchy	I-ADR
pulmonary	I-ADR
infiltrates	I-ADR
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	B-Drug
and	O
5-fluorouracil	O
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
diarrhoea	B-ADR
,	O
t-cd4+	O
lymphopenia	O
and	O
bilateral	O
patchy	O
pulmonary	O
infiltrates	O
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	O
and	O
5-fluorouracil	B-Drug
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
diarrhoea	B-ADR
,	O
t-cd4+	O
lymphopenia	O
and	O
bilateral	O
patchy	O
pulmonary	O
infiltrates	O
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	B-Drug
and	O
5-fluorouracil	O
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
diarrhoea	O
,	O
t-cd4+	B-ADR
lymphopenia	I-ADR
and	O
bilateral	O
patchy	O
pulmonary	O
infiltrates	O
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	O
and	O
5-fluorouracil	B-Drug
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
diarrhoea	O
,	O
t-cd4+	B-ADR
lymphopenia	I-ADR
and	O
bilateral	O
patchy	O
pulmonary	O
infiltrates	O
developed	O
in	O
a	O
male	O
60	O
yr	O
of	O
age	O
,	O
who	O
wa	O
treated	O
with	O
oxaliplatinum	B-Drug
and	O
5-fluorouracil	O
for	O
unresectable	O
rectum	O
carcinoma	O
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
the	O
aforementioned	O
pathological	O
manifestation	O
were	O
due	O
to	O
chemotherapy	O
and	O
included	O
a	O
pulmonary	B-ADR
adverse	I-ADR
reaction	I-ADR
,	O
a	O
feature	O
never	O
previously	O
associated	O
with	O
oxaliplatinum	O
and	O
5-fluorouracil	B-Drug
regimen	O
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
the	O
aforementioned	O
pathological	O
manifestation	O
were	O
due	O
to	O
chemotherapy	O
and	O
included	O
a	O
pulmonary	B-ADR
adverse	I-ADR
reaction	I-ADR
,	O
a	O
feature	O
never	O
previously	O
associated	O
with	O
oxaliplatinum	B-Drug
and	O
5-fluorouracil	O
regimen	O
0	O
<EOS>	O
background	O
:	O
accutane	B-Drug
a	O
teratogenic	B-ADR
prescription	O
drug	O
licensed	O
to	O
treat	O
severe	O
,	O
recalcitrant	O
nodular	O
acne	O
0	O
<EOS>	O
result	O
:	O
the	O
estimated	O
number	O
of	O
accutane	B-Drug
prescription	O
for	O
reproductive-aged	O
woman	O
ha	O
more	O
than	O
doubled	O
in	O
the	O
past	O
10	O
year	O
;	O
it	O
is	O
the	O
most	O
widely	O
used	O
teratogenic	B-ADR
drug	O
in	O
the	O
united	O
state	O
,	O
with	O
approximately	O
2.5	O
per	O
1000	O
reproductive-aged	O
woman	O
exposed	O
to	O
accutane	O
in	O
1999	O
0	O
<EOS>	O
a	O
62-year-old	O
woman	O
treated	O
with	O
pranlukast	B-Drug
for	O
2	O
month	O
developed	O
interstitial	O
pneumonitis	O
with	O
a	O
high	B-ADR
fever	I-ADR
0	O
<EOS>	O
a	O
62-year-old	O
woman	O
treated	O
with	O
pranlukast	B-Drug
for	O
2	O
month	O
developed	O
interstitial	B-ADR
pneumonitis	I-ADR
with	O
a	O
high	O
fever	O
0	O
<EOS>	O
acute	O
interstitial	B-ADR
pneumonia	I-ADR
induced	O
by	O
ono-1078	B-Drug
(	O
pranlukast	O
)	O
,	O
a	O
leukotriene	O
receptor	O
antagonist	O
0	O
<EOS>	O
acute	O
interstitial	B-ADR
pneumonia	I-ADR
induced	O
by	O
ono-1078	O
(	O
pranlukast	B-Drug
)	O
,	O
a	O
leukotriene	O
receptor	O
antagonist	O
0	O
<EOS>	O
an	O
asymptomatic	O
hiv-infected	O
woman	O
experienced	O
right-sided	O
renal	B-ADR
colicky	I-ADR
pain	I-ADR
during	O
treatment	O
with	O
indinavir	B-Drug
0	O
<EOS>	O
indinavir-associated	B-Drug
nephrolithiasis	O
and	O
chronic	O
interstitial	B-ADR
nephritis	I-ADR
were	O
the	O
only	O
possible	O
cause	O
identified	O
in	O
this	O
patient	O
0	O
<EOS>	O
indinavir-associated	B-Drug
nephrolithiasis	B-ADR
and	O
chronic	O
interstitial	O
nephritis	O
were	O
the	O
only	O
possible	O
cause	O
identified	O
in	O
this	O
patient	O
0	O
<EOS>	O
papillary	B-ADR
necrosis	I-ADR
associated	O
with	O
the	O
hiv	O
protease	O
inhibitor	O
indinavir	B-Drug
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
that	O
indinavir	B-Drug
nephrolithiasis	B-ADR
may	O
cause	O
papillary	O
necrosis	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
that	O
indinavir	B-Drug
nephrolithiasis	O
may	O
cause	O
papillary	B-ADR
necrosis	I-ADR
0	O
<EOS>	O
the	O
hiv	O
protease	O
inhibitor	O
indinavir	B-Drug
may	O
cause	O
nephrolithiasis	O
and	O
interstitial	B-ADR
nephritis	I-ADR
0	O
<EOS>	O
the	O
hiv	O
protease	O
inhibitor	O
indinavir	B-Drug
may	O
cause	O
nephrolithiasis	B-ADR
and	O
interstitial	O
nephritis	O
0	O
<EOS>	O
the	O
renal	O
consequence	O
of	O
indinavir-associated	B-Drug
nephrotoxicity	B-ADR
are	O
uncertain	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
papillary	B-ADR
necrosis	I-ADR
in	O
a	O
patient	O
treated	O
with	O
indinavir	B-Drug
0	O
<EOS>	O
we	O
describe	O
2	O
male	O
patient	O
,	O
a	O
49-year-old	O
with	O
psoriatic	O
arthritis	O
and	O
impaired	O
renal	O
function	O
and	O
a	O
43-year-old	O
renal	O
transplant	O
recipient	O
,	O
who	O
both	O
sustained	O
a	O
marked	O
decline	B-ADR
in	I-ADR
glomerular	I-ADR
filtration	I-ADR
rate	I-ADR
in	O
conjunction	O
with	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	O
(	O
cox-2	O
)	O
,	O
rofecoxib	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
ltg	B-Drug
overdose	O
may	O
result	O
in	O
a	O
severe	O
but	O
reversible	O
encephalopathy	B-ADR
,	O
a	O
previously	O
undescribed	O
phenomenon	O
0	O
<EOS>	O
evaluation	O
revealed	O
elevated	B-ADR
serum	I-ADR
ltg	B-Drug
level	I-ADR
and	O
no	O
other	O
etiology	O
for	O
encephalopathy	O
0	O
<EOS>	O
method	O
:	O
a	O
55-year-old	O
woman	O
became	O
stuporous	B-ADR
after	O
overdose	O
with	O
lamotrigine	B-Drug
(	O
ltg	O
)	O
and	O
valproic	O
acid	O
(	O
vpa	O
)	O
tablet	O
0	O
<EOS>	O
method	O
:	O
a	O
55-year-old	O
woman	O
became	O
stuporous	B-ADR
after	O
overdose	O
with	O
lamotrigine	O
(	O
ltg	B-Drug
)	O
and	O
valproic	O
acid	O
(	O
vpa	O
)	O
tablet	O
0	O
<EOS>	O
method	O
:	O
a	O
55-year-old	O
woman	O
became	O
stuporous	B-ADR
after	O
overdose	O
with	O
lamotrigine	O
(	O
ltg	O
)	O
and	O
valproic	B-Drug
acid	I-Drug
(	O
vpa	O
)	O
tablet	O
0	O
<EOS>	O
method	O
:	O
a	O
55-year-old	O
woman	O
became	O
stuporous	B-ADR
after	O
overdose	O
with	O
lamotrigine	O
(	O
ltg	O
)	O
and	O
valproic	O
acid	O
(	O
vpa	B-Drug
)	O
tablet	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
that	O
acute	O
lamotrigine	B-Drug
poisoning	O
may	O
result	O
in	O
severe	O
encephalopathy	B-ADR
0	O
<EOS>	O
stupor	B-ADR
from	O
lamotrigine	B-Drug
toxicity	O
0	O
<EOS>	O
the	O
cause	O
of	O
death	O
wa	O
determined	O
to	O
be	O
acute	B-ADR
intoxication	I-ADR
by	O
olanzapine	B-Drug
,	O
and	O
the	O
manner	O
of	O
death	O
wa	O
accidental	O
0	O
<EOS>	O
this	O
article	O
describes	O
the	O
case	O
of	O
a	O
25-year-old	O
man	O
found	O
dead	B-ADR
at	O
home	O
who	O
had	O
been	O
prescribed	O
olanzapine	B-Drug
for	O
schizophrenia	O
0	O
<EOS>	O
lichenoid	B-ADR
drug	I-ADR
eruption	I-ADR
to	O
salsalate	B-Drug
0	O
<EOS>	O
this	O
eruption	B-ADR
emerged	O
after	O
1	O
month	O
of	O
therapy	O
with	O
salsalate	B-Drug
,	O
persisted	O
for	O
a	O
long	O
a	O
salsalate	O
wa	O
administered	O
,	O
and	O
cleared	O
within	O
3	O
week	O
of	O
discontinuing	O
the	O
medication	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
experienced	O
a	O
lichenoid	B-ADR
eruption	I-ADR
after	O
the	O
initiation	O
of	O
salsalate	B-Drug
for	O
relief	O
of	O
arthritic	O
pain	O
0	O
<EOS>	O
amphotericin	B-Drug
b-induced	I-Drug
seizure	B-ADR
in	O
a	O
patient	O
with	O
aid	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
46-year-old	O
african-american	O
man	O
experienced	O
recurrent	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
during	O
intravenous	O
infusion	O
of	O
amphotericin	B-Drug
b	I-Drug
,	O
then	O
petit	O
mal	O
seizure	O
a	O
the	O
infusion	O
wa	O
stopped	O
and	O
the	O
drug	O
concentration	O
decreased	O
with	O
time	O
0	O
<EOS>	O
conclusion	O
:	O
amphotericin	B-Drug
b	I-Drug
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizure	B-ADR
0	O
<EOS>	O
despite	O
administration	O
of	O
phenytoin	O
and	O
lorazepam	O
,	O
the	O
seizure	B-ADR
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-Drug
b	I-Drug
administration	O
0	O
<EOS>	O
didanosine	B-Drug
also	O
ha	O
a	O
potential	O
for	O
inducing	O
seizure	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
multiple	O
episode	O
of	O
seizure	B-ADR
activity	O
in	O
an	O
aid	O
patent	O
following	O
amphotericin	B-Drug
b	I-Drug
infusion	O
0	O
<EOS>	O
the	O
time	O
course	O
of	O
event	O
suggested	O
that	O
amphotericin	B-Drug
b	I-Drug
wa	O
the	O
cause	O
of	O
the	O
seizure	B-ADR
in	O
this	O
aid	O
patient	O
0	O
<EOS>	O
to	O
date	O
,	O
only	O
three	O
case	O
of	O
seizure	B-ADR
associated	O
with	O
amphotericin	B-Drug
b	I-Drug
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
provider	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
0	O
<EOS>	O
vocal	B-ADR
cord	I-ADR
paralysis	I-ADR
a	O
a	O
consequence	O
of	O
peritonsillar	O
infiltration	O
with	O
bupivacaine	B-Drug
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
5-year-old	O
girl	O
who	O
developed	O
bilateral	B-ADR
vocal	I-ADR
cord	I-ADR
paralysis	I-ADR
following	O
preoperative	O
peritonsillar	O
bupivacaine	B-Drug
infiltration	O
0	O
<EOS>	O
a	O
53	O
year	O
old	O
greenlandic	O
male	O
wa	O
admitted	O
twice	O
over	O
a	O
period	O
of	O
4	O
year	O
with	O
a	O
new	O
complete	O
right	B-ADR
bundle	I-ADR
branch	I-ADR
block	I-ADR
after	O
ingestion	O
of	O
10	O
g	O
and	O
4	O
g	O
of	O
carbamazepine	B-Drug
respectively	O
0	O
<EOS>	O
carbamazepine	B-Drug
induced	O
right	B-ADR
bundle	I-ADR
branch	I-ADR
block	I-ADR
in	O
a	O
greenlandic	O
patient	O
0	O
<EOS>	O
cicatricial	B-ADR
entropion	I-ADR
associated	O
with	O
chronic	O
dipivefrin	B-Drug
application	O
0	O
<EOS>	O
conclusion	O
:	O
cicatrization	O
in	O
the	O
substantia	O
propria	O
of	O
the	O
conjunctiva	O
by	O
excessive	O
lymphocytic	O
infiltration	O
after	O
topically	O
administered	O
antiglaucoma	O
drug	O
including	O
dipivefrin	B-Drug
is	O
a	O
possible	O
mechanism	O
of	O
action	O
for	O
entropion	B-ADR
0	O
<EOS>	O
nine	O
eye	O
from	O
6	O
patient	O
,	O
74	O
year	O
to	O
90	O
year	O
of	O
age	O
,	O
referred	O
by	O
ophthalmologist	O
for	O
repair	O
of	O
cicatricial	B-ADR
entropion	I-ADR
after	O
at	O
least	O
2	O
year	O
of	O
twice-a-day	O
application	O
of	O
dipivefrin	B-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
patient	O
who	O
presented	O
to	O
the	O
oculoplastics	O
department	O
for	O
repair	O
of	O
cicatrical	B-ADR
entropion	I-ADR
after	O
topical	O
use	O
of	O
dipivefrin	B-Drug
0	O
<EOS>	O
a	O
34-year-old	O
lady	O
developed	O
a	O
constellation	B-ADR
of	I-ADR
dermatitis	I-ADR
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Drug
for	O
sero-negative	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
34-year-old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	B-ADR
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Drug
for	O
sero-negative	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
34-year-old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	B-ADR
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Drug
for	O
sero-negative	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
34-year-old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	B-ADR
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Drug
for	O
sero-negative	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	O
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADR
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	O
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADR
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	O
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	B-ADR
reaction	I-ADR
to	O
sulphasalazine	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	O
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	B-ADR
reaction	I-ADR
to	O
sulphasalazine	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	I-ADR
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
0	O
<EOS>	O
it	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
feature	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmark	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	B-Drug
syndrome	I-ADR
'	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
0	O
<EOS>	O
the	O
3-week	O
sulphasalazine	B-Drug
syndrome	I-ADR
strike	O
again	O
0	O
<EOS>	O
interestingly	O
,	O
the	O
use	O
of	O
carboplatin	O
(	O
cbdca	O
)	O
and	O
vd	O
in	O
the	O
subsequent	O
treatment	O
course	O
wa	O
well	O
tolerated	O
indicating	O
that	O
the	O
siadh	B-ADR
wa	O
most	O
likely	O
to	O
have	O
been	O
induced	O
by	O
administration	O
of	O
cddp	B-Drug
0	O
<EOS>	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
adh	O
(	O
siadh	B-ADR
)	O
following	O
cisplatin	B-Drug
administration	O
in	O
a	O
pulmonary	O
adenocarcinoma	O
patient	O
with	O
a	O
malignant	O
pleural	O
effusion	O
0	O
<EOS>	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
adh	I-ADR
(	O
siadh	O
)	O
following	O
cisplatin	B-Drug
administration	O
in	O
a	O
pulmonary	O
adenocarcinoma	O
patient	O
with	O
a	O
malignant	O
pleural	O
effusion	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	B-Drug
)	O
and	O
vindesine	O
(	O
vd	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-Drug
(	O
cddp	O
)	O
and	O
vindesine	O
(	O
vd	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	O
)	O
and	O
vindesine	O
(	O
vd	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	O
)	O
and	O
vindesine	B-Drug
(	O
vd	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	B-Drug
)	O
and	O
vindesine	O
(	O
vd	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-Drug
(	O
cddp	O
)	O
and	O
vindesine	O
(	O
vd	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	O
)	O
and	O
vindesine	O
(	O
vd	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	O
(	O
cddp	O
)	O
and	O
vindesine	B-Drug
(	O
vd	O
)	O
0	O
<EOS>	O
after	O
extensive	O
neurological	O
work	O
up	O
	O
,	O
we	O
realized	O
that	O
the	O
anisocoria	B-ADR
wa	O
related	O
to	O
the	O
transdermal	O
scopolamine	B-Drug
patch	O
that	O
we	O
had	O
prescribed	O
for	O
weaning	O
off	O
the	O
opioid	O
0	O
<EOS>	O
anisocoria	B-ADR
from	O
transdermal	O
scopolamine	B-Drug
0	O
<EOS>	O
de	B-ADR
novo	I-ADR
absence	I-ADR
status	I-ADR
of	O
late	O
onset	O
following	O
withdrawal	O
of	O
lorazepam	B-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
aim	O
of	O
this	O
report	O
is	O
to	O
describe	O
the	O
clinical	O
and	O
electroencephalographic	O
finding	O
seen	O
in	O
an	O
elderly	O
woman	O
without	O
previous	O
history	O
of	O
seizure	O
who	O
developed	O
a	O
nonconvulsive	B-ADR
generalized	I-ADR
status	I-ADR
epilepticus	I-ADR
following	O
acute	O
withdrawal	O
of	O
lorazepam	B-Drug
0	O
<EOS>	O
early	O
recognition	O
of	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
type	O
1	O
can	O
avoid	O
life-threatening	B-ADR
vincristine	B-Drug
neurotoxicity	I-ADR
0	O
<EOS>	O
recognizing	O
early	O
sign	O
of	O
hmsn	O
,	O
such	O
a	O
areflexia	O
and	O
pe	O
cavus	O
deformity	O
,	O
can	O
prevent	O
severe	B-ADR
neurotoxicity	I-ADR
of	O
polychemotherapy	O
by	O
avoiding	O
vincristine	B-Drug
0	O
<EOS>	O
the	O
disease	O
predisposes	O
to	O
severe	O
vincristine	B-Drug
neurotoxicity	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
31-year-old	O
woman	O
with	O
recurrent	O
hodgkin	O
lymphoma	O
and	O
unrecognized	O
hmsn-1	O
who	O
developed	O
severe	B-ADR
motor	I-ADR
neuropathy	I-ADR
3	O
week	O
after	O
the	O
first	O
cycle	O
of	O
treatment	O
including	O
2	O
mg	O
of	O
vincristine	B-Drug
0	O
<EOS>	O
acute	O
asymptomatic	B-ADR
hepatitis	I-ADR
in	O
a	O
healthy	O
normal	O
volunteer	O
exposed	O
to	O
2	O
oral	O
dos	O
of	O
amodiaquine	B-Drug
and	O
artesunate	O
0	O
<EOS>	O
acute	O
asymptomatic	B-ADR
hepatitis	I-ADR
in	O
a	O
healthy	O
normal	O
volunteer	O
exposed	O
to	O
2	O
oral	O
dos	O
of	O
amodiaquine	O
and	O
artesunate	B-Drug
0	O
<EOS>	O
this	O
report	O
describes	O
an	O
unexpected	O
drug-induced	O
hepatitis	B-ADR
in	O
a	O
previously	O
healthy	O
young	O
woman	O
exposed	O
to	O
2	O
dos	O
of	O
amodiaquine	B-Drug
and	O
artesunate	O
0	O
<EOS>	O
this	O
report	O
describes	O
an	O
unexpected	O
drug-induced	O
hepatitis	B-ADR
in	O
a	O
previously	O
healthy	O
young	O
woman	O
exposed	O
to	O
2	O
dos	O
of	O
amodiaquine	O
and	O
artesunate	B-Drug
0	O
<EOS>	O
systemic	B-ADR
allergic	I-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
8-methoxypsoralen	B-Drug
(	O
8-mop	O
)	O
0	O
<EOS>	O
systemic	B-ADR
allergic	I-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
8-methoxypsoralen	O
(	O
8-mop	B-Drug
)	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
had	O
a	O
systemic	B-ADR
allergic	I-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
8-mop	B-Drug
develop	O
during	O
her	O
second	O
course	O
of	O
puva	O
treatment	O
for	O
psoriasis	O
0	O
<EOS>	O
a	O
33-year-old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-Drug
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	O
,	O
abdominal	B-ADR
pain	I-ADR
,	O
and	O
distention	O
0	O
<EOS>	O
a	O
33-year-old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-Drug
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	B-ADR
,	O
abdominal	O
pain	O
,	O
and	O
distention	O
0	O
<EOS>	O
a	O
33-year-old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-Drug
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	O
,	O
abdominal	O
pain	O
,	O
and	O
distention	B-ADR
0	O
<EOS>	O
agranulocytosis	B-ADR
and	O
granulocytopenia	O
associated	O
with	O
quetiapine	B-Drug
0	O
<EOS>	O
agranulocytosis	O
and	O
granulocytopenia	B-ADR
associated	O
with	O
quetiapine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
although	O
a	O
definite	O
association	O
ha	O
not	O
been	O
proven	O
,	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
agranulocytosis	B-ADR
while	O
using	O
quetiapine	B-Drug
0	O
<EOS>	O
method	O
:	O
we	O
describe	O
three	O
case-reports	O
concerning	O
haematological	B-ADR
adverse	I-ADR
effect	I-ADR
of	O
quetiapine	B-Drug
0	O
<EOS>	O
result	O
:	O
quetiapine	B-Drug
wa	O
associated	O
with	O
leucopenia	O
in	O
two	O
patient	O
and	O
clinically	O
apparent	O
agranulocytosis	B-ADR
in	O
one	O
patient	O
0	O
<EOS>	O
result	O
:	O
quetiapine	B-Drug
wa	O
associated	O
with	O
leucopenia	B-ADR
in	O
two	O
patient	O
and	O
clinically	O
apparent	O
agranulocytosis	O
in	O
one	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
there	O
is	O
very	O
little	O
published	O
information	O
regarding	O
ofloxacin-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
0	O
<EOS>	O
however	O
,	O
a	O
large	O
case-control	O
study	O
included	O
three	O
case	O
of	O
either	O
stevens-johnson	B-ADR
syndrome	I-ADR
or	O
toxic	O
epidermal	O
necrolysis	O
associated	O
with	O
ofloxacin	B-Drug
use	O
,	O
but	O
no	O
detail	O
of	O
the	O
case	O
were	O
given	O
0	O
<EOS>	O
however	O
,	O
a	O
large	O
case-control	O
study	O
included	O
three	O
case	O
of	O
either	O
stevens-johnson	O
syndrome	O
or	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
associated	O
with	O
ofloxacin	B-Drug
use	O
,	O
but	O
no	O
detail	O
of	O
the	O
case	O
were	O
given	O
0	O
<EOS>	O
it	O
is	O
hoped	O
that	O
this	O
case	O
report	O
creates	O
awareness	O
that	O
ofloxacin-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
is	O
possible	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
in	O
a	O
man	O
who	O
wa	O
treated	O
with	O
oral	O
ofloxacin	B-Drug
for	O
epididymitis	O
0	O
<EOS>	O
ofloxacin	B-Drug
:	O
a	O
probable	O
cause	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
0	O
<EOS>	O
this	O
report	O
rule	O
out	O
other	O
cause	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
and	O
implicates	O
ofloxacin	B-Drug
in	O
what	O
appears	O
to	O
be	O
an	O
atypical	O
presentation	O
of	O
drug-induced	O
toxic	O
epidermal	O
necrolysis	O
0	O
<EOS>	O
this	O
report	O
rule	O
out	O
other	O
cause	O
of	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
and	O
implicates	O
ofloxacin	B-Drug
in	O
what	O
appears	O
to	O
be	O
an	O
atypical	O
presentation	O
of	O
drug-induced	O
toxic	O
epidermal	O
necrolysis	O
0	O
<EOS>	O
a	O
boy	O
with	O
chronic	O
neutropenia	O
and	O
recurrent	O
inflammatory	O
skin	O
lesion	O
developed	O
multiple	B-ADR
erythematous	I-ADR
nodule	I-ADR
following	O
administration	O
of	O
g-csf	B-Drug
0	O
<EOS>	O
a	O
girl	O
with	O
cystic	O
fibrosis	O
and	O
cyclic	O
neutropenia	O
developed	O
an	O
erythematous	B-ADR
papular	I-ADR
eruption	I-ADR
without	O
fever	O
or	O
neutrophilia	O
7	O
month	O
after	O
commencing	O
therapy	O
with	O
g-csf	B-Drug
0	O
<EOS>	O
neutrophilic	B-ADR
dermatosis	I-ADR
in	O
two	O
child	O
with	O
idiopathic	O
neutropenia	O
:	O
association	O
with	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	B-Drug
)	O
therapy	O
0	O
<EOS>	O
neutrophilic	B-ADR
dermatosis	I-ADR
in	O
two	O
child	O
with	O
idiopathic	O
neutropenia	O
:	O
association	O
with	O
granulocyte	B-Drug
colony-stimulating	I-Drug
factor	I-Drug
(	O
g-csf	O
)	O
therapy	O
0	O
<EOS>	O
painful	O
neutrophilic	B-ADR
skin	I-ADR
lesion	I-ADR
were	O
observed	O
in	O
two	O
child	O
receiving	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	B-Drug
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
0	O
<EOS>	O
painful	O
neutrophilic	B-ADR
skin	I-ADR
lesion	I-ADR
were	O
observed	O
in	O
two	O
child	O
receiving	O
granulocyte	B-Drug
colony-stimulating	I-Drug
factor	I-Drug
(	O
g-csf	O
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
0	O
<EOS>	O
painful	B-ADR
neutrophilic	O
skin	O
lesion	O
were	O
observed	O
in	O
two	O
child	O
receiving	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	B-Drug
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
0	O
<EOS>	O
painful	B-ADR
neutrophilic	O
skin	O
lesion	O
were	O
observed	O
in	O
two	O
child	O
receiving	O
granulocyte	B-Drug
colony-stimulating	I-Drug
factor	I-Drug
(	O
g-csf	O
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
0	O
<EOS>	O
we	O
believe	O
that	O
these	O
skin	O
eruption	O
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	B-ADR
dermatosis	I-ADR
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
g-csf	B-Drug
therapy	O
0	O
<EOS>	O
we	O
believe	O
that	O
these	O
skin	B-ADR
eruption	I-ADR
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	O
dermatosis	O
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
g-csf	B-Drug
therapy	O
0	O
<EOS>	O
there	O
is	O
a	O
putative	O
role	O
of	O
liothyronine	B-Drug
administration	O
in	O
precipitating	O
or	O
activating	O
hyperthyroidism	B-ADR
0	O
<EOS>	O
triiodothyronine-induced	B-Drug
thyrotoxicosis	B-ADR
in	O
ophthalmic	O
graf	O
disease	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	O
visual	O
field	O
defect	O
(	O
vfds	B-ADR
)	O
in	O
a	O
psychiatric	O
patient	O
with	O
bipolar	O
disorder	O
receiving	O
adjunctive	O
tiagabine	B-Drug
treatment	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	O
visual	B-ADR
field	I-ADR
defect	I-ADR
(	O
vfds	O
)	O
in	O
a	O
psychiatric	O
patient	O
with	O
bipolar	O
disorder	O
receiving	O
adjunctive	O
tiagabine	B-Drug
treatment	O
0	O
<EOS>	O
pulmonary	B-ADR
toxicity	I-ADR
with	O
mefloquine	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
second	O
report	O
of	O
acute	B-ADR
lung	I-ADR
injury	I-ADR
and	O
diffuse	O
alveolar	O
damage	O
caused	O
by	O
mefloquine	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
second	O
report	O
of	O
acute	O
lung	O
injury	O
and	O
diffuse	B-ADR
alveolar	I-ADR
damage	I-ADR
caused	O
by	O
mefloquine	B-Drug
0	O
<EOS>	O
this	O
report	O
present	O
a	O
case	O
of	O
acute	B-ADR
lung	I-ADR
injury	I-ADR
developing	O
within	O
hour	O
after	O
administration	O
of	O
mefloquine	B-Drug
for	O
a	O
low-level	O
plasmodium	O
falciparum	O
malaria	O
,	O
which	O
wa	O
persistent	O
despite	O
halofantrine	O
therapy	O
0	O
<EOS>	O
an	O
adult	O
male	O
presented	O
with	O
central	B-ADR
blindness	I-ADR
after	O
ingesting	O
methanol	B-Drug
0	O
<EOS>	O
reversal	O
of	O
severe	O
methanol-induced	B-Drug
visual	B-ADR
impairment	I-ADR
:	O
no	O
evidence	O
of	O
retinal	O
toxicity	O
due	O
to	O
fomepizole	O
0	O
<EOS>	O
extra	O
caution	O
should	O
be	O
taken	O
in	O
using	O
octreotide	B-Drug
or	O
it	O
long-acting	O
analog	O
in	O
patient	O
otherwise	O
predisposed	O
to	O
intrahepatic	B-ADR
bile	I-ADR
stasis	I-ADR
0	O
<EOS>	O
gallstone	O
and	O
bile	B-ADR
sludge	I-ADR
are	O
common	O
side	O
effect	O
of	O
octreotide	B-Drug
therapy	O
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
0	O
<EOS>	O
gallstone	B-ADR
and	O
bile	O
sludge	O
are	O
common	O
side	O
effect	O
of	O
octreotide	B-Drug
therapy	O
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
0	O
<EOS>	O
hepatolithiasis	B-ADR
(	O
intrahepatic	O
stone	O
)	O
during	O
octreotide	B-Drug
therapy	O
for	O
acromegaly	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
in	O
addition	O
to	O
it	O
known	O
effect	O
on	O
gallbladder	O
stasis	O
,	O
octreotide	B-Drug
alters	B-ADR
bile	I-ADR
acid	I-ADR
composition	I-ADR
and	O
may	O
thus	O
hasten	O
intrahepatic	O
sludge	O
and	O
stone	O
formation	O
0	O
<EOS>	O
in	O
addition	O
to	O
it	O
known	O
effect	O
on	O
gallbladder	B-ADR
stasis	I-ADR
,	O
octreotide	B-Drug
alters	O
bile	O
acid	O
composition	O
and	O
may	O
thus	O
hasten	O
intrahepatic	O
sludge	O
and	O
stone	O
formation	O
0	O
<EOS>	O
in	O
addition	O
to	O
it	O
known	O
effect	O
on	O
gallbladder	O
stasis	O
,	O
octreotide	B-Drug
alters	O
bile	O
acid	O
composition	O
and	O
may	O
thus	O
hasten	B-ADR
intrahepatic	I-ADR
sludge	I-ADR
and	O
stone	O
formation	O
0	O
<EOS>	O
in	O
addition	O
to	O
it	O
known	O
effect	O
on	O
gallbladder	O
stasis	O
,	O
octreotide	B-Drug
alters	O
bile	O
acid	O
composition	O
and	O
may	O
thus	O
hasten	O
intrahepatic	O
sludge	O
and	O
stone	B-ADR
formation	I-ADR
0	O
<EOS>	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
hepatolithiasis	B-ADR
during	O
octreotide	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
hepatolithiasis	B-ADR
(	O
intrahepatic	O
stone	O
)	O
complicated	O
by	O
gram-negative	O
sepsis	O
in	O
a	O
37	O
year	O
old	O
male	O
with	O
acromegaly	O
being	O
treated	O
with	O
octreotide	B-Drug
0	O
<EOS>	O
however	O
,	O
in	O
the	O
mid-to-late	O
1980s	O
,	O
a	O
series	O
of	O
letter	O
to	O
the	O
editor	O
and	O
case	O
report	O
announced	O
an	O
association	O
between	O
tamoxifen	B-Drug
therapy	O
in	O
woman	O
with	O
breast	O
cancer	O
and	O
the	O
development	O
of	O
endometrial	B-ADR
carcinoma	I-ADR
0	O
<EOS>	O
in	O
this	O
healthy	O
population	O
,	O
the	O
relative	O
risk	O
of	O
developing	O
endometrial	B-ADR
carcinoma	I-ADR
in	O
the	O
tamoxifen	B-Drug
arm	O
wa	O
2.54	O
,	O
although	O
when	O
stratified	O
by	O
age	O
,	O
in	O
woman	O
over	O
50	O
,	O
the	O
risk	O
grew	O
to	O
4.01	O
0	O
<EOS>	O
inh	B-Drug
,	O
which	O
is	O
a	O
leading	O
cause	O
of	O
drug	B-ADR
eruption	I-ADR
in	O
the	O
above	O
group	O
of	O
drug	O
wa	O
withdrawn	O
0	O
<EOS>	O
isonicotinic	B-Drug
acid	I-Drug
hydrazide	I-Drug
induced	O
anagen	B-ADR
effluvium	I-ADR
and	O
associated	O
lichenoid	O
eruption	O
0	O
<EOS>	O
isonicotinic	B-Drug
acid	I-Drug
hydrazide	I-Drug
induced	O
anagen	O
effluvium	O
and	O
associated	O
lichenoid	B-ADR
eruption	I-ADR
0	O
<EOS>	O
such	O
anagen	B-ADR
effluvium	I-ADR
with	O
lichenoid	O
eruption	O
following	O
inh	B-Drug
therapy	O
ha	O
not	O
been	O
observed	O
previously	O
0	O
<EOS>	O
such	O
anagen	O
effluvium	O
with	O
lichenoid	B-ADR
eruption	I-ADR
following	O
inh	B-Drug
therapy	O
ha	O
not	O
been	O
observed	O
previously	O
0	O
<EOS>	O
linear	B-ADR
iga	I-ADR
bullous	I-ADR
dermatosis	I-ADR
occurring	O
after	O
carbamazepine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
who	O
experienced	O
labd	B-ADR
shortly	O
after	O
starting	O
carbamazepine	B-Drug
therapy	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	B-ADR
,	O
fever	O
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
tachycardia	O
,	O
and	O
hypertension	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADR
,	O
agitation	O
,	O
fever	O
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
tachycardia	O
,	O
and	O
hypertension	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	O
,	O
fever	O
,	O
diaphoresis	B-ADR
,	O
tachypnea	O
,	O
tachycardia	O
,	O
and	O
hypertension	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	O
,	O
fever	B-ADR
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
tachycardia	O
,	O
and	O
hypertension	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	O
,	O
fever	O
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
tachycardia	O
,	O
and	O
hypertension	B-ADR
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	O
,	O
fever	O
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
tachycardia	B-ADR
,	O
and	O
hypertension	O
0	O
<EOS>	O
after	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptom	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	O
,	O
agitation	O
,	O
fever	O
,	O
diaphoresis	O
,	O
tachypnea	B-ADR
,	O
tachycardia	O
,	O
and	O
hypertension	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
reaction	I-ADR
in	O
patient	O
receiving	O
sertraline	O
or	O
venlafaxine	O
when	O
metoclopramide	B-Drug
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
reaction	I-ADR
in	O
patient	O
receiving	O
sertraline	B-Drug
or	O
venlafaxine	O
when	O
metoclopramide	O
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
reaction	I-ADR
in	O
patient	O
receiving	O
sertraline	O
or	O
venlafaxine	B-Drug
when	O
metoclopramide	O
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
reaction	O
in	O
patient	O
receiving	O
sertraline	O
or	O
venlafaxine	O
when	O
metoclopramide	B-Drug
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
reaction	O
in	O
patient	O
receiving	O
sertraline	B-Drug
or	O
venlafaxine	O
when	O
metoclopramide	O
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
reaction	O
in	O
patient	O
receiving	O
sertraline	O
or	O
venlafaxine	B-Drug
when	O
metoclopramide	O
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
movement	I-ADR
disorder	I-ADR
occurring	O
when	O
metoclopramide	B-Drug
wa	O
coadministered	O
with	O
sertraline	O
or	O
venlafaxine	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
movement	I-ADR
disorder	I-ADR
occurring	O
when	O
metoclopramide	O
wa	O
coadministered	O
with	O
sertraline	B-Drug
or	O
venlafaxine	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	O
syndrome	O
with	O
serious	O
extrapyramidal	B-ADR
movement	I-ADR
disorder	I-ADR
occurring	O
when	O
metoclopramide	O
wa	O
coadministered	O
with	O
sertraline	O
or	O
venlafaxine	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
movement	O
disorder	O
occurring	O
when	O
metoclopramide	B-Drug
wa	O
coadministered	O
with	O
sertraline	O
or	O
venlafaxine	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
movement	O
disorder	O
occurring	O
when	O
metoclopramide	O
wa	O
coadministered	O
with	O
sertraline	B-Drug
or	O
venlafaxine	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
with	O
serious	O
extrapyramidal	O
movement	O
disorder	O
occurring	O
when	O
metoclopramide	O
wa	O
coadministered	O
with	O
sertraline	O
or	O
venlafaxine	B-Drug
0	O
<EOS>	O
serotonin	B-ADR
syndrome	I-ADR
caused	O
by	O
selective	O
serotonin	O
reuptake-inhibitors-metoclopramide	B-Drug
interaction	O
0	O
<EOS>	O
she	O
wa	O
administered	O
metoclopramide	B-Drug
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hour	O
,	O
developed	O
agitation	B-ADR
,	O
dysarthria	O
,	O
diaphoresis	O
,	O
and	O
a	O
movement	O
disorder	O
0	O
<EOS>	O
she	O
wa	O
administered	O
metoclopramide	B-Drug
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hour	O
,	O
developed	O
agitation	O
,	O
dysarthria	O
,	O
diaphoresis	B-ADR
,	O
and	O
a	O
movement	O
disorder	O
0	O
<EOS>	O
she	O
wa	O
administered	O
metoclopramide	B-Drug
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hour	O
,	O
developed	O
agitation	O
,	O
dysarthria	B-ADR
,	O
diaphoresis	O
,	O
and	O
a	O
movement	O
disorder	O
0	O
<EOS>	O
she	O
wa	O
administered	O
metoclopramide	B-Drug
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hour	O
,	O
developed	O
agitation	O
,	O
dysarthria	O
,	O
diaphoresis	O
,	O
and	O
a	O
movement	B-ADR
disorder	I-ADR
0	O
<EOS>	O
she	O
wa	O
admitted	O
following	O
a	O
fall	O
and	O
,	O
after	O
being	O
given	O
metoclopramide	B-Drug
,	O
developed	O
movement	B-ADR
disorder	I-ADR
and	O
a	O
period	O
of	O
unresponsiveness	O
0	O
<EOS>	O
she	O
wa	O
admitted	O
following	O
a	O
fall	O
and	O
,	O
after	O
being	O
given	O
metoclopramide	B-Drug
,	O
developed	O
movement	O
disorder	O
and	O
a	O
period	O
of	O
unresponsiveness	B-ADR
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
a	O
rare	O
enzyme	O
deficiency	O
developed	O
a	O
malignant	B-ADR
neuroleptic	I-ADR
syndrome	I-ADR
after	O
having	O
been	O
treated	O
with	O
one	O
single	O
dose	O
of	O
haloperidol	B-Drug
0	O
<EOS>	O
background	O
:	O
report	O
on	O
delated	B-ADR
cutaneous	I-ADR
reaction	I-ADR
to	O
captopril	B-Drug
have	O
been	O
seldom	O
reported	O
0	O
<EOS>	O
captopril	B-Drug
is	O
an	O
angiotensin-converting	O
enzyme	O
(	O
ace	O
)	O
inhibitor	O
and	O
their	O
cutaneous	B-ADR
side-effects	I-ADR
are	O
documented	O
,	O
but	O
little	O
ha	O
been	O
published	O
concerning	O
the	O
usefulness	O
of	O
patch	O
test	O
when	O
they	O
occur	O
0	O
<EOS>	O
dermatitis	B-ADR
to	O
captopril	B-Drug
0	O
<EOS>	O
we	O
presented	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
a	O
cutaneous	B-ADR
reaction	I-ADR
induced	O
by	O
captopril	B-Drug
with	O
positive	O
patch	O
test	O
0	O
<EOS>	O
a	O
62-year-old	O
caucasian	O
man	O
with	O
atrial	O
fibrillation	O
who	O
wa	O
taking	O
warfarin	B-Drug
reported	O
an	O
episode	O
of	O
hematochezia	B-ADR
;	O
his	O
international	O
normalized	O
ratio	O
(	O
inr	O
)	O
wa	O
1.74	O
0	O
<EOS>	O
warfarin-associated	B-Drug
bleeding	B-ADR
complication	O
saved	O
life	O
0	O
<EOS>	O
warfarin-associated	B-Drug
bleeding	B-ADR
generally	O
is	O
considered	O
deleterious	O
;	O
however	O
,	O
in	O
our	O
patient	O
it	O
unmasked	O
an	O
early	O
stage	O
of	O
colon	O
cancer	O
and	O
thus	O
may	O
have	O
saved	O
the	O
patient	O
life	O
0	O
<EOS>	O
a	O
case	O
of	O
polymyositis	O
with	O
dilated	B-ADR
cardiomyopathy	I-ADR
associated	O
with	O
interferon	B-Drug
alpha	I-Drug
treatment	O
for	O
hepatitis	O
b	O
0	O
<EOS>	O
a	O
case	O
of	O
polymyositis	B-ADR
with	O
dilated	O
cardiomyopathy	O
associated	O
with	O
interferon	B-Drug
alpha	I-Drug
treatment	O
for	O
hepatitis	O
b	O
0	O
<EOS>	O
in	O
this	O
case	O
,	O
interferon	B-Drug
alpha	I-Drug
induced	O
polymyositis	O
and	O
cardiomyopathy	B-ADR
is	O
diagnosed	O
in	O
a	O
33-yr-old	O
male	O
patient	O
with	O
history	O
of	O
chronic	O
hepatitis	O
b	O
0	O
<EOS>	O
in	O
this	O
case	O
,	O
interferon	B-Drug
alpha	I-Drug
induced	O
polymyositis	B-ADR
and	O
cardiomyopathy	O
is	O
diagnosed	O
in	O
a	O
33-yr-old	O
male	O
patient	O
with	O
history	O
of	O
chronic	O
hepatitis	O
b	O
0	O
<EOS>	O
polymyositis	B-ADR
is	O
a	O
rare	O
complication	O
of	O
interferon	B-Drug
alpha	I-Drug
treatment	O
a	O
a	O
result	O
of	O
immune-modulating	O
role	O
of	O
the	O
drug	O
itself	O
0	O
<EOS>	O
to	O
treat	O
hepatitis	O
b	O
,	O
interferon	B-Drug
alpha	I-Drug
wa	O
administered	O
until	O
the	O
proximal	O
muscle	B-ADR
weakness	I-ADR
developed	O
0	O
<EOS>	O
long-term	O
follow-up	O
after	O
neoplastic	B-ADR
seeding	I-ADR
complicating	O
percutaneous	O
ethanol	B-Drug
injection	O
for	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
subcutaneous	B-ADR
metastasis	I-ADR
along	O
the	O
needle	O
track	O
after	O
percutaneous	O
ethanol	B-Drug
injection	O
(	O
pei	O
)	O
for	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
0	O
<EOS>	O
aggressive	B-ADR
endometrial	I-ADR
carcinoma	I-ADR
in	O
a	O
breast	O
cancer	O
patient	O
treated	O
with	O
tamoxifen	B-Drug
with	O
normal	O
transvaginal	O
ultrasonography	O
0	O
<EOS>	O
since	O
tamoxifen	B-Drug
therapy	O
can	O
induce	O
endometrial	B-ADR
disorder	I-ADR
,	O
surveillance	O
scheme	O
of	O
woman	O
taking	O
tamoxifen	O
have	O
been	O
recommended	O
0	O
<EOS>	O
since	O
tamoxifen	B-Drug
therapy	O
can	O
induce	O
endometrial	B-ADR
disorder	I-ADR
,	O
surveillance	O
scheme	O
of	O
woman	O
taking	O
tamoxifen	O
have	O
been	O
recommended	O
0	O
<EOS>	O
we	O
described	O
a	O
very	O
atypical	O
case	O
of	O
a	O
high	O
stage	O
,	O
high	O
grade	O
endometrial	B-ADR
cancer	I-ADR
associated	O
with	O
tamoxifen	B-Drug
in	O
a	O
64-year-old	O
woman	O
with	O
a	O
past	O
history	O
of	O
breast	O
cancer	O
0	O
<EOS>	O
beginning	O
ductopenia	O
wa	O
present	O
in	O
two	O
,	O
suggesting	O
that	O
itraconazole	B-Drug
might	O
be	O
responsible	O
for	O
the	O
occurrence	O
of	O
prolonged	O
drug-induced	O
cholangiopathy	B-ADR
0	O
<EOS>	O
beginning	O
ductopenia	B-ADR
wa	O
present	O
in	O
two	O
,	O
suggesting	O
that	O
itraconazole	B-Drug
might	O
be	O
responsible	O
for	O
the	O
occurrence	O
of	O
prolonged	O
drug-induced	O
cholangiopathy	O
0	O
<EOS>	O
conclusion	O
:	O
itraconazole-induced	B-Drug
liver	O
injury	O
present	O
with	O
a	O
cholestatic	B-ADR
pattern	I-ADR
of	I-ADR
injury	I-ADR
with	O
damage	O
to	O
the	O
interlobular	O
bile	O
duct	O
,	O
possibly	O
leading	O
to	O
ductopenia	O
0	O
<EOS>	O
conclusion	O
:	O
itraconazole-induced	B-Drug
liver	O
injury	O
present	O
with	O
a	O
cholestatic	O
pattern	O
of	O
injury	O
with	O
damage	B-ADR
to	I-ADR
the	I-ADR
interlobular	I-ADR
bile	I-ADR
duct	I-ADR
,	O
possibly	O
leading	O
to	O
ductopenia	O
0	O
<EOS>	O
conclusion	O
:	O
itraconazole-induced	B-Drug
liver	O
injury	O
present	O
with	O
a	O
cholestatic	O
pattern	O
of	O
injury	O
with	O
damage	O
to	O
the	O
interlobular	O
bile	O
duct	O
,	O
possibly	O
leading	O
to	O
ductopenia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
itraconazole-induced	B-Drug
liver	B-ADR
injury	I-ADR
present	O
with	O
a	O
cholestatic	O
pattern	O
of	O
injury	O
with	O
damage	O
to	O
the	O
interlobular	O
bile	O
duct	O
,	O
possibly	O
leading	O
to	O
ductopenia	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
related	O
to	O
itraconazole	B-Drug
:	O
report	O
of	O
three	O
case	O
0	O
<EOS>	O
method	O
:	O
three	O
patient	O
with	O
apparent	O
itraconazole-induced	B-Drug
liver	B-ADR
injury	I-ADR
were	O
studied	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
acute	O
hepatitis	B-ADR
is	O
best	O
known	O
for	O
ketoconazole	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
three	O
patient	O
who	O
developed	O
acute	O
liver	B-ADR
damage	I-ADR
during	O
therapy	O
with	O
itraconazole	B-Drug
,	O
and	O
in	O
whom	O
liver	O
biopsy	O
specimen	O
were	O
obtained	O
0	O
<EOS>	O
we	O
suggest	O
that	O
itraconazole	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drug	O
that	O
may	O
be	O
responsible	O
for	O
a	O
drug-induced	O
vanishing	B-ADR
bile	I-ADR
duct	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
with	O
itraconazole	B-Drug
,	O
hepatotoxic	B-ADR
reaction	O
have	O
only	O
very	O
rarely	O
been	O
reported	O
,	O
and	O
histologic	O
data	O
are	O
lacking	O
0	O
<EOS>	O
thrombotic	B-ADR
stroke	I-ADR
associated	O
with	O
the	O
use	O
of	O
porcine	B-Drug
factor	I-Drug
viii	I-Drug
in	O
a	O
patient	O
with	O
acquired	O
haemophilia	O
0	O
<EOS>	O
we	O
have	O
recently	O
encountered	O
a	O
patient	O
with	O
acquired	O
haemophilia	O
who	O
developed	O
a	O
thrombotic	B-ADR
left	I-ADR
middle	I-ADR
cerebral	I-ADR
artery	I-ADR
distribution	I-ADR
stroke	I-ADR
while	O
being	O
treated	O
with	O
pfviii	B-Drug
0	O
<EOS>	O
we	O
speculate	O
that	O
platelet	O
activation	O
induced	O
by	O
pfviii	B-Drug
may	O
have	O
contributed	O
to	O
thrombosis	B-ADR
and	O
suggest	O
that	O
pfviii	O
be	O
used	O
with	O
caution	O
in	O
elderly	O
patient	O
with	O
pre-existing	O
cardiovascular	O
risk	O
factor	O
0	O
<EOS>	O
cutaneous	B-ADR
sarcoidosis	I-ADR
during	O
interferon	B-Drug
alfa	I-Drug
and	O
ribavirin	O
treatment	O
of	O
hepatitis	O
c	O
virus	O
infection	O
:	O
two	O
case	O
0	O
<EOS>	O
cutaneous	B-ADR
sarcoidosis	I-ADR
during	O
interferon	O
alfa	O
and	O
ribavirin	B-Drug
treatment	O
of	O
hepatitis	O
c	O
virus	O
infection	O
:	O
two	O
case	O
0	O
<EOS>	O
there	O
have	O
been	O
more	O
than	O
20	O
observation	O
of	O
the	O
appearance	O
or	O
aggravation	O
of	O
this	O
granulomatosis	B-ADR
with	O
interferon	B-Drug
alfa	I-Drug
and	O
more	O
recently	O
with	O
the	O
combination	O
of	O
interferon	O
alfa	O
plus	O
ribavirin	O
0	O
<EOS>	O
there	O
have	O
been	O
more	O
than	O
20	O
observation	O
of	O
the	O
appearance	O
or	O
aggravation	O
of	O
this	O
granulomatosis	B-ADR
with	O
interferon	B-Drug
alfa	I-Drug
and	O
more	O
recently	O
with	O
the	O
combination	O
of	O
interferon	O
alfa	O
plus	O
ribavirin	O
0	O
<EOS>	O
there	O
have	O
been	O
more	O
than	O
20	O
observation	O
of	O
the	O
appearance	O
or	O
aggravation	O
of	O
this	O
granulomatosis	B-ADR
with	O
interferon	O
alfa	O
and	O
more	O
recently	O
with	O
the	O
combination	O
of	O
interferon	O
alfa	O
plus	O
ribavirin	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
new	O
case	O
of	O
sarcoidosis	B-ADR
in	O
two	O
patient	O
with	O
hepatitis	O
c	O
virus	O
infection	O
treated	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
ribavirin	O
0	O
<EOS>	O
we	O
report	O
two	O
new	O
case	O
of	O
sarcoidosis	B-ADR
in	O
two	O
patient	O
with	O
hepatitis	O
c	O
virus	O
infection	O
treated	O
with	O
interferon	O
alfa	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
although	O
mirtazapine	B-Drug
offer	O
clinician	O
a	O
combination	O
of	O
strong	O
efficacy	O
and	O
good	O
safety	O
,	O
we	O
suggest	O
bearing	O
s	B-ADR
in	O
mind	O
when	O
prescribing	O
this	O
drug	O
,	O
especially	O
in	O
frail	O
,	O
elderly	O
patient	O
with	O
underlying	O
chronic	O
condition	O
0	O
<EOS>	O
discussion	O
:	O
a	O
review	O
of	O
the	O
case	O
of	O
s	B-ADR
with	O
implication	O
of	O
mirtazapine	B-Drug
a	O
the	O
cause	O
wa	O
performed	O
0	O
<EOS>	O
objective	O
:	O
to	O
document	O
a	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
(	O
s	O
)	O
associated	O
with	O
mirtazapine	B-Drug
monotherapy	O
,	O
review	O
the	O
previously	O
reported	O
case	O
of	O
s	O
associated	O
with	O
this	O
tetracyclic	O
antidepressant	O
,	O
and	O
discus	O
the	O
possible	O
pathogenic	O
mechanism	O
leading	O
to	O
this	O
serious	O
adverse	O
drug	O
reaction	O
0	O
<EOS>	O
objective	O
:	O
to	O
document	O
a	O
case	O
of	O
serotonin	O
syndrome	O
(	O
s	B-ADR
)	O
associated	O
with	O
mirtazapine	B-Drug
monotherapy	O
,	O
review	O
the	O
previously	O
reported	O
case	O
of	O
s	O
associated	O
with	O
this	O
tetracyclic	O
antidepressant	O
,	O
and	O
discus	O
the	O
possible	O
pathogenic	O
mechanism	O
leading	O
to	O
this	O
serious	O
adverse	O
drug	O
reaction	O
0	O
<EOS>	O
severe	O
serotonin	B-ADR
syndrome	I-ADR
induced	O
by	O
mirtazapine	B-Drug
monotherapy	O
0	O
<EOS>	O
pulmonary	B-ADR
toxicity	I-ADR
secondary	O
to	O
procarbazine	B-Drug
0	O
<EOS>	O
a	O
64-year-old	O
man	O
presented	O
with	O
proteinuria	B-ADR
during	O
postoperative	O
interferon	B-Drug
(	I-Drug
ifn	I-Drug
)	I-Drug
-beta	I-Drug
therapy	O
against	O
malignant	O
melanoma	O
0	O
<EOS>	O
minimal	B-ADR
change	I-ADR
nephrotic	I-ADR
syndrome	I-ADR
developing	O
during	O
postoperative	O
interferon-beta	B-Drug
therapy	O
for	O
malignant	O
melanoma	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
that	O
demonstrates	O
histological	B-ADR
abnormality	I-ADR
of	I-ADR
the	I-ADR
glomerulus	I-ADR
associated	O
with	O
postoperative	O
ifn-beta	B-Drug
therapy	O
for	O
the	O
malignant	O
melanoma	O
0	O
<EOS>	O
the	O
author	O
report	O
two	O
case	O
of	O
delayed	B-ADR
elimination	I-ADR
of	O
methotrexate	O
in	O
patient	O
receiving	O
ciprofloxacin	B-Drug
,	O
with	O
severe	O
toxicity	O
0	O
<EOS>	O
the	O
author	O
report	O
two	O
case	O
of	O
delayed	B-ADR
elimination	I-ADR
of	O
methotrexate	B-Drug
in	O
patient	O
receiving	O
ciprofloxacin	O
,	O
with	O
severe	O
toxicity	O
0	O
<EOS>	O
the	O
author	O
report	O
two	O
case	O
of	O
delayed	O
elimination	O
of	O
methotrexate	O
in	O
patient	O
receiving	O
ciprofloxacin	B-Drug
,	O
with	O
severe	O
toxicity	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
of	O
thrombocytopenia	B-ADR
with	O
lansoprazole	B-Drug
and	O
discontinue	O
the	O
drug	O
if	O
thrombocytopenia	O
becomes	O
apparent	O
0	O
<EOS>	O
discussion	O
:	O
after	O
exclusion	O
of	O
other	O
cause	O
,	O
the	O
onset	O
of	O
thrombocytopenia	B-ADR
after	O
administration	O
of	O
lansoprazole	B-Drug
,	O
the	O
resolution	O
of	O
the	O
adverse	O
reaction	O
after	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
the	O
fact	O
that	O
no	O
other	O
medicine	O
were	O
introduced	O
during	O
this	O
time	O
frame	O
lead	O
u	O
to	O
believe	O
that	O
this	O
wa	O
most	O
likely	O
an	O
idiosyncratic	O
thrombocytopenic	O
response	O
to	O
lansoprazole	O
0	O
<EOS>	O
discussion	O
:	O
after	O
exclusion	O
of	O
other	O
cause	O
,	O
the	O
onset	O
of	O
thrombocytopenia	O
after	O
administration	O
of	O
lansoprazole	B-Drug
,	O
the	O
resolution	O
of	O
the	O
adverse	O
reaction	O
after	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
the	O
fact	O
that	O
no	O
other	O
medicine	O
were	O
introduced	O
during	O
this	O
time	O
frame	O
lead	O
u	O
to	O
believe	O
that	O
this	O
wa	O
most	O
likely	O
an	O
idiosyncratic	O
thrombocytopenic	B-ADR
response	O
to	O
lansoprazole	O
0	O
<EOS>	O
he	O
wa	O
started	O
on	O
oral	O
lansoprazole	B-Drug
60	O
mg	O
twice	O
daily	O
and	O
,	O
on	O
hospital	O
day	O
2	O
,	O
his	O
platelet	B-ADR
count	I-ADR
decreased	I-ADR
to	O
102	O
x	O
10	O
(	O
3	O
)	O
/mm	O
(	O
3	O
)	O
;	O
on	O
hospital	O
day	O
3	O
,	O
the	O
platelet	O
count	O
wa	O
36	O
x	O
10	O
(	O
3	O
)	O
/mm	O
(	O
3	O
)	O
0	O
<EOS>	O
lansoprazole-induced	B-Drug
thrombocytopenia	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
thrombocytopenia	B-ADR
associated	O
with	O
the	O
administration	O
of	O
lansoprazole	B-Drug
0	O
<EOS>	O
to	O
date	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
what	O
appears	O
to	O
be	O
isolated	O
thrombocytopenia	B-ADR
associated	O
with	O
lansoprazole	B-Drug
0	O
<EOS>	O
life-threatening	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
amifostine	B-Drug
used	O
with	O
concurrent	O
chemoradiotherapy	O
for	O
nasopharyngeal	O
cancer	O
in	O
a	O
patient	O
with	O
dermatomyositis	O
:	O
a	O
case	O
report	O
with	O
literature	O
review	O
0	O
<EOS>	O
the	O
most	O
common	O
side	O
effect	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	O
,	O
vomiting	O
,	O
hypotension	O
,	O
hypocalcemia	O
and	O
allergic	B-ADR
reaction	I-ADR
0	O
<EOS>	O
the	O
most	O
common	O
side	O
effect	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	O
,	O
vomiting	O
,	O
hypotension	O
,	O
hypocalcemia	B-ADR
and	O
allergic	O
reaction	O
0	O
<EOS>	O
the	O
most	O
common	O
side	O
effect	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	O
,	O
vomiting	O
,	O
hypotension	B-ADR
,	O
hypocalcemia	O
and	O
allergic	O
reaction	O
0	O
<EOS>	O
the	O
most	O
common	O
side	O
effect	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	B-ADR
,	O
vomiting	O
,	O
hypotension	O
,	O
hypocalcemia	O
and	O
allergic	O
reaction	O
0	O
<EOS>	O
the	O
most	O
common	O
side	O
effect	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	O
,	O
vomiting	B-ADR
,	O
hypotension	O
,	O
hypocalcemia	O
and	O
allergic	O
reaction	O
0	O
<EOS>	O
the	O
patient	O
suffered	O
a	O
life-threatening	B-ADR
anaphylactoid	I-ADR
reaction	I-ADR
to	O
amifostine	B-Drug
0	O
<EOS>	O
agranulocytosis	B-ADR
during	O
clozapine	B-Drug
therapy	O
0	O
<EOS>	O
granulocytopenia	O
and	O
agranulocytosis	B-ADR
are	O
considered	O
among	O
the	O
most	O
dangerous	O
adverse	O
effect	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
granulocytopenia	B-ADR
and	O
agranulocytosis	O
are	O
considered	O
among	O
the	O
most	O
dangerous	O
adverse	O
effect	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
the	O
female	O
patient	O
received	O
clozapine	B-Drug
in	O
a	O
daily	O
dose	O
of	O
400	O
mg	O
,	O
which	O
induced	O
agranulocytosis	B-ADR
after	O
2	O
month	O
0	O
<EOS>	O
the	O
male	O
patient	O
wa	O
treated	O
with	O
225-mg	O
/	O
day	O
clozapine	B-Drug
and	O
the	O
time	O
to	O
the	O
diagnosis	O
of	O
agranulocytosis	B-ADR
wa	O
6	O
week	O
0	O
<EOS>	O
a	O
53-year-old	O
man	O
developed	O
nm	B-ADR
without	O
rigidity	O
while	O
taking	O
olanzapine	B-Drug
0	O
<EOS>	O
atypical	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
we	O
report	O
the	O
case	O
of	O
a	O
31-year-old	O
patient	O
hospitalized	O
due	O
to	O
behavioral	O
alteration	O
and	O
treated	O
with	O
oral	O
zuclopenthixol	B-Drug
,	O
an	O
antipsychotic	O
from	O
the	O
thioxanthene	O
family	O
,	O
who	O
developed	O
an	O
acute	O
,	O
painful	B-ADR
erection	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
priapism	B-ADR
is	O
an	O
uncommon	O
but	O
potentially	O
serious	O
adverse	O
effect	O
of	O
zuclopenthixol	B-Drug
that	O
practitioner	O
,	O
a	O
with	O
many	O
other	O
antipsychotic	O
,	O
should	O
be	O
aware	O
of	O
0	O
<EOS>	O
discussion	O
:	O
the	O
occurrence	O
of	O
priapism	B-ADR
in	O
our	O
patient	O
wa	O
related	O
to	O
zuclopenthixol	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
present	O
a	O
single	O
case	O
of	O
zuclopenthixol-induced	B-Drug
priapism	B-ADR
and	O
a	O
literature	O
review	O
0	O
<EOS>	O
priapism	B-ADR
associated	O
with	O
zuclopenthixol	B-Drug
0	O
<EOS>	O
the	O
capacity	O
of	O
zuclopenthixol	B-Drug
to	O
induce	O
priapism	B-ADR
is	O
thought	O
to	O
be	O
due	O
to	O
it	O
antagonist	O
activity	O
on	O
alpha-adrenergic	O
receptor	O
0	O
<EOS>	O
after	O
identification	O
of	O
the	O
index	O
patient	O
,	O
additional	O
inquiry	O
revealed	O
that	O
the	O
patient	O
mother	O
wa	O
hospitalized	O
previously	O
for	O
overwhelming	O
sepsis	B-ADR
associated	O
with	O
metamizole	B-Drug
use	O
0	O
<EOS>	O
metamizole	B-Drug
,	O
a	O
nonsteroidal	O
antiinflammatory	O
agent	O
,	O
is	O
prohibited	O
in	O
the	O
united	O
state	O
because	O
of	O
the	O
risk	O
of	O
agranulocytosis	B-ADR
but	O
is	O
widely	O
used	O
in	O
mexico	O
and	O
other	O
country	O
0	O
<EOS>	O
erythropoietin	O
is	O
beneficial	O
in	O
mitomycin-induced	B-Drug
hemolytic-uremic	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
developed	O
hus	B-ADR
after	O
treatment	O
with	O
mitomycin	B-Drug
c	I-Drug
(	O
total	O
dose	O
144	O
mg	O
/	O
m2	O
)	O
due	O
to	O
a	O
carcinoma	O
of	O
the	O
ascending	O
colon	O
0	O
<EOS>	O
levofloxacin-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
in	O
an	O
elderly	O
patient	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
case	O
is	O
the	O
first	O
published	O
report	O
of	O
levofloxacin-induced	B-Drug
ten	B-ADR
0	O
<EOS>	O
a	O
31-year-old	O
female	O
developed	O
multiple	O
episode	O
of	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
after	O
combination	O
chemotherapy	O
with	O
cisplatin	O
,	O
vinblastine	O
and	O
bleomycin	B-Drug
for	O
germ	O
cell	O
ovarian	O
cancer	O
stage	O
ic	O
0	O
<EOS>	O
a	O
31-year-old	O
female	O
developed	O
multiple	O
episode	O
of	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
after	O
combination	O
chemotherapy	O
with	O
cisplatin	B-Drug
,	O
vinblastine	O
and	O
bleomycin	O
for	O
germ	O
cell	O
ovarian	O
cancer	O
stage	O
ic	O
0	O
<EOS>	O
a	O
31-year-old	O
female	O
developed	O
multiple	O
episode	O
of	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
after	O
combination	O
chemotherapy	O
with	O
cisplatin	O
,	O
vinblastine	B-Drug
and	O
bleomycin	O
for	O
germ	O
cell	O
ovarian	O
cancer	O
stage	O
ic	O
0	O
<EOS>	O
posterior	B-ADR
leukoencephalopathy	I-ADR
following	O
cisplatin	O
,	O
bleomycin	B-Drug
and	O
vinblastine	O
therapy	O
for	O
germ	O
cell	O
tumor	O
of	O
the	O
ovary	O
0	O
<EOS>	O
posterior	B-ADR
leukoencephalopathy	I-ADR
following	O
cisplatin	B-Drug
,	O
bleomycin	O
and	O
vinblastine	O
therapy	O
for	O
germ	O
cell	O
tumor	O
of	O
the	O
ovary	O
0	O
<EOS>	O
posterior	B-ADR
leukoencephalopathy	I-ADR
following	O
cisplatin	O
,	O
bleomycin	O
and	O
vinblastine	B-Drug
therapy	O
for	O
germ	O
cell	O
tumor	O
of	O
the	O
ovary	O
0	O
<EOS>	O
after	O
5	O
day	O
of	O
treatment	O
with	O
il-2	B-Drug
,	O
the	O
patient	O
developed	O
a	O
hemorrhagic	B-ADR
lesion	I-ADR
that	O
progressed	O
to	O
toxic	O
epidermal	O
necrolysis	O
,	O
a	O
well	O
a	O
grade	O
4	O
pancytopenia	O
0	O
<EOS>	O
after	O
5	O
day	O
of	O
treatment	O
with	O
il-2	B-Drug
,	O
the	O
patient	O
developed	O
a	O
hemorrhagic	O
lesion	O
that	O
progressed	O
to	O
toxic	O
epidermal	O
necrolysis	O
,	O
a	O
well	O
a	O
grade	O
4	O
pancytopenia	B-ADR
0	O
<EOS>	O
after	O
5	O
day	O
of	O
treatment	O
with	O
il-2	B-Drug
,	O
the	O
patient	O
developed	O
a	O
hemorrhagic	O
lesion	O
that	O
progressed	O
to	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
,	O
a	O
well	O
a	O
grade	O
4	O
pancytopenia	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
cutaneous	B-ADR
and	I-ADR
hematologic	I-ADR
toxicity	I-ADR
in	O
a	O
patient	O
treated	O
with	O
il-2	B-Drug
0	O
<EOS>	O
subcutaneous	O
il-2	B-Drug
is	O
safe	O
and	O
well	O
tolerated	O
,	O
with	O
a	O
mortality	B-ADR
rate	I-ADR
<	I-ADR
3	I-ADR
%	O
0	O
<EOS>	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
associated	O
with	O
interleukin-2	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
anaphylactoid	B-ADR
reaction	I-ADR
due	O
solely	O
to	O
the	O
use	O
of	O
gelofusine	B-Drug
in	O
a	O
patient	O
with	O
non-haemorrhagic	O
hypovolaemia	O
is	O
presented	O
,	O
with	O
a	O
discussion	O
on	O
the	O
management	O
and	O
the	O
use	O
of	O
allergy	O
identification	O
jewellery	O
0	O
<EOS>	O
gelofusine	B-Drug
allergy	I-ADR
--	O
the	O
need	O
for	O
identification	O
jewellery	O
0	O
<EOS>	O
the	O
author	O
describe	O
valproate-induced	B-Drug
hyperammonemia	B-ADR
and	O
mental	O
status	O
change	O
in	O
an	O
88-year-old	O
man	O
,	O
the	O
first	O
known	O
reported	O
case	O
in	O
an	O
elderly	O
patient	O
0	O
<EOS>	O
the	O
author	O
describe	O
valproate-induced	B-Drug
hyperammonemia	O
and	O
mental	B-ADR
status	I-ADR
change	I-ADR
in	O
an	O
88-year-old	O
man	O
,	O
the	O
first	O
known	O
reported	O
case	O
in	O
an	O
elderly	O
patient	O
0	O
<EOS>	O
valproate-induced	B-Drug
hyperammonemia	O
a	O
a	O
cause	O
of	O
altered	B-ADR
mental	I-ADR
status	I-ADR
0	O
<EOS>	O
valproate-induced	B-Drug
hyperammonemia	B-ADR
a	O
a	O
cause	O
of	O
altered	O
mental	O
status	O
0	O
<EOS>	O
leiomyosarcoma	B-ADR
in	O
urinary	O
bladder	O
after	O
cyclophosphamide	B-Drug
therapy	O
for	O
retinoblastoma	O
and	O
review	O
of	O
bladder	O
sarcoma	O
0	O
<EOS>	O
the	O
epivodes	O
of	O
nm	B-ADR
occured	O
under	O
treatment	O
with	O
clozapine	O
,	O
risperidone	O
,	O
and	O
amisulpride	B-Drug
0	O
<EOS>	O
the	O
epivodes	O
of	O
nm	B-ADR
occured	O
under	O
treatment	O
with	O
clozapine	B-Drug
,	O
risperidone	O
,	O
and	O
amisulpride	O
0	O
<EOS>	O
the	O
epivodes	O
of	O
nm	B-ADR
occured	O
under	O
treatment	O
with	O
clozapine	O
,	O
risperidone	B-Drug
,	O
and	O
amisulpride	O
0	O
<EOS>	O
a	O
73-year-old	O
woman	O
presented	O
with	O
fever	O
and	O
cough	B-ADR
2	O
week	O
after	O
completing	O
the	O
third	O
cycle	O
of	O
fludarabine	B-Drug
for	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	O
)	O
0	O
<EOS>	O
a	O
73-year-old	O
woman	O
presented	O
with	O
fever	B-ADR
and	O
cough	O
2	O
week	O
after	O
completing	O
the	O
third	O
cycle	O
of	O
fludarabine	B-Drug
for	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	O
)	O
0	O
<EOS>	O
fludarabine	B-Drug
induced	O
lung	B-ADR
toxicity	I-ADR
must	O
be	O
considered	O
in	O
all	O
patient	O
who	O
develop	O
unexplained	O
lung	O
disease	O
while	O
receiving	O
fludarabine	O
0	O
<EOS>	O
fludarabine	B-Drug
induced	O
lung	B-ADR
toxicity	I-ADR
must	O
be	O
considered	O
in	O
all	O
patient	O
who	O
develop	O
unexplained	O
lung	O
disease	O
while	O
receiving	O
fludarabine	O
0	O
<EOS>	O
fludarabine	B-Drug
induced	O
lung	B-ADR
toxicity	I-ADR
must	O
be	O
considered	O
in	O
all	O
patient	O
who	O
develop	O
unexplained	O
lung	O
disease	O
while	O
receiving	O
fludarabine	O
0	O
<EOS>	O
multiple	B-ADR
pulmonary	I-ADR
nodule	I-ADR
:	O
an	O
unusual	O
presentation	O
of	O
fludarabine	B-Drug
pulmonary	O
toxicity	O
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
multiple	O
pulmonary	O
nodule	O
:	O
an	O
unusual	O
presentation	O
of	O
fludarabine	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
this	O
case	O
extends	O
the	O
spectrum	O
of	O
fludarabine	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
to	O
include	O
pulmonary	O
nodule	O
0	O
<EOS>	O
this	O
case	O
extends	O
the	O
spectrum	O
of	O
fludarabine	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
to	O
include	O
pulmonary	O
nodule	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
four	O
case	O
of	O
interstitial	B-ADR
pneumonitis	I-ADR
associated	O
with	O
fludarabine	B-Drug
have	O
been	O
reported	O
in	O
medical	O
literature	O
0	O
<EOS>	O
epoprostenol	B-Drug
may	O
be	O
associated	O
rarely	O
with	O
severe	O
erythroderma	B-ADR
0	O
<EOS>	O
severe	O
erythroderma	B-ADR
a	O
a	O
complication	O
of	O
continuous	O
epoprostenol	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
month	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	O
progressive	O
erythema	O
,	O
scaling	O
,	O
nausea	O
and	O
vomiting	O
,	O
and	O
fever	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
month	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	O
progressive	O
erythema	O
,	O
scaling	O
,	O
nausea	B-ADR
and	O
vomiting	O
,	O
and	O
fever	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
month	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	B-ADR
progressive	I-ADR
erythema	I-ADR
,	O
scaling	O
,	O
nausea	O
and	O
vomiting	O
,	O
and	O
fever	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
month	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	O
progressive	O
erythema	O
,	O
scaling	B-ADR
,	O
nausea	O
and	O
vomiting	O
,	O
and	O
fever	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
month	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	O
progressive	O
erythema	O
,	O
scaling	O
,	O
nausea	O
and	O
vomiting	B-ADR
,	O
and	O
fever	O
0	O
<EOS>	O
a	O
50-year-old	O
diabetic	O
and	O
hypertensive	O
male	O
patient	O
is	O
reported	O
who	O
had	O
ticlopidine-induced	B-Drug
marrow	B-ADR
aplasia	I-ADR
partially	O
responsive	O
to	O
colony-stimulating	O
factor	O
and	O
corticosteroid	O
,	O
but	O
experienced	O
complete	O
recovery	O
with	O
cyclosporine	O
0	O
<EOS>	O
there	O
is	O
no	O
consensus	O
on	O
the	O
treatment	O
of	O
ticlopidine-induced	B-Drug
marrow	B-ADR
aplasia	I-ADR
0	O
<EOS>	O
ticlopidine-induced	B-Drug
marrow	B-ADR
aplasia	I-ADR
treated	O
with	O
cyclosporine	O
0	O
<EOS>	O
a	O
53-year-old	O
man	O
developed	O
lower	B-ADR
leg	I-ADR
edema	I-ADR
4	O
week	O
after	O
rosiglitazone	B-Drug
wa	O
increased	O
from	O
4	O
mg	O
once	O
/	O
day	O
to	O
4	O
mg	O
twice	O
/	O
day	O
0	O
<EOS>	O
a	O
75-year-old	O
man	O
developed	O
bilateral	B-ADR
lower	I-ADR
leg	I-ADR
edema	I-ADR
6	O
month	O
after	O
switching	O
from	O
troglitazone	O
to	O
pioglitazone	B-Drug
0	O
<EOS>	O
a	O
77-year-old	O
man	O
developed	O
ankle	B-ADR
,	I-ADR
hand	I-ADR
,	I-ADR
and	I-ADR
facial	I-ADR
swelling	I-ADR
2	O
week	O
after	O
starting	O
rosiglitazone	B-Drug
0	O
<EOS>	O
two	O
case	O
of	O
polymorphic	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
induced	O
by	O
the	O
administration	O
of	O
verapamil	B-Drug
against	O
paroxysmal	O
supraventricular	O
tachycardia	O
0	O
<EOS>	O
verapamil	B-Drug
is	O
widely	O
used	O
for	O
the	O
termination	O
of	O
paroxysmal	O
supraventricular	O
tachycardia	O
(	O
psvt	O
)	O
with	O
little	O
proarrhythmic	B-ADR
effect	I-ADR
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
of	O
psvt	O
that	O
changed	O
to	O
non-sustained	B-ADR
polymorphic	I-ADR
ventricular	I-ADR
tachycardia	I-ADR
after	O
administration	O
of	O
verapamil	B-Drug
0	O
<EOS>	O
epsilon-aminocaproic	B-Drug
acid	I-Drug
and	O
renal	B-ADR
complication	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
neonatal	O
mydriasis	B-ADR
:	O
intravenous	O
lidocaine	B-Drug
adverse	O
reaction	O
0	O
<EOS>	O
we	O
present	O
a	O
neonate	O
with	O
a	O
seizure	O
disorder	O
who	O
acutely	O
developed	O
pupillary	B-ADR
mydriasis	I-ADR
secondary	O
to	O
lidocaine	B-Drug
overdose	O
0	O
<EOS>	O
we	O
suggest	O
adding	O
this	O
side	O
effect	O
to	O
the	O
list	O
of	O
untoward	O
effect	O
of	O
lidocaine	B-Drug
and	O
to	O
the	O
differential	O
diagnosis	O
of	O
fixed	O
dilated	B-ADR
pupil	I-ADR
in	O
neonate	O
treated	O
with	O
lidocaine	O
0	O
<EOS>	O
myelodysplasia	O
terminating	O
in	O
acute	B-ADR
myeloid	I-ADR
leukemia	I-ADR
in	O
a	O
hairy	O
cell	O
leukemia	O
patient	O
treated	O
with	O
2-deoxycoformycin	B-Drug
0	O
<EOS>	O
myelodysplasia	B-ADR
terminating	O
in	O
acute	O
myeloid	O
leukemia	O
in	O
a	O
hairy	O
cell	O
leukemia	O
patient	O
treated	O
with	O
2-deoxycoformycin	B-Drug
0	O
<EOS>	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
only	O
two	O
previous	O
case	O
of	O
aml	B-ADR
have	O
been	O
linked	O
to	O
treatment	O
of	O
hcl	O
with	O
purine	O
analog	O
,	O
both	O
with	O
2-chlorodeoxyadenosine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
peripheral	O
administration	O
of	O
low-dose	O
vasopressin	B-Drug
for	O
septic	O
shock	O
should	O
be	O
discouraged	O
because	O
of	O
the	O
risk	O
of	O
ischemic	B-ADR
skin	I-ADR
complication	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
severe	O
skin	B-ADR
necrosis	I-ADR
resulting	O
from	O
peripheral	O
intravenous	O
administration	O
of	O
low-dose	O
vasopressin	B-Drug
in	O
a	O
patient	O
with	O
catecholamine-resistant	O
septic	O
shock	O
0	O
<EOS>	O
skin	B-ADR
necrosis	I-ADR
after	O
extravasation	O
of	O
low-dose	O
vasopressin	B-Drug
administered	O
for	O
septic	O
shock	O
0	O
<EOS>	O
mitomycin-c	B-Drug
induced	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
mitomycin-c	B-Drug
is	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
malignancy	O
and	O
is	O
associated	O
with	O
serious	O
dose	O
related	O
adverse	O
effect	O
including	O
the	O
occurrence	O
of	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
although	O
vasculitis	B-ADR
ha	O
been	O
reported	O
in	O
the	O
course	O
of	O
hairy	O
cell	O
leukaemia	O
,	O
it	O
ha	O
only	O
rarely	O
been	O
reported	O
a	O
the	O
consequence	O
of	O
cladribine	B-Drug
treatment	O
0	O
<EOS>	O
systemic	B-ADR
vasculitis	I-ADR
complicating	O
hairy	O
cell	O
leukaemia	O
treatment	O
with	O
cladribine	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
73-year-old	O
woman	O
who	O
developed	O
serious	O
systemic	B-ADR
vasculitis	I-ADR
with	O
associated	O
thrombocytopenia	O
in	O
the	O
course	O
of	O
treatment	O
with	O
cladribine	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
73-year-old	O
woman	O
who	O
developed	O
serious	O
systemic	O
vasculitis	O
with	O
associated	O
thrombocytopenia	B-ADR
in	O
the	O
course	O
of	O
treatment	O
with	O
cladribine	B-Drug
0	O
<EOS>	O
drug-induced	O
mammary	B-ADR
hyperplasia	I-ADR
have	O
been	O
reported	O
a	O
rare	O
complication	O
of	O
d-penicillamine	B-Drug
and	O
neothetazone	O
0	O
<EOS>	O
drug-induced	O
mammary	B-ADR
hyperplasia	I-ADR
have	O
been	O
reported	O
a	O
rare	O
complication	O
of	O
d-penicillamine	O
and	O
neothetazone	B-Drug
0	O
<EOS>	O
gigantomastia	B-ADR
induced	O
by	O
bucillamine	B-Drug
0	O
<EOS>	O
retrospectively	O
,	O
bucillamine	B-Drug
wa	O
believed	O
to	O
be	O
the	O
cause	O
of	O
the	O
giant	B-ADR
hypertrophy	I-ADR
because	O
of	O
it	O
structural	O
similarity	O
to	O
d-penicillamine	O
,	O
which	O
wa	O
the	O
subject	O
of	O
an	O
abundance	O
of	O
report	O
of	O
mammary	O
hyperplasia	O
0	O
<EOS>	O
retrospectively	O
,	O
bucillamine	O
wa	O
believed	O
to	O
be	O
the	O
cause	O
of	O
the	O
giant	O
hypertrophy	O
because	O
of	O
it	O
structural	O
similarity	O
to	O
d-penicillamine	B-Drug
,	O
which	O
wa	O
the	O
subject	O
of	O
an	O
abundance	O
of	O
report	O
of	O
mammary	B-ADR
hyperplasia	I-ADR
0	O
<EOS>	O
the	O
author	O
report	O
the	O
first	O
case	O
of	O
bucillamine-induced	B-Drug
giant	B-ADR
mammary	I-ADR
hyperplasia	I-ADR
0	O
<EOS>	O
the	O
author	O
describe	O
three	O
family	O
in	O
whom	O
the	O
occurrence	O
of	O
fvs	B-ADR
in	O
all	O
the	O
sibling	O
strongly	O
suggests	O
hereditary	O
susceptibility	O
to	O
valproic	B-Drug
acid-induced	I-Drug
adverse	O
outcome	O
0	O
<EOS>	O
the	O
fetal	O
valproate	B-Drug
syndrome	O
(	O
fvs	O
)	O
is	O
characterized	O
by	O
distinctive	O
facial	O
appearance	O
,	O
major	O
and	O
minor	O
malformation	O
,	O
and	O
developmental	B-ADR
delay	I-ADR
0	O
<EOS>	O
the	O
fetal	O
valproate	B-Drug
syndrome	O
(	O
fvs	O
)	O
is	O
characterized	O
by	O
distinctive	B-ADR
facial	I-ADR
appearance	I-ADR
,	O
major	O
and	O
minor	O
malformation	O
,	O
and	O
developmental	O
delay	O
0	O
<EOS>	O
the	O
fetal	B-ADR
valproate	B-Drug
syndrome	I-ADR
(	O
fvs	O
)	O
is	O
characterized	O
by	O
distinctive	O
facial	O
appearance	O
,	O
major	O
and	O
minor	O
malformation	O
,	O
and	O
developmental	O
delay	O
0	O
<EOS>	O
the	O
fetal	O
valproate	B-Drug
syndrome	O
(	O
fvs	B-ADR
)	O
is	O
characterized	O
by	O
distinctive	O
facial	O
appearance	O
,	O
major	O
and	O
minor	O
malformation	O
,	O
and	O
developmental	O
delay	O
0	O
<EOS>	O
the	O
fetal	O
valproate	B-Drug
syndrome	O
(	O
fvs	O
)	O
is	O
characterized	O
by	O
distinctive	O
facial	O
appearance	O
,	O
major	B-ADR
and	I-ADR
minor	I-ADR
malformation	I-ADR
,	O
and	O
developmental	O
delay	O
0	O
<EOS>	O
valproate	B-Drug
embryopathy	I-ADR
in	O
three	O
set	O
of	O
sibling	O
:	O
further	O
proof	O
of	O
hereditary	O
susceptibility	O
0	O
<EOS>	O
generalised	B-ADR
pustular	I-ADR
psoriasis	I-ADR
induced	O
by	O
cyclosporin	B-Drug
a	I-Drug
withdrawal	O
responding	O
to	O
the	O
tumour	O
necrosis	O
factor	O
alpha	O
inhibitor	O
etanercept	O
0	O
<EOS>	O
we	O
report	O
a	O
50-year-old	O
male	O
patient	O
with	O
a	O
15-year	O
history	O
of	O
psoriasis	O
including	O
mutilating	O
psoriatic	O
arthritis	O
,	O
in	O
whom	O
the	O
withdrawal	O
of	O
cyclosporin	B-Drug
a	I-Drug
induced	O
a	O
generalised	O
pustular	O
exacerbation	O
and	O
a	O
aggravation	B-ADR
of	I-ADR
the	I-ADR
joint	I-ADR
condition	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
50-year-old	O
male	O
patient	O
with	O
a	O
15-year	O
history	O
of	O
psoriasis	O
including	O
mutilating	O
psoriatic	O
arthritis	O
,	O
in	O
whom	O
the	O
withdrawal	O
of	O
cyclosporin	B-Drug
a	I-Drug
induced	O
a	O
generalised	B-ADR
pustular	I-ADR
exacerbation	I-ADR
and	O
a	O
aggravation	O
of	O
the	O
joint	O
condition	O
0	O
<EOS>	O
the	O
first	O
case	O
concern	O
a	O
70-year-old	O
man	O
who	O
developed	O
severe	O
aplastic	B-ADR
anemia	I-ADR
7	O
week	O
after	O
treatment	O
with	O
500	O
mg	O
of	O
ticlopidine	B-Drug
daily	O
0	O
<EOS>	O
the	O
second	O
wa	O
an	O
82-year-old	O
man	O
receiving	O
ticlopidine	B-Drug
for	O
2	O
year	O
when	O
,	O
during	O
a	O
febrile	O
episode	O
,	O
he	O
wa	O
found	O
neutropenic	O
with	O
marrow	B-ADR
aplasia	I-ADR
0	O
<EOS>	O
the	O
second	O
wa	O
an	O
82-year-old	O
man	O
receiving	O
ticlopidine	B-Drug
for	O
2	O
year	O
when	O
,	O
during	O
a	O
febrile	O
episode	O
,	O
he	O
wa	O
found	O
neutropenic	B-ADR
with	O
marrow	O
aplasia	O
0	O
<EOS>	O
ticlopidine-induced	B-Drug
aplastic	B-ADR
anemia	I-ADR
(	O
tiaa	O
)	O
is	O
considered	O
very	O
uncommon	O
0	O
<EOS>	O
ticlopidine-induced	B-Drug
aplastic	O
anemia	O
(	O
tiaa	B-ADR
)	O
is	O
considered	O
very	O
uncommon	O
0	O
<EOS>	O
ticlopidine-induced	B-Drug
aplastic	B-ADR
anemia	I-ADR
:	O
two	O
new	O
case	O
report	O
,	O
review	O
,	O
and	O
meta-analysis	O
of	O
55	O
additional	O
case	O
0	O
<EOS>	O
when	O
the	O
data	O
of	O
the	O
57	O
patient	O
are	O
evaluated	O
,	O
a	O
reversible	O
direct	O
cytotoxic	B-ADR
effect	I-ADR
of	O
ticlopidine	B-Drug
on	O
the	O
pluripotent	O
/	O
bipotent	O
hematopoietic	O
progenitor	O
stem	O
cell	O
is	O
proposed	O
0	O
<EOS>	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
to	O
rofecoxib	B-Drug
0	O
<EOS>	O
rofecoxib	B-Drug
,	O
used	O
for	O
dysmenorrhea	O
,	O
caused	O
a	O
herpetiform	B-ADR
fixed	I-ADR
drug	I-ADR
eruption	I-ADR
predominantly	O
involving	O
the	O
lip	O
with	O
classic	O
clinical	O
and	O
histological	O
finding	O
in	O
a	O
red-brown	O
lesion	O
on	O
the	O
dorsal	O
hand	O
0	O
<EOS>	O
rofecoxib	B-Drug
,	O
used	O
for	O
dysmenorrhea	O
,	O
caused	O
a	O
herpetiform	O
fixed	O
drug	O
eruption	O
predominantly	O
involving	O
the	O
lip	O
with	O
classic	O
clinical	O
and	O
histological	O
finding	O
in	O
a	O
red-brown	B-ADR
lesion	I-ADR
on	O
the	O
dorsal	O
hand	O
0	O
<EOS>	O
a	O
patient	O
who	O
had	O
been	O
treated	O
with	O
large	O
dos	O
of	O
thyroid	B-Drug
hormone	I-Drug
for	O
several	O
year	O
developed	O
feature	O
of	O
secondary	O
hypothyroidism	B-ADR
after	O
thyroid	O
hormone	O
withdrawal	O
0	O
<EOS>	O
background	O
:	O
gemcitabine	O
ha	O
mild	O
renal	O
toxicity	O
,	O
but	O
case	O
of	O
gemcitabine-associated	B-Drug
hemolytic-uremic	B-ADR
syndrome	I-ADR
(	O
hus	O
)	O
have	O
been	O
reported	O
0	O
<EOS>	O
background	O
:	O
gemcitabine	O
ha	O
mild	O
renal	O
toxicity	O
,	O
but	O
case	O
of	O
gemcitabine-associated	B-Drug
hemolytic-uremic	B-ADR
syndrome	I-ADR
(	O
hus	O
)	O
have	O
been	O
reported	O
0	O
<EOS>	O
background	O
:	O
gemcitabine	O
ha	O
mild	O
renal	O
toxicity	O
,	O
but	O
case	O
of	O
gemcitabine-associated	B-Drug
hemolytic-uremic	O
syndrome	O
(	O
hus	B-ADR
)	O
have	O
been	O
reported	O
0	O
<EOS>	O
background	O
:	O
gemcitabine	O
ha	O
mild	O
renal	O
toxicity	O
,	O
but	O
case	O
of	O
gemcitabine-associated	B-Drug
hemolytic-uremic	O
syndrome	O
(	O
hus	B-ADR
)	O
have	O
been	O
reported	O
0	O
<EOS>	O
background	O
:	O
gemcitabine	O
ha	O
mild	O
renal	B-ADR
toxicity	I-ADR
,	O
but	O
case	O
of	O
gemcitabine-associated	B-Drug
hemolytic-uremic	O
syndrome	O
(	O
hus	O
)	O
have	O
been	O
reported	O
0	O
<EOS>	O
conclusion	O
:	O
there	O
are	O
only	O
a	O
few	O
confirmed	O
case	O
of	O
gemcitabine-associated	B-Drug
hus	B-ADR
despite	O
the	O
widespread	O
use	O
of	O
the	O
drug	O
0	O
<EOS>	O
gemcitabine-associated	B-Drug
hemolytic-uremic	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
mean	O
time	O
between	O
initiation	O
of	O
gemcitabine	B-Drug
therapy	O
and	O
onset	O
of	O
hus	B-ADR
wa	O
7.4	O
+	O
/	O
-	O
3.5	O
month	O
,	O
or	O
21.9	O
+	O
/	O
-	O
10.9	O
dos	O
of	O
gemcitabine	O
0	O
<EOS>	O
mean	O
time	O
between	O
initiation	O
of	O
gemcitabine	B-Drug
therapy	O
and	O
onset	O
of	O
hus	B-ADR
wa	O
7.4	O
+	O
/	O
-	O
3.5	O
month	O
,	O
or	O
21.9	O
+	O
/	O
-	O
10.9	O
dos	O
of	O
gemcitabine	O
0	O
<EOS>	O
method	O
:	O
a	O
case	O
is	O
presented	O
of	O
a	O
45-year-old	O
woman	O
on	O
prolonged	O
gemcitabine	B-Drug
treatment	O
for	O
ovarian	O
cancer	O
who	O
developed	O
hus	B-ADR
and	O
recovered	O
after	O
drug	O
discontinuation	O
0	O
<EOS>	O
result	O
:	O
including	O
our	O
own	O
patient	O
,	O
a	O
total	O
of	O
26	O
case	O
of	O
gemcitabine-associated	B-Drug
hus	B-ADR
were	O
identified	O
0	O
<EOS>	O
an	O
amiodarone	B-Drug
optic	B-ADR
neuropathy	I-ADR
ha	O
been	O
described	O
0	O
<EOS>	O
biomicroscopy	O
revealed	O
amiodarone	B-Drug
corneal	B-ADR
deposit	I-ADR
0	O
<EOS>	O
case	O
report	O
:	O
soon	O
after	O
initiation	O
of	O
amiodarone	B-Drug
hcl	I-Drug
(	O
200	O
mg	O
/	O
day	O
)	O
,	O
a	O
76-year-old	O
man	O
came	O
to	O
u	O
with	O
symptom	O
of	O
visual	O
``	O
shining	O
,	O
'	O
glare	O
,	O
color	B-ADR
vision	I-ADR
anomaly	I-ADR
,	O
and	O
gradually	O
decreased	O
vision	O
0	O
<EOS>	O
case	O
report	O
:	O
soon	O
after	O
initiation	O
of	O
amiodarone	B-Drug
hcl	I-Drug
(	O
200	O
mg	O
/	O
day	O
)	O
,	O
a	O
76-year-old	O
man	O
came	O
to	O
u	O
with	O
symptom	O
of	O
visual	O
``	O
shining	O
,	O
'	O
glare	O
,	O
color	O
vision	O
anomaly	O
,	O
and	O
gradually	O
decreased	B-ADR
vision	I-ADR
0	O
<EOS>	O
case	O
report	O
:	O
soon	O
after	O
initiation	O
of	O
amiodarone	B-Drug
hcl	I-Drug
(	O
200	O
mg	O
/	O
day	O
)	O
,	O
a	O
76-year-old	O
man	O
came	O
to	O
u	O
with	O
symptom	O
of	O
visual	O
``	O
shining	O
,	O
'	O
glare	B-ADR
,	O
color	O
vision	O
anomaly	O
,	O
and	O
gradually	O
decreased	O
vision	O
0	O
<EOS>	O
case	O
report	O
:	O
soon	O
after	O
initiation	O
of	O
amiodarone	B-Drug
hcl	I-Drug
(	O
200	O
mg	O
/	O
day	O
)	O
,	O
a	O
76-year-old	O
man	O
came	O
to	O
u	O
with	O
symptom	O
of	O
visual	B-ADR
``	I-ADR
shining	I-ADR
,	O
'	O
glare	O
,	O
color	O
vision	O
anomaly	O
,	O
and	O
gradually	O
decreased	O
vision	O
0	O
<EOS>	O
visual	B-ADR
change	I-ADR
secondary	O
to	O
initiation	O
of	O
amiodarone	B-Drug
:	O
a	O
case	O
report	O
and	O
review	O
involving	O
ocular	O
management	O
in	O
cardiac	O
polypharmacy	O
0	O
<EOS>	O
while	O
both	O
amiodarone	B-Drug
and	O
digoxin	O
can	O
cause	O
permanent	O
visual	O
change	O
,	O
the	O
ocular	B-ADR
effect	I-ADR
are	O
often	O
reversible	O
0	O
<EOS>	O
while	O
both	O
amiodarone	O
and	O
digoxin	B-Drug
can	O
cause	O
permanent	O
visual	O
change	O
,	O
the	O
ocular	B-ADR
effect	I-ADR
are	O
often	O
reversible	O
0	O
<EOS>	O
while	O
both	O
amiodarone	B-Drug
and	O
digoxin	O
can	O
cause	O
permanent	O
visual	B-ADR
change	I-ADR
,	O
the	O
ocular	O
effect	O
are	O
often	O
reversible	O
0	O
<EOS>	O
while	O
both	O
amiodarone	O
and	O
digoxin	B-Drug
can	O
cause	O
permanent	O
visual	B-ADR
change	I-ADR
,	O
the	O
ocular	O
effect	O
are	O
often	O
reversible	O
0	O
<EOS>	O
infant	O
twin	O
sustained	O
severe	O
circumoral	B-ADR
and	I-ADR
pharyngeal	I-ADR
burn	I-ADR
from	O
a	O
concentrated	O
solution	O
of	O
benzalkonium	B-Drug
(	O
zephiran	O
)	O
chloride	O
prescribed	O
for	O
treatment	O
of	O
candidiasis	O
0	O
<EOS>	O
infant	O
twin	O
sustained	O
severe	O
circumoral	B-ADR
and	I-ADR
pharyngeal	I-ADR
burn	I-ADR
from	O
a	O
concentrated	O
solution	O
of	O
benzalkonium	O
(	O
zephiran	B-Drug
)	O
chloride	O
prescribed	O
for	O
treatment	O
of	O
candidiasis	O
0	O
<EOS>	O
conclusion	O
:	O
long-term	O
treatment	O
with	O
rifabutin	B-Drug
may	O
have	O
a	O
reversible	O
and	O
previously	O
undescribed	O
side-effect	B-ADR
on	I-ADR
retinal	I-ADR
function	I-ADR
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
the	O
clinical	O
and	O
electrophysiological	O
finding	O
in	O
a	O
young	O
boy	O
with	O
decreased	B-ADR
vision	I-ADR
possibly	O
due	O
to	O
retinal	O
damage	O
by	O
rifabutin	B-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
the	O
clinical	O
and	O
electrophysiological	O
finding	O
in	O
a	O
young	O
boy	O
with	O
decreased	O
vision	O
possibly	O
due	O
to	O
retinal	B-ADR
damage	I-ADR
by	O
rifabutin	B-Drug
0	O
<EOS>	O
retinal	O
dysfunction	O
and	O
anterior	B-ADR
segment	I-ADR
deposit	I-ADR
in	O
a	O
patient	O
treated	O
with	O
rifabutin	B-Drug
0	O
<EOS>	O
retinal	B-ADR
dysfunction	I-ADR
and	O
anterior	O
segment	O
deposit	O
in	O
a	O
patient	O
treated	O
with	O
rifabutin	B-Drug
0	O
<EOS>	O
we	O
suggest	O
that	O
objective	O
evaluation	O
of	O
retinal	O
function	O
with	O
electrophysiological	O
method	O
should	O
be	O
performed	O
in	O
patient	O
with	O
visual	B-ADR
disturbance	I-ADR
during	O
treatment	O
with	O
rifabutin	B-Drug
0	O
<EOS>	O
a	O
case	O
is	O
presented	O
of	O
a	O
patient	O
who	O
experienced	O
benzodiazepine	B-ADR
withdrawal	I-ADR
symptom	I-ADR
on	O
discontinuation	O
of	O
nefazodone	B-Drug
,	O
an	O
antidepressant	O
that	O
inhibits	O
the	O
cytochrome	O
p450	O
3a4	O
isoenzyme	O
0	O
<EOS>	O
a	O
case	O
of	O
siadh	B-ADR
induced	O
by	O
mizoribin	B-Drug
administration	O
0	O
<EOS>	O
adh	B-ADR
hypersecretion	I-ADR
in	O
relation	O
to	O
plasma	O
osmolality	O
wa	O
reversed	O
by	O
mizoribin	B-Drug
withdrawal	O
,	O
suggesting	O
that	O
bredinin	O
might	O
adversely	O
induce	O
siadh	O
0	O
<EOS>	O
adh	O
hypersecretion	O
in	O
relation	O
to	O
plasma	O
osmolality	O
wa	O
reversed	O
by	O
mizoribin	O
withdrawal	O
,	O
suggesting	O
that	O
bredinin	B-Drug
might	O
adversely	O
induce	O
siadh	B-ADR
0	O
<EOS>	O
in	O
summary	O
,	O
we	O
report	O
herein	O
the	O
first	O
case	O
of	O
siadh	B-ADR
believed	O
to	O
be	O
an	O
adverse	O
effect	O
of	O
mizoribin	B-Drug
,	O
which	O
may	O
therefore	O
needed	O
to	O
be	O
added	O
to	O
the	O
list	O
of	O
drug	O
which	O
can	O
induce	O
siadh	O
0	O
<EOS>	O
in	O
summary	O
,	O
we	O
report	O
herein	O
the	O
first	O
case	O
of	O
siadh	B-ADR
believed	O
to	O
be	O
an	O
adverse	O
effect	O
of	O
mizoribin	B-Drug
,	O
which	O
may	O
therefore	O
needed	O
to	O
be	O
added	O
to	O
the	O
list	O
of	O
drug	O
which	O
can	O
induce	O
siadh	O
0	O
<EOS>	O
we	O
describe	O
a	O
74-year-old	O
man	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
who	O
developed	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
1.5	O
month	O
after	O
commencement	O
of	O
mizoribin	B-Drug
prescription	O
when	O
his	O
arthritis	O
wa	O
improved	O
0	O
<EOS>	O
we	O
describe	O
a	O
74-year-old	O
man	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
who	O
developed	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
1.5	O
month	O
after	O
commencement	O
of	O
mizoribin	B-Drug
prescription	O
when	O
his	O
arthritis	O
wa	O
improved	O
0	O
<EOS>	O
the	O
disease-modifying	O
drug	O
he	O
wa	O
taking	O
,	O
cyclosporin	B-Drug
and	O
methotrexate	O
,	O
were	O
stopped	O
,	O
and	O
the	O
lymphoma	B-ADR
resolved	O
spontaneously	O
without	O
the	O
use	O
of	O
chemotherapy	O
0	O
<EOS>	O
the	O
disease-modifying	O
drug	O
he	O
wa	O
taking	O
,	O
cyclosporin	O
and	O
methotrexate	B-Drug
,	O
were	O
stopped	O
,	O
and	O
the	O
lymphoma	B-ADR
resolved	O
spontaneously	O
without	O
the	O
use	O
of	O
chemotherapy	O
0	O
<EOS>	O
acute	O
onset	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
during	O
interferon-alpha	B-Drug
retreatment	O
for	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
we	O
herein	O
report	O
this	O
rare	O
case	O
of	O
acute	O
onset	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
during	O
interferon-alpha	B-Drug
retreatment	O
0	O
<EOS>	O
a	O
21-year-old	O
man	O
with	O
tourette	O
syndrome	O
,	O
pedophilia	O
,	O
asperger	O
syndrome	O
,	O
and	O
multiple	O
sclerosis	O
experienced	O
seizure	B-ADR
after	O
receiving	O
therapy	O
with	O
interferon	B-Drug
beta-1a	I-Drug
0	O
<EOS>	O
seizure	O
and	O
extrapyramidal	B-ADR
symptom	I-ADR
in	O
a	O
patient	O
with	O
tourette	O
syndrome	O
,	O
asperger	O
syndrome	O
,	O
and	O
multiple	O
sclerosis	O
treated	O
with	O
interferon	O
beta-1a	O
and	O
clomipramine	B-Drug
0	O
<EOS>	O
seizure	O
and	O
extrapyramidal	B-ADR
symptom	I-ADR
in	O
a	O
patient	O
with	O
tourette	O
syndrome	O
,	O
asperger	O
syndrome	O
,	O
and	O
multiple	O
sclerosis	O
treated	O
with	O
interferon	B-Drug
beta-1a	I-Drug
and	O
clomipramine	O
0	O
<EOS>	O
seizure	B-ADR
and	O
extrapyramidal	O
symptom	O
in	O
a	O
patient	O
with	O
tourette	O
syndrome	O
,	O
asperger	O
syndrome	O
,	O
and	O
multiple	O
sclerosis	O
treated	O
with	O
interferon	O
beta-1a	O
and	O
clomipramine	B-Drug
0	O
<EOS>	O
seizure	B-ADR
and	O
extrapyramidal	O
symptom	O
in	O
a	O
patient	O
with	O
tourette	O
syndrome	O
,	O
asperger	O
syndrome	O
,	O
and	O
multiple	O
sclerosis	O
treated	O
with	O
interferon	B-Drug
beta-1a	I-Drug
and	O
clomipramine	O
0	O
<EOS>	O
a	O
68-year-old	O
female	O
patient	O
with	O
advanced	O
ovarian	O
carcinoma	O
collapsed	B-ADR
whilst	O
receiving	O
a	O
carboplatin	B-Drug
and	O
cyclophosphamide	O
infusion	O
0	O
<EOS>	O
a	O
68-year-old	O
female	O
patient	O
with	O
advanced	O
ovarian	O
carcinoma	O
collapsed	B-ADR
whilst	O
receiving	O
a	O
carboplatin	O
and	O
cyclophosphamide	B-Drug
infusion	O
0	O
<EOS>	O
carboplatin	B-Drug
hypersensitivity	O
presenting	O
a	O
coronary	B-ADR
vasospasm	I-ADR
-	O
a	O
case	O
report	O
0	O
<EOS>	O
hypersensitivity	O
to	O
carboplatin	B-Drug
is	O
a	O
rare	O
but	O
real	O
complication	O
of	O
therapy	O
and	O
should	O
be	O
considered	O
in	O
patient	O
presenting	O
with	O
hyperacute	B-ADR
change	I-ADR
on	I-ADR
ecg	I-ADR
whilst	O
receiving	O
carboplatin	O
therapy	O
0	O
<EOS>	O
hypersensitivity	B-ADR
to	O
carboplatin	B-Drug
is	O
a	O
rare	O
but	O
real	O
complication	O
of	O
therapy	O
and	O
should	O
be	O
considered	O
in	O
patient	O
presenting	O
with	O
hyperacute	O
change	O
on	O
ecg	O
whilst	O
receiving	O
carboplatin	O
therapy	O
0	O
<EOS>	O
a	O
60-year-old	O
white	O
man	O
with	O
chronic	O
bronchitis	O
wa	O
noted	O
to	O
develop	O
acute	B-ADR
respiratory	I-ADR
failure	I-ADR
and	O
metabolic	O
acidosis	O
four	O
day	O
after	O
being	O
started	O
on	O
methazolamide	B-Drug
(	O
neptazane	O
)	O
for	O
an	O
ophthalmologic	O
problem	O
0	O
<EOS>	O
a	O
60-year-old	O
white	O
man	O
with	O
chronic	O
bronchitis	O
wa	O
noted	O
to	O
develop	O
acute	B-ADR
respiratory	I-ADR
failure	I-ADR
and	O
metabolic	O
acidosis	O
four	O
day	O
after	O
being	O
started	O
on	O
methazolamide	O
(	O
neptazane	B-Drug
)	O
for	O
an	O
ophthalmologic	O
problem	O
0	O
<EOS>	O
a	O
60-year-old	O
white	O
man	O
with	O
chronic	O
bronchitis	O
wa	O
noted	O
to	O
develop	O
acute	O
respiratory	O
failure	O
and	O
metabolic	B-ADR
acidosis	I-ADR
four	O
day	O
after	O
being	O
started	O
on	O
methazolamide	B-Drug
(	O
neptazane	O
)	O
for	O
an	O
ophthalmologic	O
problem	O
0	O
<EOS>	O
a	O
60-year-old	O
white	O
man	O
with	O
chronic	O
bronchitis	O
wa	O
noted	O
to	O
develop	O
acute	O
respiratory	O
failure	O
and	O
metabolic	B-ADR
acidosis	I-ADR
four	O
day	O
after	O
being	O
started	O
on	O
methazolamide	O
(	O
neptazane	B-Drug
)	O
for	O
an	O
ophthalmologic	O
problem	O
0	O
<EOS>	O
capecitabine	B-Drug
wa	O
discontinued	O
and	O
the	O
allergic	B-ADR
reaction	I-ADR
resolved	O
after	O
the	O
woman	O
took	O
diphenhydramine	O
for	O
1	O
week	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
use	O
of	O
fluorouracil	O
treatment	O
with	O
careful	O
monitoring	O
can	O
be	O
considered	O
in	O
a	O
patient	O
with	O
mild	O
allergic	B-ADR
reaction	I-ADR
to	O
capecitabine	B-Drug
0	O
<EOS>	O
fluorouracil	O
for	O
allergic	B-ADR
reaction	I-ADR
to	O
capecitabine	B-Drug
0	O
<EOS>	O
it	O
wa	O
postulated	O
that	O
the	O
allergic	B-ADR
reaction	I-ADR
wa	O
most	O
likely	O
caused	O
by	O
capecitabine	B-Drug
or	O
the	O
intermediate	O
metabolite	O
based	O
on	O
the	O
immediate	O
reappearance	O
of	O
symptom	O
from	O
the	O
rechallenge	O
,	O
pharmacokinetic	O
data	O
,	O
and	O
well-tolerance	O
of	O
fluorouracil	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
safe	O
use	O
of	O
fluorouracil	O
in	O
a	O
patient	O
with	O
breast	O
cancer	O
who	O
had	O
allergic	B-ADR
reaction	I-ADR
to	O
capecitabine	B-Drug
0	O
<EOS>	O
she	O
developed	O
a	O
generalized	O
rash	O
and	O
itching	O
,	O
sore	O
throat	O
,	O
and	O
dizziness	B-ADR
approximately	O
4	O
hour	O
after	O
the	O
first	O
dose	O
of	O
capecitabine	B-Drug
0	O
<EOS>	O
she	O
developed	O
a	O
generalized	B-ADR
rash	I-ADR
and	O
itching	O
,	O
sore	O
throat	O
,	O
and	O
dizziness	O
approximately	O
4	O
hour	O
after	O
the	O
first	O
dose	O
of	O
capecitabine	B-Drug
0	O
<EOS>	O
she	O
developed	O
a	O
generalized	O
rash	O
and	O
itching	B-ADR
,	O
sore	O
throat	O
,	O
and	O
dizziness	O
approximately	O
4	O
hour	O
after	O
the	O
first	O
dose	O
of	O
capecitabine	B-Drug
0	O
<EOS>	O
she	O
developed	O
a	O
generalized	O
rash	O
and	O
itching	O
,	O
sore	B-ADR
throat	I-ADR
,	O
and	O
dizziness	O
approximately	O
4	O
hour	O
after	O
the	O
first	O
dose	O
of	O
capecitabine	B-Drug
0	O
<EOS>	O
after	O
five	O
and	O
six	O
week	O
of	O
continuous	O
oral	O
administration	O
of	O
methylprednisolone	B-Drug
,	O
the	O
boy	O
developed	O
steroid	B-ADR
diabetes	I-ADR
0	O
<EOS>	O
reduction	O
of	O
methylprednisolone	B-Drug
dosage	O
rather	O
than	O
insulin	O
therapy	O
resulted	O
in	O
better	O
control	O
of	O
glycemia	B-ADR
0	O
<EOS>	O
contrary	O
to	O
previous	O
recommendation	O
,	O
our	O
experience	O
caution	O
against	O
the	O
further	O
use	O
of	O
high-dose	O
cytarabine	B-Drug
in	O
patient	O
who	O
develop	O
ppe	B-ADR
,	O
and	O
is	O
a	O
timely	O
reminder	O
of	O
the	O
potential	O
toxicity	O
of	O
this	O
agent	O
,	O
which	O
is	O
now	O
increasingly	O
being	O
used	O
a	O
first-line	O
treatment	O
in	O
the	O
management	O
of	O
haematologic	O
malignancy	O
0	O
<EOS>	O
it	O
ha	O
been	O
suggested	O
that	O
ppe	B-ADR
caused	O
by	O
cytarabine	B-Drug
doe	O
not	O
recur	O
with	O
subsequent	O
cytarabine	O
re-challenge	O
0	O
<EOS>	O
recurrent	O
palmar-plantar	B-ADR
erythrodysaesthesia	I-ADR
following	O
high-dose	O
cytarabine	B-Drug
treatment	O
for	O
acute	O
lymphoblastic	O
leukemia	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
recurrent	O
,	O
increasingly	O
severe	O
episode	O
of	O
ppe	O
,	O
ultimately	O
complicated	O
by	O
a	O
severe	O
bullous	B-ADR
eruption	I-ADR
,	O
following	O
successive	O
cycle	O
of	O
high-dose	O
cytarabine	B-Drug
for	O
the	O
treatment	O
of	O
acute	O
lymphoblastic	O
leukaemia	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
recurrent	O
,	O
increasingly	O
severe	O
episode	O
of	O
ppe	B-ADR
,	O
ultimately	O
complicated	O
by	O
a	O
severe	O
bullous	O
eruption	O
,	O
following	O
successive	O
cycle	O
of	O
high-dose	O
cytarabine	B-Drug
for	O
the	O
treatment	O
of	O
acute	O
lymphoblastic	O
leukaemia	O
0	O
<EOS>	O
atypical	O
endometriosis	O
may	O
act	O
a	O
a	O
precancerous	O
lesion	O
in	O
the	O
process	O
of	O
tamoxifen-induced	B-Drug
malignant	B-ADR
transformation	I-ADR
of	I-ADR
endometriosis	I-ADR
0	O
<EOS>	O
background	O
:	O
ovarian	B-ADR
cancer	I-ADR
arising	O
from	O
an	O
endometriotic	O
cyst	O
in	O
a	O
postmenopausal	O
woman	O
under	O
tamoxifen	B-Drug
therapy	O
is	O
rare	O
0	O
<EOS>	O
conclusion	O
:	O
tamoxifen	B-Drug
may	O
cause	O
malignant	B-ADR
transformation	I-ADR
of	I-ADR
endometriosis	I-ADR
through	O
atypical	O
endometriosis	O
even	O
in	O
the	O
postmenopausal	O
state	O
0	O
<EOS>	O
ovarian	B-ADR
endometrioid	I-ADR
adenocarcinoma	I-ADR
arising	O
from	O
an	O
endometriotic	O
cyst	O
in	O
a	O
postmenopausal	O
woman	O
under	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
clinical	B-ADR
,	I-ADR
spectroscopic	I-ADR
,	I-ADR
and	I-ADR
imaging	I-ADR
abnormality	I-ADR
resolved	O
with	O
discontinuation	O
of	O
metronidazole	B-Drug
0	O
<EOS>	O
proton	O
mr	O
examination	O
demonstrated	O
a	O
persistent	O
lactate	B-ADR
elevation	I-ADR
during	O
metronidazole	B-Drug
treatment	O
0	O
<EOS>	O
reversible	B-ADR
mr	I-ADR
imaging	I-ADR
and	I-ADR
mr	I-ADR
spectroscopy	I-ADR
abnormality	I-ADR
in	O
association	O
with	O
metronidazole	B-Drug
therapy	O
0	O
<EOS>	O
after	O
nine	O
previous	O
uncomplicated	O
cycle	O
she	O
developed	O
severe	O
anaphylaxis	B-ADR
to	O
cisplatin	B-Drug
0	O
<EOS>	O
anaphylaxis	B-ADR
to	O
cisplatin	B-Drug
following	O
nine	O
previous	O
uncomplicated	O
cycle	O
0	O
<EOS>	O
anaphylaxis	B-ADR
to	O
cisplatin	B-Drug
is	O
an	O
infrequent	O
life-threatening	O
complication	O
which	O
may	O
occur	O
even	O
in	O
patient	O
who	O
have	O
received	O
prior	O
treatment	O
with	O
cisplatin	O
0	O
<EOS>	O
although	O
isradipine	B-Drug
ha	O
been	O
associated	O
with	O
hepatocellular	B-ADR
injury	I-ADR
,	O
there	O
are	O
no	O
report	O
of	O
fulminant	O
liver	O
failure	O
with	O
this	O
agent	O
,	O
and	O
our	O
patient	O
had	O
been	O
treated	O
for	O
>	O
2	O
year	O
without	O
sign	O
of	O
toxicity	O
0	O
<EOS>	O
a	O
second	O
possibility	O
is	O
an	O
interaction	O
between	O
clarithromycin	B-Drug
and	O
isradipine	O
,	O
potentially	O
increasing	B-ADR
the	I-ADR
hepatic	I-ADR
toxicity	I-ADR
of	O
isradipine	O
0	O
<EOS>	O
a	O
second	O
possibility	O
is	O
an	O
interaction	O
between	O
clarithromycin	O
and	O
isradipine	B-Drug
,	O
potentially	O
increasing	B-ADR
the	I-ADR
hepatic	I-ADR
toxicity	I-ADR
of	O
isradipine	O
0	O
<EOS>	O
a	O
second	O
possibility	O
is	O
an	O
interaction	O
between	O
clarithromycin	O
and	O
isradipine	B-Drug
,	O
potentially	O
increasing	B-ADR
the	I-ADR
hepatic	I-ADR
toxicity	I-ADR
of	O
isradipine	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
58-year-old	O
white	O
woman	O
developed	O
fulminant	B-ADR
liver	I-ADR
failure	I-ADR
while	O
being	O
treated	O
with	O
the	O
macrolide	O
antibiotic	O
clarithromycin	B-Drug
for	O
pneumonia	O
0	O
<EOS>	O
conclusion	O
:	O
clarithromycin	B-Drug
may	O
be	O
a	O
cause	O
of	O
fulminant	B-ADR
liver	I-ADR
failure	I-ADR
either	O
alone	O
or	O
by	O
inhibiting	O
the	O
metabolism	O
of	O
other	O
drug	O
0	O
<EOS>	O
fulminant	B-ADR
liver	I-ADR
failure	I-ADR
associated	O
with	O
clarithromycin	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
patient	O
developing	O
fulminant	B-ADR
liver	I-ADR
failure	I-ADR
while	O
being	O
treated	O
with	O
clarithromycin	B-Drug
for	O
pneumonia	O
0	O
<EOS>	O
the	O
most	O
likely	O
cause	O
of	O
liver	O
failure	O
in	O
this	O
patient	O
wa	O
,	O
therefore	O
,	O
clarithromycin	B-Drug
,	O
which	O
undergoes	O
hepatic	O
metabolism	O
and	O
ha	O
been	O
reported	O
to	O
cause	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
0	O
<EOS>	O
the	O
most	O
likely	O
cause	O
of	O
liver	B-ADR
failure	I-ADR
in	O
this	O
patient	O
wa	O
,	O
therefore	O
,	O
clarithromycin	B-Drug
,	O
which	O
undergoes	O
hepatic	O
metabolism	O
and	O
ha	O
been	O
reported	O
to	O
cause	O
fulminant	O
hepatic	O
failure	O
0	O
<EOS>	O
a	O
paradoxical	B-ADR
ocular	I-ADR
effect	I-ADR
of	O
brimonidine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
under	O
certain	O
circumstance	O
topical	O
brimonidine	B-Drug
can	O
cause	O
paradoxical	B-ADR
raised	I-ADR
iop	I-ADR
necessitating	O
vigilance	O
in	O
follow-up	O
of	O
patient	O
on	O
topical	O
brimonidine	O
0	O
<EOS>	O
purpose	O
:	O
we	O
report	O
an	O
unusual	O
paradoxical	B-ADR
effect	I-ADR
of	O
brimonidine	B-Drug
0	O
<EOS>	O
result	O
:	O
brimonidine	B-Drug
wa	O
observed	O
to	O
cause	O
iop	B-ADR
elevation	I-ADR
,	O
confirmed	O
on	O
rechallenge	O
,	O
scoring	O
8	O
(	O
strong	O
probability	O
)	O
on	O
an	O
adverse	O
drug	O
reaction	O
probability	O
score	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	B-ADR
,	O
diaphoresis	O
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	O
seizure	O
and	O
status	O
epilepticus	O
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	B-ADR
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	O
seizure	O
and	O
status	O
epilepticus	O
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	O
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	B-ADR
seizure	I-ADR
and	O
status	O
epilepticus	O
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	O
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	B-ADR
seizure	I-ADR
and	O
status	O
epilepticus	O
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	O
,	O
and	O
palpitation	B-ADR
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	O
seizure	O
and	O
status	O
epilepticus	O
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	O
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	O
seizure	O
and	O
status	B-ADR
epilepticus	I-ADR
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
although	O
gabapentin	B-Drug
withdrawal	O
ha	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	O
,	O
diaphoresis	O
,	O
and	O
palpitation	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	O
seizure	O
and	O
status	B-ADR
epilepticus	I-ADR
secondary	O
to	O
gabapentin	O
withdrawal	O
0	O
<EOS>	O
gabapentin	B-Drug
withdrawal	O
presenting	O
a	O
status	B-ADR
epilepticus	I-ADR
0	O
<EOS>	O
although	O
visual	O
hallucination	O
have	O
not	O
been	O
reported	O
a	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patient	O
who	O
experienced	O
complex	O
visual	O
hallucination	O
and	O
altered	B-ADR
mental	I-ADR
status	I-ADR
after	O
zonisamide	B-Drug
treatment	O
wa	O
begun	O
or	O
it	O
dosage	O
increased	O
0	O
<EOS>	O
although	O
visual	B-ADR
hallucination	I-ADR
have	O
not	O
been	O
reported	O
a	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patient	O
who	O
experienced	O
complex	O
visual	O
hallucination	O
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Drug
treatment	O
wa	O
begun	O
or	O
it	O
dosage	O
increased	O
0	O
<EOS>	O
visual	B-ADR
hallucination	I-ADR
associated	O
with	O
zonisamide	B-Drug
0	O
<EOS>	O
doxycycline-induced	B-Drug
hypoglycemia	B-ADR
in	O
a	O
nondiabetic	O
young	O
man	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
doxycycline-induced	B-Drug
hypoglycemia	B-ADR
in	O
a	O
young	O
nondiabetic	O
man	O
0	O
<EOS>	O
for	O
patient	O
who	O
suffer	O
from	O
osteogenic	O
sarcoma	O
and	O
have	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
mtx	B-Drug
,	O
this	O
desensitization	O
protocol	O
will	O
allow	O
these	O
patient	O
to	O
continue	O
with	O
needed	O
therapeutic	O
or	O
palliative	O
chemotherapy	O
0	O
<EOS>	O
he	O
had	O
an	O
immediate	O
hypersensitivity	O
reaction	O
during	O
the	O
initiation	O
of	O
the	O
mtx	B-Drug
infusion	O
with	O
diffuse	O
urticaria	O
,	O
facial	O
swelling	O
,	O
cough	O
,	O
and	O
chest	B-ADR
tightness	I-ADR
0	O
<EOS>	O
he	O
had	O
an	O
immediate	O
hypersensitivity	O
reaction	O
during	O
the	O
initiation	O
of	O
the	O
mtx	B-Drug
infusion	O
with	O
diffuse	O
urticaria	O
,	O
facial	O
swelling	O
,	O
cough	B-ADR
,	O
and	O
chest	O
tightness	O
0	O
<EOS>	O
he	O
had	O
an	O
immediate	O
hypersensitivity	O
reaction	O
during	O
the	O
initiation	O
of	O
the	O
mtx	B-Drug
infusion	O
with	O
diffuse	B-ADR
urticaria	I-ADR
,	O
facial	O
swelling	O
,	O
cough	O
,	O
and	O
chest	O
tightness	O
0	O
<EOS>	O
he	O
had	O
an	O
immediate	O
hypersensitivity	O
reaction	O
during	O
the	O
initiation	O
of	O
the	O
mtx	B-Drug
infusion	O
with	O
diffuse	O
urticaria	O
,	O
facial	B-ADR
swelling	I-ADR
,	O
cough	O
,	O
and	O
chest	O
tightness	O
0	O
<EOS>	O
he	O
had	O
an	O
immediate	O
hypersensitivity	B-ADR
reaction	I-ADR
during	O
the	O
initiation	O
of	O
the	O
mtx	B-Drug
infusion	O
with	O
diffuse	O
urticaria	O
,	O
facial	O
swelling	O
,	O
cough	O
,	O
and	O
chest	O
tightness	O
0	O
<EOS>	O
he	O
wa	O
later	O
skin	O
tested	O
to	O
confirm	O
allergy	B-ADR
to	O
mtx	B-Drug
0	O
<EOS>	O
successful	O
desensitization	O
to	O
high-dose	O
methotrexate	B-Drug
after	O
systemic	B-ADR
anaphylaxis	I-ADR
0	O
<EOS>	O
the	O
successful	O
development	O
and	O
implementation	O
of	O
this	O
protocol	O
will	O
have	O
impact	O
on	O
patient	O
who	O
have	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
mtx	B-Drug
but	O
require	O
this	O
medication	O
for	O
specific	O
disease	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
balint	B-ADR
syndrome	I-ADR
with	O
irreversible	O
posterior	O
leukoencephalopathy	O
on	O
mri	O
following	O
intrathecal	O
methotrexate	O
and	O
cytarabine	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
balint	B-ADR
syndrome	I-ADR
with	O
irreversible	O
posterior	O
leukoencephalopathy	O
on	O
mri	O
following	O
intrathecal	O
methotrexate	B-Drug
and	O
cytarabine	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
balint	O
syndrome	O
with	O
irreversible	O
posterior	B-ADR
leukoencephalopathy	I-ADR
on	O
mri	O
following	O
intrathecal	O
methotrexate	O
and	O
cytarabine	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
balint	O
syndrome	O
with	O
irreversible	O
posterior	B-ADR
leukoencephalopathy	I-ADR
on	O
mri	O
following	O
intrathecal	O
methotrexate	B-Drug
and	O
cytarabine	O
0	O
<EOS>	O
we	O
present	O
a	O
unique	O
case	O
of	O
gtbm	B-ADR
in	O
a	O
patient	O
with	O
myeloma	O
following	O
treatment	O
with	O
melphalan	B-Drug
0	O
<EOS>	O
patient	O
with	O
lymphoblastic	O
lymphoma	O
who	O
had	O
treatment	O
with	O
l-asparaginase	B-Drug
and	O
steroid	O
are	O
predisposed	O
to	O
the	O
development	O
of	O
cortical	B-ADR
venous	I-ADR
thrombosis	I-ADR
and	O
may	O
have	O
this	O
syndrome	O
in	O
addition	O
to	O
a	O
dural	O
puncture	O
headache	O
0	O
<EOS>	O
patient	O
with	O
lymphoblastic	O
lymphoma	O
who	O
had	O
treatment	O
with	O
l-asparaginase	B-Drug
and	O
steroid	O
are	O
predisposed	O
to	O
the	O
development	O
of	O
cortical	O
venous	O
thrombosis	O
and	O
may	O
have	O
this	O
syndrome	O
in	O
addition	O
to	O
a	O
dural	B-ADR
puncture	I-ADR
headache	I-ADR
0	O
<EOS>	O
interstitial	B-ADR
pneumonitis	I-ADR
associated	O
with	O
sirolimus	B-Drug
:	O
a	O
dilemma	O
for	O
lung	O
transplantation	O
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus-induced	O
pneumonitis	B-ADR
ha	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipient	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart-lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	O
infiltrate	O
that	O
reversed	O
after	O
ceasing	O
sr	O
therapy	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus-induced	B-Drug
pneumonitis	B-ADR
ha	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipient	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart-lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	O
infiltrate	O
that	O
reversed	O
after	O
ceasing	O
sr	O
therapy	O
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus-induced	O
pneumonitis	O
ha	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipient	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart-lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	B-ADR
infiltrate	I-ADR
that	O
reversed	O
after	O
ceasing	O
sr	O
therapy	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus-induced	B-Drug
pneumonitis	O
ha	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipient	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart-lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	B-ADR
infiltrate	I-ADR
that	O
reversed	O
after	O
ceasing	O
sr	O
therapy	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus-induced	O
pneumonitis	O
ha	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipient	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart-lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	B-ADR
infiltrate	I-ADR
that	O
reversed	O
after	O
ceasing	O
sr	B-Drug
therapy	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	B-Drug
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	B-ADR
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	B-ADR
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	B-Drug
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	B-ADR
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	B-Drug
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	B-ADR
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	B-Drug
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	B-ADR
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	B-ADR
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	B-Drug
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	B-ADR
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	B-Drug
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	B-ADR
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	B-Drug
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	B-ADR
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	B-ADR
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	B-Drug
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	B-ADR
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	B-Drug
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	B-ADR
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	B-Drug
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	B-ADR
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	B-Drug
/	O
sirolimus	O
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	B-ADR
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	B-Drug
(	O
sr	O
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	B-ADR
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
rapamycin	O
/	O
sirolimus	O
(	O
sr	B-Drug
)	O
,	O
trade	O
named	O
rapammune	O
(	O
wyeth-ayerst	O
,	O
sydney	O
,	O
australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	B-ADR
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
infection	O
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	B-ADR
,	O
generalized	O
rigidity	O
,	O
leukocytosis	O
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	O
and	O
lithium	B-Drug
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	B-ADR
,	O
generalized	O
rigidity	O
,	O
leukocytosis	O
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	B-Drug
and	O
lithium	O
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	B-ADR
rigidity	I-ADR
,	O
leukocytosis	O
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	O
and	O
lithium	B-Drug
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	B-ADR
rigidity	I-ADR
,	O
leukocytosis	O
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	B-Drug
and	O
lithium	O
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	O
rigidity	O
,	O
leukocytosis	O
,	O
and	O
increased	B-ADR
serum	I-ADR
transaminase	I-ADR
and	I-ADR
creatine	I-ADR
kinase	I-ADR
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	O
and	O
lithium	B-Drug
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	O
rigidity	O
,	O
leukocytosis	O
,	O
and	O
increased	B-ADR
serum	I-ADR
transaminase	I-ADR
and	I-ADR
creatine	I-ADR
kinase	I-ADR
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	B-Drug
and	O
lithium	O
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	O
rigidity	O
,	O
leukocytosis	B-ADR
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	O
and	O
lithium	B-Drug
0	O
<EOS>	O
a	O
16-year-old	O
boy	O
developed	O
fever	O
,	O
generalized	O
rigidity	O
,	O
leukocytosis	B-ADR
,	O
and	O
increased	O
serum	O
transaminase	O
and	O
creatine	O
kinase	O
level	O
while	O
receiving	O
treatment	O
with	O
olanzapine	B-Drug
and	O
lithium	O
0	O
<EOS>	O
concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
olanzapine	O
may	O
place	O
patient	O
at	O
risk	O
for	O
nm	B-ADR
0	O
<EOS>	O
concomitant	O
administration	O
of	O
lithium	O
with	O
olanzapine	B-Drug
may	O
place	O
patient	O
at	O
risk	O
for	O
nm	B-ADR
0	O
<EOS>	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
in	O
an	O
adolescent	O
receiving	O
olanzapine-lithium	B-Drug
combination	O
therapy	O
0	O
<EOS>	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
in	O
an	O
adolescent	O
receiving	O
olanzapine-lithium	B-Drug
combination	O
therapy	O
0	O
<EOS>	O
both	O
6-mp	B-Drug
and	O
aza	O
are	O
widely	O
used	O
and	O
are	O
known	O
to	O
cause	O
hepatotoxicity	B-ADR
in	O
a	O
proportion	O
of	O
patient	O
0	O
<EOS>	O
both	O
6-mp	O
and	O
aza	B-Drug
are	O
widely	O
used	O
and	O
are	O
known	O
to	O
cause	O
hepatotoxicity	B-ADR
in	O
a	O
proportion	O
of	O
patient	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
associated	O
with	O
6-thioguanine	B-Drug
therapy	O
for	O
crohn	O
disease	O
0	O
<EOS>	O
this	O
case	O
highlight	O
the	O
need	O
to	O
monitor	O
liver	O
enzyme	O
in	O
patient	O
treated	O
with	O
6-tg	O
and	O
identifies	O
the	O
need	O
for	O
additional	O
research	O
focused	O
on	O
the	O
mechanism	O
of	O
thiopurine-induced	B-Drug
hepatic	B-ADR
injury	I-ADR
0	O
<EOS>	O
we	O
believe	O
the	O
temporal	O
association	O
of	O
the	O
abnormal	B-ADR
liver	I-ADR
enzyme	I-ADR
in	O
this	O
patient	O
,	O
in	O
the	O
absence	O
of	O
other	O
offending	O
agent	O
,	O
argues	O
strongly	O
in	O
favor	O
of	O
6-tg	B-Drug
a	O
a	O
cause	O
of	O
liver	O
enzyme	O
abnormality	O
0	O
<EOS>	O
we	O
believe	O
the	O
temporal	O
association	O
of	O
the	O
abnormal	O
liver	O
enzyme	O
in	O
this	O
patient	O
,	O
in	O
the	O
absence	O
of	O
other	O
offending	O
agent	O
,	O
argues	O
strongly	O
in	O
favor	O
of	O
6-tg	B-Drug
a	O
a	O
cause	O
of	O
liver	B-ADR
enzyme	I-ADR
abnormality	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
significant	O
elevation	B-ADR
of	I-ADR
serum	I-ADR
transaminase	I-ADR
in	O
a	O
patient	O
treated	O
with	O
6-tg	B-Drug
for	O
a	O
flare	O
of	O
crohn	O
disease	O
0	O
<EOS>	O
early	O
peritoneal	O
dialysis	O
ha	O
not	O
previously	O
been	O
reported	O
for	O
lisinopril	B-Drug
induced	O
multiorgan	B-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
observed	O
transient	O
panhypogammaglobulinaemia	B-ADR
in	O
a	O
patient	O
with	O
neuropsychiatric	O
sle	O
after	O
treatment	O
with	O
prednisolone	O
and	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
we	O
observed	O
transient	O
panhypogammaglobulinaemia	B-ADR
in	O
a	O
patient	O
with	O
neuropsychiatric	O
sle	O
after	O
treatment	O
with	O
prednisolone	B-Drug
and	O
cyclophosphamide	O
0	O
<EOS>	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
developed	O
in	O
a	O
24-year-old	O
black	O
woman	O
who	O
had	O
been	O
treated	O
with	O
propylthiouracil	O
and	O
propranolol	B-Drug
for	O
hyperthyroidism	O
0	O
<EOS>	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
developed	O
in	O
a	O
24-year-old	O
black	O
woman	O
who	O
had	O
been	O
treated	O
with	O
propylthiouracil	B-Drug
and	O
propranolol	O
for	O
hyperthyroidism	O
0	O
<EOS>	O
fulminant	B-ADR
hepatitis	I-ADR
and	O
lymphocyte	O
sensitization	O
due	O
to	O
propylthiouracil	B-Drug
0	O
<EOS>	O
these	O
observation	O
indicate	O
that	O
submassive	O
hepatic	O
necrosis	O
may	O
result	O
from	O
treatment	O
with	O
propylthiouracil	B-Drug
and	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
sensitization	O
mechanism	O
may	O
be	O
responsible	O
for	O
the	O
hepatic	B-ADR
injury	I-ADR
induced	O
by	O
this	O
drug	O
0	O
<EOS>	O
these	O
observation	O
indicate	O
that	O
submassive	B-ADR
hepatic	I-ADR
necrosis	I-ADR
may	O
result	O
from	O
treatment	O
with	O
propylthiouracil	B-Drug
and	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
sensitization	O
mechanism	O
may	O
be	O
responsible	O
for	O
the	O
hepatic	O
injury	O
induced	O
by	O
this	O
drug	O
0	O
<EOS>	O
the	O
diagnosis	O
of	O
hypothermia	B-ADR
wa	O
delayed	O
until	O
it	O
wa	O
apparent	O
for	O
several	O
day	O
but	O
resolved	O
with	O
the	O
discontinuation	O
of	O
risperidone	B-Drug
and	O
continuation	O
of	O
clozapine	O
0	O
<EOS>	O
this	O
is	O
a	O
case	O
report	O
of	O
subtle	O
,	O
mild	O
hypothermia	B-ADR
in	O
a	O
54-year	O
old	O
female	O
patient	O
receiving	O
risperidone	B-Drug
for	O
schizophrenia	O
0	O
<EOS>	O
akathisia	B-ADR
is	O
a	O
relatively	O
rare	O
side	O
effect	O
with	O
the	O
newer	O
atypical	O
antipsychotic	O
agent	O
,	O
particularly	O
clozapine	B-Drug
,	O
and	O
is	O
easily	O
misdiagnosed	O
in	O
child	O
0	O
<EOS>	O
clozapine-induced	B-Drug
akathisia	B-ADR
in	O
child	O
with	O
schizophrenia	O
0	O
<EOS>	O
two	O
case	O
of	O
childhood-onset	O
schizophrenia	O
associated	O
with	O
clozapine-induced	B-Drug
akathisia	B-ADR
responsive	O
to	O
beta-blocker	O
treatment	O
are	O
described	O
0	O
<EOS>	O
after	O
reviewing	O
the	O
literature	O
we	O
suggest	O
the	O
cpm	O
wa	O
a	O
complication	O
of	O
lithium	B-Drug
toxicity	O
which	O
affected	O
the	O
lateral	O
geniculate	O
nucleus	O
which	O
produced	O
blindness	B-ADR
0	O
<EOS>	O
after	O
reviewing	O
the	O
literature	O
we	O
suggest	O
the	O
cpm	B-ADR
wa	O
a	O
complication	O
of	O
lithium	B-Drug
toxicity	O
which	O
affected	O
the	O
lateral	O
geniculate	O
nucleus	O
which	O
produced	O
blindness	O
0	O
<EOS>	O
central	B-ADR
pontine	I-ADR
myelinolysis	I-ADR
manifested	O
by	O
temporary	O
blindness	O
:	O
a	O
possible	O
complication	O
of	O
lithium	B-Drug
toxicity	O
0	O
<EOS>	O
central	O
pontine	O
myelinolysis	O
manifested	O
by	O
temporary	B-ADR
blindness	I-ADR
:	O
a	O
possible	O
complication	O
of	O
lithium	B-Drug
toxicity	O
0	O
<EOS>	O
antithyroid	O
treatment	O
with	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
resulted	O
in	O
elevated	B-ADR
hepatic	I-ADR
enzyme	I-ADR
and	O
after	O
the	O
12th	O
week	O
of	O
pregnancy	O
treatment	O
wa	O
changed	O
to	O
carbimazole	O
(	O
cbz	O
)	O
0	O
<EOS>	O
antithyroid	O
treatment	O
with	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
resulted	O
in	O
elevated	B-ADR
hepatic	I-ADR
enzyme	I-ADR
and	O
after	O
the	O
12th	O
week	O
of	O
pregnancy	O
treatment	O
wa	O
changed	O
to	O
carbimazole	O
(	O
cbz	O
)	O
0	O
<EOS>	O
successful	O
treatment	O
with	O
carbimazole	O
of	O
a	O
hyperthyroid	O
pregnancy	O
with	O
hepatic	B-ADR
impairment	I-ADR
after	O
propylthiouracil	B-Drug
administration	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
interferon-alpha	O
(	O
ifn-alpha	B-Drug
)	O
may	O
precipitate	O
or	O
exacerbate	O
the	O
occurrence	O
of	O
mpgn	B-ADR
0	O
<EOS>	O
interferon-alpha	B-Drug
(	O
ifn-alpha	O
)	O
may	O
precipitate	O
or	O
exacerbate	O
the	O
occurrence	O
of	O
mpgn	B-ADR
0	O
<EOS>	O
minimal	B-ADR
change	I-ADR
disease	I-ADR
in	O
a	O
patient	O
receiving	O
ifn-alpha	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
c	O
virus	O
infection	O
0	O
<EOS>	O
a	O
58-yr-old	O
male	O
patient	O
with	O
essential	O
thrombocythaemia	O
(	O
et	O
)	O
developed	O
chronic	B-ADR
myeloid	I-ADR
leukaemia	I-ADR
(	O
cml	O
)	O
after	O
continuous	O
uneventful	O
treatment	O
with	O
hydroxyurea	B-Drug
for	O
18	O
yr	O
0	O
<EOS>	O
a	O
58-yr-old	O
male	O
patient	O
with	O
essential	O
thrombocythaemia	O
(	O
et	O
)	O
developed	O
chronic	O
myeloid	O
leukaemia	O
(	O
cml	B-ADR
)	O
after	O
continuous	O
uneventful	O
treatment	O
with	O
hydroxyurea	B-Drug
for	O
18	O
yr	O
0	O
<EOS>	O
emergence	O
of	O
philadelphia	B-ADR
positive	I-ADR
chronic	I-ADR
myeloid	I-ADR
leukaemia	I-ADR
during	O
treatment	O
with	O
hydroxyurea	B-Drug
for	O
philadelphia	O
negative	O
essential	O
thrombocythaemia	O
0	O
<EOS>	O
there	O
are	O
no	O
previous	O
report	O
in	O
the	O
literature	O
about	O
the	O
emergence	O
of	O
cml	B-ADR
during	O
treatment	O
with	O
hydroxyurea	B-Drug
0	O
<EOS>	O
his	O
fever	O
resolved	O
,	O
but	O
he	O
developed	O
symptom	O
consistent	O
with	O
those	O
of	O
chloroquine	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
severe	B-ADR
chloroquine	B-Drug
toxicity	I-ADR
in	O
the	O
presence	O
of	O
high-grade	O
chloroquine-resistant	O
plasmodium	O
vivax	O
0	O
<EOS>	O
toxicity	B-ADR
related	O
to	O
chloroquine	B-Drug
treatment	O
of	O
resistant	O
vivax	O
malaria	O
0	O
<EOS>	O
a	O
72-year-old	O
woman	O
with	O
a	O
history	O
of	O
thyrotoxicosis	O
presented	O
with	O
sore	O
throat	O
and	O
fever	B-ADR
two	O
week	O
after	O
starting	O
carbimazole	B-Drug
0	O
<EOS>	O
a	O
72-year-old	O
woman	O
with	O
a	O
history	O
of	O
thyrotoxicosis	O
presented	O
with	O
sore	B-ADR
throat	I-ADR
and	O
fever	O
two	O
week	O
after	O
starting	O
carbimazole	B-Drug
0	O
<EOS>	O
treatment	O
of	O
carbimazole-induced	B-Drug
agranulocytosis	B-ADR
and	O
sepsis	O
with	O
granulocyte	O
colony	O
stimulating	O
factor	O
0	O
<EOS>	O
treatment	O
of	O
carbimazole-induced	B-Drug
agranulocytosis	O
and	O
sepsis	B-ADR
with	O
granulocyte	O
colony	O
stimulating	O
factor	O
0	O
<EOS>	O
we	O
present	O
the	O
management	O
of	O
agranulocytosis	B-ADR
and	O
neutropenic	O
sepsis	O
secondary	O
to	O
carbimazole	B-Drug
with	O
recombinant	O
human	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
g-csf	O
)	O
0	O
<EOS>	O
we	O
present	O
the	O
management	O
of	O
agranulocytosis	O
and	O
neutropenic	B-ADR
sepsis	I-ADR
secondary	O
to	O
carbimazole	B-Drug
with	O
recombinant	O
human	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
g-csf	O
)	O
0	O
<EOS>	O
comeoscleral	B-ADR
perforation	I-ADR
after	O
pterygium	O
excision	O
and	O
intraoperative	O
mitomycin	B-Drug
c	I-Drug
0	O
<EOS>	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
corneoscleral	B-ADR
melting	I-ADR
in	O
the	O
first	O
postoperative	O
week	O
after	O
a	O
single	O
intraoperative	O
application	O
of	O
mitomycin	B-Drug
c	I-Drug
ha	O
not	O
been	O
reported	O
0	O
<EOS>	O
a	O
71-year-old	O
man	O
,	O
who	O
had	O
a	O
history	O
of	O
a	O
previous	O
bullous	B-ADR
drug	I-ADR
reaction	I-ADR
to	O
a	O
sulfonamide	B-Drug
,	O
began	O
receiving	O
an	O
ophthalmic	O
preparation	O
that	O
contained	O
sulfacetamide	O
sodium	O
0	O
<EOS>	O
the	O
patient	O
received	O
only	O
the	O
ophthalmic	O
sulfonamide	B-Drug
,	O
and	O
it	O
wa	O
used	O
for	O
one	O
day	O
,	O
but	O
he	O
developed	O
stevens-johnson	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
the	O
sulfonamide	B-Drug
are	O
the	O
best	O
verified	O
drug-trigger	O
for	O
erythema	B-ADR
multiforme	I-ADR
and	O
stevens-johnson	O
syndrome	O
0	O
<EOS>	O
the	O
sulfonamide	B-Drug
are	O
the	O
best	O
verified	O
drug-trigger	O
for	O
erythema	O
multiforme	O
and	O
stevens-johnson	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
based	O
on	O
these	O
finding	O
,	O
the	O
patient	O
wa	O
diagnosed	O
with	O
diabetes	B-ADR
insipidus	I-ADR
secondary	O
to	O
lithium	B-Drug
therapy	O
and	O
wa	O
treated	O
successfully	O
with	O
amiloride	O
0	O
<EOS>	O
clinician	O
have	O
been	O
aware	O
of	O
lithium	B-ADR
toxicity	I-ADR
for	O
many	O
year	O
and	O
traditionally	O
have	O
administered	O
thiazide	O
diuretic	O
for	O
lithium-induced	B-Drug
polyuria	O
and	O
nephrogenic	O
diabetes	O
insipidus	O
0	O
<EOS>	O
clinician	O
have	O
been	O
aware	O
of	O
lithium	O
toxicity	O
for	O
many	O
year	O
and	O
traditionally	O
have	O
administered	O
thiazide	O
diuretic	O
for	O
lithium-induced	B-Drug
polyuria	O
and	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
0	O
<EOS>	O
clinician	O
have	O
been	O
aware	O
of	O
lithium	O
toxicity	O
for	O
many	O
year	O
and	O
traditionally	O
have	O
administered	O
thiazide	O
diuretic	O
for	O
lithium-induced	B-Drug
polyuria	O
and	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
0	O
<EOS>	O
clinician	O
have	O
been	O
aware	O
of	O
lithium	O
toxicity	O
for	O
many	O
year	O
and	O
traditionally	O
have	O
administered	O
thiazide	O
diuretic	O
for	O
lithium-induced	B-Drug
polyuria	B-ADR
and	O
nephrogenic	O
diabetes	O
insipidus	O
0	O
<EOS>	O
clinician	O
have	O
been	O
aware	O
of	O
lithium	O
toxicity	O
for	O
many	O
year	O
and	O
traditionally	O
have	O
administered	O
thiazide	O
diuretic	O
for	O
lithium-induced	B-Drug
polyuria	B-ADR
and	O
nephrogenic	O
diabetes	O
insipidus	O
0	O
<EOS>	O
treatment	O
of	O
lithium-induced	B-Drug
diabetes	B-ADR
insipidus	I-ADR
with	O
amiloride	O
0	O
<EOS>	O
systemic	B-ADR
capillary	I-ADR
leak	I-ADR
syndrome	I-ADR
after	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	B-Drug
)	O
0	O
<EOS>	O
systemic	B-ADR
capillary	I-ADR
leak	I-ADR
syndrome	I-ADR
after	O
granulocyte	B-Drug
colony-stimulating	I-Drug
factor	I-Drug
(	O
g-csf	O
)	O
0	O
<EOS>	O
we	O
present	O
two	O
case	O
in	O
which	O
both	O
patient	O
suffered	O
with	O
cl	B-ADR
,	O
which	O
we	O
believe	O
wa	O
caused	O
following	O
administration	O
of	O
granulocyte	B-Drug
colony-stimulating	I-Drug
factor	I-Drug
,	O
to	O
our	O
knowledge	O
not	O
described	O
in	O
the	O
intensive	O
care	O
patient	O
previously	O
0	O
<EOS>	O
fk506	B-Drug
,	O
which	O
began	O
to	O
be	O
administered	O
12	O
day	O
earlier	O
,	O
rose	O
to	O
a	O
level	O
of	O
44	O
ng	O
/	O
ml	O
(	O
normal	O
range	O
,	O
10-20	O
ng	O
/	O
ml	O
)	O
1	O
day	O
before	O
neurologic	B-ADR
abnormality	I-ADR
began	O
0	O
<EOS>	O
rapid	O
identification	O
of	O
speech	B-ADR
loss	I-ADR
linked	O
to	O
fk506	B-Drug
may	O
be	O
important	O
because	O
reduction	O
or	O
cessation	O
of	O
the	O
drug	O
may	O
be	O
associated	O
with	O
reverse	O
of	O
speech	O
loss	O
0	O
<EOS>	O
tacrolimus	O
(	O
fk506	B-Drug
)	O
,	O
an	O
immunosuppressant	O
,	O
ha	O
been	O
associated	O
with	O
mutism	B-ADR
in	O
adult	O
after	O
liver	O
transplant	O
0	O
<EOS>	O
tacrolimus	B-Drug
(	O
fk506	O
)	O
,	O
an	O
immunosuppressant	O
,	O
ha	O
been	O
associated	O
with	O
mutism	B-ADR
in	O
adult	O
after	O
liver	O
transplant	O
0	O
<EOS>	O
tacrolimus	O
(	O
fk506	B-Drug
)	O
-induced	O
mutism	B-ADR
after	O
liver	O
transplant	O
0	O
<EOS>	O
tacrolimus	B-Drug
(	O
fk506	O
)	O
-induced	O
mutism	B-ADR
after	O
liver	O
transplant	O
0	O
<EOS>	O
doe	O
the	O
use	O
of	O
insulin	B-Drug
in	O
a	O
patient	O
with	O
liver	O
dysfunction	O
increase	O
water	O
retention	O
in	O
the	O
body	O
,	O
i.e	O
0	O
cause	O
insulin	O
oedema	B-ADR
?	O
<EOS>	O
soon	O
after	O
introduction	O
of	O
insulin	B-Drug
therapy	O
,	O
she	O
developed	O
severe	O
anasarca	O
,	O
including	O
marked	O
peripheral	O
oedema	O
,	O
ascites	B-ADR
and	O
pleural	O
effusion	O
0	O
<EOS>	O
soon	O
after	O
introduction	O
of	O
insulin	B-Drug
therapy	O
,	O
she	O
developed	O
severe	O
anasarca	O
,	O
including	O
marked	O
peripheral	B-ADR
oedema	I-ADR
,	O
ascites	O
and	O
pleural	O
effusion	O
0	O
<EOS>	O
soon	O
after	O
introduction	O
of	O
insulin	B-Drug
therapy	O
,	O
she	O
developed	O
severe	O
anasarca	O
,	O
including	O
marked	O
peripheral	O
oedema	O
,	O
ascites	O
and	O
pleural	B-ADR
effusion	I-ADR
0	O
<EOS>	O
soon	O
after	O
introduction	O
of	O
insulin	B-Drug
therapy	O
,	O
she	O
developed	O
severe	B-ADR
anasarca	I-ADR
,	O
including	O
marked	O
peripheral	O
oedema	O
,	O
ascites	O
and	O
pleural	O
effusion	O
0	O
<EOS>	O
the	O
induced	O
hyperglycaemia	O
could	O
not	O
be	O
controlled	O
sufficiently	O
,	O
despite	O
a	O
high	O
dose	O
of	O
insulin	B-Drug
(	O
>	O
110	O
unit	O
/	O
day	O
)	O
,	O
suggesting	O
the	O
existence	O
of	O
insulin	O
insensitivity	O
and	O
hyperinsulinaemia	B-ADR
0	O
<EOS>	O
the	O
induced	O
hyperglycaemia	O
could	O
not	O
be	O
controlled	O
sufficiently	O
,	O
despite	O
a	O
high	O
dose	O
of	O
insulin	B-Drug
(	O
>	O
110	O
unit	O
/	O
day	O
)	O
,	O
suggesting	O
the	O
existence	O
of	O
insulin	B-ADR
insensitivity	I-ADR
and	O
hyperinsulinaemia	B-ADR
0	O
<EOS>	O
we	O
conjectured	O
that	O
the	O
side	O
effect	O
of	O
insulin	B-Drug
,	O
such	O
a	O
anti-natriuresis	B-ADR
and	O
increased	O
vascular	O
permeability	O
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	O
insensitivity	O
,	O
hyperinsulinaemia	O
and	O
hypoalbuminaemia	O
0	O
<EOS>	O
we	O
conjectured	O
that	O
the	O
side	O
effect	O
of	O
insulin	B-Drug
,	O
such	O
a	O
anti-natriuresis	O
and	O
increased	O
vascular	O
permeability	O
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	O
insensitivity	O
,	O
hyperinsulinaemia	B-ADR
and	O
hypoalbuminaemia	O
0	O
<EOS>	O
we	O
conjectured	O
that	O
the	O
side	O
effect	O
of	O
insulin	B-Drug
,	O
such	O
a	O
anti-natriuresis	O
and	O
increased	O
vascular	O
permeability	O
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	O
insensitivity	O
,	O
hyperinsulinaemia	O
and	O
hypoalbuminaemia	B-ADR
0	O
<EOS>	O
we	O
conjectured	O
that	O
the	O
side	O
effect	O
of	O
insulin	B-Drug
,	O
such	O
a	O
anti-natriuresis	O
and	O
increased	B-ADR
vascular	I-ADR
permeability	I-ADR
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	O
insensitivity	O
,	O
hyperinsulinaemia	O
and	O
hypoalbuminaemia	O
0	O
<EOS>	O
we	O
conjectured	O
that	O
the	O
side	O
effect	O
of	O
insulin	B-Drug
,	O
such	O
a	O
anti-natriuresis	O
and	O
increased	O
vascular	O
permeability	O
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	B-ADR
insensitivity	I-ADR
,	O
hyperinsulinaemia	B-ADR
and	O
hypoalbuminaemia	B-ADR
0	O
<EOS>	O
while	O
40	O
mg	O
/	O
day	O
of	O
prednisolone	B-Drug
improved	O
hepatic	O
dysfunction	O
dramatically	O
,	O
her	O
diabetic	B-ADR
milieu	I-ADR
deteriorated	I-ADR
seriously	O
0	O
<EOS>	O
intrathecal	O
methotrexate-induced	B-Drug
acute	B-ADR
cerebellar	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
developed	O
acute	B-ADR
cerebellar	I-ADR
syndrome	I-ADR
after	O
prophylactic	O
intrathecal	O
methotrexate	B-Drug
administration	O
and	O
recovered	O
spontaneously	O
0	O
<EOS>	O
angioimmunoblastic	B-ADR
lymphadenopathy	I-ADR
with	I-ADR
dysproteinemia	I-ADR
following	O
doxycycline	B-Drug
administration	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
aild	B-ADR
in	O
an	O
80-year-old	O
male	O
who	O
presented	O
with	O
a	O
generalized	O
pruritic	O
maculopapular	O
eruption	O
and	O
fever	O
following	O
doxycycline	B-Drug
administration	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
aild	O
in	O
an	O
80-year-old	O
male	O
who	O
presented	O
with	O
a	O
generalized	O
pruritic	O
maculopapular	O
eruption	O
and	O
fever	B-ADR
following	O
doxycycline	B-Drug
administration	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
aild	O
in	O
an	O
80-year-old	O
male	O
who	O
presented	O
with	O
a	O
generalized	B-ADR
pruritic	I-ADR
maculopapular	I-ADR
eruption	I-ADR
and	O
fever	O
following	O
doxycycline	B-Drug
administration	O
0	O
<EOS>	O
anaphylaxis	B-ADR
from	O
isoniazid	B-Drug
is	O
a	O
possible	O
side	O
effect	O
to	O
this	O
commonly	O
prescribed	O
antibiotic	O
0	O
<EOS>	O
isoniazid-induced	B-Drug
anaphylaxis	B-ADR
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
in	O
which	O
severe	O
hypocalcemia	O
,	O
with	O
a	O
low	B-ADR
plasma	I-ADR
parathyroid	I-ADR
hormone	I-ADR
(	O
pth	O
)	O
concentration	O
,	O
resulted	O
from	O
the	O
therapeutic	O
use	O
of	O
magnesium	B-Drug
sulfate	I-Drug
for	O
toxemia	O
of	O
pregnancy	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
in	O
which	O
severe	O
hypocalcemia	O
,	O
with	O
a	O
low	O
plasma	O
parathyroid	O
hormone	O
(	O
pth	B-ADR
)	O
concentration	O
,	O
resulted	O
from	O
the	O
therapeutic	O
use	O
of	O
magnesium	B-Drug
sulfate	I-Drug
for	O
toxemia	O
of	O
pregnancy	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
in	O
which	O
severe	B-ADR
hypocalcemia	I-ADR
,	O
with	O
a	O
low	O
plasma	O
parathyroid	O
hormone	O
(	O
pth	O
)	O
concentration	O
,	O
resulted	O
from	O
the	O
therapeutic	O
use	O
of	O
magnesium	B-Drug
sulfate	I-Drug
for	O
toxemia	O
of	O
pregnancy	O
0	O
<EOS>	O
carbamazepine-related	B-Drug
hyponatremia	B-ADR
following	O
cardiopulmonary	O
bypass	O
0	O
<EOS>	O
we	O
discus	O
the	O
association	O
between	O
carbamazepine	B-Drug
and	O
hyponatremia	B-ADR
and	O
the	O
cause	O
of	O
hyponatremia	O
after	O
cardiopulmonary	O
bypass	O
0	O
<EOS>	O
after	O
5-asa	B-Drug
wa	O
discontinued	O
,	O
the	O
polyneuropathy	B-ADR
symptom	O
recovered	O
gradually	O
0	O
<EOS>	O
sensorimotor	B-ADR
polyneuropathy	I-ADR
with	O
5-aminosalicylic	B-Drug
acid	I-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
this	O
clinical	O
course	O
suggests	O
that	O
the	O
sensorimotor	B-ADR
polyneuropathy	I-ADR
may	O
have	O
been	O
caused	O
by	O
5-asa	B-Drug
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
5-asa	O
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	B-ADR
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	O
acid	O
(	O
5-asa	B-Drug
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	B-ADR
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
5-asa	O
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	B-ADR
disturbance	I-ADR
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	O
acid	O
(	O
5-asa	B-Drug
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	B-ADR
disturbance	I-ADR
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
5-asa	O
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	B-ADR
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	O
acid	O
(	O
5-asa	B-Drug
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	B-ADR
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	O
of	O
the	O
dysesthesia	O
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
5-asa	O
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	B-ADR
of	I-ADR
the	I-ADR
dysesthesia	I-ADR
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
when	O
sasp	O
wa	O
changed	O
to	O
5-aminosalicylic	O
acid	O
(	O
5-asa	B-Drug
)	O
,	O
his	O
skin	O
eruption	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	O
and	O
atrophy	O
in	O
his	O
right	O
arm	O
a	O
well	O
a	O
progressive	O
worsening	B-ADR
of	I-ADR
the	I-ADR
dysesthesia	I-ADR
in	O
his	O
leg	O
and	O
gait	O
disturbance	O
0	O
<EOS>	O
disseminated	B-ADR
cellulitic	I-ADR
cryptococcosis	I-ADR
in	O
the	O
setting	O
of	O
prednisone	B-Drug
monotherapy	O
for	O
pemphigus	O
vulgaris	O
0	O
<EOS>	O
in	O
both	O
case	O
,	O
high	O
fever	O
,	O
skin	O
rash	O
,	O
liver	O
dysfunction	O
and	O
atypical	B-ADR
lymphocytosis	I-ADR
developed	O
3	O
week	O
after	O
initiating	O
treatment	O
with	O
sasp	B-Drug
0	O
<EOS>	O
in	O
both	O
case	O
,	O
high	B-ADR
fever	I-ADR
,	O
skin	O
rash	O
,	O
liver	O
dysfunction	O
and	O
atypical	O
lymphocytosis	O
developed	O
3	O
week	O
after	O
initiating	O
treatment	O
with	O
sasp	B-Drug
0	O
<EOS>	O
in	O
both	O
case	O
,	O
high	O
fever	O
,	O
skin	O
rash	O
,	O
liver	B-ADR
dysfunction	I-ADR
and	O
atypical	O
lymphocytosis	O
developed	O
3	O
week	O
after	O
initiating	O
treatment	O
with	O
sasp	B-Drug
0	O
<EOS>	O
in	O
both	O
case	O
,	O
high	O
fever	O
,	O
skin	B-ADR
rash	I-ADR
,	O
liver	O
dysfunction	O
and	O
atypical	O
lymphocytosis	O
developed	O
3	O
week	O
after	O
initiating	O
treatment	O
with	O
sasp	B-Drug
0	O
<EOS>	O
slow	O
acetylator	O
genotype	O
a	O
a	O
possible	O
risk	O
factor	O
for	O
infectious	B-ADR
mononucleosis-like	I-ADR
syndrome	I-ADR
induced	O
by	O
salazosulfapyridine	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
with	O
infectious	B-ADR
mononucleosis-like	I-ADR
syndrome	I-ADR
induced	O
by	O
salazosulfapyridine	B-Drug
(	O
sasp	O
)	O
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
with	O
infectious	B-ADR
mononucleosis-like	I-ADR
syndrome	I-ADR
induced	O
by	O
salazosulfapyridine	O
(	O
sasp	B-Drug
)	O
0	O
<EOS>	O
a	O
45-year-old	O
woman	O
with	O
steroid-dependent	O
crohn	O
colitis	O
,	O
successfully	O
managed	O
with	O
maintenance	O
infliximab	B-Drug
infusion	O
and	O
methotrexate	O
,	O
developed	O
a	O
lupus-like	B-ADR
syndrome	I-ADR
eight	O
month	O
after	O
her	O
initial	O
infusion	O
0	O
<EOS>	O
a	O
45-year-old	O
woman	O
with	O
steroid-dependent	O
crohn	O
colitis	O
,	O
successfully	O
managed	O
with	O
maintenance	O
infliximab	O
infusion	O
and	O
methotrexate	B-Drug
,	O
developed	O
a	O
lupus-like	B-ADR
syndrome	I-ADR
eight	O
month	O
after	O
her	O
initial	O
infusion	O
0	O
<EOS>	O
a	O
lupus-like	B-ADR
syndrome	I-ADR
associated	O
with	O
infliximab	B-Drug
therapy	O
0	O
<EOS>	O
infliximab	B-Drug
therapy	O
may	O
cause	O
a	O
lupus-like	B-ADR
syndrome	I-ADR
that	O
is	O
reversible	O
upon	O
discontinuing	O
this	O
agent	O
0	O
<EOS>	O
we	O
report	O
in	O
detail	O
an	O
unusual	O
adverse	O
reaction	O
to	O
infliximab	B-Drug
therapy	O
,	O
a	O
drug-induced	O
lupus-like	B-ADR
clinical	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
chronic	O
myelogenous	O
leukemia	O
(	O
cml	O
)	O
,	O
hepatitis	O
c	O
,	O
and	O
interferon	O
alpha	O
(	O
ifnalpha	B-Drug
)	O
have	O
all	O
been	O
associated	O
with	O
renal	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
chronic	O
myelogenous	O
leukemia	O
(	O
cml	O
)	O
,	O
hepatitis	O
c	O
,	O
and	O
interferon	B-Drug
alpha	I-Drug
(	O
ifnalpha	O
)	O
have	O
all	O
been	O
associated	O
with	O
renal	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
despite	O
the	O
underlying	O
hepatitis	O
c	O
,	O
this	O
case	O
represents	O
renal	B-ADR
abnormality	I-ADR
consistent	O
with	O
ifnalpha	B-Drug
therapy	O
for	O
cml	O
0	O
<EOS>	O
interferon-alpha-induced	B-Drug
focal	B-ADR
segmental	I-ADR
glomerulosclerosis	I-ADR
in	O
chronic	O
myelogenous	O
leukemia	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
the	O
renal	O
biopsy	O
showed	O
focal	B-ADR
segmental	I-ADR
glomerulosclerosis	I-ADR
,	O
which	O
ha	O
only	O
been	O
previously	O
reported	O
in	O
two	O
case	O
of	O
cml	O
treated	O
with	O
ifnalpha	B-Drug
0	O
<EOS>	O
severe	O
autoimmune	B-ADR
hemolytic	I-ADR
anemia	I-ADR
following	O
rituximab	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
a	O
lymphoproliferative	O
disorder	O
0	O
<EOS>	O
the	O
pathophysiological	O
mechanism	O
remain	O
unknown	O
,	O
although	O
the	O
drug	O
could	O
act	O
through	O
massive	O
cytokine	O
liberation	O
after	O
destruction	B-ADR
of	I-ADR
cd20	I-ADR
positive	I-ADR
cell	I-ADR
by	O
rituximab	B-Drug
0	O
<EOS>	O
the	O
pathophysiological	O
mechanism	O
remain	O
unknown	O
,	O
although	O
the	O
drug	O
could	O
act	O
through	O
massive	B-ADR
cytokine	I-ADR
liberation	I-ADR
after	O
destruction	O
of	O
cd20	O
positive	O
cell	O
by	O
rituximab	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
rituximab-related	B-Drug
autoimmune	B-ADR
hemolytic	I-ADR
anemia	I-ADR
0	O
<EOS>	O
early-onset	O
acute	B-ADR
transverse	I-ADR
myelitis	I-ADR
following	O
hepatitis	B-Drug
b	I-Drug
vaccination	I-Drug
and	O
respiratory	O
infection	O
:	O
case	O
report	O
0	O
<EOS>	O
in	O
this	O
paper	O
,	O
we	O
report	O
a	O
case	O
of	O
3	O
years-old	O
boy	O
who	O
developed	O
acute	B-ADR
onset	I-ADR
tetraparesia	I-ADR
following	O
a	O
viral	O
respiratory	O
infecction	O
and	O
hepatitis	B-Drug
b	I-Drug
vaccination	I-Drug
0	O
<EOS>	O
although	O
it	O
would	O
be	O
expected	O
that	O
,	O
like	O
other	O
type	O
ia	O
toxicity	O
,	O
diphenhydramine-induced	B-Drug
cardiotoxicity	B-ADR
could	O
be	O
responsive	O
to	O
hypertonic	O
sodium	O
bicarbonate	O
,	O
this	O
finding	O
is	O
largely	O
unappreciated	O
0	O
<EOS>	O
diphenhydramine-induced	B-Drug
wide	O
complex	O
dysrhythmia	B-ADR
responds	O
to	O
treatment	O
with	O
sodium	O
bicarbonate	O
0	O
<EOS>	O
however	O
,	O
because	O
diphenhydramine	B-Drug
also	O
exhibit	O
type	O
ia	O
sodium	O
channel	O
blockade	O
,	O
cardiac	B-ADR
toxicity	I-ADR
is	O
also	O
possible	O
0	O
<EOS>	O
we	O
describe	O
3	O
case	O
of	O
diphenhydramine-induced	B-Drug
cardiac	B-ADR
toxicity	I-ADR
that	O
were	O
responsive	O
to	O
bicarbonate	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
extranodal	O
non-hodgkin	O
lymphoma	O
who	O
developed	O
systemic	B-ADR
candidiasis	I-ADR
after	O
treatment	O
with	O
a	O
cyclophosphamide-based	B-Drug
chemotherapy	O
regimen	O
0	O
<EOS>	O
stevens-johnson	B-ADR
syndrome	I-ADR
in	O
a	O
boy	O
with	O
nephrotic	O
syndrome	O
during	O
prednisolone	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
sjs	B-ADR
in	O
a	O
14-year-old	O
male	O
with	O
nephrotic	O
syndrome	O
,	O
who	O
wa	O
treated	O
with	O
oral	O
prednisolone	B-Drug
for	O
6	O
week	O
0	O
<EOS>	O
a	O
25-year-old	O
man	O
with	O
a	O
history	O
of	O
mid-borderline	O
(	O
bb	O
)	O
hansen	O
disease	O
developing	O
a	O
reversal	B-ADR
reaction	I-ADR
after	O
starting	O
dapsone	B-Drug
and	O
rifampin	O
therapy	O
is	O
presented	O
0	O
<EOS>	O
a	O
25-year-old	O
man	O
with	O
a	O
history	O
of	O
mid-borderline	O
(	O
bb	O
)	O
hansen	O
disease	O
developing	O
a	O
reversal	B-ADR
reaction	I-ADR
after	O
starting	O
dapsone	O
and	O
rifampin	B-Drug
therapy	O
is	O
presented	O
0	O
<EOS>	O
however	O
,	O
in	O
order	O
to	O
avoid	O
neuropathic	B-ADR
side	I-ADR
effect	I-ADR
,	O
patient	O
under	O
thalidomide	B-Drug
therapy	O
should	O
be	O
monitored	O
every	O
6	O
month	O
with	O
nerve	O
conduction	O
study	O
while	O
taking	O
the	O
drug	O
0	O
<EOS>	O
after	O
a	O
two-month	O
interruption	O
of	O
interferon	B-Drug
administration	O
,	O
natural	O
interferon	O
alpha	B-Drug
wa	O
given	O
but	O
followed	O
by	O
another	O
episode	O
of	O
the	O
same	O
neurological	B-ADR
manifestation	I-ADR
0	O
<EOS>	O
case	O
1	O
,	O
a	O
62-year-old	O
woman	O
,	O
developed	O
bilateral	B-ADR
optic	I-ADR
neuritis	I-ADR
with	O
decreased	O
sensation	O
of	O
vibration	O
and	O
increased	O
deep	O
tendon	O
reflex	O
in	O
the	O
lower	O
extremity	O
after	O
a	O
seven-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
for	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
case	O
1	O
,	O
a	O
62-year-old	O
woman	O
,	O
developed	O
bilateral	O
optic	O
neuritis	O
with	O
decreased	B-ADR
sensation	I-ADR
of	I-ADR
vibration	I-ADR
and	O
increased	O
deep	O
tendon	O
reflex	O
in	O
the	O
lower	O
extremity	O
after	O
a	O
seven-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
for	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
case	O
1	O
,	O
a	O
62-year-old	O
woman	O
,	O
developed	O
bilateral	O
optic	O
neuritis	O
with	O
decreased	O
sensation	O
of	O
vibration	O
and	O
increased	B-ADR
deep	I-ADR
tendon	I-ADR
reflex	I-ADR
in	O
the	O
lower	O
extremity	O
after	O
a	O
seven-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
for	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
case	O
2	O
,	O
a	O
29-year-old	O
woman	O
,	O
developed	O
bilateral	B-ADR
optic	I-ADR
neuritis	I-ADR
combined	O
with	O
numbness	O
of	O
the	O
lower	O
extremity	O
a	O
well	O
a	O
bowel	O
and	O
bladder	O
dysfunction	O
after	O
a	O
22-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2b	I-Drug
for	O
chronic	O
myelogenous	O
leukemia	O
0	O
<EOS>	O
case	O
2	O
,	O
a	O
29-year-old	O
woman	O
,	O
developed	O
bilateral	O
optic	O
neuritis	O
combined	O
with	O
numbness	O
of	O
the	O
lower	O
extremity	O
a	O
well	O
a	O
bowel	B-ADR
and	I-ADR
bladder	I-ADR
dysfunction	I-ADR
after	O
a	O
22-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2b	I-Drug
for	O
chronic	O
myelogenous	O
leukemia	O
0	O
<EOS>	O
case	O
2	O
,	O
a	O
29-year-old	O
woman	O
,	O
developed	O
bilateral	O
optic	O
neuritis	O
combined	O
with	O
numbness	B-ADR
of	I-ADR
the	I-ADR
lower	I-ADR
extremity	I-ADR
a	O
well	O
a	O
bowel	O
and	O
bladder	O
dysfunction	O
after	O
a	O
22-month	O
use	O
of	O
recombinant	B-Drug
interferon	I-Drug
alpha-2b	I-Drug
for	O
chronic	O
myelogenous	O
leukemia	O
0	O
<EOS>	O
conclusion	O
:	O
optic	O
neuritis	O
in	O
combination	O
with	O
other	O
neurological	B-ADR
sign	I-ADR
,	O
simulating	O
multiple	O
sclerosis	O
,	O
should	O
be	O
included	O
in	O
the	O
list	O
of	O
adverse	O
effect	O
of	O
recombinant	O
and	O
natural	O
interferon	B-Drug
alpha	I-Drug
administration	O
0	O
<EOS>	O
conclusion	O
:	O
optic	B-ADR
neuritis	I-ADR
in	O
combination	O
with	O
other	O
neurological	O
sign	O
,	O
simulating	O
multiple	O
sclerosis	O
,	O
should	O
be	O
included	O
in	O
the	O
list	O
of	O
adverse	O
effect	O
of	O
recombinant	O
and	O
natural	O
interferon	B-Drug
alpha	I-Drug
administration	O
0	O
<EOS>	O
multiple	B-ADR
sclerosis-like	I-ADR
disease	I-ADR
secondary	O
to	O
alpha	B-Drug
interferon	I-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
bilateral	B-ADR
optic	I-ADR
neuritis	I-ADR
that	O
occurred	O
a	O
an	O
adverse	O
effect	O
of	O
recombinant	O
and	O
natural	O
interferon	B-Drug
alpha	I-Drug
administration	O
0	O
<EOS>	O
acute	B-ADR
abdomen	I-ADR
due	O
to	O
endometriosis	O
in	O
a	O
premenopausal	O
woman	O
taking	O
tamoxifen	B-Drug
0	O
<EOS>	O
acute	O
abdomen	O
due	O
to	O
endometriosis	B-ADR
in	O
a	O
premenopausal	O
woman	O
taking	O
tamoxifen	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
premenopausal	O
woman	O
who	O
,	O
while	O
having	O
tamoxifen	B-Drug
due	O
to	O
a	O
diagnosis	O
of	O
in	O
situ	O
ductal	O
carcinoma	O
,	O
developed	O
endometriosis	B-ADR
requiring	O
surgery	O
0	O
<EOS>	O
a	O
case	O
report	O
of	O
fatal	O
dapsone-induced	B-Drug
agranulocytosis	B-ADR
in	O
an	O
indian	O
mid-borderline	O
leprosy	O
patient	O
0	O
<EOS>	O
fatal	B-ADR
agranulocytosis	I-ADR
in	O
an	O
indian	O
male	O
receiving	O
100mg	O
of	O
dapsone	B-Drug
daily	O
,	O
hospitalized	O
for	O
mid-borderline	O
leprosy	O
in	O
type	O
i	O
reaction	O
with	O
triple	O
nerve	O
paralysis	O
is	O
reported	O
0	O
<EOS>	O
various	O
case	O
report	O
concerning	O
dapsone-induced	B-Drug
agranulocytosis	B-ADR
are	O
reviewed	O
0	O
<EOS>	O
massive	B-ADR
pulmonary	I-ADR
embolism	I-ADR
due	O
to	O
late-onset	O
heparin-induced	B-Drug
thrombocytopenia	O
following	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
:	O
successful	O
treatment	O
with	O
lepirudin	O
0	O
<EOS>	O
massive	O
pulmonary	O
embolism	O
due	O
to	O
late-onset	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
following	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
:	O
successful	O
treatment	O
with	O
lepirudin	O
0	O
<EOS>	O
most	O
cardiac	O
surgical	O
patient	O
have	O
had	O
previous	O
exposure	O
to	O
heparin	O
for	O
diagnostic	O
or	O
therapeutic	O
intervention	O
and	O
hence	O
have	O
an	O
increased	O
susceptibility	O
to	O
developing	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
(	O
hit	O
)	O
postoperatively	O
0	O
<EOS>	O
acute	B-ADR
psychosis	I-ADR
associated	O
with	O
levetiracetam	B-Drug
0	O
<EOS>	O
a	O
twelve	O
year-old-girl	O
with	O
idiopathic	O
partial	O
epilepsy	O
with	O
secondary	O
generalization	O
,	O
developed	O
acute	B-ADR
psychosis	I-ADR
10	O
day	O
after	O
the	O
administration	O
of	O
levetiracetam	B-Drug
0	O
<EOS>	O
the	O
psychotic	B-ADR
behavior	I-ADR
resolved	O
completely	O
soon	O
after	O
the	O
discontinuation	O
of	O
levetiracetam	B-Drug
0	O
<EOS>	O
case	O
:	O
``	O
a	O
'	O
wa	O
an	O
8-year-old	O
boy	O
with	O
attention	O
deficit	O
and	O
chronic	O
tic	O
disorder	O
who	O
developed	O
obsessive-compulsive	B-ADR
symptom	I-ADR
within	O
2	O
week	O
of	O
starting	O
risperidone	B-Drug
0	O
<EOS>	O
obsessive-compulsive	B-ADR
symptom	I-ADR
suddenly	O
emerged	O
10	O
day	O
after	O
starting	O
risperidone	B-Drug
and	O
resolved	O
within	O
3	O
day	O
of	O
discontinuation	O
0	O
<EOS>	O
risperidone-induced	B-Drug
obsessive-compulsive	B-ADR
symptom	I-ADR
in	O
two	O
child	O
0	O
<EOS>	O
proliferation	B-ADR
of	I-ADR
abnormal	I-ADR
bone	I-ADR
marrow	I-ADR
histiocyte	I-ADR
,	O
an	O
undesired	O
effect	O
of	O
granulocyte	B-Drug
macrophage-colony-stimulating	I-Drug
factor	I-Drug
therapy	O
in	O
a	O
patient	O
with	O
hurler	O
syndrome	O
undergoing	O
bone	O
marrow	O
transplantation	O
0	O
<EOS>	O
possible	O
heart	B-ADR
failure	I-ADR
exacerbation	I-ADR
associated	O
with	O
rosiglitazone	B-Drug
:	O
case	O
report	O
and	O
literature	O
review	O
0	O
<EOS>	O
enoxaparin-induced	B-Drug
generalized	B-ADR
exanthem	I-ADR
0	O
<EOS>	O
only	O
one	O
case	O
of	O
a	O
generalized	B-ADR
maculopapular	I-ADR
rash	I-ADR
with	O
enoxaparin	B-Drug
ha	O
been	O
reported	O
in	O
europe	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
reported	O
in	O
the	O
english	O
literature	O
of	O
a	O
generalized	B-ADR
exanthem	I-ADR
due	O
to	O
subcutaneous	O
injection	O
of	O
enoxaparin	B-Drug
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	O
,	O
aggression	B-ADR
,	O
hyperactivity	O
,	O
irritability	O
,	O
property	O
destruction	O
,	O
and	O
temper	O
tantrum	O
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	B-ADR
,	O
aggression	O
,	O
hyperactivity	O
,	O
irritability	O
,	O
property	O
destruction	O
,	O
and	O
temper	O
tantrum	O
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	O
,	O
aggression	O
,	O
hyperactivity	B-ADR
,	O
irritability	O
,	O
property	O
destruction	O
,	O
and	O
temper	O
tantrum	O
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	O
,	O
aggression	O
,	O
hyperactivity	O
,	O
irritability	B-ADR
,	O
property	O
destruction	O
,	O
and	O
temper	O
tantrum	O
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	O
,	O
aggression	O
,	O
hyperactivity	O
,	O
irritability	O
,	O
property	B-ADR
destruction	I-ADR
,	O
and	O
temper	O
tantrum	O
0	O
<EOS>	O
behavioral	O
side	O
effect	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	O
,	O
aggression	O
,	O
hyperactivity	O
,	O
irritability	O
,	O
property	O
destruction	O
,	O
and	O
temper	B-ADR
tantrum	I-ADR
0	O
<EOS>	O
this	O
report	O
describes	O
an	O
individual	O
with	O
mental	O
retardation	O
who	O
experienced	O
behavioral	B-ADR
exacerbation	I-ADR
associated	O
with	O
clonazepam	B-Drug
prescribed	O
at	O
2	O
mg	O
/	O
day	O
(	O
0.02	O
mg	O
/	O
kg	O
/	O
day	O
)	O
to	O
treat	O
aggression	O
,	O
self-injurious	O
behavior	O
,	O
property	O
destruction	O
,	O
and	O
screaming	O
,	O
which	O
wa	O
measured	O
with	O
a	O
15-minute	O
partial	O
interval	O
recording	O
measurement	O
method	O
0	O
<EOS>	O
cefuroxime-induced	B-Drug
immune	B-ADR
hemolysis	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
iha	B-ADR
associated	O
with	O
cefuroxime	B-Drug
administration	O
0	O
<EOS>	O
after	O
39	O
hour	O
on	O
argatroban	B-Drug
,	O
the	O
infusion	O
wa	O
stopped	O
when	O
minor	O
bleeding	B-ADR
wa	O
observed	O
with	O
a	O
concurrent	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aptt	O
)	O
of	O
100	O
second	O
0	O
<EOS>	O
argatroban	O
for	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
in	O
hepato-renal	O
failure	O
and	O
cvvhd	O
0	O
<EOS>	O
argatroban	B-Drug
is	O
hepatically	O
cleared	O
and	O
may	O
be	O
the	O
preferred	O
direct	O
thrombin	O
inhibitor	O
in	O
the	O
presence	O
of	O
significant	O
renal	O
impairment	O
,	O
but	O
conversely	O
ha	O
prolonged	O
effect	O
in	O
hepatic	B-ADR
failure	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
significant	O
hepatic	B-ADR
and	I-ADR
renal	I-ADR
failure	I-ADR
with	O
the	O
use	O
of	O
argatroban	B-Drug
in	O
a	O
patient	O
with	O
heparin-induced	O
thrombocytopenia	O
(	O
hit	O
)	O
requiring	O
continuous	O
veno-veno	O
hemodialysis	O
(	O
cvvhd	O
)	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
significant	O
hepatic	O
and	O
renal	O
failure	O
with	O
the	O
use	O
of	O
argatroban	O
in	O
a	O
patient	O
with	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
(	O
hit	O
)	O
requiring	O
continuous	O
veno-veno	O
hemodialysis	O
(	O
cvvhd	O
)	O
0	O
<EOS>	O
schneiderian	B-ADR
first-rank	I-ADR
symptom	I-ADR
associated	O
with	O
fluvoxamine	B-Drug
treatment	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
patient	O
,	O
a	O
28-year-old	O
man	O
suffering	O
from	O
panic	O
disorder	O
,	O
developed	O
several	O
first-rank	B-ADR
symptom	I-ADR
during	O
fluvoxamine	B-Drug
administration	O
0	O
<EOS>	O
this	O
communication	O
describes	O
a	O
patient	O
who	O
developed	O
schneiderian	B-ADR
first-rank	I-ADR
symptom	I-ADR
in	O
the	O
course	O
of	O
treatment	O
with	O
fluvoxamine	B-Drug
0	O
<EOS>	O
this	O
finding	O
suggests	O
that	O
fluvoxamine	B-Drug
can	O
precipitate	O
schneiderian	B-ADR
first-rank	I-ADR
symptom	I-ADR
in	O
some	O
susceptible	O
patient	O
0	O
<EOS>	O
we	O
present	O
a	O
surprising	O
case	O
of	O
a	O
woman	O
schizophrenic	O
patient	O
treated	O
with	O
clozapine	B-Drug
suffering	O
from	O
eps	B-ADR
0	O
<EOS>	O
hyperpigmentation	B-ADR
during	O
interferon-alpha	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
c	O
virus	O
infection	O
0	O
<EOS>	O
these	O
skin	B-ADR
lesion	I-ADR
may	O
be	O
induced	O
or	O
worsened	O
during	O
antiviral	O
therapy	O
with	O
interferon-alpha	O
(	O
ifn	B-Drug
)	O
0	O
<EOS>	O
these	O
skin	B-ADR
lesion	I-ADR
may	O
be	O
induced	O
or	O
worsened	O
during	O
antiviral	O
therapy	O
with	O
interferon-alpha	B-Drug
(	O
ifn	O
)	O
0	O
<EOS>	O
we	O
describe	O
two	O
dark-skinned	O
patient	O
who	O
developed	O
hyperpigmented	B-ADR
skin	I-ADR
and	O
tongue	O
lesion	O
during	O
combination	O
therapy	O
with	O
ifn	B-Drug
and	O
ribavirin	O
0	O
<EOS>	O
we	O
describe	O
two	O
dark-skinned	O
patient	O
who	O
developed	O
hyperpigmented	B-ADR
skin	I-ADR
and	O
tongue	O
lesion	O
during	O
combination	O
therapy	O
with	O
ifn	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
we	O
describe	O
two	O
dark-skinned	O
patient	O
who	O
developed	O
hyperpigmented	O
skin	O
and	O
tongue	B-ADR
lesion	I-ADR
during	O
combination	O
therapy	O
with	O
ifn	B-Drug
and	O
ribavirin	O
0	O
<EOS>	O
we	O
describe	O
two	O
dark-skinned	O
patient	O
who	O
developed	O
hyperpigmented	O
skin	O
and	O
tongue	B-ADR
lesion	I-ADR
during	O
combination	O
therapy	O
with	O
ifn	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
simultaneous	O
administration	O
of	O
ciprofloxacin	B-Drug
and	O
tazobactam	O
/	O
piperacillin	O
may	O
cause	O
marked	O
thrombocytosis	B-ADR
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
simultaneous	O
administration	O
of	O
ciprofloxacin	O
and	O
tazobactam	O
/	O
piperacillin	B-Drug
may	O
cause	O
marked	O
thrombocytosis	B-ADR
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
simultaneous	O
administration	O
of	O
ciprofloxacin	O
and	O
tazobactam	B-Drug
/	O
piperacillin	O
may	O
cause	O
marked	O
thrombocytosis	B-ADR
0	O
<EOS>	O
since	O
the	O
thrombocyte	B-ADR
count	I-ADR
started	I-ADR
to	I-ADR
increase	I-ADR
immediately	O
after	O
initiation	O
and	O
dropped	O
immediately	O
after	O
discontinuation	O
of	O
ciprofloxacin	B-Drug
and	O
tazobactam	O
/	O
piperacillin	O
and	O
all	O
other	O
drug	O
were	O
discontinued	O
already	O
before	O
or	O
were	O
started	O
after	O
the	O
nadir	O
of	O
the	O
thrombocyte	O
count	O
,	O
these	O
two	O
antibiotic	O
were	O
regarded	O
causative	O
0	O
<EOS>	O
since	O
the	O
thrombocyte	B-ADR
count	I-ADR
started	I-ADR
to	I-ADR
increase	I-ADR
immediately	O
after	O
initiation	O
and	O
dropped	O
immediately	O
after	O
discontinuation	O
of	O
ciprofloxacin	O
and	O
tazobactam	O
/	O
piperacillin	B-Drug
and	O
all	O
other	O
drug	O
were	O
discontinued	O
already	O
before	O
or	O
were	O
started	O
after	O
the	O
nadir	O
of	O
the	O
thrombocyte	O
count	O
,	O
these	O
two	O
antibiotic	O
were	O
regarded	O
causative	O
0	O
<EOS>	O
since	O
the	O
thrombocyte	B-ADR
count	I-ADR
started	I-ADR
to	I-ADR
increase	I-ADR
immediately	O
after	O
initiation	O
and	O
dropped	O
immediately	O
after	O
discontinuation	O
of	O
ciprofloxacin	O
and	O
tazobactam	B-Drug
/	O
piperacillin	O
and	O
all	O
other	O
drug	O
were	O
discontinued	O
already	O
before	O
or	O
were	O
started	O
after	O
the	O
nadir	O
of	O
the	O
thrombocyte	O
count	O
,	O
these	O
two	O
antibiotic	O
were	O
regarded	O
causative	O
0	O
<EOS>	O
thrombocytosis	B-ADR
under	O
ciprofloxacin	B-Drug
and	O
tazobactam	O
/	O
piperacillin	O
0	O
<EOS>	O
thrombocytosis	B-ADR
under	O
ciprofloxacin	O
and	O
tazobactam	O
/	O
piperacillin	B-Drug
0	O
<EOS>	O
thrombocytosis	B-ADR
under	O
ciprofloxacin	O
and	O
tazobactam	B-Drug
/	O
piperacillin	O
0	O
<EOS>	O
anaphylaxis	B-ADR
after	O
the	O
injection	O
of	O
chymopapain	B-Drug
occurs	O
in	O
about	O
1	O
%	O
of	O
such	O
case	O
0	O
<EOS>	O
both	O
patient	O
suddenly	O
became	O
hypotensive	B-ADR
after	O
injection	O
of	O
chymopapain	B-Drug
into	O
a	O
disk	O
0	O
<EOS>	O
lethargy	B-ADR
in	O
a	O
newborn	O
:	O
lithium	B-Drug
toxicity	O
or	O
lab	O
error	O
?	O
<EOS>	O
lethargy	O
in	O
a	O
newborn	O
:	O
lithium	B-Drug
toxicity	I-ADR
or	O
lab	O
error	O
?	O
<EOS>	O
the	O
newborn	O
manifested	O
a	O
four	O
day	O
course	O
of	O
lethargy	B-ADR
with	O
unexplained	O
high	O
lithium	B-Drug
level	O
in	O
the	O
adult	O
toxic	O
range	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	B-ADR
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	B-Drug
(	O
cbz	O
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	B-ADR
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	B-Drug
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	B-ADR
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	O
;	O
tegretol	B-Drug
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	B-ADR
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	B-Drug
(	O
cbz	O
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	B-ADR
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	B-Drug
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	B-ADR
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	O
;	O
tegretol	B-Drug
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	B-ADR
anti-nuclear	I-ADR
antibody	I-ADR
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	B-Drug
(	O
cbz	O
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	B-ADR
anti-nuclear	I-ADR
antibody	I-ADR
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	B-Drug
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	B-ADR
anti-nuclear	I-ADR
antibody	I-ADR
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	O
;	O
tegretol	B-Drug
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	B-ADR
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	B-Drug
(	O
cbz	O
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	B-ADR
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	B-Drug
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
-like	O
symptom	O
,	O
rash	B-ADR
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	O
;	O
tegretol	B-Drug
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	I-ADR
sle	I-ADR
)	I-ADR
-like	I-ADR
symptom	I-ADR
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	B-Drug
(	O
cbz	O
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	I-ADR
sle	I-ADR
)	I-ADR
-like	I-ADR
symptom	I-ADR
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	B-Drug
;	O
tegretol	O
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
a	O
14-year-old	O
female	O
developed	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	I-ADR
sle	I-ADR
)	I-ADR
-like	I-ADR
symptom	I-ADR
,	O
rash	O
,	O
fever	O
,	O
leukopenia	O
and	O
positive	O
anti-nuclear	O
antibody	O
(	O
ana	O
)	O
two	O
week	O
after	O
administration	O
of	O
carbamazepine	O
(	O
cbz	O
;	O
tegretol	B-Drug
)	O
used	O
against	O
benign	O
rolandic	O
epilepsy	O
0	O
<EOS>	O
carbamazepine-induced	B-Drug
systemic	B-ADR
lupus	I-ADR
erythematosus-like	I-ADR
disease	I-ADR
0	O
<EOS>	O
the	O
case	O
of	O
cbz-induced	B-Drug
sle	B-ADR
reported	O
in	O
the	O
literature	O
were	O
reviewed	O
0	O
<EOS>	O
after	O
four	O
month	O
,	O
while	O
receiving	O
rh	B-Drug
,	O
he	O
developed	O
painful	O
bilateral	B-ADR
gynaecomastia	I-ADR
0	O
<EOS>	O
gynaecomastia	B-ADR
is	O
a	O
rarely	O
reported	O
adverse	O
drug	O
reaction	O
due	O
to	O
isoniazid	B-Drug
therapy	O
0	O
<EOS>	O
isoniazid	B-Drug
associated	O
,	O
painful	O
,	O
bilateral	B-ADR
gynaecomastia	I-ADR
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	B-ADR
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	B-ADR
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	O
)	O
,	O
recurrent	B-ADR
arteriothromboses	I-ADR
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	O
(	O
hat	O
)	O
,	O
recurrent	B-ADR
arteriothromboses	I-ADR
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
(	O
hat	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
suffering	O
from	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
(	O
hat	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
0	O
<EOS>	O
by	O
mean	O
of	O
the	O
in	O
vitro	O
heparin-induced	O
platelet	B-ADR
activation	I-ADR
(	O
hipa	O
)	O
assay	O
it	O
wa	O
shown	O
that	O
standard	O
heparin	O
and	O
the	O
lmw	O
heparin	O
fragmin	O
and	O
fraxiparin	O
(	O
sanofi	O
labaz	O
,	O
munich	O
,	O
frg	O
)	O
,	O
a	O
well	O
a	O
the	O
enoxaparine	O
clexane	B-Drug
(	O
nattermann	O
,	O
cologne	O
,	O
frg	O
)	O
,	O
all	O
induced	O
platelet	O
activation	O
with	O
the	O
patient	O
serum	O
0	O
<EOS>	O
by	O
mean	O
of	O
the	O
in	O
vitro	O
heparin-induced	O
platelet	B-ADR
activation	I-ADR
(	O
hipa	O
)	O
assay	O
it	O
wa	O
shown	O
that	O
standard	O
heparin	O
and	O
the	O
lmw	O
heparin	O
fragmin	B-Drug
and	O
fraxiparin	O
(	O
sanofi	O
labaz	O
,	O
munich	O
,	O
frg	O
)	O
,	O
a	O
well	O
a	O
the	O
enoxaparine	O
clexane	O
(	O
nattermann	O
,	O
cologne	O
,	O
frg	O
)	O
,	O
all	O
induced	O
platelet	O
activation	O
with	O
the	O
patient	O
serum	O
0	O
<EOS>	O
by	O
mean	O
of	O
the	O
in	O
vitro	O
heparin-induced	O
platelet	B-ADR
activation	I-ADR
(	O
hipa	O
)	O
assay	O
it	O
wa	O
shown	O
that	O
standard	O
heparin	O
and	O
the	O
lmw	O
heparin	O
fragmin	O
and	O
fraxiparin	B-Drug
(	O
sanofi	O
labaz	O
,	O
munich	O
,	O
frg	O
)	O
,	O
a	O
well	O
a	O
the	O
enoxaparine	O
clexane	O
(	O
nattermann	O
,	O
cologne	O
,	O
frg	O
)	O
,	O
all	O
induced	O
platelet	O
activation	O
with	O
the	O
patient	O
serum	O
0	O
<EOS>	O
by	O
mean	O
of	O
the	O
in	O
vitro	O
heparin-induced	B-Drug
platelet	B-ADR
activation	I-ADR
(	O
hipa	O
)	O
assay	O
it	O
wa	O
shown	O
that	O
standard	O
heparin	O
and	O
the	O
lmw	O
heparin	O
fragmin	O
and	O
fraxiparin	O
(	O
sanofi	O
labaz	O
,	O
munich	O
,	O
frg	O
)	O
,	O
a	O
well	O
a	O
the	O
enoxaparine	O
clexane	O
(	O
nattermann	O
,	O
cologne	O
,	O
frg	O
)	O
,	O
all	O
induced	O
platelet	O
activation	O
with	O
the	O
patient	O
serum	O
0	O
<EOS>	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
:	O
successful	O
therapy	O
with	O
the	O
heparinoid	O
org	O
10172	O
in	O
a	O
patient	O
showing	O
cross-reaction	O
to	O
lmw	O
heparin	O
0	O
<EOS>	O
hemodynamic	B-ADR
collapse	I-ADR
following	O
labetalol	B-Drug
administration	O
in	O
preeclampsia	O
0	O
<EOS>	O
a	O
patient	O
with	O
parkinson	O
disease	O
,	O
initially	O
treated	O
with	O
bromocriptine	B-Drug
and	O
subsequently	O
with	O
cabergoline	O
,	O
developed	O
progressive	O
pleuropulmonary	B-ADR
abnormality	I-ADR
during	O
the	O
latter	O
therapy	O
0	O
<EOS>	O
a	O
patient	O
with	O
parkinson	O
disease	O
,	O
initially	O
treated	O
with	O
bromocriptine	O
and	O
subsequently	O
with	O
cabergoline	B-Drug
,	O
developed	O
progressive	O
pleuropulmonary	B-ADR
abnormality	I-ADR
during	O
the	O
latter	O
therapy	O
0	O
<EOS>	O
pleuropulmonary	B-ADR
change	I-ADR
during	O
treatment	O
of	O
parkinson	O
disease	O
with	O
a	O
long-acting	O
ergot	O
derivative	O
,	O
cabergoline	B-Drug
0	O
<EOS>	O
thus	O
cabergoline	O
may	O
cause	O
similar	O
pleuropulmonary	B-ADR
abnormality	I-ADR
to	O
bromocriptine	B-Drug
0	O
<EOS>	O
thus	O
cabergoline	B-Drug
may	O
cause	O
similar	O
pleuropulmonary	B-ADR
abnormality	I-ADR
to	O
bromocriptine	O
0	O
<EOS>	O
acute	B-ADR
myopathy	I-ADR
with	O
selective	O
degeneration	O
of	O
myosin	O
filament	O
following	O
status	O
asthmaticus	O
treated	O
with	O
methylprednisolone	B-Drug
and	O
vecuronium	O
0	O
<EOS>	O
acute	B-ADR
myopathy	I-ADR
with	O
selective	O
degeneration	O
of	O
myosin	O
filament	O
following	O
status	O
asthmaticus	O
treated	O
with	O
methylprednisolone	O
and	O
vecuronium	B-Drug
0	O
<EOS>	O
acute	O
myopathy	O
with	O
selective	O
degeneration	B-ADR
of	I-ADR
myosin	I-ADR
filament	I-ADR
following	O
status	O
asthmaticus	O
treated	O
with	O
methylprednisolone	B-Drug
and	O
vecuronium	O
0	O
<EOS>	O
acute	O
myopathy	O
with	O
selective	O
degeneration	B-ADR
of	I-ADR
myosin	I-ADR
filament	I-ADR
following	O
status	O
asthmaticus	O
treated	O
with	O
methylprednisolone	O
and	O
vecuronium	B-Drug
0	O
<EOS>	O
flaccid	B-ADR
quadriparesis	I-ADR
wa	O
noted	O
after	O
discontinuation	O
of	O
vecuronium	B-Drug
0	O
<EOS>	O
this	O
entity	O
is	O
probably	O
related	O
to	O
a	O
combination	O
of	O
high	O
dos	O
of	O
corticosteroid	O
,	O
vecuronium	B-Drug
administration	O
and	O
metabolic	O
abnormality	O
associated	O
with	O
respiratory	B-ADR
failure	I-ADR
0	O
<EOS>	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
developed	O
skin	O
pigmentation	O
and	O
diffuse	B-ADR
pulmonary	I-ADR
shadowing	I-ADR
without	O
respiratory	O
symptomatology	O
,	O
while	O
taking	O
sulfasalazine	B-Drug
0	O
<EOS>	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
developed	O
skin	B-ADR
pigmentation	I-ADR
and	O
diffuse	O
pulmonary	O
shadowing	O
without	O
respiratory	O
symptomatology	O
,	O
while	O
taking	O
sulfasalazine	B-Drug
0	O
<EOS>	O
pulmonary	B-ADR
infiltrates	I-ADR
and	O
skin	O
pigmentation	O
associated	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
pulmonary	O
infiltrates	O
and	O
skin	B-ADR
pigmentation	I-ADR
associated	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
lung	B-ADR
disorder	I-ADR
is	O
an	O
extremely	O
rare	O
entity	O
which	O
must	O
be	O
considered	O
in	O
all	O
ulcerative	O
colitis	O
patient	O
while	O
on	O
sulfasalazine	O
therapy	O
,	O
despite	O
the	O
absence	O
of	O
pulmonary	O
symptomatology	O
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
lung	O
disorder	O
is	O
an	O
extremely	O
rare	O
entity	O
which	O
must	O
be	O
considered	O
in	O
all	O
ulcerative	B-ADR
colitis	I-ADR
patient	O
while	O
on	O
sulfasalazine	O
therapy	O
,	O
despite	O
the	O
absence	O
of	O
pulmonary	O
symptomatology	O
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
lung	O
disorder	O
is	O
an	O
extremely	O
rare	O
entity	O
which	O
must	O
be	O
considered	O
in	O
all	O
ulcerative	B-ADR
colitis	I-ADR
patient	O
while	O
on	O
sulfasalazine	O
therapy	O
,	O
despite	O
the	O
absence	O
of	O
pulmonary	O
symptomatology	O
0	O
<EOS>	O
reversible	O
sclerotic	B-ADR
change	I-ADR
of	I-ADR
lumbar	I-ADR
spine	I-ADR
and	I-ADR
femur	I-ADR
due	O
to	O
long-term	O
oral	O
isotretinoin	B-Drug
therapy	O
0	O
<EOS>	O
although	O
an	O
association	O
between	O
exposure	O
to	O
bleomycin	B-Drug
and	O
the	O
development	O
of	O
scleroderma	B-ADR
ha	O
been	O
suspected	O
,	O
few	O
case	O
are	O
reported	O
0	O
<EOS>	O
our	O
series	O
of	O
3	O
patient	O
support	O
a	O
causal	O
connection	O
between	O
bleomycin	B-Drug
and	O
scleroderma	B-ADR
0	O
<EOS>	O
scleroderma	B-ADR
in	O
association	O
with	O
the	O
use	O
of	O
bleomycin	B-Drug
:	O
a	O
report	O
of	O
3	O
case	O
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
cutaneous	B-ADR
scleroderma	I-ADR
in	O
3	O
patient	O
coincident	O
with	O
the	O
use	O
of	O
bleomycin	B-Drug
in	O
low	O
cumulative	O
dos	O
of	O
le	O
than	O
100	O
u	O
0	O
<EOS>	O
a	O
patient	O
presented	O
with	O
dilated	B-ADR
cardiomyopathy	I-ADR
after	O
many	O
year	O
of	O
overusing	O
an	O
adrenaline	B-Drug
inhaler	O
0	O
<EOS>	O
dilated	B-ADR
cardiomyopathy	I-ADR
associated	O
with	O
chronic	O
overuse	O
of	O
an	O
adrenaline	B-Drug
inhaler	O
0	O
<EOS>	O
a	O
21-year-old	O
woman	O
suffering	O
from	O
bipolar	O
affective	O
disorder	O
developed	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	B-ADR
)	O
with	O
characteristic	O
laboratory	O
finding	O
,	O
18	O
month	O
after	O
starting	O
carbamazepine	B-Drug
maintenance	O
treatment	O
0	O
<EOS>	O
a	O
21-year-old	O
woman	O
suffering	O
from	O
bipolar	O
affective	O
disorder	O
developed	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	O
sle	O
)	O
with	O
characteristic	O
laboratory	O
finding	O
,	O
18	O
month	O
after	O
starting	O
carbamazepine	B-Drug
maintenance	O
treatment	O
0	O
<EOS>	O
although	O
both	O
the	O
spontaneous	O
occurrence	O
of	O
sle	B-ADR
and	O
the	O
psychosis	O
a	O
a	O
sign	O
of	O
cns	O
involvement	O
of	O
sle	O
can	O
not	O
be	O
excluded	O
,	O
sle	O
could	O
be	O
considered	O
a	O
an	O
adverse	O
effect	O
of	O
carbamazepine	B-Drug
0	O
<EOS>	O
although	O
both	O
the	O
spontaneous	O
occurrence	O
of	O
sle	B-ADR
and	O
the	O
psychosis	O
a	O
a	O
sign	O
of	O
cns	O
involvement	O
of	O
sle	O
can	O
not	O
be	O
excluded	O
,	O
sle	O
could	O
be	O
considered	O
a	O
an	O
adverse	O
effect	O
of	O
carbamazepine	B-Drug
0	O
<EOS>	O
although	O
both	O
the	O
spontaneous	O
occurrence	O
of	O
sle	B-ADR
and	O
the	O
psychosis	O
a	O
a	O
sign	O
of	O
cns	O
involvement	O
of	O
sle	O
can	O
not	O
be	O
excluded	O
,	O
sle	O
could	O
be	O
considered	O
a	O
an	O
adverse	O
effect	O
of	O
carbamazepine	B-Drug
0	O
<EOS>	O
carbamazepine-induced	B-Drug
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
0	O
<EOS>	O
sle	B-ADR
receded	O
after	O
withdrawal	O
of	O
carbamazepine	B-Drug
and	O
treatment	O
with	O
anti-inflammatory	O
drug	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acne	B-ADR
fulminans	I-ADR
occurring	O
during	O
treatment	O
with	O
13-cis-retinoic	B-Drug
acid	I-Drug
for	O
cystic	O
acne	O
0	O
<EOS>	O
carbamyl	O
phosphate	O
synthetase-1	O
deficiency	O
discovered	O
after	O
valproic	B-Drug
acid-induced	I-Drug
coma	B-ADR
0	O
<EOS>	O
valproic	B-Drug
acid	I-Drug
induced	O
coma	B-ADR
is	O
presented	O
in	O
an	O
adult	O
patient	O
without	O
a	O
history	O
of	O
metabolic	O
disease	O
0	O
<EOS>	O
asterixis	B-ADR
induced	O
by	O
carbamazepine	B-Drug
therapy	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
present	O
four	O
patient	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drug	O
,	O
in	O
whom	O
asterixis	B-ADR
wa	O
triggered	O
either	O
by	O
adding	O
carbamazepine	B-Drug
(	O
cbz	O
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
it	O
dosage	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
present	O
four	O
patient	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drug	O
,	O
in	O
whom	O
asterixis	B-ADR
wa	O
triggered	O
either	O
by	O
adding	O
carbamazepine	O
(	O
cbz	B-Drug
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
it	O
dosage	O
0	O
<EOS>	O
we	O
consider	O
asterixis	B-ADR
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	O
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	O
or	O
clozapine	O
are	O
used	O
in	O
combination	O
with	O
cbz	B-Drug
0	O
<EOS>	O
we	O
consider	O
asterixis	B-ADR
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	O
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	O
or	O
clozapine	B-Drug
are	O
used	O
in	O
combination	O
with	O
cbz	O
0	O
<EOS>	O
we	O
consider	O
asterixis	B-ADR
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	O
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	B-Drug
or	O
clozapine	O
are	O
used	O
in	O
combination	O
with	O
cbz	O
0	O
<EOS>	O
we	O
consider	O
asterixis	O
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-ADR
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	O
or	O
clozapine	O
are	O
used	O
in	O
combination	O
with	O
cbz	B-Drug
0	O
<EOS>	O
we	O
consider	O
asterixis	O
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-ADR
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	O
or	O
clozapine	B-Drug
are	O
used	O
in	O
combination	O
with	O
cbz	O
0	O
<EOS>	O
we	O
consider	O
asterixis	O
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-ADR
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
level	O
,	O
if	O
certain	O
drug	O
a	O
lithium	B-Drug
or	O
clozapine	O
are	O
used	O
in	O
combination	O
with	O
cbz	O
0	O
<EOS>	O
encephalopathy	B-ADR
and	O
seizure	O
induced	O
by	O
intravesical	O
alum	B-Drug
irrigation	O
0	O
<EOS>	O
encephalopathy	O
and	O
seizure	B-ADR
induced	O
by	O
intravesical	O
alum	B-Drug
irrigation	O
0	O
<EOS>	O
hemorrhagic	B-ADR
cystitis	I-ADR
is	O
a	O
significant	O
toxic	O
effect	O
of	O
cyclophosphamide	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
encephalopathy	O
coincident	O
with	O
elevated	B-ADR
aluminum	I-ADR
level	I-ADR
a	O
well	O
a	O
one	O
patient	O
who	O
developed	O
seizure	O
while	O
receiving	O
continuous	O
bladder	O
irrigation	O
with	O
alum	B-Drug
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
encephalopathy	B-ADR
coincident	O
with	O
elevated	O
aluminum	O
level	O
a	O
well	O
a	O
one	O
patient	O
who	O
developed	O
seizure	O
while	O
receiving	O
continuous	O
bladder	O
irrigation	O
with	O
alum	B-Drug
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
encephalopathy	O
coincident	O
with	O
elevated	O
aluminum	O
level	O
a	O
well	O
a	O
one	O
patient	O
who	O
developed	O
seizure	B-ADR
while	O
receiving	O
continuous	O
bladder	O
irrigation	O
with	O
alum	B-Drug
0	O
<EOS>	O
seizure	O
with	O
hyponatremia	B-ADR
in	O
a	O
child	O
prescribed	O
desmopressin	B-Drug
for	O
nocturnal	O
enuresis	O
0	O
<EOS>	O
seizure	B-ADR
with	O
hyponatremia	O
in	O
a	O
child	O
prescribed	O
desmopressin	B-Drug
for	O
nocturnal	O
enuresis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
hyponatremia	O
associated	O
with	O
a	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
in	O
a	O
28	O
month-old	O
child	O
after	O
intra-nasal	O
desmopressin	B-Drug
administration	O
for	O
high	O
fluid	O
intake	O
with	O
nocturnal	O
enuresis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
hyponatremia	B-ADR
associated	O
with	O
a	O
grand	O
mal	O
seizure	O
in	O
a	O
28	O
month-old	O
child	O
after	O
intra-nasal	O
desmopressin	B-Drug
administration	O
for	O
high	O
fluid	O
intake	O
with	O
nocturnal	O
enuresis	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
a	O
38-year-old	O
male	O
in	O
whom	O
siadh	B-ADR
wa	O
strongly	O
suspected	O
secondary	O
to	O
tegretol	B-Drug
therapy	O
to	O
control	O
a	O
seizure	O
disorder	O
0	O
<EOS>	O
gestational	B-ADR
diabetes	I-ADR
wa	O
no	O
le	O
severe	O
(	O
degree	O
of	O
hyperglycaemia	O
,	O
need	O
for	O
insulin	O
therapy	O
)	O
when	O
associated	O
with	O
norethisterone	B-Drug
0	O
<EOS>	O
however	O
,	O
follow-up	O
revealed	O
that	O
gestational	O
diabetes	O
when	O
associated	O
with	O
norethisterone	B-Drug
had	O
a	O
lesser	O
risk	O
of	O
emerging	O
diabetes	B-ADR
mellitus	I-ADR
and	O
impaired	O
glucose	O
tolerance	O
0	O
<EOS>	O
however	O
,	O
follow-up	O
revealed	O
that	O
gestational	B-ADR
diabetes	I-ADR
when	O
associated	O
with	O
norethisterone	B-Drug
had	O
a	O
lesser	O
risk	O
of	O
emerging	O
diabetes	O
mellitus	O
and	O
impaired	O
glucose	O
tolerance	O
0	O
<EOS>	O
however	O
,	O
follow-up	O
revealed	O
that	O
gestational	O
diabetes	O
when	O
associated	O
with	O
norethisterone	B-Drug
had	O
a	O
lesser	O
risk	O
of	O
emerging	O
diabetes	O
mellitus	O
and	O
impaired	B-ADR
glucose	I-ADR
tolerance	I-ADR
0	O
<EOS>	O
in	O
a	O
single	O
practice	O
during	O
the	O
21	O
year	O
1971-1991	O
,	O
the	O
incidence	O
of	O
gestational	B-ADR
diabetes	I-ADR
in	O
pregnancy	O
in	O
which	O
norethisterone	B-Drug
wa	O
prescribed	O
wa	O
32.4	O
%	O
(	O
22	O
of	O
69	O
)	O
in	O
comparison	O
with	O
7.1	O
%	O
in	O
pregnancy	O
in	O
which	O
the	O
woman	O
did	O
not	O
take	O
norethisterone	O
(	O
137	O
of	O
1684	O
)	O
(	O
p	O
<	O
0.001	O
)	O
0	O
<EOS>	O
masculinization	O
of	O
a	O
female	O
fetus	O
occurred	O
in	O
5	O
of	O
39	O
(	O
12.8	O
%	O
)	O
exposed	O
to	O
norethisterone	B-Drug
;	O
all	O
were	O
case	O
of	O
clitoral	B-ADR
hypertrophy	I-ADR
not	O
requiring	O
surgical	O
treatment	O
0	O
<EOS>	O
masculinization	B-ADR
of	I-ADR
a	I-ADR
female	I-ADR
fetus	I-ADR
occurred	O
in	O
5	O
of	O
39	O
(	O
12.8	O
%	O
)	O
exposed	O
to	O
norethisterone	B-Drug
;	O
all	O
were	O
case	O
of	O
clitoral	O
hypertrophy	O
not	O
requiring	O
surgical	O
treatment	O
0	O
<EOS>	O
norethisterone	B-Drug
in	O
these	O
69	O
pregnancy	O
accounted	O
for	O
33.3	O
%	O
(	O
5	O
of	O
15	O
)	O
case	O
of	O
clitoral	B-ADR
hypertrophy	I-ADR
diagnosed	O
in	O
100756	O
consecutive	O
birth	O
0	O
<EOS>	O
an	O
adverse	O
reaction	O
to	O
ifn	B-Drug
wa	O
strongly	O
suspected	O
a	O
the	O
cause	O
of	O
chf	B-ADR
0	O
<EOS>	O
multiple	O
myeloma	O
complicated	O
by	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
following	O
first	O
administration	O
of	O
recombinant	B-Drug
alpha-interferon	I-Drug
0	O
<EOS>	O
sixteen	O
hour	O
after	O
the	O
first	O
administration	O
of	O
ifn	B-Drug
,	O
ifn	O
wa	O
suspended	O
by	O
the	O
symptom	O
of	O
congestive	O
heart	O
failure	O
(	O
chf	B-ADR
)	O
0	O
<EOS>	O
sixteen	O
hour	O
after	O
the	O
first	O
administration	O
of	O
ifn	B-Drug
,	O
ifn	O
wa	O
suspended	O
by	O
the	O
symptom	O
of	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
(	O
chf	O
)	O
0	O
<EOS>	O
neutrophilic	B-ADR
eccrine	I-ADR
hidradenitis	I-ADR
mimicking	O
cutaneous	O
vasculitis	O
in	O
a	O
lupus	O
patient	O
:	O
a	O
complication	O
of	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
neh	B-ADR
masquerading	O
a	O
cutaneous	O
vasculitis	O
in	O
a	O
woman	O
receiving	O
cyclophosphamide	B-Drug
for	O
lupus	O
nephritis	O
0	O
<EOS>	O
generalised	B-ADR
cutaneous	I-ADR
rash	I-ADR
associated	O
with	O
ganciclovir	B-Drug
therapy	O
ha	O
rarely	O
been	O
reported	O
in	O
literature	O
0	O
<EOS>	O
skin	B-ADR
rash	I-ADR
and	O
splinter	O
hemorrhage	O
from	O
ganciclovir	B-Drug
0	O
<EOS>	O
skin	O
rash	O
and	O
splinter	B-ADR
hemorrhage	I-ADR
from	O
ganciclovir	B-Drug
0	O
<EOS>	O
can	O
roxithromycin	O
and	O
betamethasone	B-Drug
induce	O
acute	B-ADR
pancreatitis	I-ADR
?	O
a	O
case	O
report	O
0	O
<EOS>	O
can	O
roxithromycin	B-Drug
and	O
betamethasone	O
induce	O
acute	B-ADR
pancreatitis	I-ADR
?	O
a	O
case	O
report	O
0	O
<EOS>	O
case	O
report	O
:	O
we	O
report	O
the	O
case	O
of	O
a	O
58	O
year	O
old	O
patient	O
who	O
,	O
after	O
2	O
day	O
of	O
treatment	O
with	O
roxithromycin	O
and	O
betamethasone	B-Drug
,	O
manifested	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
case	O
report	O
:	O
we	O
report	O
the	O
case	O
of	O
a	O
58	O
year	O
old	O
patient	O
who	O
,	O
after	O
2	O
day	O
of	O
treatment	O
with	O
roxithromycin	B-Drug
and	O
betamethasone	O
,	O
manifested	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
renal	B-ADR
tubular	I-ADR
acidosis	I-ADR
secondary	O
to	O
fk506	B-Drug
in	O
living	O
donor	O
liver	O
transplantation	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
rta	O
is	O
one	O
type	O
of	O
nephrotoxicity	B-ADR
induced	O
by	O
fk506	B-Drug
,	O
and	O
it	O
is	O
reversible	O
in	O
mild	O
case	O
when	O
appropriately	O
treated	O
0	O
<EOS>	O
rta	B-ADR
is	O
one	O
type	O
of	O
nephrotoxicity	O
induced	O
by	O
fk506	B-Drug
,	O
and	O
it	O
is	O
reversible	O
in	O
mild	O
case	O
when	O
appropriately	O
treated	O
0	O
<EOS>	O
surgeon	O
and	O
physician	O
should	O
therefore	O
be	O
aware	O
of	O
the	O
potential	O
for	O
rta	B-ADR
to	O
occur	O
with	O
fk506	B-Drug
after	O
any	O
organ	O
transplantation	O
0	O
<EOS>	O
the	O
mechanism	O
of	O
rta	B-ADR
induced	O
by	O
fk506	B-Drug
ha	O
not	O
yet	O
been	O
clearly	O
elucidated	O
0	O
<EOS>	O
the	O
treatment	O
for	O
acidosis	O
and	O
hyperkalaemia	O
should	O
be	O
started	O
a	O
soon	O
a	O
rta	B-ADR
is	O
diagnosed	O
,	O
and	O
the	O
dosage	O
of	O
fk506	B-Drug
should	O
also	O
be	O
reduced	O
if	O
possible	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
rta	B-ADR
secondary	O
to	O
fk506	B-Drug
administration	O
in	O
liver	O
transplantation	O
0	O
<EOS>	O
a	O
74-year-old	O
patient	O
with	O
idiopathic	O
parkinson	O
disease	O
wa	O
evaluated	O
for	O
unintended	B-ADR
sleep	I-ADR
episode	I-ADR
that	O
occurred	O
after	O
long-term	O
treatment	O
with	O
400	O
mg	O
/	O
day	O
of	O
l-dopa	B-Drug
0	O
<EOS>	O
l-dopa-induced	B-Drug
excessive	O
daytime	B-ADR
sleepiness	I-ADR
in	O
pd	O
:	O
a	O
placebo-controlled	O
case	O
with	O
mslt	O
assessment	O
0	O
<EOS>	O
the	O
author	O
	O
result	O
suggest	O
that	O
l-dopa	B-Drug
may	O
cause	O
daytime	B-ADR
somnolence	I-ADR
in	O
some	O
patient	O
with	O
parkinson	O
disease	O
0	O
<EOS>	O
neurotoxicity	B-ADR
of	O
intrathecal	O
methotrexate	B-Drug
:	O
mr	O
imaging	O
finding	O
0	O
<EOS>	O
we	O
attribute	O
the	O
clinical	O
and	O
radiographic	O
finding	O
to	O
cytotoxic	B-ADR
edema	I-ADR
secondary	O
to	O
intrathecal	O
methotrexate	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
intrathecal	O
methotrexate	B-Drug
neurotoxicity	O
manifesting	O
a	O
left	O
arm	O
weakness	O
and	O
aphasia	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
intrathecal	O
methotrexate	B-Drug
neurotoxicity	O
manifesting	O
a	O
left	B-ADR
arm	I-ADR
weakness	I-ADR
and	O
aphasia	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
intrathecal	O
methotrexate	B-Drug
neurotoxicity	B-ADR
manifesting	O
a	O
left	O
arm	O
weakness	O
and	O
aphasia	O
0	O
<EOS>	O
in	O
this	O
article	O
lithium	B-Drug
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concern	O
about	O
lithium	O
potential	O
teratogenicity	O
,	O
and	O
it	O
ha	O
been	O
implicated	O
in	O
epstein	B-ADR
anomaly	I-ADR
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infant	O
born	O
to	O
woman	O
taking	O
lithium	O
;	O
a	O
with	O
other	O
medication	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitation	O
0	O
<EOS>	O
in	O
this	O
article	O
lithium	B-Drug
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concern	O
about	O
lithium	O
potential	O
teratogenicity	O
,	O
and	O
it	O
ha	O
been	O
implicated	O
in	O
epstein	B-ADR
anomaly	I-ADR
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infant	O
born	O
to	O
woman	O
taking	O
lithium	O
;	O
a	O
with	O
other	O
medication	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitation	O
0	O
<EOS>	O
in	O
this	O
article	O
lithium	B-Drug
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concern	O
about	O
lithium	O
potential	O
teratogenicity	B-ADR
,	O
and	O
it	O
ha	O
been	O
implicated	O
in	O
epstein	O
anomaly	O
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infant	O
born	O
to	O
woman	O
taking	O
lithium	O
;	O
a	O
with	O
other	O
medication	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitation	O
0	O
<EOS>	O
in	O
this	O
article	O
lithium	B-Drug
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concern	O
about	O
lithium	O
potential	O
teratogenicity	B-ADR
,	O
and	O
it	O
ha	O
been	O
implicated	O
in	O
epstein	O
anomaly	O
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infant	O
born	O
to	O
woman	O
taking	O
lithium	O
;	O
a	O
with	O
other	O
medication	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitation	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
a	O
20-year-old	O
woman	O
who	O
ingested	O
900	O
mg	O
of	O
glyburide	B-Drug
causing	O
refractory	O
hypoglycemia	B-ADR
resistant	O
to	O
treatment	O
with	O
intravenous	O
dextrose	O
,	O
glucagon	O
,	O
and	O
diazoxide	O
0	O
<EOS>	O
ocular	B-ADR
ethambutol	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
the	O
most	O
commonly	O
recognized	O
toxic	O
effect	O
of	O
ethambutol	B-Drug
is	O
optic	B-ADR
neuropathy	I-ADR
,	O
which	O
generally	O
is	O
considered	O
uncommon	O
and	O
reversible	O
in	O
medical	O
literature	O
0	O
<EOS>	O
this	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
show	O
the	O
severe	O
and	O
unpredictable	O
nature	O
of	O
ethambutol	B-Drug
toxicity	I-ADR
and	O
it	O
potential	O
for	O
irreversible	O
vision	O
loss	O
despite	O
careful	O
ophthalmologic	O
monitoring	O
0	O
<EOS>	O
this	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
show	O
the	O
severe	O
and	O
unpredictable	O
nature	O
of	O
ethambutol	B-Drug
toxicity	O
and	O
it	O
potential	O
for	O
irreversible	O
vision	B-ADR
loss	I-ADR
despite	O
careful	O
ophthalmologic	O
monitoring	O
0	O
<EOS>	O
we	O
describe	O
a	O
43-year-old	O
man	O
who	O
developed	O
sign	O
and	O
symptom	O
of	O
bilateral	B-ADR
optic	I-ADR
neuropathy	I-ADR
during	O
treatment	O
with	O
ethambutol	B-Drug
0	O
<EOS>	O
the	O
case	O
history	O
and	O
toxicological	O
finding	O
of	O
an	O
infant	O
fatality	B-ADR
involving	O
pseudoephedrine	O
,	O
brompheniramine	B-Drug
,	O
and	O
dextromethorphan	O
are	O
presented	O
0	O
<EOS>	O
the	O
case	O
history	O
and	O
toxicological	O
finding	O
of	O
an	O
infant	O
fatality	B-ADR
involving	O
pseudoephedrine	O
,	O
brompheniramine	O
,	O
and	O
dextromethorphan	B-Drug
are	O
presented	O
0	O
<EOS>	O
the	O
case	O
history	O
and	O
toxicological	O
finding	O
of	O
an	O
infant	O
fatality	B-ADR
involving	O
pseudoephedrine	B-Drug
,	O
brompheniramine	O
,	O
and	O
dextromethorphan	O
are	O
presented	O
0	O
<EOS>	O
early	O
overanticoagulation	B-ADR
with	O
acenocoumarol	B-Drug
due	O
to	O
a	O
genetic	O
polymorphism	O
of	O
cytochrome	O
p450	O
cyp2c9	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
young	O
healthy	O
woman	O
who	O
presented	O
an	O
early	O
overanticoagulation	B-ADR
when	O
receiving	O
acenocoumarol	B-Drug
for	O
a	O
first	O
thromboembolic	O
episode	O
0	O
<EOS>	O
colchicine-induced	B-Drug
myopathy	B-ADR
in	O
a	O
teenager	O
with	O
familial	O
mediterranean	O
fever	O
0	O
<EOS>	O
conclusion	O
:	O
colchicine-induced	B-Drug
myopathy	B-ADR
should	O
be	O
excluded	O
in	O
patient	O
with	O
fmf	O
who	O
present	O
with	O
generalized	O
muscle	O
weakness	O
0	O
<EOS>	O
discussion	O
:	O
colchicine	B-Drug
,	O
the	O
most	O
important	O
drug	O
in	O
treatment	O
of	O
fmf	O
,	O
can	O
cause	O
myopathy	B-ADR
in	O
patient	O
with	O
impaired	O
renal	O
and	O
hepatic	O
function	O
0	O
<EOS>	O
in	O
our	O
patient	O
,	O
an	O
objective	O
causality	O
scale	O
showed	O
that	O
therapeutic	O
dos	O
of	O
colchicine	B-Drug
for	O
fmf	O
were	O
the	O
definite	O
cause	O
of	O
myopathy	B-ADR
,	O
even	O
though	O
his	O
renal	O
and	O
hepatic	O
function	O
were	O
normal	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
colchicine-induced	B-Drug
myopathy	B-ADR
in	O
a	O
teenager	O
with	O
familial	O
mediterranean	O
fever	O
(	O
fmf	O
)	O
0	O
<EOS>	O
angioedema	B-ADR
and	O
dysphagia	O
caused	O
by	O
contact	O
allergy	O
to	O
inhaled	O
budesonide	B-Drug
0	O
<EOS>	O
angioedema	O
and	O
dysphagia	B-ADR
caused	O
by	O
contact	O
allergy	O
to	O
inhaled	O
budesonide	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	O
throat	O
,	O
swelling	O
of	O
the	O
lip	O
and	O
oral	O
cavity	O
and	O
dysphagia	B-ADR
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	O
spray	O
(	O
budefat	B-Drug
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	O
throat	O
,	O
swelling	O
of	O
the	O
lip	O
and	O
oral	O
cavity	O
and	O
dysphagia	B-ADR
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	B-Drug
spray	O
(	O
budefat	O
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	B-ADR
throat	I-ADR
,	O
swelling	O
of	O
the	O
lip	O
and	O
oral	O
cavity	O
and	O
dysphagia	O
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	O
spray	O
(	O
budefat	B-Drug
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	B-ADR
throat	I-ADR
,	O
swelling	O
of	O
the	O
lip	O
and	O
oral	O
cavity	O
and	O
dysphagia	O
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	B-Drug
spray	O
(	O
budefat	O
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	O
throat	O
,	O
swelling	B-ADR
of	I-ADR
the	I-ADR
lip	I-ADR
and	I-ADR
oral	I-ADR
cavity	I-ADR
and	O
dysphagia	O
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	O
spray	O
(	O
budefat	B-Drug
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
we	O
report	O
a	O
43-year-old	O
woman	O
who	O
developed	O
sore	O
throat	O
,	O
swelling	B-ADR
of	I-ADR
the	I-ADR
lip	I-ADR
and	I-ADR
oral	I-ADR
cavity	I-ADR
and	O
dysphagia	O
,	O
2	O
week	O
after	O
the	O
use	O
of	O
budesonide	B-Drug
spray	O
(	O
budefat	O
)	O
for	O
treatment	O
of	O
bronchial	O
asthma	O
0	O
<EOS>	O
infectious	B-ADR
toxicity	I-ADR
of	O
dexamethasone	B-Drug
during	O
all	O
remission-induction	O
chemotherapy	O
:	O
report	O
of	O
two	O
case	O
and	O
literature	O
review	O
0	O
<EOS>	O
we	O
describe	O
the	O
infectious	O
toxicity	O
experienced	O
by	O
the	O
first	O
two	O
patient	O
in	O
our	O
institution	O
treated	O
with	O
dexamethasone	B-Drug
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/day	O
for	O
4	O
week	O
with	O
gradual	O
tapering	O
)	O
during	O
induction	O
according	O
to	O
the	O
dexamethasone	O
arm	O
of	O
bfm	O
2000	O
and	O
review	O
the	O
relevant	O
literature	O
that	O
suggests	O
an	O
increased	O
risk	O
of	O
infectious	B-ADR
complication	I-ADR
with	O
dexamethasone	O
0	O
<EOS>	O
we	O
describe	O
the	O
infectious	B-ADR
toxicity	I-ADR
experienced	O
by	O
the	O
first	O
two	O
patient	O
in	O
our	O
institution	O
treated	O
with	O
dexamethasone	B-Drug
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/day	O
for	O
4	O
week	O
with	O
gradual	O
tapering	O
)	O
during	O
induction	O
according	O
to	O
the	O
dexamethasone	O
arm	O
of	O
bfm	O
2000	O
and	O
review	O
the	O
relevant	O
literature	O
that	O
suggests	O
an	O
increased	O
risk	O
of	O
infectious	O
complication	O
with	O
dexamethasone	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
developed	O
neh	B-ADR
on	O
three	O
separate	O
occasion	O
provoked	O
by	O
two	O
different	O
chemotherapeutic	O
agent	O
--	O
cytarabine	B-Drug
and	O
mitoxantrone	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
developed	O
neh	B-ADR
on	O
three	O
separate	O
occasion	O
provoked	O
by	O
two	O
different	O
chemotherapeutic	O
agent	O
--	O
cytarabine	O
and	O
mitoxantrone	B-Drug
0	O
<EOS>	O
a	O
diagnosis	O
of	O
infliximab-induced	B-Drug
lupus	B-ADR
wa	O
made	O
and	O
the	O
drug	O
treatment	O
wa	O
withdrawn	O
0	O
<EOS>	O
infliximab-induced	B-Drug
lupus	B-ADR
in	O
crohn	O
disease	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
onset	O
of	O
prolonged	O
infliximab-induced	B-Drug
lupus	B-ADR
0	O
<EOS>	O
treatment	O
with	O
infliximab	B-Drug
is	O
known	O
to	O
produce	O
an	O
increase	O
of	O
autoantibody	O
(	O
antinuclear	O
antibody	O
,	O
anti-double-stranded	B-ADR
dna	I-ADR
)	O
,	O
but	O
not	O
clinical	O
disease	O
0	O
<EOS>	O
treatment	O
with	O
infliximab	B-Drug
is	O
known	O
to	O
produce	O
an	O
increase	O
of	O
autoantibody	O
(	O
antinuclear	B-ADR
antibody	I-ADR
,	O
anti-double-stranded	O
dna	O
)	O
,	O
but	O
not	O
clinical	O
disease	O
0	O
<EOS>	O
treatment	O
with	O
infliximab	B-Drug
is	O
known	O
to	O
produce	O
an	O
increase	B-ADR
of	I-ADR
autoantibody	I-ADR
(	O
antinuclear	O
antibody	O
,	O
anti-double-stranded	O
dna	O
)	O
,	O
but	O
not	O
clinical	O
disease	O
0	O
<EOS>	O
severe	B-ADR
raynaud	I-ADR
phenomenon	I-ADR
with	O
yohimbine	B-Drug
therapy	O
for	O
erectile	O
dysfunction	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
crest	O
syndrome	O
(	O
calcinosis	O
,	O
raynaud	O
phenomenon	O
,	O
esophageal	O
dysfunction	O
,	O
sclerodactyly	O
,	O
and	O
telangiectasia	O
)	O
who	O
paradoxically	O
experienced	O
worsening	B-ADR
of	I-ADR
raynaud	I-ADR
phenomenon	I-ADR
when	O
using	O
yohimbine	B-Drug
for	O
ed	O
0	O
<EOS>	O
after	O
initiation	O
of	O
topical	O
vitamin	B-Drug
d3	I-Drug
ointment	O
(	O
20	O
micro	O
g	O
/	O
g	O
of	O
tacalcitol	O
)	O
10	O
g	O
/	O
day	O
for	O
the	O
skin	O
lesion	O
,	O
both	O
the	O
serum	B-ADR
level	I-ADR
of	I-ADR
calcium	I-ADR
and	I-ADR
urinary	I-ADR
excretion	I-ADR
of	I-ADR
calcium	I-ADR
increased	I-ADR
gradually	O
0	O
<EOS>	O
iatrogenic	O
hypercalcemia	B-ADR
due	O
to	O
vitamin	O
d3	O
ointment	O
(	O
1,24	B-Drug
(	I-Drug
oh	I-Drug
)	I-Drug
2d3	I-Drug
)	O
combined	O
with	O
thiazide	O
diuretic	O
in	O
a	O
case	O
of	O
psoriasis	O
0	O
<EOS>	O
iatrogenic	O
hypercalcemia	B-ADR
due	O
to	O
vitamin	O
d3	O
ointment	O
(	O
1,24	O
(	O
oh	O
)	O
2d3	O
)	O
combined	O
with	O
thiazide	B-Drug
diuretic	O
in	O
a	O
case	O
of	O
psoriasis	O
0	O
<EOS>	O
iatrogenic	O
hypercalcemia	B-ADR
due	O
to	O
vitamin	B-Drug
d3	I-Drug
ointment	O
(	O
1,24	O
(	O
oh	O
)	O
2d3	O
)	O
combined	O
with	O
thiazide	O
diuretic	O
in	O
a	O
case	O
of	O
psoriasis	O
0	O
<EOS>	O
the	O
present	O
case	O
is	O
the	O
first	O
report	O
of	O
hypercalcemia	B-ADR
induced	O
by	O
vitamin	O
d3	O
ointment	O
and	O
thiazide	B-Drug
simultaneously	O
0	O
<EOS>	O
the	O
present	O
case	O
is	O
the	O
first	O
report	O
of	O
hypercalcemia	B-ADR
induced	O
by	O
vitamin	B-Drug
d3	I-Drug
ointment	O
and	O
thiazide	O
simultaneously	O
0	O
<EOS>	O
we	O
experienced	O
a	O
male	O
patient	O
with	O
psoriasis	O
and	O
hypertension	O
whose	O
condition	O
were	O
treated	O
with	O
tacalcitol	B-Drug
ointment	O
and	O
thiazide	O
,	O
respectively	O
,	O
resulting	O
in	O
hypercalciuria	O
and	O
hypercalcemia	B-ADR
0	O
<EOS>	O
we	O
experienced	O
a	O
male	O
patient	O
with	O
psoriasis	O
and	O
hypertension	O
whose	O
condition	O
were	O
treated	O
with	O
tacalcitol	O
ointment	O
and	O
thiazide	B-Drug
,	O
respectively	O
,	O
resulting	O
in	O
hypercalciuria	O
and	O
hypercalcemia	B-ADR
0	O
<EOS>	O
we	O
experienced	O
a	O
male	O
patient	O
with	O
psoriasis	O
and	O
hypertension	O
whose	O
condition	O
were	O
treated	O
with	O
tacalcitol	B-Drug
ointment	O
and	O
thiazide	O
,	O
respectively	O
,	O
resulting	O
in	O
hypercalciuria	B-ADR
and	O
hypercalcemia	O
0	O
<EOS>	O
we	O
experienced	O
a	O
male	O
patient	O
with	O
psoriasis	O
and	O
hypertension	O
whose	O
condition	O
were	O
treated	O
with	O
tacalcitol	O
ointment	O
and	O
thiazide	B-Drug
,	O
respectively	O
,	O
resulting	O
in	O
hypercalciuria	B-ADR
and	O
hypercalcemia	O
0	O
<EOS>	O
2-cda	B-Drug
typically	O
cause	O
a	O
long-lasting	O
state	O
of	O
immunodeficiency	B-ADR
and	O
the	O
profound	O
influence	O
of	O
this	O
drug	O
on	O
the	O
immune	O
system	O
ha	O
raised	O
question	O
concerning	O
the	O
emergence	O
of	O
secondary	O
neoplasm	O
after	O
it	O
use	O
0	O
<EOS>	O
2-cda	B-Drug
typically	O
cause	O
a	O
long-lasting	O
state	O
of	O
immunodeficiency	O
and	O
the	O
profound	O
influence	O
of	O
this	O
drug	O
on	O
the	O
immune	O
system	O
ha	O
raised	O
question	O
concerning	O
the	O
emergence	O
of	O
secondary	B-ADR
neoplasm	I-ADR
after	O
it	O
use	O
0	O
<EOS>	O
2-chloro-deoxyadenosine	B-Drug
induces	O
durable	O
complete	O
remission	O
in	O
castleman	O
disease	O
but	O
may	O
accelerate	O
it	O
transformation	O
to	O
non-hodgkin	B-ADR
lymphoma	I-ADR
0	O
<EOS>	O
therefore	O
,	O
it	O
is	O
reasonable	O
to	O
conclude	O
that	O
:	O
1	O
)	O
2-cda	B-Drug
can	O
induce	O
durable	O
complete	O
remission	O
in	O
mcd	O
patient	O
but	O
unfortunately	O
it	O
can	O
not	O
cure	O
the	O
disease	O
;	O
2	O
)	O
the	O
possibility	O
that	O
2-cda	O
may	O
accelerate	O
the	O
transformation	B-ADR
of	I-ADR
mcd	I-ADR
to	I-ADR
nhl	I-ADR
can	O
not	O
be	O
ruled	O
out	O
0	O
<EOS>	O
since	O
this	O
amount	O
of	O
fab	O
wa	O
insufficient	O
to	O
bind	O
all	O
dgtx	B-Drug
present	O
in	O
the	O
serum	O
,	O
cardiac	B-ADR
dgtx	I-ADR
toxicity	I-ADR
(	O
total	O
av-block	O
)	O
persisted	O
0	O
<EOS>	O
since	O
this	O
amount	O
of	O
fab	O
wa	O
insufficient	O
to	O
bind	O
all	O
dgtx	B-Drug
present	O
in	O
the	O
serum	O
,	O
cardiac	O
dgtx	O
toxicity	O
(	O
total	B-ADR
av-block	I-ADR
)	O
persisted	O
0	O
<EOS>	O
all	O
patient	O
had	O
taken	O
phenytoin	B-Drug
for	O
variable	O
time	O
period	O
(	O
range	O
16-80	O
day	O
;	O
mean	O
:	O
40	O
)	O
and	O
were	O
on	O
the	O
medication	O
when	O
the	O
skin	B-ADR
lesion	I-ADR
first	O
appeared	O
0	O
<EOS>	O
erythema	B-ADR
multiforme	I-ADR
associated	O
with	O
phenytoin	B-Drug
and	O
cranial	O
radiation	O
therapy	O
:	O
a	O
report	O
of	O
three	O
patient	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
in	O
conclusion	O
,	O
rsds	B-ADR
is	O
a	O
relevant	O
osteoarticular	O
complication	O
in	O
patient	O
receiving	O
either	O
anticalcineurinic	O
drug	O
(	O
cya	B-Drug
or	O
tacrolimus	O
)	O
,	O
even	O
under	O
monotherapy	O
or	O
with	O
a	O
low	O
steroid	O
dose	O
0	O
<EOS>	O
in	O
conclusion	O
,	O
rsds	B-ADR
is	O
a	O
relevant	O
osteoarticular	O
complication	O
in	O
patient	O
receiving	O
either	O
anticalcineurinic	O
drug	O
(	O
cya	O
or	O
tacrolimus	B-Drug
)	O
,	O
even	O
under	O
monotherapy	O
or	O
with	O
a	O
low	O
steroid	O
dose	O
0	O
<EOS>	O
reflex	B-ADR
sympathetic	I-ADR
dystrophy	I-ADR
syndrome	I-ADR
in	O
renal	O
transplanted	O
patient	O
under	O
immunosuppression	O
with	O
tacrolimus	B-Drug
0	O
<EOS>	O
we	O
now	O
present	O
four	O
case	O
of	O
rsds	B-ADR
in	O
kidney	O
transplant	O
recipient	O
treated	O
with	O
tacrolimus	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	O
effusion	O
with	O
forward	O
displacement	O
of	O
the	O
lens-iris	O
diaphragm	O
and	O
anterior	O
chamber	O
shallowing	O
,	O
resulting	O
in	O
acute	B-ADR
myopia	I-ADR
and	O
angle-closure	O
glaucoma	O
0	O
<EOS>	O
conclusion	O
:	O
topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	O
effusion	O
with	O
forward	O
displacement	O
of	O
the	O
lens-iris	O
diaphragm	O
and	O
anterior	O
chamber	O
shallowing	O
,	O
resulting	O
in	O
acute	O
myopia	O
and	O
angle-closure	B-ADR
glaucoma	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	O
effusion	O
with	O
forward	O
displacement	O
of	O
the	O
lens-iris	O
diaphragm	O
and	O
anterior	B-ADR
chamber	I-ADR
shallowing	I-ADR
,	O
resulting	O
in	O
acute	O
myopia	O
and	O
angle-closure	O
glaucoma	O
0	O
<EOS>	O
conclusion	O
:	O
topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	B-ADR
effusion	I-ADR
with	O
forward	O
displacement	O
of	O
the	O
lens-iris	O
diaphragm	O
and	O
anterior	O
chamber	O
shallowing	O
,	O
resulting	O
in	O
acute	O
myopia	O
and	O
angle-closure	O
glaucoma	O
0	O
<EOS>	O
conclusion	O
:	O
topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	O
effusion	O
with	O
forward	O
displacement	B-ADR
of	I-ADR
the	I-ADR
lens-iris	I-ADR
diaphragm	I-ADR
and	O
anterior	O
chamber	O
shallowing	O
,	O
resulting	O
in	O
acute	O
myopia	O
and	O
angle-closure	O
glaucoma	O
0	O
<EOS>	O
mechanism	O
of	O
topiramate-induced	B-Drug
acute-onset	B-ADR
myopia	I-ADR
and	O
angle	O
closure	O
glaucoma	O
0	O
<EOS>	O
mechanism	O
of	O
topiramate-induced	B-Drug
acute-onset	O
myopia	O
and	O
angle	B-ADR
closure	I-ADR
glaucoma	I-ADR
0	O
<EOS>	O
method	O
:	O
in	O
an	O
institutional	O
practice	O
setting	O
,	O
two	O
woman	O
,	O
aged	O
25	O
and	O
45	O
,	O
developed	O
acute	B-ADR
myopia	I-ADR
after	O
starting	O
topiramate	B-Drug
for	O
epilepsy	O
0	O
<EOS>	O
doxycycline-induced	B-Drug
photo-onycholysis	B-ADR
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
photo-onycholysis	B-ADR
in	O
a	O
patient	O
treated	O
with	O
doxycycline	B-Drug
for	O
acne	O
vulgaris	O
0	O
<EOS>	O
a	O
new	O
type	O
of	O
minocycline-induced	B-Drug
cutaneous	B-ADR
hyperpigmentation	I-ADR
0	O
<EOS>	O
pigmentary	B-ADR
disorder	I-ADR
are	O
recognized	O
adverse	O
effect	O
of	O
the	O
semi-synthetic	O
tetracycline	O
derivative	O
antibiotic	O
,	O
minocycline	B-Drug
0	O
<EOS>	O
this	O
fourth	O
type	O
of	O
cutaneous	O
minocycline	B-Drug
hyperpigmentation	B-ADR
may	O
be	O
a	O
variant	O
of	O
type	O
i	O
,	O
but	O
based	O
on	O
clinical	O
,	O
pathological	O
and	O
microanalytical	O
difference	O
,	O
appears	O
to	O
be	O
a	O
new	O
entity	O
0	O
<EOS>	O
three	O
distinct	O
type	O
of	O
minocycline-induced	B-Drug
cutaneous	B-ADR
pigmentation	I-ADR
have	O
been	O
described	O
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
with	O
acne	O
vulgaris	O
with	O
a	O
fourth	O
type	O
of	O
minocycline-induced	B-Drug
cutaneous	B-ADR
pigmentation	I-ADR
0	O
<EOS>	O
ciprofloxacin-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
in	O
a	O
patient	O
with	O
systemic	O
lupus	O
erythematosus	O
0	O
<EOS>	O
we	O
report	O
here	O
a	O
case	O
of	O
ten	B-ADR
after	O
administration	O
of	O
ciprofloxacin	B-Drug
0	O
<EOS>	O
a	O
56-year-old	O
caucasian	O
man	O
who	O
received	O
concomitant	O
chemotherapy	O
and	O
radiation	O
for	O
head	O
and	O
neck	O
cancer	O
developed	O
fever	B-ADR
concurrent	O
with	O
the	O
administration	O
of	O
amifostine	B-Drug
0	O
<EOS>	O
amifostine-induced	B-Drug
fever	B-ADR
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
patient	O
receiving	O
amifostine	B-Drug
who	O
develop	O
only	O
fever	B-ADR
should	O
be	O
evaluated	O
for	O
an	O
adverse	O
drug	O
reaction	O
,	O
a	O
well	O
a	O
for	O
sepsis	O
and	O
fever	O
of	O
neutropenia	O
,	O
and	O
it	O
may	O
be	O
necessary	O
to	O
discontinue	O
the	O
drug	O
0	O
<EOS>	O
patient	O
receiving	O
amifostine	B-Drug
who	O
develop	O
only	O
fever	O
should	O
be	O
evaluated	O
for	O
an	O
adverse	O
drug	O
reaction	O
,	O
a	O
well	O
a	O
for	O
sepsis	O
and	O
fever	B-ADR
of	I-ADR
neutropenia	I-ADR
,	O
and	O
it	O
may	O
be	O
necessary	O
to	O
discontinue	O
the	O
drug	O
0	O
<EOS>	O
patient	O
receiving	O
amifostine	B-Drug
who	O
develop	O
only	O
fever	O
should	O
be	O
evaluated	O
for	O
an	O
adverse	O
drug	O
reaction	O
,	O
a	O
well	O
a	O
for	O
sepsis	B-ADR
and	O
fever	O
of	O
neutropenia	O
,	O
and	O
it	O
may	O
be	O
necessary	O
to	O
discontinue	O
the	O
drug	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
that	O
demonstrates	O
the	O
occurrence	O
of	O
fever	B-ADR
with	O
low-dose	O
amifostine	B-Drug
therapy	O
without	O
the	O
manifestation	O
of	O
accompanying	O
rash	O
or	O
hypotension	O
0	O
<EOS>	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
due	O
to	O
pantoprazole	B-Drug
0	O
<EOS>	O
after	O
5	O
week	O
of	O
therapy	O
,	O
she	O
stopped	O
taking	O
pantoprazole	B-Drug
due	O
to	O
general	B-ADR
malaise	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
what	O
is	O
believed	O
,	O
a	O
of	O
november	O
4	O
,	O
2003	O
,	O
to	O
be	O
the	O
first	O
case	O
published	O
in	O
the	O
literature	O
of	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
(	O
ain	O
)	O
due	O
to	O
pantoprazole	B-Drug
0	O
<EOS>	O
the	O
naranjo	O
probability	O
scale	O
suggests	O
a	O
highly	O
probable	O
relationship	O
between	O
ain	B-ADR
and	O
pantoprazole	B-Drug
therapy	O
in	O
this	O
patient	O
0	O
<EOS>	O
there	O
have	O
been	O
several	O
reported	O
case	O
of	O
omeprazole-induced	B-Drug
ain	B-ADR
0	O
<EOS>	O
it	O
wa	O
highly	O
suspected	O
that	O
finasteride	B-Drug
wa	O
associated	O
with	O
the	O
anterior	B-ADR
subcapsular	I-ADR
opacity	I-ADR
on	I-ADR
the	I-ADR
lens	I-ADR
,	O
and	O
the	O
patient	O
therefore	O
discontinued	O
use	O
of	O
finasteride	O
0	O
<EOS>	O
it	O
wa	O
highly	O
suspected	O
that	O
finasteride	B-Drug
wa	O
associated	O
with	O
the	O
anterior	B-ADR
subcapsular	I-ADR
opacity	I-ADR
on	I-ADR
the	I-ADR
lens	I-ADR
,	O
and	O
the	O
patient	O
therefore	O
discontinued	O
use	O
of	O
finasteride	O
0	O
<EOS>	O
propecia-associated	B-Drug
bilateral	B-ADR
cataract	I-ADR
0	O
<EOS>	O
to	O
the	O
best	O
of	O
the	O
author	O
	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
propecia-associated	B-Drug
cataract	B-ADR
0	O
<EOS>	O
scleromyxedema	B-ADR
in	O
a	O
patient	O
with	O
multiple	O
sclerosis	O
and	O
monoclonal	O
gammopathy	O
on	O
interferon	B-Drug
beta-1a	I-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
two	O
child	O
with	O
attention	O
deficit	O
disorder	O
treated	O
with	O
methylphenidate	B-Drug
a	O
a	O
simple	O
drug	O
developed	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
of	I-ADR
the	I-ADR
scrotum	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
fixed	B-ADR
drug	I-ADR
rash	I-ADR
induced	O
by	O
methylphenidate	B-Drug
is	O
a	O
possible	O
but	O
rare	O
phenomenon	O
0	O
<EOS>	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
of	I-ADR
the	I-ADR
scrotum	I-ADR
due	O
to	O
methylphenidate	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
two	O
case	O
of	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
induced	O
by	O
methylphenidate	B-Drug
0	O
<EOS>	O
methotrexate	B-Drug
pneumonitis	B-ADR
in	O
nonsurgical	O
treatment	O
of	O
ectopic	O
pregnancy	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
pneumonitis	B-ADR
following	O
local	O
administration	O
of	O
methotrexate	B-Drug
for	O
nonsurgical	O
termination	O
of	O
an	O
ectopic	O
pregnancy	O
0	O
<EOS>	O
background	O
:	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
warfarin	B-Drug
therapy	O
change	O
in	O
the	O
over	O
75s	O
,	O
when	O
haemorrhagic	B-ADR
side-effects	I-ADR
become	O
more	O
common	O
0	O
<EOS>	O
case	O
report	O
:	O
a	O
woman	O
of	O
80	O
year	O
,	O
on	O
long-term	O
warfarin	B-Drug
therapy	O
presented	O
with	O
an	O
acute	B-ADR
dissecting	I-ADR
thoracic	I-ADR
aortic	I-ADR
aneurysm	I-ADR
;	O
on	O
investigation	O
the	O
only	O
precipitating	O
factor	O
found	O
wa	O
an	O
international	O
normalised	O
ratio	O
of	O
4.8	O
0	O
<EOS>	O
warfarin-associated	B-Drug
thoracic	B-ADR
aortic	I-ADR
dissection	I-ADR
in	O
an	O
elderly	O
woman	O
0	O
<EOS>	O
cutaneous	B-ADR
vasculitis	I-ADR
secondary	O
to	O
ramipril	B-Drug
0	O
<EOS>	O
here	O
we	O
report	O
ramipril-induced	B-Drug
cutaneous	B-ADR
vasculitis	I-ADR
in	O
a	O
patient	O
who	O
required	O
steroid	O
therapy	O
to	O
control	O
it	O
0	O
<EOS>	O
ramipril-induced	B-Drug
cutaneous	B-ADR
vasculitis	I-ADR
is	O
particularly	O
rare	O
and	O
our	O
case	O
wa	O
atypical	O
because	O
the	O
patient	O
had	O
tolerated	O
lisinopril	O
before	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
report	O
of	O
severe	B-ADR
myelopathy	I-ADR
following	O
accidental	O
intrathecal	O
administration	O
of	O
doxorubicin	B-Drug
0	O
<EOS>	O
neurological	O
improvement	O
and	O
rehabilitation	O
potential	O
following	O
toxic	B-ADR
myelopathy	I-ADR
due	O
to	O
intrathecal	O
injection	O
of	O
doxorubicin	B-Drug
0	O
<EOS>	O
result	O
:	O
evidence	O
of	O
neurological	O
improvement	O
and	O
rehabilitation	O
potential	O
after	O
severe	B-ADR
myelopathy	I-ADR
due	O
to	O
intrathecal	O
injection	O
of	O
doxorubicin	B-Drug
0	O
<EOS>	O
study	O
design	O
:	O
case	O
report	O
of	O
a	O
31-year-old	O
woman	O
who	O
presented	O
with	O
toxic	B-ADR
myelopathy	I-ADR
due	O
to	O
intrathecal	O
administration	O
of	O
doxorubicin	B-Drug
0	O
<EOS>	O
after	O
infliximab	B-Drug
treatment	O
,	O
additional	O
sleep	O
study	O
revealed	O
an	O
increase	B-ADR
in	I-ADR
the	I-ADR
number	I-ADR
of	I-ADR
apneic	I-ADR
event	I-ADR
and	O
sao2	O
dip	O
suggesting	O
that	O
tnfalpha	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
sleep	O
apnea	O
0	O
<EOS>	O
after	O
infliximab	B-Drug
treatment	O
,	O
additional	O
sleep	O
study	O
revealed	O
an	O
increase	O
in	O
the	O
number	O
of	O
apneic	O
event	O
and	O
sao2	B-ADR
dip	I-ADR
suggesting	O
that	O
tnfalpha	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
sleep	O
apnea	O
0	O
<EOS>	O
thus	O
,	O
clinical	O
recognition	O
of	O
sleep	B-ADR
disordered	I-ADR
breathing	I-ADR
should	O
be	O
taken	O
into	O
account	O
when	O
rheumatoid	O
arthritis	O
patient	O
are	O
to	O
be	O
treated	O
with	O
infliximab	B-Drug
0	O
<EOS>	O
hypernatraemia	B-ADR
induced	O
by	O
sodium	O
polystyrene	O
sulphonate	O
(	O
kayexalate	B-Drug
)	O
in	O
two	O
extremely	O
low	O
birth	O
weight	O
newborn	O
0	O
<EOS>	O
hypernatraemia	B-ADR
induced	O
by	O
sodium	B-Drug
polystyrene	I-Drug
sulphonate	I-Drug
(	O
kayexalate	O
)	O
in	O
two	O
extremely	O
low	O
birth	O
weight	O
newborn	O
0	O
<EOS>	O
we	O
describe	O
two	O
elbw	O
infant	O
affected	O
by	O
hyperkalaemia	O
,	O
treated	O
with	O
kayexalate	B-Drug
,	O
who	O
developed	O
serious	O
hypernatraemia	B-ADR
,	O
that	O
ha	O
never	O
been	O
reported	O
before	O
in	O
preterm	O
infant	O
0	O
<EOS>	O
bull's-eye	B-ADR
maculopathy	I-ADR
associated	O
with	O
quinacrine	B-Drug
therapy	O
for	O
malaria	O
0	O
<EOS>	O
conclusion	O
:	O
low	O
dosage	O
of	O
quinacrine	O
used	O
for	O
malaria	O
prophylaxis	O
can	O
be	O
associated	O
with	O
a	O
delayed	O
,	O
severe	O
maculopathy	B-ADR
indistinguishable	O
from	O
chloroquine	B-Drug
maculopathy	O
in	O
certain	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
low	O
dosage	O
of	O
quinacrine	B-Drug
used	O
for	O
malaria	O
prophylaxis	O
can	O
be	O
associated	O
with	O
a	O
delayed	O
,	O
severe	B-ADR
maculopathy	I-ADR
indistinguishable	O
from	O
chloroquine	O
maculopathy	O
in	O
certain	O
patient	O
0	O
<EOS>	O
result	O
:	O
a	O
patient	O
developed	O
a	O
bilaterally	B-ADR
symmetric	I-ADR
bull's-eye	I-ADR
maculopathy	I-ADR
45	O
year	O
after	O
taking	O
quinacrine	B-Drug
for	O
18	O
month	O
a	O
prophylaxis	O
against	O
malaria	O
0	O
<EOS>	O
the	O
clinical	O
picture	O
wa	O
identical	O
to	O
that	O
of	O
chloroquine	B-Drug
and	O
hydroxychloroquine	O
maculopathy	B-ADR
0	O
<EOS>	O
the	O
clinical	O
picture	O
wa	O
identical	O
to	O
that	O
of	O
chloroquine	O
and	O
hydroxychloroquine	B-Drug
maculopathy	B-ADR
0	O
<EOS>	O
cerebral	B-ADR
infarct	I-ADR
in	O
a	O
pediatric	O
patient	O
secondary	O
to	O
phenylpropanolamine	B-Drug
,	O
a	O
recalled	O
medication	O
0	O
<EOS>	O
phenylpropanolamine	B-Drug
(	O
ppa	O
)	O
recently	O
ha	O
been	O
publicly	O
implicated	O
a	O
a	O
cause	O
of	O
stroke	O
and	O
other	O
neurologic	B-ADR
event	I-ADR
0	O
<EOS>	O
phenylpropanolamine	O
(	O
ppa	B-Drug
)	O
recently	O
ha	O
been	O
publicly	O
implicated	O
a	O
a	O
cause	O
of	O
stroke	O
and	O
other	O
neurologic	B-ADR
event	I-ADR
0	O
<EOS>	O
phenylpropanolamine	B-Drug
(	O
ppa	O
)	O
recently	O
ha	O
been	O
publicly	O
implicated	O
a	O
a	O
cause	O
of	O
stroke	B-ADR
and	O
other	O
neurologic	O
event	O
0	O
<EOS>	O
phenylpropanolamine	O
(	O
ppa	B-Drug
)	O
recently	O
ha	O
been	O
publicly	O
implicated	O
a	O
a	O
cause	O
of	O
stroke	B-ADR
and	O
other	O
neurologic	O
event	O
0	O
<EOS>	O
the	O
patient	O
developed	O
occipital	O
infarct	O
and	O
wa	O
found	O
to	O
have	O
extremely	B-ADR
elevated	I-ADR
level	I-ADR
of	I-ADR
ppa	B-Drug
in	O
his	O
blood	O
and	O
dialysis	O
fluid	O
0	O
<EOS>	O
the	O
patient	O
developed	O
occipital	B-ADR
infarct	I-ADR
and	O
wa	O
found	O
to	O
have	O
extremely	O
elevated	O
level	O
of	O
ppa	B-Drug
in	O
his	O
blood	O
and	O
dialysis	O
fluid	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
stroke	B-ADR
after	O
ppa	B-Drug
ingestion	O
that	O
occurred	O
4	O
month	O
after	O
the	O
recall	O
in	O
an	O
8-year-old	O
boy	O
on	O
chronic	O
peritoneal	O
dialysis	O
0	O
<EOS>	O
central	O
nervous	O
system	O
effect	O
secondary	O
to	O
ciprofloxacin	B-Drug
treatment	O
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	O
dizziness	O
or	O
mild	O
headache	O
,	O
although	O
rare	O
occurrence	O
of	O
seizure	O
and	O
hallucination	B-ADR
have	O
been	O
reported	O
0	O
<EOS>	O
central	O
nervous	O
system	O
effect	O
secondary	O
to	O
ciprofloxacin	B-Drug
treatment	O
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	O
dizziness	O
or	O
mild	B-ADR
headache	I-ADR
,	O
although	O
rare	O
occurrence	O
of	O
seizure	O
and	O
hallucination	O
have	O
been	O
reported	O
0	O
<EOS>	O
central	O
nervous	O
system	O
effect	O
secondary	O
to	O
ciprofloxacin	B-Drug
treatment	O
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	B-ADR
dizziness	I-ADR
or	O
mild	O
headache	O
,	O
although	O
rare	O
occurrence	O
of	O
seizure	O
and	O
hallucination	O
have	O
been	O
reported	O
0	O
<EOS>	O
central	O
nervous	O
system	O
effect	O
secondary	O
to	O
ciprofloxacin	B-Drug
treatment	O
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	O
dizziness	O
or	O
mild	O
headache	O
,	O
although	O
rare	O
occurrence	O
of	O
seizure	B-ADR
and	O
hallucination	O
have	O
been	O
reported	O
0	O
<EOS>	O
ciprofloxacin-induced	B-Drug
psychosis	B-ADR
0	O
<EOS>	O
data	O
synthesis	O
:	O
a	O
49-year-old	O
man	O
developed	O
symptom	O
of	O
severe	B-ADR
psychosis	I-ADR
concomitant	O
with	O
ciprofloxacin	B-Drug
(	O
250	O
mg	O
bid	O
)	O
treatment	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
ciprofloxacin-induced	B-Drug
psychosis	B-ADR
and	O
to	O
discus	O
occurrence	O
rate	O
,	O
risk	O
factor	O
,	O
possible	O
etiology	O
,	O
preventive	O
measure	O
,	O
and	O
treatment	O
course	O
for	O
this	O
adverse	O
reaction	O
0	O
<EOS>	O
agranulocytosis	B-ADR
induced	O
by	O
vancomycin	B-Drug
in	O
an	O
esrd	O
patient	O
on	O
capd	O
0	O
<EOS>	O
agranulocytosis	B-ADR
is	O
a	O
rare	O
adverse	O
effect	O
associated	O
with	O
prolonged	O
vancomycin	B-Drug
therapy	O
,	O
and	O
is	O
potentially	O
serious	O
,	O
especially	O
in	O
end	O
stage	O
renal	O
disease	O
(	O
esrd	O
)	O
patient	O
0	O
<EOS>	O
we	O
describe	O
a	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
capd	O
)	O
patient	O
that	O
developed	O
vancomycin-induced	B-Drug
agranulocytosis	B-ADR
during	O
treatment	O
for	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
mrsa	O
)	O
-associated	O
external	O
cuff	O
infection	O
and	O
pneumonia	O
0	O
<EOS>	O
it	O
is	O
very	O
likely	O
that	O
the	O
dexamethasone	B-Drug
used	O
in	O
the	O
antiemetic	O
drug	O
regimen	O
contributed	O
to	O
the	O
development	O
of	O
osteonecrosis	B-ADR
in	O
these	O
patient	O
0	O
<EOS>	O
osteonecrosis	B-ADR
is	O
a	O
serious	O
side	O
effect	O
of	O
antiemetic	O
treatment	O
with	O
dexamethasone	B-Drug
and	O
this	O
serious	O
complication	O
should	O
be	O
incorporated	O
in	O
the	O
current	O
guideline	O
0	O
<EOS>	O
patient	O
should	O
be	O
informed	O
about	O
the	O
risk	O
of	O
osteonecrosis	B-ADR
when	O
taking	O
dexamethasone	B-Drug
a	O
an	O
antiemetic	O
drug	O
0	O
<EOS>	O
development	O
of	O
peyronie	B-ADR
disease	I-ADR
during	O
long-term	O
colchicine	B-Drug
treatment	O
0	O
<EOS>	O
however	O
here	O
we	O
reported	O
two	O
patient	O
,	O
presenting	O
with	O
pd	B-ADR
during	O
high	O
dose	O
colchicine	B-Drug
treatment	O
for	O
familiar	O
mediterranean	O
fever	O
(	O
fmf	O
)	O
0	O
<EOS>	O
a	O
patient	O
developed	O
cholestatic	B-ADR
hepatitis	I-ADR
while	O
being	O
treated	O
with	O
nitrofurantoin	B-Drug
0	O
<EOS>	O
a	O
second	O
episode	O
of	O
jaundice	B-ADR
followed	O
the	O
intravaginal	O
administration	O
of	O
a	O
mixture	O
of	O
furazolidone	B-Drug
and	O
nifuroxime	O
0	O
<EOS>	O
a	O
second	O
episode	O
of	O
jaundice	B-ADR
followed	O
the	O
intravaginal	O
administration	O
of	O
a	O
mixture	O
of	O
furazolidone	O
and	O
nifuroxime	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
phenobarbital	B-Drug
exacerbation	B-ADR
of	I-ADR
a	I-ADR
preexisting	I-ADR
maladaptive	I-ADR
behavior	I-ADR
partially	O
suppressed	O
by	O
chlorpromazine	O
and	O
misinterpreted	O
a	O
chlorpromazine	O
efficacy	O
0	O
<EOS>	O
ten	O
year	O
of	O
behavioral	O
data	O
are	O
presented	O
to	O
support	O
the	O
hypothesis	O
that	O
phenobarbital	B-Drug
wa	O
exacerbating	O
maladaptive	B-ADR
behavior	I-ADR
0	O
<EOS>	O
this	O
profile	O
should	O
trigger	O
a	O
``	O
red	O
flag	O
'	O
a	O
to	O
the	O
possibility	O
of	O
phenobarbital	B-Drug
behavioral	B-ADR
side	I-ADR
effect	I-ADR
or	O
exacerbation	O
of	O
preexisting	O
maladaptive	O
behavior	O
0	O
<EOS>	O
this	O
profile	O
should	O
trigger	O
a	O
``	O
red	O
flag	O
'	O
a	O
to	O
the	O
possibility	O
of	O
phenobarbital	B-Drug
behavioral	O
side	O
effect	O
or	O
exacerbation	B-ADR
of	I-ADR
preexisting	I-ADR
maladaptive	I-ADR
behavior	I-ADR
0	O
<EOS>	O
pilocarpine	B-Drug
toxicity	I-ADR
and	O
the	O
treatment	O
of	O
xerostomia	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
unintentional	O
overdose	O
of	O
oral	O
pilocarpine	B-Drug
tablet	O
that	O
resulted	O
in	O
bradycardia	B-ADR
,	O
mild	O
hypotension	O
,	O
and	O
muscarinic	O
symptom	O
in	O
a	O
patient	O
with	O
sjogren	O
syndrome	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
unintentional	O
overdose	O
of	O
oral	O
pilocarpine	B-Drug
tablet	O
that	O
resulted	O
in	O
bradycardia	O
,	O
mild	B-ADR
hypotension	I-ADR
,	O
and	O
muscarinic	O
symptom	O
in	O
a	O
patient	O
with	O
sjogren	O
syndrome	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
unintentional	O
overdose	O
of	O
oral	O
pilocarpine	B-Drug
tablet	O
that	O
resulted	O
in	O
bradycardia	O
,	O
mild	O
hypotension	O
,	O
and	O
muscarinic	B-ADR
symptom	I-ADR
in	O
a	O
patient	O
with	O
sjogren	O
syndrome	O
0	O
<EOS>	O
although	O
combination	O
of	O
belladonna	B-Drug
,	O
ergotamine	O
,	O
and	O
phenobarbital	O
have	O
been	O
used	O
for	O
medical	O
treatment	O
of	O
menopausal	O
symptom	O
since	O
the	O
1960s	O
,	O
this	O
is	O
the	O
first	O
known	O
case	O
report	O
of	O
it	O
association	O
with	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
although	O
combination	O
of	O
belladonna	O
,	O
ergotamine	B-Drug
,	O
and	O
phenobarbital	O
have	O
been	O
used	O
for	O
medical	O
treatment	O
of	O
menopausal	O
symptom	O
since	O
the	O
1960s	O
,	O
this	O
is	O
the	O
first	O
known	O
case	O
report	O
of	O
it	O
association	O
with	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
although	O
combination	O
of	O
belladonna	O
,	O
ergotamine	O
,	O
and	O
phenobarbital	B-Drug
have	O
been	O
used	O
for	O
medical	O
treatment	O
of	O
menopausal	O
symptom	O
since	O
the	O
1960s	O
,	O
this	O
is	O
the	O
first	O
known	O
case	O
report	O
of	O
it	O
association	O
with	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
associated	O
with	O
bellamine	B-Drug
s	I-Drug
,	O
a	O
therapy	O
for	O
menopausal	O
symptom	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
previously	O
healthy	O
,	O
postmenopausal	O
woman	O
who	O
developed	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
while	O
taking	O
bellamine	O
s	O
(	O
belladonna	B-Drug
alkaloid	I-Drug
;	O
ergotamine	O
;	O
phenobarbital	O
)	O
for	O
hot	O
flash	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
previously	O
healthy	O
,	O
postmenopausal	O
woman	O
who	O
developed	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
while	O
taking	O
bellamine	B-Drug
s	I-Drug
(	O
belladonna	O
alkaloid	O
;	O
ergotamine	O
;	O
phenobarbital	O
)	O
for	O
hot	O
flash	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
previously	O
healthy	O
,	O
postmenopausal	O
woman	O
who	O
developed	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
while	O
taking	O
bellamine	O
s	O
(	O
belladonna	O
alkaloid	O
;	O
ergotamine	B-Drug
;	O
phenobarbital	O
)	O
for	O
hot	O
flash	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
previously	O
healthy	O
,	O
postmenopausal	O
woman	O
who	O
developed	O
anticonvulsant	B-ADR
hypersensitivity	I-ADR
syndrome	I-ADR
while	O
taking	O
bellamine	O
s	O
(	O
belladonna	O
alkaloid	O
;	O
ergotamine	O
;	O
phenobarbital	B-Drug
)	O
for	O
hot	O
flash	O
0	O
<EOS>	O
a	O
case	O
of	O
heatstroke	B-ADR
is	O
reported	O
in	O
a	O
32-year-old	O
man	O
diagnosed	O
with	O
schizophrenia	O
and	O
on	O
clozapine	B-Drug
monotherapy	O
0	O
<EOS>	O
heat	B-ADR
stroke	I-ADR
in	O
schizophrenia	O
during	O
clozapine	B-Drug
treatment	O
:	O
rapid	O
recognition	O
and	O
management	O
0	O
<EOS>	O
gemcitabine-related	B-Drug
radiation	B-ADR
recall	I-ADR
preferentially	O
involves	O
internal	O
tissue	O
and	O
organ	O
0	O
<EOS>	O
the	O
author	O
also	O
determined	O
that	O
their	O
case	O
of	O
myositis	B-ADR
developing	O
in	O
the	O
rectus	O
abdominus	O
muscle	O
of	O
a	O
patient	O
with	O
pancreatic	O
adenocarcinoma	O
wa	O
the	O
manifestation	O
of	O
radiation	O
recall	O
,	O
thereby	O
bringing	O
the	O
number	O
of	O
patient	O
who	O
developed	O
radiation	O
recall	O
to	O
gemcitabine	B-Drug
and	O
were	O
discussed	O
in	O
the	O
current	O
study	O
to	O
13	O
0	O
<EOS>	O
the	O
author	O
also	O
determined	O
that	O
their	O
case	O
of	O
myositis	O
developing	O
in	O
the	O
rectus	O
abdominus	O
muscle	O
of	O
a	O
patient	O
with	O
pancreatic	O
adenocarcinoma	O
wa	O
the	O
manifestation	O
of	O
radiation	B-ADR
recall	I-ADR
,	O
thereby	O
bringing	O
the	O
number	O
of	O
patient	O
who	O
developed	O
radiation	O
recall	O
to	O
gemcitabine	B-Drug
and	O
were	O
discussed	O
in	O
the	O
current	O
study	O
to	O
13	O
0	O
<EOS>	O
the	O
author	O
also	O
determined	O
that	O
their	O
case	O
of	O
myositis	O
developing	O
in	O
the	O
rectus	O
abdominus	O
muscle	O
of	O
a	O
patient	O
with	O
pancreatic	O
adenocarcinoma	O
wa	O
the	O
manifestation	O
of	O
radiation	B-ADR
recall	I-ADR
,	O
thereby	O
bringing	O
the	O
number	O
of	O
patient	O
who	O
developed	O
radiation	O
recall	O
to	O
gemcitabine	B-Drug
and	O
were	O
discussed	O
in	O
the	O
current	O
study	O
to	O
13	O
0	O
<EOS>	O
the	O
literature	O
search	O
found	O
12	O
case	O
of	O
radiation	B-ADR
recall	I-ADR
caused	O
by	O
gemcitabine	B-Drug
0	O
<EOS>	O
the	O
majority	O
of	O
radiation	B-ADR
recall	I-ADR
reaction	I-ADR
attributed	O
to	O
gemcitabine	B-Drug
are	O
reported	O
to	O
affect	O
internal	O
tissue	O
or	O
organ	O
0	O
<EOS>	O
cystoid	B-ADR
macular	I-ADR
edema	I-ADR
in	O
a	O
low-risk	O
patient	O
after	O
switching	O
from	O
latanoprost	O
to	O
bimatoprost	B-Drug
0	O
<EOS>	O
cystoid	B-ADR
macular	I-ADR
edema	I-ADR
in	O
a	O
low-risk	O
patient	O
after	O
switching	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	O
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	O
conjunctival	O
hyperemia	O
and	O
cystoid	B-ADR
macula	I-ADR
edema	I-ADR
after	O
switching	O
from	O
latanoprost	O
to	O
bimatoprost	B-Drug
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	O
macular	O
edema	O
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	O
conjunctival	O
hyperemia	O
and	O
cystoid	B-ADR
macula	I-ADR
edema	I-ADR
after	O
switching	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	O
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	O
macular	O
edema	O
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	O
conjunctival	O
hyperemia	O
and	O
cystoid	O
macula	O
edema	O
after	O
switching	O
from	O
latanoprost	O
to	O
bimatoprost	B-Drug
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	B-ADR
macular	I-ADR
edema	I-ADR
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	O
conjunctival	O
hyperemia	O
and	O
cystoid	O
macula	O
edema	O
after	O
switching	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	O
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	B-ADR
macular	I-ADR
edema	I-ADR
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	B-ADR
conjunctival	I-ADR
hyperemia	I-ADR
and	O
cystoid	O
macula	O
edema	O
after	O
switching	O
from	O
latanoprost	O
to	O
bimatoprost	B-Drug
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	O
macular	O
edema	O
0	O
<EOS>	O
method	O
:	O
a	O
68-year-old	O
man	O
developed	O
intense	B-ADR
conjunctival	I-ADR
hyperemia	I-ADR
and	O
cystoid	O
macula	O
edema	O
after	O
switching	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	O
9	O
month	O
after	O
cataract	O
surgery	O
in	O
an	O
eye	O
at	O
low-risk	O
for	O
this	O
cystoid	O
macular	O
edema	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
angiographically	O
documented	O
cystoid	B-ADR
macula	I-ADR
edema	I-ADR
occurring	O
after	O
switching	O
a	O
pseudophakic	O
patient	O
from	O
latanoprost	O
to	O
bimatoprost	B-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
angiographically	O
documented	O
cystoid	B-ADR
macula	I-ADR
edema	I-ADR
occurring	O
after	O
switching	O
a	O
pseudophakic	O
patient	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	O
0	O
<EOS>	O
an	O
immediate	O
hemolytic	B-ADR
reaction	I-ADR
induced	O
by	O
repeated	O
administration	O
of	O
oxaliplatin	B-Drug
0	O
<EOS>	O
case	O
report	O
:	O
we	O
report	O
a	O
patient	O
who	O
developed	O
a	O
dat-positive	B-ADR
hemolytic	I-ADR
episode	I-ADR
after	O
a	O
red	O
cell	O
(	O
rbc	O
)	O
transfusion	O
wa	O
delivered	O
during	O
the	O
infusion	O
of	O
her	O
17th	O
cycle	O
of	O
oxaliplatin	B-Drug
0	O
<EOS>	O
although	O
neurotoxicity	O
is	O
a	O
frequent	O
complication	O
of	O
methotrexate	B-Drug
therapy	O
,	O
fatal	B-ADR
acute	I-ADR
neurotoxicity	I-ADR
is	O
extremely	O
uncommon	O
,	O
especially	O
in	O
adult	O
0	O
<EOS>	O
although	O
neurotoxicity	B-ADR
is	O
a	O
frequent	O
complication	O
of	O
methotrexate	B-Drug
therapy	O
,	O
fatal	O
acute	O
neurotoxicity	O
is	O
extremely	O
uncommon	O
,	O
especially	O
in	O
adult	O
0	O
<EOS>	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
sign	O
and	O
symptom	O
of	O
neurotoxicity	B-ADR
during	O
treatment	O
,	O
a	O
well	O
a	O
predisposing	O
factor	O
that	O
put	O
patient	O
receiving	O
methotrexate	B-Drug
at	O
risk	O
for	O
neurotoxic	O
effect	O
0	O
<EOS>	O
fatal	B-ADR
acute	I-ADR
encephalomyelitis	I-ADR
after	O
a	O
single	O
dose	O
of	O
intrathecal	O
methotrexate	B-Drug
0	O
<EOS>	O
the	O
day	O
after	O
methotrexate	B-Drug
administration	O
,	O
the	O
patient	O
complained	O
of	O
severe	B-ADR
back	I-ADR
pain	I-ADR
and	O
urinary	O
retention	O
0	O
<EOS>	O
the	O
day	O
after	O
methotrexate	B-Drug
administration	O
,	O
the	O
patient	O
complained	O
of	O
severe	O
back	O
pain	O
and	O
urinary	B-ADR
retention	I-ADR
0	O
<EOS>	O
this	O
patient	O
rapidly	O
progressed	O
from	O
mild	O
neurotoxicity	O
to	O
fatal	B-ADR
encephalopathy	I-ADR
after	O
one	O
dose	O
of	O
intrathecal	O
methotrexate	B-Drug
during	O
his	O
third	O
cycle	O
of	O
chemotherapy	O
0	O
<EOS>	O
this	O
patient	O
rapidly	O
progressed	O
from	O
mild	B-ADR
neurotoxicity	I-ADR
to	O
fatal	O
encephalopathy	O
after	O
one	O
dose	O
of	O
intrathecal	O
methotrexate	B-Drug
during	O
his	O
third	O
cycle	O
of	O
chemotherapy	O
0	O
<EOS>	O
we	O
report	O
a	O
third	O
case	O
of	O
a	O
6-week-old	O
infant	O
with	O
escherichia	O
coli	O
sepsis	O
who	O
received	O
ampicillin	B-Drug
and	O
other	O
antibiotic	O
and	O
subsequently	O
developed	O
ten	B-ADR
0	O
<EOS>	O
one	O
patient	O
developed	O
large	B-ADR
intramural	I-ADR
esophageal	I-ADR
hematoma	I-ADR
a	O
a	O
complication	O
of	O
heparin	B-Drug
therapy	O
0	O
<EOS>	O
eosinophilic	B-ADR
cystitis	I-ADR
after	O
bladder	O
instillation	O
with	O
dimethyl	B-Drug
sulfoxide	I-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
an	O
acute	O
flare	O
of	O
eosinophilic	B-ADR
cystitis	I-ADR
in	O
a	O
51-year-old	O
woman	O
after	O
bladder	O
instillation	O
with	O
dimethyl	B-Drug
sulfoxide	I-Drug
(	O
dmso	O
)	O
for	O
presumed	O
interstitial	O
cystitis	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
an	O
acute	O
flare	O
of	O
eosinophilic	B-ADR
cystitis	I-ADR
in	O
a	O
51-year-old	O
woman	O
after	O
bladder	O
instillation	O
with	O
dimethyl	O
sulfoxide	O
(	O
dmso	B-Drug
)	O
for	O
presumed	O
interstitial	O
cystitis	O
0	O
<EOS>	O
acute	B-ADR
dystonia	I-ADR
during	O
pegylated	B-Drug
interferon	I-Drug
alpha	I-Drug
therapy	O
in	O
a	O
case	O
with	O
chronic	O
hepatitis	O
b	O
infection	O
0	O
<EOS>	O
in	O
this	O
case	O
report	O
,	O
we	O
present	O
clinical	O
and	O
laboratory	O
finding	O
of	O
a	O
case	O
with	O
chronic	O
hepatitis	O
b	O
that	O
developed	O
acute	B-ADR
dystonia	I-ADR
soon	O
after	O
the	O
first	O
dose	O
of	O
pegylated	B-Drug
interferon	I-Drug
alpha	I-Drug
0	O
<EOS>	O
therapy	O
with	O
ifn-alpha	B-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	O
symptom	O
,	O
such	O
a	O
parkinsonism	O
,	O
akathisia	B-ADR
,	O
seizure	O
,	O
and	O
depressive	O
disorder	O
0	O
<EOS>	O
therapy	O
with	O
ifn-alpha	B-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	O
symptom	O
,	O
such	O
a	O
parkinsonism	O
,	O
akathisia	O
,	O
seizure	O
,	O
and	O
depressive	B-ADR
disorder	I-ADR
0	O
<EOS>	O
therapy	O
with	O
ifn-alpha	B-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	B-ADR
symptom	I-ADR
,	O
such	O
a	O
parkinsonism	O
,	O
akathisia	O
,	O
seizure	O
,	O
and	O
depressive	O
disorder	O
0	O
<EOS>	O
therapy	O
with	O
ifn-alpha	B-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	O
symptom	O
,	O
such	O
a	O
parkinsonism	B-ADR
,	O
akathisia	O
,	O
seizure	O
,	O
and	O
depressive	O
disorder	O
0	O
<EOS>	O
therapy	O
with	O
ifn-alpha	B-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	O
symptom	O
,	O
such	O
a	O
parkinsonism	O
,	O
akathisia	O
,	O
seizure	B-ADR
,	O
and	O
depressive	O
disorder	O
0	O
<EOS>	O
a	O
patient	O
developed	O
restless	B-ADR
leg	I-ADR
symptom	I-ADR
paralleling	O
the	O
course	O
of	O
interferon-alpha	O
(	O
ifn	B-Drug
alpha	I-Drug
)	O
therapy	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
a	O
patient	O
developed	O
restless	B-ADR
leg	I-ADR
symptom	I-ADR
paralleling	O
the	O
course	O
of	O
interferon-alpha	B-Drug
(	O
ifn	O
alpha	O
)	O
therapy	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
restless	B-ADR
leg	I-ADR
syndrome	I-ADR
due	O
to	O
interferon-alpha	B-Drug
0	O
<EOS>	O
restless	B-ADR
leg	I-ADR
syndrome	I-ADR
may	O
thus	O
be	O
an	O
adverse	O
effect	O
of	O
ifn	B-Drug
alpha	I-Drug
treatment	O
0	O
<EOS>	O
many	O
clinician	O
appear	O
to	O
be	O
concerned	O
about	O
the	O
potential	O
hepatotoxicity	B-ADR
of	O
the	O
opiate	O
antagonist	O
naltrexone	B-Drug
(	O
ntx	O
)	O
and	O
this	O
may	O
be	O
one	O
reason	O
why	O
it	O
is	O
not	O
used	O
more	O
widely	O
in	O
treating	O
both	O
heroin	O
and	O
alcohol	O
abuser	O
0	O
<EOS>	O
many	O
clinician	O
appear	O
to	O
be	O
concerned	O
about	O
the	O
potential	O
hepatotoxicity	B-ADR
of	O
the	O
opiate	O
antagonist	O
naltrexone	O
(	O
ntx	B-Drug
)	O
and	O
this	O
may	O
be	O
one	O
reason	O
why	O
it	O
is	O
not	O
used	O
more	O
widely	O
in	O
treating	O
both	O
heroin	O
and	O
alcohol	O
abuser	O
0	O
<EOS>	O
we	O
describe	O
a	O
heroin	O
abuser	O
in	O
whom	O
clinical	O
and	O
laboratory	O
manifestation	O
of	O
acute	B-ADR
hepatitis	I-ADR
b	I-ADR
and	I-ADR
c	I-ADR
appeared	O
a	O
few	O
day	O
after	O
the	O
insertion	O
of	O
a	O
subcutaneous	O
naltrexone	B-Drug
implant	O
0	O
<EOS>	O
sweet	B-ADR
syndrome	I-ADR
associated	O
with	O
sargramostim	B-Drug
(	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
)	O
treatment	O
0	O
<EOS>	O
sweet	O
syndrome	O
is	O
an	O
acute	B-ADR
febrile	I-ADR
neutrophilic	I-ADR
dermatosis	I-ADR
that	O
is	O
a	O
known	O
complication	O
of	O
the	O
administration	O
of	O
filgrastim	B-Drug
,	O
a	O
drug	O
that	O
cause	O
increased	O
neutrophil	O
proliferation	O
and	O
differentiation	O
0	O
<EOS>	O
sweet	B-ADR
syndrome	I-ADR
is	O
an	O
acute	O
febrile	O
neutrophilic	O
dermatosis	O
that	O
is	O
a	O
known	O
complication	O
of	O
the	O
administration	O
of	O
filgrastim	B-Drug
,	O
a	O
drug	O
that	O
cause	O
increased	O
neutrophil	O
proliferation	O
and	O
differentiation	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
sweet	B-ADR
syndrome	I-ADR
in	O
association	O
with	O
sargramostim	B-Drug
treatment	O
following	O
chemotherapy	O
for	O
acute	O
myelogenous	O
leukemia	O
0	O
<EOS>	O
sudden	O
cardiac	O
death	O
due	O
to	O
hypersensitivity	B-ADR
myocarditis	I-ADR
during	O
clozapine	B-Drug
treatment	O
0	O
<EOS>	O
sudden	B-ADR
cardiac	I-ADR
death	I-ADR
due	O
to	O
hypersensitivity	O
myocarditis	O
during	O
clozapine	B-Drug
treatment	O
0	O
<EOS>	O
the	O
autopsy	O
finding	O
and	O
a	O
detailed	O
medical	O
history	O
supported	O
the	O
conclusion	O
that	O
clozapine-induced	B-Drug
hypersensitivity	B-ADR
myocarditis	I-ADR
wa	O
the	O
most	O
likely	O
cause	O
of	O
death	O
0	O
<EOS>	O
the	O
case	O
concern	O
the	O
sudden	B-ADR
death	I-ADR
of	O
a	O
29-year-old	O
male	O
during	O
clozapine	B-Drug
therapy	O
started	O
2	O
week	O
before	O
0	O
<EOS>	O
purple	O
glove	O
syndrome	O
,	O
named	O
for	O
it	O
distinctive	O
purple	B-ADR
discoloration	I-ADR
and	O
swelling	O
of	O
the	O
hand	O
in	O
the	O
distribution	O
of	O
a	O
glove	O
,	O
is	O
an	O
uncommon	O
complication	O
of	O
intravenous	O
phenytoin	B-Drug
administration	O
through	O
small	O
dorsal	O
vein	O
of	O
the	O
hand	O
0	O
<EOS>	O
purple	B-ADR
glove	I-ADR
syndrome	I-ADR
,	O
named	O
for	O
it	O
distinctive	O
purple	O
discoloration	O
and	O
swelling	O
of	O
the	O
hand	O
in	O
the	O
distribution	O
of	O
a	O
glove	O
,	O
is	O
an	O
uncommon	O
complication	O
of	O
intravenous	O
phenytoin	B-Drug
administration	O
through	O
small	O
dorsal	O
vein	O
of	O
the	O
hand	O
0	O
<EOS>	O
purple	O
glove	O
syndrome	O
,	O
named	O
for	O
it	O
distinctive	O
purple	O
discoloration	O
and	O
swelling	B-ADR
of	I-ADR
the	I-ADR
hand	I-ADR
in	O
the	O
distribution	O
of	O
a	O
glove	O
,	O
is	O
an	O
uncommon	O
complication	O
of	O
intravenous	O
phenytoin	B-Drug
administration	O
through	O
small	O
dorsal	O
vein	O
of	O
the	O
hand	O
0	O
<EOS>	O
the	O
finding	O
were	O
judged	O
to	O
be	O
consistent	O
with	O
soft-tissue	O
injury	O
associated	O
with	O
intravenous	O
administration	O
of	O
phenytoin	B-Drug
,	O
also	O
termed	O
purple	B-ADR
glove	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
the	O
finding	O
were	O
judged	O
to	O
be	O
consistent	O
with	O
soft-tissue	B-ADR
injury	I-ADR
associated	O
with	O
intravenous	O
administration	O
of	O
phenytoin	B-Drug
,	O
also	O
termed	O
purple	O
glove	O
syndrome	O
0	O
<EOS>	O
our	O
patient	O
wa	O
a	O
72-year-old	O
man	O
with	O
advanced	O
parkinson	O
disease	O
(	O
pd	O
)	O
who	O
received	O
levodopa	B-Drug
and	O
anti-cholinergic	O
drug	O
and	O
whose	O
head	O
had	O
become	O
almost	O
completely	B-ADR
bald	I-ADR
0	O
<EOS>	O
a	O
patient	O
with	O
monocular	O
open-angle	O
glaucoma	O
had	O
trichiasis	B-ADR
,	O
a	O
condition	O
associated	O
with	O
the	O
use	O
of	O
a	O
prostaglandin	B-Drug
analog	O
0	O
<EOS>	O
increased	B-ADR
lash	I-ADR
length	I-ADR
,	O
thickness	O
,	O
and	O
pigmentation	O
are	O
well-documented	O
side	O
effect	O
of	O
prostaglandin	B-Drug
analog	O
glaucoma	O
drop	O
0	O
<EOS>	O
increased	O
lash	O
length	O
,	O
thickness	O
,	O
and	O
pigmentation	B-ADR
are	O
well-documented	O
side	O
effect	O
of	O
prostaglandin	B-Drug
analog	O
glaucoma	O
drop	O
0	O
<EOS>	O
trichiasis	B-ADR
associated	O
with	O
prostaglandin	B-Drug
analog	O
use	O
0	O
<EOS>	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
associated	O
with	O
bcnu	B-Drug
:	O
the	O
relative	O
role	O
of	O
platelet-derived	O
growth	O
factor-b	O
,	O
insulin-like	O
growth	O
factor	O
i	O
,	O
transforming	O
growth	O
factor-beta1	O
and	O
cyclooxygenase-2	O
0	O
<EOS>	O
pulmonary	B-ADR
fibrosis	I-ADR
is	O
a	O
severe	O
complication	O
associated	O
with	O
bis-chloronitrosourea	O
(	O
bcnu	B-Drug
)	O
therapy	O
0	O
<EOS>	O
pulmonary	B-ADR
fibrosis	I-ADR
is	O
a	O
severe	O
complication	O
associated	O
with	O
bis-chloronitrosourea	B-Drug
(	O
bcnu	O
)	O
therapy	O
0	O
<EOS>	O
these	O
novel	O
finding	O
may	O
offer	O
specific	O
therapeutic	O
target	O
in	O
the	O
treatment	O
of	O
bcnu-associated	B-Drug
pulmonary	B-ADR
fibrosis	I-ADR
0	O
<EOS>	O
we	O
further	O
used	O
immunohistochemistry	O
(	O
ihc	O
)	O
to	O
examine	O
the	O
relative	O
role	O
of	O
platelet-derived	O
growth	O
factor-b	O
(	O
pdgf-b	O
)	O
,	O
insulin-like	O
growth	O
factor	O
i	O
(	O
igf-i	O
)	O
,	O
transforming	O
growth	O
factor-beta1	O
(	O
tgf-beta1	O
)	O
and	O
cyclooxygenase-2	O
(	O
cox-2	O
)	O
in	O
the	O
pathogenesis	O
of	O
bcnu-related	B-Drug
pulmonary	B-ADR
fibrosis	I-ADR
0	O
<EOS>	O
we	O
report	O
here	O
a	O
26-year-old	O
female	O
with	O
diffuse	O
large	O
b-cell	O
lymphoma	O
who	O
died	O
of	O
severe	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
81	O
day	O
after	O
the	O
administration	O
of	O
high-dose	O
bcnu	B-Drug
(	O
600	O
mg	O
/	O
m2	O
)	O
0	O
<EOS>	O
dorzolamide-induced	B-Drug
choroidal	B-ADR
detachment	I-ADR
in	O
a	O
surgically	O
untreated	O
eye	O
0	O
<EOS>	O
method	O
:	O
a	O
76-year-old	O
woman	O
with	O
primary	O
open-angle	O
glaucoma	O
and	O
no	O
history	O
of	O
ocular	O
surgery	O
developed	O
a	O
choroidal	B-ADR
detachment	I-ADR
12	O
hour	O
after	O
initiation	O
of	O
therapy	O
with	O
dorzolamide	B-Drug
eye	O
drop	O
0	O
<EOS>	O
we	O
document	O
the	O
abrupt	O
development	O
of	O
an	O
extensive	O
choroidal	B-ADR
detachment	I-ADR
after	O
initiation	O
of	O
dorzolamide	B-Drug
therapy	O
in	O
a	O
surgically	O
untreated	O
eye	O
with	O
primary	O
open-angle	O
glaucoma	O
0	O
<EOS>	O
deepening	B-ADR
of	I-ADR
lid	I-ADR
sulcus	I-ADR
from	O
topical	O
bimatoprost	B-Drug
therapy	O
0	O
<EOS>	O
in	O
each	O
of	O
the	O
three	O
reported	O
patient	O
,	O
alteration	B-ADR
of	I-ADR
eyelid	I-ADR
appearance	I-ADR
with	O
deepening	O
of	O
the	O
lid	O
sulcus	O
wa	O
evident	O
a	O
the	O
result	O
of	O
topical	O
bimatoprost	B-Drug
therapy	O
0	O
<EOS>	O
in	O
each	O
of	O
the	O
three	O
reported	O
patient	O
,	O
alteration	O
of	O
eyelid	O
appearance	O
with	O
deepening	B-ADR
of	I-ADR
the	I-ADR
lid	I-ADR
sulcus	I-ADR
wa	O
evident	O
a	O
the	O
result	O
of	O
topical	O
bimatoprost	B-Drug
therapy	O
0	O
<EOS>	O
lichen	B-ADR
planus	I-ADR
induced	O
by	O
hepatitis	B-Drug
b	I-Drug
vaccination	I-Drug
:	O
a	O
new	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
case	O
report	O
:	O
life-threatening	B-ADR
hypoglycaemia	I-ADR
associated	O
with	O
sulfadoxine-pyrimethamine	B-Drug
,	O
a	O
commonly	O
used	O
antimalarial	O
drug	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
present	O
a	O
case	O
of	O
hypoglycaemic	B-ADR
coma	I-ADR
associated	O
with	O
sp	B-Drug
,	O
an	O
adverse	O
reaction	O
that	O
is	O
likely	O
to	O
be	O
underreported	O
and	O
expected	O
to	O
occur	O
with	O
greater	O
frequency	O
a	O
the	O
use	O
of	O
sp	O
increase	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
present	O
a	O
case	O
of	O
hypoglycaemic	B-ADR
coma	I-ADR
associated	O
with	O
sp	B-Drug
,	O
an	O
adverse	O
reaction	O
that	O
is	O
likely	O
to	O
be	O
underreported	O
and	O
expected	O
to	O
occur	O
with	O
greater	O
frequency	O
a	O
the	O
use	O
of	O
sp	O
increase	O
0	O
<EOS>	O
initial	O
treatment	O
with	O
heparin	B-Drug
wa	O
substituted	O
with	O
thrombolysis	O
,	O
which	O
resulted	O
in	O
clinical	O
improvement	O
and	O
dissolution	O
of	O
right	O
heart	O
thrombus	O
but	O
wa	O
followed	O
by	O
fatal	B-ADR
intracerebral	I-ADR
haemorrhage	I-ADR
0	O
<EOS>	O
extensive	B-ADR
forearm	I-ADR
deep	I-ADR
venous	I-ADR
thrombosis	I-ADR
following	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
(	O
iir	B-ADR
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	O
swelling	O
of	O
the	O
forearm	O
and	O
hand	O
ipsilateral	O
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
(	O
iir	B-ADR
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	O
swelling	O
of	O
the	O
forearm	O
and	O
hand	O
ipsilateral	O
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	B-ADR
infliximab	B-Drug
infusion	I-ADR
reaction	I-ADR
(	O
iir	O
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	O
swelling	O
of	O
the	O
forearm	O
and	O
hand	O
ipsilateral	O
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	B-ADR
infliximab	B-Drug
infusion	I-ADR
reaction	I-ADR
(	O
iir	O
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	O
swelling	O
of	O
the	O
forearm	O
and	O
hand	O
ipsilateral	O
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
(	O
iir	O
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	B-ADR
swelling	I-ADR
of	I-ADR
the	I-ADR
forearm	I-ADR
and	I-ADR
hand	I-ADR
ipsilateral	I-ADR
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
here	O
we	O
describe	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
(	O
iir	O
)	O
,	O
complicated	O
1	O
day	O
later	O
by	O
severe	B-ADR
swelling	I-ADR
of	I-ADR
the	I-ADR
forearm	I-ADR
and	I-ADR
hand	I-ADR
ipsilateral	I-ADR
to	O
the	O
site	O
of	O
infliximab	O
infusion	O
0	O
<EOS>	O
the	O
site	O
of	O
thrombosis	O
and	O
the	O
chronological	O
relationship	O
with	O
the	O
iir	O
implicates	O
a	O
hypersensitivity	B-ADR
to	O
infliximab	B-Drug
in	O
the	O
causation	O
of	O
the	O
venous	O
thrombosis	O
in	O
this	O
case	O
0	O
<EOS>	O
the	O
site	O
of	O
thrombosis	O
and	O
the	O
chronological	O
relationship	O
with	O
the	O
iir	B-ADR
implicates	O
a	O
hypersensitivity	O
to	O
infliximab	B-Drug
in	O
the	O
causation	O
of	O
the	O
venous	O
thrombosis	O
in	O
this	O
case	O
0	O
<EOS>	O
the	O
site	O
of	O
thrombosis	O
and	O
the	O
chronological	O
relationship	O
with	O
the	O
iir	O
implicates	O
a	O
hypersensitivity	O
to	O
infliximab	B-Drug
in	O
the	O
causation	O
of	O
the	O
venous	B-ADR
thrombosis	I-ADR
in	O
this	O
case	O
0	O
<EOS>	O
after	O
3-	O
to	O
13-month	O
period	O
of	O
therapy	O
without	O
indapamide	B-Drug
,	O
glucose	O
level	O
of	O
all	O
patient	O
decreased	O
and	O
diabetes	B-ADR
disappeared	O
0	O
<EOS>	O
after	O
stopping	O
indapamide	B-Drug
,	O
glucose	B-ADR
tolerance	I-ADR
impairing	I-ADR
may	O
be	O
reversed	O
0	O
<EOS>	O
conclusion	O
:	O
therapy	O
with	O
indapamide	B-Drug
may	O
induce	O
diabetes	B-ADR
in	O
essential	O
hypertension	O
patient	O
0	O
<EOS>	O
objective	O
:	O
to	O
study	O
therapy	O
with	O
indapamide	B-Drug
impairing	O
carbohydrate	O
metabolism	O
in	O
essential	O
hypertension	O
patient	O
and	O
achieve	O
earlier	O
prevention	O
,	O
diagnosis	O
and	O
treatment	O
of	O
diabetes	B-ADR
induced	O
by	O
indapamide	O
0	O
<EOS>	O
objective	O
:	O
to	O
study	O
therapy	O
with	O
indapamide	B-Drug
impairing	O
carbohydrate	O
metabolism	O
in	O
essential	O
hypertension	O
patient	O
and	O
achieve	O
earlier	O
prevention	O
,	O
diagnosis	O
and	O
treatment	O
of	O
diabetes	B-ADR
induced	O
by	O
indapamide	O
0	O
<EOS>	O
objective	O
:	O
to	O
study	O
therapy	O
with	O
indapamide	B-Drug
impairing	B-ADR
carbohydrate	I-ADR
metabolism	I-ADR
in	O
essential	O
hypertension	O
patient	O
and	O
achieve	O
earlier	O
prevention	O
,	O
diagnosis	O
and	O
treatment	O
of	O
diabetes	O
induced	O
by	O
indapamide	O
0	O
<EOS>	O
possible	O
induction	O
of	O
diabetes	B-ADR
by	O
treatment	O
of	O
hypertension	O
with	O
indapamide	B-Drug
(	O
with	O
four	O
case	O
report	O
)	O
0	O
<EOS>	O
result	O
:	O
after	O
4-	O
to	O
14-month	O
period	O
of	O
therapy	O
with	O
the	O
combination	O
of	O
indapamide	O
(	O
2.5	O
mg	O
/	O
day	O
)	O
and	O
fosinopril	B-Drug
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
three	O
patient	O
and	O
6-month	O
period	O
of	O
monotherapy	O
with	O
indapamide	O
(	O
2.5	O
mg	O
/	O
day	O
)	O
in	O
one	O
patient	O
,	O
glucose	O
level	O
of	O
all	O
patient	O
increased	O
and	O
achieve	O
criterion	O
of	O
diabetes	B-ADR
diagnosis	O
0	O
<EOS>	O
result	O
:	O
after	O
4-	O
to	O
14-month	O
period	O
of	O
therapy	O
with	O
the	O
combination	O
of	O
indapamide	B-Drug
(	O
2.5	O
mg	O
/	O
day	O
)	O
and	O
fosinopril	O
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
three	O
patient	O
and	O
6-month	O
period	O
of	O
monotherapy	O
with	O
indapamide	O
(	O
2.5	O
mg	O
/	O
day	O
)	O
in	O
one	O
patient	O
,	O
glucose	O
level	O
of	O
all	O
patient	O
increased	O
and	O
achieve	O
criterion	O
of	O
diabetes	B-ADR
diagnosis	O
0	O
<EOS>	O
result	O
:	O
after	O
4-	O
to	O
14-month	O
period	O
of	O
therapy	O
with	O
the	O
combination	O
of	O
indapamide	B-Drug
(	O
2.5	O
mg	O
/	O
day	O
)	O
and	O
fosinopril	O
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
three	O
patient	O
and	O
6-month	O
period	O
of	O
monotherapy	O
with	O
indapamide	O
(	O
2.5	O
mg	O
/	O
day	O
)	O
in	O
one	O
patient	O
,	O
glucose	O
level	O
of	O
all	O
patient	O
increased	O
and	O
achieve	O
criterion	O
of	O
diabetes	B-ADR
diagnosis	O
0	O
<EOS>	O
context	O
:	O
previous	O
investigator	O
have	O
reported	O
discrepancy	B-ADR
between	I-ADR
hematologic	I-ADR
,	I-ADR
marrow	I-ADR
morphologic	I-ADR
,	I-ADR
and	I-ADR
cytogenetic	I-ADR
response	I-ADR
to	O
imatinib	B-Drug
mesylate	I-Drug
among	O
patient	O
with	O
chronic	O
myeloid	O
leukemia	O
(	O
cml	O
)	O
0	O
<EOS>	O
despite	O
a	O
hematologic	O
response	O
in	O
all	O
3	O
patient	O
,	O
none	O
of	O
them	O
achieved	O
cytogenetic	O
remission	O
,	O
and	O
all	O
progressed	O
to	O
blast	B-ADR
crisis	I-ADR
at	O
7	O
to	O
10	O
month	O
of	O
imatinib	B-Drug
therapy	O
0	O
<EOS>	O
in	O
addition	O
to	O
disease	O
refractoriness	O
,	O
rare	O
instance	O
of	O
disease	O
progression	O
from	O
chronic	O
phase	O
to	O
blast	B-ADR
crisis	I-ADR
during	O
imatinib	B-Drug
therapy	O
have	O
recently	O
been	O
anecdotally	O
reported	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
the	O
clinicopathologic	O
feature	O
of	O
3	O
patient	O
with	O
cml	O
who	O
rapidly	O
progressed	O
from	O
chronic	O
phase	O
to	O
blast	B-ADR
crisis	I-ADR
while	O
taking	O
imatinib	B-Drug
and	O
to	O
perform	O
a	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
our	O
finding	O
suggest	O
that	O
significant	O
progression	B-ADR
of	I-ADR
marrow	I-ADR
reticulin	I-ADR
fibrosis	I-ADR
during	O
imatinib	B-Drug
therapy	O
can	O
be	O
an	O
indicator	O
for	O
a	O
return	O
or	O
progression	O
of	O
cml	O
and	O
,	O
in	O
some	O
patient	O
with	O
cml	O
,	O
imatinib	O
may	O
promote	O
cytogenetic	O
clonal	O
evolution	O
,	O
resulting	O
in	O
a	O
poor	O
response	O
to	O
treatment	O
0	O
<EOS>	O
progression	O
of	O
chronic	O
myeloid	O
leukemia	O
to	O
blast	B-ADR
crisis	I-ADR
during	O
treatment	O
with	O
imatinib	B-Drug
mesylate	I-Drug
0	O
<EOS>	O
easily	O
reversible	O
hypoxemia	O
and	O
hypotension	B-ADR
induced	O
by	O
nimodipine	B-Drug
0	O
<EOS>	O
easily	O
reversible	O
hypoxemia	B-ADR
and	O
hypotension	O
induced	O
by	O
nimodipine	B-Drug
0	O
<EOS>	O
in	O
this	O
paper	O
we	O
report	O
a	O
case	O
of	O
nimodipine	B-Drug
overdosage	O
resulting	O
in	O
prolonged	O
hypotension	O
and	O
hypoxemia	B-ADR
,	O
which	O
wa	O
successfully	O
treated	O
with	O
calcium	O
gluconate	O
0	O
<EOS>	O
in	O
this	O
paper	O
we	O
report	O
a	O
case	O
of	O
nimodipine	B-Drug
overdosage	O
resulting	O
in	O
prolonged	B-ADR
hypotension	I-ADR
and	O
hypoxemia	O
,	O
which	O
wa	O
successfully	O
treated	O
with	O
calcium	O
gluconate	O
0	O
<EOS>	O
refractory	B-ADR
hypoglycemia	I-ADR
from	O
ciprofloxacin	B-Drug
and	O
glyburide	O
interaction	O
0	O
<EOS>	O
refractory	B-ADR
hypoglycemia	I-ADR
from	O
ciprofloxacin	O
and	O
glyburide	B-Drug
interaction	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
a	O
diabetic	O
patient	O
taking	O
glyburide	O
who	O
wa	O
prescribed	O
ciprofloxacin	B-Drug
and	O
developed	O
prolonged	B-ADR
hypoglycemia	I-ADR
,	O
which	O
persisted	O
for	O
over	O
24	O
hour	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
a	O
diabetic	O
patient	O
taking	O
glyburide	B-Drug
who	O
wa	O
prescribed	O
ciprofloxacin	O
and	O
developed	O
prolonged	B-ADR
hypoglycemia	I-ADR
,	O
which	O
persisted	O
for	O
over	O
24	O
hour	O
0	O
<EOS>	O
aminophylline	B-Drug
hypersensitivity	I-ADR
apparently	O
due	O
to	O
ethylenediamine	O
0	O
<EOS>	O
aminophylline	B-ADR
hypersensitivity	I-ADR
apparently	O
due	O
to	O
ethylenediamine	B-Drug
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
ethylenediamine-induced	O
delayed	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
in	O
a	O
46-year-old	O
woman	O
who	O
received	O
parenteral	O
aminophylline	B-Drug
for	O
an	O
acute	O
asthma	O
exacerbation	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
ethylenediamine-induced	B-Drug
delayed	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
in	O
a	O
46-year-old	O
woman	O
who	O
received	O
parenteral	O
aminophylline	O
for	O
an	O
acute	O
asthma	O
exacerbation	O
0	O
<EOS>	O
l-asparaginase-induced	B-Drug
pancreatitis	O
is	O
an	O
uncommon	O
but	O
potential	O
lethal	B-ADR
complication	I-ADR
of	O
the	O
treatment	O
of	O
leukemia	O
0	O
<EOS>	O
l-asparaginase-induced	B-Drug
pancreatitis	B-ADR
is	O
an	O
uncommon	O
but	O
potential	O
lethal	O
complication	O
of	O
the	O
treatment	O
of	O
leukemia	O
0	O
<EOS>	O
l-asparaginase-induced	B-Drug
severe	B-ADR
necrotizing	I-ADR
pancreatitis	I-ADR
successfully	O
treated	O
with	O
percutaneous	O
drainage	O
0	O
<EOS>	O
most	O
case	O
of	O
pancreatitis	B-ADR
associated	O
with	O
l-asparaginase	B-Drug
toxicity	O
are	O
self-limiting	O
and	O
respond	O
favorably	O
to	O
nasogastric	O
decompression	O
and	O
intravenous	O
hyperalimentation	O
0	O
<EOS>	O
pancreatitis	B-ADR
ha	O
been	O
noted	O
to	O
be	O
a	O
complication	O
in	O
2-16	O
%	O
of	O
patient	O
undergoing	O
treatment	O
with	O
l-asparaginase	B-Drug
for	O
a	O
variety	O
of	O
pediatric	O
neoplasm	O
0	O
<EOS>	O
we	O
present	O
a	O
pediatric	O
patient	O
with	O
leukemia	O
and	O
a	O
severe	O
,	O
l-asparaginase-induced	B-Drug
necrotizing	B-ADR
pancreatitis	I-ADR
,	O
treated	O
successfully	O
with	O
percutaneous	O
drainage	O
used	O
to	O
flush	O
the	O
infected	O
necrotic	O
part	O
0	O
<EOS>	O
disulfiram-induced	B-Drug
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
in	O
an	O
active	O
duty	O
soldier	O
0	O
<EOS>	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
is	O
a	O
rare	O
complication	O
of	O
disulfiram	B-Drug
treatment	O
for	O
alcoholism	O
0	O
<EOS>	O
this	O
case	O
describes	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
in	O
a	O
patient	O
taking	O
disulfiram	B-Drug
with	O
no	O
previous	O
liver	O
disease	O
and	O
report	O
of	O
being	O
compliant	O
with	O
alcohol	O
abstinence	O
0	O
<EOS>	O
tiagabine	B-Drug
overdose	O
cause	O
an	O
unusual	B-ADR
array	I-ADR
of	I-ADR
neurological	I-ADR
symptom	I-ADR
,	O
many	O
similar	O
to	O
reported	O
adverse	O
effect	O
during	O
therapeutic	O
use	O
0	O
<EOS>	O
a	O
case	O
of	O
sideroblastic	B-ADR
anemia	I-ADR
is	O
presented	O
in	O
a	O
patient	O
with	O
a	O
left	O
ventricular	O
assist	O
device	O
drive-line	O
infection	O
who	O
wa	O
receiving	O
linezolid	B-Drug
,	O
an	O
antibiotic	O
used	O
for	O
serious	O
infection	O
with	O
gram-positive	O
organism	O
0	O
<EOS>	O
a	O
linezolid	B-Drug
ha	O
been	O
shown	O
to	O
have	O
hematologic	B-ADR
side	I-ADR
effect	I-ADR
,	O
blood	O
count	O
monitoring	O
is	O
recommended	O
in	O
patient	O
receiving	O
this	O
drug	O
for	O
long-term	O
therapy	O
0	O
<EOS>	O
sideroblastic	B-ADR
anemia	I-ADR
due	O
to	O
linezolid	B-Drug
in	O
a	O
patient	O
with	O
a	O
left	O
ventricular	O
assist	O
device	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
two	O
newborn	O
with	O
congenital	O
heart	O
anomaly	O
demonstrated	O
the	O
harlequin	B-ADR
color	I-ADR
change	I-ADR
,	O
one	O
whose	O
skin	O
finding	O
showed	O
a	O
course	O
related	O
to	O
the	O
dose	O
of	O
systemic	O
prostaglandin	B-Drug
e1	I-Drug
,	O
suggesting	O
a	O
possible	O
association	O
0	O
<EOS>	O
the	O
harlequin	B-ADR
color	I-ADR
change	I-ADR
and	O
association	O
with	O
prostaglandin	B-Drug
e1	I-Drug
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
insufficiency	I-ADR
is	O
known	O
to	O
occur	O
in	O
patient	O
who	O
are	O
taking	O
ciprofloxacin	B-Drug
,	O
particularly	O
the	O
elderly	O
0	O
<EOS>	O
ciprofloxacin-induced	B-Drug
renal	B-ADR
insufficiency	I-ADR
in	O
cystic	O
fibrosis	O
0	O
<EOS>	O
multiple	O
mechanism	O
for	O
ciprofloxacin-induced	B-Drug
nephrotoxicity	B-ADR
have	O
been	O
proposed	O
0	O
<EOS>	O
we	O
report	O
two	O
young	O
patient	O
with	O
cystic	O
fibrosis	O
who	O
presented	O
with	O
acute	B-ADR
renal	I-ADR
insufficiency	I-ADR
after	O
2-3	O
week	O
of	O
oral	O
ciprofloxacin	B-Drug
therapy	O
0	O
<EOS>	O
sensory	O
neuropathy	O
revealing	O
necrotizing	B-ADR
vasculitis	I-ADR
during	O
infliximab	B-Drug
therapy	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
sensory	B-ADR
neuropathy	I-ADR
revealing	O
necrotizing	O
vasculitis	O
during	O
infliximab	B-Drug
therapy	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
severe	O
erosive	O
rheumatoid	O
arthritis	O
and	O
rheumatoid	O
vasculitis	O
,	O
respectively	O
,	O
in	O
whom	O
infliximab	B-Drug
therapy	O
wa	O
associated	O
with	O
peripheral	O
neuropathy	O
due	O
to	O
necrotizing	B-ADR
vasculitis	I-ADR
in	O
one	O
patient	O
and	O
to	O
progression	O
of	O
preexisting	O
mononeuritis	O
multiplex	O
in	O
the	O
other	O
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
severe	O
erosive	O
rheumatoid	O
arthritis	O
and	O
rheumatoid	O
vasculitis	O
,	O
respectively	O
,	O
in	O
whom	O
infliximab	B-Drug
therapy	O
wa	O
associated	O
with	O
peripheral	B-ADR
neuropathy	I-ADR
due	O
to	O
necrotizing	O
vasculitis	O
in	O
one	O
patient	O
and	O
to	O
progression	O
of	O
preexisting	O
mononeuritis	O
multiplex	O
in	O
the	O
other	O
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
severe	O
erosive	O
rheumatoid	O
arthritis	O
and	O
rheumatoid	O
vasculitis	O
,	O
respectively	O
,	O
in	O
whom	O
infliximab	B-Drug
therapy	O
wa	O
associated	O
with	O
peripheral	O
neuropathy	O
due	O
to	O
necrotizing	O
vasculitis	O
in	O
one	O
patient	O
and	O
to	O
progression	B-ADR
of	I-ADR
preexisting	I-ADR
mononeuritis	I-ADR
multiplex	I-ADR
in	O
the	O
other	O
0	O
<EOS>	O
progressive	B-ADR
anemia	I-ADR
following	O
combination	O
therapy	O
with	O
interferon-alpha	B-Drug
and	O
interleukin-2	O
in	O
a	O
patient	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
progressive	B-ADR
anemia	I-ADR
following	O
combination	O
therapy	O
with	O
interferon-alpha	O
and	O
interleukin-2	B-Drug
in	O
a	O
patient	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
severe	B-ADR
anemia	I-ADR
,	O
which	O
responded	O
well	O
to	O
steroid	O
therapy	O
,	O
in	O
a	O
patient	O
receiving	O
il-2	O
plus	O
ifn-alpha	B-Drug
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
severe	B-ADR
anemia	I-ADR
,	O
which	O
responded	O
well	O
to	O
steroid	O
therapy	O
,	O
in	O
a	O
patient	O
receiving	O
il-2	B-Drug
plus	O
ifn-alpha	O
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
an	O
objective	O
causality	O
assessment	O
indicated	O
a	O
probable	O
relationship	O
between	O
clotting	B-ADR
abnormality	I-ADR
and	O
warfarin	B-Drug
administration	O
,	O
although	O
the	O
degree	O
of	O
elevation	O
of	O
the	O
inr	O
wa	O
unusual	O
in	O
the	O
light	O
of	O
the	O
daily	O
warfarin	O
dose	O
and	O
duration	O
of	O
it	O
exposure	O
0	O
<EOS>	O
based	O
on	O
the	O
clinical	O
status	O
of	O
the	O
patient	O
,	O
it	O
wa	O
suspected	O
that	O
several	O
condition	O
contributed	O
to	O
the	O
abnormal	B-ADR
hypersensitivity	I-ADR
to	O
warfarin	B-Drug
0	O
<EOS>	O
despite	O
the	O
low	O
dosage	O
of	O
warfarin	B-Drug
,	O
international	O
normalized	O
ratio	O
(	O
inr	O
)	O
wa	O
markedly	O
elevated	O
from	O
1.15	O
to	O
11.28	O
for	O
only	O
4	O
day	O
,	O
and	O
bleeding	B-ADR
symptom	I-ADR
concurrently	O
developed	O
0	O
<EOS>	O
in	O
view	O
of	O
our	O
experience	O
in	O
the	O
present	O
case	O
,	O
it	O
should	O
be	O
stressed	O
that	O
close	O
monitoring	O
of	O
coagulation	O
capacity	O
is	O
necessary	O
in	O
critically	O
ill	O
patient	O
in	O
order	O
to	O
avoid	O
fatal	B-ADR
haemorrhage	I-ADR
after	O
initiating	O
warfarin	B-Drug
therapy	O
regardless	O
of	O
the	O
dosage	O
0	O
<EOS>	O
unusual	O
hypersensitivity	B-ADR
to	O
warfarin	B-Drug
in	O
a	O
critically	O
ill	O
patient	O
0	O
<EOS>	O
we	O
report	O
an	O
allogeneic	O
bone	O
marrow	O
transplant	O
recipient	O
who	O
developed	O
cmv	B-ADR
infection	I-ADR
refractory	O
to	O
sequential	O
therapy	O
with	O
ganciclovir	O
,	O
foscarnet	O
,	O
and	O
cidofovir	B-Drug
0	O
<EOS>	O
we	O
report	O
an	O
allogeneic	O
bone	O
marrow	O
transplant	O
recipient	O
who	O
developed	O
cmv	B-ADR
infection	I-ADR
refractory	O
to	O
sequential	O
therapy	O
with	O
ganciclovir	O
,	O
foscarnet	B-Drug
,	O
and	O
cidofovir	O
0	O
<EOS>	O
we	O
report	O
an	O
allogeneic	O
bone	O
marrow	O
transplant	O
recipient	O
who	O
developed	O
cmv	B-ADR
infection	I-ADR
refractory	O
to	O
sequential	O
therapy	O
with	O
ganciclovir	B-Drug
,	O
foscarnet	O
,	O
and	O
cidofovir	O
0	O
<EOS>	O
5-fluorouracil	B-Drug
(	O
5-fu	O
)	O
-associated	O
peripheral	B-ADR
neuropathy	I-ADR
is	O
an	O
uncommon	O
event	O
0	O
<EOS>	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
-associated	O
peripheral	B-ADR
neuropathy	I-ADR
is	O
an	O
uncommon	O
event	O
0	O
<EOS>	O
during	O
analysis	O
of	O
28	O
patient	O
receiving	O
cap	B-Drug
with	O
concomitant	O
radiation	O
(	O
xrt	O
)	O
for	O
pancreatic	O
cancer	O
(	O
resected	O
or	O
locally	O
advanced	O
)	O
,	O
two	O
patient	O
developed	O
sign	O
and	O
symptom	O
consistent	O
with	O
peripheral	B-ADR
neuropathy	I-ADR
0	O
<EOS>	O
knowledge	O
regarding	O
potential	O
adverse	O
effect	O
of	O
cap	B-Drug
is	O
paramount	O
and	O
dose	O
modification	O
is	O
indicated	O
with	O
development	O
of	O
neurotoxicity	B-ADR
0	O
<EOS>	O
neurologic	B-ADR
symptom	I-ADR
resolved	O
after	O
stopping	O
cap	B-Drug
for	O
4	O
week	O
in	O
patient	O
a	O
,	O
with	O
no	O
recurrence	O
after	O
reinitiating	O
cap	O
alone	O
at	O
2000	O
mg	O
/	O
m2	O
0	O
<EOS>	O
neurologic	B-ADR
symptom	I-ADR
resolved	O
after	O
stopping	O
cap	B-Drug
for	O
4	O
week	O
in	O
patient	O
a	O
,	O
with	O
no	O
recurrence	O
after	O
reinitiating	O
cap	O
alone	O
at	O
2000	O
mg	O
/	O
m2	O
0	O
<EOS>	O
patient	O
a	O
reported	O
right	O
leg	O
weakness	O
(	O
foot	B-ADR
drop	I-ADR
)	O
during	O
week	O
4	O
of	O
cap-xrt	B-Drug
(	O
1600	O
mg	O
/	O
m2	O
)	O
0	O
<EOS>	O
patient	O
a	O
reported	O
right	B-ADR
leg	I-ADR
weakness	I-ADR
(	O
foot	O
drop	O
)	O
during	O
week	O
4	O
of	O
cap-xrt	B-Drug
(	O
1600	O
mg	O
/	O
m2	O
)	O
0	O
<EOS>	O
patient	O
b	O
developed	O
perioral	B-ADR
and	I-ADR
upper	I-ADR
extremity	I-ADR
paresthesia	I-ADR
during	O
the	O
fourth	O
cycle	O
of	O
cap	B-Drug
alone	O
(	O
2500	O
mg	O
/	O
m2	O
)	O
0	O
<EOS>	O
peripheral	B-ADR
neuropathy	I-ADR
associated	O
with	O
capecitabine	B-Drug
0	O
<EOS>	O
we	O
conclude	O
peripheral	B-ADR
neuropathy	I-ADR
with	O
5-fu	B-Drug
is	O
rare	O
0	O
<EOS>	O
severe	B-ADR
hypo-alpha-lipoproteinemia	I-ADR
during	O
treatment	O
with	O
rosiglitazone	B-Drug
0	O
<EOS>	O
we	O
report	O
three	O
patient	O
,	O
all	O
of	O
whom	O
had	O
preexisting	O
diabetic	O
dyslipidemia	O
,	O
who	O
showed	O
a	O
profound	O
reduction	B-ADR
in	I-ADR
plasma	I-ADR
hdl	I-ADR
cholesterol	I-ADR
and	I-ADR
apolipoprotein	I-ADR
ai	I-ADR
level	I-ADR
soon	O
after	O
the	O
initiation	O
of	O
rosiglitazone	B-Drug
therapy	O
0	O
<EOS>	O
severe	O
leukopenia	O
associated	O
with	O
mild	B-ADR
hepatotoxicity	I-ADR
in	O
an	O
hiv	O
carrier	O
treated	O
with	O
nevirapine	B-Drug
0	O
<EOS>	O
severe	B-ADR
leukopenia	I-ADR
associated	O
with	O
mild	O
hepatotoxicity	O
in	O
an	O
hiv	O
carrier	O
treated	O
with	O
nevirapine	B-Drug
0	O
<EOS>	O
we	O
report	O
an	O
hiv-infected	O
woman	O
who	O
developed	O
mild	O
leukopenia	B-ADR
a	O
the	O
first	O
sign	O
of	O
a	O
nevirapine-related	B-Drug
adverse	O
event	O
,	O
which	O
wa	O
followed	O
by	O
skin	O
and	O
hepatic	O
toxicity	O
associated	O
with	O
a	O
more	O
severe	O
leukopenia	O
0	O
<EOS>	O
we	O
report	O
an	O
hiv-infected	O
woman	O
who	O
developed	O
mild	O
leukopenia	B-ADR
a	O
the	O
first	O
sign	O
of	O
a	O
nevirapine-related	B-Drug
adverse	O
event	O
,	O
which	O
wa	O
followed	O
by	O
skin	O
and	O
hepatic	O
toxicity	O
associated	O
with	O
a	O
more	O
severe	O
leukopenia	O
0	O
<EOS>	O
we	O
report	O
an	O
hiv-infected	O
woman	O
who	O
developed	O
mild	O
leukopenia	O
a	O
the	O
first	O
sign	O
of	O
a	O
nevirapine-related	B-Drug
adverse	O
event	O
,	O
which	O
wa	O
followed	O
by	O
skin	B-ADR
and	I-ADR
hepatic	I-ADR
toxicity	I-ADR
associated	O
with	O
a	O
more	O
severe	O
leukopenia	O
0	O
<EOS>	O
in	O
all	O
case	O
,	O
drug	O
in	O
addition	O
to	O
quetiapine	B-Drug
were	O
detected	O
,	O
but	O
in	O
case	O
1	O
and	O
2	O
,	O
the	O
cause	O
of	O
death	B-ADR
wa	O
considered	O
to	O
be	O
a	O
quetiapine	O
overdose	O
and	O
the	O
other	O
drug	O
were	O
not	O
considered	O
to	O
be	O
contributory	O
0	O
<EOS>	O
these	O
case	O
were	O
chosen	O
for	O
study	O
because	O
they	O
were	O
all	O
death	B-ADR
a	O
a	O
result	O
of	O
suicidal	O
ingestion	O
of	O
drug	O
in	O
which	O
quetiapine	B-Drug
wa	O
considered	O
a	O
significant	O
factor	O
0	O
<EOS>	O
we	O
present	O
three	O
case	O
from	O
the	O
provincial	O
toxicology	O
center	O
of	O
british	O
columbia	O
,	O
canada	O
in	O
which	O
suicidal	B-ADR
overdose	I-ADR
death	I-ADR
were	O
associated	O
with	O
quetiapine	B-Drug
0	O
<EOS>	O
after	O
approximately	O
two	O
week	O
of	O
sertraline	B-Drug
treatment	O
he	O
noted	O
an	O
intense	B-ADR
itching	I-ADR
sensation	I-ADR
in	O
his	O
scalp	O
after	O
eating	O
a	O
piece	O
of	O
chocolate	O
cake	O
0	O
<EOS>	O
itch	B-ADR
and	O
skin	O
rash	O
from	O
chocolate	O
during	O
fluoxetine	B-Drug
and	O
sertraline	O
treatment	O
:	O
case	O
report	O
0	O
<EOS>	O
itch	B-ADR
and	O
skin	O
rash	O
from	O
chocolate	O
during	O
fluoxetine	O
and	O
sertraline	B-Drug
treatment	O
:	O
case	O
report	O
0	O
<EOS>	O
itch	O
and	O
skin	B-ADR
rash	I-ADR
from	O
chocolate	O
during	O
fluoxetine	B-Drug
and	O
sertraline	O
treatment	O
:	O
case	O
report	O
0	O
<EOS>	O
itch	O
and	O
skin	B-ADR
rash	I-ADR
from	O
chocolate	O
during	O
fluoxetine	O
and	O
sertraline	B-Drug
treatment	O
:	O
case	O
report	O
0	O
<EOS>	O
pulmonary	B-ADR
lymphohistiocytic	I-ADR
reaction	I-ADR
temporally	O
related	O
to	O
etanercept	B-Drug
therapy	O
0	O
<EOS>	O
this	O
report	O
detail	O
the	O
pulmonary	O
pathologic	O
finding	O
in	O
four	O
patient	O
with	O
rheumatoid	O
arthritis	O
,	O
who	O
developed	O
new	O
onset	O
of	O
pulmonary	B-ADR
sign	I-ADR
and	I-ADR
symptom	I-ADR
with	I-ADR
alveolar	I-ADR
infiltrates	I-ADR
temporally	O
related	O
to	O
the	O
institution	O
of	O
etanercept	B-Drug
therapy	O
0	O
<EOS>	O
paradoxical	B-ADR
cerebral	I-ADR
cortical	I-ADR
hyperexcitability	I-ADR
following	O
flupirtine	B-Drug
overdose	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
increased	B-ADR
cerebral	I-ADR
cortical	I-ADR
excitability	I-ADR
following	O
intoxication	O
with	O
flupirtine	B-Drug
,	O
a	O
centrally	O
acting	O
analgesic	O
and	O
antispastic	O
drug	O
0	O
<EOS>	O
aim	O
:	O
report	O
of	O
a	O
case	O
of	O
a	O
woman	O
patient	O
who	O
developed	O
celiac	B-ADR
disease	I-ADR
after	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	O
use	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
aim	O
:	O
report	O
of	O
a	O
case	O
of	O
a	O
woman	O
patient	O
who	O
developed	O
celiac	B-ADR
disease	I-ADR
after	O
pegylated	O
interferon	O
alpha-2a	O
and	O
ribavirin	B-Drug
use	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
celiac	B-ADR
disease	I-ADR
onset	O
after	O
pegylated	B-Drug
interferon	I-Drug
and	O
ribavirin	O
treatment	O
of	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
celiac	B-ADR
disease	I-ADR
onset	O
after	O
pegylated	O
interferon	O
and	O
ribavirin	B-Drug
treatment	O
of	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
patient	O
and	O
method	O
:	O
a	O
34-year-old	O
woman	O
with	O
chronic	O
hepatitis	O
c	O
,	O
genotype	O
3	O
,	O
receiving	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	O
for	O
6	O
month	O
,	O
developed	O
progressive	O
malaise	O
and	O
anemia	B-ADR
6	O
month	O
after	O
the	O
end	O
of	O
treatment	O
0	O
<EOS>	O
patient	O
and	O
method	O
:	O
a	O
34-year-old	O
woman	O
with	O
chronic	O
hepatitis	O
c	O
,	O
genotype	O
3	O
,	O
receiving	O
pegylated	O
interferon	O
alpha-2a	O
and	O
ribavirin	B-Drug
for	O
6	O
month	O
,	O
developed	O
progressive	O
malaise	O
and	O
anemia	B-ADR
6	O
month	O
after	O
the	O
end	O
of	O
treatment	O
0	O
<EOS>	O
patient	O
and	O
method	O
:	O
a	O
34-year-old	O
woman	O
with	O
chronic	O
hepatitis	O
c	O
,	O
genotype	O
3	O
,	O
receiving	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	O
for	O
6	O
month	O
,	O
developed	O
progressive	B-ADR
malaise	I-ADR
and	O
anemia	O
6	O
month	O
after	O
the	O
end	O
of	O
treatment	O
0	O
<EOS>	O
patient	O
and	O
method	O
:	O
a	O
34-year-old	O
woman	O
with	O
chronic	O
hepatitis	O
c	O
,	O
genotype	O
3	O
,	O
receiving	O
pegylated	O
interferon	O
alpha-2a	O
and	O
ribavirin	B-Drug
for	O
6	O
month	O
,	O
developed	O
progressive	B-ADR
malaise	I-ADR
and	O
anemia	O
6	O
month	O
after	O
the	O
end	O
of	O
treatment	O
0	O
<EOS>	O
we	O
present	O
two	O
case	O
of	O
anaphylaxis	B-ADR
under	O
anaesthesia	O
where	O
return	O
of	O
spontaneous	O
circulation	O
wa	O
refractory	O
to	O
epinephrine	O
,	O
but	O
occurred	O
following	O
the	O
administration	O
of	O
the	O
alpha-agonist	O
metaraminol	B-Drug
0	O
<EOS>	O
in	O
this	O
article	O
,	O
we	O
describe	O
another	O
case	O
of	O
subcutaneous	O
change	O
following	O
repeated	O
glatiramer	B-Drug
acetate	I-Drug
injection	O
,	O
presented	O
a	O
localized	B-ADR
panniculitis	I-ADR
in	O
the	O
area	O
around	O
the	O
injection	O
site	O
,	O
in	O
a	O
46-year-old	O
female	O
patient	O
who	O
wa	O
treated	O
with	O
glatiramer	O
acetate	O
for	O
18	O
month	O
0	O
<EOS>	O
in	O
this	O
article	O
,	O
we	O
describe	O
another	O
case	O
of	O
subcutaneous	O
change	O
following	O
repeated	O
glatiramer	B-Drug
acetate	I-Drug
injection	O
,	O
presented	O
a	O
localized	B-ADR
panniculitis	I-ADR
in	O
the	O
area	O
around	O
the	O
injection	O
site	O
,	O
in	O
a	O
46-year-old	O
female	O
patient	O
who	O
wa	O
treated	O
with	O
glatiramer	O
acetate	O
for	O
18	O
month	O
0	O
<EOS>	O
in	O
this	O
article	O
,	O
we	O
describe	O
another	O
case	O
of	O
subcutaneous	B-ADR
change	I-ADR
following	O
repeated	O
glatiramer	B-Drug
acetate	I-Drug
injection	O
,	O
presented	O
a	O
localized	O
panniculitis	O
in	O
the	O
area	O
around	O
the	O
injection	O
site	O
,	O
in	O
a	O
46-year-old	O
female	O
patient	O
who	O
wa	O
treated	O
with	O
glatiramer	O
acetate	O
for	O
18	O
month	O
0	O
<EOS>	O
localized	O
panniculitis	O
and	O
subsequent	O
lipoatrophy	B-ADR
with	O
subcutaneous	O
glatiramer	O
acetate	O
(	O
copaxone	B-Drug
)	O
injection	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
0	O
<EOS>	O
localized	O
panniculitis	O
and	O
subsequent	O
lipoatrophy	B-ADR
with	O
subcutaneous	O
glatiramer	B-Drug
acetate	I-Drug
(	O
copaxone	O
)	O
injection	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
0	O
<EOS>	O
localized	B-ADR
panniculitis	I-ADR
and	O
subsequent	O
lipoatrophy	O
with	O
subcutaneous	O
glatiramer	O
acetate	O
(	O
copaxone	B-Drug
)	O
injection	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
0	O
<EOS>	O
localized	B-ADR
panniculitis	I-ADR
and	O
subsequent	O
lipoatrophy	O
with	O
subcutaneous	O
glatiramer	B-Drug
acetate	I-Drug
(	O
copaxone	O
)	O
injection	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
0	O
<EOS>	O
in	O
a	O
postoperative	O
patient	O
with	O
pre-existent	O
myasthenia	O
gravis	O
,	O
oral	O
verapamil	B-Drug
caused	O
a	O
marked	O
exacerbation	B-ADR
in	I-ADR
myasthenic	I-ADR
weakness	I-ADR
0	O
<EOS>	O
in	O
four	O
patient	O
,	O
thrombosis	O
occurred	O
2-45	O
day	O
after	O
severe	O
hepatic	B-ADR
veno-occlusive	I-ADR
disease	I-ADR
(	O
hvod	O
)	O
secondary	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
0	O
<EOS>	O
in	O
four	O
patient	O
,	O
thrombosis	O
occurred	O
2-45	O
day	O
after	O
severe	O
hepatic	O
veno-occlusive	O
disease	O
(	O
hvod	B-ADR
)	O
secondary	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
0	O
<EOS>	O
in	O
four	O
patient	O
,	O
thrombosis	B-ADR
occurred	O
2-45	O
day	O
after	O
severe	O
hepatic	O
veno-occlusive	O
disease	O
(	O
hvod	O
)	O
secondary	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
0	O
<EOS>	O
pvt	O
during	O
chemotherapy	O
in	O
child	O
is	O
a	O
rare	O
event	O
and	O
appears	O
to	O
be	O
closely	O
related	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
and	O
to	O
be	O
associated	O
with	O
hvod	B-ADR
0	O
<EOS>	O
pvt	B-ADR
during	O
chemotherapy	O
in	O
child	O
is	O
a	O
rare	O
event	O
and	O
appears	O
to	O
be	O
closely	O
related	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
and	O
to	O
be	O
associated	O
with	O
hvod	O
0	O
<EOS>	O
here	O
,	O
we	O
describe	O
a	O
case	O
of	O
vogt-koyanagi-harada	B-ADR
disease	I-ADR
occurring	O
4	O
month	O
after	O
the	O
start	O
of	O
interferon	B-Drug
alpha	O
treatment	O
,	O
probably	O
induced	O
by	O
the	O
immunomodulatory	O
effect	O
of	O
interferon	O
0	O
<EOS>	O
here	O
,	O
we	O
describe	O
a	O
case	O
of	O
vogt-koyanagi-harada	B-ADR
disease	I-ADR
occurring	O
4	O
month	O
after	O
the	O
start	O
of	O
interferon	B-Drug
alpha	I-Drug
treatment	O
,	O
probably	O
induced	O
by	O
the	O
immunomodulatory	O
effect	O
of	O
interferon	O
0	O
<EOS>	O
retinal	O
abnormality	O
,	O
including	O
retinal	O
hemorrhage	O
and	O
``	O
cotton-wool	B-ADR
spot	I-ADR
,	O
often	O
occur	O
within	O
the	O
first	O
8	O
week	O
in	O
the	O
course	O
of	O
interferon	B-Drug
therapy	O
in	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
retinal	B-ADR
abnormality	I-ADR
,	O
including	O
retinal	O
hemorrhage	O
and	O
``	O
cotton-wool	O
'	O
spot	O
,	O
often	O
occur	O
within	O
the	O
first	O
8	O
week	O
in	O
the	O
course	O
of	O
interferon	B-Drug
therapy	O
in	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
retinal	O
abnormality	O
,	O
including	O
retinal	B-ADR
hemorrhage	I-ADR
and	O
``	O
cotton-wool	O
'	O
spot	O
,	O
often	O
occur	O
within	O
the	O
first	O
8	O
week	O
in	O
the	O
course	O
of	O
interferon	B-Drug
therapy	O
in	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
vogt-koyanagi-harada	B-ADR
disease	I-ADR
occurring	O
during	O
interferon	B-Drug
alpha	I-Drug
therapy	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
acute	B-ADR
hepatic	I-ADR
failure	I-ADR
is	O
a	O
rare	O
and	O
potentially	O
lethal	O
complication	O
of	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
use	O
for	O
hyperthyroidism	O
0	O
<EOS>	O
acute	B-ADR
hepatic	I-ADR
failure	I-ADR
is	O
a	O
rare	O
and	O
potentially	O
lethal	O
complication	O
of	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
use	O
for	O
hyperthyroidism	O
0	O
<EOS>	O
after	O
an	O
extensive	O
review	O
of	O
the	O
literature	O
,	O
we	O
believe	O
that	O
this	O
is	O
the	O
first	O
communication	O
of	O
the	O
successful	O
use	O
of	O
amiodarone	O
to	O
control	O
hyperthyroidism	O
in	O
a	O
patient	O
with	O
ptu-induced	B-Drug
fulminant	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
successful	O
treatment	O
of	O
hyperthyroidism	O
with	O
amiodarone	O
in	O
a	O
patient	O
with	O
propylthiouracil-induced	B-Drug
acute	B-ADR
hepatic	I-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
present	O
a	O
20-year-old	O
woman	O
with	O
basedow-graves	O
	O
disease	O
who	O
developed	O
ptu-induced	B-Drug
fulminant	B-ADR
hepatitis	I-ADR
,	O
which	O
progressed	O
to	O
acute	O
hepatic	O
failure	O
with	O
grade	O
iii	O
hepatic	O
encephalopathy	O
0	O
<EOS>	O
epstein-barr	B-ADR
virus-associated	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
on	O
methotrexate	B-Drug
and	O
rofecoxib	O
:	O
idiosyncratic	O
reaction	O
or	O
pharmacogenetics	O
?	O
<EOS>	O
epstein-barr	B-ADR
virus-associated	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
on	O
methotrexate	O
and	O
rofecoxib	B-Drug
:	O
idiosyncratic	O
reaction	O
or	O
pharmacogenetics	O
?	O
<EOS>	O
methotrexate	B-Drug
(	O
mtx	O
)	O
is	O
a	O
commonly	O
used	O
second	O
line	O
agent	O
for	O
ra	O
,	O
and	O
there	O
have	O
been	O
several	O
recent	O
report	O
of	O
epstein-barr	B-ADR
virus	I-ADR
(	I-ADR
ebv	I-ADR
)	I-ADR
-associated	I-ADR
polyclonal	I-ADR
b	I-ADR
cell	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
in	O
mtx-treated	O
ra	O
patient	O
0	O
<EOS>	O
methotrexate	O
(	O
mtx	O
)	O
is	O
a	O
commonly	O
used	O
second	O
line	O
agent	O
for	O
ra	O
,	O
and	O
there	O
have	O
been	O
several	O
recent	O
report	O
of	O
epstein-barr	B-ADR
virus	I-ADR
(	I-ADR
ebv	I-ADR
)	I-ADR
-associated	I-ADR
polyclonal	I-ADR
b	I-ADR
cell	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
in	O
mtx-treated	B-Drug
ra	O
patient	O
0	O
<EOS>	O
methotrexate	O
(	O
mtx	O
)	O
is	O
a	O
commonly	O
used	O
second	O
line	O
agent	O
for	O
ra	O
,	O
and	O
there	O
have	O
been	O
several	O
recent	O
report	O
of	O
epstein-barr	B-ADR
virus	I-ADR
(	I-ADR
ebv	I-ADR
)	I-ADR
-associated	I-ADR
polyclonal	I-ADR
b	I-ADR
cell	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
in	O
mtx-treated	B-Drug
ra	O
patient	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	B-ADR
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	B-ADR
liver	I-ADR
transaminase	I-ADR
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	B-ADR
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	B-ADR
ulceration	I-ADR
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	B-ADR
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	B-ADR
0	O
<EOS>	O
previous	O
study	O
have	O
demonstrated	O
the	O
interaction	O
of	O
mtx	B-Drug
and	O
a	O
variety	O
of	O
non-steroidal	O
,	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
with	O
various	O
clinical	O
manifestation	O
including	O
acute	O
renal	O
failure	O
,	O
pancytopenia	O
,	O
vomiting	B-ADR
,	O
diarrhea	O
,	O
elevated	O
liver	O
transaminase	O
,	O
jaundice	O
,	O
mucosal	O
ulceration	O
,	O
and	O
pyrexia	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
decreased	O
renal	O
elimination	O
of	O
mtx	B-Drug
induced	O
by	O
the	O
cox-2	O
inhibitor	O
resulted	O
in	O
enhanced	O
hematopoietic	O
toxicity	O
and	O
immunosuppression	O
causing	O
the	O
ebv-associated	B-ADR
lymphoproliferative	I-ADR
disease	I-ADR
0	O
<EOS>	O
we	O
hypothesize	O
that	O
decreased	O
renal	O
elimination	O
of	O
mtx	B-Drug
induced	O
by	O
the	O
cox-2	O
inhibitor	O
resulted	O
in	O
enhanced	O
hematopoietic	B-ADR
toxicity	I-ADR
and	O
immunosuppression	O
causing	O
the	O
ebv-associated	O
lymphoproliferative	O
disease	O
0	O
<EOS>	O
we	O
hypothesize	O
that	O
decreased	O
renal	O
elimination	O
of	O
mtx	B-Drug
induced	O
by	O
the	O
cox-2	O
inhibitor	O
resulted	O
in	O
enhanced	O
hematopoietic	O
toxicity	O
and	O
immunosuppression	B-ADR
causing	O
the	O
ebv-associated	O
lymphoproliferative	O
disease	O
0	O
<EOS>	O
observation	O
:	O
we	O
observed	O
aggravation	B-ADR
and	I-ADR
spreading	I-ADR
of	I-ADR
a	I-ADR
psoriatic	I-ADR
plaque	I-ADR
when	O
treated	O
topically	O
with	O
the	O
toll-like	O
receptor	O
(	O
tlr	O
)	O
7	O
agonist	O
imiquimod	B-Drug
0	O
<EOS>	O
psoriasis	B-ADR
triggered	O
by	O
toll-like	O
receptor	O
7	O
agonist	O
imiquimod	B-Drug
in	O
the	O
presence	O
of	O
dermal	O
plasmacytoid	O
dendritic	O
cell	O
precursor	O
0	O
<EOS>	O
since	O
imiquimod	B-Drug
induces	O
large	B-ADR
amount	I-ADR
of	I-ADR
type	I-ADR
i	I-ADR
interferon	I-ADR
production	I-ADR
from	O
tlr7-expressing	O
plasmacytoid	O
dendritic	O
cell	O
precursor	O
(	O
pdcs	O
)	O
,	O
the	O
natural	O
interferon-producing	O
cell	O
of	O
the	O
peripheral	O
blood	O
,	O
we	O
asked	O
whether	O
pdcs	O
are	O
present	O
in	O
psoriatic	O
skin	O
0	O
<EOS>	O
the	O
exacerbation	B-ADR
of	I-ADR
psoriasis	I-ADR
wa	O
accompanied	O
by	O
a	O
massive	O
induction	O
of	O
lesional	O
type	O
i	O
interferon	O
activity	O
,	O
detected	O
by	O
mxa	O
expression	O
after	O
imiquimod	B-Drug
therapy	O
0	O
<EOS>	O
vision	B-ADR
declined	I-ADR
after	O
treatment	O
with	O
methylprednisolone	B-Drug
,	O
after	O
which	O
fundus	O
examination	O
became	O
consistent	O
with	O
progressive	O
outer	O
retinal	O
necrosis	O
0	O
<EOS>	O
allergic	O
side	O
effect	O
of	O
aza	B-Drug
are	O
rare	O
,	O
and	O
reported	O
allergic	B-ADR
skin	I-ADR
eruption	I-ADR
from	O
aza	O
are	O
very	O
limited	O
in	O
japan	O
0	O
<EOS>	O
allergic	O
side	O
effect	O
of	O
aza	B-Drug
are	O
rare	O
,	O
and	O
reported	O
allergic	B-ADR
skin	I-ADR
eruption	I-ADR
from	O
aza	O
are	O
very	O
limited	O
in	O
japan	O
0	O
<EOS>	O
dlst	O
is	O
a	O
good	O
diagnostic	O
tool	O
for	O
aza	B-Drug
allergy	B-ADR
,	O
especially	O
for	O
severe	O
drug	O
allergy	O
case	O
0	O
<EOS>	O
drug	B-ADR
eruption	I-ADR
caused	O
by	O
azathioprine	B-Drug
:	O
value	O
of	O
using	O
the	O
drug-induced	O
lymphocyte	O
stimulation	O
test	O
for	O
diagnosis	O
0	O
<EOS>	O
we	O
report	O
aza-induced	B-Drug
drug	B-ADR
eruption	I-ADR
that	O
developed	O
in	O
two	O
case	O
of	O
systemic	O
scleroderma	O
with	O
polymyositis	O
0	O
<EOS>	O
tardive	B-ADR
dyskinesia	I-ADR
in	O
2	O
patient	O
treated	O
with	O
ziprasidone	B-Drug
0	O
<EOS>	O
two	O
of	O
our	O
patient	O
developed	O
td	B-ADR
after	O
23	O
month	O
and	O
34	O
month	O
of	O
ziprasidone	B-Drug
monotherapy	O
,	O
respectively	O
0	O
<EOS>	O
ziprasidone	B-Drug
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
is	O
believed	O
to	O
have	O
a	O
low	O
propensity	O
for	O
inducing	O
extrapyramidal	B-ADR
symptom	I-ADR
,	O
including	O
tardive	O
dyskinesia	O
(	O
td	O
)	O
0	O
<EOS>	O
ziprasidone	B-Drug
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
is	O
believed	O
to	O
have	O
a	O
low	O
propensity	O
for	O
inducing	O
extrapyramidal	O
symptom	O
,	O
including	O
tardive	B-ADR
dyskinesia	I-ADR
(	O
td	O
)	O
0	O
<EOS>	O
ziprasidone	B-Drug
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
is	O
believed	O
to	O
have	O
a	O
low	O
propensity	O
for	O
inducing	O
extrapyramidal	O
symptom	O
,	O
including	O
tardive	O
dyskinesia	O
(	O
td	B-ADR
)	O
0	O
<EOS>	O
asthenozoospermia	B-ADR
:	O
possible	O
association	O
with	O
long-term	O
exposure	O
to	O
an	O
anti-epileptic	O
drug	O
of	O
carbamazepine	B-Drug
0	O
<EOS>	O
the	O
patient	O
wa	O
found	O
to	O
have	O
no	B-ADR
motile	I-ADR
sperm	I-ADR
with	O
a	O
normal	O
sperm	O
count	O
,	O
while	O
taking	O
a	O
dose	O
of	O
400	O
mg	O
/	O
day	O
of	O
carbamazepine	B-Drug
0	O
<EOS>	O
scrotal	B-ADR
ulceration	I-ADR
induced	O
by	O
all-trans	O
retinoic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
0	O
<EOS>	O
the	O
ulcer	B-ADR
did	O
not	O
respond	O
to	O
antibiotic	O
treatment	O
and	O
healed	O
shortly	O
after	O
withholding	O
atra	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
development	O
of	O
scrotal	B-ADR
ulcer	I-ADR
in	O
a	O
patient	O
with	O
acute	O
promyleocytic	O
leukemia	O
(	O
apl	O
)	O
within	O
10	O
day	O
of	O
treatment	O
with	O
atra	B-Drug
at	O
a	O
dose	O
of	O
40	O
mg	O
orally	O
twice	O
daily	O
0	O
<EOS>	O
a	O
case	O
of	O
clozapine-induced	B-Drug
tonic-clonic	B-ADR
seizure	I-ADR
managed	O
with	O
valproate	O
:	O
implication	O
for	O
clinical	O
care	O
0	O
<EOS>	O
following	O
discontinuation	O
of	O
clozapine	B-Drug
,	O
she	O
wa	O
rechallenged	O
and	O
again	O
wa	O
observed	O
to	O
have	O
seizure	B-ADR
0	O
<EOS>	O
these	O
finding	O
suggest	O
that	O
clozapine-induced	B-Drug
seizure	B-ADR
can	O
be	O
successfully	O
treated	O
,	O
that	O
gradual	O
dose	O
titration	O
can	O
reduce	O
the	O
likelihood	O
of	O
further	O
episode	O
of	O
seizure	O
and	O
that	O
concomitant	O
use	O
of	O
a	O
suitable	O
mood	O
stabilizer	O
/	O
anti-epileptic	O
medication	O
can	O
improve	O
the	O
outcome	O
of	O
treatment-resistant	O
schizophrenia	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
clozapine-induced	B-Drug
seizure	B-ADR
in	O
a	O
patient	O
with	O
treatment-resistant	O
schizophrenia	O
0	O
<EOS>	O
conclusion	O
:	O
symptom	O
and	O
pathologic	O
change	O
of	O
colitis	B-ADR
are	O
associated	O
with	O
exposure	O
to	O
rofecoxib	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
clinical	O
and	O
pathologic	O
finding	O
in	O
patient	O
noted	O
to	O
develop	O
lower	B-ADR
gastrointestinal	I-ADR
symptom	I-ADR
when	O
exposed	O
to	O
rofecoxib	B-Drug
0	O
<EOS>	O
result	O
:	O
three	O
patient	O
who	O
developed	O
symptom	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
ibd	B-ADR
)	O
during	O
rofecoxib	B-Drug
exposure	O
are	O
described	O
along	O
with	O
pathology	O
finding	O
0	O
<EOS>	O
result	O
:	O
three	O
patient	O
who	O
developed	O
symptom	O
of	O
inflammatory	B-ADR
bowel	I-ADR
disease	I-ADR
(	O
ibd	O
)	O
during	O
rofecoxib	B-Drug
exposure	O
are	O
described	O
along	O
with	O
pathology	O
finding	O
0	O
<EOS>	O
after	O
administration	O
of	O
oxybutynin	O
concomitantly	O
with	O
an	O
increase	O
in	O
the	O
dose	O
of	O
dantrolene	O
,	O
she	O
presented	O
the	O
clinical	O
symptom	O
and	O
laboratory	O
finding	O
of	O
carbamazepine	B-Drug
intoxication	I-ADR
0	O
<EOS>	O
after	O
administration	O
of	O
oxybutynin	O
concomitantly	O
with	O
an	O
increase	O
in	O
the	O
dose	O
of	O
dantrolene	B-Drug
,	O
she	O
presented	O
the	O
clinical	O
symptom	O
and	O
laboratory	O
finding	O
of	O
carbamazepine	B-ADR
intoxication	I-ADR
0	O
<EOS>	O
after	O
administration	O
of	O
oxybutynin	B-Drug
concomitantly	O
with	O
an	O
increase	O
in	O
the	O
dose	O
of	O
dantrolene	O
,	O
she	O
presented	O
the	O
clinical	O
symptom	O
and	O
laboratory	O
finding	O
of	O
carbamazepine	B-ADR
intoxication	I-ADR
0	O
<EOS>	O
carbamazepine	B-Drug
toxicity	I-ADR
following	O
oxybutynin	O
and	O
dantrolene	O
administration	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
carbamazepine	B-ADR
toxicity	I-ADR
following	O
oxybutynin	O
and	O
dantrolene	B-Drug
administration	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
carbamazepine	B-ADR
toxicity	I-ADR
following	O
oxybutynin	B-Drug
and	O
dantrolene	O
administration	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
carbamazepine	B-Drug
toxicity	I-ADR
following	O
the	O
administration	O
of	O
oxybutynin	O
and	O
dantrolene	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
carbamazepine	B-ADR
toxicity	I-ADR
following	O
the	O
administration	O
of	O
oxybutynin	O
and	O
dantrolene	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
carbamazepine	B-ADR
toxicity	I-ADR
following	O
the	O
administration	O
of	O
oxybutynin	B-Drug
and	O
dantrolene	O
0	O
<EOS>	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
captopril-induced	B-Drug
pemphigus	B-ADR
in	O
whom	O
no	O
new	O
lesion	O
developed	O
after	O
subsequent	O
treatment	O
with	O
enalapril	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
drug-induced	O
pemphigus	B-ADR
caused	O
by	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
,	O
captopril	B-Drug
0	O
<EOS>	O
neuropathy	B-ADR
is	O
a	O
significant	O
side	O
effect	O
of	O
thalidomide	B-Drug
therapy	O
,	O
which	O
may	O
limit	O
it	O
clinical	O
use	O
0	O
<EOS>	O
thalidomide	B-Drug
neuropathy	B-ADR
in	O
childhood	O
0	O
<EOS>	O
thalidomide	B-Drug
neuropathy	B-ADR
is	O
often	O
associated	O
with	O
proximal	O
weakness	O
and	O
may	O
progress	O
even	O
after	O
discontinuation	O
of	O
treatment	O
,	O
in	O
the	O
phenomenon	O
of	O
coasting	O
	O
0	O
<EOS>	O
thalidomide	B-Drug
neuropathy	O
is	O
often	O
associated	O
with	O
proximal	B-ADR
weakness	I-ADR
and	O
may	O
progress	O
even	O
after	O
discontinuation	O
of	O
treatment	O
,	O
in	O
the	O
phenomenon	O
of	O
coasting	O
	O
0	O
<EOS>	O
thalidomide	B-Drug
wa	O
withdrawn	O
from	O
world	O
market	O
in	O
1961	O
following	O
recognition	O
of	O
it	O
teratogenic	B-ADR
effect	I-ADR
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
sensorimotor	B-ADR
axonal	I-ADR
neuropathy	I-ADR
in	O
child	O
aged	O
10-15	O
year	O
,	O
treated	O
with	O
thalidomide	B-Drug
for	O
myxopapillary	O
ependymoma	O
,	O
crohn	O
disease	O
and	O
recurrent	O
giant	O
aphthous	O
ulceration	O
0	O
<EOS>	O
cerebral	B-ADR
edema	I-ADR
associated	O
with	O
gliadel	B-Drug
wafer	O
:	O
two	O
case	O
study	O
0	O
<EOS>	O
following	O
are	O
two	O
clinical	O
case	O
report	O
demonstrating	O
profound	O
cerebral	B-ADR
edema	I-ADR
associated	O
with	O
implantation	O
of	O
gliadel	B-Drug
wafer	O
0	O
<EOS>	O
while	O
the	O
introduction	O
of	O
carmustine	B-Drug
wafer	O
(	O
gliadel	O
wafer	O
)	O
into	O
the	O
tumor	O
resection	O
cavity	O
ha	O
been	O
shown	O
to	O
be	O
a	O
beneficial	O
therapy	O
for	O
malignant	O
glioma	O
,	O
it	O
is	O
recognized	O
that	O
clinically	O
significant	O
cerebral	B-ADR
edema	I-ADR
is	O
a	O
potential	O
adverse	O
effect	O
0	O
<EOS>	O
while	O
the	O
introduction	O
of	O
carmustine	O
wafer	O
(	O
gliadel	B-Drug
wafer	O
)	O
into	O
the	O
tumor	O
resection	O
cavity	O
ha	O
been	O
shown	O
to	O
be	O
a	O
beneficial	O
therapy	O
for	O
malignant	O
glioma	O
,	O
it	O
is	O
recognized	O
that	O
clinically	O
significant	O
cerebral	B-ADR
edema	I-ADR
is	O
a	O
potential	O
adverse	O
effect	O
0	O
<EOS>	O
cis-retinoic	B-Drug
acid	I-Drug
(	O
ra	O
)	O
may	O
further	O
increase	O
the	O
risk	O
of	O
developing	O
bmtn	B-ADR
0	O
<EOS>	O
cis-retinoic	O
acid	O
(	O
ra	B-Drug
)	O
may	O
further	O
increase	O
the	O
risk	O
of	O
developing	O
bmtn	B-ADR
0	O
<EOS>	O
it	O
is	O
likely	O
that	O
ra	B-Drug
contributed	O
to	O
the	O
deterioration	B-ADR
in	I-ADR
renal	I-ADR
function	I-ADR
in	O
these	O
patient	O
0	O
<EOS>	O
retinoic	B-Drug
acid	I-Drug
may	O
increase	O
the	O
risk	O
of	O
bone	B-ADR
marrow	I-ADR
transplant	I-ADR
nephropathy	I-ADR
0	O
<EOS>	O
the	O
occurrence	O
of	O
bmtn	B-ADR
in	O
two	O
child	O
treated	O
with	O
ra	B-Drug
in	O
our	O
unit	O
is	O
unlikely	O
to	O
be	O
coincidental	O
0	O
<EOS>	O
he	O
developed	O
a	O
late	O
secondary	B-ADR
infection	I-ADR
in	O
some	O
site	O
treated	O
with	O
imiquimod	B-Drug
0	O
<EOS>	O
a	O
64-year-old	O
man	O
with	O
schizophrenia	O
developed	O
myoclonic	B-ADR
jerk	I-ADR
when	O
given	O
higher	O
dos	O
of	O
quetiapine	B-Drug
0	O
<EOS>	O
quetiapine-induced	B-Drug
myoclonus	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
myoclonus	B-ADR
induced	O
by	O
quetiapine	B-Drug
0	O
<EOS>	O
treatment-related	O
myelodysplastic	B-ADR
syndrome	I-ADR
after	O
temozolomide	B-Drug
for	O
recurrent	O
high-grade	O
glioma	O
0	O
<EOS>	O
we	O
report	O
a	O
44-year-old	O
woman	O
with	O
t-mds	O
(	O
refractory	B-ADR
anemia	I-ADR
with	I-ADR
excess	I-ADR
blast	I-ADR
)	O
following	O
treatment	O
of	O
recurrent	O
anaplastic	O
astrocytoma	O
with	O
temozolomide	B-Drug
(	O
tmz	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
44-year-old	O
woman	O
with	O
t-mds	O
(	O
refractory	B-ADR
anemia	I-ADR
with	I-ADR
excess	I-ADR
blast	I-ADR
)	O
following	O
treatment	O
of	O
recurrent	O
anaplastic	O
astrocytoma	O
with	O
temozolomide	O
(	O
tmz	B-Drug
)	O
0	O
<EOS>	O
typically	O
,	O
drug-induced	O
neutropenia	B-ADR
occurs	O
in	O
a	O
patient	O
receiving	O
a	O
semisynthetic	O
penicillin	B-Drug
for	O
two	O
week	O
or	O
more	O
0	O
<EOS>	O
livedo	B-ADR
reticularis	I-ADR
associated	O
with	O
interferon	B-Drug
alpha	I-Drug
therapy	O
in	O
two	O
melanoma	O
patient	O
0	O
<EOS>	O
these	O
case	O
highlight	O
the	O
occurrence	O
of	O
livedo	B-ADR
reticularis	I-ADR
a	O
an	O
uncommon	O
side-effect	O
of	O
interferon	B-Drug
alpha	I-Drug
treatment	O
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
who	O
developed	O
intense	O
livedo	B-ADR
reticularis	I-ADR
clearly	O
related	O
to	O
the	O
administration	O
of	O
interferon	B-Drug
alpha	I-Drug
2b	I-Drug
a	O
an	O
adjuvant	O
therapy	O
for	O
melanoma	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
rare	O
case	O
of	O
ptu-induced	B-Drug
anca-associated	B-ADR
vasculitis	I-ADR
manifested	O
with	O
ototoxicity	O
in	O
combination	O
with	O
systemic	O
involvement	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
rare	O
case	O
of	O
ptu-induced	B-Drug
anca-associated	O
vasculitis	O
manifested	O
with	O
ototoxicity	B-ADR
in	O
combination	O
with	O
systemic	O
involvement	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
with	O
graf	O
	O
disease	O
in	O
whom	O
ototoxicity	O
developed	O
because	O
of	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
-induced	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody	I-ADR
(	I-ADR
anca	I-ADR
)	I-ADR
-associated	I-ADR
vasculitis	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
with	O
graf	O
	O
disease	O
in	O
whom	O
ototoxicity	O
developed	O
because	O
of	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
-induced	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody	I-ADR
(	I-ADR
anca	I-ADR
)	I-ADR
-associated	I-ADR
vasculitis	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
with	O
graf	O
	O
disease	O
in	O
whom	O
ototoxicity	B-ADR
developed	O
because	O
of	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
-induced	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
anca	O
)	O
-associated	O
vasculitis	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
with	O
graf	O
	O
disease	O
in	O
whom	O
ototoxicity	B-ADR
developed	O
because	O
of	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
-induced	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
anca	O
)	O
-associated	O
vasculitis	O
0	O
<EOS>	O
propylthiouracil-induced	B-Drug
sensorineural	O
hearing	O
loss	O
associated	O
with	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody	I-ADR
0	O
<EOS>	O
propylthiouracil-induced	B-Drug
sensorineural	B-ADR
hearing	I-ADR
loss	I-ADR
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	O
0	O
<EOS>	O
result	O
:	O
in	O
a	O
22-year-old	O
thai	O
woman	O
with	O
graf	O
	O
disease	O
,	O
tinnitus	O
,	O
hearing	B-ADR
impairment	I-ADR
in	I-ADR
the	I-ADR
left	I-ADR
ear	I-ADR
(	I-ADR
with	I-ADR
progression	I-ADR
to	I-ADR
the	I-ADR
right	I-ADR
ear	I-ADR
)	I-ADR
,	O
and	O
vertigo	O
developed	O
after	O
3	O
year	O
of	O
therapy	O
with	O
ptu	B-Drug
0	O
<EOS>	O
result	O
:	O
in	O
a	O
22-year-old	O
thai	O
woman	O
with	O
graf	O
	O
disease	O
,	O
tinnitus	B-ADR
,	O
hearing	O
impairment	O
in	O
the	O
left	O
ear	O
(	O
with	O
progression	O
to	O
the	O
right	O
ear	O
)	O
,	O
and	O
vertigo	O
developed	O
after	O
3	O
year	O
of	O
therapy	O
with	O
ptu	B-Drug
0	O
<EOS>	O
result	O
:	O
in	O
a	O
22-year-old	O
thai	O
woman	O
with	O
graf	O
	O
disease	O
,	O
tinnitus	O
,	O
hearing	O
impairment	O
in	O
the	O
left	O
ear	O
(	O
with	O
progression	O
to	O
the	O
right	O
ear	O
)	O
,	O
and	O
vertigo	B-ADR
developed	O
after	O
3	O
year	O
of	O
therapy	O
with	O
ptu	B-Drug
0	O
<EOS>	O
the	O
hearing	B-ADR
impairment	I-ADR
and	O
tinnitus	O
were	O
gradually	O
reduced	O
after	O
ptu	B-Drug
withdrawal	O
and	O
corticosteroid	O
and	O
azathioprine	O
treatment	O
0	O
<EOS>	O
the	O
hearing	O
impairment	O
and	O
tinnitus	B-ADR
were	O
gradually	O
reduced	O
after	O
ptu	B-Drug
withdrawal	O
and	O
corticosteroid	O
and	O
azathioprine	O
treatment	O
0	O
<EOS>	O
anti-tuberculous	O
drug	O
had	O
been	O
stopped	O
on	O
the	O
2nd	O
day	O
of	O
therapy	O
due	O
to	O
development	O
of	O
optic	B-ADR
neuritis	I-ADR
secondary	O
to	O
ethambutol	B-Drug
administration	O
at	O
another	O
hospital	O
0	O
<EOS>	O
during	O
the	O
anti-tuberculous	O
therapy	O
,	O
visual	B-ADR
loss	I-ADR
can	O
be	O
related	O
to	O
ethambutol	B-Drug
toxicity	O
or	O
the	O
tuberculosis	O
infection	O
itself	O
0	O
<EOS>	O
in	O
addition	O
,	O
ethambutol	B-Drug
rarely	O
cause	O
visual	B-ADR
loss	I-ADR
during	O
the	O
early	O
period	O
or	O
when	O
given	O
at	O
lower	O
dos	O
0	O
<EOS>	O
flucloxacillin-induced	B-Drug
aplastic	B-ADR
anaemia	I-ADR
and	O
liver	O
failure	O
0	O
<EOS>	O
flucloxacillin-induced	B-Drug
aplastic	O
anaemia	O
and	O
liver	B-ADR
failure	I-ADR
0	O
<EOS>	O
it	O
is	O
well-recognized	O
that	O
flucloxacillin	B-Drug
may	O
occasionally	O
result	O
in	O
fatal	B-ADR
hepatic	I-ADR
injury	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
40-year-old	O
woman	O
who	O
developed	O
fulminant	O
hepatic	O
failure	O
and	O
aplastic	B-ADR
anaemia	I-ADR
following	O
a	O
course	O
of	O
oral	O
flucloxacillin	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
40-year-old	O
woman	O
who	O
developed	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
and	O
aplastic	O
anaemia	O
following	O
a	O
course	O
of	O
oral	O
flucloxacillin	B-Drug
0	O
<EOS>	O
four	O
day	O
after	O
intravenous	O
zoledronic	B-Drug
acid	I-Drug
,	O
the	O
patient	O
presented	O
to	O
emergency	O
room	O
with	O
complaint	O
of	O
carpopedal	O
spasm	O
and	O
bronchospasm	B-ADR
0	O
<EOS>	O
four	O
day	O
after	O
intravenous	O
zoledronic	B-Drug
acid	I-Drug
,	O
the	O
patient	O
presented	O
to	O
emergency	O
room	O
with	O
complaint	O
of	O
carpopedal	B-ADR
spasm	I-ADR
and	O
bronchospasm	O
0	O
<EOS>	O
zoledronic	B-Drug
acid-induced	I-Drug
severe	B-ADR
hypocalcaemia	I-ADR
in	O
a	O
prostate	O
cancer	O
patient	O
with	O
extensive	O
osteoblastic	O
bone	O
metastasis	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
an	O
adolescent	O
with	O
severe	B-ADR
lupus	I-ADR
erythematosus	I-ADR
who	O
received	O
cyclophosphamide	O
(	O
cy	B-Drug
)	O
paired	O
with	O
taste	O
(	O
cod	O
liver	O
oil	O
)	O
and	O
smell	O
(	O
rose	O
perfume	O
)	O
a	O
conditioned	O
stimulus	O
0	O
<EOS>	O
this	O
case	O
report	O
describes	O
an	O
adolescent	O
with	O
severe	B-ADR
lupus	I-ADR
erythematosus	I-ADR
who	O
received	O
cyclophosphamide	B-Drug
(	O
cy	O
)	O
paired	O
with	O
taste	O
(	O
cod	O
liver	O
oil	O
)	O
and	O
smell	O
(	O
rose	O
perfume	O
)	O
a	O
conditioned	O
stimulus	O
0	O
<EOS>	O
mucosal	B-ADR
pigmentation	I-ADR
after	O
oral	O
lichen	O
planus	O
treatment	O
with	O
topical	O
tacrolimus	B-Drug
0	O
<EOS>	O
the	O
relation	O
between	O
tacrolimus	B-Drug
treatment	O
and	O
staining	O
wa	O
suggested	O
by	O
the	O
appearance	O
of	O
pigmentation	B-ADR
during	O
topical	O
tacrolimus	O
treatment	O
and	O
it	O
clinical	O
disappearance	O
when	O
treatment	O
wa	O
stopped	O
0	O
<EOS>	O
the	O
relation	O
between	O
tacrolimus	B-Drug
treatment	O
and	O
staining	O
wa	O
suggested	O
by	O
the	O
appearance	O
of	O
pigmentation	B-ADR
during	O
topical	O
tacrolimus	O
treatment	O
and	O
it	O
clinical	O
disappearance	O
when	O
treatment	O
wa	O
stopped	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
histopathologically	O
documented	O
case	O
of	O
oral	B-ADR
mucosa	I-ADR
pigmentation	I-ADR
after	O
olp	O
treatment	O
with	O
topical	O
tacrolimus	B-Drug
0	O
<EOS>	O
recently	O
,	O
some	O
study	O
have	O
also	O
reported	O
association	O
between	O
patient	O
with	O
juvenile	O
rheumatoid	O
arthritis	O
(	O
jra	O
)	O
treated	O
with	O
methotrexate	B-Drug
(	O
mtx	O
)	O
and	O
malignant	B-ADR
lymphoma	I-ADR
developing	O
0	O
<EOS>	O
recently	O
,	O
some	O
study	O
have	O
also	O
reported	O
association	O
between	O
patient	O
with	O
juvenile	O
rheumatoid	O
arthritis	O
(	O
jra	O
)	O
treated	O
with	O
methotrexate	O
(	O
mtx	B-Drug
)	O
and	O
malignant	B-ADR
lymphoma	I-ADR
developing	O
0	O
<EOS>	O
risperidone	B-Drug
is	O
a	O
frequently	O
used	O
member	O
of	O
a	O
new	O
class	O
of	O
atypical	O
antipsychotics-the	O
serotonin-dopamine	O
antagonist	O
(	O
sdas	O
)	O
-due	O
to	O
it	O
comparatively	O
high	O
efficacy	O
and	O
low	O
d2	O
/	O
5ht2	O
binding	O
ratio	O
,	O
which	O
result	O
in	O
a	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effect	O
including	O
tardive	B-ADR
dyskinesia	I-ADR
(	O
td	O
)	O
0	O
<EOS>	O
risperidone	B-Drug
is	O
a	O
frequently	O
used	O
member	O
of	O
a	O
new	O
class	O
of	O
atypical	O
antipsychotics-the	O
serotonin-dopamine	O
antagonist	O
(	O
sdas	O
)	O
-due	O
to	O
it	O
comparatively	O
high	O
efficacy	O
and	O
low	O
d2	O
/	O
5ht2	O
binding	O
ratio	O
,	O
which	O
result	O
in	O
a	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effect	O
including	O
tardive	O
dyskinesia	O
(	O
td	B-ADR
)	O
0	O
<EOS>	O
risperidone	B-Drug
withdrawal-related	O
respiratory	B-ADR
dyskinesia	I-ADR
:	O
a	O
case	O
diagnosed	O
by	O
spirography	O
and	O
fibroscopy	O
0	O
<EOS>	O
the	O
author	O
present	O
an	O
elderly	O
patient	O
with	O
mixed	O
dementia	O
who	O
developed	O
td	O
at	O
multiple	O
site	O
,	O
(	O
including	O
respiratory	O
dyskinesia	O
[	O
rd	O
]	O
,	O
limb	B-ADR
dyskinesia	I-ADR
,	O
and	O
orofacial	O
dyskinesia	O
)	O
following	O
abrupt	O
withdrawal	O
of	O
risperidone	B-Drug
therapy	O
0	O
<EOS>	O
the	O
author	O
present	O
an	O
elderly	O
patient	O
with	O
mixed	O
dementia	O
who	O
developed	O
td	O
at	O
multiple	O
site	O
,	O
(	O
including	O
respiratory	O
dyskinesia	O
[	O
rd	O
]	O
,	O
limb	O
dyskinesia	O
,	O
and	O
orofacial	B-ADR
dyskinesia	I-ADR
)	O
following	O
abrupt	O
withdrawal	O
of	O
risperidone	B-Drug
therapy	O
0	O
<EOS>	O
the	O
author	O
present	O
an	O
elderly	O
patient	O
with	O
mixed	O
dementia	O
who	O
developed	O
td	O
at	O
multiple	O
site	O
,	O
(	O
including	O
respiratory	O
dyskinesia	O
[	O
rd	B-ADR
]	O
,	O
limb	O
dyskinesia	O
,	O
and	O
orofacial	O
dyskinesia	O
)	O
following	O
abrupt	O
withdrawal	O
of	O
risperidone	B-Drug
therapy	O
0	O
<EOS>	O
the	O
author	O
present	O
an	O
elderly	O
patient	O
with	O
mixed	O
dementia	O
who	O
developed	O
td	O
at	O
multiple	O
site	O
,	O
(	O
including	O
respiratory	B-ADR
dyskinesia	I-ADR
[	O
rd	O
]	O
,	O
limb	O
dyskinesia	O
,	O
and	O
orofacial	O
dyskinesia	O
)	O
following	O
abrupt	O
withdrawal	O
of	O
risperidone	B-Drug
therapy	O
0	O
<EOS>	O
the	O
author	O
present	O
an	O
elderly	O
patient	O
with	O
mixed	O
dementia	O
who	O
developed	O
td	B-ADR
at	O
multiple	O
site	O
,	O
(	O
including	O
respiratory	O
dyskinesia	O
[	O
rd	O
]	O
,	O
limb	O
dyskinesia	O
,	O
and	O
orofacial	O
dyskinesia	O
)	O
following	O
abrupt	O
withdrawal	O
of	O
risperidone	B-Drug
therapy	O
0	O
<EOS>	O
therefore	O
,	O
clinician	O
should	O
pay	O
close	O
attention	O
to	O
possible	O
onset	O
of	O
rd	B-ADR
in	O
patient	O
with	O
multiple	O
risk	O
factor	O
for	O
td	O
,	O
even	O
when	O
sda	B-Drug
therapy	O
is	O
used	O
0	O
<EOS>	O
in	O
this	O
study	O
,	O
we	O
report	O
on	O
three	O
individual	O
patient	O
who	O
received	O
btx-b	B-Drug
and	O
who	O
subsequently	O
developed	O
parasympathetic	B-ADR
dysfunction	I-ADR
of	I-ADR
the	I-ADR
visual	I-ADR
system	I-ADR
after	O
injection	O
of	O
btx-b	O
at	O
remote	O
site	O
0	O
<EOS>	O
in	O
this	O
study	O
,	O
we	O
report	O
on	O
three	O
individual	O
patient	O
who	O
received	O
btx-b	B-Drug
and	O
who	O
subsequently	O
developed	O
parasympathetic	B-ADR
dysfunction	I-ADR
of	I-ADR
the	I-ADR
visual	I-ADR
system	I-ADR
after	O
injection	O
of	O
btx-b	O
at	O
remote	O
site	O
0	O
<EOS>	O
to	O
date	O
,	O
there	O
have	O
been	O
few	O
report	O
of	O
visual	B-ADR
disturbance	I-ADR
associated	O
with	O
btx-b	B-Drug
use	O
0	O
<EOS>	O
visual	O
system	O
side	O
effect	O
caused	O
by	O
parasympathetic	B-ADR
dysfunction	I-ADR
after	O
botulinum	B-Drug
toxin	I-Drug
type	I-Drug
b	I-Drug
injection	O
0	O
<EOS>	O
visual	B-ADR
system	I-ADR
side	I-ADR
effect	I-ADR
caused	O
by	O
parasympathetic	O
dysfunction	O
after	O
botulinum	B-Drug
toxin	I-Drug
type	I-Drug
b	I-Drug
injection	O
0	O
<EOS>	O
enalapril-induced	B-Drug
anemia	B-ADR
in	O
two	O
kidney	O
transplant	O
recipient	O
0	O
<EOS>	O
two	O
renal	O
transplant	O
patient	O
developed	O
anemia	B-ADR
during	O
treatment	O
of	O
hypertension	O
with	O
enalapril	B-Drug
medication	O
0	O
<EOS>	O
a	O
74-year-old	O
hypercholestrerolaemic	O
woman	O
taking	O
cerivastatin	B-Drug
(	O
0.15	O
mg	O
/	O
day	O
)	O
for	O
22	O
day	O
complained	O
of	O
general	O
muscle	B-ADR
weakness	I-ADR
and	O
muscle	B-ADR
pain	I-ADR
0	O
<EOS>	O
a	O
74-year-old	O
hypercholestrerolaemic	O
woman	O
taking	O
cerivastatin	B-Drug
(	O
0.15	O
mg	O
/	O
day	O
)	O
for	O
22	O
day	O
complained	O
of	O
general	O
muscle	B-ADR
weakness	I-ADR
and	O
muscle	O
pain	O
0	O
<EOS>	O
clearance	O
rate	O
of	O
cerivastatin	O
metabolite	O
in	O
a	O
patient	O
with	O
cerivastatin-induced	B-Drug
rhabdomyolysis	B-ADR
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
who	O
developed	O
acute	B-ADR
rhabdomyolysis	I-ADR
after	O
taking	O
cerivastatin	B-Drug
0	O
<EOS>	O
carboplatin	B-Drug
hypersensitivity	B-ADR
induced	O
by	O
low-dose	O
paclitaxel	O
/	O
carboplatin	O
in	O
multiple	O
platinum-treated	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
0	O
<EOS>	O
carboplatin	B-Drug
hypersensitivity	B-ADR
induced	O
by	O
low-dose	O
paclitaxel	O
/	O
carboplatin	O
in	O
multiple	O
platinum-treated	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
0	O
<EOS>	O
carboplatin	O
hypersensitivity	B-ADR
induced	O
by	O
low-dose	O
paclitaxel	B-Drug
/	O
carboplatin	O
in	O
multiple	O
platinum-treated	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	O
hypersensitivity	O
reaction	O
including	O
cardiac	O
arrest	O
and	O
apnea	B-ADR
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	O
,	O
hypotension	O
,	O
and	O
tachycardia	O
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	O
hypersensitivity	O
reaction	O
including	O
cardiac	B-ADR
arrest	I-ADR
and	O
apnea	O
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	O
,	O
hypotension	O
,	O
and	O
tachycardia	O
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	O
hypersensitivity	O
reaction	O
including	O
cardiac	O
arrest	O
and	O
apnea	O
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	B-ADR
,	O
hypotension	O
,	O
and	O
tachycardia	O
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	O
hypersensitivity	O
reaction	O
including	O
cardiac	O
arrest	O
and	O
apnea	O
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	O
,	O
hypotension	B-ADR
,	O
and	O
tachycardia	O
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
including	O
cardiac	O
arrest	O
and	O
apnea	O
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	O
,	O
hypotension	O
,	O
and	O
tachycardia	O
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
however	O
,	O
one	O
patient	O
exhibited	O
severe	O
hypersensitivity	O
reaction	O
including	O
cardiac	O
arrest	O
and	O
apnea	O
,	O
and	O
another	O
four	O
patient	O
developed	O
eruption	O
,	O
hypotension	O
,	O
and	O
tachycardia	B-ADR
soon	O
after	O
administration	O
of	O
cbdca	B-Drug
0	O
<EOS>	O
our	O
report	O
suggested	O
that	O
cbdca	B-Drug
hypersensitivity	B-ADR
wa	O
correlated	O
with	O
the	O
total	O
dose	O
of	O
previously	O
administered	O
platinum	O
agent	O
and	O
that	O
cbdca	O
should	O
be	O
excluded	O
in	O
patient	O
who	O
have	O
received	O
multiple	O
platinum-based	O
chemotherapy	O
,	O
even	O
in	O
platinum-sensitive	O
case	O
,	O
because	O
cbdca	O
hypersensitivity	O
can	O
occur	O
even	O
with	O
low-dose	O
cbdca	O
administration	O
0	O
<EOS>	O
our	O
report	O
suggested	O
that	O
cbdca	B-Drug
hypersensitivity	B-ADR
wa	O
correlated	O
with	O
the	O
total	O
dose	O
of	O
previously	O
administered	O
platinum	O
agent	O
and	O
that	O
cbdca	O
should	O
be	O
excluded	O
in	O
patient	O
who	O
have	O
received	O
multiple	O
platinum-based	O
chemotherapy	O
,	O
even	O
in	O
platinum-sensitive	O
case	O
,	O
because	O
cbdca	O
hypersensitivity	O
can	O
occur	O
even	O
with	O
low-dose	O
cbdca	O
administration	O
0	O
<EOS>	O
our	O
report	O
suggested	O
that	O
cbdca	B-Drug
hypersensitivity	B-ADR
wa	O
correlated	O
with	O
the	O
total	O
dose	O
of	O
previously	O
administered	O
platinum	O
agent	O
and	O
that	O
cbdca	O
should	O
be	O
excluded	O
in	O
patient	O
who	O
have	O
received	O
multiple	O
platinum-based	O
chemotherapy	O
,	O
even	O
in	O
platinum-sensitive	O
case	O
,	O
because	O
cbdca	O
hypersensitivity	O
can	O
occur	O
even	O
with	O
low-dose	O
cbdca	O
administration	O
0	O
<EOS>	O
our	O
report	O
suggested	O
that	O
cbdca	B-Drug
hypersensitivity	B-ADR
wa	O
correlated	O
with	O
the	O
total	O
dose	O
of	O
previously	O
administered	O
platinum	O
agent	O
and	O
that	O
cbdca	O
should	O
be	O
excluded	O
in	O
patient	O
who	O
have	O
received	O
multiple	O
platinum-based	O
chemotherapy	O
,	O
even	O
in	O
platinum-sensitive	O
case	O
,	O
because	O
cbdca	O
hypersensitivity	O
can	O
occur	O
even	O
with	O
low-dose	O
cbdca	O
administration	O
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
carboplatin	B-Drug
(	O
cbdca	O
)	O
hypersensitivity	B-ADR
after	O
weekly	O
low-dose	O
paclitaxel	O
(	O
60	O
mg	O
/	O
m2	O
)	O
/cbdca	O
(	O
area	O
under	O
the	O
concentration	O
curve	O
=	O
2	O
)	O
therapy	O
in	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
receiving	O
multiple	O
platinum-based	O
chemotherapy	O
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
carboplatin	O
(	O
cbdca	B-Drug
)	O
hypersensitivity	B-ADR
after	O
weekly	O
low-dose	O
paclitaxel	O
(	O
60	O
mg	O
/	O
m2	O
)	O
/cbdca	O
(	O
area	O
under	O
the	O
concentration	O
curve	O
=	O
2	O
)	O
therapy	O
in	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
receiving	O
multiple	O
platinum-based	O
chemotherapy	O
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
carboplatin	O
(	O
cbdca	O
)	O
hypersensitivity	B-ADR
after	O
weekly	O
low-dose	O
paclitaxel	B-Drug
(	O
60	O
mg	O
/	O
m2	O
)	O
/cbdca	O
(	O
area	O
under	O
the	O
concentration	O
curve	O
=	O
2	O
)	O
therapy	O
in	O
patient	O
with	O
recurrent	O
ovarian	O
cancer	O
receiving	O
multiple	O
platinum-based	O
chemotherapy	O
0	O
<EOS>	O
treatment	O
/	O
outcome	O
:	O
standard	O
anti-tuberculosis	O
therapy	O
wa	O
administered	O
but	O
wa	O
complicated	O
by	O
interaction	O
with	O
cyclosporine	B-Drug
and	O
drug-induced	O
cholestasis	B-ADR
0	O
<EOS>	O
chronic	O
fentanyl	B-Drug
application	O
induces	O
adrenocortical	B-ADR
insufficiency	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
64-year-old	O
man	O
with	O
secondary	O
adrenocortical	B-ADR
insufficiency	I-ADR
who	O
ha	O
been	O
on	O
a	O
chronic	O
transdermal	O
fentanyl	B-Drug
treatment	O
because	O
of	O
sciatic	O
pain	O
syndrome	O
0	O
<EOS>	O
fluphenazine-induced	B-Drug
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
in	O
a	O
schizophrenic	O
patient	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
(	O
nm	O
)	O
associated	O
with	O
fluphenazine	B-Drug
in	O
a	O
schizophrenic	O
patient	O
and	O
review	O
the	O
literature	O
related	O
to	O
this	O
condition	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
neuroleptic	O
malignant	O
syndrome	O
(	O
nm	B-ADR
)	O
associated	O
with	O
fluphenazine	B-Drug
in	O
a	O
schizophrenic	O
patient	O
and	O
review	O
the	O
literature	O
related	O
to	O
this	O
condition	O
0	O
<EOS>	O
intraventricular	O
vancomycin-induced	B-Drug
cerebrospinal	B-ADR
fluid	I-ADR
eosinophilia	I-ADR
:	O
report	O
of	O
two	O
patient	O
0	O
<EOS>	O
we	O
propose	O
a	O
mechanism	O
of	O
vancomycin-induced	B-Drug
mast	O
cell	O
degranulation	O
and	O
subsequent	O
release	O
of	O
eosinophil	O
chemotactic	O
factor	O
a	O
a	O
cause	O
of	O
csfe	B-ADR
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
cerebrospinal	B-ADR
fluid	I-ADR
eosinophilia	I-ADR
(	O
csfe	O
)	O
secondary	O
to	O
the	O
intraventricular	O
administration	O
of	O
vancomycin	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
cerebrospinal	O
fluid	O
eosinophilia	O
(	O
csfe	B-ADR
)	O
secondary	O
to	O
the	O
intraventricular	O
administration	O
of	O
vancomycin	B-Drug
0	O
<EOS>	O
successful	O
recovery	O
from	O
interstitial	B-ADR
pneumonitis	I-ADR
,	O
induced	O
by	O
bicalutamide	B-Drug
and	O
leuprorelin	O
acetate	O
given	O
a	O
treatment	O
for	O
prostate	O
cancer	O
0	O
<EOS>	O
successful	O
recovery	O
from	O
interstitial	B-ADR
pneumonitis	I-ADR
,	O
induced	O
by	O
bicalutamide	O
and	O
leuprorelin	B-Drug
acetate	I-Drug
given	O
a	O
treatment	O
for	O
prostate	O
cancer	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
interstitial	B-ADR
pneumonitis	I-ADR
induced	O
by	O
bicalutamide	B-Drug
and	O
/	O
or	O
leuprorelin	O
acetate	O
given	O
a	O
therapy	O
for	O
prostate	O
cancer	O
,	O
in	O
which	O
the	O
pneumonitis	O
wa	O
successfully	O
managed	O
by	O
steroid	O
treatment	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
interstitial	B-ADR
pneumonitis	I-ADR
induced	O
by	O
bicalutamide	O
and	O
/	O
or	O
leuprorelin	B-Drug
acetate	I-Drug
given	O
a	O
therapy	O
for	O
prostate	O
cancer	O
,	O
in	O
which	O
the	O
pneumonitis	O
wa	O
successfully	O
managed	O
by	O
steroid	O
treatment	O
0	O
<EOS>	O
conclusion	O
:	O
in	O
these	O
3	O
case	O
,	O
the	O
unique	O
positive	O
ocular	O
finding	O
wa	O
corneal	B-ADR
endothelial	I-ADR
deposit	I-ADR
,	O
which	O
may	O
be	O
related	O
to	O
the	O
use	O
of	O
rifabutin	B-Drug
0	O
<EOS>	O
corneal	B-ADR
endothelial	I-ADR
deposit	I-ADR
associated	O
with	O
rifabutin	B-Drug
use	O
0	O
<EOS>	O
purpose	O
:	O
the	O
aim	O
of	O
this	O
study	O
wa	O
to	O
report	O
on	O
the	O
possible	O
development	O
of	O
corneal	B-ADR
endothelial	I-ADR
deposit	I-ADR
resulting	O
from	O
the	O
use	O
of	O
rifabutin	B-Drug
0	O
<EOS>	O
result	O
:	O
all	O
case	O
developed	O
corneal	B-ADR
endothelial	I-ADR
deposit	I-ADR
after	O
previous	O
use	O
of	O
rifabutin	B-Drug
0	O
<EOS>	O
case	O
:	O
a	O
malignant	B-ADR
mixed	I-ADR
mesodermal	I-ADR
tumor	I-ADR
wa	O
diagnosed	O
in	O
a	O
64-year-old	O
woman	O
with	O
a	O
bicornuate	O
uterus	O
while	O
she	O
wa	O
taking	O
raloxifene	B-Drug
for	O
osteoporosis	O
prevention	O
0	O
<EOS>	O
conclusion	O
:	O
there	O
may	O
be	O
an	O
association	O
between	O
raloxifene	B-Drug
and	O
the	O
development	O
of	O
malignant	B-ADR
mixed	I-ADR
mesodermal	I-ADR
tumor	I-ADR
0	O
<EOS>	O
malignant	B-ADR
mixed	I-ADR
mullerian	I-ADR
tumor	I-ADR
of	I-ADR
the	I-ADR
uterus	I-ADR
in	O
a	O
patient	O
taking	O
raloxifene	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
woman	O
in	O
whom	O
a	O
malignant	B-ADR
mixed	I-ADR
mesodermal	I-ADR
tumor	I-ADR
wa	O
diagnosed	O
while	O
she	O
wa	O
taking	O
raloxifene	B-Drug
,	O
which	O
is	O
also	O
a	O
selective	O
estrogen	O
receptor	O
modulator	O
0	O
<EOS>	O
herein	O
we	O
report	O
four	O
patient	O
who	O
underwent	O
liver	O
transplantation	O
and	O
developed	O
neutropenia	B-ADR
while	O
receiving	O
mmf	B-Drug
0	O
<EOS>	O
mycophenolate	B-Drug
mofetil-induced	I-Drug
neutropenia	B-ADR
in	O
liver	O
transplantation	O
0	O
<EOS>	O
the	O
mean	O
time	O
from	O
starting	O
mmf	B-Drug
to	O
the	O
development	O
of	O
neutropenia	B-ADR
wa	O
4	O
month	O
0	O
<EOS>	O
the	O
side	O
effect	O
of	O
mmf	B-Drug
,	O
such	O
a	O
bone	B-ADR
marrow	I-ADR
toxicity	I-ADR
,	O
have	O
been	O
reported	O
0	O
<EOS>	O
a	O
previous	O
review	O
described	O
data	O
on	O
15	O
patient	O
who	O
experienced	O
acute	B-ADR
hemoglobinemia	I-ADR
or	O
hemoglobinuria	O
following	O
anti-d	B-Drug
igiv	I-Drug
administration	O
for	O
itp	O
or	O
secondary	O
thrombocytopenia	O
0	O
<EOS>	O
a	O
previous	O
review	O
described	O
data	O
on	O
15	O
patient	O
who	O
experienced	O
acute	O
hemoglobinemia	O
or	O
hemoglobinuria	B-ADR
following	O
anti-d	B-Drug
igiv	I-Drug
administration	O
for	O
itp	O
or	O
secondary	O
thrombocytopenia	O
0	O
<EOS>	O
disseminated	O
intravascular	O
coagulation	O
associated	O
with	O
acute	B-ADR
hemoglobinemia	I-ADR
or	O
hemoglobinuria	O
following	O
rh	B-Drug
(	I-Drug
0	I-Drug
)	I-Drug
(	I-Drug
d	I-Drug
)	I-Drug
immune	I-Drug
globulin	I-Drug
intravenous	O
administration	O
for	O
immune	O
thrombocytopenic	O
purpura	O
0	O
<EOS>	O
disseminated	B-ADR
intravascular	I-ADR
coagulation	I-ADR
associated	O
with	O
acute	O
hemoglobinemia	O
or	O
hemoglobinuria	O
following	O
rh	B-Drug
(	I-Drug
0	I-Drug
)	I-Drug
(	I-Drug
d	I-Drug
)	I-Drug
immune	I-Drug
globulin	I-Drug
intravenous	O
administration	O
for	O
immune	O
thrombocytopenic	O
purpura	O
0	O
<EOS>	O
disseminated	O
intravascular	O
coagulation	O
associated	O
with	O
acute	O
hemoglobinemia	O
or	O
hemoglobinuria	B-ADR
following	O
rh	B-Drug
(	I-Drug
0	I-Drug
)	I-Drug
(	I-Drug
d	I-Drug
)	I-Drug
immune	I-Drug
globulin	I-Drug
intravenous	O
administration	O
for	O
immune	O
thrombocytopenic	O
purpura	O
0	O
<EOS>	O
that	O
review	O
suggested	O
that	O
patient	O
receiving	O
anti-d	B-Drug
igiv	I-Drug
be	O
monitored	O
for	O
those	O
and	O
other	O
potential	O
complication	O
of	O
hemoglobinemia	O
,	O
particularly	O
disseminated	O
intravascular	O
coagulation	O
(	O
dic	B-ADR
)	O
0	O
<EOS>	O
that	O
review	O
suggested	O
that	O
patient	O
receiving	O
anti-d	B-Drug
igiv	I-Drug
be	O
monitored	O
for	O
those	O
and	O
other	O
potential	O
complication	O
of	O
hemoglobinemia	O
,	O
particularly	O
disseminated	B-ADR
intravascular	I-ADR
coagulation	I-ADR
(	O
dic	O
)	O
0	O
<EOS>	O
that	O
review	O
suggested	O
that	O
patient	O
receiving	O
anti-d	B-Drug
igiv	I-Drug
be	O
monitored	O
for	O
those	O
and	O
other	O
potential	O
complication	O
of	O
hemoglobinemia	B-ADR
,	O
particularly	O
disseminated	O
intravascular	O
coagulation	O
(	O
dic	O
)	O
0	O
<EOS>	O
the	O
purpose	O
of	O
this	O
review	O
is	O
to	O
increase	O
awareness	O
among	O
physician	O
and	O
other	O
health	O
care	O
professional	O
that	O
dic	B-ADR
may	O
be	O
a	O
rare	O
but	O
potentially	O
severe	O
complication	O
of	O
anti-d	B-Drug
igiv	I-Drug
treatment	O
0	O
<EOS>	O
this	O
review	O
present	O
the	O
first	O
case	O
series	O
of	O
dic	O
associated	O
with	O
acute	B-ADR
hemoglobinemia	I-ADR
or	O
hemoglobinuria	O
following	O
anti-d	B-Drug
igiv	I-Drug
administration	O
for	O
itp	O
0	O
<EOS>	O
this	O
review	O
present	O
the	O
first	O
case	O
series	O
of	O
dic	B-ADR
associated	O
with	O
acute	O
hemoglobinemia	O
or	O
hemoglobinuria	O
following	O
anti-d	B-Drug
igiv	I-Drug
administration	O
for	O
itp	O
0	O
<EOS>	O
this	O
review	O
present	O
the	O
first	O
case	O
series	O
of	O
dic	O
associated	O
with	O
acute	O
hemoglobinemia	O
or	O
hemoglobinuria	B-ADR
following	O
anti-d	B-Drug
igiv	I-Drug
administration	O
for	O
itp	O
0	O
<EOS>	O
after	O
the	O
second	O
infliximab	B-Drug
infusion	O
,	O
he	O
wa	O
found	O
to	O
have	O
a	O
severe	B-ADR
transient	I-ADR
neutropenia	I-ADR
(	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
0	O
<EOS>	O
drug-induced	O
agranulocytosis	B-ADR
during	O
treatment	O
with	O
infliximab	B-Drug
in	O
enteropathic	O
spondyloarthropathy	O
0	O
<EOS>	O
these	O
data	O
indicated	O
that	O
infliximab	B-Drug
possibly	O
triggered	O
production	O
of	O
granulocyte	O
and	O
neutrophil	O
autoantibody	O
with	O
resultant	O
autoimmune	B-ADR
agranulocytosis	I-ADR
0	O
<EOS>	O
these	O
data	O
indicated	O
that	O
infliximab	B-Drug
possibly	O
triggered	O
production	B-ADR
of	I-ADR
granulocyte	I-ADR
and	I-ADR
neutrophil	I-ADR
autoantibody	I-ADR
with	O
resultant	O
autoimmune	O
agranulocytosis	O
0	O
<EOS>	O
however	O
,	O
peripheral	O
neuropathy	O
and	O
bone	B-ADR
marrow	I-ADR
depression	I-ADR
led	O
to	O
linezolid	B-Drug
withdrawal	O
in	O
seven	O
patient	O
,	O
and	O
neuropathy	O
may	O
not	O
be	O
fully	O
reversible	O
in	O
all	O
patient	O
0	O
<EOS>	O
however	O
,	O
peripheral	O
neuropathy	B-ADR
and	O
bone	O
marrow	O
depression	O
led	O
to	O
linezolid	B-Drug
withdrawal	O
in	O
seven	O
patient	O
,	O
and	O
neuropathy	O
may	O
not	O
be	O
fully	O
reversible	O
in	O
all	O
patient	O
0	O
<EOS>	O
however	O
,	O
peripheral	B-ADR
neuropathy	I-ADR
and	O
bone	O
marrow	O
depression	O
led	O
to	O
linezolid	B-Drug
withdrawal	O
in	O
seven	O
patient	O
,	O
and	O
neuropathy	O
may	O
not	O
be	O
fully	O
reversible	O
in	O
all	O
patient	O
0	O
<EOS>	O
six	O
patient	O
developed	O
peripheral	O
neuropathy	O
and	O
five	O
patient	O
bone	B-ADR
marrow	I-ADR
depression	I-ADR
,	O
blood	O
transfusion	O
were	O
given	O
to	O
three	O
patient	O
and	O
in	O
all	O
five	O
patient	O
bone	O
marrow	O
function	O
normalized	O
after	O
cessation	O
of	O
linezolid	B-Drug
0	O
<EOS>	O
six	O
patient	O
developed	O
peripheral	B-ADR
neuropathy	I-ADR
and	O
five	O
patient	O
bone	O
marrow	O
depression	O
,	O
blood	O
transfusion	O
were	O
given	O
to	O
three	O
patient	O
and	O
in	O
all	O
five	O
patient	O
bone	O
marrow	O
function	O
normalized	O
after	O
cessation	O
of	O
linezolid	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
high-grade	B-ADR
endometrial	I-ADR
stromal	I-ADR
sarcoma	I-ADR
,	O
confined	O
into	O
an	O
intrauterine	O
polypoid	O
growth	O
,	O
in	O
a	O
woman	O
with	O
a	O
history	O
of	O
breast	O
cancer	O
who	O
wa	O
treated	O
with	O
adjuvant	O
tamoxifen	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
high-grade	O
endometrial	O
stromal	O
sarcoma	O
,	O
confined	O
into	O
an	O
intrauterine	B-ADR
polypoid	I-ADR
growth	I-ADR
,	O
in	O
a	O
woman	O
with	O
a	O
history	O
of	O
breast	O
cancer	O
who	O
wa	O
treated	O
with	O
adjuvant	O
tamoxifen	B-Drug
0	O
<EOS>	O
high-grade	B-ADR
endometrial	I-ADR
stromal	I-ADR
sarcoma	I-ADR
after	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
0	O
<EOS>	O
in	O
deciding	O
if	O
tamoxifen	B-Drug
therapy	O
is	O
warranted	O
,	O
all	O
potentially	O
life-threatening	O
adverse	O
event	O
associated	O
with	O
tamoxifen	O
should	O
be	O
considered	O
,	O
including	O
endometrial	B-ADR
adenocarcinoma	I-ADR
or	O
uterine	O
sarcoma	O
0	O
<EOS>	O
in	O
deciding	O
if	O
tamoxifen	B-Drug
therapy	O
is	O
warranted	O
,	O
all	O
potentially	O
life-threatening	O
adverse	O
event	O
associated	O
with	O
tamoxifen	O
should	O
be	O
considered	O
,	O
including	O
endometrial	B-ADR
adenocarcinoma	I-ADR
or	O
uterine	O
sarcoma	O
0	O
<EOS>	O
in	O
deciding	O
if	O
tamoxifen	B-Drug
therapy	O
is	O
warranted	O
,	O
all	O
potentially	O
life-threatening	O
adverse	O
event	O
associated	O
with	O
tamoxifen	O
should	O
be	O
considered	O
,	O
including	O
endometrial	O
adenocarcinoma	O
or	O
uterine	B-ADR
sarcoma	I-ADR
0	O
<EOS>	O
in	O
deciding	O
if	O
tamoxifen	B-Drug
therapy	O
is	O
warranted	O
,	O
all	O
potentially	O
life-threatening	O
adverse	O
event	O
associated	O
with	O
tamoxifen	O
should	O
be	O
considered	O
,	O
including	O
endometrial	O
adenocarcinoma	O
or	O
uterine	B-ADR
sarcoma	I-ADR
0	O
<EOS>	O
after	O
only	O
the	O
third	O
dose	O
of	O
pentamidine	B-Drug
,	O
it	O
wa	O
noted	O
that	O
the	O
patient	O
heart	B-ADR
rate	I-ADR
had	I-ADR
decreased	I-ADR
to	O
48	O
beat	O
/	O
minute	O
0	O
<EOS>	O
although	O
various	O
manifestation	O
of	O
pentamidine-induced	B-Drug
cardiotoxicity	B-ADR
have	O
been	O
reported	O
,	O
to	O
our	O
knowledge	O
,	O
second-degree	O
heart	O
block	O
associated	O
with	O
this	O
agent	O
ha	O
not	O
been	O
described	O
0	O
<EOS>	O
although	O
various	O
manifestation	O
of	O
pentamidine-induced	B-Drug
cardiotoxicity	O
have	O
been	O
reported	O
,	O
to	O
our	O
knowledge	O
,	O
second-degree	B-ADR
heart	I-ADR
block	I-ADR
associated	O
with	O
this	O
agent	O
ha	O
not	O
been	O
described	O
0	O
<EOS>	O
clinician	O
should	O
be	O
vigilant	O
when	O
monitoring	O
for	O
cardiotoxicity	B-ADR
in	O
patient	O
receiving	O
pentamidine	B-Drug
throughout	O
the	O
duration	O
of	O
therapy	O
0	O
<EOS>	O
early-onset	O
pentamidine-associated	B-Drug
second-degree	B-ADR
heart	I-ADR
block	I-ADR
and	O
sinus	O
bradycardia	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
early-onset	O
pentamidine-associated	B-Drug
second-degree	O
heart	O
block	O
and	O
sinus	B-ADR
bradycardia	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
falling	B-ADR
backward	I-ADR
in	O
two	O
elderly	O
patient	O
taking	O
bupropion	B-Drug
0	O
<EOS>	O
result	O
:	O
both	O
patient	O
experienced	O
a	O
previously	O
unreported	O
side	O
effect	O
--	O
falling	B-ADR
backward	I-ADR
--	O
associated	O
with	O
bupropion	B-Drug
use	O
0	O
<EOS>	O
ophthalmologic	B-ADR
and	I-ADR
neurologic	I-ADR
finding	I-ADR
in	O
two	O
child	O
exposed	O
to	O
vigabatrin	B-Drug
in	O
utero	O
0	O
<EOS>	O
the	O
knowledge	O
concerning	O
vgb-associated	B-Drug
visual	B-ADR
dysfunction	I-ADR
in	O
pediatric	O
patient	O
,	O
particularly	O
in	O
those	O
who	O
have	O
been	O
exposed	O
to	O
vgb	O
in	O
utero	O
is	O
limited	O
0	O
<EOS>	O
vigabatrin-induced	B-Drug
visual	B-ADR
field	I-ADR
defect	I-ADR
are	O
at	O
present	O
the	O
most	O
important	O
safety	O
issue	O
in	O
the	O
use	O
of	O
the	O
drug	O
0	O
<EOS>	O
we	O
explored	O
ophthalmic	B-ADR
and	I-ADR
neurologic	I-ADR
finding	I-ADR
in	O
two	O
child	O
who	O
have	O
been	O
exposed	O
prenatally	O
to	O
vgb	B-Drug
0	O
<EOS>	O
background	O
:	O
interferon	O
(	O
ifn	B-Drug
)	O
-associated	O
retinopathy	O
is	O
typically	O
characterized	O
by	O
retinal	O
hemorrhage	O
and	O
cotton	B-ADR
wool	I-ADR
spot	I-ADR
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
background	O
:	O
interferon	B-Drug
(	O
ifn	O
)	O
-associated	O
retinopathy	O
is	O
typically	O
characterized	O
by	O
retinal	O
hemorrhage	O
and	O
cotton	B-ADR
wool	I-ADR
spot	I-ADR
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
background	O
:	O
interferon	O
(	O
ifn	B-Drug
)	O
-associated	O
retinopathy	O
is	O
typically	O
characterized	O
by	O
retinal	B-ADR
hemorrhage	I-ADR
and	O
cotton	O
wool	O
spot	O
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
background	O
:	O
interferon	B-Drug
(	O
ifn	O
)	O
-associated	O
retinopathy	O
is	O
typically	O
characterized	O
by	O
retinal	B-ADR
hemorrhage	I-ADR
and	O
cotton	O
wool	O
spot	O
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
background	O
:	O
interferon	O
(	O
ifn	B-Drug
)	O
-associated	O
retinopathy	B-ADR
is	O
typically	O
characterized	O
by	O
retinal	O
hemorrhage	O
and	O
cotton	O
wool	O
spot	O
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
background	O
:	O
interferon	B-Drug
(	O
ifn	O
)	O
-associated	O
retinopathy	B-ADR
is	O
typically	O
characterized	O
by	O
retinal	O
hemorrhage	O
and	O
cotton	O
wool	O
spot	O
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
0	O
<EOS>	O
clinical	O
course	O
of	O
macular	B-ADR
edema	I-ADR
in	O
two	O
case	O
of	O
interferon-associated	B-Drug
retinopathy	O
observed	O
by	O
optical	O
coherence	O
tomography	O
0	O
<EOS>	O
clinical	O
course	O
of	O
macular	O
edema	O
in	O
two	O
case	O
of	O
interferon-associated	B-Drug
retinopathy	B-ADR
observed	O
by	O
optical	O
coherence	O
tomography	O
0	O
<EOS>	O
conclusion	O
:	O
during	O
and	O
after	O
ifn	B-Drug
therapy	O
,	O
oct	O
is	O
a	O
useful	O
examination	O
technique	O
for	O
revealing	O
macular	O
edema	O
in	O
patient	O
who	O
have	O
decreased	B-ADR
vision	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
during	O
and	O
after	O
ifn	B-Drug
therapy	O
,	O
oct	O
is	O
a	O
useful	O
examination	O
technique	O
for	O
revealing	O
macular	B-ADR
edema	I-ADR
in	O
patient	O
who	O
have	O
decreased	O
vision	O
0	O
<EOS>	O
ophthalmologist	O
should	O
be	O
aware	O
of	O
the	O
ocular	O
side	O
effect	O
of	O
ifn	B-Drug
therapy	O
and	O
carefully	O
monitor	O
patient	O
for	O
the	O
possible	O
occurrence	O
of	O
hypoalbuminemia	B-ADR
and	O
thrombocytopenia	O
0	O
<EOS>	O
ophthalmologist	O
should	O
be	O
aware	O
of	O
the	O
ocular	B-ADR
side	I-ADR
effect	I-ADR
of	O
ifn	B-Drug
therapy	O
and	O
carefully	O
monitor	O
patient	O
for	O
the	O
possible	O
occurrence	O
of	O
hypoalbuminemia	O
and	O
thrombocytopenia	O
0	O
<EOS>	O
ophthalmologist	O
should	O
be	O
aware	O
of	O
the	O
ocular	O
side	O
effect	O
of	O
ifn	B-Drug
therapy	O
and	O
carefully	O
monitor	O
patient	O
for	O
the	O
possible	O
occurrence	O
of	O
hypoalbuminemia	O
and	O
thrombocytopenia	B-ADR
0	O
<EOS>	O
the	O
former	O
patient	O
had	O
complained	O
once	O
that	O
his	O
visual	B-ADR
acuity	I-ADR
had	I-ADR
decreased	I-ADR
after	O
the	O
termination	O
of	O
ifn	B-Drug
therapy	O
,	O
and	O
the	O
latter	O
patient	O
complained	O
twice	O
during	O
ifn	O
therapy	O
that	O
his	O
visual	O
acuity	O
had	O
decreased	O
0	O
<EOS>	O
the	O
former	O
patient	O
had	O
complained	O
once	O
that	O
his	O
visual	B-ADR
acuity	I-ADR
had	I-ADR
decreased	I-ADR
after	O
the	O
termination	O
of	O
ifn	B-Drug
therapy	O
,	O
and	O
the	O
latter	O
patient	O
complained	O
twice	O
during	O
ifn	O
therapy	O
that	O
his	O
visual	O
acuity	O
had	O
decreased	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	O
who	O
had	O
developed	O
macular	B-ADR
edema	I-ADR
and	O
reduced	O
visual	O
acuity	O
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	O
who	O
had	O
developed	O
macular	B-ADR
edema	I-ADR
and	O
reduced	O
visual	O
acuity	O
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	O
who	O
had	O
developed	O
macular	O
edema	O
and	O
reduced	B-ADR
visual	I-ADR
acuity	I-ADR
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	O
who	O
had	O
developed	O
macular	O
edema	O
and	O
reduced	B-ADR
visual	I-ADR
acuity	I-ADR
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	B-ADR
who	O
had	O
developed	O
macular	O
edema	O
and	O
reduced	O
visual	O
acuity	O
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
with	O
the	O
use	O
of	O
optical	O
coherence	O
tomography	O
(	O
oct	O
)	O
,	O
two	O
patient	O
with	O
ifn-associated	B-Drug
retinopathy	B-ADR
who	O
had	O
developed	O
macular	O
edema	O
and	O
reduced	O
visual	O
acuity	O
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
0	O
<EOS>	O
late	O
development	O
of	O
diabetes	B-ADR
mellitus	I-ADR
after	O
interferon-alfa	B-Drug
and	O
ribavirin	O
therapy	O
for	O
chronic	O
hepatitis	O
c	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
late	O
development	O
of	O
diabetes	B-ADR
mellitus	I-ADR
after	O
interferon-alfa	O
and	O
ribavirin	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
c	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
late	O
development	O
of	O
immune-mediated	B-ADR
diabetes	I-ADR
mellitus	I-ADR
after	O
completion	O
of	O
alfa-interferon	B-Drug
therapy	O
for	O
hepatitis	O
c	O
in	O
an	O
asian	O
patient	O
0	O
<EOS>	O
cutaneous	B-ADR
necrosis	I-ADR
after	O
injection	O
of	O
polyethylene	O
glycol-modified	O
interferon	B-Drug
alfa	I-Drug
0	O
<EOS>	O
cutaneous	B-ADR
necrosis	I-ADR
a	O
a	O
result	O
of	O
interferon	B-Drug
alfa	I-Drug
is	O
an	O
infrequent	O
complication	O
with	O
unknown	O
pathogenesis	O
,	O
in	O
which	O
a	O
cutaneous	O
local	O
immune-mediated	O
inflammatory	O
process	O
might	O
be	O
involved	O
0	O
<EOS>	O
we	O
report	O
5	O
patient	O
(	O
3	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
treated	O
with	O
pegylated	B-Drug
interferon	I-Drug
alfa-2b	I-Drug
in	O
association	O
with	O
oral	O
ribavirin	O
and	O
two	O
patient	O
with	O
chronic	O
myelocytic	O
leukemia	O
)	O
who	O
developed	O
local	B-ADR
cutaneous	I-ADR
reaction	I-ADR
at	O
site	O
of	O
injection	O
after	O
the	O
administration	O
of	O
weekly	O
subcutaneous	O
injection	O
of	O
pegylated	O
interferon	O
alfa-2b	O
at	O
different	O
dos	O
0	O
<EOS>	O
we	O
report	O
5	O
patient	O
(	O
3	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
treated	O
with	O
pegylated	B-Drug
interferon	I-Drug
alfa-2b	I-Drug
in	O
association	O
with	O
oral	O
ribavirin	O
and	O
two	O
patient	O
with	O
chronic	O
myelocytic	O
leukemia	O
)	O
who	O
developed	O
local	B-ADR
cutaneous	I-ADR
reaction	I-ADR
at	O
site	O
of	O
injection	O
after	O
the	O
administration	O
of	O
weekly	O
subcutaneous	O
injection	O
of	O
pegylated	O
interferon	O
alfa-2b	O
at	O
different	O
dos	O
0	O
<EOS>	O
we	O
report	O
5	O
patient	O
(	O
3	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
treated	O
with	O
pegylated	O
interferon	O
alfa-2b	O
in	O
association	O
with	O
oral	O
ribavirin	B-Drug
and	O
two	O
patient	O
with	O
chronic	O
myelocytic	O
leukemia	O
)	O
who	O
developed	O
local	B-ADR
cutaneous	I-ADR
reaction	I-ADR
at	O
site	O
of	O
injection	O
after	O
the	O
administration	O
of	O
weekly	O
subcutaneous	O
injection	O
of	O
pegylated	O
interferon	O
alfa-2b	O
at	O
different	O
dos	O
0	O
<EOS>	O
we	O
review	O
the	O
literature	O
on	O
previously	O
reported	O
case	O
of	O
cutaneous	B-ADR
necrosis	I-ADR
after	O
injection	O
of	O
standard	O
interferon	B-Drug
alfa	I-Drug
or	O
pegylated	O
interferon	O
alfa-2b	O
and	O
discus	O
the	O
different	O
pathophysiologic	O
mechanism	O
that	O
might	O
be	O
involved	O
0	O
<EOS>	O
we	O
review	O
the	O
literature	O
on	O
previously	O
reported	O
case	O
of	O
cutaneous	B-ADR
necrosis	I-ADR
after	O
injection	O
of	O
standard	O
interferon	O
alfa	O
or	O
pegylated	B-Drug
interferon	I-Drug
alfa-2b	I-Drug
and	O
discus	O
the	O
different	O
pathophysiologic	O
mechanism	O
that	O
might	O
be	O
involved	O
0	O
<EOS>	O
potential	O
mechanism	O
involved	O
in	O
the	O
occurrence	O
of	O
ischemic	B-ADR
colitis	I-ADR
in	O
patient	O
receiving	O
tegaserod	B-Drug
are	O
also	O
discussed	O
0	O
<EOS>	O
tegaserod-associated	B-Drug
ischemic	B-ADR
colitis	I-ADR
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	O
colitis	O
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	B-ADR
bowel	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	O
colitis	O
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	B-ADR
bowel	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	B-ADR
colitis	I-ADR
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	O
bowel	O
syndrome	O
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	B-ADR
colitis	I-ADR
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	O
bowel	O
syndrome	O
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	B-ADR
colitis	I-ADR
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	O
bowel	O
syndrome	O
0	O
<EOS>	O
we	O
describe	O
the	O
development	O
of	O
ischemic	B-ADR
colitis	I-ADR
in	O
a	O
woman	O
who	O
wa	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	O
bowel	O
syndrome	O
0	O
<EOS>	O
a	O
57-year-old	O
man	O
developed	O
chronic	B-ADR
,	I-ADR
watery	I-ADR
diarrhea	I-ADR
four	O
week	O
after	O
helicobacter	O
pylorus	O
eradication	O
therapy	O
including	O
lansoprazole	B-Drug
followed	O
by	O
lansoprazole	O
monotherapy	O
for	O
gastroesophageal	O
reflux	O
disease	O
0	O
<EOS>	O
a	O
57-year-old	O
man	O
developed	O
chronic	B-ADR
,	I-ADR
watery	I-ADR
diarrhea	I-ADR
four	O
week	O
after	O
helicobacter	O
pylorus	O
eradication	O
therapy	O
including	O
lansoprazole	B-Drug
followed	O
by	O
lansoprazole	O
monotherapy	O
for	O
gastroesophageal	O
reflux	O
disease	O
0	O
<EOS>	O
lansoprazole-associated	B-Drug
collagenous	B-ADR
colitis	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
reported	O
case	O
represents	O
an	O
unusual	O
association	O
between	O
medication	O
with	O
the	O
proton	O
pump	O
inhibitor	O
lansoprazole	B-Drug
and	O
the	O
development	O
of	O
collagenous	B-ADR
colitis	I-ADR
suggesting	O
the	O
importance	O
of	O
evaluation	O
of	O
drug	O
use	O
in	O
patient	O
with	O
microscopic	O
colitis	O
0	O
<EOS>	O
46-year-old	O
woman	O
developed	O
painful	B-ADR
ulcer	I-ADR
over	O
her	O
lower	O
abdomen	O
in	O
the	O
form	O
of	O
reticulate	O
erythema	O
after	O
injecting	O
interferon	B-Drug
beta-1b	I-Drug
subcutaneously	O
for	O
multiple	O
sclerosis	O
0	O
<EOS>	O
46-year-old	O
woman	O
developed	O
painful	O
ulcer	O
over	O
her	O
lower	O
abdomen	O
in	O
the	O
form	O
of	O
reticulate	B-ADR
erythema	I-ADR
after	O
injecting	O
interferon	B-Drug
beta-1b	I-Drug
subcutaneously	O
for	O
multiple	O
sclerosis	O
0	O
<EOS>	O
abdominal	B-ADR
wall	I-ADR
ulceration	I-ADR
and	O
mucinosis	O
secondary	O
to	O
recombinant	B-Drug
human	I-Drug
interferon-beta-1b	I-Drug
0	O
<EOS>	O
abdominal	O
wall	O
ulceration	O
and	O
mucinosis	B-ADR
secondary	O
to	O
recombinant	B-Drug
human	I-Drug
interferon-beta-1b	I-Drug
0	O
<EOS>	O
itraconazole-related	B-Drug
increased	O
vincristine	B-ADR
neurotoxicity	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
itraconazole-related	O
increased	O
vincristine	B-Drug
neurotoxicity	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
nineteen	O
case	O
of	O
unusual	O
enhanced	O
vincristine	O
neurotoxicity	B-ADR
related	O
to	O
itraconazole	B-Drug
have	O
been	O
reported	O
in	O
child	O
0	O
<EOS>	O
nineteen	O
case	O
of	O
unusual	O
enhanced	O
vincristine	B-Drug
neurotoxicity	B-ADR
related	O
to	O
itraconazole	O
have	O
been	O
reported	O
in	O
child	O
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	O
ileus	O
,	O
neurogenic	O
bladder	O
,	O
mild	O
left	O
ptosis	O
,	O
and	O
absence	B-ADR
of	I-ADR
deep	I-ADR
reflex	I-ADR
,	O
with	O
severe	O
paralysis	O
of	O
the	O
lower	O
extremity	O
and	O
mild	O
weakness	O
of	O
the	O
upper	O
extremity	O
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	O
ileus	O
,	O
neurogenic	O
bladder	O
,	O
mild	B-ADR
left	I-ADR
ptosis	I-ADR
,	O
and	O
absence	O
of	O
deep	O
reflex	O
,	O
with	O
severe	O
paralysis	O
of	O
the	O
lower	O
extremity	O
and	O
mild	O
weakness	O
of	O
the	O
upper	O
extremity	O
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	O
ileus	O
,	O
neurogenic	O
bladder	O
,	O
mild	O
left	O
ptosis	O
,	O
and	O
absence	O
of	O
deep	O
reflex	O
,	O
with	O
severe	O
paralysis	O
of	O
the	O
lower	O
extremity	O
and	O
mild	B-ADR
weakness	I-ADR
of	I-ADR
the	I-ADR
upper	I-ADR
extremity	I-ADR
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	O
ileus	O
,	O
neurogenic	B-ADR
bladder	I-ADR
,	O
mild	O
left	O
ptosis	O
,	O
and	O
absence	O
of	O
deep	O
reflex	O
,	O
with	O
severe	O
paralysis	O
of	O
the	O
lower	O
extremity	O
and	O
mild	O
weakness	O
of	O
the	O
upper	O
extremity	O
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	B-ADR
ileus	I-ADR
,	O
neurogenic	O
bladder	O
,	O
mild	O
left	O
ptosis	O
,	O
and	O
absence	O
of	O
deep	O
reflex	O
,	O
with	O
severe	O
paralysis	O
of	O
the	O
lower	O
extremity	O
and	O
mild	O
weakness	O
of	O
the	O
upper	O
extremity	O
0	O
<EOS>	O
ten	O
day	O
after	O
itraconazole	B-Drug
wa	O
started	O
,	O
he	O
developed	O
paralytic	O
ileus	O
,	O
neurogenic	O
bladder	O
,	O
mild	O
left	O
ptosis	O
,	O
and	O
absence	O
of	O
deep	O
reflex	O
,	O
with	O
severe	B-ADR
paralysis	I-ADR
of	I-ADR
the	I-ADR
lower	I-ADR
extremity	I-ADR
and	O
mild	O
weakness	O
of	O
the	O
upper	O
extremity	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
any	O
proven	O
benefit	O
of	O
itraconazole	B-Drug
prophylaxis	O
,	O
and	O
given	O
the	O
interaction	O
of	O
this	O
drug	O
with	O
vincristine	O
leading	O
to	O
severe	O
and	O
even	O
potentially	O
fatal	B-ADR
toxicity	I-ADR
,	O
the	O
combination	O
use	O
of	O
these	O
drug	O
should	O
be	O
avoided	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
any	O
proven	O
benefit	O
of	O
itraconazole	O
prophylaxis	O
,	O
and	O
given	O
the	O
interaction	O
of	O
this	O
drug	O
with	O
vincristine	B-Drug
leading	O
to	O
severe	O
and	O
even	O
potentially	O
fatal	B-ADR
toxicity	I-ADR
,	O
the	O
combination	O
use	O
of	O
these	O
drug	O
should	O
be	O
avoided	O
0	O
<EOS>	O
case	O
report	O
:	O
we	O
report	O
a	O
case	O
of	O
intracerebral	B-ADR
hemorrhage	I-ADR
occurring	O
in	O
a	O
middle-aged	O
man	O
who	O
suffered	O
from	O
chronic	O
sinusitis	O
and	O
had	O
been	O
ingesting	O
pseudoephedrine	B-Drug
daily	O
for	O
one	O
year	O
0	O
<EOS>	O
only	O
one	O
report	O
link	O
phenylpropanolamine	B-Drug
consumption	O
to	O
an	O
intracerebral	B-ADR
hemorrhage	I-ADR
in	O
a	O
patient	O
with	O
an	O
avm	O
0	O
<EOS>	O
pseudoephedrine-induced	B-Drug
hemorrhage	O
associated	O
with	O
a	O
cerebral	B-ADR
vascular	I-ADR
malformation	I-ADR
0	O
<EOS>	O
pseudoephedrine-induced	B-Drug
hemorrhage	B-ADR
associated	O
with	O
a	O
cerebral	O
vascular	O
malformation	O
0	O
<EOS>	O
since	O
1979	O
,	O
over	O
30	O
published	O
case	O
report	O
have	O
documented	O
the	O
relationship	O
between	O
phenylpropanolamine	B-Drug
and	O
stroke	B-ADR
0	O
<EOS>	O
this	O
is	O
a	O
case	O
of	O
pseudoephedrine-induced	B-Drug
intracerebral	B-ADR
hemorrhage	I-ADR
in	O
a	O
patient	O
with	O
an	O
underlying	O
vascular	O
malformation	O
0	O
<EOS>	O
rapid	O
onset	O
of	O
quetiapine-induced	B-Drug
diabetic	B-ADR
ketoacidosis	I-ADR
in	O
an	O
elderly	O
patient	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
reversible	O
dka	B-ADR
and	O
new-onset	O
dm	O
that	O
developed	O
in	O
a	O
demented	O
patient	O
who	O
wa	O
treated	O
with	O
quetiapine	B-Drug
for	O
14	O
day	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
reversible	O
dka	O
and	O
new-onset	O
dm	B-ADR
that	O
developed	O
in	O
a	O
demented	O
patient	O
who	O
wa	O
treated	O
with	O
quetiapine	B-Drug
for	O
14	O
day	O
0	O
<EOS>	O
pulmonary	B-ADR
leukostasis	I-ADR
secondary	O
to	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
in	O
first	O
relapse	O
0	O
<EOS>	O
eruptive	B-ADR
epidermoid	I-ADR
cyst	I-ADR
resulting	O
from	O
treatment	O
with	O
imiquimod	B-Drug
0	O
<EOS>	O
method	O
:	O
a	O
79-year-old	O
woman	O
being	O
treated	O
with	O
imiquimod	B-Drug
5	O
day	O
per	O
week	O
for	O
a	O
nodular	O
basal	O
cell	O
developed	O
a	O
verrucous	B-ADR
plaque	I-ADR
over	O
the	O
treatment	O
area	O
after	O
7	O
week	O
of	O
therapy	O
0	O
<EOS>	O
the	O
multiple	B-ADR
comedo	I-ADR
and	O
ruptured	O
epidermoid	O
cyst	O
are	O
newly	O
reported	O
adverse	O
effect	O
of	O
imiquimod	B-Drug
therapy	O
0	O
<EOS>	O
the	O
multiple	O
comedo	O
and	O
ruptured	B-ADR
epidermoid	I-ADR
cyst	I-ADR
are	O
newly	O
reported	O
adverse	O
effect	O
of	O
imiquimod	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
an	O
unusual	O
case	O
of	O
massive	O
fluoxetine	B-Drug
ingestion	O
resulting	O
in	O
neurological	O
and	O
cardiovascular	O
toxicity	O
resulting	O
in	O
death	B-ADR
0	O
<EOS>	O
we	O
report	O
an	O
unusual	O
case	O
of	O
massive	O
fluoxetine	B-Drug
ingestion	O
resulting	O
in	O
neurological	B-ADR
and	I-ADR
cardiovascular	I-ADR
toxicity	I-ADR
resulting	O
in	O
death	O
0	O
<EOS>	O
hepatocellular	B-ADR
damage	I-ADR
following	O
therapeutic	O
intravenous	O
iron	B-Drug
sucrose	I-Drug
infusion	O
in	O
a	O
child	O
0	O
<EOS>	O
the	O
case	O
reported	O
here	O
is	O
of	O
a	O
child	O
given	O
a	O
large	O
dose	O
of	O
intravenous	O
iron	B-Drug
sucrose	I-Drug
(	O
16	O
mg	O
/	O
kg	O
)	O
over	O
3	O
hour	O
,	O
who	O
subsequently	O
developed	O
feature	O
of	O
systemic	B-ADR
iron	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
five	O
personal	O
observation	O
of	O
an	O
acute	B-ADR
amnestic	I-ADR
episode	I-ADR
in	O
younger	O
individual	O
after	O
intake	O
of	O
clioquinol	B-Drug
are	O
described	O
together	O
with	O
three	O
observation	O
from	O
the	O
medical	O
literature	O
0	O
<EOS>	O
the	O
clinical	O
aspect	O
closely	O
resembled	O
classical	O
transient	O
global	O
amnesia	O
but	O
the	O
episode	O
after	O
clioquinol	B-Drug
lasted	O
longer	O
(	O
24	O
hour	O
to	O
three	O
day	O
)	O
and	O
a	O
more	O
or	O
le	O
extensive	O
retrograde	B-ADR
amnesia	I-ADR
persisted	O
permanently	O
0	O
<EOS>	O
the	O
clinical	O
aspect	O
closely	O
resembled	O
classical	O
transient	B-ADR
global	I-ADR
amnesia	I-ADR
but	O
the	O
episode	O
after	O
clioquinol	B-Drug
lasted	O
longer	O
(	O
24	O
hour	O
to	O
three	O
day	O
)	O
and	O
a	O
more	O
or	O
le	O
extensive	O
retrograde	O
amnesia	O
persisted	O
permanently	O
0	O
<EOS>	O
transient	B-ADR
global	I-ADR
amnesia	I-ADR
after	O
clioquinol	B-Drug
:	O
five	O
personal	O
observation	O
from	O
outside	O
japan	O
0	O
<EOS>	O
in	O
the	O
other	O
patient	O
,	O
a	O
78-year-old	O
woman	O
,	O
neisseria	B-ADR
mucosa	I-ADR
knee	I-ADR
arthritis	I-ADR
occurred	O
after	O
a	O
single	O
sodium	B-Drug
hyaluronate	I-Drug
injection	O
0	O
<EOS>	O
one	O
patient	O
wa	O
an	O
80-year-old	O
woman	O
who	O
wa	O
admitted	O
for	O
staphylococcus	B-ADR
aureus	I-ADR
knee	I-ADR
arthritis	I-ADR
after	O
several	O
intraarticular	O
injection	O
of	O
sodium	O
hyaluronate	O
and	O
corticosteroid	B-Drug
0	O
<EOS>	O
one	O
patient	O
wa	O
an	O
80-year-old	O
woman	O
who	O
wa	O
admitted	O
for	O
staphylococcus	B-ADR
aureus	I-ADR
knee	I-ADR
arthritis	I-ADR
after	O
several	O
intraarticular	O
injection	O
of	O
sodium	B-Drug
hyaluronate	I-Drug
and	O
corticosteroid	O
0	O
<EOS>	O
septic	B-ADR
knee	I-ADR
arthritis	I-ADR
after	O
intra-articular	O
hyaluronate	B-Drug
injection	O
0	O
<EOS>	O
acute	B-ADR
dystonia	I-ADR
induced	O
by	O
lamivudine	B-Drug
0	O
<EOS>	O
adr	B-ADR
induced	O
by	O
drug	O
treatment	O
can	O
be	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
antipsychotic	O
drug	O
and	O
other	O
drug	O
;	O
however	O
,	O
there	O
have	O
been	O
no	O
report	O
of	O
lamivudine-induced	B-Drug
adr	O
in	O
the	O
english	O
literature	O
0	O
<EOS>	O
the	O
author	O
report	O
two	O
case	O
of	O
acute	B-ADR
dystonic	I-ADR
reaction	I-ADR
(	O
adrs	O
)	O
a	O
a	O
side	O
effect	O
of	O
lamivudine	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
two	O
case	O
of	O
acute	O
dystonic	O
reaction	O
(	O
adrs	B-ADR
)	O
a	O
a	O
side	O
effect	O
of	O
lamivudine	B-Drug
0	O
<EOS>	O
the	O
author	O
think	O
that	O
although	O
lamivudine	B-Drug
is	O
widely	O
used	O
and	O
well	O
tolerated	O
,	O
it	O
can	O
cause	O
adrs	B-ADR
,	O
which	O
are	O
reversible	O
after	O
drug	O
withdrawal	O
0	O
<EOS>	O
pleuropulmonary	B-ADR
fibrosis	I-ADR
after	O
long-term	O
treatment	O
with	O
the	O
dopamine	O
agonist	O
pergolide	B-Drug
for	O
parkinson	O
disease	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
observation	O
of	O
``	O
on-off	O
'	O
risperidone	B-Drug
treatment	O
suggests	O
that	O
risperidone	O
may	O
have	O
worsened	O
both	O
psychiatric	B-ADR
and	I-ADR
physical	I-ADR
manifestation	I-ADR
of	O
the	O
mitochondrial	O
disorder	O
in	O
this	O
adolescent	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
observation	O
of	O
``	O
on-off	O
'	O
risperidone	B-Drug
treatment	O
suggests	O
that	O
risperidone	O
may	O
have	O
worsened	O
both	O
psychiatric	B-ADR
and	I-ADR
physical	I-ADR
manifestation	I-ADR
of	O
the	O
mitochondrial	O
disorder	O
in	O
this	O
adolescent	O
0	O
<EOS>	O
objective	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
an	O
adolescent	O
girl	O
with	O
a	O
mitochondrial	O
disorder	O
and	O
depression	O
who	O
displayed	O
both	O
new-onset	O
psychotic	O
and	O
increased	B-ADR
mood	I-ADR
symptom	I-ADR
during	O
treatment	O
with	O
risperidone	B-Drug
0	O
<EOS>	O
risperidone-induced	B-Drug
psychosis	O
and	O
depression	B-ADR
in	O
a	O
child	O
with	O
a	O
mitochondrial	O
disorder	O
0	O
<EOS>	O
risperidone-induced	B-Drug
psychosis	B-ADR
and	O
depression	O
in	O
a	O
child	O
with	O
a	O
mitochondrial	O
disorder	O
0	O
<EOS>	O
fatal	B-ADR
radiation	I-ADR
myelopathy	I-ADR
after	O
high-dose	O
busulfan	B-Drug
and	O
melphalan	O
chemotherapy	O
and	O
radiotherapy	O
for	O
ewing	O
sarcoma	O
:	O
a	O
review	O
of	O
the	O
literature	O
and	O
implication	O
for	O
practice	O
0	O
<EOS>	O
fatal	B-ADR
radiation	I-ADR
myelopathy	I-ADR
after	O
high-dose	O
busulfan	O
and	O
melphalan	B-Drug
chemotherapy	O
and	O
radiotherapy	O
for	O
ewing	O
sarcoma	O
:	O
a	O
review	O
of	O
the	O
literature	O
and	O
implication	O
for	O
practice	O
0	O
<EOS>	O
gemcitabine-induced	B-Drug
pericardial	B-ADR
effusion	I-ADR
and	O
tamponade	O
after	O
unblocked	O
cardiac	O
irradiation	O
0	O
<EOS>	O
gemcitabine-induced	B-Drug
pericardial	O
effusion	O
and	O
tamponade	B-ADR
after	O
unblocked	O
cardiac	O
irradiation	O
0	O
<EOS>	O
gemcitabine	B-Drug
therapy	O
ha	O
been	O
associated	O
with	O
radiation	B-ADR
recall	I-ADR
reaction	I-ADR
when	O
used	O
in	O
the	O
treatment	O
of	O
carcinoma	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
developing	O
a	O
gemcitabine-induced	B-Drug
radiation	O
recall	O
reaction	O
resulting	O
in	O
hemodynamically	O
significant	O
pericardial	B-ADR
effusion	I-ADR
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
developing	O
a	O
gemcitabine-induced	B-Drug
radiation	B-ADR
recall	I-ADR
reaction	I-ADR
resulting	O
in	O
hemodynamically	O
significant	O
pericardial	O
effusion	O
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
hemodynamically	O
significant	O
pericardial	B-ADR
effusion	I-ADR
in	O
patient	O
with	O
refractory	O
lymphoma	O
who	O
were	O
receiving	O
gemcitabine	B-Drug
,	O
all	O
of	O
whom	O
had	O
a	O
history	O
of	O
mediastinal	O
radiation	O
without	O
subcarinal	O
blocking	O
0	O
<EOS>	O
a	O
patient	O
with	O
generalized	O
mg	O
wa	O
effectively	O
managed	O
with	O
mm	B-Drug
but	O
developed	O
cns	B-ADR
lymphoma	I-ADR
after	O
3	O
year	O
of	O
treatment	O
0	O
<EOS>	O
despite	O
minimal	O
short-term	O
side	O
effect	O
and	O
apparent	O
efficacy	O
,	O
chronic	O
treatment	O
of	O
mg	O
with	O
mm	B-Drug
may	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
lymphoproliferative	B-ADR
disorder	I-ADR
0	O
<EOS>	O
primary	O
cns	B-ADR
lymphoma	I-ADR
complicating	O
treatment	O
of	O
myasthenia	O
gravis	O
with	O
mycophenolate	B-Drug
mofetil	I-Drug
0	O
<EOS>	O
primary	O
cns	B-ADR
lymphoma	I-ADR
regressed	O
on	O
withdrawal	O
of	O
mm	B-Drug
0	O
<EOS>	O
baclofen	B-Drug
withdrawal	O
:	O
a	O
cause	O
of	O
prolonged	O
fever	B-ADR
in	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
baclofen	B-Drug
withdrawal	B-ADR
syndrome	I-ADR
resulting	O
from	O
underdosing	O
of	O
oral	O
baclofen	O
should	O
be	O
considered	O
a	O
a	O
potential	O
source	O
of	O
prolonged	O
fever	O
in	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
baclofen	B-Drug
withdrawal	B-ADR
syndrome	I-ADR
resulting	O
from	O
underdosing	O
of	O
oral	O
baclofen	O
should	O
be	O
considered	O
a	O
a	O
potential	O
source	O
of	O
prolonged	O
fever	O
in	O
the	O
intensive	O
care	O
unit	O
0	O
<EOS>	O
the	O
patient	O
continued	O
to	O
have	O
fever	O
and	O
autonomic	B-ADR
instability	I-ADR
without	O
evidence	O
of	O
infection	O
which	O
entirely	O
resolved	O
within	O
24	O
hour	O
of	O
reinstitution	O
of	O
full	O
preadmission	O
dosing	O
of	O
oral	O
baclofen	B-Drug
0	O
<EOS>	O
the	O
patient	O
continued	O
to	O
have	O
fever	B-ADR
and	O
autonomic	O
instability	O
without	O
evidence	O
of	O
infection	O
which	O
entirely	O
resolved	O
within	O
24	O
hour	O
of	O
reinstitution	O
of	O
full	O
preadmission	O
dosing	O
of	O
oral	O
baclofen	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
baclofen	B-Drug
withdrawal	B-ADR
syndrome	I-ADR
resulting	O
from	O
oral	O
baclofen	O
underdosing	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
baclofen	B-Drug
withdrawal	B-ADR
syndrome	I-ADR
resulting	O
from	O
oral	O
baclofen	O
underdosing	O
0	O
<EOS>	O
after	O
discontinuing	O
captopril	B-Drug
and	O
starting	O
systemic	O
steroid	O
,	O
her	O
symptomatology	O
rapidly	O
improved	O
,	O
and	O
her	O
eosinophilia	B-ADR
and	O
radiographic	O
abnormality	O
both	O
resolved	O
0	O
<EOS>	O
after	O
discontinuing	O
captopril	B-Drug
and	O
starting	O
systemic	O
steroid	O
,	O
her	O
symptomatology	O
rapidly	O
improved	O
,	O
and	O
her	O
eosinophilia	O
and	O
radiographic	B-ADR
abnormality	I-ADR
both	O
resolved	O
0	O
<EOS>	O
captopril-induced	B-Drug
pulmonary	B-ADR
infiltrates	I-ADR
with	I-ADR
eosinophilia	I-ADR
in	O
an	O
infant	O
with	O
congenital	O
heart	O
disease	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
an	O
infant	O
with	O
complex	O
congenital	O
heart	O
disease	O
who	O
wa	O
placed	O
on	O
captopril	B-Drug
for	O
afterload	O
reduction	O
following	O
cardiac	O
surgery	O
and	O
subsequently	O
developed	O
pulmonary	B-ADR
infiltrates	I-ADR
with	I-ADR
eosinophilia	I-ADR
0	O
<EOS>	O
can	O
propofol	B-Drug
precipitate	O
pancreatitis	B-ADR
in	O
patient	O
with	O
cushing	O
syndrome	O
?	O
<EOS>	O
since	O
elevated	O
cortisol	O
level	O
in	O
cushing	O
disease	O
pose	O
a	O
threat	O
for	O
pancreatitis	O
,	O
there	O
is	O
a	O
possibility	O
that	O
patient	O
with	O
cushing	O
disease	O
might	O
be	O
more	O
prone	O
to	O
acute	B-ADR
pancreatitis	I-ADR
following	O
propofol	B-Drug
administration	O
0	O
<EOS>	O
since	O
recent	O
study	O
have	O
reported	O
no	O
negative	O
interaction	O
with	O
concurrent	O
use	O
,	O
we	O
here	O
report	O
three	O
case	O
(	O
one	O
case	O
of	O
a	O
prolonged	O
seizure	O
,	O
a	O
serotonin	O
syndrome	O
and	O
a	O
focal	B-ADR
seizure	I-ADR
)	O
of	O
severe	O
lithium-induced	B-Drug
side	O
effect	O
while	O
patient	O
underwent	O
ect	O
without	O
complication	O
and	O
lithium	O
serum	O
level	O
were	O
still	O
subtherapeutic	O
0	O
<EOS>	O
since	O
recent	O
study	O
have	O
reported	O
no	O
negative	O
interaction	O
with	O
concurrent	O
use	O
,	O
we	O
here	O
report	O
three	O
case	O
(	O
one	O
case	O
of	O
a	O
prolonged	B-ADR
seizure	I-ADR
,	O
a	O
serotonin	O
syndrome	O
and	O
a	O
focal	O
seizure	O
)	O
of	O
severe	O
lithium-induced	B-Drug
side	O
effect	O
while	O
patient	O
underwent	O
ect	O
without	O
complication	O
and	O
lithium	O
serum	O
level	O
were	O
still	O
subtherapeutic	O
0	O
<EOS>	O
since	O
recent	O
study	O
have	O
reported	O
no	O
negative	O
interaction	O
with	O
concurrent	O
use	O
,	O
we	O
here	O
report	O
three	O
case	O
(	O
one	O
case	O
of	O
a	O
prolonged	O
seizure	O
,	O
a	O
serotonin	B-ADR
syndrome	I-ADR
and	O
a	O
focal	O
seizure	O
)	O
of	O
severe	O
lithium-induced	B-Drug
side	O
effect	O
while	O
patient	O
underwent	O
ect	O
without	O
complication	O
and	O
lithium	O
serum	O
level	O
were	O
still	O
subtherapeutic	O
0	O
<EOS>	O
cd20-negative	B-ADR
t-cell-rich	I-ADR
b-cell	I-ADR
lymphoma	I-ADR
a	O
a	O
progression	O
of	O
a	O
nodular	O
lymphocyte-predominant	O
hodgkin	O
lymphoma	O
treated	O
with	O
rituximab	B-Drug
:	O
a	O
molecular	O
analysis	O
using	O
laser	O
capture	O
microdissection	O
0	O
<EOS>	O
recently	O
,	O
cd20-negative	B-ADR
tumor	I-ADR
have	O
been	O
described	O
after	O
rituximab	B-Drug
therapy	O
0	O
<EOS>	O
a	O
51-year	O
old	O
physically	O
fit	O
woman	O
experienced	O
angio-oedema	B-ADR
and	O
hypotensive	O
shock	O
after	O
irbesartan	B-Drug
ingestion	O
requiring	O
noradrenaline	O
infusion	O
0	O
<EOS>	O
a	O
51-year	O
old	O
physically	O
fit	O
woman	O
experienced	O
angio-oedema	O
and	O
hypotensive	B-ADR
shock	I-ADR
after	O
irbesartan	B-Drug
ingestion	O
requiring	O
noradrenaline	O
infusion	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
our	O
report	O
is	O
one	O
of	O
the	O
first	O
on	O
shock	O
and	O
angio-oedema	B-ADR
from	O
irbesartan	B-Drug
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
our	O
report	O
is	O
one	O
of	O
the	O
first	O
on	O
shock	B-ADR
and	O
angio-oedema	O
from	O
irbesartan	B-Drug
0	O
<EOS>	O
she	O
died	O
within	O
six	O
week	O
of	O
developing	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
coupled	O
with	O
liver	O
failure	O
due	O
to	O
haemosiderosis	O
despite	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
0	O
<EOS>	O
she	O
died	O
within	O
six	O
week	O
of	O
developing	O
congestive	O
heart	O
failure	O
coupled	O
with	O
liver	O
failure	O
due	O
to	O
haemosiderosis	B-ADR
despite	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
0	O
<EOS>	O
she	O
died	O
within	O
six	O
week	O
of	O
developing	O
congestive	O
heart	O
failure	O
coupled	O
with	O
liver	B-ADR
failure	I-ADR
due	O
to	O
haemosiderosis	O
despite	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
0	O
<EOS>	O
transfusion	B-ADR
haemosiderosis	I-ADR
inspite	O
of	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
:	O
case	O
report	O
0	O
<EOS>	O
one	O
of	O
the	O
side-effects	O
of	O
intravitreal	O
triamcinolone	B-Drug
is	O
the	O
development	O
of	O
cataract	B-ADR
,	O
and	O
it	O
is	O
known	O
that	O
cataract	O
extraction	O
can	O
exacerbate	O
macular	O
degeneration	O
0	O
<EOS>	O
severe	O
loss	O
of	O
vision	O
after	O
removal	O
of	O
cataract	B-ADR
caused	O
by	O
intravitreal	O
triamcinolone	B-Drug
in	O
combination	O
with	O
photodynamic	O
therapy	O
for	O
exudative	O
age-related	O
macular	O
degeneration	O
0	O
<EOS>	O
severe	B-ADR
loss	I-ADR
of	I-ADR
vision	I-ADR
after	O
removal	O
of	O
cataract	O
caused	O
by	O
intravitreal	O
triamcinolone	B-Drug
in	O
combination	O
with	O
photodynamic	O
therapy	O
for	O
exudative	O
age-related	O
macular	O
degeneration	O
0	O
<EOS>	O
rhabdomyolysis	B-ADR
caused	O
by	O
tocolysis	O
with	O
oral	O
ritodrine	B-Drug
hydrochloride	I-Drug
in	O
a	O
pregnant	O
patient	O
with	O
myotonic	O
dystrophy	O
0	O
<EOS>	O
rhabdomyolysis	B-ADR
ha	O
been	O
recognized	O
a	O
a	O
complication	O
of	O
tocolytic	O
therapy	O
with	O
ritodrine	B-Drug
hydrochloride	I-Drug
0	O
<EOS>	O
we	O
report	O
here	O
a	O
rare	O
case	O
of	O
ritodrine-hydrochloride-induced	B-Drug
rhabdomyolysis	B-ADR
in	O
a	O
pregnant	O
patient	O
with	O
myotonic	O
dystrophy	O
0	O
<EOS>	O
acute	B-ADR
myocardial	I-ADR
ischemia	I-ADR
following	O
accidental	O
intravenous	O
administration	O
of	O
epinephrine	B-Drug
in	O
high	O
concentration	O
0	O
<EOS>	O
inadvertent	O
and	O
accidental	O
epinephrine	B-Drug
overdose	O
might	O
result	O
in	O
potentially	O
lethal	B-ADR
complication	I-ADR
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
acute	O
epinephrine	B-Drug
toxicity	O
resulting	O
in	O
acute	B-ADR
myocardial	I-ADR
ischemia	I-ADR
in	O
a	O
young	O
boy	O
with	O
combined	O
variable	O
immunodeficiency	O
syndrome	O
who	O
developed	O
severe	O
allergic	O
reaction	O
to	O
intravenous	O
immunoglobulin	O
,	O
and	O
wa	O
subsequently	O
given	O
epinephrine	O
by	O
mistake	O
intravenously	O
rather	O
than	O
subcutaneously	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
acute	O
epinephrine	B-Drug
toxicity	O
resulting	O
in	O
acute	O
myocardial	O
ischemia	O
in	O
a	O
young	O
boy	O
with	O
combined	O
variable	O
immunodeficiency	O
syndrome	O
who	O
developed	O
severe	B-ADR
allergic	I-ADR
reaction	I-ADR
to	O
intravenous	O
immunoglobulin	O
,	O
and	O
wa	O
subsequently	O
given	O
epinephrine	O
by	O
mistake	O
intravenously	O
rather	O
than	O
subcutaneously	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
acute	O
epinephrine	B-Drug
toxicity	O
resulting	O
in	O
acute	O
myocardial	O
ischemia	O
in	O
a	O
young	O
boy	O
with	O
combined	O
variable	O
immunodeficiency	O
syndrome	O
who	O
developed	O
severe	B-ADR
allergic	I-ADR
reaction	I-ADR
to	O
intravenous	O
immunoglobulin	O
,	O
and	O
wa	O
subsequently	O
given	O
epinephrine	O
by	O
mistake	O
intravenously	O
rather	O
than	O
subcutaneously	O
0	O
<EOS>	O
polysomnographic	O
and	O
pharmacokinetic	O
finding	O
in	O
levodopa-induced	B-Drug
augmentation	O
of	O
restless	B-ADR
leg	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
symptom	O
and	O
sign	O
of	O
augmentation	B-ADR
were	O
related	O
to	O
low	O
plasma	O
levodopa	B-Drug
level	O
,	O
abating	O
75	O
minute	O
after	O
oral	O
levodopa	O
administration	O
and	O
reappearing	O
after	O
3	O
hour	O
,	O
closely	O
mirroring	O
the	O
rapid	O
rise	O
and	O
fall	O
of	O
plasma	O
levodopa	O
concentration	O
0	O
<EOS>	O
symptom	O
and	O
sign	O
of	O
augmentation	B-ADR
were	O
related	O
to	O
low	O
plasma	O
levodopa	B-Drug
level	O
,	O
abating	O
75	O
minute	O
after	O
oral	O
levodopa	O
administration	O
and	O
reappearing	O
after	O
3	O
hour	O
,	O
closely	O
mirroring	O
the	O
rapid	O
rise	O
and	O
fall	O
of	O
plasma	O
levodopa	O
concentration	O
0	O
<EOS>	O
videopolysomnographic	O
and	O
pharmacokinetic	O
study	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
level	O
demonstrated	O
marked	O
motor	O
hyperactivity	O
during	O
augmentation	O
,	O
with	O
anarchic	B-ADR
discharge	I-ADR
of	I-ADR
motor	I-ADR
unit	I-ADR
potential	I-ADR
,	O
tonic	O
grouped	O
discharge	O
and	O
flexor	O
spasm	O
,	O
associated	O
with	O
painful	O
dysesthesia	O
0	O
<EOS>	O
videopolysomnographic	O
and	O
pharmacokinetic	O
study	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
level	O
demonstrated	O
marked	O
motor	O
hyperactivity	O
during	O
augmentation	O
,	O
with	O
anarchic	O
discharge	O
of	O
motor	O
unit	O
potential	O
,	O
tonic	O
grouped	O
discharge	O
and	O
flexor	B-ADR
spasm	I-ADR
,	O
associated	O
with	O
painful	O
dysesthesia	O
0	O
<EOS>	O
videopolysomnographic	O
and	O
pharmacokinetic	O
study	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
level	O
demonstrated	O
marked	B-ADR
motor	I-ADR
hyperactivity	I-ADR
during	O
augmentation	O
,	O
with	O
anarchic	O
discharge	O
of	O
motor	O
unit	O
potential	O
,	O
tonic	O
grouped	O
discharge	O
and	O
flexor	O
spasm	O
,	O
associated	O
with	O
painful	O
dysesthesia	O
0	O
<EOS>	O
videopolysomnographic	O
and	O
pharmacokinetic	O
study	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
level	O
demonstrated	O
marked	O
motor	O
hyperactivity	O
during	O
augmentation	O
,	O
with	O
anarchic	O
discharge	O
of	O
motor	O
unit	O
potential	O
,	O
tonic	O
grouped	O
discharge	O
and	O
flexor	O
spasm	O
,	O
associated	O
with	O
painful	B-ADR
dysesthesia	I-ADR
0	O
<EOS>	O
videopolysomnographic	O
and	O
pharmacokinetic	O
study	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
level	O
demonstrated	O
marked	O
motor	O
hyperactivity	O
during	O
augmentation	O
,	O
with	O
anarchic	O
discharge	O
of	O
motor	O
unit	O
potential	O
,	O
tonic	B-ADR
grouped	I-ADR
discharge	I-ADR
and	O
flexor	O
spasm	O
,	O
associated	O
with	O
painful	O
dysesthesia	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
idiopathic	O
rls	O
who	O
developed	O
augmentation	B-ADR
after	O
8	O
month	O
of	O
levodopa	B-Drug
treatment	O
0	O
<EOS>	O
the	O
major	O
side	O
effect	O
of	O
infliximab	B-Drug
is	O
infection	B-ADR
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
probable	O
case	O
of	O
infliximab-induced	B-Drug
membranous	B-ADR
nephropathy	I-ADR
0	O
<EOS>	O
linezolid-induced	B-Drug
dyserythropoiesis	B-ADR
:	O
chloramphenicol	O
toxicity	O
revisited	O
0	O
<EOS>	O
we	O
report	O
here	O
two	O
case	O
of	O
dyserythropoietic	B-ADR
anaemia	I-ADR
associated	O
with	O
long-term	O
linezolid	B-Drug
use	O
that	O
share	O
striking	O
similarity	O
to	O
chloramphenicol-associated	O
myelotoxicity	O
0	O
<EOS>	O
we	O
report	O
here	O
two	O
case	O
of	O
dyserythropoietic	O
anaemia	O
associated	O
with	O
long-term	O
linezolid	O
use	O
that	O
share	O
striking	O
similarity	O
to	O
chloramphenicol-associated	B-Drug
myelotoxicity	B-ADR
0	O
<EOS>	O
a	O
selective	O
association	O
between	O
fluoxetine	B-Drug
and	O
extensive	O
,	O
prominent	O
eye	B-ADR
movement	I-ADR
in	I-ADR
nonrapid	I-ADR
eye	I-ADR
movement	I-ADR
(	I-ADR
nrem	I-ADR
)	I-ADR
sleep	I-ADR
wa	O
detected	O
,	O
utilizing	O
fisher	O
exact	O
one-tailed	O
statistic	O
(	O
p	O
le	O
than	O
0.00001	O
for	O
each	O
comparison	O
)	O
0	O
<EOS>	O
in	O
addition	O
,	O
a	O
31-year-old	O
man	O
with	O
obsessive-compulsive	O
disorder	O
developed	O
rbd	B-ADR
soon	O
after	O
starting	O
fluoxetine	B-Drug
therapy	O
,	O
which	O
persisted	O
at	O
psg	O
study	O
19	O
month	O
after	O
fluoxetine	O
discontinuation	O
0	O
<EOS>	O
in	O
addition	O
,	O
a	O
31-year-old	O
man	O
with	O
obsessive-compulsive	O
disorder	O
developed	O
rbd	B-ADR
soon	O
after	O
starting	O
fluoxetine	B-Drug
therapy	O
,	O
which	O
persisted	O
at	O
psg	O
study	O
19	O
month	O
after	O
fluoxetine	O
discontinuation	O
0	O
<EOS>	O
prominent	B-ADR
eye	I-ADR
movement	I-ADR
during	I-ADR
nrem	I-ADR
sleep	I-ADR
and	O
rem	O
sleep	O
behavior	O
disorder	O
associated	O
with	O
fluoxetine	B-Drug
treatment	O
of	O
depression	O
and	O
obsessive-compulsive	O
disorder	O
0	O
<EOS>	O
prominent	O
eye	O
movement	O
during	O
nrem	O
sleep	O
and	O
rem	B-ADR
sleep	I-ADR
behavior	I-ADR
disorder	I-ADR
associated	O
with	O
fluoxetine	B-Drug
treatment	O
of	O
depression	O
and	O
obsessive-compulsive	O
disorder	O
0	O
<EOS>	O
because	O
of	O
serious	O
side	O
effect	O
of	O
an	O
increase	B-ADR
in	I-ADR
the	I-ADR
qt	I-ADR
interval	I-ADR
causing	O
torsades	O
de	O
pointes	O
,	O
dofetilide	B-Drug
must	O
be	O
initiated	O
with	O
close	O
monitoring	O
of	O
the	O
qt	O
interval	O
in	O
an	O
inpatient	O
setting	O
0	O
<EOS>	O
because	O
of	O
serious	O
side	O
effect	O
of	O
an	O
increase	O
in	O
the	O
qt	O
interval	O
causing	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
,	O
dofetilide	B-Drug
must	O
be	O
initiated	O
with	O
close	O
monitoring	O
of	O
the	O
qt	O
interval	O
in	O
an	O
inpatient	O
setting	O
0	O
<EOS>	O
marked	O
qt	O
prolongation	O
and	O
torsades	O
de	O
pointes	O
secondary	O
to	O
acute	B-ADR
ischemia	I-ADR
in	O
an	O
elderly	O
man	O
taking	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
:	O
a	O
cautionary	O
tale	O
0	O
<EOS>	O
marked	B-ADR
qt	I-ADR
prolongation	I-ADR
and	O
torsades	O
de	O
pointes	O
secondary	O
to	O
acute	O
ischemia	O
in	O
an	O
elderly	O
man	O
taking	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
:	O
a	O
cautionary	O
tale	O
0	O
<EOS>	O
marked	O
qt	O
prolongation	O
and	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
secondary	O
to	O
acute	O
ischemia	O
in	O
an	O
elderly	O
man	O
taking	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
:	O
a	O
cautionary	O
tale	O
0	O
<EOS>	O
we	O
report	O
marked	O
qt	O
prolongation	O
and	O
torsades	O
de	O
pointes	O
in	O
a	O
setting	O
of	O
flash	O
pulmonary	O
edema	O
resulting	O
from	O
acute	B-ADR
myocardial	I-ADR
ischemia	I-ADR
in	O
a	O
patient	O
who	O
wa	O
being	O
treated	O
with	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
0	O
<EOS>	O
we	O
report	O
marked	O
qt	O
prolongation	O
and	O
torsades	O
de	O
pointes	O
in	O
a	O
setting	O
of	O
flash	B-ADR
pulmonary	I-ADR
edema	I-ADR
resulting	O
from	O
acute	O
myocardial	O
ischemia	O
in	O
a	O
patient	O
who	O
wa	O
being	O
treated	O
with	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
0	O
<EOS>	O
we	O
report	O
marked	O
qt	B-ADR
prolongation	I-ADR
and	O
torsades	O
de	O
pointes	O
in	O
a	O
setting	O
of	O
flash	O
pulmonary	O
edema	O
resulting	O
from	O
acute	O
myocardial	O
ischemia	O
in	O
a	O
patient	O
who	O
wa	O
being	O
treated	O
with	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
0	O
<EOS>	O
we	O
report	O
marked	O
qt	O
prolongation	O
and	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
in	O
a	O
setting	O
of	O
flash	O
pulmonary	O
edema	O
resulting	O
from	O
acute	O
myocardial	O
ischemia	O
in	O
a	O
patient	O
who	O
wa	O
being	O
treated	O
with	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
0	O
<EOS>	O
prominent	O
positive	B-ADR
u	I-ADR
wave	I-ADR
appearing	O
with	O
high-dose	O
intravenous	O
phenylephrine	B-Drug
0	O
<EOS>	O
while	O
on	O
a	O
maximal	O
dose	O
of	O
phenylephrine	B-Drug
she	O
developed	O
prominent	O
positive	B-ADR
u	I-ADR
wave	I-ADR
,	O
which	O
disappeared	O
with	O
the	O
cessation	O
of	O
the	O
drug	O
0	O
<EOS>	O
hepatoxicity	B-ADR
is	O
a	O
rare	O
complication	O
of	O
srl	B-Drug
therapy	O
and	O
may	O
be	O
connected	O
with	O
some	O
diagnostic	O
and	O
/	O
or	O
therapeutic	O
problem	O
0	O
<EOS>	O
sirolimus-associated	B-Drug
hepatotoxicity	B-ADR
in	O
the	O
kidney	O
graft	O
recipient	O
0	O
<EOS>	O
the	O
aim	O
of	O
our	O
paper	O
wa	O
to	O
describe	O
hepatotoxicity	B-ADR
of	O
sirolimus	B-Drug
(	O
srl	O
)	O
in	O
a	O
kidney	O
graft	O
recipient	O
0	O
<EOS>	O
case	O
report	O
:	O
we	O
present	O
a	O
case	O
of	O
a	O
28-yr-old	O
male	O
who	O
developed	O
a	O
severe	O
case	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
while	O
being	O
treated	O
for	O
relapsing	O
/	O
remitting	O
multiple	O
sclerosis	O
(	O
rrms	O
)	O
with	O
weekly	O
injection	O
of	O
interferon	B-Drug
beta	I-Drug
1a	I-Drug
0	O
<EOS>	O
nephrotic	B-ADR
syndrome	I-ADR
in	O
a	O
multiple	O
sclerosis	O
patient	O
treated	O
with	O
interferon	B-Drug
beta	I-Drug
1a	I-Drug
0	O
<EOS>	O
subsequent	O
course	O
:	O
the	O
nephrosis	B-ADR
resolved	O
almost	O
completely	O
once	O
the	O
interferon	B-Drug
wa	O
stopped	O
and	O
after	O
immunosuppressive	O
treatment	O
0	O
<EOS>	O
this	O
latest	O
(	O
third	O
)	O
report	O
suggests	O
that	O
the	O
safety	O
profile	O
should	O
be	O
reexamined	O
and	O
at	O
least	O
raise	O
the	O
question	O
of	O
potential	O
renal	B-ADR
toxicity	I-ADR
of	O
interferon	B-Drug
in	O
m	O
0	O
<EOS>	O
capecitabine-induced	B-Drug
multifocal	B-ADR
leukoencephalopathy	I-ADR
:	O
a	O
report	O
of	O
five	O
case	O
0	O
<EOS>	O
the	O
author	O
report	O
five	O
additional	O
case	O
of	O
capecitabine-induced	B-Drug
multifocal	B-ADR
leukoencephalopathy	I-ADR
0	O
<EOS>	O
a	O
56-year-old	O
white	O
woman	O
with	O
a	O
diagnosis	O
of	O
reactive	O
depression	O
developed	O
severe	O
ui	B-ADR
after	O
a	O
30	O
day	O
	O
treatment	O
with	O
venlafaxine	B-Drug
75	O
mg	O
/	O
day	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
urinary	O
incontinence	O
(	O
ui	B-ADR
)	O
that	O
occurred	O
in	O
a	O
woman	O
after	O
administration	O
of	O
venlafaxine	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
urinary	B-ADR
incontinence	I-ADR
(	O
ui	O
)	O
that	O
occurred	O
in	O
a	O
woman	O
after	O
administration	O
of	O
venlafaxine	B-Drug
0	O
<EOS>	O
venlafaxine-induced	B-Drug
urinary	B-ADR
incontinence	I-ADR
resolved	O
after	O
switching	O
to	O
sertraline	O
0	O
<EOS>	O
diagnosis	O
of	O
hypothyroidism	B-ADR
during	O
treatment	O
can	O
be	O
difficult	O
because	O
of	O
the	O
common	O
side	O
effect	O
of	O
alpha	B-Drug
interferon	I-Drug
0	O
<EOS>	O
sustained	B-ADR
hypothyroidism	I-ADR
induced	O
by	O
recombinant	B-Drug
alpha	I-Drug
interferon	I-Drug
in	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
thyroid	B-ADR
dysfunction	I-ADR
ha	O
been	O
reported	O
in	O
patient	O
with	O
malignant	O
disease	O
treated	O
with	O
recombinant	B-Drug
alpha	I-Drug
interferon	I-Drug
0	O
<EOS>	O
two	O
case	O
of	O
hypothyroidism	B-ADR
in	O
patient	O
with	O
chronic	O
hepatitis	O
c	O
treated	O
with	O
recombinant	B-Drug
alpha	I-Drug
interferon	I-Drug
are	O
reported	O
0	O
<EOS>	O
atrial	B-ADR
fibrillation	I-ADR
after	O
vardenafil	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
admitted	O
with	O
a	O
first-detected	O
,	O
symptomatic	B-ADR
paroxysmal	I-ADR
atrial	I-ADR
fibrillation	I-ADR
in	O
a	O
healthy	O
patient	O
after	O
self-medication	O
with	O
vardenafil	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
infection	O
with	O
mycobacterium	B-ADR
abscessus	I-ADR
in	O
a	O
67-year-old	O
woman	O
receiving	O
infliximab	B-Drug
a	O
a	O
component	O
of	O
her	O
therapy	O
for	O
ra	O
0	O
<EOS>	O
diagnosis	O
:	O
interferon	B-Drug
alpha-2b-induced	I-Drug
cardiomyopathy	B-ADR
0	O
<EOS>	O
reversible	B-ADR
cardiomyopathy	I-ADR
caused	O
by	O
administration	O
of	O
interferon	B-Drug
alpha	I-Drug
0	O
<EOS>	O
in	O
this	O
case	O
senna	B-Drug
wa	O
likely	O
the	O
cause	O
of	O
a	O
subacute	O
cholestatic	O
hepatitis	O
exemplifying	O
again	O
the	O
potential	O
role	O
of	O
herbal	O
related	O
liver	B-ADR
injury	I-ADR
0	O
<EOS>	O
in	O
this	O
case	O
senna	B-Drug
wa	O
likely	O
the	O
cause	O
of	O
a	O
subacute	B-ADR
cholestatic	I-ADR
hepatitis	I-ADR
exemplifying	O
again	O
the	O
potential	O
role	O
of	O
herbal	O
related	O
liver	O
injury	O
0	O
<EOS>	O
subacute	B-ADR
cholestatic	I-ADR
hepatitis	I-ADR
likely	O
related	O
to	O
the	O
use	O
of	O
senna	B-Drug
for	O
chronic	O
constipation	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
senna-induced	B-Drug
cholestatic	B-ADR
hepatitis	I-ADR
which	O
wa	O
not	O
diagnosed	O
at	O
presentation	O
0	O
<EOS>	O
based	O
on	O
the	O
history	O
and	O
clinical	O
feature	O
,	O
a	O
diagnosis	O
of	O
insulin-induced	B-Drug
lipohypertrophy	B-ADR
wa	O
made	O
0	O
<EOS>	O
insulin-induced	B-Drug
lipohypertrophy	B-ADR
:	O
report	O
of	O
a	O
case	O
with	O
histopathology	O
0	O
<EOS>	O
thus	O
,	O
the	O
possible	O
in	O
vivo	O
effect	O
of	O
insulin	O
on	O
adipocytes	O
were	O
clearly	O
observed	O
in	O
this	O
case	O
of	O
insulin-induced	B-Drug
lipohypertrophy	B-ADR
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
insulin-induced	B-Drug
lipohypertrophy	B-ADR
with	O
detailed	O
histological	O
examination	O
0	O
<EOS>	O
a	O
7-year-old	O
girl	O
developed	O
diabetes	B-ADR
mellitus	I-ADR
and	O
exocrine	O
pancreatic	O
insufficiency	O
after	O
3.5	O
year	O
of	O
almost	O
continuous	O
treatment	O
with	O
azathioprine	B-Drug
and	O
/	O
or	O
prednisone	O
for	O
idiopathic	O
auto-immune	O
haemolytic	O
anaemia	O
0	O
<EOS>	O
a	O
7-year-old	O
girl	O
developed	O
diabetes	B-ADR
mellitus	I-ADR
and	O
exocrine	O
pancreatic	O
insufficiency	O
after	O
3.5	O
year	O
of	O
almost	O
continuous	O
treatment	O
with	O
azathioprine	O
and	O
/	O
or	O
prednisone	B-Drug
for	O
idiopathic	O
auto-immune	O
haemolytic	O
anaemia	O
0	O
<EOS>	O
a	O
7-year-old	O
girl	O
developed	O
diabetes	O
mellitus	O
and	O
exocrine	B-ADR
pancreatic	I-ADR
insufficiency	I-ADR
after	O
3.5	O
year	O
of	O
almost	O
continuous	O
treatment	O
with	O
azathioprine	B-Drug
and	O
/	O
or	O
prednisone	O
for	O
idiopathic	O
auto-immune	O
haemolytic	O
anaemia	O
0	O
<EOS>	O
a	O
7-year-old	O
girl	O
developed	O
diabetes	O
mellitus	O
and	O
exocrine	B-ADR
pancreatic	I-ADR
insufficiency	I-ADR
after	O
3.5	O
year	O
of	O
almost	O
continuous	O
treatment	O
with	O
azathioprine	O
and	O
/	O
or	O
prednisone	B-Drug
for	O
idiopathic	O
auto-immune	O
haemolytic	O
anaemia	O
0	O
<EOS>	O
an	O
objective	O
causality	O
assessment	O
suggests	O
that	O
the	O
jhr	B-ADR
in	O
our	O
patient	O
wa	O
probably	O
related	O
to	O
penicillin	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
45-year-old	O
hiv-positive	O
man	O
(	O
cd4+	O
count	O
450	O
cell	O
/	O
mm	O
(	O
3	O
)	O
and	O
history	O
of	O
aids-defining	O
illness	O
)	O
presented	O
with	O
jhr	B-ADR
after	O
an	O
initial	O
intravenous	O
dose	O
of	O
penicillin	B-Drug
g	I-Drug
for	O
presumed	O
neurosyphilis	O
0	O
<EOS>	O
penicillin-induced	B-Drug
jarisch-herxheimer	B-ADR
reaction	I-ADR
0	O
<EOS>	O
the	O
patient	O
described	O
feeling	O
cold	O
with	O
worsening	O
headache	O
and	O
chill	B-ADR
approximately	O
one	O
hour	O
after	O
infusion	O
of	O
the	O
first	O
dose	O
of	O
penicillin	B-Drug
0	O
<EOS>	O
the	O
patient	O
described	O
feeling	B-ADR
cold	I-ADR
with	O
worsening	O
headache	O
and	O
chill	O
approximately	O
one	O
hour	O
after	O
infusion	O
of	O
the	O
first	O
dose	O
of	O
penicillin	B-Drug
0	O
<EOS>	O
the	O
patient	O
described	O
feeling	O
cold	O
with	O
worsening	B-ADR
headache	I-ADR
and	O
chill	O
approximately	O
one	O
hour	O
after	O
infusion	O
of	O
the	O
first	O
dose	O
of	O
penicillin	B-Drug
0	O
<EOS>	O
acute	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
after	O
rituximab	B-Drug
infusion	O
0	O
<EOS>	O
ards	B-ADR
ha	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibody	O
,	O
such	O
a	O
infliximab	O
,	O
gemtuzumab	B-Drug
ozogamicin	I-Drug
,	O
and	O
okt3	O
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokine	O
0	O
<EOS>	O
ards	B-ADR
ha	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibody	O
,	O
such	O
a	O
infliximab	B-Drug
,	O
gemtuzumab	O
ozogamicin	O
,	O
and	O
okt3	O
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokine	O
0	O
<EOS>	O
ards	B-ADR
ha	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibody	O
,	O
such	O
a	O
infliximab	O
,	O
gemtuzumab	O
ozogamicin	O
,	O
and	O
okt3	B-Drug
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokine	O
0	O
<EOS>	O
ards	B-ADR
is	O
rarely	O
associated	O
with	O
rituximab	B-Drug
infusion	O
for	O
lympho-proliferative	O
disorder	O
,	O
but	O
it	O
should	O
be	O
considered	O
by	O
those	O
administering	O
rituximab	O
,	O
especially	O
when	O
a	O
patient	O
develops	O
severe	O
pulmonary	O
symptom	O
soon	O
after	O
infusion	O
0	O
<EOS>	O
ards	B-ADR
is	O
rarely	O
associated	O
with	O
rituximab	B-Drug
infusion	O
for	O
lympho-proliferative	O
disorder	O
,	O
but	O
it	O
should	O
be	O
considered	O
by	O
those	O
administering	O
rituximab	O
,	O
especially	O
when	O
a	O
patient	O
develops	O
severe	O
pulmonary	O
symptom	O
soon	O
after	O
infusion	O
0	O
<EOS>	O
ards	O
is	O
rarely	O
associated	O
with	O
rituximab	B-Drug
infusion	O
for	O
lympho-proliferative	O
disorder	O
,	O
but	O
it	O
should	O
be	O
considered	O
by	O
those	O
administering	O
rituximab	O
,	O
especially	O
when	O
a	O
patient	O
develops	O
severe	B-ADR
pulmonary	I-ADR
symptom	I-ADR
soon	O
after	O
infusion	O
0	O
<EOS>	O
dyspnea	B-ADR
,	O
hypoxemia	O
,	O
and	O
pleuritic	O
chest	O
pain	O
occurred	O
within	O
24	O
hour	O
of	O
rituximab	B-Drug
administration	O
,	O
and	O
there	O
wa	O
no	O
other	O
apparent	O
explanation	O
0	O
<EOS>	O
dyspnea	O
,	O
hypoxemia	B-ADR
,	O
and	O
pleuritic	O
chest	O
pain	O
occurred	O
within	O
24	O
hour	O
of	O
rituximab	B-Drug
administration	O
,	O
and	O
there	O
wa	O
no	O
other	O
apparent	O
explanation	O
0	O
<EOS>	O
dyspnea	O
,	O
hypoxemia	O
,	O
and	O
pleuritic	B-ADR
chest	I-ADR
pain	I-ADR
occurred	O
within	O
24	O
hour	O
of	O
rituximab	B-Drug
administration	O
,	O
and	O
there	O
wa	O
no	O
other	O
apparent	O
explanation	O
0	O
<EOS>	O
progressive	B-ADR
hypoxemia	I-ADR
mandated	O
endotracheal	O
intubation	O
1	O
week	O
after	O
rituximab	B-Drug
administration	O
and	O
led	O
to	O
death	O
4	O
week	O
after	O
admission	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
43-year-old	O
man	O
with	O
itp	O
refractory	O
to	O
steroid	O
and	O
intravenous	O
immunoglobulin	O
who	O
developed	O
acute	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
(	O
ards	O
)	O
after	O
a	O
single	O
infusion	O
of	O
rituximab	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
43-year-old	O
man	O
with	O
itp	O
refractory	O
to	O
steroid	O
and	O
intravenous	O
immunoglobulin	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ards	B-ADR
)	O
after	O
a	O
single	O
infusion	O
of	O
rituximab	B-Drug
0	O
<EOS>	O
symptomatic	O
hypocalcaemia	O
and	O
renal	B-ADR
impairment	I-ADR
associated	O
with	O
bisphosphonate	B-Drug
treatment	O
in	O
patient	O
with	O
multiple	O
myeloma	O
0	O
<EOS>	O
symptomatic	B-ADR
hypocalcaemia	I-ADR
and	O
renal	O
impairment	O
associated	O
with	O
bisphosphonate	B-Drug
treatment	O
in	O
patient	O
with	O
multiple	O
myeloma	O
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
severe	B-ADR
hypocalcaemia	I-ADR
associated	O
with	O
i.v	O
0	O
bisphosphonate	B-Drug
treatment	O
in	O
patient	O
with	O
multiple	O
myeloma	O
0	O
<EOS>	O
gemcitabine-related	B-Drug
radiation	B-ADR
recall	I-ADR
in	O
a	O
patient	O
with	O
pancreatic	O
cancer	O
0	O
<EOS>	O
gemcitabine	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drug	O
known	O
to	O
cause	O
radiation	B-ADR
recall	I-ADR
0	O
<EOS>	O
radiation	B-ADR
recall	I-ADR
from	O
gemcitabine	B-Drug
is	O
rare	O
,	O
but	O
can	O
potentially	O
arise	O
in	O
any	O
site	O
that	O
ha	O
been	O
previously	O
irradiated	O
0	O
<EOS>	O
radiation	B-ADR
recall	I-ADR
related	O
to	O
gemcitabine	B-Drug
ha	O
been	O
reported	O
in	O
lung	O
and	O
breast	O
cancer	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
inoperable	O
pancreatic	O
cancer	O
who	O
developed	O
gastrointestinal	B-ADR
bleeding	I-ADR
secondary	O
to	O
radiation-recall	O
related	O
to	O
gemcitabine	B-Drug
and	O
review	O
literature	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
inoperable	O
pancreatic	O
cancer	O
who	O
developed	O
gastrointestinal	O
bleeding	O
secondary	O
to	O
radiation-recall	B-ADR
related	O
to	O
gemcitabine	B-Drug
and	O
review	O
literature	O
0	O
<EOS>	O
we	O
suggest	O
discontinuing	O
gemcitabine	B-Drug
if	O
radiation	B-ADR
recall	I-ADR
is	O
observed	O
0	O
<EOS>	O
a	O
17-year-old	O
boy	O
with	O
acute	O
lymphoblastic	O
leukemia	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
within	O
48	O
h	O
of	O
an	O
intravenous	O
high-dose	O
methotrexate	B-Drug
(	O
5	O
g	O
/	O
m2	O
)	O
infusion	O
0	O
<EOS>	O
high-dose	O
methotrexate-associated	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
may	O
be	O
an	O
avoidable	O
complication	O
0	O
<EOS>	O
methotrexate-associated	B-Drug
nephropathy	B-ADR
is	O
a	O
rare	O
complication	O
in	O
pediatric	O
oncology	O
,	O
and	O
a	O
review	O
of	O
the	O
literature	O
suggests	O
that	O
exposure	O
to	O
nephrotoxic	O
agent	O
may	O
be	O
a	O
significant	O
but	O
perhaps	O
underrecognized	O
risk	O
factor	O
for	O
it	O
development	O
0	O
<EOS>	O
massive	O
prolapse	B-ADR
of	I-ADR
the	I-ADR
urethral	I-ADR
mucosa	I-ADR
following	O
periurethral	O
injection	O
of	O
calcium	B-Drug
hydroxylapatite	I-Drug
for	O
stress	O
urinary	O
incontinence	O
0	O
<EOS>	O
the	O
author	O
present	O
a	O
case	O
report	O
of	O
a	O
granulomatous	B-ADR
reaction	I-ADR
leading	O
to	O
urethral	O
prolapse	O
,	O
3	O
month	O
after	O
the	O
transurethral	O
injection	O
of	O
calcium	B-Drug
hydroxylapatite	I-Drug
0	O
<EOS>	O
the	O
author	O
present	O
a	O
case	O
report	O
of	O
a	O
granulomatous	O
reaction	O
leading	O
to	O
urethral	B-ADR
prolapse	I-ADR
,	O
3	O
month	O
after	O
the	O
transurethral	O
injection	O
of	O
calcium	B-Drug
hydroxylapatite	I-Drug
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
granulomatous	B-ADR
reaction	I-ADR
described	O
after	O
calcium	B-Drug
hydroxylapatite	I-Drug
injection	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
57-year-old	O
female	O
with	O
cardiomyopathy	O
and	O
``	O
sulfa	O
'	O
(	O
trimethoprim	O
/	O
sulfamethoxazole	O
)	O
allergy	O
documented	O
a	O
pancreatitis	B-ADR
presented	O
with	O
symptom	O
consistent	O
with	O
pancreatitis	O
after	O
use	O
of	O
furosemide	B-Drug
0	O
<EOS>	O
in	O
addition	O
,	O
while	O
case	O
of	O
loop	O
diuretic-induced	O
pancreatitis	B-ADR
,	O
including	O
furosemide	B-Drug
,	O
have	O
been	O
published	O
,	O
the	O
allergic	O
manifestation	O
with	O
both	O
sulfonamide	O
antibiotic	O
and	O
non-antibiotics	O
in	O
our	O
patient	O
suggest	O
possible	O
cross-reactivity	O
between	O
these	O
2	O
drug	O
class	O
0	O
<EOS>	O
torsemide	B-Drug
appears	O
to	O
also	O
be	O
a	O
part	O
of	O
a	O
long	O
list	O
of	O
agent	O
that	O
can	O
cause	O
pancreatitis	B-ADR
0	O
<EOS>	O
heparin-induced	B-Drug
thrombocytopenia	O
complicated	O
with	O
massive	B-ADR
thrombosis	I-ADR
of	I-ADR
the	I-ADR
inferior	I-ADR
vena	I-ADR
cava	I-ADR
after	O
filter	O
placement	O
0	O
<EOS>	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
complicated	O
with	O
massive	O
thrombosis	O
of	O
the	O
inferior	O
vena	O
cava	O
after	O
filter	O
placement	O
0	O
<EOS>	O
on	O
the	O
3rd	O
day	O
,	O
an	O
inferior	O
vena	O
cava	O
(	O
ivc	O
)	O
filter	O
wa	O
placed	O
with	O
a	O
heparin	B-Drug
flush	O
,	O
after	O
which	O
massive	O
ivc	B-ADR
thrombosis	I-ADR
developed	O
0	O
<EOS>	O
the	O
patient	O
wa	O
positive	O
for	O
antibody	O
against	O
complex	O
of	O
heparin	O
and	O
platelet	O
factor	O
4	O
,	O
and	O
wa	O
diagnosed	O
a	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
with	O
thrombosis	O
syndrome	O
(	O
hitts	O
)	O
0	O
<EOS>	O
the	O
patient	O
wa	O
positive	O
for	O
antibody	O
against	O
complex	O
of	O
heparin	O
and	O
platelet	O
factor	O
4	O
,	O
and	O
wa	O
diagnosed	O
a	O
heparin-induced	B-Drug
thrombocytopenia	O
with	O
thrombosis	B-ADR
syndrome	I-ADR
(	O
hitts	O
)	O
0	O
<EOS>	O
when	O
thrombosis	B-ADR
develops	O
during	O
heparin	B-Drug
treatment	O
,	O
it	O
is	O
important	O
to	O
suspect	O
hitts	O
and	O
to	O
assay	O
for	O
the	O
associated	O
antibody	O
,	O
regardless	O
of	O
the	O
actual	O
platelet	O
count	O
0	O
<EOS>	O
after	O
gastric-outlet	B-ADR
obstruction	I-ADR
wa	O
recognized	O
in	O
several	O
infant	O
who	O
received	O
prostaglandin	B-Drug
e1	I-Drug
,	O
we	O
studied	O
the	O
association	O
between	O
the	O
drug	O
and	O
this	O
complication	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
administration	O
of	O
prostaglandin	B-Drug
e1	I-Drug
to	O
neonate	O
can	O
cause	O
gastric-outlet	O
obstruction	O
due	O
to	O
antral	B-ADR
hyperplasia	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
administration	O
of	O
prostaglandin	B-Drug
e1	I-Drug
to	O
neonate	O
can	O
cause	O
gastric-outlet	B-ADR
obstruction	I-ADR
due	O
to	O
antral	O
hyperplasia	O
0	O
<EOS>	O
moreover	O
,	O
treatment	O
with	O
immunosuppressive	O
drug	O
such	O
a	O
cyclosporine	O
,	O
cisplatin	B-Drug
,	O
tacrolimus	O
,	O
and	O
interferon-alpha	O
can	O
induce	O
a	O
condition	O
resembling	O
rpls	B-ADR
0	O
<EOS>	O
moreover	O
,	O
treatment	O
with	O
immunosuppressive	O
drug	O
such	O
a	O
cyclosporine	B-Drug
,	O
cisplatin	O
,	O
tacrolimus	O
,	O
and	O
interferon-alpha	O
can	O
induce	O
a	O
condition	O
resembling	O
rpls	B-ADR
0	O
<EOS>	O
moreover	O
,	O
treatment	O
with	O
immunosuppressive	O
drug	O
such	O
a	O
cyclosporine	O
,	O
cisplatin	O
,	O
tacrolimus	O
,	O
and	O
interferon-alpha	B-Drug
can	O
induce	O
a	O
condition	O
resembling	O
rpls	B-ADR
0	O
<EOS>	O
moreover	O
,	O
treatment	O
with	O
immunosuppressive	O
drug	O
such	O
a	O
cyclosporine	O
,	O
cisplatin	O
,	O
tacrolimus	B-Drug
,	O
and	O
interferon-alpha	O
can	O
induce	O
a	O
condition	O
resembling	O
rpls	B-ADR
0	O
<EOS>	O
reversible	B-ADR
posterior	I-ADR
leukoencephalopathy	I-ADR
syndrome	I-ADR
in	O
systemic	O
lupus	O
erythematosus	O
with	O
thrombocytopenia	O
treated	O
with	O
cyclosporine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
young	O
woman	O
with	O
sle	O
and	O
thrombocytopenia	O
,	O
who	O
developed	O
severe	O
perspiration	O
,	O
headache	B-ADR
,	O
and	O
seizure	O
after	O
receiving	O
cyclosporine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
young	O
woman	O
with	O
sle	O
and	O
thrombocytopenia	O
,	O
who	O
developed	O
severe	O
perspiration	O
,	O
headache	O
,	O
and	O
seizure	B-ADR
after	O
receiving	O
cyclosporine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
young	O
woman	O
with	O
sle	O
and	O
thrombocytopenia	O
,	O
who	O
developed	O
severe	B-ADR
perspiration	I-ADR
,	O
headache	O
,	O
and	O
seizure	O
after	O
receiving	O
cyclosporine	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
exacerbated	O
mania	B-ADR
potentially	O
related	O
to	O
an	O
interaction	O
between	O
lopinavir	B-Drug
/	O
ritonavir	O
and	O
valproic	O
acid	O
(	O
vpa	O
)	O
and	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
this	O
interaction	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
exacerbated	O
mania	B-ADR
potentially	O
related	O
to	O
an	O
interaction	O
between	O
lopinavir	O
/	O
ritonavir	B-Drug
and	O
valproic	O
acid	O
(	O
vpa	O
)	O
and	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
this	O
interaction	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
exacerbated	O
mania	B-ADR
potentially	O
related	O
to	O
an	O
interaction	O
between	O
lopinavir	O
/	O
ritonavir	O
and	O
valproic	B-Drug
acid	I-Drug
(	O
vpa	O
)	O
and	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
this	O
interaction	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
exacerbated	O
mania	B-ADR
potentially	O
related	O
to	O
an	O
interaction	O
between	O
lopinavir	O
/	O
ritonavir	O
and	O
valproic	O
acid	O
(	O
vpa	B-Drug
)	O
and	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
this	O
interaction	O
0	O
<EOS>	O
possible	O
interaction	O
between	O
lopinavir	B-Drug
/	O
ritonavir	O
and	O
valproic	O
acid	O
exacerbates	O
bipolar	B-ADR
disorder	I-ADR
0	O
<EOS>	O
possible	O
interaction	O
between	O
lopinavir	O
/	O
ritonavir	B-Drug
and	O
valproic	O
acid	O
exacerbates	O
bipolar	B-ADR
disorder	I-ADR
0	O
<EOS>	O
possible	O
interaction	O
between	O
lopinavir	O
/	O
ritonavir	O
and	O
valproic	B-Drug
acid	I-Drug
exacerbates	O
bipolar	B-ADR
disorder	I-ADR
0	O
<EOS>	O
after	O
intravitreal	O
injection	O
of	O
triamcinolone	B-Drug
acetonide	I-Drug
,	O
cataract	B-ADR
may	O
rapidly	O
develop	O
in	O
eye	O
that	O
have	O
been	O
intensively	O
treated	O
,	O
topically	O
and	O
systemically	O
,	O
by	O
corticosteroid	O
for	O
several	O
year	O
0	O
<EOS>	O
arthritis	B-ADR
and	O
bursitis	O
in	O
multiple	O
sclerosis	O
patient	O
treated	O
with	O
interferon-beta	B-Drug
0	O
<EOS>	O
arthritis	O
and	O
bursitis	B-ADR
in	O
multiple	O
sclerosis	O
patient	O
treated	O
with	O
interferon-beta	B-Drug
0	O
<EOS>	O
our	O
literature	O
review	O
revealed	O
an	O
additional	O
six	O
case	O
of	O
onset	O
of	O
inflammatory	B-ADR
arthritis	I-ADR
in	O
m	O
patient	O
receiving	O
ifn-beta	B-Drug
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
a	O
monoarthritis	B-ADR
2	O
week	O
after	O
initiation	O
of	O
ifn-beta	B-Drug
,	O
which	O
persisted	O
during	O
the	O
14	O
month	O
of	O
therapy	O
and	O
resolved	O
with	O
discontinuation	O
of	O
the	O
medication	O
0	O
<EOS>	O
therapy	O
with	O
ifn-beta	B-Drug
ha	O
rarely	O
been	O
associated	O
with	O
the	O
development	O
of	O
autoimmune	B-ADR
disorder	I-ADR
0	O
<EOS>	O
the	O
second	O
patient	O
developed	O
both	O
autoimmune	B-ADR
thyroid	I-ADR
disease	I-ADR
and	O
a	O
refractory	O
pre-patellar	O
bursitis	O
after	O
50	O
month	O
of	O
ifn-beta	B-Drug
therapy	O
0	O
<EOS>	O
the	O
second	O
patient	O
developed	O
both	O
autoimmune	O
thyroid	O
disease	O
and	O
a	O
refractory	B-ADR
pre-patellar	I-ADR
bursitis	I-ADR
after	O
50	O
month	O
of	O
ifn-beta	B-Drug
therapy	O
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
two	O
female	O
patient	O
diagnosed	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
rrms	O
)	O
who	O
developed	O
inflammatory	B-ADR
musculoskeletal	I-ADR
manifestation	I-ADR
,	O
following	O
ifn-beta	B-Drug
therapy	O
0	O
<EOS>	O
trimethoprim-sulfamethoxazole-induced	B-Drug
aseptic	B-ADR
meningitis	I-ADR
0	O
<EOS>	O
we	O
present	O
a	O
46-year-old	O
african-american	O
man	O
with	O
aid	O
who	O
wa	O
admitted	O
on	O
two	O
different	O
occasion	O
within	O
three	O
week	O
for	O
sign	O
and	O
symptom	O
of	O
meningitis	B-ADR
after	O
using	O
trimethoprim	O
/	O
sulfamethoxazole	O
(	O
tmp	O
/	O
smx	B-Drug
)	O
0	O
<EOS>	O
we	O
present	O
a	O
46-year-old	O
african-american	O
man	O
with	O
aid	O
who	O
wa	O
admitted	O
on	O
two	O
different	O
occasion	O
within	O
three	O
week	O
for	O
sign	O
and	O
symptom	O
of	O
meningitis	B-ADR
after	O
using	O
trimethoprim	O
/	O
sulfamethoxazole	B-Drug
(	O
tmp	O
/	O
smx	O
)	O
0	O
<EOS>	O
we	O
present	O
a	O
46-year-old	O
african-american	O
man	O
with	O
aid	O
who	O
wa	O
admitted	O
on	O
two	O
different	O
occasion	O
within	O
three	O
week	O
for	O
sign	O
and	O
symptom	O
of	O
meningitis	B-ADR
after	O
using	O
trimethoprim	O
/	O
sulfamethoxazole	O
(	O
tmp	B-Drug
/	O
smx	O
)	O
0	O
<EOS>	O
we	O
present	O
a	O
46-year-old	O
african-american	O
man	O
with	O
aid	O
who	O
wa	O
admitted	O
on	O
two	O
different	O
occasion	O
within	O
three	O
week	O
for	O
sign	O
and	O
symptom	O
of	O
meningitis	B-ADR
after	O
using	O
trimethoprim	B-Drug
/	O
sulfamethoxazole	O
(	O
tmp	O
/	O
smx	O
)	O
0	O
<EOS>	O
we	O
reviewed	O
the	O
literature	O
in	O
an	O
attempt	O
to	O
characterize	O
the	O
pattern	O
and	O
predictor	O
of	O
tmp	O
/	O
smx-induced	B-Drug
aseptic	B-ADR
meningitis	I-ADR
0	O
<EOS>	O
we	O
reviewed	O
the	O
literature	O
in	O
an	O
attempt	O
to	O
characterize	O
the	O
pattern	O
and	O
predictor	O
of	O
tmp	B-Drug
/	O
smx-induced	O
aseptic	B-ADR
meningitis	I-ADR
0	O
<EOS>	O
in	O
this	O
paper	O
,	O
we	O
report	O
a	O
patient	O
with	O
primary	O
anti-phospholipid	O
syndrome	O
treated	O
by	O
corticosteroid	B-Drug
,	O
who	O
developed	O
disseminated	B-ADR
nocardiosis	I-ADR
0	O
<EOS>	O
chloroquine-induced	B-Drug
bilateral	B-ADR
ptosis	I-ADR
0	O
<EOS>	O
ptosis	B-ADR
occurring	O
24	O
h	O
after	O
chloroquine	B-Drug
therapy	O
,	O
with	O
full	O
recovery	O
48	O
h	O
after	O
cessation	O
of	O
chloroquine	O
,	O
ha	O
not	O
been	O
described	O
previously	O
0	O
<EOS>	O
ptosis	B-ADR
occurring	O
24	O
h	O
after	O
chloroquine	B-Drug
therapy	O
,	O
with	O
full	O
recovery	O
48	O
h	O
after	O
cessation	O
of	O
chloroquine	O
,	O
ha	O
not	O
been	O
described	O
previously	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
bilateral	B-ADR
ptosis	I-ADR
induced	O
by	O
chloroquine	B-Drug
0	O
<EOS>	O
design	O
:	O
we	O
reviewed	O
the	O
medical	O
record	O
of	O
four	O
patient	O
,	O
who	O
were	O
seen	O
by	O
u	O
between	O
july	O
2000	O
and	O
february	O
2004	O
for	O
sudden	O
onset	O
of	O
a	O
central	B-ADR
neurological	I-ADR
syndrome	I-ADR
within	O
day	O
of	O
intrathecal	O
mtx	B-Drug
0	O
<EOS>	O
diffusion-weighted	O
mri	O
correlate	O
of	O
subacute	O
methotrexate-related	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
objective	O
:	O
a	O
delayed	O
stroke-like	B-ADR
leukoencephalopathy	I-ADR
ha	O
been	O
observed	O
in	O
patient	O
receiving	O
methotrexate	B-Drug
(	O
mtx	O
)	O
for	O
childhood	O
leukemia	O
0	O
<EOS>	O
objective	O
:	O
a	O
delayed	O
stroke-like	B-ADR
leukoencephalopathy	I-ADR
ha	O
been	O
observed	O
in	O
patient	O
receiving	O
methotrexate	O
(	O
mtx	B-Drug
)	O
for	O
childhood	O
leukemia	O
0	O
<EOS>	O
our	O
objective	O
is	O
to	O
present	O
a	O
retrospective	O
analysis	O
of	O
the	O
dwi	O
finding	O
in	O
four	O
patient	O
who	O
suffered	O
subacute	B-ADR
neurotoxicity	I-ADR
after	O
intrathecal	O
mtx	B-Drug
0	O
<EOS>	O
this	O
is	O
a	O
rare	O
case	O
of	O
ards	B-ADR
associated	O
with	O
lithium	B-Drug
intoxication	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
present	O
finding	O
suggest	O
that	O
:	O
(	O
i	O
)	O
amantadine	O
probably	O
exerts	O
it	O
anti-dyskinetic	O
effect	O
by	O
acting	O
on	O
the	O
``	O
indirect	O
'	O
pathway	O
;	O
(	O
ii	O
)	O
the	O
pathophysiological	O
mechanism	O
of	O
subthalamotomy	O
induced	O
dyskinesia	B-ADR
may	O
differ	O
from	O
those	O
involved	O
in	O
l-dopa	B-Drug
induced	O
dyskinesia	O
;	O
(	O
iii	O
)	O
dyskinesia	O
induced	O
by	O
stn	O
surgery	O
resolve	O
spontaneously	O
a	O
compensatory	O
mechanism	O
develop	O
0	O
<EOS>	O
prior	O
to	O
surgery	O
,	O
levodopa	B-Drug
induced	O
dyskinesia	B-ADR
had	O
improved	O
(	O
<	O
or	O
=	O
50	O
%	O
)	O
under	O
treatment	O
with	O
amantadine	O
(	O
400	O
mg	O
/	O
day	O
,	O
po	O
)	O
in	O
all	O
three	O
patient	O
0	O
<EOS>	O
a	O
combination	O
of	O
behavioural	O
and	O
cognitive	O
adverse	O
effect	O
is	O
illustrated	O
in	O
this	O
case	O
report	O
of	O
a	O
recurrent	O
triazolam-induced	B-Drug
eating	B-ADR
disorder	I-ADR
0	O
<EOS>	O
triazolam-induced	B-Drug
nocturnal	O
bingeing	O
with	O
amnesia	B-ADR
0	O
<EOS>	O
triazolam-induced	B-Drug
nocturnal	B-ADR
bingeing	I-ADR
with	O
amnesia	O
0	O
<EOS>	O
although	O
interferon	B-Drug
gamma	O
ha	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sarcoidosis	B-ADR
,	O
only	O
a	O
few	O
case	O
of	O
sarcoidosis	O
associated	O
with	O
interferon	O
alpha	B-Drug
therapy	O
have	O
been	O
reported	O
0	O
<EOS>	O
development	O
of	O
sarcoidosis	B-ADR
during	O
interferon	B-Drug
alpha	I-Drug
2b	I-Drug
and	O
ribavirin	O
combination	O
therapy	O
for	O
chronic	O
hepatitis	O
c	O
--	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
development	O
of	O
sarcoidosis	B-ADR
during	O
interferon	O
alpha	O
2b	O
and	O
ribavirin	B-Drug
combination	O
therapy	O
for	O
chronic	O
hepatitis	O
c	O
--	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
with	O
chronic	O
hepatitis	O
c	O
(	O
chc	O
)	O
who	O
developed	O
sarcoidosis	B-ADR
after	O
the	O
treatment	O
by	O
interferon	B-Drug
alpha	I-Drug
and	O
ribavirin	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
with	O
chronic	O
hepatitis	O
c	O
(	O
chc	O
)	O
who	O
developed	O
sarcoidosis	B-ADR
after	O
the	O
treatment	O
by	O
interferon	O
alpha	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
we	O
suggest	O
that	O
sarcoidosis	B-ADR
may	O
develop	O
in	O
chronic	O
hepatitis	O
c	O
patient	O
during	O
interferon	B-Drug
alpha	I-Drug
and	O
/	O
or	O
ribavirin	O
treatment	O
,	O
and	O
diagnostic	O
test	O
for	O
this	O
adverse	O
effect	O
should	O
be	O
performed	O
during	O
the	O
follow-up	O
0	O
<EOS>	O
we	O
suggest	O
that	O
sarcoidosis	B-ADR
may	O
develop	O
in	O
chronic	O
hepatitis	O
c	O
patient	O
during	O
interferon	O
alpha	O
and	O
/	O
or	O
ribavirin	B-Drug
treatment	O
,	O
and	O
diagnostic	O
test	O
for	O
this	O
adverse	O
effect	O
should	O
be	O
performed	O
during	O
the	O
follow-up	O
0	O
<EOS>	O
neutropenic	B-ADR
colitis	I-ADR
during	O
standard	O
dose	O
combination	O
chemotherapy	O
with	O
nedaplatin	O
and	O
irinotecan	B-Drug
for	O
testicular	O
cancer	O
0	O
<EOS>	O
neutropenic	B-ADR
colitis	I-ADR
during	O
standard	O
dose	O
combination	O
chemotherapy	O
with	O
nedaplatin	B-Drug
and	O
irinotecan	O
for	O
testicular	O
cancer	O
0	O
<EOS>	O
in	O
this	O
paper	O
,	O
we	O
report	O
a	O
case	O
of	O
severe	B-ADR
hypercalcemia	I-ADR
of	O
immobilization	O
in	O
a	O
40-year-old	O
hemodialyzed	O
woman	O
treated	O
by	O
cinacalcet	B-Drug
hcl	I-Drug
for	O
a	O
severe	O
hpth-ii	O
(	O
pth	O
>	O
1000	O
pg	O
/	O
ml	O
)	O
0	O
<EOS>	O
here	O
,	O
we	O
present	O
a	O
case	O
of	O
sirolimus-associated	B-Drug
interstitial	B-ADR
pneumonitis	I-ADR
in	O
a	O
cardiac	O
transplant	O
recipient	O
that	O
resolved	O
completely	O
with	O
withdrawal	O
of	O
the	O
drug	O
and	O
treatment	O
with	O
corticosteroid	O
0	O
<EOS>	O
reversible	O
sirolimus-associated	B-Drug
pneumonitis	B-ADR
after	O
heart	O
transplantation	O
0	O
<EOS>	O
two	O
case	O
of	O
sirolimus-associated	B-Drug
pneumonitis	B-ADR
have	O
been	O
reported	O
after	O
cardiac	O
transplantation	O
0	O
<EOS>	O
an	O
objective	O
causality	O
assessment	O
by	O
use	O
of	O
the	O
naranjo	O
probability	O
scale	O
revealed	O
that	O
ncse	B-ADR
due	O
to	O
ifosfamide	B-Drug
wa	O
probable	O
0	O
<EOS>	O
case	O
summary	O
:	O
two	O
patient	O
who	O
received	O
ifosfamide-containing	B-Drug
chemotherapy	O
developed	O
ncse	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
among	O
the	O
many	O
presentation	O
of	O
ifosfamide	B-Drug
neurotoxicity	B-ADR
,	O
clinician	O
should	O
consider	O
ncse	O
a	O
a	O
possible	O
explanation	O
for	O
change	O
in	O
consciousness	O
in	O
a	O
patient	O
receiving	O
this	O
agent	O
0	O
<EOS>	O
ncse	B-ADR
,	O
an	O
epileptic	O
disorder	O
in	O
which	O
typical	O
convulsive	O
activity	O
is	O
absent	O
,	O
ha	O
previously	O
been	O
reported	O
in	O
only	O
4	O
patient	O
receiving	O
ifosfamide	B-Drug
0	O
<EOS>	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
due	O
to	O
ifosfamide	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
nonconvulsive	O
status	O
epilepticus	O
(	O
ncse	B-ADR
)	O
following	O
infusion	O
of	O
ifosfamide	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
2	O
case	O
of	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
(	O
ncse	O
)	O
following	O
infusion	O
of	O
ifosfamide	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
intraoperative	O
gelatine-induced	B-Drug
anaphylaxis	B-ADR
whose	O
diagnosis	O
wa	O
delayed	O
a	O
the	O
use	O
of	O
gelatine	O
during	O
surgical	O
procedure	O
wa	O
omitted	O
for	O
two	O
time	O
in	O
patient	O
medical	O
record	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
intraoperative	O
gelatine-induced	B-Drug
anaphylaxis	B-ADR
whose	O
diagnosis	O
wa	O
delayed	O
a	O
the	O
use	O
of	O
gelatine	O
during	O
surgical	O
procedure	O
wa	O
omitted	O
for	O
two	O
time	O
in	O
patient	O
medical	O
record	O
0	O
<EOS>	O
cutaneous	B-ADR
mycobacterial	I-ADR
infection	I-ADR
post	O
intravesical	O
bcg	B-Drug
installation	O
0	O
<EOS>	O
disseminated	B-ADR
tuberculous	I-ADR
lesion	I-ADR
post	O
intravesical	O
bcg	B-Drug
therapy	O
are	O
rare	O
but	O
need	O
to	O
be	O
identified	O
and	O
treated	O
quickly	O
0	O
<EOS>	O
some	O
patient	O
develop	O
hypersensitivity	B-ADR
rash	I-ADR
in	O
response	O
to	O
hcq	B-Drug
0	O
<EOS>	O
administration	O
of	O
sumatriptan	B-Drug
in	O
subarachnoid	O
haemorrhage	O
(	O
sah	O
)	O
patient	O
,	O
misdiagnosed	O
a	O
migraine	O
patient	O
,	O
may	O
induce	O
symptomatic	B-ADR
cerebral	I-ADR
vasospasm	I-ADR
with	O
potentially	O
dangerous	O
consequence	O
0	O
<EOS>	O
method	O
:	O
we	O
describe	O
two	O
patient	O
who	O
presented	O
with	O
diabetic	B-ADR
ketoacidosis	I-ADR
after	O
treatment	O
with	O
quetiapine	B-Drug
and	O
risperidone	O
,	O
respectively	O
0	O
<EOS>	O
method	O
:	O
we	O
describe	O
two	O
patient	O
who	O
presented	O
with	O
diabetic	B-ADR
ketoacidosis	I-ADR
after	O
treatment	O
with	O
quetiapine	O
and	O
risperidone	B-Drug
,	O
respectively	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	B-ADR
lymphocytosis	I-ADR
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	B-ADR
lymphocytosis	I-ADR
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	B-ADR
lymphocytosis	I-ADR
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	B-ADR
lymphocytosis	I-ADR
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	B-ADR
lymphadenopathy	I-ADR
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	B-ADR
lymphadenopathy	I-ADR
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	B-ADR
lymphadenopathy	I-ADR
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	B-ADR
lymphadenopathy	I-ADR
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	B-ADR
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	B-ADR
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	B-ADR
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	B-ADR
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	B-ADR
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	B-ADR
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	B-ADR
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	B-ADR
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	B-ADR
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	B-ADR
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	B-ADR
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	O
eruption	O
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	B-ADR
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	B-ADR
eruption	I-ADR
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	B-Drug
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	B-ADR
eruption	I-ADR
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	O
)	O
sulfamethoxazole	B-Drug
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	B-ADR
eruption	I-ADR
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	O
(	O
tmp	B-Drug
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
a	O
27-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	O
,	O
skin	B-ADR
eruption	I-ADR
,	O
cervical	O
lymphadenopathy	O
,	O
hepatosplenomegaly	O
,	O
atypical	O
lymphocytosis	O
,	O
and	O
eosinophilia	O
two	O
week	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
tmp	O
)	O
-sulfamethoxazole	O
(	O
smx	O
)	O
treatment	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
case	O
of	O
tmp-smx-induced	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
associated	O
with	O
the	O
reactivation	O
of	O
a	O
latent	O
viral	O
infection	O
0	O
<EOS>	O
trimethoprim-sulfamethoxazole-induced	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
associated	O
with	O
reactivation	O
of	O
human	O
herpesvirus-6	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
severe	O
corticosteroid-induced	B-Drug
glaucoma	B-ADR
after	O
intravitreal	O
injection	O
of	O
triamcinolone	O
acetate	O
in	O
a	O
34-year-old	O
man	O
without	O
a	O
history	O
of	O
glaucoma	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
severe	O
corticosteroid-induced	O
glaucoma	B-ADR
after	O
intravitreal	O
injection	O
of	O
triamcinolone	B-Drug
acetate	I-Drug
in	O
a	O
34-year-old	O
man	O
without	O
a	O
history	O
of	O
glaucoma	O
0	O
<EOS>	O
result	O
:	O
a	O
34-year-old	O
man	O
acquired	O
visual	O
field	O
defect	O
and	O
severe	B-ADR
vision	I-ADR
loss	I-ADR
in	O
both	O
eye	O
after	O
intravitreal	O
injection	O
of	O
triamcinolone	B-Drug
for	O
diabetic	O
macular	O
edema	O
0	O
<EOS>	O
result	O
:	O
a	O
34-year-old	O
man	O
acquired	O
visual	B-ADR
field	I-ADR
defect	I-ADR
and	O
severe	O
vision	O
loss	O
in	O
both	O
eye	O
after	O
intravitreal	O
injection	O
of	O
triamcinolone	B-Drug
for	O
diabetic	O
macular	O
edema	O
0	O
<EOS>	O
severe	O
steroid-induced	B-Drug
glaucoma	B-ADR
following	O
intravitreal	O
injection	O
of	O
triamcinolone	O
acetonide	O
0	O
<EOS>	O
severe	O
steroid-induced	O
glaucoma	B-ADR
following	O
intravitreal	O
injection	O
of	O
triamcinolone	B-Drug
acetonide	I-Drug
0	O
<EOS>	O
this	O
treatment	O
ha	O
the	O
potential	O
to	O
cause	O
severe	O
vision	O
loss	O
a	O
a	O
result	O
of	O
intractable	O
corticosteroid-induced	B-Drug
glaucoma	B-ADR
0	O
<EOS>	O
this	O
treatment	O
ha	O
the	O
potential	O
to	O
cause	O
severe	B-ADR
vision	I-ADR
loss	I-ADR
a	O
a	O
result	O
of	O
intractable	O
corticosteroid-induced	B-Drug
glaucoma	O
0	O
<EOS>	O
autoimmune	B-ADR
thyroid	I-ADR
disease	I-ADR
is	O
a	O
common	O
side-effect	O
of	O
interferon-alpha	O
(	O
ifn-alpha	B-Drug
)	O
treatment	O
of	O
viral	O
hepatitis	O
c	O
0	O
<EOS>	O
autoimmune	B-ADR
thyroid	I-ADR
disease	I-ADR
is	O
a	O
common	O
side-effect	O
of	O
interferon-alpha	B-Drug
(	O
ifn-alpha	O
)	O
treatment	O
of	O
viral	O
hepatitis	O
c	O
0	O
<EOS>	O
destructive	O
thyrotoxicosis	O
appeared	O
4-6	O
month	O
after	O
starting	O
ifn-alpha	B-Drug
,	O
followed	O
by	O
graf	B-ADR
	I-ADR
hyperthyroidism	I-ADR
within	O
8	O
to	O
11	O
month	O
0	O
<EOS>	O
destructive	O
thyrotoxicosis	B-ADR
appeared	O
4-6	O
month	O
after	O
starting	O
ifn-alpha	B-Drug
,	O
followed	O
by	O
graf	O
	O
hyperthyroidism	O
within	O
8	O
to	O
11	O
month	O
0	O
<EOS>	O
hence	O
,	O
hyperthyroidism	B-ADR
induced	O
by	O
ifn-alpha	B-Drug
could	O
correspond	O
to	O
the	O
first	O
phase	O
of	O
silent	O
thyroiditis	O
,	O
to	O
graf	O
	O
disease	O
or	O
to	O
the	O
succession	O
of	O
both	O
0	O
<EOS>	O
interferon-alpha-induced	B-Drug
hyperthyroidism	B-ADR
:	O
a	O
three-stage	O
evolution	O
from	O
silent	O
thyroiditis	O
towards	O
graf	O
	O
disease	O
0	O
<EOS>	O
we	O
have	O
described	O
three	O
patient	O
with	O
hepatitis	O
c	O
for	O
whom	O
ifn-alpha	B-Drug
and	O
ribavirin	O
were	O
prescribed	O
and	O
who	O
developed	O
two	O
successive	O
phase	O
of	O
silent	O
thyroiditis	O
followed	O
by	O
hyperthryroidism	B-ADR
relapse	O
due	O
to	O
graf	O
	O
disease	O
0	O
<EOS>	O
we	O
have	O
described	O
three	O
patient	O
with	O
hepatitis	O
c	O
for	O
whom	O
ifn-alpha	O
and	O
ribavirin	B-Drug
were	O
prescribed	O
and	O
who	O
developed	O
two	O
successive	O
phase	O
of	O
silent	O
thyroiditis	O
followed	O
by	O
hyperthryroidism	B-ADR
relapse	O
due	O
to	O
graf	O
	O
disease	O
0	O
<EOS>	O
we	O
have	O
described	O
three	O
patient	O
with	O
hepatitis	O
c	O
for	O
whom	O
ifn-alpha	B-Drug
and	O
ribavirin	O
were	O
prescribed	O
and	O
who	O
developed	O
two	O
successive	O
phase	O
of	O
silent	O
thyroiditis	B-ADR
followed	O
by	O
hyperthryroidism	O
relapse	O
due	O
to	O
graf	O
	O
disease	O
0	O
<EOS>	O
we	O
have	O
described	O
three	O
patient	O
with	O
hepatitis	O
c	O
for	O
whom	O
ifn-alpha	O
and	O
ribavirin	B-Drug
were	O
prescribed	O
and	O
who	O
developed	O
two	O
successive	O
phase	O
of	O
silent	O
thyroiditis	B-ADR
followed	O
by	O
hyperthryroidism	O
relapse	O
due	O
to	O
graf	O
	O
disease	O
0	O
<EOS>	O
dipyrone	B-Drug
,	O
also	O
known	O
a	O
metamizole	O
,	O
is	O
an	O
analgesic	O
and	O
antipyretic	O
drug	O
that	O
wa	O
banned	O
by	O
the	O
united	O
state	O
food	O
and	O
drug	O
administration	O
because	O
of	O
it	O
association	O
with	O
agranulocytosis	B-ADR
0	O
<EOS>	O
dipyrone	O
,	O
also	O
known	O
a	O
metamizole	B-Drug
,	O
is	O
an	O
analgesic	O
and	O
antipyretic	O
drug	O
that	O
wa	O
banned	O
by	O
the	O
united	O
state	O
food	O
and	O
drug	O
administration	O
because	O
of	O
it	O
association	O
with	O
agranulocytosis	B-ADR
0	O
<EOS>	O
dipyrone-induced	B-Drug
granulocytopenia	B-ADR
:	O
a	O
case	O
for	O
awareness	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
developed	O
granulocytopenia	B-ADR
and	O
fever	O
after	O
taking	O
dipyrone	B-Drug
and	O
discus	O
the	O
available	O
literature	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
2	O
patient	O
who	O
developed	O
unusual	O
cd8+	B-ADR
cutaneous	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
after	O
treatment	O
with	O
efalizumab	B-Drug
and	O
infliximab	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
2	O
patient	O
who	O
developed	O
unusual	O
cd8+	B-ADR
cutaneous	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
after	O
treatment	O
with	O
efalizumab	O
and	O
infliximab	B-Drug
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	B-Drug
and	O
sulfadiazine	O
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	B-ADR
pain	I-ADR
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	O
and	O
sulfadiazine	B-Drug
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	B-ADR
pain	I-ADR
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	B-Drug
and	O
sulfadiazine	O
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	B-ADR
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	O
and	O
sulfadiazine	B-Drug
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	B-ADR
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	B-Drug
and	O
sulfadiazine	O
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	B-ADR
cutaneous	I-ADR
involvement	I-ADR
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	O
and	O
sulfadiazine	B-Drug
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	B-ADR
cutaneous	I-ADR
involvement	I-ADR
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	B-Drug
and	O
sulfadiazine	O
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	B-ADR
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	O
and	O
sulfadiazine	B-Drug
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	B-ADR
,	O
abdominal	O
pain	O
and	O
transaminitis	O
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	B-Drug
and	O
sulfadiazine	O
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	B-ADR
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
a	O
7-year-old	O
with	O
congenital	O
toxoplasmosis	O
who	O
took	O
pyrimethamine	O
and	O
sulfadiazine	B-Drug
for	O
reactivated	O
chorioretinitis	O
developed	O
fever	O
,	O
severe	O
cutaneous	O
involvement	O
,	O
swelling	O
,	O
abdominal	O
pain	O
and	O
transaminitis	B-ADR
,	O
persisting	O
week	O
after	O
withholding	O
medicine	O
0	O
<EOS>	O
severe	O
sulfadiazine	B-Drug
hypersensitivity	B-ADR
in	O
a	O
child	O
with	O
reactivated	O
congenital	O
toxoplasmic	O
chorioretinitis	O
0	O
<EOS>	O
this	O
case	O
underscore	O
problem	O
in	O
clinical	O
management	O
with	O
sulfadiazine	B-Drug
hypersensitivity	B-ADR
,	O
potential	O
immunosuppression	O
from	O
corticosteroid	O
and	O
selection	O
of	O
medication	O
for	O
recurrence	O
of	O
toxoplasmic	O
chorioretinitis	O
0	O
<EOS>	O
fatal	B-ADR
lung	I-ADR
fibrosis	I-ADR
caused	O
by	O
paclitaxel	O
toxicity	O
ha	O
not	O
been	O
reported	O
in	O
this	O
report	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
62-year-old	O
woman	O
who	O
received	O
six	O
cycle	O
of	O
paclitaxel	O
and	O
carboplatin	B-Drug
a	O
combination	O
chemotherapy	O
for	O
advanced	O
ovarian	O
cancer	O
0	O
<EOS>	O
fatal	B-ADR
lung	I-ADR
fibrosis	I-ADR
caused	O
by	O
paclitaxel	B-Drug
toxicity	O
ha	O
not	O
been	O
reported	O
in	O
this	O
report	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
62-year-old	O
woman	O
who	O
received	O
six	O
cycle	O
of	O
paclitaxel	O
and	O
carboplatin	O
a	O
combination	O
chemotherapy	O
for	O
advanced	O
ovarian	O
cancer	O
0	O
<EOS>	O
fatal	B-ADR
lung	I-ADR
fibrosis	I-ADR
caused	O
by	O
paclitaxel	B-Drug
toxicity	O
ha	O
not	O
been	O
reported	O
in	O
this	O
report	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
62-year-old	O
woman	O
who	O
received	O
six	O
cycle	O
of	O
paclitaxel	O
and	O
carboplatin	O
a	O
combination	O
chemotherapy	O
for	O
advanced	O
ovarian	O
cancer	O
0	O
<EOS>	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
induced	O
by	O
paclitaxel	B-Drug
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
physician	O
should	O
keep	O
in	O
mind	O
that	O
taxanes	O
such	O
a	O
paclitaxel	B-Drug
have	O
the	O
potential	O
to	O
cause	O
pneumonitis	O
and	O
lung	B-ADR
fibrosis	I-ADR
0	O
<EOS>	O
physician	O
should	O
keep	O
in	O
mind	O
that	O
taxanes	O
such	O
a	O
paclitaxel	B-Drug
have	O
the	O
potential	O
to	O
cause	O
pneumonitis	B-ADR
and	O
lung	O
fibrosis	O
0	O
<EOS>	O
pulmonary	B-ADR
fibrosis	I-ADR
is	O
a	O
complication	O
of	O
paclitaxel	B-Drug
therapy	O
that	O
may	O
occur	O
despite	O
treatment	O
with	O
corticosteroid	O
0	O
<EOS>	O
infection	B-ADR
are	O
a	O
major	O
adverse	O
effect	O
during	O
the	O
treatment	O
with	O
anti-tnf-alpha	B-Drug
0	O
<EOS>	O
in	O
this	O
case	O
report	O
,	O
we	O
have	O
described	O
a	O
patient	O
with	O
crohn	O
disease	O
who	O
developed	O
subfulminant	B-ADR
hepatitis	I-ADR
b	I-ADR
after	O
the	O
fourth	O
infusion	O
of	O
infliximab	B-Drug
due	O
to	O
an	O
unrecognized	O
hbs-antigen	O
carrier	O
state	O
0	O
<EOS>	O
subfulminant	B-ADR
hepatitis	I-ADR
b	I-ADR
after	O
infliximab	B-Drug
in	O
crohn	O
disease	O
:	O
need	O
for	O
hbv-screening	O
?	O
<EOS>	O
acute	B-ADR
unilateral	I-ADR
total	I-ADR
visual	I-ADR
loss	I-ADR
after	O
retrogasserian	O
phenol	B-Drug
injection	O
for	O
the	O
treatment	O
of	O
trigeminal	O
neuralgia	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
visual	O
loss	O
in	O
this	O
patient	O
seems	O
to	O
result	O
from	O
phenol	B-Drug
neurotoxicity	B-ADR
rather	O
than	O
mechanical	O
compression	O
of	O
the	O
intraorbital	O
optic	O
nerve	O
0	O
<EOS>	O
the	O
visual	B-ADR
loss	I-ADR
in	O
this	O
patient	O
seems	O
to	O
result	O
from	O
phenol	B-Drug
neurotoxicity	O
rather	O
than	O
mechanical	O
compression	O
of	O
the	O
intraorbital	O
optic	O
nerve	O
0	O
<EOS>	O
we	O
report	O
a	O
78-year-old	O
man	O
who	O
had	O
acute	B-ADR
unilateral	I-ADR
total	I-ADR
visual	I-ADR
loss	I-ADR
after	O
retrogasserian	O
phenol	B-Drug
injection	O
for	O
the	O
treatment	O
of	O
trigeminal	O
neuralgia	O
0	O
<EOS>	O
drug	O
induced	O
liver	B-ADR
injury	I-ADR
secondary	O
to	O
interferon-beta	O
(	O
ifn-beta	B-Drug
)	O
in	O
multiple	O
sclerosis	O
0	O
<EOS>	O
drug	O
induced	O
liver	B-ADR
injury	I-ADR
secondary	O
to	O
interferon-beta	B-Drug
(	O
ifn-beta	O
)	O
in	O
multiple	O
sclerosis	O
0	O
<EOS>	O
grade	B-ADR
3	I-ADR
hepatotoxicity	I-ADR
(	O
ast	O
and	O
alt	O
>	O
5	O
to	O
20	O
upper	O
limit	O
normal	O
)	O
or	O
higher	O
ha	O
been	O
observed	O
in	O
a	O
many	O
a	O
1.4	O
%	O
of	O
m	O
patient	O
on	O
ifn	B-Drug
beta	I-Drug
0	O
<EOS>	O
post	O
marketing	O
study	O
of	O
interferon-beta	O
(	O
ifn	B-Drug
beta	I-Drug
)	O
therapy	O
in	O
multiple	O
sclerosis	O
(	O
m	O
)	O
have	O
demonstrated	O
surprisingly	O
high	O
rate	O
of	O
hepatotoxicity	B-ADR
0	O
<EOS>	O
post	O
marketing	O
study	O
of	O
interferon-beta	B-Drug
(	O
ifn	O
beta	O
)	O
therapy	O
in	O
multiple	O
sclerosis	O
(	O
m	O
)	O
have	O
demonstrated	O
surprisingly	O
high	O
rate	O
of	O
hepatotoxicity	B-ADR
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
ifn	B-Drug
beta	I-Drug
induced	O
hepatitis	B-ADR
in	O
m	O
and	O
discus	O
the	O
pathology	O
finding	O
and	O
possible	O
mechanism	O
of	O
drug-induced	O
liver	O
injury	O
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
ifn	B-Drug
beta	I-Drug
induced	O
hepatitis	O
in	O
m	O
and	O
discus	O
the	O
pathology	O
finding	O
and	O
possible	O
mechanism	O
of	O
drug-induced	O
liver	B-ADR
injury	I-ADR
0	O
<EOS>	O
a	O
55-year-old	O
woman	O
presented	O
an	O
episode	O
of	O
acute	B-ADR
urticaria	I-ADR
and	O
labial	O
angioedema	O
60	O
minute	O
after	O
ingesting	O
500	O
mg	O
of	O
cloxacillin	B-Drug
for	O
a	O
skin	O
abscess	O
0	O
<EOS>	O
a	O
55-year-old	O
woman	O
presented	O
an	O
episode	O
of	O
acute	O
urticaria	O
and	O
labial	B-ADR
angioedema	I-ADR
60	O
minute	O
after	O
ingesting	O
500	O
mg	O
of	O
cloxacillin	B-Drug
for	O
a	O
skin	O
abscess	O
0	O
<EOS>	O
allergy	B-ADR
to	O
cloxacillin	B-Drug
with	O
normal	O
tolerance	O
to	O
amoxicillin	O
and	O
cefuroxime	O
0	O
<EOS>	O
several	O
hypersensitivity	B-ADR
reaction	O
to	O
cloxacillin	B-Drug
have	O
been	O
reported	O
,	O
although	O
ige-mediated	O
allergic	O
reaction	O
to	O
the	O
drug	O
are	O
rare	O
and	O
there	O
is	O
little	O
information	O
about	O
possible	O
tolerance	O
to	O
other	O
semisynthetic	O
penicillin	O
or	O
cephalosporin	O
in	O
patient	O
with	O
cloxacillin	O
allergy	O
0	O
<EOS>	O
several	O
hypersensitivity	O
reaction	O
to	O
cloxacillin	B-Drug
have	O
been	O
reported	O
,	O
although	O
ige-mediated	B-ADR
allergic	I-ADR
reaction	I-ADR
to	O
the	O
drug	O
are	O
rare	O
and	O
there	O
is	O
little	O
information	O
about	O
possible	O
tolerance	O
to	O
other	O
semisynthetic	O
penicillin	O
or	O
cephalosporin	O
in	O
patient	O
with	O
cloxacillin	O
allergy	O
0	O
<EOS>	O
cardiac	B-ADR
toxicity	I-ADR
related	O
to	O
bcnu	B-Drug
ha	O
not	O
been	O
described	O
well	O
0	O
<EOS>	O
myocardial	B-ADR
ischemia	I-ADR
associated	O
with	O
high-dose	O
carmustine	B-Drug
infusion	O
0	O
<EOS>	O
three	O
patient	O
are	O
reported	O
without	O
a	O
history	O
of	O
angina	O
pectoris	O
who	O
had	O
clinical	O
and	O
electrocardiographic	O
evidence	O
of	O
myocardial	B-ADR
ischemia	I-ADR
during	O
and	O
immediately	O
after	O
bcnu	B-Drug
infusion	O
0	O
<EOS>	O
adverse	O
reaction	O
in	O
a	O
patient	O
with	O
aspirin-induced	B-Drug
asthma	B-ADR
treated	O
with	O
zafirlukast	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hypereosinophilia	B-ADR
related	O
to	O
zafirlukast	B-Drug
therapy	O
0	O
<EOS>	O
shortly	O
after	O
chemotherapy	O
and	O
an	O
injection	O
of	O
pegfilgrastim	B-Drug
,	O
the	O
patient	O
developed	O
poorly	O
defined	O
,	O
rapidly	O
progressive	O
erythema	O
,	O
edema	B-ADR
,	O
and	O
pain	O
in	O
his	O
right	O
forearm	O
0	O
<EOS>	O
shortly	O
after	O
chemotherapy	O
and	O
an	O
injection	O
of	O
pegfilgrastim	B-Drug
,	O
the	O
patient	O
developed	O
poorly	O
defined	O
,	O
rapidly	O
progressive	O
erythema	O
,	O
edema	O
,	O
and	O
pain	B-ADR
in	I-ADR
his	I-ADR
right	I-ADR
forearm	I-ADR
0	O
<EOS>	O
shortly	O
after	O
chemotherapy	O
and	O
an	O
injection	O
of	O
pegfilgrastim	B-Drug
,	O
the	O
patient	O
developed	O
poorly	O
defined	O
,	O
rapidly	B-ADR
progressive	I-ADR
erythema	I-ADR
,	O
edema	O
,	O
and	O
pain	O
in	O
his	O
right	O
forearm	O
0	O
<EOS>	O
a	O
few	O
recent	O
individual	O
case	O
report	O
have	O
suggested	O
that	O
a	O
myasthenic	B-ADR
syndrome	I-ADR
may	O
be	O
associated	O
with	O
statin	B-Drug
treatment	O
,	O
but	O
this	O
association	O
is	O
not	O
well	O
described	O
0	O
<EOS>	O
statin-associated	B-Drug
myasthenia	B-ADR
gravis	I-ADR
:	O
report	O
of	O
4	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
who	O
developed	O
symptom	O
of	O
myasthenia	B-ADR
gravis	I-ADR
within	O
2	O
week	O
of	O
starting	O
treatment	O
with	O
a	O
statin	B-Drug
drug	O
0	O
<EOS>	O
reactivation	B-ADR
of	I-ADR
cytomegalovirus	I-ADR
probably	O
followed	O
the	O
treatment	O
of	O
wegener	O
granulomatosis	O
with	O
corticosteroid	O
and	O
azathioprine	B-Drug
0	O
<EOS>	O
after	O
excluding	O
other	O
cause	O
of	O
long	O
qt	O
syndrome	O
,	O
the	O
hcq	B-Drug
wa	O
suspected	O
a	O
the	O
cause	O
of	O
her	O
ventricular	B-ADR
tachycardia	I-ADR
0	O
<EOS>	O
chronic	O
hydroxychloroquine	B-Drug
use	O
associated	O
with	O
qt	B-ADR
prolongation	I-ADR
and	O
refractory	O
ventricular	O
arrhythmia	O
0	O
<EOS>	O
chronic	O
hydroxychloroquine	B-Drug
use	O
associated	O
with	O
qt	O
prolongation	O
and	O
refractory	B-ADR
ventricular	I-ADR
arrhythmia	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
chronic	O
use	O
of	O
hcq	B-Drug
for	O
rheumatic	O
disease	O
,	O
or	O
a	O
an	O
anti-malarial	O
drug	O
,	O
should	O
be	O
balanced	O
against	O
the	O
risk	O
of	O
developing	O
potentially	O
lethal	O
cardiac	B-ADR
arrhythmia	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
chronic	O
use	O
of	O
hcq	B-Drug
associated	O
with	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
increasing	O
prevalence	O
of	O
type	O
2	O
diabetes	O
and	O
it	O
treatment	O
with	O
metformin	B-Drug
might	O
result	O
in	O
more	O
case	O
of	O
lactic	B-ADR
acidosis	I-ADR
0	O
<EOS>	O
severe	B-ADR
acidosis	I-ADR
in	O
patient	O
taking	O
metformin	B-Drug
--	O
rapid	O
reversal	O
and	O
survival	O
despite	O
high	O
apache	O
score	O
0	O
<EOS>	O
case	O
report	O
:	O
lack	O
of	O
control	O
of	O
diabetes	B-ADR
and	O
weight	O
gain	O
in	O
a	O
patient	O
on	O
initiation	O
and	O
rechallenge	O
of	O
therapy	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
case	O
report	O
:	O
lack	O
of	O
control	O
of	O
diabetes	O
and	O
weight	B-ADR
gain	I-ADR
in	O
a	O
patient	O
on	O
initiation	O
and	O
rechallenge	O
of	O
therapy	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
the	O
following	O
is	O
a	O
case	O
report	O
analysis	O
intended	O
to	O
draw	O
attention	O
to	O
the	O
need	O
for	O
better	O
care	O
coordination	O
by	O
describing	O
the	O
observed	O
relationship	O
of	O
olanzapine	B-Drug
to	O
metabolic	O
change	O
manifested	O
a	O
uncontrolled	B-ADR
diabetes	I-ADR
mellitus	I-ADR
and	O
weight	O
gain	O
0	O
<EOS>	O
the	O
following	O
is	O
a	O
case	O
report	O
analysis	O
intended	O
to	O
draw	O
attention	O
to	O
the	O
need	O
for	O
better	O
care	O
coordination	O
by	O
describing	O
the	O
observed	O
relationship	O
of	O
olanzapine	B-Drug
to	O
metabolic	O
change	O
manifested	O
a	O
uncontrolled	O
diabetes	O
mellitus	O
and	O
weight	B-ADR
gain	I-ADR
0	O
<EOS>	O
the	O
patient	O
wa	O
enrolled	O
in	O
a	O
weight-loss	O
clinic	O
,	O
and	O
his	O
diabetes	O
medication	O
were	O
adjusted.subsequently	O
,	O
olanzapine	B-Drug
wa	O
discontinued	O
because	O
of	O
weight	O
gain	O
and	O
uncontrolled	B-ADR
diabetes	I-ADR
0	O
<EOS>	O
the	O
patient	O
wa	O
enrolled	O
in	O
a	O
weight-loss	O
clinic	O
,	O
and	O
his	O
diabetes	O
medication	O
were	O
adjusted.subsequently	O
,	O
olanzapine	B-Drug
wa	O
discontinued	O
because	O
of	O
weight	B-ADR
gain	I-ADR
and	O
uncontrolled	O
diabetes	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
traumatic	O
flap	O
dehiscence	O
and	O
enterobacter	B-ADR
keratitis	I-ADR
34	O
month	O
after	O
lasik	B-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
traumatic	B-ADR
flap	I-ADR
dehiscence	I-ADR
and	O
enterobacter	O
keratitis	O
34	O
month	O
after	O
lasik	B-Drug
0	O
<EOS>	O
traumatic	O
late	O
flap	O
dehiscence	O
and	O
enterobacter	B-ADR
keratitis	I-ADR
following	O
lasik	B-Drug
0	O
<EOS>	O
traumatic	B-ADR
late	I-ADR
flap	I-ADR
dehiscence	I-ADR
and	O
enterobacter	O
keratitis	O
following	O
lasik	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	B-ADR
after	O
chemotherapy	O
with	O
docetaxel	B-Drug
and	O
gemcitabine	O
producing	O
severe	O
respiratory	O
insufficiency	O
,	O
and	O
simulating	O
a	O
progression	O
of	O
the	O
tumor	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	B-ADR
after	O
chemotherapy	O
with	O
docetaxel	O
and	O
gemcitabine	B-Drug
producing	O
severe	O
respiratory	O
insufficiency	O
,	O
and	O
simulating	O
a	O
progression	O
of	O
the	O
tumor	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	O
after	O
chemotherapy	O
with	O
docetaxel	B-Drug
and	O
gemcitabine	O
producing	O
severe	O
respiratory	O
insufficiency	O
,	O
and	O
simulating	O
a	O
progression	B-ADR
of	I-ADR
the	I-ADR
tumor	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	O
after	O
chemotherapy	O
with	O
docetaxel	O
and	O
gemcitabine	B-Drug
producing	O
severe	O
respiratory	O
insufficiency	O
,	O
and	O
simulating	O
a	O
progression	B-ADR
of	I-ADR
the	I-ADR
tumor	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	O
after	O
chemotherapy	O
with	O
docetaxel	B-Drug
and	O
gemcitabine	O
producing	O
severe	B-ADR
respiratory	I-ADR
insufficiency	I-ADR
,	O
and	O
simulating	O
a	O
progression	O
of	O
the	O
tumor	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
lung	O
cancer	O
patient	O
with	O
bronquiloalveolar	O
carcinoma	O
(	O
bac	O
)	O
presenting	O
with	O
boop	O
after	O
chemotherapy	O
with	O
docetaxel	O
and	O
gemcitabine	B-Drug
producing	O
severe	B-ADR
respiratory	I-ADR
insufficiency	I-ADR
,	O
and	O
simulating	O
a	O
progression	O
of	O
the	O
tumor	O
0	O
<EOS>	O
a	O
65-year-old	O
man	O
on	O
warfarin	B-Drug
therapy	O
with	O
a	O
sudden	O
spontaneous	O
onset	O
of	O
sub-conjunctival	O
haematoma	O
associated	O
with	O
bloody	B-ADR
tear	I-ADR
wa	O
assessed	O
in	O
the	O
clinic	O
following	O
a	O
referral	O
from	O
an	O
optometrist	O
0	O
<EOS>	O
a	O
65-year-old	O
man	O
on	O
warfarin	B-Drug
therapy	O
with	O
a	O
sudden	O
spontaneous	O
onset	O
of	O
sub-conjunctival	B-ADR
haematoma	I-ADR
associated	O
with	O
bloody	O
tear	O
wa	O
assessed	O
in	O
the	O
clinic	O
following	O
a	O
referral	O
from	O
an	O
optometrist	O
0	O
<EOS>	O
an	O
unusual	O
presentation	O
of	O
spontaneous	O
sub-conjunctival	B-ADR
haematoma	I-ADR
in	O
a	O
patient	O
receiving	O
warfarin	B-Drug
0	O
<EOS>	O
due	O
to	O
discomfort	O
,	O
diplopia	B-ADR
and	O
lagophthalmos	O
,	O
the	O
haematoma	O
necessitated	O
suspension	O
of	O
warfarin	B-Drug
therapy	O
and	O
a	O
surgical	O
evacuation	O
0	O
<EOS>	O
due	O
to	O
discomfort	B-ADR
,	O
diplopia	O
and	O
lagophthalmos	O
,	O
the	O
haematoma	O
necessitated	O
suspension	O
of	O
warfarin	B-Drug
therapy	O
and	O
a	O
surgical	O
evacuation	O
0	O
<EOS>	O
due	O
to	O
discomfort	O
,	O
diplopia	O
and	O
lagophthalmos	O
,	O
the	O
haematoma	B-ADR
necessitated	O
suspension	O
of	O
warfarin	B-Drug
therapy	O
and	O
a	O
surgical	O
evacuation	O
0	O
<EOS>	O
due	O
to	O
discomfort	O
,	O
diplopia	O
and	O
lagophthalmos	B-ADR
,	O
the	O
haematoma	O
necessitated	O
suspension	O
of	O
warfarin	B-Drug
therapy	O
and	O
a	O
surgical	O
evacuation	O
0	O
<EOS>	O
the	O
sub-conjunctival	B-ADR
haematoma	I-ADR
in	O
a	O
patient	O
receiving	O
warfarin	B-Drug
can	O
pose	O
a	O
significant	O
management	O
challenge	O
0	O
<EOS>	O
angioedema	B-ADR
and	O
maculopapular	O
eruption	O
associated	O
with	O
carbamazepine	B-Drug
administration	O
0	O
<EOS>	O
angioedema	O
and	O
maculopapular	B-ADR
eruption	I-ADR
associated	O
with	O
carbamazepine	B-Drug
administration	O
0	O
<EOS>	O
angioedema	B-ADR
,	O
a	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Drug
,	O
involves	O
vascular	O
leakage	O
in	O
dermis	O
and	O
subcutis	O
mediated	O
by	O
immunoglobulin	O
e	O
and	O
/	O
or	O
bradykinins	O
0	O
<EOS>	O
cutaneous	B-ADR
eruption	I-ADR
occur	O
in	O
3	O
%	O
of	O
individual	O
administered	O
carbamazepine	B-Drug
0	O
<EOS>	O
cutaneous	B-ADR
rash	I-ADR
and	O
eruption	O
can	O
be	O
caused	O
by	O
many	O
medication	O
,	O
including	O
carbamazepine	B-Drug
0	O
<EOS>	O
cutaneous	O
rash	O
and	O
eruption	B-ADR
can	O
be	O
caused	O
by	O
many	O
medication	O
,	O
including	O
carbamazepine	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
27-year-old	O
indian	O
woman	O
who	O
developed	O
maculopapular	O
rash	O
and	O
angioedema	B-ADR
secondary	O
to	O
carbamazepine	B-Drug
administration	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
27-year-old	O
indian	O
woman	O
who	O
developed	O
maculopapular	B-ADR
rash	I-ADR
and	O
angioedema	O
secondary	O
to	O
carbamazepine	B-Drug
administration	O
0	O
<EOS>	O
severe	O
adenovirus	O
pneumonia	O
(	O
avp	B-ADR
)	O
following	O
infliximab	B-Drug
infusion	O
for	O
the	O
treatment	O
of	O
crohn	O
disease	O
0	O
<EOS>	O
severe	B-ADR
adenovirus	I-ADR
pneumonia	I-ADR
(	O
avp	O
)	O
following	O
infliximab	B-Drug
infusion	O
for	O
the	O
treatment	O
of	O
crohn	O
disease	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
severe	B-ADR
avp	I-ADR
three	O
week	O
following	O
the	O
administration	O
of	O
infliximab	B-Drug
for	O
the	O
treatment	O
of	O
crohn	O
disease	O
(	O
cd	O
)	O
0	O
<EOS>	O
first	O
case	O
of	O
ivermectin-induced	B-Drug
severe	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
ivermectin-induced	B-Drug
severe	B-ADR
liver	I-ADR
disease	I-ADR
published	O
in	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
20-year-old	O
woman	O
originally	O
from	O
cameroon	O
who	O
wa	O
infected	O
by	O
the	O
l.	O
loa	O
parasite	O
and	O
developed	O
severe	B-ADR
hepatitis	I-ADR
,	O
identified	O
1	O
month	O
after	O
a	O
single	O
dose	O
of	O
ivermectin	B-Drug
0	O
<EOS>	O
case	O
report	O
:	O
we	O
hereby	O
report	O
a	O
case	O
of	O
radiation	O
recall	O
dermatitis	O
and	O
myositis	B-ADR
occurring	O
on	O
gemcitabine	B-Drug
monotherapy	O
,	O
five	O
month	O
after	O
completing	O
chemoradiation	O
for	O
locally	O
advanced	O
pancreatic	O
cancer	O
0	O
<EOS>	O
case	O
report	O
:	O
we	O
hereby	O
report	O
a	O
case	O
of	O
radiation	B-ADR
recall	I-ADR
dermatitis	I-ADR
and	O
myositis	O
occurring	O
on	O
gemcitabine	B-Drug
monotherapy	O
,	O
five	O
month	O
after	O
completing	O
chemoradiation	O
for	O
locally	O
advanced	O
pancreatic	O
cancer	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
second	O
case	O
report	O
that	O
describes	O
gemcitabine-induced	B-Drug
radiation	B-ADR
recall	I-ADR
in	O
rectus	O
abdominus	O
muscle	O
after	O
gemcitabine-based	B-Drug
radiation	O
therapy	O
0	O
<EOS>	O
gemcitabine-induced	B-Drug
rectus	B-ADR
abdominus	I-ADR
radiation	I-ADR
recall	I-ADR
0	O
<EOS>	O
sporadic	B-ADR
rippling	I-ADR
muscle	I-ADR
disease	I-ADR
unmasked	O
by	O
simvastatin	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
53-year-old-man	O
who	O
developed	O
rippling	B-ADR
muscle	I-ADR
disease	I-ADR
(	O
rmd	O
)	O
2	O
month	O
after	O
starting	O
simvastatin	B-Drug
therapy	O
for	O
hypercholesterolemia	O
0	O
<EOS>	O
we	O
report	O
a	O
53-year-old-man	O
who	O
developed	O
rippling	O
muscle	O
disease	O
(	O
rmd	B-ADR
)	O
2	O
month	O
after	O
starting	O
simvastatin	B-Drug
therapy	O
for	O
hypercholesterolemia	O
0	O
<EOS>	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
induced	O
by	O
capecitabine	B-Drug
therapy	O
0	O
<EOS>	O
this	O
case	O
highlight	O
the	O
possible	O
development	O
of	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
a	O
a	O
side	O
effect	O
of	O
capecitabine	B-Drug
therapy	O
0	O
<EOS>	O
acute	O
severe	O
intoxication	O
with	O
carbamazepine	B-Drug
is	O
associated	O
with	O
seizure	O
,	O
coma	B-ADR
and	O
respiratory	O
depression	O
0	O
<EOS>	O
acute	O
severe	O
intoxication	O
with	O
carbamazepine	B-Drug
is	O
associated	O
with	O
seizure	O
,	O
coma	O
and	O
respiratory	B-ADR
depression	I-ADR
0	O
<EOS>	O
acute	O
severe	O
intoxication	O
with	O
carbamazepine	B-Drug
is	O
associated	O
with	O
seizure	B-ADR
,	O
coma	O
and	O
respiratory	O
depression	O
0	O
<EOS>	O
after	O
rechallenge	O
with	O
monotherapy	O
pegvisomant	B-Drug
,	O
however	O
,	O
the	O
hepatic	B-ADR
enzyme	I-ADR
disturbance	I-ADR
reappeared	O
within	O
a	O
few	O
week	O
,	O
indicating	O
that	O
most	O
likely	O
pegvisomant	O
alone	O
and	O
not	O
the	O
long-acting	O
somatostatin	O
analog	O
or	O
the	O
combination	O
of	O
these	O
two	O
drug	O
wa	O
responsible	O
for	O
this	O
case	O
of	O
drug-induced	O
hepatitis	O
0	O
<EOS>	O
after	O
rechallenge	O
with	O
monotherapy	O
pegvisomant	B-Drug
,	O
however	O
,	O
the	O
hepatic	B-ADR
enzyme	I-ADR
disturbance	I-ADR
reappeared	O
within	O
a	O
few	O
week	O
,	O
indicating	O
that	O
most	O
likely	O
pegvisomant	O
alone	O
and	O
not	O
the	O
long-acting	O
somatostatin	O
analog	O
or	O
the	O
combination	O
of	O
these	O
two	O
drug	O
wa	O
responsible	O
for	O
this	O
case	O
of	O
drug-induced	O
hepatitis	O
0	O
<EOS>	O
after	O
rechallenge	O
with	O
monotherapy	O
pegvisomant	B-Drug
,	O
however	O
,	O
the	O
hepatic	O
enzyme	O
disturbance	O
reappeared	O
within	O
a	O
few	O
week	O
,	O
indicating	O
that	O
most	O
likely	O
pegvisomant	O
alone	O
and	O
not	O
the	O
long-acting	O
somatostatin	O
analog	O
or	O
the	O
combination	O
of	O
these	O
two	O
drug	O
wa	O
responsible	O
for	O
this	O
case	O
of	O
drug-induced	O
hepatitis	B-ADR
0	O
<EOS>	O
drug-induced	O
hepatitis	B-ADR
in	O
an	O
acromegalic	O
patient	O
during	O
combined	O
treatment	O
with	O
pegvisomant	O
and	O
octreotide	B-Drug
long-acting	O
repeatable	O
attributed	O
to	O
the	O
use	O
of	O
pegvisomant	O
0	O
<EOS>	O
drug-induced	O
hepatitis	B-ADR
in	O
an	O
acromegalic	O
patient	O
during	O
combined	O
treatment	O
with	O
pegvisomant	B-Drug
and	O
octreotide	O
long-acting	O
repeatable	O
attributed	O
to	O
the	O
use	O
of	O
pegvisomant	O
0	O
<EOS>	O
drug-induced	O
hepatitis	B-ADR
in	O
an	O
acromegalic	O
patient	O
during	O
combined	O
treatment	O
with	O
pegvisomant	B-Drug
and	O
octreotide	O
long-acting	O
repeatable	O
attributed	O
to	O
the	O
use	O
of	O
pegvisomant	O
0	O
<EOS>	O
the	O
hepatic	B-ADR
enzyme	I-ADR
disturbance	I-ADR
normalized	O
after	O
discontinuation	O
of	O
pegvisomant	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
acromegaly	O
who	O
developed	O
severe	O
drug-induced	O
hepatitis	B-ADR
during	O
combined	O
treatment	O
with	O
the	O
long-acting	O
somatostatin-analog	O
octreotide	B-Drug
and	O
the	O
gh	O
receptor	O
antagonist	O
pegvisomant	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
acromegaly	O
who	O
developed	O
severe	O
drug-induced	O
hepatitis	B-ADR
during	O
combined	O
treatment	O
with	O
the	O
long-acting	O
somatostatin-analog	O
octreotide	O
and	O
the	O
gh	O
receptor	O
antagonist	O
pegvisomant	B-Drug
0	O
<EOS>	O
amphotericin	O
b	O
(	O
amb	B-Drug
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	B-ADR
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
(	O
amb	O
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	B-ADR
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	O
b	O
(	O
amb	B-Drug
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	B-ADR
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
(	O
amb	O
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	B-ADR
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	O
b	O
(	O
amb	B-Drug
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	B-ADR
are	O
common	O
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
(	O
amb	O
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	B-ADR
are	O
common	O
0	O
<EOS>	O
amphotericin	O
b	O
(	O
amb	B-Drug
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	O
,	O
malaise	B-ADR
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
(	O
amb	O
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	O
impairment	O
,	O
anaemia	O
,	O
fever	O
,	O
malaise	B-ADR
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	O
b	O
(	O
amb	B-Drug
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	B-ADR
impairment	I-ADR
,	O
anaemia	O
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
(	O
amb	O
)	O
is	O
effective	O
,	O
but	O
it	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	B-ADR
impairment	I-ADR
,	O
anaemia	O
,	O
fever	O
,	O
malaise	O
,	O
and	O
hypokalaemia	O
are	O
common	O
0	O
<EOS>	O
diagnosis	O
:	O
severe	O
temozolomide-induced	B-Drug
immunosuppression	O
,	O
exacerbated	O
by	O
corticosteroid	O
,	O
with	O
profound	O
t-cell	O
lymphocytopenia	O
and	O
simultaneous	O
opportunistic	O
infection	O
with	O
pneumocystis	O
jiroveci	O
pneumonia	O
,	O
brain	B-ADR
abscess	I-ADR
with	I-ADR
listeria	I-ADR
monocytogenes	I-ADR
,	O
and	O
cutaneous	O
kaposi	O
sarcoma	O
0	O
<EOS>	O
diagnosis	O
:	O
severe	O
temozolomide-induced	B-Drug
immunosuppression	O
,	O
exacerbated	O
by	O
corticosteroid	O
,	O
with	O
profound	O
t-cell	O
lymphocytopenia	O
and	O
simultaneous	O
opportunistic	O
infection	O
with	O
pneumocystis	O
jiroveci	O
pneumonia	O
,	O
brain	O
abscess	O
with	O
listeria	O
monocytogenes	O
,	O
and	O
cutaneous	B-ADR
kaposi	I-ADR
sarcoma	I-ADR
0	O
<EOS>	O
diagnosis	O
:	O
severe	O
temozolomide-induced	B-Drug
immunosuppression	B-ADR
,	O
exacerbated	O
by	O
corticosteroid	O
,	O
with	O
profound	O
t-cell	O
lymphocytopenia	O
and	O
simultaneous	O
opportunistic	O
infection	O
with	O
pneumocystis	O
jiroveci	O
pneumonia	O
,	O
brain	O
abscess	O
with	O
listeria	O
monocytogenes	O
,	O
and	O
cutaneous	O
kaposi	O
sarcoma	O
0	O
<EOS>	O
diagnosis	O
:	O
severe	O
temozolomide-induced	B-Drug
immunosuppression	O
,	O
exacerbated	O
by	O
corticosteroid	O
,	O
with	O
profound	O
t-cell	O
lymphocytopenia	O
and	O
simultaneous	O
opportunistic	O
infection	B-ADR
with	I-ADR
pneumocystis	I-ADR
jiroveci	I-ADR
pneumonia	I-ADR
,	O
brain	O
abscess	O
with	O
listeria	O
monocytogenes	O
,	O
and	O
cutaneous	O
kaposi	O
sarcoma	O
0	O
<EOS>	O
diagnosis	O
:	O
severe	O
temozolomide-induced	B-Drug
immunosuppression	O
,	O
exacerbated	O
by	O
corticosteroid	O
,	O
with	O
profound	O
t-cell	B-ADR
lymphocytopenia	I-ADR
and	O
simultaneous	O
opportunistic	O
infection	O
with	O
pneumocystis	O
jiroveci	O
pneumonia	O
,	O
brain	O
abscess	O
with	O
listeria	O
monocytogenes	O
,	O
and	O
cutaneous	O
kaposi	O
sarcoma	O
0	O
<EOS>	O
listeria	O
brain	O
abscess	O
,	O
pneumocystis	O
pneumonia	O
and	O
kaposi	B-ADR
sarcoma	I-ADR
after	O
temozolomide	B-Drug
0	O
<EOS>	O
listeria	B-ADR
brain	I-ADR
abscess	I-ADR
,	O
pneumocystis	O
pneumonia	O
and	O
kaposi	O
sarcoma	O
after	O
temozolomide	B-Drug
0	O
<EOS>	O
listeria	O
brain	O
abscess	O
,	O
pneumocystis	B-ADR
pneumonia	I-ADR
and	O
kaposi	O
sarcoma	O
after	O
temozolomide	B-Drug
0	O
<EOS>	O
purpose	O
:	O
topiramate-induced	B-Drug
angle-closure	B-ADR
glaucoma	I-ADR
(	O
tiacg	O
)	O
is	O
believed	O
to	O
be	O
related	O
to	O
it	O
sulfonamide	O
moiety	O
0	O
<EOS>	O
rapid	O
resolution	O
of	O
topiramate-induced	O
angle-closure	B-ADR
glaucoma	I-ADR
with	O
methylprednisolone	O
and	O
mannitol	B-Drug
0	O
<EOS>	O
rapid	O
resolution	O
of	O
topiramate-induced	O
angle-closure	B-ADR
glaucoma	I-ADR
with	O
methylprednisolone	B-Drug
and	O
mannitol	O
0	O
<EOS>	O
rapid	O
resolution	O
of	O
topiramate-induced	B-Drug
angle-closure	B-ADR
glaucoma	I-ADR
with	O
methylprednisolone	O
and	O
mannitol	O
0	O
<EOS>	O
spontaneous	B-ADR
splenic	I-ADR
infarction	I-ADR
associated	O
with	O
sumatriptan	B-Drug
use	O
0	O
<EOS>	O
though	O
they	O
are	O
generally	O
considered	O
safe	O
,	O
there	O
have	O
been	O
a	O
few	O
report	O
of	O
myocardial	B-ADR
infarction	I-ADR
and	O
stroke	O
associated	O
with	O
triptan	B-Drug
use	O
0	O
<EOS>	O
though	O
they	O
are	O
generally	O
considered	O
safe	O
,	O
there	O
have	O
been	O
a	O
few	O
report	O
of	O
myocardial	O
infarction	O
and	O
stroke	B-ADR
associated	O
with	O
triptan	B-Drug
use	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
who	O
developed	O
spontaneous	B-ADR
splenic	I-ADR
infarction	I-ADR
after	O
the	O
use	O
of	O
sumatriptan	B-Drug
for	O
the	O
treatment	O
of	O
migraine	O
headache	O
0	O
<EOS>	O
acute	B-ADR
myocardial	I-ADR
infarction	I-ADR
during	O
high-dose	O
methylprednisolone	B-Drug
therapy	O
for	O
graf	O
	O
ophthalmopathy	O
0	O
<EOS>	O
except	O
hypothyroidism	B-ADR
after	O
radioiodine	B-Drug
treatment	O
(	O
euthyroid	O
under	O
substitutional	O
therapy	O
)	O
,	O
she	O
suffered	O
from	O
no	O
other	O
disease	O
0	O
<EOS>	O
here	O
we	O
present	O
the	O
case	O
of	O
a	O
woman	O
who	O
received	O
high	O
dos	O
of	O
methylprednisolone	B-Drug
(	O
1	O
g	O
iv	O
daily	O
)	O
for	O
active	O
graf	O
	O
ophthalmopathy	O
,	O
and	O
developed	O
severe	O
hypertension	O
followed	O
by	O
myocardial	B-ADR
infarction	I-ADR
on	O
the	O
fifth	O
day	O
of	O
treatment	O
0	O
<EOS>	O
here	O
we	O
present	O
the	O
case	O
of	O
a	O
woman	O
who	O
received	O
high	O
dos	O
of	O
methylprednisolone	B-Drug
(	O
1	O
g	O
iv	O
daily	O
)	O
for	O
active	O
graf	O
	O
ophthalmopathy	O
,	O
and	O
developed	O
severe	B-ADR
hypertension	I-ADR
followed	O
by	O
myocardial	O
infarction	O
on	O
the	O
fifth	O
day	O
of	O
treatment	O
0	O
<EOS>	O
we	O
conclude	O
that	O
myocardial	B-ADR
infarction	I-ADR
may	O
develop	O
in	O
patient	O
treated	O
with	O
high-dose	O
glucocorticoid	B-Drug
for	O
graf	O
	O
ophthalmopathy	O
,	O
and	O
increased	O
blood	O
pressure	O
may	O
herald	O
this	O
complication	O
0	O
<EOS>	O
presented	O
is	O
a	O
case	O
story	O
of	O
a	O
woman	O
with	O
classical	O
rheumatoid	O
arthritis	O
,	O
who	O
during	O
introduction	O
of	O
sulphasalazine	O
(	O
sasp	B-Drug
)	O
therapy	O
developed	O
a	O
severe	O
and	O
lasting	O
psoriasis-like	B-ADR
skin	I-ADR
reaction	I-ADR
0	O
<EOS>	O
presented	O
is	O
a	O
case	O
story	O
of	O
a	O
woman	O
with	O
classical	O
rheumatoid	O
arthritis	O
,	O
who	O
during	O
introduction	O
of	O
sulphasalazine	B-Drug
(	O
sasp	O
)	O
therapy	O
developed	O
a	O
severe	O
and	O
lasting	O
psoriasis-like	B-ADR
skin	I-ADR
reaction	I-ADR
0	O
<EOS>	O
psoriasis-like	B-ADR
skin	I-ADR
reaction	I-ADR
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
after	O
sulphasalazine	B-Drug
therapy	O
0	O
<EOS>	O
five	O
day	O
after	O
the	O
fourth	O
dose	O
of	O
vincristine	B-Drug
,	O
she	O
presented	O
with	O
bilateral	B-ADR
ptosis	I-ADR
0	O
<EOS>	O
vincristine	B-Drug
induced	O
cranial	B-ADR
polyneuropathy	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
5-year-old	O
girl	O
showed	O
recovery	O
of	O
vincristine	B-Drug
induced	O
cranial	B-ADR
polyneuropathy	I-ADR
with	O
pyridoxine	O
and	O
pyridostigmine	O
treatment	O
0	O
<EOS>	O
acute	B-ADR
generalized	I-ADR
exanthematous	I-ADR
pustulosis	I-ADR
caused	O
by	O
morphine	B-Drug
,	O
confirmed	O
by	O
positive	O
patch	O
test	O
and	O
lymphocyte	O
transformation	O
test	O
0	O
<EOS>	O
morphine	B-Drug
,	O
an	O
opium	O
alkaloid	O
,	O
frequently	O
cause	O
side	O
effect	O
such	O
a	O
hyperhidrosis	O
and	O
facial	B-ADR
flushing	I-ADR
,	O
but	O
serious	O
cutaneous	O
adverse	O
drug	O
reaction	O
are	O
seldom	O
observed	O
0	O
<EOS>	O
morphine	B-Drug
,	O
an	O
opium	O
alkaloid	O
,	O
frequently	O
cause	O
side	O
effect	O
such	O
a	O
hyperhidrosis	B-ADR
and	O
facial	O
flushing	O
,	O
but	O
serious	O
cutaneous	O
adverse	O
drug	O
reaction	O
are	O
seldom	O
observed	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
a	O
man	O
treated	O
with	O
an	O
egfr-inhibitor	O
(	O
erlotinib	B-Drug
)	O
for	O
a	O
cell	O
lung	O
cancer	O
who	O
developed	O
skin	B-ADR
manifestation	I-ADR
localized	O
in	O
an	O
uncommon	O
area	O
and	O
with	O
an	O
atypical	O
evolution	O
0	O
<EOS>	O
olanzapine-associated	B-Drug
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
allergic	B-ADR
contact	I-ADR
angioedema	I-ADR
to	O
benzoyl	B-Drug
peroxide	I-Drug
0	O
<EOS>	O
factor	O
that	O
suggested	O
an	O
association	O
between	O
the	O
severe	B-ADR
angioedematous	I-ADR
reaction	I-ADR
and	O
bp	B-Drug
topical	O
application	O
include	O
the	O
strong	O
reaction	O
to	O
bp	O
in	O
the	O
patch-test	O
,	O
the	O
temporal	O
relationship	O
,	O
the	O
complete	O
resolution	O
of	O
symptom	O
after	O
the	O
drug	O
wa	O
withdrawn	O
and	O
the	O
absence	O
of	O
other	O
identified	O
explanation	O
0	O
<EOS>	O
a	O
35-year-old	O
woman	O
presented	O
with	O
neurotoxicity	O
correlated	O
to	O
an	O
i.v	O
0	O
regimen	O
of	O
5-fluorouracil	B-Drug
a	O
episode	O
of	O
acute	B-ADR
confusional	I-ADR
state	I-ADR
and	O
abnormality	O
of	O
symmetrically	O
restricted	O
diffusion	O
in	O
the	O
periventricular	O
white	O
matter	O
and	O
corpus	O
callosum	O
0	O
<EOS>	O
a	O
35-year-old	O
woman	O
presented	O
with	O
neurotoxicity	B-ADR
correlated	O
to	O
an	O
i.v	O
0	O
regimen	O
of	O
5-fluorouracil	B-Drug
a	O
episode	O
of	O
acute	O
confusional	O
state	O
and	O
abnormality	O
of	O
symmetrically	O
restricted	O
diffusion	O
in	O
the	O
periventricular	O
white	O
matter	O
and	O
corpus	O
callosum	O
0	O
<EOS>	O
reversible	O
finding	O
of	O
restricted	O
diffusion	O
in	O
5-fluorouracil	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
58-year-old	O
woman	O
who	O
ingested	O
more	O
than	O
35	O
g	O
of	O
caffeine	B-Drug
in	O
a	O
suicide	B-ADR
attempt	I-ADR
0	O
<EOS>	O
it	O
may	O
cause	O
a	O
severe	O
adverse	O
drug	O
reaction	O
with	O
multiorgan	O
involvement	O
known	O
a	O
dapsone	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
severe	O
dapsone	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
21-year-old	O
female	O
patient	O
with	O
dapsone	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
anaphylaxis	B-ADR
to	O
intrathecal	O
diamorphine	B-Drug
0	O
<EOS>	O
we	O
believe	O
this	O
is	O
the	O
first	O
report	O
of	O
intrathecal	O
diamorphine	B-Drug
causing	O
anaphylaxis	B-ADR
0	O
<EOS>	O
we	O
highlight	O
two	O
instance	O
of	O
systemic	B-ADR
allergic	I-ADR
reaction	I-ADR
,	O
and	O
discus	O
the	O
potential	O
side	O
effect	O
of	O
local	O
aprotinin	B-Drug
injection	O
in	O
the	O
orthopaedic	O
setting	O
a	O
well	O
a	O
the	O
evidence	O
base	O
for	O
it	O
use	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	B-Drug
)	O
presenting	O
with	O
mixed	O
s	O
/	O
nm	B-ADR
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	B-Drug
sodium	I-Drug
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	O
/	O
nm	B-ADR
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	B-Drug
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	O
/	O
nm	B-ADR
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	B-Drug
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	O
/	O
nm	B-ADR
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	B-Drug
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	O
/	O
nm	B-ADR
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	B-Drug
)	O
presenting	O
with	O
mixed	O
s	B-ADR
/	O
nm	O
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	B-Drug
sodium	I-Drug
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	B-ADR
/	O
nm	O
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	B-Drug
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	B-ADR
/	O
nm	O
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	O
,	O
topiramate	B-Drug
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	B-ADR
/	O
nm	O
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
method	O
:	O
case	O
analysis	O
of	O
a	O
poly-drug	O
overdose	O
(	O
venlafaxine	B-Drug
,	O
topiramate	O
,	O
divalproex	O
sodium	O
,	O
risperidone	O
,	O
and	O
carbamazepine	O
)	O
presenting	O
with	O
mixed	O
s	B-ADR
/	O
nm	O
feature	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
s	O
/	O
nm	O
in	O
critical	O
care	O
setting	O
0	O
<EOS>	O
fever	B-ADR
and	O
maculopapular	O
rash	O
appeared	O
at	O
10	O
day	O
after	O
phenytoin	B-Drug
initiation	O
,	O
and	O
then	O
the	O
drug	O
wa	O
discontinued	O
0	O
<EOS>	O
fever	O
and	O
maculopapular	B-ADR
rash	I-ADR
appeared	O
at	O
10	O
day	O
after	O
phenytoin	B-Drug
initiation	O
,	O
and	O
then	O
the	O
drug	O
wa	O
discontinued	O
0	O
<EOS>	O
localized	B-ADR
purpura	I-ADR
associated	O
with	O
lamotrigine	B-Drug
0	O
<EOS>	O
this	O
case	O
study	O
is	O
the	O
second	O
report	O
of	O
localized	B-ADR
purpura	I-ADR
after	O
prolonged	O
lamotrigine	O
treatment	O
suggesting	O
this	O
may	O
be	O
an	O
atypical	O
lamotrigine-induced	B-Drug
drug	O
reaction	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
13-year-old	O
female	O
with	O
a	O
right	O
frontal	O
high-grade	O
glioma	O
and	O
complex	O
partial	O
seizure	O
who	O
developed	O
localized	B-ADR
purpura	I-ADR
after	O
23	O
month	O
of	O
lamotrigine	B-Drug
monotherapy	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
during	O
lisinopril	B-Drug
and	O
losartan	O
therapy	O
for	O
proteinuria	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
during	O
lisinopril	O
and	O
losartan	B-Drug
therapy	O
for	O
proteinuria	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
acute	O
compromise	O
of	O
renal	O
function	O
associated	O
with	O
hypotension	B-ADR
in	O
a	O
7-year-old	O
boy	O
treated	O
with	O
the	O
ace	O
inhibitor	O
lisinopril	B-Drug
and	O
the	O
arb	O
losartan	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
acute	O
compromise	O
of	O
renal	O
function	O
associated	O
with	O
hypotension	B-ADR
in	O
a	O
7-year-old	O
boy	O
treated	O
with	O
the	O
ace	O
inhibitor	O
lisinopril	O
and	O
the	O
arb	O
losartan	B-Drug
0	O
<EOS>	O
reversible	B-ADR
corneal	I-ADR
keratinization	I-ADR
following	O
trabeculectomy	O
and	O
treatment	O
with	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
bronchiolitis	B-ADR
obliterans	I-ADR
with	I-ADR
organizing	I-ADR
pneumonia	I-ADR
after	O
rituximab	B-Drug
therapy	O
for	O
non-hodgkin	O
lymphoma	O
0	O
<EOS>	O
moreover	O
,	O
these	O
finding	O
suggest	O
that	O
the	O
incidence	O
of	O
boop	B-ADR
following	O
rituximab	B-Drug
therapy	O
may	O
be	O
higher	O
than	O
ha	O
been	O
previously	O
appreciated	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
boop	B-ADR
associated	O
with	O
single-agent	O
rituximab	O
,	O
and	O
along	O
with	O
two	O
other	O
patient	O
we	O
describe	O
,	O
a	O
well	O
a	O
two	O
prior	O
report	O
of	O
boop	O
in	O
nhl	O
patient	O
receiving	O
rituximab-based	B-Drug
combination	O
,	O
strengthens	O
the	O
possibility	O
of	O
a	O
causal	O
relationship	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
boop	B-ADR
associated	O
with	O
single-agent	O
rituximab	O
,	O
and	O
along	O
with	O
two	O
other	O
patient	O
we	O
describe	O
,	O
a	O
well	O
a	O
two	O
prior	O
report	O
of	O
boop	O
in	O
nhl	O
patient	O
receiving	O
rituximab-based	B-Drug
combination	O
,	O
strengthens	O
the	O
possibility	O
of	O
a	O
causal	O
relationship	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
an	O
nhl	O
patient	O
who	O
received	O
rituximab	B-Drug
and	O
developed	O
symptomatic	O
,	O
biopsy-proven	O
multinodular	O
bronchiolitis	B-ADR
obliterans	I-ADR
with	I-ADR
organizing	I-ADR
pneumonia	I-ADR
(	O
boop	O
)	O
0	O
<EOS>	O
despite	O
a	O
very	O
low	O
complication	O
rate	O
,	O
several	O
severe	B-ADR
arterial	I-ADR
thrombotic	I-ADR
event	I-ADR
have	O
been	O
reported	O
following	O
thrombin	B-Drug
injection	O
of	O
pseudoaneurysms	O
0	O
<EOS>	O
lower	O
extremity	O
arterial	B-ADR
thrombosis	I-ADR
following	O
sonographically	O
guided	O
thrombin	B-Drug
injection	O
of	O
a	O
femoral	O
pseudoaneurysm	O
0	O
<EOS>	O
native	O
arterial	B-ADR
thrombosis	I-ADR
,	O
though	O
recognized	O
a	O
a	O
severe	O
complication	O
of	O
thrombin	B-Drug
injection	O
,	O
ha	O
not	O
been	O
well	O
described	O
in	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
successful	O
surgical	O
management	O
of	O
arterial	B-ADR
thrombosis	I-ADR
after	O
percutaneous	O
thrombin	B-Drug
injection	O
of	O
a	O
femoral	O
artery	O
pseudoaneurysm	O
in	O
a	O
69-year-old	O
woman	O
0	O
<EOS>	O
a	O
small	O
number	O
of	O
oxaliplatin-related	B-Drug
hemolytic	B-ADR
and	I-ADR
/	I-ADR
or	I-ADR
thrombocytopenic	I-ADR
reaction	I-ADR
have	O
been	O
reported	O
0	O
<EOS>	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
following	O
the	O
infusion	O
of	O
oxaliplatin	B-Drug
:	O
case	O
report	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
that	O
developed	O
during	O
the	O
4th	O
cycle	O
of	O
combination	O
chemotherapy	O
with	O
oxaliplatin	O
,	O
5-fluorouracil	B-Drug
and	O
leucovorin	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
that	O
developed	O
during	O
the	O
4th	O
cycle	O
of	O
combination	O
chemotherapy	O
with	O
oxaliplatin	O
,	O
5-fluorouracil	O
and	O
leucovorin	B-Drug
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
that	O
developed	O
during	O
the	O
4th	O
cycle	O
of	O
combination	O
chemotherapy	O
with	O
oxaliplatin	B-Drug
,	O
5-fluorouracil	O
and	O
leucovorin	O
0	O
<EOS>	O
first	O
,	O
a	O
review	O
of	O
the	O
literature	O
produced	O
41	O
anecdotic	O
case	O
of	O
neutropenia	O
or	O
agranulocytosis	B-ADR
during	O
treatment	O
with	O
olanzapine	B-Drug
(	O
zyprexa	O
)	O
reported	O
in	O
a	O
total	O
of	O
24	O
publication	O
0	O
<EOS>	O
first	O
,	O
a	O
review	O
of	O
the	O
literature	O
produced	O
41	O
anecdotic	O
case	O
of	O
neutropenia	O
or	O
agranulocytosis	B-ADR
during	O
treatment	O
with	O
olanzapine	O
(	O
zyprexa	B-Drug
)	O
reported	O
in	O
a	O
total	O
of	O
24	O
publication	O
0	O
<EOS>	O
first	O
,	O
a	O
review	O
of	O
the	O
literature	O
produced	O
41	O
anecdotic	O
case	O
of	O
neutropenia	B-ADR
or	O
agranulocytosis	O
during	O
treatment	O
with	O
olanzapine	B-Drug
(	O
zyprexa	O
)	O
reported	O
in	O
a	O
total	O
of	O
24	O
publication	O
0	O
<EOS>	O
first	O
,	O
a	O
review	O
of	O
the	O
literature	O
produced	O
41	O
anecdotic	O
case	O
of	O
neutropenia	B-ADR
or	O
agranulocytosis	O
during	O
treatment	O
with	O
olanzapine	O
(	O
zyprexa	B-Drug
)	O
reported	O
in	O
a	O
total	O
of	O
24	O
publication	O
0	O
<EOS>	O
neutropenia	O
and	O
agranulocytosis	B-ADR
are	O
risk	O
known	O
to	O
occur	O
with	O
phenothiazine	O
and	O
clozapine	B-Drug
0	O
<EOS>	O
neutropenia	O
and	O
agranulocytosis	B-ADR
are	O
risk	O
known	O
to	O
occur	O
with	O
phenothiazine	B-Drug
and	O
clozapine	O
0	O
<EOS>	O
neutropenia	B-ADR
and	O
agranulocytosis	O
are	O
risk	O
known	O
to	O
occur	O
with	O
phenothiazine	O
and	O
clozapine	B-Drug
0	O
<EOS>	O
neutropenia	B-ADR
and	O
agranulocytosis	O
are	O
risk	O
known	O
to	O
occur	O
with	O
phenothiazine	B-Drug
and	O
clozapine	O
0	O
<EOS>	O
second	O
,	O
we	O
report	O
a	O
case	O
of	O
neutropenia	B-ADR
,	O
which	O
proved	O
to	O
be	O
fatal	O
in	O
a	O
schizophrenia	O
patient	O
receiving	O
olanzapine	B-Drug
and	O
thiazide	O
0	O
<EOS>	O
second	O
,	O
we	O
report	O
a	O
case	O
of	O
neutropenia	B-ADR
,	O
which	O
proved	O
to	O
be	O
fatal	O
in	O
a	O
schizophrenia	O
patient	O
receiving	O
olanzapine	O
and	O
thiazide	B-Drug
0	O
<EOS>	O
thus	O
any	O
case	O
of	O
severe	B-ADR
neutropenia	I-ADR
occurring	O
in	O
a	O
patient	O
receiving	O
olanzapine	B-Drug
is	O
alarming	O
to	O
clinician	O
0	O
<EOS>	O
we	O
present	O
a	O
depressive	O
patient	O
who	O
developed	O
mild	O
parkinsonian	O
sign	O
and	O
camptocormia	B-ADR
after	O
the	O
introduction	O
of	O
olanzapine	B-Drug
0	O
<EOS>	O
we	O
present	O
a	O
depressive	O
patient	O
who	O
developed	O
mild	B-ADR
parkinsonian	I-ADR
sign	I-ADR
and	O
camptocormia	O
after	O
the	O
introduction	O
of	O
olanzapine	B-Drug
0	O
<EOS>	O
five	O
month	O
after	O
initiating	O
mirtazapine	B-Drug
therapy	O
,	O
she	O
developed	O
symptomatic	B-ADR
hyponatremia	I-ADR
0	O
<EOS>	O
in	O
this	O
case	O
,	O
unlike	O
those	O
previously	O
reported	O
,	O
hyponatremia	B-ADR
recurred	O
5	O
month	O
after	O
switching	O
from	O
citalopram	B-Drug
to	O
mirtazapine	O
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
safe	O
antidepressant	O
0	O
<EOS>	O
in	O
this	O
case	O
,	O
unlike	O
those	O
previously	O
reported	O
,	O
hyponatremia	B-ADR
recurred	O
5	O
month	O
after	O
switching	O
from	O
citalopram	O
to	O
mirtazapine	B-Drug
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
safe	O
antidepressant	O
0	O
<EOS>	O
recurrent	B-ADR
hyponatremia	I-ADR
associated	O
with	O
citalopram	B-Drug
and	O
mirtazapine	O
0	O
<EOS>	O
recurrent	B-ADR
hyponatremia	I-ADR
associated	O
with	O
citalopram	O
and	O
mirtazapine	B-Drug
0	O
<EOS>	O
a	O
43-year-old	O
woman	O
with	O
multiple	O
sclerosis	O
(	O
m	O
)	O
had	O
nephrotic	B-ADR
syndrome	I-ADR
21	O
month	O
after	O
starting	O
treatment	O
with	O
interferon	B-Drug
(	I-Drug
ifn	I-Drug
)	I-Drug
-beta-1b	I-Drug
(	O
subcutaneous	O
administration	O
)	O
0	O
<EOS>	O
because	O
nephrotic	B-ADR
syndrome	I-ADR
may	O
be	O
induced	O
by	O
ifn	B-Drug
therapy	O
,	O
the	O
ifn	O
wa	O
stopped	O
0	O
<EOS>	O
because	O
nephrotic	B-ADR
syndrome	I-ADR
may	O
be	O
induced	O
by	O
ifn	B-Drug
therapy	O
,	O
the	O
ifn	O
wa	O
stopped	O
0	O
<EOS>	O
nephrotic	B-ADR
syndrome	I-ADR
associated	O
with	O
interferon-beta-1b	B-Drug
therapy	O
for	O
multiple	O
sclerosis	O
0	O
<EOS>	O
though	O
proteinuria	O
and	O
nephrotic	B-ADR
syndrome	I-ADR
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ifn-beta-1b	B-Drug
therapy	O
,	O
physician	O
treating	O
m	O
patient	O
with	O
this	O
agent	O
should	O
pay	O
careful	O
attention	O
to	O
new	O
clinical	O
symptom	O
and	O
laboratory	O
finding	O
0	O
<EOS>	O
though	O
proteinuria	B-ADR
and	O
nephrotic	O
syndrome	O
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ifn-beta-1b	B-Drug
therapy	O
,	O
physician	O
treating	O
m	O
patient	O
with	O
this	O
agent	O
should	O
pay	O
careful	O
attention	O
to	O
new	O
clinical	O
symptom	O
and	O
laboratory	O
finding	O
0	O
<EOS>	O
a	O
70-year-old	O
man	O
wa	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
dyspnea	B-ADR
after	O
taking	O
an	O
antihistaminic	O
agent	O
(	O
homochlorcyclizine	B-Drug
hydrochloride	I-Drug
)	O
for	O
itching	O
0	O
<EOS>	O
acute	B-ADR
eosinophilic	I-ADR
pneumonia	I-ADR
caused	O
by	O
calcium	B-Drug
stearate	I-Drug
,	O
an	O
additive	O
agent	O
for	O
an	O
oral	O
antihistaminic	O
medication	O
0	O
<EOS>	O
therefore	O
,	O
we	O
concluded	O
that	O
this	O
patient	O
pulmonary	B-ADR
disease	I-ADR
wa	O
caused	O
by	O
calcium	B-Drug
stearate	I-Drug
,	O
an	O
additive	O
for	O
an	O
antihistaminic	O
drug	O
0	O
<EOS>	O
scleritis	B-ADR
complicating	O
zoledronic	B-Drug
acid	I-Drug
infusion	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
severe	B-ADR
unilateral	I-ADR
posterior	I-ADR
scleritis	I-ADR
associated	O
with	O
zoledronic	B-Drug
acid	I-Drug
administration	O
that	O
wa	O
recognized	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
0	O
<EOS>	O
late	O
lethal	O
hepatitis	B-ADR
b	I-ADR
virus	I-ADR
reactivation	I-ADR
after	O
rituximab	B-Drug
treatment	O
of	O
low-grade	O
cutaneous	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
several	O
such	O
hbv	B-ADR
reactivations	I-ADR
were	O
reported	O
after	O
combined	O
rituximab	B-Drug
and	O
multiagent	O
chemotherapy	O
for	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
case	O
of	O
hbv	B-ADR
reactivation	I-ADR
occurring	O
during	O
the	O
year	O
following	O
rituximab	B-Drug
monotherapy	O
in	O
the	O
absence	O
of	O
any	O
other	O
immunosuppressive	O
factor	O
0	O
<EOS>	O
this	O
is	O
a	O
case	O
report	O
of	O
fatal	O
cryptococcal	B-ADR
meningitis	I-ADR
in	O
a	O
child	O
with	O
systemic	O
lupus	O
erythematosus	O
being	O
treated	O
with	O
prednisolone	O
and	O
azathioprine	B-Drug
0	O
<EOS>	O
this	O
is	O
a	O
case	O
report	O
of	O
fatal	O
cryptococcal	B-ADR
meningitis	I-ADR
in	O
a	O
child	O
with	O
systemic	O
lupus	O
erythematosus	O
being	O
treated	O
with	O
prednisolone	B-Drug
and	O
azathioprine	O
0	O
<EOS>	O
an	O
intertrigo-like	B-ADR
eruption	I-ADR
from	O
pegylated	O
liposomal	O
doxorubicin	B-Drug
0	O
<EOS>	O
this	O
eruption	B-ADR
appears	O
to	O
be	O
a	O
distinct	O
cutaneous	O
toxicity	O
of	O
pld	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
60-year-old	O
woman	O
who	O
developed	O
erythema	O
and	O
erosion	B-ADR
in	I-ADR
the	I-ADR
axilla	I-ADR
and	I-ADR
groin	I-ADR
while	O
on	O
pld	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
60-year-old	O
woman	O
who	O
developed	O
erythema	B-ADR
and	O
erosion	O
in	O
the	O
axilla	O
and	O
groin	O
while	O
on	O
pld	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
herein	O
is	O
reported	O
an	O
unusual	O
case	O
of	O
coexistent	O
warfarin-induced	B-Drug
skin	B-ADR
necrosis	I-ADR
and	O
heparin-induced	O
thrombocytopenia	O
following	O
mitral	O
valve	O
replacement	O
for	O
thromboembolic	O
phenomenon	O
associated	O
with	O
marantic	O
endocarditis	O
and	O
bronchial	O
adenocarcinoma	O
0	O
<EOS>	O
herein	O
is	O
reported	O
an	O
unusual	O
case	O
of	O
coexistent	O
warfarin-induced	O
skin	O
necrosis	O
and	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
following	O
mitral	O
valve	O
replacement	O
for	O
thromboembolic	O
phenomenon	O
associated	O
with	O
marantic	O
endocarditis	O
and	O
bronchial	O
adenocarcinoma	O
0	O
<EOS>	O
warfarin-induced	B-Drug
skin	B-ADR
necrosis	I-ADR
and	O
heparin-induced	O
thrombocytopenia	O
following	O
mitral	O
valve	O
replacement	O
for	O
marantic	O
endocarditis	O
0	O
<EOS>	O
warfarin-induced	O
skin	O
necrosis	O
and	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
following	O
mitral	O
valve	O
replacement	O
for	O
marantic	O
endocarditis	O
0	O
<EOS>	O
exposure	O
of	O
the	O
fetus	O
to	O
indomethacin	B-Drug
by	O
administration	O
of	O
the	O
drug	O
to	O
the	O
mother	O
may	O
cause	O
many	O
side	O
effect	O
,	O
including	O
premature	B-ADR
closure	I-ADR
of	I-ADR
the	I-ADR
ductus	I-ADR
arteriosus	I-ADR
0	O
<EOS>	O
hypoxia	B-ADR
is	O
a	O
predisposing	O
factor	O
for	O
premature	O
ductal	O
closure	O
and	O
often	O
occurs	O
after	O
maternal	O
indomethacin	B-Drug
therapy	O
0	O
<EOS>	O
hypoxia	O
is	O
a	O
predisposing	O
factor	O
for	O
premature	B-ADR
ductal	I-ADR
closure	I-ADR
and	O
often	O
occurs	O
after	O
maternal	O
indomethacin	B-Drug
therapy	O
0	O
<EOS>	O
premature	B-ADR
closure	I-ADR
of	I-ADR
the	I-ADR
ductus	I-ADR
arteriosus	I-ADR
:	O
variable	O
response	O
among	O
monozygotic	O
twin	O
after	O
in	O
utero	O
exposure	O
to	O
indomethacin	B-Drug
0	O
<EOS>	O
this	O
selective	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
suggests	O
that	O
the	O
affected	O
twin	O
wa	O
predisposed	O
to	O
hypoxia	O
and	O
thus	O
wa	O
more	O
susceptible	O
to	O
ductal	B-ADR
closure	I-ADR
in	O
response	O
to	O
indomethacin	B-Drug
exposure	O
0	O
<EOS>	O
this	O
selective	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
suggests	O
that	O
the	O
affected	O
twin	O
wa	O
predisposed	O
to	O
hypoxia	B-ADR
and	O
thus	O
wa	O
more	O
susceptible	O
to	O
ductal	O
closure	O
in	O
response	O
to	O
indomethacin	B-Drug
exposure	O
0	O
<EOS>	O
conclusion	O
:	O
these	O
case	O
suggest	O
that	O
moxifloxacin	B-Drug
may	O
interfere	O
with	O
the	O
healing	O
of	O
corneal	B-ADR
ulcer	I-ADR
0	O
<EOS>	O
result	O
:	O
both	O
case	O
presented	O
here	O
describe	O
corneal	B-ADR
ulcer	I-ADR
that	O
persisted	O
and	O
showed	O
sign	O
of	O
worsening	O
during	O
week	O
of	O
frequent	O
topical	O
dosing	O
with	O
moxifloxacin	B-Drug
0	O
<EOS>	O
severe	B-ADR
corneal	I-ADR
toxicity	I-ADR
after	O
topical	O
fluoroquinolone	B-Drug
therapy	O
:	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
acute	B-ADR
generalized	I-ADR
exanthematous	I-ADR
pustulosis	I-ADR
induced	O
by	O
nimesulide	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acute	B-ADR
generalized	I-ADR
exanthematous	I-ADR
pustulosis	I-ADR
(	O
agep	O
)	O
in	O
a	O
50-year-old	O
woman	O
that	O
wa	O
attributed	O
to	O
the	O
ingestion	O
of	O
nimesulide	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(	O
agep	B-ADR
)	O
in	O
a	O
50-year-old	O
woman	O
that	O
wa	O
attributed	O
to	O
the	O
ingestion	O
of	O
nimesulide	B-Drug
0	O
<EOS>	O
discussion	O
:	O
amphotericin	B-Drug
b	I-Drug
deoxycholate	I-Drug
ha	O
been	O
reported	O
to	O
produce	O
significant	O
cardiac	O
toxicity	O
,	O
with	O
ventricular	O
arrhythmia	O
and	O
bradycardia	B-ADR
reported	O
in	O
overdoses	O
in	O
child	O
and	O
in	O
adult	O
with	O
preexisting	O
cardiac	O
disease	O
,	O
even	O
when	O
administered	O
in	O
conventional	O
dosage	O
and	O
infusion	O
rate	O
0	O
<EOS>	O
discussion	O
:	O
amphotericin	B-Drug
b	I-Drug
deoxycholate	I-Drug
ha	O
been	O
reported	O
to	O
produce	O
significant	O
cardiac	B-ADR
toxicity	I-ADR
,	O
with	O
ventricular	O
arrhythmia	O
and	O
bradycardia	O
reported	O
in	O
overdoses	O
in	O
child	O
and	O
in	O
adult	O
with	O
preexisting	O
cardiac	O
disease	O
,	O
even	O
when	O
administered	O
in	O
conventional	O
dosage	O
and	O
infusion	O
rate	O
0	O
<EOS>	O
discussion	O
:	O
amphotericin	B-Drug
b	I-Drug
deoxycholate	I-Drug
ha	O
been	O
reported	O
to	O
produce	O
significant	O
cardiac	O
toxicity	O
,	O
with	O
ventricular	B-ADR
arrhythmia	I-ADR
and	O
bradycardia	O
reported	O
in	O
overdoses	O
in	O
child	O
and	O
in	O
adult	O
with	O
preexisting	O
cardiac	O
disease	O
,	O
even	O
when	O
administered	O
in	O
conventional	O
dosage	O
and	O
infusion	O
rate	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
clinical	O
course	O
of	O
a	O
woman	O
with	O
cryptococcal	O
meningitis	O
and	O
no	O
previous	O
cardiac	O
disease	O
who	O
developed	O
a	O
fatal	B-ADR
cardiac	I-ADR
arrhythmia	I-ADR
after	O
an	O
acute	O
overdose	O
of	O
amphotericin	B-Drug
b	I-Drug
and	O
to	O
review	O
it	O
toxicity	O
0	O
<EOS>	O
use	O
of	O
the	O
naranjo	O
probability	O
scale	O
indicated	O
a	O
highly	O
probable	O
relationship	O
between	O
the	O
observed	O
cardiac	B-ADR
toxicity	I-ADR
and	O
amphotericin	B-Drug
b	I-Drug
deoxycholate	I-Drug
therapy	O
in	O
this	O
patient	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
valvular	B-ADR
heart	I-ADR
disease	I-ADR
in	O
a	O
48-year-old	O
woman	O
receiving	O
benfluorex	B-Drug
(	O
150	O
mg	O
t.i.d	O
0	O
for	O
8	O
year	O
)	O
and	O
leading	O
to	O
surgical	O
mitral	O
valve	O
replacement	O
0	O
<EOS>	O
valvular	B-ADR
heart	I-ADR
disease	I-ADR
in	O
a	O
patient	O
taking	O
benfluorex	B-Drug
0	O
<EOS>	O
the	O
main	O
side-effects	O
of	O
lp-tae	B-Drug
combined	O
with	O
ht	O
were	O
low-grade	O
fever	O
,	O
localized	O
pain	O
,	O
myelo-suppression	O
and	O
liver	B-ADR
dysfunction	I-ADR
,	O
but	O
these	O
were	O
transient	O
and	O
eventually	O
disappeared	O
0	O
<EOS>	O
the	O
main	O
side-effects	O
of	O
lp-tae	B-Drug
combined	O
with	O
ht	O
were	O
low-grade	O
fever	O
,	O
localized	B-ADR
pain	I-ADR
,	O
myelo-suppression	O
and	O
liver	O
dysfunction	O
,	O
but	O
these	O
were	O
transient	O
and	O
eventually	O
disappeared	O
0	O
<EOS>	O
the	O
main	O
side-effects	O
of	O
lp-tae	B-Drug
combined	O
with	O
ht	O
were	O
low-grade	B-ADR
fever	I-ADR
,	O
localized	O
pain	O
,	O
myelo-suppression	O
and	O
liver	O
dysfunction	O
,	O
but	O
these	O
were	O
transient	O
and	O
eventually	O
disappeared	O
0	O
<EOS>	O
the	O
main	O
side-effects	O
of	O
lp-tae	B-Drug
combined	O
with	O
ht	O
were	O
low-grade	O
fever	O
,	O
localized	O
pain	O
,	O
myelo-suppression	B-ADR
and	O
liver	O
dysfunction	O
,	O
but	O
these	O
were	O
transient	O
and	O
eventually	O
disappeared	O
0	O
<EOS>	O
tacrolimus-induced	B-Drug
hus	O
:	O
an	O
unusual	O
cause	O
of	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
tacrolimus-induced	B-Drug
hus	B-ADR
:	O
an	O
unusual	O
cause	O
of	O
acute	O
renal	O
failure	O
in	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
thus	O
,	O
tacrolimus-induced	B-Drug
hus	O
is	O
a	O
rare	O
cause	O
of	O
arf	B-ADR
in	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
thus	O
,	O
tacrolimus-induced	B-Drug
hus	B-ADR
is	O
a	O
rare	O
cause	O
of	O
arf	O
in	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
liver	O
transplantation	O
for	O
fulminant	B-ADR
hepatitis	I-ADR
related	O
to	O
nevirapine	B-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
a	O
detailed	O
case	O
of	O
fulminant	B-ADR
hepatitis	I-ADR
induced	O
by	O
nevirapine	B-Drug
(	O
viramune	O
)	O
and	O
treated	O
by	O
liver	O
transplantation	O
0	O
<EOS>	O
we	O
describe	O
a	O
detailed	O
case	O
of	O
fulminant	B-ADR
hepatitis	I-ADR
induced	O
by	O
nevirapine	O
(	O
viramune	B-Drug
)	O
and	O
treated	O
by	O
liver	O
transplantation	O
0	O
<EOS>	O
cholelithiasis	B-ADR
and	O
thrombosis	O
of	O
the	O
central	O
retinal	O
vein	O
in	O
a	O
renal	O
transplant	O
recipient	O
treated	O
with	O
cyclosporin	B-Drug
0	O
<EOS>	O
cholelithiasis	O
and	O
thrombosis	B-ADR
of	I-ADR
the	I-ADR
central	I-ADR
retinal	I-ADR
vein	I-ADR
in	O
a	O
renal	O
transplant	O
recipient	O
treated	O
with	O
cyclosporin	B-Drug
0	O
<EOS>	O
in	O
this	O
report	O
,	O
a	O
patient	O
who	O
had	O
undergone	O
a	O
renal	O
transplantation	O
a	O
a	O
result	O
of	O
malignant	O
hypertension	O
,	O
and	O
who	O
wa	O
on	O
immunosuppressive	O
therapy	O
consisting	O
of	O
cyclosporin	O
,	O
prednisone	O
and	O
azathioprine	B-Drug
,	O
developed	O
thrombosis	B-ADR
of	O
the	O
central	O
retinal	O
vein	O
5	O
year	O
following	O
the	O
transplantation	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
a	O
patient	O
who	O
had	O
undergone	O
a	O
renal	O
transplantation	O
a	O
a	O
result	O
of	O
malignant	O
hypertension	O
,	O
and	O
who	O
wa	O
on	O
immunosuppressive	O
therapy	O
consisting	O
of	O
cyclosporin	B-Drug
,	O
prednisone	O
and	O
azathioprine	O
,	O
developed	O
thrombosis	B-ADR
of	O
the	O
central	O
retinal	O
vein	O
5	O
year	O
following	O
the	O
transplantation	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
a	O
patient	O
who	O
had	O
undergone	O
a	O
renal	O
transplantation	O
a	O
a	O
result	O
of	O
malignant	O
hypertension	O
,	O
and	O
who	O
wa	O
on	O
immunosuppressive	O
therapy	O
consisting	O
of	O
cyclosporin	O
,	O
prednisone	B-Drug
and	O
azathioprine	O
,	O
developed	O
thrombosis	B-ADR
of	O
the	O
central	O
retinal	O
vein	O
5	O
year	O
following	O
the	O
transplantation	O
0	O
<EOS>	O
the	O
use	O
of	O
cyclosporin	B-Drug
ha	O
been	O
associated	O
with	O
the	O
development	O
of	O
cholelithiasis	B-ADR
in	O
transplant	O
recipient	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
induced	O
by	O
cyproterone	B-Drug
acetate	I-Drug
:	O
a	O
report	O
of	O
three	O
case	O
0	O
<EOS>	O
three	O
male	O
patient	O
aged	O
78-83	O
year	O
are	O
presented	O
,	O
in	O
whom	O
severe	B-ADR
hepatotoxic	I-ADR
reaction	I-ADR
emerged	O
after	O
cpa	B-Drug
administration	O
0	O
<EOS>	O
case	O
presentation	O
:	O
three	O
case	O
of	O
leishmania	O
infantum	O
leishmaniasis	O
in	O
corticosteroid	O
(	O
c	B-Drug
)	O
-treated	O
patient	O
are	O
reported	O
:	O
an	O
isolated	O
lingual	O
leishmaniasis	O
in	O
a	O
farmer	O
treated	O
with	O
c	O
for	O
asthma	O
,	O
a	O
severe	O
visceral	O
leishmaniasis	O
associated	O
with	O
cutaneous	O
lesion	O
in	O
a	O
woman	O
with	O
myasthenia	O
gravis	O
,	O
and	O
a	O
visceral	O
involvement	O
after	O
cutaneous	B-ADR
leishmaniasis	I-ADR
in	O
a	O
man	O
receiving	O
c	O
0	O
<EOS>	O
case	O
presentation	O
:	O
three	O
case	O
of	O
leishmania	B-ADR
infantum	I-ADR
leishmaniasis	I-ADR
in	O
corticosteroid	B-Drug
(	O
c	O
)	O
-treated	O
patient	O
are	O
reported	O
:	O
an	O
isolated	O
lingual	O
leishmaniasis	O
in	O
a	O
farmer	O
treated	O
with	O
c	O
for	O
asthma	O
,	O
a	O
severe	O
visceral	O
leishmaniasis	O
associated	O
with	O
cutaneous	O
lesion	O
in	O
a	O
woman	O
with	O
myasthenia	O
gravis	O
,	O
and	O
a	O
visceral	O
involvement	O
after	O
cutaneous	O
leishmaniasis	O
in	O
a	O
man	O
receiving	O
c	O
0	O
<EOS>	O
case	O
presentation	O
:	O
three	O
case	O
of	O
leishmania	B-ADR
infantum	I-ADR
leishmaniasis	I-ADR
in	O
corticosteroid	O
(	O
c	B-Drug
)	O
-treated	O
patient	O
are	O
reported	O
:	O
an	O
isolated	O
lingual	O
leishmaniasis	O
in	O
a	O
farmer	O
treated	O
with	O
c	O
for	O
asthma	O
,	O
a	O
severe	O
visceral	O
leishmaniasis	O
associated	O
with	O
cutaneous	O
lesion	O
in	O
a	O
woman	O
with	O
myasthenia	O
gravis	O
,	O
and	O
a	O
visceral	O
involvement	O
after	O
cutaneous	O
leishmaniasis	O
in	O
a	O
man	O
receiving	O
c	O
0	O
<EOS>	O
case	O
presentation	O
:	O
three	O
case	O
of	O
leishmania	O
infantum	O
leishmaniasis	O
in	O
corticosteroid	B-Drug
(	O
c	O
)	O
-treated	O
patient	O
are	O
reported	O
:	O
an	O
isolated	O
lingual	B-ADR
leishmaniasis	I-ADR
in	O
a	O
farmer	O
treated	O
with	O
c	O
for	O
asthma	O
,	O
a	O
severe	O
visceral	O
leishmaniasis	O
associated	O
with	O
cutaneous	O
lesion	O
in	O
a	O
woman	O
with	O
myasthenia	O
gravis	O
,	O
and	O
a	O
visceral	O
involvement	O
after	O
cutaneous	O
leishmaniasis	O
in	O
a	O
man	O
receiving	O
c	O
0	O
<EOS>	O
case	O
presentation	O
:	O
three	O
case	O
of	O
leishmania	O
infantum	O
leishmaniasis	O
in	O
corticosteroid	O
(	O
c	B-Drug
)	O
-treated	O
patient	O
are	O
reported	O
:	O
an	O
isolated	O
lingual	B-ADR
leishmaniasis	I-ADR
in	O
a	O
farmer	O
treated	O
with	O
c	O
for	O
asthma	O
,	O
a	O
severe	O
visceral	O
leishmaniasis	O
associated	O
with	O
cutaneous	O
lesion	O
in	O
a	O
woman	O
with	O
myasthenia	O
gravis	O
,	O
and	O
a	O
visceral	O
involvement	O
after	O
cutaneous	O
leishmaniasis	O
in	O
a	O
man	O
receiving	O
c	O
0	O
<EOS>	O
leishmania	B-ADR
infantum	I-ADR
leishmaniasis	I-ADR
in	O
corticosteroid	B-Drug
--	O
treated	O
patient	O
0	O
<EOS>	O
however	O
,	O
an	O
association	O
of	O
ritalin	B-Drug
with	O
glaucoma	B-ADR
ha	O
been	O
reported	O
0	O
<EOS>	O
large	O
dose	O
of	O
methylphenidate	B-Drug
may	O
cause	O
cataract	B-ADR
and	O
glaucoma	O
0	O
<EOS>	O
large	O
dose	O
of	O
methylphenidate	B-Drug
may	O
cause	O
cataract	O
and	O
glaucoma	B-ADR
0	O
<EOS>	O
methylphenidate	B-Drug
(	O
ritalin	O
)	O
-associated	O
cataract	B-ADR
and	O
glaucoma	O
0	O
<EOS>	O
methylphenidate	O
(	O
ritalin	B-Drug
)	O
-associated	O
cataract	B-ADR
and	O
glaucoma	O
0	O
<EOS>	O
methylphenidate	B-Drug
(	O
ritalin	O
)	O
-associated	O
cataract	O
and	O
glaucoma	B-ADR
0	O
<EOS>	O
methylphenidate	O
(	O
ritalin	B-Drug
)	O
-associated	O
cataract	O
and	O
glaucoma	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
ritalin-associated	B-Drug
cataract	B-ADR
and	O
glaucoma	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
ritalin-associated	B-Drug
cataract	O
and	O
glaucoma	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
a	O
typical	O
symptom	O
of	O
charles-bonnet	O
syndrome	O
(	O
cbs	B-ADR
)	O
in	O
patient	O
with	O
severe	O
amd	O
after	O
intravitreal	O
avastin-injections	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
a	O
typical	O
symptom	O
of	O
charles-bonnet	B-ADR
syndrome	I-ADR
(	O
cbs	O
)	O
in	O
patient	O
with	O
severe	O
amd	O
after	O
intravitreal	O
avastin-injections	B-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
transient	B-ADR
structured	I-ADR
visual	I-ADR
hallucination	I-ADR
in	O
a	O
patient	O
with	O
vascular	O
age-related	O
macular	O
degeneration	O
(	O
amd	O
)	O
,	O
following	O
an	O
intravitreal	O
avastin-injection	B-Drug
0	O
<EOS>	O
visual	B-ADR
hallucination	I-ADR
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
in	O
vascular	O
age-related	O
macular	O
degeneration	O
0	O
<EOS>	O
a	O
case	O
of	O
metoclopramide-induced	B-Drug
oculogyric	B-ADR
crisis	I-ADR
in	O
a	O
16-year-old	O
girl	O
with	O
cystic	O
fibrosis	O
0	O
<EOS>	O
a	O
case	O
of	O
oculogyric	B-ADR
crisis	I-ADR
induced	O
by	O
metoclopramide	B-Drug
is	O
described	O
in	O
this	O
paper	O
0	O
<EOS>	O
however	O
,	O
cyclosporine	B-Drug
dependency	O
is	O
associated	O
with	O
the	O
risk	O
of	O
nephrotoxicity	B-ADR
0	O
<EOS>	O
quinapril	B-Drug
is	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
ace-inhibitor	O
)	O
and	O
overdose	O
can	O
lead	O
to	O
prolonged	B-ADR
hypotension	I-ADR
and	O
,	O
le	O
frequently	O
,	O
transient	O
renal	O
impairment	O
0	O
<EOS>	O
quinapril	B-Drug
is	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
ace-inhibitor	O
)	O
and	O
overdose	O
can	O
lead	O
to	O
prolonged	O
hypotension	O
and	O
,	O
le	O
frequently	O
,	O
transient	B-ADR
renal	I-ADR
impairment	I-ADR
0	O
<EOS>	O
cardiomyopathy	B-ADR
after	O
widely	O
separated	O
course	O
of	O
adriamycin	O
exacerbated	O
by	O
actinomycin-d	B-Drug
and	O
mithramycin	O
0	O
<EOS>	O
cardiomyopathy	B-ADR
after	O
widely	O
separated	O
course	O
of	O
adriamycin	B-Drug
exacerbated	O
by	O
actinomycin-d	O
and	O
mithramycin	O
0	O
<EOS>	O
cardiomyopathy	B-ADR
after	O
widely	O
separated	O
course	O
of	O
adriamycin	O
exacerbated	O
by	O
actinomycin-d	O
and	O
mithramycin	B-Drug
0	O
<EOS>	O
exacerbation	B-ADR
of	I-ADR
the	I-ADR
heart	I-ADR
failure	I-ADR
were	O
temporally	O
related	O
to	O
the	O
administration	O
of	O
the	O
antitumor	O
antibiotic	O
actinomycin-d	B-Drug
(	O
nsc-3053	O
)	O
and	O
mithramycin	O
(	O
nsc-24559	O
)	O
0	O
<EOS>	O
exacerbation	B-ADR
of	I-ADR
the	I-ADR
heart	I-ADR
failure	I-ADR
were	O
temporally	O
related	O
to	O
the	O
administration	O
of	O
the	O
antitumor	O
antibiotic	O
actinomycin-d	O
(	O
nsc-3053	O
)	O
and	O
mithramycin	B-Drug
(	O
nsc-24559	O
)	O
0	O
<EOS>	O
exacerbation	B-ADR
of	I-ADR
the	I-ADR
heart	I-ADR
failure	I-ADR
were	O
temporally	O
related	O
to	O
the	O
administration	O
of	O
the	O
antitumor	O
antibiotic	O
actinomycin-d	O
(	O
nsc-3053	O
)	O
and	O
mithramycin	O
(	O
nsc-24559	B-Drug
)	O
0	O
<EOS>	O
exacerbation	B-ADR
of	I-ADR
the	I-ADR
heart	I-ADR
failure	I-ADR
were	O
temporally	O
related	O
to	O
the	O
administration	O
of	O
the	O
antitumor	O
antibiotic	O
actinomycin-d	O
(	O
nsc-3053	B-Drug
)	O
and	O
mithramycin	O
(	O
nsc-24559	O
)	O
0	O
<EOS>	O
the	O
pathogenic	O
mechanism	O
involved	O
in	O
the	O
development	O
of	O
adriamycin	B-Drug
cardiomyopathy	B-ADR
are	O
reviewed	O
,	O
and	O
the	O
possible	O
synergistic	O
effect	O
of	O
other	O
antitumor	O
antibiotic	O
is	O
discussed	O
0	O
<EOS>	O
cardiac	B-ADR
hypersensitivity	I-ADR
and	O
myopericarditis	O
have	O
been	O
reported	O
during	O
long-term	O
treatment	O
with	O
mesalazine	B-Drug
0	O
<EOS>	O
cardiac	O
hypersensitivity	O
and	O
myopericarditis	B-ADR
have	O
been	O
reported	O
during	O
long-term	O
treatment	O
with	O
mesalazine	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
man	O
,	O
treated	O
with	O
mesalazine	B-Drug
for	O
crohn	O
disease	O
who	O
developed	O
drug-induced	O
pericarditis	B-ADR
0	O
<EOS>	O
acute	O
drug	O
induced	O
hepatitis	B-ADR
due	O
to	O
erlotinib	B-Drug
0	O
<EOS>	O
case	O
report	O
:	O
we	O
report	O
a	O
case	O
of	O
acute	B-ADR
severe	I-ADR
hepatitis	I-ADR
resulting	O
from	O
erlotinib	B-Drug
monotherapy	O
in	O
a	O
patient	O
with	O
locally	O
advanced	O
pancreatic	O
cancer	O
0	O
<EOS>	O
conclusion	O
:	O
acute	B-ADR
severe	I-ADR
hepatitis	I-ADR
though	O
rare	O
is	O
occasionally	O
observed	O
with	O
egfr	O
inhibitor	O
gefitinib	O
or	O
erlotinib	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
acute	B-ADR
severe	I-ADR
hepatitis	I-ADR
though	O
rare	O
is	O
occasionally	O
observed	O
with	O
egfr	O
inhibitor	O
gefitinib	B-Drug
or	O
erlotinib	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
resolved	O
once	O
erlotinib	B-Drug
wa	O
discontinued	O
and	O
serum	O
transaminase	O
returned	O
to	O
baseline	O
normal	O
value	O
0	O
<EOS>	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
and	O
thrombosis	O
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	O
therapy	O
0	O
<EOS>	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
and	O
thrombosis	O
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	O
therapy	O
0	O
<EOS>	O
heparin-associated	B-Drug
thrombocytopenia	O
and	O
thrombosis	B-ADR
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	O
therapy	O
0	O
<EOS>	O
heparin-associated	B-Drug
thrombocytopenia	O
and	O
thrombosis	B-ADR
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	O
therapy	O
0	O
<EOS>	O
this	O
experience	O
support	O
the	O
hypothesis	O
that	O
heparin	O
can	O
be	O
readministered	O
early	O
to	O
patient	O
with	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
and	O
thrombosis	O
,	O
provided	O
antiplatelet	O
therapy	O
is	O
given	O
0	O
<EOS>	O
this	O
experience	O
support	O
the	O
hypothesis	O
that	O
heparin	O
can	O
be	O
readministered	O
early	O
to	O
patient	O
with	O
heparin-associated	B-Drug
thrombocytopenia	O
and	O
thrombosis	B-ADR
,	O
provided	O
antiplatelet	O
therapy	O
is	O
given	O
0	O
<EOS>	O
usefulness	O
of	O
antiplatelet	O
drug	O
in	O
the	O
management	O
of	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
and	O
thrombosis	O
0	O
<EOS>	O
usefulness	O
of	O
antiplatelet	O
drug	O
in	O
the	O
management	O
of	O
heparin-associated	B-Drug
thrombocytopenia	O
and	O
thrombosis	B-ADR
0	O
<EOS>	O
result	O
:	O
a	O
clinical	O
diagnosis	O
of	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
owing	O
to	O
use	O
of	O
the	O
pde5	O
inhibitor	O
tadalafil	O
(	O
cialis	B-Drug
)	O
wa	O
made	O
0	O
<EOS>	O
result	O
:	O
a	O
clinical	O
diagnosis	O
of	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
owing	O
to	O
use	O
of	O
the	O
pde5	O
inhibitor	O
tadalafil	B-Drug
(	O
cialis	O
)	O
wa	O
made	O
0	O
<EOS>	O
even	O
though	O
only	O
a	O
few	O
case	O
of	O
this	O
adverse	O
event	O
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
severe	O
docetaxel-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
need	O
to	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
when	O
such	O
patient	O
present	O
with	O
respiratory	O
symptom	O
0	O
<EOS>	O
fatal	B-ADR
interstitial	I-ADR
pneumonitis	I-ADR
associated	O
with	O
docetaxel	B-Drug
administration	O
in	O
a	O
patient	O
with	O
hormone-refractory	O
prostate	O
cancer	O
0	O
<EOS>	O
the	O
case	O
is	O
presented	O
of	O
a	O
72-year-old	O
man	O
with	O
hormone-refractory	O
prostate	O
cancer	O
and	O
weekly	O
administration	O
of	O
30	O
mg	O
/	O
m2	O
docetaxel	B-Drug
who	O
developed	O
subacute	B-ADR
interstitial	I-ADR
pneumonitis-related	I-ADR
pulmonary	I-ADR
fibrosis	I-ADR
after	O
seven	O
dos	O
and	O
died	O
despite	O
mechanical	O
ventilation	O
and	O
high-dose	O
corticosteroid	O
treatment	O
0	O
<EOS>	O
the	O
patient	O
presented	O
with	O
fulminant	B-ADR
microangiopathic	I-ADR
hemolytic	I-ADR
anemia	I-ADR
and	O
thrombocytopenia	O
within	O
48	O
hr	O
of	O
initiating	O
therapy	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
the	O
patient	O
presented	O
with	O
fulminant	B-ADR
microangiopathic	I-ADR
hemolytic	I-ADR
anemia	I-ADR
and	O
thrombocytopenia	O
within	O
48	O
hr	O
of	O
initiating	O
therapy	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
the	O
patient	O
presented	O
with	O
fulminant	O
microangiopathic	O
hemolytic	O
anemia	O
and	O
thrombocytopenia	B-ADR
within	O
48	O
hr	O
of	O
initiating	O
therapy	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
the	O
patient	O
presented	O
with	O
fulminant	O
microangiopathic	O
hemolytic	O
anemia	O
and	O
thrombocytopenia	B-ADR
within	O
48	O
hr	O
of	O
initiating	O
therapy	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
induced	O
by	O
trimethoprim-sulfamethoxazole	B-Drug
in	O
a	O
jehovah	O
witness	O
0	O
<EOS>	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
induced	O
by	O
trimethoprim-sulfamethoxazole	B-Drug
in	O
a	O
jehovah	O
witness	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
occurring	O
a	O
an	O
allergic	O
response	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
therapy	O
(	O
bactrim	O
,	O
septra	O
)	O
in	O
a	O
jehovah	O
witness	O
patient	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
occurring	O
a	O
an	O
allergic	O
response	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
therapy	O
(	O
bactrim	O
,	O
septra	O
)	O
in	O
a	O
jehovah	O
witness	O
patient	O
0	O
<EOS>	O
juvenile	B-ADR
absence	I-ADR
epilepsy	I-ADR
exacerbated	O
by	O
valproic	B-Drug
acid	I-Drug
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
paradoxical	B-Drug
,	O
intravenous	O
valproic	O
acid-induced	O
seizure	B-ADR
exacerbation	I-ADR
in	O
a	O
child	O
with	O
juvenile	O
absence	O
epilepsy	O
,	O
documented	O
by	O
video-electroencephalography	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
paradoxical	O
,	O
intravenous	O
valproic	B-Drug
acid-induced	I-Drug
seizure	B-ADR
exacerbation	I-ADR
in	O
a	O
child	O
with	O
juvenile	O
absence	O
epilepsy	O
,	O
documented	O
by	O
video-electroencephalography	O
0	O
<EOS>	O
acute	B-ADR
endophthalmitis	I-ADR
following	O
intravitreal	O
bevacizumab	O
(	O
avastin	B-Drug
)	O
injection	O
0	O
<EOS>	O
acute	B-ADR
endophthalmitis	I-ADR
following	O
intravitreal	O
bevacizumab	B-Drug
(	O
avastin	O
)	O
injection	O
0	O
<EOS>	O
conclusion	O
:	O
infectious	B-ADR
endophthalmitis	I-ADR
is	O
a	O
potential	O
complication	O
of	O
intravitreal	O
bevacizumab	B-Drug
injection	O
0	O
<EOS>	O
method	O
:	O
two	O
patient	O
with	O
exudative	O
age-related	B-ADR
macular	I-ADR
degeneration	I-ADR
were	O
treated	O
sequentially	O
with	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
and	O
developed	O
sign	O
of	O
severe	O
but	O
painless	O
infectious	O
endophthalmitis	O
2	O
day	O
later	O
0	O
<EOS>	O
method	O
:	O
two	O
patient	O
with	O
exudative	O
age-related	O
macular	O
degeneration	O
were	O
treated	O
sequentially	O
with	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
and	O
developed	O
sign	O
of	O
severe	O
but	O
painless	B-ADR
infectious	I-ADR
endophthalmitis	I-ADR
2	O
day	O
later	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
two	O
case	O
of	O
acute	B-ADR
endophthalmitis	I-ADR
following	O
intravitreal	O
bevacizumab	B-Drug
injection	O
0	O
<EOS>	O
pulmonary	B-ADR
hypertension	I-ADR
during	O
lithium	B-Drug
therapy	O
:	O
clinical	O
case	O
study	O
0	O
<EOS>	O
the	O
author	O
presented	O
a	O
case	O
of	O
pulmonary	B-ADR
hypertension	I-ADR
during	O
lithium	B-Drug
therapy	O
,	O
while	O
she	O
ha	O
been	O
on	O
lithium	O
for	O
6	O
year	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
pulmonary	B-ADR
hypertension	I-ADR
in	O
an	O
adult	O
patient	O
during	O
lithium	B-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
arthritis	B-ADR
flared	O
after	O
the	O
second	O
infusion	O
of	O
infliximab	B-Drug
,	O
which	O
wa	O
discontinued	O
0	O
<EOS>	O
a	O
32-year-old	O
man	O
with	O
a	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
mellitus	O
presented	O
with	O
circulatory	B-ADR
collapse	I-ADR
and	O
deep	O
coma	O
after	O
9	O
day	O
of	O
treatment	O
with	O
perospirone	B-Drug
hydrochloride	I-Drug
,	O
a	O
recently	O
developed	O
atypical	O
antipsychotic	O
agent	O
available	O
only	O
in	O
japan	O
0	O
<EOS>	O
a	O
32-year-old	O
man	O
with	O
a	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
mellitus	O
presented	O
with	O
circulatory	O
collapse	O
and	O
deep	B-ADR
coma	I-ADR
after	O
9	O
day	O
of	O
treatment	O
with	O
perospirone	B-Drug
hydrochloride	I-Drug
,	O
a	O
recently	O
developed	O
atypical	O
antipsychotic	O
agent	O
available	O
only	O
in	O
japan	O
0	O
<EOS>	O
the	O
risk	O
of	O
new-onset	O
diabetic	B-ADR
ketoacidosis	I-ADR
in	O
patient	O
with	O
diabetic	O
risk	O
factor	O
who	O
are	O
taking	O
perospirone	B-Drug
hydrochloride	I-Drug
or	O
other	O
atypical	O
antipsychotic	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
fatal	B-ADR
venous	I-ADR
thrombembolism	I-ADR
complicating	O
imatinib	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
metastatic	O
gastrointestinal	O
stromal	O
tumor	O
0	O
<EOS>	O
the	O
possibility	O
of	O
deep	B-ADR
vein	I-ADR
thrombosis	I-ADR
caused	O
by	O
the	O
compression	O
of	O
the	O
vein	O
by	O
necrotic	O
tumor	O
should	O
be	O
considered	O
in	O
patient	O
with	O
abdominal	O
or	O
pelvic	O
metastasis	O
of	O
gist	O
,	O
including	O
patient	O
treated	O
with	O
imatinib	B-Drug
0	O
<EOS>	O
we	O
describe	O
the	O
case	O
of	O
a	O
50-year-old	O
woman	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
who	O
developed	O
status	B-ADR
epilepticus	I-ADR
shortly	O
after	O
receiving	O
cisplatin	B-Drug
and	O
gemcitabine	O
chemotherapy	O
0	O
<EOS>	O
we	O
describe	O
the	O
case	O
of	O
a	O
50-year-old	O
woman	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
who	O
developed	O
status	B-ADR
epilepticus	I-ADR
shortly	O
after	O
receiving	O
cisplatin	O
and	O
gemcitabine	B-Drug
chemotherapy	O
0	O
<EOS>	O
of	O
particular	O
interest	O
in	O
this	O
patient	O
is	O
the	O
fluctuation	B-ADR
of	I-ADR
the	I-ADR
qt	I-ADR
interval	I-ADR
at	O
a	O
stable	O
dose	O
of	O
methadone	B-Drug
,	O
suggesting	O
that	O
a	O
single	O
normal	O
electrocardiogram	O
(	O
ecg	O
)	O
doe	O
not	O
guarantee	O
that	O
the	O
patient	O
is	O
not	O
at	O
risk	O
of	O
ventricular	O
arrhythmia	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
who	O
developed	O
a	O
prolonged	B-ADR
qt	I-ADR
while	O
being	O
treated	O
with	O
oral	O
methadone	B-Drug
for	O
a	O
chronic	O
pain	O
syndrome	O
0	O
<EOS>	O
aim	O
:	O
to	O
present	O
a	O
case	O
of	O
piloerection	B-ADR
after	O
replacing	O
fluvoxamine	B-Drug
maleate	I-Drug
with	O
milnacipran	O
hydrochloride	O
,	O
and	O
to	O
analyse	O
this	O
effect	O
based	O
on	O
receptor	O
occupancy	O
theory	O
0	O
<EOS>	O
aim	O
:	O
to	O
present	O
a	O
case	O
of	O
piloerection	B-ADR
after	O
replacing	O
fluvoxamine	O
maleate	O
with	O
milnacipran	B-Drug
hydrochloride	I-Drug
,	O
and	O
to	O
analyse	O
this	O
effect	O
based	O
on	O
receptor	O
occupancy	O
theory	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
piloerection	B-ADR
observed	O
after	O
the	O
replacement	O
of	O
fluvoxamine	B-Drug
with	O
milnacipran	O
in	O
this	O
patient	O
appears	O
to	O
have	O
been	O
due	O
to	O
an	O
increase	O
in	O
the	O
alpha	O
(	O
1	O
)	O
-adrenoceptor	O
occupancy	O
by	O
endogenous	O
norepinephrine	O
induced	O
by	O
milnacipran	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
piloerection	B-ADR
observed	O
after	O
the	O
replacement	O
of	O
fluvoxamine	O
with	O
milnacipran	B-Drug
in	O
this	O
patient	O
appears	O
to	O
have	O
been	O
due	O
to	O
an	O
increase	O
in	O
the	O
alpha	O
(	O
1	O
)	O
-adrenoceptor	O
occupancy	O
by	O
endogenous	O
norepinephrine	O
induced	O
by	O
milnacipran	O
0	O
<EOS>	O
piloerection	B-ADR
induced	O
by	O
replacing	O
fluvoxamine	B-Drug
with	O
milnacipran	O
0	O
<EOS>	O
piloerection	B-ADR
induced	O
by	O
replacing	O
fluvoxamine	O
with	O
milnacipran	B-Drug
0	O
<EOS>	O
case	O
presentation	O
:	O
we	O
report	O
a	O
patient	O
with	O
cf	O
who	O
developed	O
recurrent	B-ADR
eosinophilia	I-ADR
and	O
severe	O
persistent	O
bronchospasm	O
following	O
repeated	O
administration	O
of	O
preservative-free	O
tobramycin	B-Drug
by	O
inhalation	O
,	O
beginning	O
at	O
16	O
month	O
of	O
age	O
0	O
<EOS>	O
case	O
presentation	O
:	O
we	O
report	O
a	O
patient	O
with	O
cf	O
who	O
developed	O
recurrent	O
eosinophilia	O
and	O
severe	B-ADR
persistent	I-ADR
bronchospasm	I-ADR
following	O
repeated	O
administration	O
of	O
preservative-free	O
tobramycin	B-Drug
by	O
inhalation	O
,	O
beginning	O
at	O
16	O
month	O
of	O
age	O
0	O
<EOS>	O
conclusion	O
:	O
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
in	O
patient	O
who	O
develop	O
recurrent	O
eosinophilia	O
and	O
deterioration	B-ADR
of	I-ADR
pulmonary	I-ADR
function	I-ADR
following	O
the	O
use	O
of	O
tobramycin	B-Drug
by	O
inhalation	O
or	O
by	O
intravenous	O
administration	O
0	O
<EOS>	O
conclusion	O
:	O
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
in	O
patient	O
who	O
develop	O
recurrent	B-ADR
eosinophilia	I-ADR
and	O
deterioration	O
of	O
pulmonary	O
function	O
following	O
the	O
use	O
of	O
tobramycin	B-Drug
by	O
inhalation	O
or	O
by	O
intravenous	O
administration	O
0	O
<EOS>	O
inhaled	O
tobramycin	B-Drug
solution-associated	O
recurrent	B-ADR
eosinophilia	I-ADR
and	O
severe	O
persistent	O
bronchospasm	O
in	O
a	O
patient	O
with	O
cystic	O
fibrosis	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
inhaled	O
tobramycin	B-Drug
solution-associated	O
recurrent	O
eosinophilia	O
and	O
severe	B-ADR
persistent	I-ADR
bronchospasm	I-ADR
in	O
a	O
patient	O
with	O
cystic	O
fibrosis	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
most	O
serious	O
dental	O
side	O
effect	O
of	O
bisphosphonate	B-Drug
treatment	O
(	O
particularly	O
when	O
it	O
is	O
administered	O
intravenously	O
)	O
is	O
,	O
paradoxically	O
,	O
osteonecrosis	B-ADR
of	I-ADR
the	I-ADR
mandible	I-ADR
or	O
the	O
maxilla	O
represented	O
by	O
exposed	O
nonhealing	O
bone	O
0	O
<EOS>	O
adverse	O
effect	O
of	O
amiodarone	B-Drug
including	O
pulmonary	O
toxicity	O
,	O
hepatotoxicity	O
,	O
aggravation	B-ADR
of	I-ADR
arrhythmia	I-ADR
,	O
and	O
thyroid	O
disease	O
are	O
well	O
understood	O
0	O
<EOS>	O
adverse	O
effect	O
of	O
amiodarone	B-Drug
including	O
pulmonary	O
toxicity	O
,	O
hepatotoxicity	B-ADR
,	O
aggravation	O
of	O
arrhythmia	O
,	O
and	O
thyroid	O
disease	O
are	O
well	O
understood	O
0	O
<EOS>	O
adverse	O
effect	O
of	O
amiodarone	B-Drug
including	O
pulmonary	B-ADR
toxicity	I-ADR
,	O
hepatotoxicity	O
,	O
aggravation	O
of	O
arrhythmia	O
,	O
and	O
thyroid	O
disease	O
are	O
well	O
understood	O
0	O
<EOS>	O
adverse	O
effect	O
of	O
amiodarone	B-Drug
including	O
pulmonary	O
toxicity	O
,	O
hepatotoxicity	O
,	O
aggravation	O
of	O
arrhythmia	O
,	O
and	O
thyroid	B-ADR
disease	I-ADR
are	O
well	O
understood	O
0	O
<EOS>	O
pancreatitis	B-ADR
is	O
a	O
very	O
rare	O
adverse	O
effect	O
associated	O
with	O
the	O
use	O
of	O
amiodarone	O
,	O
and	O
only	O
four	O
case	O
of	O
amiodarone-induced	B-Drug
pancreatitis	O
have	O
been	O
reported	O
in	O
literature	O
0	O
<EOS>	O
pancreatitis	B-ADR
is	O
a	O
very	O
rare	O
adverse	O
effect	O
associated	O
with	O
the	O
use	O
of	O
amiodarone	O
,	O
and	O
only	O
four	O
case	O
of	O
amiodarone-induced	B-Drug
pancreatitis	O
have	O
been	O
reported	O
in	O
literature	O
0	O
<EOS>	O
under	O
the	O
suspicion	O
of	O
amiodarone-induced	B-Drug
acute	B-ADR
pancreatitis	I-ADR
,	O
amiodarone	O
wa	O
substituted	O
by	O
propafenone	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
who	O
developed	O
acute	B-ADR
pancreatitis	I-ADR
during	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
discussion	O
:	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
tuberculous	B-ADR
uveitis	I-ADR
following	O
treatment	O
with	O
etanercept	B-Drug
0	O
<EOS>	O
tuberculous	B-ADR
uveitis	I-ADR
after	O
treatment	O
with	O
etanercept	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
tuberculous	B-ADR
uveitis	I-ADR
due	O
to	O
etanercept	B-Drug
0	O
<EOS>	O
a	O
complex	O
pattern	O
of	O
melanonychia	B-ADR
and	O
onycholysis	O
after	O
treatment	O
with	O
pemetrexed	B-Drug
for	O
lung	O
cancer	O
0	O
<EOS>	O
a	O
complex	O
pattern	O
of	O
melanonychia	O
and	O
onycholysis	B-ADR
after	O
treatment	O
with	O
pemetrexed	B-Drug
for	O
lung	O
cancer	O
0	O
<EOS>	O
infliximab	B-Drug
and	O
it	O
serious	O
adverse	O
effect	O
are	O
discussed	O
,	O
and	O
other	O
case	O
of	O
osteomyelitis	B-ADR
with	O
infliximab	O
use	O
are	O
also	O
reviewed	O
0	O
<EOS>	O
infliximab	B-Drug
and	O
it	O
serious	O
adverse	O
effect	O
are	O
discussed	O
,	O
and	O
other	O
case	O
of	O
osteomyelitis	B-ADR
with	O
infliximab	O
use	O
are	O
also	O
reviewed	O
0	O
<EOS>	O
osteomyelitis	B-ADR
occurring	O
during	O
infliximab	B-Drug
treatment	O
of	O
severe	O
psoriasis	O
0	O
<EOS>	O
based	O
on	O
the	O
naranjo	O
probability	O
scale	O
,	O
serotonin	B-ADR
syndrome	I-ADR
wa	O
a	O
probable	O
adverse	O
reaction	O
associated	O
with	O
co-administration	O
of	O
citalopram	B-Drug
and	O
fentanyl	O
0	O
<EOS>	O
based	O
on	O
the	O
naranjo	O
probability	O
scale	O
,	O
serotonin	B-ADR
syndrome	I-ADR
wa	O
a	O
probable	O
adverse	O
reaction	O
associated	O
with	O
co-administration	O
of	O
citalopram	O
and	O
fentanyl	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	B-ADR
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	B-ADR
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	B-ADR
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	B-ADR
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	B-ADR
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	B-ADR
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	B-ADR
jerk	I-ADR
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	B-ADR
jerk	I-ADR
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	B-ADR
jerk	I-ADR
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	B-ADR
syndrome	I-ADR
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	B-ADR
syndrome	I-ADR
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	B-ADR
syndrome	I-ADR
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	B-ADR
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	B-ADR
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	B-ADR
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	B-ADR
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	B-ADR
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	B-ADR
,	O
myoclonic	O
jerk	O
and	O
unsteady	O
gait	O
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	B-Drug
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	B-ADR
gait	I-ADR
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	O
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	B-ADR
gait	I-ADR
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
65-year-old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
citalopram	O
developed	O
confusion	O
,	O
agitation	O
,	O
tachycardia	O
,	O
tremor	O
,	O
myoclonic	O
jerk	O
and	O
unsteady	B-ADR
gait	I-ADR
,	O
consistent	O
with	O
serotonin	O
syndrome	O
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptom	O
and	O
sign	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
conclusion	O
:	O
healthcare	O
professional	O
should	O
be	O
aware	O
of	O
the	O
possible	O
development	O
of	O
serotonin	B-ADR
syndrome	I-ADR
a	O
a	O
complication	O
of	O
initiation	O
of	O
fentanyl	B-Drug
and	O
other	O
phenylpiperidine	O
opioids	O
in	O
patient	O
treated	O
with	O
ssri	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
associated	O
with	O
interaction	O
between	O
fentanyl	O
and	O
citalopram	B-Drug
,	O
a	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
feature	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
associated	O
with	O
interaction	O
between	O
fentanyl	B-Drug
and	O
citalopram	O
,	O
a	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
feature	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
serotonin	B-ADR
syndrome	I-ADR
associated	O
with	O
interaction	O
between	O
fentanyl	B-Drug
and	O
citalopram	O
,	O
a	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
feature	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	O
0	O
<EOS>	O
serotonin	B-ADR
syndrome	I-ADR
caused	O
by	O
interaction	O
between	O
citalopram	B-Drug
and	O
fentanyl	O
0	O
<EOS>	O
serotonin	B-ADR
syndrome	I-ADR
caused	O
by	O
interaction	O
between	O
citalopram	O
and	O
fentanyl	B-Drug
0	O
<EOS>	O
renal	B-ADR
failure	I-ADR
after	O
high-dose	O
methotrexate	B-Drug
in	O
a	O
child	O
homozygous	O
for	O
mthfr	O
c677t	O
polymorphism	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
11-year-old	O
female	O
treated	O
for	O
mediastinal	O
t-cell	O
lymphoma	O
who	O
presented	O
renal	B-ADR
failure	I-ADR
following	O
the	O
second	O
cycle	O
of	O
high-dose	O
methotrexate	O
(	O
hdmtx	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
11-year-old	O
female	O
treated	O
for	O
mediastinal	O
t-cell	O
lymphoma	O
who	O
presented	O
renal	B-ADR
failure	I-ADR
following	O
the	O
second	O
cycle	O
of	O
high-dose	O
methotrexate	B-Drug
(	O
hdmtx	O
)	O
0	O
<EOS>	O
docetaxel	B-Drug
induced	O
meibomian	B-ADR
duct	I-ADR
inflammation	I-ADR
and	I-ADR
blockage	I-ADR
is	O
the	O
likely	O
cause	O
of	O
this	O
presentation	O
in	O
a	O
patient	O
with	O
no	O
history	O
of	O
eyelid	O
mass	O
in	O
the	O
past	O
0	O
<EOS>	O
docetaxel-induced	B-Drug
meibomian	O
duct	O
inflammation	O
and	O
blockage	O
leading	O
to	O
chalazion	B-ADR
formation	O
0	O
<EOS>	O
docetaxel-induced	B-Drug
meibomian	B-ADR
duct	I-ADR
inflammation	I-ADR
and	I-ADR
blockage	I-ADR
leading	O
to	O
chalazion	O
formation	O
0	O
<EOS>	O
we	O
report	O
a	O
71-year	O
male	O
with	O
castration-resistant	O
metastatic	O
prostate	O
cancer	O
who	O
wa	O
treated	O
with	O
weekly	O
docetaxel	B-Drug
for	O
12	O
week	O
and	O
developed	O
significant	O
eye	B-ADR
irritation	I-ADR
and	I-ADR
dryness	I-ADR
during	O
treatment	O
0	O
<EOS>	O
a	O
case	O
of	O
recall	B-ADR
pneumonitis	I-ADR
induced	O
by	O
gemcitabine	B-Drug
is	O
reported	O
0	O
<EOS>	O
after	O
having	O
received	O
gemcitabine	B-Drug
on	O
day	O
1	O
of	O
the	O
second	O
course	O
,	O
the	O
patient	O
developed	O
dry	B-ADR
cough	I-ADR
,	O
subfebrile	O
temperature	O
and	O
dyspnea	O
within	O
48	O
h	O
0	O
<EOS>	O
after	O
having	O
received	O
gemcitabine	B-Drug
on	O
day	O
1	O
of	O
the	O
second	O
course	O
,	O
the	O
patient	O
developed	O
dry	O
cough	O
,	O
subfebrile	O
temperature	O
and	O
dyspnea	B-ADR
within	O
48	O
h	O
0	O
<EOS>	O
after	O
having	O
received	O
gemcitabine	B-Drug
on	O
day	O
1	O
of	O
the	O
second	O
course	O
,	O
the	O
patient	O
developed	O
dry	O
cough	O
,	O
subfebrile	B-ADR
temperature	I-ADR
and	O
dyspnea	O
within	O
48	O
h	O
0	O
<EOS>	O
conclusion	O
:	O
gemcitabine-induced	B-Drug
recall	B-ADR
pneumonitis	I-ADR
is	O
a	O
rarely	O
reported	O
phenomenon	O
and	O
should	O
be	O
taken	O
into	O
account	O
even	O
after	O
extended	O
time	O
interval	O
to	O
the	O
previous	O
radiotherapy	O
0	O
<EOS>	O
radiation	B-ADR
recall	I-ADR
pneumonitis	I-ADR
induced	O
by	O
gemcitabine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
for	O
all	O
patient	O
with	O
vancomycin-induced	B-Drug
neutropenia	B-ADR
,	O
possible	O
cross-reactivity	O
of	O
teicoplanin	O
should	O
be	O
monitored	O
0	O
<EOS>	O
however	O
,	O
a	O
new	O
episode	O
of	O
neutropenia	B-ADR
,	O
with	O
a	O
wbc	O
count	O
of	O
2.8	O
x	O
10	O
(	O
3	O
)	O
/mm3	O
and	O
anc	O
of	O
0.448	O
x	O
10	O
(	O
3	O
)	O
/mm3	O
,	O
occurred	O
11	O
day	O
after	O
teicoplanin	B-Drug
initiation	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
teicoplanin-related	B-Drug
neutropenia	B-ADR
that	O
developed	O
after	O
an	O
episode	O
of	O
neutropenia	O
induced	O
by	O
vancomycin	O
therapy	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
teicoplanin-related	O
neutropenia	B-ADR
that	O
developed	O
after	O
an	O
episode	O
of	O
neutropenia	O
induced	O
by	O
vancomycin	B-Drug
therapy	O
0	O
<EOS>	O
teicoplanin-induced	B-Drug
agranulocytosis	B-ADR
that	O
followed	O
vancomycin-induced	O
agranulocytosis	O
suggests	O
a	O
possible	O
cross-reactivity	O
between	O
the	O
2	O
drug	O
0	O
<EOS>	O
teicoplanin-induced	O
agranulocytosis	B-ADR
that	O
followed	O
vancomycin-induced	B-Drug
agranulocytosis	O
suggests	O
a	O
possible	O
cross-reactivity	O
between	O
the	O
2	O
drug	O
0	O
<EOS>	O
cutaneous	B-ADR
ulceration	I-ADR
:	O
an	O
unusual	O
complication	O
of	O
intravenous	O
pentamidine	B-Drug
therapy	O
0	O
<EOS>	O
this	O
is	O
a	O
report	O
of	O
a	O
renal	O
transplant	O
patient	O
with	O
pneumocystis	O
pneumonia	O
who	O
developed	O
chemical	B-ADR
cellulitis	I-ADR
and	O
ulceration	O
following	O
the	O
extravasation	O
of	O
intravenous	O
pentamidine	B-Drug
into	O
the	O
soft	O
tissue	O
of	O
the	O
left	O
hand	O
and	O
forearm	O
0	O
<EOS>	O
this	O
is	O
a	O
report	O
of	O
a	O
renal	O
transplant	O
patient	O
with	O
pneumocystis	O
pneumonia	O
who	O
developed	O
chemical	O
cellulitis	O
and	O
ulceration	B-ADR
following	O
the	O
extravasation	O
of	O
intravenous	O
pentamidine	B-Drug
into	O
the	O
soft	O
tissue	O
of	O
the	O
left	O
hand	O
and	O
forearm	O
0	O
<EOS>	O
observation	O
:	O
a	O
48-year-old	O
woman	O
presented	O
with	O
disfiguring	B-ADR
facial	I-ADR
edema	I-ADR
10	O
week	O
after	O
she	O
began	O
antiviral	O
therapy	O
with	O
peginterferon	B-Drug
alfa-2a	I-Drug
and	O
ribavirin	O
for	O
chronic	O
hepatitis	O
c	O
infection	O
0	O
<EOS>	O
observation	O
:	O
a	O
48-year-old	O
woman	O
presented	O
with	O
disfiguring	B-ADR
facial	I-ADR
edema	I-ADR
10	O
week	O
after	O
she	O
began	O
antiviral	O
therapy	O
with	O
peginterferon	O
alfa-2a	O
and	O
ribavirin	B-Drug
for	O
chronic	O
hepatitis	O
c	O
infection	O
0	O
<EOS>	O
tumor-volume	B-ADR
increase	I-ADR
at	O
beginning	O
of	O
primary	O
treatment	O
with	O
topical	O
interferon	B-Drug
alpha	I-Drug
2-beta	I-Drug
in	O
a	O
case	O
of	O
conjunctiva-cornea	O
intraepithelial	O
neoplasia	O
0	O
<EOS>	O
flecainide	B-Drug
overdose	O
can	O
rapidly	O
result	O
in	O
profound	O
cardiovascular	B-ADR
collapse	I-ADR
,	O
and	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
mortality	O
0	O
<EOS>	O
managing	O
cardiovascular	B-ADR
collapse	I-ADR
in	O
severe	O
flecainide	B-Drug
overdose	O
without	O
recourse	O
to	O
extracorporeal	O
therapy	O
0	O
<EOS>	O
ezetimibe-induced	B-Drug
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
since	O
it	O
fda	O
approval	O
in	O
2002	O
,	O
there	O
are	O
no	O
known	O
citation	O
of	O
ezetimibe-induced	B-Drug
pancreatitis	B-ADR
0	O
<EOS>	O
selective	O
estrogen	O
receptor	O
modulator	O
raloxifene-associated	B-Drug
aggravation	B-ADR
of	I-ADR
nonalcoholic	I-ADR
steatohepatitis	I-ADR
0	O
<EOS>	O
this	O
is	O
the	O
first	O
histologically	O
confirmed	O
case	O
of	O
nash	B-ADR
that	O
wa	O
aggravated	O
by	O
raloxifene	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
liver	B-ADR
damage	I-ADR
following	O
treatment	O
with	O
danazol	B-Drug
for	O
fibrocystic	O
breast	O
disease	O
is	O
reported	O
0	O
<EOS>	O
hepatic	B-ADR
damage	I-ADR
after	O
danazol	B-Drug
treatment	O
0	O
<EOS>	O
hypersensitivity	B-ADR
pneumonitis-like	I-ADR
syndrome	I-ADR
associated	O
with	O
the	O
use	O
of	O
lenalidomide	B-Drug
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
receiving	O
lenalidomide	B-Drug
in	O
whom	O
dyspnea	O
,	O
fever	O
,	O
hypoxia	O
,	O
and	O
diffuse	B-ADR
pulmonary	I-ADR
infiltrates	I-ADR
developed	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
receiving	O
lenalidomide	B-Drug
in	O
whom	O
dyspnea	B-ADR
,	O
fever	O
,	O
hypoxia	O
,	O
and	O
diffuse	O
pulmonary	O
infiltrates	O
developed	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
receiving	O
lenalidomide	B-Drug
in	O
whom	O
dyspnea	O
,	O
fever	B-ADR
,	O
hypoxia	O
,	O
and	O
diffuse	O
pulmonary	O
infiltrates	O
developed	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
receiving	O
lenalidomide	B-Drug
in	O
whom	O
dyspnea	O
,	O
fever	O
,	O
hypoxia	B-ADR
,	O
and	O
diffuse	O
pulmonary	O
infiltrates	O
developed	O
0	O
<EOS>	O
physician	O
should	O
be	O
cognizant	O
of	O
this	O
potential	O
complication	O
in	O
patient	O
receiving	O
thalidomide	O
or	O
thalidomide-like	B-Drug
drug	O
who	O
present	O
with	O
fever	B-ADR
and	O
pulmonary	O
infiltrates	O
and	O
fail	O
to	O
improve	O
despite	O
treatment	O
with	O
broad-spectrum	O
antibiotic	O
0	O
<EOS>	O
physician	O
should	O
be	O
cognizant	O
of	O
this	O
potential	O
complication	O
in	O
patient	O
receiving	O
thalidomide	O
or	O
thalidomide-like	B-Drug
drug	O
who	O
present	O
with	O
fever	O
and	O
pulmonary	B-ADR
infiltrates	I-ADR
and	O
fail	O
to	O
improve	O
despite	O
treatment	O
with	O
broad-spectrum	O
antibiotic	O
0	O
<EOS>	O
thus	O
,	O
the	O
patient	O
clinical	O
course	O
and	O
workup	O
strongly	O
support	O
a	O
diagnosis	O
of	O
lenalidomide-induced	B-Drug
hypersensitivity	B-ADR
pneumonitis-like	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
intravitreal	O
triamcinolone	B-Drug
may	O
have	O
had	O
an	O
influence	O
on	O
the	O
exacerbation	B-ADR
of	I-ADR
retinochoroiditis	I-ADR
in	O
the	O
posterior	O
pole	O
of	O
the	O
patient	O
0	O
<EOS>	O
a	O
40-year-old	O
man	O
with	O
advanced	O
hiv	O
infection	O
and	O
mycobacterium	O
avium	O
complex	O
infection	O
experienced	O
rapid	B-ADR
cognitive	I-ADR
decline	I-ADR
after	O
commencement	O
of	O
ethambutol	B-Drug
,	O
and	O
symptom	O
fully	O
resolved	O
with	O
cessation	O
0	O
<EOS>	O
ethambutol	B-Drug
toxicity	O
manifesting	O
a	O
acute	B-ADR
onset	I-ADR
psychosis	I-ADR
0	O
<EOS>	O
psoriasis	B-ADR
induced	O
by	O
interferon-alpha	B-Drug
0	O
<EOS>	O
recombinant	B-Drug
human	I-Drug
interferon-alpha	I-Drug
ha	O
been	O
used	O
in	O
the	O
treatment	O
of	O
several	O
cancer	O
,	O
but	O
there	O
have	O
been	O
several	O
report	O
that	O
it	O
may	O
exacerbate	B-ADR
psoriasis	I-ADR
or	I-ADR
trigger	I-ADR
off	I-ADR
it	I-ADR
onset	I-ADR
0	O
<EOS>	O
we	O
report	O
four	O
patient	O
,	O
three	O
of	O
whom	O
first	O
developed	O
psoriasis	B-ADR
and	O
one	O
who	O
had	O
an	O
aggravation	O
of	O
the	O
condition	O
during	O
treatment	O
with	O
interferon-alpha	B-Drug
0	O
<EOS>	O
a	O
61-year-old	O
man	O
with	O
early	O
diffuse	O
cutaneous	O
scleroderma	O
with	O
myositis	O
and	O
progressive	O
interstitial	O
pneumonia	O
developed	O
generalized	B-ADR
erythema	I-ADR
with	O
high	O
fever	O
3	O
week	O
after	O
taking	O
sulfamethoxazole	B-Drug
/	O
trimethoprim	O
0	O
<EOS>	O
a	O
61-year-old	O
man	O
with	O
early	O
diffuse	O
cutaneous	O
scleroderma	O
with	O
myositis	O
and	O
progressive	O
interstitial	O
pneumonia	O
developed	O
generalized	B-ADR
erythema	I-ADR
with	O
high	O
fever	O
3	O
week	O
after	O
taking	O
sulfamethoxazole	O
/	O
trimethoprim	B-Drug
0	O
<EOS>	O
introduction	O
:	O
we	O
describe	O
the	O
neurointensive	O
care	O
(	O
nic	O
)	O
management	O
of	O
a	O
patient	O
with	O
severe	O
cerebral	O
swelling	O
and	O
raised	B-ADR
intracranial	I-ADR
pressure	I-ADR
(	O
icp	O
)	O
after	O
severe	O
sodium	B-Drug
valproic	I-Drug
acid	I-Drug
(	O
vpa	O
)	O
intoxication	O
0	O
<EOS>	O
introduction	O
:	O
we	O
describe	O
the	O
neurointensive	O
care	O
(	O
nic	O
)	O
management	O
of	O
a	O
patient	O
with	O
severe	O
cerebral	O
swelling	O
and	O
raised	B-ADR
intracranial	I-ADR
pressure	I-ADR
(	O
icp	O
)	O
after	O
severe	O
sodium	O
valproic	O
acid	O
(	O
vpa	B-Drug
)	O
intoxication	O
0	O
<EOS>	O
introduction	O
:	O
we	O
describe	O
the	O
neurointensive	O
care	O
(	O
nic	O
)	O
management	O
of	O
a	O
patient	O
with	O
severe	B-ADR
cerebral	I-ADR
swelling	I-ADR
and	O
raised	O
intracranial	O
pressure	O
(	O
icp	O
)	O
after	O
severe	O
sodium	B-Drug
valproic	I-Drug
acid	I-Drug
(	O
vpa	O
)	O
intoxication	O
0	O
<EOS>	O
introduction	O
:	O
we	O
describe	O
the	O
neurointensive	O
care	O
(	O
nic	O
)	O
management	O
of	O
a	O
patient	O
with	O
severe	B-ADR
cerebral	I-ADR
swelling	I-ADR
and	O
raised	O
intracranial	O
pressure	O
(	O
icp	O
)	O
after	O
severe	O
sodium	O
valproic	O
acid	O
(	O
vpa	B-Drug
)	O
intoxication	O
0	O
<EOS>	O
neurointensive	O
care	O
management	O
of	O
raised	B-ADR
intracranial	I-ADR
pressure	I-ADR
caused	O
by	O
severe	O
valproic	B-Drug
acid	I-Drug
intoxication	O
0	O
<EOS>	O
bleomycin	B-Drug
induced	O
hyperpigmentation	B-ADR
with	O
yolk	O
sac	O
tumor	O
0	O
<EOS>	O
the	O
hyperpigmentation	O
wa	O
diffuse	O
scattered	O
,	O
flagellate	O
like	O
and	O
linear	O
streaking	O
which	O
wa	O
thought	O
to	O
be	O
mainly	O
related	O
to	O
the	O
skin	B-ADR
toxicity	I-ADR
of	O
bleomycin	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
child	O
with	O
yolk	O
sac	O
tumor	O
who	O
developed	O
localized	B-ADR
pigmentation	I-ADR
after	O
the	O
first	O
course	O
of	O
chemotherapy	O
regimen	O
that	O
included	O
cisplatin	O
,	O
etoposide	O
and	O
bleomycin	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
child	O
with	O
yolk	O
sac	O
tumor	O
who	O
developed	O
localized	B-ADR
pigmentation	I-ADR
after	O
the	O
first	O
course	O
of	O
chemotherapy	O
regimen	O
that	O
included	O
cisplatin	B-Drug
,	O
etoposide	O
and	O
bleomycin	O
0	O
<EOS>	O
we	O
report	O
a	O
child	O
with	O
yolk	O
sac	O
tumor	O
who	O
developed	O
localized	B-ADR
pigmentation	I-ADR
after	O
the	O
first	O
course	O
of	O
chemotherapy	O
regimen	O
that	O
included	O
cisplatin	O
,	O
etoposide	B-Drug
and	O
bleomycin	O
0	O
<EOS>	O
a	O
cause-effect	O
relationship	O
to	O
capecitabine	B-Drug
wa	O
suggested	O
due	O
to	O
resolution	O
of	O
headache	B-ADR
with	O
capecitabine	O
withdrawal	O
and	O
reappearance	O
with	O
capecitabine	O
rechallenge	O
0	O
<EOS>	O
background	O
:	O
headache	B-ADR
have	O
been	O
reported	O
a	O
a	O
potential	O
side	O
effect	O
of	O
capecitabine	B-Drug
therapy	O
0	O
<EOS>	O
capecitabine-induced	B-Drug
headache	B-ADR
responding	O
to	O
diltiazem	O
0	O
<EOS>	O
ccbs	O
should	O
be	O
considered	O
in	O
the	O
treatment	O
of	O
5-fu	B-Drug
or	O
capecitabine-induced	O
headache	B-ADR
0	O
<EOS>	O
ccbs	O
should	O
be	O
considered	O
in	O
the	O
treatment	O
of	O
5-fu	O
or	O
capecitabine-induced	B-Drug
headache	B-ADR
0	O
<EOS>	O
the	O
patient	O
developed	O
grade	O
3	O
capecitabine-induced	B-Drug
headache	B-ADR
0	O
<EOS>	O
we	O
hypothesize	O
that	O
capecitabine-induced	B-Drug
headache	B-ADR
is	O
vascular	O
in	O
nature	O
0	O
<EOS>	O
brugada	B-ADR
type	I-ADR
electrocardiographic	I-ADR
change	I-ADR
induced	O
by	O
concomitant	O
use	O
of	O
lithium	B-Drug
and	O
propafenone	O
in	O
patient	O
with	O
wolff-parkinson-white	O
syndrome	O
0	O
<EOS>	O
brugada	B-ADR
type	I-ADR
electrocardiographic	I-ADR
change	I-ADR
induced	O
by	O
concomitant	O
use	O
of	O
lithium	O
and	O
propafenone	B-Drug
in	O
patient	O
with	O
wolff-parkinson-white	O
syndrome	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
st	B-ADR
elevation	I-ADR
in	I-ADR
right	I-ADR
precordial	I-ADR
lead	I-ADR
compatible	O
with	O
type	O
1	O
brugada	O
syndrome	O
following	O
administration	O
of	O
propafenone	B-Drug
in	O
a	O
patient	O
with	O
wolff-parkinson-white	O
syndrome	O
who	O
wa	O
receiving	O
lithium	O
at	O
concentration	O
within	O
therapeutic	O
level	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
st	O
elevation	O
in	O
right	O
precordial	O
lead	O
compatible	O
with	O
type	B-ADR
1	I-ADR
brugada	I-ADR
syndrome	I-ADR
following	O
administration	O
of	O
propafenone	B-Drug
in	O
a	O
patient	O
with	O
wolff-parkinson-white	O
syndrome	O
who	O
wa	O
receiving	O
lithium	O
at	O
concentration	O
within	O
therapeutic	O
level	O
0	O
<EOS>	O
we	O
postulate	O
that	O
gastritis	B-ADR
caused	O
by	O
dexamethasone	B-Drug
,	O
mucositis	O
caused	O
by	O
doxorubicin	O
,	O
and	O
the	O
unique	O
anatomic	O
nature	O
of	O
a	O
meckel	O
diverticulum	O
may	O
have	O
contributed	O
to	O
this	O
extremely	O
unlikely	O
and	O
previously	O
unreported	O
event	O
0	O
<EOS>	O
we	O
postulate	O
that	O
gastritis	O
caused	O
by	O
dexamethasone	O
,	O
mucositis	B-ADR
caused	O
by	O
doxorubicin	B-Drug
,	O
and	O
the	O
unique	O
anatomic	O
nature	O
of	O
a	O
meckel	O
diverticulum	O
may	O
have	O
contributed	O
to	O
this	O
extremely	O
unlikely	O
and	O
previously	O
unreported	O
event	O
0	O
<EOS>	O
bortezomib-induced	B-Drug
paralytic	O
ileus	O
is	O
a	O
potential	O
gastrointestinal	B-ADR
side	I-ADR
effect	I-ADR
of	O
this	O
first-in-class	O
anticancer	O
proteasome	O
inhibitor	O
0	O
<EOS>	O
bortezomib-induced	B-Drug
paralytic	B-ADR
ileus	I-ADR
is	O
a	O
potential	O
gastrointestinal	O
side	O
effect	O
of	O
this	O
first-in-class	O
anticancer	O
proteasome	O
inhibitor	O
0	O
<EOS>	O
paralytic	B-ADR
ileus	I-ADR
in	O
patient	O
undergoing	O
bortezomib	B-Drug
treatment	O
ha	O
been	O
reported	O
,	O
although	O
a	O
definite	O
attribution	O
to	O
bortezomib	O
administration	O
ha	O
not	O
been	O
established	O
0	O
<EOS>	O
we	O
report	O
a	O
myeloma	O
patient	O
who	O
developed	O
severe	B-ADR
paralytic	I-ADR
ileus	I-ADR
during	O
bortezomib	B-Drug
therapy	O
,	O
which	O
presented	O
in	O
the	O
context	O
of	O
progressive	O
constipation	O
without	O
other	O
known	O
cause	O
and	O
which	O
regressed	O
promptly	O
with	O
medical	O
management	O
after	O
drug	O
cessation	O
,	O
suggesting	O
a	O
direct	O
causal	O
relationship	O
0	O
<EOS>	O
a	O
woman	O
developed	O
delusional	B-ADR
parasitosis	I-ADR
when	O
taking	O
phenelzine	B-Drug
0	O
<EOS>	O
delusional	B-ADR
parasitosis	I-ADR
associated	O
with	O
phenelzine	B-Drug
0	O
<EOS>	O
interstitial	O
pneumonitis	O
and	O
alveolar	B-ADR
hemorrhage	I-ADR
complicating	O
use	O
of	O
rituximab	B-Drug
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
interstitial	B-ADR
pneumonitis	I-ADR
and	O
alveolar	O
hemorrhage	O
complicating	O
use	O
of	O
rituximab	B-Drug
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
the	O
use	O
of	O
rituximab	B-Drug
ha	O
been	O
uncommonly	O
associated	O
with	O
delayed	B-ADR
pulmonary	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
fulminant	O
metoclopramide	B-Drug
induced	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
rapidly	O
responsive	O
to	O
intravenous	O
dantrolene	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
fulminant	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
in	O
a	O
man	O
aged	O
70	O
developing	O
within	O
12	O
hour	O
of	O
starting	O
six-hourly	O
intravenous	O
metoclopramide	B-Drug
0	O
<EOS>	O
the	O
clinical	O
symptom	O
of	O
gastric	B-ADR
mucosa	I-ADR
foveolar	I-ADR
hyperplasia	I-ADR
due	O
to	O
long-term	O
pge1	B-Drug
therapy	O
simulate	O
hypertrophic	O
pyloric	O
stenosis	O
0	O
<EOS>	O
the	O
result	O
of	O
the	O
ultrasound	O
examination	O
combined	O
with	O
clinical	O
anamnesis	O
allowed	O
diagnosis	O
of	O
gastric	B-ADR
mucosa	I-ADR
foveolar	I-ADR
hyperplasia	I-ADR
due	O
to	O
prolonged	O
pge1	B-Drug
therapy	O
0	O
<EOS>	O
a	O
79-year-old	O
man	O
with	O
ischemic	O
heart	O
disease	O
,	O
chronic	O
atrial	O
fibrillation	O
,	O
chronic	O
renal	O
failure	O
,	O
hypothyroidism	O
,	O
and	O
gout	O
arthritis	O
wa	O
hospitalized	O
because	O
of	O
fatigue	B-ADR
,	O
myalgia	O
,	O
and	O
leg	O
weakness	O
,	O
shortly	O
after	O
starting	O
treatment	O
with	O
colchicine	B-Drug
0	O
<EOS>	O
a	O
79-year-old	O
man	O
with	O
ischemic	O
heart	O
disease	O
,	O
chronic	O
atrial	O
fibrillation	O
,	O
chronic	O
renal	O
failure	O
,	O
hypothyroidism	O
,	O
and	O
gout	O
arthritis	O
wa	O
hospitalized	O
because	O
of	O
fatigue	O
,	O
myalgia	O
,	O
and	O
leg	B-ADR
weakness	I-ADR
,	O
shortly	O
after	O
starting	O
treatment	O
with	O
colchicine	B-Drug
0	O
<EOS>	O
a	O
79-year-old	O
man	O
with	O
ischemic	O
heart	O
disease	O
,	O
chronic	O
atrial	O
fibrillation	O
,	O
chronic	O
renal	O
failure	O
,	O
hypothyroidism	O
,	O
and	O
gout	O
arthritis	O
wa	O
hospitalized	O
because	O
of	O
fatigue	O
,	O
myalgia	B-ADR
,	O
and	O
leg	O
weakness	O
,	O
shortly	O
after	O
starting	O
treatment	O
with	O
colchicine	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
colchicine-induced	B-Drug
rhabdomyolysis	B-ADR
is	O
reported	O
0	O
<EOS>	O
colchicine-induced	B-Drug
rhabdomyolysis	B-ADR
is	O
a	O
rare	O
complication	O
,	O
and	O
the	O
postulated	O
mechanism	O
and	O
risk	O
factor	O
for	O
this	O
severe	O
complication	O
are	O
discussed	O
0	O
<EOS>	O
colchicine-induced	B-Drug
rhabdomyolysis	B-ADR
0	O
<EOS>	O
investigation	O
confirmed	O
the	O
diagnosis	O
of	O
rhabdomyolysis	O
,	O
and	O
discontinuation	O
of	O
colchicine	B-Drug
resulted	O
in	O
resolution	O
of	O
clinical	O
and	O
biochemical	O
feature	O
of	O
rhabdomylysis	B-ADR
0	O
<EOS>	O
5-fluorouracil	B-Drug
cardiotoxicity	B-ADR
complicating	O
treatment	O
of	O
stage	O
iib	O
cervical	O
cancer	O
--	O
case	O
report	O
0	O
<EOS>	O
conclusion	O
:	O
acetic	B-Drug
acid	I-Drug
is	O
corrosive	O
and	O
may	O
cause	O
vagina	B-ADR
bleeding	I-ADR
0	O
<EOS>	O
induction	O
of	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
by	O
interferon-gamma	B-Drug
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
development	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	B-ADR
)	O
after	O
38	O
month	O
of	O
therapy	O
with	O
recombinant	B-Drug
human	I-Drug
interferon	I-Drug
gamma	I-Drug
(	O
rifn-gamma	O
)	O
wa	O
observed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
development	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	B-ADR
)	O
after	O
38	O
month	O
of	O
therapy	O
with	O
recombinant	O
human	O
interferon	O
gamma	O
(	O
rifn-gamma	B-Drug
)	O
wa	O
observed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
development	O
of	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	O
sle	O
)	O
after	O
38	O
month	O
of	O
therapy	O
with	O
recombinant	B-Drug
human	I-Drug
interferon	I-Drug
gamma	I-Drug
(	O
rifn-gamma	O
)	O
wa	O
observed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
development	O
of	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
(	O
sle	O
)	O
after	O
38	O
month	O
of	O
therapy	O
with	O
recombinant	O
human	O
interferon	O
gamma	O
(	O
rifn-gamma	B-Drug
)	O
wa	O
observed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
we	O
assume	O
that	O
rifn-gamma	B-Drug
induced	O
the	O
de	O
novo	O
development	O
of	O
sle	B-ADR
in	O
our	O
patient	O
0	O
<EOS>	O
bisphosphonate	B-Drug
induced	O
osteochemonecrosis	B-ADR
of	I-ADR
the	I-ADR
jaw	I-ADR
mimicking	O
a	O
tumour	O
0	O
<EOS>	O
clozapine-induced	B-Drug
eosinophilia	B-ADR
and	O
switch	O
to	O
quetiapine	O
in	O
a	O
patient	O
with	O
chronic	O
schizophrenia	O
with	O
suicidal	O
tendency	O
0	O
<EOS>	O
drug-induced	O
eosinophilia	B-ADR
is	O
a	O
non-dose-dependent	O
side	O
effect	O
of	O
clozapine	B-Drug
0	O
<EOS>	O
occasionally	O
,	O
despite	O
good	O
therapeutic	O
response	O
,	O
clozapine	B-Drug
must	O
be	O
stopped	O
due	O
to	O
dangerous	O
side	O
effect	O
such	O
a	O
agranulocytosis	B-ADR
0	O
<EOS>	O
metformin-associated	B-Drug
lactic	B-ADR
acidosis	I-ADR
(	O
mala	O
)	O
is	O
a	O
serious	O
metabolic	O
complication	O
that	O
occurs	O
because	O
of	O
metformin	O
accumulation	O
in	O
patient	O
who	O
become	O
dehydrated	O
or	O
developed	O
acute	O
renal	O
failure	O
0	O
<EOS>	O
metformin-associated	B-Drug
lactic	B-ADR
acidosis	I-ADR
(	O
mala	O
)	O
is	O
a	O
serious	O
metabolic	O
complication	O
that	O
occurs	O
because	O
of	O
metformin	O
accumulation	O
in	O
patient	O
who	O
become	O
dehydrated	O
or	O
developed	O
acute	O
renal	O
failure	O
0	O
<EOS>	O
metformin-associated	B-Drug
lactic	B-ADR
acidosis	I-ADR
precipitated	O
by	O
diarrhea	O
0	O
<EOS>	O
an	O
apparent	O
link	O
is	O
described	O
between	O
the	O
use	O
of	O
mmf	B-Drug
with	O
prednisone	O
to	O
treat	O
pemphigus	O
vulgaris	O
and	O
the	O
development	O
of	O
red	B-ADR
blood	I-ADR
cell	I-ADR
anemia	I-ADR
0	O
<EOS>	O
an	O
apparent	O
link	O
is	O
described	O
between	O
the	O
use	O
of	O
mmf	O
with	O
prednisone	B-Drug
to	O
treat	O
pemphigus	O
vulgaris	O
and	O
the	O
development	O
of	O
red	B-ADR
blood	I-ADR
cell	I-ADR
anemia	I-ADR
0	O
<EOS>	O
red	B-ADR
blood	I-ADR
cell	I-ADR
anemia	I-ADR
in	O
a	O
patient	O
with	O
pemphigus	O
vulgaris	O
induced	O
by	O
the	O
use	O
of	O
mycophenolate	B-Drug
mofetil	I-Drug
and	O
prednisone	O
0	O
<EOS>	O
red	B-ADR
blood	I-ADR
cell	I-ADR
anemia	I-ADR
in	O
a	O
patient	O
with	O
pemphigus	O
vulgaris	O
induced	O
by	O
the	O
use	O
of	O
mycophenolate	O
mofetil	O
and	O
prednisone	B-Drug
0	O
<EOS>	O
the	O
dermatology	O
literature	O
heretofore	O
ha	O
not	O
noted	O
that	O
anemia	B-ADR
is	O
a	O
side	O
effect	O
of	O
patient	O
taking	O
mmf	B-Drug
to	O
treat	O
pemphigus	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
anemia	B-ADR
can	O
occur	O
due	O
to	O
mmf	O
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	O
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	B-Drug
and	O
prednisone	O
is	O
used	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
anemia	B-ADR
can	O
occur	O
due	O
to	O
mmf	B-Drug
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	O
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	O
and	O
prednisone	O
is	O
used	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
anemia	B-ADR
can	O
occur	O
due	O
to	O
mmf	B-Drug
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	O
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	O
and	O
prednisone	O
is	O
used	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
anemia	B-ADR
can	O
occur	O
due	O
to	O
mmf	O
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	B-Drug
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	O
and	O
prednisone	O
is	O
used	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
anemia	B-ADR
can	O
occur	O
due	O
to	O
mmf	O
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	B-Drug
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	O
and	O
prednisone	O
is	O
used	O
0	O
<EOS>	O
a	O
search	O
of	O
the	O
united	O
state	O
food	O
and	O
drug	O
administration	O
adverse	O
event	O
reporting	O
system	O
identified	O
nine	O
case	O
of	O
oxcarbazepine-associated	B-Drug
angioedema	B-ADR
in	O
pediatric	O
patient	O
aged	O
16	O
year	O
and	O
younger	O
0	O
<EOS>	O
clinical	O
profile	O
of	O
oxcarbazepine-related	B-Drug
angioneurotic	B-ADR
edema	I-ADR
:	O
case	O
report	O
and	O
review	O
0	O
<EOS>	O
oxcarbazepine-associated	B-Drug
angioedema	B-ADR
manifested	O
by	O
swelling	O
of	O
the	O
face	O
,	O
eye	O
,	O
lip	O
,	O
or	O
tongue	O
or	O
difficulty	O
swallowing	O
or	O
breathing	O
(	O
or	O
both	O
)	O
is	O
a	O
rare	O
but	O
potentially	O
life-threatening	O
reaction	O
for	O
which	O
early	O
recognition	O
and	O
management	O
are	O
vital	O
0	O
<EOS>	O
we	O
describe	O
in	O
detail	O
the	O
first	O
u.s.	O
case	O
report	O
,	O
of	O
a	O
4	O
(	O
1	O
/	O
2	O
)	O
-year-old	O
boy	O
who	O
experienced	O
angioedema	B-ADR
during	O
treatment	O
with	O
oxcarbazepine	B-Drug
0	O
<EOS>	O
here	O
we	O
describe	O
another	O
case	O
of	O
vod	B-ADR
occurring	O
after	O
lt	O
,	O
but	O
in	O
which	O
the	O
causative	O
role	O
wa	O
played	O
by	O
azathioprine	B-Drug
0	O
<EOS>	O
one	O
case	O
of	O
tacrolimus-induced	B-Drug
hepatic	B-ADR
vod	I-ADR
developing	O
after	O
lung	O
transplantation	O
(	O
lt	O
)	O
ha	O
been	O
recently	O
reported	O
0	O
<EOS>	O
carbamazepine	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
is	O
a	O
rare	O
,	O
life-threatening	O
condition	O
0	O
<EOS>	O
a	O
patient	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
developed	O
drug-induced	O
pulmonary	B-ADR
toxicity	I-ADR
after	O
using	O
low	O
dose	O
oral	O
etoposide	B-Drug
0	O
<EOS>	O
because	O
etoposide-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
is	O
an	O
uncommon	O
but	O
serious	O
adverse	O
event	O
,	O
clinician	O
must	O
be	O
vigilant	O
about	O
the	O
possibility	O
of	O
it	O
,	O
so	O
that	O
the	O
optimal	O
treatment	O
can	O
start	O
a	O
soon	O
a	O
possible	O
0	O
<EOS>	O
pet	O
scintigraphy	O
of	O
etoposide-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
detection	O
of	O
antineutrophil	O
cytoplasmic	O
antibody	O
in	O
a	O
patient	O
with	O
l-tryptophan	B-Drug
induced	O
eosinophilia-myalgia	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
the	O
center	O
for	O
disease	O
control	O
ha	O
received	O
numerous	O
report	O
of	O
an	O
eosinophilia-myalgia	B-ADR
syndrome	I-ADR
related	O
to	O
product	O
containing	O
l-tryptophan	B-Drug
0	O
<EOS>	O
here	O
,	O
we	O
report	O
a	O
case	O
of	O
rfp-induced	B-Drug
hypothyroidism	B-ADR
without	O
underlying	O
thyroid	O
disease	O
0	O
<EOS>	O
rifampin-induced	B-Drug
hypothyroidism	B-ADR
without	O
underlying	O
thyroid	O
disease	O
0	O
<EOS>	O
rifampin	O
(	O
rfp	O
)	O
increase	O
hepatic	O
microsomal	O
enzyme	O
activity	O
,	O
and	O
there	O
are	O
case	O
report	O
of	O
rfp-induced	B-Drug
hypothyroidism	O
,	O
all	O
associated	O
with	O
hashimoto	B-ADR
thyroiditis	I-ADR
0	O
<EOS>	O
rifampin	B-Drug
(	O
rfp	O
)	O
increase	O
hepatic	O
microsomal	O
enzyme	O
activity	O
,	O
and	O
there	O
are	O
case	O
report	O
of	O
rfp-induced	O
hypothyroidism	O
,	O
all	O
associated	O
with	O
hashimoto	B-ADR
thyroiditis	I-ADR
0	O
<EOS>	O
rifampin	O
(	O
rfp	O
)	O
increase	O
hepatic	O
microsomal	O
enzyme	O
activity	O
,	O
and	O
there	O
are	O
case	O
report	O
of	O
rfp-induced	B-Drug
hypothyroidism	B-ADR
,	O
all	O
associated	O
with	O
hashimoto	O
thyroiditis	O
0	O
<EOS>	O
rifampin	B-Drug
(	O
rfp	O
)	O
increase	O
hepatic	O
microsomal	O
enzyme	O
activity	O
,	O
and	O
there	O
are	O
case	O
report	O
of	O
rfp-induced	O
hypothyroidism	B-ADR
,	O
all	O
associated	O
with	O
hashimoto	O
thyroiditis	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
who	O
developed	O
a	O
rapid	O
onset	O
of	O
pulmonary	B-ADR
fibrosis	I-ADR
following	O
treatment	O
with	O
a	O
new	O
non-steroidal	O
anti-inflammatory	O
drug	O
,	O
nabumetone	B-Drug
0	O
<EOS>	O
pulmonary	B-ADR
fibrosis	I-ADR
associated	O
with	O
nabumetone	B-Drug
0	O
<EOS>	O
cyclosporine	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
simvastatin	O
metabolism	O
,	O
and	O
may	O
therefore	O
facilitate	O
simvastatin-induced	O
rhabdomyolysis	B-ADR
0	O
<EOS>	O
cyclosporine	O
is	O
a	O
potent	O
inhibitor	O
of	O
simvastatin	O
metabolism	O
,	O
and	O
may	O
therefore	O
facilitate	O
simvastatin-induced	B-Drug
rhabdomyolysis	B-ADR
0	O
<EOS>	O
discontinuation	O
of	O
simvastatin	O
and	O
cyclosporine	B-Drug
resulted	O
in	O
resolution	O
of	O
rhabdomyolysis	B-ADR
and	O
normalization	O
of	O
renal	O
function	O
0	O
<EOS>	O
discontinuation	O
of	O
simvastatin	B-Drug
and	O
cyclosporine	O
resulted	O
in	O
resolution	O
of	O
rhabdomyolysis	B-ADR
and	O
normalization	O
of	O
renal	O
function	O
0	O
<EOS>	O
simvastatin-induced	O
rhabdomyolysis	B-ADR
following	O
cyclosporine	B-Drug
treatment	O
for	O
uveitis	O
0	O
<EOS>	O
simvastatin-induced	B-Drug
rhabdomyolysis	B-ADR
following	O
cyclosporine	O
treatment	O
for	O
uveitis	O
0	O
<EOS>	O
generalized	B-ADR
lichen	I-ADR
nitidus	I-ADR
with	O
involvement	O
of	O
the	O
palm	O
following	O
interferon	B-Drug
alpha	I-Drug
treatment	O
0	O
<EOS>	O
here	O
we	O
present	O
the	O
case	O
of	O
a	O
generalized	B-ADR
lichen	I-ADR
nitidus	I-ADR
with	O
involvement	O
of	O
the	O
palm	O
in	O
a	O
patient	O
with	O
hepatitis	O
c	O
after	O
systemic	O
treatment	O
with	O
interferon	B-Drug
alpha	I-Drug
and	O
ribavirin	O
0	O
<EOS>	O
here	O
we	O
present	O
the	O
case	O
of	O
a	O
generalized	B-ADR
lichen	I-ADR
nitidus	I-ADR
with	O
involvement	O
of	O
the	O
palm	O
in	O
a	O
patient	O
with	O
hepatitis	O
c	O
after	O
systemic	O
treatment	O
with	O
interferon	O
alpha	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
interferon	B-Drug
alpha	I-Drug
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
lichen	B-ADR
nitidus	I-ADR
0	O
<EOS>	O
sirolimus-eluting	B-ADR
stent	I-ADR
thrombosis	I-ADR
several	O
year	O
after	O
clopidogrel	B-Drug
discontinuation	O
0	O
<EOS>	O
treatment	O
of	O
apl	O
in	O
pregnancy	O
is	O
controversial	O
a	O
the	O
use	O
of	O
atra	B-Drug
ha	O
been	O
questioned	O
due	O
to	O
the	O
teratogenic	B-ADR
effect	I-ADR
of	O
retinoids	O
0	O
<EOS>	O
interstitial	O
lung	O
disease	O
(	O
ild	B-ADR
)	O
related	O
to	O
therapy	O
with	O
the	O
drug	O
gefitinib	B-Drug
ha	O
been	O
well	O
reported	O
0	O
<EOS>	O
interstitial	B-ADR
lung	I-ADR
disease	I-ADR
(	O
ild	O
)	O
related	O
to	O
therapy	O
with	O
the	O
drug	O
gefitinib	B-Drug
ha	O
been	O
well	O
reported	O
0	O
<EOS>	O
pulmonary	B-ADR
toxicity	I-ADR
associated	O
with	O
erlotinib	B-Drug
0	O
<EOS>	O
similar	O
to	O
report	O
in	O
patient	O
receiving	O
gefitinib	O
,	O
those	O
with	O
pathologic	O
finding	O
of	O
uip	O
on	O
resected	O
lung	O
specimen	O
or	O
known	O
pulmonary	B-ADR
fibrosis	I-ADR
may	O
be	O
at	O
particular	O
risk	O
for	O
erlotinib	B-Drug
pulmonary	O
toxicity	O
0	O
<EOS>	O
similar	O
to	O
report	O
in	O
patient	O
receiving	O
gefitinib	O
,	O
those	O
with	O
pathologic	O
finding	O
of	O
uip	O
on	O
resected	O
lung	O
specimen	O
or	O
known	O
pulmonary	O
fibrosis	O
may	O
be	O
at	O
particular	O
risk	O
for	O
erlotinib	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
this	O
case	O
and	O
other	O
published	O
evidence	O
should	O
alert	O
physician	O
to	O
the	O
possibility	O
of	O
fatal	O
erlotinib-induced	B-Drug
ild	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
fatal	B-ADR
pulmonary	I-ADR
toxicity	I-ADR
in	O
a	O
patient	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
who	O
received	O
erlotinib	B-Drug
0	O
<EOS>	O
it	O
ha	O
been	O
reported	O
that	O
fluoroquinolone	B-Drug
antimicrobial	O
prolong	O
the	O
corrected	O
qt	O
interval	O
but	O
rarely	O
cause	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
0	O
<EOS>	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
associated	O
with	O
moxifloxacin	B-Drug
:	O
a	O
rare	O
but	O
potentially	O
fatal	O
adverse	O
event	O
0	O
<EOS>	O
aim	O
:	O
to	O
report	O
three	O
case	O
of	O
extensive	O
skin	B-ADR
necrosis	I-ADR
in	O
cirrhotic	O
patient	O
treated	O
with	O
the	O
vasoconstrictor	O
agent	O
terlipressin	O
(	O
glypressin	B-Drug
)	O
0	O
<EOS>	O
aim	O
:	O
to	O
report	O
three	O
case	O
of	O
extensive	O
skin	B-ADR
necrosis	I-ADR
in	O
cirrhotic	O
patient	O
treated	O
with	O
the	O
vasoconstrictor	O
agent	O
terlipressin	B-Drug
(	O
glypressin	O
)	O
0	O
<EOS>	O
both	O
colchicine	B-Drug
and	O
statin	O
therapy	O
may	O
be	O
associated	O
with	O
myopathy	B-ADR
,	O
which	O
usually	O
occurs	O
after	O
several	O
month	O
of	O
therapy	O
0	O
<EOS>	O
both	O
colchicine	O
and	O
statin	B-Drug
therapy	O
may	O
be	O
associated	O
with	O
myopathy	B-ADR
,	O
which	O
usually	O
occurs	O
after	O
several	O
month	O
of	O
therapy	O
0	O
<EOS>	O
rapid	O
onset	O
of	O
muscle	B-ADR
weakness	I-ADR
(	O
rhabdomyolysis	O
)	O
associated	O
with	O
the	O
combined	O
use	O
of	O
simvastatin	O
and	O
colchicine	B-Drug
0	O
<EOS>	O
rapid	O
onset	O
of	O
muscle	B-ADR
weakness	I-ADR
(	O
rhabdomyolysis	O
)	O
associated	O
with	O
the	O
combined	O
use	O
of	O
simvastatin	B-Drug
and	O
colchicine	O
0	O
<EOS>	O
rapid	O
onset	O
of	O
muscle	O
weakness	O
(	O
rhabdomyolysis	B-ADR
)	O
associated	O
with	O
the	O
combined	O
use	O
of	O
simvastatin	O
and	O
colchicine	B-Drug
0	O
<EOS>	O
rapid	O
onset	O
of	O
muscle	O
weakness	O
(	O
rhabdomyolysis	B-ADR
)	O
associated	O
with	O
the	O
combined	O
use	O
of	O
simvastatin	B-Drug
and	O
colchicine	O
0	O
<EOS>	O
the	O
concomitant	O
use	O
,	O
however	O
,	O
of	O
colchicine	B-Drug
and	O
statin	O
ha	O
been	O
associated	O
with	O
the	O
rapid	O
onset	O
of	O
muscle	B-ADR
weakness	I-ADR
0	O
<EOS>	O
the	O
concomitant	O
use	O
,	O
however	O
,	O
of	O
colchicine	O
and	O
statin	B-Drug
ha	O
been	O
associated	O
with	O
the	O
rapid	O
onset	O
of	O
muscle	B-ADR
weakness	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
mild	O
chronic	O
renal	O
insufficiency	O
who	O
had	O
been	O
taking	O
simvastatin	O
for	O
over	O
a	O
year	O
and	O
developed	O
acute	B-ADR
weakness	I-ADR
within	O
3	O
week	O
after	O
the	O
start	O
of	O
treatment	O
with	O
colchicine	B-Drug
for	O
acute	O
gouty	O
bursitis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
mild	O
chronic	O
renal	O
insufficiency	O
who	O
had	O
been	O
taking	O
simvastatin	B-Drug
for	O
over	O
a	O
year	O
and	O
developed	O
acute	B-ADR
weakness	I-ADR
within	O
3	O
week	O
after	O
the	O
start	O
of	O
treatment	O
with	O
colchicine	O
for	O
acute	O
gouty	O
bursitis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
mild	B-ADR
chronic	I-ADR
renal	I-ADR
insufficiency	I-ADR
who	O
had	O
been	O
taking	O
simvastatin	B-Drug
for	O
over	O
a	O
year	O
and	O
developed	O
acute	O
weakness	O
within	O
3	O
week	O
after	O
the	O
start	O
of	O
treatment	O
with	O
colchicine	O
for	O
acute	O
gouty	O
bursitis	O
0	O
<EOS>	O
pneumocystis	B-ADR
carinii	I-ADR
pneumonia	I-ADR
a	O
a	O
complication	O
of	O
methotrexate	B-Drug
treatment	O
of	O
asthma	O
0	O
<EOS>	O
pneumocystis	O
pneumonia	O
should	O
be	O
considered	O
in	O
asthmatic	O
patient	O
taking	O
methotrexate	B-Drug
who	O
present	O
with	O
fever	B-ADR
,	O
pulmonary	O
infiltrates	O
,	O
and	O
hypoxia	O
0	O
<EOS>	O
pneumocystis	O
pneumonia	O
should	O
be	O
considered	O
in	O
asthmatic	O
patient	O
taking	O
methotrexate	B-Drug
who	O
present	O
with	O
fever	O
,	O
pulmonary	O
infiltrates	O
,	O
and	O
hypoxia	B-ADR
0	O
<EOS>	O
pneumocystis	B-ADR
pneumonia	I-ADR
should	O
be	O
considered	O
in	O
asthmatic	O
patient	O
taking	O
methotrexate	B-Drug
who	O
present	O
with	O
fever	O
,	O
pulmonary	O
infiltrates	O
,	O
and	O
hypoxia	O
0	O
<EOS>	O
pneumocystis	O
pneumonia	O
should	O
be	O
considered	O
in	O
asthmatic	O
patient	O
taking	O
methotrexate	B-Drug
who	O
present	O
with	O
fever	O
,	O
pulmonary	B-ADR
infiltrates	I-ADR
,	O
and	O
hypoxia	O
0	O
<EOS>	O
case	O
report	O
:	O
a	O
six-year-old	O
boy	O
with	O
transfusion-dependent	O
beta-thalassaemia	O
developed	O
a	O
unilateral	B-ADR
hearing	I-ADR
loss	I-ADR
shortly	O
after	O
commencing	O
desferrioxamine	B-Drug
therapy	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	B-ADR
sepsis	I-ADR
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	B-ADR
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	B-ADR
herpes	I-ADR
zoster	I-ADR
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	B-ADR
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	B-ADR
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	B-ADR
respiratory	I-ADR
tract	I-ADR
infection	I-ADR
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	O
liver	O
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	B-ADR
aneurysm	I-ADR
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
eleven	O
patient	O
developed	O
infection	O
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	B-Drug
including	O
:	O
lower	O
respiratory	O
tract	O
infection	O
(	O
3	O
)	O
,	O
cellulitis	O
(	O
2	O
)	O
,	O
disseminated	O
herpes	O
zoster	O
(	O
2	O
)	O
,	O
probable	O
tb	B-ADR
liver	I-ADR
(	O
1	O
)	O
,	O
abdominal	O
sepsis	O
(	O
1	O
)	O
,	O
mycotic	O
aneurysm	O
(	O
1	O
)	O
and	O
gastroenteritis	O
(	O
1	O
)	O
0	O
<EOS>	O
leflunomide-associated	B-Drug
infection	B-ADR
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
nz	O
pharmacovigilance	O
centre	O
ha	O
received	O
7	O
additional	O
report	O
of	O
severe	B-ADR
infection	I-ADR
in	O
patient	O
with	O
ra	O
taking	O
leflunomide	B-Drug
0	O
<EOS>	O
a	O
58-year-old	O
woman	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
developed	O
fever	B-ADR
,	O
skin	O
eruption	O
,	O
leukocytopenia	O
,	O
and	O
thrombocytopenia	O
,	O
3	O
week	O
after	O
treatment	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
a	O
58-year-old	O
woman	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
developed	O
fever	O
,	O
skin	O
eruption	O
,	O
leukocytopenia	B-ADR
,	O
and	O
thrombocytopenia	O
,	O
3	O
week	O
after	O
treatment	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
a	O
58-year-old	O
woman	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
developed	O
fever	O
,	O
skin	B-ADR
eruption	I-ADR
,	O
leukocytopenia	O
,	O
and	O
thrombocytopenia	O
,	O
3	O
week	O
after	O
treatment	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
a	O
58-year-old	O
woman	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
developed	O
fever	O
,	O
skin	O
eruption	O
,	O
leukocytopenia	O
,	O
and	O
thrombocytopenia	B-ADR
,	O
3	O
week	O
after	O
treatment	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
hypersensitivity	O
syndrome	O
and	O
hemophagocytic	B-ADR
syndrome	I-ADR
associated	O
with	O
reactivation	O
of	O
epstein-barr	O
virus	O
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
and	O
hemophagocytic	O
syndrome	O
associated	O
with	O
reactivation	O
of	O
epstein-barr	O
virus	O
0	O
<EOS>	O
this	O
case	O
illustrates	O
that	O
the	O
hemophagocytic	B-ADR
syndrome	I-ADR
associated	O
with	O
reactivation	O
of	O
ebv	O
can	O
occur	O
a	O
part	O
of	O
drug	O
hypersensitivity	O
reaction	O
in	O
ra	O
patient	O
taking	O
sulfasalazine	B-Drug
0	O
<EOS>	O
the	O
goal	O
of	O
this	O
study	O
is	O
to	O
describe	O
three	O
patient	O
diagnosed	O
with	O
migraine	O
and	O
epilepsy	O
(	O
both	O
under	O
control	O
)	O
who	O
evolved	O
into	O
status	B-ADR
migrainosus	I-ADR
after	O
the	O
introduction	O
of	O
oxcarbazepine	O
(	O
oxc	O
)	O
,	O
a	O
part	O
of	O
a	O
switch	O
off	O
from	O
carbamazepine	B-Drug
(	O
cbz	O
)	O
0	O
<EOS>	O
the	O
goal	O
of	O
this	O
study	O
is	O
to	O
describe	O
three	O
patient	O
diagnosed	O
with	O
migraine	O
and	O
epilepsy	O
(	O
both	O
under	O
control	O
)	O
who	O
evolved	O
into	O
status	B-ADR
migrainosus	I-ADR
after	O
the	O
introduction	O
of	O
oxcarbazepine	O
(	O
oxc	O
)	O
,	O
a	O
part	O
of	O
a	O
switch	O
off	O
from	O
carbamazepine	O
(	O
cbz	B-Drug
)	O
0	O
<EOS>	O
the	O
goal	O
of	O
this	O
study	O
is	O
to	O
describe	O
three	O
patient	O
diagnosed	O
with	O
migraine	O
and	O
epilepsy	O
(	O
both	O
under	O
control	O
)	O
who	O
evolved	O
into	O
status	B-ADR
migrainosus	I-ADR
after	O
the	O
introduction	O
of	O
oxcarbazepine	O
(	O
oxc	B-Drug
)	O
,	O
a	O
part	O
of	O
a	O
switch	O
off	O
from	O
carbamazepine	O
(	O
cbz	O
)	O
0	O
<EOS>	O
the	O
goal	O
of	O
this	O
study	O
is	O
to	O
describe	O
three	O
patient	O
diagnosed	O
with	O
migraine	O
and	O
epilepsy	O
(	O
both	O
under	O
control	O
)	O
who	O
evolved	O
into	O
status	B-ADR
migrainosus	I-ADR
after	O
the	O
introduction	O
of	O
oxcarbazepine	B-Drug
(	O
oxc	O
)	O
,	O
a	O
part	O
of	O
a	O
switch	O
off	O
from	O
carbamazepine	O
(	O
cbz	O
)	O
0	O
<EOS>	O
uncontrolled	O
headache	B-ADR
induced	O
by	O
oxcarbazepine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
patient	O
with	O
chf	O
and	O
esrd	O
developed	O
myoclonic	B-ADR
muscle	I-ADR
spasm	I-ADR
after	O
receiving	O
dobutamine	B-Drug
by	O
continuous	O
i.v	O
0	O
infusion	O
0	O
<EOS>	O
myoclonus	B-ADR
associated	O
with	O
continuous	O
dobutamine	B-Drug
infusion	O
in	O
a	O
patient	O
with	O
end-stage	O
renal	O
disease	O
0	O
<EOS>	O
purpose	O
:	O
the	O
occurrence	O
of	O
myoclonus	B-ADR
associated	O
with	O
continuous	O
i.v	O
0	O
infusion	O
of	O
dobutamine	B-Drug
in	O
a	O
patient	O
with	O
end-stage	O
renal	O
disease	O
(	O
esrd	O
)	O
is	O
described	O
0	O
<EOS>	O
report	O
of	O
colonic	B-ADR
perforation	I-ADR
a	O
a	O
result	O
of	O
the	O
administration	O
of	O
calcium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
and	O
sorbitol	O
are	O
rare	O
0	O
<EOS>	O
report	O
of	O
colonic	B-ADR
perforation	I-ADR
a	O
a	O
result	O
of	O
the	O
administration	O
of	O
calcium	O
polystyrene	O
sulfonate	O
and	O
sorbitol	B-Drug
are	O
rare	O
0	O
<EOS>	O
we	O
concluded	O
that	O
the	O
colonic	B-ADR
ulcer	I-ADR
and	O
the	O
sigmoidovesical	O
fistula	O
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
and	O
sorbitol	O
0	O
<EOS>	O
we	O
concluded	O
that	O
the	O
colonic	B-ADR
ulcer	I-ADR
and	O
the	O
sigmoidovesical	O
fistula	O
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	O
polystyrene	O
sulfonate	O
and	O
sorbitol	B-Drug
0	O
<EOS>	O
we	O
concluded	O
that	O
the	O
colonic	O
ulcer	O
and	O
the	O
sigmoidovesical	B-ADR
fistula	I-ADR
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
and	O
sorbitol	O
0	O
<EOS>	O
we	O
concluded	O
that	O
the	O
colonic	O
ulcer	O
and	O
the	O
sigmoidovesical	B-ADR
fistula	I-ADR
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	O
polystyrene	O
sulfonate	O
and	O
sorbitol	B-Drug
0	O
<EOS>	O
psychosis	B-ADR
in	O
a	O
12-year-old	O
hiv-positive	O
girl	O
with	O
an	O
increased	O
serum	O
concentration	O
of	O
efavirenz	B-Drug
0	O
<EOS>	O
we	O
report	O
(	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
in	O
a	O
child	O
)	O
the	O
emergence	O
of	O
psychosis	B-ADR
in	O
a	O
12-year	O
old	O
white	O
girl	O
with	O
an	O
increased	O
efavirenz	B-Drug
concentration	O
and	O
heterozygous	O
gene	O
polymorphism	O
of	O
the	O
cyp2b6-g516t	O
0	O
<EOS>	O
mycobacterium	B-ADR
marinum	I-ADR
infection	I-ADR
complicating	O
crohn	O
disease	O
,	O
treated	O
with	O
infliximab	B-Drug
0	O
<EOS>	O
sustained	B-ADR
monomorphic	I-ADR
ventricular	I-ADR
tachycardia	I-ADR
after	O
adenosine	B-Drug
infusion	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
a	O
sustained	B-ADR
monomorphic	I-ADR
ventricular	I-ADR
tachycardia	I-ADR
following	O
adenosine	B-Drug
infusion	O
0	O
<EOS>	O
surprisingly	O
,	O
we	O
found	O
that	O
three	O
patient	O
appeared	O
to	O
develop	O
tardive	B-ADR
ogc	I-ADR
while	O
taking	O
clozapine	B-Drug
0	O
<EOS>	O
tardive	B-ADR
oculogyric	I-ADR
crisis	I-ADR
during	O
treatment	O
with	O
clozapine	B-Drug
:	O
report	O
of	O
three	O
case	O
0	O
<EOS>	O
metronidazole	B-Drug
neuropathy	B-ADR
0	O
<EOS>	O
two	O
patient	O
are	O
described	O
who	O
developed	O
sensory	B-ADR
neuropathy	I-ADR
after	O
the	O
ingestion	O
of	O
30.6	O
and	O
114	O
g	O
metronidazole	B-Drug
respectively	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
low-dose	O
methotrexate	B-Drug
(	O
15	O
mg	O
/	O
week	O
)	O
who	O
developed	O
infection	B-ADR
with	I-ADR
both	I-ADR
m.	I-ADR
tuberculosis	I-ADR
and	I-ADR
m.	I-ADR
chelonae	I-ADR
after	O
the	O
revision	O
of	O
a	O
prosthetic	O
hip	O
0	O
<EOS>	O
diagnosis	O
:	O
sustained	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
possibly	O
owing	O
to	O
thalidomide	B-Drug
treatment	O
0	O
<EOS>	O
multiple	B-ADR
syncopal	I-ADR
episode	I-ADR
started	O
to	O
occur	O
during	O
thalidomide	B-Drug
treatment	O
,	O
and	O
a	O
holter	O
electrocardiogram	O
showed	O
multiple	O
abnormality	O
,	O
with	O
an	O
episode	O
of	O
sustained	O
ventricular	O
tachycardia	O
0	O
<EOS>	O
multiple	O
syncopal	O
episode	O
started	O
to	O
occur	O
during	O
thalidomide	B-Drug
treatment	O
,	O
and	O
a	O
holter	O
electrocardiogram	O
showed	O
multiple	O
abnormality	O
,	O
with	O
an	O
episode	O
of	O
sustained	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
0	O
<EOS>	O
sustained	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
in	O
a	O
thalidomide-treated	B-Drug
patient	O
with	O
primary	O
plasma-cell	O
leukemia	O
0	O
<EOS>	O
a	O
patient	O
developed	O
typical	O
ecm	B-ADR
after	O
subcutaneous	O
selfinjection	O
of	O
glatiramer	B-Drug
acetate	I-Drug
for	O
multiple	O
sclerosis	O
0	O
<EOS>	O
embolia	B-ADR
cutis	I-ADR
medicamentosa	I-ADR
following	O
subcutaneous	O
injection	O
of	O
glatiramer	B-Drug
acetate	I-Drug
0	O
<EOS>	O
this	O
case	O
is	O
remarkable	O
since	O
1	O
)	O
ecm	O
developed	O
after	O
subcutaneous	O
and	O
not	O
after	O
intramuscular	O
injection	O
,	O
2	O
)	O
the	O
injection	O
wa	O
given	O
by	O
the	O
patient	O
himself	O
,	O
and	O
3	O
)	O
glatiramer	B-Drug
acetate	I-Drug
can	O
induce	O
skin	B-ADR
necrosis	I-ADR
a	O
a	O
side	O
effect	O
0	O
<EOS>	O
although	O
it	O
is	O
difficult	O
to	O
be	O
certain	O
of	O
the	O
direct	O
link	O
of	O
amiodarone	O
on	O
the	O
basis	O
of	O
a	O
single	O
case	O
,	O
it	O
is	O
reasonable	O
to	O
presume	O
that	O
this	O
histopathology	O
is	O
associated	O
with	O
amiodarone-induced	B-Drug
hypothyroidism	B-ADR
and	O
that	O
involution	O
change	O
represent	O
the	O
hypofunctional	O
status	O
of	O
this	O
drug-induced	O
disorder	O
0	O
<EOS>	O
amiodarone	B-Drug
is	O
well	O
recognized	O
a	O
an	O
anti-arrhythmic	O
drug	O
containing	O
a	O
high	O
dose	O
of	O
iodine	O
with	O
considerable	O
potential	O
to	O
cause	O
thyroid	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
histopathology	O
of	O
the	O
thyroid	O
in	O
amiodarone-induced	B-Drug
hypothyroidism	B-ADR
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
on	O
the	O
histopathological	O
finding	O
of	O
thyroid	O
tissue	O
from	O
a	O
patient	O
with	O
amiodarone-induced	B-Drug
hypothyroidism	B-ADR
0	O
<EOS>	O
although	O
adverse	O
effect	O
are	O
usually	O
mild	O
,	O
the	O
author	O
report	O
here	O
a	O
case	O
of	O
leucocytopenia	B-ADR
and	O
thrombocytopenia	O
with	O
quetiapine	B-Drug
treatment	O
that	O
required	O
it	O
discontinuation	O
0	O
<EOS>	O
although	O
adverse	O
effect	O
are	O
usually	O
mild	O
,	O
the	O
author	O
report	O
here	O
a	O
case	O
of	O
leucocytopenia	O
and	O
thrombocytopenia	B-ADR
with	O
quetiapine	B-Drug
treatment	O
that	O
required	O
it	O
discontinuation	O
0	O
<EOS>	O
quetiapine-induced	B-Drug
leucopenia	B-ADR
and	O
thrombocytopenia	O
0	O
<EOS>	O
quetiapine-induced	B-Drug
leucopenia	O
and	O
thrombocytopenia	B-ADR
0	O
<EOS>	O
amphotericin	B-Drug
b-induced	I-Drug
cutaneous	B-ADR
leucocytoclastic	I-ADR
vasculitis	I-ADR
:	O
case	O
report	O
0	O
<EOS>	O
palpable	B-ADR
purpuric	I-ADR
skin	I-ADR
lesion	I-ADR
on	O
the	O
anterior	O
surface	O
of	O
both	O
leg	O
appeared	O
on	O
the	O
55th	O
day	O
of	O
amphotericin	B-Drug
b	I-Drug
treatment	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
cutaneous	B-ADR
leucocytoclastic	I-ADR
vasculitis	I-ADR
in	O
which	O
amphotericin	B-Drug
b	I-Drug
might	O
presumably	O
be	O
the	O
aetiological	O
factor	O
0	O
<EOS>	O
the	O
incidence	O
of	O
5-fluorouracil	B-Drug
(	O
5-fu	O
)	O
-related	O
cardiotoxicity	B-ADR
seems	O
to	O
be	O
dosage	O
and	O
schedule	O
dependent	O
0	O
<EOS>	O
the	O
incidence	O
of	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
-related	O
cardiotoxicity	B-ADR
seems	O
to	O
be	O
dosage	O
and	O
schedule	O
dependent	O
0	O
<EOS>	O
transient	B-ADR
asymptomatic	I-ADR
bradycardia	I-ADR
in	O
patient	O
on	O
infusional	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
we	O
report	O
such	O
a	O
series	O
of	O
patient	O
who	O
had	O
transient	B-ADR
asymptomatic	I-ADR
bradycardia	I-ADR
after	O
being	O
treated	O
with	O
continuous	O
infusion	O
5-fu	B-Drug
0	O
<EOS>	O
according	O
to	O
the	O
naranjo	O
probability	O
scale	O
,	O
the	O
papular	B-ADR
eruption	I-ADR
wa	O
probably	O
caused	O
by	O
methotrexate	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
the	O
pathogenesis	O
of	O
methotrexate-induced	B-Drug
papular	B-ADR
eruption	I-ADR
in	O
collagen	O
vascular	O
disease	O
may	O
suggest	O
cutaneous	O
small-vessel	O
vasculitis	O
0	O
<EOS>	O
discussion	O
:	O
methotrexate-induced	B-Drug
papular	B-ADR
eruption	I-ADR
is	O
rarely	O
reported	O
shortly	O
after	O
beginning	O
methotrexate	O
therapy	O
in	O
patient	O
with	O
acute	O
exacerbation	O
of	O
collagen	O
vascular	O
disease	O
0	O
<EOS>	O
methotrexate-induced	B-Drug
papular	B-ADR
eruption	I-ADR
following	O
treatment	O
of	O
psoriasis	O
ha	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
methotrexate-induced	B-Drug
papular	B-ADR
eruption	I-ADR
following	O
treatment	O
of	O
psoriasis	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
a	O
diffuse	B-ADR
papular	I-ADR
eruption	I-ADR
following	O
treatment	O
of	O
psoriasis	O
with	O
methotrexate	B-Drug
injection	O
0	O
<EOS>	O
pathogenesis	O
of	O
methotrexate-induced	B-Drug
papular	O
eruption	O
in	O
psoriasis	O
may	O
involve	O
immune	O
mechanism	O
other	O
than	O
those	O
of	O
methotrexate-induced	O
cutaneous	B-ADR
vasculitis	I-ADR
in	O
collagen	O
vascular	O
disease	O
0	O
<EOS>	O
pathogenesis	O
of	O
methotrexate-induced	B-Drug
papular	B-ADR
eruption	I-ADR
in	O
psoriasis	O
may	O
involve	O
immune	O
mechanism	O
other	O
than	O
those	O
of	O
methotrexate-induced	O
cutaneous	O
vasculitis	O
in	O
collagen	O
vascular	O
disease	O
0	O
<EOS>	O
ten	O
hour	O
after	O
the	O
second	O
methotrexate	B-Drug
injection	O
,	O
the	O
patient	O
experienced	O
a	O
diffuse	B-ADR
pruritic	I-ADR
papular	I-ADR
eruption	I-ADR
located	O
mainly	O
on	O
the	O
limb	O
0	O
<EOS>	O
metabolic	B-ADR
acidosis	I-ADR
induced	O
by	O
acetazolamide	B-Drug
0	O
<EOS>	O
pericardial	B-ADR
hemorrhage	I-ADR
due	O
to	O
acetylsalicylic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
0	O
<EOS>	O
the	O
author	O
describe	O
pericardial	B-ADR
hemorrhage	I-ADR
,	O
which	O
is	O
related	O
to	O
the	O
use	O
of	O
low-dose	O
acetylsalicylic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
0	O
<EOS>	O
from	O
1996	O
to	O
2002	O
several	O
medication	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effect	O
:	O
indinavir	O
(	O
renal	O
colic	O
and	O
fever	O
)	O
,	O
nelfinavir	B-Drug
(	O
cutaneous	B-ADR
rash	I-ADR
)	O
,	O
and	O
efavirenz	O
(	O
nausea	O
and	O
temporary	O
memory	O
loss	O
)	O
0	O
<EOS>	O
from	O
1996	O
to	O
2002	O
several	O
medication	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effect	O
:	O
indinavir	B-Drug
(	O
renal	O
colic	O
and	O
fever	B-ADR
)	O
,	O
nelfinavir	O
(	O
cutaneous	O
rash	O
)	O
,	O
and	O
efavirenz	O
(	O
nausea	O
and	O
temporary	O
memory	O
loss	O
)	O
0	O
<EOS>	O
from	O
1996	O
to	O
2002	O
several	O
medication	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effect	O
:	O
indinavir	O
(	O
renal	O
colic	O
and	O
fever	O
)	O
,	O
nelfinavir	O
(	O
cutaneous	O
rash	O
)	O
,	O
and	O
efavirenz	B-Drug
(	O
nausea	B-ADR
and	O
temporary	O
memory	O
loss	O
)	O
0	O
<EOS>	O
from	O
1996	O
to	O
2002	O
several	O
medication	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effect	O
:	O
indinavir	B-Drug
(	O
renal	B-ADR
colic	I-ADR
and	O
fever	O
)	O
,	O
nelfinavir	O
(	O
cutaneous	O
rash	O
)	O
,	O
and	O
efavirenz	O
(	O
nausea	O
and	O
temporary	O
memory	O
loss	O
)	O
0	O
<EOS>	O
from	O
1996	O
to	O
2002	O
several	O
medication	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effect	O
:	O
indinavir	O
(	O
renal	O
colic	O
and	O
fever	O
)	O
,	O
nelfinavir	O
(	O
cutaneous	O
rash	O
)	O
,	O
and	O
efavirenz	B-Drug
(	O
nausea	O
and	O
temporary	B-ADR
memory	I-ADR
loss	I-ADR
)	O
0	O
<EOS>	O
conventional	O
and	O
diffusion-weighted	O
mri	O
finding	O
of	O
methotrexate	B-Drug
related	O
sub-acute	B-ADR
neurotoxicity	I-ADR
0	O
<EOS>	O
this	O
case	O
demonstrates	O
the	O
value	O
of	O
dwi	O
in	O
evaluation	O
and	O
diagnosis	O
of	O
sub-acute	B-ADR
toxic	I-ADR
leukoencephalopathy	I-ADR
in	O
patient	O
being	O
treated	O
with	O
methotrexate	B-Drug
0	O
<EOS>	O
we	O
describe	O
longitudinal	O
diffusion-weighted	O
mri	O
finding	O
of	O
sub-acute	B-ADR
leukoencephalopathy	I-ADR
following	O
methotrexate	B-Drug
therapy	O
in	O
a	O
24-year-old	O
man	O
diagnosed	O
with	O
pre-b-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
,	O
presenting	O
with	O
right-sided	O
paralysis	O
and	O
aphasia	O
after	O
second	O
consolidation	O
with	O
intrathecal	O
triple-drug	O
therapy	O
given	O
intrathecally	O
0	O
<EOS>	O
new	O
onset	O
of	O
cd	B-ADR
may	O
be	O
considered	O
a	O
an	O
immune-mediated	O
injury	O
induced	O
by	O
etanercept	B-Drug
0	O
<EOS>	O
new	O
onset	O
of	O
cd	O
may	O
be	O
considered	O
a	O
an	O
immune-mediated	B-ADR
injury	I-ADR
induced	O
by	O
etanercept	B-Drug
0	O
<EOS>	O
new	O
onset	O
of	O
crohn	B-ADR
disease	I-ADR
during	O
treatment	O
of	O
active	O
ankylosing	O
spondylitis	O
with	O
etanercept	B-Drug
0	O
<EOS>	O
typical	O
symptom	O
of	O
active	O
cd	B-ADR
occurred	O
11	O
,	O
12	O
,	O
and	O
26	O
month	O
after	O
start	O
of	O
etanercept	B-Drug
therapy	O
,	O
respectively	O
0	O
<EOS>	O
we	O
describe	O
3	O
a	O
patient	O
treated	O
with	O
etanercept	B-Drug
for	O
active	O
a	O
who	O
developed	O
new	O
onset	O
of	O
cd	B-ADR
while	O
a	O
related	O
symptom	O
responded	O
well	O
to	O
etanercept	O
0	O
<EOS>	O
upper	B-ADR
gastrointestinal	I-ADR
haemorrhage	I-ADR
is	O
a	O
serious	O
complication	O
of	O
aspirin	B-Drug
and	O
clopidogrel	O
(	O
dual	O
)	O
anti-platelet	O
therapy	O
with	O
a	O
high	O
morbidity	O
and	O
mortality	O
0	O
<EOS>	O
upper	B-ADR
gastrointestinal	I-ADR
haemorrhage	I-ADR
is	O
a	O
serious	O
complication	O
of	O
aspirin	O
and	O
clopidogrel	B-Drug
(	O
dual	O
)	O
anti-platelet	O
therapy	O
with	O
a	O
high	O
morbidity	O
and	O
mortality	O
0	O
<EOS>	O
while	O
doxorubicin	B-Drug
wa	O
administered	O
,	O
the	O
patient	O
presented	O
thoracic	O
pain	O
and	O
breathing	B-ADR
distress	I-ADR
due	O
to	O
superior	O
vena	O
cava	O
perforation	O
by	O
the	O
central	O
catheter	O
and	O
subsequent	O
extravasation	O
of	O
the	O
drug	O
into	O
the	O
mediastinum	O
0	O
<EOS>	O
while	O
doxorubicin	B-Drug
wa	O
administered	O
,	O
the	O
patient	O
presented	O
thoracic	B-ADR
pain	I-ADR
and	O
breathing	O
distress	O
due	O
to	O
superior	O
vena	O
cava	O
perforation	O
by	O
the	O
central	O
catheter	O
and	O
subsequent	O
extravasation	O
of	O
the	O
drug	O
into	O
the	O
mediastinum	O
0	O
<EOS>	O
severe	B-ADR
hepatocellular	I-ADR
dysfunction	I-ADR
following	O
cyproterone	B-Drug
acetate	I-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
3	O
patient	O
with	O
severe	O
hepatocellular	O
damage	O
due	O
to	O
cpa	B-Drug
therapy	O
,	O
2	O
with	O
fatal	B-ADR
fulminant	I-ADR
hepatitis	I-ADR
0	O
<EOS>	O
we	O
report	O
3	O
patient	O
with	O
severe	B-ADR
hepatocellular	I-ADR
damage	I-ADR
due	O
to	O
cpa	B-Drug
therapy	O
,	O
2	O
with	O
fatal	O
fulminant	O
hepatitis	O
0	O
<EOS>	O
she	O
wa	O
treated	O
with	O
acyclovir	B-Drug
and	O
subsequently	O
developed	O
vzv	B-ADR
antigen-positive	I-ADR
zoster	I-ADR
0	O
<EOS>	O
according	O
to	O
the	O
naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
,	O
the	O
likelihood	O
that	O
temozolomide	B-Drug
wa	O
responsible	O
for	O
the	O
adverse	O
drug	O
reaction	O
of	O
fever	B-ADR
wa	O
probable	O
(	O
score	O
of	O
6	O
)	O
0	O
<EOS>	O
clinician	O
should	O
be	O
aware	O
that	O
an	O
erythematous	O
and	O
exfoliative	B-ADR
rash	I-ADR
may	O
be	O
induced	O
by	O
temozolomide	B-Drug
,	O
and	O
be	O
familiar	O
with	O
the	O
pharmacologic	O
and	O
supportive	O
measure	O
necessary	O
for	O
it	O
treatment	O
0	O
<EOS>	O
due	O
to	O
the	O
severity	O
of	O
the	O
rash	B-ADR
,	O
temozolomide	B-Drug
wa	O
permanently	O
discontinued	O
0	O
<EOS>	O
temozolomide-induced	B-Drug
desquamative	B-ADR
skin	I-ADR
rash	I-ADR
in	O
a	O
patient	O
with	O
metastatic	O
melanoma	O
0	O
<EOS>	O
temozolomide	B-Drug
wa	O
restarted	O
2	O
month	O
later	O
;	O
the	O
patient	O
again	O
developed	O
a	O
fever	B-ADR
0	O
<EOS>	O
exfoliative	B-ADR
dermatitis	I-ADR
secondary	O
to	O
tobramycin	B-Drug
sulfate	I-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
exfoliative	B-ADR
dermatitis	I-ADR
clearly	O
linked	O
to	O
intravenous	O
and	O
intraperitoneal	O
administration	O
of	O
tobramycin	B-Drug
0	O
<EOS>	O
rituximab-chop	B-Drug
induced	O
interstitial	B-ADR
pneumonitis	I-ADR
in	O
patient	O
with	O
disseminated	O
extranodal	O
marginal	O
zone	O
b	O
cell	O
lymphoma	O
0	O
<EOS>	O
phenytoin	B-Drug
toxicity	O
:	O
an	O
easily	O
missed	O
cause	O
of	O
cerebellar	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
a	O
diagnosis	O
of	O
trastuzumab-induced	B-Drug
pneumonitis	B-ADR
wa	O
made	O
0	O
<EOS>	O
a	O
female	O
patient	O
with	O
her2	O
positive	O
,	O
metastatic	O
breast	O
cancer	O
presented	O
with	O
pulmonary	O
infiltrates	O
,	O
and	O
a	O
plural	B-ADR
effusion	I-ADR
dyspnoea	I-ADR
after	O
several	O
month	O
of	O
trastuzumab	B-Drug
treatment	O
0	O
<EOS>	O
a	O
female	O
patient	O
with	O
her2	O
positive	O
,	O
metastatic	O
breast	O
cancer	O
presented	O
with	O
pulmonary	B-ADR
infiltrates	I-ADR
,	O
and	O
a	O
plural	O
effusion	O
dyspnoea	O
after	O
several	O
month	O
of	O
trastuzumab	B-Drug
treatment	O
0	O
<EOS>	O
life-threatening	O
interstitial	B-ADR
lung	I-ADR
disease	I-ADR
associated	O
with	O
trastuzumab	B-Drug
:	O
case	O
report	O
0	O
<EOS>	O
a	O
30-year-old	O
pharmacist	O
suffered	O
from	O
acute	B-ADR
allergic	I-ADR
contact	I-ADR
dermatitis	I-ADR
due	O
to	O
4-chloro-7-nitrobenzofurazan	B-Drug
(	O
nbd-cl	O
)	O
0	O
<EOS>	O
a	O
30-year-old	O
pharmacist	O
suffered	O
from	O
acute	B-ADR
allergic	I-ADR
contact	I-ADR
dermatitis	I-ADR
due	O
to	O
4-chloro-7-nitrobenzofurazan	O
(	O
nbd-cl	B-Drug
)	O
0	O
<EOS>	O
allergic	B-ADR
contact	I-ADR
dermatitis	I-ADR
from	O
4-chloro-7-nitrobenzofurazan	B-Drug
0	O
<EOS>	O
photo-onycholysis	B-ADR
caused	O
by	O
olanzapine	O
and	O
aripiprazole	B-Drug
0	O
<EOS>	O
photo-onycholysis	B-ADR
caused	O
by	O
olanzapine	B-Drug
and	O
aripiprazole	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
photo-onycholysis	B-ADR
on	O
multiple	O
nail	O
after	O
uptake	O
of	O
olanzapine	B-Drug
0	O
<EOS>	O
diffuse	B-ADR
alveolar	I-ADR
hemorrhage	I-ADR
after	O
leflunomide	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
young	O
man	O
,	O
affected	O
by	O
rheumatoid	O
arthritis	O
who	O
developed	O
a	O
rapid-onset	O
short-of-breath	O
,	O
hemoptysis	B-ADR
,	O
and	O
severe	O
weakness	O
,	O
about	O
2	O
week	O
after	O
the	O
administration	O
of	O
leflunomide	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
young	O
man	O
,	O
affected	O
by	O
rheumatoid	O
arthritis	O
who	O
developed	O
a	O
rapid-onset	O
short-of-breath	O
,	O
hemoptysis	O
,	O
and	O
severe	B-ADR
weakness	I-ADR
,	O
about	O
2	O
week	O
after	O
the	O
administration	O
of	O
leflunomide	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
young	O
man	O
,	O
affected	O
by	O
rheumatoid	O
arthritis	O
who	O
developed	O
a	O
rapid-onset	O
short-of-breath	B-ADR
,	O
hemoptysis	O
,	O
and	O
severe	O
weakness	O
,	O
about	O
2	O
week	O
after	O
the	O
administration	O
of	O
leflunomide	B-Drug
0	O
<EOS>	O
hyponatraemia	B-ADR
developed	O
after	O
rechallenge	O
with	O
controlled	O
release	O
carbamazepine	B-Drug
0	O
<EOS>	O
hyponatraemia	B-ADR
during	O
low-dose	O
carbamazepine	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
the	O
syndrome	O
of	O
inappropriate	O
antidiuresis	B-ADR
a	O
a	O
much	O
earlier	O
side-effect	O
of	O
carbamazepine	B-Drug
administration	O
in	O
a	O
29-year	O
nigerian	O
female	O
patient	O
with	O
generalized	O
tonic-elonic	O
seizure	O
0	O
<EOS>	O
in	O
the	O
present	O
paper	O
,	O
we	O
describe	O
two	O
patient	O
with	O
active	O
uc	O
who	O
developed	O
a	O
severe	B-ADR
systemic	I-ADR
cmv	I-ADR
infection	I-ADR
during	O
a	O
treatment	O
with	O
an	O
oral	O
microemulsion	O
form	O
of	O
cyclosporine	B-Drug
0	O
<EOS>	O
a	O
short	O
review	O
on	O
imatinib-related	B-Drug
hepatotoxicity	B-ADR
is	O
also	O
presented	O
0	O
<EOS>	O
imatinib	B-Drug
mesylate-related	I-Drug
fatal	B-ADR
acute	I-ADR
hepatic	I-ADR
failure	I-ADR
in	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
and	O
chronic	O
hepatitis	O
b	O
infection	O
0	O
<EOS>	O
up	O
to	O
four	O
percent	O
of	O
patient	O
treated	O
with	O
imatinib	B-Drug
may	O
develop	O
hepatotoxicity	B-ADR
,	O
which	O
usually	O
resolve	O
with	O
discontinuation	O
of	O
the	O
drug	O
0	O
<EOS>	O
we	O
report	O
a	O
45-year-old	O
chinese	O
man	O
with	O
cml	O
and	O
chronic	O
hepatitis	O
b	O
virus	O
infection	O
,	O
on	O
imatinib	B-Drug
treatment	O
,	O
presenting	O
with	O
herpetic	O
rash	O
and	O
acute	B-ADR
liver	I-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
45-year-old	O
chinese	O
man	O
with	O
cml	O
and	O
chronic	O
hepatitis	O
b	O
virus	O
infection	O
,	O
on	O
imatinib	B-Drug
treatment	O
,	O
presenting	O
with	O
herpetic	B-ADR
rash	I-ADR
and	O
acute	O
liver	O
failure	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
treating	O
elderly	O
patient	O
with	O
olanzapine	B-Drug
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
rapidly	O
developing	O
hyperglycemia	B-ADR
and	O
monitor	O
such	O
patient	O
accordingly	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
rapidly	O
occurring	O
hyperglycemia	B-ADR
that	O
occurred	O
in	O
a	O
geriatric	O
patient	O
3	O
day	O
after	O
treatment	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
rapidly	O
developing	O
hyperglycemia	B-ADR
during	O
treatment	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
subsequently	O
,	O
he	O
developed	O
hyperglycemia	B-ADR
(	O
fasting	O
blood	O
glucose	O
138	O
mg	O
/	O
dl	O
)	O
that	O
resolved	O
when	O
olanzapine	B-Drug
wa	O
stopped	O
and	O
recurred	O
(	O
fasting	O
blood	O
glucose	O
150	O
mg	O
/	O
dl	O
)	O
after	O
2	O
day	O
of	O
rechallenge	O
with	O
olanzapine	O
2.5	O
mg	O
twice	O
daily	O
0	O
<EOS>	O
there	O
have	O
been	O
numerous	O
case	O
report	O
of	O
hyperglycemia	B-ADR
with	O
olanzapine	B-Drug
in	O
the	O
literature	O
,	O
but	O
none	O
reported	O
hyperglycemia	O
within	O
day	O
of	O
initiation	O
of	O
the	O
medication	O
0	O
<EOS>	O
adult	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
after	O
treatment	O
with	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	O
0	O
<EOS>	O
adult	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
after	O
treatment	O
with	O
pegylated	O
interferon	O
alpha-2a	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
(	O
ards	O
)	O
associated	O
with	O
pegylated	O
interferon	O
alpha-2a	O
(	O
pegifnalpha-2a	B-Drug
)	O
and	O
ribavirin	O
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
(	O
ards	O
)	O
associated	O
with	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
(	O
pegifnalpha-2a	O
)	O
and	O
ribavirin	O
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	B-ADR
respiratory	I-ADR
distress	I-ADR
syndrome	I-ADR
(	O
ards	O
)	O
associated	O
with	O
pegylated	O
interferon	O
alpha-2a	O
(	O
pegifnalpha-2a	O
)	O
and	O
ribavirin	B-Drug
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ards	B-ADR
)	O
associated	O
with	O
pegylated	O
interferon	O
alpha-2a	O
(	O
pegifnalpha-2a	B-Drug
)	O
and	O
ribavirin	O
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ards	B-ADR
)	O
associated	O
with	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
(	O
pegifnalpha-2a	O
)	O
and	O
ribavirin	O
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
fulminant	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ards	B-ADR
)	O
associated	O
with	O
pegylated	O
interferon	O
alpha-2a	O
(	O
pegifnalpha-2a	O
)	O
and	O
ribavirin	B-Drug
use	O
for	O
hepatitis	O
c	O
,	O
complicated	O
by	O
subsequent	O
and	O
ultimately	O
fatal	O
sepsis	O
and	O
multiorgan	O
failure	O
0	O
<EOS>	O
bilateral	B-ADR
anterior	I-ADR
uveitis	I-ADR
associated	O
with	O
clomiphene	B-Drug
citrate	I-Drug
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
bilateral	B-ADR
anterior	I-ADR
uveitis	I-ADR
associated	O
with	O
ovulation	O
induction	O
therapy	O
using	O
clomiphene	B-Drug
citrate	I-Drug
0	O
<EOS>	O
development	O
of	O
tic	B-ADR
in	O
a	O
thirteen-year-old	O
male	O
following	O
atomoxetine	B-Drug
use	O
0	O
<EOS>	O
there	O
are	O
,	O
however	O
,	O
case	O
study	O
describing	O
patient	O
experiencing	O
recurrence	O
of	O
tic	B-ADR
following	O
treatment	O
with	O
atomoxetine	B-Drug
0	O
<EOS>	O
a	O
51-year-old	O
man	O
developed	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
following	O
24	O
week	O
of	O
treatment	O
with	O
recombinant	O
alpha-2b	B-Drug
peginterferon	I-Drug
plus	O
ribavirin	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
a	O
51-year-old	O
man	O
developed	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
following	O
24	O
week	O
of	O
treatment	O
with	O
recombinant	O
alpha-2b	O
peginterferon	O
plus	O
ribavirin	B-Drug
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggested	O
that	O
recombinant	B-Drug
alpha-2b	I-Drug
peginterferon	I-Drug
plus	O
ribavirin	O
provoked	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
,	O
therefore	O
,	O
in	O
patient	O
who	O
are	O
candidate	O
for	O
interferon	O
therapy	O
the	O
presence	O
of	O
pancreatic	O
autoantibody	O
and	O
the	O
fasting	O
plasma	O
glucose	O
level	O
should	O
be	O
investigated	O
before	O
and	O
during	O
treatment	O
0	O
<EOS>	O
the	O
clinical	O
course	O
suggested	O
that	O
recombinant	O
alpha-2b	O
peginterferon	O
plus	O
ribavirin	B-Drug
provoked	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
,	O
therefore	O
,	O
in	O
patient	O
who	O
are	O
candidate	O
for	O
interferon	O
therapy	O
the	O
presence	O
of	O
pancreatic	O
autoantibody	O
and	O
the	O
fasting	O
plasma	O
glucose	O
level	O
should	O
be	O
investigated	O
before	O
and	O
during	O
treatment	O
0	O
<EOS>	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
provoked	O
by	O
peginterferon	B-Drug
alpha-2b	I-Drug
plus	O
ribavirin	O
treatment	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
type	B-ADR
1	I-ADR
diabetes	I-ADR
mellitus	I-ADR
provoked	O
by	O
peginterferon	O
alpha-2b	O
plus	O
ribavirin	B-Drug
treatment	O
for	O
chronic	O
hepatitis	O
c	O
0	O
<EOS>	O
background	O
:	O
to	O
describe	O
the	O
occurrence	O
of	O
ocular	B-ADR
hypertension	I-ADR
in	O
four	O
patient	O
following	O
injection	O
of	O
ranibizumab	B-Drug
intravitreally	O
0	O
<EOS>	O
conclusion	O
:	O
severe	O
and	O
sustained	B-ADR
ocular	I-ADR
hypertension	I-ADR
may	O
occur	O
after	O
intravitreal	O
ranibizumab	B-Drug
0	O
<EOS>	O
ocular	B-ADR
hypertension	I-ADR
occurred	O
1	O
month	O
after	O
the	O
second	O
ranibizumab	B-Drug
injection	O
in	O
patient	O
1	O
and	O
3	O
,	O
and	O
1	O
month	O
after	O
the	O
first	O
ranibizumab	O
in	O
patient	O
2	O
0	O
<EOS>	O
persisent	B-ADR
ocular	I-ADR
hypertension	I-ADR
following	O
intravitreal	O
ranibizumab	B-Drug
0	O
<EOS>	O
methylphenidate	O
and	O
dextroamphetamine-induced	B-Drug
peripheral	B-ADR
vasculopathy	I-ADR
0	O
<EOS>	O
methylphenidate	B-Drug
and	O
dextroamphetamine-induced	O
peripheral	B-ADR
vasculopathy	I-ADR
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	O
and	O
2	O
on	O
dextroamphetamine	B-Drug
who	O
presented	O
with	O
acral	B-ADR
cyanosis	I-ADR
,	O
livedo	O
reticularis	O
,	O
or	O
raynaud	O
phenomenon	O
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	B-Drug
and	O
2	O
on	O
dextroamphetamine	O
who	O
presented	O
with	O
acral	B-ADR
cyanosis	I-ADR
,	O
livedo	O
reticularis	O
,	O
or	O
raynaud	O
phenomenon	O
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	O
and	O
2	O
on	O
dextroamphetamine	B-Drug
who	O
presented	O
with	O
acral	O
cyanosis	O
,	O
livedo	B-ADR
reticularis	I-ADR
,	O
or	O
raynaud	O
phenomenon	O
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	B-Drug
and	O
2	O
on	O
dextroamphetamine	O
who	O
presented	O
with	O
acral	O
cyanosis	O
,	O
livedo	B-ADR
reticularis	I-ADR
,	O
or	O
raynaud	O
phenomenon	O
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	O
and	O
2	O
on	O
dextroamphetamine	B-Drug
who	O
presented	O
with	O
acral	O
cyanosis	O
,	O
livedo	O
reticularis	O
,	O
or	O
raynaud	B-ADR
phenomenon	I-ADR
0	O
<EOS>	O
we	O
report	O
4	O
patient	O
,	O
2	O
on	O
methylphenidate	B-Drug
and	O
2	O
on	O
dextroamphetamine	O
who	O
presented	O
with	O
acral	O
cyanosis	O
,	O
livedo	O
reticularis	O
,	O
or	O
raynaud	B-ADR
phenomenon	I-ADR
0	O
<EOS>	O
disseminated	B-ADR
eruptive	I-ADR
giant	I-ADR
mollusca	I-ADR
contagiosa	I-ADR
in	O
an	O
adult	O
psoriasis	O
patient	O
during	O
efalizumab	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
45-year-old	O
psoriasis	O
patient	O
who	O
developed	O
eruptive	B-ADR
mollusca	I-ADR
contagiosa	I-ADR
during	O
an	O
antipsoriatic	O
treatment	O
with	O
efalizumab	B-Drug
0	O
<EOS>	O
gastric	O
tumor	O
,	O
endometrial	O
carcinoma	O
and	O
cervical	B-ADR
adenocarcinoma	I-ADR
in	O
situ	O
were	O
detected	O
after	O
treatment	O
with	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
gastric	O
tumor	O
,	O
endometrial	B-ADR
carcinoma	I-ADR
and	O
cervical	O
adenocarcinoma	O
in	O
situ	O
were	O
detected	O
after	O
treatment	O
with	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
gastric	B-ADR
tumor	I-ADR
,	O
endometrial	O
carcinoma	O
and	O
cervical	O
adenocarcinoma	O
in	O
situ	O
were	O
detected	O
after	O
treatment	O
with	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
incomplete	B-ADR
posterior	I-ADR
hyaloid	I-ADR
detachment	I-ADR
after	O
intravitreal	O
pegaptanib	B-Drug
injection	O
in	O
diabetic	O
macular	O
edema	O
0	O
<EOS>	O
the	O
author	O
report	O
one	O
case	O
of	O
incomplete	B-ADR
posterior	I-ADR
hyaloid	I-ADR
detachment	I-ADR
(	O
phd	O
)	O
following	O
intravitreal	O
pegaptanib	B-Drug
to	O
treat	O
dme	O
0	O
<EOS>	O
enalaprilat	B-Drug
induced	O
acute	B-ADR
parotitis	I-ADR
0	O
<EOS>	O
we	O
present	O
here	O
a	O
female	O
patient	O
who	O
developed	O
acute	B-ADR
bilateral	I-ADR
parotitis	I-ADR
within	O
minute	O
of	O
i.v	O
0	O
enalaprilat	B-Drug
injection	O
and	O
recovered	O
within	O
24	O
hour	O
of	O
stopping	O
the	O
drug	O
and	O
with	O
symptomatic	O
treatment	O
0	O
<EOS>	O
we	O
report	O
a	O
4-year-old	O
girl	O
who	O
presented	O
with	O
acute	B-ADR
bilateral	I-ADR
blindness	I-ADR
,	O
a	O
focal	O
seizure	O
and	O
hypertension	O
10	O
day	O
after	O
commencing	O
oxybutynin	B-Drug
to	O
treat	O
enuresis	O
0	O
<EOS>	O
we	O
report	O
a	O
4-year-old	O
girl	O
who	O
presented	O
with	O
acute	O
bilateral	O
blindness	O
,	O
a	O
focal	B-ADR
seizure	I-ADR
and	O
hypertension	O
10	O
day	O
after	O
commencing	O
oxybutynin	B-Drug
to	O
treat	O
enuresis	O
0	O
<EOS>	O
we	O
report	O
a	O
4-year-old	O
girl	O
who	O
presented	O
with	O
acute	O
bilateral	O
blindness	O
,	O
a	O
focal	O
seizure	O
and	O
hypertension	B-ADR
10	O
day	O
after	O
commencing	O
oxybutynin	B-Drug
to	O
treat	O
enuresis	O
0	O
<EOS>	O
severe	B-ADR
symptomatic	I-ADR
hyponatremia	I-ADR
during	O
sibutramine	B-Drug
therapy	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
known	O
side	O
effect	O
of	O
sibutramine	B-Drug
,	O
ie	O
,	O
hypertension	B-ADR
and	O
tachycardia	O
,	O
depend	O
on	O
it	O
adrenergic	O
and	O
serotoninergic	O
effect	O
0	O
<EOS>	O
the	O
known	O
side	O
effect	O
of	O
sibutramine	B-Drug
,	O
ie	O
,	O
hypertension	O
and	O
tachycardia	B-ADR
,	O
depend	O
on	O
it	O
adrenergic	O
and	O
serotoninergic	O
effect	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
life-threatening	O
hyponatremia	B-ADR
associated	O
with	O
sibutramine	B-Drug
use	O
in	O
an	O
obese	O
woman	O
0	O
<EOS>	O
our	O
finding	O
reveal	O
that	O
even	O
in	O
patient	O
without	O
a	O
history	O
of	O
seizure	O
,	O
pregabalin	B-Drug
can	O
cause	O
a	O
cortical	B-ADR
negative	I-ADR
myoclonus	I-ADR
0	O
<EOS>	O
pregabalin-induced	B-Drug
cortical	B-ADR
negative	I-ADR
myoclonus	I-ADR
in	O
a	O
patient	O
with	O
neuropathic	O
pain	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
,	O
after	O
receiving	O
his	O
first	O
dose	O
of	O
pregabalin	B-Drug
to	O
relieve	O
neuropathic	O
pain	O
,	O
presented	O
with	O
a	O
negative	B-ADR
myoclonus	I-ADR
0	O
<EOS>	O
muzolimine-induced	B-Drug
severe	B-ADR
neuromyeloencephalopathy	I-ADR
:	O
report	O
of	O
seven	O
case	O
0	O
<EOS>	O
we	O
report	O
on	O
7	O
patient	O
(	O
2	O
woman	O
,	O
5	O
men	O
)	O
with	O
chronic	O
renal	O
failure	O
,	O
who	O
developed	O
under	O
a	O
high	O
dosage	O
of	O
the	O
new	O
diuretic	O
muzolimine	B-Drug
(	O
range	O
240	O
to	O
1440	O
mg	O
per	O
day	O
)	O
fatal	B-ADR
neuromyeloencephalopathy	I-ADR
0	O
<EOS>	O
l-asparaginase-induced	B-Drug
posterior	B-ADR
reversible	I-ADR
encephalopathy	I-ADR
syndrome	O
during	O
acute	O
lymphoblastic	O
leukemia	O
treatment	O
in	O
child	O
0	O
<EOS>	O
the	O
purpose	O
of	O
this	O
article	O
is	O
to	O
present	O
the	O
first	O
case-series	O
of	O
posterior	B-ADR
reversible	I-ADR
encephalopathy	I-ADR
syndrome	I-ADR
(	O
pres	O
)	O
associated	O
with	O
l-asparaginase	B-Drug
treatment	O
0	O
<EOS>	O
the	O
purpose	O
of	O
this	O
article	O
is	O
to	O
present	O
the	O
first	O
case-series	O
of	O
posterior	O
reversible	O
encephalopathy	O
syndrome	O
(	O
pres	B-ADR
)	O
associated	O
with	O
l-asparaginase	B-Drug
treatment	O
0	O
<EOS>	O
we	O
report	O
3	O
case	O
of	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
developed	O
seizure	O
and	O
altered	B-ADR
sensorium	I-ADR
after	O
l-asparaginase	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
3	O
case	O
of	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
developed	O
seizure	B-ADR
and	O
altered	O
sensorium	O
after	O
l-asparaginase	B-Drug
therapy	O
0	O
<EOS>	O
anastrozole-associated	B-Drug
sclerosing	B-ADR
glomerulonephritis	I-ADR
in	O
a	O
patient	O
with	O
breast	O
cancer	O
0	O
<EOS>	O
conclusion	O
:	O
anastrozole	B-Drug
may	O
be	O
the	O
causative	O
factor	O
in	O
patient	O
with	O
sclerosing	B-ADR
glomerulonephritis	I-ADR
0	O
<EOS>	O
diagnosis	O
of	O
sclerosing	B-ADR
glomerulonephritis	I-ADR
occurred	O
in	O
this	O
patient	O
during	O
anastrozole	B-Drug
use	O
,	O
suggesting	O
a	O
newly	O
defined	O
side	O
effect	O
of	O
anastrozole	O
0	O
<EOS>	O
renal	B-ADR
injury	I-ADR
due	O
to	O
anastrozole	B-Drug
ha	O
not	O
been	O
published	O
in	O
the	O
english	O
literature	O
0	O
<EOS>	O
there	O
are	O
major	O
side	O
effect	O
of	O
anastrozole	B-Drug
including	O
decrease	B-ADR
in	I-ADR
both	I-ADR
lumbar	I-ADR
spine	I-ADR
and	O
total	O
hip	O
bone	O
mineral	O
density	O
,	O
increase	O
in	O
the	O
incidence	O
of	O
all	O
bone	O
fracture	O
(	O
especially	O
fracture	O
of	O
spine	O
,	O
hip	O
and	O
wrist	O
)	O
,	O
joint	O
disorder	O
and	O
increase	O
in	O
the	O
cholesterol	O
level	O
0	O
<EOS>	O
there	O
are	O
major	O
side	O
effect	O
of	O
anastrozole	B-Drug
including	O
decrease	O
in	O
both	O
lumbar	O
spine	O
and	O
total	O
hip	O
bone	O
mineral	O
density	O
,	O
increase	B-ADR
in	I-ADR
the	I-ADR
incidence	O
of	O
all	O
bone	O
fracture	O
(	O
especially	O
fracture	O
of	O
spine	O
,	O
hip	O
and	O
wrist	O
)	O
,	O
joint	O
disorder	O
and	O
increase	B-ADR
in	I-ADR
the	I-ADR
cholesterol	I-ADR
level	I-ADR
0	O
<EOS>	O
there	O
are	O
major	O
side	O
effect	O
of	O
anastrozole	B-Drug
including	O
decrease	O
in	O
both	O
lumbar	O
spine	O
and	O
total	O
hip	O
bone	O
mineral	O
density	O
,	O
increase	B-ADR
in	I-ADR
the	I-ADR
incidence	I-ADR
of	I-ADR
all	I-ADR
bone	I-ADR
fracture	I-ADR
(	O
especially	O
fracture	O
of	O
spine	O
,	O
hip	O
and	O
wrist	O
)	O
,	O
joint	O
disorder	O
and	O
increase	O
in	O
the	O
cholesterol	O
level	O
0	O
<EOS>	O
there	O
are	O
major	O
side	O
effect	O
of	O
anastrozole	B-Drug
including	O
decrease	O
in	O
both	O
lumbar	O
spine	O
and	O
total	O
hip	O
bone	O
mineral	O
density	O
,	O
increase	O
in	O
the	O
incidence	O
of	O
all	O
bone	O
fracture	O
(	O
especially	O
fracture	O
of	O
spine	O
,	O
hip	O
and	O
wrist	O
)	O
,	O
joint	B-ADR
disorder	I-ADR
and	O
increase	O
in	O
the	O
cholesterol	O
level	O
0	O
<EOS>	O
we	O
believe	O
that	O
the	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
our	O
patient	O
wa	O
associated	O
with	O
anastrozole	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
61-year-old	O
woman	O
with	O
no	O
apparent	O
risk	O
factor	O
for	O
liver	O
injury	O
developed	O
acute	B-ADR
hepatitis	I-ADR
one	O
week	O
after	O
the	O
final	O
dose	O
of	O
a	O
long-term	O
course	O
of	O
pulse	O
itraconazole	B-Drug
therapy	O
(	O
200	O
mg	O
orally	O
twice	O
daily	O
,	O
1	O
wk	O
on	O
,	O
3	O
wk	O
off	O
,	O
for	O
24	O
wk	O
)	O
for	O
onychomycosis	O
0	O
<EOS>	O
conclusion	O
:	O
prolonged	O
exposure	O
to	O
itraconazole	B-Drug
,	O
administered	O
either	O
continuously	O
or	O
intermittently	O
,	O
may	O
precipitate	O
severe	B-ADR
and	I-ADR
irreversible	I-ADR
hepatotoxic	I-ADR
event	I-ADR
0	O
<EOS>	O
fatal	B-ADR
hepatitis	I-ADR
after	O
long-term	O
pulse	O
itraconazole	B-Drug
treatment	O
for	O
onychomycosis	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
occurrence	O
of	O
acute	B-ADR
cytolytic	I-ADR
hepatitis	I-ADR
in	O
a	O
patient	O
exposed	O
to	O
pulse	O
itraconazole	O
therapy	O
for	O
24	O
week	O
and	O
provide	O
a	O
concise	O
review	O
of	O
the	O
literature	O
on	O
case	O
of	O
itraconazole-induced	B-Drug
hepatitis	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
occurrence	O
of	O
acute	O
cytolytic	O
hepatitis	B-ADR
in	O
a	O
patient	O
exposed	O
to	O
pulse	O
itraconazole	O
therapy	O
for	O
24	O
week	O
and	O
provide	O
a	O
concise	O
review	O
of	O
the	O
literature	O
on	O
case	O
of	O
itraconazole-induced	B-Drug
hepatitis	O
0	O
<EOS>	O
only	O
one	O
case	O
of	O
severe	B-ADR
symptomatic	I-ADR
hepatitis	I-ADR
occurring	O
after	O
pulse	O
therapy	O
with	O
itraconazole	B-Drug
for	O
onychomycosis	O
and	O
requiring	O
transplantation	O
ha	O
been	O
reported	O
previously	O
0	O
<EOS>	O
conclusion	O
:	O
intrathecal	O
baclofen	B-Drug
can	O
impair	B-ADR
sexual	I-ADR
function	I-ADR
and	O
ejaculation	O
in	O
some	O
patient	O
0	O
<EOS>	O
result	O
:	O
a	O
male	O
and	O
a	O
female	O
patient	O
with	O
spasticity	O
treated	O
with	O
intrathecal	O
baclofen	B-Drug
were	O
recognized	O
to	O
have	O
sexual	B-ADR
dysfunction	I-ADR
side	O
effect	O
from	O
treatment	O
0	O
<EOS>	O
sexual	B-ADR
dysfunction	I-ADR
associated	O
with	O
intrathecal	O
baclofen	B-Drug
use	O
:	O
a	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
recombinant	B-Drug
insulin-like	I-Drug
growth	I-Drug
factor-i	I-Drug
0	O
<EOS>	O
we	O
report	O
a	O
13	O
year-old	O
male	O
who	O
developed	O
life-threatening	O
anaphylaxis	B-ADR
early	O
in	O
the	O
course	O
of	O
increlex	B-Drug
therapy	O
0	O
<EOS>	O
increasing	O
the	O
olanzapine	B-Drug
dosage	O
severely	O
aggravated	O
the	O
symptom	O
of	O
rls	B-ADR
0	O
<EOS>	O
restless	O
leg	O
syndrome	O
and	O
periodic	B-ADR
limb	I-ADR
movement	I-ADR
during	I-ADR
sleep	I-ADR
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
restless	B-ADR
leg	I-ADR
syndrome	I-ADR
and	O
periodic	O
limb	O
movement	O
during	O
sleep	O
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
the	O
fifth	O
patient	O
exhibited	O
paraesthesia	O
and	O
agitation	B-ADR
caused	O
by	O
olanzapine	B-Drug
that	O
wa	O
misdiagnosed	O
a	O
psychotic	O
agitation	O
0	O
<EOS>	O
the	O
fifth	O
patient	O
exhibited	O
paraesthesia	B-ADR
and	O
agitation	O
caused	O
by	O
olanzapine	B-Drug
that	O
wa	O
misdiagnosed	O
a	O
psychotic	O
agitation	O
0	O
<EOS>	O
the	O
fourth	O
patient	O
showed	O
rls	B-ADR
symptom	I-ADR
that	O
were	O
initially	O
caused	O
by	O
a	O
20-mg	O
daily	O
olanzapine	B-Drug
dosage	O
and	O
were	O
later	O
mitigated	O
when	O
olanzapine	O
wa	O
reduced	O
and	O
ropinirole	O
wa	O
administered	O
0	O
<EOS>	O
the	O
second	O
patient	O
exhibited	O
sudden	O
plms	B-ADR
following	O
olanzapine	B-Drug
injection	O
0	O
<EOS>	O
the	O
third	O
patient	O
had	O
been	O
suffering	O
from	O
serious	O
akathisia	B-ADR
while	O
on	O
risperidone	O
,	O
and	O
wa	O
cured	O
after	O
switching	O
to	O
olanzapine	B-Drug
,	O
but	O
thereafter	O
the	O
patient	O
suffered	O
from	O
rls	O
at	O
nighttime	O
0	O
<EOS>	O
the	O
third	O
patient	O
had	O
been	O
suffering	O
from	O
serious	O
akathisia	B-ADR
while	O
on	O
risperidone	B-Drug
,	O
and	O
wa	O
cured	O
after	O
switching	O
to	O
olanzapine	O
,	O
but	O
thereafter	O
the	O
patient	O
suffered	O
from	O
rls	O
at	O
nighttime	O
0	O
<EOS>	O
the	O
third	O
patient	O
had	O
been	O
suffering	O
from	O
serious	O
akathisia	O
while	O
on	O
risperidone	O
,	O
and	O
wa	O
cured	O
after	O
switching	O
to	O
olanzapine	B-Drug
,	O
but	O
thereafter	O
the	O
patient	O
suffered	O
from	O
rls	B-ADR
at	O
nighttime	O
0	O
<EOS>	O
the	O
third	O
patient	O
had	O
been	O
suffering	O
from	O
serious	O
akathisia	O
while	O
on	O
risperidone	B-Drug
,	O
and	O
wa	O
cured	O
after	O
switching	O
to	O
olanzapine	O
,	O
but	O
thereafter	O
the	O
patient	O
suffered	O
from	O
rls	B-ADR
at	O
nighttime	O
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
restless	O
leg	O
syndrome	O
(	O
rls	O
)	O
and	O
periodic	B-ADR
limb	I-ADR
movement	I-ADR
during	I-ADR
sleep	I-ADR
(	O
plms	O
)	O
that	O
were	O
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
restless	O
leg	O
syndrome	O
(	O
rls	O
)	O
and	O
periodic	O
limb	O
movement	O
during	O
sleep	O
(	O
plms	B-ADR
)	O
that	O
were	O
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
restless	B-ADR
leg	I-ADR
syndrome	I-ADR
(	O
rls	O
)	O
and	O
periodic	O
limb	O
movement	O
during	O
sleep	O
(	O
plms	O
)	O
that	O
were	O
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
we	O
report	O
five	O
case	O
of	O
restless	O
leg	O
syndrome	O
(	O
rls	B-ADR
)	O
and	O
periodic	O
limb	O
movement	O
during	O
sleep	O
(	O
plms	O
)	O
that	O
were	O
probably	O
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
alendronate	B-Drug
led	O
to	O
nodular	B-ADR
scleritis	I-ADR
and	O
rechallenge	O
caused	O
recurrence	O
of	O
scleritis	O
0	O
<EOS>	O
conclusion	O
:	O
alendronate	B-Drug
led	O
to	O
nodular	O
scleritis	B-ADR
and	O
rechallenge	O
caused	O
recurrence	O
of	O
scleritis	O
0	O
<EOS>	O
nodular	B-ADR
scleritis	I-ADR
following	O
alendronate	B-Drug
therapy	O
0	O
<EOS>	O
purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
nodular	B-ADR
scleritis	I-ADR
following	O
alendronate	B-Drug
sodium	I-Drug
0	O
<EOS>	O
two	O
week	O
following	O
rechallenge	O
with	O
alendronate	B-Drug
sodium	I-Drug
resulted	O
in	O
recurrence	O
of	O
his	O
scleritis	B-ADR
0	O
<EOS>	O
in	O
addition	O
,	O
there	O
is	O
a	O
report	O
on	O
prolonged	B-ADR
ect	I-ADR
seizure	I-ADR
related	O
to	O
ciprofloxacin	B-Drug
,	O
which	O
ha	O
an	O
epileptogenic	O
property	O
with	O
a	O
similar	O
action	O
to	O
beta-lactam	O
antibiotic	O
0	O
<EOS>	O
thus	O
,	O
tardive	B-ADR
seizure	I-ADR
in	O
our	O
case	O
are	O
thought	O
to	O
be	O
related	O
to	O
piperacillin	O
and	O
cefotiam	B-Drug
0	O
<EOS>	O
thus	O
,	O
tardive	B-ADR
seizure	I-ADR
in	O
our	O
case	O
are	O
thought	O
to	O
be	O
related	O
to	O
piperacillin	B-Drug
and	O
cefotiam	O
0	O
<EOS>	O
acute	B-ADR
delirium	I-ADR
resulting	O
from	O
levofloxacin	B-Drug
therapy	O
is	O
an	O
exceedingly	O
rare	O
complication	O
that	O
ha	O
been	O
thought	O
to	O
occur	O
more	O
commonly	O
in	O
elderly	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	B-Drug
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	B-Drug
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	B-Drug
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	B-Drug
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	B-Drug
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	B-Drug
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	B-ADR
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	B-Drug
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	B-Drug
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	B-Drug
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	B-Drug
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	B-Drug
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	B-Drug
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	B-ADR
,	O
dizziness	O
and	O
insomnia	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	B-Drug
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	B-Drug
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	B-Drug
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	B-Drug
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	B-Drug
,	O
grepafloxacin	O
,	O
trovafloxacin	O
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
new	O
quinolone	O
derivative	O
(	O
levofloxacin	O
,	O
sparfloxacin	O
,	O
grepafloxacin	O
,	O
trovafloxacin	B-Drug
,	O
gatifloxacin	O
and	O
moxifloxacin	O
)	O
,	O
also	O
called	O
gyrase	O
inhibitor	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system-related	O
adverse	O
effect	O
,	O
including	O
headache	O
,	O
dizziness	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
here	O
,	O
we	O
describe	O
levofloxacin-induced	B-Drug
delirium	B-ADR
with	I-ADR
psychotic	I-ADR
feature	I-ADR
in	O
a	O
relatively	O
young	O
,	O
otherwise	O
healthy	O
female	O
0	O
<EOS>	O
levofloxacin-induced	B-Drug
delirium	B-ADR
with	I-ADR
psychotic	I-ADR
feature	I-ADR
0	O
<EOS>	O
result	O
:	O
a	O
previously	O
healthy	O
42-year-old	O
woman	O
presented	O
with	O
acute-onset	B-ADR
delirium	I-ADR
with	I-ADR
psychotic	I-ADR
feature	I-ADR
a	O
a	O
consequence	O
of	O
levofloxacin	B-Drug
therapy	O
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
that	O
crohn	B-ADR
disease	I-ADR
is	O
a	O
potential	O
novel	O
adverse	O
drug	O
effect	O
of	O
copaxone	B-Drug
0	O
<EOS>	O
development	O
of	O
crohn	B-ADR
disease	I-ADR
in	O
a	O
patient	O
with	O
multiple	O
sclerosis	O
treated	O
with	O
copaxone	B-Drug
0	O
<EOS>	O
result	O
:	O
our	O
patient	O
developed	O
crohn	B-ADR
disease	I-ADR
while	O
on	O
copaxone	B-Drug
treatment	O
a	O
a	O
consequence	O
of	O
long-term	O
immunosuppression	O
0	O
<EOS>	O
result	O
:	O
our	O
patient	O
developed	O
crohn	O
disease	O
while	O
on	O
copaxone	B-Drug
treatment	O
a	O
a	O
consequence	O
of	O
long-term	B-ADR
immunosuppression	I-ADR
0	O
<EOS>	O
she	O
had	O
been	O
on	O
copaxone	B-Drug
20	O
mg	O
/	O
day	O
treatment	O
for	O
2	O
year	O
when	O
she	O
first	O
exhibited	O
gastrointestinal	B-ADR
symptom	I-ADR
0	O
<EOS>	O
the	O
author	O
present	O
a	O
case	O
study	O
of	O
a	O
mentally	O
healthy	O
man	O
who	O
repeatedly	O
experienced	O
short-lived	O
,	O
obsessional-like	B-ADR
suicidal	I-ADR
idea	I-ADR
and	I-ADR
image	I-ADR
after	O
ingestion	O
of	O
the	O
anti-fungal	O
drug	O
ketoconazole	B-Drug
0	O
<EOS>	O
during	O
intravenous	O
treatment	O
with	O
terlipressin	B-Drug
for	O
recurrent	O
gastrointestinal	O
(	O
gi	O
)	O
bleeding	O
,	O
a	O
50-year-old	O
male	O
with	O
no	O
history	O
of	O
heart	O
disease	O
developed	O
a	O
newly	O
prolonged	B-ADR
qt	I-ADR
interval	I-ADR
and	O
torsade	O
de	O
pointes	O
0	O
<EOS>	O
during	O
intravenous	O
treatment	O
with	O
terlipressin	B-Drug
for	O
recurrent	O
gastrointestinal	O
(	O
gi	O
)	O
bleeding	O
,	O
a	O
50-year-old	O
male	O
with	O
no	O
history	O
of	O
heart	O
disease	O
developed	O
a	O
newly	O
prolonged	O
qt	O
interval	O
and	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
0	O
<EOS>	O
terlipressin-induced	B-Drug
ventricular	B-ADR
arrhythmia	I-ADR
0	O
<EOS>	O
spontaneous	B-ADR
nasal	I-ADR
septal	I-ADR
perforation	I-ADR
with	O
antiangiogenic	O
bevacizumab	B-Drug
therapy	O
0	O
<EOS>	O
this	O
case	O
describes	O
a	O
52-year-old	O
white	O
woman	O
who	O
developed	O
a	O
spontaneous	B-ADR
nasal	I-ADR
septal	I-ADR
perforation	I-ADR
after	O
given	O
the	O
antiangiogenic	O
drug	O
,	O
bevacizumab	B-Drug
,	O
for	O
metastatic	O
ovarian	O
cancer	O
treatment	O
0	O
<EOS>	O
a	O
37-year-old	O
woman	O
with	O
relapsing	O
invasive	O
vertebral	O
aspergillosis	O
received	O
intravenous	O
vrc	B-Drug
and	O
developed	O
angio-oedema	B-ADR
10	O
day	O
after	O
starting	O
therapy	O
0	O
<EOS>	O
angio-oedema	B-ADR
a	O
an	O
unusual	O
tolerable	O
side	O
effect	O
of	O
voriconazole	B-Drug
therapy	O
0	O
<EOS>	O
here	O
,	O
we	O
report	O
a	O
case	O
of	O
angio-oedema	B-ADR
associated	O
with	O
vrc	B-Drug
therapy	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
angio-oedema	B-ADR
associated	O
with	O
vrc	B-Drug
0	O
<EOS>	O
voriconazole	B-Drug
(	O
vrc	O
)	O
ha	O
not	O
previously	O
been	O
reported	O
to	O
cause	O
angio-oedema	B-ADR
0	O
<EOS>	O
voriconazole	O
(	O
vrc	B-Drug
)	O
ha	O
not	O
previously	O
been	O
reported	O
to	O
cause	O
angio-oedema	B-ADR
0	O
<EOS>	O
multiple	B-ADR
seizure	I-ADR
after	O
bupropion	B-Drug
overdose	O
in	O
a	O
small	O
child	O
0	O
<EOS>	O
the	O
patient	O
experienced	O
hallucination	O
,	O
agitation	B-ADR
,	O
vomiting	O
,	O
tachycardia	O
and	O
seizure	O
after	O
ingestion	O
of	O
1050	O
(	O
48	O
mg	O
/	O
kg	O
)	O
of	O
extended-release	O
bupropion	B-Drug
0	O
<EOS>	O
the	O
patient	O
experienced	O
hallucination	B-ADR
,	O
agitation	O
,	O
vomiting	O
,	O
tachycardia	O
and	O
seizure	O
after	O
ingestion	O
of	O
1050	O
(	O
48	O
mg	O
/	O
kg	O
)	O
of	O
extended-release	O
bupropion	B-Drug
0	O
<EOS>	O
the	O
patient	O
experienced	O
hallucination	O
,	O
agitation	O
,	O
vomiting	O
,	O
tachycardia	O
and	O
seizure	B-ADR
after	O
ingestion	O
of	O
1050	O
(	O
48	O
mg	O
/	O
kg	O
)	O
of	O
extended-release	O
bupropion	B-Drug
0	O
<EOS>	O
the	O
patient	O
experienced	O
hallucination	O
,	O
agitation	O
,	O
vomiting	O
,	O
tachycardia	B-ADR
and	O
seizure	O
after	O
ingestion	O
of	O
1050	O
(	O
48	O
mg	O
/	O
kg	O
)	O
of	O
extended-release	O
bupropion	B-Drug
0	O
<EOS>	O
the	O
patient	O
experienced	O
hallucination	O
,	O
agitation	O
,	O
vomiting	B-ADR
,	O
tachycardia	O
and	O
seizure	O
after	O
ingestion	O
of	O
1050	O
(	O
48	O
mg	O
/	O
kg	O
)	O
of	O
extended-release	O
bupropion	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
pediatric	O
bupropion	B-Drug
ingestion	O
resulting	O
in	O
multiple	B-ADR
seizure	I-ADR
0	O
<EOS>	O
methylphenidate-associated	B-Drug
enuresis	B-ADR
in	O
attention	O
deficit	O
hyperactivity	O
disorder	O
0	O
<EOS>	O
this	O
is	O
a	O
case	O
report	O
of	O
possible	O
association	O
of	O
methylphenidate	B-Drug
and	O
enuresis	B-ADR
in	O
an	O
11-year-old	O
boy	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
0	O
<EOS>	O
cephalosporin-induced	B-Drug
leukopenia	B-ADR
following	O
rechallenge	O
with	O
cefoxitin	O
0	O
<EOS>	O
conclusion	O
:	O
cefazolin	B-Drug
wa	O
a	O
probable	O
cause	O
of	O
this	O
patient	O
leukopenia	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
cefazolin-induced	B-Drug
leukopenia	B-ADR
in	O
a	O
critically	O
ill	O
patient	O
who	O
developed	O
this	O
adverse	O
reaction	O
upon	O
rechallenge	O
with	O
cefoxitin	O
0	O
<EOS>	O
use	O
of	O
the	O
naranjo	O
probability	O
scale	O
determined	O
the	O
association	O
between	O
cephalosporin	B-Drug
use	O
and	O
leukopenia	B-ADR
to	O
be	O
probable	O
0	O
<EOS>	O
posterior	O
reversible	O
encephalopathy	O
syndrome	O
(	O
pres	B-Drug
)	O
induced	O
by	O
cyclosporine	B-ADR
use	O
in	O
a	O
patient	O
with	O
collapsing	O
focal	O
glomeruloesclerosis	O
0	O
<EOS>	O
posterior	B-ADR
reversible	I-ADR
encephalopathy	I-ADR
syndrome	I-ADR
(	O
pres	B-Drug
)	O
induced	O
by	O
cyclosporine	O
use	O
in	O
a	O
patient	O
with	O
collapsing	O
focal	O
glomeruloesclerosis	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
pres	B-ADR
in	O
a	O
patient	O
with	O
collapsing	O
focal	O
glomeruloesclerosis	O
(	O
collapsing	O
fgs	O
)	O
with	O
complete	O
recovery	O
after	O
withdrawal	O
of	O
cyclosporine	O
(	O
csa	B-Drug
)	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
pres	B-ADR
in	O
a	O
patient	O
with	O
collapsing	O
focal	O
glomeruloesclerosis	O
(	O
collapsing	O
fgs	O
)	O
with	O
complete	O
recovery	O
after	O
withdrawal	O
of	O
cyclosporine	B-Drug
(	O
csa	O
)	O
0	O
<EOS>	O
stuttering	B-ADR
priapism	I-ADR
complicating	O
warfarin	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
protein	O
c	O
deficiency	O
0	O
<EOS>	O
this	O
therapy	O
wa	O
also	O
complicated	O
by	O
warfarin-induced	B-Drug
skin	B-ADR
necrosis	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
rare	O
case	O
of	O
recurrent	O
(	O
stuttering	O
)	O
priapism	B-ADR
in	O
a	O
patient	O
with	O
protein	O
c	O
deficiency	O
while	O
maintained	O
on	O
warfarin	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
rare	O
case	O
of	O
recurrent	O
(	O
stuttering	B-ADR
)	O
priapism	O
in	O
a	O
patient	O
with	O
protein	O
c	O
deficiency	O
while	O
maintained	O
on	O
warfarin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
expired	O
after	O
seven	O
cycle	O
of	O
treatment	O
had	O
been	O
completed	O
because	O
of	O
pulmonary	B-ADR
fibrosis	I-ADR
and	O
the	O
drug	O
toxicity	O
of	O
bleomycin	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
an	O
80-year-old	O
white	O
female	O
,	O
followed	O
up	O
at	O
the	O
memory	O
clinic	O
for	O
mild	B-ADR
cognitive	I-ADR
impairment	I-ADR
,	O
had	O
been	O
taking	O
propafenone	B-Drug
900	O
mg	O
/	O
d	O
for	O
>	O
10	O
year	O
for	O
paroxysmal	O
atrial	O
fibrillation	O
without	O
adverse	O
effect	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	O
and	O
citalopram	B-Drug
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	O
,	O
fall	O
)	O
and	O
mimicked	O
coronary	B-ADR
artery	I-ADR
disease	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	B-Drug
and	O
citalopram	O
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	O
,	O
fall	O
)	O
and	O
mimicked	O
coronary	B-ADR
artery	I-ADR
disease	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	O
and	O
citalopram	B-Drug
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	B-ADR
,	O
fall	O
)	O
and	O
mimicked	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	B-Drug
and	O
citalopram	O
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	B-ADR
,	O
fall	O
)	O
and	O
mimicked	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	O
and	O
citalopram	B-Drug
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	O
,	O
fall	B-ADR
)	O
and	O
mimicked	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	B-Drug
and	O
citalopram	O
,	O
which	O
caused	O
propafenone	O
adverse	O
effect	O
(	O
eg	O
,	O
dizziness	O
,	O
fall	B-ADR
)	O
and	O
mimicked	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
three	O
month	O
after	O
starting	O
citalopram	B-Drug
,	O
she	O
experienced	O
episode	O
of	O
chest	B-ADR
tightness	I-ADR
and	O
dizziness	O
0	O
<EOS>	O
three	O
month	O
after	O
starting	O
citalopram	B-Drug
,	O
she	O
experienced	O
episode	O
of	O
chest	O
tightness	O
and	O
dizziness	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
clinician	O
should	O
be	O
aware	O
of	O
this	O
adverse	O
reaction	O
when	O
facing	O
similar	O
complex	O
neurologic	B-ADR
symptom	I-ADR
in	O
patient	O
who	O
are	O
receiving	O
the	O
antibiotic	O
treatment	O
described	O
here	O
,	O
especially	O
vancomycin	B-Drug
0	O
<EOS>	O
discussion	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
illustrating	O
neuralgic	B-ADR
amyotrophy	I-ADR
triggered	O
by	O
exposure	O
to	O
the	O
antibiotic	O
vancomycin	O
,	O
tobramycin	O
,	O
and	O
piperacillin	B-Drug
/	O
tazobactam	O
0	O
<EOS>	O
discussion	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
illustrating	O
neuralgic	B-ADR
amyotrophy	I-ADR
triggered	O
by	O
exposure	O
to	O
the	O
antibiotic	O
vancomycin	O
,	O
tobramycin	O
,	O
and	O
piperacillin	O
/	O
tazobactam	B-Drug
0	O
<EOS>	O
discussion	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
illustrating	O
neuralgic	B-ADR
amyotrophy	I-ADR
triggered	O
by	O
exposure	O
to	O
the	O
antibiotic	O
vancomycin	O
,	O
tobramycin	B-Drug
,	O
and	O
piperacillin	O
/	O
tazobactam	O
0	O
<EOS>	O
discussion	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
illustrating	O
neuralgic	B-ADR
amyotrophy	I-ADR
triggered	O
by	O
exposure	O
to	O
the	O
antibiotic	O
vancomycin	B-Drug
,	O
tobramycin	O
,	O
and	O
piperacillin	O
/	O
tazobactam	O
0	O
<EOS>	O
seizure	B-ADR
and	O
transient	O
blindness	O
following	O
intravenous	O
pulse	O
methylprednisolone	B-Drug
in	O
child	O
with	O
primary	O
glomerulonephritis	O
0	O
<EOS>	O
seizure	O
and	O
transient	B-ADR
blindness	I-ADR
following	O
intravenous	O
pulse	O
methylprednisolone	B-Drug
in	O
child	O
with	O
primary	O
glomerulonephritis	O
0	O
<EOS>	O
two	O
child	O
,	O
1	O
with	O
idiopathic	O
nephrotic	O
syndrome	O
and	O
1	O
with	O
endo-extracapillary	O
glomerulonephritis	O
,	O
presented	O
an	O
episode	O
of	O
seizure	B-ADR
and	O
transient	O
blindness	O
at	O
different	O
time	O
after	O
i.v	O
0	O
pulse	O
methylprednisolone	B-Drug
(	O
ivpmp	O
)	O
treatment	O
0	O
<EOS>	O
two	O
child	O
,	O
1	O
with	O
idiopathic	O
nephrotic	O
syndrome	O
and	O
1	O
with	O
endo-extracapillary	O
glomerulonephritis	O
,	O
presented	O
an	O
episode	O
of	O
seizure	O
and	O
transient	B-ADR
blindness	I-ADR
at	O
different	O
time	O
after	O
i.v	O
0	O
pulse	O
methylprednisolone	B-Drug
(	O
ivpmp	O
)	O
treatment	O
0	O
<EOS>	O
background	O
:	O
hydroxyurea	B-Drug
is	O
a	O
cytostatic	O
agent	O
used	O
to	O
treat	O
myeloproliferative	O
disorder	O
and	O
long-term	O
treatment	O
is	O
associated	O
with	O
mucocutaneous	B-ADR
adverse	I-ADR
event	I-ADR
and	O
nail	O
hyperpigmentation	O
0	O
<EOS>	O
background	O
:	O
hydroxyurea	B-Drug
is	O
a	O
cytostatic	O
agent	O
used	O
to	O
treat	O
myeloproliferative	O
disorder	O
and	O
long-term	O
treatment	O
is	O
associated	O
with	O
mucocutaneous	O
adverse	O
event	O
and	O
nail	B-ADR
hyperpigmentation	I-ADR
0	O
<EOS>	O
based	O
on	O
the	O
naranjo	O
algorithm	O
,	O
the	O
adverse	O
reaction	O
observed	O
wa	O
probably	O
related	O
to	O
the	O
hydroxyurea	B-Drug
treatment	O
(	O
score	O
=	O
6	O
)	O
;	O
however	O
,	O
the	O
hydroxyurea	O
chemotherapy	O
could	O
not	O
be	O
discontinued	O
because	O
of	O
the	O
myeloproliferative	B-ADR
disorder	I-ADR
0	O
<EOS>	O
both	O
the	O
longitudinal	B-ADR
melanonychia	I-ADR
and	O
the	O
multiple	O
skin	O
cancer	O
first	O
appeared	O
after	O
approximately	O
6	O
month	O
of	O
hydroxyurea	B-Drug
treatment	O
0	O
<EOS>	O
both	O
the	O
longitudinal	O
melanonychia	O
and	O
the	O
multiple	B-ADR
skin	I-ADR
cancer	I-ADR
first	O
appeared	O
after	O
approximately	O
6	O
month	O
of	O
hydroxyurea	B-Drug
treatment	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
this	O
case	O
of	O
the	O
concomitant	O
appearance	O
of	O
multiple	B-ADR
skin	I-ADR
cancer	I-ADR
and	O
nail	O
change	O
associated	O
with	O
hydroxyurea	B-Drug
use	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
this	O
case	O
of	O
the	O
concomitant	O
appearance	O
of	O
multiple	O
skin	O
cancer	O
and	O
nail	B-ADR
change	I-ADR
associated	O
with	O
hydroxyurea	B-Drug
use	O
0	O
<EOS>	O
hydroxyurea	B-Drug
associated	O
with	O
concomitant	O
occurrence	O
of	O
diffuse	B-ADR
longitudinal	I-ADR
melanonychia	I-ADR
and	O
multiple	O
squamous	O
cell	O
carcinoma	O
in	O
an	O
elderly	O
subject	O
0	O
<EOS>	O
hydroxyurea	B-Drug
associated	O
with	O
concomitant	O
occurrence	O
of	O
diffuse	O
longitudinal	O
melanonychia	O
and	O
multiple	B-ADR
squamous	I-ADR
cell	I-ADR
carcinoma	I-ADR
in	O
an	O
elderly	O
subject	O
0	O
<EOS>	O
objective	O
:	O
the	O
purpose	O
of	O
this	O
study	O
wa	O
to	O
report	O
the	O
concomitant	O
occurrence	O
of	O
multiple	O
squamous	O
cell	O
carcinoma	O
and	O
diffuse	B-ADR
nail	I-ADR
hyperpigmentation	I-ADR
associated	O
with	O
hydroxyurea	B-Drug
treatment	O
,	O
and	O
to	O
describe	O
a	O
successful	O
therapeutic	O
approach	O
using	O
imiquimod	O
5	O
%	O
0	O
<EOS>	O
objective	O
:	O
the	O
purpose	O
of	O
this	O
study	O
wa	O
to	O
report	O
the	O
concomitant	O
occurrence	O
of	O
multiple	B-ADR
squamous	I-ADR
cell	I-ADR
carcinoma	I-ADR
and	O
diffuse	O
nail	O
hyperpigmentation	O
associated	O
with	O
hydroxyurea	B-Drug
treatment	O
,	O
and	O
to	O
describe	O
a	O
successful	O
therapeutic	O
approach	O
using	O
imiquimod	O
5	O
%	O
0	O
<EOS>	O
the	O
patient	O
completed	O
a	O
10-month	O
follow-up	O
,	O
maintaining	O
a	O
complete	O
resolution	O
of	O
the	O
treated	O
skin	O
lesion	O
;	O
however	O
,	O
the	O
development	O
of	O
a	O
painful	B-ADR
hand	I-ADR
ulcer	I-ADR
,	O
possibly	O
associated	O
with	O
the	O
hydroxyurea	B-Drug
,	O
and	O
new	O
skin	O
cancer	O
were	O
observed	O
at	O
the	O
last	O
follow-up	O
visit	O
0	O
<EOS>	O
the	O
patient	O
completed	O
a	O
10-month	O
follow-up	O
,	O
maintaining	O
a	O
complete	O
resolution	O
of	O
the	O
treated	O
skin	O
lesion	O
;	O
however	O
,	O
the	O
development	O
of	O
a	O
painful	O
hand	O
ulcer	O
,	O
possibly	O
associated	O
with	O
the	O
hydroxyurea	B-Drug
,	O
and	O
new	O
skin	B-ADR
cancer	I-ADR
were	O
observed	O
at	O
the	O
last	O
follow-up	O
visit	O
0	O
<EOS>	O
it	O
is	O
the	O
first	O
case	O
of	O
ciprofloxacin-induced	B-Drug
vbds	B-ADR
successfully	O
treated	O
with	O
tacrolimus	O
0	O
<EOS>	O
vanishing	O
bile	O
duct	O
and	O
stevens-johnson	B-ADR
syndrome	I-ADR
associated	O
with	O
ciprofloxacin	B-Drug
treated	O
with	O
tacrolimus	O
0	O
<EOS>	O
vanishing	B-ADR
bile	I-ADR
duct	I-ADR
and	O
stevens-johnson	O
syndrome	O
associated	O
with	O
ciprofloxacin	B-Drug
treated	O
with	O
tacrolimus	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
ciprofloxacin-induced	B-Drug
sjs	B-ADR
and	O
acute	O
onset	O
of	O
vbds	O
,	O
and	O
reviewed	O
the	O
related	O
literature	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
ciprofloxacin-induced	B-Drug
sjs	O
and	O
acute	O
onset	O
of	O
vbds	B-ADR
,	O
and	O
reviewed	O
the	O
related	O
literature	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
woman	O
with	O
previous	O
history	O
of	O
coronary	O
stenting	O
five	O
day	O
before	O
wa	O
admitted	O
in	O
our	O
institution	O
for	O
intracranial	B-ADR
bleeding	I-ADR
while	O
receiving	O
aspirin	B-Drug
and	O
clopidogrel	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
woman	O
with	O
previous	O
history	O
of	O
coronary	O
stenting	O
five	O
day	O
before	O
wa	O
admitted	O
in	O
our	O
institution	O
for	O
intracranial	B-ADR
bleeding	I-ADR
while	O
receiving	O
aspirin	O
and	O
clopidogrel	B-Drug
0	O
<EOS>	O
disseminated	B-ADR
salmonellosis	I-ADR
in	O
a	O
patient	O
treated	O
with	O
temozolomide	B-Drug
0	O
<EOS>	O
we	O
describe	O
the	O
first	O
case	O
of	O
disseminated	B-ADR
salmonellosis	I-ADR
in	O
a	O
patient	O
treated	O
with	O
temozolomide	B-Drug
0	O
<EOS>	O
ceftriaxone-induced	B-Drug
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
:	O
first	O
report	O
0	O
<EOS>	O
fde	B-ADR
from	O
cephalosporin	B-Drug
ha	O
been	O
rarely	O
reported	O
,	O
and	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
there	O
is	O
no	O
published	O
report	O
of	O
ceftriaxone-induced	O
fde	O
in	O
the	O
literature	O
0	O
<EOS>	O
fde	B-ADR
from	O
cephalosporin	O
ha	O
been	O
rarely	O
reported	O
,	O
and	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
there	O
is	O
no	O
published	O
report	O
of	O
ceftriaxone-induced	B-Drug
fde	O
in	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
a	O
54-year-old	O
turkish	O
woman	O
who	O
presented	O
with	O
ceftriaxone-induced	B-Drug
fde	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
all	O
doctor	O
need	O
to	O
be	O
aware	O
of	O
the	O
need	O
to	O
review	O
the	O
indication	O
for	O
gabapentin	B-Drug
use	O
during	O
period	O
of	O
acute	O
illness	O
,	O
especially	O
with	O
regard	O
to	O
renal	B-ADR
impairment	I-ADR
0	O
<EOS>	O
gabapentin	B-Drug
toxicity	O
in	O
renal	B-ADR
failure	I-ADR
:	O
the	O
importance	O
of	O
dose	O
adjustment	O
0	O
<EOS>	O
objective	O
:	O
this	O
case	O
report	O
outline	O
a	O
significant	O
type	O
of	O
morbidity	O
due	O
to	O
continued	O
use	O
of	O
gabapentin	B-Drug
during	O
an	O
episode	O
of	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
acute	B-ADR
syphilitic	I-ADR
posterior	I-ADR
placoid	I-ADR
chorioretinitis	I-ADR
following	O
intravitreal	O
triamcinolone	B-Drug
acetonide	I-Drug
injection	O
0	O
<EOS>	O
background	O
:	O
we	O
describe	O
the	O
ophthalmic	O
feature	O
and	O
clinical	O
course	O
of	O
two	O
case	O
of	O
acute	B-ADR
syphilitic	I-ADR
posterior	I-ADR
placoid	I-ADR
chorioretinitis	I-ADR
(	O
asppc	O
)	O
that	O
developed	O
after	O
intravitreal	O
triamcinolone	O
acetonide	O
(	O
ivta	B-Drug
)	O
injection	O
0	O
<EOS>	O
background	O
:	O
we	O
describe	O
the	O
ophthalmic	O
feature	O
and	O
clinical	O
course	O
of	O
two	O
case	O
of	O
acute	B-ADR
syphilitic	I-ADR
posterior	I-ADR
placoid	I-ADR
chorioretinitis	I-ADR
(	O
asppc	O
)	O
that	O
developed	O
after	O
intravitreal	O
triamcinolone	B-Drug
acetonide	I-Drug
(	O
ivta	O
)	O
injection	O
0	O
<EOS>	O
background	O
:	O
we	O
describe	O
the	O
ophthalmic	O
feature	O
and	O
clinical	O
course	O
of	O
two	O
case	O
of	O
acute	O
syphilitic	O
posterior	O
placoid	O
chorioretinitis	O
(	O
asppc	B-ADR
)	O
that	O
developed	O
after	O
intravitreal	O
triamcinolone	O
acetonide	O
(	O
ivta	B-Drug
)	O
injection	O
0	O
<EOS>	O
background	O
:	O
we	O
describe	O
the	O
ophthalmic	O
feature	O
and	O
clinical	O
course	O
of	O
two	O
case	O
of	O
acute	O
syphilitic	O
posterior	O
placoid	O
chorioretinitis	O
(	O
asppc	B-ADR
)	O
that	O
developed	O
after	O
intravitreal	O
triamcinolone	B-Drug
acetonide	I-Drug
(	O
ivta	O
)	O
injection	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
fundus	O
picture	O
shown	O
in	O
these	O
case	O
may	O
be	O
typical	O
of	O
asppc	B-ADR
after	O
ivta	B-Drug
injection	O
0	O
<EOS>	O
result	O
:	O
two	O
patient	O
with	O
ocular	O
inflammation	O
of	O
unknown	O
origin	O
developed	O
severe	B-ADR
chorioretinitis	I-ADR
after	O
ivta	B-Drug
injection	O
0	O
<EOS>	O
although	O
it	O
is	O
difficult	O
to	O
solely	O
attribute	O
intratumoral	B-ADR
hemorrhage	I-ADR
to	O
aspirin	B-Drug
,	O
we	O
have	O
to	O
be	O
careful	O
when	O
prescribing	O
aspirin	O
for	O
patient	O
who	O
have	O
asymptomatic	O
meningioma	O
0	O
<EOS>	O
hemorrhage	B-ADR
from	O
a	O
falx	O
meningioma	O
after	O
internal	O
use	O
of	O
low-dose	O
aspirin	B-Drug
0	O
<EOS>	O
on	O
the	O
other	O
hand	O
,	O
aspirin	B-Drug
may	O
have	O
promoted	O
the	O
enlargement	B-ADR
of	I-ADR
spontaneous	I-ADR
hemorrhage	I-ADR
from	O
meningioma	O
0	O
<EOS>	O
our	O
case	O
is	O
the	O
second	O
one	O
in	O
which	O
hemorrhage	B-ADR
from	O
a	O
meningioma	O
may	O
have	O
been	O
induced	O
by	O
aspirin	B-Drug
prophylaxis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
in	O
which	O
hemorrhage	B-ADR
occurred	O
in	O
an	O
asymptomatic	O
falx	O
meningioma	O
known	O
beforehand	O
,	O
after	O
the	O
internal	O
use	O
of	O
low-dose	O
aspirin	B-Drug
for	O
16	O
month	O
0	O
<EOS>	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
can	O
be	O
associated	O
with	O
the	O
infusion	O
of	O
rituximab	B-Drug
0	O
<EOS>	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
complicating	O
the	O
first	O
infusion	O
of	O
rituximab	B-Drug
0	O
<EOS>	O
the	O
aim	O
of	O
this	O
study	O
wa	O
to	O
describe	O
the	O
occurrence	O
of	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
in	O
3	O
case	O
of	O
rituximab	B-Drug
infusion	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
symptom	O
that	O
could	O
be	O
ascribed	O
to	O
an	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
should	O
always	O
be	O
taken	O
seriously	O
during	O
the	O
first	O
rituximab	B-Drug
infusion	O
and	O
investigated	O
aggressively	O
0	O
<EOS>	O
we	O
reviewed	O
the	O
record	O
of	O
3	O
patient	O
with	O
lymphoproliferative	O
disorder	O
who	O
experienced	O
acute	B-ADR
coronary	I-ADR
syndrome	I-ADR
associated	O
with	O
their	O
initial	O
infusion	O
of	O
rituximab	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
describes	O
a	O
case	O
of	O
a	O
probable	O
interaction	O
between	O
topical	O
econazole	O
lotion	O
1	O
%	O
and	O
acenocoumarol	B-Drug
that	O
resulted	O
in	O
overanticoagulation	O
and	O
a	O
life-threatening	O
laryngeal	B-ADR
hematoma	I-ADR
in	O
this	O
elderly	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
describes	O
a	O
case	O
of	O
a	O
probable	O
interaction	O
between	O
topical	O
econazole	B-Drug
lotion	O
1	O
%	O
and	O
acenocoumarol	O
that	O
resulted	O
in	O
overanticoagulation	O
and	O
a	O
life-threatening	O
laryngeal	B-ADR
hematoma	I-ADR
in	O
this	O
elderly	O
patient	O
0	O
<EOS>	O
laryngeal	B-ADR
dyspnea	I-ADR
in	O
relation	O
to	O
an	O
interaction	O
between	O
acenocoumarol	B-Drug
and	O
topical	O
econazole	O
lotion	O
0	O
<EOS>	O
laryngeal	B-ADR
dyspnea	I-ADR
in	O
relation	O
to	O
an	O
interaction	O
between	O
acenocoumarol	O
and	O
topical	O
econazole	B-Drug
lotion	O
0	O
<EOS>	O
adrenal	B-ADR
suppression	I-ADR
in	I-ADR
a	I-ADR
fetus	I-ADR
due	O
to	O
administration	O
of	O
methylprednisolone	B-Drug
ha	O
hitherto	O
been	O
rarely	O
published	O
0	O
<EOS>	O
conclusion	O
:	O
life-threatening	O
adrenal	B-ADR
suppression	I-ADR
,	O
requiring	O
hydrocortisone	O
supplementation	O
and	O
intensive	O
therapy	O
,	O
wa	O
observed	O
and	O
successfully	O
treated	O
in	O
a	O
newborn	O
,	O
whose	O
mother	O
had	O
received	O
high-dose	O
methylprednisolone	B-Drug
in	O
late	O
pregnancy	O
0	O
<EOS>	O
high-dose	O
methylprednisolone	B-Drug
in	O
a	O
pregnant	O
woman	O
with	O
crohn	O
disease	O
and	O
adrenal	B-ADR
suppression	I-ADR
in	O
her	O
newborn	O
0	O
<EOS>	O
a	O
10-year-old	O
asthmatic	O
boy	O
began	O
to	O
suffer	O
from	O
urticarial	O
rash	O
and	O
moderately	B-ADR
severe	I-ADR
bronchospasm	I-ADR
after	O
8	O
week	O
	O
treatment	O
with	O
disodium	B-Drug
cromoglycate	I-Drug
0	O
<EOS>	O
a	O
10-year-old	O
asthmatic	O
boy	O
began	O
to	O
suffer	O
from	O
urticarial	B-ADR
rash	I-ADR
and	O
moderately	O
severe	O
bronchospasm	O
after	O
8	O
week	O
	O
treatment	O
with	O
disodium	B-Drug
cromoglycate	I-Drug
0	O
<EOS>	O
asthma	B-ADR
and	O
urticaria	O
during	O
disodium	B-Drug
cromoglycate	I-Drug
treatment	O
0	O
<EOS>	O
asthma	O
and	O
urticaria	B-ADR
during	O
disodium	B-Drug
cromoglycate	I-Drug
treatment	O
0	O
<EOS>	O
when	O
dscg	B-Drug
wa	O
withdrawn	O
,	O
urticaria	B-ADR
vanished	O
and	O
the	O
child	O
remained	O
symptom-free	O
0	O
<EOS>	O
after	O
the	O
first	O
oral	O
dose	O
of	O
propranolol	B-Drug
,	O
syncope	O
developed	O
together	O
with	O
atrioventricular	B-ADR
block	I-ADR
0	O
<EOS>	O
after	O
the	O
first	O
oral	O
dose	O
of	O
propranolol	B-Drug
,	O
syncope	B-ADR
developed	O
together	O
with	O
atrioventricular	O
block	O
0	O
<EOS>	O
syncope	B-ADR
induced	O
by	O
propranolol	B-Drug
in	O
hypertrophic	O
cardiomyopathy	O
0	O
<EOS>	O
olanzapine-induced	B-Drug
hyperglycaemic	B-ADR
coma	I-ADR
and	O
neuroleptic	O
malignant	O
syndrome	O
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
olanzapine-induced	B-Drug
hyperglycaemic	O
coma	O
and	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	O
,	O
nausea	O
,	O
liver	O
enzyme	O
elevation	O
,	O
hypertension	O
,	O
alopecia	O
,	O
and	O
allergic	B-ADR
skin	I-ADR
reaction	I-ADR
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	O
,	O
nausea	O
,	O
liver	O
enzyme	O
elevation	O
,	O
hypertension	O
,	O
alopecia	B-ADR
,	O
and	O
allergic	O
skin	O
reaction	O
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	B-ADR
,	O
nausea	O
,	O
liver	O
enzyme	O
elevation	O
,	O
hypertension	O
,	O
alopecia	O
,	O
and	O
allergic	O
skin	O
reaction	O
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	O
,	O
nausea	O
,	O
liver	O
enzyme	O
elevation	O
,	O
hypertension	B-ADR
,	O
alopecia	O
,	O
and	O
allergic	O
skin	O
reaction	O
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	O
,	O
nausea	O
,	O
liver	B-ADR
enzyme	I-ADR
elevation	I-ADR
,	O
hypertension	O
,	O
alopecia	O
,	O
and	O
allergic	O
skin	O
reaction	O
0	O
<EOS>	O
discussion	O
:	O
the	O
main	O
adverse	O
effect	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	O
,	O
nausea	B-ADR
,	O
liver	O
enzyme	O
elevation	O
,	O
hypertension	O
,	O
alopecia	O
,	O
and	O
allergic	O
skin	O
reaction	O
0	O
<EOS>	O
leflunomide-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
described	O
a	O
case	O
of	O
juvenile	O
idiopathic	O
arthritis	O
patient	O
who	O
developed	O
thymic	O
enlargement	O
(	O
true	O
thymic	O
hyperplasia	O
)	O
,	O
mediastinal	B-ADR
lymphadenopathy	I-ADR
and	O
pleurisy	O
associated	O
with	O
systemic	O
symptom	O
under	O
etanercept	B-Drug
treatment	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
described	O
a	O
case	O
of	O
juvenile	O
idiopathic	O
arthritis	O
patient	O
who	O
developed	O
thymic	O
enlargement	O
(	O
true	O
thymic	O
hyperplasia	O
)	O
,	O
mediastinal	O
lymphadenopathy	O
and	O
pleurisy	B-ADR
associated	O
with	O
systemic	O
symptom	O
under	O
etanercept	B-Drug
treatment	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
described	O
a	O
case	O
of	O
juvenile	O
idiopathic	O
arthritis	O
patient	O
who	O
developed	O
thymic	B-ADR
enlargement	I-ADR
(	O
true	O
thymic	O
hyperplasia	O
)	O
,	O
mediastinal	O
lymphadenopathy	O
and	O
pleurisy	O
associated	O
with	O
systemic	O
symptom	O
under	O
etanercept	B-Drug
treatment	O
0	O
<EOS>	O
in	O
this	O
report	O
we	O
described	O
a	O
case	O
of	O
juvenile	O
idiopathic	O
arthritis	O
patient	O
who	O
developed	O
thymic	O
enlargement	O
(	O
true	O
thymic	B-ADR
hyperplasia	I-ADR
)	O
,	O
mediastinal	O
lymphadenopathy	O
and	O
pleurisy	O
associated	O
with	O
systemic	O
symptom	O
under	O
etanercept	B-Drug
treatment	O
0	O
<EOS>	O
thymic	B-ADR
enlargement	I-ADR
in	O
a	O
patient	O
with	O
juvenile	O
idiopathic	O
arthritis	O
during	O
etanercept	B-Drug
therapy	O
0	O
<EOS>	O
oxcarbazepine-induced	B-Drug
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	B-ADR
)	O
0	O
<EOS>	O
oxcarbazepine-induced	B-Drug
drug	B-ADR
reaction	I-ADR
with	I-ADR
eosinophilia	I-ADR
and	I-ADR
systemic	I-ADR
symptom	I-ADR
(	O
dress	O
)	O
0	O
<EOS>	O
this	O
is	O
an	O
image	O
and	O
brief	O
case	O
report	O
of	O
a	O
13-year-old	O
boy	O
who	O
presented	O
with	O
severe	B-ADR
rash	I-ADR
and	O
systemic	O
symptom	O
after	O
starting	O
oxcarbazepine	B-Drug
0	O
<EOS>	O
after	O
treatment	O
with	O
a	O
beta-sympathomimetic	O
drug	O
(	O
partusisten	B-Drug
)	O
one	O
fetus	O
developed	O
supraventricular	B-ADR
tachycardia	I-ADR
0	O
<EOS>	O
rosaceiform	B-ADR
eruption	I-ADR
induced	O
by	O
erlotinib	B-Drug
0	O
<EOS>	O
the	O
aim	O
of	O
this	O
paper	O
is	O
to	O
report	O
the	O
case	O
of	O
rosaceiform	B-ADR
eruption	I-ADR
induced	O
by	O
erlotinib	B-Drug
in	O
an	O
81-year-old-man	O
and	O
to	O
discus	O
the	O
pathogenetic	O
role	O
of	O
demodex	O
folliculorum	O
mite	O
,	O
found	O
in	O
the	O
present	O
patient	O
,	O
using	O
skin	O
scraping	O
0	O
<EOS>	O
in	O
patient	O
with	O
methotrexate-induced	B-Drug
anaphylaxis	B-ADR
,	O
discontinuation	O
of	O
treatment	O
may	O
increase	O
the	O
risk	O
of	O
death	O
due	O
to	O
cancer	O
progression	O
0	O
<EOS>	O
management	O
and	O
successful	O
desensitization	O
in	O
methotrexate-induced	B-Drug
anaphylaxis	B-ADR
0	O
<EOS>	O
thus	O
,	O
we	O
confirm	O
that	O
desensitization	O
may	O
be	O
a	O
safe	O
procedure	O
in	O
patient	O
with	O
cancer	O
who	O
experience	O
methotrexate-induced	B-Drug
anaphylaxis	B-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
child	O
with	O
metastatic	O
osteosarcoma	O
,	O
who	O
experienced	O
an	O
anaphylactic	B-ADR
/	I-ADR
anaphylactoid	I-ADR
reaction	I-ADR
to	O
methotrexate	B-Drug
0	O
<EOS>	O
drug-induced	O
fever	B-ADR
due	O
to	O
diltiazem	B-Drug
0	O
<EOS>	O
drug-induced	O
fever	B-ADR
should	O
be	O
considered	O
in	O
patient	O
who	O
have	O
unexplained	O
high	O
temperature	O
during	O
diltiazem	B-Drug
therapy	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
drug-induced	O
fever	B-ADR
ha	O
not	O
been	O
reported	O
with	O
the	O
use	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
,	O
a	O
commonly	O
prescribed	O
calcium	O
channel	O
blocker	O
0	O
<EOS>	O
a	O
case	O
of	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
in	O
a	O
child	O
with	O
wilms	O
	O
tumor	O
treated	O
adriamycin	B-Drug
is	O
presented	O
and	O
discussed	O
0	O
<EOS>	O
radiologic	O
recognition	O
of	O
adriamycin	B-Drug
cardiotoxicity	B-ADR
0	O
<EOS>	O
the	O
role	O
of	O
adriamycin	B-Drug
in	O
the	O
production	O
of	O
cardiotoxicity	B-ADR
is	O
reviewed	O
0	O
<EOS>	O
carbamazepine-induced	B-Drug
diabetes	B-ADR
mellitus	I-ADR
0	O
<EOS>	O
diabetes	B-ADR
mellitus	I-ADR
wa	O
observed	O
in	O
a	O
patient	O
given	O
carbamazepine	B-Drug
0	O
<EOS>	O
the	O
present	O
study	O
describes	O
a	O
patient	O
who	O
had	O
unusual	B-ADR
weight	I-ADR
fluctuation	I-ADR
under	O
corticosteroid	O
and	O
psychotropic	O
treatment	O
such	O
a	O
mianserin	O
and	O
aripiprazole	B-Drug
0	O
<EOS>	O
the	O
present	O
study	O
describes	O
a	O
patient	O
who	O
had	O
unusual	B-ADR
weight	I-ADR
fluctuation	I-ADR
under	O
corticosteroid	O
and	O
psychotropic	O
treatment	O
such	O
a	O
mianserin	B-Drug
and	O
aripiprazole	O
0	O
<EOS>	O
although	O
heparin-dependent	B-Drug
antibody	O
(	O
hdas	O
)	O
typically	O
manifest	O
with	O
thrombocytopenia	B-ADR
a	O
in	O
heparin-induced	B-Drug
thrombocytopenia	O
(	O
hit	O
)	O
,	O
they	O
may	O
also	O
manifest	O
with	O
preserved	O
platelet	O
count	O
0	O
<EOS>	O
clinician	O
should	O
be	O
cognizant	O
of	O
this	O
possibility	O
and	O
consider	O
a	O
diagnosis	O
of	O
hdas	O
in	O
patient	O
with	O
ongoing	O
thrombosis	B-ADR
who	O
are	O
receiving	O
heparin	B-Drug
therapy	O
0	O
<EOS>	O
heparin-dependent	B-Drug
antibody	O
and	O
thrombosis	O
without	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
0	O
<EOS>	O
despite	O
these	O
antithrombotic	O
effect	O
,	O
the	O
patient	O
developed	O
repeated	O
venous	B-ADR
thromboembolism	I-ADR
during	O
treatment	O
with	O
low-molecular-weight	O
heparin	B-Drug
0	O
<EOS>	O
four	O
month	O
after	O
receiving	O
an	O
orthotopic	O
liver	O
transplant	O
,	O
a	O
51-year-old	O
man	O
wa	O
admitted	O
for	O
progressive	B-ADR
liver	I-ADR
failure	I-ADR
and	O
severe	O
hepatocellular	O
necrosis	O
thought	O
to	O
be	O
due	O
to	O
tacrolimus	B-Drug
0	O
<EOS>	O
four	O
month	O
after	O
receiving	O
an	O
orthotopic	O
liver	O
transplant	O
,	O
a	O
51-year-old	O
man	O
wa	O
admitted	O
for	O
progressive	O
liver	O
failure	O
and	O
severe	B-ADR
hepatocellular	I-ADR
necrosis	I-ADR
thought	O
to	O
be	O
due	O
to	O
tacrolimus	B-Drug
0	O
<EOS>	O
initiation	O
of	O
posaconazole	B-Drug
led	O
to	O
clinical	O
improvement	O
until	O
the	O
patient	O
demise	O
from	O
bacteremic	O
vancomycin-resistant	O
enterococcal	B-ADR
peritonitis	I-ADR
0	O
<EOS>	O
iatrogenic	B-ADR
cushing	I-ADR
syndrome	I-ADR
after	O
epidural	O
triamcinolone	B-Drug
injection	O
in	O
an	O
hiv	O
type	O
1-infected	O
patient	O
receiving	O
therapy	O
with	O
ritonavir-lopinavir	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
hiv-1	O
)	O
-infected	O
individual	O
receiving	O
combination	O
antiretroviral	O
therapy	O
,	O
which	O
included	O
ritonavir	O
,	O
who	O
developed	O
cushing	B-ADR
syndrome	I-ADR
with	O
profound	O
complication	O
after	O
epidural	O
triamcinolone	B-Drug
injection	O
0	O
<EOS>	O
a	O
22-year-old	O
drug-abuser	O
injected	O
flunitrazepam	B-Drug
tablet	O
dissolved	O
in	O
tap	O
water	O
into	O
her	O
left	O
femoral	O
artery	O
and	O
presented	O
with	O
clinical	O
sign	O
of	O
acute	B-ADR
ischaemia	I-ADR
of	I-ADR
the	I-ADR
left	I-ADR
leg	I-ADR
0	O
<EOS>	O
acute	B-ADR
ischaemia	I-ADR
of	I-ADR
the	I-ADR
leg	I-ADR
following	O
accidental	O
intra-arterial	O
injection	O
of	O
dissolved	O
flunitrazepam	B-Drug
tablet	O
0	O
<EOS>	O
a	O
17-year-old	O
boy	O
with	O
refractory	O
psoriatic	O
arthritis	O
and	O
alpha-1	O
antitrypsin	O
deficiency	O
who	O
developed	O
a	O
syringotropic	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
after	O
9	O
month	O
of	O
therapy	O
with	O
infliximab	B-Drug
and	O
leflunomide	O
is	O
described	O
0	O
<EOS>	O
a	O
17-year-old	O
boy	O
with	O
refractory	O
psoriatic	O
arthritis	O
and	O
alpha-1	O
antitrypsin	O
deficiency	O
who	O
developed	O
a	O
syringotropic	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
after	O
9	O
month	O
of	O
therapy	O
with	O
infliximab	O
and	O
leflunomide	B-Drug
is	O
described	O
0	O
<EOS>	O
syringotropic	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
associated	O
with	O
infliximab	B-Drug
and	O
leflunomide	O
combination	O
therapy	O
in	O
a	O
child	O
with	O
psoriatic	O
arthritis	O
0	O
<EOS>	O
syringotropic	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
associated	O
with	O
infliximab	O
and	O
leflunomide	B-Drug
combination	O
therapy	O
in	O
a	O
child	O
with	O
psoriatic	O
arthritis	O
0	O
<EOS>	O
a	O
case	O
of	O
severe	B-ADR
aplastic	I-ADR
anemia	I-ADR
secondary	O
to	O
treatment	O
with	O
lenalidomide	B-Drug
for	O
multiple	O
myeloma	O
0	O
<EOS>	O
although	O
moderate	O
myelosuppression	O
is	O
not	O
uncommonly	O
seen	O
in	O
patient	O
treated	O
with	O
lenalidomide	B-Drug
,	O
aplastic	B-ADR
anemia	I-ADR
ha	O
not	O
previously	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
agent	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
severe	O
aplastic	O
anemia	O
(	O
aa	B-ADR
)	O
that	O
wa	O
probably	O
induced	O
by	O
lenalidomide	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
severe	B-ADR
aplastic	I-ADR
anemia	I-ADR
(	O
aa	O
)	O
that	O
wa	O
probably	O
induced	O
by	O
lenalidomide	B-Drug
0	O
<EOS>	O
after	O
cessation	O
of	O
amantadine	B-Drug
,	O
the	O
edema	B-ADR
resolved	O
,	O
and	O
the	O
endothelial	O
cell	O
density	O
were	O
<	O
or=600	O
/	O
mm	O
0	O
<EOS>	O
conclusion	O
:	O
amantadine	B-Drug
can	O
cause	O
reversible	B-ADR
corneal	I-ADR
edema	I-ADR
but	O
can	O
irreversibly	O
reduce	O
the	O
density	O
of	O
endothelial	O
cell	O
0	O
<EOS>	O
corneal	B-ADR
edema	I-ADR
recurred	O
when	O
the	O
administration	O
of	O
amantadine	B-Drug
wa	O
resumed	O
0	O
<EOS>	O
corneal	B-ADR
endothelial	I-ADR
dysfunction	I-ADR
associated	O
with	O
amantadine	B-Drug
toxicity	O
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
bilateral	B-ADR
corneal	I-ADR
endothelial	I-ADR
dysfunction	I-ADR
in	O
a	O
patient	O
with	O
parkinson	O
disease	O
who	O
wa	O
treated	O
with	O
long-term	O
amantadine	B-Drug
0	O
<EOS>	O
result	O
:	O
a	O
52-year-old	O
woman	O
with	O
parkinson	O
disease	O
who	O
had	O
taken	O
amantadine	B-Drug
for	O
6	O
year	O
had	O
bilateral	B-ADR
corneal	I-ADR
edema	I-ADR
for	O
2	O
month	O
at	O
baseline	O
0	O
<EOS>	O
therefore	O
,	O
amantadine	B-Drug
wa	O
permanently	O
discontinued	O
and	O
the	O
cornea	B-ADR
cleared	O
again	O
0	O
<EOS>	O
biopsy-proven	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
associated	O
with	O
the	O
tyrosine	O
kinase	O
inhibitor	O
sunitinib	B-Drug
:	O
a	O
class	O
effect	O
?	O
<EOS>	O
we	O
report	O
the	O
first	O
biopsy	O
confirmed	O
occurrence	O
of	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
in	O
a	O
patient	O
receiving	O
treatment	O
with	O
sunitinib	B-Drug
for	O
metastatic	O
renal	O
cell	O
cancer	O
0	O
<EOS>	O
extrapyramidal	B-ADR
symptom	I-ADR
are	O
well-documented	O
complication	O
of	O
therapy	O
with	O
haloperidol	B-Drug
,	O
even	O
when	O
small	O
dos	O
are	O
used	O
0	O
<EOS>	O
this	O
report	O
highlight	O
a	O
case	O
of	O
drug-induced	O
dysphagia	B-ADR
in	O
a	O
patient	O
receiving	O
haloperidol	B-Drug
for	O
obsessive	O
nocturnal	O
thought	O
and	O
auditory	O
disturbance	O
0	O
<EOS>	O
a	O
52	O
year-old	O
male	O
patient	O
diagnosed	O
of	O
ankylosing	O
spondylitis	O
presented	O
with	O
an	O
iron	B-ADR
deficiency	I-ADR
anemia	I-ADR
after	O
a	O
ten-month	O
treatment	O
of	O
methotrexate	B-Drug
0	O
<EOS>	O
methotrexate	B-Drug
induced	O
sprue-like	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
only	O
3	O
case	O
of	O
imatinib-induced	B-Drug
tumor	B-ADR
lysis	I-ADR
syndrome	I-ADR
have	O
been	O
reported	O
0	O
<EOS>	O
we	O
herein	O
described	O
an	O
additional	O
patient	O
with	O
bcr-abl	O
(	O
ela2	O
)	O
positive	O
acute	O
lymphoblastic	O
leukemia	O
who	O
developed	O
tumor	B-ADR
lysis	I-ADR
syndrome	I-ADR
after	O
10-day	O
treatment	O
with	O
imatinib	B-Drug
0	O
<EOS>	O
ifnalpha-induced	B-Drug
recurrence	O
of	O
graf	B-ADR
	I-ADR
disease	I-ADR
ten	O
year	O
after	O
thyroidectomy	O
in	O
chronic	O
viral	O
hepatitis	O
c	O
0	O
<EOS>	O
in	O
contrast	O
to	O
chronic	O
or	O
subacute	O
thyroiditis	O
,	O
graf	B-ADR
	I-ADR
disease	I-ADR
rarely	O
complicates	O
ifn-alpha	B-Drug
therapy	O
for	O
chronic	O
viral	O
c	O
hepatitis	O
0	O
<EOS>	O
in	O
contrast	O
to	O
chronic	O
or	O
subacute	B-ADR
thyroiditis	I-ADR
,	O
graf	O
	O
disease	O
rarely	O
complicates	O
ifn-alpha	B-Drug
therapy	O
for	O
chronic	O
viral	O
c	O
hepatitis	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
51-year-old	O
man	O
in	O
whom	O
ifn-alpha	B-Drug
treatment	O
wa	O
followed	O
by	O
recurrence	O
of	O
graf	B-ADR
	I-ADR
disease	I-ADR
10	O
year	O
after	O
thyroidectomy	O
wa	O
performed	O
and	O
the	O
patient	O
wa	O
declared	O
cured	O
0	O
<EOS>	O
interstitial	B-ADR
granulomatous	I-ADR
dermatitis	I-ADR
associated	O
with	O
darifenacin	B-Drug
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
interstitial	B-ADR
granulomatous	I-ADR
dermatitis	I-ADR
associated	O
with	O
darifenacin	B-Drug
0	O
<EOS>	O
gemcitabine	B-Drug
is	O
a	O
known	O
risk	O
factor	O
for	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
(	O
hus	O
)	O
,	O
which	O
can	O
often	O
have	O
a	O
rapidly	O
fatal	O
clinical	O
course	O
despite	O
intervention	O
with	O
steroid	O
,	O
plasmapheresis	O
and	O
hemodialysis	O
0	O
<EOS>	O
gemcitabine	B-Drug
is	O
a	O
known	O
risk	O
factor	O
for	O
hemolytic	O
uremic	O
syndrome	O
(	O
hus	B-ADR
)	O
,	O
which	O
can	O
often	O
have	O
a	O
rapidly	O
fatal	O
clinical	O
course	O
despite	O
intervention	O
with	O
steroid	O
,	O
plasmapheresis	O
and	O
hemodialysis	O
0	O
<EOS>	O
method	O
:	O
a	O
retrospective	O
report	O
of	O
the	O
first	O
case	O
of	O
gemcitabine-related	B-Drug
hus	B-ADR
,	O
in	O
a	O
patient	O
with	O
metastatic	O
pancreatic	O
adenocarcinoma	O
,	O
treated	O
with	O
a	O
variety	O
of	O
standard	O
therapy	O
in	O
addition	O
to	O
rituximab	O
is	O
presented	O
0	O
<EOS>	O
rituximab-based	O
therapy	O
for	O
gemcitabine-induced	B-Drug
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
a	O
patient	O
with	O
metastatic	O
pancreatic	O
adenocarcinoma	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
drug	B-ADR
rash	I-ADR
with	I-ADR
eosinophilia	I-ADR
and	I-ADR
systemic	I-ADR
symptom	I-ADR
after	O
chlorambucil	B-Drug
treatment	O
in	O
chronic	O
lymphocytic	O
leukaemia	O
0	O
<EOS>	O
he	O
developed	O
recurrent	O
skin	O
rash	O
,	O
fever	O
,	O
hypereosinophilia	O
,	O
and	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
after	O
rechallenge	O
with	O
chlorambucil	B-Drug
0	O
<EOS>	O
he	O
developed	O
recurrent	O
skin	O
rash	O
,	O
fever	B-ADR
,	O
hypereosinophilia	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
rechallenge	O
with	O
chlorambucil	B-Drug
0	O
<EOS>	O
he	O
developed	O
recurrent	O
skin	O
rash	O
,	O
fever	O
,	O
hypereosinophilia	B-ADR
,	O
and	O
acute	O
renal	O
failure	O
after	O
rechallenge	O
with	O
chlorambucil	B-Drug
0	O
<EOS>	O
he	O
developed	O
recurrent	O
skin	B-ADR
rash	I-ADR
,	O
fever	O
,	O
hypereosinophilia	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
rechallenge	O
with	O
chlorambucil	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
chlorambucil-induced	B-Drug
dress	B-ADR
syndrome	I-ADR
in	O
a	O
70-year-old	O
man	O
recently	O
diagnosed	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	O
toxicity	O
and	O
extreme	O
elevation	O
of	O
aspartate	O
aminotrasferase	O
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	B-Drug
(	O
mtx	O
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	O
toxicity	O
and	O
extreme	O
elevation	O
of	O
aspartate	O
aminotrasferase	O
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	O
(	O
mtx	B-Drug
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	O
toxicity	O
and	O
extreme	O
elevation	B-ADR
of	I-ADR
aspartate	I-ADR
aminotrasferase	I-ADR
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	B-Drug
(	O
mtx	O
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	O
renal	O
failure	O
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	O
toxicity	O
and	O
extreme	O
elevation	B-ADR
of	I-ADR
aspartate	I-ADR
aminotrasferase	I-ADR
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	O
(	O
mtx	B-Drug
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	O
renal	O
failure	O
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	B-ADR
toxicity	I-ADR
and	O
extreme	O
elevation	O
of	O
aspartate	O
aminotrasferase	O
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	B-Drug
(	O
mtx	O
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	O
renal	O
failure	O
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
a	O
10-year-old	O
boy	O
with	O
osteosarcoma	O
and	O
normal	O
renal	O
function	O
manifested	O
laboratory	O
evidence	O
of	O
impending	O
renal	B-ADR
toxicity	I-ADR
and	O
extreme	O
elevation	O
of	O
aspartate	O
aminotrasferase	O
and	O
alanine	O
aminotransferase	O
within	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
infusion	O
of	O
high-dose	O
methotrexate	O
(	O
mtx	B-Drug
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
,	O
and	O
went	O
on	O
to	O
develop	O
acute	O
renal	O
failure	O
with	O
life-threatening	O
hyperkalemia	O
29	O
hour	O
later	O
0	O
<EOS>	O
although	O
his	O
renal	O
function	O
recovered	O
completely	O
with	O
high-dose	O
leucovorin	O
,	O
hemodialysis	O
,	O
charcoal	O
hemoperfusion	O
,	O
and	O
carboxypeptidase	O
g2	O
,	O
we	O
present	O
this	O
case	O
to	O
emphasize	O
that	O
sign	O
of	O
renal	B-ADR
toxicity	I-ADR
may	O
be	O
present	O
a	O
early	O
a	O
2	O
hour	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
mtx	B-Drug
infusion	O
,	O
and	O
to	O
suggest	O
that	O
monitoring	O
for	O
mtx	O
toxicity	O
should	O
perhaps	O
begin	O
within	O
a	O
few	O
hour	O
after	O
the	O
completion	O
of	O
4-hour	O
mtx	O
infusion	O
0	O
<EOS>	O
early	O
recognition	O
of	O
renal	B-ADR
toxicity	I-ADR
of	O
high-dose	O
methotrexate	B-Drug
therapy	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
multifocal	O
electroretinographic	O
abnormality	O
in	O
ethambutol-induced	B-Drug
visual	B-ADR
loss	I-ADR
0	O
<EOS>	O
these	O
are	O
the	O
first	O
reported	O
patient	O
to	O
show	O
mferg	O
abnormality	O
that	O
correspond	O
to	O
bitemporal	B-ADR
visual	I-ADR
field	I-ADR
defect	I-ADR
and	O
add	O
to	O
the	O
growing	O
evidence	O
that	O
ethambutol	B-Drug
damage	O
the	O
retina	O
0	O
<EOS>	O
these	O
are	O
the	O
first	O
reported	O
patient	O
to	O
show	O
mferg	B-ADR
abnormality	I-ADR
that	O
correspond	O
to	O
bitemporal	O
visual	O
field	O
defect	O
and	O
add	O
to	O
the	O
growing	O
evidence	O
that	O
ethambutol	B-Drug
damage	O
the	O
retina	O
0	O
<EOS>	O
two	O
patient	O
who	O
developed	O
decreased	O
visual	O
acuity	O
after	O
several	O
month	O
of	O
ethambutol	B-Drug
treatment	O
for	O
mycobacterium	O
avium-intracellulare	O
infection	O
had	O
bitemporal	B-ADR
visual	I-ADR
field	I-ADR
defect	I-ADR
that	O
suggested	O
optic	O
chiasm	O
damage	O
0	O
<EOS>	O
two	O
patient	O
who	O
developed	O
decreased	B-ADR
visual	I-ADR
acuity	I-ADR
after	O
several	O
month	O
of	O
ethambutol	B-Drug
treatment	O
for	O
mycobacterium	O
avium-intracellulare	O
infection	O
had	O
bitemporal	O
visual	O
field	O
defect	O
that	O
suggested	O
optic	O
chiasm	O
damage	O
0	O
<EOS>	O
tenofovir-associated	B-Drug
nephrotoxicity	B-ADR
in	O
two	O
hiv-infected	O
adolescent	O
male	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
these	O
case	O
represent	O
the	O
first	O
report	O
of	O
tdf-associated	B-Drug
irreversible	B-ADR
renal	I-ADR
failure	I-ADR
and	O
rickets	O
in	O
pediatric	O
patient	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
these	O
case	O
represent	O
the	O
first	O
report	O
of	O
tdf-associated	B-Drug
irreversible	O
renal	O
failure	O
and	O
rickets	B-ADR
in	O
pediatric	O
patient	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
tenofovir	O
(	O
tdf	B-Drug
)	O
-associated	O
nephrotoxicity	B-ADR
in	O
perinatally	O
hiv-infected	O
adolescent	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
tenofovir	B-Drug
(	O
tdf	O
)	O
-associated	O
nephrotoxicity	B-ADR
in	O
perinatally	O
hiv-infected	O
adolescent	O
0	O
<EOS>	O
in	O
this	O
case	O
,	O
discontinuing	O
piroxicam	B-Drug
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
and	O
starting	O
a	O
palliative	O
treatment	O
plan	O
helped	O
resolve	O
a	O
patient	O
ulcer	B-ADR
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
following	O
intravenous	O
immunoglobulin	B-Drug
therapy	O
in	O
a	O
hiv-infected	O
patient	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
is	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
ivig	O
)	O
0	O
<EOS>	O
the	O
exact	O
mechanism	O
of	O
ivig-associated	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
remains	O
unclear	O
0	O
<EOS>	O
a	O
58-year-old	O
man	O
with	O
advanced	O
renal	O
cell	O
carcinoma	O
developed	O
grade	O
3	O
proteinuria	B-ADR
(	O
8.5	O
g	O
/	O
24	O
h	O
)	O
without	O
microscopic	O
hematuria	O
or	O
renal	O
insufficiency	O
five	O
day	O
after	O
temsirolimus	B-Drug
infusion	O
0	O
<EOS>	O
temsirolimus-induced	B-Drug
glomerulopathy	B-ADR
0	O
<EOS>	O
hypoglycemia	B-ADR
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	B-Drug
in	O
patient	O
already	O
on	O
antidiabetic	O
medication	O
known	O
to	O
cause	O
hypoglycemia	O
,	O
such	O
a	O
sulfonylurea	O
,	O
meglitinides	O
,	O
and	O
insulin	O
0	O
<EOS>	O
hypoglycemia	B-ADR
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	B-Drug
in	O
patient	O
already	O
on	O
antidiabetic	O
medication	O
known	O
to	O
cause	O
hypoglycemia	O
,	O
such	O
a	O
sulfonylurea	O
,	O
meglitinides	O
,	O
and	O
insulin	O
0	O
<EOS>	O
hypoglycemia	B-ADR
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	O
in	O
patient	O
already	O
on	O
antidiabetic	O
medication	O
known	O
to	O
cause	O
hypoglycemia	O
,	O
such	O
a	O
sulfonylurea	O
,	O
meglitinides	O
,	O
and	O
insulin	B-Drug
0	O
<EOS>	O
hypoglycemia	B-ADR
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	O
in	O
patient	O
already	O
on	O
antidiabetic	O
medication	O
known	O
to	O
cause	O
hypoglycemia	O
,	O
such	O
a	O
sulfonylurea	O
,	O
meglitinides	B-Drug
,	O
and	O
insulin	O
0	O
<EOS>	O
hypoglycemia	B-ADR
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	O
in	O
patient	O
already	O
on	O
antidiabetic	O
medication	O
known	O
to	O
cause	O
hypoglycemia	O
,	O
such	O
a	O
sulfonylurea	B-Drug
,	O
meglitinides	O
,	O
and	O
insulin	O
0	O
<EOS>	O
persistent	B-ADR
hypoglycemia	I-ADR
in	O
a	O
patient	O
with	O
diabetes	O
taking	O
etanercept	B-Drug
for	O
the	O
treatment	O
of	O
psoriasis	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
with	O
type	O
2	O
diabetes	O
mellitus	O
who	O
,	O
while	O
treated	O
with	O
the	O
antitumor	O
necrosis	O
factor-alpha	O
blocking	O
agent	O
etanercept	B-Drug
for	O
severe	O
plaque	O
psoriasis	O
,	O
experienced	O
persistent	B-ADR
hypoglycemia	I-ADR
requiring	O
the	O
lowering	O
and	O
eventual	O
elimination	O
of	O
his	O
previous	O
insulin	O
regimen	O
0	O
<EOS>	O
we	O
report	O
on	O
three	O
case	O
wherein	O
treatment	O
of	O
dexmedetomidine-induced	B-Drug
bradycardia	B-ADR
with	O
i.v	O
0	O
glycopyrrolate	O
(	O
5	O
microg	O
/	O
kg	O
)	O
not	O
only	O
resulting	O
in	O
resolution	O
of	O
bradycardia	O
but	O
also	O
resulting	O
in	O
an	O
exaggerated	O
increase	O
of	O
arterial	O
blood	O
pressure	O
0	O
<EOS>	O
we	O
report	O
on	O
three	O
case	O
wherein	O
treatment	O
of	O
dexmedetomidine-induced	O
bradycardia	O
with	O
i.v	O
0	O
glycopyrrolate	B-Drug
(	O
5	O
microg	O
/	O
kg	O
)	O
not	O
only	O
resulting	O
in	O
resolution	O
of	O
bradycardia	O
but	O
also	O
resulting	O
in	O
an	O
exaggerated	B-ADR
increase	I-ADR
of	I-ADR
arterial	I-ADR
blood	I-ADR
pressure	I-ADR
0	O
<EOS>	O
bisphosphonate-related	B-Drug
osteonecrosis	B-ADR
of	I-ADR
the	I-ADR
jaw	I-ADR
(	O
bronj	O
)	O
is	O
reported	O
in	O
up	O
to	O
18.6	O
%	O
of	O
patient	O
treated	O
with	O
intravenous	O
bisphosphonates	O
and	O
can	O
result	O
in	O
significant	O
morbidity	O
0	O
<EOS>	O
bisphosphonate-related	B-Drug
osteonecrosis	B-ADR
of	I-ADR
the	I-ADR
skull	I-ADR
base	I-ADR
0	O
<EOS>	O
a	O
previous	O
study	O
of	O
patient	O
with	O
``	O
quinine-associated	B-Drug
ttp	B-ADR
/	I-ADR
hus	I-ADR
'	O
found	O
that	O
adamts13	O
activity	O
were	O
not	O
abnormal	O
in	O
12	O
/	O
12	O
patient	O
0	O
<EOS>	O
a	O
retrospective	O
review	O
of	O
ttp	O
patient	O
with	O
quinine-associated	B-Drug
thrombotic	B-ADR
microangiopathy	I-ADR
(	O
tma	O
)	O
for	O
whom	O
adamts13	O
wa	O
measured	O
before	O
plasma	O
exchange	O
wa	O
performed	O
0	O
<EOS>	O
a	O
retrospective	O
review	O
of	O
ttp	O
patient	O
with	O
quinine-associated	B-Drug
thrombotic	O
microangiopathy	O
(	O
tma	B-ADR
)	O
for	O
whom	O
adamts13	O
wa	O
measured	O
before	O
plasma	O
exchange	O
wa	O
performed	O
0	O
<EOS>	O
thrombocytopenia	B-ADR
with	O
or	O
without	O
microangiopathy	O
following	O
quinine	O
is	O
often	O
referred	O
to	O
a	O
quinine	O
``	O
hypersensitivity	O
0	O
'	O
when	O
schistocytes	O
are	O
present	O
it	O
is	O
frequently	O
termed	O
``	O
quinine-associated	B-Drug
ttp	O
/	O
hus	O
0	O
'	O
a	O
severe	O
deficiency	O
of	O
the	O
vwf-cleaving	O
protease	O
,	O
adamts13	O
,	O
is	O
associated	O
with	O
idiopathic	O
ttp	O
0	O
<EOS>	O
thrombocytopenia	O
with	O
or	O
without	O
microangiopathy	O
following	O
quinine	O
is	O
often	O
referred	O
to	O
a	O
quinine	O
``	O
hypersensitivity	O
0	O
'	O
when	O
schistocytes	O
are	O
present	O
it	O
is	O
frequently	O
termed	O
``	O
quinine-associated	B-Drug
ttp	B-ADR
/	I-ADR
hus	I-ADR
0	O
'	O
a	O
severe	O
deficiency	O
of	O
the	O
vwf-cleaving	O
protease	O
,	O
adamts13	O
,	O
is	O
associated	O
with	O
idiopathic	O
ttp	O
0	O
<EOS>	O
we	O
conclude	O
that	O
while	O
thrombocytopenia	O
and	O
schistocytosis	B-ADR
can	O
be	O
seen	O
in	O
quinine-associated	B-Drug
ttp	O
/	O
hus	O
,	O
the	O
pathophysiology	O
seems	O
to	O
be	O
distinct	O
from	O
that	O
seen	O
in	O
most	O
case	O
of	O
idiopathic	O
ttp	O
(	O
i.e.	O
,	O
severely	O
decreased	O
adamts13	O
with	O
an	O
inhibitor	O
)	O
0	O
<EOS>	O
we	O
conclude	O
that	O
while	O
thrombocytopenia	B-ADR
and	O
schistocytosis	O
can	O
be	O
seen	O
in	O
quinine-associated	B-Drug
ttp	O
/	O
hus	O
,	O
the	O
pathophysiology	O
seems	O
to	O
be	O
distinct	O
from	O
that	O
seen	O
in	O
most	O
case	O
of	O
idiopathic	O
ttp	O
(	O
i.e.	O
,	O
severely	O
decreased	O
adamts13	O
with	O
an	O
inhibitor	O
)	O
0	O
<EOS>	O
we	O
conclude	O
that	O
while	O
thrombocytopenia	O
and	O
schistocytosis	O
can	O
be	O
seen	O
in	O
quinine-associated	B-Drug
ttp	B-ADR
/	I-ADR
hus	I-ADR
,	O
the	O
pathophysiology	O
seems	O
to	O
be	O
distinct	O
from	O
that	O
seen	O
in	O
most	O
case	O
of	O
idiopathic	O
ttp	O
(	O
i.e.	O
,	O
severely	O
decreased	O
adamts13	O
with	O
an	O
inhibitor	O
)	O
0	O
<EOS>	O
we	O
recommend	O
that	O
a	O
tma	O
in	O
association	O
with	O
quinine	O
be	O
consistently	O
referred	O
to	O
a	O
quinine-associated	B-Drug
thrombotic	B-ADR
microangiopathy	I-ADR
(	O
quinine-tma	O
)	O
to	O
better	O
distinguish	O
this	O
entity	O
from	O
idiopathic	O
ttp	O
0	O
<EOS>	O
complication	O
associated	O
with	O
primary	B-ADR
and	I-ADR
secondary	I-ADR
perforation	I-ADR
of	I-ADR
the	I-ADR
bladder	I-ADR
following	O
immediate	O
instillation	O
of	O
epirubicin	B-Drug
after	O
transurethral	O
resection	O
of	O
superficial	O
urothelial	O
tumour	O
0	O
<EOS>	O
material	O
and	O
method	O
:	O
we	O
present	O
two	O
case	O
of	O
significant	O
morbidity	O
related	O
to	O
primary	B-ADR
and	I-ADR
secondary	I-ADR
perforation	I-ADR
of	I-ADR
the	I-ADR
bladder	I-ADR
following	O
two	O
instillation	O
of	O
epirubicin	B-Drug
0	O
<EOS>	O
aliskiren-associated	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
hyperkalemia	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
hyperkalemia	O
associated	O
with	O
the	O
recently	O
marketed	O
direct	O
renin	O
inhibitor	O
aliskiren	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
acute	O
renal	O
failure	O
with	O
hyperkalemia	B-ADR
associated	O
with	O
the	O
recently	O
marketed	O
direct	O
renin	O
inhibitor	O
aliskiren	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
acute	B-ADR
cardiomyopathy	I-ADR
and	O
pericarditis	O
associated	O
with	O
methylphenidate	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
acute	O
cardiomyopathy	O
and	O
pericarditis	B-ADR
associated	O
with	O
methylphenidate	B-Drug
0	O
<EOS>	O
however	O
,	O
acute	B-ADR
cardiomyopathy	I-ADR
and	O
pericarditis	O
secondary	O
to	O
methylphenidate	B-Drug
use	O
ha	O
been	O
rarely	O
reported	O
0	O
<EOS>	O
however	O
,	O
acute	O
cardiomyopathy	O
and	O
pericarditis	B-ADR
secondary	O
to	O
methylphenidate	B-Drug
use	O
ha	O
been	O
rarely	O
reported	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
17-year-old	O
male	O
who	O
developed	O
chest	O
pain	O
,	O
elevated	O
cardiac	O
biomarkers	O
,	O
and	O
acute	B-ADR
left	I-ADR
ventricular	I-ADR
dysfunction	I-ADR
following	O
a	O
single	O
dose	O
of	O
methylphenidate	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
17-year-old	O
male	O
who	O
developed	O
chest	B-ADR
pain	I-ADR
,	O
elevated	O
cardiac	O
biomarkers	O
,	O
and	O
acute	O
left	O
ventricular	O
dysfunction	O
following	O
a	O
single	O
dose	O
of	O
methylphenidate	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
17-year-old	O
male	O
who	O
developed	O
chest	O
pain	O
,	O
elevated	B-ADR
cardiac	I-ADR
biomarkers	I-ADR
,	O
and	O
acute	O
left	O
ventricular	O
dysfunction	O
following	O
a	O
single	O
dose	O
of	O
methylphenidate	B-Drug
0	O
<EOS>	O
according	O
to	O
the	O
naranjo	O
et	O
al	O
0	O
adverse-reaction	O
probability	O
scale	O
,	O
enoxaparin	B-Drug
wa	O
the	O
probable	O
cause	O
of	O
hepatotoxicity	B-ADR
in	O
this	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
a	O
woman	O
receiving	O
enoxaparin	B-Drug
every	O
12	O
hour	O
developed	O
sign	O
and	O
symptom	O
of	O
hepatotoxicity	B-ADR
after	O
the	O
second	O
dose	O
0	O
<EOS>	O
probable	O
enoxaparin-induced	B-Drug
hepatotoxicity	B-ADR
0	O
<EOS>	O
purpose	O
:	O
a	O
case	O
of	O
probable	O
enoxaparin-induced	B-Drug
hepatotoxicity	B-ADR
is	O
described	O
0	O
<EOS>	O
posterior	B-ADR
reversible	I-ADR
encephalopathy	I-ADR
syndrome	I-ADR
associated	O
with	O
methotrexate	B-Drug
neurotoxicity	O
:	O
conventional	O
magnetic	O
resonance	O
and	O
diffusion-weighted	O
imaging	O
finding	O
0	O
<EOS>	O
the	O
addition	O
of	O
intrathecal	O
methotrexate	B-Drug
to	O
treatment	O
protocol	O
ha	O
increased	O
survival	O
rate	O
in	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
but	O
is	O
also	O
associated	O
with	O
varying	O
degree	O
of	O
neurotoxicity	B-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
15-year-old	O
female	O
patient	O
diagnosed	O
with	O
acute	B-ADR
lymphoblastic	I-ADR
leukemia	I-ADR
presenting	O
with	O
status	O
epilepticus	O
after	O
receiving	O
intrathecal	O
methotrexate	B-Drug
0	O
<EOS>	O
cyclosporine-induced	B-Drug
pain	B-ADR
syndrome	I-ADR
in	O
a	O
child	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplant	O
0	O
<EOS>	O
in	O
this	O
case	O
,	O
cips	B-ADR
wa	O
considered	O
to	O
be	O
probably	O
associated	O
with	O
cyclosporine	B-Drug
according	O
to	O
the	O
naranjo	O
probability	O
scale	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
calcineurin-induced	B-Drug
pain	B-ADR
syndrome	I-ADR
(	O
cips	O
)	O
in	O
a	O
child	O
undergoing	O
his	O
second	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
hsct	O
)	O
0	O
<EOS>	O
with	O
the	O
first	O
cyclosporine	B-Drug
dose	O
,	O
the	O
patient	O
complained	O
of	O
leg	B-ADR
pain	I-ADR
that	O
wa	O
most	O
severe	O
during	O
the	O
cyclosporine	O
infusion	O
0	O
<EOS>	O
with	O
the	O
first	O
cyclosporine	B-Drug
dose	O
,	O
the	O
patient	O
complained	O
of	O
leg	B-ADR
pain	I-ADR
that	O
wa	O
most	O
severe	O
during	O
the	O
cyclosporine	O
infusion	O
0	O
<EOS>	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
due	O
to	O
risperidone	B-Drug
treatment	O
in	O
a	O
child	O
with	O
joubert	O
syndrome	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
due	O
to	O
risperidone	B-Drug
in	O
a	O
child	O
with	O
joubert	O
syndrome	O
0	O
<EOS>	O
a	O
case	O
of	O
tuberculosis	B-ADR
in	O
a	O
patient	O
on	O
efalizumab	B-Drug
and	O
etanercept	O
for	O
treatment	O
of	O
refractory	O
palmopustular	O
psoriasis	O
and	O
psoriatic	O
arthritis	O
0	O
<EOS>	O
a	O
case	O
of	O
tuberculosis	B-ADR
in	O
a	O
patient	O
on	O
efalizumab	O
and	O
etanercept	B-Drug
for	O
treatment	O
of	O
refractory	O
palmopustular	O
psoriasis	O
and	O
psoriatic	O
arthritis	O
0	O
<EOS>	O
the	O
most	O
common	O
complication	O
of	O
warfarin	B-Drug
use	O
is	O
adverse	O
bleeding	B-ADR
0	O
<EOS>	O
case	O
report	O
:	O
we	O
describe	O
here	O
a	O
case	O
of	O
a	O
60	O
year	O
old	O
female	O
that	O
experienced	O
a	O
relapse	O
of	O
symptomatic	B-ADR
hyperlactatemia	I-ADR
after	O
being	O
switched	O
from	O
stavudine	B-Drug
to	O
zidovudine	O
and	O
how	O
the	O
case	O
wa	O
managed	O
at	O
the	O
infectious	O
disease	O
institute	O
,	O
kampala	O
,	O
uganda	O
0	O
<EOS>	O
case	O
report	O
:	O
we	O
describe	O
here	O
a	O
case	O
of	O
a	O
60	O
year	O
old	O
female	O
that	O
experienced	O
a	O
relapse	O
of	O
symptomatic	B-ADR
hyperlactatemia	I-ADR
after	O
being	O
switched	O
from	O
stavudine	O
to	O
zidovudine	B-Drug
and	O
how	O
the	O
case	O
wa	O
managed	O
at	O
the	O
infectious	O
disease	O
institute	O
,	O
kampala	O
,	O
uganda	O
0	O
<EOS>	O
discussion	O
:	O
this	O
case	O
show	O
that	O
switching	O
to	O
zidovudine	B-Drug
potentially	O
can	O
lead	O
to	O
a	O
hyperlactatemia	B-ADR
relapse	I-ADR
0	O
<EOS>	O
introduction	O
:	O
in	O
resource	O
limited	O
setting	O
patient	O
on	O
antiretroviral	O
treatment	O
who	O
develop	O
stavudine	B-Drug
induced	O
hyperlactatemia	B-ADR
are	O
often	O
switched	O
to	O
zidovudine	O
on	O
the	O
basis	O
of	O
published	O
study	O
that	O
demonstrate	O
that	O
this	O
agent	O
can	O
be	O
a	O
safe	O
alternative	O
0	O
<EOS>	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
bacitracin	B-Drug
ointment	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
an	O
11-year-old	O
boy	O
who	O
experienced	O
an	O
anaphylactic	B-ADR
reaction	I-ADR
after	O
administration	O
of	O
bacitracin	B-Drug
ointment	O
0	O
<EOS>	O
herein	O
,	O
we	O
present	O
a	O
patient	O
with	O
severe	O
and	O
prolonged	B-ADR
hypoglycemia	I-ADR
after	O
long-acting	O
octreotide	B-Drug
treatment	O
0	O
<EOS>	O
hypoglycemia	B-ADR
induced	O
by	O
long-acting	O
somatostatin	B-Drug
analogue	O
in	O
a	O
patient	O
with	O
nonfunctional	O
neuroendocrine	O
tumor	O
0	O
<EOS>	O
in	O
these	O
patient	O
,	O
long-acting	O
octreotide	B-Drug
may	O
trigger	O
serious	B-ADR
hypoglycemia	I-ADR
0	O
<EOS>	O
leukopenia	B-ADR
due	O
to	O
parvovirus	O
b19	O
in	O
a	O
crohn	O
disease	O
patient	O
using	O
azathioprine	B-Drug
0	O
<EOS>	O
the	O
uncomplicated	O
long-term	O
use	O
of	O
adequately-dosed	O
aza	B-Drug
and	O
stable	O
non-toxic	O
metabolite	O
level	O
could	O
not	O
acknowledge	O
tpmt	O
deficiency	O
a	O
a	O
primary	O
cause	O
of	O
the	O
leukopenia	B-ADR
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
an	O
adult	O
crohn	O
disease	O
patient	O
with	O
a	O
parvovirus	O
b19	O
infection	O
and	O
leukopenia	B-ADR
during	O
long-term	O
aza	B-Drug
therapy	O
0	O
<EOS>	O
isoniazid	B-Drug
causing	O
breast	B-ADR
tissue	I-ADR
enlargement	I-ADR
ha	O
been	O
very	O
rarely	O
reported	O
0	O
<EOS>	O
isoniazid	B-Drug
induced	O
gynaecomastia	B-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
cryptococcus	B-ADR
neoformans	I-ADR
fatal	I-ADR
sepsis	I-ADR
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
alemtuzumab	B-Drug
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
the	O
international	O
literature	O
regarding	O
opportunistic	O
infection	O
after	O
immunosuppressive	O
therapy	O
with	O
alemtuzumab	B-Drug
with	O
particular	O
attention	O
on	O
fungal	B-ADR
infection	I-ADR
ha	O
also	O
been	O
reviewed	O
0	O
<EOS>	O
the	O
international	O
literature	O
regarding	O
opportunistic	B-ADR
infection	I-ADR
after	O
immunosuppressive	O
therapy	O
with	O
alemtuzumab	B-Drug
with	O
particular	O
attention	O
on	O
fungal	O
infection	O
ha	O
also	O
been	O
reviewed	O
0	O
<EOS>	O
secondary	O
acute	B-ADR
myeloid	I-ADR
leukemia	I-ADR
after	O
etoposide	B-Drug
therapy	O
for	O
haemophagocytic	O
lymphohistiocytosis	O
0	O
<EOS>	O
the	O
risk	O
of	O
developing	O
saml	B-ADR
is	O
estimated	O
to	O
be	O
between	O
1	O
%	O
and	O
5	O
%	O
,	O
2-20	O
year	O
after	O
exposure	O
to	O
etoposide	B-Drug
but	O
may	O
also	O
be	O
related	O
to	O
cumulative	O
drug	O
dos	O
,	O
treatment	O
schedule	O
,	O
host	O
factor	O
and	O
co-administration	O
of	O
other	O
antineoplastic	O
agent	O
0	O
<EOS>	O
two	O
patient	O
with	O
hlh	O
developed	O
etoposide-related	B-Drug
secondary	O
acute	O
myeloid	O
leukemia	O
(	O
saml	B-ADR
)	O
following	O
therapy	O
for	O
hlh	O
0	O
<EOS>	O
two	O
patient	O
with	O
hlh	O
developed	O
etoposide-related	B-Drug
secondary	B-ADR
acute	I-ADR
myeloid	I-ADR
leukemia	I-ADR
(	O
saml	O
)	O
following	O
therapy	O
for	O
hlh	O
0	O
<EOS>	O
polymyoclonus	B-ADR
seizure	I-ADR
resulting	O
from	O
accidental	O
injection	O
of	O
tranexamic	B-Drug
acid	I-Drug
in	O
spinal	O
anesthesia	O
0	O
<EOS>	O
rhabdomyolysis	B-ADR
following	O
clarithromycin	B-Drug
monotherapy	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
rhabdomyolysis	B-ADR
related	O
to	O
the	O
administration	O
of	O
clarithromycin	B-Drug
without	O
concurrent	O
use	O
of	O
other	O
medication	O
0	O
<EOS>	O
at	O
the	O
end	O
of	O
his	O
fifth	O
cycle	O
of	O
sunitinib	B-Drug
therapy	O
,	O
the	O
patient	O
complained	O
of	O
the	O
development	B-ADR
of	I-ADR
abnormally	I-ADR
large	I-ADR
mammary	I-ADR
gland	I-ADR
associated	O
with	O
pain	O
and	O
peri-areolar	O
erythema	O
0	O
<EOS>	O
at	O
the	O
end	O
of	O
his	O
fifth	O
cycle	O
of	O
sunitinib	B-Drug
therapy	O
,	O
the	O
patient	O
complained	O
of	O
the	O
development	O
of	O
abnormally	O
large	O
mammary	O
gland	O
associated	O
with	O
pain	B-ADR
and	O
peri-areolar	O
erythema	O
0	O
<EOS>	O
at	O
the	O
end	O
of	O
his	O
fifth	O
cycle	O
of	O
sunitinib	B-Drug
therapy	O
,	O
the	O
patient	O
complained	O
of	O
the	O
development	O
of	O
abnormally	O
large	O
mammary	O
gland	O
associated	O
with	O
pain	O
and	O
peri-areolar	B-ADR
erythema	I-ADR
0	O
<EOS>	O
however	O
,	O
re-initiation	O
of	O
sunitinib	B-Drug
treatment	O
wa	O
followed	O
by	O
bilateral	B-ADR
breast	I-ADR
enlargement	I-ADR
again	O
0	O
<EOS>	O
onset	O
of	O
male	O
gynaecomastia	B-ADR
in	O
a	O
patient	O
treated	O
with	O
sunitinib	B-Drug
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
the	O
mechanism	O
by	O
which	O
sunitinib	B-Drug
induces	O
gynaecomastia	B-ADR
is	O
thought	O
to	O
be	O
associated	O
with	O
an	O
unknown	O
direct	O
action	O
on	O
breast	O
hormonal	O
receptor	O
0	O
<EOS>	O
the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effect	O
of	O
sunitinib	B-Drug
include	O
hypertension	O
,	O
fatigue	O
,	O
hand-foot	O
syndrome	O
,	O
elevated	B-ADR
lipase	I-ADR
and	O
lymphopenia	O
0	O
<EOS>	O
the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effect	O
of	O
sunitinib	B-Drug
include	O
hypertension	O
,	O
fatigue	B-ADR
,	O
hand-foot	O
syndrome	O
,	O
elevated	O
lipase	O
and	O
lymphopenia	O
0	O
<EOS>	O
the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effect	O
of	O
sunitinib	B-Drug
include	O
hypertension	O
,	O
fatigue	O
,	O
hand-foot	B-ADR
syndrome	I-ADR
,	O
elevated	O
lipase	O
and	O
lymphopenia	O
0	O
<EOS>	O
the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effect	O
of	O
sunitinib	B-Drug
include	O
hypertension	B-ADR
,	O
fatigue	O
,	O
hand-foot	O
syndrome	O
,	O
elevated	O
lipase	O
and	O
lymphopenia	O
0	O
<EOS>	O
the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effect	O
of	O
sunitinib	B-Drug
include	O
hypertension	O
,	O
fatigue	O
,	O
hand-foot	O
syndrome	O
,	O
elevated	O
lipase	O
and	O
lymphopenia	B-ADR
0	O
<EOS>	O
divalproex	B-Drug
sodium-induced	I-Drug
eosinophilic	B-ADR
pleural	I-ADR
effusion	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
48-year-old	O
woman	O
with	O
seizure	O
disorder	O
on	O
divalproex	O
sodium	O
(	O
depakote	B-Drug
)	O
who	O
presented	O
with	O
dyspnea	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
48-year-old	O
woman	O
with	O
seizure	O
disorder	O
on	O
divalproex	B-Drug
sodium	I-Drug
(	O
depakote	O
)	O
who	O
presented	O
with	O
dyspnea	B-ADR
0	O
<EOS>	O
withdrawal	O
of	O
depakote	B-Drug
resulted	O
in	O
resolution	O
of	O
the	O
effusion	B-ADR
0	O
<EOS>	O
flurbiprofen-associated	B-Drug
acute	B-ADR
tubulointerstitial	I-ADR
nephritis	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
biopsy-proven	O
acute	B-ADR
tubulointerstitial	I-ADR
nephritis	I-ADR
associated	O
with	O
a	O
second	O
course	O
of	O
flurbiprofen	B-Drug
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
of	O
the	O
propionic	O
acid	O
class	O
0	O
<EOS>	O
stupor	B-ADR
and	O
fast	O
activity	O
on	O
electroencephalography	O
in	O
a	O
child	O
treated	O
with	O
valproate	B-Drug
0	O
<EOS>	O
the	O
case	O
of	O
a	O
4-year-old	O
girl	O
with	O
valproate-induced	B-Drug
stupor	B-ADR
and	O
electroencephalographic	O
pattern	O
of	O
increased	O
fast	O
activity	O
is	O
reported	O
0	O
<EOS>	O
localized	B-ADR
dyskeratotic	I-ADR
plaque	I-ADR
with	O
milium	O
associated	O
with	O
sorafenib	B-Drug
0	O
<EOS>	O
localized	O
dyskeratotic	O
plaque	O
with	O
milium	B-ADR
associated	O
with	O
sorafenib	B-Drug
0	O
<EOS>	O
this	O
article	O
present	O
a	O
case	O
of	O
an	O
atypical	B-ADR
localized	I-ADR
cutaneous	I-ADR
eruption	I-ADR
with	O
an	O
unusual	O
course	O
and	O
protracted	O
resolution	O
time	O
associated	O
with	O
sorafenib	B-Drug
therapy	O
0	O
<EOS>	O
according	O
to	O
the	O
naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
,	O
tigecycline	B-Drug
wa	O
the	O
probable	O
cause	O
of	O
her	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
following	O
7	O
day	O
of	O
tigecycline	B-Drug
she	O
developed	O
severe	O
abdominal	O
pain	O
and	O
elevated	O
pancreatic	O
enzyme	O
suggesting	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
following	O
7	O
day	O
of	O
tigecycline	B-Drug
she	O
developed	O
severe	O
abdominal	O
pain	O
and	O
elevated	B-ADR
pancreatic	I-ADR
enzyme	I-ADR
suggesting	O
acute	O
pancreatitis	O
0	O
<EOS>	O
following	O
7	O
day	O
of	O
tigecycline	B-Drug
she	O
developed	O
severe	B-ADR
abdominal	I-ADR
pain	I-ADR
and	O
elevated	O
pancreatic	O
enzyme	O
suggesting	O
acute	O
pancreatitis	O
0	O
<EOS>	O
pancreatitis	O
ha	O
been	O
associated	O
with	O
the	O
tetracycline	O
class	O
of	O
antibiotic	O
and	O
concern	O
about	O
tigecycline-induced	B-Drug
acute	B-ADR
pancreatitis	I-ADR
have	O
recently	O
been	O
raised	O
0	O
<EOS>	O
tigecycline-induced	B-Drug
acute	B-ADR
pancreatitis	I-ADR
:	O
case	O
report	O
and	O
literature	O
review	O
0	O
<EOS>	O
we	O
recommend	O
that	O
clinician	O
monitor	O
patient	O
for	O
sign	O
and	O
symptom	O
of	O
pancreatitis	O
,	O
including	O
abdominal	B-ADR
pain	I-ADR
,	O
during	O
treatment	O
with	O
tigecycline	B-Drug
0	O
<EOS>	O
we	O
recommend	O
that	O
clinician	O
monitor	O
patient	O
for	O
sign	O
and	O
symptom	O
of	O
pancreatitis	B-ADR
,	O
including	O
abdominal	O
pain	O
,	O
during	O
treatment	O
with	O
tigecycline	B-Drug
0	O
<EOS>	O
drug	O
induced	O
polymyositis	B-ADR
secondary	O
to	O
leuprolide	B-Drug
acetate	I-Drug
(	O
lupron	O
)	O
therapy	O
for	O
prostate	O
carcinoma	O
0	O
<EOS>	O
drug	O
induced	O
polymyositis	B-ADR
secondary	O
to	O
leuprolide	O
acetate	O
(	O
lupron	B-Drug
)	O
therapy	O
for	O
prostate	O
carcinoma	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
biopsy	O
proven	O
myositis	B-ADR
whose	O
symptom	O
began	O
within	O
10	O
day	O
of	O
receiving	O
leuprolide	B-Drug
acetate	I-Drug
therapy	O
for	O
prostate	O
cancer	O
0	O
<EOS>	O
aripiprazole-induced	B-Drug
hiccup	B-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
of	O
organic	O
bipolar	O
affective	O
disorder	O
who	O
developed	O
hiccup	B-ADR
with	O
the	O
atypical	O
antipsychotic	O
aripiprazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
this	O
patient	O
rhabdomyolysis	B-ADR
wa	O
probably	O
induced	O
by	O
sertraline	B-Drug
therapy	O
0	O
<EOS>	O
discussion	O
:	O
the	O
naranjo	O
probability	O
scale	O
indicated	O
a	O
probable	O
relationship	O
between	O
sertraline	B-Drug
treatment	O
and	O
the	O
onset	O
of	O
rhabdomyolysis	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
sertraline-induced	B-Drug
rhabdomyolysis	B-ADR
in	O
an	O
elderly	O
patient	O
with	O
dementia	O
and	O
comorbidities	O
0	O
<EOS>	O
sertraline-induced	B-Drug
rhabdomyolysis	B-ADR
in	O
an	O
elderly	O
patient	O
with	O
dementia	O
and	O
comorbidities	O
0	O
<EOS>	O
the	O
patient	O
other	O
comorbidities	O
and	O
medication	O
have	O
not	O
been	O
suggested	O
a	O
possible	O
interaction	O
with	O
sertraline	B-Drug
that	O
can	O
cause	O
rhabdomyolysis	B-ADR
0	O
<EOS>	O
tumor	B-ADR
lysis	I-ADR
syndrome	I-ADR
after	O
transcatheter	O
arterial	O
infusion	O
of	O
cisplatin	B-Drug
and	O
embolization	O
therapy	O
for	O
liver	O
metastasis	O
of	O
melanoma	O
0	O
<EOS>	O
he	O
had	O
priapism	B-ADR
following	O
the	O
use	O
of	O
olanzapine	B-Drug
0	O
<EOS>	O
priapism	B-ADR
associated	O
with	O
olanzapine	B-Drug
0	O
<EOS>	O
can	O
ketamine	B-Drug
prescribed	O
for	O
pain	O
cause	O
damage	B-ADR
to	I-ADR
the	I-ADR
urinary	I-ADR
tract	I-ADR
?	O
<EOS>	O
possible	O
mechanism	O
for	O
damage	B-ADR
to	I-ADR
the	I-ADR
urothelium	I-ADR
by	O
ketamine	B-Drug
are	O
suggested	O
0	O
<EOS>	O
presentation	O
of	O
three	O
palliative	O
care	O
patient	O
who	O
were	O
given	O
ketamine	B-Drug
a	O
an	O
analgesic	O
and	O
subsequently	O
developed	O
significant	O
and	O
debilitating	O
urological	B-ADR
symptom	I-ADR
0	O
<EOS>	O
these	O
two	O
case	O
highlight	O
the	O
importance	O
of	O
considering	O
lopinavir	B-Drug
/	O
ritonavir	O
induced	O
arrhythmia	B-ADR
when	O
dealing	O
with	O
hiv-positive	O
individual	O
0	O
<EOS>	O
these	O
two	O
case	O
highlight	O
the	O
importance	O
of	O
considering	O
lopinavir	O
/	O
ritonavir	B-Drug
induced	O
arrhythmia	B-ADR
when	O
dealing	O
with	O
hiv-positive	O
individual	O
0	O
<EOS>	O
transient	B-ADR
cardiac	I-ADR
arrhythmia	I-ADR
related	O
to	O
lopinavir	B-Drug
/	O
ritonavir	O
in	O
two	O
patient	O
with	O
hiv	O
infection	O
0	O
<EOS>	O
transient	B-ADR
cardiac	I-ADR
arrhythmia	I-ADR
related	O
to	O
lopinavir	O
/	O
ritonavir	B-Drug
in	O
two	O
patient	O
with	O
hiv	O
infection	O
0	O
<EOS>	O
colitis	B-ADR
a	O
a	O
manifestation	O
of	O
infliximab-associated	B-Drug
disseminated	O
cryptococcosis	O
0	O
<EOS>	O
colitis	O
a	O
a	O
manifestation	O
of	O
infliximab-associated	B-Drug
disseminated	B-ADR
cryptococcosis	I-ADR
0	O
<EOS>	O
after	O
three	O
week	O
of	O
carbamazepine	B-Drug
therapy	O
,	O
the	O
patient	O
arrived	O
at	O
the	O
emergency	O
department	O
(	O
ed	O
)	O
with	O
severe	O
agitation	O
and	O
aggressive	B-ADR
behavior	I-ADR
0	O
<EOS>	O
after	O
three	O
week	O
of	O
carbamazepine	B-Drug
therapy	O
,	O
the	O
patient	O
arrived	O
at	O
the	O
emergency	O
department	O
(	O
ed	O
)	O
with	O
severe	B-ADR
agitation	I-ADR
and	O
aggressive	O
behavior	O
0	O
<EOS>	O
carbamazepine-induced	B-Drug
hyperammonemia	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
a	O
26-year-old	O
man	O
with	O
bipolar	O
disorder	O
developed	O
hyperammonemia	B-ADR
three	O
week	O
after	O
initiating	O
carbamazepine	B-Drug
therapy	O
0	O
<EOS>	O
he	O
had	O
also	O
developed	O
elevated	B-ADR
serum	I-ADR
ammonia	I-ADR
level	I-ADR
while	O
on	O
valproic	B-Drug
acid	I-Drug
0	O
<EOS>	O
purpose	O
:	O
a	O
case	O
of	O
carbamazepine-induced	B-Drug
hyperammonemia	B-ADR
is	O
presented	O
0	O
<EOS>	O
adriamycin-induced	B-Drug
cardiomyopathy	B-ADR
aggravated	O
by	O
cis-platinum	O
nephrotoxicity	O
requiring	O
dialysis	O
0	O
<EOS>	O
adriamycin-induced	O
cardiomyopathy	O
aggravated	O
by	O
cis-platinum	B-Drug
nephrotoxicity	B-ADR
requiring	O
dialysis	O
0	O
<EOS>	O
complication	O
of	O
chemotherapy	O
for	O
a	O
synovial	O
sarcoma	O
in	O
an	O
eight-year	O
old	O
boy	O
included	O
cisplatinum	O
nephrotoxicity	O
and	O
adriamycin	B-Drug
cardiotoxicity	B-ADR
0	O
<EOS>	O
complication	O
of	O
chemotherapy	O
for	O
a	O
synovial	O
sarcoma	O
in	O
an	O
eight-year	O
old	O
boy	O
included	O
cisplatinum	B-Drug
nephrotoxicity	B-ADR
and	O
adriamycin	O
cardiotoxicity	O
0	O
<EOS>	O
a	O
65-year-old	O
female	O
patient	O
presented	O
with	O
jaundice	B-ADR
followed	O
2	O
day	O
later	O
by	O
severe	O
dyspnea	O
and	O
tachypnea	O
which	O
worsened	O
when	O
patient	O
wa	O
lying	O
flat	O
,	O
1	O
week	O
after	O
the	O
fourth	O
dose	O
of	O
adalimumab	B-Drug
0	O
<EOS>	O
a	O
65-year-old	O
female	O
patient	O
presented	O
with	O
jaundice	O
followed	O
2	O
day	O
later	O
by	O
severe	B-ADR
dyspnea	I-ADR
and	O
tachypnea	O
which	O
worsened	O
when	O
patient	O
wa	O
lying	O
flat	O
,	O
1	O
week	O
after	O
the	O
fourth	O
dose	O
of	O
adalimumab	B-Drug
0	O
<EOS>	O
a	O
65-year-old	O
female	O
patient	O
presented	O
with	O
jaundice	O
followed	O
2	O
day	O
later	O
by	O
severe	O
dyspnea	O
and	O
tachypnea	B-ADR
which	O
worsened	O
when	O
patient	O
wa	O
lying	O
flat	O
,	O
1	O
week	O
after	O
the	O
fourth	O
dose	O
of	O
adalimumab	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
acute	B-ADR
respiratory	I-ADR
failure	I-ADR
due	O
to	O
diaphragmatic	O
weakness	O
following	O
adalimumab	B-Drug
therapy	O
for	O
psoriasis	O
is	O
described	O
0	O
<EOS>	O
acute	B-ADR
bilateral	I-ADR
phrenic	I-ADR
neuropathy	I-ADR
following	O
treatment	O
with	O
adalimumab	B-Drug
0	O
<EOS>	O
the	O
potential	O
development	O
of	O
sjs	B-ADR
/	O
ten	O
,	O
a	O
severe	O
life-threatening	O
illness	O
,	O
emphasizes	O
the	O
need	O
for	O
judicious	O
use	O
of	O
tmp-sx	B-Drug
and	O
close	O
monitoring	O
and	O
follow-up	O
for	O
patient	O
who	O
were	O
given	O
tmp-sx	O
for	O
sstis	O
0	O
<EOS>	O
the	O
potential	O
development	O
of	O
sjs	O
/	O
ten	B-ADR
,	O
a	O
severe	O
life-threatening	O
illness	O
,	O
emphasizes	O
the	O
need	O
for	O
judicious	O
use	O
of	O
tmp-sx	B-Drug
and	O
close	O
monitoring	O
and	O
follow-up	O
for	O
patient	O
who	O
were	O
given	O
tmp-sx	O
for	O
sstis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	B-ADR
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	O
(	O
tmp-sx	B-Drug
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	B-ADR
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
(	O
tmp-sx	O
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	B-ADR
syndrome	I-ADR
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	O
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	O
(	O
tmp-sx	B-Drug
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	B-ADR
syndrome	I-ADR
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	O
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
(	O
tmp-sx	O
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	O
/	O
ten	B-ADR
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	O
(	O
tmp-sx	B-Drug
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	O
epidermal	O
necrolysis	O
(	O
sjs	O
/	O
ten	B-ADR
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
(	O
tmp-sx	O
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
(	O
sjs	O
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	O
(	O
tmp-sx	B-Drug
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
stevens-johnson	O
syndrome	O
/	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
(	O
sjs	O
/	O
ten	O
)	O
secondary	O
to	O
trimethoprim-sulfamethoxazole	B-Drug
(	O
tmp-sx	O
)	O
therapy	O
for	O
presumed	O
community-associated	O
methicillin-resistant	O
staphylococcus	O
aureus	O
(	O
ca-mrsa	O
)	O
infection	O
0	O
<EOS>	O
conclusion	O
:	O
spontaneous	B-ADR
hemothorax	I-ADR
is	O
a	O
rare	O
phenomenon	O
in	O
conjunction	O
with	O
lmwh	B-Drug
but	O
should	O
be	O
considered	O
in	O
case	O
of	O
acute	O
respiratory	O
distress	O
following	O
commencement	O
of	O
lmwh	O
0	O
<EOS>	O
on	O
day	O
4	O
,	O
following	O
3	O
dos	O
of	O
dalteparin	B-Drug
,	O
the	O
patient	O
developed	O
acute	B-ADR
respiratory	I-ADR
distress	I-ADR
attributable	O
to	O
a	O
massive	O
right	O
hemothorax	O
confirmed	O
by	O
computed	O
tomography	O
pulmonary	O
angiography	O
(	O
ctpa	O
)	O
and	O
intercostal	O
drainage	O
of	O
1500	O
ml	O
of	O
frank	O
blood	O
0	O
<EOS>	O
spontaneous	B-ADR
hemothorax	I-ADR
following	O
anticoagulation	O
with	O
low-molecular-weight	O
heparin	B-Drug
0	O
<EOS>	O
acute	B-ADR
ocular	I-ADR
ischemic	I-ADR
change	I-ADR
may	O
be	O
associated	O
with	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
in	O
patient	O
with	O
vascular	O
compromised	O
diabetic	O
retinopathy	O
and	O
/	O
or	O
underlying	O
stenosis	O
of	O
the	O
carotid	O
artery	O
0	O
<EOS>	O
acute	B-ADR
vision	I-ADR
loss	I-ADR
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
(	O
avastin	B-Drug
)	O
associated	O
with	O
ocular	O
ischemic	O
syndrome	O
0	O
<EOS>	O
acute	B-ADR
vision	I-ADR
loss	I-ADR
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
avastin	O
)	O
associated	O
with	O
ocular	O
ischemic	O
syndrome	O
0	O
<EOS>	O
acute	O
vision	O
loss	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
(	O
avastin	B-Drug
)	O
associated	O
with	O
ocular	B-ADR
ischemic	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
acute	O
vision	O
loss	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
avastin	O
)	O
associated	O
with	O
ocular	B-ADR
ischemic	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
aim	O
:	O
to	O
report	O
a	O
patient	O
with	O
diabetic	O
rubeosis	O
who	O
suffered	O
from	O
acute	B-ADR
retinal	I-ADR
ischemic	I-ADR
change	I-ADR
and	O
stroke	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
0	O
<EOS>	O
aim	O
:	O
to	O
report	O
a	O
patient	O
with	O
diabetic	O
rubeosis	O
who	O
suffered	O
from	O
acute	O
retinal	O
ischemic	O
change	O
and	O
stroke	B-ADR
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
patient	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
should	O
be	O
evaluated	O
for	O
potential	O
systemic	O
risk	O
factor	O
such	O
a	O
carotid	B-ADR
insufficiency	I-ADR
,	O
coagulopathy	O
and	O
poorly	O
controlled	O
diabetes	O
mellitus	O
0	O
<EOS>	O
conclusion	O
:	O
patient	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
should	O
be	O
evaluated	O
for	O
potential	O
systemic	O
risk	O
factor	O
such	O
a	O
carotid	O
insufficiency	O
,	O
coagulopathy	B-ADR
and	O
poorly	O
controlled	O
diabetes	O
mellitus	O
0	O
<EOS>	O
conclusion	O
:	O
patient	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
should	O
be	O
evaluated	O
for	O
potential	O
systemic	O
risk	O
factor	O
such	O
a	O
carotid	O
insufficiency	O
,	O
coagulopathy	O
and	O
poorly	B-ADR
controlled	I-ADR
diabetes	I-ADR
mellitus	I-ADR
0	O
<EOS>	O
three	O
day	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
,	O
acute	B-ADR
ocular	I-ADR
ischemic	I-ADR
syndrome	I-ADR
occurred	O
0	O
<EOS>	O
three	O
day	O
after	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
1.25	O
mg	O
in	O
0.1	O
ml	O
)	O
,	O
he	O
developed	O
acute	B-ADR
vision	I-ADR
loss	I-ADR
and	O
change	O
of	O
consciousness	O
0	O
<EOS>	O
three	O
day	O
after	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
1.25	O
mg	O
in	O
0.1	O
ml	O
)	O
,	O
he	O
developed	O
acute	O
vision	O
loss	O
and	O
change	B-ADR
of	I-ADR
consciousness	I-ADR
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	O
,	O
prednisone	O
,	O
vincristine	O
,	O
cyclophosphamide	B-Drug
,	O
doxorubicin	O
,	O
and	O
rituximab	O
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	O
,	O
prednisone	O
,	O
vincristine	O
,	O
cyclophosphamide	O
,	O
doxorubicin	B-Drug
,	O
and	O
rituximab	O
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	B-Drug
,	O
prednisone	O
,	O
vincristine	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
rituximab	O
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	O
,	O
prednisone	B-Drug
,	O
vincristine	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
rituximab	O
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	O
,	O
prednisone	O
,	O
vincristine	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
rituximab	B-Drug
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
herein	O
,	O
we	O
describe	O
a	O
patient	O
with	O
aid	O
who	O
presented	O
to	O
medical	O
attention	O
with	O
pancytopenia	B-ADR
48	O
month	O
postchemotherapy	O
with	O
etoposide	O
,	O
prednisone	O
,	O
vincristine	B-Drug
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
rituximab	O
(	O
r-epoch	O
)	O
for	O
diffuse	O
large	O
b-cell	O
lymphoma	O
0	O
<EOS>	O
favorable	O
outcome	O
of	O
de	O
novo	O
hepatitis	B-ADR
b	I-ADR
infection	I-ADR
after	O
liver	O
transplantation	O
with	O
lamivudine	O
and	O
adefovir	B-Drug
therapy	O
0	O
<EOS>	O
favorable	O
outcome	O
of	O
de	O
novo	O
hepatitis	B-ADR
b	I-ADR
infection	I-ADR
after	O
liver	O
transplantation	O
with	O
lamivudine	B-Drug
and	O
adefovir	O
therapy	O
0	O
<EOS>	O
linezolid-associated	B-Drug
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
and	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	O
)	O
syndrome	O
0	O
<EOS>	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
and	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	B-ADR
)	O
syndrome	O
0	O
<EOS>	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
and	O
drug	B-ADR
rash	I-ADR
with	I-ADR
eosinophilia	I-ADR
and	I-ADR
systemic	I-ADR
symptom	I-ADR
(	O
dress	O
)	O
syndrome	O
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pruritus	O
,	O
macular	O
rash	O
,	O
facial	O
edema	O
,	O
eosinophilia	B-ADR
,	O
marked	O
increase	O
in	O
serum	O
creatinine	O
level	O
,	O
and	O
mild	O
hepatitis	O
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pruritus	O
,	O
macular	O
rash	O
,	O
facial	B-ADR
edema	I-ADR
,	O
eosinophilia	O
,	O
marked	O
increase	O
in	O
serum	O
creatinine	O
level	O
,	O
and	O
mild	O
hepatitis	O
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pruritus	O
,	O
macular	B-ADR
rash	I-ADR
,	O
facial	O
edema	O
,	O
eosinophilia	O
,	O
marked	O
increase	O
in	O
serum	O
creatinine	O
level	O
,	O
and	O
mild	O
hepatitis	O
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pruritus	O
,	O
macular	O
rash	O
,	O
facial	O
edema	O
,	O
eosinophilia	O
,	O
marked	B-ADR
increase	I-ADR
in	I-ADR
serum	I-ADR
creatinine	I-ADR
level	I-ADR
,	O
and	O
mild	O
hepatitis	O
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pruritus	O
,	O
macular	O
rash	O
,	O
facial	O
edema	O
,	O
eosinophilia	O
,	O
marked	O
increase	O
in	O
serum	O
creatinine	O
level	O
,	O
and	O
mild	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
on	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	B-ADR
pruritus	I-ADR
,	O
macular	O
rash	O
,	O
facial	O
edema	O
,	O
eosinophilia	O
,	O
marked	O
increase	O
in	O
serum	O
creatinine	O
level	O
,	O
and	O
mild	O
hepatitis	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
within	O
the	O
context	O
of	O
a	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	O
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
within	O
the	O
context	O
of	O
a	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	O
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
within	O
the	O
context	O
of	O
a	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	B-ADR
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
within	O
the	O
context	O
of	O
a	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptom	O
(	O
dress	B-ADR
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
within	O
the	O
context	O
of	O
a	O
drug	B-ADR
rash	I-ADR
with	I-ADR
eosinophilia	I-ADR
and	I-ADR
systemic	I-ADR
symptom	I-ADR
(	O
dress	O
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
this	O
case	O
of	O
linezolid-associated	B-Drug
acute	O
interstitial	O
nephritis	O
within	O
the	O
context	O
of	O
a	O
drug	B-ADR
rash	I-ADR
with	I-ADR
eosinophilia	I-ADR
and	I-ADR
systemic	I-ADR
symptom	I-ADR
(	O
dress	O
)	O
syndrome	O
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raise	O
concern	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
0	O
<EOS>	O
increased	O
awareness	O
is	O
needed	O
on	O
the	O
possible	O
occurrence	O
of	O
lpd	B-ADR
resembling	O
gastric	O
cancer	O
in	O
rheumatoid	O
arthritis	O
patient	O
treated	O
with	O
mtx	B-Drug
0	O
<EOS>	O
reversible	O
methotrexate-associated	B-Drug
lymphoproliferative	B-ADR
disorder	I-ADR
resembling	O
advanced	O
gastric	O
cancer	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
she	O
wa	O
diagnosed	O
with	O
epstein-barr	B-ADR
virus-associated	I-ADR
polymorphic	I-ADR
lymphoproliferative	I-ADR
disorder	I-ADR
(	O
lpd	O
)	O
due	O
to	O
immunodeficiency	O
caused	O
by	O
mtx	B-Drug
administration	O
0	O
<EOS>	O
she	O
wa	O
diagnosed	O
with	O
epstein-barr	O
virus-associated	O
polymorphic	O
lymphoproliferative	O
disorder	O
(	O
lpd	O
)	O
due	O
to	O
immunodeficiency	B-ADR
caused	O
by	O
mtx	B-Drug
administration	O
0	O
<EOS>	O
she	O
wa	O
diagnosed	O
with	O
epstein-barr	O
virus-associated	O
polymorphic	O
lymphoproliferative	O
disorder	O
(	O
lpd	B-ADR
)	O
due	O
to	O
immunodeficiency	O
caused	O
by	O
mtx	B-Drug
administration	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
spontaneous	O
remission	O
of	O
mtx-associated	B-Drug
gastric	B-ADR
lpd	I-ADR
after	O
discontinuation	O
of	O
mtx	O
therapy	O
0	O
<EOS>	O
however	O
,	O
he	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
,	O
hyperkalemia	O
,	O
and	O
hyperuricemia	O
30	O
d	O
after	O
receiving	O
the	O
sorafenib	B-Drug
treatment	O
0	O
<EOS>	O
however	O
,	O
he	O
developed	O
acute	O
renal	O
failure	O
,	O
hyperkalemia	B-ADR
,	O
and	O
hyperuricemia	O
30	O
d	O
after	O
receiving	O
the	O
sorafenib	B-Drug
treatment	O
0	O
<EOS>	O
however	O
,	O
he	O
developed	O
acute	O
renal	O
failure	O
,	O
hyperkalemia	O
,	O
and	O
hyperuricemia	B-ADR
30	O
d	O
after	O
receiving	O
the	O
sorafenib	B-Drug
treatment	O
0	O
<EOS>	O
sorafenib	B-Drug
induced	O
tumor	B-ADR
lysis	I-ADR
syndrome	I-ADR
in	O
an	O
advanced	O
hepatocellular	O
carcinoma	O
patient	O
0	O
<EOS>	O
are	O
nasal	O
decongestant	O
safer	O
than	O
rhinitis	O
?	O
a	O
case	O
of	O
oxymetazoline-induced	B-Drug
syncope	B-ADR
0	O
<EOS>	O
we	O
report	O
here	O
a	O
case	O
of	O
cardiovascular	O
and	O
neurological	B-ADR
depression	I-ADR
induced	O
by	O
oxymetalzoline	B-Drug
in	O
a	O
toddler	O
0	O
<EOS>	O
given	O
that	O
discontinuation	O
of	O
nitrofurantoin	B-Drug
and	O
introduction	O
of	O
methylprednisolon	O
therapy	O
significantly	O
lowered	O
liver	O
enzyme	O
level	O
,	O
restoring	O
most	O
of	O
them	O
to	O
normal	O
,	O
we	O
concluded	O
that	O
this	O
wa	O
probably	O
the	O
case	O
of	O
toxic	B-ADR
liver	I-ADR
damage	I-ADR
caused	O
by	O
nitrofurantoin	O
0	O
<EOS>	O
nitrofurantoin-induced	B-Drug
acute	B-ADR
liver	I-ADR
damage	I-ADR
in	O
pregnancy	O
0	O
<EOS>	O
a	O
40-year-old	O
man	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
m	O
)	O
developed	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
(	O
pcnsl	B-ADR
)	O
after	O
having	O
received	O
21	O
dos	O
of	O
natalizumab	B-Drug
monotherapy	O
0	O
<EOS>	O
a	O
40-year-old	O
man	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
m	O
)	O
developed	O
primary	B-ADR
central	I-ADR
nervous	I-ADR
system	I-ADR
lymphoma	I-ADR
(	O
pcnsl	O
)	O
after	O
having	O
received	O
21	O
dos	O
of	O
natalizumab	B-Drug
monotherapy	O
0	O
<EOS>	O
primary	B-ADR
central	I-ADR
nervous	I-ADR
system	I-ADR
lymphoma	I-ADR
in	O
a	O
patient	O
treated	O
with	O
natalizumab	B-Drug
0	O
<EOS>	O
the	O
first	O
patient	O
is	O
undergoing	O
hemodialysis	O
and	O
,	O
though	O
responding	O
to	O
sunitinib	B-Drug
,	O
is	O
having	O
significant	O
fatigue	B-ADR
and	O
hypertension	O
0	O
<EOS>	O
the	O
first	O
patient	O
is	O
undergoing	O
hemodialysis	O
and	O
,	O
though	O
responding	O
to	O
sunitinib	B-Drug
,	O
is	O
having	O
significant	O
fatigue	O
and	O
hypertension	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
severe	B-ADR
apnea	I-ADR
in	O
an	O
infant	O
exposed	O
to	O
lamotrigine	B-Drug
through	O
breast-feeding	O
0	O
<EOS>	O
severe	B-ADR
apnea	I-ADR
in	O
an	O
infant	O
exposed	O
to	O
lamotrigine	B-Drug
in	O
breast	O
milk	O
0	O
<EOS>	O
the	O
naranjo	O
probability	O
scale	O
indicated	O
a	O
probable	O
relationship	O
between	O
apnea	B-ADR
and	O
exposure	O
to	O
lamotrigine	B-Drug
through	O
breast-feeding	O
in	O
this	O
infant	O
0	O
<EOS>	O
although	O
there	O
have	O
been	O
numerous	O
report	O
of	O
effusion	O
,	O
none	O
have	O
provided	O
complete	O
pleural	O
fluid	O
analysis	O
;	O
therefore	O
,	O
we	O
report	O
2	O
patient	O
with	O
dasatinib-induced	B-Drug
pleural	B-ADR
effusion	I-ADR
with	O
complete	O
pleural	O
fluid	O
analysis	O
0	O
<EOS>	O
dasatinib-induced	B-Drug
pleural	B-ADR
effusion	I-ADR
:	O
a	O
lymphatic	O
network	O
disorder	O
?	O
<EOS>	O
result	O
:	O
one	O
case	O
of	O
recurrent	O
primary	O
peritoneal	O
carcinoma	O
previously	O
treated	O
with	O
a	O
carboplatin-based	B-Drug
regimen	O
,	O
developed	O
a	O
platinum	B-ADR
hypersensitivity	I-ADR
0	O
<EOS>	O
one	O
week	O
after	O
the	O
initial-dose	O
of	O
adalimumab	B-Drug
(	O
160	O
mg	O
)	O
,	O
which	O
wa	O
initiated	O
due	O
to	O
an	O
acute	O
exacerbation	O
of	O
crohn	O
disease	O
,	O
the	O
patient	O
developed	O
a	O
fulminant	B-ADR
cardiomyopathy	I-ADR
0	O
<EOS>	O
severe	B-ADR
cardiomyopathy	I-ADR
following	O
treatment	O
with	O
the	O
tumour	O
necrosis	O
factor-alpha	O
inhibitor	O
adalimumab	B-Drug
for	O
crohn	O
disease	O
0	O
<EOS>	O
amikacin-induced	B-Drug
type	O
5	O
bartter-like	O
syndrome	O
with	O
severe	B-ADR
hypocalcemia	I-ADR
0	O
<EOS>	O
amikacin-induced	B-Drug
type	B-ADR
5	I-ADR
bartter-like	I-ADR
syndrome	I-ADR
with	O
severe	O
hypocalcemia	O
0	O
<EOS>	O
recovery	O
of	O
the	O
tubular	B-ADR
dysfunction	I-ADR
took	O
15	O
day	O
following	O
cessation	O
of	O
the	O
offending	O
drug	O
,	O
amikacin	B-Drug
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	O
renal	O
tubular	O
dysfunction	O
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	O
hypokalemia	O
,	O
hypocalcemia	B-ADR
,	O
hypomagnesemia	O
,	O
metabolic	O
alkalosis	O
,	O
and	O
polyuria	O
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	O
renal	O
tubular	O
dysfunction	O
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	O
hypokalemia	O
,	O
hypocalcemia	O
,	O
hypomagnesemia	B-ADR
,	O
metabolic	O
alkalosis	O
,	O
and	O
polyuria	O
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	O
renal	O
tubular	O
dysfunction	O
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	O
hypokalemia	O
,	O
hypocalcemia	O
,	O
hypomagnesemia	O
,	O
metabolic	B-ADR
alkalosis	I-ADR
,	O
and	O
polyuria	O
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	O
renal	O
tubular	O
dysfunction	O
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	O
hypokalemia	O
,	O
hypocalcemia	O
,	O
hypomagnesemia	O
,	O
metabolic	O
alkalosis	O
,	O
and	O
polyuria	B-ADR
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	O
renal	O
tubular	O
dysfunction	O
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	B-ADR
hypokalemia	I-ADR
,	O
hypocalcemia	O
,	O
hypomagnesemia	O
,	O
metabolic	O
alkalosis	O
,	O
and	O
polyuria	O
0	O
<EOS>	O
we	O
discus	O
a	O
patient	O
who	O
developed	O
severe	B-ADR
renal	I-ADR
tubular	I-ADR
dysfunction	I-ADR
secondary	O
to	O
short-term	O
therapy	O
with	O
amikacin	B-Drug
,	O
resulting	O
in	O
refractory	O
hypokalemia	O
,	O
hypocalcemia	O
,	O
hypomagnesemia	O
,	O
metabolic	O
alkalosis	O
,	O
and	O
polyuria	O
0	O
<EOS>	O
postoperatively	O
,	O
the	O
first	O
two	O
patient	O
treated	O
with	O
1	O
to	O
2	O
cc	O
of	O
thrombin	B-Drug
were	O
slow	O
to	O
awaken	O
;	O
one	O
had	O
evidence	O
of	O
vasospasm	O
by	O
transcranial	O
doppler	O
ultrasound	O
study	O
and	O
multiple	B-ADR
infarct	I-ADR
on	O
cranial	O
computerized	O
tomography	O
,	O
while	O
the	O
other	O
had	O
a	O
moderate-sized	O
frontal	O
hematoma	O
with	O
intracranial	O
hypertension	O
0	O
<EOS>	O
postoperatively	O
,	O
the	O
first	O
two	O
patient	O
treated	O
with	O
1	O
to	O
2	O
cc	O
of	O
thrombin	B-Drug
were	O
slow	B-ADR
to	I-ADR
awaken	I-ADR
;	O
one	O
had	O
evidence	O
of	O
vasospasm	O
by	O
transcranial	O
doppler	O
ultrasound	O
study	O
and	O
multiple	O
infarct	O
on	O
cranial	O
computerized	O
tomography	O
,	O
while	O
the	O
other	O
had	O
a	O
moderate-sized	O
frontal	O
hematoma	O
with	O
intracranial	O
hypertension	O
0	O
<EOS>	O
postoperatively	O
,	O
the	O
first	O
two	O
patient	O
treated	O
with	O
1	O
to	O
2	O
cc	O
of	O
thrombin	B-Drug
were	O
slow	O
to	O
awaken	O
;	O
one	O
had	O
evidence	O
of	O
vasospasm	B-ADR
by	O
transcranial	O
doppler	O
ultrasound	O
study	O
and	O
multiple	O
infarct	O
on	O
cranial	O
computerized	O
tomography	O
,	O
while	O
the	O
other	O
had	O
a	O
moderate-sized	O
frontal	O
hematoma	O
with	O
intracranial	O
hypertension	O
0	O
<EOS>	O
thrombin	B-Drug
is	O
highly	O
effective	O
for	O
stopping	O
intractable	O
arterial	O
hemorrhage	O
during	O
stereotactic	O
brain	O
biopsy	O
;	O
however	O
,	O
it	O
is	O
a	O
vasospastic	O
agent	O
and	O
may	O
have	O
been	O
responsible	O
for	O
the	O
cerebral	B-ADR
infarction	I-ADR
in	O
one	O
patient	O
0	O
<EOS>	O
ciprofloxacin-induced	B-Drug
hemorrhagic	B-ADR
vasculitis	I-ADR
0	O
<EOS>	O
ciprofloxacin-induced	B-Drug
hemorrhagic	B-ADR
vasculitis	I-ADR
is	O
a	O
rare	O
side	O
effect	O
0	O
<EOS>	O
ciprofloxacin	O
is	O
among	O
the	O
standard	O
treatment	O
for	O
infected	O
ischemic	O
ulcer	O
;	O
in	O
the	O
rare	O
case	O
of	O
ciprofloxacin-induced	B-Drug
hemorrhagic	B-ADR
vasculitis	I-ADR
,	O
it	O
might	O
be	O
interpreted	O
a	O
progression	O
of	O
infection	O
,	O
instead	O
of	O
a	O
complication	O
of	O
the	O
treatment	O
,	O
thus	O
leading	O
to	O
faulty	O
diagnosis	O
and	O
treatment	O
0	O
<EOS>	O
in	O
one	O
patient	O
the	O
vasculitis	O
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	O
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin-induced	B-Drug
hemorrhagic	O
vasculitis	O
wa	O
superimposed	O
on	O
a	O
severe	O
forefoot	O
infection	O
,	O
leading	O
to	O
progressive	O
gangrene	O
and	O
a	O
below-knee	B-ADR
amputation	I-ADR
0	O
<EOS>	O
in	O
one	O
patient	O
the	O
vasculitis	O
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	O
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin-induced	B-Drug
hemorrhagic	B-ADR
vasculitis	I-ADR
wa	O
superimposed	O
on	O
a	O
severe	O
forefoot	O
infection	O
,	O
leading	O
to	O
progressive	O
gangrene	O
and	O
a	O
below-knee	O
amputation	O
0	O
<EOS>	O
in	O
one	O
patient	O
the	O
vasculitis	O
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	O
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin-induced	B-Drug
hemorrhagic	O
vasculitis	O
wa	O
superimposed	O
on	O
a	O
severe	O
forefoot	O
infection	O
,	O
leading	O
to	O
progressive	B-ADR
gangrene	I-ADR
and	O
a	O
below-knee	O
amputation	O
0	O
<EOS>	O
in	O
one	O
patient	O
the	O
vasculitis	O
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	O
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin-induced	B-Drug
hemorrhagic	O
vasculitis	O
wa	O
superimposed	O
on	O
a	O
severe	B-ADR
forefoot	I-ADR
infection	I-ADR
,	O
leading	O
to	O
progressive	O
gangrene	O
and	O
a	O
below-knee	O
amputation	O
0	O
<EOS>	O
in	O
one	O
patient	O
the	O
vasculitis	B-ADR
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	O
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin-induced	B-Drug
hemorrhagic	O
vasculitis	O
wa	O
superimposed	O
on	O
a	O
severe	O
forefoot	O
infection	O
,	O
leading	O
to	O
progressive	O
gangrene	O
and	O
a	O
below-knee	O
amputation	O
0	O
<EOS>	O
however	O
,	O
a	O
recent	O
post-marketing	O
survey	O
in	O
japan	O
revealed	O
that	O
interstitial	B-ADR
pneumonia	I-ADR
occurred	O
in	O
4	O
among	O
approximately	O
2	O
0	O
japanese	O
patient	O
treated	O
with	O
sorafenib	B-Drug
0	O
<EOS>	O
interstitial	B-ADR
pneumonia	I-ADR
probably	O
associated	O
with	O
sorafenib	B-Drug
treatment	O
:	O
an	O
alert	O
of	O
an	O
adverse	O
event	O
0	O
<EOS>	O
in	O
this	O
article	O
,	O
we	O
describe	O
a	O
japanese	O
patient	O
with	O
severe	B-ADR
interstitial	I-ADR
pneumonia	I-ADR
probably	O
caused	O
by	O
sorafenib	B-Drug
treatment	O
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
0	O
<EOS>	O
oncologist	O
supervising	O
future	O
clinical	O
trial	O
for	O
lung	O
cancer	O
should	O
be	O
alert	O
to	O
the	O
fact	O
that	O
sorafenib	B-Drug
can	O
potentially	O
induce	O
serious	O
interstitial	B-ADR
lung	I-ADR
disease	I-ADR
,	O
although	O
this	O
might	O
depend	O
on	O
racial	O
difference	O
0	O
<EOS>	O
fatal	O
gemcitabine-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
in	O
metastatic	O
gallbladder	O
adenocarcinoma	O
0	O
<EOS>	O
gemcitabine-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
is	O
usually	O
a	O
dramatic	O
condition	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
we	O
describe	O
a	O
fatal	O
gemcitabine-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
in	O
a	O
patient	O
with	O
gallbladder	O
metastatic	O
adenocarcinoma	O
0	O
<EOS>	O
he	O
had	O
hypokalemia	B-ADR
(	O
k	O
2.3	O
mmol	O
/	O
l	O
)	O
induced	O
by	O
licorice	B-Drug
and	O
also	O
had	O
received	O
disopyramide	O
for	O
arrhythmia	O
,	O
bicalutamide	O
for	O
prostate	O
cancer	O
,	O
and	O
silodosin	O
for	O
prostate	O
hypertrophy	O
0	O
<EOS>	O
therefore	O
,	O
although	O
garenoxacin	B-Drug
reportedly	O
cause	O
fewer	O
adverse	O
reaction	O
for	O
cardiac	B-ADR
rhythm	I-ADR
than	O
third-generation	O
quinolone	O
antibiotic	O
,	O
one	O
must	O
be	O
cautious	O
of	O
the	O
interference	O
of	O
other	O
drug	O
during	O
hypokalemia	O
in	O
order	O
to	O
prevent	O
tdp	O
0	O
<EOS>	O
therefore	O
,	O
although	O
garenoxacin	B-Drug
reportedly	O
cause	O
fewer	O
adverse	O
reaction	O
for	O
cardiac	O
rhythm	O
than	O
third-generation	O
quinolone	O
antibiotic	O
,	O
one	O
must	O
be	O
cautious	O
of	O
the	O
interference	O
of	O
other	O
drug	O
during	O
hypokalemia	B-ADR
in	O
order	O
to	O
prevent	O
tdp	O
0	O
<EOS>	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
induced	O
by	O
a	O
combination	O
of	O
garenoxacin	O
and	O
disopyramide	B-Drug
and	O
other	O
cytochrome	O
p450	O
,	O
family	O
3	O
,	O
subfamily	O
a	O
polypeptide-4-influencing	O
drug	O
during	O
hypokalemia	O
due	O
to	O
licorice	O
0	O
<EOS>	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
induced	O
by	O
a	O
combination	O
of	O
garenoxacin	B-Drug
and	O
disopyramide	O
and	O
other	O
cytochrome	O
p450	O
,	O
family	O
3	O
,	O
subfamily	O
a	O
polypeptide-4-influencing	O
drug	O
during	O
hypokalemia	O
due	O
to	O
licorice	O
0	O
<EOS>	O
we	O
report	O
an	O
82-year-old	O
man	O
who	O
developed	O
ventricular	O
tachycardia	O
and	O
torsades	O
de	O
pointes	O
(	O
tdp	B-ADR
)	O
after	O
oral	O
administration	O
of	O
garenoxacin	B-Drug
,	O
a	O
novel	O
quinolone	O
antibiotic	O
agent	O
that	O
differs	O
from	O
the	O
third-generation	O
quinolones	O
,	O
for	O
pneumonia	O
0	O
<EOS>	O
we	O
report	O
an	O
82-year-old	O
man	O
who	O
developed	O
ventricular	O
tachycardia	O
and	O
torsades	B-ADR
de	I-ADR
pointes	I-ADR
(	O
tdp	O
)	O
after	O
oral	O
administration	O
of	O
garenoxacin	B-Drug
,	O
a	O
novel	O
quinolone	O
antibiotic	O
agent	O
that	O
differs	O
from	O
the	O
third-generation	O
quinolones	O
,	O
for	O
pneumonia	O
0	O
<EOS>	O
we	O
report	O
an	O
82-year-old	O
man	O
who	O
developed	O
ventricular	B-ADR
tachycardia	I-ADR
and	O
torsades	O
de	O
pointes	O
(	O
tdp	O
)	O
after	O
oral	O
administration	O
of	O
garenoxacin	B-Drug
,	O
a	O
novel	O
quinolone	O
antibiotic	O
agent	O
that	O
differs	O
from	O
the	O
third-generation	O
quinolones	O
,	O
for	O
pneumonia	O
0	O
<EOS>	O
of	O
371	O
patient	O
treated	O
with	O
8mop	B-Drug
,	O
three	O
(	O
0.8	O
%	O
)	O
developed	O
an	O
acute	B-ADR
dermatitis	I-ADR
in	O
the	O
puva-treated	O
area	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
after	O
high-dose	O
methylprednisolone	B-Drug
for	O
demyelinating	O
disease	O
0	O
<EOS>	O
we	O
observed	O
2	O
case	O
of	O
hepatotoxicity	B-ADR
after	O
a	O
high-dose	O
methylprednisolone	B-Drug
treatment	O
of	O
a	O
demyelinating	O
disease	O
and	O
evaluated	O
the	O
potential	O
relationship	O
in	O
the	O
light	O
of	O
available	O
evidence	O
0	O
<EOS>	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
following	O
administration	O
of	O
calcium	B-Drug
polystryrene	I-Drug
sulfonate	I-Drug
(	O
kalimate	O
)	O
in	O
a	O
uremic	O
patient	O
0	O
<EOS>	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
following	O
administration	O
of	O
calcium	O
polystryrene	O
sulfonate	O
(	O
kalimate	B-Drug
)	O
in	O
a	O
uremic	O
patient	O
0	O
<EOS>	O
colonic	B-ADR
necrosis	I-ADR
is	O
known	O
a	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
kayexalate	B-Drug
(	O
sodium	O
polystryrene	O
sulfonate	O
)	O
in	O
sorbitol	O
0	O
<EOS>	O
colonic	B-ADR
necrosis	I-ADR
is	O
known	O
a	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
kayexalate	O
(	O
sodium	B-Drug
polystryrene	I-Drug
sulfonate	I-Drug
)	O
in	O
sorbitol	O
0	O
<EOS>	O
two	O
day	O
after	O
administration	O
of	O
kalimate	B-Drug
enema	O
,	O
he	O
had	O
profuse	O
hematochezia	O
,	O
and	O
a	O
sigmoidoscopy	O
showed	O
diffuse	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
in	I-ADR
the	I-ADR
rectum	I-ADR
and	O
sigmoid	O
colon	O
0	O
<EOS>	O
two	O
day	O
after	O
administration	O
of	O
kalimate	B-Drug
enema	O
,	O
he	O
had	O
profuse	B-ADR
hematochezia	I-ADR
,	O
and	O
a	O
sigmoidoscopy	O
showed	O
diffuse	O
colonic	O
mucosal	O
necrosis	O
in	O
the	O
rectum	O
and	O
sigmoid	O
colon	O
0	O
<EOS>	O
we	O
report	O
a	O
rare	O
case	O
of	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
following	O
kalimate	O
(	O
calcium	B-Drug
polystryrene	I-Drug
sulfonate	I-Drug
)	O
,	O
an	O
analogue	O
of	O
kayexalate	O
without	O
sorbitol	O
in	O
a	O
34-yr-old	O
man	O
0	O
<EOS>	O
we	O
report	O
a	O
rare	O
case	O
of	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
following	O
kalimate	B-Drug
(	O
calcium	O
polystryrene	O
sulfonate	O
)	O
,	O
an	O
analogue	O
of	O
kayexalate	O
without	O
sorbitol	O
in	O
a	O
34-yr-old	O
man	O
0	O
<EOS>	O
we	O
report	O
a	O
rare	O
case	O
of	O
colonic	B-ADR
mucosal	I-ADR
necrosis	I-ADR
following	O
kalimate	O
(	O
calcium	O
polystryrene	O
sulfonate	O
)	O
,	O
an	O
analogue	O
of	O
kayexalate	B-Drug
without	O
sorbitol	O
in	O
a	O
34-yr-old	O
man	O
0	O
<EOS>	O
clozapine-induced	B-Drug
tardive	B-ADR
dyskinesia	I-ADR
in	O
schizophrenic	O
patient	O
taking	O
clozapine	O
a	O
a	O
first-line	O
antipsychotic	O
drug	O
0	O
<EOS>	O
conclusion	O
:	O
these	O
result	O
suggest	O
that	O
clozapine	B-Drug
may	O
cause	O
td	O
;	O
however	O
,	O
the	O
prevalence	O
is	O
low	O
and	O
the	O
severity	O
is	O
relatively	O
mild	O
,	O
with	O
no	O
or	O
mild	O
self-reported	O
discomfort	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
these	O
result	O
suggest	O
that	O
clozapine	B-Drug
may	O
cause	O
td	B-ADR
;	O
however	O
,	O
the	O
prevalence	O
is	O
low	O
and	O
the	O
severity	O
is	O
relatively	O
mild	O
,	O
with	O
no	O
or	O
mild	O
self-reported	O
discomfort	O
0	O
<EOS>	O
however	O
,	O
several	O
case	O
report	O
have	O
suggested	O
that	O
clozapine	B-Drug
could	O
also	O
cause	O
td	B-ADR
0	O
<EOS>	O
objective	O
:	O
clozapine	B-Drug
cause	O
few	O
extrapyramidal	B-ADR
symptom	I-ADR
and	O
is	O
recommended	O
a	O
a	O
treatment	O
drug	O
for	O
severe	O
tardive	O
dyskinesia	O
(	O
td	O
)	O
0	O
<EOS>	O
all-trans	B-Drug
retinoic	I-Drug
acid-induced	I-Drug
focal	B-ADR
myositis	I-ADR
,	O
synovitis	O
,	O
and	O
mononeuritis	O
0	O
<EOS>	O
all-trans	B-Drug
retinoic	I-Drug
acid-induced	I-Drug
focal	O
myositis	O
,	O
synovitis	O
,	O
and	O
mononeuritis	B-ADR
0	O
<EOS>	O
all-trans	B-Drug
retinoic	I-Drug
acid-induced	I-Drug
focal	O
myositis	O
,	O
synovitis	B-ADR
,	O
and	O
mononeuritis	O
0	O
<EOS>	O
here	O
we	O
report	O
a	O
patient	O
with	O
newly	O
diagnosed	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
acute	B-ADR
focal	I-ADR
myositis	I-ADR
,	O
synovitis	O
,	O
and	O
possible	O
vasculitis	O
,	O
after	O
receiving	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
here	O
we	O
report	O
a	O
patient	O
with	O
newly	O
diagnosed	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
acute	O
focal	O
myositis	O
,	O
synovitis	O
,	O
and	O
possible	B-ADR
vasculitis	I-ADR
,	O
after	O
receiving	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
here	O
we	O
report	O
a	O
patient	O
with	O
newly	O
diagnosed	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
acute	O
focal	O
myositis	O
,	O
synovitis	B-ADR
,	O
and	O
possible	O
vasculitis	O
,	O
after	O
receiving	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
background	O
:	O
to	O
ass	O
the	O
nature	O
,	O
incidence	O
,	O
and	O
risk	O
factor	O
of	O
retinopathy	B-ADR
associated	O
with	O
pegylated	B-Drug
interferon	I-Drug
and	O
ribavirin	O
combination	O
therapy	O
in	O
chronic	O
hepatitis	O
c	O
patient	O
0	O
<EOS>	O
background	O
:	O
to	O
ass	O
the	O
nature	O
,	O
incidence	O
,	O
and	O
risk	O
factor	O
of	O
retinopathy	B-ADR
associated	O
with	O
pegylated	O
interferon	O
and	O
ribavirin	B-Drug
combination	O
therapy	O
in	O
chronic	O
hepatitis	O
c	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
significant	O
ocular	O
complication	O
such	O
a	O
an	O
irreversible	B-ADR
decrease	I-ADR
of	I-ADR
visual	I-ADR
acuity	I-ADR
may	O
develop	O
in	O
patient	O
treated	O
with	O
pegylated	B-Drug
interferon	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
significant	O
ocular	B-ADR
complication	I-ADR
such	O
a	O
an	O
irreversible	O
decrease	O
of	O
visual	O
acuity	O
may	O
develop	O
in	O
patient	O
treated	O
with	O
pegylated	B-Drug
interferon	I-Drug
0	O
<EOS>	O
retinopathy	B-ADR
in	O
hepatitis	O
c	O
patient	O
due	O
to	O
combination	O
therapy	O
with	O
pegylated	B-Drug
interferon	I-Drug
and	O
ribavirin	O
0	O
<EOS>	O
retinopathy	B-ADR
in	O
hepatitis	O
c	O
patient	O
due	O
to	O
combination	O
therapy	O
with	O
pegylated	O
interferon	O
and	O
ribavirin	B-Drug
0	O
<EOS>	O
administration	O
of	O
cisplatin	O
in	O
three	O
patient	O
with	O
carboplatin	B-Drug
hypersensitivity	B-ADR
:	O
is	O
skin	O
testing	O
useful	O
?	O
<EOS>	O
hypersensitivity	B-ADR
to	O
carboplatin	B-Drug
ha	O
been	O
reported	O
in	O
up	O
to	O
44	O
%	O
of	O
patient	O
receiving	O
this	O
antineoplastic	O
agent	O
,	O
usually	O
occurring	O
after	O
several	O
course	O
of	O
treatment	O
0	O
<EOS>	O
prick	O
test	O
and	O
intradermal	O
test	O
with	O
a	O
series	O
of	O
dilution	O
of	O
carboplatin	B-Drug
and	O
cisplatin	O
were	O
performed	O
on	O
three	O
patient	O
who	O
had	O
exhibited	O
medium	O
and	O
severe	B-ADR
hypersensitivity	I-ADR
reaction	O
to	O
carboplatin	O
0	O
<EOS>	O
aseptic	B-ADR
meningitis	I-ADR
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	B-ADR
meningitis	I-ADR
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
and	O
orthostatic	O
hypotension	O
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	B-ADR
hypotension	I-ADR
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	B-ADR
hypotension	I-ADR
in	O
a	O
patient	O
treated	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	B-ADR
meningitis	I-ADR
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	B-ADR
meningitis	I-ADR
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
orthostatic	O
hypotension	O
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
orthostatic	B-ADR
hypotension	I-ADR
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
a	O
37-year-old	O
african-	O
american	O
man	O
with	O
g6pd	O
deficiency	O
developed	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
orthostatic	B-ADR
hypotension	I-ADR
,	O
and	O
aseptic	O
meningitis	O
simultaneously	O
after	O
using	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	B-ADR
with	I-ADR
speech	I-ADR
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	B-ADR
with	I-ADR
speech	I-ADR
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	B-ADR
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	B-ADR
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	B-ADR
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	B-ADR
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	B-ADR
on	I-ADR
the	I-ADR
trunk	I-ADR
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	B-ADR
on	I-ADR
the	I-ADR
trunk	I-ADR
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	B-ADR
rash	I-ADR
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	O
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	B-ADR
rash	I-ADR
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	B-ADR
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
he	O
had	O
been	O
taking	O
trimethoprim-sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
day	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headache	O
,	O
dizziness	O
,	O
difficulty	O
with	O
speech	O
,	O
weakness	B-ADR
,	O
and	O
itching	O
on	O
the	O
trunk	O
of	O
his	O
body	O
and	O
leg	O
,	O
where	O
a	O
maculopapular	O
rash	O
wa	O
noted	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	B-ADR
meningitis	I-ADR
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	B-ADR
meningitis	I-ADR
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	B-ADR
anemia	I-ADR
,	O
hepatitis	O
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	B-ADR
,	O
and	O
orthostatic	O
hypotension	O
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	B-ADR
hypotension	I-ADR
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
purpose	O
:	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	O
meningitis	O
,	O
hemolytic	O
anemia	O
,	O
hepatitis	O
,	O
and	O
orthostatic	B-ADR
hypotension	I-ADR
simultaneously	O
during	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Drug
is	O
described	O
0	O
<EOS>	O
a	O
patient	O
,	O
while	O
on	O
intravenous	O
ritodrine	B-Drug
therapy	O
for	O
preterm	O
labor	O
,	O
experienced	O
an	O
episode	O
of	O
acute	B-ADR
chest	I-ADR
pain	I-ADR
0	O
<EOS>	O
the	O
electrocardiogram	O
(	O
ecg	O
)	O
,	O
which	O
wa	O
read	O
a	O
normal	O
prior	O
to	O
ritodrine	B-Drug
infusion	O
,	O
demonstrated	O
a	O
type	B-ADR
i	I-ADR
second-degree	I-ADR
av	I-ADR
block	I-ADR
which	O
disappeared	O
upon	O
discontinuation	O
of	O
ritodrine	O
therapy	O
0	O
<EOS>	O
the	O
electrocardiogram	O
(	O
ecg	O
)	O
,	O
which	O
wa	O
read	O
a	O
normal	O
prior	O
to	O
ritodrine	B-Drug
infusion	O
,	O
demonstrated	O
a	O
type	B-ADR
i	I-ADR
second-degree	I-ADR
av	I-ADR
block	I-ADR
which	O
disappeared	O
upon	O
discontinuation	O
of	O
ritodrine	O
therapy	O
0	O
<EOS>	O
type	O
i	O
second-degree	O
av	O
block	O
(	O
mobitz	B-ADR
type	I-ADR
i	I-ADR
,	O
wenckebach	O
av	O
block	O
)	O
during	O
ritodrine	B-Drug
therapy	O
for	O
preterm	O
labor	O
0	O
<EOS>	O
type	B-ADR
i	I-ADR
second-degree	I-ADR
av	I-ADR
block	I-ADR
(	O
mobitz	O
type	O
i	O
,	O
wenckebach	O
av	O
block	O
)	O
during	O
ritodrine	B-Drug
therapy	O
for	O
preterm	O
labor	O
0	O
<EOS>	O
type	O
i	O
second-degree	O
av	O
block	O
(	O
mobitz	O
type	O
i	O
,	O
wenckebach	B-ADR
av	I-ADR
block	I-ADR
)	O
during	O
ritodrine	B-Drug
therapy	O
for	O
preterm	O
labor	O
0	O
<EOS>	O
exacerbation	O
of	O
anthracycline-induced	B-Drug
early	B-ADR
chronic	I-ADR
cardiomyopathy	I-ADR
with	O
atra	O
:	O
role	O
of	O
b-type	O
natriuretic	O
peptide	O
a	O
an	O
indicator	O
of	O
cardiac	O
dysfunction	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
14-year-old	O
female	O
with	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
symptomatic	B-ADR
cardiomyopathy	I-ADR
only	O
4	O
month	O
into	O
treatment	O
with	O
a	O
combination	O
of	O
daunomycin	O
and	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
(	O
atra	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
14-year-old	O
female	O
with	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
symptomatic	B-ADR
cardiomyopathy	I-ADR
only	O
4	O
month	O
into	O
treatment	O
with	O
a	O
combination	O
of	O
daunomycin	O
and	O
all-trans	O
retinoic	O
acid	O
(	O
atra	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
14-year-old	O
female	O
with	O
acute	O
promyelocytic	O
leukemia	O
who	O
developed	O
symptomatic	B-ADR
cardiomyopathy	I-ADR
only	O
4	O
month	O
into	O
treatment	O
with	O
a	O
combination	O
of	O
daunomycin	B-Drug
and	O
all-trans	O
retinoic	O
acid	O
(	O
atra	O
)	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
present	O
a	O
case	O
of	O
a	O
patient	O
with	O
cml	O
who	O
developed	O
k	B-ADR
12	O
month	O
after	O
starting	O
treatment	O
with	O
imatinib	B-Drug
400	O
mg	O
/	O
d	O
0	O
<EOS>	O
flare	O
of	O
kaposi	B-ADR
sarcoma	I-ADR
(	O
k	O
)	O
is	O
well	O
described	O
in	O
immunosuppressed	O
patient	O
treated	O
with	O
corticosteroid	O
and	O
rituximab	B-Drug
,	O
but	O
ha	O
not	O
yet	O
been	O
reported	O
during	O
treatment	O
with	O
imatinib	O
0	O
<EOS>	O
flare	O
of	O
kaposi	O
sarcoma	O
(	O
k	B-ADR
)	O
is	O
well	O
described	O
in	O
immunosuppressed	O
patient	O
treated	O
with	O
corticosteroid	O
and	O
rituximab	B-Drug
,	O
but	O
ha	O
not	O
yet	O
been	O
reported	O
during	O
treatment	O
with	O
imatinib	O
0	O
<EOS>	O
kaposi	B-ADR
sarcoma	I-ADR
in	O
a	O
patient	O
treated	O
with	O
imatinib	B-Drug
mesylate	I-Drug
for	O
chronic	O
myeloid	O
leukemia	O
0	O
<EOS>	O
objective	O
:	O
we	O
report	O
a	O
case	O
of	O
cutaneous	B-ADR
k	I-ADR
lesion	I-ADR
in	O
a	O
patient	O
affected	O
by	O
cml	O
treated	O
with	O
imatinib	B-Drug
0	O
<EOS>	O
bulbar	B-ADR
and	O
pseudobulbar	O
palsy	O
complicating	O
therapy	O
with	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
in	O
child	O
with	O
leukemia	O
0	O
<EOS>	O
bulbar	O
and	O
pseudobulbar	B-ADR
palsy	I-ADR
complicating	O
therapy	O
with	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
in	O
child	O
with	O
leukemia	O
0	O
<EOS>	O
interferon-based	B-Drug
treatment	O
have	O
the	O
potential	O
to	O
decrease	O
the	O
burden	O
of	O
disease	O
,	O
but	O
are	O
complicated	O
by	O
side	O
effect	O
,	O
including	O
neuropsychiatric	B-ADR
symptom	I-ADR
0	O
<EOS>	O
interferon-induced	B-Drug
psychosis	B-ADR
a	O
a	O
``	O
psychiatric	O
contraindication	O
'	O
to	O
hepatitis	O
c	O
treatment	O
:	O
a	O
review	O
and	O
case-based	O
discussion	O
0	O
<EOS>	O
method	O
:	O
the	O
author	O
followed	O
a	O
patient	O
with	O
chronic	O
hcv	O
who	O
received	O
interferon	B-Drug
and	O
ribavirin	O
and	O
who	O
developed	O
hallucination	B-ADR
ultimately	O
requiring	O
psychiatric	O
hospitalization	O
0	O
<EOS>	O
method	O
:	O
the	O
author	O
followed	O
a	O
patient	O
with	O
chronic	O
hcv	O
who	O
received	O
interferon	O
and	O
ribavirin	B-Drug
and	O
who	O
developed	O
hallucination	B-ADR
ultimately	O
requiring	O
psychiatric	O
hospitalization	O
0	O
<EOS>	O
objective	O
:	O
the	O
author	O
described	O
a	O
case	O
of	O
interferon-induced	B-Drug
psychosis	B-ADR
a	O
a	O
framework	O
to	O
review	O
the	O
literature	O
and	O
discus	O
the	O
decision	O
to	O
pursue	O
antiviral	O
treatment	O
in	O
psychiatrically	O
ill	O
patient	O
with	O
hepatitis	O
c	O
0	O
<EOS>	O
conclusion	O
:	O
zidovudine	B-Drug
is	O
well	O
a	O
known	O
cause	O
of	O
anaemia	B-ADR
and	O
thus	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
initiation	O
of	O
antiretroviral	O
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
zidovudine	B-Drug
induced	O
anaemia	B-ADR
and	O
bone	O
marrow	O
aplasia	O
in	O
a	O
patient	O
infected	O
with	O
hiv	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
zidovudine	B-Drug
induced	O
anaemia	O
and	O
bone	B-ADR
marrow	I-ADR
aplasia	I-ADR
in	O
a	O
patient	O
infected	O
with	O
hiv	O
0	O
<EOS>	O
zidovudine	B-Drug
induced	O
pure	B-ADR
red	I-ADR
cell	I-ADR
aplasia	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
conclusion	O
:	O
sd-oct	O
and	O
ao	O
detected	O
abnormality	O
that	O
correlate	O
topographically	O
with	O
visual	O
field	O
loss	O
from	O
hydroxychloroquine	B-Drug
toxicity	O
a	O
demonstrated	O
by	O
hvf	O
10-2	O
and	O
may	O
be	O
useful	O
in	O
the	O
detection	O
of	O
subclinical	O
abnormality	O
that	O
precede	O
symptom	O
or	O
objective	B-ADR
visual	I-ADR
field	I-ADR
loss	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
sd-oct	O
and	O
ao	O
detected	O
abnormality	O
that	O
correlate	O
topographically	O
with	O
visual	B-ADR
field	I-ADR
loss	I-ADR
from	O
hydroxychloroquine	B-Drug
toxicity	O
a	O
demonstrated	O
by	O
hvf	O
10-2	O
and	O
may	O
be	O
useful	O
in	O
the	O
detection	O
of	O
subclinical	O
abnormality	O
that	O
precede	O
symptom	O
or	O
objective	O
visual	O
field	O
loss	O
0	O
<EOS>	O
purpose	O
:	O
to	O
describe	O
spectral-domain	O
optical	O
coherence	O
tomography	O
(	O
sd-oct	O
)	O
and	O
adaptive	O
optic	O
(	O
ao	O
)	O
imaging	O
in	O
hydroxychloroquine	B-Drug
retinal	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
spectral-domain	O
optical	O
coherence	O
tomography	O
and	O
adaptive	O
optic	O
may	O
detect	O
hydroxychloroquine	B-Drug
retinal	B-ADR
toxicity	I-ADR
before	O
symptomatic	O
vision	O
loss	O
0	O
<EOS>	O
transient	O
trazodone-induced	B-Drug
hypomanic	B-ADR
symptom	I-ADR
occurred	O
in	O
three	O
depressed	O
patient	O
0	O
<EOS>	O
trazodone-induced	B-Drug
transient	B-ADR
hypomanic	I-ADR
symptom	I-ADR
and	O
their	O
management	O
0	O
<EOS>	O
introduction	O
of	O
etanercept	B-Drug
wa	O
also	O
clinically	O
effective	O
but	O
followed	O
by	O
development	O
of	O
severe	B-ADR
heart	I-ADR
failure	I-ADR
0	O
<EOS>	O
reversible	B-ADR
heart	I-ADR
failure	I-ADR
in	O
a	O
patient	O
receiving	O
etanercept	B-Drug
for	O
ankylosing	O
spondylitis	O
0	O
<EOS>	O
combining	O
methylephedrine	B-Drug
and	O
chinese	O
herbal	O
drug	O
might	O
carry	O
a	O
risk	O
of	O
stroke	B-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
experienced	O
chronic	B-ADR
nausea	I-ADR
and	O
an	O
episode	O
of	O
confusion	O
while	O
treated	O
with	O
a	O
small	O
,	O
stable	O
dose	O
of	O
oral	O
morphine	B-Drug
in	O
the	O
setting	O
of	O
mild	O
renal	O
insufficiency	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
experienced	O
chronic	O
nausea	O
and	O
an	O
episode	O
of	O
confusion	B-ADR
while	O
treated	O
with	O
a	O
small	O
,	O
stable	O
dose	O
of	O
oral	O
morphine	B-Drug
in	O
the	O
setting	O
of	O
mild	O
renal	O
insufficiency	O
0	O
<EOS>	O
common	O
adverse	O
event	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	B-Drug
dos	O
up	O
to	O
600	O
mg	O
/	O
day	O
include	O
nonspecific	O
central	O
nervous	O
system	O
effect	O
(	O
e.g.	O
,	O
dizziness	O
,	O
ataxia	B-ADR
,	O
diplopia	O
,	O
and	O
somnolence	O
)	O
0	O
<EOS>	O
common	O
adverse	O
event	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	B-Drug
dos	O
up	O
to	O
600	O
mg	O
/	O
day	O
include	O
nonspecific	O
central	O
nervous	O
system	O
effect	O
(	O
e.g.	O
,	O
dizziness	O
,	O
ataxia	O
,	O
diplopia	B-ADR
,	O
and	O
somnolence	O
)	O
0	O
<EOS>	O
common	O
adverse	O
event	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	B-Drug
dos	O
up	O
to	O
600	O
mg	O
/	O
day	O
include	O
nonspecific	O
central	O
nervous	O
system	O
effect	O
(	O
e.g.	O
,	O
dizziness	B-ADR
,	O
ataxia	O
,	O
diplopia	O
,	O
and	O
somnolence	O
)	O
0	O
<EOS>	O
common	O
adverse	O
event	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	B-Drug
dos	O
up	O
to	O
600	O
mg	O
/	O
day	O
include	O
nonspecific	O
central	O
nervous	O
system	O
effect	O
(	O
e.g.	O
,	O
dizziness	O
,	O
ataxia	O
,	O
diplopia	O
,	O
and	O
somnolence	B-ADR
)	O
0	O
<EOS>	O
a	O
case	O
of	O
aseptic	B-ADR
pleuropericarditis	I-ADR
in	O
a	O
patient	O
with	O
chronic	O
plaque	O
psoriasis	O
under	O
methotrexate	B-Drug
therapy	O
0	O
<EOS>	O
methotrexate	B-Drug
may	O
rarely	O
provoke	O
serositis	B-ADR
,	O
even	O
with	O
low	O
dos	O
and	O
after	O
just	O
a	O
few	O
week	O
of	O
therapy	O
0	O
<EOS>	O
we	O
report	O
here	O
a	O
rare	O
case	O
of	O
pleuropericarditis	B-ADR
due	O
to	O
methotrexate	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
five	O
case	O
of	O
tremor	B-ADR
related	O
to	O
itraconazole	B-Drug
therapy	O
,	O
which	O
occurred	O
within	O
1-12	O
month	O
of	O
initiating	O
treatment	O
and	O
resolved	O
gradually	O
following	O
itraconazole	O
withdrawal	O
0	O
<EOS>	O
the	O
author	O
report	O
five	O
case	O
of	O
tremor	B-ADR
related	O
to	O
itraconazole	B-Drug
therapy	O
,	O
which	O
occurred	O
within	O
1-12	O
month	O
of	O
initiating	O
treatment	O
and	O
resolved	O
gradually	O
following	O
itraconazole	O
withdrawal	O
0	O
<EOS>	O
tremor	B-ADR
:	O
a	O
newly	O
described	O
adverse	O
event	O
with	O
long-term	O
itraconazole	B-Drug
therapy	O
0	O
<EOS>	O
acute	B-ADR
kidney	I-ADR
injury	I-ADR
caused	O
by	O
zonisamide-induced	B-Drug
hypersensitivity	O
syndrome	O
0	O
<EOS>	O
acute	O
kidney	O
injury	O
caused	O
by	O
zonisamide-induced	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
hypersensitivity	B-ADR
to	O
zonisamide	B-Drug
wa	O
confirmed	O
by	O
the	O
skin	O
patch	O
test	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	B-ADR
kidney	I-ADR
injury	I-ADR
,	O
high-grade	O
fever	O
,	O
eosinophilia	O
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	O
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	O
fever	O
,	O
eosinophilia	O
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	O
and	O
an	B-ADR
increase	I-ADR
in	I-ADR
antihuman	I-ADR
herpesvirus-6	I-ADR
immunoglobulin	I-ADR
g	I-ADR
titer	I-ADR
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	O
fever	O
,	O
eosinophilia	B-ADR
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	O
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	B-ADR
fever	I-ADR
,	O
eosinophilia	O
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	O
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	O
fever	O
,	O
eosinophilia	O
,	O
liver	B-ADR
dysfunction	I-ADR
,	O
lymphadenopathy	O
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	O
rash	O
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	O
fever	O
,	O
eosinophilia	O
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	B-ADR
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
the	O
current	O
report	O
describes	O
a	O
man	O
who	O
wa	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	B-ADR
rash	I-ADR
,	O
acute	O
kidney	O
injury	O
,	O
high-grade	O
fever	O
,	O
eosinophilia	O
,	O
liver	O
dysfunction	O
,	O
lymphadenopathy	O
and	O
an	O
increase	O
in	O
antihuman	O
herpesvirus-6	O
immunoglobulin	O
g	O
titer	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
acute	B-ADR
kidney	I-ADR
injury	I-ADR
due	O
to	O
zonisamide-induced	B-Drug
dress	O
/	O
dihs	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
acute	O
kidney	O
injury	O
due	O
to	O
zonisamide-induced	B-Drug
dress	O
/	O
dihs	B-ADR
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
acute	O
kidney	O
injury	O
due	O
to	O
zonisamide-induced	B-Drug
dress	B-ADR
/	O
dihs	O
0	O
<EOS>	O
only	O
two	O
case	O
report	O
of	O
adult	O
with	O
allergic	B-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
this	O
chemical	O
exist	O
in	O
the	O
literature	O
,	O
and	O
we	O
describe	O
three	O
more	O
case	O
of	O
child	O
with	O
recalcitrant	O
atopic	O
dermatitis	O
found	O
to	O
have	O
potential	O
allergic	O
contact	O
dermatitis	O
to	O
bisabolol	B-Drug
a	O
component	O
of	O
the	O
aquaphor	O
emollient	O
they	O
were	O
using	O
to	O
treat	O
their	O
atopic	O
dermatitis	O
0	O
<EOS>	O
case	O
report	O
:	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
after	O
administering	O
intravenous	O
immunoglobulin	B-Drug
0	O
<EOS>	O
the	O
hospital	O
course	O
of	O
the	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
is	O
presented	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
case	O
of	O
acute	O
renal	O
failure	O
after	O
ivig	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	O
of	O
breath	O
,	O
azotemia	B-ADR
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
ivig	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	O
of	O
breath	O
,	O
azotemia	B-ADR
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	O
(	O
ivig	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	O
of	O
breath	O
,	O
azotemia	O
,	O
and	O
hyperkalemia	B-ADR
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
ivig	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	O
of	O
breath	O
,	O
azotemia	O
,	O
and	O
hyperkalemia	B-ADR
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	O
(	O
ivig	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	B-ADR
,	O
shortness	O
of	O
breath	O
,	O
azotemia	O
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
ivig	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	B-ADR
,	O
shortness	O
of	O
breath	O
,	O
azotemia	O
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	O
(	O
ivig	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	B-ADR
of	I-ADR
breath	I-ADR
,	O
azotemia	O
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
ivig	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
an	O
87-year-old	O
white	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
presented	O
with	O
nausea	O
,	O
shortness	B-ADR
of	I-ADR
breath	I-ADR
,	O
azotemia	O
,	O
and	O
hyperkalemia	O
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	O
immunoglobulin	O
(	O
ivig	B-Drug
)	O
0	O
<EOS>	O
however	O
,	O
the	O
use	O
of	O
lithium	B-Drug
should	O
be	O
avoided	O
with	O
any	O
patient	O
who	O
is	O
purging	O
,	O
since	O
it	O
may	O
exacerbate	O
the	O
loss	O
of	O
intracellular	O
potassium	O
,	O
thereby	O
increasing	O
the	O
risk	O
of	O
cardiac	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
however	O
,	O
the	O
use	O
of	O
lithium	B-Drug
should	O
be	O
avoided	O
with	O
any	O
patient	O
who	O
is	O
purging	O
,	O
since	O
it	O
may	O
exacerbate	O
the	O
loss	B-ADR
of	I-ADR
intracellular	I-ADR
potassium	I-ADR
,	O
thereby	O
increasing	O
the	O
risk	O
of	O
cardiac	O
toxicity	O
0	O
<EOS>	O
severe	O
vancomycin-induced	B-Drug
anaphylactic	B-ADR
reaction	I-ADR
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	B-ADR
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	B-ADR
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	B-ADR
disorder	I-ADR
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	B-ADR
disturbance	I-ADR
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	B-ADR
reaction	I-ADR
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	B-ADR
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	B-ADR
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	O
man	O
syndrome	O
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effect	O
such	O
a	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
gastrointestinal	O
disturbance	O
,	O
blood	O
disorder	O
,	O
and	O
two	O
type	O
of	O
hypersensitivity	O
reaction	O
-	O
an	O
anaphylactoid	O
reaction	O
known	O
a	O
``	O
red	B-ADR
man	I-ADR
syndrome	I-ADR
'	O
and	O
anaphylaxis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
23-year-old	O
man	O
who	O
developed	O
a	O
vancomycin-induced	B-Drug
anaphylactic	B-ADR
reaction	I-ADR
in	O
the	O
treatment	O
of	O
methicillin-resistant	O
staphylococcus	O
aureus	O
infection	O
0	O
<EOS>	O
four	O
patient	O
in	O
whom	O
pulmonary	B-ADR
oedema	I-ADR
developed	O
during	O
tocolysis	O
with	O
hexoprenaline	B-Drug
are	O
described	O
and	O
the	O
aetiological	O
factor	O
and	O
pathogenesis	O
of	O
this	O
potentially	O
lethal	O
complication	O
discussed	O
0	O
<EOS>	O
pulmonary	B-ADR
oedema	I-ADR
after	O
hexoprenaline	B-Drug
administration	O
in	O
preterm	O
labour	O
0	O
<EOS>	O
fatal	B-ADR
interstitial	I-ADR
lung	I-ADR
disease	I-ADR
after	O
erlotinib	B-Drug
administration	O
in	O
a	O
patient	O
with	O
radiation	O
fibrosis	O
0	O
<EOS>	O
high-resolution	O
computed	O
tomography	O
scan	O
finding	O
were	O
consistent	O
with	O
ild	B-ADR
,	O
which	O
wa	O
sufficient	O
to	O
diagnose	O
a	O
erlotinib-induced	B-Drug
ild	O
0	O
<EOS>	O
introduction	O
:	O
although	O
gefitinib	B-Drug
used	O
for	O
the	O
treatment	O
of	O
non-small-cell	O
lung	O
cancer	O
is	O
a	O
well-known	O
cause	O
of	O
interstitial	O
lung	O
disease	O
(	O
ild	B-ADR
)	O
,	O
few	O
case	O
report	O
on	O
erlotinib-induced	O
ild	O
have	O
been	O
issued	O
0	O
<EOS>	O
introduction	O
:	O
although	O
gefitinib	O
used	O
for	O
the	O
treatment	O
of	O
non-small-cell	O
lung	O
cancer	O
is	O
a	O
well-known	O
cause	O
of	O
interstitial	O
lung	O
disease	O
(	O
ild	B-ADR
)	O
,	O
few	O
case	O
report	O
on	O
erlotinib-induced	B-Drug
ild	O
have	O
been	O
issued	O
0	O
<EOS>	O
introduction	O
:	O
although	O
gefitinib	B-Drug
used	O
for	O
the	O
treatment	O
of	O
non-small-cell	O
lung	O
cancer	O
is	O
a	O
well-known	O
cause	O
of	O
interstitial	B-ADR
lung	I-ADR
disease	I-ADR
(	O
ild	O
)	O
,	O
few	O
case	O
report	O
on	O
erlotinib-induced	O
ild	O
have	O
been	O
issued	O
0	O
<EOS>	O
result	O
:	O
we	O
recently	O
experienced	O
a	O
case	O
of	O
fatal	O
erlotinib-induced	B-Drug
ild	B-ADR
,	O
diagnosed	O
based	O
on	O
clinical	O
and	O
radiologic	O
finding	O
,	O
which	O
occurred	O
in	O
a	O
patient	O
with	O
radiation	O
fibrosis	O
0	O
<EOS>	O
this	O
case	O
had	O
radiation	O
fibrosis	O
,	O
so	O
we	O
suggest	O
that	O
radiation	O
fibrosis	O
may	O
be	O
another	O
contributor	O
of	O
the	O
occurrence	O
of	O
ild	B-ADR
in	O
patient	O
taking	O
erlotinib	B-Drug
0	O
<EOS>	O
one	O
patient	O
suffered	O
coronary	B-ADR
artery	I-ADR
vasospasm	I-ADR
,	O
attributed	O
to	O
the	O
use	O
of	O
topical	O
1:1000	O
epinephrine	B-Drug
during	O
surgery	O
0	O
<EOS>	O
the	O
other	O
patient	O
developed	O
transient	B-ADR
intraoperative	I-ADR
hypertension	I-ADR
immediately	O
after	O
inadvertent	O
submucosal	O
injection	O
of	O
concentrated	O
epinephrine	B-Drug
0	O
<EOS>	O
cisplatin-induced	B-Drug
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
in	O
a	O
patient	O
with	O
neuroendocrine	O
tumor	O
of	O
the	O
cervix	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
cisplatin-induced	B-Drug
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
in	O
a	O
patient	O
with	O
neuroendocrine	O
tumor	O
of	O
the	O
cervix	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
the	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
secondary	O
to	O
cisplatin	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
advanced-stage	O
large	O
cell	O
neuroendocrine	O
carcinoma	O
of	O
the	O
cervix	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
secondary	O
to	O
cisplatin	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
advanced-stage	O
large	O
cell	O
neuroendocrine	O
carcinoma	O
of	O
the	O
cervix	O
0	O
<EOS>	O
however	O
,	O
to	O
our	O
knowledge	O
,	O
in	O
newborn	O
there	O
have	O
been	O
no	O
reported	O
case	O
to	O
date	O
of	O
thrombocytosis	B-ADR
induced	O
by	O
enoxaparin	B-Drug
0	O
<EOS>	O
thrombocytosis	B-ADR
associated	O
with	O
enoxaparin	B-Drug
:	O
a	O
very	O
rare	O
cause	O
in	O
newborn	O
0	O
<EOS>	O
thrombocytosis	B-ADR
induced	O
by	O
enoxaparin	B-Drug
ha	O
been	O
reported	O
a	O
a	O
rare	O
adverse	O
effect	O
of	O
this	O
medication	O
in	O
adult	O
0	O
<EOS>	O
objective	O
:	O
1	O
)	O
to	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
receiving	O
adalimumab	B-Drug
who	O
developed	O
fever	O
,	O
pancytopenia	O
,	O
splenomegaly	O
,	O
and	O
extreme	B-ADR
hyperferritinemia	I-ADR
0	O
<EOS>	O
objective	O
:	O
1	O
)	O
to	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
receiving	O
adalimumab	B-Drug
who	O
developed	O
fever	B-ADR
,	O
pancytopenia	O
,	O
splenomegaly	O
,	O
and	O
extreme	O
hyperferritinemia	O
0	O
<EOS>	O
objective	O
:	O
1	O
)	O
to	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
receiving	O
adalimumab	B-Drug
who	O
developed	O
fever	O
,	O
pancytopenia	B-ADR
,	O
splenomegaly	O
,	O
and	O
extreme	O
hyperferritinemia	O
0	O
<EOS>	O
objective	O
:	O
1	O
)	O
to	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
receiving	O
adalimumab	B-Drug
who	O
developed	O
fever	O
,	O
pancytopenia	O
,	O
splenomegaly	B-ADR
,	O
and	O
extreme	O
hyperferritinemia	O
0	O
<EOS>	O
visceral	O
leishmaniasis	O
and	O
macrophagic	B-ADR
activation	I-ADR
syndrome	I-ADR
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
under	O
treatment	O
with	O
adalimumab	B-Drug
0	O
<EOS>	O
visceral	B-ADR
leishmaniasis	I-ADR
and	O
macrophagic	O
activation	O
syndrome	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
under	O
treatment	O
with	O
adalimumab	B-Drug
0	O
<EOS>	O
this	O
case	O
presentation	O
is	O
of	O
a	O
patient	O
who	O
had	O
the	O
clinical	O
appearance	O
of	O
epiglottitis	B-ADR
,	O
but	O
actually	O
had	O
an	O
oro-pharyngeal	O
dystonic	O
reaction	O
to	O
prochlorperazine	B-Drug
0	O
<EOS>	O
this	O
case	O
presentation	O
is	O
of	O
a	O
patient	O
who	O
had	O
the	O
clinical	O
appearance	O
of	O
epiglottitis	O
,	O
but	O
actually	O
had	O
an	O
oro-pharyngeal	B-ADR
dystonic	I-ADR
reaction	I-ADR
to	O
prochlorperazine	B-Drug
0	O
<EOS>	O
normalization	O
of	O
generalized	O
retinal	O
function	O
and	O
progression	O
of	O
maculopathy	O
after	O
cessation	O
of	O
therapy	O
in	O
a	O
case	O
of	O
severe	O
hydroxychloroquine	B-Drug
retinopathy	B-ADR
with	O
19	O
year	O
follow-up	O
0	O
<EOS>	O
after	O
other	O
potential	O
cause	O
of	O
liver	O
toxicity	O
were	O
excluded	O
,	O
tmp-smx	B-Drug
wa	O
determined	O
to	O
be	O
the	O
cause	O
of	O
his	O
acute	B-ADR
liver	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
after	O
other	O
potential	O
cause	O
of	O
liver	B-ADR
toxicity	I-ADR
were	O
excluded	O
,	O
tmp-smx	B-Drug
wa	O
determined	O
to	O
be	O
the	O
cause	O
of	O
his	O
acute	O
liver	O
toxicity	O
0	O
<EOS>	O
although	O
this	O
combination	O
agent	O
ha	O
been	O
associated	O
with	O
a	O
hypersensitivity	O
syndrome	O
involving	O
cutaneous	B-ADR
skin	I-ADR
eruption	I-ADR
,	O
pediatric	O
case	O
of	O
tmp-smx-induced	B-Drug
hepatotoxicity	O
are	O
rare	O
0	O
<EOS>	O
although	O
this	O
combination	O
agent	O
ha	O
been	O
associated	O
with	O
a	O
hypersensitivity	O
syndrome	O
involving	O
cutaneous	O
skin	O
eruption	O
,	O
pediatric	O
case	O
of	O
tmp-smx-induced	B-Drug
hepatotoxicity	B-ADR
are	O
rare	O
0	O
<EOS>	O
although	O
this	O
combination	O
agent	O
ha	O
been	O
associated	O
with	O
a	O
hypersensitivity	B-ADR
syndrome	I-ADR
involving	O
cutaneous	O
skin	O
eruption	O
,	O
pediatric	O
case	O
of	O
tmp-smx-induced	B-Drug
hepatotoxicity	O
are	O
rare	O
0	O
<EOS>	O
due	O
to	O
the	O
increasing	O
use	O
of	O
tmp-smx	B-Drug
in	O
child	O
,	O
clinician	O
should	O
be	O
aware	O
of	O
this	O
potentially	O
life-threatening	O
,	O
immunemediated	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
0	O
<EOS>	O
trimethoprim-sulfamethoxazole-induced	B-Drug
hepatotoxicity	B-ADR
in	O
a	O
pediatric	O
patient	O
0	O
<EOS>	O
use	O
of	O
the	O
naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
indicated	O
a	O
probable	O
relationship	O
(	O
score	O
of	O
5	O
)	O
between	O
the	O
patient	O
development	O
of	O
hepatotoxicity	B-ADR
and	O
the	O
tmp-smx	B-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
a	O
relatively	O
healthy	O
,	O
9-year-old	O
boy	O
who	O
developed	O
a	O
ca-mrsa	O
skin	O
and	O
soft	B-ADR
tissue	I-ADR
infection	I-ADR
and	O
wa	O
treated	O
with	O
tmp-smx	B-Drug
0	O
<EOS>	O
amiodarone	B-Drug
wa	O
discontinued	O
,	O
and	O
thyrotoxicosis	B-ADR
gradually	O
abated	O
0	O
<EOS>	O
goiter	B-ADR
and	O
hypothyroidism	O
during	O
re-treatment	O
with	O
amiodarone	O
in	O
a	O
patient	O
who	O
previously	O
experienced	O
amiodarone-induced	B-Drug
thyrotoxicosis	O
0	O
<EOS>	O
goiter	O
and	O
hypothyroidism	B-ADR
during	O
re-treatment	O
with	O
amiodarone	O
in	O
a	O
patient	O
who	O
previously	O
experienced	O
amiodarone-induced	B-Drug
thyrotoxicosis	O
0	O
<EOS>	O
goiter	O
and	O
hypothyroidism	O
during	O
re-treatment	O
with	O
amiodarone	O
in	O
a	O
patient	O
who	O
previously	O
experienced	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
0	O
<EOS>	O
background	O
:	O
aphthous	B-ADR
stomatitis	I-ADR
,	O
a	O
common	O
mucocutaneous	O
disorder	O
,	O
is	O
a	O
well	O
accepted	O
complication	O
of	O
sirolimus	B-Drug
therapy	O
0	O
<EOS>	O
case	O
:	O
we	O
present	O
an	O
11-year	O
old	O
male	O
with	O
budd-chiari	O
syndrome	O
who	O
experienced	O
profound	O
worsening	B-ADR
of	I-ADR
chronic	I-ADR
aphthous	I-ADR
ulcer	I-ADR
after	O
immunosuppressive	O
therapy	O
wa	O
changed	O
from	O
tacrolimus	O
to	O
sirolimus	B-Drug
0	O
<EOS>	O
case	O
:	O
we	O
present	O
an	O
11-year	O
old	O
male	O
with	O
budd-chiari	O
syndrome	O
who	O
experienced	O
profound	O
worsening	B-ADR
of	I-ADR
chronic	I-ADR
aphthous	I-ADR
ulcer	I-ADR
after	O
immunosuppressive	O
therapy	O
wa	O
changed	O
from	O
tacrolimus	B-Drug
to	O
sirolimus	O
0	O
<EOS>	O
severe	B-ADR
aphthous	I-ADR
stomatitis	I-ADR
associated	O
with	O
oral	O
calcineurin	B-Drug
and	O
mtor	O
inhibitor	O
0	O
<EOS>	O
these	O
finding	O
mean	O
that	O
the	O
effect	O
of	O
the	O
mp	O
pulse	O
therapy	O
on	O
renal	O
function	O
depends	O
on	O
the	O
clinical	O
state	O
of	O
the	O
patient	O
and	O
that	O
renal	O
deterioration	O
after	O
the	O
pulse	O
therapy	O
may	O
be	O
more	O
marked	O
in	O
patient	O
who	O
are	O
more	O
nephrotic	O
and	O
more	O
impaired	O
in	O
renal	O
function	O
and	O
suggest	O
that	O
increasing	O
sodium	O
and	O
water	O
retention	O
during	O
an	O
mp	O
therapy	O
and	O
the	O
associated	O
renal	O
interstitial	O
edema	O
,	O
proposed	O
a	O
one	O
of	O
the	O
mechanism	O
of	O
acute	O
renal	O
failure	O
occurring	O
in	O
patient	O
with	O
minimal-change	O
nephrotic	O
syndrome	O
,	O
may	O
be	O
responsible	O
for	O
the	O
mp-induced	B-Drug
transient	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
three	O
nephrotic	O
patient	O
who	O
had	O
reduced	O
renal	O
function	O
and	O
active	O
renal	O
disease	O
with	O
progressive	O
deterioration	O
of	O
renal	O
function	O
prior	O
to	O
the	O
use	O
of	O
mp	B-Drug
developed	O
transient	B-ADR
renal	I-ADR
failure	I-ADR
following	O
an	O
mp	O
pulse	O
therapy	O
0	O
<EOS>	O
three	O
nephrotic	O
patient	O
who	O
had	O
reduced	O
renal	O
function	O
and	O
active	O
renal	O
disease	O
with	O
progressive	O
deterioration	O
of	O
renal	O
function	O
prior	O
to	O
the	O
use	O
of	O
mp	B-Drug
developed	O
transient	B-ADR
renal	I-ADR
failure	I-ADR
following	O
an	O
mp	O
pulse	O
therapy	O
0	O
<EOS>	O
a	O
67-year-old	O
patient	O
,	O
with	O
primary	O
polymyositis	O
and	O
without	O
previous	O
evidence	O
of	O
liver	O
disease	O
,	O
developed	O
clinical	O
and	O
biochemical	O
feature	O
of	O
severe	B-ADR
cholestasis	I-ADR
3	O
month	O
after	O
initiation	O
of	O
azathioprine	B-Drug
therapy	O
0	O
<EOS>	O
it	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine-induced	B-Drug
cholestasis	B-ADR
associated	O
with	O
histological	O
evidence	O
of	O
bile	O
duct	O
injury	O
0	O
<EOS>	O
reversible	O
cholestasis	O
with	O
bile	B-ADR
duct	I-ADR
injury	I-ADR
following	O
azathioprine	B-Drug
therapy	O
0	O
<EOS>	O
reversible	O
cholestasis	B-ADR
with	O
bile	O
duct	O
injury	O
following	O
azathioprine	B-Drug
therapy	O
0	O
<EOS>	O
a	O
case	O
of	O
the	O
rett	O
syndrome	O
with	O
acute	B-ADR
encephalopathy	I-ADR
induced	O
during	O
calcium	B-Drug
hopantenate	I-Drug
treatment	O
0	O
<EOS>	O
we	O
report	O
a	O
girl	O
with	O
the	O
rett	O
syndrome	O
who	O
had	O
acute	B-ADR
encephalopathy	I-ADR
probably	O
induced	O
by	O
calcium	B-Drug
hopantenate	I-Drug
(	O
hopa	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
girl	O
with	O
the	O
rett	O
syndrome	O
who	O
had	O
acute	B-ADR
encephalopathy	I-ADR
probably	O
induced	O
by	O
calcium	O
hopantenate	O
(	O
hopa	B-Drug
)	O
0	O
<EOS>	O
persistent	B-ADR
light	I-ADR
reactivity	I-ADR
from	O
systemic	O
quinine	B-Drug
0	O
<EOS>	O
the	O
photosensitivity	B-ADR
is	O
still	O
present	O
3	O
year	O
after	O
the	O
withdrawal	O
of	O
quinine	B-Drug
0	O
<EOS>	O
two	O
case	O
are	O
reported	O
of	O
patient	O
who	O
developed	O
a	O
hematologic	B-ADR
malignancy	I-ADR
several	O
year	O
after	O
intravesical	O
chemotherapy	O
of	O
superficial	O
bladder	O
cancer	O
with	O
etoglucid	O
,	O
doxorubicin	B-Drug
,	O
and	O
mitomycin	O
c	O
0	O
<EOS>	O
two	O
case	O
are	O
reported	O
of	O
patient	O
who	O
developed	O
a	O
hematologic	B-ADR
malignancy	I-ADR
several	O
year	O
after	O
intravesical	O
chemotherapy	O
of	O
superficial	O
bladder	O
cancer	O
with	O
etoglucid	B-Drug
,	O
doxorubicin	O
,	O
and	O
mitomycin	O
c	O
0	O
<EOS>	O
two	O
case	O
are	O
reported	O
of	O
patient	O
who	O
developed	O
a	O
hematologic	B-ADR
malignancy	I-ADR
several	O
year	O
after	O
intravesical	O
chemotherapy	O
of	O
superficial	O
bladder	O
cancer	O
with	O
etoglucid	O
,	O
doxorubicin	O
,	O
and	O
mitomycin	B-Drug
c	I-Drug
0	O
<EOS>	O
a	O
patient	O
with	O
wegener	O
granulomatosis	O
rapidly	O
developed	O
a	O
circumferential	B-ADR
subglottic	I-ADR
stenosis	I-ADR
while	O
on	O
a	O
cyclophosphamide	B-Drug
regimen	O
that	O
had	O
caused	O
resolution	O
of	O
systemic	O
symptom	O
and	O
pulmonary	O
infiltrates	O
0	O
<EOS>	O
subglottic	B-ADR
stenosis	I-ADR
in	O
wegener	O
granulomatosis	O
:	O
development	O
during	O
cyclophosphamide	B-Drug
treatment	O
with	O
response	O
to	O
carbon	O
dioxide	O
laser	O
therapy	O
0	O
<EOS>	O
a	O
case	O
is	O
described	O
of	O
severe	B-ADR
splenic	I-ADR
hemorrhage	I-ADR
and	I-ADR
rupture	I-ADR
which	O
developed	O
3	O
h	O
after	O
completion	O
of	O
tpa	B-Drug
infusion	O
for	O
suspected	O
acute	O
myocardial	O
infarction	O
0	O
<EOS>	O
splenic	B-ADR
hemorrhage	I-ADR
:	O
a	O
complication	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
treatment	O
0	O
<EOS>	O
thrombolytic	O
therapy	O
with	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
(	O
tpa	O
)	O
for	O
acute	O
myocardial	O
infarction	O
may	O
result	O
in	O
major	O
bleeding	O
complication	O
such	O
a	O
gastrointestinal	B-ADR
or	I-ADR
intracranial	I-ADR
bleeding	I-ADR
0	O
<EOS>	O
thrombolytic	O
therapy	O
with	O
tissue	O
plasminogen	O
activator	O
(	O
tpa	B-Drug
)	O
for	O
acute	O
myocardial	O
infarction	O
may	O
result	O
in	O
major	O
bleeding	O
complication	O
such	O
a	O
gastrointestinal	B-ADR
or	I-ADR
intracranial	I-ADR
bleeding	I-ADR
0	O
<EOS>	O
a	O
case	O
of	O
severe	B-ADR
acute	I-ADR
hepatitis	I-ADR
caused	O
by	O
cyproterone	B-Drug
acetate	I-Drug
in	O
a	O
71	O
year	O
old	O
man	O
with	O
prostatic	O
carcinoma	O
is	O
reported	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
hepatic	O
reaction	O
to	O
this	O
drug	O
0	O
<EOS>	O
monitoring	O
of	O
liver	O
function	O
test	O
should	O
be	O
mandatory	O
in	O
patient	O
receiving	O
high	O
dos	O
of	O
cyproterone	B-Drug
acetate	I-Drug
;	O
the	O
drug	O
should	O
be	O
withdrawn	O
immediately	O
if	O
abnormal	B-ADR
liver	I-ADR
function	I-ADR
test	I-ADR
are	O
found	O
0	O
<EOS>	O
severe	B-ADR
hepatitis	I-ADR
caused	O
by	O
cyproterone	B-Drug
acetate	I-Drug
0	O
<EOS>	O
a	O
unique	O
case	O
of	O
a	O
transient	O
,	O
nonpigmenting	O
fixed	B-ADR
drug	I-ADR
eruption	I-ADR
caused	O
by	O
the	O
radiopaque	O
contrast	O
medium	O
iothalamate	B-Drug
is	O
reported	O
0	O
<EOS>	O
one	O
patient	O
with	O
systemic	O
lupus	O
erythematosus	O
developed	O
erythema	B-ADR
multiforme	I-ADR
after	O
taking	O
griseofulvin	B-Drug
0	O
<EOS>	O
aminoglutethimide	B-Drug
wa	O
discontinued	O
until	O
completion	O
of	O
radiotherapy	O
,	O
and	O
the	O
rash	B-ADR
resolved	O
0	O
<EOS>	O
concomitant	O
irradiation	O
apparently	O
enhanced	O
the	O
skin	B-ADR
toxicity	I-ADR
of	O
aminoglutethimide	B-Drug
or	O
possibly	O
aminoglutethimide	O
had	O
a	O
radiosensitizing	O
role	O
in	O
this	O
patient	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
radiotherapy-enhanced	O
aminoglutethimide	B-Drug
skin	B-ADR
toxicity	I-ADR
in	O
a	O
patient	O
with	O
metastatic	O
breast	O
cancer	O
0	O
<EOS>	O
data	O
have	O
been	O
published	O
regarding	O
the	O
possibility	O
that	O
tamoxifen	B-Drug
may	O
be	O
responsible	O
for	O
the	O
subsequent	O
development	O
of	O
carcinoma	B-ADR
of	I-ADR
the	I-ADR
corpus	I-ADR
uterus	I-ADR
in	O
these	O
patient	O
0	O
<EOS>	O
the	O
author	O
intend	O
to	O
carry	O
out	O
a	O
case-control	O
study	O
on	O
patient	O
treated	O
with	O
tamoxifen	B-Drug
for	O
breast	O
carcinoma	O
to	O
reveal	O
the	O
possible	O
presence	O
of	O
endometrial	B-ADR
carcinoma	I-ADR
0	O
<EOS>	O
disulfiram-induced	B-Drug
hepatitis	B-ADR
0	O
<EOS>	O
our	O
patient	O
had	O
headache	O
,	O
mild	O
fever	O
,	O
nausea	O
,	O
vomiting	O
,	O
rash	O
,	O
and	O
eosinophilia	B-ADR
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
our	O
patient	O
had	O
headache	B-ADR
,	O
mild	O
fever	O
,	O
nausea	O
,	O
vomiting	O
,	O
rash	O
,	O
and	O
eosinophilia	O
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
our	O
patient	O
had	O
headache	O
,	O
mild	B-ADR
fever	I-ADR
,	O
nausea	O
,	O
vomiting	O
,	O
rash	O
,	O
and	O
eosinophilia	O
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
our	O
patient	O
had	O
headache	O
,	O
mild	O
fever	O
,	O
nausea	B-ADR
,	O
vomiting	O
,	O
rash	O
,	O
and	O
eosinophilia	O
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
our	O
patient	O
had	O
headache	O
,	O
mild	O
fever	O
,	O
nausea	O
,	O
vomiting	O
,	O
rash	B-ADR
,	O
and	O
eosinophilia	O
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
our	O
patient	O
had	O
headache	O
,	O
mild	O
fever	O
,	O
nausea	O
,	O
vomiting	B-ADR
,	O
rash	O
,	O
and	O
eosinophilia	O
after	O
3	O
week	O
of	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
we	O
reported	O
a	O
case	O
of	O
disulfiram-induced	B-Drug
hepatitis	B-ADR
with	O
unique	O
clinical	O
feature	O
and	O
compared	O
our	O
case	O
with	O
others	O
in	O
the	O
literature	O
0	O
<EOS>	O
an	O
episode	O
of	O
leukoencephalopathy	B-ADR
is	O
reported	O
in	O
a	O
13-year-old	O
girl	O
who	O
,	O
after	O
standard	O
radiotherapy	O
for	O
a	O
posterior	O
fossa	O
medulloblastoma	O
,	O
received	O
8	O
treatment	O
with	O
a	O
protocol	O
containing	O
a	O
4-hour	O
infusion	O
of	O
500	O
mg	O
/	O
m2	O
methotrexate	B-Drug
and	O
12	O
mg	O
intrathecal	O
methotrexate	O
0	O
<EOS>	O
an	O
episode	O
of	O
leukoencephalopathy	B-ADR
is	O
reported	O
in	O
a	O
13-year-old	O
girl	O
who	O
,	O
after	O
standard	O
radiotherapy	O
for	O
a	O
posterior	O
fossa	O
medulloblastoma	O
,	O
received	O
8	O
treatment	O
with	O
a	O
protocol	O
containing	O
a	O
4-hour	O
infusion	O
of	O
500	O
mg	O
/	O
m2	O
methotrexate	B-Drug
and	O
12	O
mg	O
intrathecal	O
methotrexate	O
0	O
<EOS>	O
methotrexate-induced	B-Drug
leukoencephalopathy	B-ADR
is	O
treatable	O
with	O
high-dose	O
folinic	O
acid	O
:	O
a	O
case	O
report	O
and	O
analysis	O
of	O
the	O
literature	O
0	O
<EOS>	O
severe	O
heparin	B-Drug
associated	O
thrombocytopenia	B-ADR
is	O
a	O
rare	O
complication	O
of	O
heparin	O
therapy	O
0	O
<EOS>	O
severe	O
heparin	B-Drug
associated	O
thrombocytopenia	B-ADR
is	O
a	O
rare	O
complication	O
of	O
heparin	O
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
who	O
developed	O
heparin	B-Drug
associated	O
thrombocytopenia	B-ADR
during	O
continuous	O
arteriovenous	O
haemofiltration	O
and	O
discus	O
it	O
implication	O
and	O
alternative	O
anticoagulant	O
treatment	O
0	O
<EOS>	O
acute	O
aluminum	B-ADR
toxicity	I-ADR
after	O
continuous	O
intravesical	O
alum	B-Drug
irrigation	O
for	O
hemorrhagic	O
cystitis	O
0	O
<EOS>	O
an	O
encephalopathy	O
and	O
cardiomyopathy	B-ADR
developed	O
in	O
a	O
seventeen-year-old	O
girl	O
with	O
chemotherapy-induced	O
renal	O
failure	O
while	O
receiving	O
an	O
intravesical	O
aluminum	B-Drug
infusion	O
for	O
hemorrhagic	O
cystitis	O
0	O
<EOS>	O
an	O
encephalopathy	B-ADR
and	O
cardiomyopathy	O
developed	O
in	O
a	O
seventeen-year-old	O
girl	O
with	O
chemotherapy-induced	O
renal	O
failure	O
while	O
receiving	O
an	O
intravesical	O
aluminum	B-Drug
infusion	O
for	O
hemorrhagic	O
cystitis	O
0	O
<EOS>	O
a	O
62-year-old	O
woman	O
who	O
wa	O
being	O
treated	O
for	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
a	O
chemotherapy-related	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
during	O
the	O
second	O
cycle	O
of	O
neoadjuvant	O
chemotherapy	O
consisting	O
of	O
cisplatin	O
,	O
bleomycin	B-Drug
,	O
and	O
methotrexate	O
0	O
<EOS>	O
a	O
62-year-old	O
woman	O
who	O
wa	O
being	O
treated	O
for	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
a	O
chemotherapy-related	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
during	O
the	O
second	O
cycle	O
of	O
neoadjuvant	O
chemotherapy	O
consisting	O
of	O
cisplatin	B-Drug
,	O
bleomycin	O
,	O
and	O
methotrexate	O
0	O
<EOS>	O
a	O
62-year-old	O
woman	O
who	O
wa	O
being	O
treated	O
for	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
a	O
chemotherapy-related	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
during	O
the	O
second	O
cycle	O
of	O
neoadjuvant	O
chemotherapy	O
consisting	O
of	O
cisplatin	O
,	O
bleomycin	O
,	O
and	O
methotrexate	B-Drug
0	O
<EOS>	O
awareness	O
of	O
this	O
route	O
of	O
intoxication	O
might	O
be	O
important	O
in	O
patient	O
in	O
whom	O
neurologic	O
or	O
psychiatric	B-ADR
symptom	I-ADR
develop	O
while	O
large	O
amount	O
of	O
lidocaine	B-Drug
cream	O
are	O
being	O
used	O
0	O
<EOS>	O
nitrendipine-induced	B-Drug
gingival	B-ADR
hyperplasia	I-ADR
0	O
<EOS>	O
nitrendipine	B-Drug
is	O
an	O
experimental	O
calcium	O
channel	O
blocking	O
agent	O
that	O
also	O
appears	O
to	O
cause	O
the	O
side	O
effect	O
of	O
drug-induced	O
gingival	B-ADR
hyperplasia	I-ADR
0	O
<EOS>	O
physician	O
using	O
this	O
``	O
new	O
'	O
drug	O
must	O
be	O
aware	O
of	O
the	O
potential	O
danger	O
of	O
sulfonamide-induced	B-Drug
injury	B-ADR
to	I-ADR
the	I-ADR
urinary	I-ADR
tract	I-ADR
0	O
<EOS>	O
sulfadiazine	B-Drug
crystalluria	B-ADR
revisited	O
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
of	O
sulfadiazine-induced	B-Drug
crystalluria	B-ADR
and	O
renal	O
failure	O
in	O
patient	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
,	O
review	O
the	O
pertinent	O
literature	O
,	O
and	O
discus	O
the	O
pathogenesis	O
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
of	O
sulfadiazine-induced	B-Drug
crystalluria	O
and	O
renal	B-ADR
failure	I-ADR
in	O
patient	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
,	O
review	O
the	O
pertinent	O
literature	O
,	O
and	O
discus	O
the	O
pathogenesis	O
0	O
<EOS>	O
glaucoma	B-ADR
secondary	O
to	O
epithelial	O
downgrowth	O
and	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
secondary	O
glaucoma	B-ADR
caused	O
by	O
epithelial	O
downgrowth	O
in	O
which	O
filtration	O
surgery	O
wa	O
performed	O
with	O
adjunctive	O
use	O
of	O
subconjunctival	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
antacid	O
and	O
sucralfate-induced	B-Drug
hypophosphatemic	B-ADR
osteomalacia	I-ADR
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
because	O
of	O
a	O
hypersensitivity	B-ADR
reaction	I-ADR
,	O
initial	O
therapy	O
with	O
penicillin	O
g	O
and	O
gentamicin	B-Drug
wa	O
stopped	O
and	O
substituted	O
with	O
cefazolin	O
0	O
<EOS>	O
because	O
of	O
a	O
hypersensitivity	B-ADR
reaction	I-ADR
,	O
initial	O
therapy	O
with	O
penicillin	B-Drug
g	I-Drug
and	O
gentamicin	O
wa	O
stopped	O
and	O
substituted	O
with	O
cefazolin	O
0	O
<EOS>	O
prenatal	O
cytomegalovirus	O
(	O
cmv	O
)	O
infection	O
associated	O
with	O
severe	O
brain	B-ADR
damage	I-ADR
wa	O
detected	O
in	O
an	O
infant	O
whose	O
mother	O
had	O
been	O
treated	O
with	O
prednisolone	O
and	O
azathioprine	B-Drug
for	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
0	O
<EOS>	O
prenatal	O
cytomegalovirus	O
(	O
cmv	O
)	O
infection	O
associated	O
with	O
severe	O
brain	B-ADR
damage	I-ADR
wa	O
detected	O
in	O
an	O
infant	O
whose	O
mother	O
had	O
been	O
treated	O
with	O
prednisolone	B-Drug
and	O
azathioprine	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
0	O
<EOS>	O
prenatal	B-ADR
cytomegalovirus	I-ADR
(	I-ADR
cmv	I-ADR
)	I-ADR
infection	I-ADR
associated	O
with	O
severe	O
brain	O
damage	O
wa	O
detected	O
in	O
an	O
infant	O
whose	O
mother	O
had	O
been	O
treated	O
with	O
prednisolone	O
and	O
azathioprine	B-Drug
for	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
0	O
<EOS>	O
prenatal	B-ADR
cytomegalovirus	I-ADR
(	I-ADR
cmv	I-ADR
)	I-ADR
infection	I-ADR
associated	O
with	O
severe	O
brain	O
damage	O
wa	O
detected	O
in	O
an	O
infant	O
whose	O
mother	O
had	O
been	O
treated	O
with	O
prednisolone	B-Drug
and	O
azathioprine	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
0	O
<EOS>	O
acute	B-ADR
coronary	I-ADR
event	I-ADR
following	O
cisplatin-based	B-Drug
chemotherapy	O
0	O
<EOS>	O
six	O
patient	O
with	O
no	O
previous	O
sign	O
or	O
symptom	O
suggestive	O
of	O
coronary	O
artery	O
disease	O
developed	O
acute	B-ADR
coronary	I-ADR
ischemia	I-ADR
/	O
infarction	O
shortly	O
after	O
cis-diamine-dichloroplatinum	B-Drug
ii	I-Drug
(	O
cisplatin	O
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
six	O
patient	O
with	O
no	O
previous	O
sign	O
or	O
symptom	O
suggestive	O
of	O
coronary	O
artery	O
disease	O
developed	O
acute	B-ADR
coronary	I-ADR
ischemia	I-ADR
/	O
infarction	O
shortly	O
after	O
cis-diamine-dichloroplatinum	O
ii	O
(	O
cisplatin	B-Drug
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
six	O
patient	O
with	O
no	O
previous	O
sign	O
or	O
symptom	O
suggestive	O
of	O
coronary	O
artery	O
disease	O
developed	O
acute	O
coronary	O
ischemia	O
/	O
infarction	B-ADR
shortly	O
after	O
cis-diamine-dichloroplatinum	B-Drug
ii	I-Drug
(	O
cisplatin	O
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
six	O
patient	O
with	O
no	O
previous	O
sign	O
or	O
symptom	O
suggestive	O
of	O
coronary	O
artery	O
disease	O
developed	O
acute	O
coronary	O
ischemia	O
/	O
infarction	B-ADR
shortly	O
after	O
cis-diamine-dichloroplatinum	O
ii	O
(	O
cisplatin	B-Drug
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
bowel	B-ADR
perforation	I-ADR
associated	O
with	O
intraperitoneal	O
chromic	B-Drug
phosphate	I-Drug
instillation	O
0	O
<EOS>	O
delayed	O
bowel	B-ADR
injury	I-ADR
is	O
an	O
infrequently	O
observed	O
complication	O
of	O
chromic	B-Drug
phosphate	I-Drug
administration	O
0	O
<EOS>	O
this	O
report	O
present	O
a	O
case	O
of	O
colon	B-ADR
perforation	I-ADR
which	O
occurred	O
4	O
month	O
after	O
treatment	O
with	O
intraperitoneal	O
chromic	B-Drug
phosphate	I-Drug
for	O
stage	O
ib	O
ovarian	O
papillary	O
serous	O
cystadenocarcinoma	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	O
treatment	O
a	O
progressive	O
visual	O
loss	O
and	O
loss	O
of	O
consciousness	O
which	O
worsened	O
during	O
subsequent	O
ara-c	B-Drug
treatment	O
and	O
led	O
to	O
death	B-ADR
within	O
3	O
week	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	B-Drug
treatment	O
a	O
progressive	O
visual	O
loss	O
and	O
loss	O
of	O
consciousness	O
which	O
worsened	O
during	O
subsequent	O
ara-c	O
treatment	O
and	O
led	O
to	O
death	B-ADR
within	O
3	O
week	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	O
treatment	O
a	O
progressive	O
visual	O
loss	O
and	O
loss	B-ADR
of	I-ADR
consciousness	I-ADR
which	O
worsened	O
during	O
subsequent	O
ara-c	B-Drug
treatment	O
and	O
led	O
to	O
death	O
within	O
3	O
week	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	B-Drug
treatment	O
a	O
progressive	O
visual	O
loss	O
and	O
loss	B-ADR
of	I-ADR
consciousness	I-ADR
which	O
worsened	O
during	O
subsequent	O
ara-c	O
treatment	O
and	O
led	O
to	O
death	O
within	O
3	O
week	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	O
treatment	O
a	O
progressive	B-ADR
visual	I-ADR
loss	I-ADR
and	O
loss	O
of	O
consciousness	O
which	O
worsened	O
during	O
subsequent	O
ara-c	B-Drug
treatment	O
and	O
led	O
to	O
death	O
within	O
3	O
week	O
0	O
<EOS>	O
despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
mtx	B-Drug
treatment	O
a	O
progressive	B-ADR
visual	I-ADR
loss	I-ADR
and	O
loss	O
of	O
consciousness	O
which	O
worsened	O
during	O
subsequent	O
ara-c	O
treatment	O
and	O
led	O
to	O
death	O
within	O
3	O
week	O
0	O
<EOS>	O
a	O
59-year-old	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
received	O
a	O
large	O
dose	O
of	O
pyridostigmine	B-Drug
bromide	I-Drug
developed	O
postoperative	O
psychosis	O
and	O
wa	O
diagnosed	O
a	O
having	O
bromide	B-ADR
intoxication	I-ADR
0	O
<EOS>	O
a	O
59-year-old	O
woman	O
with	O
myasthenia	O
gravis	O
who	O
received	O
a	O
large	O
dose	O
of	O
pyridostigmine	B-Drug
bromide	I-Drug
developed	O
postoperative	B-ADR
psychosis	I-ADR
and	O
wa	O
diagnosed	O
a	O
having	O
bromide	O
intoxication	O
0	O
<EOS>	O
bromide	B-ADR
intoxication	I-ADR
secondary	O
to	O
pyridostigmine	B-Drug
bromide	I-Drug
therapy	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
bromide	B-ADR
intoxication	I-ADR
due	O
to	O
pyridostigmine	B-Drug
bromide	I-Drug
administration	O
0	O
<EOS>	O
diazepam	B-Drug
use	O
by	O
pregnant	O
woman	O
can	O
be	O
associated	O
with	O
a	O
later	O
presentation	O
of	O
withdrawal	B-ADR
symptom	I-ADR
in	O
the	O
neonate	O
than	O
that	O
induced	O
by	O
the	O
use	O
of	O
other	O
drug	O
0	O
<EOS>	O
we	O
conclude	O
that	O
neurosurgeon	O
and	O
neurologist	O
should	O
be	O
aware	O
of	O
calcium	O
antagonist	O
--	O
related	O
ileus	B-ADR
in	O
patient	O
treated	O
with	O
nimodipine	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
subarachnoid	O
haemorrhage	O
who	O
developed	O
an	O
acute	O
life-threatening	O
pseudo-obstruction	O
of	O
the	O
colon	O
,	O
a	O
variant	O
of	O
adynamic	B-ADR
ileus	I-ADR
,	O
while	O
being	O
treated	O
with	O
intravenous	O
nimodipine	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
subarachnoid	O
haemorrhage	O
who	O
developed	O
an	O
acute	O
life-threatening	O
pseudo-obstruction	B-ADR
of	I-ADR
the	I-ADR
colon	I-ADR
,	O
a	O
variant	O
of	O
adynamic	O
ileus	O
,	O
while	O
being	O
treated	O
with	O
intravenous	O
nimodipine	B-Drug
0	O
<EOS>	O
after	O
discontinuation	O
of	O
danazol	B-Drug
the	O
diabetes	B-ADR
completely	O
resolved	O
0	O
<EOS>	O
insulin-dependent	B-ADR
diabetes	I-ADR
mellitus	I-ADR
associated	O
with	O
danazol	B-Drug
0	O
<EOS>	O
insulin-dependent	B-ADR
diabetes	I-ADR
mellitus	I-ADR
developed	O
in	O
a	O
young	O
woman	O
8	O
week	O
after	O
the	O
initiation	O
of	O
danazol	B-Drug
for	O
treatment	O
of	O
pelvic	O
endometriosis	O
0	O
<EOS>	O
an	O
83-year-old	O
man	O
receiving	O
glipizide	B-Drug
10	O
mg	O
bid	O
developed	O
symptomatic	B-ADR
hypoglycemia	I-ADR
within	O
three	O
day	O
of	O
adding	O
trimethoprim	O
/	O
sulfamethoxazole	O
(	O
tmp	O
/	O
smx	O
)	O
to	O
his	O
regimen	O
0	O
<EOS>	O
an	O
83-year-old	O
man	O
receiving	O
glipizide	O
10	O
mg	O
bid	O
developed	O
symptomatic	B-ADR
hypoglycemia	I-ADR
within	O
three	O
day	O
of	O
adding	O
trimethoprim	O
/	O
sulfamethoxazole	O
(	O
tmp	O
/	O
smx	B-Drug
)	O
to	O
his	O
regimen	O
0	O
<EOS>	O
an	O
83-year-old	O
man	O
receiving	O
glipizide	O
10	O
mg	O
bid	O
developed	O
symptomatic	B-ADR
hypoglycemia	I-ADR
within	O
three	O
day	O
of	O
adding	O
trimethoprim	O
/	O
sulfamethoxazole	B-Drug
(	O
tmp	O
/	O
smx	O
)	O
to	O
his	O
regimen	O
0	O
<EOS>	O
an	O
83-year-old	O
man	O
receiving	O
glipizide	O
10	O
mg	O
bid	O
developed	O
symptomatic	B-ADR
hypoglycemia	I-ADR
within	O
three	O
day	O
of	O
adding	O
trimethoprim	O
/	O
sulfamethoxazole	O
(	O
tmp	B-Drug
/	O
smx	O
)	O
to	O
his	O
regimen	O
0	O
<EOS>	O
an	O
83-year-old	O
man	O
receiving	O
glipizide	O
10	O
mg	O
bid	O
developed	O
symptomatic	B-ADR
hypoglycemia	I-ADR
within	O
three	O
day	O
of	O
adding	O
trimethoprim	B-Drug
/	O
sulfamethoxazole	O
(	O
tmp	O
/	O
smx	O
)	O
to	O
his	O
regimen	O
0	O
<EOS>	O
symptomatic	B-ADR
hypoglycemia	I-ADR
secondary	O
to	O
a	O
glipizide-trimethoprim	B-Drug
/	O
sulfamethoxazole	O
drug	O
interaction	O
0	O
<EOS>	O
symptomatic	B-ADR
hypoglycemia	I-ADR
secondary	O
to	O
a	O
glipizide-trimethoprim	O
/	O
sulfamethoxazole	B-Drug
drug	O
interaction	O
0	O
<EOS>	O
symptomatic	B-ADR
hypoglycemia	I-ADR
secondary	O
to	O
a	O
glipizide-trimethoprim	B-Drug
/	O
sulfamethoxazole	O
drug	O
interaction	O
0	O
<EOS>	O
a	O
sixty-year-old	O
woman	O
with	O
advanced	O
breast	O
cancer	O
,	O
previously	O
treated	O
with	O
cisplatin	O
,	O
developed	O
an	O
irreversible	O
lethal	O
renal	O
failure	O
with	O
anuria	B-ADR
,	O
the	O
day	O
after	O
5	O
g	O
/	O
m2	O
bolus	O
ifosfamide	B-Drug
0	O
<EOS>	O
a	O
sixty-year-old	O
woman	O
with	O
advanced	O
breast	O
cancer	O
,	O
previously	O
treated	O
with	O
cisplatin	O
,	O
developed	O
an	O
irreversible	B-ADR
lethal	I-ADR
renal	I-ADR
failure	I-ADR
with	O
anuria	O
,	O
the	O
day	O
after	O
5	O
g	O
/	O
m2	O
bolus	O
ifosfamide	B-Drug
0	O
<EOS>	O
ifosfamide	B-Drug
is	O
a	O
known	O
nephrotoxic	O
drug	O
with	O
demonstrated	O
tubulopathies	B-ADR
0	O
<EOS>	O
lethal	B-ADR
anuria	I-ADR
complicating	O
high	O
dose	O
ifosfamide	B-Drug
chemotherapy	O
in	O
a	O
breast	O
cancer	O
patient	O
with	O
an	O
impaired	O
renal	O
function	O
0	O
<EOS>	O
we	O
strongly	O
suspect	O
that	O
this	O
lethal	B-ADR
anuria	I-ADR
wa	O
mainly	O
due	O
to	O
ifosfamide	B-Drug
,	O
occurring	O
in	O
a	O
patient	O
having	O
received	O
previous	O
cisplatin	O
chemotherapy	O
and	O
with	O
poor	O
kidney	O
perfusion	O
due	O
to	O
transient	O
hypotension	O
0	O
<EOS>	O
ciprofloxacin	B-Drug
is	O
one	O
drug	O
that	O
ha	O
been	O
reported	O
to	O
cause	O
interstitial	B-ADR
nephritis	I-ADR
0	O
<EOS>	O
renal	B-ADR
toxicity	I-ADR
have	O
been	O
reported	O
in	O
le	O
than	O
one	O
percent	O
of	O
the	O
patient	O
receiving	O
ciprofloxacin	B-Drug
therapy	O
0	O
<EOS>	O
suspected	O
ciprofloxacin-induced	B-Drug
interstitial	B-ADR
nephritis	I-ADR
0	O
<EOS>	O
this	O
article	O
describes	O
a	O
patient	O
with	O
suspected	O
ciprofloxacin-induced	B-Drug
interstitial	B-ADR
nephritis	I-ADR
0	O
<EOS>	O
in	O
a	O
female	O
with	O
acute	O
lymphoblastic	O
leukemia	O
,	O
inadvertent	O
doxorubicin	B-Drug
administration	O
intrathecally	O
caused	O
severe	O
,	O
life-threatening	O
,	O
acute	B-ADR
encephalopathy	I-ADR
with	O
high-pressure	O
hydrocephalus	O
0	O
<EOS>	O
in	O
a	O
female	O
with	O
acute	O
lymphoblastic	O
leukemia	O
,	O
inadvertent	O
doxorubicin	B-Drug
administration	O
intrathecally	O
caused	O
severe	O
,	O
life-threatening	O
,	O
acute	O
encephalopathy	O
with	O
high-pressure	B-ADR
hydrocephalus	I-ADR
0	O
<EOS>	O
severe	B-ADR
acute	I-ADR
encephalopathy	I-ADR
following	O
inadvertent	O
intrathecal	O
doxorubicin	B-Drug
administration	O
0	O
<EOS>	O
phenobarbital	B-Drug
hepatotoxicity	B-ADR
in	O
an	O
8-month-old	O
infant	O
0	O
<EOS>	O
severe	B-ADR
hepatotoxicity	I-ADR
from	O
phenobarbital	B-Drug
occurred	O
in	O
an	O
infant	O
boy	O
who	O
had	O
a	O
complicated	O
illness	O
with	O
chronic	O
bilateral	O
subdural	O
hematoma	O
and	O
sepsis	O
0	O
<EOS>	O
skin	O
rash	O
began	O
after	O
2	O
week	O
of	O
treatment	O
,	O
and	O
sign	O
of	O
hepatocellular	B-ADR
failure	I-ADR
developed	O
3	O
week	O
after	O
phenobarbital	B-Drug
had	O
been	O
started	O
0	O
<EOS>	O
skin	B-ADR
rash	I-ADR
began	O
after	O
2	O
week	O
of	O
treatment	O
,	O
and	O
sign	O
of	O
hepatocellular	O
failure	O
developed	O
3	O
week	O
after	O
phenobarbital	B-Drug
had	O
been	O
started	O
0	O
<EOS>	O
atenolol-induced	B-Drug
pseudolymphoma	B-ADR
0	O
<EOS>	O
although	O
tardive	B-ADR
dyskinesia	I-ADR
is	O
a	O
known	O
adverse	O
reaction	O
of	O
sustained	O
treatment	O
with	O
traditional	O
neuroleptic	O
agent	O
,	O
it	O
wa	O
only	O
rarely	O
reported	O
in	O
association	O
with	O
sulpiride	B-Drug
,	O
a	O
selective	O
d2-receptor	O
antagonist	O
0	O
<EOS>	O
tardive	B-ADR
dyskinesia	I-ADR
induced	O
by	O
sulpiride	B-Drug
0	O
<EOS>	O
these	O
case	O
indicate	O
that	O
sulpiride	B-Drug
can	O
cause	O
tardive	B-ADR
dyskinesia	I-ADR
and	O
that	O
this	O
drug	O
should	O
be	O
administered	O
with	O
caution	O
0	O
<EOS>	O
we	O
describe	O
six	O
patient	O
who	O
developed	O
tardive	B-ADR
dyskinesia	I-ADR
after	O
treatment	O
with	O
sulpiride	B-Drug
for	O
depression	O
or	O
gastrointestinal	O
symptom	O
0	O
<EOS>	O
a	O
patient	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
developed	O
ascites	B-ADR
while	O
taking	O
weekly	O
dos	O
of	O
methotrexate	B-Drug
(	O
mtx	O
)	O
0	O
<EOS>	O
a	O
patient	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
developed	O
ascites	B-ADR
while	O
taking	O
weekly	O
dos	O
of	O
methotrexate	O
(	O
mtx	B-Drug
)	O
0	O
<EOS>	O
hepatitis	O
with	O
bridging	B-ADR
fibrosis	I-ADR
and	O
reversible	O
hepatic	O
insufficiency	O
in	O
a	O
woman	O
with	O
rheumatoid	O
arthritis	O
taking	O
methotrexate	B-Drug
0	O
<EOS>	O
hepatitis	B-ADR
with	O
bridging	O
fibrosis	O
and	O
reversible	O
hepatic	O
insufficiency	O
in	O
a	O
woman	O
with	O
rheumatoid	O
arthritis	O
taking	O
methotrexate	B-Drug
0	O
<EOS>	O
hepatitis	O
with	O
bridging	O
fibrosis	O
and	O
reversible	B-ADR
hepatic	I-ADR
insufficiency	I-ADR
in	O
a	O
woman	O
with	O
rheumatoid	O
arthritis	O
taking	O
methotrexate	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
third	O
report	O
of	O
reversible	O
hepatic	B-ADR
decompensation	I-ADR
associated	O
with	O
prolonged	O
mtx	B-Drug
therapy	O
in	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
upon	O
discontinuation	O
of	O
mtx	B-Drug
,	O
her	O
ascites	B-ADR
resolved	O
,	O
and	O
her	O
arthritis	O
became	O
more	O
active	O
0	O
<EOS>	O
although	O
high-dose	O
methotrexate	B-Drug
ha	O
been	O
shown	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
primary	O
osteogenic	O
sarcoma	O
,	O
the	O
tumoricidal	O
effect	O
of	O
therapy	O
appear	O
to	O
have	O
caused	O
a	O
fatal	B-ADR
rise	I-ADR
in	I-ADR
intracranial	I-ADR
pressure	I-ADR
0	O
<EOS>	O
a	O
patient	O
with	O
intracranial	O
osteosarcoma	O
that	O
arose	O
16	O
year	O
after	O
radiation	O
therapy	O
for	O
hereditary	O
retinoblastoma	O
developed	O
fatal	O
cerebral	O
edema	O
and	O
brainstem	B-ADR
herniation	I-ADR
after	O
she	O
received	O
a	O
single	O
dose	O
of	O
intravenous	O
methotrexate	B-Drug
0	O
<EOS>	O
a	O
patient	O
with	O
intracranial	O
osteosarcoma	O
that	O
arose	O
16	O
year	O
after	O
radiation	O
therapy	O
for	O
hereditary	O
retinoblastoma	O
developed	O
fatal	B-ADR
cerebral	I-ADR
edema	I-ADR
and	O
brainstem	O
herniation	O
after	O
she	O
received	O
a	O
single	O
dose	O
of	O
intravenous	O
methotrexate	B-Drug
0	O
<EOS>	O
transtentorial	O
herniation	O
caused	O
by	O
an	O
intracranial	B-ADR
mass	I-ADR
lesion	I-ADR
following	O
high-dose	O
methotrexate	B-Drug
0	O
<EOS>	O
transtentorial	B-ADR
herniation	I-ADR
caused	O
by	O
an	O
intracranial	O
mass	O
lesion	O
following	O
high-dose	O
methotrexate	B-Drug
0	O
<EOS>	O
fever	B-ADR
,	O
pulmonary	O
infiltrates	O
,	O
and	O
pleural	O
effusion	O
following	O
acyclovir	B-Drug
therapy	O
for	O
herpes	O
zoster	O
ophthalmicus	O
0	O
<EOS>	O
fever	O
,	O
pulmonary	O
infiltrates	O
,	O
and	O
pleural	B-ADR
effusion	I-ADR
following	O
acyclovir	B-Drug
therapy	O
for	O
herpes	O
zoster	O
ophthalmicus	O
0	O
<EOS>	O
fever	O
,	O
pulmonary	B-ADR
infiltrates	I-ADR
,	O
and	O
pleural	O
effusion	O
following	O
acyclovir	B-Drug
therapy	O
for	O
herpes	O
zoster	O
ophthalmicus	O
0	O
<EOS>	O
following	O
the	O
institution	O
of	O
intravenous	O
therapy	O
with	O
acyclovir	B-Drug
,	O
the	O
patient	O
developed	O
fever	B-ADR
,	O
hemoptysis	O
,	O
and	O
a	O
pleural	O
friction	O
rub	O
0	O
<EOS>	O
following	O
the	O
institution	O
of	O
intravenous	O
therapy	O
with	O
acyclovir	B-Drug
,	O
the	O
patient	O
developed	O
fever	O
,	O
hemoptysis	B-ADR
,	O
and	O
a	O
pleural	O
friction	O
rub	O
0	O
<EOS>	O
following	O
the	O
institution	O
of	O
intravenous	O
therapy	O
with	O
acyclovir	B-Drug
,	O
the	O
patient	O
developed	O
fever	O
,	O
hemoptysis	O
,	O
and	O
a	O
pleural	B-ADR
friction	I-ADR
rub	I-ADR
0	O
<EOS>	O
the	O
fever	B-ADR
abated	O
promptly	O
following	O
discontinuation	O
of	O
acyclovir	B-Drug
,	O
and	O
radiographic	O
abnormality	O
resolved	O
over	O
ten	O
day	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
the	O
syndrome	O
of	O
fever	B-ADR
,	O
pulmonary	O
infiltrates	O
,	O
and	O
pleural	O
effusion	O
following	O
use	O
of	O
acyclovir	B-Drug
ha	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
the	O
syndrome	O
of	O
fever	O
,	O
pulmonary	O
infiltrates	O
,	O
and	O
pleural	B-ADR
effusion	I-ADR
following	O
use	O
of	O
acyclovir	B-Drug
ha	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
the	O
syndrome	O
of	O
fever	O
,	O
pulmonary	B-ADR
infiltrates	I-ADR
,	O
and	O
pleural	O
effusion	O
following	O
use	O
of	O
acyclovir	B-Drug
ha	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
quinine-induced	B-Drug
hearing	B-ADR
loss	I-ADR
0	O
<EOS>	O
sensorineural	B-ADR
hearing	I-ADR
loss	I-ADR
due	O
to	O
quinine	B-Drug
therapy	O
for	O
malaria	O
ha	O
frequently	O
been	O
mentioned	O
in	O
the	O
literature	O
but	O
ha	O
not	O
been	O
a	O
subject	O
of	O
research	O
during	O
the	O
last	O
decade	O
0	O
<EOS>	O
the	O
case	O
of	O
a	O
29-year-old	O
man	O
suffering	O
from	O
falciparum	O
malaria	O
disease	O
who	O
got	O
a	O
reversible	B-ADR
hearing	I-ADR
loss	I-ADR
from	O
quinine	B-Drug
therapy	O
is	O
presented	O
0	O
<EOS>	O
the	O
ototoxicity	B-ADR
of	O
quinine	B-Drug
can	O
accurately	O
be	O
studied	O
with	O
ultrahigh	O
frequency	O
audiometry	O
(	O
up	O
to	O
20	O
khz	O
)	O
0	O
<EOS>	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
a	O
patient	O
on	O
cis-platinum	O
,	O
vinblastine	O
and	O
bleomycin	B-Drug
0	O
<EOS>	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
a	O
patient	O
on	O
cis-platinum	B-Drug
,	O
vinblastine	O
and	O
bleomycin	O
0	O
<EOS>	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
a	O
patient	O
on	O
cis-platinum	O
,	O
vinblastine	B-Drug
and	O
bleomycin	O
0	O
<EOS>	O
a	O
case	O
of	O
a	O
53-year-old	O
man	O
who	O
developed	O
acute	B-ADR
pneumonitis	I-ADR
after	O
bleomycin	B-Drug
and	O
moderate	O
oxygen	O
administration	O
is	O
presented	O
0	O
<EOS>	O
a	O
case	O
of	O
a	O
53-year-old	O
man	O
who	O
developed	O
acute	B-ADR
pneumonitis	I-ADR
after	O
bleomycin	O
and	O
moderate	O
oxygen	B-Drug
administration	O
is	O
presented	O
0	O
<EOS>	O
autopsy	O
finding	O
were	O
consistent	O
with	O
bleomycin	B-Drug
and	O
oxygen-induced	O
pulmonary	B-ADR
damage	I-ADR
0	O
<EOS>	O
autopsy	O
finding	O
were	O
consistent	O
with	O
bleomycin	O
and	O
oxygen-induced	B-Drug
pulmonary	B-ADR
damage	I-ADR
0	O
<EOS>	O
bleomycin	B-Drug
pneumonitis	B-ADR
potentiated	O
by	O
oxygen	O
administration	O
0	O
<EOS>	O
oxygen	O
potentiation	O
of	O
bleomycin-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
is	O
discussed	O
0	O
<EOS>	O
oxygen	B-Drug
potentiation	O
of	O
bleomycin-induced	O
pulmonary	B-ADR
toxicity	I-ADR
is	O
discussed	O
0	O
<EOS>	O
a	O
patient	O
with	O
the	O
wolff-parkinson-white	O
syndrome	O
presented	O
with	O
incessant	B-ADR
orthodromic	I-ADR
atrioventricular	I-ADR
tachycardia	I-ADR
following	O
initiation	O
of	O
procainamide	B-Drug
therapy	O
0	O
<EOS>	O
escape	O
atrial	O
complex	O
,	O
which	O
occurred	O
following	O
junctional	O
premature	O
complex	O
,	O
failed	O
to	O
initiate	O
tachycardia	B-ADR
in	O
the	O
control	O
state	O
but	O
tachycardia	O
wa	O
always	O
reinitiated	O
by	O
an	O
identical	O
escape	O
sequence	O
after	O
procainamide	B-Drug
0	O
<EOS>	O
in	O
addition	O
,	O
the	O
tachycardia	B-ADR
persisted	O
and	O
wa	O
repeatedly	O
spontaneously	O
reinitiated	O
for	O
prolonged	O
period	O
after	O
procainamide	B-Drug
0	O
<EOS>	O
procainamide-induced	B-Drug
incessant	B-ADR
supraventricular	I-ADR
tachycardia	I-ADR
in	O
the	O
wolff-parkinson-white	O
syndrome	O
0	O
<EOS>	O
the	O
pro-arrhythmic	B-ADR
effect	I-ADR
of	O
procainamide	B-Drug
may	O
be	O
explained	O
on	O
the	O
basis	O
of	O
both	O
it	O
vagolytic	O
action	O
on	O
the	O
atrioventricular	O
node	O
a	O
well	O
a	O
by	O
prolongation	O
of	O
refractoriness	O
in	O
the	O
accessory	O
pathway	O
0	O
<EOS>	O
multicentric	B-ADR
hepatocellular	I-ADR
carcinoma	I-ADR
following	O
phosphate	B-Drug
diethylstilbestrol	I-Drug
therapy	O
for	O
prostatic	O
cancer	O
0	O
<EOS>	O
this	O
is	O
a	O
unique	O
autopsy	O
case	O
of	O
hepatocellular	B-ADR
carcinoma	I-ADR
closely	O
related	O
to	O
diethylstilbestrol	O
(	O
de	B-Drug
)	O
therapy	O
for	O
prostatic	O
cancer	O
0	O
<EOS>	O
this	O
is	O
a	O
unique	O
autopsy	O
case	O
of	O
hepatocellular	B-ADR
carcinoma	I-ADR
closely	O
related	O
to	O
diethylstilbestrol	B-Drug
(	O
de	O
)	O
therapy	O
for	O
prostatic	O
cancer	O
0	O
<EOS>	O
this	O
paper	O
report	O
an	O
autopsy	O
case	O
of	O
a	O
78-year-old	O
male	O
with	O
multiple	B-ADR
nodule	I-ADR
in	I-ADR
the	I-ADR
liver	I-ADR
developed	O
after	O
long-termed	O
administration	O
of	O
phosphate	O
diethylstilbestrol	O
(	O
pdes	B-Drug
)	O
for	O
prostatic	O
cancer	O
0	O
<EOS>	O
this	O
paper	O
report	O
an	O
autopsy	O
case	O
of	O
a	O
78-year-old	O
male	O
with	O
multiple	B-ADR
nodule	I-ADR
in	I-ADR
the	I-ADR
liver	I-ADR
developed	O
after	O
long-termed	O
administration	O
of	O
phosphate	B-Drug
diethylstilbestrol	I-Drug
(	O
pdes	O
)	O
for	O
prostatic	O
cancer	O
0	O
<EOS>	O
a	O
52-year-old	O
woman	O
developed	O
symmetric	O
sensorimotor	O
polyneuropathy	O
and	O
cerebellar	B-ADR
syndrome	I-ADR
after	O
24	O
month	O
of	O
amiodarone	B-Drug
treatment	O
0	O
<EOS>	O
a	O
52-year-old	O
woman	O
developed	O
symmetric	B-ADR
sensorimotor	I-ADR
polyneuropathy	I-ADR
and	O
cerebellar	O
syndrome	O
after	O
24	O
month	O
of	O
amiodarone	B-Drug
treatment	O
0	O
<EOS>	O
peripheral	O
neuropathy	O
and	O
cerebellar	B-ADR
syndrome	I-ADR
associated	O
with	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
peripheral	B-ADR
neuropathy	I-ADR
and	O
cerebellar	O
syndrome	O
associated	O
with	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
life-threatening	O
hyponatremia	B-ADR
caused	O
by	O
vinblastine	B-Drug
0	O
<EOS>	O
the	O
most	O
likely	O
cause	O
of	O
such	O
hyponatremic	B-ADR
episode	I-ADR
is	O
vinblastine	B-Drug
0	O
<EOS>	O
although	O
this	O
type	O
of	O
hyperpigmentation	B-ADR
ha	O
been	O
previously	O
seen	O
in	O
patient	O
with	O
cancer	O
who	O
are	O
receiving	O
bleomycin	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
reported	O
case	O
of	O
bleomycin-induced	B-Drug
hyperpigmentation	O
in	O
an	O
aid	O
patient	O
and	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
cutaneous	O
eruption	O
seen	O
in	O
these	O
patient	O
0	O
<EOS>	O
although	O
this	O
type	O
of	O
hyperpigmentation	B-ADR
ha	O
been	O
previously	O
seen	O
in	O
patient	O
with	O
cancer	O
who	O
are	O
receiving	O
bleomycin	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
reported	O
case	O
of	O
bleomycin-induced	B-Drug
hyperpigmentation	O
in	O
an	O
aid	O
patient	O
and	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
cutaneous	O
eruption	O
seen	O
in	O
these	O
patient	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
hyperpigmentation	B-ADR
due	O
to	O
bleomycin	B-Drug
treatment	O
in	O
a	O
patient	O
with	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
aid	O
)	O
0	O
<EOS>	O
a	O
typical	O
case	O
of	O
dextran-40	B-Drug
associated	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
is	O
presented	O
0	O
<EOS>	O
renal	B-ADR
failure	I-ADR
associated	O
with	O
the	O
use	O
of	O
dextran-40	B-Drug
0	O
<EOS>	O
several	O
possible	O
explanation	O
of	O
the	O
mechanism	O
of	O
renal	B-ADR
failure	I-ADR
associated	O
with	O
the	O
use	O
of	O
dextran-40	B-Drug
are	O
discussed	O
0	O
<EOS>	O
while	O
the	O
mechanism	O
of	O
dextran-associated	B-Drug
renal	B-ADR
failure	I-ADR
remains	O
unsolved	O
,	O
plasma	O
exchange	O
seems	O
to	O
be	O
effective	O
therapy	O
0	O
<EOS>	O
mr	O
finding	O
in	O
methotrexate-induced	B-Drug
cns	B-ADR
abnormality	I-ADR
0	O
<EOS>	O
a	O
57-year-old	O
man	O
developed	O
morphea	B-ADR
while	O
taking	O
bromocriptine	B-Drug
0	O
<EOS>	O
morphea	B-ADR
after	O
bromocriptine	B-Drug
therapy	O
0	O
<EOS>	O
a	O
35-year-old	O
female	O
with	O
borderline	O
lepromatous	O
(	O
bl	O
)	O
leprosy	O
who	O
suffered	O
from	O
dapsone-induced	B-Drug
erythroderma	B-ADR
is	O
reported	O
0	O
<EOS>	O
dapsone-induced	B-Drug
erythroderma	B-ADR
with	O
beau	O
line	O
0	O
<EOS>	O
akathisia	B-ADR
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-Drug
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta-adrenergic	O
antagonist	O
propranolol	O
,	O
dose	O
reduction	O
,	O
or	O
both	O
0	O
<EOS>	O
five	O
patient	O
receiving	O
fluoxetine	B-Drug
for	O
the	O
treatment	O
of	O
obsessive	O
compulsive	O
disorder	O
or	O
major	O
depression	O
developed	O
akathisia	B-ADR
0	O
<EOS>	O
fluoxetine-induced	B-Drug
akathisia	B-ADR
:	O
clinical	O
and	O
theoretical	O
implication	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
fluoxetine-induced	B-Drug
akathisia	B-ADR
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine-induced	O
akathisia	O
and	O
tricyclic	O
antidepressant-induced	O
``	O
jitteriness	O
'	O
may	O
be	O
identical	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
fluoxetine-induced	B-Drug
akathisia	B-ADR
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine-induced	O
akathisia	O
and	O
tricyclic	O
antidepressant-induced	O
``	O
jitteriness	O
'	O
may	O
be	O
identical	O
0	O
<EOS>	O
the	O
typical	O
fluoxetine-induced	B-Drug
symptom	O
of	O
restlessness	O
,	O
constant	B-ADR
pacing	I-ADR
,	O
purposeless	O
movement	O
of	O
the	O
foot	O
and	O
leg	O
,	O
and	O
marked	O
anxiety	O
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	O
0	O
<EOS>	O
the	O
typical	O
fluoxetine-induced	B-Drug
symptom	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movement	O
of	O
the	O
foot	O
and	O
leg	O
,	O
and	O
marked	B-ADR
anxiety	I-ADR
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	O
0	O
<EOS>	O
the	O
typical	O
fluoxetine-induced	B-Drug
symptom	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	B-ADR
movement	I-ADR
of	I-ADR
the	I-ADR
foot	I-ADR
and	I-ADR
leg	I-ADR
,	O
and	O
marked	O
anxiety	O
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	O
0	O
<EOS>	O
the	O
typical	O
fluoxetine-induced	B-Drug
symptom	O
of	O
restlessness	B-ADR
,	O
constant	O
pacing	O
,	O
purposeless	O
movement	O
of	O
the	O
foot	O
and	O
leg	O
,	O
and	O
marked	O
anxiety	O
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	O
0	O
<EOS>	O
three	O
patient	O
who	O
had	O
experienced	O
neuroleptic-induced	O
akathisia	B-ADR
in	O
the	O
past	O
reported	O
that	O
the	O
symptom	O
of	O
fluoxetine-induced	B-Drug
akathisia	O
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
0	O
<EOS>	O
horner	O
syndrome	O
and	O
demyelinating	B-ADR
peripheral	I-ADR
neuropathy	I-ADR
caused	O
by	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
horner	B-ADR
syndrome	I-ADR
and	O
demyelinating	O
peripheral	O
neuropathy	O
caused	O
by	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
peripheral	B-ADR
nerve	I-ADR
dysfunction	I-ADR
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
peripheral	B-ADR
nervous	I-ADR
system	I-ADR
disturbance	I-ADR
caused	O
by	O
cytosine	B-Drug
arabinoside	I-Drug
have	O
rarely	O
been	O
reported	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
leukemia	O
who	O
developed	O
horner	O
syndrome	O
and	O
a	O
severe	O
demyelinating	O
peripheral	O
neuropathy	O
leading	O
to	O
death	B-ADR
after	O
receiving	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
leukemia	O
who	O
developed	O
horner	B-ADR
syndrome	I-ADR
and	O
a	O
severe	O
demyelinating	O
peripheral	O
neuropathy	O
leading	O
to	O
death	O
after	O
receiving	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
leukemia	O
who	O
developed	O
horner	O
syndrome	O
and	O
a	O
severe	B-ADR
demyelinating	I-ADR
peripheral	I-ADR
neuropathy	I-ADR
leading	O
to	O
death	O
after	O
receiving	O
high-dose	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
nail-changes	B-ADR
induced	O
by	O
penicillamine	B-Drug
0	O
<EOS>	O
peculiar	O
nail-changes	B-ADR
in	O
a	O
70-year-old	O
woman	O
with	O
rheumatoid	O
arthritis	O
occurring	O
after	O
approximately	O
1	O
year	O
of	O
penicillamine	B-Drug
treatment	O
are	O
described	O
0	O
<EOS>	O
reinstitution	O
of	O
penicillamine	B-Drug
treatment	O
caused	O
a	O
recurrence	O
thus	O
proving	O
a	O
causal	O
relationship	O
between	O
penicillamine	O
and	O
the	O
described	O
nail-changes	B-ADR
0	O
<EOS>	O
ibuprofen-induced	B-Drug
meningitis	B-ADR
:	O
detection	O
of	O
intrathecal	O
igg	O
synthesis	O
and	O
immune	O
complex	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
ibuprofen-induced	B-Drug
meningitis	B-ADR
in	O
an	O
otherwise	O
healthy	O
individual	O
0	O
<EOS>	O
metoclopramide-induced	B-Drug
parkinsonism	B-ADR
is	O
not	O
rare	O
,	O
and	O
appropriate	O
dose	O
reduction	O
in	O
patient	O
with	O
renal	O
failure	O
will	O
help	O
reduce	O
the	O
incidence	O
of	O
this	O
morbidity	O
0	O
<EOS>	O
metoclopramide-induced	B-Drug
parkinsonism	B-ADR
0	O
<EOS>	O
their	O
parkinsonism	B-ADR
improved	O
on	O
discontinuation	O
of	O
metoclopramide	B-Drug
therapy	O
0	O
<EOS>	O
we	O
have	O
reported	O
six	O
case	O
of	O
metoclopramide-induced	B-Drug
parkinsonism	B-ADR
seen	O
in	O
consultation	O
over	O
a	O
two-year	O
period	O
0	O
<EOS>	O
it	O
is	O
suggested	O
that	O
the	O
fatal	O
stroke	O
may	O
have	O
resulted	O
from	O
arterial	B-ADR
spasm	I-ADR
caused	O
by	O
ergotamine	B-Drug
overdosage	O
and	O
possibly	O
complicated	O
by	O
thrombosis	O
0	O
<EOS>	O
it	O
is	O
suggested	O
that	O
the	O
fatal	B-ADR
stroke	I-ADR
may	O
have	O
resulted	O
from	O
arterial	O
spasm	O
caused	O
by	O
ergotamine	B-Drug
overdosage	O
and	O
possibly	O
complicated	O
by	O
thrombosis	O
0	O
<EOS>	O
life-threatening	O
acute	B-ADR
hyponatraemia	I-ADR
induced	O
by	O
low	O
dose	O
cyclophosphamide	B-Drug
and	O
indomethacin	O
0	O
<EOS>	O
life-threatening	O
acute	B-ADR
hyponatraemia	I-ADR
induced	O
by	O
low	O
dose	O
cyclophosphamide	O
and	O
indomethacin	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
multiple	O
myeloma	O
who	O
developed	O
acute	O
life-threatening	B-ADR
water	I-ADR
intoxication	I-ADR
following	O
treatment	O
with	O
oral	O
indomethacin	O
and	O
low	O
dose	O
intravenous	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
multiple	O
myeloma	O
who	O
developed	O
acute	O
life-threatening	B-ADR
water	I-ADR
intoxication	I-ADR
following	O
treatment	O
with	O
oral	O
indomethacin	B-Drug
and	O
low	O
dose	O
intravenous	O
cyclophosphamide	O
0	O
<EOS>	O
clofazimine	B-Drug
induced	O
nail	B-ADR
change	I-ADR
0	O
<EOS>	O
these	O
nail	B-ADR
change	I-ADR
gradually	O
disappeared	O
when	O
the	O
dose	O
of	O
clofazimine	B-Drug
wa	O
reduced	O
0	O
<EOS>	O
two	O
case	O
of	O
lepromatous	O
leprosy	O
with	O
erythema	O
nodosum	O
leprosum	O
who	O
were	O
on	O
high	O
dos	O
of	O
clofazimine	B-Drug
,	O
showed	O
discoloration	B-ADR
of	I-ADR
nail	I-ADR
plate	I-ADR
,	O
subungual	O
hyperkeratosis	O
and	O
onycholysis	O
0	O
<EOS>	O
two	O
case	O
of	O
lepromatous	O
leprosy	O
with	O
erythema	O
nodosum	O
leprosum	O
who	O
were	O
on	O
high	O
dos	O
of	O
clofazimine	B-Drug
,	O
showed	O
discoloration	O
of	O
nail	O
plate	O
,	O
subungual	O
hyperkeratosis	O
and	O
onycholysis	B-ADR
0	O
<EOS>	O
two	O
case	O
of	O
lepromatous	O
leprosy	O
with	O
erythema	O
nodosum	O
leprosum	O
who	O
were	O
on	O
high	O
dos	O
of	O
clofazimine	B-Drug
,	O
showed	O
discoloration	O
of	O
nail	O
plate	O
,	O
subungual	B-ADR
hyperkeratosis	I-ADR
and	O
onycholysis	O
0	O
<EOS>	O
attenuation	O
of	O
asparaginase-induced	B-Drug
hyperglycemia	B-ADR
after	O
substitution	O
of	O
the	O
erwinia	O
carotovora	O
for	O
the	O
escherichia	O
coli	O
enzyme	O
preparation	O
0	O
<EOS>	O
development	O
of	O
persistent	B-ADR
late	I-ADR
onset	I-ADR
asthma	I-ADR
following	O
treatment	O
with	O
captopril	B-Drug
0	O
<EOS>	O
we	O
describe	O
the	O
first	O
case	O
of	O
de	O
novo	O
asthma	B-ADR
following	O
treatment	O
with	O
the	O
angiotensin	O
converting	O
enzyme	O
(	O
ace	O
)	O
inhibitor	O
captopril	B-Drug
0	O
<EOS>	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
probable	O
cisplatin	O
and	O
bleomycin-induced	B-Drug
tma	B-ADR
is	O
presented	O
0	O
<EOS>	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
probable	O
cisplatin	B-Drug
and	O
bleomycin-induced	O
tma	B-ADR
is	O
presented	O
0	O
<EOS>	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
treated	O
with	O
busulphan	B-Drug
for	O
4-5	O
year	O
,	O
developed	O
sign	O
of	O
busulphan	O
toxicity	O
and	O
portal	O
hypertension	O
with	O
ascites	B-ADR
,	O
oesophageal	O
varix	O
and	O
jaundice	O
0	O
<EOS>	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
treated	O
with	O
busulphan	B-Drug
for	O
4-5	O
year	O
,	O
developed	O
sign	O
of	O
busulphan	O
toxicity	O
and	O
portal	O
hypertension	O
with	O
ascites	O
,	O
oesophageal	O
varix	O
and	O
jaundice	B-ADR
0	O
<EOS>	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
treated	O
with	O
busulphan	B-Drug
for	O
4-5	O
year	O
,	O
developed	O
sign	O
of	O
busulphan	O
toxicity	O
and	O
portal	O
hypertension	O
with	O
ascites	O
,	O
oesophageal	B-ADR
varix	I-ADR
and	O
jaundice	O
0	O
<EOS>	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
treated	O
with	O
busulphan	B-Drug
for	O
4-5	O
year	O
,	O
developed	O
sign	O
of	O
busulphan	O
toxicity	O
and	O
portal	B-ADR
hypertension	I-ADR
with	O
ascites	O
,	O
oesophageal	O
varix	O
and	O
jaundice	O
0	O
<EOS>	O
although	O
a	O
lot	O
of	O
amiodarone-induced	B-Drug
torsades	B-ADR
de	I-ADR
pointe	I-ADR
have	O
been	O
published	O
,	O
a	O
review	O
of	O
all	O
these	O
case	O
and	O
the	O
underlying	O
risk-factors	O
ha	O
never	O
been	O
made	O
0	O
<EOS>	O
amiodarone	B-Drug
induced	O
torsades	B-ADR
de	I-ADR
pointe	I-ADR
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
amiodarone-induced	B-Drug
torsades	B-ADR
de	I-ADR
pointe	I-ADR
0	O
<EOS>	O
the	O
syndrome	O
of	O
irreversible	O
lithium-effectuated	B-Drug
neurotoxicity	B-ADR
(	O
silent	O
)	O
0	O
<EOS>	O
long	O
lasting	O
respiratory	B-ADR
depression	I-ADR
induced	O
by	O
morphine-6-glucuronide	B-Drug
?	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
long	O
lasting	O
respiratory	B-ADR
depression	I-ADR
after	O
intravenous	O
administration	O
of	O
morphine	B-Drug
to	O
a	O
7	O
year	O
old	O
girl	O
with	O
haemolytic	O
uraemic	O
syndrome	O
0	O
<EOS>	O
rifampin-associated	B-Drug
thrombocytopenia	B-ADR
secondary	O
to	O
poor	O
compliance	O
0	O
<EOS>	O
rifampin	B-Drug
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effect	O
such	O
a	O
hepatitis	O
,	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
,	O
hemolytic	O
anemia	O
,	O
and	O
thrombocytopenia	O
0	O
<EOS>	O
rifampin	B-Drug
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effect	O
such	O
a	O
hepatitis	O
,	O
acute	O
renal	O
failure	O
,	O
hemolytic	B-ADR
anemia	I-ADR
,	O
and	O
thrombocytopenia	O
0	O
<EOS>	O
rifampin	B-Drug
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effect	O
such	O
a	O
hepatitis	B-ADR
,	O
acute	O
renal	O
failure	O
,	O
hemolytic	O
anemia	O
,	O
and	O
thrombocytopenia	O
0	O
<EOS>	O
rifampin	B-Drug
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effect	O
such	O
a	O
hepatitis	O
,	O
acute	O
renal	O
failure	O
,	O
hemolytic	O
anemia	O
,	O
and	O
thrombocytopenia	B-ADR
0	O
<EOS>	O
this	O
article	O
report	O
the	O
occurrence	O
of	O
rifampin-associated	B-Drug
thrombocytopenia	B-ADR
in	O
an	O
indigent	O
patient	O
after	O
a	O
four-month	O
lapse	O
in	O
therapy	O
for	O
pulmonary	O
tuberculosis	O
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
of	O
wes	B-ADR
in	O
an	O
infant	O
born	O
to	O
a	O
mother	O
taking	O
haloperidol	B-Drug
during	O
her	O
pregnancy	O
0	O
<EOS>	O
withdrawal	B-ADR
emergent	I-ADR
syndrome	I-ADR
in	O
an	O
infant	O
associated	O
with	O
maternal	O
haloperidol	B-Drug
therapy	O
0	O
<EOS>	O
this	O
report	O
describes	O
two	O
patient	O
who	O
developed	O
acute	B-ADR
myelocytic	I-ADR
leukemia	I-ADR
only	O
after	O
exposure	O
to	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
and	O
5-fluorouracil	B-Drug
adjuvant	O
therapy	O
0	O
<EOS>	O
this	O
report	O
describes	O
two	O
patient	O
who	O
developed	O
acute	B-ADR
myelocytic	I-ADR
leukemia	I-ADR
only	O
after	O
exposure	O
to	O
cyclophosphamide	B-Drug
,	O
methotrexate	O
,	O
and	O
5-fluorouracil	O
adjuvant	O
therapy	O
0	O
<EOS>	O
this	O
report	O
describes	O
two	O
patient	O
who	O
developed	O
acute	B-ADR
myelocytic	I-ADR
leukemia	I-ADR
only	O
after	O
exposure	O
to	O
cyclophosphamide	O
,	O
methotrexate	B-Drug
,	O
and	O
5-fluorouracil	O
adjuvant	O
therapy	O
0	O
<EOS>	O
ibuprofen	B-Drug
rarely	O
cause	O
lower	O
gastrointestinal	B-ADR
adverse	I-ADR
reaction	I-ADR
but	O
ha	O
been	O
implicated	O
in	O
systemic	O
and	O
local	O
side	O
effect	O
in	O
patient	O
with	O
lupus	O
0	O
<EOS>	O
ulcerative	B-ADR
proctitis	I-ADR
in	O
juvenile	O
systemic	O
lupus	O
erythematosus	O
after	O
ibuprofen	B-Drug
treatment	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
ulcerative	B-ADR
proctitis	I-ADR
after	O
ibuprofen	B-Drug
treatment	O
in	O
a	O
girl	O
with	O
juvenile	O
systemic	O
lupus	O
erythematosus	O
0	O
<EOS>	O
intravenous	O
cytarabine	B-Drug
and	O
methotrexate	O
appear	O
to	O
act	O
synergistically	O
to	O
enhance	O
the	O
potential	O
for	O
central	B-ADR
nervous	I-ADR
system	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
intravenous	O
cytarabine	O
and	O
methotrexate	B-Drug
appear	O
to	O
act	O
synergistically	O
to	O
enhance	O
the	O
potential	O
for	O
central	B-ADR
nervous	I-ADR
system	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
we	O
present	O
two	O
child	O
with	O
acute	O
lymphocytic	O
leukemia	O
who	O
developed	O
leukoencephalopathy	B-ADR
following	O
administration	O
of	O
a	O
combination	O
of	O
intravenous	O
ara	B-Drug
=	I-Drug
c	I-Drug
and	O
methotrexate	O
during	O
the	O
consolidation	O
phase	O
of	O
chemotherapy	O
0	O
<EOS>	O
we	O
present	O
two	O
child	O
with	O
acute	O
lymphocytic	O
leukemia	O
who	O
developed	O
leukoencephalopathy	B-ADR
following	O
administration	O
of	O
a	O
combination	O
of	O
intravenous	O
ara	O
=	O
c	O
and	O
methotrexate	B-Drug
during	O
the	O
consolidation	O
phase	O
of	O
chemotherapy	O
0	O
<EOS>	O
dexamethasone	O
treatment	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
(	O
ait	O
)	O
with	O
or	O
without	O
persistent	O
administration	O
of	O
the	O
drug	O
0	O
<EOS>	O
treatment	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
(	O
ait	O
)	O
with	O
thionamide	O
,	O
lithium	O
or	O
radioactive	O
iodine	O
is	O
ineffective	O
0	O
<EOS>	O
acute	B-ADR
myelogenous	I-ADR
leukemia	I-ADR
in	O
patient	O
receiving	O
chlorambucil	B-Drug
a	O
long-term	O
adjuvant	O
chemotherapy	O
for	O
stage	O
ii	O
breast	O
cancer	O
0	O
<EOS>	O
after	O
the	O
chlorambucil	B-Drug
wa	O
discontinued	O
,	O
the	O
wbc	O
count	O
began	O
to	O
slowly	O
rise	O
and	O
the	O
patient	O
developed	O
clinical	O
aml	B-ADR
0	O
<EOS>	O
panic	B-ADR
anxiety	I-ADR
after	O
abrupt	O
discontinuation	O
of	O
mianserin	B-Drug
0	O
<EOS>	O
this	O
panic	B-ADR
anxiety	I-ADR
wa	O
not	O
relieved	O
by	O
taking	O
etizolam	O
and	O
flunitrazepam	O
again	O
,	O
but	O
subsided	O
rapidly	O
by	O
the	O
re-administration	O
of	O
mianserin	B-Drug
30	O
mg	O
/	O
day	O
,	O
and	O
because	O
of	O
that	O
the	O
depressive	O
symptom	O
also	O
disappeared	O
0	O
<EOS>	O
prior	O
neurologic	O
illness	O
and	O
the	O
syndrome	O
of	O
irreversible	O
lithium-effectuated	B-Drug
neurotoxicity	B-ADR
(	O
silent	O
)	O
0	O
<EOS>	O
prior	O
neurologic	O
illness	O
or	O
cns	O
insult	O
of	O
any	O
kind	O
is	O
known	O
to	O
increase	O
the	O
vulnerability	O
to	O
neurotoxicity	B-ADR
of	O
lithium	B-Drug
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
patient	O
with	O
hemiparesis	O
who	O
developed	O
the	O
syndrome	O
of	O
irreversible	O
lithium-effectuated	B-Drug
neurotoxicity	B-ADR
(	O
silent	O
)	O
while	O
being	O
treated	O
with	O
lithium	O
for	O
a	O
manic	O
episode	O
0	O
<EOS>	O
abrupt	O
,	O
accidental	O
withdrawal	O
of	O
trihexyphenidyl	B-Drug
triggered	O
severe	O
exacerbation	O
of	O
the	O
cranial	O
dystonia	O
associated	O
with	O
inspiratory	O
stridor	O
and	O
acute	B-ADR
respiratory	I-ADR
difficulty	I-ADR
,	O
prompting	O
emergency	O
admission	O
0	O
<EOS>	O
abrupt	O
,	O
accidental	O
withdrawal	O
of	O
trihexyphenidyl	B-Drug
triggered	O
severe	O
exacerbation	O
of	O
the	O
cranial	B-ADR
dystonia	I-ADR
associated	O
with	O
inspiratory	O
stridor	O
and	O
acute	O
respiratory	O
difficulty	O
,	O
prompting	O
emergency	O
admission	O
0	O
<EOS>	O
abrupt	O
,	O
accidental	O
withdrawal	O
of	O
trihexyphenidyl	B-Drug
triggered	O
severe	O
exacerbation	O
of	O
the	O
cranial	O
dystonia	O
associated	O
with	O
inspiratory	B-ADR
stridor	I-ADR
and	O
acute	O
respiratory	O
difficulty	O
,	O
prompting	O
emergency	O
admission	O
0	O
<EOS>	O
life-threatening	O
cranial	B-ADR
dystonia	I-ADR
following	O
trihexyphenidyl	B-Drug
withdrawal	O
0	O
<EOS>	O
mr	O
finding	O
in	O
methotrexate-induced	B-Drug
cns	B-ADR
abnormality	I-ADR
0	O
<EOS>	O
administration	O
of	O
intrathecal	O
ara-c	B-Drug
in	O
the	O
same	O
dose	O
over	O
longer	O
interval	O
within	O
3-5	O
day	O
between	O
consecutive	O
dos	O
resulted	O
in	O
mild	O
,	O
transient	O
neurological	O
symptom	O
(	O
paresthesia	B-ADR
)	O
in	O
only	O
one	O
of	O
30	O
patient	O
so	O
treated	O
0	O
<EOS>	O
paraplegia	B-ADR
following	O
intrathecal	O
cytosine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
paraplegia	B-ADR
following	O
prophylactic	O
intrathecal	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
is	O
described	O
in	O
a	O
patient	O
with	O
acute	O
myelogenous	O
leukemia	O
in	O
remission	O
who	O
received	O
dos	O
of	O
100	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
consecutive	O
day	O
0	O
<EOS>	O
paraplegia	B-ADR
following	O
prophylactic	O
intrathecal	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
is	O
described	O
in	O
a	O
patient	O
with	O
acute	O
myelogenous	O
leukemia	O
in	O
remission	O
who	O
received	O
dos	O
of	O
100	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
consecutive	O
day	O
0	O
<EOS>	O
both	O
patient	O
developed	O
hypoadrenalism	B-ADR
while	O
on	O
o	B-Drug
,	I-Drug
p'-ddd	I-Drug
and	O
apparently	O
adequate	O
dexamethasone	O
replacement	O
therapy	O
0	O
<EOS>	O
alprazolam-induced	B-Drug
mania	B-ADR
:	O
two	O
clinical	O
case	O
0	O
<EOS>	O
the	O
author	O
caution	O
that	O
treatment	O
with	O
alprazolam	B-Drug
may	O
be	O
complicated	O
by	O
the	O
induction	O
of	O
mania	B-ADR
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
alprazolam	B-Drug
had	O
history	O
suggestive	O
of	O
a	O
bipolar	O
disorder	O
and	O
developed	O
lithium-responsive	O
manic	B-ADR
episode	I-ADR
0	O
<EOS>	O
a	O
case	O
is	O
presented	O
in	O
which	O
a	O
68-year-old	O
man	O
became	O
delirious	B-ADR
after	O
being	O
withdrawn	O
from	O
a	O
low	O
dosage	O
of	O
alprazolam	B-Drug
0	O
<EOS>	O
alprazolam	B-Drug
withdrawal	O
delirium	B-ADR
unresponsive	O
to	O
diazepam	O
:	O
case	O
report	O
0	O
<EOS>	O
sulfasalazine	B-Drug
ha	O
been	O
associated	O
with	O
bronchopulmonary	B-ADR
complication	I-ADR
of	I-ADR
inflammatory	I-ADR
bowel	I-ADR
disease	I-ADR
(	O
ibd	O
)	O
in	O
adult	O
0	O
<EOS>	O
sulfasalazine	B-Drug
ha	O
been	O
associated	O
with	O
bronchopulmonary	O
complication	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
ibd	B-ADR
)	O
in	O
adult	O
0	O
<EOS>	O
we	O
discus	O
a	O
variety	O
of	O
bronchopulmonary	O
complication	O
of	O
ibd	B-ADR
and	O
their	O
association	O
with	O
sulfasalazine	B-Drug
0	O
<EOS>	O
administration	O
of	O
amantadine	B-Drug
wa	O
associated	O
with	O
psychotic	B-ADR
decompensations	I-ADR
in	O
two	O
schizophrenic	O
patient	O
being	O
maintained	O
on	O
concomitant	O
neuroleptic	O
medication	O
0	O
<EOS>	O
despite	O
a	O
postulated	O
dopaminergic	O
mechanism	O
,	O
there	O
seems	O
to	O
have	O
been	O
only	O
one	O
previous	O
report	O
of	O
amantadine	B-Drug
precipitating	B-ADR
psychosis	I-ADR
in	O
a	O
schizophrenic	O
patient	O
0	O
<EOS>	O
exacerbation	O
of	O
schizophrenia	B-ADR
associated	O
with	O
amantadine	B-Drug
0	O
<EOS>	O
soon	O
after	O
it	O
introduction	O
in	O
1952	O
,	O
chlorpromazine	B-Drug
wa	O
noted	O
to	O
induce	O
symptom	B-ADR
resembling	I-ADR
parkinson	I-ADR
disease	I-ADR
0	O
<EOS>	O
it	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine-induced	B-Drug
lupus	B-ADR
,	O
which	O
manifested	O
with	O
serositis	O
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptom	O
0	O
<EOS>	O
it	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine-induced	B-Drug
lupus	O
,	O
which	O
manifested	O
with	O
serositis	O
and	O
pulmonary	B-ADR
parenchymal	I-ADR
involvement	I-ADR
in	O
the	O
absence	O
of	O
joint	O
symptom	O
0	O
<EOS>	O
it	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine-induced	B-Drug
lupus	O
,	O
which	O
manifested	O
with	O
serositis	B-ADR
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptom	O
0	O
<EOS>	O
physician	O
who	O
use	O
sulfasalazine	O
to	O
treat	O
patient	O
with	O
inflammatory	O
bowel	O
disease	O
should	O
be	O
aware	O
of	O
the	O
sign	O
of	O
sulfasalazine-induced	B-Drug
lupus	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
pneumonitis	O
,	O
bilateral	B-ADR
pleural	I-ADR
effusion	I-ADR
,	O
echocardiographic	O
evidence	O
of	O
cardiac	O
tamponade	O
,	O
and	O
positive	O
autoantibody	O
developed	O
in	O
a	O
43-year-old	O
man	O
,	O
who	O
wa	O
receiving	O
long-term	O
sulfasalazine	B-Drug
therapy	O
for	O
chronic	O
ulcerative	O
colitis	O
0	O
<EOS>	O
pneumonitis	O
,	O
bilateral	O
pleural	O
effusion	O
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-ADR
tamponade	I-ADR
,	O
and	O
positive	O
autoantibody	O
developed	O
in	O
a	O
43-year-old	O
man	O
,	O
who	O
wa	O
receiving	O
long-term	O
sulfasalazine	B-Drug
therapy	O
for	O
chronic	O
ulcerative	O
colitis	O
0	O
<EOS>	O
pneumonitis	B-ADR
,	O
bilateral	O
pleural	O
effusion	O
,	O
echocardiographic	O
evidence	O
of	O
cardiac	O
tamponade	O
,	O
and	O
positive	O
autoantibody	O
developed	O
in	O
a	O
43-year-old	O
man	O
,	O
who	O
wa	O
receiving	O
long-term	O
sulfasalazine	B-Drug
therapy	O
for	O
chronic	O
ulcerative	O
colitis	O
0	O
<EOS>	O
pneumonitis	O
,	O
bilateral	O
pleural	O
effusion	O
,	O
echocardiographic	O
evidence	O
of	O
cardiac	O
tamponade	O
,	O
and	O
positive	B-ADR
autoantibody	I-ADR
developed	O
in	O
a	O
43-year-old	O
man	O
,	O
who	O
wa	O
receiving	O
long-term	O
sulfasalazine	B-Drug
therapy	O
for	O
chronic	O
ulcerative	O
colitis	O
0	O
<EOS>	O
sulfasalazine-induced	B-Drug
lupus	B-ADR
erythematosus	I-ADR
0	O
<EOS>	O
acute	B-ADR
myocardial	I-ADR
infarction	I-ADR
due	O
to	O
coronary	O
spasm	O
associated	O
with	O
l-thyroxine	B-Drug
therapy	O
0	O
<EOS>	O
acute	O
myocardial	O
infarction	O
due	O
to	O
coronary	B-ADR
spasm	I-ADR
associated	O
with	O
l-thyroxine	B-Drug
therapy	O
0	O
<EOS>	O
electrocardiographic	O
finding	O
and	O
laboratory	O
data	O
indicated	O
a	O
diagnosis	O
of	O
acute	B-ADR
myocardial	I-ADR
infarction	I-ADR
due	O
to	O
the	O
l-thyroxine	B-Drug
therapy	O
0	O
<EOS>	O
we	O
believe	O
this	O
is	O
the	O
first	O
report	O
of	O
myocardial	O
infarction	O
due	O
to	O
coronary	B-ADR
spasm	I-ADR
,	O
demonstrated	O
by	O
angiography	O
associated	O
with	O
l-thyroxine	B-Drug
therapy	O
0	O
<EOS>	O
we	O
believe	O
this	O
is	O
the	O
first	O
report	O
of	O
myocardial	B-ADR
infarction	I-ADR
due	O
to	O
coronary	O
spasm	O
,	O
demonstrated	O
by	O
angiography	O
associated	O
with	O
l-thyroxine	B-Drug
therapy	O
0	O
<EOS>	O
a	O
study	O
of	O
in	O
vitro	O
reactivity	O
to	O
l-t4	B-Drug
,	O
a	O
assessed	O
by	O
peripheral	O
blood	O
lymphocyte	O
transformation	O
,	O
wa	O
carried	O
out	O
in	O
a	O
patient	O
with	O
hashimoto	O
disease	O
who	O
developed	O
leukopenia	B-ADR
during	O
treatment	O
with	O
l-t4	O
0	O
<EOS>	O
l-thyroxine-induced	B-Drug
leukopenia	B-ADR
in	O
a	O
patient	O
with	O
hashimoto	O
disease	O
:	O
involvement	O
of	O
suppressor-cytotoxic	O
t	O
cell	O
0	O
<EOS>	O
ampicillin-induced	B-Drug
interstitial	O
nephritis	O
with	O
generalised	B-ADR
exfoliative	I-ADR
dermatitis	I-ADR
0	O
<EOS>	O
ampicillin-induced	B-Drug
interstitial	B-ADR
nephritis	I-ADR
with	O
generalised	O
exfoliative	O
dermatitis	O
0	O
<EOS>	O
however	O
,	O
there	O
are	O
few	O
report	O
in	O
the	O
literature	O
of	O
ampicillin	B-Drug
a	O
a	O
cause	O
of	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
0	O
<EOS>	O
in	O
the	O
following	O
case	O
report	O
,	O
a	O
patient	O
developed	O
acute	B-ADR
interstitial	I-ADR
nephritis	I-ADR
with	O
renal	O
failure	O
and	O
exfoliative	O
dermatitis	O
following	O
ampicillin	B-Drug
therapy	O
0	O
<EOS>	O
in	O
the	O
following	O
case	O
report	O
,	O
a	O
patient	O
developed	O
acute	O
interstitial	O
nephritis	O
with	O
renal	O
failure	O
and	O
exfoliative	B-ADR
dermatitis	I-ADR
following	O
ampicillin	B-Drug
therapy	O
0	O
<EOS>	O
in	O
the	O
following	O
case	O
report	O
,	O
a	O
patient	O
developed	O
acute	O
interstitial	O
nephritis	O
with	O
renal	B-ADR
failure	I-ADR
and	O
exfoliative	O
dermatitis	O
following	O
ampicillin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
diagnosis	O
wa	O
based	O
on	O
the	O
rapid	O
onset	O
of	O
renal	O
failure	O
,	O
presence	O
of	O
eosinophilia	B-ADR
,	O
skin	O
rash	O
,	O
and	O
characteristic	O
renal	O
biopsy	O
finding	O
,	O
following	O
the	O
administration	O
of	O
ampicillin	B-Drug
0	O
<EOS>	O
the	O
diagnosis	O
wa	O
based	O
on	O
the	O
rapid	O
onset	O
of	O
renal	B-ADR
failure	I-ADR
,	O
presence	O
of	O
eosinophilia	O
,	O
skin	O
rash	O
,	O
and	O
characteristic	O
renal	O
biopsy	O
finding	O
,	O
following	O
the	O
administration	O
of	O
ampicillin	B-Drug
0	O
<EOS>	O
the	O
diagnosis	O
wa	O
based	O
on	O
the	O
rapid	O
onset	O
of	O
renal	O
failure	O
,	O
presence	O
of	O
eosinophilia	O
,	O
skin	B-ADR
rash	I-ADR
,	O
and	O
characteristic	O
renal	O
biopsy	O
finding	O
,	O
following	O
the	O
administration	O
of	O
ampicillin	B-Drug
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	O
syndrome	O
characterized	O
by	O
a	O
malar	O
rash	O
,	O
pain	O
and	O
erythema	B-ADR
of	I-ADR
the	I-ADR
cartilage	I-ADR
of	I-ADR
both	I-ADR
ear	I-ADR
,	O
and	O
tender	O
erythematous	O
and	O
hemorrhagic	O
lesion	O
of	O
the	O
finger	O
tip	O
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	O
syndrome	O
characterized	O
by	O
a	O
malar	O
rash	O
,	O
pain	O
and	O
erythema	O
of	O
the	O
cartilage	O
of	O
both	O
ear	O
,	O
and	O
tender	O
erythematous	O
and	O
hemorrhagic	B-ADR
lesion	I-ADR
of	I-ADR
the	I-ADR
finger	I-ADR
tip	I-ADR
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	B-ADR
syndrome	I-ADR
characterized	O
by	O
a	O
malar	O
rash	O
,	O
pain	O
and	O
erythema	O
of	O
the	O
cartilage	O
of	O
both	O
ear	O
,	O
and	O
tender	O
erythematous	O
and	O
hemorrhagic	O
lesion	O
of	O
the	O
finger	O
tip	O
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	O
syndrome	O
characterized	O
by	O
a	O
malar	B-ADR
rash	I-ADR
,	O
pain	O
and	O
erythema	O
of	O
the	O
cartilage	O
of	O
both	O
ear	O
,	O
and	O
tender	O
erythematous	O
and	O
hemorrhagic	O
lesion	O
of	O
the	O
finger	O
tip	O
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	O
syndrome	O
characterized	O
by	O
a	O
malar	O
rash	O
,	O
pain	B-ADR
and	O
erythema	O
of	O
the	O
cartilage	O
of	O
both	O
ear	O
,	O
and	O
tender	O
erythematous	O
and	O
hemorrhagic	O
lesion	O
of	O
the	O
finger	O
tip	O
0	O
<EOS>	O
a	O
patient	O
receiving	O
vancomycin	B-Drug
for	O
a	O
serious	O
staphylococcal	O
infection	O
had	O
a	O
lupus-like	O
syndrome	O
characterized	O
by	O
a	O
malar	O
rash	O
,	O
pain	O
and	O
erythema	O
of	O
the	O
cartilage	O
of	O
both	O
ear	O
,	O
and	O
tender	B-ADR
erythematous	I-ADR
and	O
hemorrhagic	O
lesion	O
of	O
the	O
finger	O
tip	O
0	O
<EOS>	O
the	O
possible	O
development	O
of	O
a	O
drug-induced	O
vasculitis	O
or	O
lupus-like	B-ADR
syndrome	I-ADR
should	O
be	O
added	O
to	O
the	O
list	O
of	O
rare	O
toxic	O
effect	O
of	O
vancomycin	B-Drug
0	O
<EOS>	O
the	O
possible	O
development	O
of	O
a	O
drug-induced	O
vasculitis	B-ADR
or	O
lupus-like	O
syndrome	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
rare	O
toxic	O
effect	O
of	O
vancomycin	B-Drug
0	O
<EOS>	O
vancomycin-induced	B-Drug
vasculitis	B-ADR
0	O
<EOS>	O
abnormal	B-ADR
retinal	I-ADR
function	I-ADR
associated	O
with	O
isotretinoin	B-Drug
therapy	O
for	O
acne	O
0	O
<EOS>	O
three	O
of	O
50	O
patient	O
treated	O
with	O
isotretinoin	B-Drug
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
cystic	O
acne	O
complained	O
of	O
poor	O
night	O
vision	O
and	O
/	O
or	O
excessive	B-ADR
glare	I-ADR
sensitivity	I-ADR
0	O
<EOS>	O
three	O
of	O
50	O
patient	O
treated	O
with	O
isotretinoin	B-Drug
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
cystic	O
acne	O
complained	O
of	O
poor	B-ADR
night	I-ADR
vision	I-ADR
and	O
/	O
or	O
excessive	O
glare	O
sensitivity	O
0	O
<EOS>	O
neurologic	B-ADR
toxicity	I-ADR
associated	O
with	O
hepatic	O
artery	O
infusion	O
hai	O
of	O
fudr	B-Drug
0	O
<EOS>	O
ethambutol	B-Drug
is	O
frequently	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
and	O
,	O
although	O
optic	B-ADR
neuropathy	I-ADR
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
ethambutol	O
,	O
this	O
adverse	O
side	O
effect	O
ha	O
been	O
considered	O
to	O
be	O
rare	O
and	O
generally	O
reversible	O
with	O
discontinuation	O
of	O
the	O
medication	O
0	O
<EOS>	O
however	O
,	O
we	O
recently	O
saw	O
two	O
patient	O
with	O
renal	O
tuberculosis	O
treated	O
with	O
ethambutol	B-Drug
in	O
whom	O
visual	O
loss	O
from	O
toxic	B-ADR
optic	I-ADR
neuropathy	I-ADR
wa	O
severe	O
and	O
irreversible	O
despite	O
careful	O
ophthalmological	O
monitoring	O
and	O
prompt	O
discontinuation	O
of	O
the	O
agent	O
at	O
the	O
first	O
sign	O
of	O
impaired	O
visual	O
function	O
0	O
<EOS>	O
however	O
,	O
we	O
recently	O
saw	O
two	O
patient	O
with	O
renal	O
tuberculosis	O
treated	O
with	O
ethambutol	B-Drug
in	O
whom	O
visual	B-ADR
loss	I-ADR
from	O
toxic	O
optic	O
neuropathy	O
wa	O
severe	O
and	O
irreversible	O
despite	O
careful	O
ophthalmological	O
monitoring	O
and	O
prompt	O
discontinuation	O
of	O
the	O
agent	O
at	O
the	O
first	O
sign	O
of	O
impaired	O
visual	O
function	O
0	O
<EOS>	O
optic	B-ADR
neuropathy	I-ADR
in	O
ethambutol-treated	B-Drug
renal	O
tuberculosis	O
0	O
<EOS>	O
since	O
ethambutol	B-Drug
is	O
actively	O
excreted	O
via	O
the	O
renal	O
system	O
,	O
compromise	O
of	O
renal	O
function	O
such	O
a	O
due	O
to	O
renal	O
tuberculosis	O
may	O
lead	O
to	O
serum	O
concentration	O
elevation	O
of	O
ethambutol	O
sufficient	O
to	O
produce	O
optic	B-ADR
neuropathy	I-ADR
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
presented	O
with	O
a	O
3-week	O
history	O
of	O
dysphagia	B-ADR
for	I-ADR
solid	I-ADR
,	O
6	O
month	O
after	O
starting	O
treatment	O
with	O
nifedipine	B-Drug
0	O
<EOS>	O
gastro-oesophageal	B-ADR
reflux	I-ADR
associated	O
with	O
nifedipine	B-Drug
0	O
<EOS>	O
nifedipine	B-Drug
may	O
induce	O
,	O
or	O
aggravate	O
,	O
pre-existing	O
,	O
gastro-oesophageal	B-ADR
reflux	I-ADR
0	O
<EOS>	O
a	O
young	O
diamond	O
dealer	O
developed	O
visual	O
impairment	O
attributed	O
to	O
bilateral	B-ADR
posterior	I-ADR
subcapsular	I-ADR
cataract	I-ADR
following	O
only	O
four	O
course	O
of	O
intermittent	O
decadron	B-Drug
used	O
a	O
part	O
of	O
a	O
five-drug	O
antiemetic	O
regimen	O
for	O
cisplatin-associated	O
nausea	O
0	O
<EOS>	O
a	O
young	O
diamond	O
dealer	O
developed	O
visual	O
impairment	O
attributed	O
to	O
bilateral	O
posterior	O
subcapsular	O
cataract	O
following	O
only	O
four	O
course	O
of	O
intermittent	O
decadron	O
used	O
a	O
part	O
of	O
a	O
five-drug	O
antiemetic	O
regimen	O
for	O
cisplatin-associated	B-Drug
nausea	B-ADR
0	O
<EOS>	O
a	O
young	O
diamond	O
dealer	O
developed	O
visual	B-ADR
impairment	I-ADR
attributed	O
to	O
bilateral	O
posterior	O
subcapsular	O
cataract	O
following	O
only	O
four	O
course	O
of	O
intermittent	O
decadron	B-Drug
used	O
a	O
part	O
of	O
a	O
five-drug	O
antiemetic	O
regimen	O
for	O
cisplatin-associated	O
nausea	O
0	O
<EOS>	O
cataract	B-ADR
induced	O
by	O
intermittent	O
decadron	B-Drug
used	O
a	O
an	O
antiemetic	O
0	O
<EOS>	O
recent	O
report	O
have	O
shown	O
that	O
decadron	O
(	O
dexamethasone	O
;	O
merck	O
sharp	O
&	O
dohme	O
,	O
west	O
point	O
,	O
pa	O
)	O
ha	O
a	O
significant	O
antiemetic	O
effect	O
on	O
cisplatin-induced	B-Drug
vomiting	B-ADR
0	O
<EOS>	O
transient	O
phenytoin	B-Drug
induced	O
iga	B-ADR
deficiency	I-ADR
and	O
permanent	O
ige	O
increase	O
0	O
<EOS>	O
transient	O
phenytoin	B-Drug
induced	O
iga	O
deficiency	O
and	O
permanent	O
ige	B-ADR
increase	I-ADR
0	O
<EOS>	O
the	O
pharmacology	O
and	O
toxicology	O
of	O
chloral	B-Drug
hydrate	I-Drug
are	O
discussed	O
with	O
particular	O
reference	O
to	O
the	O
cardiac	B-ADR
arrhythmia	I-ADR
that	O
are	O
seen	O
with	O
overdosage	O
0	O
<EOS>	O
adrenaline	B-Drug
dacryolith	B-ADR
:	O
detection	O
by	O
ultrasound	O
examination	O
of	O
the	O
nasolacrimal	O
duct	O
0	O
<EOS>	O
histological	O
examination	O
of	O
the	O
dacryolith	B-ADR
suggested	O
it	O
derivation	O
from	O
breakdown	O
product	O
of	O
adrenaline	B-Drug
0	O
<EOS>	O
possible	O
pathophysiological	O
mechanism	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
cns	O
)	O
toxic	O
effect	O
of	O
valproic	B-Drug
acid	O
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
cns	O
toxic	O
effect	O
mediated	O
through	O
valproic	O
acid-induced	B-Drug
hyperammonemia	B-ADR
0	O
<EOS>	O
reversible	O
valproic	B-Drug
acid-induced	I-Drug
dementia	B-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
reversible	O
valproic	B-Drug
acid-induced	I-Drug
dementia	B-ADR
wa	O
documented	O
in	O
a	O
21-year-old	O
man	O
with	O
epilepsy	O
who	O
had	O
a	O
3-year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
ability	O
documented	O
by	O
serial	O
neuropsychological	O
study	O
0	O
<EOS>	O
co-trimoxazole	B-Drug
red	B-ADR
cell	I-ADR
aplasia	I-ADR
in	O
leukaemia	O
0	O
<EOS>	O
when	O
co-trimoxazole	B-Drug
wa	O
stopped	O
the	O
red	B-ADR
cell	I-ADR
aplasia	I-ADR
resolved	O
0	O
<EOS>	O
a	O
patient	O
developed	O
optic	B-ADR
neuropathy	I-ADR
while	O
being	O
treated	O
with	O
isoniazid	O
and	O
ethambutol	B-Drug
0	O
<EOS>	O
a	O
patient	O
developed	O
optic	B-ADR
neuropathy	I-ADR
while	O
being	O
treated	O
with	O
isoniazid	B-Drug
and	O
ethambutol	O
0	O
<EOS>	O
a	O
well-recognized	O
complication	O
of	O
ethambutol	O
use	O
is	O
optic	O
neuropathy	O
,	O
but	O
the	O
potential	O
ocular	B-ADR
toxicity	I-ADR
of	O
isoniazid	B-Drug
is	O
often	O
overlooked	O
0	O
<EOS>	O
a	O
well-recognized	O
complication	O
of	O
ethambutol	B-Drug
use	O
is	O
optic	B-ADR
neuropathy	I-ADR
,	O
but	O
the	O
potential	O
ocular	O
toxicity	O
of	O
isoniazid	O
is	O
often	O
overlooked	O
0	O
<EOS>	O
isoniazid	O
and	O
ethambutol	B-Drug
a	O
a	O
cause	O
of	O
optic	B-ADR
neuropathy	I-ADR
0	O
<EOS>	O
isoniazid	B-Drug
and	O
ethambutol	O
a	O
a	O
cause	O
of	O
optic	B-ADR
neuropathy	I-ADR
0	O
<EOS>	O
a	O
woman	O
38-year-old	O
,	O
suffering	O
for	O
about	O
ten	O
year	O
from	O
multiple	O
sclerosis	O
and	O
treated	O
with	O
repeated	O
therapy	O
cycle	O
of	O
intrathecal	O
depo-medrol	B-Drug
,	O
developed	O
a	O
spastic	B-ADR
paraparesis	I-ADR
at	I-ADR
the	I-ADR
lower	I-ADR
limb	I-ADR
0	O
<EOS>	O
calcification	B-ADR
and	O
ossification	O
of	O
the	O
spinal	O
arachnoid	O
after	O
intrathecal	O
administration	O
of	O
depo-medrol	B-Drug
0	O
<EOS>	O
calcification	O
and	O
ossification	B-ADR
of	I-ADR
the	I-ADR
spinal	I-ADR
arachnoid	I-ADR
after	O
intrathecal	O
administration	O
of	O
depo-medrol	B-Drug
0	O
<EOS>	O
a	O
young	O
woman	O
with	O
epilepsy	O
had	O
tonic-clonic	B-ADR
seizure	I-ADR
during	O
antineoplastic	O
therapy	O
with	O
adriamycin	B-Drug
and	O
cisplatin	O
0	O
<EOS>	O
a	O
young	O
woman	O
with	O
epilepsy	O
had	O
tonic-clonic	B-ADR
seizure	I-ADR
during	O
antineoplastic	O
therapy	O
with	O
adriamycin	O
and	O
cisplatin	B-Drug
0	O
<EOS>	O
hyperkalemia	B-ADR
a	O
a	O
late	O
side	O
effect	O
of	O
prolonged	O
adrenocorticotropic	B-Drug
hormone	I-Drug
therapy	O
for	O
infantile	O
spasm	O
0	O
<EOS>	O
two	O
infant	O
developed	O
hyperkalemia	B-ADR
shortly	O
after	O
cessation	O
of	O
prolonged	O
acth	B-Drug
therapy	O
for	O
infantile	O
spasm	O
0	O
<EOS>	O
we	O
wish	O
to	O
call	O
for	O
cautious	O
approach	O
at	O
time	O
of	O
cessation	O
of	O
prolonged	O
acth	B-Drug
therapy	O
because	O
of	O
possible	O
unexpected	O
and	O
only	O
partially	O
understood	O
hazardous	O
side	O
effect	O
such	O
a	O
hyperkalemia	B-ADR
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	B-ADR
renal	I-ADR
impairment	I-ADR
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	B-ADR
renal	I-ADR
impairment	I-ADR
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	B-ADR
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	B-ADR
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	B-ADR
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	B-ADR
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	B-ADR
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	B-ADR
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	B-ADR
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	B-ADR
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	B-ADR
acidosis	I-ADR
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	B-ADR
acidosis	I-ADR
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	B-ADR
shower	I-ADR
syndrome	I-ADR
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	B-ADR
shower	I-ADR
syndrome	I-ADR
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	O
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	O
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	B-ADR
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
three	O
patient	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	O
acid	O
rescue	O
,	O
resulted	O
in	O
the	O
phosphate	O
shower	O
syndrome	O
	O
(	O
hyper-uricaemia	O
,	O
hyperkalaemia	O
and	O
hyperphosphataemia	O
with	O
hypocalcaemia	O
and	O
tetany	B-ADR
,	O
with	O
metabolic	O
acidosis	O
and	O
acute	O
renal	O
impairment	O
)	O
are	O
described	O
0	O
<EOS>	O
accordingly	O
,	O
camptocormia	B-ADR
is	O
a	O
dose-dependent	O
side	O
effect	O
of	O
valproate	B-Drug
0	O
<EOS>	O
a	O
mentally	O
retarded	O
23-year-old	O
woman	O
with	O
myoclonic	O
astatic	O
epilepsy	O
developed	O
an	O
abnormal	B-ADR
posture	I-ADR
of	I-ADR
extreme	I-ADR
forward	I-ADR
flexion	I-ADR
,	O
called	O
camptocormia	O
,	O
during	O
valproate	B-Drug
monotherapy	O
0	O
<EOS>	O
a	O
mentally	O
retarded	O
23-year-old	O
woman	O
with	O
myoclonic	O
astatic	O
epilepsy	O
developed	O
an	O
abnormal	O
posture	O
of	O
extreme	O
forward	O
flexion	O
,	O
called	O
camptocormia	B-ADR
,	O
during	O
valproate	B-Drug
monotherapy	O
0	O
<EOS>	O
camptocormia	B-ADR
,	O
a	O
new	O
side	O
effect	O
of	O
sodium	B-Drug
valproate	I-Drug
0	O
<EOS>	O
four	O
week	O
earlier	O
she	O
had	O
developed	O
hepatopathy	B-ADR
during	O
a	O
regimen	O
of	O
carbamazepine	B-Drug
,	O
lynestrenol	O
and	O
sodium	O
valproate	O
0	O
<EOS>	O
four	O
week	O
earlier	O
she	O
had	O
developed	O
hepatopathy	B-ADR
during	O
a	O
regimen	O
of	O
carbamazepine	O
,	O
lynestrenol	B-Drug
and	O
sodium	O
valproate	O
0	O
<EOS>	O
four	O
week	O
earlier	O
she	O
had	O
developed	O
hepatopathy	B-ADR
during	O
a	O
regimen	O
of	O
carbamazepine	O
,	O
lynestrenol	O
and	O
sodium	B-Drug
valproate	I-Drug
0	O
<EOS>	O
hepatopathy	B-ADR
subsided	O
after	O
the	O
cessation	O
of	O
carbamazepine	B-Drug
and	O
lynestrenol	O
0	O
<EOS>	O
hepatopathy	B-ADR
subsided	O
after	O
the	O
cessation	O
of	O
carbamazepine	O
and	O
lynestrenol	B-Drug
0	O
<EOS>	O
a	O
10-year-old	O
girl	O
with	O
lennox-gastaut	O
syndrome	O
who	O
received	O
intravenous	O
lorazepam	B-Drug
for	O
atypical	O
absence	O
status	O
seizure	B-ADR
is	O
reported	O
0	O
<EOS>	O
paradoxical	B-ADR
precipitation	I-ADR
of	I-ADR
tonic	I-ADR
seizure	I-ADR
by	O
lorazepam	B-Drug
in	O
a	O
child	O
with	O
atypical	O
absence	O
seizure	O
0	O
<EOS>	O
atrial	B-ADR
fibrillation	I-ADR
following	O
methylprednisolone	B-Drug
pulse	O
therapy	O
0	O
<EOS>	O
isotretinoin	B-Drug
,	O
a	O
drug	O
used	O
for	O
the	O
treatment	O
of	O
acne	O
,	O
ha	O
been	O
shown	O
to	O
have	O
teratogenic	B-ADR
effect	I-ADR
0	O
<EOS>	O
isotretinoin	B-Drug
teratogenicity	B-ADR
0	O
<EOS>	O
we	O
report	O
an	O
additional	O
case	O
of	O
isotretinoin	B-Drug
teratogenicity	O
in	O
which	O
the	O
patient	O
had	O
agenesis	O
of	O
the	O
cerebellar	O
vermis	O
,	O
multiple	O
leptomeningeal	O
neuroglial	O
heterotopias	O
,	O
hydrocephalus	O
,	O
and	O
abnormality	B-ADR
of	I-ADR
the	I-ADR
corticospinal	I-ADR
tract	I-ADR
0	O
<EOS>	O
we	O
report	O
an	O
additional	O
case	O
of	O
isotretinoin	B-Drug
teratogenicity	O
in	O
which	O
the	O
patient	O
had	O
agenesis	B-ADR
of	I-ADR
the	I-ADR
cerebellar	I-ADR
vermis	I-ADR
,	O
multiple	O
leptomeningeal	O
neuroglial	O
heterotopias	O
,	O
hydrocephalus	O
,	O
and	O
abnormality	O
of	O
the	O
corticospinal	O
tract	O
0	O
<EOS>	O
we	O
report	O
an	O
additional	O
case	O
of	O
isotretinoin	B-Drug
teratogenicity	O
in	O
which	O
the	O
patient	O
had	O
agenesis	O
of	O
the	O
cerebellar	O
vermis	O
,	O
multiple	O
leptomeningeal	O
neuroglial	O
heterotopias	O
,	O
hydrocephalus	B-ADR
,	O
and	O
abnormality	O
of	O
the	O
corticospinal	O
tract	O
0	O
<EOS>	O
we	O
report	O
an	O
additional	O
case	O
of	O
isotretinoin	B-Drug
teratogenicity	O
in	O
which	O
the	O
patient	O
had	O
agenesis	O
of	O
the	O
cerebellar	O
vermis	O
,	O
multiple	B-ADR
leptomeningeal	I-ADR
neuroglial	I-ADR
heterotopias	I-ADR
,	O
hydrocephalus	O
,	O
and	O
abnormality	O
of	O
the	O
corticospinal	O
tract	O
0	O
<EOS>	O
we	O
report	O
an	O
additional	O
case	O
of	O
isotretinoin	B-Drug
teratogenicity	B-ADR
in	O
which	O
the	O
patient	O
had	O
agenesis	O
of	O
the	O
cerebellar	O
vermis	O
,	O
multiple	O
leptomeningeal	O
neuroglial	O
heterotopias	O
,	O
hydrocephalus	O
,	O
and	O
abnormality	O
of	O
the	O
corticospinal	O
tract	O
0	O
<EOS>	O
a	O
case	O
of	O
allopurinol	B-Drug
hypersensitivity	B-ADR
,	O
possibly	O
the	O
first	O
in	O
a	O
black	O
african	O
,	O
is	O
reported	O
0	O
<EOS>	O
allopurinol	B-Drug
hypersensitivity	B-ADR
0	O
<EOS>	O
the	O
allopurinol	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
is	O
a	O
rare	O
adverse	O
drug	O
reaction	O
0	O
<EOS>	O
bone	B-ADR
formation	I-ADR
induced	O
in	O
an	O
infant	O
by	O
systemic	O
prostaglandin-e2	B-Drug
administration	O
0	O
<EOS>	O
a	O
case	O
of	O
severe	B-ADR
visual	I-ADR
loss	I-ADR
following	O
a	O
single	O
dose	O
of	O
vincristine	B-Drug
is	O
described	O
0	O
<EOS>	O
although	O
differential	O
diagnostic	O
alternative	O
can	O
be	O
considered	O
in	O
all	O
described	O
case	O
it	O
is	O
very	O
likely	O
that	O
vincristine	B-Drug
doe	O
cause	O
severe	B-ADR
visual	I-ADR
loss	I-ADR
in	O
a	O
small	O
number	O
of	O
patient	O
0	O
<EOS>	O
severe	B-ADR
visual	I-ADR
loss	I-ADR
after	O
a	O
single	O
dose	O
of	O
vincristine	B-Drug
in	O
a	O
patient	O
with	O
spinal	O
cord	O
astrocytoma	O
0	O
<EOS>	O
the	O
literature	O
of	O
vincristine	B-Drug
optic	B-ADR
nerve	I-ADR
toxicity	I-ADR
is	O
reviewed	O
0	O
<EOS>	O
visual	B-ADR
loss	I-ADR
after	O
a	O
single	O
small	O
dose	O
of	O
vincristine	B-Drug
ha	O
never	O
been	O
reported	O
0	O
<EOS>	O
niacin	B-Drug
cause	O
a	O
reversible	B-ADR
toxic	I-ADR
cystoid	I-ADR
maculopathy	I-ADR
that	O
occurs	O
in	O
approximately	O
0.67	O
%	O
of	O
patient	O
taking	O
high	O
dos	O
of	O
the	O
drug	O
0	O
<EOS>	O
niacin	B-Drug
maculopathy	B-ADR
0	O
<EOS>	O
the	O
author	O
conclude	O
that	O
among	O
patient	O
taking	O
high	O
dos	O
of	O
oral	O
niacin	B-Drug
only	O
those	O
who	O
experience	O
visual	B-ADR
symptom	I-ADR
need	O
to	O
be	O
ophthalmologically	O
evaluated	O
0	O
<EOS>	O
three	O
patient	O
with	O
niacin-induced	B-Drug
visual	O
symptom	O
had	O
cystoid	B-ADR
maculopathy	I-ADR
without	O
leakage	O
on	O
fluorescein	O
angiography	O
,	O
and	O
a	O
fourth	O
patient	O
with	O
no	O
fundus	O
abnormality	O
experienced	O
cessation	O
of	O
visual	O
symptom	O
upon	O
discontinuation	O
of	O
niacin	O
0	O
<EOS>	O
three	O
patient	O
with	O
niacin-induced	B-Drug
visual	B-ADR
symptom	I-ADR
had	O
cystoid	O
maculopathy	O
without	O
leakage	O
on	O
fluorescein	O
angiography	O
,	O
and	O
a	O
fourth	O
patient	O
with	O
no	O
fundus	O
abnormality	O
experienced	O
cessation	O
of	O
visual	O
symptom	O
upon	O
discontinuation	O
of	O
niacin	O
0	O
<EOS>	O
three	O
patient	O
with	O
niacin-induced	B-Drug
visual	B-ADR
symptom	I-ADR
had	O
cystoid	O
maculopathy	O
without	O
leakage	O
on	O
fluorescein	O
angiography	O
,	O
and	O
a	O
fourth	O
patient	O
with	O
no	O
fundus	O
abnormality	O
experienced	O
cessation	O
of	O
visual	O
symptom	O
upon	O
discontinuation	O
of	O
niacin	O
0	O
<EOS>	O
a	O
case	O
report	O
of	O
the	O
hypersensitivity	B-ADR
syndrome	I-ADR
occurring	O
in	O
a	O
patient	O
being	O
treated	O
with	O
dapsone	B-Drug
for	O
a	O
brown	O
recluse	O
spider	O
bite	O
is	O
presented	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	B-ADR
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	B-ADR
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	B-ADR
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	B-ADR
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	B-ADR
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	B-ADR
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	B-ADR
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	B-ADR
,	O
vomiting	O
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
a	O
dapsone	B-Drug
hypersensitivity	O
syndrome	O
,	O
consisting	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	B-ADR
,	O
lymphadenopathy	O
,	O
hepatitis	O
,	O
hemolysis	O
,	O
leukopenia	O
,	O
and	O
mononucleosis	O
,	O
ha	O
been	O
described	O
in	O
patient	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
0	O
<EOS>	O
case	O
report	O
:	O
dapsone	B-Drug
hypersensitivity	B-ADR
syndrome	I-ADR
associated	O
with	O
treatment	O
of	O
the	O
bite	O
of	O
a	O
brown	O
recluse	O
spider	O
0	O
<EOS>	O
rifampicin-induced	B-Drug
adrenal	B-ADR
insufficiency	I-ADR
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
:	O
difficulty	O
in	O
diagnosis	O
and	O
treatment	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
treated	O
with	O
rifampicin	B-Drug
who	O
had	O
a	O
normal	O
	O
screening	O
test	O
for	O
adrenal	O
insufficiency	O
,	O
yet	O
had	O
clinical	O
evidence	O
of	O
adrenal	B-ADR
failure	I-ADR
0	O
<EOS>	O
two	O
case	O
of	O
widespread	O
cutaneous	B-ADR
vasculitis	I-ADR
are	O
described	O
in	O
association	O
with	O
diltiazem	B-Drug
,	O
a	O
recently	O
introduced	O
calcium	O
antagonist	O
0	O
<EOS>	O
widespread	O
cutaneous	B-ADR
vasculitis	I-ADR
associated	O
with	O
diltiazem	B-Drug
0	O
<EOS>	O
intraventricular	O
nafcillin-induced	B-Drug
seizure	B-ADR
in	O
a	O
neonate	O
0	O
<EOS>	O
we	O
report	O
a	O
premature	O
infant	O
who	O
developed	O
seizure	B-ADR
associated	O
with	O
intraventricular	O
administration	O
of	O
nafcillin	B-Drug
and	O
discus	O
the	O
need	O
for	O
electroencephalographic	O
monitoring	O
of	O
patient	O
receiving	O
intraventricular	O
antibiotic	O
0	O
<EOS>	O
a	O
58-year	O
old	O
patient	O
is	O
reported	O
who	O
developed	O
an	O
ischaemic	B-ADR
cerebrovascular	I-ADR
accident	I-ADR
22	O
hour	O
after	O
successful	O
thrombolysis	O
with	O
streptokinase	B-Drug
for	O
life-threatening	O
pulmonary	O
embolus	O
0	O
<EOS>	O
thrombo-embolic	B-ADR
complication	I-ADR
after	O
streptokinase	B-Drug
therapy	O
of	O
pulmonary	O
embolus	O
0	O
<EOS>	O
renal	B-ADR
hypophosphatemia	I-ADR
in	O
this	O
patient	O
wa	O
caused	O
by	O
the	O
erroneous	O
intake	O
of	O
1	O
g	O
doxycycline	B-Drug
0	O
<EOS>	O
a	O
clinically	O
atypical	O
,	O
neuropathologically	O
verified	O
case	O
of	O
creutzfeldt-jakob	B-ADR
disease	I-ADR
is	O
described	O
in	O
a	O
32-year-old	O
new	O
zealand	O
woman	O
with	O
idiopathic	O
hypopituitarism	O
who	O
had	O
been	O
treated	O
in	O
late	O
adolescence	O
(	O
1970	O
to	O
1973	O
)	O
with	O
human	B-Drug
growth	I-Drug
hormone	I-Drug
processed	O
from	O
pooled	O
cadaveric	O
pituitary	O
gland	O
0	O
<EOS>	O
a	O
new	O
case	O
of	O
creutzfeldt-jakob	B-ADR
disease	I-ADR
associated	O
with	O
human	B-Drug
growth	I-Drug
hormone	I-Drug
therapy	O
in	O
new	O
zealand	O
0	O
<EOS>	O
a	O
case	O
of	O
a	O
21-year-old	O
woman	O
who	O
had	O
developed	O
mild	O
hepatotoxicity	B-ADR
while	O
receiving	O
choline	B-Drug
magnesium	I-Drug
trisalicylate	I-Drug
therapy	O
is	O
described	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
associated	O
with	O
choline	O
magnesium	O
trisalicylate	O
:	O
case	O
report	O
and	O
review	O
of	O
salicylate-induced	B-Drug
hepatotoxicity	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
associated	O
with	O
choline	B-Drug
magnesium	I-Drug
trisalicylate	I-Drug
:	O
case	O
report	O
and	O
review	O
of	O
salicylate-induced	O
hepatotoxicity	O
0	O
<EOS>	O
salicylate-induced	B-Drug
hepatotoxicity	B-ADR
is	O
reviewed	O
0	O
<EOS>	O
they	O
continued	O
to	O
rise	O
for	O
five	O
more	O
day	O
before	O
salicylate	B-Drug
hepatotoxicity	B-ADR
wa	O
suspected	O
0	O
<EOS>	O
a	O
51-yr-old	O
nonsmoking	O
male	O
patient	O
without	O
any	O
history	O
of	O
previous	O
allergy	O
,	O
asthma	O
,	O
hay	O
fever	O
,	O
or	O
urticaria	O
developed	O
attack	B-ADR
of	I-ADR
asthma	I-ADR
when	O
captopril	B-Drug
wa	O
added	O
to	O
the	O
nadolol	O
and	O
dyazide	O
treatment	O
for	O
his	O
high	O
blood	O
pressure	O
0	O
<EOS>	O
a	O
51-yr-old	O
nonsmoking	O
male	O
patient	O
without	O
any	O
history	O
of	O
previous	O
allergy	O
,	O
asthma	O
,	O
hay	O
fever	O
,	O
or	O
urticaria	O
developed	O
attack	B-ADR
of	I-ADR
asthma	I-ADR
when	O
captopril	O
wa	O
added	O
to	O
the	O
nadolol	O
and	O
dyazide	B-Drug
treatment	O
for	O
his	O
high	O
blood	O
pressure	O
0	O
<EOS>	O
a	O
51-yr-old	O
nonsmoking	O
male	O
patient	O
without	O
any	O
history	O
of	O
previous	O
allergy	O
,	O
asthma	O
,	O
hay	O
fever	O
,	O
or	O
urticaria	O
developed	O
attack	B-ADR
of	I-ADR
asthma	I-ADR
when	O
captopril	O
wa	O
added	O
to	O
the	O
nadolol	B-Drug
and	O
dyazide	O
treatment	O
for	O
his	O
high	O
blood	O
pressure	O
0	O
<EOS>	O
captopril-related	B-Drug
(	O
and	O
-induced	O
?	O
)	O
asthma	B-ADR
0	O
<EOS>	O
this	O
confirmed	O
the	O
history	O
of	O
captopril-related	B-Drug
asthma	B-ADR
0	O
<EOS>	O
we	O
also	O
describe	O
a	O
case	O
of	O
timolol-induced	B-Drug
ocular	B-ADR
pemphigoid	I-ADR
0	O
<EOS>	O
deposit	B-ADR
of	I-ADR
plasma	I-ADR
protein	I-ADR
in	I-ADR
the	I-ADR
skin	I-ADR
during	O
treatment	O
with	O
carbamazepine	B-Drug
and	O
diphenylhydantoin	O
0	O
<EOS>	O
deposit	B-ADR
of	I-ADR
plasma	I-ADR
protein	I-ADR
in	I-ADR
the	I-ADR
skin	I-ADR
during	O
treatment	O
with	O
carbamazepine	O
and	O
diphenylhydantoin	B-Drug
0	O
<EOS>	O
the	O
observation	O
suggest	O
that	O
testicular	O
swelling	O
and	O
pain	B-ADR
are	O
side	O
effect	O
of	O
desipramine	B-Drug
0	O
<EOS>	O
the	O
observation	O
suggest	O
that	O
testicular	B-ADR
swelling	I-ADR
and	O
pain	O
are	O
side	O
effect	O
of	O
desipramine	B-Drug
0	O
<EOS>	O
two	O
patient	O
are	O
described	O
who	O
developed	O
testicular	O
swelling	O
and	O
pain	B-ADR
during	O
treatment	O
with	O
desipramine	B-Drug
0	O
<EOS>	O
two	O
patient	O
are	O
described	O
who	O
developed	O
testicular	B-ADR
swelling	I-ADR
and	O
pain	O
during	O
treatment	O
with	O
desipramine	B-Drug
0	O
<EOS>	O
benzocaine	B-Drug
,	O
an	O
ester-type	O
local	O
anesthetic	O
,	O
wa	O
believed	O
responsible	O
for	O
apparent	O
methemoglobinemia	B-ADR
in	O
a	O
cat	O
0	O
<EOS>	O
benzocaine-induced	B-Drug
methemoglobinemia	B-ADR
ha	O
been	O
reported	O
in	O
man	O
,	O
dog	O
,	O
and	O
cat	O
0	O
<EOS>	O
methemoglobinemia	B-ADR
associated	O
with	O
dermal	O
application	O
of	O
benzocaine	B-Drug
cream	O
in	O
a	O
cat	O
0	O
<EOS>	O
a	O
43-year-old	O
white	O
man	O
developed	O
a	O
shallow	O
erosion	B-ADR
of	I-ADR
a	I-ADR
psoriatic	I-ADR
plaque	I-ADR
after	O
chronic	O
administration	O
of	O
methotrexate	B-Drug
0	O
<EOS>	O
erosion	B-ADR
of	I-ADR
psoriatic	I-ADR
plaque	I-ADR
after	O
chronic	O
methotrexate	B-Drug
administration	O
0	O
<EOS>	O
after	O
a	O
six-week	O
course	O
of	O
low-dose	O
cyclosporine	B-Drug
a	I-Drug
,	O
she	O
developed	O
a	O
severe	O
but	O
reversible	O
loss	O
of	O
glomerular	O
filtration	O
rate	O
and	O
effective	B-ADR
renal	I-ADR
plasma	I-ADR
flow	I-ADR
despite	O
of	O
low	O
cyclosporine	O
a	O
plasma	O
level	O
0	O
<EOS>	O
after	O
a	O
six-week	O
course	O
of	O
low-dose	O
cyclosporine	B-Drug
a	I-Drug
,	O
she	O
developed	O
a	O
severe	O
but	O
reversible	O
loss	B-ADR
of	I-ADR
glomerular	I-ADR
filtration	I-ADR
rate	I-ADR
and	O
effective	O
renal	O
plasma	O
flow	O
despite	O
of	O
low	O
cyclosporine	O
a	O
plasma	O
level	O
0	O
<EOS>	O
based	O
upon	O
the	O
observed	O
fall	B-ADR
of	I-ADR
the	I-ADR
filtration	I-ADR
fraction	I-ADR
,	O
the	O
rise	O
in	O
the	O
relative	O
clearance	O
of	O
99tc-dimercaptosuccinic	O
acid	O
and	O
the	O
increase	O
in	O
proteinuria	O
,	O
we	O
suggest	O
that	O
in	O
this	O
case	O
the	O
tubule	O
and	O
/	O
or	O
interstitium	O
are	O
the	O
main	O
target	O
for	O
cyclosporine	B-Drug
a	I-Drug
nephrotoxicity	O
0	O
<EOS>	O
based	O
upon	O
the	O
observed	O
fall	O
of	O
the	O
filtration	O
fraction	O
,	O
the	O
rise	O
in	O
the	O
relative	O
clearance	O
of	O
99tc-dimercaptosuccinic	O
acid	O
and	O
the	O
increase	B-ADR
in	I-ADR
proteinuria	I-ADR
,	O
we	O
suggest	O
that	O
in	O
this	O
case	O
the	O
tubule	O
and	O
/	O
or	O
interstitium	O
are	O
the	O
main	O
target	O
for	O
cyclosporine	B-Drug
a	I-Drug
nephrotoxicity	O
0	O
<EOS>	O
based	O
upon	O
the	O
observed	O
fall	O
of	O
the	O
filtration	O
fraction	O
,	O
the	O
rise	O
in	O
the	O
relative	O
clearance	O
of	O
99tc-dimercaptosuccinic	O
acid	O
and	O
the	O
increase	O
in	O
proteinuria	O
,	O
we	O
suggest	O
that	O
in	O
this	O
case	O
the	O
tubule	O
and	O
/	O
or	O
interstitium	O
are	O
the	O
main	O
target	O
for	O
cyclosporine	B-Drug
a	I-Drug
nephrotoxicity	B-ADR
0	O
<EOS>	O
based	O
upon	O
the	O
observed	O
fall	O
of	O
the	O
filtration	O
fraction	O
,	O
the	O
rise	B-ADR
in	I-ADR
the	I-ADR
relative	I-ADR
clearance	I-ADR
of	I-ADR
99tc-dimercaptosuccinic	I-ADR
acid	I-ADR
and	O
the	O
increase	O
in	O
proteinuria	O
,	O
we	O
suggest	O
that	O
in	O
this	O
case	O
the	O
tubule	O
and	O
/	O
or	O
interstitium	O
are	O
the	O
main	O
target	O
for	O
cyclosporine	B-Drug
a	I-Drug
nephrotoxicity	O
0	O
<EOS>	O
unexpected	O
severe	O
reversible	O
cyclosporine	B-Drug
a-induced	I-Drug
nephrotoxicity	B-ADR
in	O
a	O
patient	O
with	O
systemic	O
lupus	O
erythematosus	O
and	O
tubulointerstitial	O
renal	O
disease	O
0	O
<EOS>	O
a	O
patient	O
is	O
presented	O
with	O
typical	O
hyperthyroidism	B-ADR
,	O
who	O
developed	O
a	O
severe	O
proximal	O
muscle	O
weakness	O
and	O
a	O
raised	O
creatine	O
phosphokinase	O
after	O
treatment	O
for	O
hyperthyroidism	O
with	O
propylthiouracil	B-Drug
(	O
100	O
mg	O
orally	O
,	O
three	O
time	O
a	O
day	O
)	O
0	O
<EOS>	O
a	O
patient	O
is	O
presented	O
with	O
typical	O
hyperthyroidism	O
,	O
who	O
developed	O
a	O
severe	O
proximal	O
muscle	O
weakness	O
and	O
a	O
raised	B-ADR
creatine	I-ADR
phosphokinase	I-ADR
after	O
treatment	O
for	O
hyperthyroidism	O
with	O
propylthiouracil	B-Drug
(	O
100	O
mg	O
orally	O
,	O
three	O
time	O
a	O
day	O
)	O
0	O
<EOS>	O
a	O
patient	O
is	O
presented	O
with	O
typical	O
hyperthyroidism	O
,	O
who	O
developed	O
a	O
severe	B-ADR
proximal	I-ADR
muscle	I-ADR
weakness	I-ADR
and	O
a	O
raised	O
creatine	O
phosphokinase	O
after	O
treatment	O
for	O
hyperthyroidism	O
with	O
propylthiouracil	B-Drug
(	O
100	O
mg	O
orally	O
,	O
three	O
time	O
a	O
day	O
)	O
0	O
<EOS>	O
polymyositis	B-ADR
after	O
propylthiouracil	B-Drug
treatment	O
for	O
hyperthyroidism	O
0	O
<EOS>	O
cardiopulmonary	B-ADR
arrest	I-ADR
following	O
intravenous	O
phenytoin	B-Drug
loading	O
0	O
<EOS>	O
evidence	O
obtained	O
indicated	O
that	O
the	O
reye-like	O
syndrome	O
might	O
be	O
caused	O
by	O
calcium	B-Drug
hopantenate	I-Drug
possibly	O
due	O
to	O
the	O
induction	O
of	O
pantothenic	B-ADR
acid	I-ADR
deficiency	I-ADR
0	O
<EOS>	O
evidence	O
obtained	O
indicated	O
that	O
the	O
reye-like	B-ADR
syndrome	I-ADR
might	O
be	O
caused	O
by	O
calcium	B-Drug
hopantenate	I-Drug
possibly	O
due	O
to	O
the	O
induction	O
of	O
pantothenic	O
acid	O
deficiency	O
0	O
<EOS>	O
reye-like	B-ADR
syndrome	I-ADR
following	O
treatment	O
with	O
the	O
pantothenic	O
acid	O
antagonist	O
,	O
calcium	B-Drug
hopantenate	I-Drug
0	O
<EOS>	O
three	O
senile	O
patient	O
developed	O
fatal	B-ADR
acute	I-ADR
encephalopathy	I-ADR
while	O
receiving	O
calcium	B-Drug
hopantenate	I-Drug
0	O
<EOS>	O
dyspnea	B-ADR
possibly	O
associated	O
with	O
controlled-release	O
morphine	B-Drug
sulfate	I-Drug
tablet	O
0	O
<EOS>	O
anhedonic	B-ADR
ejaculation	I-ADR
with	O
desipramine	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
with	O
anhedonic	B-ADR
ejaculation	I-ADR
(	O
ejaculation	O
without	O
orgasm	O
)	O
associated	O
with	O
initiation	O
of	O
treatment	O
with	O
desipramine	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
patient	O
with	O
anhedonic	O
ejaculation	O
(	O
ejaculation	B-ADR
without	I-ADR
orgasm	I-ADR
)	O
associated	O
with	O
initiation	O
of	O
treatment	O
with	O
desipramine	B-Drug
0	O
<EOS>	O
myoclonic	B-ADR
spasm	I-ADR
following	O
intrathecal	O
morphine	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
halothane	B-Drug
induced	O
hepatitis	B-ADR
is	O
reported	O
in	O
a	O
middle	O
aged	O
woman	O
who	O
underwent	O
gastric	O
surgery	O
for	O
morbid	O
obesity	O
0	O
<EOS>	O
halothane	B-Drug
hepatitis	B-ADR
and	O
prompt	O
resolution	O
with	O
methionine	O
therapy	O
:	O
case	O
report	O
0	O
<EOS>	O
development	O
of	O
porphyria	B-ADR
cutanea	I-ADR
tarda	I-ADR
after	O
treatment	O
with	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
46-yr-old	O
woman	O
with	O
ovarian	O
carcinoma	O
who	O
developed	O
porphyria	B-ADR
cutanea	I-ADR
tarda	I-ADR
while	O
undergoing	O
treatment	O
with	O
cisplatin	B-Drug
and	O
cyclophosphamide	O
0	O
<EOS>	O
we	O
report	O
a	O
46-yr-old	O
woman	O
with	O
ovarian	O
carcinoma	O
who	O
developed	O
porphyria	B-ADR
cutanea	I-ADR
tarda	I-ADR
while	O
undergoing	O
treatment	O
with	O
cisplatin	O
and	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
a	O
patient	O
treated	O
by	O
continuous	O
povidone-iodine	B-Drug
mediastinal	O
irrigation	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
a	O
patient	O
treated	O
by	O
continuous	O
povidone-iodine	B-Drug
mediastinal	O
irrigation	O
0	O
<EOS>	O
we	O
describe	O
a	O
63	O
year	O
old	O
woman	O
with	O
a	O
suppurative	O
mediastinitis	O
,	O
treated	O
with	O
continuous	O
pi	B-Drug
irrigation	O
who	O
developed	O
an	O
acute	B-ADR
oliguric	I-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
a	O
56-year-old	O
woman	O
with	O
scleroderma	O
developed	O
rapidly	O
progressive	O
glomerulonephritis	O
with	O
epithelial	B-ADR
crescent	I-ADR
associated	O
with	O
hemoptysis	O
after	O
27	O
month	O
of	O
d-penicillamine	B-Drug
therapy	O
and	O
a	O
cumulative	O
dose	O
of	O
1200	O
g	O
0	O
<EOS>	O
a	O
56-year-old	O
woman	O
with	O
scleroderma	O
developed	O
rapidly	O
progressive	O
glomerulonephritis	O
with	O
epithelial	O
crescent	O
associated	O
with	O
hemoptysis	B-ADR
after	O
27	O
month	O
of	O
d-penicillamine	B-Drug
therapy	O
and	O
a	O
cumulative	O
dose	O
of	O
1200	O
g	O
0	O
<EOS>	O
a	O
56-year-old	O
woman	O
with	O
scleroderma	O
developed	O
rapidly	B-ADR
progressive	I-ADR
glomerulonephritis	I-ADR
with	O
epithelial	O
crescent	O
associated	O
with	O
hemoptysis	O
after	O
27	O
month	O
of	O
d-penicillamine	B-Drug
therapy	O
and	O
a	O
cumulative	O
dose	O
of	O
1200	O
g	O
0	O
<EOS>	O
d-penicillamine	B-Drug
induced	O
crescentic	B-ADR
glomerulonephritis	I-ADR
:	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
the	O
9	O
other	O
reported	O
case	O
of	O
d-penicillamine	B-Drug
induced	O
rapidly	B-ADR
progressive	I-ADR
glomerulonephritis	I-ADR
have	O
been	O
reviewed	O
0	O
<EOS>	O
gold-induced	B-Drug
pneumonitis	B-ADR
is	O
a	O
rare	O
complication	O
of	O
gold	O
salt	O
therapy	O
0	O
<EOS>	O
gold-induced	B-Drug
pneumonitis	B-ADR
0	O
<EOS>	O
this	O
case	O
support	O
the	O
view	O
that	O
in	O
gold-induced	B-Drug
pneumonitis	B-ADR
a	O
prolonged	O
treatment	O
with	O
corticosteroid	O
may	O
be	O
necessary	O
,	O
a	O
lung	O
function	O
continued	O
to	O
improve	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
gold	B-Drug
salt	O
,	O
who	O
developed	O
bilateral	B-ADR
interstitial	I-ADR
pulmonary	I-ADR
abnormality	I-ADR
and	O
showed	O
a	O
dramatic	O
response	O
on	O
corticosteroid	O
therapy	O
0	O
<EOS>	O
gold-induced	B-Drug
aplastic	B-ADR
anemia	I-ADR
0	O
<EOS>	O
three	O
patient	O
receiving	O
gold	B-Drug
salt	O
treatment	O
for	O
rheumatoid	O
arthritis	O
developed	O
severe	O
aplastic	B-ADR
anemia	I-ADR
0	O
<EOS>	O
pharmacokinetic	O
determinant	O
of	O
6-mercaptopurine	B-Drug
myelotoxicity	B-ADR
and	O
therapeutic	O
failure	O
in	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
0	O
<EOS>	O
because	O
the	O
cerebellar	B-ADR
toxicity	I-ADR
may	O
be	O
worsened	O
by	O
continuation	O
of	O
therapy	O
after	O
initial	O
onset	O
of	O
symptom	O
,	O
prompt	O
termination	O
of	O
hdarac	B-Drug
is	O
recommended	O
0	O
<EOS>	O
cytarabine-induced	B-Drug
cerebellar	B-ADR
syndrome	I-ADR
:	O
case	O
report	O
and	O
literature	O
review	O
0	O
<EOS>	O
during	O
the	O
first	O
treatment	O
,	O
dysarthria	O
and	O
ataxia	B-ADR
were	O
seen	O
after	O
completion	O
of	O
the	O
patient	O
eighth	O
and	O
final	O
dose	O
of	O
hdarac	B-Drug
0	O
<EOS>	O
during	O
the	O
first	O
treatment	O
,	O
dysarthria	B-ADR
and	O
ataxia	O
were	O
seen	O
after	O
completion	O
of	O
the	O
patient	O
eighth	O
and	O
final	O
dose	O
of	O
hdarac	B-Drug
0	O
<EOS>	O
the	O
neurotoxicity	B-ADR
seen	O
with	O
hdarac	B-Drug
is	O
dose-related	O
and	O
ha	O
occurred	O
in	O
up	O
to	O
60	O
percent	O
of	O
treated	O
patient	O
0	O
<EOS>	O
this	O
case	O
report	O
illustrates	O
the	O
neurotoxicity	B-ADR
unique	O
to	O
hdarac	B-Drug
0	O
<EOS>	O
macular	B-ADR
infarction	I-ADR
after	O
endophthalmitis	O
treated	O
with	O
vitrectomy	O
and	O
intravitreal	O
gentamicin	B-Drug
0	O
<EOS>	O
we	O
are	O
concerned	O
that	O
the	O
macular	B-ADR
lesion	I-ADR
wa	O
a	O
retinal	O
toxic	O
effect	O
of	O
gentamicin	B-Drug
because	O
of	O
the	O
recent	O
description	O
of	O
similar	O
lesion	O
occurring	O
after	O
the	O
inadvertent	O
intraocular	O
injection	O
of	O
massive	O
dos	O
of	O
this	O
drug	O
0	O
<EOS>	O
a	O
woman	O
with	O
a	O
20-year	O
history	O
of	O
acral	O
pustular	O
psoriasis	O
of	O
hallopeau	O
and	O
recurrent	O
pustular	O
lesion	O
of	O
the	O
forearm	O
and	O
lower	O
leg	O
,	O
developed	O
a	O
b-cell	B-ADR
lymphoma	I-ADR
of	O
the	O
lip	O
following	O
4	O
1	O
/	O
2	O
year	O
of	O
treatment	O
with	O
razoxane	B-Drug
0	O
<EOS>	O
extensive	O
immunological	O
investigation	O
were	O
performed	O
in	O
a	O
patient	O
with	O
definite	O
seronegative	O
rheumatoid	O
arthritis	O
who	O
developed	O
hypogammaglobulinemia	B-ADR
in	O
the	O
course	O
of	O
gold	B-Drug
therapy	O
0	O
<EOS>	O
hypogammaglobulinemia	B-ADR
associated	O
with	O
gold	B-Drug
therapy	O
:	O
evidence	O
for	O
a	O
partial	O
maturation	O
blockade	O
of	O
b	O
cell	O
0	O
<EOS>	O
transient	O
leucopenia	B-ADR
and	O
thrombocytopenia	O
associated	O
with	O
sodium	B-Drug
nitroprusside	I-Drug
infusion	O
0	O
<EOS>	O
transient	O
leucopenia	O
and	O
thrombocytopenia	B-ADR
associated	O
with	O
sodium	B-Drug
nitroprusside	I-Drug
infusion	O
0	O
<EOS>	O
herpes	B-ADR
simplex	I-ADR
esophagitis	I-ADR
in	O
a	O
renal	O
transplant	O
patient	O
treated	O
with	O
cyclosporine	B-Drug
a	I-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
herpes	B-ADR
esophagitis	I-ADR
in	O
a	O
renal	O
transplant	O
patient	O
treated	O
with	O
cyclosporine	B-Drug
a	I-Drug
while	O
on	O
chronic	O
steroid	O
therapy	O
0	O
<EOS>	O
with	O
the	O
increasing	O
use	O
of	O
cyclosporine	B-Drug
a	I-Drug
in	O
transplant	O
patient	O
,	O
the	O
incidence	O
of	O
herpes	B-ADR
esophagitis	I-ADR
may	O
increase	O
0	O
<EOS>	O
administration	O
of	O
excessive	O
insulin	B-Drug
induced	O
hypoglycemia	B-ADR
within	O
4	O
to	O
8	O
hour	O
,	O
followed	O
by	O
rebound	O
hyperglycemia	O
0	O
<EOS>	O
administration	O
of	O
excessive	O
insulin	B-Drug
induced	O
hypoglycemia	O
within	O
4	O
to	O
8	O
hour	O
,	O
followed	O
by	O
rebound	B-ADR
hyperglycemia	I-ADR
0	O
<EOS>	O
posthypoglycemic	B-ADR
hyperglycemia	I-ADR
(	O
rebound	O
hyperglycemia	O
)	O
after	O
overdosing	O
of	O
insulin	B-Drug
wa	O
diagnosed	O
in	O
6	O
cat	O
with	O
diabetes	O
mellitus	O
0	O
<EOS>	O
posthypoglycemic	O
hyperglycemia	O
(	O
rebound	B-ADR
hyperglycemia	I-ADR
)	O
after	O
overdosing	O
of	O
insulin	B-Drug
wa	O
diagnosed	O
in	O
6	O
cat	O
with	O
diabetes	O
mellitus	O
0	O
<EOS>	O
rebound	O
hyperglycemia	B-ADR
following	O
overdosing	O
of	O
insulin	B-Drug
in	O
cat	O
with	O
diabetes	O
mellitus	O
0	O
<EOS>	O
rebound	B-ADR
hyperglycemia	I-ADR
wa	O
observed	O
with	O
both	O
intermediate	O
(	O
neutral	O
protamine	B-Drug
hagedorn	I-Drug
)	O
and	O
long-acting	O
(	O
protamine	O
zinc	O
iletin	O
)	O
insulin	O
,	O
and	O
the	O
range	O
of	O
insulin	O
dos	O
at	O
which	O
the	O
disorder	O
developed	O
overlapped	O
previously	O
determined	O
therapeutic	O
dos	O
for	O
these	O
insulin	O
in	O
the	O
cat	O
0	O
<EOS>	O
rebound	B-ADR
hyperglycemia	I-ADR
wa	O
observed	O
with	O
both	O
intermediate	O
(	O
neutral	O
protamine	B-Drug
hagedorn	O
)	O
and	O
long-acting	O
(	O
protamine	O
zinc	B-Drug
iletin	I-Drug
)	O
insulin	O
,	O
and	O
the	O
range	O
of	O
insulin	O
dos	O
at	O
which	O
the	O
disorder	O
developed	O
overlapped	O
previously	O
determined	O
therapeutic	O
dos	O
for	O
these	O
insulin	O
in	O
the	O
cat	O
0	O
<EOS>	O
captopril-induced	B-Drug
lichen	B-ADR
planus	I-ADR
pemphigoides	I-ADR
with	O
pemphigus-like	O
feature	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
bullous	B-ADR
lichenoid	I-ADR
eruption	I-ADR
due	O
to	O
the	O
intake	O
of	O
captopril	B-Drug
0	O
<EOS>	O
an	O
8-year-old	O
girl	O
,	O
who	O
had	O
been	O
vaccinated	O
with	O
bcg	B-Drug
without	O
subsequent	O
regional	O
reaction	O
,	O
developed	O
osteomyelitis	B-ADR
in	I-ADR
the	I-ADR
left	I-ADR
calcaneus	I-ADR
7	O
month	O
later	O
0	O
<EOS>	O
metastatic	B-ADR
osteomyelitis	I-ADR
following	O
bcg	B-Drug
vaccination	O
0	O
<EOS>	O
one	O
of	O
the	O
subject	O
who	O
wa	O
using	O
extemporaneous	O
topical	O
minoxidil	B-Drug
had	O
hypertension	O
and	O
arteriosclerotic	B-ADR
disease	I-ADR
and	O
the	O
other	O
died	O
of	O
a	O
myocardial	O
infarction	O
0	O
<EOS>	O
one	O
of	O
the	O
subject	O
who	O
wa	O
using	O
extemporaneous	O
topical	O
minoxidil	B-Drug
had	O
hypertension	B-ADR
and	O
arteriosclerotic	O
disease	O
and	O
the	O
other	O
died	O
of	O
a	O
myocardial	O
infarction	O
0	O
<EOS>	O
one	O
of	O
the	O
subject	O
who	O
wa	O
using	O
extemporaneous	O
topical	O
minoxidil	B-Drug
had	O
hypertension	O
and	O
arteriosclerotic	O
disease	O
and	O
the	O
other	O
died	O
of	O
a	O
myocardial	B-ADR
infarction	I-ADR
0	O
<EOS>	O
amoxapine-induced	B-Drug
cognitive	B-ADR
impairment	I-ADR
in	O
two	O
patient	O
0	O
<EOS>	O
two	O
patient	O
are	O
described	O
in	O
whom	O
subtle	O
cognitive	B-ADR
impairment	I-ADR
are	O
associated	O
with	O
therapeutic	O
dos	O
of	O
amoxapine	B-Drug
0	O
<EOS>	O
a	O
23-year-old	O
woman	O
with	O
systemic	O
lupus	O
erythematosus	O
had	O
a	O
severe	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
to	O
the	O
drug	O
ibuprofen	B-Drug
0	O
<EOS>	O
severe	B-ADR
systemic	I-ADR
hypersensitivity	I-ADR
reaction	I-ADR
to	O
ibuprofen	B-Drug
occurring	O
after	O
prolonged	O
therapy	O
0	O
<EOS>	O
a	O
brief	O
review	O
of	O
reported	O
case	O
of	O
chloramphenicol	B-Drug
hypersensitivity	B-ADR
in	O
the	O
english-language	O
literature	O
,	O
a	O
well	O
a	O
possible	O
alternative	O
explanation	O
in	O
this	O
case	O
,	O
are	O
provided	O
0	O
<EOS>	O
hypersensitivity	B-ADR
reaction	I-ADR
following	O
chloramphenicol	B-Drug
administration	O
in	O
a	O
patient	O
with	O
typhoid	O
fever	O
0	O
<EOS>	O
hypersensitivity	B-ADR
reaction	I-ADR
due	O
to	O
chloramphenicol	B-Drug
are	O
rarely	O
reported	O
in	O
the	O
literature	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
typhoid	O
fever	O
who	O
experienced	O
a	O
hypersensitivity	B-ADR
reaction	I-ADR
subsequent	O
to	O
the	O
infusion	O
of	O
chloramphenicol	B-Drug
sodium	I-Drug
succinate	I-Drug
0	O
<EOS>	O
replicate	O
brain	O
magnetic	O
resonance	O
imaging	O
examination	O
after	O
six	O
week	O
and	O
11	O
month	O
of	O
penicillamine	B-Drug
therapy	O
documented	O
the	O
development	O
of	O
new	O
brain	B-ADR
lesion	I-ADR
during	O
this	O
period	O
,	O
while	O
liver	O
biopsy	O
specimen	O
data	O
disclosed	O
that	O
excellent	O
hepatic	O
decoppering	O
had	O
occurred	O
0	O
<EOS>	O
to	O
develop	O
information	O
on	O
the	O
relative	O
rarity	O
or	O
frequency	O
of	O
neurologic	O
worsening	O
with	O
the	O
initiation	O
of	O
penicillamine	B-Drug
therapy	O
,	O
we	O
conducted	O
a	O
retrospective	O
survey	O
of	O
25	O
additional	O
patient	O
with	O
wilson	O
disease	O
who	O
met	O
the	O
criterion	O
of	O
presenting	O
with	O
neurologic	B-ADR
disease	I-ADR
and	O
having	O
been	O
treated	O
with	O
penicillamine	O
0	O
<EOS>	O
to	O
develop	O
information	O
on	O
the	O
relative	O
rarity	O
or	O
frequency	O
of	O
neurologic	B-ADR
worsening	I-ADR
with	O
the	O
initiation	O
of	O
penicillamine	B-Drug
therapy	O
,	O
we	O
conducted	O
a	O
retrospective	O
survey	O
of	O
25	O
additional	O
patient	O
with	O
wilson	O
disease	O
who	O
met	O
the	O
criterion	O
of	O
presenting	O
with	O
neurologic	O
disease	O
and	O
having	O
been	O
treated	O
with	O
penicillamine	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
wilson	O
disease	O
who	O
presented	O
with	O
neurologic	O
disease	O
,	O
wa	O
treated	O
with	O
d-penicillamine	B-Drug
,	O
and	O
suffered	O
sudden	O
neurologic	B-ADR
deterioration	I-ADR
coincident	O
with	O
therapy	O
0	O
<EOS>	O
worsening	B-ADR
of	I-ADR
neurologic	I-ADR
syndrome	I-ADR
in	O
patient	O
with	O
wilson	O
disease	O
with	O
initial	O
penicillamine	B-Drug
therapy	O
0	O
<EOS>	O
other	O
upper	B-ADR
tract	I-ADR
neoplasm	I-ADR
after	O
cyclophosphamide	B-Drug
are	O
reviewed	O
0	O
<EOS>	O
upper	B-ADR
tract	I-ADR
urothelial	I-ADR
malignancy	I-ADR
after	O
cyclophosphamide	B-Drug
therapy	O
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
0	O
<EOS>	O
we	O
report	O
an	O
unusual	O
case	O
of	O
simultaneous	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
renal	O
pelvis	O
and	O
distal	B-ADR
ureter	I-ADR
without	I-ADR
transitional	I-ADR
cell	I-ADR
carcinoma	I-ADR
of	I-ADR
the	I-ADR
bladder	I-ADR
occurring	O
after	O
chronic	O
cyclophosphamide	B-Drug
therapy	O
for	O
nonhodgkin	O
lymphoma	O
0	O
<EOS>	O
we	O
report	O
an	O
unusual	O
case	O
of	O
simultaneous	O
transitional	B-ADR
cell	I-ADR
carcinoma	I-ADR
of	I-ADR
the	I-ADR
renal	I-ADR
pelvis	I-ADR
and	O
distal	O
ureter	O
without	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
occurring	O
after	O
chronic	O
cyclophosphamide	B-Drug
therapy	O
for	O
nonhodgkin	O
lymphoma	O
0	O
<EOS>	O
progressive	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
complicating	O
cyclophosphamide	B-Drug
therapy	O
0	O
<EOS>	O
the	O
change	O
were	O
progressive	O
regardless	O
of	O
discontinuation	O
of	O
cyclophosphamide	B-Drug
and	O
led	O
to	O
severe	B-ADR
restrictive	I-ADR
ventilatory	I-ADR
defect	I-ADR
0	O
<EOS>	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
during	O
loading	O
with	O
amiodarone	B-Drug
0	O
<EOS>	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
following	O
a	O
single	O
oral	O
dose	O
of	O
amiodarone	B-Drug
(	O
1400	O
mg	O
or	O
30	O
mg	O
kg-1	O
)	O
administered	O
after	O
short	O
intravenous	O
loading	O
for	O
prevention	O
of	O
paroxysmal	O
atrial	O
flutter	O
0	O
<EOS>	O
pulmonary	B-ADR
edema	I-ADR
a	O
a	O
delayed	O
complication	O
of	O
ritodrine	B-Drug
therapy	O
0	O
<EOS>	O
pulmonary	B-ADR
edema	I-ADR
occurred	O
24	O
hour	O
after	O
intravenous	O
ritodrine	B-Drug
therapy	O
and	O
10	O
hour	O
after	O
subcutaneous	O
terbutaline	O
therapy	O
0	O
<EOS>	O
pulmonary	B-ADR
edema	I-ADR
occurred	O
24	O
hour	O
after	O
intravenous	O
ritodrine	O
therapy	O
and	O
10	O
hour	O
after	O
subcutaneous	O
terbutaline	B-Drug
therapy	O
0	O
<EOS>	O
cyclosporin	B-Drug
side	O
effect	O
included	O
hirsutism	O
,	O
hypertension	O
,	O
increased	O
blood	O
level	O
of	O
urea	O
and	O
creatinine	O
,	O
and	O
abnormality	B-ADR
in	I-ADR
liver	I-ADR
function	I-ADR
test	I-ADR
0	O
<EOS>	O
cyclosporin	B-Drug
side	O
effect	O
included	O
hirsutism	B-ADR
,	O
hypertension	O
,	O
increased	O
blood	O
level	O
of	O
urea	O
and	O
creatinine	O
,	O
and	O
abnormality	O
in	O
liver	O
function	O
test	O
0	O
<EOS>	O
cyclosporin	B-Drug
side	O
effect	O
included	O
hirsutism	O
,	O
hypertension	B-ADR
,	O
increased	O
blood	O
level	O
of	O
urea	O
and	O
creatinine	O
,	O
and	O
abnormality	O
in	O
liver	O
function	O
test	O
0	O
<EOS>	O
cyclosporin	B-Drug
side	O
effect	O
included	O
hirsutism	O
,	O
hypertension	O
,	O
increased	B-ADR
blood	I-ADR
level	I-ADR
of	I-ADR
urea	I-ADR
and	I-ADR
creatinine	I-ADR
,	O
and	O
abnormality	O
in	O
liver	O
function	O
test	O
0	O
<EOS>	O
rupture	B-ADR
of	I-ADR
a	I-ADR
cerebral	I-ADR
aneurysm	I-ADR
associated	O
with	O
nifedipine	B-Drug
treatment	O
0	O
<EOS>	O
we	O
describe	O
rupture	B-ADR
of	I-ADR
a	I-ADR
cerebral	I-ADR
arterial	I-ADR
aneurysm	I-ADR
in	O
a	O
32	O
year	O
old	O
hypertensive	O
woman	O
following	O
the	O
introduction	O
of	O
nifedipine	B-Drug
treatment	O
0	O
<EOS>	O
a	O
small	O
initial	O
dose	O
of	O
prazosin	B-Drug
ranging	O
from	O
0.5	O
to	O
1	O
mg	O
ha	O
been	O
recommended	O
to	O
avoid	O
the	O
first-dose	O
phenomenon	O
characterized	O
by	O
a	O
sudden	O
and	O
severe	B-ADR
drop	I-ADR
in	I-ADR
blood	I-ADR
pressure	I-ADR
after	O
the	O
administration	O
of	O
the	O
first	O
dose	O
of	O
prazosin	O
0	O
<EOS>	O
a	O
small	O
initial	O
dose	O
of	O
prazosin	B-Drug
ranging	O
from	O
0.5	O
to	O
1	O
mg	O
ha	O
been	O
recommended	O
to	O
avoid	O
the	O
first-dose	O
phenomenon	O
characterized	O
by	O
a	O
sudden	O
and	O
severe	B-ADR
drop	I-ADR
in	I-ADR
blood	I-ADR
pressure	I-ADR
after	O
the	O
administration	O
of	O
the	O
first	O
dose	O
of	O
prazosin	O
0	O
<EOS>	O
prazosin-induced	B-Drug
first-dose	O
phenomenon	O
possibly	O
associated	O
with	O
hemorrhagic	B-ADR
stroke	I-ADR
:	O
a	O
report	O
of	O
three	O
case	O
0	O
<EOS>	O
a	O
fatal	B-ADR
massive	I-ADR
pulmonary	I-ADR
embolus	I-ADR
developed	O
in	O
a	O
patient	O
treated	O
with	O
streptokinase	B-Drug
for	O
acute	O
deep	O
vein	O
thrombosis	O
0	O
<EOS>	O
massive	B-ADR
pulmonary	I-ADR
embolism	I-ADR
complicating	O
streptokinase	B-Drug
treatment	O
for	O
deep	O
vein	O
thrombosis	O
0	O
<EOS>	O
fatal	B-ADR
digoxin	B-Drug
poisoning	I-ADR
:	O
an	O
unsuccessful	O
resuscitation	O
with	O
use	O
of	O
digoxin-immune	O
fab	O
0	O
<EOS>	O
a	O
case	O
of	O
phenytoin-induced	B-Drug
hepatitis	B-ADR
with	O
mononucleosis	O
is	O
reported	O
,	O
and	O
syndrome	O
associated	O
with	O
phenytoin	O
hypersensitivity	O
reaction	O
are	O
discussed	O
0	O
<EOS>	O
a	O
case	O
of	O
phenytoin-induced	B-Drug
hepatitis	O
with	O
mononucleosis	O
is	O
reported	O
,	O
and	O
syndrome	O
associated	O
with	O
phenytoin	O
hypersensitivity	B-ADR
reaction	I-ADR
are	O
discussed	O
0	O
<EOS>	O
a	O
case	O
of	O
phenytoin-induced	B-Drug
hepatitis	O
with	O
mononucleosis	B-ADR
is	O
reported	O
,	O
and	O
syndrome	O
associated	O
with	O
phenytoin	O
hypersensitivity	O
reaction	O
are	O
discussed	O
0	O
<EOS>	O
phenytoin-induced	B-Drug
hypersensitivity	B-ADR
reaction	I-ADR
0	O
<EOS>	O
phenytoin	B-Drug
wa	O
discontinued	O
after	O
admission	O
;	O
however	O
,	O
phenytoin	O
1	O
g	O
i.v	O
0	O
wa	O
given	O
for	O
a	O
tonic-clonic	O
seizure	O
two	O
day	O
after	O
admission	O
,	O
after	O
which	O
swelling	O
of	O
the	O
face	O
and	O
leg	O
and	O
pruritus	B-ADR
developed	O
0	O
<EOS>	O
phenytoin	B-Drug
wa	O
discontinued	O
after	O
admission	O
;	O
however	O
,	O
phenytoin	O
1	O
g	O
i.v	O
0	O
wa	O
given	O
for	O
a	O
tonic-clonic	O
seizure	O
two	O
day	O
after	O
admission	O
,	O
after	O
which	O
swelling	B-ADR
of	I-ADR
the	I-ADR
face	I-ADR
and	I-ADR
leg	I-ADR
and	O
pruritus	O
developed	O
0	O
<EOS>	O
serious	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
may	O
appear	O
a	O
dermatologic	B-ADR
,	I-ADR
lymphoid	I-ADR
,	I-ADR
or	I-ADR
hepatic	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
serious	O
phenytoin	B-Drug
hypersensitivity	B-ADR
reaction	I-ADR
may	O
appear	O
a	O
dermatologic	O
,	O
lymphoid	O
,	O
or	O
hepatic	O
syndrome	O
0	O
<EOS>	O
she	O
wa	O
receiving	O
phenytoin	O
sodium	O
300	O
mg	O
/	O
day	O
;	O
carbamazepine	B-Drug
200	O
mg	O
four	O
time	O
daily	O
had	O
been	O
discontinued	O
four	O
day	O
before	O
admission	O
because	O
of	O
leukopenia	B-ADR
0	O
<EOS>	O
she	O
wa	O
receiving	O
phenytoin	B-Drug
sodium	I-Drug
300	O
mg	O
/	O
day	O
;	O
carbamazepine	O
200	O
mg	O
four	O
time	O
daily	O
had	O
been	O
discontinued	O
four	O
day	O
before	O
admission	O
because	O
of	O
leukopenia	B-ADR
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	B-ADR
,	O
rash	O
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	B-ADR
,	O
rash	O
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	B-ADR
reaction	I-ADR
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	O
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	B-ADR
reaction	I-ADR
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	O
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	O
,	O
and	O
lymphadenopathy	B-ADR
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	O
,	O
and	O
lymphadenopathy	B-ADR
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	B-ADR
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
the	O
possibility	O
of	O
phenytoin	B-Drug
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
when	O
patient	O
receiving	O
phenytoin	O
have	O
unusual	O
symptom	O
,	O
particularly	O
fever	O
,	O
rash	B-ADR
,	O
and	O
lymphadenopathy	O
0	O
<EOS>	O
it	O
wa	O
restarted	O
6	O
week	O
later	O
,	O
and	O
10	O
week	O
after	O
that	O
,	O
the	O
patient	O
presented	O
with	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
,	O
which	O
resolved	O
rapidly	O
after	O
cessation	O
of	O
nicotinic	B-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
nicotinic	B-Drug
acid-induced	I-Drug
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
suggest	O
that	O
nicotinic	B-Drug
acid	I-Drug
wa	O
the	O
cause	O
of	O
his	O
liver	O
disease	O
,	O
that	O
this	O
case	O
is	O
of	O
particular	O
note	O
because	O
of	O
the	O
rather	O
short	O
period	O
of	O
therapy	O
before	O
the	O
onset	O
of	O
liver	O
injury	O
and	O
the	O
severity	O
of	O
the	O
hepatic	O
failure	O
,	O
and	O
that	O
the	O
probable	O
increased	O
use	O
of	O
nicotinic	O
acid	O
for	O
serum	O
cholesterol	O
control	O
make	O
it	O
especially	O
important	O
for	O
physician	O
and	O
their	O
patient	O
to	O
be	O
alert	O
to	O
the	O
sign	O
of	O
hepatotoxicity	B-ADR
0	O
<EOS>	O
we	O
suggest	O
that	O
nicotinic	B-Drug
acid	I-Drug
wa	O
the	O
cause	O
of	O
his	O
liver	B-ADR
disease	I-ADR
,	O
that	O
this	O
case	O
is	O
of	O
particular	O
note	O
because	O
of	O
the	O
rather	O
short	O
period	O
of	O
therapy	O
before	O
the	O
onset	O
of	O
liver	O
injury	O
and	O
the	O
severity	O
of	O
the	O
hepatic	O
failure	O
,	O
and	O
that	O
the	O
probable	O
increased	O
use	O
of	O
nicotinic	O
acid	O
for	O
serum	O
cholesterol	O
control	O
make	O
it	O
especially	O
important	O
for	O
physician	O
and	O
their	O
patient	O
to	O
be	O
alert	O
to	O
the	O
sign	O
of	O
hepatotoxicity	O
0	O
<EOS>	O
we	O
suggest	O
that	O
nicotinic	B-Drug
acid	I-Drug
wa	O
the	O
cause	O
of	O
his	O
liver	B-ADR
disease	I-ADR
,	O
that	O
this	O
case	O
is	O
of	O
particular	O
note	O
because	O
of	O
the	O
rather	O
short	O
period	O
of	O
therapy	O
before	O
the	O
onset	O
of	O
liver	O
injury	O
and	O
the	O
severity	O
of	O
the	O
hepatic	O
failure	O
,	O
and	O
that	O
the	O
probable	O
increased	O
use	O
of	O
nicotinic	O
acid	O
for	O
serum	O
cholesterol	O
control	O
make	O
it	O
especially	O
important	O
for	O
physician	O
and	O
their	O
patient	O
to	O
be	O
alert	O
to	O
the	O
sign	O
of	O
hepatotoxicity	O
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	O
atresia	O
,	O
athelia	B-ADR
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	O
retardation	O
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	B-Drug
and	O
propranolol	O
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	O
atresia	O
,	O
athelia	B-ADR
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	O
retardation	O
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	O
and	O
propranolol	B-Drug
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	B-ADR
atresia	I-ADR
,	O
athelia	O
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	O
retardation	O
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	B-Drug
and	O
propranolol	O
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	B-ADR
atresia	I-ADR
,	O
athelia	O
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	O
retardation	O
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	O
and	O
propranolol	B-Drug
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	O
atresia	O
,	O
athelia	O
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	B-ADR
retardation	I-ADR
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	B-Drug
and	O
propranolol	O
0	O
<EOS>	O
an	O
infant	O
girl	O
with	O
choanal	O
atresia	O
,	O
athelia	O
,	O
minor	O
anomaly	O
,	O
and	O
mild	O
to	O
moderate	O
mental	B-ADR
retardation	I-ADR
wa	O
born	O
to	O
a	O
woman	O
treated	O
for	O
hyperthyroidism	O
throughout	O
pregnancy	O
with	O
methimazole	O
and	O
propranolol	B-Drug
0	O
<EOS>	O
choanal	O
atresia	O
and	O
athelia	B-ADR
:	O
methimazole	B-Drug
teratogenicity	O
or	O
a	O
new	O
syndrome	O
?	O
<EOS>	O
choanal	B-ADR
atresia	I-ADR
and	O
athelia	O
:	O
methimazole	B-Drug
teratogenicity	O
or	O
a	O
new	O
syndrome	O
?	O
<EOS>	O
choanal	O
atresia	O
and	O
athelia	O
:	O
methimazole	B-Drug
teratogenicity	B-ADR
or	O
a	O
new	O
syndrome	O
?	O
<EOS>	O
the	O
patient	O
defect	O
may	O
be	O
due	O
to	O
methimazole	B-Drug
teratogenicity	B-ADR
or	O
could	O
represent	O
a	O
previously	O
undescribed	O
syndrome	O
affecting	O
ectodermal	O
structure	O
0	O
<EOS>	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
resulted	O
after	O
19	O
day	O
of	O
treatment	O
with	O
5-fluorocytosine	B-Drug
and	O
amphotericin	O
b	O
0	O
<EOS>	O
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
resulted	O
after	O
19	O
day	O
of	O
treatment	O
with	O
5-fluorocytosine	O
and	O
amphotericin	B-Drug
b	I-Drug
0	O
<EOS>	O
five	O
and	O
one-half	O
year	O
after	O
the	O
diagnosis	O
of	O
myeloma	O
,	O
while	O
in	O
remission	O
on	O
cyclophosphamide	B-Drug
therapy	O
,	O
the	O
patient	O
experienced	O
severe	O
abdominal	B-ADR
right	I-ADR
lower	I-ADR
quadrant	I-ADR
pain	I-ADR
due	O
to	O
a	O
large	O
cecal	O
lymphoma	O
0	O
<EOS>	O
five	O
and	O
one-half	O
year	O
after	O
the	O
diagnosis	O
of	O
myeloma	O
,	O
while	O
in	O
remission	O
on	O
cyclophosphamide	B-Drug
therapy	O
,	O
the	O
patient	O
experienced	O
severe	O
abdominal	O
right	O
lower	O
quadrant	O
pain	O
due	O
to	O
a	O
large	O
cecal	B-ADR
lymphoma	I-ADR
0	O
<EOS>	O
after	O
therapy	O
with	O
parenteral	O
amiodarone	B-Drug
(	O
2300	O
mg	O
in	O
3	O
day	O
)	O
and	O
other	O
measure	O
,	O
sign	O
of	O
congestive	O
heart	O
failure	O
disappeared	O
;	O
subsequently	O
the	O
patient	O
developed	O
jaundice	O
,	O
marked	O
increase	O
in	O
serum	O
transaminase	O
level	O
and	O
fall	B-ADR
in	I-ADR
prothrombin	I-ADR
time	I-ADR
,	O
and	O
histologic	O
change	O
of	O
severe	O
centrilobular	O
necrosis	O
were	O
observed	O
in	O
hepatic	O
biopsy	O
0	O
<EOS>	O
after	O
therapy	O
with	O
parenteral	O
amiodarone	B-Drug
(	O
2300	O
mg	O
in	O
3	O
day	O
)	O
and	O
other	O
measure	O
,	O
sign	O
of	O
congestive	O
heart	O
failure	O
disappeared	O
;	O
subsequently	O
the	O
patient	O
developed	O
jaundice	B-ADR
,	O
marked	O
increase	O
in	O
serum	O
transaminase	O
level	O
and	O
fall	O
in	O
prothrombin	O
time	O
,	O
and	O
histologic	O
change	O
of	O
severe	O
centrilobular	O
necrosis	O
were	O
observed	O
in	O
hepatic	O
biopsy	O
0	O
<EOS>	O
after	O
therapy	O
with	O
parenteral	O
amiodarone	B-Drug
(	O
2300	O
mg	O
in	O
3	O
day	O
)	O
and	O
other	O
measure	O
,	O
sign	O
of	O
congestive	O
heart	O
failure	O
disappeared	O
;	O
subsequently	O
the	O
patient	O
developed	O
jaundice	O
,	O
marked	B-ADR
increase	I-ADR
in	I-ADR
serum	I-ADR
transaminase	I-ADR
level	I-ADR
and	O
fall	O
in	O
prothrombin	O
time	O
,	O
and	O
histologic	O
change	O
of	O
severe	O
centrilobular	O
necrosis	O
were	O
observed	O
in	O
hepatic	O
biopsy	O
0	O
<EOS>	O
after	O
therapy	O
with	O
parenteral	O
amiodarone	B-Drug
(	O
2300	O
mg	O
in	O
3	O
day	O
)	O
and	O
other	O
measure	O
,	O
sign	O
of	O
congestive	O
heart	O
failure	O
disappeared	O
;	O
subsequently	O
the	O
patient	O
developed	O
jaundice	O
,	O
marked	O
increase	O
in	O
serum	O
transaminase	O
level	O
and	O
fall	O
in	O
prothrombin	O
time	O
,	O
and	O
histologic	O
change	O
of	O
severe	B-ADR
centrilobular	I-ADR
necrosis	I-ADR
were	O
observed	O
in	O
hepatic	O
biopsy	O
0	O
<EOS>	O
a	O
patient	O
with	O
acute	O
change	O
suggesting	O
acute	B-ADR
hepatitis	I-ADR
after	O
parenteral	O
amiodarone	B-Drug
administration	O
is	O
described	O
0	O
<EOS>	O
probable	O
early	O
acute	B-ADR
hepatitis	I-ADR
with	O
parenteral	O
amiodarone	B-Drug
0	O
<EOS>	O
therefore	O
,	O
parenteral	O
amiodarone	B-Drug
wa	O
implicated	O
a	O
the	O
cause	O
of	O
acute	B-ADR
hepatitis	I-ADR
in	O
this	O
patient	O
0	O
<EOS>	O
he	O
became	O
hyperkalemic	B-ADR
on	O
rechallenge	O
with	O
timolol	B-Drug
and	O
normokalemic	O
following	O
it	O
withdrawal	O
0	O
<EOS>	O
severe	B-ADR
hyperkalemia	I-ADR
a	O
a	O
complication	O
of	O
timolol	B-Drug
,	O
a	O
topically	O
applied	O
beta-adrenergic	O
antagonist	O
0	O
<EOS>	O
severe	B-ADR
hyperkalemia	I-ADR
occurred	O
in	O
a	O
patient	O
with	O
radiation	O
pneumonitis	O
and	O
glaucoma	O
shortly	O
after	O
beginning	O
prednisone	B-Drug
therapy	O
0	O
<EOS>	O
noncardiogenic	B-ADR
pulmonary	I-ADR
edema	I-ADR
during	O
intrabiliary	O
infusion	O
of	O
mono-octanoin	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
in	O
whom	O
noncardiogenic	B-ADR
pulmonary	I-ADR
edema	I-ADR
developed	O
during	O
intrabiliary	O
infusion	O
of	O
monooctanoin	B-Drug
0	O
<EOS>	O
paroxysmal	B-ADR
supraventricular	I-ADR
tachycardia	I-ADR
during	O
treatment	O
with	O
cisplatin	B-Drug
and	O
etoposide	O
combination	O
0	O
<EOS>	O
paroxysmal	B-ADR
supraventricular	I-ADR
tachycardia	I-ADR
during	O
treatment	O
with	O
cisplatin	O
and	O
etoposide	B-Drug
combination	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
60-year-old	O
woman	O
affected	O
by	O
squamous	O
lung	O
carcinoma	O
,	O
who	O
developed	O
paroxysmal	B-ADR
supraventricular	I-ADR
tachycardia	I-ADR
during	O
cisplatin	B-Drug
and	O
etoposide	O
combination	O
chemotherapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
60-year-old	O
woman	O
affected	O
by	O
squamous	O
lung	O
carcinoma	O
,	O
who	O
developed	O
paroxysmal	B-ADR
supraventricular	I-ADR
tachycardia	I-ADR
during	O
cisplatin	O
and	O
etoposide	B-Drug
combination	O
chemotherapy	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
theophylline	O
intoxication	O
due	O
to	O
a	O
dramatic	O
decrease	B-ADR
in	I-ADR
theophylline	I-ADR
clearance	I-ADR
following	O
concomitant	O
administration	O
of	O
viloxazine	B-Drug
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
theophylline	B-Drug
intoxication	I-ADR
due	O
to	O
a	O
dramatic	O
decrease	O
in	O
theophylline	O
clearance	O
following	O
concomitant	O
administration	O
of	O
viloxazine	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
theophylline	B-ADR
intoxication	I-ADR
due	O
to	O
a	O
dramatic	O
decrease	O
in	O
theophylline	O
clearance	O
following	O
concomitant	O
administration	O
of	O
viloxazine	B-Drug
0	O
<EOS>	O
theophylline	O
intoxication	O
following	O
viloxazine	B-Drug
induced	O
decrease	B-ADR
in	I-ADR
clearance	I-ADR
0	O
<EOS>	O
theophylline	B-Drug
intoxication	I-ADR
following	O
viloxazine	O
induced	O
decrease	O
in	O
clearance	O
0	O
<EOS>	O
theophylline	B-ADR
intoxication	I-ADR
following	O
viloxazine	B-Drug
induced	O
decrease	O
in	O
clearance	O
0	O
<EOS>	O
idiosyncratic	O
pulmonary	O
reaction	O
to	O
nitrofurantoin	B-Drug
are	O
not	O
unusual	O
,	O
often	O
presenting	O
a	O
eosinophilic	B-ADR
pneumonia	I-ADR
0	O
<EOS>	O
idiosyncratic	B-ADR
pulmonary	I-ADR
reaction	I-ADR
to	O
nitrofurantoin	B-Drug
are	O
not	O
unusual	O
,	O
often	O
presenting	O
a	O
eosinophilic	O
pneumonia	O
0	O
<EOS>	O
acute	B-ADR
myocardial	I-ADR
necrosis	I-ADR
during	O
administration	O
of	O
amsacrine	B-Drug
0	O
<EOS>	O
in	O
addition	O
to	O
the	O
recognized	O
arrhythmic	O
complication	O
,	O
the	O
author	O
emphasize	O
myocardial	O
necrosis	O
a	O
a	O
possible	O
further	O
manifestation	O
of	O
amsacrine-related	B-Drug
cardiotoxicity	B-ADR
0	O
<EOS>	O
in	O
addition	O
to	O
the	O
recognized	O
arrhythmic	O
complication	O
,	O
the	O
author	O
emphasize	O
myocardial	B-ADR
necrosis	I-ADR
a	O
a	O
possible	O
further	O
manifestation	O
of	O
amsacrine-related	B-Drug
cardiotoxicity	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
focal	O
myocardial	O
necrosis	O
,	O
presenting	O
clinically	O
a	O
an	O
acute	B-ADR
myocardial	I-ADR
infarction	I-ADR
during	O
the	O
administration	O
of	O
the	O
antineoplastic	O
drug	O
,	O
amsacrine	B-Drug
,	O
in	O
a	O
patient	O
without	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
focal	B-ADR
myocardial	I-ADR
necrosis	I-ADR
,	O
presenting	O
clinically	O
a	O
an	O
acute	O
myocardial	O
infarction	O
during	O
the	O
administration	O
of	O
the	O
antineoplastic	O
drug	O
,	O
amsacrine	B-Drug
,	O
in	O
a	O
patient	O
without	O
coronary	O
artery	O
disease	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	B-ADR
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	B-ADR
desquamating	I-ADR
erythrodermic	I-ADR
rash	I-ADR
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	B-ADR
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	B-ADR
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	B-ADR
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	B-ADR
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	O
enteropathy	O
,	O
myositis	O
,	O
and	O
nephritis	B-ADR
,	O
is	O
described	O
0	O
<EOS>	O
a	O
child	O
in	O
whom	O
a	O
phenobarbital	B-Drug
hypersensitivity	O
drug	O
reaction	O
developed	O
which	O
consisted	O
of	O
fever	O
,	O
a	O
pruritic	O
desquamating	O
erythrodermic	O
rash	O
,	O
alopecia	O
,	O
icterus	O
,	O
protein-losing	B-ADR
enteropathy	I-ADR
,	O
myositis	O
,	O
and	O
nephritis	O
,	O
is	O
described	O
0	O
<EOS>	O
graft	B-ADR
versus	I-ADR
host-like	I-ADR
illness	I-ADR
in	O
a	O
child	O
with	O
phenobarbital	B-Drug
hypersensitivity	O
0	O
<EOS>	O
graft	O
versus	O
host-like	O
illness	O
in	O
a	O
child	O
with	O
phenobarbital	B-Drug
hypersensitivity	B-ADR
0	O
<EOS>	O
the	O
clinical	O
finding	O
and	O
laboratory	O
study	O
suggested	O
an	O
autoimmune	B-ADR
cell-mediated	I-ADR
hypersensitivity	I-ADR
reaction	O
triggered	O
by	O
phenobarbital	B-Drug
0	O
<EOS>	O
duodenal	B-ADR
ulceration	I-ADR
:	O
a	O
complication	O
of	O
tolazoline	B-Drug
therapy	O
0	O
<EOS>	O
two	O
patient	O
who	O
were	O
receiving	O
tolazoline	B-Drug
by	O
infusion	O
developed	O
duodenal	B-ADR
ulceration	I-ADR
and	O
subsequent	O
intestinal	O
perforation	O
0	O
<EOS>	O
two	O
patient	O
who	O
were	O
receiving	O
tolazoline	B-Drug
by	O
infusion	O
developed	O
duodenal	O
ulceration	O
and	O
subsequent	O
intestinal	B-ADR
perforation	I-ADR
0	O
<EOS>	O
the	O
latter	O
form	O
(	O
macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
le	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effect	O
a	O
the	O
conventional	O
form	O
--	O
liver	O
damage	O
,	O
acute	B-ADR
and	I-ADR
chronic	I-ADR
pulmonary	I-ADR
reaction	I-ADR
,	O
peripheral	O
neuropathy	O
,	O
blood	O
dyscrasia	O
and	O
allergic	O
reaction	O
--	O
and	O
doe	O
so	O
just	O
a	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
0	O
<EOS>	O
the	O
latter	O
form	O
(	O
macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
le	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effect	O
a	O
the	O
conventional	O
form	O
--	O
liver	O
damage	O
,	O
acute	O
and	O
chronic	O
pulmonary	O
reaction	O
,	O
peripheral	O
neuropathy	O
,	O
blood	O
dyscrasia	O
and	O
allergic	B-ADR
reaction	I-ADR
--	O
and	O
doe	O
so	O
just	O
a	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
0	O
<EOS>	O
the	O
latter	O
form	O
(	O
macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
le	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effect	O
a	O
the	O
conventional	O
form	O
--	O
liver	O
damage	O
,	O
acute	O
and	O
chronic	O
pulmonary	O
reaction	O
,	O
peripheral	O
neuropathy	O
,	O
blood	B-ADR
dyscrasia	I-ADR
and	O
allergic	O
reaction	O
--	O
and	O
doe	O
so	O
just	O
a	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
0	O
<EOS>	O
the	O
latter	O
form	O
(	O
macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
le	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effect	O
a	O
the	O
conventional	O
form	O
--	O
liver	B-ADR
damage	I-ADR
,	O
acute	O
and	O
chronic	O
pulmonary	O
reaction	O
,	O
peripheral	O
neuropathy	O
,	O
blood	O
dyscrasia	O
and	O
allergic	O
reaction	O
--	O
and	O
doe	O
so	O
just	O
a	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
0	O
<EOS>	O
the	O
latter	O
form	O
(	O
macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
le	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effect	O
a	O
the	O
conventional	O
form	O
--	O
liver	O
damage	O
,	O
acute	O
and	O
chronic	O
pulmonary	O
reaction	O
,	O
peripheral	B-ADR
neuropathy	I-ADR
,	O
blood	O
dyscrasia	O
and	O
allergic	O
reaction	O
--	O
and	O
doe	O
so	O
just	O
a	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
0	O
<EOS>	O
generalized	B-ADR
pustular	I-ADR
psoriasis	I-ADR
precipitated	O
by	O
trazodone	B-Drug
in	O
the	O
treatment	O
of	O
depression	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
in	O
whom	O
the	O
anti-depressant	O
trazodone	O
hydrochloride	O
(	O
molipaxin	B-Drug
,	O
roussel	O
)	O
,	O
a	O
serotonin	O
antagonist	O
,	O
provoked	O
generalized	B-ADR
pustular	I-ADR
psoriasis	I-ADR
(	O
gpp	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
in	O
whom	O
the	O
anti-depressant	O
trazodone	B-Drug
hydrochloride	I-Drug
(	O
molipaxin	O
,	O
roussel	O
)	O
,	O
a	O
serotonin	O
antagonist	O
,	O
provoked	O
generalized	B-ADR
pustular	I-ADR
psoriasis	I-ADR
(	O
gpp	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
in	O
whom	O
the	O
anti-depressant	O
trazodone	O
hydrochloride	O
(	O
molipaxin	B-Drug
,	O
roussel	O
)	O
,	O
a	O
serotonin	O
antagonist	O
,	O
provoked	O
generalized	O
pustular	O
psoriasis	O
(	O
gpp	B-ADR
)	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
in	O
whom	O
the	O
anti-depressant	O
trazodone	B-Drug
hydrochloride	I-Drug
(	O
molipaxin	O
,	O
roussel	O
)	O
,	O
a	O
serotonin	O
antagonist	O
,	O
provoked	O
generalized	O
pustular	O
psoriasis	O
(	O
gpp	B-ADR
)	O
0	O
<EOS>	O
intravenous	O
verapamil	O
therapy	O
in	O
baby	O
may	O
cause	O
apnea	B-ADR
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	B-Drug
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	B-Drug
therapy	O
in	O
baby	O
may	O
cause	O
apnea	B-ADR
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	O
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	B-Drug
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	B-ADR
flutter	I-ADR
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	O
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	B-Drug
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	O
,	O
and	O
bradycardia	B-ADR
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	O
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	O
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	B-ADR
;	O
quinidine	B-Drug
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	B-Drug
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	B-ADR
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	O
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
intravenous	O
verapamil	O
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	O
death	O
;	O
quinidine	B-Drug
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	B-ADR
qt	I-ADR
interval	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
intravenous	O
verapamil	B-Drug
therapy	O
in	O
baby	O
may	O
cause	O
apnea	O
,	O
hypotension	O
,	O
and	O
bradycardia	O
;	O
continued	O
episode	O
of	O
atrial	O
flutter	O
in	O
a	O
child	O
may	O
cause	O
sudden	B-ADR
death	I-ADR
;	O
quinidine	O
may	O
be	O
related	O
to	O
the	O
death	O
;	O
child	O
with	O
``	O
familial	O
seizure	O
disorder	O
'	O
may	O
in	O
fact	O
have	O
the	O
long	O
qt	O
interval	O
syndrome	O
0	O
<EOS>	O
methimazole-associated	B-Drug
cholestatic	B-ADR
liver	I-ADR
injury	I-ADR
:	O
case	O
report	O
and	O
brief	O
literature	O
review	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
further	O
case	O
of	O
methimazole-associated	B-Drug
liver	B-ADR
damage	I-ADR
and	O
present	O
a	O
brief	O
review	O
of	O
eleven	O
previous	O
case	O
found	O
in	O
the	O
literature	O
0	O
<EOS>	O
the	O
main	O
clinical	O
feature	O
of	O
this	O
58-year-old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	O
and	O
cholestasis	O
,	O
and	O
biopsy	O
feature	O
of	O
fatty	O
liver	O
parenchyma	O
degeneration	O
with	O
granulocytic	O
portal	O
infiltration	O
and	O
bile	B-ADR
stasis	I-ADR
,	O
demonstrated	O
20	O
day	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
0	O
<EOS>	O
the	O
main	O
clinical	O
feature	O
of	O
this	O
58-year-old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	O
and	O
cholestasis	B-ADR
,	O
and	O
biopsy	O
feature	O
of	O
fatty	O
liver	O
parenchyma	O
degeneration	O
with	O
granulocytic	O
portal	O
infiltration	O
and	O
bile	O
stasis	O
,	O
demonstrated	O
20	O
day	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
0	O
<EOS>	O
the	O
main	O
clinical	O
feature	O
of	O
this	O
58-year-old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	O
and	O
cholestasis	O
,	O
and	O
biopsy	O
feature	O
of	O
fatty	B-ADR
liver	I-ADR
parenchyma	I-ADR
degeneration	I-ADR
with	O
granulocytic	O
portal	O
infiltration	O
and	O
bile	O
stasis	O
,	O
demonstrated	O
20	O
day	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
0	O
<EOS>	O
the	O
main	O
clinical	O
feature	O
of	O
this	O
58-year-old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	O
and	O
cholestasis	O
,	O
and	O
biopsy	O
feature	O
of	O
fatty	O
liver	O
parenchyma	O
degeneration	O
with	O
granulocytic	B-ADR
portal	I-ADR
infiltration	I-ADR
and	O
bile	O
stasis	O
,	O
demonstrated	O
20	O
day	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
0	O
<EOS>	O
the	O
main	O
clinical	O
feature	O
of	O
this	O
58-year-old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	B-ADR
and	O
cholestasis	O
,	O
and	O
biopsy	O
feature	O
of	O
fatty	O
liver	O
parenchyma	O
degeneration	O
with	O
granulocytic	O
portal	O
infiltration	O
and	O
bile	O
stasis	O
,	O
demonstrated	O
20	O
day	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
0	O
<EOS>	O
fibrosis	B-ADR
of	I-ADR
corpus	I-ADR
cavernosum	I-ADR
after	O
intracavernous	O
injection	O
of	O
phentolamine	O
/	O
papaverine	B-Drug
0	O
<EOS>	O
fibrosis	B-ADR
of	I-ADR
corpus	I-ADR
cavernosum	I-ADR
after	O
intracavernous	O
injection	O
of	O
phentolamine	B-Drug
/	O
papaverine	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
penile	B-ADR
fibrosis	I-ADR
after	O
intracavernous	O
self-injection	O
of	O
a	O
combination	O
of	O
phentolamine	O
and	O
papaverine	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
penile	B-ADR
fibrosis	I-ADR
after	O
intracavernous	O
self-injection	O
of	O
a	O
combination	O
of	O
phentolamine	B-Drug
and	O
papaverine	O
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
developed	O
pulmonary	B-ADR
sarcoidosis	I-ADR
during	O
therapy	O
with	O
interferon	B-Drug
beta	I-Drug
for	O
advanced	O
renal	O
cell	O
carcinoma	O
metastatic	O
to	O
mediastinal	O
lymph	O
node	O
0	O
<EOS>	O
the	O
possible	O
role	O
of	O
interferon	B-Drug
beta	I-Drug
in	O
the	O
pathogenesis	O
of	O
sarcoidosis	B-ADR
in	O
this	O
patient	O
is	O
discussed	O
0	O
<EOS>	O
fatal	B-ADR
outcome	I-ADR
of	O
intravesical	O
formalin	B-Drug
instillation	O
,	O
with	O
change	O
mimicking	O
renal	O
tuberculosis	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
alveolar	O
hydatid	O
disease	O
,	O
whose	O
treatment	O
with	O
mebendazole	B-Drug
wa	O
brief	O
due	O
to	O
side	O
effect	O
of	O
alopecia	B-ADR
and	O
granulocytopenia	O
;	O
and	O
review	O
the	O
feature	O
of	O
this	O
disease	O
which	O
,	O
with	O
increasing	O
international	O
migration	O
,	O
may	O
be	O
encountered	O
more	O
frequently	O
in	O
australia	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
alveolar	O
hydatid	O
disease	O
,	O
whose	O
treatment	O
with	O
mebendazole	B-Drug
wa	O
brief	O
due	O
to	O
side	O
effect	O
of	O
alopecia	O
and	O
granulocytopenia	B-ADR
;	O
and	O
review	O
the	O
feature	O
of	O
this	O
disease	O
which	O
,	O
with	O
increasing	O
international	O
migration	O
,	O
may	O
be	O
encountered	O
more	O
frequently	O
in	O
australia	O
0	O
<EOS>	O
antibiotic-associated	O
colitis	B-ADR
(	O
pseudomembranous	O
colitis	O
)	O
developed	O
in	O
four	O
patient	O
with	O
spinal	O
cord	O
injury	O
and	O
taking	O
oral	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
antibiotic-associated	O
colitis	B-ADR
(	O
pseudomembranous	O
colitis	O
)	O
developed	O
in	O
four	O
patient	O
with	O
spinal	O
cord	O
injury	O
and	O
taking	O
oral	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
antibiotic-associated	O
colitis	O
(	O
pseudomembranous	B-ADR
colitis	I-ADR
)	O
developed	O
in	O
four	O
patient	O
with	O
spinal	O
cord	O
injury	O
and	O
taking	O
oral	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
antibiotic-associated	O
colitis	O
(	O
pseudomembranous	B-ADR
colitis	I-ADR
)	O
developed	O
in	O
four	O
patient	O
with	O
spinal	O
cord	O
injury	O
and	O
taking	O
oral	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
pseudomembranous	B-ADR
colitis	I-ADR
readily	O
occurs	O
in	O
at	O
least	O
certain	O
population	O
group	O
receiving	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
pseudomembranous	B-ADR
colitis	I-ADR
readily	O
occurs	O
in	O
at	O
least	O
certain	O
population	O
group	O
receiving	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
a	O
lethal	B-ADR
complication	I-ADR
of	O
peripheral	O
vein	O
vasopressin	B-Drug
infusion	O
0	O
<EOS>	O
the	O
condition	O
should	O
be	O
suspected	O
in	O
patient	O
who	O
develop	O
unexplained	O
abdominal	B-ADR
pain	I-ADR
or	O
collapse	O
following	O
vasopressin	B-Drug
treatment	O
0	O
<EOS>	O
the	O
condition	O
should	O
be	O
suspected	O
in	O
patient	O
who	O
develop	O
unexplained	O
abdominal	O
pain	O
or	O
collapse	B-ADR
following	O
vasopressin	B-Drug
treatment	O
0	O
<EOS>	O
although	O
adverse	O
reaction	O
to	O
protamine	B-Drug
are	O
reported	O
infrequently	O
and	O
are	O
usually	O
mild	O
,	O
we	O
recently	O
observed	O
the	O
first	O
fatal	O
case	O
of	O
type	B-ADR
i	I-ADR
anaphylaxis	I-ADR
resulting	O
from	O
protamine	O
0	O
<EOS>	O
protamine-induced	B-Drug
fatal	B-ADR
anaphylaxis	I-ADR
0	O
<EOS>	O
ototoxicity	B-ADR
a	O
a	O
result	O
of	O
cis-platinum	B-Drug
administration	O
is	O
well	O
documented	O
0	O
<EOS>	O
controversy	O
concerning	O
the	O
nephrotoxicity	B-ADR
of	O
lithium	B-Drug
is	O
discussed	O
,	O
and	O
recommendation	O
for	O
the	O
evaluation	O
of	O
renal	O
failure	O
during	O
lithium	O
therapy	O
are	O
provided	O
0	O
<EOS>	O
controversy	O
concerning	O
the	O
nephrotoxicity	O
of	O
lithium	B-Drug
is	O
discussed	O
,	O
and	O
recommendation	O
for	O
the	O
evaluation	O
of	O
renal	B-ADR
failure	I-ADR
during	O
lithium	O
therapy	O
are	O
provided	O
0	O
<EOS>	O
controversy	O
concerning	O
the	O
nephrotoxicity	O
of	O
lithium	B-Drug
is	O
discussed	O
,	O
and	O
recommendation	O
for	O
the	O
evaluation	O
of	O
renal	B-ADR
failure	I-ADR
during	O
lithium	O
therapy	O
are	O
provided	O
0	O
<EOS>	O
administration	O
of	O
intravenous	O
nitroglycerin	B-Drug
in	O
a	O
patient	O
with	O
idiopathic	O
pulmonary	O
hypertension	O
resulted	O
in	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
associated	O
with	O
a	O
decrease	B-ADR
in	I-ADR
blood	I-ADR
flow	I-ADR
that	O
is	O
best	O
explained	O
by	O
an	O
increase	O
in	O
pulmonary	O
vascular	O
resistance	O
0	O
<EOS>	O
administration	O
of	O
intravenous	O
nitroglycerin	B-Drug
in	O
a	O
patient	O
with	O
idiopathic	O
pulmonary	O
hypertension	O
resulted	O
in	O
an	O
increase	B-ADR
in	I-ADR
pulmonary	I-ADR
artery	I-ADR
pressure	I-ADR
associated	O
with	O
a	O
decrease	O
in	O
blood	O
flow	O
that	O
is	O
best	O
explained	O
by	O
an	O
increase	O
in	O
pulmonary	O
vascular	O
resistance	O
0	O
<EOS>	O
administration	O
of	O
intravenous	O
nitroglycerin	B-Drug
in	O
a	O
patient	O
with	O
idiopathic	O
pulmonary	O
hypertension	O
resulted	O
in	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
associated	O
with	O
a	O
decrease	O
in	O
blood	O
flow	O
that	O
is	O
best	O
explained	O
by	O
an	O
increase	B-ADR
in	I-ADR
pulmonary	I-ADR
vascular	I-ADR
resistance	I-ADR
0	O
<EOS>	O
paradoxical	B-ADR
pulmonary	I-ADR
vasoconstriction	I-ADR
induced	O
by	O
nitroglycerin	B-Drug
in	O
idiopathic	O
pulmonary	O
hypertension	O
0	O
<EOS>	O
atrioventricular	B-ADR
block	I-ADR
complicating	O
amiodarone-induced	B-Drug
hypothyroidism	O
in	O
a	O
patient	O
with	O
pre-excitation	O
and	O
rate-dependent	O
bilateral	O
bundle	O
branch	O
block	O
0	O
<EOS>	O
atrioventricular	O
block	O
complicating	O
amiodarone-induced	B-Drug
hypothyroidism	B-ADR
in	O
a	O
patient	O
with	O
pre-excitation	O
and	O
rate-dependent	O
bilateral	O
bundle	O
branch	O
block	O
0	O
<EOS>	O
such	O
a	O
case	O
induced	O
by	O
hypothyroidism	B-ADR
complicating	O
long-term	O
therapy	O
with	O
amiodarone	B-Drug
in	O
a	O
45	O
year	O
old	O
woman	O
with	O
pre-excitation	O
is	O
presented	O
0	O
<EOS>	O
ampicillin	B-Drug
increased	O
the	O
preexisting	O
electrical	B-ADR
decrement	I-ADR
in	O
three	O
rabbit	O
with	O
experimental	O
autoimmune	O
myasthenia	O
gravis	O
while	O
the	O
drug	O
had	O
no	O
deleterious	O
effect	O
in	O
le	O
affected	O
or	O
normal	O
animal	O
0	O
<EOS>	O
ampicillin	B-Drug
may	O
aggravate	O
clinical	O
and	O
experimental	O
myasthenia	B-ADR
gravis	I-ADR
0	O
<EOS>	O
myasthenic	O
patient	O
receiving	O
ampicillin	B-Drug
should	O
be	O
closely	O
monitored	O
for	O
possible	O
acute	B-ADR
exacerbation	I-ADR
0	O
<EOS>	O
one	O
patient	O
had	O
severe	B-ADR
temporary	I-ADR
weakness	I-ADR
after	O
an	O
ampicillin	B-Drug
sodium	I-Drug
challenge	O
0	O
<EOS>	O
a	O
study	O
following	O
large	O
patient	O
group	O
on	O
theophylline	B-Drug
and	O
a	O
combination	O
of	O
theophylline	O
and	O
steroid	O
might	O
clarify	O
the	O
risk	O
of	O
ulcer	B-ADR
formation	O
in	O
patient	O
being	O
treated	O
with	O
these	O
medication	O
for	O
asthma	O
0	O
<EOS>	O
a	O
study	O
following	O
large	O
patient	O
group	O
on	O
theophylline	B-Drug
and	O
a	O
combination	O
of	O
theophylline	O
and	O
steroid	O
might	O
clarify	O
the	O
risk	O
of	O
ulcer	B-ADR
formation	O
in	O
patient	O
being	O
treated	O
with	O
these	O
medication	O
for	O
asthma	O
0	O
<EOS>	O
we	O
presented	O
a	O
patient	O
with	O
status	O
asthmaticus	O
treated	O
with	O
a	O
combination	O
of	O
theophylline	O
and	O
prednisone	B-Drug
who	O
developed	O
a	O
perforated	B-ADR
gastric	I-ADR
ulcer	I-ADR
0	O
<EOS>	O
we	O
presented	O
a	O
patient	O
with	O
status	O
asthmaticus	O
treated	O
with	O
a	O
combination	O
of	O
theophylline	B-Drug
and	O
prednisone	O
who	O
developed	O
a	O
perforated	B-ADR
gastric	I-ADR
ulcer	I-ADR
0	O
<EOS>	O
a	O
case	O
of	O
propranolol	B-Drug
overdose	O
complicated	O
by	O
esophageal	B-ADR
spasm	I-ADR
preventing	O
extrication	O
of	O
an	O
orogastric	O
lavage	O
tube	O
and	O
relieved	O
by	O
intravenous	O
glucagon	O
is	O
presented	O
0	O
<EOS>	O
esophageal	B-ADR
spasm	I-ADR
following	O
propranolol	B-Drug
overdose	O
relieved	O
by	O
glucagon	O
0	O
<EOS>	O
hypotension	B-ADR
and	O
sinus	O
arrest	O
with	O
nifedipine	B-Drug
in	O
pulmonary	O
hypertension	O
0	O
<EOS>	O
hypotension	O
and	O
sinus	B-ADR
arrest	I-ADR
with	O
nifedipine	B-Drug
in	O
pulmonary	O
hypertension	O
0	O
<EOS>	O
a	O
patient	O
presented	O
with	O
a	O
painful	B-ADR
,	I-ADR
oedematous	I-ADR
,	I-ADR
cyanosed	I-ADR
hand	I-ADR
having	O
injected	O
a	O
solution	O
of	O
diamorphine	B-Drug
and	O
methylphenidate	O
into	O
his	O
radial	O
artery	O
0	O
<EOS>	O
a	O
patient	O
presented	O
with	O
a	O
painful	B-ADR
,	I-ADR
oedematous	I-ADR
,	I-ADR
cyanosed	I-ADR
hand	I-ADR
having	O
injected	O
a	O
solution	O
of	O
diamorphine	O
and	O
methylphenidate	B-Drug
into	O
his	O
radial	O
artery	O
0	O
<EOS>	O
ischaemia	B-ADR
following	O
selfadministered	O
intra-arterial	O
injection	O
of	O
methylphenidate	O
and	O
diamorphine	B-Drug
0	O
<EOS>	O
ischaemia	B-ADR
following	O
selfadministered	O
intra-arterial	O
injection	O
of	O
methylphenidate	B-Drug
and	O
diamorphine	O
0	O
<EOS>	O
chronic	B-ADR
photosensitivity	I-ADR
associated	O
with	O
hydrochlorothiazide	B-Drug
ingestion	O
occurred	O
in	O
four	O
patient	O
0	O
<EOS>	O
cardiac	B-ADR
decompensation	I-ADR
following	O
verapamil	B-Drug
therapy	O
in	O
infant	O
with	O
supraventricular	O
tachycardia	O
0	O
<EOS>	O
however	O
,	O
each	O
infant	O
demonstrated	O
hemodynamic	B-ADR
decompensation	I-ADR
shortly	O
after	O
verapamil	B-Drug
administration	O
and	O
required	O
cardiopulmonary	O
resuscitation	O
0	O
<EOS>	O
the	O
risk	O
of	O
cardiac	B-ADR
decompensation	I-ADR
in	O
infant	O
with	O
supraventricular	O
tachycardia	O
and	O
congestive	O
cardiac	O
failure	O
should	O
be	O
kept	O
in	O
mind	O
prior	O
to	O
administration	O
of	O
verapamil	B-Drug
0	O
<EOS>	O
pneumonitis	O
with	O
pleural	O
and	O
pericardial	O
effusion	O
and	O
neuropathy	B-ADR
during	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
pneumonitis	O
with	O
pleural	B-ADR
and	I-ADR
pericardial	I-ADR
effusion	I-ADR
and	O
neuropathy	O
during	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
pneumonitis	B-ADR
with	O
pleural	O
and	O
pericardial	O
effusion	O
and	O
neuropathy	O
during	O
amiodarone	B-Drug
therapy	O
0	O
<EOS>	O
review	O
of	O
this	O
and	O
previously	O
reported	O
case	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-Drug
pneumonitis	B-ADR
,	O
immediate	O
withdrawal	O
of	O
amiodarone	O
,	O
and	O
prompt	O
but	O
continued	O
steroid	O
therapy	O
to	O
ensure	O
full	O
recovery	O
0	O
<EOS>	O
heparin-induced	B-Drug
hyperkalemia	B-ADR
0	O
<EOS>	O
our	O
finding	O
suggest	O
that	O
hyperkalemia	B-ADR
can	O
develop	O
with	O
the	O
use	O
of	O
low-dose	O
heparin	B-Drug
,	O
within	O
seven	O
day	O
of	O
initiating	O
heparin	O
therapy	O
,	O
and	O
that	O
patient	O
with	O
diabetes	O
mellitus	O
or	O
chronic	O
renal	O
insufficiency	O
are	O
especially	O
predisposed	O
to	O
this	O
complication	O
0	O
<EOS>	O
our	O
finding	O
suggest	O
that	O
hyperkalemia	B-ADR
can	O
develop	O
with	O
the	O
use	O
of	O
low-dose	O
heparin	B-Drug
,	O
within	O
seven	O
day	O
of	O
initiating	O
heparin	O
therapy	O
,	O
and	O
that	O
patient	O
with	O
diabetes	O
mellitus	O
or	O
chronic	O
renal	O
insufficiency	O
are	O
especially	O
predisposed	O
to	O
this	O
complication	O
0	O
<EOS>	O
we	O
present	O
four	O
case	O
in	O
which	O
the	O
use	O
of	O
heparin	B-Drug
wa	O
associated	O
with	O
hyperkalemia	B-ADR
and	O
discus	O
the	O
pathophysiology	O
0	O
<EOS>	O
while	O
most	O
physician	O
are	O
aware	O
of	O
heparin-induced	B-Drug
thrombocytopenia	O
and	O
skin	O
necrosis	O
,	O
the	O
association	O
of	O
heparin	O
and	O
hyperkalemia	B-ADR
is	O
le	O
well	O
recognized	O
0	O
<EOS>	O
while	O
most	O
physician	O
are	O
aware	O
of	O
heparin-induced	B-Drug
thrombocytopenia	O
and	O
skin	B-ADR
necrosis	I-ADR
,	O
the	O
association	O
of	O
heparin	O
and	O
hyperkalemia	O
is	O
le	O
well	O
recognized	O
0	O
<EOS>	O
while	O
most	O
physician	O
are	O
aware	O
of	O
heparin-induced	B-Drug
thrombocytopenia	B-ADR
and	O
skin	O
necrosis	O
,	O
the	O
association	O
of	O
heparin	O
and	O
hyperkalemia	O
is	O
le	O
well	O
recognized	O
0	O
<EOS>	O
careful	O
follow-up	O
of	O
so-called	O
``	O
self-limited	O
'	O
insulin	B-Drug
edema	B-ADR
is	O
encouraged	O
,	O
and	O
the	O
early	O
institution	O
of	O
diuretic	O
therapy	O
is	O
advocated	O
in	O
elderly	O
patient	O
to	O
prevent	O
the	O
development	O
of	O
overt	O
cardiac	O
failure	O
0	O
<EOS>	O
insulin-induced	B-Drug
cardiac	B-ADR
failure	I-ADR
0	O
<EOS>	O
self-limited	B-ADR
edema	I-ADR
is	O
a	O
well-recognized	O
complication	O
of	O
insulin	B-Drug
therapy	O
0	O
<EOS>	O
this	O
report	O
describes	O
the	O
first	O
case	O
of	O
insulin-induced	B-Drug
cardiac	B-ADR
failure	I-ADR
in	O
a	O
patient	O
without	O
underlying	O
heart	O
disease	O
0	O
<EOS>	O
a	O
case	O
of	O
pyridoxine-dependent	B-Drug
seizure	B-ADR
is	O
reported	O
0	O
<EOS>	O
administration	O
of	O
pyridoxine	B-Drug
to	O
an	O
infant	O
after	O
a	O
long	O
period	O
of	O
convulsion	O
wa	O
followed	O
by	O
acute	B-ADR
hypotonia	I-ADR
0	O
<EOS>	O
prolonged	O
severe	B-ADR
cholestasis	I-ADR
induced	O
by	O
oxacillin	B-Drug
derivative	O
0	O
<EOS>	O
two	O
patient	O
with	O
osteomyelitis	O
who	O
developed	O
reversible	B-ADR
cholestatic	I-ADR
jaundice	I-ADR
during	O
treatment	O
with	O
oxacillin	B-Drug
derivative	O
are	O
described	O
0	O
<EOS>	O
in	O
all	O
the	O
patient	O
,	O
pellagra	B-ADR
symptom	O
appeared	O
during	O
isoniazid	B-Drug
therapy	O
0	O
<EOS>	O
isoniazid	B-Drug
inhibits	O
the	O
conversion	O
of	O
tryptophan	O
to	O
niacin	O
and	O
may	O
induce	O
pellagra	B-ADR
,	O
particularly	O
in	O
poorly	O
nourished	O
patient	O
0	O
<EOS>	O
pellagra	B-ADR
encephalopathy	I-ADR
among	O
tuberculous	O
patient	O
:	O
it	O
relation	O
to	O
isoniazid	B-Drug
therapy	O
0	O
<EOS>	O
pellagra	O
should	O
be	O
suspected	O
whenever	O
tuberculous	O
patient	O
under	O
treatment	O
with	O
isoniazid	B-Drug
develop	O
mental	B-ADR
,	I-ADR
neurological	I-ADR
or	I-ADR
gastrointestinal	I-ADR
symptom	I-ADR
,	O
even	O
in	O
the	O
absence	O
of	O
typical	O
pellagra	O
dermatitis	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
the	O
development	O
of	O
r	B-ADR
among	O
child	O
who	O
are	O
receiving	O
long-term	O
aspirin	B-Drug
therapy	O
for	O
the	O
treatment	O
of	O
systemic	O
inflammatory	O
illness	O
0	O
<EOS>	O
reye	B-ADR
syndrome	I-ADR
(	O
r	O
)	O
is	O
believed	O
to	O
occur	O
infrequently	O
among	O
child	O
receiving	O
long-term	O
aspirin	B-Drug
therapy	O
0	O
<EOS>	O
reye	O
syndrome	O
(	O
r	B-ADR
)	O
is	O
believed	O
to	O
occur	O
infrequently	O
among	O
child	O
receiving	O
long-term	O
aspirin	B-Drug
therapy	O
0	O
<EOS>	O
these	O
finding	O
support	O
previous	O
study	O
that	O
showed	O
that	O
the	O
use	O
of	O
aspirin	B-Drug
during	O
the	O
antecedent	O
illness	O
may	O
be	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
r	B-ADR
0	O
<EOS>	O
atrial	B-ADR
fibrillation	I-ADR
wa	O
induced	O
by	O
diltiazem	B-Drug
in	O
two	O
patient	O
and	O
verapamil	O
induced	O
syncope	O
in	O
one	O
patient	O
0	O
<EOS>	O
atrial	O
fibrillation	O
wa	O
induced	O
by	O
diltiazem	O
in	O
two	O
patient	O
and	O
verapamil	B-Drug
induced	O
syncope	B-ADR
in	O
one	O
patient	O
0	O
<EOS>	O
a	O
54-year-old	O
man	O
,	O
treated	O
with	O
amiodarone	B-Drug
,	O
developed	O
thyrotoxicosis	B-ADR
0	O
<EOS>	O
amiodarone-induced	B-Drug
dysthyroidism	B-ADR
0	O
<EOS>	O
iv	O
propranolol	B-Drug
wa	O
used	O
a	O
the	O
initial	O
treatment	O
for	O
his	O
hyperadrenergic	O
state	O
,	O
resulting	O
in	O
a	O
decrease	B-ADR
in	I-ADR
heart	I-ADR
rate	I-ADR
but	O
a	O
paroxsymal	O
increase	O
in	O
blood	O
pressure	O
0	O
<EOS>	O
iv	O
propranolol	B-Drug
wa	O
used	O
a	O
the	O
initial	O
treatment	O
for	O
his	O
hyperadrenergic	O
state	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
heart	O
rate	O
but	O
a	O
paroxsymal	B-ADR
increase	I-ADR
in	I-ADR
blood	I-ADR
pressure	I-ADR
0	O
<EOS>	O
propranolol-induced	B-Drug
hypertension	B-ADR
in	O
treatment	O
of	O
cocaine	O
intoxication	O
0	O
<EOS>	O
according	O
to	O
the	O
literature	O
,	O
chlorambucil	B-Drug
central	B-ADR
nervous	I-ADR
toxicity	I-ADR
is	O
found	O
almost	O
exclusively	O
in	O
childhood	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
chlorambucil	B-Drug
central	B-ADR
nervous	I-ADR
toxicity	I-ADR
:	O
a	O
significant	O
side	O
effect	O
of	O
chlorambucil	O
therapy	O
in	O
childhood	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
eeg	B-ADR
abnormality	I-ADR
were	O
observed	O
in	O
two	O
of	O
the	O
nine	O
child	O
during	O
chlorambucil	B-Drug
therapy	O
0	O
<EOS>	O
a	O
35-year-old	O
man	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
developed	O
selective	O
iga	B-ADR
deficiency	I-ADR
during	O
treatment	O
with	O
fenclofenac	B-Drug
0	O
<EOS>	O
fenclofenac-induced	B-Drug
selective	O
iga	B-ADR
deficiency	I-ADR
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
this	O
case	O
demonstrates	O
the	O
association	O
of	O
selective	O
iga	B-ADR
deficiency	I-ADR
with	O
remission	O
in	O
rheumatoid	O
arthritis	O
induced	O
by	O
fenclofenac	O
a	O
well	O
a	O
aurothiomalate	B-Drug
and	O
sulphasalazine	O
0	O
<EOS>	O
this	O
case	O
demonstrates	O
the	O
association	O
of	O
selective	O
iga	B-ADR
deficiency	I-ADR
with	O
remission	O
in	O
rheumatoid	O
arthritis	O
induced	O
by	O
fenclofenac	B-Drug
a	O
well	O
a	O
aurothiomalate	O
and	O
sulphasalazine	O
0	O
<EOS>	O
this	O
case	O
demonstrates	O
the	O
association	O
of	O
selective	O
iga	B-ADR
deficiency	I-ADR
with	O
remission	O
in	O
rheumatoid	O
arthritis	O
induced	O
by	O
fenclofenac	O
a	O
well	O
a	O
aurothiomalate	O
and	O
sulphasalazine	B-Drug
0	O
<EOS>	O
a	O
65-year-old	O
woman	O
with	O
bipolar	O
disorder	O
and	O
complicated	O
cardiovascular	O
disease	O
who	O
wa	O
on	O
maintenance	O
lithium	B-Drug
therapy	O
developed	O
a	O
movement	B-ADR
disorder	I-ADR
following	O
high	O
dos	O
of	O
trazodone	O
for	O
treatment	O
of	O
an	O
acute	O
depression	O
0	O
<EOS>	O
a	O
65-year-old	O
woman	O
with	O
bipolar	O
disorder	O
and	O
complicated	O
cardiovascular	O
disease	O
who	O
wa	O
on	O
maintenance	O
lithium	O
therapy	O
developed	O
a	O
movement	B-ADR
disorder	I-ADR
following	O
high	O
dos	O
of	O
trazodone	B-Drug
for	O
treatment	O
of	O
an	O
acute	O
depression	O
0	O
<EOS>	O
although	O
the	O
movement	B-ADR
disorder	I-ADR
could	O
not	O
with	O
certainty	O
be	O
attributed	O
to	O
trazodone	B-Drug
alone	O
,	O
the	O
drug	O
at	O
least	O
acted	O
a	O
an	O
eliciting	O
agent	O
0	O
<EOS>	O
the	O
elicitation	O
of	O
a	O
movement	B-ADR
disorder	I-ADR
by	O
trazodone	B-Drug
:	O
case	O
report	O
0	O
<EOS>	O
when	O
the	O
trazodone	B-Drug
wa	O
reduced	O
,	O
the	O
involuntary	B-ADR
movement	I-ADR
promptly	O
ceased	O
0	O
<EOS>	O
a	O
review	O
of	O
the	O
literature	O
showed	O
no	O
previous	O
description	O
of	O
this	O
pattern	O
in	O
benzodiazepine	B-Drug
coma	B-ADR
0	O
<EOS>	O
spindle	B-ADR
coma	I-ADR
in	O
benzodiazepine	B-Drug
toxicity	O
:	O
case	O
report	O
0	O
<EOS>	O
two	O
report	O
of	O
spindle	B-ADR
coma	I-ADR
are	O
noted	O
with	O
alcohol	O
and	O
imipramine	B-Drug
0	O
<EOS>	O
a	O
literature	O
review	O
revealed	O
83	O
other	O
reported	O
case	O
of	O
rifampicin-induced	B-Drug
renal	B-ADR
insufficiency	I-ADR
0	O
<EOS>	O
renal	B-ADR
failure	I-ADR
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampicin	B-Drug
for	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
usually	O
occurring	O
well	O
into	O
the	O
course	O
of	O
therapy	O
0	O
<EOS>	O
rifampicin-induced	B-Drug
renal	B-ADR
failure	I-ADR
0	O
<EOS>	O
the	O
following	O
is	O
a	O
report	O
of	O
2	O
case	O
of	O
rifampicin-induced	B-Drug
renal	B-ADR
insufficiency	I-ADR
0	O
<EOS>	O
cerebral	B-ADR
and	I-ADR
ocular	I-ADR
toxicity	I-ADR
induced	O
by	O
desferrioxamine	B-Drug
0	O
<EOS>	O
subsequent	O
in	O
vivo	O
/	O
vitro	O
study	O
clearly	O
demonstrated	O
that	O
the	O
neurological	B-ADR
effect	I-ADR
were	O
due	O
to	O
a	O
synergistic	O
action	O
of	O
desferrioxamine	B-Drug
and	O
prochlorperazine	O
,	O
probably	O
resulting	O
in	O
exceptional	O
flux	O
of	O
intra	O
/	O
extra	O
cellular	O
iron	O
/	O
copper	O
disturbing	O
noradrenergic	O
and	O
serotonergic	O
system	O
0	O
<EOS>	O
subsequent	O
in	O
vivo	O
/	O
vitro	O
study	O
clearly	O
demonstrated	O
that	O
the	O
neurological	B-ADR
effect	I-ADR
were	O
due	O
to	O
a	O
synergistic	O
action	O
of	O
desferrioxamine	O
and	O
prochlorperazine	B-Drug
,	O
probably	O
resulting	O
in	O
exceptional	O
flux	O
of	O
intra	O
/	O
extra	O
cellular	O
iron	O
/	O
copper	O
disturbing	O
noradrenergic	O
and	O
serotonergic	O
system	O
0	O
<EOS>	O
two	O
of	O
these	O
patient	O
,	O
who	O
also	O
received	O
the	O
anti-emetic	O
prochlorperazine	B-Drug
,	O
lost	B-ADR
consciousness	I-ADR
for	O
48-72	O
h	O
and	O
then	O
fully	O
recovered	O
0	O
<EOS>	O
two	O
other	O
patient	O
who	O
did	O
not	O
receive	O
prochlorperazine	O
,	O
developed	O
retinal	B-ADR
problem	I-ADR
which	O
later	O
improved	O
,	O
one	O
after	O
only	O
15	O
g	O
of	O
desferrioxamine	B-Drug
0	O
<EOS>	O
gold	B-Drug
nephropathy	B-ADR
:	O
tissue	O
analysis	O
by	O
x-ray	O
fluorescent	O
spectroscopy	O
0	O
<EOS>	O
these	O
finding	O
are	O
consistent	O
with	O
an	O
immune-complex	O
form	O
of	O
glomerulopathy	O
in	O
which	O
gold	B-Drug
is	O
neither	O
the	O
antigen	O
nor	O
a	O
hapten	O
in	O
the	O
glomerular	O
deposit	O
,	O
and	O
they	O
suggest	O
the	O
hypothesis	O
that	O
antibody	O
to	O
tubular	O
epithelial	O
antigen	O
induced	O
by	O
gold	O
therapy	O
may	O
be	O
a	O
causative	O
factor	O
in	O
the	O
renal	B-ADR
disease	I-ADR
associated	O
with	O
gold	O
therapy	O
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
these	O
finding	O
are	O
consistent	O
with	O
an	O
immune-complex	O
form	O
of	O
glomerulopathy	O
in	O
which	O
gold	B-Drug
is	O
neither	O
the	O
antigen	O
nor	O
a	O
hapten	O
in	O
the	O
glomerular	O
deposit	O
,	O
and	O
they	O
suggest	O
the	O
hypothesis	O
that	O
antibody	O
to	O
tubular	O
epithelial	O
antigen	O
induced	O
by	O
gold	O
therapy	O
may	O
be	O
a	O
causative	O
factor	O
in	O
the	O
renal	B-ADR
disease	I-ADR
associated	O
with	O
gold	O
therapy	O
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
three	O
patient	O
developed	O
proteinuria	B-ADR
following	O
gold	B-Drug
therapy	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
four	O
case	O
of	O
fat	B-ADR
embolism	I-ADR
are	O
described	O
in	O
infant	O
receiving	O
prolonged	O
intravenous	O
infusion	O
of	O
fat	O
(	O
intralipid	B-Drug
20	O
%	O
)	O
0	O
<EOS>	O
conversely	O
,	O
diffuse	O
interstitial	O
pulmonary	O
fibrosis	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patient	O
receiving	O
methotrexate	B-Drug
who	O
develop	O
bilateral	B-ADR
pulmonary	I-ADR
infiltrates	I-ADR
seen	O
on	O
chest	O
roentgenogram	O
0	O
<EOS>	O
conversely	O
,	O
diffuse	B-ADR
interstitial	I-ADR
pulmonary	I-ADR
fibrosis	I-ADR
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patient	O
receiving	O
methotrexate	B-Drug
who	O
develop	O
bilateral	O
pulmonary	O
infiltrates	O
seen	O
on	O
chest	O
roentgenogram	O
0	O
<EOS>	O
in	O
all	O
three	O
case	O
,	O
autopsy	O
revealed	O
gross	O
and	O
microscopic	O
feature	O
indistinguishable	O
from	O
those	O
seen	O
in	O
the	O
hamman-rich	O
syndrome	O
,	O
and	O
methotrexate	B-Drug
hepatotoxicity	B-ADR
wa	O
present	O
in	O
one	O
0	O
<EOS>	O
it	O
is	O
suggested	O
therefore	O
that	O
methotrexate	B-Drug
be	O
added	O
to	O
the	O
list	O
of	O
agent	O
capable	O
of	O
inducing	O
diffuse	B-ADR
interstitial	I-ADR
pulmonary	I-ADR
fibrosis	I-ADR
0	O
<EOS>	O
methotrexate-induced	B-Drug
diffuse	B-ADR
interstitial	I-ADR
pulmonary	I-ADR
fibrosis	I-ADR
0	O
<EOS>	O
pulmonary	O
eosinophilia	O
or	O
granuloma	B-ADR
,	O
classically	O
seen	O
in	O
previously	O
reported	O
case	O
of	O
methotrexate	B-Drug
pneumonitis	O
,	O
were	O
not	O
observed	O
0	O
<EOS>	O
pulmonary	O
eosinophilia	O
or	O
granuloma	O
,	O
classically	O
seen	O
in	O
previously	O
reported	O
case	O
of	O
methotrexate	B-Drug
pneumonitis	B-ADR
,	O
were	O
not	O
observed	O
0	O
<EOS>	O
pulmonary	B-ADR
eosinophilia	I-ADR
or	O
granuloma	O
,	O
classically	O
seen	O
in	O
previously	O
reported	O
case	O
of	O
methotrexate	B-Drug
pneumonitis	O
,	O
were	O
not	O
observed	O
0	O
<EOS>	O
three	O
patient	O
received	O
respectively	O
190	O
mg	O
,	O
175	O
mg	O
,	O
and	O
196	O
mg	O
of	O
methotrexate	B-Drug
and	O
developed	O
bilateral	B-ADR
pulmonary	I-ADR
infiltrates	I-ADR
without	O
evidence	O
of	O
peripheral	O
blood	O
eosinophilia	O
0	O
<EOS>	O
a	O
patient	O
with	O
disseminated	O
herpes	O
zoster	O
developed	O
a	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
and	O
profound	O
hyponatremia	B-ADR
secondary	O
to	O
the	O
administration	O
of	O
adenine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
a	O
patient	O
with	O
disseminated	O
herpes	O
zoster	O
developed	O
a	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
and	O
profound	O
hyponatremia	O
secondary	O
to	O
the	O
administration	O
of	O
adenine	B-Drug
arabinoside	I-Drug
0	O
<EOS>	O
inappropriate	B-ADR
antidiuretic	I-ADR
hormone	I-ADR
following	O
adenine	B-Drug
arabinoside	I-Drug
administration	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	O
liver	O
transaminase	O
(	O
3	O
/	O
4	O
)	O
,	O
nausea	O
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	B-ADR
pain	I-ADR
(	O
2	O
/	O
4	O
)	O
,	O
bone	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
mild	O
neutropenia	O
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	O
pruritus	O
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	O
liver	O
transaminase	O
(	O
3	O
/	O
4	O
)	O
,	O
nausea	O
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
bone	B-ADR
pain	I-ADR
(	O
2	O
/	O
4	O
)	O
,	O
mild	O
neutropenia	O
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	O
pruritus	O
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	B-ADR
liver	I-ADR
transaminase	I-ADR
(	O
3	O
/	O
4	O
)	O
,	O
nausea	O
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
bone	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
mild	O
neutropenia	O
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	O
pruritus	O
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	O
liver	O
transaminase	O
(	O
3	O
/	O
4	O
)	O
,	O
nausea	O
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
bone	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
mild	B-ADR
neutropenia	I-ADR
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	O
pruritus	O
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	O
liver	O
transaminase	O
(	O
3	O
/	O
4	O
)	O
,	O
nausea	O
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
bone	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
mild	O
neutropenia	O
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	B-ADR
pruritus	I-ADR
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
the	O
toxic	O
effect	O
of	O
methotrexate	B-Drug
included	O
elevated	O
liver	O
transaminase	O
(	O
3	O
/	O
4	O
)	O
,	O
nausea	B-ADR
(	O
2	O
/	O
4	O
)	O
,	O
abdominal	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
bone	O
pain	O
(	O
2	O
/	O
4	O
)	O
,	O
mild	O
neutropenia	O
(	O
1	O
/	O
4	O
)	O
,	O
and	O
mild	O
pruritus	O
(	O
1	O
/	O
4	O
)	O
0	O
<EOS>	O
dystonia	B-ADR
associated	O
with	O
carbamazepine	B-Drug
administration	O
:	O
experience	O
in	O
brain-damaged	O
child	O
0	O
<EOS>	O
in	O
one	O
child	O
,	O
a	O
second	O
course	O
of	O
carbamazepine	B-Drug
resulted	O
in	O
a	O
return	O
of	O
the	O
dystonia	B-ADR
0	O
<EOS>	O
the	O
currently	O
available	O
clinical	O
and	O
neuropharmacologic	O
data	O
suggest	O
that	O
carbamazepine	B-Drug
may	O
be	O
an	O
antagonist	O
of	O
dopamine	O
and	O
that	O
this	O
property	O
is	O
responsible	O
for	O
the	O
production	O
of	O
dystonia	B-ADR
0	O
<EOS>	O
we	O
have	O
cared	O
for	O
three	O
child	O
in	O
whom	O
four	O
episode	O
of	O
dystonia	B-ADR
proceeding	O
to	O
opisthotonus	O
occurred	O
in	O
association	O
with	O
carbamazepine	B-Drug
use	O
0	O
<EOS>	O
we	O
have	O
cared	O
for	O
three	O
child	O
in	O
whom	O
four	O
episode	O
of	O
dystonia	O
proceeding	O
to	O
opisthotonus	B-ADR
occurred	O
in	O
association	O
with	O
carbamazepine	B-Drug
use	O
0	O
<EOS>	O
aplastic	O
anemia	O
and	O
agranulocytosis	B-ADR
in	O
patient	O
using	O
methazolamide	B-Drug
for	O
glaucoma	O
0	O
<EOS>	O
aplastic	B-ADR
anemia	I-ADR
and	O
agranulocytosis	O
in	O
patient	O
using	O
methazolamide	B-Drug
for	O
glaucoma	O
0	O
<EOS>	O
several	O
case	O
report	O
of	O
aplastic	B-ADR
anemia	I-ADR
with	O
use	O
of	O
acetazolamide	B-Drug
,	O
and	O
two	O
case	O
with	O
use	O
of	O
methazolamide	O
,	O
have	O
appeared	O
in	O
the	O
literature	O
0	O
<EOS>	O
several	O
case	O
report	O
of	O
aplastic	B-ADR
anemia	I-ADR
with	O
use	O
of	O
acetazolamide	O
,	O
and	O
two	O
case	O
with	O
use	O
of	O
methazolamide	B-Drug
,	O
have	O
appeared	O
in	O
the	O
literature	O
0	O
<EOS>	O
this	O
article	O
describes	O
two	O
case	O
of	O
aplastic	O
anemia	O
,	O
at	O
least	O
one	O
of	O
which	O
wa	O
almost	O
certainly	O
induced	O
by	O
the	O
use	O
of	O
methazolamide	B-Drug
,	O
and	O
one	O
case	O
of	O
agranulocytosis	B-ADR
related	O
to	O
the	O
use	O
of	O
methazolamide	O
0	O
<EOS>	O
this	O
article	O
describes	O
two	O
case	O
of	O
aplastic	B-ADR
anemia	I-ADR
,	O
at	O
least	O
one	O
of	O
which	O
wa	O
almost	O
certainly	O
induced	O
by	O
the	O
use	O
of	O
methazolamide	B-Drug
,	O
and	O
one	O
case	O
of	O
agranulocytosis	O
related	O
to	O
the	O
use	O
of	O
methazolamide	O
0	O
<EOS>	O
squamous-cell	B-ADR
carcinoma	I-ADR
arising	O
in	O
a	O
basal-cell	O
epithelioma	O
treated	O
with	O
5-fluorouracil	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
development	O
of	O
squamous-cell	B-ADR
carcinoma	I-ADR
within	O
a	O
basal-cell	O
epithelioma	O
that	O
wa	O
treated	O
with	O
intralesional	O
injection	O
of	O
5-fu	B-Drug
0	O
<EOS>	O
lower	O
extremity	O
arterial	B-ADR
insufficiency	I-ADR
after	O
long-term	O
methysergide	B-Drug
maleate	I-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
whose	O
case	O
is	O
reviewed	O
had	O
migraine	B-ADR
headache	I-ADR
and	O
received	O
methysergide	B-Drug
maleate	O
for	O
13	O
year	O
0	O
<EOS>	O
a	O
case	O
of	O
erythema	B-ADR
multiforme	I-ADR
bullosum	I-ADR
in	O
patient	O
of	O
lepromatous	O
leprosy	O
with	O
pulmonary	O
tuberculosis	O
due	O
to	O
rifampicin	B-Drug
is	O
described	O
0	O
<EOS>	O
erythema	B-ADR
multiforme	I-ADR
bullosum	I-ADR
due	O
to	O
rifampicin	B-Drug
0	O
<EOS>	O
renal	B-ADR
damage	I-ADR
associated	O
with	O
long	O
term	O
use	O
of	O
lithium	B-Drug
carbonate	I-Drug
0	O
<EOS>	O
the	O
author	O
report	O
2	O
case	O
of	O
renal	B-ADR
damage	I-ADR
associated	O
with	O
lithium	B-Drug
carbonate	I-Drug
treatment	O
0	O
<EOS>	O
in	O
two	O
patient	O
with	O
mycosis	O
fungoides	O
,	O
a	O
squamous	B-ADR
cell	I-ADR
carcinoma	I-ADR
developed	O
during	O
therapy	O
with	O
psoralens	B-Drug
plus	O
long-wave	O
ultraviolet	O
radiation	O
(	O
puva	O
)	O
0	O
<EOS>	O
hyperglycemia	O
and	O
diabetic	B-ADR
coma	I-ADR
:	O
possible	O
relationship	O
to	O
diuretic-propranolol	B-Drug
therapy	O
0	O
<EOS>	O
hyperglycemia	B-ADR
and	O
diabetic	O
coma	O
:	O
possible	O
relationship	O
to	O
diuretic-propranolol	B-Drug
therapy	O
0	O
<EOS>	O
two	O
patient	O
developed	O
diabetic	B-ADR
coma	I-ADR
when	O
taking	O
a	O
combination	O
of	O
a	O
thiazide	O
diuretic	O
and	O
propranolol	B-Drug
0	O
<EOS>	O
two	O
patient	O
developed	O
diabetic	B-ADR
coma	I-ADR
when	O
taking	O
a	O
combination	O
of	O
a	O
thiazide	B-Drug
diuretic	O
and	O
propranolol	O
0	O
<EOS>	O
an	O
insulin-dependent	O
diabetic	O
patient	O
with	O
nephropathy	O
developed	O
severe	B-ADR
acidosis	I-ADR
after	O
treatment	O
with	O
acetazolamide	B-Drug
for	O
glaucoma	O
0	O
<EOS>	O
severe	B-ADR
acidosis	I-ADR
from	O
acetazolamide	B-Drug
in	O
a	O
diabetic	O
patient	O
0	O
<EOS>	O
this	O
progressed	O
to	O
tracheal	B-ADR
compression	I-ADR
with	O
stridor	O
after	O
he	O
had	O
taken	O
some	O
aspirin	B-Drug
for	O
relief	O
of	O
the	O
neck	O
pain	O
0	O
<EOS>	O
five	O
case	O
of	O
clindamycin-associated	B-Drug
pseudomembranous	B-ADR
colitis	I-ADR
in	O
leukaemic	O
patient	O
are	O
reported	O
0	O
<EOS>	O
an	O
infertile	O
patient	O
with	O
amenorrhea-galactorrhea	O
syndrome	O
lost	B-ADR
vision	I-ADR
during	O
a	O
pregnancy	O
occurring	O
after	O
bromocryptine	B-Drug
treatment	O
0	O
<EOS>	O
fatal	B-ADR
acute	I-ADR
tubular	I-ADR
necrosis	I-ADR
occurred	O
in	O
1	O
patient	O
in	O
whom	O
intravesical	O
formalin	B-Drug
wa	O
used	O
to	O
control	O
massive	O
persistent	O
hemorrhage	O
from	O
radiation	O
cystitis	O
0	O
<EOS>	O
fatal	B-ADR
complication	I-ADR
of	O
intravesical	O
formalin	B-Drug
during	O
control	O
of	O
intractable	O
hemorrhage	O
from	O
radiation	O
cystitis	O
0	O
<EOS>	O
intravenous	O
sodium	O
bicarbonate	O
appears	O
to	O
be	O
indicated	O
prophylactically	O
in	O
combating	O
the	O
associated	O
metabolic	B-ADR
acidosis	I-ADR
due	O
to	O
absorbed	O
formic	B-Drug
acid	I-Drug
0	O
<EOS>	O
a	O
young	O
woman	O
developed	O
galactorrhea	B-ADR
during	O
treatment	O
with	O
a	O
new	O
dibenzoxazepine	O
antidepressant	O
,	O
amoxapine	B-Drug
0	O
<EOS>	O
a	O
young	O
woman	O
developed	O
galactorrhea	B-ADR
during	O
treatment	O
with	O
a	O
new	O
dibenzoxazepine	B-Drug
antidepressant	O
,	O
amoxapine	O
0	O
<EOS>	O
a	O
15-kg	B-ADR
weight	I-ADR
gain	I-ADR
developed	O
in	O
a	O
patient	O
during	O
the	O
third	O
week	O
of	O
ibuprofen	B-Drug
therapy	O
0	O
<EOS>	O
edema	B-ADR
associated	O
with	O
ibuprofen	B-Drug
therapy	O
0	O
<EOS>	O
it	O
should	O
be	O
recognized	O
that	O
ibuprofen	B-Drug
may	O
be	O
associated	O
with	O
salt	B-ADR
and	I-ADR
water	I-ADR
retention	I-ADR
in	O
the	O
same	O
fashion	O
a	O
previously	O
described	O
with	O
phenylbutazone	O
and	O
indomethacin	O
0	O
<EOS>	O
it	O
should	O
be	O
recognized	O
that	O
ibuprofen	O
may	O
be	O
associated	O
with	O
salt	B-ADR
and	I-ADR
water	I-ADR
retention	I-ADR
in	O
the	O
same	O
fashion	O
a	O
previously	O
described	O
with	O
phenylbutazone	O
and	O
indomethacin	B-Drug
0	O
<EOS>	O
it	O
should	O
be	O
recognized	O
that	O
ibuprofen	O
may	O
be	O
associated	O
with	O
salt	B-ADR
and	I-ADR
water	I-ADR
retention	I-ADR
in	O
the	O
same	O
fashion	O
a	O
previously	O
described	O
with	O
phenylbutazone	B-Drug
and	O
indomethacin	O
0	O
<EOS>	O
allopurinol-associated	B-Drug
hand	B-ADR
and	I-ADR
foot	I-ADR
deformity	I-ADR
in	O
chronic	O
tophaceous	O
gout	O
0	O
<EOS>	O
telescoped	B-ADR
digit	I-ADR
of	I-ADR
the	I-ADR
hand	I-ADR
and	I-ADR
foot	I-ADR
developed	O
in	O
a	O
69-year-old	O
male	O
with	O
severe	O
chronic	O
tophaceous	O
gout	O
during	O
allopurinol	B-Drug
treatment	O
0	O
<EOS>	O
a	O
patient	O
with	O
coccidioidal	O
meningitis	O
wa	O
treated	O
with	O
intrathecally	O
administered	O
amphotericin	B-Drug
b	I-Drug
,	O
and	O
an	O
acute	B-ADR
toxic	I-ADR
delirium	I-ADR
with	O
eeg	O
abnormality	O
developed	O
0	O
<EOS>	O
a	O
patient	O
with	O
coccidioidal	O
meningitis	O
wa	O
treated	O
with	O
intrathecally	O
administered	O
amphotericin	B-Drug
b	I-Drug
,	O
and	O
an	O
acute	O
toxic	O
delirium	O
with	O
eeg	B-ADR
abnormality	I-ADR
developed	O
0	O
<EOS>	O
neurotoxicity	B-ADR
of	O
intrathecal	O
administration	O
of	O
amphotericin	B-Drug
b	I-Drug
0	O
<EOS>	O
in	O
keeping	O
with	O
finding	O
in	O
the	O
literature	O
,	O
the	O
aortic	B-ADR
wall	I-ADR
in	I-ADR
this	I-ADR
case	I-ADR
wa	I-ADR
damaged	I-ADR
by	O
secondary	O
change	O
following	O
irradiation	O
and	O
bleomycin	B-Drug
treatment	O
0	O
<EOS>	O
cardiac	O
glycoside	O
are	O
thought	O
to	O
prevent	O
doxorubicin	B-Drug
cardiomyopathy	B-ADR
by	O
competitively	O
inhibiting	O
doxorubicin	O
at	O
it	O
receptor	O
site	O
,	O
but	O
ouabain	O
ha	O
a	O
much	O
shorter	O
half	O
life	O
than	O
doxorubicin	O
and	O
it	O
metabolite	O
and	O
so	O
is	O
le	O
effective	O
than	O
digoxin	O
0	O
<EOS>	O
doxorubicin	B-Drug
cardiotoxicity	B-ADR
:	O
possible	O
role	O
of	O
digoxin	O
in	O
it	O
prevention	O
0	O
<EOS>	O
minor	B-ADR
electrocardiographical	I-ADR
change	I-ADR
were	O
noted	O
in	O
five	O
out	O
of	O
six	O
patient	O
who	O
were	O
not	O
receiving	O
a	O
cardiac	O
glycoside	O
and	O
four	O
out	O
of	O
six	O
who	O
were	O
receiving	O
ouabain	B-Drug
,	O
and	O
none	O
of	O
the	O
16	O
who	O
were	O
receiving	O
digoxin	O
0	O
<EOS>	O
one	O
other	O
patient	O
on	O
digoxin	B-Drug
stopped	O
taking	O
it	O
and	O
developed	O
cardiomyopathy	B-ADR
0	O
<EOS>	O
one	O
patient	O
on	O
ouabain	B-Drug
also	O
developed	O
cardiomyopathy	B-ADR
0	O
<EOS>	O
a	O
healthy	O
,	O
30-year-old	O
man	O
,	O
exposed	O
to	O
sulindac	B-Drug
on	O
two	O
separate	O
occasion	O
,	O
had	O
an	O
incapacitating	O
isolated	B-ADR
idential	I-ADR
sensory	I-ADR
neuropathy	I-ADR
0	O
<EOS>	O
sulindac	O
(	O
clinoril	B-Drug
)	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
agent	O
,	O
ha	O
few	O
reported	O
neurologic	B-ADR
toxic	I-ADR
effect	I-ADR
,	O
all	O
of	O
which	O
have	O
been	O
associated	O
with	O
systemic	O
disease	O
0	O
<EOS>	O
sulindac	B-Drug
(	O
clinoril	O
)	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
agent	O
,	O
ha	O
few	O
reported	O
neurologic	B-ADR
toxic	I-ADR
effect	I-ADR
,	O
all	O
of	O
which	O
have	O
been	O
associated	O
with	O
systemic	O
disease	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
isolated	B-ADR
paresthesia	I-ADR
and	O
peripheral	O
neuropathy	O
,	O
without	O
systemic	O
involvement	O
,	O
secondary	O
to	O
sulindac	B-Drug
administration	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
isolated	O
paresthesia	O
and	O
peripheral	B-ADR
neuropathy	I-ADR
,	O
without	O
systemic	O
involvement	O
,	O
secondary	O
to	O
sulindac	B-Drug
administration	O
0	O
<EOS>	O
in	O
addition	O
,	O
loading	O
with	O
one	O
low	O
oral	O
dose	O
of	O
serine	B-Drug
produced	O
psychotic	B-ADR
symptom	I-ADR
5	O
h	O
later	O
which	O
lasted	O
3-6	O
h	O
0	O
<EOS>	O
reversal	O
of	O
ergotamine-induced	B-Drug
arteriospasm	B-ADR
by	O
mechanical	O
intra-arterial	O
dilatation	O
0	O
<EOS>	O
two	O
patient	O
with	O
imminent	O
gangrene	O
of	O
the	O
extremity	O
caused	O
by	O
ergot-induced	B-Drug
arteriospasm	B-ADR
underwent	O
mechanical	O
dilatation	O
of	O
the	O
artery	O
when	O
conventional	O
measure	O
such	O
a	O
anticoagulation	O
,	O
vasodilation	O
,	O
and	O
sympathetic	O
blockade	O
produced	O
no	O
improvement	O
0	O
<EOS>	O
two	O
patient	O
with	O
imminent	O
gangrene	B-ADR
of	I-ADR
the	I-ADR
extremity	I-ADR
caused	O
by	O
ergot-induced	B-Drug
arteriospasm	O
underwent	O
mechanical	O
dilatation	O
of	O
the	O
artery	O
when	O
conventional	O
measure	O
such	O
a	O
anticoagulation	O
,	O
vasodilation	O
,	O
and	O
sympathetic	O
blockade	O
produced	O
no	O
improvement	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	O
and	O
haloperidol	B-Drug
toxicity	O
characterized	O
by	O
hyperpyrexia	B-ADR
,	O
severe	O
rigidity	O
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	B-Drug
and	O
haloperidol	O
toxicity	O
characterized	O
by	O
hyperpyrexia	B-ADR
,	O
severe	O
rigidity	O
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	O
and	O
haloperidol	B-Drug
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	O
rigidity	O
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	B-ADR
tardive	I-ADR
dyskinesia	I-ADR
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	B-Drug
and	O
haloperidol	O
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	O
rigidity	O
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	B-ADR
tardive	I-ADR
dyskinesia	I-ADR
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	O
and	O
haloperidol	B-Drug
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	O
rigidity	O
,	O
mutism	B-ADR
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	B-Drug
and	O
haloperidol	O
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	O
rigidity	O
,	O
mutism	B-ADR
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	O
and	O
haloperidol	B-Drug
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	B-ADR
rigidity	I-ADR
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
combined	O
lithium	B-Drug
and	O
haloperidol	O
toxicity	O
characterized	O
by	O
hyperpyrexia	O
,	O
severe	B-ADR
rigidity	I-ADR
,	O
mutism	O
,	O
and	O
development	O
of	O
irreversible	O
tardive	O
dyskinesia	O
0	O
<EOS>	O
the	O
author	O
postulate	O
that	O
two	O
type	O
of	O
combined	O
lithium-neuroleptic	O
toxicity	O
occur	O
:	O
a	O
neuroleptic	O
malignant	O
extrapyramidal	O
syndrome	O
and	O
a	O
lithium	B-Drug
toxicity	I-ADR
that	O
occurs	O
in	O
combination	O
with	O
phenothiazine	O
,	O
primarily	O
thioridazine	O
0	O
<EOS>	O
the	O
author	O
postulate	O
that	O
two	O
type	O
of	O
combined	O
lithium-neuroleptic	O
toxicity	O
occur	O
:	O
a	O
neuroleptic	O
malignant	O
extrapyramidal	O
syndrome	O
and	O
a	O
lithium	B-ADR
toxicity	I-ADR
that	O
occurs	O
in	O
combination	O
with	O
phenothiazine	O
,	O
primarily	O
thioridazine	B-Drug
0	O
<EOS>	O
the	O
author	O
postulate	O
that	O
two	O
type	O
of	O
combined	O
lithium-neuroleptic	O
toxicity	O
occur	O
:	O
a	O
neuroleptic	B-ADR
malignant	I-ADR
extrapyramidal	I-ADR
syndrome	I-ADR
and	O
a	O
lithium	B-Drug
toxicity	O
that	O
occurs	O
in	O
combination	O
with	O
phenothiazine	O
,	O
primarily	O
thioridazine	O
0	O
<EOS>	O
the	O
author	O
postulate	O
that	O
two	O
type	O
of	O
combined	O
lithium-neuroleptic	O
toxicity	O
occur	O
:	O
a	O
neuroleptic	B-ADR
malignant	I-ADR
extrapyramidal	I-ADR
syndrome	I-ADR
and	O
a	O
lithium	O
toxicity	O
that	O
occurs	O
in	O
combination	O
with	O
phenothiazine	O
,	O
primarily	O
thioridazine	B-Drug
0	O
<EOS>	O
chlorambucil-induced	B-Drug
chromosome	B-ADR
damage	I-ADR
to	O
human	O
lymphocyte	O
is	O
dose-dependent	O
and	O
cumulative	O
0	O
<EOS>	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
50	O
%	O
solution	O
of	O
dextrose	B-Drug
0	O
<EOS>	O
preliminary	O
result	O
suggest	O
that	O
the	O
higher	O
concentration	O
of	O
dextrose	B-Drug
induce	O
increased	B-ADR
histamine	I-ADR
release	I-ADR
from	O
blood	O
cell	O
,	O
and	O
that	O
this	O
phenomenon	O
is	O
more	O
marked	O
in	O
diabetic	O
,	O
and	O
particularly	O
diabetic-allergic	O
,	O
individual	O
0	O
<EOS>	O
two	O
patient	O
with	O
extrinsic	O
asthma	O
and	O
coexistent	O
insulin-dependent	O
diabetes	O
mellitus	O
sustained	O
an	O
anaphylactoid	B-ADR
reaction	I-ADR
after	O
the	O
intravenous	O
administration	O
of	O
50	O
%	O
solution	O
of	O
dextrose	B-Drug
0	O
<EOS>	O
salicylate	B-Drug
hepato	B-ADR
toxicity	I-ADR
in	O
rheumatic	O
fever	O
0	O
<EOS>	O
two	O
child	O
with	O
rheumatic	O
fever	O
developed	O
anicteric	B-ADR
hepatitis	I-ADR
while	O
on	O
high-dose	O
aspirin	B-Drug
therapy	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	O
,	O
and	O
bleomycin	B-Drug
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	B-ADR
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	B-Drug
,	O
vinblastine	O
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	B-ADR
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	B-Drug
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	B-ADR
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	O
,	O
and	O
bleomycin	B-Drug
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	B-ADR
homonymous	I-ADR
hemianopsia	I-ADR
,	O
encephalopathy	O
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	B-Drug
,	O
vinblastine	O
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	B-ADR
homonymous	I-ADR
hemianopsia	I-ADR
,	O
encephalopathy	O
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	B-Drug
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	B-ADR
homonymous	I-ADR
hemianopsia	I-ADR
,	O
encephalopathy	O
,	O
and	O
a	O
partial	O
nondominant	O
parietal	O
lobe	O
syndrome	O
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	O
,	O
and	O
bleomycin	B-Drug
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	O
,	O
and	O
a	O
partial	B-ADR
nondominant	I-ADR
parietal	I-ADR
lobe	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	B-Drug
,	O
vinblastine	O
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	O
,	O
and	O
a	O
partial	B-ADR
nondominant	I-ADR
parietal	I-ADR
lobe	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
a	O
36-year-old	O
man	O
being	O
treated	O
with	O
cisplatinum	O
,	O
vinblastine	B-Drug
,	O
and	O
bleomycin	O
for	O
testicular	O
carcinoma	O
developed	O
a	O
dense	O
left	O
homonymous	O
hemianopsia	O
,	O
encephalopathy	O
,	O
and	O
a	O
partial	B-ADR
nondominant	I-ADR
parietal	I-ADR
lobe	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
transient	O
left	O
homonymous	O
hemianopsia	O
and	O
encephalopathy	B-ADR
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	O
,	O
vinblastine	O
,	O
and	O
bleomycin	B-Drug
0	O
<EOS>	O
transient	O
left	O
homonymous	O
hemianopsia	O
and	O
encephalopathy	B-ADR
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	B-Drug
,	O
vinblastine	O
,	O
and	O
bleomycin	O
0	O
<EOS>	O
transient	O
left	O
homonymous	O
hemianopsia	O
and	O
encephalopathy	B-ADR
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	O
,	O
vinblastine	B-Drug
,	O
and	O
bleomycin	O
0	O
<EOS>	O
transient	B-ADR
left	I-ADR
homonymous	I-ADR
hemianopsia	I-ADR
and	O
encephalopathy	O
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	O
,	O
vinblastine	O
,	O
and	O
bleomycin	B-Drug
0	O
<EOS>	O
transient	B-ADR
left	I-ADR
homonymous	I-ADR
hemianopsia	I-ADR
and	O
encephalopathy	O
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	B-Drug
,	O
vinblastine	O
,	O
and	O
bleomycin	O
0	O
<EOS>	O
transient	B-ADR
left	I-ADR
homonymous	I-ADR
hemianopsia	I-ADR
and	O
encephalopathy	O
following	O
treatment	O
of	O
testicular	O
carcinoma	O
with	O
cisplatinum	O
,	O
vinblastine	B-Drug
,	O
and	O
bleomycin	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	B-ADR
,	O
skin	O
reaction	O
and	O
hepatitis	O
during	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	B-ADR
,	O
skin	O
reaction	O
and	O
hepatitis	O
during	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	B-ADR
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	O
during	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	B-ADR
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	O
during	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	B-ADR
during	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	B-ADR
during	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	B-ADR
reaction	I-ADR
and	O
hepatitis	O
during	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
an	O
association	O
of	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	B-ADR
reaction	I-ADR
and	O
hepatitis	O
during	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
therapy	O
for	O
thyrotoxicosis	O
in	O
a	O
47	O
year	O
old	O
black	O
female	O
is	O
reported	O
0	O
<EOS>	O
multiple	O
complication	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	O
,	O
eosinophilia	B-ADR
,	O
skin	O
reaction	O
and	O
hepatitis	O
with	O
lymphocyte	O
sensitization	O
0	O
<EOS>	O
multiple	O
complication	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	B-ADR
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	O
with	O
lymphocyte	O
sensitization	O
0	O
<EOS>	O
multiple	O
complication	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	B-ADR
with	O
lymphocyte	O
sensitization	O
0	O
<EOS>	O
multiple	O
complication	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	O
reaction	O
and	O
hepatitis	O
with	O
lymphocyte	B-ADR
sensitization	I-ADR
0	O
<EOS>	O
multiple	O
complication	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	O
,	O
eosinophilia	O
,	O
skin	B-ADR
reaction	I-ADR
and	O
hepatitis	O
with	O
lymphocyte	O
sensitization	O
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	O
irritability	O
,	O
and	O
ataxia	B-ADR
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	B-Drug
and	O
pyrilamine	O
maleate	O
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	O
irritability	O
,	O
and	O
ataxia	B-ADR
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	O
and	O
pyrilamine	B-Drug
maleate	I-Drug
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	B-ADR
level	I-ADR
of	I-ADR
consciousness	I-ADR
,	O
marked	O
irritability	O
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	B-Drug
and	O
pyrilamine	O
maleate	O
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	B-ADR
level	I-ADR
of	I-ADR
consciousness	I-ADR
,	O
marked	O
irritability	O
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	O
and	O
pyrilamine	B-Drug
maleate	I-Drug
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	B-ADR
irritability	I-ADR
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	B-Drug
and	O
pyrilamine	O
maleate	O
0	O
<EOS>	O
a	O
toxic	O
encephalopathy	O
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	B-ADR
irritability	I-ADR
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	O
and	O
pyrilamine	B-Drug
maleate	I-Drug
0	O
<EOS>	O
a	O
toxic	B-ADR
encephalopathy	I-ADR
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	O
irritability	O
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	B-Drug
and	O
pyrilamine	O
maleate	O
0	O
<EOS>	O
a	O
toxic	B-ADR
encephalopathy	I-ADR
characterized	O
by	O
depressed	O
level	O
of	O
consciousness	O
,	O
marked	O
irritability	O
,	O
and	O
ataxia	O
developed	O
in	O
seven	O
child	O
,	O
5	O
year	O
of	O
age	O
and	O
younger	O
,	O
following	O
administration	O
of	O
an	O
antiemetic	O
combination	O
of	O
pentobarbital	O
and	O
pyrilamine	B-Drug
maleate	I-Drug
0	O
<EOS>	O
optic	B-ADR
neuropathy	I-ADR
associated	O
with	O
penicillamine	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
optic	B-ADR
neuropathy	I-ADR
developed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
who	O
had	O
been	O
receiving	O
d-penicillamine	B-Drug
for	O
about	O
1	O
year	O
0	O
<EOS>	O
the	O
case	O
resembles	O
two	O
previously	O
reported	O
case	O
of	O
optic	B-ADR
neuropathy	I-ADR
which	O
occurred	O
in	O
patient	O
with	O
wilson	O
disease	O
who	O
were	O
receiving	O
penicillamine	B-Drug
0	O
<EOS>	O
a	O
patient	O
developed	O
transient	O
,	O
acute	B-ADR
myopia	I-ADR
while	O
on	O
isotretinoin	O
(	O
accutane	B-Drug
)	O
therapy	O
for	O
acne	O
0	O
<EOS>	O
a	O
patient	O
developed	O
transient	O
,	O
acute	B-ADR
myopia	I-ADR
while	O
on	O
isotretinoin	B-Drug
(	O
accutane	O
)	O
therapy	O
for	O
acne	O
0	O
<EOS>	O
there	O
wa	O
a	O
clear	O
relationship	O
between	O
restarting	O
the	O
accutane	B-Drug
and	O
recurrence	O
of	O
the	O
transient	B-ADR
myopia	I-ADR
0	O
<EOS>	O
transient	B-ADR
acute	I-ADR
myopia	I-ADR
resulting	O
from	O
isotretinoin	O
(	O
accutane	B-Drug
)	O
therapy	O
0	O
<EOS>	O
transient	B-ADR
acute	I-ADR
myopia	I-ADR
resulting	O
from	O
isotretinoin	B-Drug
(	O
accutane	O
)	O
therapy	O
0	O
<EOS>	O
allergic	B-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
compound	O
tincture	O
of	O
benzoin	B-Drug
0	O
<EOS>	O
nineteen	O
case	O
of	O
allergic	B-ADR
contact	I-ADR
dermatitis	I-ADR
to	O
compound	O
tincture	O
of	O
benzoin	B-Drug
are	O
described	O
0	O
<EOS>	O
autopsy	O
evidence	O
of	O
herpesvirus	B-ADR
infection	I-ADR
wa	O
found	O
in	O
visceral	O
organ	O
of	O
four	O
leukemic	O
patient	O
who	O
had	O
received	O
large	O
dos	O
of	O
cytarabine	O
(	O
cytosine	O
arabinoside	O
;	O
ara-c	B-Drug
)	O
shortly	O
before	O
their	O
death	O
0	O
<EOS>	O
autopsy	O
evidence	O
of	O
herpesvirus	B-ADR
infection	I-ADR
wa	O
found	O
in	O
visceral	O
organ	O
of	O
four	O
leukemic	O
patient	O
who	O
had	O
received	O
large	O
dos	O
of	O
cytarabine	B-Drug
(	O
cytosine	O
arabinoside	O
;	O
ara-c	O
)	O
shortly	O
before	O
their	O
death	O
0	O
<EOS>	O
autopsy	O
evidence	O
of	O
herpesvirus	B-ADR
infection	I-ADR
wa	O
found	O
in	O
visceral	O
organ	O
of	O
four	O
leukemic	O
patient	O
who	O
had	O
received	O
large	O
dos	O
of	O
cytarabine	O
(	O
cytosine	B-Drug
arabinoside	I-Drug
;	O
ara-c	O
)	O
shortly	O
before	O
their	O
death	O
0	O
<EOS>	O
in	O
three	O
of	O
these	O
patient	O
the	O
infection	O
wa	O
clinically	O
unsuspected	O
;	O
in	O
the	O
fourth	O
,	O
cutaneous	B-ADR
herpes	I-ADR
zoster	I-ADR
developed	O
after	O
administration	O
of	O
300	O
mg	O
of	O
cytarabine	B-Drug
daily	O
for	O
the	O
preceding	O
five	O
day	O
0	O
<EOS>	O
visceral	B-ADR
herpesvirus	I-ADR
infection	I-ADR
in	O
leukemic	O
patient	O
receiving	O
cytarabine	B-Drug
0	O
<EOS>	O
clinical	O
and	O
morphological	O
feature	O
of	O
gold	B-Drug
neuropathy	B-ADR
0	O
<EOS>	O
three	O
case	O
of	O
gold-related	B-Drug
neuropathy	B-ADR
are	O
reported	O
0	O
<EOS>	O
intra-neural	B-ADR
ceroid-like	I-ADR
pigment	I-ADR
following	O
the	O
treatment	O
of	O
lepromatous	O
leprosy	O
with	O
clofazimine	O
(	O
b663	B-Drug
;	O
lamprene	O
)	O
0	O
<EOS>	O
intra-neural	B-ADR
ceroid-like	I-ADR
pigment	I-ADR
following	O
the	O
treatment	O
of	O
lepromatous	O
leprosy	O
with	O
clofazimine	B-Drug
(	O
b663	O
;	O
lamprene	O
)	O
0	O
<EOS>	O
intra-neural	B-ADR
ceroid-like	I-ADR
pigment	I-ADR
following	O
the	O
treatment	O
of	O
lepromatous	O
leprosy	O
with	O
clofazimine	O
(	O
b663	O
;	O
lamprene	B-Drug
)	O
0	O
<EOS>	O
one	O
of	O
these	O
wa	O
clofazimine	B-Drug
,	O
an	O
aniline	O
aposafranine	O
derivative	O
known	O
to	O
produce	O
a	O
ceroid-like	B-ADR
pigment	I-ADR
in	O
the	O
tissue	O
of	O
patient	O
treated	O
with	O
this	O
drug	O
or	O
lepromatous	O
leprosy	O
0	O
<EOS>	O
severe	B-ADR
neurotoxicity	I-ADR
with	O
methyl	B-Drug
g	I-Drug
:	I-Drug
calgb	I-Drug
experience	O
0	O
<EOS>	O
a	O
young	O
patient	O
experienced	O
marked	O
sinus	B-ADR
tachycardia	I-ADR
while	O
smoking	O
marijuana	O
and	O
receiving	O
therapeutic	O
dos	O
of	O
nortriptyline	B-Drug
0	O
<EOS>	O
marked	O
sinus	B-ADR
tachycardia	I-ADR
resulting	O
from	O
the	O
synergistic	O
effect	O
of	O
marijuana	O
and	O
nortriptyline	B-Drug
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
cerebral	B-ADR
atrophy	I-ADR
	O
on	O
ct	O
scan	O
may	O
represent	O
an	O
accumulative	O
effect	O
of	O
acth	B-Drug
and	O
that	O
acth	O
should	O
be	O
given	O
with	O
the	O
utmost	O
discretion	O
,	O
and	O
in	O
a	O
low	O
a	O
dose	O
a	O
possible	O
0	O
<EOS>	O
disulfiram-like	B-ADR
reaction	I-ADR
with	O
newer	O
cephalosporin	O
:	O
cefmenoxime	B-Drug
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
disulfiram-like	B-ADR
reaction	I-ADR
with	O
cefmenoxime	B-Drug
0	O
<EOS>	O
k	O
bipolar	O
manic-depressive	O
patient	O
,	O
developed	O
while	O
on	O
lithium	B-Drug
prophylaxis	O
,	O
akathisia	B-ADR
at	O
therapeutic	O
serum	O
lithium	O
level	O
and	O
subsequently	O
bucco-linguo-masticatory	O
dyskinesia	O
0	O
<EOS>	O
k	O
bipolar	O
manic-depressive	O
patient	O
,	O
developed	O
while	O
on	O
lithium	B-Drug
prophylaxis	O
,	O
akathisia	O
at	O
therapeutic	O
serum	O
lithium	O
level	O
and	O
subsequently	O
bucco-linguo-masticatory	B-ADR
dyskinesia	I-ADR
0	O
<EOS>	O
acute	B-ADR
leukopenia	I-ADR
associated	O
with	O
silver	B-Drug
sulfadiazine	I-Drug
therapy	O
0	O
<EOS>	O
patient	O
from	O
endemic	O
area	O
referred	O
to	O
transplant	O
center	O
may	O
be	O
at	O
high	O
risk	O
for	O
disseminated	B-ADR
histoplasmosis	I-ADR
when	O
treated	O
with	O
long-term	O
prednisone	B-Drug
for	O
graft-versus-host	O
disease	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
most	O
likely	O
wa	O
secondary	O
to	O
the	O
nephrotoxic	O
effect	O
of	O
captopril	B-Drug
on	O
chronically	O
hypoperfused	O
kidney	O
0	O
<EOS>	O
in	O
a	O
patient	O
with	O
severe	O
renovascular	O
hypertension	O
,	O
nonoliguric	B-ADR
acute	I-ADR
renal	I-ADR
failure	I-ADR
developed	O
after	O
she	O
received	O
captopril	B-Drug
treatment	O
0	O
<EOS>	O
nonoliguric	B-ADR
acute	I-ADR
renal	I-ADR
failure	I-ADR
after	O
captopril	B-Drug
therapy	O
0	O
<EOS>	O
captopril-induced	B-Drug
acute	B-ADR
reversible	I-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
the	O
5	O
patient	O
had	O
severe	O
renovascular	O
disease	O
which	O
might	O
thus	O
represent	O
a	O
significant	O
risk	O
factor	O
in	O
the	O
development	O
of	O
captopril-induced	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
report	O
5	O
case	O
of	O
acute	B-ADR
reversible	I-ADR
renal	I-ADR
failure	I-ADR
coinciding	O
with	O
the	O
onset	O
of	O
treatment	O
with	O
captopril	B-Drug
in	O
patient	O
with	O
severe	O
drug-resistant	O
hypertension	O
0	O
<EOS>	O
a	O
case	O
of	O
mania	B-ADR
associated	O
with	O
fluoxetine	B-Drug
0	O
<EOS>	O
a	O
depressed	O
woman	O
with	O
no	O
history	O
of	O
bipolar	O
illness	O
developed	O
a	O
manic	B-ADR
episode	I-ADR
during	O
treatment	O
with	O
fluoxetine	B-Drug
0	O
<EOS>	O
alopecia	B-ADR
,	O
nausea	O
,	O
and	O
vomiting	O
were	O
attributed	O
to	O
the	O
cyclophosphamide	B-Drug
component	O
of	O
the	O
therapy	O
0	O
<EOS>	O
alopecia	O
,	O
nausea	B-ADR
,	O
and	O
vomiting	O
were	O
attributed	O
to	O
the	O
cyclophosphamide	B-Drug
component	O
of	O
the	O
therapy	O
0	O
<EOS>	O
alopecia	O
,	O
nausea	O
,	O
and	O
vomiting	B-ADR
were	O
attributed	O
to	O
the	O
cyclophosphamide	B-Drug
component	O
of	O
the	O
therapy	O
0	O
<EOS>	O
haemolytic-uraemic	B-ADR
syndrome	I-ADR
complicating	O
long-term	O
mitomycin	O
c	O
and	O
5-fluorouracil	B-Drug
therapy	O
for	O
gastric	O
carcinoma	O
0	O
<EOS>	O
haemolytic-uraemic	B-ADR
syndrome	I-ADR
complicating	O
long-term	O
mitomycin	B-Drug
c	I-Drug
and	O
5-fluorouracil	O
therapy	O
for	O
gastric	O
carcinoma	O
0	O
<EOS>	O
three	O
case	O
of	O
acute	B-ADR
renal	I-ADR
toxicity	I-ADR
in	O
patient	O
receiving	O
long-term	O
therapy	O
with	O
mitomycin	O
c	O
and	O
5-fluorouracil	B-Drug
are	O
reported	O
0	O
<EOS>	O
three	O
case	O
of	O
acute	B-ADR
renal	I-ADR
toxicity	I-ADR
in	O
patient	O
receiving	O
long-term	O
therapy	O
with	O
mitomycin	B-Drug
c	I-Drug
and	O
5-fluorouracil	O
are	O
reported	O
0	O
<EOS>	O
oral	O
25-hydroxyvitain	B-Drug
d3	I-Drug
in	O
treatment	O
of	O
osteomalacia	O
associated	O
with	O
ileal	B-ADR
resection	I-ADR
and	O
cholestyramine	O
therapy	O
0	O
<EOS>	O
severe	O
histological	O
osteomalacia	B-ADR
developed	O
in	O
a	O
woman	O
with	O
crohn	O
disease	O
2	O
year	O
after	O
ileal	O
resection	O
and	O
the	O
start	O
of	O
cholestyramine	B-Drug
therapy	O
0	O
<EOS>	O
treatment	O
of	O
lithium	B-Drug
tremor	B-ADR
with	O
metoprolol	O
0	O
<EOS>	O
two	O
patient	O
with	O
bipolar	O
affective	O
disorder	O
and	O
a	O
history	O
of	O
bronchospastic	O
phenomenon	O
experienced	O
tremor	B-ADR
during	O
lithium	B-Drug
carbonate	I-Drug
therapy	O
0	O
<EOS>	O
intravenous	O
diazepam	B-Drug
exacerbated	O
the	O
seizure	B-ADR
0	O
<EOS>	O
a	O
52-year-old	O
black	O
woman	O
on	O
phenytoin	B-Drug
therapy	O
for	O
post-traumatic	O
epilepsy	O
developed	O
transient	B-ADR
hemiparesis	I-ADR
contralateral	O
to	O
the	O
injury	O
0	O
<EOS>	O
a	O
possible	O
mechanism	O
for	O
focal	B-ADR
neurological	I-ADR
deficit	I-ADR
in	O
brain-damaged	O
patient	O
on	O
phenytoin	B-Drug
therapy	O
is	O
discussed	O
0	O
<EOS>	O
transient	B-ADR
hemiparesis	I-ADR
caused	O
by	O
phenytoin	B-Drug
toxicity	O
0	O
<EOS>	O
a	O
7-year-old	O
boy	O
developed	O
a	O
severe	B-ADR
unilateral	I-ADR
grand	I-ADR
mal	I-ADR
seizure	I-ADR
at	O
the	O
age	O
of	O
5	O
year	O
(	O
phenobarbitone	O
therapy	O
)	O
;	O
1.5	O
year	O
later	O
valproate	O
(	O
2-propylpentanoic	B-Drug
acid	I-Drug
,	O
vpa	O
)	O
wa	O
added	O
to	O
the	O
therapy	O
0	O
<EOS>	O
a	O
7-year-old	O
boy	O
developed	O
a	O
severe	B-ADR
unilateral	I-ADR
grand	I-ADR
mal	I-ADR
seizure	I-ADR
at	O
the	O
age	O
of	O
5	O
year	O
(	O
phenobarbitone	B-Drug
therapy	O
)	O
;	O
1.5	O
year	O
later	O
valproate	O
(	O
2-propylpentanoic	O
acid	O
,	O
vpa	O
)	O
wa	O
added	O
to	O
the	O
therapy	O
0	O
<EOS>	O
a	O
7-year-old	O
boy	O
developed	O
a	O
severe	B-ADR
unilateral	I-ADR
grand	I-ADR
mal	I-ADR
seizure	I-ADR
at	O
the	O
age	O
of	O
5	O
year	O
(	O
phenobarbitone	O
therapy	O
)	O
;	O
1.5	O
year	O
later	O
valproate	B-Drug
(	O
2-propylpentanoic	O
acid	O
,	O
vpa	O
)	O
wa	O
added	O
to	O
the	O
therapy	O
0	O
<EOS>	O
a	O
7-year-old	O
boy	O
developed	O
a	O
severe	B-ADR
unilateral	I-ADR
grand	I-ADR
mal	I-ADR
seizure	I-ADR
at	O
the	O
age	O
of	O
5	O
year	O
(	O
phenobarbitone	O
therapy	O
)	O
;	O
1.5	O
year	O
later	O
valproate	O
(	O
2-propylpentanoic	O
acid	O
,	O
vpa	B-Drug
)	O
wa	O
added	O
to	O
the	O
therapy	O
0	O
<EOS>	O
cefoxitin	B-Drug
therapy	O
for	O
mycobacterium	O
fortuitum	O
bacteremia	O
with	O
associated	O
granulomatous	B-ADR
hepatitis	I-ADR
0	O
<EOS>	O
stroke-like	B-ADR
syndrome	I-ADR
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
induced	O
vasomotor	O
reaction	O
0	O
<EOS>	O
stroke-like	O
syndrome	O
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
induced	O
vasomotor	B-ADR
reaction	I-ADR
0	O
<EOS>	O
vasomotor	B-ADR
reaction	I-ADR
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
are	O
well	O
recognized	O
0	O
<EOS>	O
gold	B-ADR
nephropathy	I-ADR
due	O
to	O
auranofin	B-Drug
obscured	O
by	O
tolmetin	O
pseudoproteinuria	O
0	O
<EOS>	O
gold	B-Drug
nephropathy	I-ADR
due	O
to	O
auranofin	O
obscured	O
by	O
tolmetin	O
pseudoproteinuria	O
0	O
<EOS>	O
gold	B-ADR
nephropathy	I-ADR
due	O
to	O
auranofin	O
obscured	O
by	O
tolmetin	B-Drug
pseudoproteinuria	O
0	O
<EOS>	O
gold	O
nephropathy	O
due	O
to	O
auranofin	O
obscured	O
by	O
tolmetin	B-Drug
pseudoproteinuria	B-ADR
0	O
<EOS>	O
a	O
52-year-old	O
,	O
white	O
female	O
developed	O
low-grade	O
fever	O
,	O
cough	B-ADR
,	O
and	O
dyspnea	O
after	O
8	O
week	O
treatment	O
with	O
sodium	B-Drug
aurothiomalate	I-Drug
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
52-year-old	O
,	O
white	O
female	O
developed	O
low-grade	O
fever	O
,	O
cough	O
,	O
and	O
dyspnea	B-ADR
after	O
8	O
week	O
treatment	O
with	O
sodium	B-Drug
aurothiomalate	I-Drug
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
52-year-old	O
,	O
white	O
female	O
developed	O
low-grade	B-ADR
fever	I-ADR
,	O
cough	O
,	O
and	O
dyspnea	O
after	O
8	O
week	O
treatment	O
with	O
sodium	B-Drug
aurothiomalate	I-Drug
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
pulmonary	B-ADR
gold	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
cyclophosphamide	B-Drug
can	O
rarely	O
cause	O
interstitial	O
pneumonitis	O
and	O
fibrosis	B-ADR
0	O
<EOS>	O
cyclophosphamide	B-Drug
can	O
rarely	O
cause	O
interstitial	B-ADR
pneumonitis	I-ADR
and	O
fibrosis	O
0	O
<EOS>	O
cyclophosphamide	B-Drug
pneumonitis	B-ADR
0	O
<EOS>	O
the	O
temporal	O
sequence	O
of	O
the	O
respiratory	O
insufficiency	O
and	O
the	O
histopathology	O
,	O
when	O
compared	O
to	O
the	O
previous	O
example	O
in	O
the	O
literature	O
,	O
suggest	O
that	O
cyclophosphamide	B-Drug
wa	O
aetiologically	O
responsible	O
for	O
the	O
lung	B-ADR
disease	I-ADR
0	O
<EOS>	O
the	O
temporal	O
sequence	O
of	O
the	O
respiratory	B-ADR
insufficiency	I-ADR
and	O
the	O
histopathology	O
,	O
when	O
compared	O
to	O
the	O
previous	O
example	O
in	O
the	O
literature	O
,	O
suggest	O
that	O
cyclophosphamide	B-Drug
wa	O
aetiologically	O
responsible	O
for	O
the	O
lung	O
disease	O
0	O
<EOS>	O
a	O
reversible	B-ADR
toxic	I-ADR
liver	I-ADR
damage	I-ADR
wa	O
observed	O
in	O
a	O
non-alcoholic	O
woman	O
treated	O
with	O
disulfiram	B-Drug
0	O
<EOS>	O
toxic	B-ADR
hepatitis	I-ADR
induced	O
by	O
disulfiram	B-Drug
in	O
a	O
non-alcoholic	O
0	O
<EOS>	O
one	O
type	O
of	O
smon	O
is	O
associated	O
with	O
acrodermatitis	B-ADR
enteropathica	I-ADR
which	O
ha	O
a	O
very	O
high	O
frequency	O
of	O
occurrence	O
in	O
association	O
with	O
administration	O
of	O
clioquinol	B-Drug
0	O
<EOS>	O
one	O
type	O
of	O
smon	B-ADR
is	O
associated	O
with	O
acrodermatitis	O
enteropathica	O
which	O
ha	O
a	O
very	O
high	O
frequency	O
of	O
occurrence	O
in	O
association	O
with	O
administration	O
of	O
clioquinol	B-Drug
0	O
<EOS>	O
four	O
patient	O
receiving	O
high-dose	O
tamoxifen	B-Drug
for	O
greater	O
than	O
1	O
year	O
have	O
demonstrated	O
similar	O
retinal	B-ADR
change	I-ADR
0	O
<EOS>	O
tamoxifen	B-Drug
retinopathy	B-ADR
0	O
<EOS>	O
these	O
finding	O
suggest	O
that	O
the	O
corneal	B-ADR
and	I-ADR
retinal	I-ADR
change	I-ADR
are	O
the	O
result	O
of	O
a	O
toxic	O
effect	O
of	O
tamoxifen	B-Drug
when	O
used	O
in	O
the	O
dos	O
and	O
duration	O
described	O
0	O
<EOS>	O
mammary	B-ADR
gigantism	I-ADR
is	O
a	O
rare	O
complication	O
of	O
d-penicillamine	B-Drug
treatment	O
0	O
<EOS>	O
although	O
they	O
had	O
complex	O
medical	O
problem	O
,	O
the	O
high	O
serum	O
concentration	O
of	O
ampicillin	B-Drug
at	O
the	O
time	O
of	O
seizure	B-ADR
without	O
their	O
recurrence	O
after	O
discontinuing	O
the	O
antibiotic	O
suggest	O
that	O
the	O
seizure	O
were	O
related	O
to	O
the	O
ampicillin	O
therapy	O
0	O
<EOS>	O
although	O
they	O
had	O
complex	O
medical	O
problem	O
,	O
the	O
high	O
serum	O
concentration	O
of	O
ampicillin	B-Drug
at	O
the	O
time	O
of	O
seizure	B-ADR
without	O
their	O
recurrence	O
after	O
discontinuing	O
the	O
antibiotic	O
suggest	O
that	O
the	O
seizure	O
were	O
related	O
to	O
the	O
ampicillin	O
therapy	O
0	O
<EOS>	O
ampicillin-associated	B-Drug
seizure	B-ADR
0	O
<EOS>	O
two	O
patient	O
had	O
ampicillin-associated	B-Drug
seizure	B-ADR
0	O
<EOS>	O
after	O
the	O
patient	O
discontinued	O
rifampicin	B-Drug
,	O
the	O
skin	B-ADR
lesion	I-ADR
cleared	O
completely	O
within	O
5	O
week	O
without	O
any	O
systemic	O
medication	O
0	O
<EOS>	O
pemphigus	B-ADR
foliaceus	I-ADR
induced	O
by	O
rifampicin	B-Drug
0	O
<EOS>	O
pemphigus	B-ADR
foliaceus	I-ADR
wa	O
seen	O
in	O
a	O
patient	O
with	O
pulmonary	O
tuberculosis	O
during	O
rifampicin	B-Drug
therapy	O
0	O
<EOS>	O
hyponatremia	B-ADR
in	O
patient	O
treated	O
with	O
lorcainide	B-Drug
,	O
a	O
new	O
antiarrhythmic	O
drug	O
0	O
<EOS>	O
in	O
eight	O
patient	O
,	O
a	O
mean	O
decrease	B-ADR
in	I-ADR
serum	I-ADR
na+	I-ADR
of	O
8.25	O
+	O
/	O
-	O
3.2	O
meq	O
/	O
l	O
wa	O
observed	O
after	O
a	O
single	O
200	O
mg	O
intravenous	O
dose	O
of	O
lorcainide	B-Drug
0	O
<EOS>	O
it	O
is	O
concluded	O
that	O
siadh	B-ADR
is	O
an	O
important	O
side	O
effect	O
of	O
lorcainide	B-Drug
therapy	O
0	O
<EOS>	O
one	O
patient	O
developed	O
severe	B-ADR
hyponatremia	I-ADR
with	O
serum	O
na+	O
of	O
108	O
meq	O
/	O
l	O
when	O
hydrochlorothiazide	B-Drug
wa	O
given	O
to	O
control	O
hypertension	O
0	O
<EOS>	O
sixteen	O
of	O
33	O
patient	O
developed	O
significant	O
hyponatremia	B-ADR
and	O
hypoosmolality	O
during	O
oral	O
treatment	O
with	O
lorcainide	B-Drug
0	O
<EOS>	O
sixteen	O
of	O
33	O
patient	O
developed	O
significant	O
hyponatremia	O
and	O
hypoosmolality	B-ADR
during	O
oral	O
treatment	O
with	O
lorcainide	B-Drug
0	O
<EOS>	O
acute	B-ADR
intravascular	I-ADR
hemolysis	I-ADR
developed	O
when	O
a	O
diabetic	O
patient	O
,	O
previously	O
treated	O
with	O
glyburide	O
,	O
wa	O
started	O
on	O
another	O
oral	O
sulfonylurea	O
drug	O
,	O
chlorpropamide	B-Drug
0	O
<EOS>	O
acute	B-ADR
intravascular	I-ADR
hemolysis	I-ADR
developed	O
when	O
a	O
diabetic	O
patient	O
,	O
previously	O
treated	O
with	O
glyburide	B-Drug
,	O
wa	O
started	O
on	O
another	O
oral	O
sulfonylurea	O
drug	O
,	O
chlorpropamide	O
0	O
<EOS>	O
chlorpropamide-induced	B-Drug
hemolytic	B-ADR
anemia	I-ADR
0	O
<EOS>	O
in	O
a	O
61-year-old	O
man	O
receiving	O
chronic	O
low-dosage	O
amiodarone	B-Drug
an	O
interstitial	B-ADR
pneumopathy	I-ADR
wa	O
observed	O
0	O
<EOS>	O
interstitial	B-ADR
pneumopathy	I-ADR
and	O
low-dosage	O
amiodarone	B-Drug
0	O
<EOS>	O
alternating	B-ADR
sinus	I-ADR
rhythm	I-ADR
and	O
intermittent	O
sinoatrial	O
block	O
induced	O
by	O
propranolol	B-Drug
0	O
<EOS>	O
alternating	O
sinus	O
rhythm	O
and	O
intermittent	B-ADR
sinoatrial	I-ADR
block	I-ADR
induced	O
by	O
propranolol	B-Drug
0	O
<EOS>	O
alternating	B-ADR
sinus	I-ADR
rhythm	I-ADR
and	O
intermittent	O
sinoatrial	O
(	O
s-a	O
)	O
block	O
wa	O
observed	O
in	O
a	O
57-year-old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	O
with	O
80	O
mg	O
propranolol	B-Drug
daily	O
0	O
<EOS>	O
alternating	O
sinus	O
rhythm	O
and	O
intermittent	B-ADR
sinoatrial	I-ADR
(	I-ADR
s-a	I-ADR
)	I-ADR
block	I-ADR
wa	O
observed	O
in	O
a	O
57-year-old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	O
with	O
80	O
mg	O
propranolol	B-Drug
daily	O
0	O
<EOS>	O
the	O
abnormal	B-ADR
rhythm	I-ADR
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	B-Drug
and	O
when	O
the	O
drug	O
wa	O
restarted	O
a	O
2	O
/	O
1	O
s-a	O
block	O
wa	O
seen	O
0	O
<EOS>	O
this	O
wa	O
accepted	O
a	O
evidence	O
for	O
propranolol	B-Drug
being	O
the	O
cause	O
of	O
this	O
conduction	B-ADR
disorder	I-ADR
0	O
<EOS>	O
a	O
further	O
case	O
of	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
methylprednisolone	B-Drug
is	O
reported	O
0	O
<EOS>	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
methylprednisolone	B-Drug
pulsed	O
therapy	O
for	O
multiple	O
sclerosis	O
0	O
<EOS>	O
although	O
lung	O
specimen	O
were	O
lacking	O
from	O
these	O
three	O
patient	O
,	O
it	O
is	O
suggested	O
that	O
the	O
pulmonary	B-ADR
toxicity	I-ADR
of	O
ccnu	B-Drug
may	O
be	O
dose-related	O
0	O
<EOS>	O
pulmonary	B-ADR
fibrosis	I-ADR
subsequent	O
to	O
high	O
dos	O
of	O
ccnu	B-Drug
for	O
chronic	O
myeloid	O
leukemia	O
0	O
<EOS>	O
the	O
responsibility	O
of	O
ccnu	B-Drug
in	O
the	O
pathogenesis	O
of	O
pulmonary	B-ADR
fibrosis	I-ADR
seems	O
very	O
likely	O
0	O
<EOS>	O
two	O
patient	O
treated	O
for	O
chronic	O
myeloid	O
leukemia	O
with	O
high	O
dos	O
of	O
ccnu	B-Drug
(	O
1100	O
mg	O
/	O
m2	O
and	O
1240	O
mg	O
/	O
m2	O
,	O
respectively	O
)	O
developed	O
a	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
0	O
<EOS>	O
additive	B-ADR
pulmonary	I-ADR
toxicity	I-ADR
with	O
melphalan	O
and	O
busulfan	B-Drug
therapy	O
0	O
<EOS>	O
additive	B-ADR
pulmonary	I-ADR
toxicity	I-ADR
with	O
melphalan	B-Drug
and	O
busulfan	O
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
59-year-old	O
patient	O
with	O
chronic	O
myeloid	O
leukemia	O
,	O
who	O
developed	O
severe	B-ADR
interstitial	I-ADR
lung	I-ADR
fibrosis	I-ADR
after	O
short	O
term	O
and	O
sequential	O
treatment	O
with	O
melphalan	O
and	O
busulfan	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
59-year-old	O
patient	O
with	O
chronic	O
myeloid	O
leukemia	O
,	O
who	O
developed	O
severe	B-ADR
interstitial	I-ADR
lung	I-ADR
fibrosis	I-ADR
after	O
short	O
term	O
and	O
sequential	O
treatment	O
with	O
melphalan	B-Drug
and	O
busulfan	O
0	O
<EOS>	O
after	O
taking	O
cholestyramine	B-Drug
ii	I-Drug
sachet	O
twice	O
daily	O
for	O
two	O
month	O
she	O
presented	O
with	O
lethargy	O
,	O
confusion	B-ADR
and	O
drowsiness	O
0	O
<EOS>	O
after	O
taking	O
cholestyramine	B-Drug
ii	I-Drug
sachet	O
twice	O
daily	O
for	O
two	O
month	O
she	O
presented	O
with	O
lethargy	O
,	O
confusion	O
and	O
drowsiness	B-ADR
0	O
<EOS>	O
after	O
taking	O
cholestyramine	B-Drug
ii	I-Drug
sachet	O
twice	O
daily	O
for	O
two	O
month	O
she	O
presented	O
with	O
lethargy	B-ADR
,	O
confusion	O
and	O
drowsiness	O
0	O
<EOS>	O
cholestyramine	B-Drug
induced	O
hyperchloremic	B-ADR
metabolic	I-ADR
acidosis	I-ADR
0	O
<EOS>	O
it	O
is	O
presumed	O
that	O
her	O
hyperchloremic	B-ADR
metabolic	I-ADR
acidosis	I-ADR
wa	O
secondary	O
to	O
cholestyramine	B-Drug
because	O
of	O
the	O
similarity	O
to	O
pediatric	O
report	O
;	O
the	O
rapid	O
and	O
lasting	O
response	O
to	O
intravenous	O
sodium	O
bicarbonate	O
;	O
the	O
absence	O
of	O
another	O
etiology	O
;	O
normal	O
serum	O
potassium	O
,	O
chloride	O
and	O
bicarbonate	O
despite	O
continued	O
spironolactone	O
therapy	O
after	O
recovery	O
0	O
<EOS>	O
the	O
first	O
reported	O
case	O
,	O
in	O
an	O
adult	O
,	O
of	O
cholestyramine	B-Drug
induced	O
hyperchloremic	B-ADR
metabolic	I-ADR
acidosis	I-ADR
is	O
a	O
70	O
year	O
old	O
female	O
with	O
a	O
two	O
year	O
history	O
of	O
primary	O
biliary	O
cirrhosis	O
confirmed	O
by	O
histologic	O
and	O
immunologic	O
criterion	O
0	O
<EOS>	O
although	O
myelosuppression	O
is	O
mild	O
,	O
immunosuppression	B-ADR
and	O
superinfection	O
are	O
potential	O
hazard	O
of	O
treatment	O
with	O
dcf	B-Drug
0	O
<EOS>	O
although	O
myelosuppression	O
is	O
mild	O
,	O
immunosuppression	O
and	O
superinfection	B-ADR
are	O
potential	O
hazard	O
of	O
treatment	O
with	O
dcf	B-Drug
0	O
<EOS>	O
the	O
ocular	O
toxicity	O
of	O
dcf	B-Drug
,	O
previously	O
described	O
a	O
conjunctivitis	B-ADR
,	O
appears	O
to	O
be	O
a	O
keratitis	O
of	O
moderate	O
severity	O
which	O
requires	O
further	O
study	O
0	O
<EOS>	O
the	O
ocular	O
toxicity	O
of	O
dcf	B-Drug
,	O
previously	O
described	O
a	O
conjunctivitis	O
,	O
appears	O
to	O
be	O
a	O
keratitis	B-ADR
of	O
moderate	O
severity	O
which	O
requires	O
further	O
study	O
0	O
<EOS>	O
the	O
ocular	B-ADR
toxicity	I-ADR
of	O
dcf	B-Drug
,	O
previously	O
described	O
a	O
conjunctivitis	O
,	O
appears	O
to	O
be	O
a	O
keratitis	O
of	O
moderate	O
severity	O
which	O
requires	O
further	O
study	O
0	O
<EOS>	O
because	O
there	O
were	O
no	O
other	O
obvious	O
cause	O
of	O
renal	O
failure	O
in	O
either	O
patient	O
,	O
we	O
propose	O
that	O
skeletal	O
muscle	O
ischemia	O
developed	O
during	O
vasopressin	B-Drug
infusion	O
,	O
followed	O
by	O
release	O
of	O
myoglobin	O
and	O
renal	B-ADR
damage	I-ADR
0	O
<EOS>	O
because	O
there	O
were	O
no	O
other	O
obvious	O
cause	O
of	O
renal	O
failure	O
in	O
either	O
patient	O
,	O
we	O
propose	O
that	O
skeletal	B-ADR
muscle	I-ADR
ischemia	I-ADR
developed	O
during	O
vasopressin	B-Drug
infusion	O
,	O
followed	O
by	O
release	O
of	O
myoglobin	O
and	O
renal	O
damage	O
0	O
<EOS>	O
myoglobinuria	O
and	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
associated	O
with	O
intravenous	O
vasopressin	B-Drug
infusion	O
0	O
<EOS>	O
myoglobinuria	B-ADR
and	O
acute	O
renal	O
failure	O
associated	O
with	O
intravenous	O
vasopressin	B-Drug
infusion	O
0	O
<EOS>	O
myoglobinuria	O
and	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
were	O
observed	O
in	O
two	O
patient	O
with	O
vasopressin-treated	B-Drug
gastrointestinal	O
hemorrhage	O
0	O
<EOS>	O
myoglobinuria	B-ADR
and	O
acute	O
renal	O
failure	O
were	O
observed	O
in	O
two	O
patient	O
with	O
vasopressin-treated	B-Drug
gastrointestinal	O
hemorrhage	O
0	O
<EOS>	O
a	O
major	O
limitation	O
in	O
the	O
use	O
of	O
amphotericin	B-Drug
b	I-Drug
is	O
it	O
potential	O
to	O
cause	O
nephrotoxicity	B-ADR
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
nephrotoxicity	B-ADR
in	O
human	O
decreased	O
by	O
salt	O
repletion	O
0	O
<EOS>	O
experience	O
with	O
five	O
patient	O
in	O
whom	O
impaired	B-ADR
renal	I-ADR
function	I-ADR
developed	O
early	O
during	O
amphotericin	B-Drug
b	I-Drug
therapy	O
is	O
reported	O
0	O
<EOS>	O
gynecomastia	B-ADR
developed	O
in	O
two	O
epileptic	O
patient	O
some	O
month	O
after	O
the	O
addition	O
of	O
oral	O
fluoresone	B-Drug
750	O
mg	O
daily	O
to	O
the	O
phenobarbital	O
and	O
phenytoin	O
already	O
being	O
administered	O
0	O
<EOS>	O
gynecomastia	B-ADR
developed	O
in	O
two	O
epileptic	O
patient	O
some	O
month	O
after	O
the	O
addition	O
of	O
oral	O
fluoresone	O
750	O
mg	O
daily	O
to	O
the	O
phenobarbital	B-Drug
and	O
phenytoin	O
already	O
being	O
administered	O
0	O
<EOS>	O
gynecomastia	B-ADR
developed	O
in	O
two	O
epileptic	O
patient	O
some	O
month	O
after	O
the	O
addition	O
of	O
oral	O
fluoresone	O
750	O
mg	O
daily	O
to	O
the	O
phenobarbital	O
and	O
phenytoin	B-Drug
already	O
being	O
administered	O
0	O
<EOS>	O
gynecomastia	B-ADR
in	O
epileptic	O
treated	O
with	O
phenobarbital	O
,	O
phenytoin	O
and	O
fluoresone	B-Drug
:	O
two	O
case	O
report	O
0	O
<EOS>	O
gynecomastia	B-ADR
in	O
epileptic	O
treated	O
with	O
phenobarbital	B-Drug
,	O
phenytoin	O
and	O
fluoresone	O
:	O
two	O
case	O
report	O
0	O
<EOS>	O
gynecomastia	B-ADR
in	O
epileptic	O
treated	O
with	O
phenobarbital	O
,	O
phenytoin	B-Drug
and	O
fluoresone	O
:	O
two	O
case	O
report	O
0	O
<EOS>	O
case	O
report	O
of	O
withdrawal	O
dyskinesia	B-ADR
associated	O
with	O
amoxapine	B-Drug
0	O
<EOS>	O
occurrence	O
of	O
withdrawal	O
dyskinesia	B-ADR
indicates	O
that	O
the	O
neuroleptic	O
effect	O
of	O
amoxapine	B-Drug
may	O
be	O
clinically	O
significant	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
oral-facial	B-ADR
dyskinesia	I-ADR
that	O
occurred	O
after	O
discontinuation	O
of	O
amoxapine	B-Drug
,	O
and	O
antidepressant	O
which	O
may	O
also	O
have	O
neuroleptic	O
effect	O
0	O
<EOS>	O
a	O
case	O
of	O
toxic	B-ADR
hepatitis	I-ADR
caused	O
by	O
combination	O
therapy	O
with	O
methotrexate	O
and	O
etretinate	B-Drug
in	O
the	O
treatment	O
of	O
severe	O
psoriasis	O
is	O
presented	O
in	O
a	O
47-year-old	O
woman	O
0	O
<EOS>	O
a	O
case	O
of	O
toxic	B-ADR
hepatitis	I-ADR
caused	O
by	O
combination	O
therapy	O
with	O
methotrexate	B-Drug
and	O
etretinate	O
in	O
the	O
treatment	O
of	O
severe	O
psoriasis	O
is	O
presented	O
in	O
a	O
47-year-old	O
woman	O
0	O
<EOS>	O
toxic	B-ADR
hepatitis	I-ADR
due	O
to	O
combination	O
therapy	O
with	O
methotrexate	O
and	O
etretinate	B-Drug
in	O
psoriasis	O
0	O
<EOS>	O
toxic	B-ADR
hepatitis	I-ADR
due	O
to	O
combination	O
therapy	O
with	O
methotrexate	B-Drug
and	O
etretinate	O
in	O
psoriasis	O
0	O
<EOS>	O
metabolic	O
balance	O
study	O
and	O
rechallenge	O
with	O
hydrochlorothiazide	B-Drug
were	O
undertaken	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
thiazide-induced	O
hyponatremia	B-ADR
0	O
<EOS>	O
a	O
58-year-old	O
woman	O
developed	O
unilateral	B-ADR
acute	I-ADR
angle-closure	I-ADR
glaucoma	I-ADR
four	O
day	O
after	O
the	O
application	O
of	O
a	O
patch	O
of	O
transdermal	O
scopolamine	B-Drug
delivery	O
system	O
(	O
transderm-v	O
)	O
0	O
<EOS>	O
a	O
case	O
history	O
of	O
a	O
15-year-old	O
boy	O
who	O
developed	O
incapacitating	O
tardive	B-ADR
dyskinesia	I-ADR
that	O
resolved	O
during	O
treatment	O
with	O
deanol	B-Drug
is	O
presented	O
0	O
<EOS>	O
cephalosporin	B-Drug
are	O
most	O
likely	O
associated	O
with	O
vitamin	B-ADR
k	I-ADR
deficiency	I-ADR
0	O
<EOS>	O
coagulopathy	B-ADR
associated	O
with	O
the	O
use	O
of	O
cephalosporin	B-Drug
or	O
moxalactam	O
antibiotic	O
in	O
acute	O
and	O
chronic	O
renal	O
failure	O
0	O
<EOS>	O
coagulopathy	B-ADR
associated	O
with	O
the	O
use	O
of	O
cephalosporin	O
or	O
moxalactam	B-Drug
antibiotic	O
in	O
acute	O
and	O
chronic	O
renal	O
failure	O
0	O
<EOS>	O
moxalactam	B-Drug
is	O
more	O
likely	O
to	O
be	O
associated	O
with	O
platelet	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
nevertheless	O
,	O
the	O
coagulopathy	B-ADR
seemed	O
to	O
be	O
most	O
closely	O
associated	O
with	O
the	O
administration	O
of	O
the	O
cephalosporin	B-Drug
0	O
<EOS>	O
nine	O
azotemic	O
patient	O
who	O
developed	O
a	O
coagulopathy	B-ADR
associated	O
with	O
the	O
use	O
of	O
either	O
cephalosporin	B-Drug
or	O
moxalactam	O
antibiotic	O
are	O
reported	O
0	O
<EOS>	O
nine	O
azotemic	O
patient	O
who	O
developed	O
a	O
coagulopathy	B-ADR
associated	O
with	O
the	O
use	O
of	O
either	O
cephalosporin	O
or	O
moxalactam	B-Drug
antibiotic	O
are	O
reported	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
a	O
child	O
with	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
following	O
bcnu	B-Drug
therapy	O
0	O
<EOS>	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
following	O
1,3-bis	B-Drug
(	I-Drug
2-chloroethyl	I-Drug
)	I-Drug
-1-nitrosourea	I-Drug
(	O
bcnu	O
)	O
therapy	O
0	O
<EOS>	O
fatal	B-ADR
pulmonary	I-ADR
fibrosis	I-ADR
following	O
1,3-bis	O
(	O
2-chloroethyl	O
)	O
-1-nitrosourea	O
(	O
bcnu	B-Drug
)	O
therapy	O
0	O
<EOS>	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
during	O
penicillamine	B-Drug
therapy	O
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
thrombotic	B-ADR
thrombocytopenic	I-ADR
purpura	I-ADR
(	O
ttp	O
)	O
developed	O
in	O
a	O
patient	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
after	O
2	O
1	O
/	O
2	O
month	O
of	O
treatment	O
with	O
penicillamine	B-Drug
0	O
<EOS>	O
thrombotic	O
thrombocytopenic	O
purpura	O
(	O
ttp	B-ADR
)	O
developed	O
in	O
a	O
patient	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
after	O
2	O
1	O
/	O
2	O
month	O
of	O
treatment	O
with	O
penicillamine	B-Drug
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
no	O
prior	O
case	O
of	O
penicillamine-induced	B-Drug
ttp	B-ADR
in	O
ra	O
have	O
been	O
reported	O
0	O
<EOS>	O
amiodarone	B-Drug
hydrochloride	I-Drug
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
ha	O
been	O
associated	O
with	O
pulmonary	O
toxicity	O
characterized	O
by	O
cough	B-ADR
,	O
dyspnea	O
and	O
diffuse	O
pulmonary	O
infiltrates	O
0	O
<EOS>	O
amiodarone	B-Drug
hydrochloride	I-Drug
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
ha	O
been	O
associated	O
with	O
pulmonary	O
toxicity	O
characterized	O
by	O
cough	O
,	O
dyspnea	O
and	O
diffuse	B-ADR
pulmonary	I-ADR
infiltrates	I-ADR
0	O
<EOS>	O
amiodarone	B-Drug
hydrochloride	I-Drug
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
ha	O
been	O
associated	O
with	O
pulmonary	O
toxicity	O
characterized	O
by	O
cough	O
,	O
dyspnea	B-ADR
and	O
diffuse	O
pulmonary	O
infiltrates	O
0	O
<EOS>	O
amiodarone	B-Drug
hydrochloride	I-Drug
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
ha	O
been	O
associated	O
with	O
pulmonary	B-ADR
toxicity	I-ADR
characterized	O
by	O
cough	O
,	O
dyspnea	O
and	O
diffuse	O
pulmonary	O
infiltrates	O
0	O
<EOS>	O
possible	O
recurrence	O
of	O
amiodarone	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
following	O
corticosteroid	O
therapy	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
recurrence	O
of	O
amiodarone	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
ha	O
not	O
been	O
reported	O
previously	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
fibrosing	B-ADR
alveolitis	I-ADR
,	O
diagnosed	O
by	O
lung	O
biopsy	O
,	O
in	O
a	O
patient	O
receiving	O
amiodarone	B-Drug
which	O
responded	O
to	O
corticosteroid	O
therapy	O
0	O
<EOS>	O
a	O
61	O
year-old	O
male	O
patient	O
developed	O
gynecomastia	B-ADR
after	O
starting	O
theophylline	B-Drug
0	O
<EOS>	O
gynecomastia	B-ADR
associated	O
with	O
theophylline	B-Drug
0	O
<EOS>	O
no	O
other	O
endogenous	O
or	O
exogenous	O
cause	O
for	O
the	O
gynecomastia	B-ADR
could	O
be	O
found	O
except	O
for	O
the	O
theophylline	B-Drug
0	O
<EOS>	O
the	O
gynecomastia	B-ADR
regressed	O
when	O
the	O
theophylline	B-Drug
wa	O
discontinued	O
0	O
<EOS>	O
parenteral-verapamil-induced	B-Drug
sustained	B-ADR
hypotension	I-ADR
0	O
<EOS>	O
the	O
incidence	O
of	O
oral-verapamil-induced	B-Drug
hypotension	B-ADR
in	O
the	O
presence	O
of	O
concomitant	O
beta-adrenergic	O
blockade	O
by	O
the	O
oral	O
route	O
is	O
quite	O
rare	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
sustained	B-ADR
hypotension	I-ADR
after	O
administration	O
of	O
parenteral	O
verapamil	B-Drug
0	O
<EOS>	O
a	O
69-year-old	O
man	O
developed	O
pure	B-ADR
red	I-ADR
cell	I-ADR
aplasia	I-ADR
after	O
taking	O
fenoprofen	B-Drug
for	O
ten	O
month	O
0	O
<EOS>	O
pure	B-ADR
red	I-ADR
cell	I-ADR
aplasia	I-ADR
associated	O
with	O
fenoprofen	B-Drug
0	O
<EOS>	O
this	O
case	O
represents	O
the	O
third	O
example	O
of	O
erythroid	B-ADR
aplasia	I-ADR
associated	O
with	O
an	O
anti-inflammatory	O
agent	O
and	O
the	O
first	O
instance	O
due	O
to	O
fenoprofen	B-Drug
0	O
<EOS>	O
drug-induced	O
psychosis	B-ADR
resulted	O
from	O
the	O
administration	O
of	O
quinacrine	B-Drug
hydrochloride	I-Drug
at	O
a	O
dosage	O
of	O
100	O
mg	O
twice	O
daily	O
for	O
the	O
treatment	O
of	O
discoid	O
lupus	O
0	O
<EOS>	O
a	O
case	O
of	O
priapism	B-ADR
associated	O
with	O
trazodone	B-Drug
is	O
described	O
0	O
<EOS>	O
priapism	B-ADR
associated	O
with	O
trazodone	B-Drug
therapy	O
:	O
case	O
report	O
0	O
<EOS>	O
charcoal	O
haemoperfusion	O
and	O
cysteamine	O
therapy	O
led	O
to	O
the	O
rapid	O
removal	O
of	O
the	O
paracetamol	B-Drug
from	O
the	O
body	O
and	O
consequently	O
prevented	O
the	O
development	O
of	O
severe	B-ADR
hepatic	I-ADR
necrosis	I-ADR
0	O
<EOS>	O
anaphylactoid	B-ADR
shock	I-ADR
,	O
disseminated	O
intravascular	O
coagulation	O
,	O
and	O
anuric	O
renal	O
failure	O
requiring	O
dialysis	O
occurred	O
in	O
a	O
patient	O
receiving	O
zomepirac	B-Drug
sodium	O
for	O
toothache	O
0	O
<EOS>	O
anaphylactoid	O
shock	O
,	O
disseminated	O
intravascular	O
coagulation	O
,	O
and	O
anuric	B-ADR
renal	I-ADR
failure	I-ADR
requiring	O
dialysis	O
occurred	O
in	O
a	O
patient	O
receiving	O
zomepirac	B-Drug
sodium	O
for	O
toothache	O
0	O
<EOS>	O
anaphylactoid	O
shock	O
,	O
disseminated	B-ADR
intravascular	I-ADR
coagulation	I-ADR
,	O
and	O
anuric	O
renal	O
failure	O
requiring	O
dialysis	O
occurred	O
in	O
a	O
patient	O
receiving	O
zomepirac	B-Drug
sodium	O
for	O
toothache	O
0	O
<EOS>	O
focal	B-ADR
renal	I-ADR
cortical	I-ADR
necrosis	I-ADR
associated	O
with	O
zomepirac	B-Drug
0	O
<EOS>	O
the	O
mechanism	O
of	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
zomepirac	B-Drug
in	O
this	O
case	O
,	O
therefore	O
,	O
remains	O
unclear	O
0	O
<EOS>	O
cimetidine-induced	B-Drug
fever	B-ADR
0	O
<EOS>	O
cimetidine	B-Drug
is	O
a	O
rare	O
cause	O
of	O
drug-induced	O
fever	B-ADR
0	O
<EOS>	O
a	O
56-year-old	O
male	O
parkinsonian	O
patient	O
developed	O
a	O
unique	O
behavioral	B-ADR
change	I-ADR
following	O
the	O
oral	O
administration	O
of	O
cinepazide	B-Drug
,	O
a	O
cerebral	O
vasodilator	O
0	O
<EOS>	O
unique	O
behavioral	B-ADR
change	I-ADR
with	O
cinepazide	B-Drug
in	O
parkinsonism	O
0	O
<EOS>	O
a	O
65-year-old	O
woman	O
,	O
in	O
the	O
intensive	O
care	O
unit	O
because	O
of	O
septic	O
shock	O
and	O
acute	O
renal	O
failure	O
,	O
had	O
a	O
small-bowel	B-ADR
obstruction	I-ADR
due	O
to	O
amphojel	B-Drug
concretion	O
0	O
<EOS>	O
a	O
patient	O
with	O
alcoholic	O
cerebellar	O
degeneration	O
had	O
periodic	B-ADR
alternating	I-ADR
nystagmus	I-ADR
during	O
a	O
period	O
of	O
phenytoin	B-Drug
intoxication	O
0	O
<EOS>	O
although	O
the	O
data	O
indicate	O
an	O
immune-complex	O
cause	O
for	O
gold-salt	B-Drug
nephropathy	B-ADR
,	O
the	O
incident	O
antigen	O
(	O
or	O
antigen	O
)	O
and	O
mechanism	O
of	O
action	O
remain	O
unidentified	O
0	O
<EOS>	O
gold	B-Drug
nephropathy	B-ADR
0	O
<EOS>	O
gold-salt	B-Drug
therapy	O
may	O
result	O
in	O
damage	B-ADR
to	I-ADR
proximal	I-ADR
tubule	I-ADR
that	O
leak	O
renal	O
tubular	O
antigen	O
,	O
which	O
in	O
turn	O
complex	O
with	O
autoantibody	O
and	O
produce	O
an	O
autoimmune	O
membranous	O
nephropathy	O
0	O
<EOS>	O
the	O
nephrotic	B-ADR
syndrome	I-ADR
developed	O
in	O
a	O
patient	O
receiving	O
therapy	O
with	O
gold	B-Drug
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
intrahepatic	O
cholestasis	O
and	O
cutaneous	B-ADR
bulla	I-ADR
associated	O
with	O
glibenclamide	B-Drug
therapy	O
are	O
described	O
in	O
a	O
61-year-old	O
diabetic	O
patient	O
who	O
presented	O
wit	O
hypoglycaemic	O
coma	O
0	O
<EOS>	O
intrahepatic	B-ADR
cholestasis	I-ADR
and	O
cutaneous	O
bulla	O
associated	O
with	O
glibenclamide	B-Drug
therapy	O
are	O
described	O
in	O
a	O
61-year-old	O
diabetic	O
patient	O
who	O
presented	O
wit	O
hypoglycaemic	O
coma	O
0	O
<EOS>	O
intrahepatic	O
cholestasis	O
and	O
cutaneous	B-ADR
bulla	I-ADR
associated	O
with	O
glibenclamide	B-Drug
therapy	O
0	O
<EOS>	O
intrahepatic	B-ADR
cholestasis	I-ADR
and	O
cutaneous	O
bulla	O
associated	O
with	O
glibenclamide	B-Drug
therapy	O
0	O
<EOS>	O
these	O
feature	O
have	O
not	O
previously	O
been	O
reported	O
a	O
side	O
effect	O
of	O
glibenclamide	O
therapy	O
,	O
but	O
intrahepatic	B-ADR
cholestasis	I-ADR
may	O
occur	O
with	O
chlorpropamide	B-Drug
,	O
a	O
similar	O
sulphonylurea	O
agent	O
0	O
<EOS>	O
in	O
four	O
patient	O
,	O
spasm	B-ADR
occurred	O
spontaneous	O
and	O
in	O
one	O
patient	O
after	O
0.05	O
mg	O
of	O
ergonovine	B-Drug
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
woman	O
with	O
chronic	O
schizophrenia	O
who	O
experienced	O
delirium	B-ADR
,	O
grand	O
mal	O
seizure	O
,	O
and	O
photosensitivity	O
after	O
the	O
addition	O
of	O
propranolol	B-Drug
to	O
her	O
neuroleptic	O
regimen	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
woman	O
with	O
chronic	O
schizophrenia	O
who	O
experienced	O
delirium	O
,	O
grand	B-ADR
mal	I-ADR
seizure	I-ADR
,	O
and	O
photosensitivity	O
after	O
the	O
addition	O
of	O
propranolol	B-Drug
to	O
her	O
neuroleptic	O
regimen	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
woman	O
with	O
chronic	O
schizophrenia	O
who	O
experienced	O
delirium	O
,	O
grand	O
mal	O
seizure	O
,	O
and	O
photosensitivity	B-ADR
after	O
the	O
addition	O
of	O
propranolol	B-Drug
to	O
her	O
neuroleptic	O
regimen	O
0	O
<EOS>	O
catatonia	B-ADR
associated	O
with	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
neurophysiological	O
mechanism	O
which	O
aid	O
in	O
elucidating	O
the	O
role	O
of	O
disulfiram	B-Drug
in	O
the	O
etiology	O
of	O
catatonia	B-ADR
are	O
discussed	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
catatonic	B-ADR
syndrome	I-ADR
occurring	O
in	O
a	O
patient	O
receiving	O
disulfiram	B-Drug
treatment	O
0	O
<EOS>	O
hepatic	B-ADR
reaction	I-ADR
to	O
cyclofenil	B-Drug
0	O
<EOS>	O
thirty	O
patient	O
with	O
hepatic	B-ADR
reaction	I-ADR
to	O
cyclofenil	B-Drug
,	O
a	O
non-steroidal	O
drug	O
with	O
a	O
stimulating	O
effect	O
on	O
ovulation	O
,	O
are	O
reviewed	O
0	O
<EOS>	O
since	O
early	O
symptom	O
of	O
the	O
toxic	O
effect	O
of	O
theophylline	B-Drug
can	O
mimic	O
peptic	B-ADR
ulcer	I-ADR
disease	I-ADR
,	O
cimetidine	O
might	O
be	O
prescribed	O
for	O
the	O
gastrointestinal	O
symptom	O
with	O
subsequent	O
worsening	O
of	O
theophylline	O
poisoning	O
0	O
<EOS>	O
a	O
case	O
of	O
siadh	B-ADR
associated	O
with	O
desipramine	B-Drug
treatment	O
in	O
an	O
elderly	O
depressed	O
woman	O
is	O
described	O
0	O
<EOS>	O
desipramine-associated	B-Drug
siadh	B-ADR
in	O
an	O
elderly	O
woman	O
:	O
case	O
report	O
0	O
<EOS>	O
prior	O
report	O
have	O
emphasized	O
the	O
tubular	B-ADR
and	I-ADR
interstitial	I-ADR
lesion	I-ADR
associated	O
with	O
intermittent	O
or	O
discontinuous	O
rifampin	B-Drug
therapy	O
for	O
tuberculosis	O
0	O
<EOS>	O
the	O
spectrum	O
of	O
renal	B-ADR
lesion	I-ADR
occurring	O
during	O
antituberculous	O
therapy	O
,	O
particularly	O
in	O
association	O
with	O
rifampin	B-Drug
,	O
may	O
be	O
wider	O
than	O
previously	O
suspected	O
0	O
<EOS>	O
within	O
3	O
week	O
of	O
beginning	O
continuous	O
daily	O
isoniazid	B-Drug
and	O
rifampin	O
therapy	O
for	O
pulmonary	O
tuberculosis	O
,	O
a	O
patient	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
within	O
3	O
week	O
of	O
beginning	O
continuous	O
daily	O
isoniazid	O
and	O
rifampin	B-Drug
therapy	O
for	O
pulmonary	O
tuberculosis	O
,	O
a	O
patient	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
nephrotic	B-ADR
range	I-ADR
pseudoproteinuria	I-ADR
in	O
a	O
tolmetin-treated	B-Drug
patient	O
0	O
<EOS>	O
when	O
tuberculosis	O
patient	O
on	O
isoniazid	B-Drug
eat	O
certain	O
variety	O
of	O
fish	O
they	O
may	O
develop	O
a	O
histamine	B-ADR
reaction	I-ADR
0	O
<EOS>	O
fulminant	B-ADR
hepatitis	I-ADR
associated	O
with	O
disulfiram	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
fatal	B-ADR
fulminant	I-ADR
hepatitis	I-ADR
caused	O
by	O
the	O
use	O
of	O
disulfiram	B-Drug
in	O
a	O
man	O
with	O
previously	O
normal	O
hepatocellular	O
function	O
0	O
<EOS>	O
a	O
45-year-old	O
woman	O
with	O
thyrotoxicosis	O
developed	O
agranulocytosis	B-ADR
after	O
treatment	O
with	O
propylthiouracil	B-Drug
0	O
<EOS>	O
the	O
patient	O
wa	O
given	O
methimazole	B-Drug
instead	O
of	O
propylthiouracil	O
but	O
,	O
10	O
week	O
later	O
,	O
agranulocytosis	B-ADR
again	O
occurred	O
0	O
<EOS>	O
this	O
is	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
first	O
report	O
of	O
a	O
case	O
in	O
which	O
agranulocytosis	B-ADR
followed	O
treatment	O
with	O
both	O
propylthiouracil	O
and	O
methimazole	B-Drug
in	O
the	O
same	O
patient	O
0	O
<EOS>	O
this	O
is	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
first	O
report	O
of	O
a	O
case	O
in	O
which	O
agranulocytosis	B-ADR
followed	O
treatment	O
with	O
both	O
propylthiouracil	B-Drug
and	O
methimazole	O
in	O
the	O
same	O
patient	O
0	O
<EOS>	O
a	O
55-yr-old	O
man	O
developed	O
prolonged	B-ADR
jaundice	I-ADR
and	O
sicca	O
complex	O
after	O
a	O
course	O
of	O
thiabendazole	B-Drug
therapy	O
0	O
<EOS>	O
a	O
55-yr-old	O
man	O
developed	O
prolonged	O
jaundice	O
and	O
sicca	B-ADR
complex	I-ADR
after	O
a	O
course	O
of	O
thiabendazole	B-Drug
therapy	O
0	O
<EOS>	O
intrahepatic	B-ADR
cholestasis	I-ADR
and	O
sicca	O
complex	O
after	O
thiabendazole	B-Drug
0	O
<EOS>	O
intrahepatic	O
cholestasis	O
and	O
sicca	B-ADR
complex	I-ADR
after	O
thiabendazole	B-Drug
0	O
<EOS>	O
the	O
literature	O
on	O
thiabendazole-induced	B-Drug
cholestasis	B-ADR
and	O
it	O
association	O
with	O
sicca	O
complex	O
is	O
reviewed	O
0	O
<EOS>	O
the	O
literature	O
on	O
thiabendazole-induced	B-Drug
cholestasis	O
and	O
it	O
association	O
with	O
sicca	B-ADR
complex	I-ADR
is	O
reviewed	O
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	B-Drug
(	O
doxorubicin	O
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	O
of	O
adriamycin	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	B-Drug
(	O
doxorubicin	O
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	O
of	O
adriamycin	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	O
(	O
doxorubicin	B-Drug
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	O
of	O
adriamycin	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	B-Drug
(	O
doxorubicin	O
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	B-ADR
of	O
adriamycin	O
toxicity	O
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	B-Drug
(	O
doxorubicin	O
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	B-ADR
of	O
adriamycin	O
toxicity	O
0	O
<EOS>	O
she	O
wa	O
placed	O
on	O
adjuvant	O
adriamycin	O
(	O
doxorubicin	B-Drug
)	O
chemotherapy	O
,	O
but	O
6	O
month	O
later	O
died	B-ADR
of	O
adriamycin	O
toxicity	O
0	O
<EOS>	O
intracranial	O
hemorrhage	O
and	O
focal	B-ADR
seizure	I-ADR
secondary	O
to	O
use	O
of	O
l-asparaginase	B-Drug
during	O
induction	O
therapy	O
of	O
acute	O
lymphocytic	O
leukemia	O
0	O
<EOS>	O
intracranial	B-ADR
hemorrhage	I-ADR
and	O
focal	O
seizure	O
secondary	O
to	O
use	O
of	O
l-asparaginase	B-Drug
during	O
induction	O
therapy	O
of	O
acute	O
lymphocytic	O
leukemia	O
0	O
<EOS>	O
dural	B-ADR
sinus	I-ADR
thrombosis	I-ADR
developed	O
in	O
two	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
during	O
induction	O
treatment	O
with	O
vincristine	O
sulfate	O
,	O
prednisone	O
,	O
and	O
asparaginase	B-Drug
0	O
<EOS>	O
dural	B-ADR
sinus	I-ADR
thrombosis	I-ADR
developed	O
in	O
two	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
during	O
induction	O
treatment	O
with	O
vincristine	O
sulfate	O
,	O
prednisone	B-Drug
,	O
and	O
asparaginase	O
0	O
<EOS>	O
dural	B-ADR
sinus	I-ADR
thrombosis	I-ADR
developed	O
in	O
two	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
during	O
induction	O
treatment	O
with	O
vincristine	B-Drug
sulfate	I-Drug
,	O
prednisone	O
,	O
and	O
asparaginase	O
0	O
<EOS>	O
the	O
cause	O
is	O
presumed	O
to	O
be	O
secondary	O
to	O
hypercoagulability	O
due	O
to	O
asparaginase-induced	B-Drug
antithrombin	B-ADR
iii	I-ADR
deficiency	I-ADR
0	O
<EOS>	O
six	O
patient	O
with	O
rheumatoid	O
arthritis	O
developed	O
a	O
syndrome	O
resembling	O
lupus	B-ADR
erythematosus	I-ADR
while	O
being	O
treated	O
with	O
penicillamine	B-Drug
0	O
<EOS>	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
during	O
penicillamine	B-Drug
therapy	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
however	O
,	O
the	O
amount	O
of	O
prednisone	B-Drug
required	O
to	O
maintain	O
normotension	O
resulted	O
in	O
cushingoid	B-ADR
feature	I-ADR
and	O
ha	O
been	O
discontinued	O
0	O
<EOS>	O
clinician	O
should	O
be	O
aware	O
of	O
fasting	B-ADR
hypoglycemia	I-ADR
a	O
an	O
unusual	O
but	O
potentially	O
serious	O
complication	O
of	O
disopyramide	B-Drug
therapy	O
0	O
<EOS>	O
disopyramide	B-Drug
(	O
norpace	O
)	O
-induced	O
hypoglycemia	B-ADR
0	O
<EOS>	O
disopyramide	O
(	O
norpace	B-Drug
)	O
-induced	O
hypoglycemia	B-ADR
0	O
<EOS>	O
cefoxitin-associated	B-Drug
renal	B-ADR
failure	I-ADR
0	O
<EOS>	O
the	O
other	O
woman	O
had	O
rheumatoid	O
arthritis	O
and	O
developed	O
acute	B-ADR
tubular	I-ADR
necrosis	I-ADR
after	O
treatment	O
with	O
gentamicin	O
and	O
cefoxitin	B-Drug
0	O
<EOS>	O
the	O
other	O
woman	O
had	O
rheumatoid	O
arthritis	O
and	O
developed	O
acute	B-ADR
tubular	I-ADR
necrosis	I-ADR
after	O
treatment	O
with	O
gentamicin	B-Drug
and	O
cefoxitin	O
0	O
<EOS>	O
two	O
elderly	O
woman	O
suffered	O
an	O
acute	B-ADR
deterioration	I-ADR
of	I-ADR
renal	I-ADR
function	I-ADR
after	O
treatment	O
with	O
cefoxitin	B-Drug
sodium	I-Drug
0	O
<EOS>	O
transient	B-ADR
anuria	I-ADR
following	O
administration	O
of	O
angiotensin	O
i-converting	O
enzyme	O
inhibitor	O
(	O
sq	B-Drug
14225	I-Drug
)	O
in	O
a	O
patient	O
with	O
renal	O
artery	O
stenosis	O
of	O
the	O
solitary	O
kidney	O
successfully	O
treated	O
with	O
renal	O
autotransplantation	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
renal	O
artery	O
stenosis	O
who	O
had	O
only	O
1	O
kidney	O
and	O
in	O
whom	O
acute	B-ADR
renal	I-ADR
impairment	I-ADR
developed	O
with	O
transient	O
anuria	O
after	O
the	O
administration	O
of	O
captopril	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
renal	O
artery	O
stenosis	O
who	O
had	O
only	O
1	O
kidney	O
and	O
in	O
whom	O
acute	O
renal	O
impairment	O
developed	O
with	O
transient	B-ADR
anuria	I-ADR
after	O
the	O
administration	O
of	O
captopril	B-Drug
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	B-Drug
,	O
disopyramide	O
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
(	O
avt	O
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	B-Drug
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
(	O
avt	O
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	O
,	O
and	O
quinidine	B-Drug
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
(	O
avt	O
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	B-Drug
,	O
disopyramide	O
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	B-ADR
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	B-Drug
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	B-ADR
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	O
,	O
and	O
quinidine	B-Drug
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	B-ADR
,	O
torsade	O
de	O
pointes	O
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	B-Drug
,	O
disopyramide	O
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	O
,	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	B-Drug
,	O
and	O
quinidine	O
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	O
,	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
)	O
0	O
<EOS>	O
a	O
44-year-old	O
woman	O
is	O
described	O
in	O
whom	O
amiodarone	O
,	O
disopyramide	O
,	O
and	O
quinidine	B-Drug
,	O
administered	O
alone	O
separately	O
,	O
induced	O
atypical	O
ventricular	O
tachycardia	O
(	O
avt	O
,	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
)	O
0	O
<EOS>	O
amiodarone	B-Drug
wa	O
the	O
third	O
drug	O
to	O
induce	O
avt	B-ADR
in	O
this	O
patient	O
;	O
she	O
received	O
200	O
mg	O
/	O
day	O
six	O
day	O
per	O
week	O
for	O
six	O
month	O
0	O
<EOS>	O
atypical	O
ventricular	O
tachycardia	O
(	O
torsade	O
de	O
pointes	O
)	O
induced	O
by	O
amiodarone	O
:	O
arrhythmia	B-ADR
previously	O
induced	O
by	O
quinidine	O
and	O
disopyramide	B-Drug
0	O
<EOS>	O
atypical	O
ventricular	O
tachycardia	O
(	O
torsade	O
de	O
pointes	O
)	O
induced	O
by	O
amiodarone	O
:	O
arrhythmia	B-ADR
previously	O
induced	O
by	O
quinidine	B-Drug
and	O
disopyramide	O
0	O
<EOS>	O
atypical	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
(	O
torsade	O
de	O
pointes	O
)	O
induced	O
by	O
amiodarone	B-Drug
:	O
arrhythmia	O
previously	O
induced	O
by	O
quinidine	O
and	O
disopyramide	O
0	O
<EOS>	O
atypical	O
ventricular	O
tachycardia	O
(	O
torsade	B-ADR
de	I-ADR
pointes	I-ADR
)	O
induced	O
by	O
amiodarone	B-Drug
:	O
arrhythmia	O
previously	O
induced	O
by	O
quinidine	O
and	O
disopyramide	O
0	O
<EOS>	O
two	O
year	O
later	O
,	O
24	O
hour	O
following	O
an	O
increase	O
in	O
the	O
dose	O
of	O
disopyramide	B-Drug
from	O
300	O
to	O
600	O
mg	O
/	O
day	O
,	O
avt	B-ADR
with	O
syncope	O
occurred	O
;	O
isoproterenol	O
abolished	O
the	O
arrhythmia	O
instantly	O
0	O
<EOS>	O
two	O
year	O
later	O
,	O
24	O
hour	O
following	O
an	O
increase	O
in	O
the	O
dose	O
of	O
disopyramide	B-Drug
from	O
300	O
to	O
600	O
mg	O
/	O
day	O
,	O
avt	O
with	O
syncope	B-ADR
occurred	O
;	O
isoproterenol	O
abolished	O
the	O
arrhythmia	O
instantly	O
0	O
<EOS>	O
although	O
the	O
existence	O
of	O
an	O
acute	O
pericarditis	O
or	O
an	O
acute	O
myocarditis	O
a	O
possible	O
cause	O
of	O
the	O
st	O
elevation	O
can	O
not	O
be	O
fully	O
ruled	O
out	O
,	O
the	O
sudden	O
onset	O
,	O
prominent	O
magnitude	O
,	O
and	O
brief	O
duration	O
of	O
the	O
st	O
elevation	O
are	O
perhaps	O
more	O
indicative	O
of	O
an	O
acute	O
ischemic	O
event	O
,	O
possibly	O
related	O
to	O
a	O
transient	O
coronary	B-ADR
vasoconstriction	I-ADR
induced	O
by	O
the	O
dopamine	B-Drug
infusion	O
0	O
<EOS>	O
complete	O
remission	O
of	O
the	O
nephrosis	B-ADR
occurred	O
after	O
discontinuation	O
of	O
hydroxychloroquine	B-Drug
therapy	O
0	O
<EOS>	O
hepatitis	B-ADR
following	O
cimetidine	B-Drug
administration	O
0	O
<EOS>	O
the	O
case	O
of	O
an	O
adult	O
who	O
developed	O
both	O
hepatic	B-ADR
dysfunction	I-ADR
and	O
an	O
impaired	O
macrophage	O
migration	O
after	O
exposure	O
to	O
cimetidine	B-Drug
is	O
discussed	O
0	O
<EOS>	O
the	O
case	O
of	O
an	O
adult	O
who	O
developed	O
both	O
hepatic	O
dysfunction	O
and	O
an	O
impaired	B-ADR
macrophage	I-ADR
migration	I-ADR
after	O
exposure	O
to	O
cimetidine	B-Drug
is	O
discussed	O
0	O
<EOS>	O
there	O
have	O
been	O
only	O
two	O
report	O
of	O
cimetidine-induced	B-Drug
hepatitis	B-ADR
0	O
<EOS>	O
a	O
66-year-old	O
mand	O
suffering	O
from	O
severe	O
coronary	O
heart	O
disease	O
took	O
digoxin	B-Drug
with	O
suicidal	O
intent	O
an	O
wa	O
treated	O
for	O
the	O
ensuing	O
complete	B-ADR
atrioventricular	I-ADR
block	I-ADR
with	O
digoxin-specific	O
antibody	O
fragment	O
0	O
<EOS>	O
verapamil	B-Drug
in	O
effort-induced	O
angina	B-ADR
pectoris	I-ADR
in	O
patient	O
with	O
normal	O
coronary	O
artery	O
0	O
<EOS>	O
flucytosine-associated	B-Drug
diarrhea	B-ADR
ha	O
been	O
previously	O
described	O
in	O
6	O
%	O
-10	O
%	O
of	O
patient	O
receiving	O
the	O
drug	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
flucytosine-associated	B-Drug
ulcerating	O
enteritis	O
in	O
which	O
the	O
small	O
bowel	O
x-ray	O
demonstrated	O
severe	O
luminal	O
narrowing	O
,	O
ulceration	O
,	O
and	O
marked	B-ADR
separation	I-ADR
of	I-ADR
loop	I-ADR
of	I-ADR
bowel	I-ADR
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
flucytosine-associated	B-Drug
ulcerating	O
enteritis	O
in	O
which	O
the	O
small	O
bowel	O
x-ray	O
demonstrated	O
severe	B-ADR
luminal	I-ADR
narrowing	I-ADR
,	O
ulceration	O
,	O
and	O
marked	O
separation	O
of	O
loop	O
of	O
bowel	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
flucytosine-associated	B-Drug
ulcerating	B-ADR
enteritis	I-ADR
in	O
which	O
the	O
small	O
bowel	O
x-ray	O
demonstrated	O
severe	O
luminal	O
narrowing	O
,	O
ulceration	O
,	O
and	O
marked	O
separation	O
of	O
loop	O
of	O
bowel	O
0	O
<EOS>	O
this	O
report	O
describes	O
a	O
case	O
of	O
flucytosine-associated	B-Drug
ulcerating	O
enteritis	O
in	O
which	O
the	O
small	O
bowel	O
x-ray	O
demonstrated	O
severe	O
luminal	O
narrowing	O
,	O
ulceration	B-ADR
,	O
and	O
marked	O
separation	O
of	O
loop	O
of	O
bowel	O
0	O
<EOS>	O
ulcerating	B-ADR
enteritis	I-ADR
associated	O
with	O
flucytosine	B-Drug
therapy	O
0	O
<EOS>	O
papilledema	B-ADR
without	O
peripheral	O
neuropathy	O
in	O
a	O
patient	O
taking	O
perhexiline	B-Drug
maleate	I-Drug
0	O
<EOS>	O
an	O
adolescent	O
male	O
developed	O
acute	B-ADR
pancreatitis	I-ADR
and	O
pseudocyst	O
of	O
the	O
pancreas	O
16	O
week	O
after	O
cessation	O
of	O
intramuscular	O
l-asparaginase	B-Drug
0	O
<EOS>	O
an	O
adolescent	O
male	O
developed	O
acute	O
pancreatitis	O
and	O
pseudocyst	B-ADR
of	I-ADR
the	I-ADR
pancreas	I-ADR
16	O
week	O
after	O
cessation	O
of	O
intramuscular	O
l-asparaginase	B-Drug
0	O
<EOS>	O
delayed	B-ADR
pseudocyst	I-ADR
of	I-ADR
the	I-ADR
pancreas	I-ADR
can	O
be	O
a	O
complication	O
of	O
intramuscular	O
l-asparaginase	B-Drug
0	O
<EOS>	O
l-asparaginase-induced	B-Drug
pancreatitis	B-ADR
ha	O
been	O
reported	O
during	O
or	O
closely	O
following	O
administration	O
of	O
the	O
drug	O
0	O
<EOS>	O
three	O
case	O
of	O
pseudocyst	B-ADR
of	I-ADR
the	I-ADR
pancreas	I-ADR
in	O
two	O
woman	O
and	O
one	O
man	O
have	O
previously	O
been	O
reported	O
with	O
the	O
use	O
of	O
intravenous	O
l-asparaginase	B-Drug
0	O
<EOS>	O
in	O
one	O
patient	O
,	O
treatment	O
with	O
dca	B-Drug
wa	O
associated	O
with	O
a	O
decrease	B-ADR
in	I-ADR
blood	I-ADR
lactate	I-ADR
level	I-ADR
from	O
11.2	O
mm	O
before	O
treatment	O
to	O
0.8	O
mm	O
16	O
h	O
later	O
0	O
<EOS>	O
nine	O
delirious	B-ADR
patient	O
suffering	O
from	O
lithium	B-Drug
intoxication	O
were	O
examined	O
with	O
the	O
mini-mental	O
state	O
exam	O
(	O
mm	O
)	O
to	O
describe	O
the	O
clinical	O
course	O
of	O
the	O
disorder	O
0	O
<EOS>	O
the	O
course	O
of	O
delirium	B-ADR
due	O
to	O
lithium	B-Drug
intoxication	O
0	O
<EOS>	O
life-threatening	O
hyperkalemia	B-ADR
induced	O
by	O
arginine	B-Drug
0	O
<EOS>	O
marked	B-ADR
hyperkalemia	I-ADR
wa	O
observed	O
during	O
and	O
immediately	O
after	O
an	O
infusion	O
of	O
arginine	B-Drug
monohydrochloride	I-Drug
in	O
two	O
patient	O
with	O
severe	O
hepatic	O
disease	O
and	O
moderate	O
renal	O
insufficiency	O
0	O
<EOS>	O
a	O
58-year-old	O
man	O
with	O
rheumatoid	O
arthritis	O
developed	O
lichen	B-ADR
planus	I-ADR
during	O
treatment	O
with	O
gold	B-Drug
0	O
<EOS>	O
acne	B-ADR
provoked	O
by	O
gold	B-Drug
seems	O
not	O
to	O
have	O
been	O
described	O
elsewhere	O
0	O
<EOS>	O
lichen	O
planus	O
and	O
acne	B-ADR
provoked	O
by	O
gold	B-Drug
0	O
<EOS>	O
lichen	B-ADR
planus	I-ADR
and	O
acne	O
provoked	O
by	O
gold	B-Drug
0	O
<EOS>	O
the	O
case	O
history	O
confirms	O
that	O
gold	B-Drug
treatment	O
,	O
even	O
in	O
the	O
same	O
patient	O
,	O
can	O
give	O
rise	O
to	O
a	O
wide	O
range	O
of	O
skin	B-ADR
disturbance	I-ADR
,	O
which	O
in	O
many	O
case	O
do	O
not	O
break	O
out	O
until	O
long	O
after	O
the	O
drug	O
ha	O
been	O
withdrawn	O
0	O
<EOS>	O
secondary	O
hyperparathyroidism	O
in	O
certain	O
patient	O
with	O
lithium	B-Drug
nephrotoxicity	B-ADR
is	O
also	O
possible	O
0	O
<EOS>	O
secondary	B-ADR
hyperparathyroidism	I-ADR
in	O
certain	O
patient	O
with	O
lithium	B-Drug
nephrotoxicity	O
is	O
also	O
possible	O
0	O
<EOS>	O
these	O
result	O
indicate	O
that	O
lithium	B-Drug
may	O
cause	O
biochemical	B-ADR
hyperparathyroidism	I-ADR
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
with	O
right	O
bundle	O
branch	O
block	O
+lph	O
and	O
ventricular	O
premature	O
contraction	O
developed	O
complete	O
heart	O
block	O
(	O
chb	B-ADR
)	O
following	O
administration	O
of	O
disopyramide	B-Drug
phosphate	I-Drug
(	O
norpace	O
)	O
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
with	O
right	O
bundle	O
branch	O
block	O
+lph	O
and	O
ventricular	O
premature	O
contraction	O
developed	O
complete	O
heart	O
block	O
(	O
chb	B-ADR
)	O
following	O
administration	O
of	O
disopyramide	O
phosphate	O
(	O
norpace	B-Drug
)	O
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
with	O
right	O
bundle	O
branch	O
block	O
+lph	O
and	O
ventricular	O
premature	O
contraction	O
developed	O
complete	B-ADR
heart	I-ADR
block	I-ADR
(	O
chb	O
)	O
following	O
administration	O
of	O
disopyramide	B-Drug
phosphate	I-Drug
(	O
norpace	O
)	O
0	O
<EOS>	O
a	O
57-year-old	O
woman	O
with	O
right	O
bundle	O
branch	O
block	O
+lph	O
and	O
ventricular	O
premature	O
contraction	O
developed	O
complete	B-ADR
heart	I-ADR
block	I-ADR
(	O
chb	O
)	O
following	O
administration	O
of	O
disopyramide	O
phosphate	O
(	O
norpace	B-Drug
)	O
0	O
<EOS>	O
disopyramide-induced	B-Drug
heart	B-ADR
block	I-ADR
0	O
<EOS>	O
although	O
transient	O
increase	O
in	O
ectopy	O
after	O
bretylium	B-Drug
therapy	O
have	O
been	O
described	O
,	O
presumably	O
due	O
to	O
catecholamine	O
release	O
,	O
the	O
occurrence	O
of	O
life-threatening	O
ventricular	O
arrhythmia	O
leading	O
to	O
cardiac	B-ADR
arrest	I-ADR
ha	O
not	O
previously	O
been	O
emphasized	O
0	O
<EOS>	O
although	O
transient	O
increase	O
in	O
ectopy	O
after	O
bretylium	B-Drug
therapy	O
have	O
been	O
described	O
,	O
presumably	O
due	O
to	O
catecholamine	O
release	O
,	O
the	O
occurrence	O
of	O
life-threatening	O
ventricular	B-ADR
arrhythmia	I-ADR
leading	O
to	O
cardiac	O
arrest	O
ha	O
not	O
previously	O
been	O
emphasized	O
0	O
<EOS>	O
in	O
the	O
first	O
patient	O
,	O
two	O
episode	O
of	O
ventricular	B-ADR
tachycardia	I-ADR
requiring	O
cardioversion	O
occurred	O
in	O
close	O
temporal	O
sequence	O
with	O
administering	O
bretylium	B-Drug
0	O
<EOS>	O
in	O
the	O
second	O
case	O
,	O
five	O
cardiac	B-ADR
arrest	I-ADR
due	O
to	O
ventricular	O
tachycardia	O
and	O
fibrillation	O
occurred	O
during	O
several	O
hour	O
after	O
beginning	O
a	O
trial	O
of	O
bretylium	B-Drug
maintenance	O
therapy	O
for	O
complex	O
ventricular	O
ectopy	O
0	O
<EOS>	O
in	O
the	O
second	O
case	O
,	O
five	O
cardiac	O
arrest	O
due	O
to	O
ventricular	O
tachycardia	O
and	O
fibrillation	B-ADR
occurred	O
during	O
several	O
hour	O
after	O
beginning	O
a	O
trial	O
of	O
bretylium	B-Drug
maintenance	O
therapy	O
for	O
complex	O
ventricular	O
ectopy	O
0	O
<EOS>	O
in	O
the	O
second	O
case	O
,	O
five	O
cardiac	O
arrest	O
due	O
to	O
ventricular	B-ADR
tachycardia	I-ADR
and	O
fibrillation	O
occurred	O
during	O
several	O
hour	O
after	O
beginning	O
a	O
trial	O
of	O
bretylium	B-Drug
maintenance	O
therapy	O
for	O
complex	O
ventricular	O
ectopy	O
0	O
<EOS>	O
paradoxical	O
ventricular	O
tachycardia	O
and	O
fibrillation	B-ADR
after	O
intravenous	O
bretylium	B-Drug
therapy	O
0	O
<EOS>	O
paradoxical	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
and	O
fibrillation	O
after	O
intravenous	O
bretylium	B-Drug
therapy	O
0	O
<EOS>	O
lithium	B-Drug
is	O
known	O
to	O
cause	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
and	O
tubulo-interstitial	O
disease	O
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	O
or	O
nephrotic	O
syndrome	O
is	O
little	O
recognized	O
0	O
<EOS>	O
lithium	B-Drug
is	O
known	O
to	O
cause	O
acute	O
renal	O
failure	O
and	O
tubulo-interstitial	O
disease	O
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	O
or	O
nephrotic	B-ADR
syndrome	I-ADR
is	O
little	O
recognized	O
0	O
<EOS>	O
lithium	B-Drug
is	O
known	O
to	O
cause	O
acute	O
renal	O
failure	O
and	O
tubulo-interstitial	O
disease	O
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	B-ADR
or	O
nephrotic	O
syndrome	O
is	O
little	O
recognized	O
0	O
<EOS>	O
lithium	B-Drug
is	O
known	O
to	O
cause	O
acute	O
renal	O
failure	O
and	O
tubulo-interstitial	B-ADR
disease	I-ADR
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	O
or	O
nephrotic	O
syndrome	O
is	O
little	O
recognized	O
0	O
<EOS>	O
nephrotic	B-ADR
syndrome	I-ADR
associated	O
with	O
lithium	B-Drug
therapy	O
0	O
<EOS>	O
two	O
patient	O
on	O
long-term	O
lithium	B-Drug
therapy	O
developed	O
the	O
nephrotic	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
a	O
67-year-old	O
man	O
developed	O
diarrhea	B-ADR
shortly	O
after	O
a	O
10-day	O
course	O
of	O
oral	O
ampicillin	B-Drug
0	O
<EOS>	O
a	O
73-year-old	O
woman	O
with	O
non-hodgkin	O
lymphoma	O
had	O
two	O
episode	O
of	O
severe	O
,	O
bilateral	O
,	O
sensori-neural	B-ADR
hearing	I-ADR
loss	I-ADR
after	O
vincristine	B-Drug
therapy	O
0	O
<EOS>	O
acute	B-ADR
acoustic	I-ADR
nerve	I-ADR
palsy	I-ADR
associated	O
with	O
vincristine	B-Drug
therapy	O
0	O
<EOS>	O
bilateral	B-ADR
acoustic	I-ADR
(	I-ADR
viii	I-ADR
)	I-ADR
nerve	I-ADR
palsy	I-ADR
in	O
this	O
patient	O
wa	O
most	O
likely	O
a	O
manifestation	O
of	O
vincristine	B-Drug
neurotoxicity	O
0	O
<EOS>	O
bilateral	O
acoustic	O
(	O
viii	O
)	O
nerve	O
palsy	O
in	O
this	O
patient	O
wa	O
most	O
likely	O
a	O
manifestation	O
of	O
vincristine	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
a	O
case	O
of	O
timolol-associated	B-Drug
heart	B-ADR
failure	I-ADR
in	O
a	O
73-year	O
old	O
white	O
man	O
is	O
reported	O
0	O
<EOS>	O
bradycardia	B-ADR
and	O
congestive	O
heart	O
failure	O
associated	O
with	O
ocular	O
timolol	B-Drug
maleate	I-Drug
0	O
<EOS>	O
bradycardia	O
and	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
associated	O
with	O
ocular	O
timolol	B-Drug
maleate	I-Drug
0	O
<EOS>	O
on	O
the	O
second	O
day	O
of	O
hospitalization	O
,	O
it	O
wa	O
noted	O
that	O
the	O
patient	O
dyspnea	B-ADR
and	O
sinus	O
bradycardia	O
could	O
be	O
related	O
to	O
a	O
recent	O
increase	O
in	O
his	O
timolol	B-Drug
dosage	O
0	O
<EOS>	O
on	O
the	O
second	O
day	O
of	O
hospitalization	O
,	O
it	O
wa	O
noted	O
that	O
the	O
patient	O
dyspnea	O
and	O
sinus	B-ADR
bradycardia	I-ADR
could	O
be	O
related	O
to	O
a	O
recent	O
increase	O
in	O
his	O
timolol	B-Drug
dosage	O
0	O
<EOS>	O
fatal	B-ADR
ventricular	I-ADR
fibrillation	I-ADR
after	O
treatment	O
with	O
digoxin	B-Drug
in	O
a	O
27-year-old	O
man	O
with	O
mitral	O
leaflet	O
prolapse	O
syndrome	O
0	O
<EOS>	O
he	O
wa	O
started	O
on	O
digoxin	B-Drug
,	O
0.25	O
mg	O
daily	O
,	O
because	O
of	O
echocardiographically	O
demonstrated	O
left	O
ventricular	O
dilatation	O
and	O
functional	B-ADR
impairment	I-ADR
;	O
he	O
died	O
of	O
ventricular	O
fibrillation	O
15	O
day	O
later	O
0	O
<EOS>	O
he	O
wa	O
started	O
on	O
digoxin	B-Drug
,	O
0.25	O
mg	O
daily	O
,	O
because	O
of	O
echocardiographically	O
demonstrated	O
left	B-ADR
ventricular	I-ADR
dilatation	I-ADR
and	O
functional	O
impairment	O
;	O
he	O
died	O
of	O
ventricular	O
fibrillation	O
15	O
day	O
later	O
0	O
<EOS>	O
he	O
wa	O
started	O
on	O
digoxin	B-Drug
,	O
0.25	O
mg	O
daily	O
,	O
because	O
of	O
echocardiographically	O
demonstrated	O
left	O
ventricular	O
dilatation	O
and	O
functional	O
impairment	O
;	O
he	O
died	O
of	O
ventricular	B-ADR
fibrillation	I-ADR
15	O
day	O
later	O
0	O
<EOS>	O
induction	O
of	O
rapid	B-ADR
mood	I-ADR
cycling	I-ADR
during	O
l-dopa	B-Drug
treatment	O
in	O
a	O
bipolar	O
patient	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
longitudinal	O
case	O
study	O
of	O
a	O
woman	O
with	O
a	O
history	O
of	O
bipolar	O
affective	O
disorder	O
in	O
which	O
l-dopa	B-Drug
shortened	B-ADR
the	I-ADR
manic-depressive	I-ADR
cycle	I-ADR
length	O
when	O
administered	O
in	O
a	O
double-blind	O
trial	O
0	O
<EOS>	O
liver	B-ADR
disease	I-ADR
induced	O
by	O
perhexiline	B-Drug
maleate	I-Drug
0	O
<EOS>	O
this	O
paper	O
report	O
a	O
case	O
of	O
fatal	B-ADR
perhexiline	B-Drug
maleate	I-Drug
liver	I-ADR
injury	I-ADR
0	O
<EOS>	O
acute	B-ADR
non-lymphocytic	I-ADR
leukemia	I-ADR
in	O
patient	O
with	O
ovarian	O
carcinoma	O
following	O
long-term	O
treatment	O
with	O
treosulfan	O
(	O
=	O
dihydroxybusulfan	B-Drug
)	O
0	O
<EOS>	O
acute	B-ADR
non-lymphocytic	I-ADR
leukemia	I-ADR
in	O
patient	O
with	O
ovarian	O
carcinoma	O
following	O
long-term	O
treatment	O
with	O
treosulfan	B-Drug
(	O
=	O
dihydroxybusulfan	O
)	O
0	O
<EOS>	O
acute	B-ADR
non-lymphocytic	I-ADR
leukemia	I-ADR
occurred	O
in	O
eight	O
woman	O
following	O
long-term	O
treatment	O
with	O
treosulfan	O
(	O
=	O
dihydroxybusulfan	B-Drug
)	O
for	O
ovarian	O
carcinoma	O
0	O
<EOS>	O
acute	B-ADR
non-lymphocytic	I-ADR
leukemia	I-ADR
occurred	O
in	O
eight	O
woman	O
following	O
long-term	O
treatment	O
with	O
treosulfan	B-Drug
(	O
=	O
dihydroxybusulfan	O
)	O
for	O
ovarian	O
carcinoma	O
0	O
<EOS>	O
seven	O
of	O
the	O
eight	O
case	O
of	O
acute	B-ADR
leukemia	I-ADR
occurred	O
in	O
a	O
series	O
of	O
553	O
patient	O
treated	O
with	O
treosulfan	B-Drug
for	O
ovarian	O
cancer	O
in	O
the	O
period	O
from	O
1970	O
to	O
1977	O
and	O
followed	O
closely	O
for	O
a	O
total	O
of	O
1159	O
patient-years	O
up	O
to	O
february	O
1978	O
0	O
<EOS>	O
the	O
probability	O
of	O
developing	O
acute	B-ADR
leukemia	I-ADR
in	O
this	O
study	O
wa	O
not	O
significantly	O
correlated	O
to	O
the	O
total	O
cumulative	O
dosage	O
of	O
treosulfan	B-Drug
0	O
<EOS>	O
propranolol-related	B-Drug
bronchospasm	B-ADR
in	O
patient	O
without	O
history	O
of	O
asthma	O
0	O
<EOS>	O
regardless	O
of	O
a	O
negative	O
history	O
of	O
asthma	O
,	O
therefore	O
,	O
life-threatening	O
bronchospasm	B-ADR
must	O
be	O
considered	O
a	O
possible	O
complication	O
of	O
propranolol	B-Drug
therapy	O
0	O
<EOS>	O
since	O
the	O
bronchospasm	B-ADR
wa	O
relieved	O
with	O
discontinuation	O
of	O
propranolol	B-Drug
and	O
supportive	O
bronchodilator	O
therapy	O
,	O
the	O
bronchospasm	O
wa	O
believed	O
to	O
be	O
caused	O
by	O
propranolol	O
0	O
<EOS>	O
since	O
the	O
bronchospasm	B-ADR
wa	O
relieved	O
with	O
discontinuation	O
of	O
propranolol	B-Drug
and	O
supportive	O
bronchodilator	O
therapy	O
,	O
the	O
bronchospasm	O
wa	O
believed	O
to	O
be	O
caused	O
by	O
propranolol	O
0	O
<EOS>	O
three	O
patient	O
with	O
no	O
history	O
of	O
asthma	O
or	O
allergy	O
developed	O
bronchospasm	B-ADR
while	O
taking	O
propranolol	B-Drug
for	O
hypertension	O
0	O
<EOS>	O
propranolol	B-Drug
:	O
an	O
unrecognized	O
cause	O
of	O
central	B-ADR
nervous	I-ADR
system	I-ADR
dysfunction	I-ADR
in	O
patient	O
undergoing	O
cardiopulmonary	O
bypass	O
0	O
<EOS>	O
the	O
potential	O
role	O
of	O
propranolol	B-Drug
in	O
inducing	O
central	B-ADR
nervous	I-ADR
system	I-ADR
disturbance	I-ADR
is	O
emphasized	O
,	O
and	O
the	O
literature	O
on	O
the	O
subject	O
is	O
reviewed	O
0	O
<EOS>	O
interstitial	B-ADR
fibrosis	I-ADR
of	I-ADR
the	I-ADR
lung	I-ADR
is	O
a	O
potential	O
complication	O
of	O
methotrexate	B-Drug
therapy	O
for	O
psoriasis	O
0	O
<EOS>	O
progressive	B-ADR
interstitial	I-ADR
fibrosis	I-ADR
with	O
roentgenographic	O
honeycombing	O
developed	O
in	O
the	O
case	O
of	O
a	O
psoriatic	O
patient	O
who	O
had	O
been	O
on	O
a	O
regimen	O
of	O
methotrexate	B-Drug
for	O
18	O
year	O
0	O
<EOS>	O
progressive	B-ADR
interstitial	I-ADR
lung	I-ADR
disease	I-ADR
from	O
prolonged	O
methotrexate	B-Drug
therapy	O
0	O
<EOS>	O
abnormality	B-ADR
of	I-ADR
the	I-ADR
pupil	I-ADR
and	O
visual-evoked	O
potential	O
in	O
quinine	B-Drug
amblyopia	O
0	O
<EOS>	O
abnormality	O
of	O
the	O
pupil	O
and	O
visual-evoked	O
potential	O
in	O
quinine	B-Drug
amblyopia	B-ADR
0	O
<EOS>	O
a	O
transient	O
tonic	O
pupillary	O
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	B-ADR
visual-evoked	I-ADR
potential	I-ADR
in	O
quinine	B-Drug
toxicity	O
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
a	O
transient	O
tonic	O
pupillary	O
response	O
,	O
denervation	B-ADR
supersensitivity	I-ADR
,	O
and	O
abnormal	O
visual-evoked	O
potential	O
in	O
quinine	B-Drug
toxicity	O
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
a	O
transient	B-ADR
tonic	I-ADR
pupillary	I-ADR
response	I-ADR
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual-evoked	O
potential	O
in	O
quinine	B-Drug
toxicity	O
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
0	O
<EOS>	O
total	O
blindness	O
with	O
a	O
transient	O
tonic	O
pupillary	O
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	B-ADR
visual-evoked	I-ADR
potential	I-ADR
developed	O
in	O
a	O
54-year-old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-Drug
sulfate	I-Drug
for	O
leg	O
cramp	O
0	O
<EOS>	O
total	O
blindness	O
with	O
a	O
transient	O
tonic	O
pupillary	O
response	O
,	O
denervation	B-ADR
supersensitivity	I-ADR
,	O
and	O
abnormal	O
visual-evoked	O
potential	O
developed	O
in	O
a	O
54-year-old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-Drug
sulfate	I-Drug
for	O
leg	O
cramp	O
0	O
<EOS>	O
total	B-ADR
blindness	I-ADR
with	I-ADR
a	I-ADR
transient	I-ADR
tonic	I-ADR
pupillary	I-ADR
response	I-ADR
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual-evoked	O
potential	O
developed	O
in	O
a	O
54-year-old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-Drug
sulfate	I-Drug
for	O
leg	O
cramp	O
0	O
<EOS>	O
diagnosis	O
:	O
practolol	B-Drug
induced	O
sclerosing	B-ADR
peritonitis	I-ADR
0	O
<EOS>	O
a	O
case	O
of	O
skeletal	B-ADR
fluorosis	I-ADR
induced	O
by	O
prolonged	O
treatment	O
with	O
niflumic	B-Drug
acid	I-Drug
,	O
a	O
fast-acting	O
non-steroid	O
antiinflammatory	O
agent	O
,	O
is	O
reported	O
in	O
a	O
35-year-old	O
woman	O
suffering	O
from	O
rheumatoid	O
arthritis	O
and	O
treated	O
,	O
in	O
addition	O
,	O
with	O
corticosteroid	O
0	O
<EOS>	O
after	O
ruling	O
out	O
a	O
hydrotelluric	O
source	O
of	O
fluorine	O
,	O
the	O
patient	O
fluorosis	B-ADR
wa	O
linked	O
to	O
chronic	O
use	O
of	O
niflumic	B-Drug
acid	I-Drug
,	O
following	O
the	O
publication	O
in	O
1978	O
of	O
the	O
2	O
previously	O
reported	O
case	O
affected	O
by	O
this	O
drug	O
0	O
<EOS>	O
niflumic	B-Drug
acid-induced	I-Drug
skeletal	B-ADR
fluorosis	I-ADR
:	O
iatrogenic	O
disease	O
or	O
therapeutic	O
perspective	O
for	O
osteoporosis	O
?	O
<EOS>	O
the	O
fluorine	O
contained	O
in	O
niflumic	B-Drug
acid	I-Drug
induced	O
a	O
marked	O
densification	B-ADR
of	I-ADR
trabecular	I-ADR
bone	I-ADR
in	O
all	O
3	O
case	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
associated	O
with	O
use	O
of	O
d-penicillamine	B-Drug
in	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
these	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
suggested	O
that	O
hepatotoxicity	B-ADR
,	O
though	O
rare	O
,	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
adverse	O
reaction	O
to	O
d-penicillamine	B-Drug
0	O
<EOS>	O
two	O
patient	O
with	O
rheumatoid	O
arthritis	O
developed	O
evidence	O
of	O
hepatotoxicity	B-ADR
while	O
receiving	O
d-penicillamine	B-Drug
0	O
<EOS>	O
a	O
62-year-old	O
indian	O
with	O
diabetic	O
nephropathy	O
controlled	O
with	O
metformin	B-Drug
,	O
developed	O
miliary	B-ADR
tuberculosis	I-ADR
for	O
which	O
he	O
wa	O
treated	O
with	O
rifampicin	O
,	O
isoniazid	O
and	O
ethambutol	O
0	O
<EOS>	O
para-aminosalicylic	B-Drug
acid-induced	I-Drug
hypoglycaemia	B-ADR
in	O
a	O
patient	O
with	O
diabetic	O
nephropathy	O
0	O
<EOS>	O
the	O
induction	O
of	O
hypoglycaemia	B-ADR
with	O
pa	B-Drug
in	O
this	O
patient	O
suggests	O
a	O
potential	O
role	O
for	O
pa	O
in	O
the	O
treatment	O
of	O
diabetes	O
mellitus	O
0	O
<EOS>	O
the	O
introduction	O
of	O
para-aminosalicylic	B-Drug
acid	I-Drug
(	O
pa	O
)	O
led	O
to	O
hypoglycaemic	B-ADR
coma	I-ADR
0	O
<EOS>	O
the	O
introduction	O
of	O
para-aminosalicylic	O
acid	O
(	O
pa	B-Drug
)	O
led	O
to	O
hypoglycaemic	B-ADR
coma	I-ADR
0	O
<EOS>	O
a	O
patient	O
developed	O
papilloedema	O
and	O
hepatic	B-ADR
dysfunction	I-ADR
while	O
being	O
treated	O
with	O
perhexiline	B-Drug
maleate	I-Drug
0	O
<EOS>	O
a	O
patient	O
developed	O
papilloedema	B-ADR
and	O
hepatic	O
dysfunction	O
while	O
being	O
treated	O
with	O
perhexiline	B-Drug
maleate	I-Drug
0	O
<EOS>	O
papilloedema	O
and	O
hepatic	B-ADR
dysfunction	I-ADR
apparently	O
induced	O
by	O
perhexiline	B-Drug
maleate	I-Drug
(	O
pexid	O
)	O
0	O
<EOS>	O
papilloedema	O
and	O
hepatic	B-ADR
dysfunction	I-ADR
apparently	O
induced	O
by	O
perhexiline	O
maleate	O
(	O
pexid	B-Drug
)	O
0	O
<EOS>	O
papilloedema	B-ADR
and	O
hepatic	O
dysfunction	O
apparently	O
induced	O
by	O
perhexiline	B-Drug
maleate	I-Drug
(	O
pexid	O
)	O
0	O
<EOS>	O
papilloedema	B-ADR
and	O
hepatic	O
dysfunction	O
apparently	O
induced	O
by	O
perhexiline	O
maleate	O
(	O
pexid	B-Drug
)	O
0	O
<EOS>	O
markedly	O
increased	B-ADR
pigmementation	I-ADR
of	I-ADR
skin	I-ADR
immediately	O
overlying	O
vein	O
used	O
for	O
multiple	O
5-fluorouracil	B-Drug
infusion	O
wa	O
noted	O
0	O
<EOS>	O
unusual	O
pigmentary	B-ADR
change	I-ADR
associated	O
with	O
5-fluorouracil	B-Drug
therapy	O
0	O
<EOS>	O
although	O
useful	O
in	O
the	O
management	O
of	O
chronic	O
alcoholism	O
,	O
disulfiram	B-Drug
is	O
being	O
increasingly	O
associated	O
with	O
a	O
wide	O
spectrum	O
of	O
side	O
effect	O
and	O
untoward	O
medical	O
sequela	O
,	O
which	O
now	O
include	O
catatonia	B-ADR
0	O
<EOS>	O
disulfiram	B-Drug
encephalopathy	O
a	O
a	O
cause	O
of	O
the	O
catatonia	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
disulfiram	B-Drug
encephalopathy	B-ADR
a	O
a	O
cause	O
of	O
the	O
catatonia	O
syndrome	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
the	O
catatonia	B-ADR
syndrome	I-ADR
associated	O
with	O
disulfiram	B-Drug
therapy	O
0	O
<EOS>	O
inappropriate	B-ADR
antidiuretic	I-ADR
hormone	I-ADR
secretion	I-ADR
after	O
high	O
dose	O
vinblastine	B-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
with	O
an	O
embryonal	O
teratocarcinoma	O
of	O
the	O
testicle	O
who	O
had	O
the	O
syndrome	O
of	O
inappropriate	B-ADR
secretion	I-ADR
of	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
after	O
receiving	O
a	O
high	O
dose	O
of	O
vinblastine	B-Drug
0	O
<EOS>	O
four	O
case	O
of	O
oesophageal	B-ADR
damage	I-ADR
associated	O
with	O
ingestion	O
of	O
the	O
urinary	O
anti-spasmodic	O
agent	O
emepronium	B-Drug
bromide	I-Drug
are	O
described	O
0	O
<EOS>	O
oesophageal	B-ADR
ulceration	I-ADR
due	O
to	O
emepronium	B-Drug
bromide	I-Drug
0	O
<EOS>	O
cardiorespiratory	B-ADR
toxicity	I-ADR
due	O
to	O
miconazole	B-Drug
0	O
<EOS>	O
none	O
of	O
them	O
had	O
a	O
history	O
of	O
cardiac	O
disease	O
,	O
and	O
with	O
the	O
possible	O
exception	O
of	O
one	O
case	O
of	O
cardiac	B-ADR
arrest	I-ADR
,	O
where	O
the	O
patient	O
received	O
doxorubicin	B-Drug
,	O
no	O
predisposing	O
factor	O
could	O
be	O
found	O
0	O
<EOS>	O
seven	O
patient	O
with	O
hematologic	O
malignancy	O
who	O
were	O
treated	O
with	O
miconazole	B-Drug
for	O
either	O
suspected	O
or	O
proven	O
fungal	O
infection	O
developed	O
eight	O
episode	O
of	O
major	O
adverse	O
cardiorespiratory	B-ADR
and	I-ADR
anaphylactic	I-ADR
reaction	I-ADR
0	O
<EOS>	O
clofibrate-induced	B-Drug
myopathy	B-ADR
in	O
patient	O
with	O
diabetes	O
insipidus	O
0	O
<EOS>	O
however	O
,	O
we	O
have	O
recently	O
had	O
four	O
case	O
of	O
clofibrate-induced	B-Drug
myopathy	B-ADR
in	O
patient	O
with	O
diabetes	O
insipidus	O
due	O
to	O
hypothalamic	O
lesion	O
0	O
<EOS>	O
physician	O
should	O
therefore	O
be	O
aware	O
of	O
it	O
occurrence	O
and	O
carefully	O
monitor	O
serum	O
level	O
of	O
cpk	O
,	O
got	O
and	O
gpt	O
during	O
the	O
treatment	O
of	O
diabetes	O
insipidus	O
with	O
clofibrate	B-Drug
,	O
especially	O
in	O
patient	O
with	O
associated	O
hypothyroidism	O
,	O
latent	O
or	O
overt	O
,	O
which	O
possibly	O
favor	O
the	O
development	O
of	O
myopathy	B-ADR
0	O
<EOS>	O
hepatotoxicity	B-ADR
of	O
hycanthone	B-Drug
in	O
patient	O
with	O
metastatic	O
breast	O
cancer	O
0	O
<EOS>	O
in	O
a	O
phase	O
ii	O
study	O
of	O
hycanthone	B-Drug
in	O
patient	O
with	O
breast	O
cancer	O
we	O
have	O
recently	O
observed	O
severe	B-ADR
hepatotoxicity	I-ADR
,	O
even	O
at	O
lower	O
dos	O
,	O
which	O
resulted	O
in	O
two	O
drug-related	O
death	O
0	O
<EOS>	O
fatal	B-ADR
interstitial	I-ADR
pneumonitis	I-ADR
following	O
high-dose	O
intermittent	O
chlorambucil	B-Drug
therapy	O
for	O
chronic	O
lymphocyte	O
leukemia	O
0	O
<EOS>	O
following	O
several	O
of	O
these	O
course	O
of	O
therapy	O
,	O
respiratory	B-ADR
distress	I-ADR
occurred	O
9	O
to	O
12	O
day	O
after	O
the	O
chlorambucil	B-Drug
wa	O
given	O
0	O
<EOS>	O
a	O
case	O
of	O
barbiturate-induced	B-Drug
submassive	B-ADR
hepatic	I-ADR
necrosis	I-ADR
is	O
presented	O
and	O
the	O
literature	O
is	O
reviewed	O
0	O
<EOS>	O
barbiturate-induced	B-Drug
submassive	B-ADR
hepatic	I-ADR
necrosis	I-ADR
0	O
<EOS>	O
the	O
patient	O
clinical	O
presentation	O
,	O
histologic	O
feature	O
on	O
liver	O
biopsy	O
and	O
favorable	O
course	O
after	O
stopping	O
the	O
drug	O
suggest	O
that	O
barbiturate	B-Drug
can	O
be	O
added	O
to	O
the	O
list	O
of	O
agent	O
which	O
can	O
cause	O
submassive	B-ADR
hepatic	I-ADR
necrosis	I-ADR
0	O
<EOS>	O
a	O
71-year-old	O
man	O
with	O
paroxysmal	O
atrial	O
fibrillation	O
who	O
had	O
a	O
previous	O
anterior	O
myocardial	O
infarction	O
exhibited	O
granulocytopenia	B-ADR
8	O
day	O
following	O
the	O
administration	O
of	O
oral	O
sustained-release	O
procainamide	B-Drug
(	O
750	O
mg	O
/	O
day	O
)	O
0	O
<EOS>	O
sustained-release	O
procainamide-induced	B-Drug
reversible	B-ADR
granulocytopenia	I-ADR
after	O
myocardial	O
infarction	O
0	O
<EOS>	O
the	O
frequency	O
and	O
relationship	O
of	O
granulocytopenia	B-ADR
caused	O
by	O
sustained-release	O
procainamide	B-Drug
in	O
patient	O
with	O
tachyarrhythmias	O
are	O
briefly	O
discussed	O
,	O
and	O
prior	O
reported	O
case	O
are	O
reviewed	O
0	O
<EOS>	O
monoclonal	B-ADR
gammopathy	I-ADR
and	O
subsequent	O
multiple	O
myeloma	O
in	O
a	O
patient	O
on	O
chronic	O
diphenylhydantoin	B-Drug
therapy	O
0	O
<EOS>	O
monoclonal	O
gammopathy	O
and	O
subsequent	O
multiple	B-ADR
myeloma	I-ADR
in	O
a	O
patient	O
on	O
chronic	O
diphenylhydantoin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
development	O
of	O
an	O
igg	B-ADR
lambda-type	I-ADR
monoclonal	I-ADR
gammopathy	I-ADR
and	O
subsequent	O
multiple	O
myeloma	O
in	O
an	O
epilepsy	O
patient	O
on	O
diphenylhydantoin	O
(	O
dilantin	B-Drug
)	O
therapy	O
for	O
20	O
year	O
is	O
reported	O
0	O
<EOS>	O
the	O
development	O
of	O
an	O
igg	B-ADR
lambda-type	I-ADR
monoclonal	I-ADR
gammopathy	I-ADR
and	O
subsequent	O
multiple	O
myeloma	O
in	O
an	O
epilepsy	O
patient	O
on	O
diphenylhydantoin	B-Drug
(	O
dilantin	O
)	O
therapy	O
for	O
20	O
year	O
is	O
reported	O
0	O
<EOS>	O
the	O
development	O
of	O
an	O
igg	O
lambda-type	O
monoclonal	O
gammopathy	O
and	O
subsequent	O
multiple	B-ADR
myeloma	I-ADR
in	O
an	O
epilepsy	O
patient	O
on	O
diphenylhydantoin	O
(	O
dilantin	B-Drug
)	O
therapy	O
for	O
20	O
year	O
is	O
reported	O
0	O
<EOS>	O
the	O
development	O
of	O
an	O
igg	O
lambda-type	O
monoclonal	O
gammopathy	O
and	O
subsequent	O
multiple	B-ADR
myeloma	I-ADR
in	O
an	O
epilepsy	O
patient	O
on	O
diphenylhydantoin	B-Drug
(	O
dilantin	O
)	O
therapy	O
for	O
20	O
year	O
is	O
reported	O
0	O
<EOS>	O
we	O
recommended	O
periodic	O
examination	O
of	O
the	O
serum	O
protein	O
in	O
patient	O
receiving	O
diphenylhydantoin	B-Drug
in	O
order	O
to	O
detect	O
development	O
of	O
monoclonal	B-ADR
gammopathy	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
atovaquone	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
agent	O
causing	O
vortex	B-ADR
keratopathy	I-ADR
involving	O
the	O
corneal	O
epithelium	O
0	O
<EOS>	O
purpose	O
:	O
we	O
studied	O
a	O
case	O
of	O
vortex	B-ADR
keratopathy	I-ADR
that	O
wa	O
associated	O
with	O
the	O
use	O
of	O
atovaquone	B-Drug
0	O
<EOS>	O
result	O
:	O
similar	O
to	O
previous	O
finding	O
of	O
drug-induced	O
vortex	B-ADR
keratopathy	I-ADR
,	O
atovaquone	B-Drug
vortex	O
keratopathy	O
is	O
presumably	O
caused	O
by	O
it	O
lipophilic	O
property	O
0	O
<EOS>	O
result	O
:	O
similar	O
to	O
previous	O
finding	O
of	O
drug-induced	O
vortex	B-ADR
keratopathy	I-ADR
,	O
atovaquone	B-Drug
vortex	O
keratopathy	O
is	O
presumably	O
caused	O
by	O
it	O
lipophilic	O
property	O
0	O
<EOS>	O
vortex	B-ADR
keratopathy	I-ADR
associated	O
with	O
atovaquone	B-Drug
0	O
<EOS>	O
used	O
injudiciously	O
,	O
naloxone	B-Drug
can	O
lead	O
to	O
withdrawal	O
syndrome	O
,	O
return	O
of	O
severe	B-ADR
pain	I-ADR
,	O
and	O
other	O
adverse	O
effect	O
0	O
<EOS>	O
used	O
injudiciously	O
,	O
naloxone	B-Drug
can	O
lead	O
to	O
withdrawal	B-ADR
syndrome	I-ADR
,	O
return	O
of	O
severe	O
pain	O
,	O
and	O
other	O
adverse	O
effect	O
0	O
<EOS>	O
however	O
,	O
there	O
remain	O
question	O
concerning	O
whether	O
these	O
drug	O
,	O
especially	O
methimazole	B-Drug
(	O
mmi	O
)	O
,	O
may	O
be	O
associated	O
with	O
aplasia	O
cutis	O
congenita	O
(	O
acc	B-ADR
)	O
and	O
how	O
best	O
to	O
avoid	O
impairment	O
of	O
fetal	O
thyroid	O
function	O
during	O
their	O
use	O
0	O
<EOS>	O
however	O
,	O
there	O
remain	O
question	O
concerning	O
whether	O
these	O
drug	O
,	O
especially	O
methimazole	O
(	O
mmi	B-Drug
)	O
,	O
may	O
be	O
associated	O
with	O
aplasia	O
cutis	O
congenita	O
(	O
acc	B-ADR
)	O
and	O
how	O
best	O
to	O
avoid	O
impairment	O
of	O
fetal	O
thyroid	O
function	O
during	O
their	O
use	O
0	O
<EOS>	O
however	O
,	O
there	O
remain	O
question	O
concerning	O
whether	O
these	O
drug	O
,	O
especially	O
methimazole	B-Drug
(	O
mmi	O
)	O
,	O
may	O
be	O
associated	O
with	O
aplasia	B-ADR
cutis	I-ADR
congenita	I-ADR
(	O
acc	O
)	O
and	O
how	O
best	O
to	O
avoid	O
impairment	O
of	O
fetal	O
thyroid	O
function	O
during	O
their	O
use	O
0	O
<EOS>	O
however	O
,	O
there	O
remain	O
question	O
concerning	O
whether	O
these	O
drug	O
,	O
especially	O
methimazole	O
(	O
mmi	B-Drug
)	O
,	O
may	O
be	O
associated	O
with	O
aplasia	B-ADR
cutis	I-ADR
congenita	I-ADR
(	O
acc	O
)	O
and	O
how	O
best	O
to	O
avoid	O
impairment	O
of	O
fetal	O
thyroid	O
function	O
during	O
their	O
use	O
0	O
<EOS>	O
a	O
73	O
year-old	O
patient	O
with	O
wolff-parkinson-white	O
syndrome	O
and	O
paroxysmic	O
supraventricular	O
tachycardia	O
developed	O
an	O
acute	B-ADR
reversible	I-ADR
encephalopathy	I-ADR
within	O
15	O
day	O
of	O
initiation	O
of	O
flecainide	B-Drug
0	O
<EOS>	O
acute	B-ADR
reversible	I-ADR
ataxo-myoclonic	I-ADR
encephalopathy	I-ADR
with	O
flecainide	B-Drug
therapy	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
man	O
with	O
recurrent	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
severe	O
skin	O
rash	O
and	O
bone	B-ADR
marrow	I-ADR
aplasia	I-ADR
4	O
and	O
7	O
day	O
,	O
respectively	O
,	O
following	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
methotrexate	B-Drug
(	O
mtx	O
)	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
man	O
with	O
recurrent	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
severe	O
skin	O
rash	O
and	O
bone	B-ADR
marrow	I-ADR
aplasia	I-ADR
4	O
and	O
7	O
day	O
,	O
respectively	O
,	O
following	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
methotrexate	O
(	O
mtx	B-Drug
)	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
man	O
with	O
recurrent	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
severe	B-ADR
skin	I-ADR
rash	I-ADR
and	O
bone	O
marrow	O
aplasia	O
4	O
and	O
7	O
day	O
,	O
respectively	O
,	O
following	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
methotrexate	B-Drug
(	O
mtx	O
)	O
0	O
<EOS>	O
a	O
64	O
year	O
old	O
man	O
with	O
recurrent	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
developed	O
severe	B-ADR
skin	I-ADR
rash	I-ADR
and	O
bone	O
marrow	O
aplasia	O
4	O
and	O
7	O
day	O
,	O
respectively	O
,	O
following	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
methotrexate	O
(	O
mtx	B-Drug
)	O
0	O
<EOS>	O
bone	B-ADR
marrow	I-ADR
aplasia	I-ADR
and	O
severe	O
skin	O
rash	O
after	O
a	O
single	O
low	O
dose	O
of	O
methotrexate	B-Drug
0	O
<EOS>	O
bone	O
marrow	O
aplasia	O
and	O
severe	B-ADR
skin	I-ADR
rash	I-ADR
after	O
a	O
single	O
low	O
dose	O
of	O
methotrexate	B-Drug
0	O
<EOS>	O
development	O
of	O
an	O
extensive	B-ADR
skin	I-ADR
rash	I-ADR
following	O
a	O
single	O
dose	O
of	O
mtx	B-Drug
may	O
be	O
an	O
early	O
warning	O
sign	O
for	O
life-threatening	O
bone	O
marrow	O
aplasia	O
0	O
<EOS>	O
in	O
the	O
absence	O
of	O
mucositis	O
or	O
diarrhea	O
,	O
severe	O
dermatologic	O
toxicity	O
following	O
a	O
single	O
low	O
dose	O
of	O
the	O
drug	O
suggests	O
an	O
allergic	O
	O
or	O
acute	B-ADR
hypersensitivity	I-ADR
reaction	I-ADR
to	O
mtx	B-Drug
in	O
this	O
patient	O
0	O
<EOS>	O
in	O
the	O
absence	O
of	O
mucositis	O
or	O
diarrhea	O
,	O
severe	B-ADR
dermatologic	I-ADR
toxicity	I-ADR
following	O
a	O
single	O
low	O
dose	O
of	O
the	O
drug	O
suggests	O
an	O
allergic	O
	O
or	O
acute	O
hypersensitivity	O
reaction	O
to	O
mtx	B-Drug
in	O
this	O
patient	O
0	O
<EOS>	O
chlormadinone	B-Drug
acetate	I-Drug
withdrawal	B-ADR
syndrome	I-ADR
under	O
combined	O
androgen	O
blockade	O
for	O
advanced	O
prostate	O
cancer	O
0	O
<EOS>	O
the	O
second	O
had	O
acute	O
cystitis	O
and	O
wa	O
treated	O
by	O
sulphonamide	O
and	O
the	O
third	O
developed	O
myopia	B-ADR
coincident	O
with	O
metronidazole	B-Drug
treatment	O
for	O
trichomonas	O
vaginalis	O
0	O
<EOS>	O
the	O
second	O
had	O
acute	O
cystitis	O
and	O
wa	O
treated	O
by	O
sulphonamide	B-Drug
and	O
the	O
third	O
developed	O
myopia	B-ADR
coincident	O
with	O
metronidazole	O
treatment	O
for	O
trichomonas	O
vaginalis	O
0	O
<EOS>	O
nephrotic	B-ADR
syndrome	I-ADR
related	O
to	O
systemic	O
lupus	O
erythematosus	O
after	O
griseofulvin	B-Drug
therapy	O
0	O
<EOS>	O
nephrotic	O
syndrome	O
related	O
to	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
after	O
griseofulvin	B-Drug
therapy	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
griseofulvin-exacerbated	B-Drug
lupus	B-ADR
in	O
which	O
nephrotic	O
syndrome	O
ha	O
been	O
observed	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
griseofulvin-exacerbated	B-Drug
lupus	O
in	O
which	O
nephrotic	B-ADR
syndrome	I-ADR
ha	O
been	O
observed	O
0	O
<EOS>	O
we	O
report	O
a	O
16-year-old	O
male	O
who	O
developed	O
nephrotic	B-ADR
syndrome	I-ADR
related	O
to	O
membranous	O
glomerulopathy	O
with	O
clinical	O
and	O
serological	O
evidence	O
of	O
systemic	O
lupus	O
erythematosus	O
after	O
treatment	O
with	O
griseofulvin	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
16-year-old	O
male	O
who	O
developed	O
nephrotic	O
syndrome	O
related	O
to	O
membranous	O
glomerulopathy	O
with	O
clinical	O
and	O
serological	O
evidence	O
of	O
systemic	B-ADR
lupus	I-ADR
erythematosus	I-ADR
after	O
treatment	O
with	O
griseofulvin	B-Drug
0	O
<EOS>	O
neurological	B-ADR
side	I-ADR
effect	I-ADR
in	O
two	O
patient	O
receiving	O
gold	B-Drug
injection	O
for	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	B-ADR
nitritoid	I-ADR
symptom	I-ADR
and	O
pain	O
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	O
dermatome	O
,	O
shortly	O
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
(	O
gstm	O
)	O
injection	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	B-ADR
nitritoid	I-ADR
symptom	I-ADR
and	O
pain	O
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	O
dermatome	O
,	O
shortly	O
after	O
gold	O
sodium	O
thiomalate	O
(	O
gstm	B-Drug
)	O
injection	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	O
nitritoid	O
symptom	O
and	O
pain	B-ADR
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	O
dermatome	O
,	O
shortly	O
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
(	O
gstm	O
)	O
injection	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	O
nitritoid	O
symptom	O
and	O
pain	B-ADR
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	O
dermatome	O
,	O
shortly	O
after	O
gold	O
sodium	O
thiomalate	O
(	O
gstm	B-Drug
)	O
injection	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	O
nitritoid	O
symptom	O
and	O
pain	O
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	B-ADR
dermatome	I-ADR
,	O
shortly	O
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
(	O
gstm	O
)	O
injection	O
0	O
<EOS>	O
the	O
first	O
patient	O
developed	O
mild	O
nitritoid	O
symptom	O
and	O
pain	O
in	O
a	O
band-like	O
distribution	O
,	O
corresponding	O
to	O
t10-t12	B-ADR
dermatome	I-ADR
,	O
shortly	O
after	O
gold	O
sodium	O
thiomalate	O
(	O
gstm	B-Drug
)	O
injection	O
0	O
<EOS>	O
the	O
second	O
patient	O
experienced	O
mild	B-ADR
nitritoid	I-ADR
symptom	I-ADR
following	O
several	O
gstm	B-Drug
injection	O
prior	O
experiencing	O
a	O
cerebrovascular	O
accident	O
within	O
several	O
hour	O
of	O
her	O
next	O
injection	O
0	O
<EOS>	O
acute	B-ADR
sensorineural	I-ADR
hearing	I-ADR
loss	I-ADR
following	O
intravenous	O
ketoralac	B-Drug
administration	O
0	O
<EOS>	O
both	O
pan	O
and	O
methotrexate	B-Drug
have	O
been	O
independently	O
demonstrated	O
to	O
cause	O
sensorineural	B-ADR
hearing	I-ADR
loss	I-ADR
0	O
<EOS>	O
both	O
pan	B-Drug
and	O
methotrexate	O
have	O
been	O
independently	O
demonstrated	O
to	O
cause	O
sensorineural	B-ADR
hearing	I-ADR
loss	I-ADR
0	O
<EOS>	O
we	O
recommend	O
the	O
cautious	O
use	O
of	O
ketorolac	B-Drug
in	O
patient	O
with	O
underlying	O
illness	O
where	O
nsaid-induced	O
ototoxicity	B-ADR
could	O
result	O
in	O
adverse	O
otologic	O
consequence	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
20-year-old	O
female	O
with	O
polyarteritis	O
nodosa	O
(	O
pan	O
)	O
who	O
developed	O
bilateral	B-ADR
sensorineural	I-ADR
hearing	I-ADR
loss	I-ADR
25	O
minute	O
after	O
receiving	O
30	O
mg	O
of	O
intravenous	O
ketoralac	B-Drug
0	O
<EOS>	O
anaphylactoid	B-ADR
reaction	I-ADR
with	O
intraperitoneal	O
cisplatin	B-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
while	O
conducting	O
a	O
protocol	O
evaluating	O
the	O
efficacy	O
of	O
intraperitoneal	O
cisplatin	B-Drug
and	O
hyperthermia	O
in	O
the	O
treatment	O
of	O
recurrent	O
ovarian	O
cancer	O
,	O
3	O
patient	O
were	O
noted	O
to	O
exhibit	O
anaphylactoid	B-ADR
reaction	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
we	O
conclude	O
that	O
a	O
high	O
dose	O
combined	O
with	O
a	O
short	O
infusion	O
time	O
increase	O
the	O
risk	O
of	O
anaphylactoid	B-ADR
reaction	I-ADR
with	O
the	O
administration	O
of	O
intraperitoneal	O
cisplatin	B-Drug
0	O
<EOS>	O
discussion	O
:	O
anaphylactoid	B-ADR
reaction	I-ADR
have	O
been	O
described	O
previously	O
with	O
cisplatin	B-Drug
administration	O
0	O
<EOS>	O
during	O
her	O
third	O
cycle	O
,	O
she	O
again	O
received	O
cisplatin	B-Drug
100	B-ADR
mg	I-ADR
/	I-ADR
m2	I-ADR
over	O
30	O
minute	O
and	O
developed	O
palmar	O
pruritus	O
,	O
urticaria	O
,	O
and	O
edema	O
0	O
<EOS>	O
during	O
her	O
third	O
cycle	O
,	O
she	O
again	O
received	O
cisplatin	B-Drug
100	O
mg	O
/	O
m2	O
over	O
30	O
minute	O
and	O
developed	O
palmar	O
pruritus	O
,	O
urticaria	O
,	O
and	O
edema	B-ADR
0	O
<EOS>	O
during	O
her	O
third	O
cycle	O
,	O
she	O
again	O
received	O
cisplatin	B-Drug
100	O
mg	O
/	O
m2	O
over	O
30	O
minute	O
and	O
developed	O
palmar	B-ADR
pruritus	I-ADR
,	O
urticaria	O
,	O
and	O
edema	O
0	O
<EOS>	O
during	O
her	O
third	O
cycle	O
,	O
she	O
again	O
received	O
cisplatin	B-Drug
100	O
mg	O
/	O
m2	O
over	O
30	O
minute	O
and	O
developed	O
palmar	O
pruritus	O
,	O
urticaria	B-ADR
,	O
and	O
edema	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
occurrence	O
of	O
anaphylactoid	B-ADR
reaction	I-ADR
to	O
intraperitoneal	O
cisplatin	B-Drug
in	O
3	O
patient	O
0	O
<EOS>	O
we	O
observed	O
5	O
reaction	O
in	O
3	O
patient	O
that	O
appear	O
to	O
be	O
related	O
to	O
a	O
high	O
dose-infusion	O
time	O
ratio	O
,	O
indicating	O
that	O
dose	O
and	O
rate	O
of	O
infusion	O
may	O
be	O
important	O
factor	O
in	O
precipitating	O
anaphylactoid	B-ADR
reaction	I-ADR
with	O
cisplatin	B-Drug
0	O
<EOS>	O
etoposide-related	B-Drug
myocardial	B-ADR
infarction	I-ADR
0	O
<EOS>	O
the	O
occurrence	O
of	O
a	O
myocardial	B-ADR
infarction	I-ADR
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	B-Drug
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factor	O
for	O
coronary	O
heart	O
disease	O
0	O
<EOS>	O
a	O
9-year-old	O
boy	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
following	O
intravenous	O
acyclovir	B-Drug
(	O
30	O
mg	O
/	O
kg	O
per	O
day	O
)	O
administered	O
for	O
6	O
day	O
to	O
treat	O
herpetic	O
encephalitis	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
a	O
child	O
associated	O
with	O
acyclovir	B-Drug
0	O
<EOS>	O
anterior	B-ADR
ischemic	I-ADR
optic	I-ADR
neuropathy	I-ADR
secondary	O
to	O
interferon	B-Drug
alfa	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
anterior	B-ADR
ischemic	I-ADR
optic	I-ADR
neuropathy	I-ADR
may	O
complicate	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
occurrence	O
of	O
anterior	B-ADR
ischemic	I-ADR
optic	I-ADR
neuropathy	I-ADR
a	O
a	O
complication	O
of	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
to	O
consider	O
the	O
possible	O
underlying	O
mechanism	O
for	O
this	O
association	O
0	O
<EOS>	O
patient	O
:	O
two	O
patient	O
,	O
age	O
40	O
and	O
51	O
year	O
,	O
undergoing	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
for	O
malignant	O
neoplasm	O
experienced	O
sudden	B-ADR
bilateral	I-ADR
,	I-ADR
sequential	I-ADR
visual	I-ADR
loss	I-ADR
with	O
disc-related	O
field	O
defect	O
and	O
segmental	O
optic	O
disc	O
edema	O
0	O
<EOS>	O
the	O
interval	O
between	O
initiating	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
onset	O
of	O
anterior	B-ADR
ischemic	I-ADR
optic	I-ADR
neuropathy	I-ADR
wa	O
similar	O
to	O
that	O
of	O
interferon-associated	O
vascular	O
retinopathy	O
0	O
<EOS>	O
the	O
interval	O
between	O
initiating	O
treatment	O
with	O
interferon	O
alfa	O
and	O
onset	O
of	O
anterior	O
ischemic	O
optic	O
neuropathy	O
wa	O
similar	O
to	O
that	O
of	O
interferon-associated	B-Drug
vascular	B-ADR
retinopathy	I-ADR
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
that	O
occurred	O
in	O
a	O
patient	O
on	O
amitriptyline	B-Drug
and	O
lithium	O
carbonate	O
0	O
<EOS>	O
the	O
author	O
describe	O
a	O
case	O
of	O
neuroleptic	B-ADR
malignant	I-ADR
syndrome	I-ADR
that	O
occurred	O
in	O
a	O
patient	O
on	O
amitriptyline	O
and	O
lithium	B-Drug
carbonate	I-Drug
0	O
<EOS>	O
case	O
summary	O
:	O
two	O
patient	O
with	O
stable	O
hypothyroidism	O
experienced	O
symptom	O
of	O
hypothyroidism	O
with	O
increased	B-ADR
serum	I-ADR
thyroid-stimulating	I-ADR
hormone	I-ADR
(	O
tsh	O
)	O
concentration	O
after	O
switching	O
from	O
1	O
levothyroxine	B-Drug
product	O
to	O
another	O
0	O
<EOS>	O
evidence	O
is	O
shown	O
in	O
this	O
report	O
that	O
adenosine	B-Drug
wa	O
associated	O
with	O
dangerous	O
worsening	O
of	O
arrhythmia	B-ADR
in	O
patient	O
with	O
atrial	O
flutter	O
0	O
<EOS>	O
life-threatening	O
alteration	B-ADR
in	I-ADR
heart	I-ADR
rate	I-ADR
after	O
the	O
use	O
of	O
adenosine	B-Drug
in	O
atrial	O
flutter	O
0	O
<EOS>	O
comparable	O
adverse	O
effect	O
,	O
such	O
a	O
disorientation	B-ADR
and	O
temporary	O
amnesia	O
,	O
have	O
been	O
reported	O
in	O
patient	O
in	O
the	O
analogous	O
agent	O
,	O
propranolol	B-Drug
0	O
<EOS>	O
comparable	O
adverse	O
effect	O
,	O
such	O
a	O
disorientation	O
and	O
temporary	B-ADR
amnesia	I-ADR
,	O
have	O
been	O
reported	O
in	O
patient	O
in	O
the	O
analogous	O
agent	O
,	O
propranolol	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
probable	O
case	O
of	O
transient	B-ADR
global	I-ADR
amnesia	I-ADR
caused	O
by	O
propafenone	B-Drug
0	O
<EOS>	O
probable	O
propafenone-induced	B-Drug
transient	B-ADR
global	I-ADR
amnesia	I-ADR
0	O
<EOS>	O
a	O
case	O
of	O
acute	B-ADR
subdural	I-ADR
haematoma	I-ADR
originating	O
spontaneously	O
from	O
an	O
angiomatous	O
meningioma	O
in	O
a	O
patient	O
receiving	O
prophylactic	O
aspirin	B-Drug
therapy	O
is	O
presented	O
0	O
<EOS>	O
intracranial	B-ADR
haemorrhage	I-ADR
from	O
a	O
meningioma	O
in	O
a	O
patient	O
receiving	O
aspirin	B-Drug
prophylaxis	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
beneficial	O
effect	O
of	O
low-dose	O
mianserin	O
on	O
fluvoxamine-induced	B-Drug
akathisia	B-ADR
in	O
an	O
obsessive-compulsive	O
patient	O
0	O
<EOS>	O
extrapyramidal	B-ADR
side	I-ADR
effect	I-ADR
induced	O
by	O
some	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
,	O
i.e	O
0	O
fluoxetine	B-Drug
and	O
sertraline	O
,	O
have	O
been	O
previously	O
reported	O
in	O
patient	O
with	O
depression	O
and	O
obsessive-compulsive	O
disorder	O
(	O
ocd	O
)	O
0	O
<EOS>	O
extrapyramidal	B-ADR
side	I-ADR
effect	I-ADR
induced	O
by	O
some	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
ssri	O
)	O
,	O
i.e	O
0	O
fluoxetine	O
and	O
sertraline	B-Drug
,	O
have	O
been	O
previously	O
reported	O
in	O
patient	O
with	O
depression	O
and	O
obsessive-compulsive	O
disorder	O
(	O
ocd	O
)	O
0	O
<EOS>	O
however	O
,	O
the	O
occurrence	O
and	O
management	O
of	O
akathisia	B-ADR
induced	O
by	O
fluvoxamine	B-Drug
have	O
not	O
been	O
described	O
0	O
<EOS>	O
in	O
the	O
presented	O
case	O
fluvoxamine-induced	B-Drug
akathisia	B-ADR
in	O
an	O
ocd	O
patient	O
wa	O
partially	O
resistant	O
to	O
the	O
anticholinergic	O
agent	O
biperiden	O
,	O
and	O
wa	O
successfully	O
treated	O
with	O
the	O
5-ht2a	O
/	O
5-ht2c	O
antagonist	O
mianserin	O
0	O
<EOS>	O
a	O
42	O
year	O
old	O
man	O
,	O
treated	O
for	O
testicular	O
carcinoma	O
with	O
combination	O
chemotherapy	O
that	O
included	O
bleomycin	B-Drug
,	O
developed	O
life	O
threatening	O
interstitial	B-ADR
pneumonitis	I-ADR
0	O
<EOS>	O
severe	O
bleomycin	B-Drug
lung	B-ADR
toxicity	I-ADR
:	O
reversal	O
with	O
high	O
dose	O
corticosteroid	O
0	O
<EOS>	O
this	O
report	O
suggests	O
that	O
bleomycin	B-Drug
lung	B-ADR
toxicity	I-ADR
may	O
be	O
reversible	O
if	O
treated	O
aggressively	O
0	O
<EOS>	O
reversal	O
of	O
gold-induced	B-Drug
neutropenia	B-ADR
with	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	O
)	O
0	O
<EOS>	O
we	O
have	O
successfully	O
overcome	O
severe	B-ADR
neutropenia	I-ADR
in	O
an	O
ra	O
patient	O
treated	O
with	O
gold	B-Drug
salt	O
,	O
using	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
g-csf	O
)	O
,	O
reducing	O
the	O
duration	O
of	O
neutropenia	O
and	O
risk	O
of	O
infection	O
0	O
<EOS>	O
arrhythmia	B-ADR
and	O
cardiac	O
arrest	O
have	O
been	O
reported	O
during	O
amphotericin	B-Drug
b	I-Drug
administration	O
but	O
no	O
effective	O
technique	O
ha	O
been	O
described	O
to	O
prevent	O
them	O
0	O
<EOS>	O
arrhythmia	O
and	O
cardiac	B-ADR
arrest	I-ADR
have	O
been	O
reported	O
during	O
amphotericin	B-Drug
b	I-Drug
administration	O
but	O
no	O
effective	O
technique	O
ha	O
been	O
described	O
to	O
prevent	O
them	O
0	O
<EOS>	O
correction	O
of	O
serum	O
electrolyte	O
imbalance	O
prevents	O
cardiac	B-ADR
arrhythmia	I-ADR
during	O
amphotericin	B-Drug
b	I-Drug
administration	O
0	O
<EOS>	O
i	O
saw	O
two	O
patient	O
with	O
kala-azar	O
resistant	O
to	O
sodium	O
stibogluconate	O
who	O
developed	O
cardiac	B-ADR
arrest	I-ADR
after	O
amphotericin	B-Drug
infusion	O
(	O
in	O
spite	O
of	O
tolerating	O
a	O
test	O
dose	O
)	O
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
that	O
illustrate	O
the	O
use	O
of	O
lithium	B-Drug
in	O
the	O
treatment	O
of	O
veteran	O
with	O
ptsd	O
who	O
complained	O
of	O
serious	O
problem	O
with	O
irritability	O
or	O
angry	B-ADR
outburst	I-ADR
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
that	O
illustrate	O
the	O
use	O
of	O
lithium	B-Drug
in	O
the	O
treatment	O
of	O
veteran	O
with	O
ptsd	O
who	O
complained	O
of	O
serious	O
problem	O
with	O
irritability	B-ADR
or	O
angry	O
outburst	O
0	O
<EOS>	O
graf	B-ADR
	I-ADR
hyperthyroidism	I-ADR
following	O
transient	O
thyrotoxicosis	O
during	O
interferon	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
type	O
c	O
0	O
<EOS>	O
graf	O
	O
hyperthyroidism	O
following	O
transient	B-ADR
thyrotoxicosis	I-ADR
during	O
interferon	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
type	O
c	O
0	O
<EOS>	O
this	O
case	O
showed	O
sequential	O
manifestation	O
from	O
transient	O
thyrotoxicosis	O
to	O
the	O
appearance	O
of	O
tsh-receptor	O
autoantibody	O
,	O
and	O
then	O
the	O
occurrence	O
of	O
graf	B-ADR
	I-ADR
hyperthyroidism	I-ADR
during	O
ifn	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
graf	B-ADR
	I-ADR
hyperthyroidism	I-ADR
induced	O
by	O
long-term	O
interferon	O
(	O
ifn	B-Drug
)	O
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
graf	B-ADR
	I-ADR
hyperthyroidism	I-ADR
induced	O
by	O
long-term	O
interferon	B-Drug
(	O
ifn	O
)	O
therapy	O
0	O
<EOS>	O
acute	O
inh	B-Drug
neurotoxicity	B-ADR
wa	O
not	O
suspected	O
on	O
the	O
first	O
admission	O
;	O
however	O
,	O
when	O
readmitted	O
4	O
week	O
later	O
with	O
another	O
seizure	O
,	O
the	O
diagnosis	O
of	O
acute	O
inh	O
neurotoxicity	O
wa	O
made	O
0	O
<EOS>	O
acute	O
inh	B-Drug
neurotoxicity	B-ADR
wa	O
not	O
suspected	O
on	O
the	O
first	O
admission	O
;	O
however	O
,	O
when	O
readmitted	O
4	O
week	O
later	O
with	O
another	O
seizure	O
,	O
the	O
diagnosis	O
of	O
acute	O
inh	O
neurotoxicity	O
wa	O
made	O
0	O
<EOS>	O
acute	O
isoniazid	B-Drug
neurotoxicity	B-ADR
in	O
an	O
urban	O
hospital	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
have	O
seen	O
an	O
increased	O
incidence	O
of	O
acute	O
inh	B-Drug
neurotoxicity	B-ADR
because	O
of	O
the	O
resurgence	O
of	O
tb	O
in	O
new	O
york	O
city	O
0	O
<EOS>	O
in	O
patient	O
with	O
a	O
known	O
access	O
to	O
inh	B-Drug
,	O
seizure	B-ADR
should	O
be	O
considered	O
to	O
be	O
caused	O
by	O
inh	O
toxicity	O
unless	O
proved	O
otherwise	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
the	O
presentation	O
and	O
treatment	O
of	O
acute	O
isoniazid	O
(	O
inh	B-Drug
)	O
neurotoxicity	B-ADR
appearing	O
at	O
an	O
inner-city	O
municipal	O
hospital	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
the	O
presentation	O
and	O
treatment	O
of	O
acute	O
isoniazid	B-Drug
(	O
inh	O
)	O
neurotoxicity	B-ADR
appearing	O
at	O
an	O
inner-city	O
municipal	O
hospital	O
0	O
<EOS>	O
parenteral	O
pyridoxine	O
,	O
the	O
specific	O
antidote	O
for	O
inh-induced	B-Drug
refractory	B-ADR
seizure	I-ADR
,	O
should	O
be	O
readily	O
available	O
in	O
every	O
emergency	O
department	O
in	O
the	O
area	O
similarly	O
experiencing	O
increasing	O
trend	O
of	O
tb	O
0	O
<EOS>	O
result	O
:	O
at	O
our	O
institution	O
,	O
no	O
child	O
appeared	O
with	O
acute	O
inh	B-Drug
neurotoxicity	B-ADR
in	O
the	O
period	O
1985	O
through	O
1990	O
,	O
whereas	O
seven	O
patient	O
were	O
treated	O
from	O
1991	O
through	O
1993	O
0	O
<EOS>	O
arterial	B-ADR
hypertension	I-ADR
associated	O
with	O
topical	O
ocular	O
use	O
of	O
phenylephrine	B-Drug
in	O
dog	O
0	O
<EOS>	O
conclusion	O
:	O
squamous	B-ADR
metaplasia	I-ADR
in	O
these	O
case	O
appears	O
to	O
be	O
a	O
consequence	O
of	O
progestin	B-Drug
therapy	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
finding	O
of	O
squamous	B-ADR
metaplasia	I-ADR
within	I-ADR
endometrial	I-ADR
gland	I-ADR
occurring	O
a	O
a	O
result	O
of	O
progestin	B-Drug
therapy	O
of	O
hyperplasia	O
0	O
<EOS>	O
result	O
:	O
extensive	O
squamous	B-ADR
metaplasia	I-ADR
wa	O
found	O
in	O
endometrial	O
gland	O
following	O
progestin	B-Drug
therapy	O
0	O
<EOS>	O
fever	B-ADR
caused	O
by	O
the	O
use	O
of	O
furosemide	B-Drug
wa	O
proved	O
;	O
the	O
fever	O
resolved	O
after	O
discontinuation	O
of	O
this	O
medication	O
and	O
recurred	O
after	O
it	O
reintroduction	O
0	O
<EOS>	O
furosemide-associated	B-Drug
fever	B-ADR
0	O
<EOS>	O
the	O
dose-limiting	O
toxicity	O
of	O
kw-2149	B-Drug
is	O
pulmonary	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
musculoskeletal	B-ADR
complaint	I-ADR
were	O
the	O
presenting	O
symptom	O
in	O
four	O
of	O
44	O
child	O
(	O
9	O
%	O
)	O
treated	O
for	O
relapsed	O
wilms	O
	O
tumor	O
with	O
ifosfamide	O
,	O
a	O
derivative	O
of	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
musculoskeletal	B-ADR
complaint	I-ADR
were	O
the	O
presenting	O
symptom	O
in	O
four	O
of	O
44	O
child	O
(	O
9	O
%	O
)	O
treated	O
for	O
relapsed	O
wilms	O
	O
tumor	O
with	O
ifosfamide	B-Drug
,	O
a	O
derivative	O
of	O
cyclophosphamide	O
0	O
<EOS>	O
recognition	O
of	O
a	O
potential	O
drug-induced	O
fanconi	B-ADR
syndrome	I-ADR
is	O
important	O
when	O
managing	O
pediatric	O
oncology	O
patient	O
previously	O
treated	O
with	O
ifosfamide	B-Drug
0	O
<EOS>	O
our	O
case	O
constitute	O
the	O
most	O
severe	O
case	O
of	O
benzarone	B-Drug
hepatotoxicity	O
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
case	O
of	O
(	O
sub	O
)	O
fulminant	O
hepatitis	O
and	O
cirrhosis	B-ADR
related	O
to	O
benzarone	O
0	O
<EOS>	O
our	O
case	O
constitute	O
the	O
most	O
severe	O
case	O
of	O
benzarone	B-Drug
hepatotoxicity	O
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
case	O
of	O
(	O
sub	O
)	O
fulminant	O
hepatitis	O
and	O
cirrhosis	B-ADR
related	O
to	O
benzarone	O
0	O
<EOS>	O
our	O
case	O
constitute	O
the	O
most	O
severe	O
case	O
of	O
benzarone	B-Drug
hepatotoxicity	B-ADR
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
case	O
of	O
(	O
sub	O
)	O
fulminant	O
hepatitis	O
and	O
cirrhosis	O
related	O
to	O
benzarone	O
0	O
<EOS>	O
our	O
case	O
constitute	O
the	O
most	O
severe	O
case	O
of	O
benzarone	B-Drug
hepatotoxicity	O
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
case	O
of	O
(	B-ADR
sub	I-ADR
)	I-ADR
fulminant	I-ADR
hepatitis	I-ADR
and	O
cirrhosis	O
related	O
to	O
benzarone	O
0	O
<EOS>	O
our	O
case	O
constitute	O
the	O
most	O
severe	O
case	O
of	O
benzarone	B-Drug
hepatotoxicity	O
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
case	O
of	O
(	B-ADR
sub	I-ADR
)	I-ADR
fulminant	I-ADR
hepatitis	I-ADR
and	O
cirrhosis	O
related	O
to	O
benzarone	O
0	O
<EOS>	O
severe	B-ADR
hepatotoxicity	I-ADR
related	O
to	O
benzarone	B-Drug
:	O
a	O
report	O
of	O
three	O
case	O
with	O
two	O
fatality	O
0	O
<EOS>	O
we	O
report	O
three	O
case	O
of	O
severe	B-ADR
hepatotoxicity	I-ADR
related	O
to	O
benzarone	B-Drug
,	O
a	O
benzofuran	O
derivative	O
0	O
<EOS>	O
we	O
stress	O
the	O
potential	O
of	O
benzarone	B-Drug
to	O
cause	O
hepatotoxicity	B-ADR
,	O
which	O
usually	O
resembles	O
severe	O
chronic	O
active	O
hepatitis	O
0	O
<EOS>	O
we	O
stress	O
the	O
potential	O
of	O
benzarone	B-Drug
to	O
cause	O
hepatotoxicity	O
,	O
which	O
usually	O
resembles	O
severe	B-ADR
chronic	I-ADR
active	I-ADR
hepatitis	I-ADR
0	O
<EOS>	O
case	O
study	O
:	O
a	O
modified	O
topical	O
treatment	O
regimen	O
for	O
sodium	O
warfarin-induced	B-Drug
necrotizing	B-ADR
fasciitis	I-ADR
0	O
<EOS>	O
this	O
case	O
study	O
describes	O
an	O
atypical	O
case	O
of	O
refractory	O
,	O
sodium	B-Drug
warfarin-induced	I-Drug
necrotizing	O
fasciitis	O
and	O
myonecrosis	B-ADR
0	O
<EOS>	O
this	O
case	O
study	O
describes	O
an	O
atypical	O
case	O
of	O
refractory	O
,	O
sodium	B-Drug
warfarin-induced	I-Drug
necrotizing	B-ADR
fasciitis	I-ADR
and	O
myonecrosis	O
0	O
<EOS>	O
clinician	O
who	O
manage	O
cachectic	O
patient	O
,	O
particularly	O
those	O
with	O
protracted	O
diarrhoea	O
and	O
/	O
or	O
receiving	O
anti-malarial	O
drug	O
including	O
mefloquine	B-Drug
,	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	B-ADR
hypoglycaemia	I-ADR
0	O
<EOS>	O
mechanism	O
and	O
triggering	O
factor	O
of	O
hypoglycaemia	B-ADR
induced	O
by	O
mefloquine	B-Drug
and	O
some	O
other	O
anti-malarial	O
quinine	O
analogue	O
are	O
discussed	O
0	O
<EOS>	O
mefloquine-associated	B-Drug
hypoglycaemia	B-ADR
in	O
a	O
cachectic	O
aid	O
patient	O
0	O
<EOS>	O
quinine	O
and	O
it	O
isomer	O
quinidine	B-Drug
are	O
well-known	O
cause	O
of	O
iatrogenic	B-ADR
hypoglycaemia	I-ADR
,	O
due	O
to	O
excessive	O
insulin	O
secretion	O
0	O
<EOS>	O
quinine	B-Drug
and	O
it	O
isomer	O
quinidine	O
are	O
well-known	O
cause	O
of	O
iatrogenic	B-ADR
hypoglycaemia	I-ADR
,	O
due	O
to	O
excessive	O
insulin	O
secretion	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
hypoglycaemia	B-ADR
after	O
mefloquine	B-Drug
therapy	O
(	O
1500	O
mg	O
over	O
two	O
day	O
)	O
for	O
severe	O
gastrointestinal	O
cryptosporidiasis	O
in	O
a	O
cachectic	O
aid	O
patient	O
with	O
protracted	O
diarrhoea	O
0	O
<EOS>	O
because	O
sumatriptan	B-Drug
can	O
cause	O
coronary	B-ADR
artery	I-ADR
vasospasm	I-ADR
,	O
patient	O
with	O
significant	O
risk	O
factor	O
for	O
coronary	O
artery	O
disease	O
should	O
be	O
carefully	O
evaluated	O
for	O
cardiovascular	O
disease	O
prior	O
to	O
the	O
use	O
of	O
sumatriptan	O
0	O
<EOS>	O
cardiac	B-ADR
arrest	I-ADR
following	O
use	O
of	O
sumatriptan	B-Drug
0	O
<EOS>	O
i	O
report	O
a	O
35-year-old	O
woman	O
with	O
occult	O
coronary	O
artery	O
disease	O
who	O
experienced	O
cardiac	B-ADR
arrest	I-ADR
within	O
minute	O
after	O
receiving	O
a	O
first-time	O
dose	O
of	O
subcutaneous	O
sumatriptan	B-Drug
for	O
migraine	O
0	O
<EOS>	O
sotalol-induced	B-Drug
bradycardia	B-ADR
reversed	O
by	O
glucagon	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
sotalol-induced	B-Drug
bradycardia	B-ADR
reversed	O
by	O
glucagon	O
0	O
<EOS>	O
secretory	B-ADR
endometrial	I-ADR
adenocarcinoma	I-ADR
in	O
a	O
patient	O
on	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
:	O
a	O
report	O
of	O
a	O
case	O
0	O
<EOS>	O
this	O
unusual	O
pattern	O
of	O
low-grade	B-ADR
endometrial	I-ADR
carcinoma	I-ADR
add	O
to	O
the	O
spectrum	O
of	O
uterine	O
neoplasia	O
associated	O
with	O
tamoxifen	B-Drug
therapy	O
0	O
<EOS>	O
this	O
unusual	O
pattern	O
of	O
low-grade	O
endometrial	O
carcinoma	O
add	O
to	O
the	O
spectrum	O
of	O
uterine	B-ADR
neoplasia	I-ADR
associated	O
with	O
tamoxifen	B-Drug
therapy	O
0	O
<EOS>	O
we	O
believe	O
that	O
this	O
is	O
the	O
first	O
report	O
of	O
secretory	B-ADR
carcinoma	I-ADR
of	I-ADR
the	I-ADR
endometrium	I-ADR
associated	O
with	O
tamoxifen	B-Drug
use	O
0	O
<EOS>	O
well-differentiated	O
endometrial	B-ADR
adenocarcinoma	I-ADR
of	I-ADR
the	I-ADR
secretory	I-ADR
type	I-ADR
(	O
figo	O
grade	O
1	O
)	O
with	O
minimal	O
myometrial	O
invasion	O
occurred	O
in	O
a	O
postmenopausal	O
patient	O
on	O
tamoxifen	B-Drug
therapy	O
5	O
year	O
after	O
mastectomy	O
for	O
breast	O
carcinoma	O
0	O
<EOS>	O
esophageal	B-ADR
candidiasis	I-ADR
following	O
omeprazole	B-Drug
therapy	O
:	O
a	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
esophageal	B-ADR
candidiasis	I-ADR
wa	O
diagnosed	O
at	O
endoscopy	O
in	O
two	O
patient	O
receiving	O
omeprazole	B-Drug
therapy	O
0	O
<EOS>	O
high-grade	B-ADR
atrioventricular	I-ADR
block	I-ADR
during	O
dipyridamole	B-Drug
stress	O
testing	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
in	O
which	O
dipyridamole	B-Drug
induced	O
high-grade	B-ADR
atrioventricular	I-ADR
(	I-ADR
av	I-ADR
)	I-ADR
block	I-ADR
that	O
responded	O
promptly	O
to	O
intravenous	O
aminophylline	O
but	O
not	O
to	O
atropine	O
0	O
<EOS>	O
aggressive	O
management	O
of	O
doxorubicin-induced	B-Drug
cardiomyopathy	B-ADR
associated	O
with	O
low	O
	O
dos	O
of	O
doxorubicin	O
0	O
<EOS>	O
aggressive	O
management	O
of	O
doxorubicin-induced	B-Drug
cardiomyopathy	B-ADR
associated	O
with	O
low	O
	O
dos	O
of	O
doxorubicin	O
0	O
<EOS>	O
there	O
is	O
a	O
dose-effect	O
relationship	O
between	O
doxorubicin	B-Drug
and	O
the	O
incidence	O
of	O
symptomatic	B-ADR
cardiac	I-ADR
failure	I-ADR
0	O
<EOS>	O
ovarian	O
endometrioid	O
carcinoma	O
and	O
endometriosis	B-ADR
developing	O
in	O
a	O
postmenopausal	O
breast	O
cancer	O
patient	O
during	O
tamoxifen	B-Drug
therapy	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
ovarian	B-ADR
endometrioid	I-ADR
carcinoma	I-ADR
and	O
endometriosis	O
developing	O
in	O
a	O
postmenopausal	O
breast	O
cancer	O
patient	O
during	O
tamoxifen	B-Drug
therapy	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
the	O
association	O
with	O
prolonged	O
unopposed	O
estrogen-like	O
stimulation	O
with	O
tamoxifen	B-Drug
a	O
a	O
possible	O
factor	O
in	O
the	O
development	O
of	O
ovarian	B-ADR
endometrioid	I-ADR
carcinoma	I-ADR
is	O
discussed	O
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
of	O
ovarian	O
endometrioid	O
carcinoma	O
and	O
endometriosis	B-ADR
in	O
a	O
postmenopausal	O
patient	O
who	O
wa	O
treated	O
with	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
of	O
ovarian	B-ADR
endometrioid	I-ADR
carcinoma	I-ADR
and	O
endometriosis	O
in	O
a	O
postmenopausal	O
patient	O
who	O
wa	O
treated	O
with	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
0	O
<EOS>	O
cerebral	B-ADR
demyelinating	I-ADR
disease	I-ADR
developed	O
in	O
a	O
patient	O
during	O
adjuvant	O
therapy	O
with	O
levamisole	B-Drug
for	O
malignant	O
melanoma	O
0	O
<EOS>	O
multifocal	B-ADR
inflammatory	I-ADR
leukoencephalopathy	I-ADR
associated	O
with	O
levamisole	B-Drug
therapy	O
0	O
<EOS>	O
observation	O
in	O
our	O
patient	O
suggest	O
that	O
the	O
leukoencephalopathy	B-ADR
that	O
developed	O
in	O
previously	O
reported	O
patient	O
who	O
received	O
5-fluorouracil	B-Drug
and	O
levamisole	O
may	O
have	O
been	O
caused	O
at	O
least	O
partly	O
by	O
levamisole	O
0	O
<EOS>	O
observation	O
in	O
our	O
patient	O
suggest	O
that	O
the	O
leukoencephalopathy	B-ADR
that	O
developed	O
in	O
previously	O
reported	O
patient	O
who	O
received	O
5-fluorouracil	O
and	O
levamisole	B-Drug
may	O
have	O
been	O
caused	O
at	O
least	O
partly	O
by	O
levamisole	O
0	O
<EOS>	O
observation	O
in	O
our	O
patient	O
suggest	O
that	O
the	O
leukoencephalopathy	B-ADR
that	O
developed	O
in	O
previously	O
reported	O
patient	O
who	O
received	O
5-fluorouracil	O
and	O
levamisole	B-Drug
may	O
have	O
been	O
caused	O
at	O
least	O
partly	O
by	O
levamisole	O
0	O
<EOS>	O
a	O
case	O
of	O
noncardiogenic	B-ADR
pulmonary	I-ADR
edema	I-ADR
by	O
ethanolamine	B-Drug
oleate	I-Drug
0	O
<EOS>	O
however	O
,	O
eo-induced	B-Drug
noncardiogenic	B-ADR
pulmonary	I-ADR
edema	I-ADR
ha	O
not	O
been	O
reported	O
in	O
human	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
noncardiogenic	B-ADR
pulmonary	I-ADR
edema	I-ADR
developed	O
after	O
therapeutic	O
trial	O
of	O
eo	B-Drug
a	O
sclerosing	O
agent	O
for	O
esophageal	O
varix	O
0	O
<EOS>	O
five	O
patient	O
are	O
described	O
in	O
whom	O
only	O
gentamicin	B-Drug
sulfate	I-Drug
appeared	O
responsible	O
for	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
gentamicin-associated	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
renal	B-ADR
failure	I-ADR
appeared	O
8	O
to	O
17	O
day	O
after	O
beginning	O
gentamicin	B-Drug
therapy	O
and	O
wa	O
characterized	O
by	O
creatinine	O
clearance	O
4	O
to	O
10	O
ml	O
/	O
min	O
,	O
urine	O
to	O
plasma	O
creatinine	O
ratio	O
le	O
than	O
20	O
,	O
urinary	O
sodium	O
concentration	O
16	O
to	O
60	O
meq	O
/	O
liter	O
,	O
proteinuria	O
,	O
and	O
cylindruria	O
0	O
<EOS>	O
a	O
15-year	O
follow-up	O
of	O
phenytoin-induced	B-Drug
unilateral	B-ADR
gingival	I-ADR
hyperplasia	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
introduction-the	O
aim	O
of	O
this	O
case	O
report	O
is	O
to	O
present	O
a	O
15-year	O
follow-up	O
of	O
a	O
patient	O
with	O
phenytoin	B-Drug
(	O
pht	O
)	O
intoxication	O
with	O
unilateral	B-ADR
gingival	I-ADR
hyperplasia	I-ADR
(	O
gh	O
)	O
0	O
<EOS>	O
introduction-the	O
aim	O
of	O
this	O
case	O
report	O
is	O
to	O
present	O
a	O
15-year	O
follow-up	O
of	O
a	O
patient	O
with	O
phenytoin	O
(	O
pht	B-Drug
)	O
intoxication	O
with	O
unilateral	B-ADR
gingival	I-ADR
hyperplasia	I-ADR
(	O
gh	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
generalized	B-ADR
cutaneous	I-ADR
sclerosis	I-ADR
associated	O
with	O
muscle	O
and	O
oesophageal	O
involvement	O
in	O
a	O
patient	O
exposed	O
to	O
herbicide	O
containing	O
bromocil	O
,	O
diuron	O
and	O
aminotriazole	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
generalized	B-ADR
cutaneous	I-ADR
sclerosis	I-ADR
associated	O
with	O
muscle	O
and	O
oesophageal	O
involvement	O
in	O
a	O
patient	O
exposed	O
to	O
herbicide	O
containing	O
bromocil	B-Drug
,	O
diuron	O
and	O
aminotriazole	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
generalized	B-ADR
cutaneous	I-ADR
sclerosis	I-ADR
associated	O
with	O
muscle	O
and	O
oesophageal	O
involvement	O
in	O
a	O
patient	O
exposed	O
to	O
herbicide	O
containing	O
bromocil	O
,	O
diuron	B-Drug
and	O
aminotriazole	O
0	O
<EOS>	O
albuterol-induced	B-Drug
hypokalemia	O
and	O
it	O
potential	O
cardiac	B-ADR
toxicity	I-ADR
are	O
discussed	O
briefly	O
0	O
<EOS>	O
albuterol-induced	B-Drug
hypokalemia	B-ADR
and	O
it	O
potential	O
cardiac	O
toxicity	O
are	O
discussed	O
briefly	O
0	O
<EOS>	O
hypokalemia	B-ADR
after	O
normal	O
dos	O
of	O
neubulized	O
albuterol	B-Drug
(	O
salbutamol	O
)	O
0	O
<EOS>	O
hypokalemia	B-ADR
after	O
normal	O
dos	O
of	O
neubulized	O
albuterol	O
(	O
salbutamol	B-Drug
)	O
0	O
<EOS>	O
the	O
case	O
of	O
two	O
asthmatic	O
patient	O
who	O
became	O
hypokalemic	B-ADR
after	O
inhalation	O
of	O
normal	O
dos	O
of	O
albuterol	B-Drug
are	O
presented	O
0	O
<EOS>	O
propoxyphene-induced	B-Drug
wide	B-ADR
complex	I-ADR
dysrhythmia	I-ADR
responsive	O
to	O
sodium	O
bicarbonate	O
therapy	O
ha	O
not	O
been	O
previously	O
reported	O
in	O
the	O
literature	O
0	O
<EOS>	O
propoxyphene-induced	B-Drug
wide	B-ADR
qrs	I-ADR
complex	I-ADR
dysrhythmia	I-ADR
responsive	O
to	O
sodium	O
bicarbonate	O
--	O
a	O
case	O
report	O
0	O
<EOS>	O
case	O
report	O
:	O
mannitol	B-Drug
nephrotoxicity	B-ADR
syndrome	I-ADR
:	O
role	O
of	O
hemodialysis	O
and	O
postulate	O
of	O
mechanism	O
0	O
<EOS>	O
hemodialysis	O
should	O
be	O
performed	O
for	O
rapid	O
reversal	O
of	O
mannitol-induced	B-Drug
arf	B-ADR
0	O
<EOS>	O
high-dose	O
intravenous	O
mannitol	B-Drug
infusion	O
in	O
various	O
clinical	O
setting	O
may	O
result	O
in	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
(	O
arf	O
)	O
0	O
<EOS>	O
high-dose	O
intravenous	O
mannitol	B-Drug
infusion	O
in	O
various	O
clinical	O
setting	O
may	O
result	O
in	O
acute	O
renal	O
failure	O
(	O
arf	B-ADR
)	O
0	O
<EOS>	O
mannitol-induced	B-Drug
arf	B-ADR
responds	O
promptly	O
to	O
hemodialysis	O
with	O
rapid	O
resolution	O
of	O
anuria	O
and	O
recovery	O
of	O
renal	O
failure	O
0	O
<EOS>	O
the	O
literature	O
is	O
also	O
reviewed	O
for	O
arf	B-ADR
associated	O
with	O
mannitol	B-Drug
infusion	O
in	O
patient	O
who	O
received	O
dialysis	O
and	O
those	O
who	O
did	O
not	O
receive	O
dialysis	O
;	O
and	O
the	O
possible	O
mechanism	O
(	O
s	O
)	O
of	O
mannitol	O
nephrotoxicity	O
are	O
discussed	O
0	O
<EOS>	O
the	O
literature	O
is	O
also	O
reviewed	O
for	O
arf	O
associated	O
with	O
mannitol	B-Drug
infusion	O
in	O
patient	O
who	O
received	O
dialysis	O
and	O
those	O
who	O
did	O
not	O
receive	O
dialysis	O
;	O
and	O
the	O
possible	O
mechanism	O
(	O
s	O
)	O
of	O
mannitol	O
nephrotoxicity	B-ADR
are	O
discussed	O
0	O
<EOS>	O
this	O
is	O
a	O
report	O
of	O
a	O
case	O
of	O
anuric	B-ADR
arf	I-ADR
after	O
high-dose	O
mannitol	B-Drug
infusion	O
for	O
treatment	O
of	O
narrow-angle	O
glaucoma	O
that	O
readily	O
responded	O
to	O
acute	O
hemodialysis	O
0	O
<EOS>	O
two	O
patient	O
with	O
extrapyramidal	B-ADR
side	I-ADR
effect	I-ADR
after	O
the	O
use	O
of	O
fluphenazine	B-Drug
decanoate	I-Drug
were	O
evaluated	O
by	O
mean	O
of	O
ibzm-spect	O
0	O
<EOS>	O
flumazenil	O
reversal	O
of	O
benzodiazepine-induced	B-Drug
sedation	B-ADR
for	O
a	O
patient	O
with	O
severe	O
pre-ect	O
anxiety	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
68-year-old	O
woman	O
developed	O
a	O
dry	O
,	O
irritating	B-ADR
cough	I-ADR
within	O
one	O
month	O
of	O
starting	O
quinapril	B-Drug
therapy	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	O
0	O
<EOS>	O
cough	B-ADR
induced	O
by	O
quinapril	B-Drug
with	O
resolution	O
after	O
changing	O
to	O
fosinopril	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
chronic	O
,	O
nonproductive	O
cough	B-ADR
secondary	O
to	O
the	O
angiotensin-converting	O
enzyme	O
(	O
ace	O
)	O
inhibitor	O
quinapril	B-Drug
,	O
with	O
complete	O
resolution	O
after	O
switching	O
to	O
another	O
ace	O
inhibitor	O
,	O
fosinopril	O
0	O
<EOS>	O
the	O
cough	B-ADR
continued	O
for	O
the	O
duration	O
of	O
therapy	O
with	O
quinapril	B-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
cough	B-ADR
following	O
the	O
administration	O
of	O
quinapril	B-Drug
,	O
with	O
complete	O
resolution	O
after	O
changing	O
to	O
the	O
alternative	O
ace	O
inhibitor	O
fosinopril	O
in	O
a	O
patient	O
with	O
essential	O
hypertension	O
0	O
<EOS>	O
fracture	B-ADR
of	I-ADR
the	I-ADR
femoral	I-ADR
neck	I-ADR
occurred	O
in	O
one	O
patient	O
during	O
psl	B-Drug
therapy	O
,	O
although	O
the	O
relationship	O
between	O
the	O
fracture	O
and	O
psl	O
therapy	O
wa	O
uncertain	O
0	O
<EOS>	O
cefuroxime-induced	B-Drug
acute	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
in	O
our	O
patient	O
,	O
dian	B-ADR
possibly	O
wa	O
related	O
to	O
cefuroxime	B-Drug
,	O
but	O
the	O
patient	O
did	O
not	O
experience	O
associated	O
allergic	O
symptom	O
0	O
<EOS>	O
the	O
diagnosis	O
wa	O
supported	O
by	O
the	O
temporal	O
course	O
of	O
renal	B-ADR
deterioration	I-ADR
during	O
exposure	O
to	O
cefuroxime	B-Drug
and	O
improvement	O
on	O
it	O
discontinuation	O
;	O
the	O
pattern	O
repeated	O
with	O
rechallenge	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
suspected	O
dian	B-ADR
due	O
to	O
cefuroxime	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
basilar	B-ADR
invagination	I-ADR
which	O
is	O
thought	O
to	O
have	O
arisen	O
from	O
the	O
patient	O
intrauterine	O
exposure	O
to	O
phenytoin	B-Drug
is	O
presented	O
0	O
<EOS>	O
basilar	B-ADR
invagination	I-ADR
and	O
mid-line	O
skeletal	O
abnormality	O
due	O
to	O
in	O
utero	O
exposure	O
to	O
phenytoin	B-Drug
0	O
<EOS>	O
basilar	O
invagination	O
and	O
mid-line	B-ADR
skeletal	I-ADR
abnormality	I-ADR
due	O
to	O
in	O
utero	O
exposure	O
to	O
phenytoin	B-Drug
0	O
<EOS>	O
his	O
symptom	O
of	O
brain	O
stem	O
compression	O
were	O
alleviated	O
and	O
the	O
role	O
of	O
phenytoin	B-Drug
in	O
the	O
production	O
of	O
his	O
craniocervical	B-ADR
abnormality	I-ADR
is	O
discussed	O
0	O
<EOS>	O
temporary	B-ADR
neurologic	I-ADR
abnormality	I-ADR
were	O
observed	O
in	O
one	O
out	O
of	O
23	O
patient	O
undergoing	O
chemotherapy	O
with	O
high-dose	O
methotrexate	B-Drug
(	O
hd-mtx	O
)	O
for	O
osteogenic	O
sarcoma	O
0	O
<EOS>	O
this	O
patient	O
developed	O
sequential	O
symptom	O
including	O
alternative	O
hemiparesis	O
,	O
dysarthria	O
and	O
altered	B-ADR
consciousness	I-ADR
5	O
day	O
after	O
the	O
second	O
course	O
of	O
hd-mtx	B-Drug
(	O
8	O
gm	O
/	O
m2	O
by	O
6	O
h	O
continuous	O
infusion	O
)	O
with	O
leucovorin	O
rescue	O
0	O
<EOS>	O
this	O
patient	O
developed	O
sequential	O
symptom	O
including	O
alternative	O
hemiparesis	O
,	O
dysarthria	B-ADR
and	O
altered	O
consciousness	O
5	O
day	O
after	O
the	O
second	O
course	O
of	O
hd-mtx	B-Drug
(	O
8	O
gm	O
/	O
m2	O
by	O
6	O
h	O
continuous	O
infusion	O
)	O
with	O
leucovorin	O
rescue	O
0	O
<EOS>	O
this	O
patient	O
developed	O
sequential	O
symptom	O
including	O
alternative	O
hemiparesis	B-ADR
,	O
dysarthria	O
and	O
altered	O
consciousness	O
5	O
day	O
after	O
the	O
second	O
course	O
of	O
hd-mtx	B-Drug
(	O
8	O
gm	O
/	O
m2	O
by	O
6	O
h	O
continuous	O
infusion	O
)	O
with	O
leucovorin	O
rescue	O
0	O
<EOS>	O
transient	B-ADR
neurological	I-ADR
disturbance	I-ADR
induced	O
by	O
the	O
chemotherapy	O
of	O
high-dose	O
methotrexate	B-Drug
for	O
osteogenic	O
sarcoma	O
0	O
<EOS>	O
we	O
report	O
a	O
5-year-old	O
boy	O
with	O
cf	O
who	O
had	O
a	O
stricture	B-ADR
of	I-ADR
the	I-ADR
hepatic	I-ADR
flexure	I-ADR
region	I-ADR
with	I-ADR
associated	I-ADR
narrowing	I-ADR
due	O
to	O
submucosal	O
fibrosis	O
of	O
the	O
transverse	O
colon	O
,	O
secondary	O
to	O
high-lipase	B-Drug
pancreatin	I-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
a	O
5-year-old	O
boy	O
with	O
cf	O
who	O
had	O
a	O
stricture	O
of	O
the	O
hepatic	O
flexure	O
region	O
with	O
associated	O
narrowing	O
due	O
to	O
submucosal	B-ADR
fibrosis	I-ADR
of	I-ADR
the	I-ADR
transverse	I-ADR
colon	I-ADR
,	O
secondary	O
to	O
high-lipase	B-Drug
pancreatin	I-Drug
therapy	O
0	O
<EOS>	O
acute	B-ADR
pancreatitis	I-ADR
associated	O
with	O
danazol	B-Drug
treatment	O
for	O
endometriosis	O
0	O
<EOS>	O
additionally	O
,	O
danazol	B-Drug
produce	O
hepatocellular	B-ADR
damage	I-ADR
in	O
approximately	O
10	O
%	O
of	O
woman	O
0	O
<EOS>	O
hypo-oestrogenic	B-ADR
and	I-ADR
anabolic	I-ADR
/	I-ADR
androgenic	I-ADR
side-effects	I-ADR
of	O
danazol	B-Drug
are	O
well	O
known	O
by	O
the	O
gynaecologist	O
and	O
some	O
of	O
them	O
are	O
present	O
in	O
>	O
50	O
%	O
of	O
patient	O
being	O
treated	O
for	O
endometriosis	O
0	O
<EOS>	O
the	O
present	O
report	O
describes	O
the	O
first	O
case	O
of	O
acute	B-ADR
pancreatitis	I-ADR
associated	O
with	O
danazol	B-Drug
treatment	O
of	O
endometriosis	O
0	O
<EOS>	O
acyclovir	B-Drug
neurotoxicity	B-ADR
:	O
clinical	O
experience	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
acyclovir	B-Drug
produce	O
neurologic	B-ADR
symptom	I-ADR
that	O
resemble	O
extension	O
of	O
viral	O
infection	O
into	O
the	O
central	O
nervous	O
system	O
0	O
<EOS>	O
systemic	O
disease	O
,	O
most	O
commonly	O
renal	O
dysfunction	O
,	O
preceded	O
all	O
30	O
reported	O
case	O
of	O
acyclovir	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
we	O
discus	O
our	O
observation	O
in	O
the	O
case	O
of	O
two	O
patient	O
with	O
acyclovir	B-Drug
neurotoxicity	B-ADR
and	O
review	O
the	O
finding	O
of	O
all	O
previous	O
report	O
in	O
the	O
english	O
language	O
literature	O
0	O
<EOS>	O
response	O
of	O
a	O
promethazine-induced	B-Drug
coma	B-ADR
to	O
flumazenil	O
0	O
<EOS>	O
we	O
report	O
the	O
first	O
case	O
of	O
a	O
patient	O
in	O
a	O
promethazine-induced	B-Drug
coma	B-ADR
responding	O
to	O
treatment	O
with	O
flumazenil	O
0	O
<EOS>	O
amebic	B-ADR
abscess	I-ADR
of	I-ADR
the	I-ADR
spleen	I-ADR
complicated	O
by	O
metronidazole-induced	B-Drug
neurotoxicity	O
:	O
case	O
report	O
0	O
<EOS>	O
amebic	O
abscess	O
of	O
the	O
spleen	O
complicated	O
by	O
metronidazole-induced	B-Drug
neurotoxicity	B-ADR
:	O
case	O
report	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
a	O
liver	O
abscess	O
due	O
to	O
entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
day	O
)	O
wa	O
complicated	O
by	O
reversible	O
deafness	O
,	O
tinnitus	O
,	O
and	O
ataxia	B-ADR
and	O
who	O
relapsed	O
5	O
month	O
later	O
with	O
a	O
splenic	O
abscess	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
a	O
liver	B-ADR
abscess	I-ADR
due	O
to	O
entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
day	O
)	O
wa	O
complicated	O
by	O
reversible	O
deafness	O
,	O
tinnitus	O
,	O
and	O
ataxia	O
and	O
who	O
relapsed	O
5	O
month	O
later	O
with	O
a	O
splenic	O
abscess	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
a	O
liver	O
abscess	O
due	O
to	O
entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
day	O
)	O
wa	O
complicated	O
by	O
reversible	B-ADR
deafness	I-ADR
,	O
tinnitus	O
,	O
and	O
ataxia	O
and	O
who	O
relapsed	O
5	O
month	O
later	O
with	O
a	O
splenic	O
abscess	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
a	O
liver	O
abscess	O
due	O
to	O
entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
day	O
)	O
wa	O
complicated	O
by	O
reversible	O
deafness	O
,	O
tinnitus	O
,	O
and	O
ataxia	O
and	O
who	O
relapsed	O
5	O
month	O
later	O
with	O
a	O
splenic	B-ADR
abscess	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
a	O
liver	O
abscess	O
due	O
to	O
entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
day	O
)	O
wa	O
complicated	O
by	O
reversible	O
deafness	O
,	O
tinnitus	B-ADR
,	O
and	O
ataxia	O
and	O
who	O
relapsed	O
5	O
month	O
later	O
with	O
a	O
splenic	O
abscess	O
0	O
<EOS>	O
actinomycin	B-Drug
d	I-Drug
associated	O
hepatic	B-ADR
veno-occlusive	I-ADR
disease	I-ADR
--	O
a	O
report	O
of	O
2	O
case	O
0	O
<EOS>	O
there	O
are	O
now	O
report	O
of	O
liver	B-ADR
failure	I-ADR
following	O
treatment	O
of	O
childhood	O
cancer	O
with	O
amd	B-Drug
0	O
<EOS>	O
phenylpropanolamine-induced	B-Drug
psychosis	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
cae	O
of	O
paranoid	B-ADR
psychosis	I-ADR
following	O
use	O
of	O
a	O
decongestant	O
containing	O
ppa	B-Drug
and	O
summarize	O
the	O
case	O
report	O
literature	O
of	O
psychiatric	O
adverse	O
effect	O
to	O
ppa	O
in	O
which	O
dos	O
were	O
known	O
and	O
stated	O
to	O
be	O
within	O
recommended	O
guideline	O
0	O
<EOS>	O
we	O
report	O
a	O
cae	O
of	O
paranoid	O
psychosis	O
following	O
use	O
of	O
a	O
decongestant	O
containing	O
ppa	B-Drug
and	O
summarize	O
the	O
case	O
report	O
literature	O
of	O
psychiatric	B-ADR
adverse	I-ADR
effect	I-ADR
to	O
ppa	O
in	O
which	O
dos	O
were	O
known	O
and	O
stated	O
to	O
be	O
within	O
recommended	O
guideline	O
0	O
<EOS>	O
conclusion	O
:	O
although	O
budesonide	B-Drug
may	O
be	O
beneficial	O
because	O
of	O
it	O
anti-inflammatory	O
effect	O
,	O
clinician	O
should	O
be	O
alert	O
to	O
it	O
potential	O
for	O
causing	O
contact	B-ADR
dermatitis	I-ADR
0	O
<EOS>	O
contact	B-ADR
dermatitis	I-ADR
due	O
to	O
budesonide	B-Drug
:	O
report	O
of	O
five	O
case	O
and	O
review	O
of	O
the	O
japanese	O
literature	O
0	O
<EOS>	O
method	O
:	O
five	O
case	O
of	O
contact	B-ADR
dermatitis	I-ADR
due	O
to	O
budesonide	B-Drug
,	O
a	O
nonhalogenated	O
steroid	O
,	O
are	O
described	O
0	O
<EOS>	O
result	O
:	O
budesonide	B-Drug
use	O
can	O
cause	O
contact	B-ADR
dermatitis	I-ADR
0	O
<EOS>	O
although	O
other	O
nitrite	O
induce	O
methemoglobinemia	B-ADR
,	O
exposure	O
to	O
methyl	B-Drug
nitrite	I-Drug
during	O
phenylpropanolamine	O
production	O
appears	O
to	O
be	O
a	O
new	O
cause	O
of	O
occupational	O
methemoglobinemia	O
0	O
<EOS>	O
although	O
other	O
nitrite	O
induce	O
methemoglobinemia	B-ADR
,	O
exposure	O
to	O
methyl	B-Drug
nitrite	I-Drug
during	O
phenylpropanolamine	O
production	O
appears	O
to	O
be	O
a	O
new	O
cause	O
of	O
occupational	O
methemoglobinemia	O
0	O
<EOS>	O
methemoglobinemia	B-ADR
:	O
an	O
occupational	O
hazard	O
of	O
phenylpropanolamine	B-Drug
production	O
0	O
<EOS>	O
during	O
and	O
after	O
ifn	B-Drug
therapy	O
we	O
should	O
consider	O
the	O
possibility	O
of	O
occurrence	O
of	O
iddm	B-ADR
a	O
well	O
a	O
other	O
autoimmune	O
disease	O
and	O
observe	O
the	O
clinical	O
course	O
carefully	O
0	O
<EOS>	O
four	O
year	O
after	O
the	O
beginning	O
of	O
ifn	B-Drug
therapy	O
,	O
he	O
acutely	O
developed	O
moderate	B-ADR
hyperglycemia	I-ADR
and	O
severe	O
ketonuria	O
with	O
positive	O
islet	O
cell	O
antibody	O
,	O
and	O
then	O
28	O
unit	O
/	O
day	O
of	O
insulin	O
injection	O
wa	O
started	O
0	O
<EOS>	O
four	O
year	O
after	O
the	O
beginning	O
of	O
ifn	B-Drug
therapy	O
,	O
he	O
acutely	O
developed	O
moderate	O
hyperglycemia	O
and	O
severe	B-ADR
ketonuria	I-ADR
with	O
positive	O
islet	O
cell	O
antibody	O
,	O
and	O
then	O
28	O
unit	O
/	O
day	O
of	O
insulin	O
injection	O
wa	O
started	O
0	O
<EOS>	O
occurrence	O
of	O
iddm	B-ADR
during	O
interferon	B-Drug
therapy	O
for	O
chronic	O
viral	O
hepatitis	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
iddm	B-ADR
which	O
occurred	O
during	O
interferon	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
0	O
<EOS>	O
four	O
patient	O
who	O
manifested	O
symptom	O
of	O
the	O
antiepileptic	O
drug	O
(	O
aed	O
)	O
hypersensitivity	B-ADR
syndrome	I-ADR
during	O
therapy	O
with	O
carbamazepine	B-Drug
are	O
reported	O
0	O
<EOS>	O
recurrent	B-ADR
hypotension	I-ADR
immediately	O
after	O
seizure	O
in	O
nortriptyline	B-Drug
overdose	O
0	O
<EOS>	O
recurrent	O
hypotension	O
immediately	O
after	O
seizure	B-ADR
in	O
nortriptyline	B-Drug
overdose	O
0	O
<EOS>	O
the	O
use	O
of	O
methotrexate	B-Drug
(	O
mtx	O
)	O
ha	O
been	O
contraindicated	O
for	O
treatment	O
of	O
severe	O
psoriasis	O
in	O
hiv	O
infection	O
on	O
the	O
basis	O
of	O
six	O
previously	O
reported	O
case	O
in	O
which	O
mtx	O
appeared	O
to	O
potentiate	O
opportunistic	O
infection	O
and	O
accelerate	B-ADR
hiv	I-ADR
disease	I-ADR
0	O
<EOS>	O
the	O
use	O
of	O
methotrexate	O
(	O
mtx	B-Drug
)	O
ha	O
been	O
contraindicated	O
for	O
treatment	O
of	O
severe	O
psoriasis	O
in	O
hiv	O
infection	O
on	O
the	O
basis	O
of	O
six	O
previously	O
reported	O
case	O
in	O
which	O
mtx	O
appeared	O
to	O
potentiate	O
opportunistic	O
infection	O
and	O
accelerate	B-ADR
hiv	I-ADR
disease	I-ADR
0	O
<EOS>	O
the	O
use	O
of	O
methotrexate	O
(	O
mtx	B-Drug
)	O
ha	O
been	O
contraindicated	O
for	O
treatment	O
of	O
severe	O
psoriasis	O
in	O
hiv	O
infection	O
on	O
the	O
basis	O
of	O
six	O
previously	O
reported	O
case	O
in	O
which	O
mtx	O
appeared	O
to	O
potentiate	O
opportunistic	O
infection	O
and	O
accelerate	B-ADR
hiv	I-ADR
disease	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
describes	O
the	O
clinically	O
significant	O
increase	B-ADR
of	I-ADR
inr	I-ADR
in	O
an	O
elderly	O
patient	O
after	O
adding	O
a	O
chemotherapy	O
regimen	O
of	O
levamisole	O
and	O
5-fu	B-Drug
to	O
a	O
previous	O
regimen	O
of	O
warfarin	O
alone	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
describes	O
the	O
clinically	O
significant	O
increase	B-ADR
of	I-ADR
inr	I-ADR
in	O
an	O
elderly	O
patient	O
after	O
adding	O
a	O
chemotherapy	O
regimen	O
of	O
levamisole	B-Drug
and	O
5-fu	O
to	O
a	O
previous	O
regimen	O
of	O
warfarin	O
alone	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
case	O
describes	O
the	O
clinically	O
significant	O
increase	B-ADR
of	I-ADR
inr	I-ADR
in	O
an	O
elderly	O
patient	O
after	O
adding	O
a	O
chemotherapy	O
regimen	O
of	O
levamisole	O
and	O
5-fu	O
to	O
a	O
previous	O
regimen	O
of	O
warfarin	B-Drug
alone	O
0	O
<EOS>	O
however	O
,	O
prolongation	O
of	O
5-fu	B-Drug
half-life	O
and	O
an	O
increase	B-ADR
in	I-ADR
inr	I-ADR
have	O
been	O
reported	O
with	O
the	O
concurrent	O
use	O
of	O
5-fu	O
and	O
warfarin	O
0	O
<EOS>	O
however	O
,	O
prolongation	O
of	O
5-fu	O
half-life	O
and	O
an	O
increase	B-ADR
in	I-ADR
inr	I-ADR
have	O
been	O
reported	O
with	O
the	O
concurrent	O
use	O
of	O
5-fu	O
and	O
warfarin	B-Drug
0	O
<EOS>	O
cholestatic	B-ADR
liver	I-ADR
disease	I-ADR
with	O
ductopenia	O
(	O
vanishing	O
bile	O
duct	O
syndrome	O
)	O
after	O
administration	O
of	O
clindamycin	B-Drug
and	O
trimethoprim-sulfamethoxazole	O
0	O
<EOS>	O
cholestatic	B-ADR
liver	I-ADR
disease	I-ADR
with	O
ductopenia	O
(	O
vanishing	O
bile	O
duct	O
syndrome	O
)	O
after	O
administration	O
of	O
clindamycin	O
and	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
cholestatic	O
liver	O
disease	O
with	O
ductopenia	B-ADR
(	O
vanishing	O
bile	O
duct	O
syndrome	O
)	O
after	O
administration	O
of	O
clindamycin	B-Drug
and	O
trimethoprim-sulfamethoxazole	O
0	O
<EOS>	O
cholestatic	O
liver	O
disease	O
with	O
ductopenia	B-ADR
(	O
vanishing	O
bile	O
duct	O
syndrome	O
)	O
after	O
administration	O
of	O
clindamycin	O
and	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
cholestatic	O
liver	O
disease	O
with	O
ductopenia	O
(	O
vanishing	B-ADR
bile	I-ADR
duct	I-ADR
syndrome	I-ADR
)	O
after	O
administration	O
of	O
clindamycin	B-Drug
and	O
trimethoprim-sulfamethoxazole	O
0	O
<EOS>	O
cholestatic	O
liver	O
disease	O
with	O
ductopenia	O
(	O
vanishing	B-ADR
bile	I-ADR
duct	I-ADR
syndrome	I-ADR
)	O
after	O
administration	O
of	O
clindamycin	O
and	O
trimethoprim-sulfamethoxazole	B-Drug
0	O
<EOS>	O
one	O
patient	O
who	O
received	O
clindamycin	B-Drug
had	O
liver	O
biopsy	O
finding	O
of	O
marked	O
cholestasis	O
,	O
portal	O
inflammation	O
,	O
bile	B-ADR
duct	I-ADR
injury	I-ADR
and	O
bile	O
duct	O
paucity	O
(	O
ductopenia	O
)	O
0	O
<EOS>	O
one	O
patient	O
who	O
received	O
clindamycin	B-Drug
had	O
liver	O
biopsy	O
finding	O
of	O
marked	O
cholestasis	O
,	O
portal	O
inflammation	O
,	O
bile	O
duct	O
injury	O
and	O
bile	B-ADR
duct	I-ADR
paucity	I-ADR
(	O
ductopenia	O
)	O
0	O
<EOS>	O
one	O
patient	O
who	O
received	O
clindamycin	B-Drug
had	O
liver	O
biopsy	O
finding	O
of	O
marked	O
cholestasis	O
,	O
portal	O
inflammation	O
,	O
bile	O
duct	O
injury	O
and	O
bile	O
duct	O
paucity	O
(	O
ductopenia	B-ADR
)	O
0	O
<EOS>	O
one	O
patient	O
who	O
received	O
clindamycin	B-Drug
had	O
liver	O
biopsy	O
finding	O
of	O
marked	B-ADR
cholestasis	I-ADR
,	O
portal	O
inflammation	O
,	O
bile	O
duct	O
injury	O
and	O
bile	O
duct	O
paucity	O
(	O
ductopenia	O
)	O
0	O
<EOS>	O
one	O
patient	O
who	O
received	O
clindamycin	B-Drug
had	O
liver	O
biopsy	O
finding	O
of	O
marked	O
cholestasis	O
,	O
portal	B-ADR
inflammation	I-ADR
,	O
bile	O
duct	O
injury	O
and	O
bile	O
duct	O
paucity	O
(	O
ductopenia	O
)	O
0	O
<EOS>	O
the	O
second	O
patient	O
,	O
who	O
developed	O
cholestasis	B-ADR
after	O
receiving	O
trimethoprim-sulfamethoxazole	B-Drug
,	O
had	O
marked	O
duct	O
paucity	O
in	O
the	O
liver	O
biopsy	O
0	O
<EOS>	O
the	O
second	O
patient	O
,	O
who	O
developed	O
cholestasis	O
after	O
receiving	O
trimethoprim-sulfamethoxazole	B-Drug
,	O
had	O
marked	O
duct	B-ADR
paucity	I-ADR
in	O
the	O
liver	O
biopsy	O
0	O
<EOS>	O
this	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
ductopenia	B-ADR
apparently	O
caused	O
by	O
clindamycin	B-Drug
0	O
<EOS>	O
three	O
year	O
later	O
,	O
treatment	O
with	O
ampicillin	B-Drug
caused	O
another	O
episode	O
of	O
cholestatic	O
hepatitis	O
with	O
cholestasis	B-ADR
and	O
duct	O
paucity	O
on	O
rebiopsy	O
0	O
<EOS>	O
three	O
year	O
later	O
,	O
treatment	O
with	O
ampicillin	B-Drug
caused	O
another	O
episode	O
of	O
cholestatic	B-ADR
hepatitis	I-ADR
with	O
cholestasis	O
and	O
duct	O
paucity	O
on	O
rebiopsy	O
0	O
<EOS>	O
three	O
year	O
later	O
,	O
treatment	O
with	O
ampicillin	B-Drug
caused	O
another	O
episode	O
of	O
cholestatic	O
hepatitis	O
with	O
cholestasis	O
and	O
duct	B-ADR
paucity	I-ADR
on	O
rebiopsy	O
0	O
<EOS>	O
method	O
:	O
a	O
patient	O
who	O
developed	O
dramatic	O
,	O
permanent	O
vision	B-ADR
loss	I-ADR
after	O
a	O
9-month	O
course	O
of	O
treatment	O
with	O
ethambutol	B-Drug
and	O
isoniazid	O
for	O
pulmonary	O
tuberculosis	O
is	O
presented	O
0	O
<EOS>	O
method	O
:	O
a	O
patient	O
who	O
developed	O
dramatic	O
,	O
permanent	O
vision	B-ADR
loss	I-ADR
after	O
a	O
9-month	O
course	O
of	O
treatment	O
with	O
ethambutol	O
and	O
isoniazid	B-Drug
for	O
pulmonary	O
tuberculosis	O
is	O
presented	O
0	O
<EOS>	O
result	O
:	O
ethambutol	B-Drug
,	O
and	O
to	O
a	O
lesser	O
extent	O
isoniazid	O
,	O
are	O
both	O
implicated	O
in	O
the	O
development	B-ADR
of	I-ADR
visually	I-ADR
related	I-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
result	O
:	O
ethambutol	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
isoniazid	B-Drug
,	O
are	O
both	O
implicated	O
in	O
the	O
development	B-ADR
of	I-ADR
visually	I-ADR
related	I-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
there	O
is	O
documentation	O
of	O
ocular	B-ADR
toxicity	I-ADR
with	O
ethambutol	B-Drug
when	O
administered	O
at	O
dosage	O
generally	O
pronounced	O
a	O
being	O
safe	O
0	O
<EOS>	O
toxic	B-ADR
optic	I-ADR
neuropathy	I-ADR
associated	O
with	O
ethambutol	B-Drug
:	O
implication	O
for	O
current	O
therapy	O
0	O
<EOS>	O
currently	O
the	O
use	O
of	O
zidovudine	B-Drug
is	O
one	O
of	O
the	O
few	O
specific	O
measure	O
available	O
,	O
and	O
a	O
a	O
potentially	O
teratogenic	O
and	O
fetotoxic	O
agent	O
,	O
any	O
decision	O
for	O
it	O
use	O
requires	O
evaluation	O
of	O
the	O
potential	O
for	O
fetal	B-ADR
damage	I-ADR
0	O
<EOS>	O
currently	O
the	O
use	O
of	O
zidovudine	B-Drug
is	O
one	O
of	O
the	O
few	O
specific	O
measure	O
available	O
,	O
and	O
a	O
a	O
potentially	O
teratogenic	O
and	O
fetotoxic	B-ADR
agent	O
,	O
any	O
decision	O
for	O
it	O
use	O
requires	O
evaluation	O
of	O
the	O
potential	O
for	O
fetal	O
damage	O
0	O
<EOS>	O
currently	O
the	O
use	O
of	O
zidovudine	B-Drug
is	O
one	O
of	O
the	O
few	O
specific	O
measure	O
available	O
,	O
and	O
a	O
a	O
potentially	O
teratogenic	B-ADR
and	O
fetotoxic	O
agent	O
,	O
any	O
decision	O
for	O
it	O
use	O
requires	O
evaluation	O
of	O
the	O
potential	O
for	O
fetal	O
damage	O
0	O
<EOS>	O
in	O
a	O
series	O
of	O
104	O
case	O
of	O
intentional	O
or	O
inadvertent	O
use	O
of	O
zidovudine	B-Drug
at	O
differing	O
gestation	O
in	O
pregnancy	O
,	O
there	O
were	O
eight	O
spontaneous	O
first	O
trimester	O
abortion	O
,	O
eight	O
therapeutic	O
termination	O
,	O
and	O
eight	O
case	O
of	O
fetal	B-ADR
abnormality	I-ADR
occurring	O
among	O
a	O
total	O
of	O
88	O
case	O
where	O
the	O
pregnancy	O
progressed	O
0	O
<EOS>	O
in	O
a	O
series	O
of	O
104	O
case	O
of	O
intentional	O
or	O
inadvertent	O
use	O
of	O
zidovudine	B-Drug
at	O
differing	O
gestation	O
in	O
pregnancy	O
,	O
there	O
were	O
eight	O
spontaneous	O
first	B-ADR
trimester	I-ADR
abortion	I-ADR
,	O
eight	O
therapeutic	O
termination	O
,	O
and	O
eight	O
case	O
of	O
fetal	O
abnormality	O
occurring	O
among	O
a	O
total	O
of	O
88	O
case	O
where	O
the	O
pregnancy	O
progressed	O
0	O
<EOS>	O
zidovudine	B-Drug
use	O
in	O
pregnancy	O
:	O
a	O
report	O
on	O
104	O
case	O
and	O
the	O
occurrence	O
of	O
birth	B-ADR
defect	I-ADR
0	O
<EOS>	O
celiprolol	B-Drug
pneumonitis	B-ADR
0	O
<EOS>	O
inadvertent	O
subsequent	O
rechallenge	O
with	O
celiprolol	B-Drug
led	O
to	O
recurrence	O
of	O
the	O
pneumonitis	B-ADR
,	O
10	O
week	O
after	O
drug	O
readministration	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
patient	O
who	O
developed	O
hypersensitivity	B-ADR
pneumonitis	I-ADR
during	O
treatment	O
with	O
the	O
beta-blocker	O
,	O
celiprolol	B-Drug
0	O
<EOS>	O
ibopamine-induced	B-Drug
reversible	O
leukopenia	B-ADR
during	O
treatment	O
for	O
congestive	O
heart	O
failure	O
0	O
<EOS>	O
reversible	B-ADR
leukopenia	I-ADR
wa	O
documented	O
in	O
an	O
81-year-old	O
woman	O
treated	O
with	O
adjunctive	O
ibopamine	B-Drug
100	O
mg	O
t.i.d	O
0	O
for	O
chronic	O
congestive	O
heart	O
failure	O
0	O
<EOS>	O
diphenylhydantoin	B-Drug
apparently	O
adversely	O
affected	O
both	O
the	O
clinical	O
and	O
biochemical	O
parameter	O
of	O
the	O
acute	B-ADR
intermittent	I-ADR
porphyria	I-ADR
0	O
<EOS>	O
significant	O
clinical	O
improvement	O
of	O
the	O
porphyria	B-ADR
followed	O
withdrawal	O
of	O
the	O
diphenylhydantoin	B-Drug
0	O
<EOS>	O
a	O
53-year-old	O
male	O
,	O
without	O
any	O
prior	O
history	O
of	O
psychosis	O
,	O
developed	O
schizophrenia	B-ADR
4	O
day	O
after	O
starting	O
low-dose	O
bromocriptine	B-Drug
therapy	O
for	O
a	O
macroprolactinoma	O
0	O
<EOS>	O
bromocriptine-induced	B-Drug
schizophrenia	B-ADR
0	O
<EOS>	O
concurrent	B-ADR
acute	I-ADR
megaloblastic	I-ADR
anaemia	I-ADR
and	O
pneumonitis	O
:	O
a	O
severe	O
side-effect	O
of	O
low-dose	O
methotrexate	B-Drug
therapy	O
during	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
concurrent	O
acute	O
megaloblastic	O
anaemia	O
and	O
pneumonitis	B-ADR
:	O
a	O
severe	O
side-effect	O
of	O
low-dose	O
methotrexate	B-Drug
therapy	O
during	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
in	O
a	O
patient	O
suffering	O
from	O
rheumatoid	O
arthritis	O
,	O
we	O
report	O
the	O
first	O
simultaneous	O
occurrence	O
of	O
two	O
side	O
effect	O
of	O
low-dose	O
methotrexate	B-Drug
:	O
an	O
acute	B-ADR
megaloblastic	I-ADR
anaemia	I-ADR
and	O
a	O
pneumonitis	O
0	O
<EOS>	O
in	O
a	O
patient	O
suffering	O
from	O
rheumatoid	O
arthritis	O
,	O
we	O
report	O
the	O
first	O
simultaneous	O
occurrence	O
of	O
two	O
side	O
effect	O
of	O
low-dose	O
methotrexate	B-Drug
:	O
an	O
acute	O
megaloblastic	O
anaemia	O
and	O
a	O
pneumonitis	B-ADR
0	O
<EOS>	O
an	O
11-year-old	O
boy	O
who	O
wa	O
treated	O
with	O
a	O
relatively	O
high	O
dose	O
of	O
methotrimeprazine	O
meleate	O
(	O
levemepromazine	B-Drug
)	O
a	O
phenothiazine	O
antipsychotic	O
drug	O
,	O
wa	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
suffering	O
from	O
respiratory	B-ADR
distress	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
an	O
11-year-old	O
boy	O
who	O
wa	O
treated	O
with	O
a	O
relatively	O
high	O
dose	O
of	O
methotrimeprazine	B-Drug
meleate	I-Drug
(	O
levemepromazine	O
)	O
a	O
phenothiazine	O
antipsychotic	O
drug	O
,	O
wa	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
suffering	O
from	O
respiratory	B-ADR
distress	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
the	O
association	O
of	O
phenothiazine	B-Drug
overdose	O
and	O
respiratory	B-ADR
distress	I-ADR
syndrome	I-ADR
merit	O
consideration	O
0	O
<EOS>	O
in	O
two	O
patient	O
,	O
apomorphine	B-Drug
remained	O
effective	O
in	O
the	O
morning	O
,	O
but	O
increased	O
the	O
intensity	O
of	O
the	O
dyskinesia	B-ADR
in	O
the	O
afternoon	O
0	O
<EOS>	O
we	O
report	O
on	O
three	O
observation	O
of	O
parkinsonian	O
patient	O
with	O
levo-dopa-induced	B-Drug
diphasic	B-ADR
dyskinesia	I-ADR
,	O
who	O
received	O
subcutaneous	O
apomorphine	O
to	O
reduce	O
the	O
duration	O
of	O
abnormal	O
movement	O
0	O
<EOS>	O
fulminant	B-ADR
hepatitis	I-ADR
with	O
severe	O
lactate	O
acidosis	O
in	O
hiv-infected	O
patient	O
on	O
didanosine	B-Drug
therapy	O
0	O
<EOS>	O
fulminant	O
hepatitis	O
with	O
severe	B-ADR
lactate	I-ADR
acidosis	I-ADR
in	O
hiv-infected	O
patient	O
on	O
didanosine	B-Drug
therapy	O
0	O
<EOS>	O
this	O
prompted	O
u	O
to	O
suspect	O
that	O
ddi	B-Drug
might	O
be	O
responsible	O
for	O
fulminant	B-ADR
hepatitis	I-ADR
in	O
all	O
three	O
aid	O
patient	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
in	O
hiv-1-infected	O
patient	O
treated	O
with	O
didanosine	O
(	O
ddi	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
in	O
hiv-1-infected	O
patient	O
treated	O
with	O
didanosine	B-Drug
(	O
ddi	O
)	O
0	O
<EOS>	O
generalized	B-ADR
argyria	I-ADR
after	O
habitual	O
use	O
of	O
agno3	B-Drug
0	O
<EOS>	O
a	O
case	O
of	O
fluoxetine	B-Drug
induced	O
seizure	B-ADR
,	O
in	O
a	O
person	O
with	O
down	O
syndrome	O
,	O
is	O
described	O
0	O
<EOS>	O
seizure	B-ADR
associated	O
with	O
fluoxetine	B-Drug
therapy	O
are	O
uncommon	O
0	O
<EOS>	O
seizure	B-ADR
associated	O
with	O
fluoxetine	B-Drug
therapy	O
0	O
<EOS>	O
although	O
fluoxetine-induced	B-Drug
headache	B-ADR
occurred	O
in	O
one	O
patient	O
,	O
the	O
other	O
five	O
reported	O
no	O
side	O
effect	O
at	O
the	O
dos	O
used	O
0	O
<EOS>	O
sodium	O
valproate	O
and	O
carbamazepine	B-Drug
,	O
antiepileptic	O
drug	O
that	O
are	O
associated	O
with	O
a	O
relatively	O
low	O
rate	O
of	O
adverse	O
cutaneous	O
reaction	O
,	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
drug	O
that	O
produce	O
psoriasiform	B-ADR
eruption	I-ADR
0	O
<EOS>	O
sodium	B-Drug
valproate	I-Drug
and	O
carbamazepine	O
,	O
antiepileptic	O
drug	O
that	O
are	O
associated	O
with	O
a	O
relatively	O
low	O
rate	O
of	O
adverse	O
cutaneous	O
reaction	O
,	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
drug	O
that	O
produce	O
psoriasiform	B-ADR
eruption	I-ADR
0	O
<EOS>	O
we	O
present	O
finding	O
from	O
three	O
patient	O
who	O
experienced	O
a	O
psoriasiform	B-ADR
eruption	I-ADR
apparently	O
due	O
to	O
the	O
antiepileptic	O
agent	O
sodium	O
valproate	O
and	O
carbamazepine	B-Drug
0	O
<EOS>	O
we	O
present	O
finding	O
from	O
three	O
patient	O
who	O
experienced	O
a	O
psoriasiform	B-ADR
eruption	I-ADR
apparently	O
due	O
to	O
the	O
antiepileptic	O
agent	O
sodium	B-Drug
valproate	I-Drug
and	O
carbamazepine	O
0	O
<EOS>	O
severe	B-ADR
diffuse	I-ADR
interstitial	I-ADR
pneumonitis	I-ADR
induced	O
by	O
carmustine	O
(	O
bcnu	B-Drug
)	O
0	O
<EOS>	O
severe	B-ADR
diffuse	I-ADR
interstitial	I-ADR
pneumonitis	I-ADR
induced	O
by	O
carmustine	B-Drug
(	O
bcnu	O
)	O
0	O
<EOS>	O
we	O
report	O
a	O
fatal	B-ADR
case	I-ADR
of	I-ADR
acute	I-ADR
interstitial	I-ADR
pneumonitis	I-ADR
in	O
a	O
patient	O
treated	O
with	O
carmustine	O
(	O
bcnu	B-Drug
)	O
for	O
a	O
brain	O
tumor	O
0	O
<EOS>	O
we	O
report	O
a	O
fatal	B-ADR
case	I-ADR
of	I-ADR
acute	I-ADR
interstitial	I-ADR
pneumonitis	I-ADR
in	O
a	O
patient	O
treated	O
with	O
carmustine	B-Drug
(	O
bcnu	O
)	O
for	O
a	O
brain	O
tumor	O
0	O
<EOS>	O
a	O
78-year-old	O
man	O
with	O
a	O
transvenous	O
cardioverter	O
defibrillator	O
system	O
developed	O
frequent	O
shock	B-ADR
during	O
oral	O
procainamide	B-Drug
therapy	O
0	O
<EOS>	O
electrical	B-ADR
proarrhythmia	I-ADR
with	O
procainamide	B-Drug
:	O
a	O
new	O
icd-drug	O
interaction	O
0	O
<EOS>	O
the	O
failure	O
of	O
therapy	O
with	O
disopyramide	O
and	O
mexiletine	O
to	O
reproduce	O
this	O
observation	O
suggests	O
either	O
a	O
previously	O
unreported	O
electrophysiologic	B-ADR
effect	I-ADR
of	O
,	O
or	O
idiosyncratic	O
response	O
to	O
,	O
procainamide	B-Drug
0	O
<EOS>	O
based	O
on	O
our	O
experience	O
and	O
on	O
previously	O
published	O
data	O
,	O
serum	O
ammonia	O
level	O
appear	O
to	O
be	O
indicated	O
in	O
all	O
ed	O
patient	O
on	O
valproic	B-Drug
acid	I-Drug
therapy	O
who	O
present	O
with	O
altered	B-ADR
mental	I-ADR
status	I-ADR
0	O
<EOS>	O
hyperammonemia	B-ADR
ha	O
been	O
described	O
a	O
a	O
complication	O
of	O
valproic	B-Drug
acid	I-Drug
therapy	O
but	O
may	O
often	O
be	O
overlooked	O
a	O
a	O
cause	O
of	O
lethargy	O
in	O
the	O
postictal	O
patient	O
who	O
present	O
to	O
the	O
emergency	O
department	O
0	O
<EOS>	O
hyperammonemia	O
ha	O
been	O
described	O
a	O
a	O
complication	O
of	O
valproic	B-Drug
acid	I-Drug
therapy	O
but	O
may	O
often	O
be	O
overlooked	O
a	O
a	O
cause	O
of	O
lethargy	B-ADR
in	O
the	O
postictal	O
patient	O
who	O
present	O
to	O
the	O
emergency	O
department	O
0	O
<EOS>	O
hyperammonemia	B-ADR
secondary	O
to	O
valproic	B-Drug
acid	I-Drug
a	O
a	O
cause	O
of	O
lethargy	O
in	O
a	O
postictal	O
patient	O
0	O
<EOS>	O
hyperammonemia	O
secondary	O
to	O
valproic	B-Drug
acid	I-Drug
a	O
a	O
cause	O
of	O
lethargy	B-ADR
in	O
a	O
postictal	O
patient	O
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
postictal	O
patient	O
with	O
lethargy	O
,	O
hyperammonemia	B-ADR
,	O
otherwise	O
normal	O
liver	O
function	O
test	O
,	O
and	O
a	O
therapeutic	O
valproic	B-Drug
acid	I-Drug
level	O
0	O
<EOS>	O
we	O
present	O
the	O
case	O
of	O
a	O
postictal	O
patient	O
with	O
lethargy	B-ADR
,	O
hyperammonemia	O
,	O
otherwise	O
normal	O
liver	O
function	O
test	O
,	O
and	O
a	O
therapeutic	O
valproic	B-Drug
acid	I-Drug
level	O
0	O
<EOS>	O
central	B-ADR
nervous	I-ADR
system	I-ADR
toxicity	I-ADR
associated	O
with	O
meperidine	B-Drug
use	O
in	O
hepatic	O
disease	O
0	O
<EOS>	O
in	O
patient	O
with	O
cirrhosis	O
,	O
the	O
metabolism	O
of	O
meperidine	B-Drug
is	O
decreased	O
,	O
leading	O
to	O
accumulation	B-ADR
of	I-ADR
the	I-ADR
parent	I-ADR
drug	I-ADR
and	O
possible	O
cns	O
depressive	O
effect	O
similar	O
to	O
hepatic	O
encephalopathy	O
0	O
<EOS>	O
in	O
patient	O
with	O
cirrhosis	O
,	O
the	O
metabolism	O
of	O
meperidine	B-Drug
is	O
decreased	O
,	O
leading	O
to	O
accumulation	O
of	O
the	O
parent	O
drug	O
and	O
possible	O
cns	B-ADR
depressive	I-ADR
effect	I-ADR
similar	O
to	O
hepatic	O
encephalopathy	O
0	O
<EOS>	O
meperidine-associated	B-Drug
central	O
nervous	O
system	O
(	O
cns	O
)	O
excitatory	O
toxicity	O
are	O
believed	O
to	O
be	O
caused	O
by	O
accumulation	B-ADR
of	I-ADR
the	I-ADR
active	I-ADR
metabolite	I-ADR
normeperidine	I-ADR
0	O
<EOS>	O
meperidine-associated	B-Drug
central	B-ADR
nervous	I-ADR
system	I-ADR
(	I-ADR
cns	I-ADR
)	I-ADR
excitatory	I-ADR
toxicity	I-ADR
are	O
believed	O
to	O
be	O
caused	O
by	O
accumulation	O
of	O
the	O
active	O
metabolite	O
normeperidine	O
0	O
<EOS>	O
she	O
received	O
an	O
accidental	O
450-mg	O
bolus	O
injection	O
of	O
morphine	B-Drug
intrathecally	O
and	O
developed	O
hypertension	B-ADR
,	O
status	O
epilepticus	O
,	O
intracerebral	O
hemorrhage	O
,	O
and	O
respiratory	O
failure	O
0	O
<EOS>	O
she	O
received	O
an	O
accidental	O
450-mg	O
bolus	O
injection	O
of	O
morphine	B-Drug
intrathecally	O
and	O
developed	O
hypertension	O
,	O
status	O
epilepticus	O
,	O
intracerebral	B-ADR
hemorrhage	I-ADR
,	O
and	O
respiratory	O
failure	O
0	O
<EOS>	O
she	O
received	O
an	O
accidental	O
450-mg	O
bolus	O
injection	O
of	O
morphine	B-Drug
intrathecally	O
and	O
developed	O
hypertension	O
,	O
status	O
epilepticus	O
,	O
intracerebral	O
hemorrhage	O
,	O
and	O
respiratory	B-ADR
failure	I-ADR
0	O
<EOS>	O
she	O
received	O
an	O
accidental	O
450-mg	O
bolus	O
injection	O
of	O
morphine	B-Drug
intrathecally	O
and	O
developed	O
hypertension	O
,	O
status	B-ADR
epilepticus	I-ADR
,	O
intracerebral	O
hemorrhage	O
,	O
and	O
respiratory	O
failure	O
0	O
<EOS>	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
is	O
an	O
alkylating	O
agent	O
that	O
ha	O
been	O
recently	O
associated	O
with	O
the	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
(	O
hus	O
)	O
0	O
<EOS>	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
is	O
an	O
alkylating	O
agent	O
that	O
ha	O
been	O
recently	O
associated	O
with	O
the	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
(	O
hus	O
)	O
0	O
<EOS>	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
is	O
an	O
alkylating	O
agent	O
that	O
ha	O
been	O
recently	O
associated	O
with	O
the	O
hemolytic-uremic	O
syndrome	O
(	O
hus	B-ADR
)	O
0	O
<EOS>	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
is	O
an	O
alkylating	O
agent	O
that	O
ha	O
been	O
recently	O
associated	O
with	O
the	O
hemolytic-uremic	O
syndrome	O
(	O
hus	B-ADR
)	O
0	O
<EOS>	O
pulmonary	O
hemorrhage	O
a	O
a	O
clinical	O
manifestation	O
of	O
hemolytic-uremic	B-ADR
syndrome	I-ADR
associated	O
with	O
mitomycin	B-Drug
c	I-Drug
therapy	O
0	O
<EOS>	O
pulmonary	B-ADR
hemorrhage	I-ADR
a	O
a	O
clinical	O
manifestation	O
of	O
hemolytic-uremic	O
syndrome	O
associated	O
with	O
mitomycin	B-Drug
c	I-Drug
therapy	O
0	O
<EOS>	O
pulmonary	O
hemorrhage	O
is	O
an	O
uncommon	O
feature	O
in	O
the	O
hus	B-ADR
,	O
and	O
seems	O
to	O
appear	O
especially	O
in	O
the	O
hus	O
associated	O
with	O
mmc	B-Drug
therapy	O
0	O
<EOS>	O
pulmonary	O
hemorrhage	O
is	O
an	O
uncommon	O
feature	O
in	O
the	O
hus	B-ADR
,	O
and	O
seems	O
to	O
appear	O
especially	O
in	O
the	O
hus	O
associated	O
with	O
mmc	B-Drug
therapy	O
0	O
<EOS>	O
pulmonary	B-ADR
hemorrhage	I-ADR
is	O
an	O
uncommon	O
feature	O
in	O
the	O
hus	O
,	O
and	O
seems	O
to	O
appear	O
especially	O
in	O
the	O
hus	O
associated	O
with	O
mmc	B-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
two	O
woman	O
who	O
developed	O
hus	B-ADR
after	O
mmc	B-Drug
therapy	O
and	O
presented	O
massive	O
pulmonary	O
bleeding	O
0	O
<EOS>	O
we	O
describe	O
two	O
woman	O
who	O
developed	O
hus	O
after	O
mmc	B-Drug
therapy	O
and	O
presented	O
massive	B-ADR
pulmonary	I-ADR
bleeding	I-ADR
0	O
<EOS>	O
clonidine-induced	B-Drug
bradycardia	B-ADR
in	O
patient	O
with	O
spinal	O
cord	O
injury	O
0	O
<EOS>	O
possible	O
mechanism	O
by	O
which	O
clonidine	B-Drug
decrease	O
spasticity	O
are	O
described	O
,	O
probable	O
mechanism	O
of	O
induced	O
bradycardia	B-ADR
are	O
reviewed	O
,	O
and	O
specific	O
treatment	O
recommendation	O
for	O
the	O
use	O
of	O
clonidine	O
in	O
spinal	O
cord	O
injured	O
patient	O
are	O
presented	O
0	O
<EOS>	O
possible	O
mechanism	O
by	O
which	O
clonidine	B-Drug
decrease	O
spasticity	O
are	O
described	O
,	O
probable	O
mechanism	O
of	O
induced	O
bradycardia	B-ADR
are	O
reviewed	O
,	O
and	O
specific	O
treatment	O
recommendation	O
for	O
the	O
use	O
of	O
clonidine	O
in	O
spinal	O
cord	O
injured	O
patient	O
are	O
presented	O
0	O
<EOS>	O
though	O
hypotension	O
,	O
dry	O
mouth	O
,	O
and	O
constipation	O
are	O
well-documented	O
possible	O
adverse	O
effect	O
,	O
the	O
possibility	O
of	O
clonidine-induced	B-Drug
bradycardia	B-ADR
is	O
le	O
well	O
recognized	O
and	O
is	O
rare	O
0	O
<EOS>	O
though	O
hypotension	O
,	O
dry	O
mouth	O
,	O
and	O
constipation	B-ADR
are	O
well-documented	O
possible	O
adverse	O
effect	O
,	O
the	O
possibility	O
of	O
clonidine-induced	B-Drug
bradycardia	O
is	O
le	O
well	O
recognized	O
and	O
is	O
rare	O
0	O
<EOS>	O
though	O
hypotension	O
,	O
dry	B-ADR
mouth	I-ADR
,	O
and	O
constipation	O
are	O
well-documented	O
possible	O
adverse	O
effect	O
,	O
the	O
possibility	O
of	O
clonidine-induced	B-Drug
bradycardia	O
is	O
le	O
well	O
recognized	O
and	O
is	O
rare	O
0	O
<EOS>	O
though	O
hypotension	B-ADR
,	O
dry	O
mouth	O
,	O
and	O
constipation	O
are	O
well-documented	O
possible	O
adverse	O
effect	O
,	O
the	O
possibility	O
of	O
clonidine-induced	B-Drug
bradycardia	O
is	O
le	O
well	O
recognized	O
and	O
is	O
rare	O
0	O
<EOS>	O
a	O
high	O
dose	O
of	O
cotrimoxazole	B-Drug
induced	O
hyperkalaemia	O
with	O
the	O
elevation	B-ADR
of	I-ADR
serum	I-ADR
creatinine	I-ADR
and	I-ADR
blood	I-ADR
urea	I-ADR
,	O
and	O
increased	O
urinary	O
n-acetyl	O
glucosaminase	O
after	O
several	O
day	O
of	O
the	O
drug	O
administration	O
in	O
these	O
patient	O
;	O
one	O
patient	O
became	O
unconscious	O
0	O
<EOS>	O
a	O
high	O
dose	O
of	O
cotrimoxazole	B-Drug
induced	O
hyperkalaemia	B-ADR
with	O
the	O
elevation	O
of	O
serum	O
creatinine	O
and	O
blood	O
urea	O
,	O
and	O
increased	O
urinary	O
n-acetyl	O
glucosaminase	O
after	O
several	O
day	O
of	O
the	O
drug	O
administration	O
in	O
these	O
patient	O
;	O
one	O
patient	O
became	O
unconscious	O
0	O
<EOS>	O
a	O
high	O
dose	O
of	O
cotrimoxazole	B-Drug
induced	O
hyperkalaemia	O
with	O
the	O
elevation	O
of	O
serum	O
creatinine	O
and	O
blood	O
urea	O
,	O
and	O
increased	B-ADR
urinary	I-ADR
n-acetyl	I-ADR
glucosaminase	I-ADR
after	O
several	O
day	O
of	O
the	O
drug	O
administration	O
in	O
these	O
patient	O
;	O
one	O
patient	O
became	O
unconscious	O
0	O
<EOS>	O
a	O
high	O
dose	O
of	O
cotrimoxazole	B-Drug
induced	O
hyperkalaemia	O
with	O
the	O
elevation	O
of	O
serum	O
creatinine	O
and	O
blood	O
urea	O
,	O
and	O
increased	O
urinary	O
n-acetyl	O
glucosaminase	O
after	O
several	O
day	O
of	O
the	O
drug	O
administration	O
in	O
these	O
patient	O
;	O
one	B-ADR
patient	I-ADR
became	I-ADR
unconscious	I-ADR
0	O
<EOS>	O
hyperkalaemia	B-ADR
with	O
renal	O
tubular	O
dysfunction	O
by	O
oral	O
therapy	O
of	O
sulfamethoxazole-trimethoprim	O
(	O
co-trimoxazole	B-Drug
)	O
is	O
described	O
in	O
2	O
elderly	O
japanese	O
patient	O
with	O
lymphoid	O
malignancy	O
,	O
who	O
developed	O
pneumocystis	O
carinii	O
pneumonia	O
and	O
improved	O
0	O
<EOS>	O
hyperkalaemia	B-ADR
with	O
renal	O
tubular	O
dysfunction	O
by	O
oral	O
therapy	O
of	O
sulfamethoxazole-trimethoprim	B-Drug
(	O
co-trimoxazole	O
)	O
is	O
described	O
in	O
2	O
elderly	O
japanese	O
patient	O
with	O
lymphoid	O
malignancy	O
,	O
who	O
developed	O
pneumocystis	O
carinii	O
pneumonia	O
and	O
improved	O
0	O
<EOS>	O
hyperkalaemia	O
with	O
renal	B-ADR
tubular	I-ADR
dysfunction	I-ADR
by	O
oral	O
therapy	O
of	O
sulfamethoxazole-trimethoprim	O
(	O
co-trimoxazole	B-Drug
)	O
is	O
described	O
in	O
2	O
elderly	O
japanese	O
patient	O
with	O
lymphoid	O
malignancy	O
,	O
who	O
developed	O
pneumocystis	O
carinii	O
pneumonia	O
and	O
improved	O
0	O
<EOS>	O
hyperkalaemia	O
with	O
renal	B-ADR
tubular	I-ADR
dysfunction	I-ADR
by	O
oral	O
therapy	O
of	O
sulfamethoxazole-trimethoprim	B-Drug
(	O
co-trimoxazole	O
)	O
is	O
described	O
in	O
2	O
elderly	O
japanese	O
patient	O
with	O
lymphoid	O
malignancy	O
,	O
who	O
developed	O
pneumocystis	O
carinii	O
pneumonia	O
and	O
improved	O
0	O
<EOS>	O
hyperkalaemia	B-ADR
with	O
renal	O
tubular	O
dysfunction	O
by	O
sulfamethoxazole-trimethoprim	B-Drug
for	O
pneumocystis	O
carinii	O
pneumonia	O
in	O
patient	O
with	O
lymphoid	O
malignancy	O
0	O
<EOS>	O
hyperkalaemia	O
with	O
renal	B-ADR
tubular	I-ADR
dysfunction	I-ADR
by	O
sulfamethoxazole-trimethoprim	B-Drug
for	O
pneumocystis	O
carinii	O
pneumonia	O
in	O
patient	O
with	O
lymphoid	O
malignancy	O
0	O
<EOS>	O
five	O
case	O
(	O
four	O
from	O
the	O
literature	O
and	O
one	O
new	O
case	O
)	O
are	O
presented	O
in	O
which	O
patient	O
unsuspected	O
of	O
having	O
vitamin	O
b12	O
deficiency	O
developed	O
subacute	B-ADR
combined	I-ADR
degeneration	I-ADR
of	I-ADR
the	I-ADR
spinal	I-ADR
cord	I-ADR
following	O
nitrous	B-Drug
oxide	I-Drug
anesthesia	O
0	O
<EOS>	O
neurologic	B-ADR
degeneration	I-ADR
associated	O
with	O
nitrous	B-Drug
oxide	I-Drug
anesthesia	O
in	O
patient	O
with	O
vitamin	O
b12	O
deficiency	O
0	O
<EOS>	O
patient	O
with	O
vitamin	O
b12	O
deficiency	O
are	O
exceedingly	O
sensitive	O
to	O
neurologic	B-ADR
deterioration	I-ADR
following	O
nitrous	B-Drug
oxide	I-Drug
anesthesia	O
0	O
<EOS>	O
background	O
:	O
fluoxetine	B-Drug
,	O
a	O
highly	O
specific	O
serotonin	O
reuptake	O
inhibitor	O
,	O
ha	O
been	O
reported	O
to	O
cause	O
sexual	B-ADR
dysfunction	I-ADR
in	O
a	O
minority	O
of	O
patient	O
0	O
<EOS>	O
captopril-induced	B-Drug
bone	B-ADR
marrow	I-ADR
suppression	I-ADR
in	O
two	O
cardiac	O
patient	O
with	O
trisomy	O
21	O
0	O
<EOS>	O
neutropenia	B-ADR
is	O
an	O
infrequent	O
complication	O
following	O
administration	O
of	O
the	O
angiotensin-converting	O
enzyme	O
(	O
ace	O
)	O
inhibitor	O
,	O
captopril	B-Drug
0	O
<EOS>	O
we	O
report	O
two	O
case	O
of	O
neutropenia	B-ADR
following	O
captopril	B-Drug
use	O
in	O
cardiac	O
patient	O
with	O
trisomy	O
21	O
0	O
<EOS>	O
can	O
magnesium	B-Drug
sulfate	I-Drug
therapy	O
impact	O
lactogenesis	B-ADR
?	O
<EOS>	O
no	O
explanation	O
for	O
this	O
delay	O
wa	O
found	O
,	O
other	O
than	O
the	O
possibility	O
that	O
magnesium	B-Drug
sulfate	I-Drug
treatment	O
impeded	B-ADR
lactogenesis	I-ADR
0	O
<EOS>	O
four	O
day	O
after	O
the	O
initial	O
injection	O
of	O
3.6	O
mg	O
of	O
goserelin	B-Drug
acetate	I-Drug
,	O
severe	O
dyspnea	O
developed	O
due	O
to	O
worsening	O
pleuritis	O
carcinomatosa	O
,	O
which	O
wa	O
considered	O
a	O
a	O
flare-up	B-ADR
0	O
<EOS>	O
four	O
day	O
after	O
the	O
initial	O
injection	O
of	O
3.6	O
mg	O
of	O
goserelin	B-Drug
acetate	I-Drug
,	O
severe	B-ADR
dyspnea	I-ADR
developed	O
due	O
to	O
worsening	O
pleuritis	O
carcinomatosa	O
,	O
which	O
wa	O
considered	O
a	O
a	O
flare-up	O
0	O
<EOS>	O
four	O
day	O
after	O
the	O
initial	O
injection	O
of	O
3.6	O
mg	O
of	O
goserelin	B-Drug
acetate	I-Drug
,	O
severe	O
dyspnea	O
developed	O
due	O
to	O
worsening	B-ADR
pleuritis	I-ADR
carcinomatosa	I-ADR
,	O
which	O
wa	O
considered	O
a	O
a	O
flare-up	O
0	O
<EOS>	O
imidazoline	B-Drug
intoxication	I-ADR
due	O
to	O
overdose	O
or	O
accidental	O
ingestion	O
but	O
also	O
after	O
normal	O
therapeutic	O
usage	O
is	O
frequent	O
in	O
child	O
0	O
<EOS>	O
imidazoline	B-Drug
intoxication	I-ADR
in	O
child	O
0	O
<EOS>	O
cerebrovascular	O
complication	O
of	O
l-asparaginase	B-Drug
therapy	O
in	O
child	O
with	O
leukemia	O
:	O
aphasia	B-ADR
and	O
other	O
neuropsychological	O
deficit	O
0	O
<EOS>	O
cerebrovascular	B-ADR
complication	I-ADR
of	O
l-asparaginase	B-Drug
therapy	O
in	O
child	O
with	O
leukemia	O
:	O
aphasia	O
and	O
other	O
neuropsychological	O
deficit	O
0	O
<EOS>	O
cerebrovascular	O
complication	O
of	O
l-asparaginase	B-Drug
therapy	O
in	O
child	O
with	O
leukemia	O
:	O
aphasia	O
and	O
other	O
neuropsychological	B-ADR
deficit	I-ADR
0	O
<EOS>	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
,	O
treated	O
with	O
l-asparaginase	B-Drug
are	O
at	O
risk	O
for	O
cerebral	B-ADR
thrombosis	I-ADR
or	O
hemorrhage	O
because	O
of	O
coagulation	O
protein	O
deficiency	O
0	O
<EOS>	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
,	O
treated	O
with	O
l-asparaginase	B-Drug
are	O
at	O
risk	O
for	O
cerebral	O
thrombosis	O
or	O
hemorrhage	O
because	O
of	O
coagulation	B-ADR
protein	I-ADR
deficiency	I-ADR
0	O
<EOS>	O
child	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
,	O
treated	O
with	O
l-asparaginase	B-Drug
are	O
at	O
risk	O
for	O
cerebral	O
thrombosis	O
or	O
hemorrhage	B-ADR
because	O
of	O
coagulation	O
protein	O
deficiency	O
0	O
<EOS>	O
myoclonus	B-ADR
and	O
seizure	O
disappeared	O
after	O
discontinuation	O
of	O
l-dopa	B-Drug
and	O
the	O
introduction	O
of	O
valproate	O
sodium	O
(	O
vpa	O
)	O
0	O
<EOS>	O
myoclonus	O
and	O
seizure	B-ADR
disappeared	O
after	O
discontinuation	O
of	O
l-dopa	B-Drug
and	O
the	O
introduction	O
of	O
valproate	O
sodium	O
(	O
vpa	O
)	O
0	O
<EOS>	O
myoclonus	B-ADR
and	O
seizure	O
in	O
a	O
patient	O
with	O
parkinsonism	O
:	O
induction	O
by	O
levodopa	B-Drug
and	O
it	O
confirmation	O
on	O
sep	O
0	O
<EOS>	O
myoclonus	O
and	O
seizure	B-ADR
in	O
a	O
patient	O
with	O
parkinsonism	O
:	O
induction	O
by	O
levodopa	B-Drug
and	O
it	O
confirmation	O
on	O
sep	O
0	O
<EOS>	O
myoclonus	O
wa	O
induced	O
and	O
enhanced	O
by	O
l-dopa	B-Drug
,	O
developing	O
into	O
generalized	B-ADR
seizure	I-ADR
0	O
<EOS>	O
myoclonus	B-ADR
wa	O
induced	O
and	O
enhanced	O
by	O
l-dopa	B-Drug
,	O
developing	O
into	O
generalized	O
seizure	O
0	O
<EOS>	O
we	O
described	O
the	O
occurrence	O
of	O
l-dopa-induced	B-Drug
myoclonus	B-ADR
and	O
seizure	O
in	O
a	O
case	O
of	O
parkinsonism	O
with	O
it	O
sep	O
finding	O
0	O
<EOS>	O
we	O
described	O
the	O
occurrence	O
of	O
l-dopa-induced	B-Drug
myoclonus	O
and	O
seizure	B-ADR
in	O
a	O
case	O
of	O
parkinsonism	O
with	O
it	O
sep	O
finding	O
0	O
<EOS>	O
unintended	O
exposure	O
to	O
acyclovir	B-Drug
early	O
in	O
pregnancy	O
,	O
which	O
is	O
not	O
uncommon	O
,	O
may	O
cause	O
excessive	B-ADR
maternal	I-ADR
and	I-ADR
physician	I-ADR
anxiety	I-ADR
0	O
<EOS>	O
a	O
severe	O
form	O
of	O
exophthalmos	B-ADR
resulting	O
from	O
lithium	B-Drug
therapy	O
ha	O
not	O
been	O
described	O
in	O
the	O
literature	O
0	O
<EOS>	O
lithium	B-Drug
therapy	O
wa	O
discontinued	O
because	O
of	O
poor	O
compliance	O
to	O
the	O
medication	O
and	O
intolerable	O
polyuria	B-ADR
0	O
<EOS>	O
regression	O
of	O
thyrotoxic	B-ADR
ophthalmopathy	I-ADR
following	O
lithium	B-Drug
withdrawal	O
0	O
<EOS>	O
the	O
case	O
of	O
a	O
bipolar	O
patient	O
who	O
developed	O
thyrotoxicosis	O
with	O
severe	B-ADR
exophthalmos	I-ADR
while	O
on	O
lithium	B-Drug
therapy	O
is	O
described	O
0	O
<EOS>	O
the	O
case	O
of	O
a	O
bipolar	O
patient	O
who	O
developed	O
thyrotoxicosis	B-ADR
with	O
severe	O
exophthalmos	O
while	O
on	O
lithium	B-Drug
therapy	O
is	O
described	O
0	O
<EOS>	O
the	O
exophthalmos	B-ADR
improved	O
dramatically	O
within	O
72	O
hour	O
of	O
the	O
withdrawal	O
of	O
lithium	B-Drug
0	O
<EOS>	O
severe	O
abdominal	B-ADR
pain	I-ADR
in	O
low	O
dosage	O
clofazimine	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
41	O
yr	O
old	O
leprosy	O
patient	O
treated	O
for	O
10	O
yr	O
with	O
clofazimine	B-Drug
who	O
underwent	O
laparotomy	O
for	O
severe	O
abdominal	B-ADR
pain	I-ADR
0	O
<EOS>	O
amphotericin	B-Drug
b	I-Drug
overdose	O
in	O
pediatric	O
patient	O
with	O
associated	O
cardiac	B-ADR
arrest	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
amphotericin	B-Drug
b	I-Drug
overdose	O
can	O
be	O
fatal	B-ADR
in	O
child	O
and	O
infant	O
0	O
<EOS>	O
hydrocortisone	O
may	O
decrease	O
the	O
incidence	O
of	O
mortality	O
associated	O
with	O
cardiac	B-ADR
arrhythmia	I-ADR
in	O
child	O
receiving	O
amphotericin	B-Drug
b	I-Drug
overdoses	O
0	O
<EOS>	O
hydrocortisone	O
may	O
decrease	O
the	O
incidence	O
of	O
mortality	B-ADR
associated	O
with	O
cardiac	O
arrhythmia	O
in	O
child	O
receiving	O
amphotericin	B-Drug
b	I-Drug
overdoses	O
0	O
<EOS>	O
intervention	O
and	O
result	O
:	O
cardiac	B-ADR
complication	I-ADR
were	O
observed	O
in	O
five	O
pediatric	O
patient	O
who	O
received	O
between	O
4.6	O
and	O
40.8	O
mg	O
/	O
kg	O
/	O
d	O
of	O
amphotericin	B-Drug
b	I-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
the	O
first	O
five	O
case	O
of	O
amphotericin	B-Drug
b	I-Drug
overdose	O
with	O
secondary	O
cardiac	B-ADR
complication	I-ADR
in	O
a	O
pediatric	O
population	O
0	O
<EOS>	O
hypertension	B-ADR
develops	O
in	O
most	O
patient	O
after	O
transplantation	O
when	O
immunosuppression	O
is	O
based	O
on	O
cyclosporine	B-Drug
and	O
prednisone	O
0	O
<EOS>	O
hypertension	B-ADR
develops	O
in	O
most	O
patient	O
after	O
transplantation	O
when	O
immunosuppression	O
is	O
based	O
on	O
cyclosporine	O
and	O
prednisone	B-Drug
0	O
<EOS>	O
sudden	B-ADR
death	I-ADR
in	O
an	O
infant	O
from	O
methemoglobinemia	O
after	O
administration	O
of	O
``	O
sweet	B-Drug
spirit	I-Drug
of	I-Drug
nitre	I-Drug
'	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	O
spirit	O
of	O
nitre	O
'	O
(	O
4	B-Drug
%	I-Drug
ethyl	I-Drug
nitrite	I-Drug
ch3ch2ono	I-Drug
in	I-Drug
70	I-Drug
%	I-Drug
ethyl	I-Drug
alcohol	I-Drug
)	O
wa	O
followed	O
by	O
acute	B-ADR
methemoglobinemia	I-ADR
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	B-Drug
spirit	I-Drug
of	I-Drug
nitre	I-Drug
'	O
(	O
4	O
%	O
ethyl	O
nitrite	O
ch3ch2ono	O
in	O
70	O
%	O
ethyl	O
alcohol	O
)	O
wa	O
followed	O
by	O
acute	B-ADR
methemoglobinemia	I-ADR
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	O
spirit	O
of	O
nitre	O
'	O
(	O
4	B-Drug
%	I-Drug
ethyl	I-Drug
nitrite	I-Drug
ch3ch2ono	I-Drug
in	I-Drug
70	I-Drug
%	I-Drug
ethyl	I-Drug
alcohol	I-Drug
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	B-ADR
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	B-Drug
spirit	I-Drug
of	I-Drug
nitre	I-Drug
'	O
(	O
4	O
%	O
ethyl	O
nitrite	O
ch3ch2ono	O
in	O
70	O
%	O
ethyl	O
alcohol	O
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	B-ADR
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	O
spirit	O
of	O
nitre	O
'	O
(	O
4	B-Drug
%	I-Drug
ethyl	I-Drug
nitrite	I-Drug
ch3ch2ono	I-Drug
in	I-Drug
70	I-Drug
%	I-Drug
ethyl	I-Drug
alcohol	I-Drug
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	B-ADR
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	B-Drug
spirit	I-Drug
of	I-Drug
nitre	I-Drug
'	O
(	O
4	O
%	O
ethyl	O
nitrite	O
ch3ch2ono	O
in	O
70	O
%	O
ethyl	O
alcohol	O
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	O
anoxic	O
metabolic	O
acidosis	O
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	B-ADR
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	O
spirit	O
of	O
nitre	O
'	O
(	O
4	B-Drug
%	I-Drug
ethyl	I-Drug
nitrite	I-Drug
ch3ch2ono	I-Drug
in	I-Drug
70	I-Drug
%	I-Drug
ethyl	I-Drug
alcohol	I-Drug
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	B-ADR
anoxic	I-ADR
metabolic	I-ADR
acidosis	I-ADR
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
the	O
administration	O
of	O
``	O
sweet	B-Drug
spirit	I-Drug
of	I-Drug
nitre	I-Drug
'	O
(	O
4	O
%	O
ethyl	O
nitrite	O
ch3ch2ono	O
in	O
70	O
%	O
ethyl	O
alcohol	O
)	O
wa	O
followed	O
by	O
acute	O
methemoglobinemia	O
and	O
severe	B-ADR
anoxic	I-ADR
metabolic	I-ADR
acidosis	I-ADR
in	O
infant	O
twin	O
,	O
methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	O
from	O
the	O
consequence	O
of	O
hypoxemia	O
0	O
<EOS>	O
hepatotoxic	B-ADR
effect	I-ADR
in	O
a	O
child	O
receiving	O
valproate	O
and	O
carnitine	B-Drug
0	O
<EOS>	O
hepatotoxic	B-ADR
effect	I-ADR
in	O
a	O
child	O
receiving	O
valproate	B-Drug
and	O
carnitine	O
0	O
<EOS>	O
l-carnitine	O
supplementation	O
ha	O
been	O
recommended	O
to	O
prevent	O
the	O
fatal	B-ADR
hepatotoxic	I-ADR
effect	I-ADR
associated	O
with	O
valproic	B-Drug
acid	I-Drug
0	O
<EOS>	O
we	O
report	O
on	O
a	O
child	O
with	O
fatal	B-ADR
valproate-related	I-Drug
hepatotoxic	O
effect	O
despite	O
this	O
supplementation	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
child	O
with	O
fatal	O
valproate-related	B-Drug
hepatotoxic	B-ADR
effect	I-ADR
despite	O
this	O
supplementation	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
a	O
40	O
year	O
old	O
woman	O
treated	O
with	O
intraventricular	O
il-2	B-Drug
for	O
leptomeningeal	O
disease	O
who	O
developed	O
progressive	O
cognitive	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
delayed	O
neurotoxicity	B-ADR
of	O
intraventricular	O
interleukin-2	B-Drug
:	O
a	O
case	O
report	O
0	O
<EOS>	O
the	O
potential	O
for	O
progressive	O
brain	B-ADR
injury	I-ADR
and	O
subsequent	O
disability	O
related	O
to	O
intraventricular	O
il-2	B-Drug
therapy	O
is	O
discussed	O
0	O
<EOS>	O
the	O
potential	O
for	O
progressive	O
brain	O
injury	O
and	O
subsequent	O
disability	B-ADR
related	O
to	O
intraventricular	O
il-2	B-Drug
therapy	O
is	O
discussed	O
0	O
<EOS>	O
albeit	O
rare	O
among	O
western	O
patient	O
,	O
such	O
lithium-associated	B-Drug
thyroid	B-ADR
dysfunction	I-ADR
appeared	O
to	O
be	O
more	O
likely	O
to	O
occur	O
in	O
hong	O
kong	O
chinese	O
0	O
<EOS>	O
four	O
chinese	O
female	O
patient	O
who	O
suffered	O
from	O
manic-depressive	O
disorder	O
and	O
underlying	O
autoimmune	O
thyroiditis	O
developed	O
transient	O
episode	O
of	O
thyrotoxicosis	B-ADR
during	O
maintenance	O
lithium	B-Drug
therapy	O
0	O
<EOS>	O
lithium-associated	B-Drug
transient	B-ADR
thyrotoxicosis	I-ADR
in	O
4	O
chinese	O
woman	O
with	O
autoimmune	O
thyroiditis	O
0	O
<EOS>	O
they	O
seemed	O
to	O
involve	O
multiple	O
aetiological	O
factor	O
,	O
such	O
a	O
autoimmune	O
thyroid	O
disease	O
,	O
the	O
toxic	B-ADR
and	I-ADR
immunomodulatory	I-ADR
role	I-ADR
of	O
lithium	B-Drug
and	O
perhaps	O
genetic	O
and	O
dietary	O
factor	O
0	O
<EOS>	O
although	O
retinoic	B-Drug
acid	I-Drug
is	O
well	O
tolerated	O
by	O
the	O
majority	O
of	O
patient	O
with	O
this	O
disease	O
,	O
a	O
potentially	O
fatal	B-ADR
complication	I-ADR
of	O
this	O
kind	O
of	O
treatment	O
ha	O
been	O
reported	O
:	O
``	O
the	O
retinoic	O
acid	O
syndrome	O
'	O
0	O
<EOS>	O
although	O
retinoic	B-Drug
acid	I-Drug
is	O
well	O
tolerated	O
by	O
the	O
majority	O
of	O
patient	O
with	O
this	O
disease	O
,	O
a	O
potentially	O
fatal	O
complication	O
of	O
this	O
kind	O
of	O
treatment	O
ha	O
been	O
reported	O
:	O
``	O
the	O
retinoic	B-ADR
acid	I-ADR
syndrome	I-ADR
'	O
0	O
<EOS>	O
conclusion	O
:	O
it	O
is	O
probable	O
that	O
foscarnet	B-Drug
contributed	O
to	O
the	O
electrolyte	B-ADR
disorder	I-ADR
and	O
symptomatology	O
in	O
this	O
patient	O
0	O
<EOS>	O
discussion	O
:	O
electrolyte	B-ADR
disorder	I-ADR
associated	O
with	O
foscarnet	B-Drug
are	O
reviewed	O
0	O
<EOS>	O
foscarnet-induced	B-Drug
severe	O
hypomagnesemia	O
and	O
other	O
electrolyte	B-ADR
disorder	I-ADR
0	O
<EOS>	O
foscarnet-induced	B-Drug
severe	B-ADR
hypomagnesemia	I-ADR
and	O
other	O
electrolyte	O
disorder	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
possible	O
foscarnet-induced	B-Drug
severe	O
hypomagnesemia	O
and	O
other	O
electrolyte	B-ADR
disorder	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
possible	O
foscarnet-induced	B-Drug
severe	B-ADR
hypomagnesemia	I-ADR
and	O
other	O
electrolyte	O
disorder	O
0	O
<EOS>	O
the	O
patient	O
experienced	O
muscle	O
twitch	O
,	O
tremulousness	O
,	O
and	O
anxiety	B-ADR
on	O
day	O
17	O
of	O
foscarnet	B-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
experienced	O
muscle	B-ADR
twitch	I-ADR
,	O
tremulousness	O
,	O
and	O
anxiety	O
on	O
day	O
17	O
of	O
foscarnet	B-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
experienced	O
muscle	O
twitch	O
,	O
tremulousness	B-ADR
,	O
and	O
anxiety	O
on	O
day	O
17	O
of	O
foscarnet	B-Drug
therapy	O
0	O
<EOS>	O
interference	B-ADR
with	I-ADR
the	I-ADR
cortisol	I-ADR
axis	I-ADR
by	O
the	O
microtubule	O
antagonist	O
,	O
cph82	B-Drug
0	O
<EOS>	O
the	O
result	O
clearly	O
demonstrate	O
that	O
cph82	B-Drug
wa	O
associated	O
with	O
suppression	O
of	O
the	O
endogeneous	O
production	O
of	O
acth	O
and	O
cortisol	O
with	O
a	O
concomitant	O
paradoxical	O
picture	O
of	O
clinical	O
hypercortisolism	B-ADR
0	O
<EOS>	O
the	O
result	O
clearly	O
demonstrate	O
that	O
cph82	B-Drug
wa	O
associated	O
with	O
suppression	B-ADR
of	I-ADR
the	I-ADR
endogeneous	I-ADR
production	I-ADR
of	I-ADR
acth	I-ADR
and	I-ADR
cortisol	I-ADR
with	O
a	O
concomitant	O
paradoxical	O
picture	O
of	O
clinical	O
hypercortisolism	O
0	O
<EOS>	O
a	O
variety	O
of	O
movement	B-ADR
disorder	I-ADR
are	O
known	O
to	O
occur	O
in	O
association	O
with	O
carbamazepine	B-Drug
(	O
cbz	O
)	O
therapy	O
in	O
adult	O
and	O
child	O
,	O
but	O
development	O
of	O
tic	O
ha	O
been	O
described	O
infrequently	O
and	O
only	O
in	O
patient	O
with	O
underlying	O
tourette	O
syndrome	O
or	O
other	O
movement	O
disorder	O
0	O
<EOS>	O
a	O
variety	O
of	O
movement	B-ADR
disorder	I-ADR
are	O
known	O
to	O
occur	O
in	O
association	O
with	O
carbamazepine	O
(	O
cbz	B-Drug
)	O
therapy	O
in	O
adult	O
and	O
child	O
,	O
but	O
development	O
of	O
tic	O
ha	O
been	O
described	O
infrequently	O
and	O
only	O
in	O
patient	O
with	O
underlying	O
tourette	O
syndrome	O
or	O
other	O
movement	O
disorder	O
0	O
<EOS>	O
a	O
variety	O
of	O
movement	O
disorder	O
are	O
known	O
to	O
occur	O
in	O
association	O
with	O
carbamazepine	B-Drug
(	O
cbz	O
)	O
therapy	O
in	O
adult	O
and	O
child	O
,	O
but	O
development	O
of	O
tic	B-ADR
ha	O
been	O
described	O
infrequently	O
and	O
only	O
in	O
patient	O
with	O
underlying	O
tourette	O
syndrome	O
or	O
other	O
movement	O
disorder	O
0	O
<EOS>	O
a	O
variety	O
of	O
movement	O
disorder	O
are	O
known	O
to	O
occur	O
in	O
association	O
with	O
carbamazepine	O
(	O
cbz	B-Drug
)	O
therapy	O
in	O
adult	O
and	O
child	O
,	O
but	O
development	O
of	O
tic	B-ADR
ha	O
been	O
described	O
infrequently	O
and	O
only	O
in	O
patient	O
with	O
underlying	O
tourette	O
syndrome	O
or	O
other	O
movement	O
disorder	O
0	O
<EOS>	O
carbamazepine-induced	B-Drug
tic	B-ADR
0	O
<EOS>	O
in	O
the	O
third	O
child	O
,	O
the	O
tic	B-ADR
ceased	O
after	O
cbz	B-Drug
discontinuation	O
0	O
<EOS>	O
these	O
case	O
demonstrate	O
that	O
cbz	B-Drug
can	O
induce	O
simple	O
motor	B-ADR
tic	I-ADR
in	O
child	O
0	O
<EOS>	O
we	O
report	O
3	O
child	O
with	O
epilepsy	O
who	O
developed	O
facial	B-ADR
motor	I-ADR
tic	I-ADR
after	O
initiation	O
of	O
cbz	B-Drug
for	O
complex	O
partial	O
seizure	O
0	O
<EOS>	O
acyclovir-induced	B-Drug
neurotoxicity	B-ADR
:	O
concentration-side	O
effect	O
relationship	O
in	O
acyclovir	O
overdose	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
observation	O
that	O
neurotoxicity	B-ADR
developed	O
with	O
a	O
delay	O
of	O
24	O
to	O
48	O
hour	O
after	O
acyclovir	B-Drug
peak	O
serum	O
concentration	O
could	O
explain	O
the	O
wide	O
range	O
of	O
acyclovir	O
level	O
reported	O
in	O
similar	O
case	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
observation	O
that	O
neurotoxicity	B-ADR
developed	O
with	O
a	O
delay	O
of	O
24	O
to	O
48	O
hour	O
after	O
acyclovir	B-Drug
peak	O
serum	O
concentration	O
could	O
explain	O
the	O
wide	O
range	O
of	O
acyclovir	O
level	O
reported	O
in	O
similar	O
case	O
0	O
<EOS>	O
method	O
:	O
repeated	O
blood	O
sample	O
were	O
drawn	O
in	O
a	O
patient	O
with	O
severe	O
acyclovir	B-Drug
overdose	O
who	O
developed	O
coma	B-ADR
and	O
nonoliguric	O
renal	O
failure	O
0	O
<EOS>	O
method	O
:	O
repeated	O
blood	O
sample	O
were	O
drawn	O
in	O
a	O
patient	O
with	O
severe	O
acyclovir	B-Drug
overdose	O
who	O
developed	O
coma	O
and	O
nonoliguric	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
purpose	O
:	O
to	O
investigate	O
the	O
concentration-side	O
effect	O
relationship	O
in	O
a	O
patient	O
with	O
severe	O
acyclovir-induced	B-Drug
neurotoxicity	O
and	O
to	O
summarize	O
the	O
information	O
available	O
in	O
the	O
literature	O
about	O
central	B-ADR
nervous	I-ADR
system	I-ADR
side	I-ADR
effect	I-ADR
due	O
to	O
acyclovir	O
0	O
<EOS>	O
purpose	O
:	O
to	O
investigate	O
the	O
concentration-side	O
effect	O
relationship	O
in	O
a	O
patient	O
with	O
severe	O
acyclovir-induced	B-Drug
neurotoxicity	B-ADR
and	O
to	O
summarize	O
the	O
information	O
available	O
in	O
the	O
literature	O
about	O
central	O
nervous	O
system	O
side	O
effect	O
due	O
to	O
acyclovir	O
0	O
<EOS>	O
a	O
16-year-old	O
white	O
male	O
with	O
acute	O
biphenotypic	O
leukemia	O
developed	O
evidence	O
of	O
the	O
eosinophilia	B-ADR
myalgia	I-ADR
syndrome	I-ADR
associated	O
with	O
total	O
parenteral	O
nutritional	O
support	O
with	O
solution	O
containing	O
tryptophan	B-Drug
,	O
which	O
were	O
given	O
during	O
his	O
initial	O
induction	O
chemotherapy	O
and	O
also	O
after	O
autologous	O
marrow	O
transplantation	O
0	O
<EOS>	O
fatal	B-ADR
eosinophilia	I-ADR
myalgia	I-ADR
syndrome	I-ADR
in	O
a	O
marrow	O
transplant	O
patient	O
attributed	O
to	O
total	O
parenteral	O
nutrition	O
with	O
a	O
solution	O
containing	O
tryptophan	B-Drug
0	O
<EOS>	O
thus	O
,	O
the	O
eosinophilia	B-ADR
myalgia	I-ADR
syndrome	I-ADR
can	O
be	O
associated	O
with	O
parenteral	O
tryptophan	B-Drug
administration	O
0	O
<EOS>	O
a	O
patient	O
with	O
acute	O
esophageal	O
variceal	O
bleeding	O
developed	O
fatal	B-ADR
rhabdomyolysis	I-ADR
during	O
treatment	O
with	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
vasopressin	B-Drug
0	O
<EOS>	O
idiosyncratic	O
factor	O
involving	O
vasopressin	O
receptor	O
affinity	O
and	O
distribution	O
,	O
vasopressin-associated	B-Drug
vasodilation	O
in	O
some	O
vascular	O
bed	O
,	O
and	O
the	O
effect	O
of	O
vasopressin	O
on	O
the	O
renin-angiotensin	O
system	O
may	O
further	O
contribute	O
to	O
impaired	B-ADR
tissue	I-ADR
perfusion	I-ADR
0	O
<EOS>	O
idiosyncratic	O
factor	O
involving	O
vasopressin	O
receptor	O
affinity	O
and	O
distribution	O
,	O
vasopressin-associated	B-Drug
vasodilation	B-ADR
in	O
some	O
vascular	O
bed	O
,	O
and	O
the	O
effect	O
of	O
vasopressin	O
on	O
the	O
renin-angiotensin	O
system	O
may	O
further	O
contribute	O
to	O
impaired	O
tissue	O
perfusion	O
0	O
<EOS>	O
rhabdomyolysis	B-ADR
associated	O
with	O
the	O
use	O
of	O
intravenous	O
vasopressin	B-Drug
0	O
<EOS>	O
these	O
multiple	O
overlapping	O
factor	O
probably	O
lead	O
to	O
rhabdomyolysis	B-ADR
in	O
a	O
minority	O
of	O
patient	O
receiving	O
vasopressin	B-Drug
infusion	O
0	O
<EOS>	O
in	O
one	O
case	O
,	O
disulfiram	B-Drug
wa	O
the	O
only	O
potential	O
teratogen	B-ADR
exposed	O
to	O
the	O
fetus	O
0	O
<EOS>	O
nonspecific	O
but	O
significant	B-ADR
abnormality	I-ADR
have	O
been	O
described	O
in	O
the	O
infant	O
of	O
woman	O
treated	O
with	O
disulfiram	B-Drug
in	O
the	O
first	O
trimester	O
of	O
their	O
pregnancy	O
0	O
<EOS>	O
although	O
the	O
essential	O
cause	O
of	O
pv	B-ADR
is	O
unclear	O
,	O
it	O
onset	O
ha	O
occasionally	O
been	O
associated	O
with	O
drug	O
therapy	O
,	O
in	O
particular	O
penicillamine	B-Drug
0	O
<EOS>	O
pemphigus	B-ADR
vulgaris	I-ADR
precipitated	O
by	O
glibenclamide	B-Drug
therapy	O
0	O
<EOS>	O
the	O
patient	O
described	O
in	O
this	O
paper	O
wa	O
a	O
78-year-old	O
diabetic	O
man	O
who	O
developed	O
oral	B-ADR
lesion	I-ADR
of	I-ADR
pv	I-ADR
following	O
institution	O
of	O
glibenclamide	B-Drug
therapy	O
0	O
<EOS>	O
piritrexim-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
the	O
pulmonary	B-ADR
toxicity	I-ADR
is	O
probably	O
induced	O
by	O
piritrexim	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
renal	O
pelvis	O
who	O
developed	O
respiratory	O
dysfunction	O
and	O
an	O
abnormal	B-ADR
chest	I-ADR
x-ray	I-ADR
with	I-ADR
diffuse	I-ADR
interstitial	I-ADR
opacity	I-ADR
while	O
on	O
chemotherapy	O
with	O
piritrexim	B-Drug
,	O
a	O
methotrexate	O
analog	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
renal	O
pelvis	O
who	O
developed	O
respiratory	B-ADR
dysfunction	I-ADR
and	O
an	O
abnormal	O
chest	O
x-ray	O
with	O
diffuse	O
interstitial	O
opacity	O
while	O
on	O
chemotherapy	O
with	O
piritrexim	B-Drug
,	O
a	O
methotrexate	O
analog	O
0	O
<EOS>	O
a	O
12	O
year	O
old	O
patient	O
with	O
atrial	O
flutter	O
is	O
presented	O
,	O
in	O
whom	O
intravenous	O
adenosine	B-Drug
wa	O
followed	O
by	O
acceleration	B-ADR
of	I-ADR
the	I-ADR
heart	I-ADR
rate	I-ADR
to	O
a	O
potentially	O
dangerous	O
arrhythmia	O
0	O
<EOS>	O
a	O
12	O
year	O
old	O
patient	O
with	O
atrial	O
flutter	O
is	O
presented	O
,	O
in	O
whom	O
intravenous	O
adenosine	B-Drug
wa	O
followed	O
by	O
acceleration	O
of	O
the	O
heart	O
rate	O
to	O
a	O
potentially	O
dangerous	O
arrhythmia	B-ADR
0	O
<EOS>	O
acceleration	B-ADR
of	I-ADR
ventricular	I-ADR
response	I-ADR
to	O
atrial	O
flutter	O
after	O
intravenous	O
adenosine	B-Drug
0	O
<EOS>	O
lymphoma	B-ADR
developing	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
taking	O
methotrexate	B-Drug
0	O
<EOS>	O
the	O
mild	O
immunosuppression	O
that	O
occurs	O
with	O
methotrexate	B-Drug
therapy	O
probably	O
place	O
patient	O
with	O
rheumatoid	O
arthritis	O
at	O
added	O
risk	O
of	O
developing	O
lymphoproliferative	B-ADR
disease	I-ADR
,	O
but	O
coincidence	O
can	O
not	O
be	O
excluded	O
0	O
<EOS>	O
we	O
report	O
one	O
case	O
of	O
non-hodgkin	B-ADR
lymphoma	I-ADR
in	O
a	O
patient	O
,	O
with	O
a	O
30-year	O
history	O
of	O
rheumatoid	O
arthritis	O
,	O
taking	O
low	O
dose	O
methotrexate	B-Drug
weekly	O
over	O
a	O
10-month	O
period	O
0	O
<EOS>	O
hepatotoxicity	B-ADR
of	O
paracetamol	B-Drug
enhanced	O
by	O
ingestion	O
of	O
alcohol	O
:	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
the	O
biochemistry	O
of	O
paracetamol	B-Drug
hepatotoxicity	O
is	O
outlined	O
and	O
the	O
increased	O
susceptibility	O
of	O
alcoholic	O
patient	O
to	O
the	O
hepatotoxic	B-ADR
effect	I-ADR
of	O
paracetamol	O
is	O
remarked	O
upon	O
0	O
<EOS>	O
the	O
biochemistry	O
of	O
paracetamol	B-Drug
hepatotoxicity	B-ADR
is	O
outlined	O
and	O
the	O
increased	O
susceptibility	O
of	O
alcoholic	O
patient	O
to	O
the	O
hepatotoxic	O
effect	O
of	O
paracetamol	O
is	O
remarked	O
upon	O
0	O
<EOS>	O
two	O
fatal	B-ADR
case	O
of	O
poisoning	O
by	O
paracetamol	B-Drug
are	O
described	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
drug-induced	O
kaposi	B-ADR
sarcoma	I-ADR
(	O
k	O
)	O
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
in	O
a	O
71-year-old	O
man	O
,	O
treated	O
for	O
6	O
month	O
with	O
corticosteroid	O
therapy	O
(	O
prednisolone	B-Drug
25	O
mg	O
/	O
day	O
)	O
for	O
pericardial	O
effusion	O
0	O
<EOS>	O
acute	B-ADR
dystonic	I-ADR
reaction	I-ADR
with	O
low-dose	O
pimozide	B-Drug
0	O
<EOS>	O
this	O
paper	O
report	O
on	O
a	O
6.9-year-old	O
autistic	O
male	O
who	O
developed	O
repeated	O
episode	O
of	O
acute	B-ADR
dystonic	I-ADR
reaction	I-ADR
associated	O
with	O
pimozide	B-Drug
administration	O
at	O
the	O
dos	O
of	O
0.096	O
mg	O
/	O
kg	O
/	O
day	O
and	O
0.032	O
mg	O
/	O
kg	O
/	O
day	O
and	O
32	O
hour	O
following	O
pimozide	O
withdrawal	O
,	O
a	O
well	O
a	O
during	O
subsequent	O
thioridazine	O
administration	O
0	O
<EOS>	O
this	O
paper	O
report	O
on	O
a	O
6.9-year-old	O
autistic	O
male	O
who	O
developed	O
repeated	O
episode	O
of	O
acute	B-ADR
dystonic	I-ADR
reaction	I-ADR
associated	O
with	O
pimozide	B-Drug
administration	O
at	O
the	O
dos	O
of	O
0.096	O
mg	O
/	O
kg	O
/	O
day	O
and	O
0.032	O
mg	O
/	O
kg	O
/	O
day	O
and	O
32	O
hour	O
following	O
pimozide	O
withdrawal	O
,	O
a	O
well	O
a	O
during	O
subsequent	O
thioridazine	O
administration	O
0	O
<EOS>	O
this	O
paper	O
report	O
on	O
a	O
6.9-year-old	O
autistic	O
male	O
who	O
developed	O
repeated	O
episode	O
of	O
acute	B-ADR
dystonic	I-ADR
reaction	I-ADR
associated	O
with	O
pimozide	O
administration	O
at	O
the	O
dos	O
of	O
0.096	O
mg	O
/	O
kg	O
/	O
day	O
and	O
0.032	O
mg	O
/	O
kg	O
/	O
day	O
and	O
32	O
hour	O
following	O
pimozide	O
withdrawal	O
,	O
a	O
well	O
a	O
during	O
subsequent	O
thioridazine	B-Drug
administration	O
0	O
<EOS>	O
although	O
there	O
is	O
one	O
case	O
report	O
of	O
cholesterol	O
crystal	O
embolization	O
following	O
t-pa	B-Drug
therapy	O
with	O
only	O
extrarenal	O
manifestation	O
(	O
n	O
engl	O
j	O
med	O
321:1270	O
,	O
1989	O
)	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
atheroembolic	B-ADR
acute	I-ADR
renal	I-ADR
failure	I-ADR
following	O
t-pa	O
therapy	O
0	O
<EOS>	O
although	O
there	O
is	O
one	O
case	O
report	O
of	O
cholesterol	B-ADR
crystal	I-ADR
embolization	I-ADR
following	O
t-pa	B-Drug
therapy	O
with	O
only	O
extrarenal	O
manifestation	O
(	O
n	O
engl	O
j	O
med	O
321:1270	O
,	O
1989	O
)	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
atheroembolic	O
acute	O
renal	O
failure	O
following	O
t-pa	O
therapy	O
0	O
<EOS>	O
although	O
there	O
is	O
one	O
case	O
report	O
of	O
cholesterol	O
crystal	O
embolization	O
following	O
t-pa	B-Drug
therapy	O
with	O
only	O
extrarenal	B-ADR
manifestation	I-ADR
(	O
n	O
engl	O
j	O
med	O
321:1270	O
,	O
1989	O
)	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
atheroembolic	O
acute	O
renal	O
failure	O
following	O
t-pa	O
therapy	O
0	O
<EOS>	O
cholesterol	B-ADR
crystal	I-ADR
embolization-associated	I-ADR
renal	O
failure	O
after	O
therapy	O
with	O
recombinant	O
tissue-type	B-Drug
plasminogen	I-Drug
activator	I-Drug
0	O
<EOS>	O
cholesterol	O
crystal	O
embolization-associated	O
renal	B-ADR
failure	I-ADR
after	O
therapy	O
with	O
recombinant	O
tissue-type	B-Drug
plasminogen	I-Drug
activator	I-Drug
0	O
<EOS>	O
we	O
report	O
the	O
occurrence	O
of	O
renal	O
failure	O
due	O
to	O
cholesterol	B-ADR
crystal	I-ADR
embolization	I-ADR
following	O
thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	B-Drug
tissue-type	I-Drug
plasminogen	I-Drug
activator	I-Drug
(	O
t-pa	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
occurrence	O
of	O
renal	O
failure	O
due	O
to	O
cholesterol	B-ADR
crystal	I-ADR
embolization	I-ADR
following	O
thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	O
tissue-type	O
plasminogen	O
activator	O
(	O
t-pa	B-Drug
)	O
0	O
<EOS>	O
we	O
report	O
the	O
occurrence	O
of	O
renal	B-ADR
failure	I-ADR
due	O
to	O
cholesterol	O
crystal	O
embolization	O
following	O
thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	B-Drug
tissue-type	I-Drug
plasminogen	I-Drug
activator	I-Drug
(	O
t-pa	O
)	O
0	O
<EOS>	O
we	O
report	O
the	O
occurrence	O
of	O
renal	B-ADR
failure	I-ADR
due	O
to	O
cholesterol	O
crystal	O
embolization	O
following	O
thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	O
tissue-type	O
plasminogen	O
activator	O
(	O
t-pa	B-Drug
)	O
0	O
<EOS>	O
intravenous	O
haloperidol	B-Drug
is	O
generally	O
well	O
tolerated	O
,	O
but	O
multiform	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
ha	O
been	O
reported	O
0	O
<EOS>	O
all	O
developed	O
mucocutaneous	B-ADR
side	I-ADR
effect	I-ADR
within	O
20	O
week	O
of	O
beginning	O
im	O
gold	B-Drug
therapy	O
,	O
at	O
a	O
time	O
when	O
ra	O
had	O
improved	O
markedly	O
compared	O
to	O
pretreatment	O
status	O
0	O
<EOS>	O
how	O
low	O
can	O
you	O
go	O
?	O
use	O
of	O
very	O
low	O
dosage	O
of	O
gold	B-Drug
in	O
patient	O
with	O
mucocutaneous	B-ADR
reaction	I-ADR
0	O
<EOS>	O
anterior	B-ADR
spinal	I-ADR
artery	I-ADR
syndrome	I-ADR
--	O
a	O
complication	O
of	O
cervical	O
intrathecal	O
phenol	B-Drug
injection	O
0	O
<EOS>	O
we	O
have	O
seen	O
a	O
case	O
of	O
terminal	O
malignant	O
melanoma	O
in	O
which	O
clinical	O
manifestation	O
,	O
indicative	O
of	O
anterior	B-ADR
spinal	I-ADR
artery	I-ADR
syndrome	I-ADR
,	O
developed	O
following	O
the	O
injection	O
of	O
0.3	O
ml	O
of	O
10	O
%	O
phenol-glycerine	B-Drug
into	O
the	O
cervical	O
subarachnoid	O
space	O
at	O
the	O
c4	O
--	O
c5	O
level	O
for	O
the	O
control	O
of	O
severe	O
right	O
arm	O
pain	O
0	O
<EOS>	O
one	O
patient	O
required	O
nursing	O
home	O
placement	O
and	O
a	O
feeding	B-ADR
gastrostomy	I-ADR
a	O
a	O
result	O
of	O
the	O
worsening	O
parkinsonism	O
during	O
risperidone	B-Drug
treatment	O
,	O
but	O
wa	O
able	O
to	O
return	O
home	O
and	O
have	O
the	O
gastrostomy	O
removed	O
after	O
switching	O
from	O
risperidone	O
to	O
clozapine	O
0	O
<EOS>	O
one	O
patient	O
required	O
nursing	O
home	O
placement	O
and	O
a	O
feeding	B-ADR
gastrostomy	I-ADR
a	O
a	O
result	O
of	O
the	O
worsening	O
parkinsonism	O
during	O
risperidone	B-Drug
treatment	O
,	O
but	O
wa	O
able	O
to	O
return	O
home	O
and	O
have	O
the	O
gastrostomy	O
removed	O
after	O
switching	O
from	O
risperidone	O
to	O
clozapine	O
0	O
<EOS>	O
one	O
patient	O
required	O
nursing	O
home	O
placement	O
and	O
a	O
feeding	O
gastrostomy	O
a	O
a	O
result	O
of	O
the	O
worsening	B-ADR
parkinsonism	I-ADR
during	O
risperidone	B-Drug
treatment	O
,	O
but	O
wa	O
able	O
to	O
return	O
home	O
and	O
have	O
the	O
gastrostomy	O
removed	O
after	O
switching	O
from	O
risperidone	O
to	O
clozapine	O
0	O
<EOS>	O
one	O
patient	O
required	O
nursing	O
home	O
placement	O
and	O
a	O
feeding	O
gastrostomy	O
a	O
a	O
result	O
of	O
the	O
worsening	B-ADR
parkinsonism	I-ADR
during	O
risperidone	B-Drug
treatment	O
,	O
but	O
wa	O
able	O
to	O
return	O
home	O
and	O
have	O
the	O
gastrostomy	O
removed	O
after	O
switching	O
from	O
risperidone	O
to	O
clozapine	O
0	O
<EOS>	O
two	O
of	O
the	O
five	O
patient	O
who	O
worsened	O
motorically	O
also	O
developed	O
encephalopathy	B-ADR
during	O
risperidone	B-Drug
treatment	O
;	O
the	O
encephalopathy	O
resolved	O
when	O
the	O
patient	O
were	O
switched	O
to	O
clozapine	O
treatment	O
0	O
<EOS>	O
two	O
of	O
the	O
five	O
patient	O
who	O
worsened	B-ADR
motorically	I-ADR
also	O
developed	O
encephalopathy	O
during	O
risperidone	B-Drug
treatment	O
;	O
the	O
encephalopathy	O
resolved	O
when	O
the	O
patient	O
were	O
switched	O
to	O
clozapine	O
treatment	O
0	O
<EOS>	O
azathioprine	B-Drug
can	O
cause	O
severe	O
myelosuppression	B-ADR
0	O
<EOS>	O
azathioprine-induced	B-Drug
myelosuppression	B-ADR
due	O
to	O
thiopurine	O
methyltransferase	O
deficiency	O
in	O
a	O
patient	O
with	O
autoimmune	O
hepatitis	O
0	O
<EOS>	O
the	O
azathioprine	B-Drug
dose	O
wa	O
low	O
(	O
1	O
mg	O
/	O
kg	O
)	O
and	O
pancytopenia	B-ADR
occurred	O
after	O
56	O
day	O
therapy	O
0	O
<EOS>	O
thiopurine	O
methyltransferase	O
deficiency	O
occurs	O
at	O
a	O
frequency	O
of	O
one	O
in	O
300	O
and	O
is	O
associated	O
with	O
profound	O
myelosuppression	B-ADR
after	O
a	O
short	O
course	O
of	O
azathioprine	B-Drug
0	O
<EOS>	O
we	O
describe	O
the	O
first	O
documented	O
case	O
of	O
azathioprine-induced	B-Drug
severe	O
myelosuppression	B-ADR
due	O
to	O
thiopurine	O
methyltransferase	O
deficiency	O
in	O
autoimmune	O
liver	O
disease	O
0	O
<EOS>	O
nabumetone-associated	B-Drug
interstitial	B-ADR
nephritis	I-ADR
0	O
<EOS>	O
she	O
had	O
been	O
taking	O
nabumetone	B-Drug
for	O
6	O
month	O
,	O
but	O
had	O
discontinued	O
the	O
agent	O
2	O
week	O
before	O
admission	O
due	O
to	O
progressive	O
edema	B-ADR
0	O
<EOS>	O
acute	B-ADR
myeloid	I-ADR
leukemia	I-ADR
evolving	O
from	O
essential	O
thrombocythemia	O
in	O
two	O
patient	O
treated	O
with	O
hydroxyurea	B-Drug
0	O
<EOS>	O
in	O
this	O
report	O
,	O
two	O
case	O
of	O
et	O
which	O
evolved	O
into	O
al	B-ADR
without	O
prior	O
exposure	O
to	O
radiation	O
or	O
alkylating	O
agent	O
,	O
and	O
which	O
were	O
treated	O
with	O
long-term	O
hydroxyurea	B-Drug
therapy	O
,	O
are	O
described	O
0	O
<EOS>	O
prolonged	O
used	O
of	O
hydroxyurea	B-Drug
in	O
patient	O
with	O
et	O
may	O
lead	O
to	O
therapy-associated	O
acute	B-ADR
leukemia	I-ADR
0	O
<EOS>	O
however	O
,	O
in	O
1993	O
,	O
a	O
clinical	O
study	O
involving	O
400	O
patient	O
on	O
the	O
thai-burmese	O
border	O
revealed	O
cardiac	B-ADR
effect	I-ADR
of	O
antimalarial	O
treatment	O
with	O
halofantrine	B-Drug
,	O
including	O
one	O
sudden	O
death	O
after	O
the	O
treatment	O
0	O
<EOS>	O
however	O
,	O
in	O
1993	O
,	O
a	O
clinical	O
study	O
involving	O
400	O
patient	O
on	O
the	O
thai-burmese	O
border	O
revealed	O
cardiac	O
effect	O
of	O
antimalarial	O
treatment	O
with	O
halofantrine	B-Drug
,	O
including	O
one	O
sudden	B-ADR
death	I-ADR
after	O
the	O
treatment	O
0	O
<EOS>	O
in	O
the	O
present	O
paper	O
,	O
we	O
discus	O
the	O
first	O
japanese	O
vivax	O
malaria	O
patient	O
whose	O
qt	B-ADR
interval	I-ADR
wa	I-ADR
prolonged	I-ADR
after	O
treatment	O
with	O
halofantrine	B-Drug
0	O
<EOS>	O
prolongation	B-ADR
of	I-ADR
the	I-ADR
qt	I-ADR
interval	I-ADR
observed	O
in	O
a	O
japanese	O
patient	O
with	O
vivax	O
malaria	O
following	O
treatment	O
with	O
halofantrine	B-Drug
0	O
<EOS>	O
the	O
pharmaceutical	O
company	O
producing	O
halfan	B-Drug
ha	O
reported	O
8	O
cardiac	B-ADR
arrest	I-ADR
,	O
leading	O
to	O
6	O
death	O
,	O
when	O
a	O
higher	O
dose	O
than	O
recommended	O
wa	O
used	O
,	O
there	O
wa	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	O
,	O
there	O
wa	O
pre-existing	O
prolongation	O
of	O
the	O
qt	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
0	O
<EOS>	O
the	O
pharmaceutical	O
company	O
producing	O
halfan	O
ha	O
reported	O
8	O
cardiac	B-ADR
arrest	I-ADR
,	O
leading	O
to	O
6	O
death	O
,	O
when	O
a	O
higher	O
dose	O
than	O
recommended	O
wa	O
used	O
,	O
there	O
wa	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	B-Drug
,	O
there	O
wa	O
pre-existing	O
prolongation	O
of	O
the	O
qt	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
0	O
<EOS>	O
the	O
pharmaceutical	O
company	O
producing	O
halfan	B-Drug
ha	O
reported	O
8	O
cardiac	O
arrest	O
,	O
leading	O
to	O
6	O
death	B-ADR
,	O
when	O
a	O
higher	O
dose	O
than	O
recommended	O
wa	O
used	O
,	O
there	O
wa	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	O
,	O
there	O
wa	O
pre-existing	O
prolongation	O
of	O
the	O
qt	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
0	O
<EOS>	O
the	O
pharmaceutical	O
company	O
producing	O
halfan	O
ha	O
reported	O
8	O
cardiac	O
arrest	O
,	O
leading	O
to	O
6	O
death	B-ADR
,	O
when	O
a	O
higher	O
dose	O
than	O
recommended	O
wa	O
used	O
,	O
there	O
wa	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	B-Drug
,	O
there	O
wa	O
pre-existing	O
prolongation	O
of	O
the	O
qt	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
0	O
<EOS>	O
supravenous	B-ADR
hyperpigmentation	I-ADR
in	O
association	O
with	O
chop	B-Drug
chemotherapy	O
of	O
a	O
cd30	O
(	O
ki-1	O
)	O
-positive	O
anaplastic	O
large-cell	O
lymphoma	O
0	O
<EOS>	O
we	O
report	O
an	O
unusual	O
pattern	O
of	O
supravenous	B-ADR
hyperpigmentation	I-ADR
occurring	O
after	O
chop	B-Drug
chemotherapy	O
0	O
<EOS>	O
phenytoin	B-Drug
toxicity	I-ADR
due	O
to	O
concomitant	O
antituberculosis	O
therapy	O
0	O
<EOS>	O
seventy-four	O
per	O
cent	O
of	O
patient	O
with	O
epileptogenic	O
disorder	O
seen	O
at	O
the	O
emergency	O
unit	O
at	O
groote	O
schuur	O
hospital	O
were	O
on	O
phenytoin	B-Drug
and	O
11.6	O
%	O
of	O
these	O
had	O
blood	B-ADR
level	I-ADR
in	I-ADR
the	I-ADR
toxic	I-ADR
range	I-ADR
0	O
<EOS>	O
slow	O
acetylators	O
,	O
who	O
comprise	O
roughly	O
50	O
%	O
of	O
the	O
south	O
african	O
population	O
,	O
are	O
likely	O
to	O
develop	O
clinical	O
and	O
biochemical	O
feature	O
of	O
phenytoin	B-Drug
toxicity	I-ADR
when	O
this	O
drug	O
is	O
given	O
together	O
with	O
antituberculosis	O
therapy	O
0	O
<EOS>	O
the	O
wide	O
use	O
of	O
phenytoin	B-Drug
during	O
the	O
recent	O
tuberculosis	O
epidemic	O
make	O
it	O
imperative	O
to	O
suspect	O
this	O
drug	O
interaction	O
in	O
patient	O
exhibiting	O
clinical	O
feature	O
that	O
might	O
be	O
related	O
to	O
phenytoin	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
the	O
wide	O
use	O
of	O
phenytoin	B-Drug
during	O
the	O
recent	O
tuberculosis	O
epidemic	O
make	O
it	O
imperative	O
to	O
suspect	O
this	O
drug	O
interaction	O
in	O
patient	O
exhibiting	O
clinical	O
feature	O
that	O
might	O
be	O
related	O
to	O
phenytoin	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
and	O
renal	O
tubular	O
acidosis	O
secondary	O
to	O
foscarnet	B-Drug
therapy	O
0	O
<EOS>	O
nephrogenic	O
diabetes	O
insipidus	O
and	O
renal	B-ADR
tubular	I-ADR
acidosis	I-ADR
secondary	O
to	O
foscarnet	B-Drug
therapy	O
0	O
<EOS>	O
no	O
case	O
of	O
renal	O
acidosis	O
,	O
and	O
only	O
one	O
case	O
of	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
,	O
ha	O
been	O
previously	O
reported	O
a	O
a	O
complication	O
of	O
foscarnet	B-Drug
treatment	O
0	O
<EOS>	O
our	O
patient	O
developed	O
both	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
and	O
renal	O
tubular	O
acidosis	O
with	O
a	O
temporal	O
pattern	O
that	O
demonstrated	O
a	O
link	O
between	O
foscarnet	B-Drug
therapy	O
and	O
these	O
abnormality	O
0	O
<EOS>	O
our	O
patient	O
developed	O
both	O
nephrogenic	O
diabetes	O
insipidus	O
and	O
renal	B-ADR
tubular	I-ADR
acidosis	I-ADR
with	O
a	O
temporal	O
pattern	O
that	O
demonstrated	O
a	O
link	O
between	O
foscarnet	B-Drug
therapy	O
and	O
these	O
abnormality	O
0	O
<EOS>	O
we	O
present	O
a	O
patient	O
with	O
human	O
immunodeficiency	O
virus	O
infection	O
under	O
treatment	O
with	O
foscarnet	B-Drug
for	O
cmv	O
retinitis	O
who	O
complained	O
of	O
thirst	O
and	O
polyuria	B-ADR
0	O
<EOS>	O
we	O
present	O
a	O
patient	O
with	O
human	O
immunodeficiency	O
virus	O
infection	O
under	O
treatment	O
with	O
foscarnet	B-Drug
for	O
cmv	O
retinitis	O
who	O
complained	O
of	O
thirst	B-ADR
and	O
polyuria	O
0	O
<EOS>	O
choroidal	B-ADR
hemorrhage	I-ADR
associated	O
with	O
systemic	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
the	O
administration	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
wa	O
responsible	O
for	O
the	O
large	O
extent	O
of	O
hemorrhage	B-ADR
and	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
hemorrhagic	O
choroidal	O
detachment	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
administration	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
wa	O
responsible	O
for	O
the	O
large	O
extent	O
of	O
hemorrhage	O
and	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
hemorrhagic	B-ADR
choroidal	I-ADR
detachment	I-ADR
0	O
<EOS>	O
purpose	O
:	O
to	O
determine	O
the	O
cause	O
of	O
spontaneous	B-ADR
choroidal	I-ADR
hemorrhage	I-ADR
in	O
a	O
67-year-old	O
man	O
after	O
a	O
myocardial	O
infarction	O
and	O
administration	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
0	O
<EOS>	O
accelerated	B-ADR
nodulosis	I-ADR
during	O
methotrexate	B-Drug
therapy	O
for	O
juvenile	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
although	O
they	O
had	O
only	O
a	O
few	O
nodule	B-ADR
at	O
diagnosis	O
,	O
the	O
nodule	O
increased	O
in	O
number	O
and	O
size	O
3	O
to	O
4	O
month	O
after	O
the	O
start	O
of	O
methotrexate	B-Drug
therapy	O
in	O
both	O
patient	O
0	O
<EOS>	O
although	O
they	O
had	O
only	O
a	O
few	O
nodule	B-ADR
at	O
diagnosis	O
,	O
the	O
nodule	O
increased	O
in	O
number	O
and	O
size	O
3	O
to	O
4	O
month	O
after	O
the	O
start	O
of	O
methotrexate	B-Drug
therapy	O
in	O
both	O
patient	O
0	O
<EOS>	O
physician	O
treating	O
patient	O
with	O
methotrexate	B-Drug
for	O
juvenile	O
rheumatoid	O
arthritis	O
must	O
be	O
aware	O
of	O
this	O
extraarticular	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
the	O
nodule	B-ADR
regressed	O
after	O
withdrawal	O
of	O
methotrexate	B-Drug
therapy	O
in	O
one	O
patient	O
and	O
were	O
arrested	O
with	O
the	O
addition	O
of	O
hydroxychloroquine	O
in	O
the	O
other	O
0	O
<EOS>	O
we	O
describe	O
two	O
patient	O
with	O
rheumatoid	O
factor-positive	O
,	O
polyarticular-onset	O
juvenile	O
rheumatoid	O
arthritis	O
in	O
whom	O
accelerated	B-ADR
nodulosis	I-ADR
developed	O
during	O
methotrexate	B-Drug
therapy	O
0	O
<EOS>	O
a	O
macrophage	B-ADR
activation	I-ADR
syndrome	I-ADR
,	O
possibly	O
related	O
to	O
methotrexate	B-Drug
toxicity	O
,	O
developed	O
in	O
a	O
boy	O
with	O
systemic	O
juvenile	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
a	O
macrophage	O
activation	O
syndrome	O
,	O
possibly	O
related	O
to	O
methotrexate	B-Drug
toxicity	I-ADR
,	O
developed	O
in	O
a	O
boy	O
with	O
systemic	O
juvenile	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
jaundice	B-ADR
induced	O
by	O
streptokinase	B-Drug
0	O
<EOS>	O
only	O
a	O
few	O
report	O
of	O
overt	O
jaundice	B-ADR
are	O
associated	O
with	O
streptokinase	B-Drug
0	O
<EOS>	O
although	O
both	O
patient	O
recovered	O
from	O
the	O
colitis	B-ADR
after	O
the	O
administration	O
of	O
vancomycin	O
,	O
the	O
first	O
case	O
demonstrated	O
a	O
relapse	O
of	O
the	O
colitis	O
after	O
receiving	O
a	O
subsequent	O
course	O
of	O
the	O
same	O
chemotherapy	O
with	O
cisplatin	B-Drug
0	O
<EOS>	O
based	O
on	O
our	O
finding	O
,	O
it	O
is	O
thus	O
concluded	O
that	O
cisplatin	B-Drug
may	O
cause	O
c.	B-ADR
difficile	I-ADR
colitis	I-ADR
0	O
<EOS>	O
both	O
patient	O
were	O
then	O
treated	O
with	O
a	O
carboplatin	O
alternative	O
to	O
cisplatin	B-Drug
in	O
the	O
following	O
course	O
,	O
which	O
resulted	O
in	O
neither	O
a	O
relapse	O
of	O
the	O
colitis	B-ADR
nor	O
a	O
recurrence	O
of	O
the	O
malignancy	O
up	O
to	O
this	O
time	O
0	O
<EOS>	O
clostridium	B-ADR
difficile	I-ADR
colitis	I-ADR
associated	O
with	O
cisplatin-based	B-Drug
chemotherapy	O
in	O
ovarian	O
cancer	O
patient	O
0	O
<EOS>	O
severe	O
c.	B-ADR
difficile	I-ADR
colitis	I-ADR
occurred	O
in	O
2	O
patient	O
(	O
6.1	O
%	O
)	O
after	O
receiving	O
cisplatin-based	B-Drug
combination	O
chemotherapy	O
for	O
ovarian	O
malignancy	O
0	O
<EOS>	O
the	O
purpose	O
of	O
this	O
study	O
wa	O
to	O
examine	O
the	O
incidence	O
and	O
cause	O
of	O
clostridium	B-ADR
difficile	I-ADR
colitis	I-ADR
occurring	O
after	O
cisplatin-based	B-Drug
combination	O
chemotherapy	O
in	O
ovarian	O
cancer	O
patient	O
0	O
<EOS>	O
a	O
patient	O
with	O
severe	B-ADR
cholestatic	I-ADR
jaundice	I-ADR
induced	O
by	O
captopril	B-Drug
is	O
presented	O
0	O
<EOS>	O
captopril-associated	B-Drug
``	O
pseudocholangitis	B-ADR
	O
0	O
<EOS>	O
captopril	B-Drug
is	O
known	O
to	O
be	O
associated	O
with	O
dermatologic	B-ADR
,	I-ADR
hematologic	I-ADR
,	I-ADR
and	I-ADR
pulmonary	I-ADR
adverse	I-ADR
effect	I-ADR
0	O
<EOS>	O
patient	O
treated	O
with	O
captopril	O
who	O
develop	O
``	O
atypical	B-ADR
cholangitis	I-ADR
'	O
should	O
be	O
suspected	O
of	O
having	O
captopril-associated	B-Drug
liver	O
damage	O
0	O
<EOS>	O
patient	O
treated	O
with	O
captopril	O
who	O
develop	O
``	O
atypical	O
cholangitis	O
'	O
should	O
be	O
suspected	O
of	O
having	O
captopril-associated	B-Drug
liver	B-ADR
damage	I-ADR
0	O
<EOS>	O
development	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
in	O
a	O
patient	O
with	O
acute	O
myeloblastic	O
leukemia	O
after	O
treatment	O
with	O
macrophage-colony-stimulating	B-Drug
factor	I-Drug
0	O
<EOS>	O
it	O
should	O
be	O
emphasized	O
that	O
the	O
recurrence	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
wa	O
observed	O
after	O
the	O
following	O
chemotherapy	O
,	O
including	O
m-csf	B-Drug
,	O
whereas	O
the	O
bone	O
marrow	O
still	O
remained	O
completely	O
remitted	O
0	O
<EOS>	O
the	O
possibility	O
can	O
be	O
raised	O
that	O
m-csf	B-Drug
accelerated	O
the	O
underlying	O
renal	O
disease	O
in	O
this	O
case	O
through	O
enhancing	O
macrophage	O
accumulation	O
into	O
the	O
glomerulus	O
,	O
leading	O
to	O
the	O
development	O
of	O
nephrotic	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
the	O
possibility	O
can	O
be	O
raised	O
that	O
m-csf	B-Drug
accelerated	O
the	O
underlying	O
renal	B-ADR
disease	I-ADR
in	O
this	O
case	O
through	O
enhancing	O
macrophage	O
accumulation	O
into	O
the	O
glomerulus	O
,	O
leading	O
to	O
the	O
development	O
of	O
nephrotic	O
syndrome	O
0	O
<EOS>	O
these	O
evolutional	O
change	O
in	O
both	O
proteinuria	O
and	O
glomerular	O
histology	O
suggest	O
a	O
close	O
linkage	O
between	O
the	O
m-csf	B-Drug
treatment	O
and	O
macrophage-related	B-ADR
glomerular	I-ADR
injury	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
myeloblastic	O
leukemia	O
(	O
aml	O
)	O
who	O
developed	O
nephrotic	B-ADR
syndrome	I-ADR
after	O
receiving	O
several	O
course	O
of	O
chemotherapy	O
,	O
including	O
macrophage-colony-stimulating	B-Drug
factor	I-Drug
(	O
m-csf	O
)	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
myeloblastic	O
leukemia	O
(	O
aml	O
)	O
who	O
developed	O
nephrotic	B-ADR
syndrome	I-ADR
after	O
receiving	O
several	O
course	O
of	O
chemotherapy	O
,	O
including	O
macrophage-colony-stimulating	O
factor	O
(	O
m-csf	B-Drug
)	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
of	O
tocolysis	O
with	O
magnesium	O
sulfate	O
,	O
nifedipine	O
,	O
terbutaline	O
and	O
betamethasone	B-Drug
,	O
edema	B-ADR
developed	O
in	O
both	O
labium	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
of	O
tocolysis	O
with	O
magnesium	B-Drug
sulfate	I-Drug
,	O
nifedipine	O
,	O
terbutaline	O
and	O
betamethasone	O
,	O
edema	B-ADR
developed	O
in	O
both	O
labium	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
of	O
tocolysis	O
with	O
magnesium	O
sulfate	O
,	O
nifedipine	B-Drug
,	O
terbutaline	O
and	O
betamethasone	O
,	O
edema	B-ADR
developed	O
in	O
both	O
labium	O
0	O
<EOS>	O
on	O
the	O
fifth	O
day	O
of	O
tocolysis	O
with	O
magnesium	O
sulfate	O
,	O
nifedipine	O
,	O
terbutaline	B-Drug
and	O
betamethasone	O
,	O
edema	B-ADR
developed	O
in	O
both	O
labium	O
0	O
<EOS>	O
milk-alkali	B-ADR
syndrome	I-ADR
induced	O
by	O
1,25	B-Drug
(	I-Drug
oh	I-Drug
)	I-Drug
2d	I-Drug
in	O
a	O
patient	O
with	O
hypoparathyroidism	O
0	O
<EOS>	O
this	O
article	O
present	O
a	O
patient	O
with	O
hypoparathyroidism	O
who	O
wa	O
treated	O
with	O
calcium	O
carbonate	O
and	O
calcitriol	B-Drug
resulting	O
in	O
two	O
admission	O
to	O
the	O
hospital	O
for	O
milk-alkali	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
this	O
article	O
present	O
a	O
patient	O
with	O
hypoparathyroidism	O
who	O
wa	O
treated	O
with	O
calcium	B-Drug
carbonate	I-Drug
and	O
calcitriol	O
resulting	O
in	O
two	O
admission	O
to	O
the	O
hospital	O
for	O
milk-alkali	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
after	O
receiving	O
3	O
dos	O
of	O
ifosfamide	B-Drug
/	O
mesna	O
,	O
she	O
wa	O
found	O
to	O
be	O
unresponsive	B-ADR
0	O
<EOS>	O
after	O
receiving	O
3	O
dos	O
of	O
ifosfamide	O
/	O
mesna	B-Drug
,	O
she	O
wa	O
found	O
to	O
be	O
unresponsive	B-ADR
0	O
<EOS>	O
conclusion	O
:	O
there	O
wa	O
a	O
temporal	O
relationship	O
between	O
the	O
onset	O
of	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
and	O
initiation	O
of	O
ifosfamide	B-Drug
infusion	O
0	O
<EOS>	O
discussion	O
:	O
central	B-ADR
nervous	I-ADR
system	I-ADR
(	I-ADR
cns	I-ADR
)	I-ADR
toxicity	I-ADR
ha	O
been	O
described	O
with	O
ifosfamide	B-Drug
,	O
with	O
most	O
case	O
reported	O
in	O
the	O
pediatric	O
population	O
0	O
<EOS>	O
ifosfamide-induced	B-Drug
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
patient	O
with	O
ifosfamide-induced	B-Drug
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
0	O
<EOS>	O
this	O
represents	O
the	O
first	O
report	O
of	O
nonconvulsive	B-ADR
status	I-ADR
epilepticus	I-ADR
induced	O
by	O
ifosfamide	B-Drug
0	O
<EOS>	O
albendazole-induced	B-Drug
pseudomembranous	B-ADR
colitis	I-ADR
0	O
<EOS>	O
although	O
a	O
few	O
case	O
report	O
link	O
metronidazole	B-Drug
with	O
the	O
development	O
of	O
pseudomembranous	B-ADR
colitis	I-ADR
,	O
albendazole	O
ha	O
not	O
been	O
associated	O
with	O
the	O
development	O
of	O
this	O
condition	O
0	O
<EOS>	O
while	O
undergoing	O
treatment	O
with	O
albendazole	B-Drug
,	O
he	O
developed	O
worsening	O
diarrhea	O
with	O
abdominal	B-ADR
pain	I-ADR
and	O
fever	O
0	O
<EOS>	O
while	O
undergoing	O
treatment	O
with	O
albendazole	B-Drug
,	O
he	O
developed	O
worsening	O
diarrhea	O
with	O
abdominal	O
pain	O
and	O
fever	B-ADR
0	O
<EOS>	O
while	O
undergoing	O
treatment	O
with	O
albendazole	B-Drug
,	O
he	O
developed	O
worsening	B-ADR
diarrhea	I-ADR
with	O
abdominal	O
pain	O
and	O
fever	O
0	O
<EOS>	O
aluminum	B-Drug
intoxication	I-ADR
,	O
along	O
with	O
other	O
factor	O
,	O
wa	O
considered	O
to	O
be	O
the	O
cause	O
of	O
tc	O
development	O
0	O
<EOS>	O
aluminum	B-Drug
intoxication	O
,	O
along	O
with	O
other	O
factor	O
,	O
wa	O
considered	O
to	O
be	O
the	O
cause	O
of	O
tc	B-ADR
development	O
0	O
<EOS>	O
oculomotor	B-ADR
disturbance	I-ADR
associated	O
with	O
5-fluorouracil	B-Drug
chemotherapy	O
0	O
<EOS>	O
the	O
ocular	O
motor	O
disturbance	O
are	O
probably	O
an	O
expression	O
of	O
regional	O
5-fu	B-Drug
neurotoxicity	B-ADR
primarily	O
affecting	O
the	O
brain	O
stem	O
0	O
<EOS>	O
the	O
ocular	B-ADR
motor	I-ADR
disturbance	I-ADR
are	O
probably	O
an	O
expression	O
of	O
regional	O
5-fu	B-Drug
neurotoxicity	O
primarily	O
affecting	O
the	O
brain	O
stem	O
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	B-Drug
(	O
5-fu	O
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	B-ADR
dysfunction	I-ADR
typical	O
of	O
5-fu	O
neurotoxicity	O
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	B-ADR
dysfunction	I-ADR
typical	O
of	O
5-fu	O
neurotoxicity	O
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	B-ADR
dysfunction	I-ADR
typical	O
of	O
5-fu	O
neurotoxicity	O
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	B-Drug
(	O
5-fu	O
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	O
dysfunction	O
typical	O
of	O
5-fu	O
neurotoxicity	B-ADR
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	O
dysfunction	O
typical	O
of	O
5-fu	O
neurotoxicity	B-ADR
0	O
<EOS>	O
two	O
patient	O
treated	O
with	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
for	O
disseminated	O
adenocarcinoma	O
of	O
the	O
colon	O
developed	O
cerebellar	O
dysfunction	O
typical	O
of	O
5-fu	O
neurotoxicity	B-ADR
0	O
<EOS>	O
assessment	O
of	O
cortisol	O
response	O
wa	O
by	O
insulin-induced	B-Drug
hypoglycaemia	B-ADR
in	O
three	O
case	O
,	O
by	O
short	O
tetracosactrin	O
test	O
in	O
two	O
,	O
and	O
by	O
low-dose	O
tetracosactrin	O
and	O
24-hour	O
urinary	O
cortisol	O
/	O
creatinine	O
ratio	O
in	O
one	O
0	O
<EOS>	O
finding	O
:	O
six	O
child	O
with	O
growth	O
retardation	O
noted	O
after	O
treatment	O
with	O
high-dose	O
fluticasone	B-Drug
propionate	I-Drug
were	O
found	O
to	O
have	O
adrenal	B-ADR
suppression	I-ADR
0	O
<EOS>	O
finding	O
:	O
six	O
child	O
with	O
growth	B-ADR
retardation	I-ADR
noted	O
after	O
treatment	O
with	O
high-dose	O
fluticasone	B-Drug
propionate	I-Drug
were	O
found	O
to	O
have	O
adrenal	O
suppression	O
0	O
<EOS>	O
growth	B-ADR
and	I-ADR
adrenal	I-ADR
suppression	I-ADR
in	O
asthmatic	O
child	O
treated	O
with	O
high-dose	O
fluticasone	B-Drug
propionate	I-Drug
0	O
<EOS>	O
interpretation	O
:	O
when	O
high	O
dos	O
of	O
fluticasone	B-Drug
propionate	I-Drug
are	O
used	O
,	O
growth	O
may	O
be	O
retarded	O
and	O
adrenal	B-ADR
suppression	I-ADR
may	O
occur	O
0	O
<EOS>	O
interpretation	O
:	O
when	O
high	O
dos	O
of	O
fluticasone	B-Drug
propionate	I-Drug
are	O
used	O
,	O
growth	B-ADR
may	I-ADR
be	I-ADR
retarded	I-ADR
and	O
adrenal	O
suppression	O
may	O
occur	O
0	O
<EOS>	O
method	O
:	O
growth	B-ADR
retardation	I-ADR
wa	O
observed	O
in	O
six	O
severely	O
asthmatic	O
child	O
after	O
introduction	O
of	O
high-dose	O
fluticasone	B-Drug
propionate	I-Drug
treatment	O
(	O
dry	O
powder	O
)	O
0	O
<EOS>	O
metipranolol	B-Drug
associated	O
granulomatous	B-ADR
anterior	I-ADR
uveitis	I-ADR
:	O
not	O
so	O
uncommon	O
a	O
thought	O
0	O
<EOS>	O
two	O
case	O
report	O
of	O
bilateral	B-ADR
granulomatous	I-ADR
anterior	I-ADR
uveitis	I-ADR
are	O
described	O
in	O
patient	O
with	O
open	O
angle	O
glaucoma	O
treated	O
with	O
metripranolol	B-Drug
0.6	O
%	O
eye	O
drop	O
0	O
<EOS>	O
a	O
review	O
of	O
the	O
literature	O
found	O
11	O
child	O
and	O
2	O
adult	O
in	O
whom	O
intranasal	O
desmopressin	B-Drug
wa	O
associated	O
with	O
hyponatremia	O
,	O
all	O
of	O
whom	O
experienced	O
seizure	O
or	O
altered	B-ADR
mental	I-ADR
status	I-ADR
0	O
<EOS>	O
a	O
review	O
of	O
the	O
literature	O
found	O
11	O
child	O
and	O
2	O
adult	O
in	O
whom	O
intranasal	O
desmopressin	B-Drug
wa	O
associated	O
with	O
hyponatremia	B-ADR
,	O
all	O
of	O
whom	O
experienced	O
seizure	O
or	O
altered	O
mental	O
status	O
0	O
<EOS>	O
a	O
review	O
of	O
the	O
literature	O
found	O
11	O
child	O
and	O
2	O
adult	O
in	O
whom	O
intranasal	O
desmopressin	B-Drug
wa	O
associated	O
with	O
hyponatremia	O
,	O
all	O
of	O
whom	O
experienced	O
seizure	B-ADR
or	O
altered	O
mental	O
status	O
0	O
<EOS>	O
intranasal	O
desmopressin-induced	B-Drug
hyponatremia	B-ADR
0	O
<EOS>	O
when	O
vague	O
symptom	O
develop	O
during	O
desmopressin	B-Drug
therapy	O
,	O
hyponatremia	B-ADR
must	O
be	O
considered	O
a	O
part	O
of	O
the	O
differential	O
diagnosis	O
0	O
<EOS>	O
when	O
vague	B-ADR
symptom	I-ADR
develop	O
during	O
desmopressin	B-Drug
therapy	O
,	O
hyponatremia	O
must	O
be	O
considered	O
a	O
part	O
of	O
the	O
differential	O
diagnosis	O
0	O
<EOS>	O
within	O
24	O
hour	O
of	O
fluid	O
restriction	O
and	O
cessation	O
of	O
desmopressin	B-Drug
,	O
her	O
symptom	O
and	O
hyponatremia	B-ADR
resolved	O
0	O
<EOS>	O
without	O
other	O
cause	O
for	O
the	O
hyponatremia	B-ADR
,	O
she	O
wa	O
diagnosed	O
with	O
the	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
,	O
presumably	O
caused	O
by	O
desmopressin	B-Drug
0	O
<EOS>	O
without	O
other	O
cause	O
for	O
the	O
hyponatremia	O
,	O
she	O
wa	O
diagnosed	O
with	O
the	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
,	O
presumably	O
caused	O
by	O
desmopressin	B-Drug
0	O
<EOS>	O
uveitis	B-ADR
during	O
treatment	O
of	O
disseminated	O
mycobacterium	O
avium-intracellulare	O
complex	O
infection	O
with	O
the	O
combination	O
of	O
rifabutin	O
,	O
clarithromycin	B-Drug
and	O
ethambutol	O
0	O
<EOS>	O
uveitis	B-ADR
during	O
treatment	O
of	O
disseminated	O
mycobacterium	O
avium-intracellulare	O
complex	O
infection	O
with	O
the	O
combination	O
of	O
rifabutin	O
,	O
clarithromycin	O
and	O
ethambutol	B-Drug
0	O
<EOS>	O
uveitis	B-ADR
during	O
treatment	O
of	O
disseminated	O
mycobacterium	O
avium-intracellulare	O
complex	O
infection	O
with	O
the	O
combination	O
of	O
rifabutin	B-Drug
,	O
clarithromycin	O
and	O
ethambutol	O
0	O
<EOS>	O
doe	O
acyclovir	B-Drug
increase	B-ADR
serum	I-ADR
lithium	I-ADR
level	I-ADR
?	O
<EOS>	O
six	O
day	O
after	O
starting	O
acyclovir	B-Drug
she	O
exhibited	O
sign	O
of	O
lithium	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
six	O
day	O
after	O
starting	O
acyclovir	O
she	O
exhibited	O
sign	O
of	O
lithium	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
this	O
case	O
suggests	O
that	O
acyclovir	B-Drug
when	O
given	O
intravenously	O
in	O
dos	O
of	O
10	O
mg	O
/	O
kg	O
may	O
result	O
in	O
increased	B-ADR
serum	I-ADR
lithium	I-ADR
concentration	O
0	O
<EOS>	O
this	O
case	O
suggests	O
that	O
acyclovir	O
when	O
given	O
intravenously	O
in	O
dos	O
of	O
10	O
mg	O
/	O
kg	O
may	O
result	O
in	O
increased	B-ADR
serum	I-ADR
lithium	B-Drug
concentration	O
0	O
<EOS>	O
until	O
additional	O
data	O
are	O
available	O
,	O
if	O
intravenous	O
acyclovir	B-Drug
is	O
administered	O
concurrently	O
with	O
lithium	O
,	O
we	O
recommend	O
closely	O
monitoring	O
patient	O
for	O
sign	O
of	O
lithium	B-ADR
toxicity	I-ADR
and	O
measuring	O
serum	O
lithium	O
level	O
every	O
second	O
or	O
third	O
day	O
0	O
<EOS>	O
until	O
additional	O
data	O
are	O
available	O
,	O
if	O
intravenous	O
acyclovir	O
is	O
administered	O
concurrently	O
with	O
lithium	B-Drug
,	O
we	O
recommend	O
closely	O
monitoring	O
patient	O
for	O
sign	O
of	O
lithium	B-ADR
toxicity	I-ADR
and	O
measuring	O
serum	O
lithium	O
level	O
every	O
second	O
or	O
third	O
day	O
0	O
<EOS>	O
when	O
measured	O
,	O
the	O
serum	B-ADR
lithium	I-ADR
level	I-ADR
had	I-ADR
increased	I-ADR
4-fold	O
during	O
acyclovir	B-Drug
therapy	O
0	O
<EOS>	O
when	O
measured	O
,	O
the	O
serum	B-ADR
lithium	B-Drug
level	I-ADR
had	I-ADR
increased	I-ADR
4-fold	O
during	O
acyclovir	O
therapy	O
0	O
<EOS>	O
dapsone	B-Drug
syndrome	I-ADR
in	O
cutaneous	O
lupus	O
erythematosus	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
potentially	O
lethal	B-ADR
side	O
effect	O
of	O
dapsone	B-Drug
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
cutaneous	O
lupus	O
erythematosus	O
who	O
developed	O
severe	O
dapsone	B-Drug
reaction	I-ADR
after	O
low	O
dose	O
therapy	O
,	O
with	O
a	O
fatal	O
outcome	O
in	O
one	O
0	O
<EOS>	O
we	O
describe	O
2	O
patient	O
with	O
cutaneous	O
lupus	O
erythematosus	O
who	O
developed	O
severe	O
dapsone	B-Drug
reaction	O
after	O
low	O
dose	O
therapy	O
,	O
with	O
a	O
fatal	B-ADR
outcome	O
in	O
one	O
0	O
<EOS>	O
a	O
case	O
is	O
presented	O
which	O
illustrates	O
a	O
probably	O
fatal	B-ADR
interaction	I-ADR
between	O
minoxidil	B-Drug
and	O
a	O
coagulation	O
disorder	O
0	O
<EOS>	O
nephrogenic	O
diabetes	O
insipidus	O
(	O
ndi	B-ADR
)	O
is	O
a	O
well-documented	O
complication	O
of	O
lithium	B-Drug
use	O
0	O
<EOS>	O
nephrogenic	B-ADR
diabetes	I-ADR
insipidus	I-ADR
(	O
ndi	O
)	O
is	O
a	O
well-documented	O
complication	O
of	O
lithium	B-Drug
use	O
0	O
<EOS>	O
potential	O
mechanism	O
regarding	O
the	O
pathophysiology	O
of	O
lithium-associated	B-Drug
cdi	B-ADR
are	O
discussed	O
0	O
<EOS>	O
the	O
association	O
of	O
central	O
diabetes	O
insipidus	O
(	O
cdi	B-ADR
)	O
with	O
lithium	B-Drug
use	O
is	O
rare	O
0	O
<EOS>	O
the	O
association	O
of	O
central	B-ADR
diabetes	I-ADR
insipidus	I-ADR
(	O
cdi	O
)	O
with	O
lithium	B-Drug
use	O
is	O
rare	O
0	O
<EOS>	O
this	O
case	O
emphasizes	O
the	O
importance	O
of	O
the	O
evaluation	O
of	O
lithium-associated	B-Drug
polyuria	B-ADR
with	O
a	O
direct	O
measurement	O
of	O
plasma	O
vasopressin	O
,	O
interpreted	O
with	O
simultaneous	O
plasma	O
and	O
urine	O
osmolality	O
to	O
secure	O
the	O
correct	O
diagnosis	O
and	O
ensure	O
appropriate	O
therapeutic	O
management	O
0	O
<EOS>	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
lithium-associated	B-Drug
cdi	B-ADR
and	O
ndi	O
presenting	O
concurrently	O
0	O
<EOS>	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
lithium-associated	B-Drug
cdi	O
and	O
ndi	B-ADR
presenting	O
concurrently	O
0	O
<EOS>	O
transient	B-ADR
central	I-ADR
diabetes	I-ADR
insipidus	I-ADR
in	O
the	O
setting	O
of	O
underlying	O
chronic	O
nephrogenic	O
diabetes	O
insipidus	O
associated	O
with	O
lithium	B-Drug
use	O
0	O
<EOS>	O
we	O
report	O
a	O
patient	O
receiving	O
chronic	O
lithium	B-Drug
therapy	O
who	O
presented	O
with	O
a	O
transient	O
cdi	B-ADR
occurring	O
in	O
the	O
setting	O
of	O
underlying	O
chronic	O
ndi	O
0	O
<EOS>	O
case	O
:	O
we	O
report	O
a	O
case	O
of	O
a	O
woman	O
with	O
severe	O
human	B-Drug
insulin-induced	I-Drug
lipoatrophy	B-ADR
who	O
ha	O
been	O
treated	O
exclusively	O
with	O
recombinant	O
dna	O
human	O
insulin	O
since	O
the	O
onset	O
of	O
iddm	O
0	O
<EOS>	O
case	O
:	O
we	O
report	O
a	O
case	O
of	O
a	O
woman	O
with	O
severe	O
human	O
insulin-induced	B-Drug
lipoatrophy	B-ADR
who	O
ha	O
been	O
treated	O
exclusively	O
with	O
recombinant	B-Drug
dna	I-Drug
human	I-Drug
insulin	O
since	O
the	O
onset	O
of	O
iddm	O
0	O
<EOS>	O
conclusion	O
:	O
jet-injection	O
device	O
might	O
constitute	O
a	O
helpful	O
method	O
to	O
treat	O
those	O
patient	O
affected	O
by	O
severe	O
human	B-Drug
insulin-induced	I-Drug
lipoatrophy	B-ADR
0	O
<EOS>	O
human	B-Drug
insulin-induced	I-Drug
lipoatrophy	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
administration	O
of	O
insulin	O
by	O
a	O
jet-injector	O
device	O
in	O
stopping	O
and	O
reversing	O
severe	O
human	B-Drug
insulin-induced	I-Drug
lipoatrophy	B-ADR
0	O
<EOS>	O
improved	O
awareness	O
of	O
and	O
further	O
investigation	O
into	O
the	O
neurotoxic	B-ADR
effect	I-ADR
of	O
ofloxacin	B-Drug
may	O
enhance	O
it	O
safe	O
use	O
0	O
<EOS>	O
seizure	B-ADR
associated	O
with	O
ofloxacin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
renal	B-ADR
insufficiency	I-ADR
of	O
three	O
patient	O
and	O
the	O
timing	O
of	O
the	O
seizure	O
implicate	O
accumulation	O
of	O
ofloxacin	B-Drug
a	O
a	O
contributing	O
factor	O
0	O
<EOS>	O
the	O
renal	O
insufficiency	O
of	O
three	O
patient	O
and	O
the	O
timing	O
of	O
the	O
seizure	B-ADR
implicate	O
accumulation	O
of	O
ofloxacin	B-Drug
a	O
a	O
contributing	O
factor	O
0	O
<EOS>	O
we	O
describe	O
four	O
patient	O
who	O
had	O
seizure	B-ADR
while	O
receiving	O
ofloxacin	B-Drug
;	O
no	O
other	O
cause	O
were	O
evident	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	O
syndrome	O
(	O
ph	O
)	O
including	O
fever	O
,	O
erythroderma	O
,	O
tibial	O
and	O
facial	O
oedema	O
,	O
pinhead-sized	O
facial	O
pustule	O
and	O
abnormal	B-ADR
liver	I-ADR
function	I-ADR
test	I-ADR
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	O
syndrome	O
(	O
ph	O
)	O
including	O
fever	O
,	O
erythroderma	B-ADR
,	O
tibial	O
and	O
facial	O
oedema	O
,	O
pinhead-sized	O
facial	O
pustule	O
and	O
abnormal	O
liver	O
function	O
test	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	O
syndrome	O
(	O
ph	O
)	O
including	O
fever	B-ADR
,	O
erythroderma	O
,	O
tibial	O
and	O
facial	O
oedema	O
,	O
pinhead-sized	O
facial	O
pustule	O
and	O
abnormal	O
liver	O
function	O
test	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	I-ADR
syndrome	I-ADR
(	O
ph	O
)	O
including	O
fever	O
,	O
erythroderma	O
,	O
tibial	O
and	O
facial	O
oedema	O
,	O
pinhead-sized	O
facial	O
pustule	O
and	O
abnormal	O
liver	O
function	O
test	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	O
syndrome	O
(	O
ph	O
)	O
including	O
fever	O
,	O
erythroderma	O
,	O
tibial	O
and	O
facial	O
oedema	O
,	O
pinhead-sized	B-ADR
facial	I-ADR
pustule	I-ADR
and	O
abnormal	O
liver	O
function	O
test	O
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
feature	O
of	O
phenytoin	B-Drug
hypersensitivity	O
syndrome	O
(	O
ph	O
)	O
including	O
fever	O
,	O
erythroderma	O
,	O
tibial	B-ADR
and	I-ADR
facial	I-ADR
oedema	I-ADR
,	O
pinhead-sized	O
facial	O
pustule	O
and	O
abnormal	O
liver	O
function	O
test	O
0	O
<EOS>	O
systemic	O
corticosteroid	O
in	O
the	O
phenytoin	B-Drug
hypersensitivity	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
a	O
patient	O
is	O
described	O
who	O
developed	O
a	O
poorly	O
differentiated	O
sarcoma	B-ADR
after	O
cyclophosphamide	B-Drug
wa	O
used	O
to	O
treat	O
his	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
sarcoma	B-ADR
complicating	O
therapy	O
with	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
a	O
chronic	O
reaction	O
associated	O
with	O
long-term	O
treatment	O
with	O
nitrofurantoin	B-Drug
ha	O
also	O
been	O
reported	O
and	O
cause	O
irreversible	O
pulmonary	B-ADR
fibrosis	I-ADR
0	O
<EOS>	O
acute	B-ADR
pulmonary	I-ADR
reaction	I-ADR
to	O
nitrofurantoin	B-Drug
are	O
an	O
uncommon	O
side	O
effect	O
of	O
therapy	O
and	O
can	O
cause	O
minor	O
or	O
life-threatening	O
pulmonary	O
dysfunction	O
0	O
<EOS>	O
acute	O
pulmonary	O
reaction	O
to	O
nitrofurantoin	B-Drug
are	O
an	O
uncommon	O
side	O
effect	O
of	O
therapy	O
and	O
can	O
cause	O
minor	O
or	O
life-threatening	O
pulmonary	B-ADR
dysfunction	I-ADR
0	O
<EOS>	O
despite	O
the	O
known	O
pulmonary	B-ADR
side	I-ADR
effect	I-ADR
of	O
nitrofurantoin	B-Drug
,	O
there	O
is	O
no	O
report	O
of	O
this	O
toxicity	O
occurring	O
in	O
pregnant	O
patient	O
0	O
<EOS>	O
nitrofurantoin-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
during	O
pregnancy	O
:	O
a	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
respiratory	B-ADR
failure	I-ADR
occurring	O
in	O
a	O
woman	O
at	O
16	O
week	O
	O
gestation	O
who	O
wa	O
being	O
treated	O
with	O
nitrofurantoin	B-Drug
for	O
a	O
urinary	O
tract	O
infection	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	B-ADR
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	B-ADR
infectious	I-ADR
mononucleosis-like	I-ADR
syndrome	I-ADR
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	B-ADR
jaundice	I-ADR
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	B-ADR
eruption	I-ADR
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	B-ADR
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	B-ADR
neurological	I-ADR
and	I-ADR
gastrointestinal	I-ADR
complaint	I-ADR
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	B-ADR
syndrome	I-ADR
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	B-ADR
neuropathy	I-ADR
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	B-ADR
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	B-ADR
papillary	I-ADR
necrosis	I-ADR
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	O
hepatitis	O
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	B-ADR
hypoalbuminemia	I-ADR
without	I-ADR
proteinuria	I-ADR
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
le	O
common	O
adverse	O
event	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reaction	O
of	O
leukopenia	O
and	O
agranulocytosis	O
,	O
cutaneous	O
eruption	O
,	O
peripheral	O
neuropathy	O
,	O
psychosis	O
,	O
toxic	B-ADR
hepatitis	I-ADR
,	O
cholestatic	O
jaundice	O
,	O
nephrotic	O
syndrome	O
,	O
renal	O
papillary	O
necrosis	O
,	O
severe	O
hypoalbuminemia	O
without	O
proteinuria	O
,	O
an	O
infectious	O
mononucleosis-like	O
syndrome	O
,	O
and	O
minor	O
neurological	O
and	O
gastrointestinal	O
complaint	O
0	O
<EOS>	O
methemoglobinemia	B-ADR
is	O
another	O
common	O
finding	O
among	O
patient	O
receiving	O
dapsone	B-Drug
therapy	O
,	O
but	O
rarely	O
doe	O
it	O
result	O
in	O
prominent	O
symptom	O
other	O
than	O
transient	O
pallor	O
0	O
<EOS>	O
acetazolamide-accelerated	B-Drug
anticonvulsant	O
osteomalacia	B-ADR
0	O
<EOS>	O
acetazolamide	B-Drug
may	O
have	O
accelerated	O
the	O
development	O
of	O
osteomalacia	B-ADR
by	O
several	O
mechanism	O
,	O
including	O
increased	O
renal	O
calcium	O
excretion	O
0	O
<EOS>	O
severe	B-ADR
osteomalacia	I-ADR
wa	O
present	O
in	O
two	O
epileptic	O
patient	O
who	O
were	O
under	O
long-term	O
treatment	O
with	O
congener	O
of	O
phenytoin	O
,	O
phenobarbital	O
,	O
and	O
acetazolamide	B-Drug
0	O
<EOS>	O
severe	B-ADR
osteomalacia	I-ADR
wa	O
present	O
in	O
two	O
epileptic	O
patient	O
who	O
were	O
under	O
long-term	O
treatment	O
with	O
congener	O
of	O
phenytoin	O
,	O
phenobarbital	B-Drug
,	O
and	O
acetazolamide	O
0	O
<EOS>	O
severe	B-ADR
osteomalacia	I-ADR
wa	O
present	O
in	O
two	O
epileptic	O
patient	O
who	O
were	O
under	O
long-term	O
treatment	O
with	O
congener	O
of	O
phenytoin	B-Drug
,	O
phenobarbital	O
,	O
and	O
acetazolamide	O
0	O
<EOS>	O
the	O
delayed	O
encephalopathy	B-ADR
developed	O
9	O
and	O
22	O
month	O
respectively	O
after	O
the	O
first	O
dose	O
of	O
intrathecal	O
methotrexate	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
history	O
of	O
identical	O
twin	O
brother	O
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
year	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	O
and	O
hydrocephalus	B-ADR
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	O
administered	O
methotrexate	O
and	O
cranial	O
irradiation	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
history	O
of	O
identical	O
twin	O
brother	O
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
year	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	O
and	O
hydrocephalus	B-ADR
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	O
administered	O
methotrexate	O
and	O
cranial	O
irradiation	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
history	O
of	O
identical	O
twin	O
brother	O
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
year	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	B-ADR
and	O
hydrocephalus	O
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	O
administered	O
methotrexate	O
and	O
cranial	O
irradiation	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
history	O
of	O
identical	O
twin	O
brother	O
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
year	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	B-ADR
and	O
hydrocephalus	O
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	O
administered	O
methotrexate	O
and	O
cranial	O
irradiation	O
0	O
<EOS>	O
a	O
retrospective	O
study	O
wa	O
conducted	O
of	O
40	O
loperamide	B-Drug
poisoning	I-ADR
case	O
recorded	O
at	O
the	O
centre	O
national	O
d'informations	O
toxicologiques	O
veterinaires	O
0	O
<EOS>	O
loperamide	B-Drug
poisoning	I-ADR
in	O
the	O
dog	O
0	O
<EOS>	O
a	O
67-year-old	O
man	O
with	O
bipolar	O
disorder	O
developed	O
a	O
creutzfeldt-jakob	B-ADR
like	I-ADR
syndrome	I-ADR
during	O
lithium	B-Drug
carbonate	I-Drug
treatment	O
0	O
<EOS>	O
lithium-induced	B-Drug
creutzfeldt-jakob	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
lithium	B-Drug
neurotoxicity	O
should	O
be	O
considered	O
in	O
creutzfeldt-jakob	B-ADR
disease	I-ADR
differential	O
diagnosis	O
,	O
serial	O
electroencephalogram	O
being	O
the	O
most	O
valuable	O
0	O
<EOS>	O
lithium	B-Drug
neurotoxicity	I-ADR
should	O
be	O
considered	O
in	O
creutzfeldt-jakob	O
disease	O
differential	O
diagnosis	O
,	O
serial	O
electroencephalogram	O
being	O
the	O
most	O
valuable	O
0	O
<EOS>	O
several	O
case	O
of	O
lithium-induced	B-Drug
creutzfeldt-jakob	B-ADR
syndrome	I-ADR
have	O
been	O
reported	O
to	O
date	O
;	O
all	O
of	O
them	O
were	O
elderly	O
patient	O
and	O
a	O
half	O
had	O
``	O
therapeutic	O
'	O
lithium	O
serum	O
level	O
0	O
<EOS>	O
several	O
case	O
of	O
lithium-induced	B-Drug
creutzfeldt-jakob	B-ADR
syndrome	I-ADR
have	O
been	O
reported	O
to	O
date	O
;	O
all	O
of	O
them	O
were	O
elderly	O
patient	O
and	O
a	O
half	O
had	O
``	O
therapeutic	O
'	O
lithium	O
serum	O
level	O
0	O
<EOS>	O
a	O
noninvasive	O
method	O
in	O
the	O
differential	O
diagnosis	O
of	O
vecuronium-induced	O
and	O
magnesium-induced	B-Drug
protracted	B-ADR
neuromuscular	I-ADR
block	I-ADR
in	O
a	O
severely	O
preeclamptic	O
patient	O
0	O
<EOS>	O
a	O
noninvasive	O
method	O
in	O
the	O
differential	O
diagnosis	O
of	O
vecuronium-induced	B-Drug
and	O
magnesium-induced	O
protracted	B-ADR
neuromuscular	I-ADR
block	I-ADR
in	O
a	O
severely	O
preeclamptic	O
patient	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
neuromuscular	B-ADR
blockade	I-ADR
and	O
the	O
resulting	O
potentiation	O
of	O
muscle	O
relaxant	O
during	O
magnesium	B-Drug
sulfate	I-Drug
(	O
mgso4	O
)	O
administration	O
is	O
well	O
known	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
neuromuscular	B-ADR
blockade	I-ADR
and	O
the	O
resulting	O
potentiation	O
of	O
muscle	O
relaxant	O
during	O
magnesium	O
sulfate	O
(	O
mgso4	B-Drug
)	O
administration	O
is	O
well	O
known	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
neuromuscular	O
blockade	O
and	O
the	O
resulting	O
potentiation	B-ADR
of	I-ADR
muscle	I-ADR
relaxant	I-ADR
during	O
magnesium	B-Drug
sulfate	I-Drug
(	O
mgso4	O
)	O
administration	O
is	O
well	O
known	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
neuromuscular	O
blockade	O
and	O
the	O
resulting	O
potentiation	B-ADR
of	I-ADR
muscle	I-ADR
relaxant	I-ADR
during	O
magnesium	O
sulfate	O
(	O
mgso4	B-Drug
)	O
administration	O
is	O
well	O
known	O
0	O
<EOS>	O
we	O
also	O
describe	O
a	O
new	O
,	O
noninvasive	O
method	O
to	O
ass	O
magnesium-induced	B-Drug
neuromuscular	B-ADR
block	I-ADR
when	O
curariform	O
muscle	O
relaxant	O
wa	O
given	O
simultaneously	O
0	O
<EOS>	O
hepatobiliary	B-ADR
disorder	I-ADR
associated	O
with	O
orally	O
administered	O
terbinafine	B-Drug
have	O
rarely	O
been	O
reported	O
0	O
<EOS>	O
terbinafine-induced	B-Drug
cholestatic	B-ADR
liver	I-ADR
disease	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
prolonged	O
terbinafine-induced	B-Drug
cholestatic	B-ADR
liver	I-ADR
disease	I-ADR
0	O
<EOS>	O
a	O
patient	O
with	O
a	O
large	O
hydatid	O
cyst	O
of	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
developed	O
metabolic	B-ADR
acidosis	I-ADR
following	O
rather	O
liberal	O
use	O
of	O
cetrimide-chlorhexidine	B-Drug
solution	O
a	O
a	O
scolicidal	O
agent	O
0	O
<EOS>	O
a	O
patient	O
with	O
a	O
large	O
hydatid	O
cyst	O
of	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
developed	O
metabolic	B-ADR
acidosis	I-ADR
following	O
rather	O
liberal	O
use	O
of	O
cetrimide-chlorhexidine	B-Drug
solution	O
a	O
a	O
scolicidal	O
agent	O
0	O
<EOS>	O
metabolic	B-ADR
acidosis	I-ADR
induced	O
by	O
cetrimide-chlorhexidine	B-Drug
solution	O
in	O
hydatid	O
cyst	O
surgery	O
0	O
<EOS>	O
metabolic	B-ADR
acidosis	I-ADR
induced	O
by	O
cetrimide-chlorhexidine	B-Drug
solution	O
in	O
hydatid	O
cyst	O
surgery	O
0	O
<EOS>	O
an	O
unusual	O
case	O
of	O
ecstasy	B-Drug
poisoning	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
poisoning	B-ADR
with	O
3,4-methylenedioxymet-amphetamine	B-Drug
ecstasy	I-Drug
that	O
presented	O
with	O
all	O
the	O
feature	O
suggestive	O
of	O
a	O
fatal	O
outcome	O
,	O
including	O
a	O
creatinine	O
phosphokinase	O
level	O
markedly	O
higher	O
than	O
any	O
previously	O
reported	O
0	O
<EOS>	O
however	O
,	O
dermatologist	O
should	O
be	O
cautious	O
about	O
a	O
photosensitivity	B-ADR
reaction	O
induced	O
by	O
mequitazine	B-Drug
or	O
other	O
phenothiazine-derivative	O
drug	O
0	O
<EOS>	O
in	O
addition	O
,	O
an	O
immediate	O
erythematous	B-ADR
macule	I-ADR
wa	O
observed	O
on	O
the	O
photopatch	O
test	O
site	O
of	O
mequitazine	B-Drug
directly	O
after	O
uv	O
exposure	O
which	O
wa	O
similar	O
to	O
the	O
immediate	O
erythema	O
noted	O
in	O
chlorpromazine	O
photoallergy	O
0	O
<EOS>	O
in	O
addition	O
,	O
an	O
immediate	O
erythematous	O
macule	O
wa	O
observed	O
on	O
the	O
photopatch	O
test	O
site	O
of	O
mequitazine	B-Drug
directly	O
after	O
uv	O
exposure	O
which	O
wa	O
similar	O
to	O
the	O
immediate	B-ADR
erythema	I-ADR
noted	O
in	O
chlorpromazine	O
photoallergy	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	B-ADR
to	I-ADR
promethazine	I-ADR
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	B-ADR
to	I-ADR
promethazine	I-ADR
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	O
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	B-ADR
to	I-ADR
promethazine	B-Drug
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	B-ADR
med	I-ADR
to	I-ADR
both	I-ADR
uva	I-ADR
and	I-ADR
uvb	I-ADR
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	B-ADR
med	I-ADR
to	I-ADR
both	I-ADR
uva	I-ADR
and	I-ADR
uvb	I-ADR
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	O
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	B-Drug
,	O
decreased	B-ADR
med	I-ADR
to	I-ADR
both	I-ADR
uva	I-ADR
and	I-ADR
uvb	I-ADR
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	B-ADR
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	B-ADR
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	O
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	B-ADR
reaction	O
,	O
cross-reaction	O
to	O
promethazine	B-Drug
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	O
of	O
the	O
photosensitivity	O
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	B-ADR
of	I-ADR
the	I-ADR
photosensitivity	I-ADR
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	B-Drug
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	O
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	B-ADR
of	I-ADR
the	I-ADR
photosensitivity	I-ADR
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
in	O
case	O
no	O
0	O
2	O
,	O
the	O
pathogenic	O
mechanism	O
seemed	O
to	O
be	O
persistent	O
light	O
reaction	O
preceded	O
by	O
systemic	O
photoallergy	O
,	O
a	O
he	O
had	O
taken	O
mequitazine	O
for	O
6	O
month	O
,	O
and	O
there	O
were	O
strong	O
positive	O
photopatch	O
test	O
result	O
with	O
immediate	O
erythema	O
reaction	O
,	O
cross-reaction	O
to	O
promethazine	B-Drug
,	O
decreased	O
med	O
to	O
both	O
uva	O
and	O
uvb	O
,	O
and	O
persistence	B-ADR
of	I-ADR
the	I-ADR
photosensitivity	I-ADR
over	O
a	O
3-year	O
follow-up	O
period	O
after	O
discontinuation	O
of	O
the	O
mequitazine	O
0	O
<EOS>	O
mequitazine	O
seemed	O
to	O
play	O
a	O
part	O
similar	O
to	O
chlorpromazine	O
,	O
and	O
absence	O
of	O
mequitazine-induced	B-Drug
photosensitivity	B-ADR
may	O
be	O
due	O
to	O
a	O
relatively	O
low	O
dosage	O
of	O
the	O
drug	O
0	O
<EOS>	O
two	O
case	O
of	O
mequitazine-induced	B-Drug
photosensitivity	B-ADR
reaction	I-ADR
0	O
<EOS>	O
we	O
experienced	O
2	O
case	O
of	O
mequitazine-induced	B-Drug
photosensitivity	B-ADR
reaction	I-ADR
in	O
patient	O
who	O
took	O
mequitazine	O
for	O
their	O
dermatologic	O
problem	O
0	O
<EOS>	O
we	O
experienced	O
2	O
case	O
of	O
mequitazine-induced	B-Drug
photosensitivity	B-ADR
reaction	I-ADR
in	O
patient	O
who	O
took	O
mequitazine	O
for	O
their	O
dermatologic	O
problem	O
0	O
<EOS>	O
keratitis	B-ADR
in	O
methamphetamine	B-Drug
abuser	O
0	O
<EOS>	O
methamphetamine	B-Drug
extensive	O
physiologic	O
effect	O
,	O
inconsistent	O
street	O
purity	O
,	O
and	O
multiple	O
route	O
of	O
administration	O
offer	O
many	O
possibility	O
for	O
injury	B-ADR
to	I-ADR
the	I-ADR
cornea	I-ADR
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	O
keratitis	B-ADR
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	O
effect	O
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	B-Drug
and	O
quinine	O
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	B-Drug
keratitis	B-ADR
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	O
effect	O
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	O
and	O
quinine	O
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	O
keratitis	B-ADR
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	O
effect	O
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	O
and	O
quinine	B-Drug
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	O
keratitis	O
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	B-ADR
effect	I-ADR
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	B-Drug
and	O
quinine	O
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	B-Drug
keratitis	O
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	B-ADR
effect	I-ADR
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	O
and	O
quinine	O
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
potential	O
cause	O
of	O
methamphetamine-related	O
keratitis	O
can	O
be	O
divided	O
into	O
four	O
category	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effect	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	B-ADR
effect	I-ADR
of	O
diluting	O
or	O
``	O
cutting	O
'	O
agent	O
such	O
a	O
lidocaine	O
and	O
quinine	B-Drug
;	O
(	O
c	O
)	O
effect	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture-related	O
effect	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminant	O
in	O
the	O
final	O
product	O
0	O
<EOS>	O
the	O
increasing	O
prevalence	O
of	O
methamphetamine	O
abuse	O
and	O
the	O
severity	O
of	O
the	O
associated	O
ulcer	O
should	O
alert	O
ophthalmologist	O
to	O
the	O
problem	O
of	O
methamphetamine-related	B-Drug
keratitis	B-ADR
0	O
<EOS>	O
the	O
increasing	O
prevalence	O
of	O
methamphetamine	O
abuse	O
and	O
the	O
severity	O
of	O
the	O
associated	O
ulcer	B-ADR
should	O
alert	O
ophthalmologist	O
to	O
the	O
problem	O
of	O
methamphetamine-related	B-Drug
keratitis	O
0	O
<EOS>	O
we	O
report	O
four	O
case	O
of	O
severe	B-ADR
corneal	I-ADR
ulceration	I-ADR
in	O
methamphetamine	B-Drug
abuser	O
0	O
<EOS>	O
background	O
:	O
methotrexate	B-Drug
(	O
mtx	O
)	O
may	O
induce	O
liver	O
damage	O
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	O
or	O
cirrhosis	B-ADR
0	O
<EOS>	O
background	O
:	O
methotrexate	O
(	O
mtx	B-Drug
)	O
may	O
induce	O
liver	O
damage	O
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	O
or	O
cirrhosis	B-ADR
0	O
<EOS>	O
background	O
:	O
methotrexate	B-Drug
(	O
mtx	O
)	O
may	O
induce	O
liver	O
damage	O
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	B-ADR
or	O
cirrhosis	O
0	O
<EOS>	O
background	O
:	O
methotrexate	O
(	O
mtx	B-Drug
)	O
may	O
induce	O
liver	O
damage	O
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	B-ADR
or	O
cirrhosis	O
0	O
<EOS>	O
background	O
:	O
methotrexate	B-Drug
(	O
mtx	O
)	O
may	O
induce	O
liver	B-ADR
damage	I-ADR
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	O
or	O
cirrhosis	O
0	O
<EOS>	O
background	O
:	O
methotrexate	O
(	O
mtx	B-Drug
)	O
may	O
induce	O
liver	B-ADR
damage	I-ADR
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	O
or	O
cirrhosis	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
study	O
confirmed	O
that	O
in	O
most	O
patient	O
mtx-induced	B-Drug
liver	B-ADR
cirrhosis	I-ADR
is	O
not	O
aggressive	O
0	O
<EOS>	O
however	O
,	O
continued	O
low-dose	O
mtx	B-Drug
led	O
,	O
in	O
spite	O
of	O
normal	O
liver	O
test	O
,	O
8	O
year	O
after	O
the	O
last	O
biopsy	O
to	O
liver	O
failure	O
and	O
death	B-ADR
in	O
1	O
of	O
our	O
patient	O
0	O
<EOS>	O
however	O
,	O
continued	O
low-dose	O
mtx	B-Drug
led	O
,	O
in	O
spite	O
of	O
normal	O
liver	O
test	O
,	O
8	O
year	O
after	O
the	O
last	O
biopsy	O
to	O
liver	B-ADR
failure	I-ADR
and	O
death	O
in	O
1	O
of	O
our	O
patient	O
0	O
<EOS>	O
methotrexate-induced	B-Drug
liver	B-ADR
cirrhosis	I-ADR
0	O
<EOS>	O
study	O
performed	O
10	O
year	O
ago	O
on	O
25	O
patient	O
with	O
mtx-induced	B-Drug
liver	O
cirrhosis	B-ADR
indicated	O
that	O
this	O
type	O
of	O
cirrhosis	O
wa	O
not	O
of	O
an	O
aggressive	O
nature	O
0	O
<EOS>	O
study	O
performed	O
10	O
year	O
ago	O
on	O
25	O
patient	O
with	O
mtx-induced	B-Drug
liver	B-ADR
cirrhosis	I-ADR
indicated	O
that	O
this	O
type	O
of	O
cirrhosis	O
wa	O
not	O
of	O
an	O
aggressive	O
nature	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	O
(	O
containing	O
the	O
preservative	O
cresol	B-Drug
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	B-ADR
fever	I-ADR
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	O
consciousness	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	B-Drug
(	O
containing	O
the	O
preservative	O
cresol	O
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	B-ADR
fever	I-ADR
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	O
consciousness	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	O
(	O
containing	O
the	O
preservative	O
cresol	B-Drug
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	B-ADR
myalgia	I-ADR
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	O
consciousness	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	B-Drug
(	O
containing	O
the	O
preservative	O
cresol	O
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	B-ADR
myalgia	I-ADR
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	O
consciousness	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	O
(	O
containing	O
the	O
preservative	O
cresol	B-Drug
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	B-ADR
consciousness	I-ADR
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	B-Drug
(	O
containing	O
the	O
preservative	O
cresol	O
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	O
and	O
metabolic	O
acidosis	O
and	O
lost	B-ADR
consciousness	I-ADR
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	O
(	O
containing	O
the	O
preservative	O
cresol	B-Drug
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	B-ADR
and	I-ADR
metabolic	I-ADR
acidosis	I-ADR
and	O
lost	O
consciousness	O
0	O
<EOS>	O
after	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	B-Drug
(	O
containing	O
the	O
preservative	O
cresol	O
)	O
and	O
electrolyte	O
solution	O
wa	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	O
myalgia	O
,	O
developed	O
a	O
high	O
fever	O
and	O
respiratory	B-ADR
and	I-ADR
metabolic	I-ADR
acidosis	I-ADR
and	O
lost	O
consciousness	O
0	O
<EOS>	O
however	O
,	O
other	O
factor	O
or	O
drug	O
(	O
e.g	O
0	O
cresol	B-Drug
)	O
are	O
thought	O
to	O
induce	O
mh	B-ADR
0	O
<EOS>	O
this	O
case	O
support	O
the	O
assessment	O
that	O
mh	B-ADR
and	O
diabetes	O
are	O
associated	O
disease	O
and	O
that	O
cresol	B-Drug
could	O
possibly	O
trigger	O
mh	O
0	O
<EOS>	O
the	O
use	O
of	O
beclomethasone	B-Drug
diproprionate	I-Drug
inhaler	O
complicated	O
by	O
the	O
development	O
of	O
an	O
eosinophilic	B-ADR
pneumonia	I-ADR
reaction	I-ADR
0	O
<EOS>	O
fatal	B-ADR
intravascular	I-ADR
autoimmune	I-ADR
hemolytic	I-ADR
anemia	I-ADR
after	O
fludarabine	B-Drug
treatment	O
for	O
chronic	O
lymphocytic	O
leukemia	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	B-ADR
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	O
of	O
the	O
dat	O
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	B-ADR
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	O
of	O
the	O
dat	O
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	B-ADR
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	O
of	O
the	O
dat	O
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	B-ADR
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	O
of	O
the	O
dat	O
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	O
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	B-ADR
of	I-ADR
the	I-ADR
dat	I-ADR
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	O
aiha	O
in	O
cll	O
patient	O
with	O
a	O
history	O
of	O
aiha	O
or	O
positivation	B-ADR
of	I-ADR
the	I-ADR
dat	I-ADR
during	O
previous	O
fludarabine	B-Drug
administration	O
,	O
or	O
in	O
case	O
of	O
secondary	O
fixation	O
of	O
complement	O
to	O
the	O
red	O
cell	O
membrane	O
occurring	O
during	O
fludarabine	O
treatment	O
0	O
<EOS>	O
the	O
occurrence	O
of	O
severe	O
aiha	B-ADR
in	O
cll	O
patient	O
treated	O
with	O
fludarabine	B-Drug
ha	O
been	O
reported	O
by	O
several	O
author	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	O
)	O
who	O
developed	O
fatal	O
intravascular	O
autoimmune	O
hemolytic	O
anemia	O
(	O
aiha	B-ADR
)	O
after	O
fludarabine	B-Drug
treatment	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	O
)	O
who	O
developed	O
fatal	B-ADR
intravascular	I-ADR
autoimmune	I-ADR
hemolytic	I-ADR
anemia	I-ADR
(	O
aiha	O
)	O
after	O
fludarabine	B-Drug
treatment	O
0	O
<EOS>	O
when	O
the	O
patient	O
wa	O
treated	O
again	O
with	O
fludarabine	B-Drug
nine	O
month	O
later	O
,	O
the	O
dat	B-ADR
became	I-ADR
positive	I-ADR
with	I-ADR
anti-igg	I-ADR
and	I-ADR
anti-c3d	I-ADR
antiglobulins	I-ADR
after	O
the	O
second	O
course	O
of	O
treatment	O
0	O
<EOS>	O
she	O
had	O
just	O
finished	O
a	O
3-week	O
course	O
of	O
intravenous	O
tobramycin	B-Drug
for	O
bronchiectasis	O
and	O
had	O
an	O
elevated	O
serum	O
tobramycin	O
trough	O
level	O
1	O
week	O
before	O
the	O
onset	O
of	O
tetany	B-ADR
0	O
<EOS>	O
tetany	B-ADR
in	O
a	O
child	O
with	O
aid	O
receiving	O
intravenous	O
tobramycin	B-Drug
0	O
<EOS>	O
this	O
pattern	O
is	O
suggestive	O
of	O
renal	B-ADR
toxicity	I-ADR
due	O
to	O
tobramycin	B-Drug
0	O
<EOS>	O
conclusion	O
:	O
in	O
our	O
reported	O
case	O
,	O
a	O
local	O
hyperproduction	O
of	O
tnf-alpha	O
from	O
macrophage	O
that	O
wa	O
induced	O
by	O
the	O
injected	O
insulin	B-Drug
could	O
explain	O
the	O
dedifferentiation	B-ADR
of	I-ADR
the	I-ADR
adipocytes	I-ADR
of	O
the	O
subcutaneous	O
tissue	O
and	O
the	O
reversion	O
that	O
wa	O
induced	O
by	O
the	O
local	O
injection	O
of	O
dexamethasone	O
0	O
<EOS>	O
conclusion	O
:	O
in	O
our	O
reported	O
case	O
,	O
a	O
local	O
hyperproduction	B-ADR
of	I-ADR
tnf-alpha	I-ADR
from	O
macrophage	O
that	O
wa	O
induced	O
by	O
the	O
injected	O
insulin	B-Drug
could	O
explain	O
the	O
dedifferentiation	O
of	O
the	O
adipocytes	O
of	O
the	O
subcutaneous	O
tissue	O
and	O
the	O
reversion	O
that	O
wa	O
induced	O
by	O
the	O
local	O
injection	O
of	O
dexamethasone	O
0	O
<EOS>	O
insulin-induced	B-Drug
lipoatrophy	B-ADR
in	O
type	O
i	O
diabetes	O
0	O
<EOS>	O
objective	O
:	O
to	O
test	O
the	O
hypothesis	O
that	O
tumor	O
necrosis	O
factor	O
(	O
tnf	O
)	O
-alpha	O
may	O
mediate	O
the	O
loss	O
and	O
the	O
dedifferentiation	O
of	O
subcutaneous	O
fat	O
tissue	O
in	O
the	O
insulin-induced	B-Drug
lipoatrophies	B-ADR
of	O
a	O
diabetic	O
patient	O
who	O
presented	O
extensive	O
lesion	O
0	O
<EOS>	O
erosion	B-ADR
of	I-ADR
psoriatic	I-ADR
plaque	I-ADR
:	O
an	O
early	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
0	O
<EOS>	O
erosion	O
of	O
psoriatic	O
plaque	O
:	O
an	O
early	O
sign	O
of	O
methotrexate	B-Drug
toxicity	I-ADR
0	O
<EOS>	O
methotrexate	B-Drug
is	O
an	O
effective	O
but	O
potentially	B-ADR
toxic	I-ADR
treatment	O
for	O
psoriasis	O
0	O
<EOS>	O
painful	O
erosion	O
of	O
psoriatic	O
plaque	O
is	O
a	O
le	O
common	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
that	O
may	O
precede	O
evidence	O
of	O
bone	B-ADR
marrow	I-ADR
suppression	I-ADR
0	O
<EOS>	O
painful	O
erosion	O
of	O
psoriatic	O
plaque	O
is	O
a	O
le	O
common	O
sign	O
of	O
methotrexate	B-Drug
toxicity	I-ADR
that	O
may	O
precede	O
evidence	O
of	O
bone	O
marrow	O
suppression	O
0	O
<EOS>	O
painful	B-ADR
erosion	I-ADR
of	I-ADR
psoriatic	I-ADR
plaque	I-ADR
is	O
a	O
le	O
common	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
that	O
may	O
precede	O
evidence	O
of	O
bone	O
marrow	O
suppression	O
0	O
<EOS>	O
we	O
describe	O
two	O
patient	O
in	O
whom	O
painful	O
erosion	O
of	O
their	O
psoriasis	O
developed	O
a	O
the	O
presenting	O
sign	O
of	O
methotrexate	B-Drug
toxicity	I-ADR
and	O
review	O
the	O
literature	O
,	O
emphasizing	O
the	O
risk	O
factor	O
associated	O
with	O
this	O
manifestation	O
0	O
<EOS>	O
we	O
describe	O
two	O
patient	O
in	O
whom	O
painful	B-ADR
erosion	I-ADR
of	I-ADR
their	I-ADR
psoriasis	I-ADR
developed	O
a	O
the	O
presenting	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
and	O
review	O
the	O
literature	O
,	O
emphasizing	O
the	O
risk	O
factor	O
associated	O
with	O
this	O
manifestation	O
0	O
<EOS>	O
well-known	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
include	O
bone	B-ADR
marrow	I-ADR
suppression	I-ADR
and	O
oral	O
and	O
gastrointestinal	O
ulceration	O
0	O
<EOS>	O
well-known	O
sign	O
of	O
methotrexate	B-Drug
toxicity	I-ADR
include	O
bone	O
marrow	O
suppression	O
and	O
oral	O
and	O
gastrointestinal	O
ulceration	O
0	O
<EOS>	O
well-known	O
sign	O
of	O
methotrexate	B-Drug
toxicity	O
include	O
bone	O
marrow	O
suppression	O
and	O
oral	B-ADR
and	I-ADR
gastrointestinal	I-ADR
ulceration	I-ADR
0	O
<EOS>	O
after	O
treatment	O
with	O
cimetidine	B-Drug
,	O
there	O
wa	O
a	O
rapid	O
deterioration	O
with	O
decreased	B-ADR
oxygen	I-ADR
saturation	I-ADR
and	I-ADR
arterial	I-ADR
po2	I-ADR
value	O
0	O
<EOS>	O
caution	O
with	O
use	O
of	O
cimetidine	B-Drug
in	O
tolazoline	O
induced	O
upper	B-ADR
gastrointestinal	I-ADR
bleeding	I-ADR
0	O
<EOS>	O
caution	O
with	O
use	O
of	O
cimetidine	O
in	O
tolazoline	B-Drug
induced	O
upper	B-ADR
gastrointestinal	I-ADR
bleeding	I-ADR
0	O
<EOS>	O
however	O
,	O
given	O
the	O
clinically	O
significant	O
result	O
to	O
the	O
interaction	O
between	O
tolazoline	O
and	O
cimetidine	B-Drug
we	O
report	O
,	O
the	O
use	O
of	O
cimetidine	O
in	O
tolazoline	O
induced	O
upper	B-ADR
gastrointestinal	I-ADR
hemorrhage	I-ADR
should	O
deserve	O
more	O
attention	O
0	O
<EOS>	O
however	O
,	O
given	O
the	O
clinically	O
significant	O
result	O
to	O
the	O
interaction	O
between	O
tolazoline	O
and	O
cimetidine	B-Drug
we	O
report	O
,	O
the	O
use	O
of	O
cimetidine	O
in	O
tolazoline	O
induced	O
upper	B-ADR
gastrointestinal	I-ADR
hemorrhage	I-ADR
should	O
deserve	O
more	O
attention	O
0	O
<EOS>	O
however	O
,	O
given	O
the	O
clinically	O
significant	O
result	O
to	O
the	O
interaction	O
between	O
tolazoline	B-Drug
and	O
cimetidine	O
we	O
report	O
,	O
the	O
use	O
of	O
cimetidine	O
in	O
tolazoline	O
induced	O
upper	B-ADR
gastrointestinal	I-ADR
hemorrhage	I-ADR
should	O
deserve	O
more	O
attention	O
0	O
<EOS>	O
however	O
,	O
given	O
the	O
clinically	O
significant	O
result	O
to	O
the	O
interaction	O
between	O
tolazoline	B-Drug
and	O
cimetidine	O
we	O
report	O
,	O
the	O
use	O
of	O
cimetidine	O
in	O
tolazoline	O
induced	O
upper	B-ADR
gastrointestinal	I-ADR
hemorrhage	I-ADR
should	O
deserve	O
more	O
attention	O
0	O
<EOS>	O
hypoxemia	O
improved	O
during	O
continuous	O
tolazoline	B-Drug
infusion	O
,	O
but	O
gastrointestinal	B-ADR
bleeding	I-ADR
occurred	O
0	O
<EOS>	O
zolpidem	O
(	O
ambien	B-Drug
)	O
,	O
a	O
relatively	O
new	O
nonbenzodiazepine	O
sedative-hypnotic	O
,	O
wa	O
involved	O
in	O
the	O
death	B-ADR
of	O
a	O
39-year-old	O
obese	O
male	O
who	O
wa	O
being	O
treated	O
for	O
depression	O
and	O
insomnia	O
0	O
<EOS>	O
zolpidem	B-Drug
(	O
ambien	O
)	O
,	O
a	O
relatively	O
new	O
nonbenzodiazepine	O
sedative-hypnotic	O
,	O
wa	O
involved	O
in	O
the	O
death	B-ADR
of	O
a	O
39-year-old	O
obese	O
male	O
who	O
wa	O
being	O
treated	O
for	O
depression	O
and	O
insomnia	O
0	O
<EOS>	O
zolpidem	O
tissue	O
concentration	O
in	O
a	O
multiple	O
drug	O
related	O
death	B-ADR
involving	O
ambien	B-Drug
0	O
<EOS>	O
zolpidem	B-Drug
tissue	O
concentration	O
in	O
a	O
multiple	O
drug	O
related	O
death	B-ADR
involving	O
ambien	O
0	O
<EOS>	O
acute	O
nitrite	B-Drug
toxicity	I-ADR
result	O
from	O
industrial	O
exposure	O
,	O
accidental	O
ingestion	O
(	O
e.g.	O
,	O
abuse	O
of	O
organic	O
nitrite	O
a	O
an	O
aphrodisiac	O
,	O
especially	O
in	O
the	O
male	O
homosexual	O
population	O
)	O
,	O
and	O
suicidal	O
ingestion	O
0	O
<EOS>	O
infant	O
are	O
particularly	O
susceptible	O
to	O
chronic	O
nitrate-induced	B-Drug
methemoglobinemia	B-ADR
because	O
of	O
their	O
low	O
stomach	O
acid	O
production	O
,	O
large	O
number	O
of	O
nitrite-reducing	O
bacteria	O
,	O
and	O
the	O
relatively	O
easy	O
oxidation	O
of	O
fetal	O
hemoglobin	O
0	O
<EOS>	O
acute	O
esmolol	B-Drug
toxicity	I-ADR
may	O
be	O
self-limiting	O
because	O
of	O
it	O
extremely	O
short	O
half-life	O
0	O
<EOS>	O
after	O
induction	O
of	O
general	O
anesthesia	O
and	O
administration	O
of	O
a	O
standard	O
dose	O
of	O
intravenous	O
esmolol	B-Drug
hydrochloride	I-Drug
,	O
her	O
cardiac	O
rhythm	O
progressed	O
to	O
asystole	B-ADR
0	O
<EOS>	O
cardiac	B-ADR
arrest	I-ADR
after	O
esmolol	B-Drug
administration	O
:	O
a	O
review	O
of	O
acute	O
beta-blocker	O
toxicity	O
0	O
<EOS>	O
atenolol	B-Drug
induced	O
memory	B-ADR
impairment	I-ADR
:	O
a	O
case	O
report	O
0	O
<EOS>	O
his	O
impaired	B-ADR
memory	I-ADR
wa	O
found	O
to	O
be	O
due	O
to	O
the	O
atenolol	B-Drug
he	O
wa	O
on	O
and	O
he	O
made	O
a	O
complete	O
recovery	O
on	O
withdrawing	O
the	O
beta-blocker	O
0	O
<EOS>	O
a	O
potential	O
role	O
for	O
renal	O
and	O
hepatic	O
impairment	O
in	O
the	O
observed	O
protracted	O
course	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
is	O
suggested	O
0	O
<EOS>	O
failure	O
of	O
plasmapheresis	O
,	O
corticosteroid	O
and	O
thionamides	O
to	O
ameliorate	O
a	O
case	O
of	O
protracted	O
amiodarone-induced	B-Drug
thyroiditis	B-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
of	O
protracted	O
duration	O
,	O
unresponsive	O
to	O
conventional	O
thionamide	O
therapy	O
,	O
with	O
therapy	O
limited	O
by	O
severe	O
adverse	O
drug	O
reaction	O
0	O
<EOS>	O
psychotic	B-ADR
disorder	I-ADR
associated	O
with	O
isoniazid	B-Drug
0	O
<EOS>	O
we	O
evaluated	O
a	O
patient	O
who	O
developed	O
a	O
psychotic	B-ADR
disorder	I-ADR
after	O
4	O
month	O
of	O
isoniazid	B-Drug
prophylaxis	O
for	O
a	O
positive	O
tuberculosis	O
tine	O
test	O
0	O
<EOS>	O
a	O
case	O
report	O
is	O
presented	O
concerning	O
the	O
administration	O
of	O
ketanserin	O
in	O
the	O
treatment	O
of	O
pulmonary	B-ADR
vasoconstriction	I-ADR
and	O
right	O
ventricular	O
failure	O
following	O
the	O
infusion	O
of	O
protamine	B-Drug
in	O
a	O
patient	O
undergoing	O
coronary	O
artery	O
bypass	O
surgery	O
and	O
mitral	O
valve	O
replacement	O
0	O
<EOS>	O
a	O
case	O
report	O
is	O
presented	O
concerning	O
the	O
administration	O
of	O
ketanserin	O
in	O
the	O
treatment	O
of	O
pulmonary	O
vasoconstriction	O
and	O
right	B-ADR
ventricular	I-ADR
failure	I-ADR
following	O
the	O
infusion	O
of	O
protamine	B-Drug
in	O
a	O
patient	O
undergoing	O
coronary	O
artery	O
bypass	O
surgery	O
and	O
mitral	O
valve	O
replacement	O
0	O
<EOS>	O
ketanserin	O
in	O
the	O
treatment	O
of	O
protamine-induced	B-Drug
pulmonary	B-ADR
hypertension	I-ADR
0	O
<EOS>	O
the	O
reversal	O
of	O
heparin	O
by	O
protamine	B-Drug
may	O
cause	O
severe	O
hemodynamic	O
deterioration	O
,	O
characterized	O
by	O
systemic	O
hypotension	O
,	O
pulmonary	O
hypertension	O
,	O
and	O
bronchoconstriction	B-ADR
0	O
<EOS>	O
the	O
reversal	O
of	O
heparin	O
by	O
protamine	B-Drug
may	O
cause	O
severe	O
hemodynamic	O
deterioration	O
,	O
characterized	O
by	O
systemic	O
hypotension	O
,	O
pulmonary	B-ADR
hypertension	I-ADR
,	O
and	O
bronchoconstriction	O
0	O
<EOS>	O
the	O
reversal	O
of	O
heparin	O
by	O
protamine	B-Drug
may	O
cause	O
severe	B-ADR
hemodynamic	I-ADR
deterioration	I-ADR
,	O
characterized	O
by	O
systemic	O
hypotension	O
,	O
pulmonary	O
hypertension	O
,	O
and	O
bronchoconstriction	O
0	O
<EOS>	O
the	O
reversal	O
of	O
heparin	O
by	O
protamine	B-Drug
may	O
cause	O
severe	O
hemodynamic	O
deterioration	O
,	O
characterized	O
by	O
systemic	B-ADR
hypotension	I-ADR
,	O
pulmonary	O
hypertension	O
,	O
and	O
bronchoconstriction	O
0	O
<EOS>	O
a	O
drug	O
addict	O
with	O
staphylococcal	O
endocarditis	O
treated	O
with	O
methicillin	B-Drug
,	O
who	O
developed	O
massive	O
proteinuria	O
and	O
acute	B-ADR
nephritic	I-ADR
syndrome	I-ADR
is	O
described	O
0	O
<EOS>	O
a	O
drug	O
addict	O
with	O
staphylococcal	O
endocarditis	O
treated	O
with	O
methicillin	B-Drug
,	O
who	O
developed	O
massive	B-ADR
proteinuria	I-ADR
and	O
acute	O
nephritic	O
syndrome	O
is	O
described	O
0	O
<EOS>	O
focal	B-ADR
glomerulonephritis	I-ADR
and	O
interstitial	O
nephritis	O
in	O
methicillin-treated	B-Drug
,	O
heroin-related	O
infective	O
endocarditis	O
0	O
<EOS>	O
focal	O
glomerulonephritis	O
and	O
interstitial	B-ADR
nephritis	I-ADR
in	O
methicillin-treated	B-Drug
,	O
heroin-related	O
infective	O
endocarditis	O
0	O
<EOS>	O
method	O
/	O
result	O
:	O
this	O
paper	O
present	O
a	O
new	O
case	O
of	O
rifabutin	B-Drug
uveitis	B-ADR
and	O
a	O
review	O
of	O
the	O
various	O
published	O
report	O
to	O
date	O
0	O
<EOS>	O
over	O
the	O
past	O
3	O
year	O
there	O
have	O
been	O
several	O
report	O
of	O
uveitis	B-ADR
associated	O
with	O
rifabutin	B-Drug
therapy	O
0	O
<EOS>	O
uveitis	B-ADR
associated	O
with	O
rifabutin	B-Drug
therapy	O
:	O
a	O
clinical	O
alert	O
0	O
<EOS>	O
case	O
description	O
:	O
a	O
59-year-old	O
man	O
with	O
known	O
neurocysticercosis	O
developed	O
a	O
large	B-ADR
cerebral	I-ADR
infarction	I-ADR
during	O
praziquantel	B-Drug
therapy	O
0	O
<EOS>	O
large	B-ADR
cerebral	I-ADR
infarction	I-ADR
during	O
praziquantel	B-Drug
therapy	O
in	O
neurocysticercosis	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	B-ADR
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	B-ADR
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	B-ADR
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	B-ADR
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	B-ADR
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	B-ADR
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	B-ADR
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	O
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	B-ADR
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	B-ADR
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
data	O
synthesis	O
:	O
genetic	O
deficiency	O
in	O
dpd	O
,	O
the	O
rate-limiting	O
enzyme	O
responsible	O
for	O
5-fu	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patient	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reaction	O
(	O
e.g.	O
,	O
diarrhea	O
,	O
stomatitis	B-ADR
,	O
mucositis	O
,	O
myelosuppression	O
,	O
neurotoxicity	O
)	O
to	O
standard	O
dos	O
of	O
5-fu	O
0	O
<EOS>	O
dihydropyrimidine	O
dehydrogenase	O
deficiency	O
:	O
a	O
pharmacogenetic	O
defect	O
causing	O
severe	B-ADR
adverse	I-ADR
reaction	I-ADR
to	O
5-fluorouracil-based	B-Drug
chemotherapy	O
0	O
<EOS>	O
purpose	O
/	O
objective	O
:	O
to	O
describe	O
the	O
pharmacogenetic	O
syndrome	O
of	O
dihydropyrimidine	O
dehydrogenase	O
(	O
dpd	O
)	O
deficiency	O
,	O
which	O
predisposes	O
patient	O
with	O
cancer	O
to	O
potentially	O
lethal	B-ADR
adverse	I-ADR
reaction	I-ADR
following	O
5-fluorouracil	B-Drug
(	O
5-fu	O
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
purpose	O
/	O
objective	O
:	O
to	O
describe	O
the	O
pharmacogenetic	O
syndrome	O
of	O
dihydropyrimidine	O
dehydrogenase	O
(	O
dpd	O
)	O
deficiency	O
,	O
which	O
predisposes	O
patient	O
with	O
cancer	O
to	O
potentially	O
lethal	B-ADR
adverse	I-ADR
reaction	I-ADR
following	O
5-fluorouracil	O
(	O
5-fu	B-Drug
)	O
-based	O
chemotherapy	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	O
and	O
coma	B-ADR
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	O
and	O
coma	B-ADR
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	B-ADR
and	O
coma	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	B-ADR
and	O
coma	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	B-ADR
symptom	I-ADR
such	O
a	O
encephalopathy	O
and	O
coma	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	O
acute	O
5-fu	O
reaction	O
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	B-ADR
symptom	I-ADR
such	O
a	O
encephalopathy	O
and	O
coma	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	B-ADR
acute	I-ADR
5-fu	I-ADR
reaction	I-ADR
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	O
and	O
coma	O
0	O
<EOS>	O
the	O
principle	O
treatment	O
for	O
dpd-deficient	O
patient	O
with	O
severe	B-ADR
acute	I-ADR
5-fu	I-ADR
reaction	I-ADR
is	O
supportive	O
care	O
;	O
however	O
,	O
the	O
administration	O
of	O
thymidine	O
potentially	O
may	O
reverse	O
severe	O
5-fu-induced	B-Drug
neurologic	O
symptom	O
such	O
a	O
encephalopathy	O
and	O
coma	O
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	O
and	O
mesalamine	O
(	O
5-asa	B-Drug
)	O
developed	O
worsening	O
respiratory	O
distress	O
and	O
fever	B-ADR
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	O
and	O
mesalamine	B-Drug
(	O
5-asa	O
)	O
developed	O
worsening	O
respiratory	O
distress	O
and	O
fever	B-ADR
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	B-Drug
and	O
mesalamine	O
(	O
5-asa	O
)	O
developed	O
worsening	O
respiratory	O
distress	O
and	O
fever	B-ADR
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	O
and	O
mesalamine	O
(	O
5-asa	B-Drug
)	O
developed	O
worsening	B-ADR
respiratory	I-ADR
distress	I-ADR
and	O
fever	O
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	O
and	O
mesalamine	B-Drug
(	O
5-asa	O
)	O
developed	O
worsening	B-ADR
respiratory	I-ADR
distress	I-ADR
and	O
fever	O
0	O
<EOS>	O
a	O
49-year-old	O
man	O
with	O
crohn	O
disease	O
treated	O
with	O
prednisone	B-Drug
and	O
mesalamine	O
(	O
5-asa	O
)	O
developed	O
worsening	B-ADR
respiratory	I-ADR
distress	I-ADR
and	O
fever	O
0	O
<EOS>	O
mesalamine-induced	B-Drug
hypersensitivity	B-ADR
pneumonitis	I-ADR
0	O
<EOS>	O
mesalamine	B-Drug
may	O
cause	O
hypersensitivity	B-ADR
pneumonitis	I-ADR
in	O
patient	O
with	O
crohn	O
disease	O
0	O
<EOS>	O
immunosuppression	O
elicited	O
by	O
the	O
extensive	O
administration	O
of	O
prednisolone	B-Drug
wa	O
suspected	O
for	O
the	O
initiation	O
of	O
the	O
generalized	O
mite	B-ADR
infestation	I-ADR
0	O
<EOS>	O
background	O
:	O
colchicine	B-Drug
ha	O
a	O
known	O
adverse	B-ADR
effect	I-ADR
on	I-ADR
wound	I-ADR
healing	I-ADR
through	O
it	O
inhibitory	O
effect	O
on	O
tubulin-dependent	O
cell	O
function	O
and	O
through	O
collagenase	O
activation	O
0	O
<EOS>	O
background	O
:	O
colchicine	B-Drug
ha	O
a	O
known	O
adverse	O
effect	O
on	O
wound	O
healing	O
through	O
it	O
inhibitory	O
effect	O
on	O
tubulin-dependent	O
cell	O
function	O
and	O
through	O
collagenase	B-ADR
activation	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
the	O
finding	O
in	O
these	O
two	O
patient	O
suggest	O
that	O
colchicine	B-Drug
may	O
delay	B-ADR
corneal	I-ADR
wound	I-ADR
healing	I-ADR
0	O
<EOS>	O
delay	B-ADR
of	I-ADR
corneal	I-ADR
wound	I-ADR
healing	I-ADR
in	O
patient	O
treated	O
with	O
colchicine	B-Drug
0	O
<EOS>	O
the	O
author	O
report	O
on	O
two	O
patient	O
with	O
corneal	B-ADR
ulcer	I-ADR
refractory	I-ADR
to	I-ADR
conventional	I-ADR
treatment	I-ADR
while	O
the	O
patient	O
were	O
undergoing	O
oral	O
colchicine	B-Drug
therapy	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
in	O
patient	O
with	O
corneal	B-ADR
ulcer	I-ADR
refractory	I-ADR
to	I-ADR
conventional	I-ADR
treatment	I-ADR
who	O
are	O
receiving	O
colchicine	B-Drug
,	O
cessation	O
of	O
colchicine	O
therapy	O
should	O
be	O
considered	O
0	O
<EOS>	O
fulminant	B-ADR
hepatic	I-ADR
failure	I-ADR
associated	O
with	O
bicalutamide	B-Drug
0	O
<EOS>	O
a	O
17-year-old	O
female	O
patient	O
who	O
had	O
been	O
taking	O
oral	O
minocycline	B-Drug
(	O
50	O
mg	O
twice	O
daily	O
)	O
for	O
3	O
week	O
for	O
acne	O
developed	O
an	O
eruption	B-ADR
that	O
progressed	O
to	O
an	O
exfoliative	O
dermatitis	O
0	O
<EOS>	O
a	O
17-year-old	O
female	O
patient	O
who	O
had	O
been	O
taking	O
oral	O
minocycline	B-Drug
(	O
50	O
mg	O
twice	O
daily	O
)	O
for	O
3	O
week	O
for	O
acne	O
developed	O
an	O
eruption	O
that	O
progressed	O
to	O
an	O
exfoliative	B-ADR
dermatitis	I-ADR
0	O
<EOS>	O
fever	O
,	O
lymphadenopathy	O
,	O
eosinophilia	O
,	O
lymphocytosis	O
,	O
hepatitis	O
,	O
and	O
dermatitis	B-ADR
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
fever	O
,	O
lymphadenopathy	O
,	O
eosinophilia	B-ADR
,	O
lymphocytosis	O
,	O
hepatitis	O
,	O
and	O
dermatitis	O
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
fever	B-ADR
,	O
lymphadenopathy	O
,	O
eosinophilia	O
,	O
lymphocytosis	O
,	O
hepatitis	O
,	O
and	O
dermatitis	O
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
fever	O
,	O
lymphadenopathy	O
,	O
eosinophilia	O
,	O
lymphocytosis	O
,	O
hepatitis	B-ADR
,	O
and	O
dermatitis	O
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
fever	O
,	O
lymphadenopathy	B-ADR
,	O
eosinophilia	O
,	O
lymphocytosis	O
,	O
hepatitis	O
,	O
and	O
dermatitis	O
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
fever	O
,	O
lymphadenopathy	O
,	O
eosinophilia	O
,	O
lymphocytosis	B-ADR
,	O
hepatitis	O
,	O
and	O
dermatitis	O
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
0	O
<EOS>	O
this	O
severe	O
illness	O
wa	O
likely	O
caused	O
by	O
minocycline	B-Drug
,	O
and	O
we	O
speculate	O
that	O
minocycline	O
may	O
have	O
acted	O
a	O
a	O
superantigen	O
,	O
causing	O
lymphocyte	B-ADR
over-activation	I-ADR
and	O
massive	O
cytokine	O
release	O
0	O
<EOS>	O
this	O
severe	O
illness	O
wa	O
likely	O
caused	O
by	O
minocycline	B-Drug
,	O
and	O
we	O
speculate	O
that	O
minocycline	O
may	O
have	O
acted	O
a	O
a	O
superantigen	O
,	O
causing	O
lymphocyte	O
over-activation	O
and	O
massive	B-ADR
cytokine	I-ADR
release	I-ADR
0	O
<EOS>	O
this	O
severe	B-ADR
illness	I-ADR
wa	O
likely	O
caused	O
by	O
minocycline	B-Drug
,	O
and	O
we	O
speculate	O
that	O
minocycline	O
may	O
have	O
acted	O
a	O
a	O
superantigen	O
,	O
causing	O
lymphocyte	O
over-activation	O
and	O
massive	O
cytokine	O
release	O
0	O
<EOS>	O
delayed	B-ADR
hypersensitivity	I-ADR
to	O
flurbiprofen	B-Drug
0	O
<EOS>	O
eye	B-ADR
movement	I-ADR
disorder	I-ADR
in	O
bone	O
marrow	O
transplant	O
patient	O
on	O
cyclosporin	B-Drug
and	O
ganciclovir	O
0	O
<EOS>	O
eye	B-ADR
movement	I-ADR
disorder	I-ADR
in	O
bone	O
marrow	O
transplant	O
patient	O
on	O
cyclosporin	O
and	O
ganciclovir	B-Drug
0	O
<EOS>	O
one	O
patient	O
had	O
mri	B-ADR
t2	I-ADR
abnormality	I-ADR
compatible	O
with	O
cyclosporin	B-Drug
neurotoxicity	O
0	O
<EOS>	O
one	O
patient	O
had	O
mri	O
t2	O
abnormality	O
compatible	O
with	O
cyclosporin	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
we	O
postulate	O
that	O
cyclosporin	B-Drug
,	O
possibly	O
together	O
with	O
ganciclovir	O
,	O
can	O
produce	O
transient	O
brain	O
stem	O
or	O
neuromuscular	O
dysfunction	O
with	O
eye	B-ADR
movement	I-ADR
abnormality	I-ADR
in	O
occasional	O
patient	O
0	O
<EOS>	O
we	O
postulate	O
that	O
cyclosporin	O
,	O
possibly	O
together	O
with	O
ganciclovir	B-Drug
,	O
can	O
produce	O
transient	O
brain	O
stem	O
or	O
neuromuscular	O
dysfunction	O
with	O
eye	B-ADR
movement	I-ADR
abnormality	I-ADR
in	O
occasional	O
patient	O
0	O
<EOS>	O
we	O
postulate	O
that	O
cyclosporin	B-Drug
,	O
possibly	O
together	O
with	O
ganciclovir	O
,	O
can	O
produce	O
transient	B-ADR
brain	I-ADR
stem	I-ADR
or	I-ADR
neuromuscular	I-ADR
dysfunction	I-ADR
with	O
eye	O
movement	O
abnormality	O
in	O
occasional	O
patient	O
0	O
<EOS>	O
we	O
postulate	O
that	O
cyclosporin	O
,	O
possibly	O
together	O
with	O
ganciclovir	B-Drug
,	O
can	O
produce	O
transient	B-ADR
brain	I-ADR
stem	I-ADR
or	I-ADR
neuromuscular	I-ADR
dysfunction	I-ADR
with	O
eye	O
movement	O
abnormality	O
in	O
occasional	O
patient	O
0	O
<EOS>	O
conclusion	O
:	O
while	O
thrombosis	B-ADR
ha	O
been	O
reported	O
with	O
gnrh-a	B-Drug
therapy	O
in	O
men	O
with	O
prostate	O
cancer	O
,	O
it	O
association	O
with	O
treatment	O
in	O
this	O
benign	O
case	O
may	O
have	O
been	O
a	O
consequence	O
of	O
the	O
massive	O
tumor	O
size	O
0	O
<EOS>	O
the	O
possible	O
effect	O
of	O
tamoxifen	B-Drug
upon	O
the	O
uterus	O
are	O
discussed	O
in	O
this	O
article	O
,	O
in	O
view	O
of	O
report	O
of	O
tamoxifen	O
associated	O
with	O
endometrial	B-ADR
carcinoma	I-ADR
and	O
endometriosis	O
0	O
<EOS>	O
the	O
possible	O
effect	O
of	O
tamoxifen	B-Drug
upon	O
the	O
uterus	O
are	O
discussed	O
in	O
this	O
article	O
,	O
in	O
view	O
of	O
report	O
of	O
tamoxifen	O
associated	O
with	O
endometrial	O
carcinoma	O
and	O
endometriosis	B-ADR
0	O
<EOS>	O
case	O
study	O
:	O
adverse	B-ADR
response	I-ADR
to	O
clonidine	B-Drug
0	O
<EOS>	O
four	O
case	O
of	O
adverse	B-ADR
experience	I-ADR
with	O
clonidine	B-Drug
are	O
described	O
0	O
<EOS>	O
in	O
one	O
instance	O
a	O
systemic	O
hypoglycemic	O
reaction	O
resulting	O
in	O
head	O
trauma	O
and	O
confusion	B-ADR
ended	O
in	O
an	O
emegency	O
hospital	O
admission	O
following	O
the	O
substitution	O
of	O
acetohexamide	B-Drug
for	O
acetazolamide	O
0	O
<EOS>	O
in	O
one	O
instance	O
a	O
systemic	O
hypoglycemic	O
reaction	O
resulting	O
in	O
head	B-ADR
trauma	I-ADR
and	O
confusion	O
ended	O
in	O
an	O
emegency	O
hospital	O
admission	O
following	O
the	O
substitution	O
of	O
acetohexamide	B-Drug
for	O
acetazolamide	O
0	O
<EOS>	O
in	O
one	O
instance	O
a	O
systemic	B-ADR
hypoglycemic	I-ADR
reaction	I-ADR
resulting	O
in	O
head	O
trauma	O
and	O
confusion	O
ended	O
in	O
an	O
emegency	O
hospital	O
admission	O
following	O
the	O
substitution	O
of	O
acetohexamide	B-Drug
for	O
acetazolamide	O
0	O
<EOS>	O
discontinuation	O
of	O
the	O
itraconazole	B-Drug
caused	O
resolution	O
of	O
the	O
drug	B-ADR
eruption	I-ADR
0	O
<EOS>	O
primary	O
cutaneous	O
coccidioidomycosis	O
and	O
subsequent	O
drug	B-ADR
eruption	I-ADR
to	O
itraconazole	B-Drug
in	O
a	O
dog	O
0	O
<EOS>	O
primary	B-ADR
cutaneous	I-ADR
coccidioidomycosis	I-ADR
and	O
subsequent	O
drug	O
eruption	O
to	O
itraconazole	B-Drug
in	O
a	O
dog	O
0	O
<EOS>	O
it	O
overall	O
toxicity	O
is	O
considerably	O
le	O
compared	O
to	O
standard	O
induction	O
chemotherapy	O
;	O
however	O
,	O
it	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
a	O
potentially	B-ADR
fatal	I-ADR
symptom	I-ADR
complex	O
referred	O
to	O
a	O
``	O
retinoic	B-Drug
acid	I-Drug
syndrome	O
0	O
'	O
this	O
report	O
describes	O
a	O
patient	O
with	O
apl	O
who	O
developed	O
the	O
syndrome	O
a	O
few	O
week	O
after	O
initiating	O
induction	O
therapy	O
with	O
atra	O
despite	O
being	O
treated	O
for	O
hyperleukocytosis	O
0	O
<EOS>	O
it	O
overall	O
toxicity	O
is	O
considerably	O
le	O
compared	O
to	O
standard	O
induction	O
chemotherapy	O
;	O
however	O
,	O
it	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
a	O
potentially	O
fatal	O
symptom	O
complex	O
referred	O
to	O
a	O
``	O
retinoic	B-Drug
acid	I-Drug
syndrome	I-ADR
0	O
'	O
this	O
report	O
describes	O
a	O
patient	O
with	O
apl	O
who	O
developed	O
the	O
syndrome	O
a	O
few	O
week	O
after	O
initiating	O
induction	O
therapy	O
with	O
atra	O
despite	O
being	O
treated	O
for	O
hyperleukocytosis	O
0	O
<EOS>	O
it	O
overall	O
toxicity	B-ADR
is	O
considerably	O
le	O
compared	O
to	O
standard	O
induction	O
chemotherapy	O
;	O
however	O
,	O
it	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
a	O
potentially	O
fatal	O
symptom	O
complex	O
referred	O
to	O
a	O
``	O
retinoic	B-Drug
acid	I-Drug
syndrome	O
0	O
'	O
this	O
report	O
describes	O
a	O
patient	O
with	O
apl	O
who	O
developed	O
the	O
syndrome	O
a	O
few	O
week	O
after	O
initiating	O
induction	O
therapy	O
with	O
atra	O
despite	O
being	O
treated	O
for	O
hyperleukocytosis	O
0	O
<EOS>	O
eleven	O
day	O
after	O
initiation	O
of	O
therapy	O
with	O
amiodarone	B-Drug
,	O
the	O
patient	O
experienced	O
syncope	O
and	O
wa	O
noted	O
to	O
have	O
recurrent	O
episode	O
of	O
polymorphous	B-ADR
ventricular	I-ADR
tachycardia	I-ADR
0	O
<EOS>	O
eleven	O
day	O
after	O
initiation	O
of	O
therapy	O
with	O
amiodarone	B-Drug
,	O
the	O
patient	O
experienced	O
syncope	B-ADR
and	O
wa	O
noted	O
to	O
have	O
recurrent	O
episode	O
of	O
polymorphous	O
ventricular	O
tachycardia	O
0	O
<EOS>	O
nonsustained	B-ADR
polymorphous	I-ADR
ventricular	I-ADR
tachycardia	I-ADR
during	O
amiodarone	B-Drug
therapy	O
for	O
atrial	O
fibrillation	O
complicating	O
cardiomyopathy	O
0	O
<EOS>	O
the	O
probable	O
proarrhythmic	B-ADR
action	O
of	O
amiodarone	B-Drug
,	O
although	O
rare	O
,	O
is	O
reviewed	O
along	O
with	O
a	O
discussion	O
of	O
the	O
novel	O
use	O
of	O
intravenous	O
magnesium	O
sulfate	O
therapy	O
0	O
<EOS>	O
acute	B-ADR
asthma	I-ADR
associated	O
with	O
sustained-release	O
verapamil	B-Drug
0	O
<EOS>	O
although	O
dyspnea	O
associated	O
with	O
verapamil	B-Drug
administration	O
ha	O
been	O
reported	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
elderly	O
asymptomatic	O
asthmatic	O
patient	O
with	O
hypertension	O
who	O
developed	O
an	O
acute	B-ADR
asthma	I-ADR
attack	O
following	O
sustained-release	O
verapamil	O
administration	O
0	O
<EOS>	O
although	O
dyspnea	B-ADR
associated	O
with	O
verapamil	B-Drug
administration	O
ha	O
been	O
reported	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
elderly	O
asymptomatic	O
asthmatic	O
patient	O
with	O
hypertension	O
who	O
developed	O
an	O
acute	O
asthma	O
attack	O
following	O
sustained-release	O
verapamil	O
administration	O
0	O
<EOS>	O
conclusion	O
:	O
sustained-release	O
verapamil	B-Drug
is	O
thought	O
to	O
be	O
the	O
cause	O
of	O
the	O
asthma	B-ADR
attack	I-ADR
in	O
this	O
patient	O
because	O
she	O
wa	O
not	O
taking	O
any	O
other	O
preparation	O
;	O
the	O
symptom	O
started	O
with	O
the	O
administration	O
of	O
sustained-release	O
verapamil	O
and	O
were	O
relieved	O
after	O
it	O
discontinuation	O
0	O
<EOS>	O
conclusion	O
:	O
sustained-release	O
verapamil	B-Drug
is	O
thought	O
to	O
be	O
the	O
cause	O
of	O
the	O
asthma	B-ADR
attack	I-ADR
in	O
this	O
patient	O
because	O
she	O
wa	O
not	O
taking	O
any	O
other	O
preparation	O
;	O
the	O
symptom	O
started	O
with	O
the	O
administration	O
of	O
sustained-release	O
verapamil	O
and	O
were	O
relieved	O
after	O
it	O
discontinuation	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
a	O
patient	O
with	O
asymptomatic	O
bronchial	O
asthma	O
and	O
hypertension	O
who	O
developed	O
an	O
acute	B-ADR
asthma	I-ADR
attack	O
after	O
receiving	O
sustained-release	O
verapamil	B-Drug
0	O
<EOS>	O
she	O
continued	O
taking	O
verapamil	B-Drug
for	O
6	O
month	O
,	O
then	O
,	O
on	O
her	O
own	O
,	O
stopped	O
all	O
medication	O
including	O
the	O
sustained-release	O
verapamil	O
,	O
and	O
her	O
asthma	B-ADR
symptom	O
disappeared	O
0	O
<EOS>	O
cephalexin	B-Drug
rash	I-ADR
in	O
infectious	O
mononucleosis	O
0	O
<EOS>	O
the	O
ampicillin	B-Drug
rash	I-ADR
occurring	O
in	O
case	O
of	O
infectious	O
mononucleosis	O
is	O
well	O
documented	O
0	O
<EOS>	O
the	O
case	O
of	O
a	O
patient	O
with	O
infectious	O
mononucleosis	O
treated	O
with	O
cephalexin	B-Drug
who	O
later	O
showed	O
a	O
rash	B-ADR
is	O
presented	O
and	O
the	O
previous	O
literature	O
is	O
reviewed	O
0	O
<EOS>	O
the	O
rash	B-ADR
seen	O
in	O
this	O
patient	O
,	O
who	O
wa	O
treated	O
with	O
cephalexin	B-Drug
,	O
may	O
be	O
similar	O
to	O
the	O
rash	O
seen	O
with	O
ampicillin	O
treatment	O
of	O
patient	O
with	O
infectious	O
mononucleosis	O
0	O
<EOS>	O
the	O
rash	B-ADR
seen	O
in	O
this	O
patient	O
,	O
who	O
wa	O
treated	O
with	O
cephalexin	O
,	O
may	O
be	O
similar	O
to	O
the	O
rash	O
seen	O
with	O
ampicillin	B-Drug
treatment	O
of	O
patient	O
with	O
infectious	O
mononucleosis	O
0	O
<EOS>	O
a	O
possible	O
case	O
of	O
carbamazepine	B-Drug
induced	O
pancreatitis	B-ADR
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
acute	O
pancreatitis	B-ADR
(	O
ap	O
)	O
occurring	O
in	O
a	O
patient	O
under	O
treatment	O
with	O
carbamazepine	B-Drug
(	O
cbz	O
)	O
for	O
post-traumatic	O
petit	O
mal	O
epilepsy	O
,	O
and	O
review	O
the	O
current	O
literature	O
of	O
drug-induced	O
ap	O
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
acute	O
pancreatitis	B-ADR
(	O
ap	O
)	O
occurring	O
in	O
a	O
patient	O
under	O
treatment	O
with	O
carbamazepine	O
(	O
cbz	B-Drug
)	O
for	O
post-traumatic	O
petit	O
mal	O
epilepsy	O
,	O
and	O
review	O
the	O
current	O
literature	O
of	O
drug-induced	O
ap	O
0	O
<EOS>	O
the	O
evidence	O
of	O
high	O
plasmatic	O
level	O
of	O
cbz	B-Drug
and	O
the	O
absence	O
of	O
other	O
aetiologic	O
factor	O
lead	O
the	O
author	O
to	O
conclude	O
that	O
the	O
overdose	O
of	O
cbz	O
could	O
have	O
represented	O
the	O
precipitating	O
of	O
the	O
episode	O
of	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
the	O
evidence	O
of	O
high	O
plasmatic	O
level	O
of	O
cbz	B-Drug
and	O
the	O
absence	O
of	O
other	O
aetiologic	O
factor	O
lead	O
the	O
author	O
to	O
conclude	O
that	O
the	O
overdose	O
of	O
cbz	O
could	O
have	O
represented	O
the	O
precipitating	O
of	O
the	O
episode	O
of	O
acute	B-ADR
pancreatitis	I-ADR
0	O
<EOS>	O
although	O
risk	O
factor	O
for	O
mtx-induced	B-Drug
pulmonary	O
toxicity	O
are	O
poorly	O
understood	O
,	O
the	O
presence	O
in	O
3	O
out	O
of	O
5	O
of	O
our	O
patient	O
of	O
pre-existing	O
lung	O
disease	O
,	O
represented	O
by	O
diffuse	O
interstitial	O
change	O
on	O
chest	O
x-ray	O
,	O
and	O
mild	O
bronchial	O
asthma	O
in	O
two	O
ra	O
patient	O
and	O
by	O
pulmonary	O
silicosis	O
in	O
the	O
patient	O
with	O
psa	O
may	O
account	O
for	O
a	O
predisposition	O
to	O
the	O
development	O
of	O
mtx	O
pneumonitis	B-ADR
0	O
<EOS>	O
although	O
risk	O
factor	O
for	O
mtx-induced	B-Drug
pulmonary	B-ADR
toxicity	I-ADR
are	O
poorly	O
understood	O
,	O
the	O
presence	O
in	O
3	O
out	O
of	O
5	O
of	O
our	O
patient	O
of	O
pre-existing	O
lung	O
disease	O
,	O
represented	O
by	O
diffuse	O
interstitial	O
change	O
on	O
chest	O
x-ray	O
,	O
and	O
mild	O
bronchial	O
asthma	O
in	O
two	O
ra	O
patient	O
and	O
by	O
pulmonary	O
silicosis	O
in	O
the	O
patient	O
with	O
psa	O
may	O
account	O
for	O
a	O
predisposition	O
to	O
the	O
development	O
of	O
mtx	O
pneumonitis	O
0	O
<EOS>	O
methotrexate-induced	B-Drug
pneumonitis	B-ADR
in	O
patient	O
with	O
rheumatoid	O
arthritis	O
and	O
psoriatic	O
arthritis	O
:	O
report	O
of	O
five	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
on	O
the	O
other	O
hand	O
,	O
mtx-induced	B-Drug
pneumonitis	B-ADR
seems	O
to	O
be	O
very	O
rare	O
in	O
psoriatic	O
arthritis	O
(	O
psa	O
)	O
0	O
<EOS>	O
our	O
review	O
of	O
194	O
ra	O
patient	O
and	O
38	O
psa	O
patient	O
receiving	O
mtx	O
ha	O
identified	O
four	O
ra	O
patient	O
and	O
one	O
psa	O
patient	O
with	O
mtx-induced	B-Drug
pneumonitis	B-ADR
,	O
giving	O
a	O
prevalence	O
of	O
2.1	O
%	O
and	O
0.03	O
%	O
,	O
respectively	O
0	O
<EOS>	O
pneumonitis	B-ADR
is	O
emerging	O
a	O
one	O
of	O
the	O
most	O
unpredictable	O
and	O
potentially	O
serious	O
,	O
adverse	O
effect	O
of	O
treatment	O
with	O
mtx	B-Drug
0	O
<EOS>	O
the	O
presence	O
of	O
a	O
lymphocyte	O
alveolitis	O
with	O
a	O
predominance	O
of	O
cd4+	O
t	O
cell	O
in	O
3	O
ra	O
patient	O
and	O
cd8+	O
t	O
cell	O
with	O
a	O
concomitant	O
increase	O
in	O
neutrophil	O
in	O
another	O
case	O
suggests	O
that	O
immunologically	O
mediated	O
reaction	O
may	O
be	O
one	O
damage	O
mechanism	O
in	O
mtx-induced	B-Drug
pneumonitis	B-ADR
0	O
<EOS>	O
a	O
retrospective	O
epidemiological	O
study	O
of	O
death	O
from	O
hepatic	B-ADR
angiosarcoma	I-ADR
(	O
ha	O
)	O
in	O
the	O
u.s.	O
showed	O
that	O
during	O
1964	O
--	O
74	O
there	O
were	O
168	O
such	O
case	O
,	O
of	O
which	O
37	O
(	O
22	O
%	O
)	O
were	O
associated	O
with	O
previously	O
known	O
cause	O
(	O
vinyl	O
chloride	O
,	O
thorotrast	O
	O
,	O
and	O
inorganic	B-Drug
arsenic	I-Drug
)	O
and	O
4	O
(	O
3.1	O
%	O
)	O
of	O
the	O
remaining	O
131	O
case	O
with	O
the	O
use	O
of	O
androgenic-anabolic	O
steroid	O
0	O
<EOS>	O
a	O
retrospective	O
epidemiological	O
study	O
of	O
death	O
from	O
hepatic	B-ADR
angiosarcoma	I-ADR
(	O
ha	O
)	O
in	O
the	O
u.s.	O
showed	O
that	O
during	O
1964	O
--	O
74	O
there	O
were	O
168	O
such	O
case	O
,	O
of	O
which	O
37	O
(	O
22	O
%	O
)	O
were	O
associated	O
with	O
previously	O
known	O
cause	O
(	O
vinyl	O
chloride	O
,	O
thorotrast	B-Drug
	O
,	O
and	O
inorganic	O
arsenic	O
)	O
and	O
4	O
(	O
3.1	O
%	O
)	O
of	O
the	O
remaining	O
131	O
case	O
with	O
the	O
use	O
of	O
androgenic-anabolic	O
steroid	O
0	O
<EOS>	O
a	O
retrospective	O
epidemiological	O
study	O
of	O
death	O
from	O
hepatic	B-ADR
angiosarcoma	I-ADR
(	O
ha	O
)	O
in	O
the	O
u.s.	O
showed	O
that	O
during	O
1964	O
--	O
74	O
there	O
were	O
168	O
such	O
case	O
,	O
of	O
which	O
37	O
(	O
22	O
%	O
)	O
were	O
associated	O
with	O
previously	O
known	O
cause	O
(	O
vinyl	B-Drug
chloride	I-Drug
,	O
thorotrast	O
	O
,	O
and	O
inorganic	O
arsenic	O
)	O
and	O
4	O
(	O
3.1	O
%	O
)	O
of	O
the	O
remaining	O
131	O
case	O
with	O
the	O
use	O
of	O
androgenic-anabolic	O
steroid	O
0	O
<EOS>	O
recent	O
study	O
have	O
shown	O
that	O
under	O
experimental	O
condition	O
ferrous	B-Drug
sulfate	I-Drug
may	O
reduce	B-ADR
the	I-ADR
gastrointestinal	I-ADR
absorption	I-ADR
of	I-ADR
orally	I-ADR
administered	I-ADR
levothyroxine	I-ADR
sodium	I-ADR
in	O
patient	O
with	O
primary	O
hypothyroidism	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
who	O
became	O
hypothyroid	B-ADR
while	O
taking	O
ferrous	B-Drug
sulfate	I-Drug
0	O
<EOS>	O
however	O
,	O
a	O
the	O
use	O
of	O
hepatitis	B-Drug
b	I-Drug
vaccination	I-Drug
is	O
growing	O
,	O
adverse	O
side	O
effect	O
,	O
including	O
mental	B-ADR
nerve	I-ADR
neuropathy	I-ADR
,	O
should	O
be	O
observed	O
with	O
an	O
increased	O
frequency	O
0	O
<EOS>	O
mental	B-ADR
nerve	I-ADR
neuropathy	I-ADR
a	O
a	O
result	O
of	O
hepatitis	B-Drug
b	I-Drug
vaccination	I-Drug
0	O
<EOS>	O
although	O
it	O
side	O
effect	O
are	O
few	O
,	O
tamoxifen	B-Drug
increase	O
the	O
incidence	O
of	O
proliferative	B-ADR
lesion	I-ADR
of	I-ADR
the	I-ADR
endometrium	I-ADR
,	O
which	O
theoretically	O
should	O
be	O
preventable	O
with	O
progestational	O
agent	O
0	O
<EOS>	O
case	O
:	O
two	O
postmenopausal	O
woman	O
treated	O
with	O
tamoxifen	B-Drug
and	O
progestational	O
agent	O
for	O
breast	O
carcinoma	O
developed	O
uterine	O
enlargement	O
and	O
intermittent	B-ADR
spotting	I-ADR
0	O
<EOS>	O
case	O
:	O
two	O
postmenopausal	O
woman	O
treated	O
with	O
tamoxifen	B-Drug
and	O
progestational	O
agent	O
for	O
breast	O
carcinoma	O
developed	O
uterine	B-ADR
enlargement	I-ADR
and	O
intermittent	O
spotting	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
value	O
of	O
multihormonal	O
therapy	O
in	O
breast	O
carcinoma	B-ADR
is	O
not	O
established	O
,	O
and	O
the	O
addition	O
of	O
progestogen	O
to	O
tamoxifen	B-Drug
may	O
not	O
reduce	O
of	O
developing	O
endometrial	O
lesion	O
,	O
including	O
carcinoma	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
value	O
of	O
multihormonal	O
therapy	O
in	O
breast	O
carcinoma	O
is	O
not	O
established	O
,	O
and	O
the	O
addition	O
of	O
progestogen	O
to	O
tamoxifen	B-Drug
may	O
not	O
reduce	O
of	O
developing	O
endometrial	B-ADR
lesion	I-ADR
,	O
including	O
carcinoma	O
0	O
<EOS>	O
bleomycin	B-Drug
and	O
cyclophosphamide	O
toxicity	O
simulating	O
metastatic	B-ADR
nodule	I-ADR
to	O
the	O
lung	O
in	O
childhood	O
cancer	O
0	O
<EOS>	O
bleomycin	O
and	O
cyclophosphamide	B-Drug
toxicity	O
simulating	O
metastatic	B-ADR
nodule	I-ADR
to	O
the	O
lung	O
in	O
childhood	O
cancer	O
0	O
<EOS>	O
thoracoscopic	O
biopsy	O
to	O
confirm	O
metastasis	O
revealed	O
instead	O
fibrotic	B-ADR
lesion	I-ADR
apparently	O
attributable	O
to	O
bleomycin	B-Drug
or	O
cyclophosphamide	O
0	O
<EOS>	O
thoracoscopic	O
biopsy	O
to	O
confirm	O
metastasis	O
revealed	O
instead	O
fibrotic	B-ADR
lesion	I-ADR
apparently	O
attributable	O
to	O
bleomycin	O
or	O
cyclophosphamide	B-Drug
0	O
<EOS>	O
an	O
elderly	O
man	O
with	O
procainamide	B-Drug
hydrochloride-induced	I-Drug
lupus	B-ADR
syndrome	I-ADR
had	O
a	O
circulating	O
anticoagulant	O
against	O
factor	O
xi	O
and	O
a	O
biologic	O
false-positive	O
(	O
bfp	O
)	O
test	O
result	O
for	O
syphilis	O
0	O
<EOS>	O
circulating	O
anticoagulant	O
in	O
the	O
procainamide-induced	B-Drug
lupus	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
clinical	O
sign	O
of	O
hypermagnesemia	B-ADR
are	O
an	O
uncommon	O
complication	O
following	O
oral	O
administration	O
of	O
magnesium	B-Drug
sulfate	I-Drug
0	O
<EOS>	O
establishment	O
of	O
diuresis	O
with	O
fluid	O
and	O
iv	O
administration	O
of	O
calcium	O
may	O
provide	O
successful	O
treatment	O
of	O
magnesium	B-Drug
toxicosis	I-ADR
in	O
horse	O
0	O
<EOS>	O
magnesium	B-Drug
toxicosis	I-ADR
in	O
two	O
horse	O
0	O
<EOS>	O
overdose	O
of	O
magnesium	B-Drug
sulfate	O
in	O
combination	O
with	O
renal	O
insufficiency	O
,	O
hypocalcemia	O
,	O
or	O
compromise	O
of	O
intestinal	O
integrity	O
may	O
predispose	O
horse	O
to	O
magnesium	B-ADR
toxicosis	I-ADR
0	O
<EOS>	O
overdose	O
of	O
magnesium	B-Drug
sulfate	I-Drug
in	O
combination	O
with	O
renal	O
insufficiency	O
,	O
hypocalcemia	O
,	O
or	O
compromise	O
of	O
intestinal	O
integrity	O
may	O
predispose	O
horse	O
to	O
magnesium	B-ADR
toxicosis	I-ADR
0	O
<EOS>	O
case	O
summary	O
:	O
in	O
each	O
case	O
,	O
the	O
patient	O
were	O
treated	O
over	O
5	O
year	O
with	O
lovastatin	B-Drug
and	O
developed	O
rhabdomyolysis	B-ADR
that	O
coincided	O
with	O
the	O
completion	O
of	O
a	O
prescribed	O
regimen	O
of	O
a	O
newer	O
macrolide	O
antibiotic	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
risk	O
of	O
drug-induced	O
rhabdomyolysis	B-ADR
due	O
to	O
the	O
potential	O
interaction	O
between	O
lovastatin	O
and	O
azithromycin	B-Drug
or	O
clarithromycin	O
should	O
be	O
considered	O
before	O
the	O
concomitant	O
use	O
of	O
these	O
agent	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
risk	O
of	O
drug-induced	O
rhabdomyolysis	B-ADR
due	O
to	O
the	O
potential	O
interaction	O
between	O
lovastatin	O
and	O
azithromycin	O
or	O
clarithromycin	B-Drug
should	O
be	O
considered	O
before	O
the	O
concomitant	O
use	O
of	O
these	O
agent	O
0	O
<EOS>	O
conclusion	O
:	O
the	O
risk	O
of	O
drug-induced	O
rhabdomyolysis	B-ADR
due	O
to	O
the	O
potential	O
interaction	O
between	O
lovastatin	B-Drug
and	O
azithromycin	O
or	O
clarithromycin	O
should	O
be	O
considered	O
before	O
the	O
concomitant	O
use	O
of	O
these	O
agent	O
0	O
<EOS>	O
discussion	O
:	O
rhabdomyolysis	B-ADR
is	O
a	O
clinical	O
syndrome	O
resulting	O
from	O
the	O
destruction	O
of	O
skeletal	O
muscle	O
that	O
may	O
progress	O
to	O
renal	O
failure	O
several	O
drug	O
have	O
been	O
associated	O
with	O
rhabdomyolysis	O
,	O
including	O
lovastatin	B-Drug
,	O
a	O
hydroxymethylglutaryl-coenzyme	O
a	O
reductase	O
inhibitor	O
0	O
<EOS>	O
erythromycin	B-Drug
is	O
a	O
macrolide	O
antibiotic	O
that	O
may	O
increase	O
the	O
risk	O
of	O
lovastatin-induced	O
rhabdomyolysis	B-ADR
0	O
<EOS>	O
erythromycin	O
is	O
a	O
macrolide	O
antibiotic	O
that	O
may	O
increase	O
the	O
risk	O
of	O
lovastatin-induced	B-Drug
rhabdomyolysis	B-ADR
0	O
<EOS>	O
lovastatin-induced	O
rhabdomyolysis	B-ADR
possibly	O
associated	O
with	O
clarithromycin	O
and	O
azithromycin	B-Drug
0	O
<EOS>	O
lovastatin-induced	O
rhabdomyolysis	B-ADR
possibly	O
associated	O
with	O
clarithromycin	B-Drug
and	O
azithromycin	O
0	O
<EOS>	O
lovastatin-induced	B-Drug
rhabdomyolysis	B-ADR
possibly	O
associated	O
with	O
clarithromycin	O
and	O
azithromycin	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
two	O
case	O
of	O
rhabdomyolysis	B-ADR
in	O
patient	O
taking	O
lovastatin	O
that	O
were	O
precipitated	O
by	O
the	O
use	O
of	O
the	O
newer	O
macrolide	O
antibiotic	O
clarithromycin	O
and	O
azithromycin	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
two	O
case	O
of	O
rhabdomyolysis	B-ADR
in	O
patient	O
taking	O
lovastatin	O
that	O
were	O
precipitated	O
by	O
the	O
use	O
of	O
the	O
newer	O
macrolide	O
antibiotic	O
clarithromycin	B-Drug
and	O
azithromycin	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
two	O
case	O
of	O
rhabdomyolysis	B-ADR
in	O
patient	O
taking	O
lovastatin	B-Drug
that	O
were	O
precipitated	O
by	O
the	O
use	O
of	O
the	O
newer	O
macrolide	O
antibiotic	O
clarithromycin	O
and	O
azithromycin	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
these	O
case	O
are	O
the	O
first	O
published	O
report	O
of	O
lovastatin-induced	O
rhabdomyolysis	B-ADR
associated	O
with	O
azithromycin	B-Drug
and	O
clarithromycin	O
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
these	O
case	O
are	O
the	O
first	O
published	O
report	O
of	O
lovastatin-induced	O
rhabdomyolysis	B-ADR
associated	O
with	O
azithromycin	O
and	O
clarithromycin	B-Drug
0	O
<EOS>	O
to	O
our	O
knowledge	O
,	O
these	O
case	O
are	O
the	O
first	O
published	O
report	O
of	O
lovastatin-induced	B-Drug
rhabdomyolysis	B-ADR
associated	O
with	O
azithromycin	O
and	O
clarithromycin	O
0	O
<EOS>	O
these	O
case	O
were	O
considered	O
unusual	O
in	O
light	O
of	O
the	O
short	O
delay	O
of	O
their	O
onset	O
after	O
initiation	O
of	O
immunosuppressive	O
therapy	O
and	O
their	O
fulminant	O
course	O
:	O
3	O
of	O
these	O
patient	O
died	B-ADR
of	O
pcp	O
occurring	O
during	O
the	O
first	O
month	O
of	O
treatment	O
with	O
prednisone	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
specific	O
of	O
12	O
case	O
of	O
severe	B-ADR
hypertension	I-ADR
after	O
the	O
intraoperative	O
use	O
of	O
topical	O
phenylephrine	O
,	O
submucosal	O
epinephrine	B-Drug
,	O
or	O
both	O
0	O
<EOS>	O
we	O
report	O
the	O
specific	O
of	O
12	O
case	O
of	O
severe	B-ADR
hypertension	I-ADR
after	O
the	O
intraoperative	O
use	O
of	O
topical	O
phenylephrine	B-Drug
,	O
submucosal	O
epinephrine	O
,	O
or	O
both	O
0	O
<EOS>	O
acute	B-ADR
leukaemia	I-ADR
during	O
tamoxifen	B-Drug
therapy	O
0	O
<EOS>	O
tamoxifen	B-Drug
is	O
suggested	O
to	O
be	O
carcinogenic	B-ADR
both	O
through	O
direct	O
genotoxic	O
and	O
epigenetic	O
mechanism	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
that	O
developed	O
acute	B-ADR
myeloid	I-ADR
leukaemia	I-ADR
(	O
aml	O
)	O
during	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
0	O
<EOS>	O
we	O
report	O
two	O
case	O
that	O
developed	O
acute	O
myeloid	O
leukaemia	O
(	O
aml	B-ADR
)	O
during	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
0	O
<EOS>	O
relapse	B-ADR
in	I-ADR
the	I-ADR
external	I-ADR
auditory	I-ADR
canal	I-ADR
of	I-ADR
acute	I-ADR
promyelocytic	I-ADR
leukemia	I-ADR
after	O
treatment	O
with	O
all-trans	B-Drug
retinoic	I-Drug
acid	I-Drug
0	O
<EOS>	O
this	O
case	O
suggests	O
the	O
importance	O
of	O
careful	O
observation	O
for	O
extramedullary	B-ADR
relapse	I-ADR
in	O
patient	O
who	O
are	O
treated	O
with	O
atra	B-Drug
0	O
<EOS>	O
cutaneous	B-ADR
reaction	I-ADR
to	O
propylthiouracil	O
and	O
methimazole	B-Drug
occur	O
in	O
3	O
%	O
-5	O
%	O
of	O
adult	O
0	O
<EOS>	O
cutaneous	B-ADR
reaction	I-ADR
to	O
propylthiouracil	B-Drug
and	O
methimazole	O
occur	O
in	O
3	O
%	O
-5	O
%	O
of	O
adult	O
0	O
<EOS>	O
generalized	B-ADR
maculopapular	I-ADR
and	I-ADR
papular	I-ADR
purpuric	I-ADR
eruption	I-ADR
are	O
perhaps	O
the	O
most	O
common	O
thionamide-induced	B-Drug
reaction	O
0	O
<EOS>	O
propylthiouracil-induced	B-Drug
cutaneous	B-ADR
vasculitis	I-ADR
0	O
<EOS>	O
the	O
observation	O
of	O
cutaneous	B-ADR
vasculitis	I-ADR
during	O
administration	O
of	O
propylthiouracil	B-Drug
suggested	O
that	O
clinical	O
awareness	O
of	O
this	O
complication	O
should	O
be	O
of	O
considerable	O
importance	O
0	O
<EOS>	O
a	O
2-year-old	O
mentally	O
retarded	O
boy	O
with	O
frontal	O
lobe	O
epilepsy	O
presented	O
with	O
an	O
episode	O
that	O
resembled	O
heat	B-ADR
stroke	I-ADR
during	O
the	O
administration	O
of	O
zonisamide	B-Drug
0	O
<EOS>	O
child	O
receiving	O
zonisamide	B-Drug
should	O
be	O
monitored	O
for	O
oligohidrosis	O
and	O
the	O
development	O
of	O
neurological	B-ADR
symptom	I-ADR
associated	O
with	O
an	O
elevation	O
of	O
body	O
temperature	O
0	O
<EOS>	O
child	O
receiving	O
zonisamide	B-Drug
should	O
be	O
monitored	O
for	O
oligohidrosis	B-ADR
and	O
the	O
development	O
of	O
neurological	O
symptom	O
associated	O
with	O
an	O
elevation	O
of	O
body	O
temperature	O
0	O
<EOS>	O
heat	B-ADR
stroke-like	I-ADR
episode	I-ADR
in	O
a	O
child	O
caused	O
by	O
zonisamide	B-Drug
0	O
<EOS>	O
the	O
oligohidrosis	B-ADR
caused	O
by	O
zonisamide	B-Drug
wa	O
reversible	O
in	O
that	O
the	O
patient	O
regained	O
the	O
ability	O
to	O
sweat	O
within	O
2	O
week	O
of	O
the	O
cessation	O
of	O
drug	O
administration	O
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
in	O
a	O
patient	O
receiving	O
treatment	O
with	O
suramin	B-Drug
0	O
<EOS>	O
acute	O
renal	B-ADR
failure	I-ADR
should	O
be	O
recognized	O
a	O
a	O
potential	O
complication	O
of	O
suramin	B-Drug
treatment	O
0	O
<EOS>	O
other	O
potential	O
cause	O
of	O
renal	B-ADR
failure	I-ADR
were	O
not	O
present	O
in	O
our	O
patient	O
and	O
his	O
renal	O
function	O
gradually	O
recovered	O
with	O
the	O
cessation	O
of	O
suramin	B-Drug
treatment	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
metastatic	O
prostate	O
cancer	O
who	O
developed	O
nonoliguric	B-ADR
renal	I-ADR
failure	I-ADR
during	O
treatment	O
with	O
suramin	B-Drug
0	O
<EOS>	O
clozapine	B-Drug
induced	O
polyserositis	B-ADR
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	B-ADR
effusion	I-ADR
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	B-ADR
effusion	I-ADR
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	O
effusion	O
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	B-ADR
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	O
effusion	O
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	B-ADR
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	O
effusion	O
,	O
pleural	B-ADR
effusion	I-ADR
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	O
(	O
pericardial	O
effusion	O
,	O
pleural	B-ADR
effusion	I-ADR
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	B-ADR
(	O
pericardial	O
effusion	O
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
polyserositis	B-ADR
(	O
pericardial	O
effusion	O
,	O
pleural	O
effusion	O
,	O
and	O
pericarditis	O
)	O
after	O
being	O
started	O
on	O
clozapine	B-Drug
,	O
and	O
whose	O
symptom	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
0	O
<EOS>	O
when	O
the	O
disease	O
recurred	O
conventional	O
amphotericin	B-Drug
b	I-Drug
wa	O
used	O
again	O
,	O
but	O
had	O
to	O
be	O
stopped	O
because	O
of	O
severe	B-ADR
side	I-ADR
effect	I-ADR
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	B-ADR
,	O
infectious	O
complication	O
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	B-ADR
,	O
infectious	O
complication	O
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	O
complication	O
,	O
gastrointestinal	B-ADR
tract	I-ADR
symptom	I-ADR
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	O
complication	O
,	O
gastrointestinal	B-ADR
tract	I-ADR
symptom	I-ADR
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	B-ADR
complication	I-ADR
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	B-ADR
complication	I-ADR
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	O
myalgia	O
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	O
arabinoside	O
(	O
ara-c	B-Drug
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	O
complication	O
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	B-ADR
myalgia	I-ADR
0	O
<EOS>	O
thirty-six	O
patient	O
with	O
al	O
received	O
,	O
in	O
a	O
three-month	O
period	O
,	O
51	O
cycle	O
of	O
combined	O
chemotherapy	O
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ara-c	O
)	O
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	O
,	O
infectious	O
complication	O
,	O
gastrointestinal	O
tract	O
symptom	O
and	O
severe	B-ADR
myalgia	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
we	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
rhgh-induced	B-Drug
hypercalcemia	B-ADR
in	O
an	O
hiv-infected	O
patient	O
0	O
<EOS>	O
hypercalcemia	B-ADR
in	O
an	O
aid	O
patient	O
treated	O
with	O
growth	B-Drug
hormone	I-Drug
0	O
<EOS>	O
the	O
hypercalcemia	B-ADR
responded	O
to	O
discontinuation	O
of	O
rhgh	B-Drug
and	O
a	O
single	O
dose	O
of	O
intravenous	O
pamidronate	O
disodium	O
and	O
ha	O
not	O
recurred	O
in	O
8	O
month	O
of	O
follow-up	O
0	O
<EOS>	O
we	O
report	O
a	O
male	O
patient	O
with	O
advanced	O
aid	O
who	O
developed	O
hypercalcemia	B-ADR
2	O
week	O
after	O
institution	O
of	O
rhgh	B-Drug
therapy	O
0	O
<EOS>	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cisplatin	B-Drug
following	O
multiple	O
uncomplicated	O
course	O
:	O
a	O
report	O
on	O
two	O
case	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	B-ADR
pain	I-ADR
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	B-ADR
pain	I-ADR
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	B-ADR
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	B-ADR
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	B-ADR
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	B-ADR
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	B-ADR
erythema	I-ADR
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	B-ADR
erythema	I-ADR
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	B-ADR
erythema	I-ADR
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	B-ADR
erythema	I-ADR
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	O
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	B-ADR
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
two	O
patient	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
course	O
of	O
cisplatin	B-Drug
without	O
complication	O
experienced	O
hypersensitivity	O
reaction	O
to	O
cisplatin	O
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	O
erythema	O
,	O
dyspnea	O
,	O
and	O
hypotension	B-ADR
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	O
pain	O
,	O
general	O
erythema	O
,	O
and	O
fever	O
0	O
<EOS>	O
we	O
report	O
an	O
unusually	O
short	O
lived	O
and	O
asymptomatic	O
episode	O
of	O
severe	O
cisplatin-induced	B-Drug
renal	B-ADR
tubular	I-ADR
salt	I-ADR
wasting	I-ADR
in	O
a	O
fit	O
41-year-old	O
patient	O
with	O
malignant	O
teratoma	O
0	O
<EOS>	O
clinician	O
should	O
include	O
phenolphthalein	B-Drug
in	O
their	O
list	O
of	O
possible	O
cause	O
of	O
drug-induced	O
ten	B-ADR
0	O
<EOS>	O
discussion	O
:	O
phenolphthalein	B-Drug
is	O
the	O
active	O
ingredient	O
in	O
several	O
over-the-counter	O
laxative	O
preparation	O
and	O
ha	O
only	O
rarely	O
been	O
reported	O
to	O
cause	O
ten	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
phenolphthalein-induced	B-Drug
toxic	O
epidermal	O
necrolysis	O
(	O
ten	B-ADR
)	O
in	O
a	O
patient	O
maintained	O
on	O
several	O
other	O
medication	O
more	O
commonly	O
known	O
to	O
be	O
associated	O
with	O
ten	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
phenolphthalein-induced	B-Drug
toxic	O
epidermal	O
necrolysis	O
(	O
ten	B-ADR
)	O
in	O
a	O
patient	O
maintained	O
on	O
several	O
other	O
medication	O
more	O
commonly	O
known	O
to	O
be	O
associated	O
with	O
ten	O
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
phenolphthalein-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
(	O
ten	O
)	O
in	O
a	O
patient	O
maintained	O
on	O
several	O
other	O
medication	O
more	O
commonly	O
known	O
to	O
be	O
associated	O
with	O
ten	O
0	O
<EOS>	O
phenolphthalein-induced	B-Drug
toxic	B-ADR
epidermal	I-ADR
necrolysis	I-ADR
0	O
<EOS>	O
the	O
patient	O
previous	O
rash	B-ADR
and	O
the	O
temporal	O
relation	O
of	O
this	O
event	O
and	O
the	O
ingestion	O
of	O
phenolphthalein	B-Drug
,	O
a	O
well	O
a	O
the	O
similarity	O
of	O
this	O
case	O
to	O
other	O
report	O
,	O
point	O
to	O
phenolphthalein	O
a	O
the	O
cause	O
of	O
ten	O
in	O
this	O
patient	O
0	O
<EOS>	O
the	O
patient	O
previous	O
rash	O
and	O
the	O
temporal	O
relation	O
of	O
this	O
event	O
and	O
the	O
ingestion	O
of	O
phenolphthalein	B-Drug
,	O
a	O
well	O
a	O
the	O
similarity	O
of	O
this	O
case	O
to	O
other	O
report	O
,	O
point	O
to	O
phenolphthalein	O
a	O
the	O
cause	O
of	O
ten	B-ADR
in	O
this	O
patient	O
0	O
<EOS>	O
carbamazepine	B-Drug
toxicity	I-ADR
induced	O
by	O
clarithromycin	O
coadministration	O
in	O
psychiatric	O
patient	O
0	O
<EOS>	O
carbamazepine	B-ADR
toxicity	I-ADR
induced	O
by	O
clarithromycin	B-Drug
coadministration	O
in	O
psychiatric	O
patient	O
0	O
<EOS>	O
during	O
clarithromycin	O
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	B-Drug
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	B-ADR
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	B-ADR
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	B-ADR
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	O
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	B-Drug
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	B-ADR
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	B-ADR
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	B-ADR
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	O
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	B-Drug
,	O
such	O
a	O
drowsiness	B-ADR
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	B-ADR
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	O
symptom	O
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	B-ADR
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	O
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	B-ADR
symptom	I-ADR
of	O
carbamazepine	B-Drug
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	B-ADR
symptom	I-ADR
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
during	O
clarithromycin	B-Drug
coadministration	O
,	O
four	O
out	O
of	O
the	O
seven	O
patient	O
developed	O
moderate-to-severe	O
toxic	B-ADR
symptom	I-ADR
of	O
carbamazepine	O
,	O
such	O
a	O
drowsiness	O
,	O
dizziness	O
,	O
and	O
ataxia	O
,	O
which	O
resolved	O
within	O
5	O
day	O
after	O
clarithromycin	O
discontinuation	O
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	O
coadministration	O
induces	O
increased	O
plasma	O
carbamazepine	B-Drug
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	O
coadministration	O
induces	O
increased	O
plasma	O
carbamazepine	B-Drug
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	B-Drug
coadministration	O
induces	O
increased	O
plasma	O
carbamazepine	O
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	B-ADR
toxicity	I-ADR
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	O
coadministration	O
induces	O
increased	B-ADR
plasma	I-ADR
carbamazepine	B-Drug
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	O
toxicity	O
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	O
coadministration	O
induces	O
increased	B-ADR
plasma	I-ADR
carbamazepine	B-Drug
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	O
toxicity	O
0	O
<EOS>	O
the	O
present	O
report	O
suggests	O
that	O
clarithromycin	B-Drug
coadministration	O
induces	O
increased	B-ADR
plasma	I-ADR
carbamazepine	I-ADR
concentration	O
,	O
which	O
may	O
result	O
in	O
carbamazepine	O
toxicity	O
0	O
<EOS>	O
acute	O
hemorrhagic	O
gastritis	O
associated	O
with	O
acetazolamide	B-Drug
intoxication	I-ADR
in	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
0	O
<EOS>	O
acute	B-ADR
hemorrhagic	I-ADR
gastritis	I-ADR
associated	O
with	O
acetazolamide	B-Drug
intoxication	O
in	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
0	O
<EOS>	O
a	O
far	O
a	O
we	O
know	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
acute	B-ADR
hemorrhagic	I-ADR
gastritis	I-ADR
associated	O
with	O
az	B-Drug
intoxication	O
0	O
<EOS>	O
a	O
far	O
a	O
we	O
know	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
acute	O
hemorrhagic	O
gastritis	O
associated	O
with	O
az	B-Drug
intoxication	I-ADR
0	O
<EOS>	O
she	O
wa	O
thus	O
diagnosed	O
a	O
having	O
az	B-Drug
intoxication	I-ADR
0	O
<EOS>	O
we	O
experienced	O
a	O
case	O
of	O
chronic	O
renal	O
failure	O
in	O
a	O
patient	O
suffering	O
from	O
acute	B-ADR
hemorrhagic	I-ADR
gastritis	I-ADR
associated	O
with	O
az	B-Drug
intoxication	O
0	O
<EOS>	O
we	O
experienced	O
a	O
case	O
of	O
chronic	O
renal	O
failure	O
in	O
a	O
patient	O
suffering	O
from	O
acute	O
hemorrhagic	O
gastritis	O
associated	O
with	O
az	B-Drug
intoxication	I-ADR
0	O
<EOS>	O
we	O
thus	O
concluded	O
that	O
an	O
excessive	O
dose	O
of	O
az	B-Drug
had	O
probably	O
destroyed	B-ADR
the	I-ADR
gastric	I-ADR
mucosal	I-ADR
barrier	I-ADR
or	O
thrombocytopenia	O
due	O
to	O
bone	O
marrow	O
disorder	O
and	O
thus	O
eventually	O
led	O
to	O
the	O
development	O
of	O
hemorrhagic	O
gastritis	O
0	O
<EOS>	O
we	O
thus	O
concluded	O
that	O
an	O
excessive	O
dose	O
of	O
az	B-Drug
had	O
probably	O
destroyed	O
the	O
gastric	O
mucosal	O
barrier	O
or	O
thrombocytopenia	O
due	O
to	O
bone	O
marrow	O
disorder	O
and	O
thus	O
eventually	O
led	O
to	O
the	O
development	O
of	O
hemorrhagic	B-ADR
gastritis	I-ADR
0	O
<EOS>	O
we	O
thus	O
concluded	O
that	O
an	O
excessive	O
dose	O
of	O
az	B-Drug
had	O
probably	O
destroyed	O
the	O
gastric	O
mucosal	O
barrier	O
or	O
thrombocytopenia	B-ADR
due	I-ADR
to	I-ADR
bone	I-ADR
marrow	I-ADR
disorder	I-ADR
and	O
thus	O
eventually	O
led	O
to	O
the	O
development	O
of	O
hemorrhagic	O
gastritis	O
0	O
<EOS>	O
in	O
association	O
with	O
this	O
tocolysis	O
,	O
urinary	B-ADR
calculus	I-ADR
of	O
magnesium	B-Drug
ammonium	I-Drug
phosphate	I-Drug
occurred	O
at	O
34	O
week	O
gestation	O
0	O
<EOS>	O
magnesium	B-Drug
tocolysis	O
a	O
the	O
cause	O
of	O
urinary	B-ADR
calculus	I-ADR
during	O
pregnancy	O
0	O
<EOS>	O
danazol	B-Drug
induced	O
thrombocytopenia	B-ADR
0	O
<EOS>	O
on	O
the	O
next	O
day	O
,	O
after	O
a	O
total	O
dose	O
of	O
only	O
600	O
mg	O
of	O
danazol	B-Drug
,	O
gingival	B-ADR
bleeding	I-ADR
and	O
purpura	O
occurred	O
0	O
<EOS>	O
on	O
the	O
next	O
day	O
,	O
after	O
a	O
total	O
dose	O
of	O
only	O
600	O
mg	O
of	O
danazol	B-Drug
,	O
gingival	O
bleeding	O
and	O
purpura	B-ADR
occurred	O
0	O
<EOS>	O
we	O
diagnosed	O
this	O
case	O
a	O
danazol	B-Drug
induced	O
thrombocytopenia	B-ADR
0	O
<EOS>	O
it	O
occasionally	O
accompanies	O
the	O
heparin-associated	B-Drug
thrombocytopenia	B-ADR
and	O
thrombosis	O
syndrome	O
0	O
<EOS>	O
it	O
occasionally	O
accompanies	O
the	O
heparin-associated	B-Drug
thrombocytopenia	O
and	O
thrombosis	B-ADR
syndrome	I-ADR
0	O
<EOS>	O
skin	B-ADR
necrosis	I-ADR
is	O
a	O
rare	O
complication	O
of	O
subcutaneous	O
heparin	B-Drug
therapy	O
that	O
usually	O
occurs	O
at	O
injection	O
site	O
0	O
<EOS>	O
skin	B-ADR
necrosis	I-ADR
secondary	O
to	O
low-molecular	B-Drug
weight	I-Drug
heparin	I-Drug
in	O
a	O
patient	O
with	O
antiphospholipid	O
antibody	O
syndrome	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
the	O
antiphospholipid	O
syndrome	O
who	O
had	O
skin	B-ADR
necrosis	I-ADR
develop	O
from	O
low-molecular	B-Drug
weight	I-Drug
heparin	I-Drug
therapy	O
at	O
site	O
distant	O
from	O
injection	O
site	O
0	O
<EOS>	O
finally	O
,	O
reserpine	B-Drug
toxicity	I-ADR
,	O
in	O
particular	O
central	O
nervous	O
system	O
(	O
cns	O
)	O
disturbance	O
,	O
wa	O
reported	O
more	O
frequently	O
in	O
patient	O
also	O
receiving	O
barbiturate	O
,	O
suggesting	O
additive	O
cns	O
effect	O
0	O
<EOS>	O
a	O
case	O
of	O
contact	B-ADR
dermatitis	I-ADR
due	O
to	O
sodium	B-Drug
bisulfite	I-Drug
in	O
an	O
ophthalmic	O
solution	O
0	O
<EOS>	O
therefore	O
,	O
we	O
diagnosed	O
her	O
eruption	O
a	O
contact	B-ADR
dermatitis	I-ADR
due	O
to	O
sodium	B-Drug
bisulfite	I-Drug
0	O
<EOS>	O
therefore	O
,	O
we	O
diagnosed	O
her	O
eruption	B-ADR
a	O
contact	O
dermatitis	O
due	O
to	O
sodium	B-Drug
bisulfite	I-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
contact	B-ADR
dermatitis	I-ADR
due	O
to	O
sodium	B-Drug
bisulfite	I-Drug
in	O
tathion	O
eye	O
drop	O
0	O
<EOS>	O
acute	B-ADR
pancreatitis	I-ADR
after	O
long-term	O
5-aminosalicylic	B-Drug
acid	I-Drug
therapy	O
0	O
<EOS>	O
acute	B-ADR
pancreatitis	I-ADR
is	O
a	O
known	O
,	O
although	O
rare	O
,	O
complication	O
of	O
mesalamine	B-Drug
treatment	O
0	O
<EOS>	O
a	O
rechallenge	O
,	O
performed	O
in	O
both	O
patient	O
,	O
confirmed	O
the	O
diagnosis	O
of	O
mesalamine-induced	B-Drug
pancreatitis	B-ADR
0	O
<EOS>	O
these	O
case	O
report	O
provide	O
evidence	O
that	O
5-aminosalicylic	B-Drug
acid	I-Drug
may	O
induce	O
acute	B-ADR
pancreatitis	I-ADR
after	O
long	O
term	O
treatment	O
0	O
<EOS>	O
we	O
describe	O
two	O
case	O
of	O
acute	B-ADR
pancreatitis	I-ADR
that	O
occurred	O
after	O
long	O
term	O
mesalamine	B-Drug
therapy	O
for	O
ulcerative	O
colitis	O
0	O
<EOS>	O
a	O
35-year-old	O
nephrotic	O
man	O
developed	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
serum	O
creatinine	O
to	O
1543	O
micromol	O
/	O
l	O
after	O
a	O
month	O
of	O
therapy	O
with	O
enalapril	B-Drug
0	O
<EOS>	O
acute	B-ADR
renal	I-ADR
failure	I-ADR
with	O
severe	O
tubulointerstitial	O
change	O
in	O
a	O
patient	O
with	O
minimal	O
change	O
nephrotic	O
syndrome	O
treated	O
with	O
enalapril	B-Drug
0	O
<EOS>	O
acute	O
renal	O
failure	O
with	O
severe	B-ADR
tubulointerstitial	I-ADR
change	I-ADR
in	O
a	O
patient	O
with	O
minimal	O
change	O
nephrotic	O
syndrome	O
treated	O
with	O
enalapril	B-Drug
0	O
<EOS>	O
early	O
ritonavir-induced	B-Drug
maculopapular	B-ADR
eruption	I-ADR
0	O
<EOS>	O
ritonavir	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drug	O
that	O
can	O
induce	O
adverse	B-ADR
cutaneous	I-ADR
reaction	I-ADR
in	O
hiv	O
patient	O
0	O
<EOS>	O
we	O
report	O
2	O
case	O
of	O
maculopapular	O
eruption	O
and	O
fever	B-ADR
in	O
patient	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
hiv	O
)	O
on	O
the	O
2nd	O
day	O
of	O
first	O
administration	O
of	O
ritonavir	B-Drug
,	O
a	O
protease	O
inhibitor	O
0	O
<EOS>	O
we	O
report	O
2	O
case	O
of	O
maculopapular	B-ADR
eruption	I-ADR
and	O
fever	O
in	O
patient	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
hiv	O
)	O
on	O
the	O
2nd	O
day	O
of	O
first	O
administration	O
of	O
ritonavir	B-Drug
,	O
a	O
protease	O
inhibitor	O
0	O
<EOS>	O
nephropathy	B-ADR
caused	O
by	O
methicillin	B-Drug
therapy	O
for	O
staphylococcal	O
septicemia	O
0	O
<EOS>	O
review	O
of	O
the	O
literature	O
relating	O
to	O
methicillin-induced	B-Drug
nephropathy	B-ADR
suggests	O
a	O
hypersensitivity	O
origin	O
for	O
this	O
disorder	O
,	O
but	O
immunologic	O
and	O
ultrastructural	O
investigation	O
to	O
date	O
ha	O
failed	O
to	O
elucidate	O
pathogenesis	O
0	O
<EOS>	O
a	O
25-year-old	O
woman	O
sought	O
medical	O
attention	O
because	O
of	O
iliocaval	O
manifestation	O
of	O
retroperitoneal	B-ADR
fibrosis	I-ADR
while	O
she	O
wa	O
taking	O
methysergide	B-Drug
0	O
<EOS>	O
methysergide-induced	B-Drug
retroperitoneal	B-ADR
fibrosis	I-ADR
:	O
successful	O
outcome	O
and	O
two	O
new	O
laboratory	O
feature	O
0	O
<EOS>	O
vitiligo	B-ADR
associated	O
with	O
alpha-interferon	B-Drug
in	O
a	O
patient	O
with	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
vitiligo	B-ADR
that	O
occurred	O
during	O
the	O
second	O
month	O
of	O
interferon	B-Drug
alpha	I-Drug
2a	I-Drug
therapy	O
for	O
chronic	O
active	O
hepatitis	O
c	O
0	O
<EOS>	O
a	O
case	O
is	O
reported	O
of	O
an	O
elderly	O
woman	O
who	O
developed	O
febrile	B-ADR
agranulocytosis	I-ADR
several	O
week	O
after	O
commencing	O
ticlopidine	B-Drug
but	O
who	O
had	O
a	O
favorable	O
outcome	O
after	O
cessation	O
of	O
that	O
drug	O
and	O
treatment	O
with	O
filgastrim	O
0	O
<EOS>	O
agranulocytosis	B-ADR
associated	O
with	O
ticlopidine	B-Drug
:	O
a	O
possible	O
benefit	O
with	O
filgastim	O
0	O
<EOS>	O
ticlopidine	B-Drug
is	O
an	O
oral	O
antiplatelet	O
agent	O
frequently	O
utilized	O
in	O
the	O
treatment	O
of	O
cerebrovascular	O
disease	O
and	O
is	O
rarely	O
associated	O
with	O
severe	O
bone	O
marrow	O
suppression	O
,	O
typically	O
aplastic	B-ADR
anemia	I-ADR
0	O
<EOS>	O
ticlopidine	B-Drug
is	O
an	O
oral	O
antiplatelet	O
agent	O
frequently	O
utilized	O
in	O
the	O
treatment	O
of	O
cerebrovascular	O
disease	O
and	O
is	O
rarely	O
associated	O
with	O
severe	B-ADR
bone	I-ADR
marrow	I-ADR
suppression	I-ADR
,	O
typically	O
aplastic	O
anemia	O
0	O
<EOS>	O
hemodialysis	O
wa	O
also	O
shown	O
to	O
reverse	O
ifosfamide-related	B-Drug
neurotoxicity	B-ADR
0	O
<EOS>	O
ifosfamide-associated	B-Drug
neurotoxicity	B-ADR
wa	O
noted	O
within	O
hour	O
of	O
drug	O
administration	O
and	O
improved	O
rapidly	O
following	O
hemodialysis	O
0	O
<EOS>	O
purpose	O
:	O
we	O
evaluated	O
the	O
in	O
vitro	O
hemodialysis	O
ratio	O
and	O
subsequent	O
toxicity	B-Drug
and	O
pharmacokinetics	O
of	O
ifosfamide	B-ADR
in	O
an	O
anephric	O
patient	O
with	O
wilms	O
	O
tumor	O
0	O
<EOS>	O
the	O
toxicity	B-ADR
and	O
plasma	O
concentration	O
of	O
ifosfamide	O
,	O
chloroacetaldehyde	O
,	O
and	O
4-hydroxyifosfamide	B-Drug
were	O
then	O
determined	O
over	O
24	O
h	O
after	O
a	O
single	O
1.6	O
g	O
/	O
m2	O
dose	O
of	O
ifosfamide	O
0	O
<EOS>	O
the	O
toxicity	B-ADR
and	O
plasma	O
concentration	O
of	O
ifosfamide	O
,	O
chloroacetaldehyde	B-Drug
,	O
and	O
4-hydroxyifosfamide	O
were	O
then	O
determined	O
over	O
24	O
h	O
after	O
a	O
single	O
1.6	O
g	O
/	O
m2	O
dose	O
of	O
ifosfamide	O
0	O
<EOS>	O
the	O
toxicity	B-ADR
and	O
plasma	O
concentration	O
of	O
ifosfamide	B-Drug
,	O
chloroacetaldehyde	O
,	O
and	O
4-hydroxyifosfamide	O
were	O
then	O
determined	O
over	O
24	O
h	O
after	O
a	O
single	O
1.6	O
g	O
/	O
m2	O
dose	O
of	O
ifosfamide	O
0	O
<EOS>	O
the	O
toxicity	B-ADR
and	O
plasma	O
concentration	O
of	O
ifosfamide	B-Drug
,	O
chloroacetaldehyde	O
,	O
and	O
4-hydroxyifosfamide	O
were	O
then	O
determined	O
over	O
24	O
h	O
after	O
a	O
single	O
1.6	O
g	O
/	O
m2	O
dose	O
of	O
ifosfamide	O
0	O
<EOS>	O
toxicity	B-ADR
,	O
pharmacokinetics	O
,	O
and	O
in	O
vitro	O
hemodialysis	O
clearance	O
of	O
ifosfamide	B-Drug
and	O
metabolite	O
in	O
an	O
anephric	O
pediatric	O
patient	O
with	O
wilms	O
	O
tumor	O
0	O
<EOS>	O
a	O
55-year-old	O
woman	O
developed	O
symptom	O
suggestive	O
of	O
hepatitis	B-ADR
12	O
week	O
after	O
first	O
receiving	O
methyldopa	B-Drug
for	O
hypertension	O
0	O
<EOS>	O
methyldopa-induced	B-Drug
liver	B-ADR
injury	I-ADR
0	O
<EOS>	O
such	O
a	O
rapid	O
and	O
relentless	O
progression	O
of	O
methyldopa-induced	B-Drug
liver	B-ADR
injury	I-ADR
is	O
undoubtedly	O
rare	O
,	O
but	O
it	O
may	O
be	O
prevented	O
by	O
careful	O
supervision	O
of	O
patient	O
who	O
exhibit	O
liver	O
function	O
abnormality	O
early	O
in	O
the	O
course	O
of	O
therapy	O
0	O
<EOS>	O
acute	B-ADR
respiratory	I-ADR
depression	I-ADR
a	O
a	O
complication	O
of	O
nebulised	O
morphine	B-Drug
0	O
<EOS>	O
approximately	O
15	O
min	O
after	O
the	O
first	O
administration	O
of	O
nebulised	O
morphine	B-Drug
the	O
patient	O
became	O
markedly	O
bradypneic	B-ADR
(	O
respiratory	O
rate	O
:	O
4-5	O
bpm	O
)	O
,	O
hypotensive	O
(	O
bp	O
70	O
/	O
40	O
mmhg	O
)	O
,	O
and	O
responded	O
only	O
partially	O
to	O
command	O
0	O
<EOS>	O
approximately	O
15	O
min	O
after	O
the	O
first	O
administration	O
of	O
nebulised	O
morphine	B-Drug
the	O
patient	O
became	O
markedly	O
bradypneic	O
(	O
respiratory	O
rate	O
:	O
4-5	O
bpm	O
)	O
,	O
hypotensive	B-ADR
(	O
bp	O
70	O
/	O
40	O
mmhg	O
)	O
,	O
and	O
responded	O
only	O
partially	O
to	O
command	O
0	O
<EOS>	O
purpose	O
:	O
to	O
present	O
a	O
case	O
of	O
respiratory	B-ADR
depression	I-ADR
following	O
the	O
administration	O
of	O
nebulised	O
morphine	B-Drug
0	O
<EOS>	O
acute	B-ADR
dystonia	I-ADR
with	O
thalamic	O
and	O
brainstem	O
lesion	O
after	O
initial	O
penicillamine	B-Drug
treatment	O
in	O
wilson	O
disease	O
0	O
<EOS>	O
acute	O
dystonia	O
with	O
thalamic	B-ADR
and	I-ADR
brainstem	I-ADR
lesion	I-ADR
after	O
initial	O
penicillamine	B-Drug
treatment	O
in	O
wilson	O
disease	O
0	O
<EOS>	O
from	O
these	O
data	O
,	O
acute	B-ADR
generalized	I-ADR
dystonia	I-ADR
with	O
brainstem	O
and	O
thalamic	O
lesion	O
may	O
occur	O
in	O
wd	O
patient	O
after	O
an	O
initial	O
d-penicillamine	B-Drug
therapy	O
0	O
<EOS>	O
from	O
these	O
data	O
,	O
acute	O
generalized	O
dystonia	O
with	O
brainstem	B-ADR
and	I-ADR
thalamic	I-ADR
lesion	I-ADR
may	O
occur	O
in	O
wd	O
patient	O
after	O
an	O
initial	O
d-penicillamine	B-Drug
therapy	O
0	O
<EOS>	O
we	O
reported	O
3	O
patient	O
who	O
developed	O
acute	B-ADR
generalized	I-ADR
dystonia	I-ADR
and	O
akinetic	O
rigid	O
syndrome	O
following	O
an	O
initial	O
therapy	O
with	O
d-penicillamine	B-Drug
125-500	O
mg	O
daily	O
0	O
<EOS>	O
we	O
reported	O
3	O
patient	O
who	O
developed	O
acute	O
generalized	O
dystonia	O
and	O
akinetic	B-ADR
rigid	I-ADR
syndrome	I-ADR
following	O
an	O
initial	O
therapy	O
with	O
d-penicillamine	B-Drug
125-500	O
mg	O
daily	O
0	O
<EOS>	O
ballistic	B-ADR
movement	I-ADR
due	O
to	O
ischemic	O
infarct	O
after	O
intravenous	O
heroin	B-Drug
overdose	O
:	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
ballistic	O
movement	O
due	O
to	O
ischemic	B-ADR
infarct	I-ADR
after	O
intravenous	O
heroin	B-Drug
overdose	O
:	O
report	O
of	O
two	O
case	O
0	O
<EOS>	O
patient	O
1	O
presented	O
bilateral	B-ADR
ballism	I-ADR
1	O
week	O
after	O
intravenous	O
heroin	B-Drug
injection	O
0	O
<EOS>	O
stroke	B-ADR
is	O
an	O
infrequent	O
but	O
recognized	O
complication	O
of	O
heroin	B-Drug
addiction	O
0	O
<EOS>	O
two	O
heroin	B-Drug
addict	O
,	O
aged	O
34	O
and	O
19	O
year	O
,	O
developed	O
ballistic	B-ADR
movement	I-ADR
after	O
intravenous	O
heroin	O
overdose	O
0	O
<EOS>	O
a	O
medline	O
search	O
identified	O
all	O
the	O
reported	O
case	O
of	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
0	O
<EOS>	O
anaphylaxis	B-ADR
to	O
intravenous	O
cyclosporine	B-Drug
and	O
tolerance	O
to	O
oral	O
cyclosporine	O
:	O
case	O
report	O
and	O
review	O
0	O
<EOS>	O
background	O
:	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
are	O
rare	O
0	O
<EOS>	O
conclusion	O
:	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	O
are	O
due	O
to	O
cremophor	B-Drug
el	I-Drug
0	O
<EOS>	O
conclusion	O
:	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
are	O
due	O
to	O
cremophor	O
el	O
0	O
<EOS>	O
fortunately	O
,	O
a	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
one	O
formulation	O
of	O
cyclosporine	B-Drug
doe	O
not	O
preclude	O
use	O
of	O
a	O
different	O
formulation	O
0	O
<EOS>	O
method	O
:	O
we	O
report	O
a	O
patient	O
who	O
had	O
an	O
anaphylactic	B-ADR
reaction	I-ADR
during	O
the	O
intravenous	O
infusion	O
of	O
cyclosporine	B-Drug
0	O
<EOS>	O
objective	O
:	O
to	O
investigate	O
the	O
mechanism	O
involved	O
in	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
and	O
determine	O
the	O
feasibility	O
of	O
future	O
cyclosporine	O
use	O
0	O
<EOS>	O
objective	O
:	O
to	O
investigate	O
the	O
mechanism	O
involved	O
in	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
and	O
determine	O
the	O
feasibility	O
of	O
future	O
cyclosporine	O
use	O
0	O
<EOS>	O
the	O
literature	O
search	O
revealed	O
22	O
case	O
of	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
cyclosporine	B-Drug
0	O
<EOS>	O
prothipendylhydrochloride-induced	B-Drug
priapism	B-ADR
:	O
case	O
report	O
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
of	O
a	O
patient	O
with	O
priapism	B-ADR
after	O
oral	O
intake	O
of	O
the	O
phenothiazine	O
prothipendylhydrochloride	B-Drug
0	O
<EOS>	O
the	O
chemotherapeutics	O
,	O
including	O
vincristine	O
,	O
actinomycin	B-Drug
d	I-Drug
,	O
and	O
epirubicin	O
in	O
case	O
1	O
and	O
vincristine	O
and	O
actinomycin	O
d	O
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADR
developed	O
0	O
<EOS>	O
the	O
chemotherapeutics	O
,	O
including	O
vincristine	O
,	O
actinomycin	B-Drug
d	I-Drug
,	O
and	O
epirubicin	O
in	O
case	O
1	O
and	O
vincristine	O
and	O
actinomycin	O
d	O
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADR
developed	O
0	O
<EOS>	O
the	O
chemotherapeutics	O
,	O
including	O
vincristine	O
,	O
actinomycin	O
d	O
,	O
and	O
epirubicin	B-Drug
in	O
case	O
1	O
and	O
vincristine	O
and	O
actinomycin	O
d	O
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADR
developed	O
0	O
<EOS>	O
the	O
chemotherapeutics	O
,	O
including	O
vincristine	B-Drug
,	O
actinomycin	O
d	O
,	O
and	O
epirubicin	O
in	O
case	O
1	O
and	O
vincristine	O
and	O
actinomycin	O
d	O
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADR
developed	O
0	O
<EOS>	O
the	O
chemotherapeutics	O
,	O
including	O
vincristine	B-Drug
,	O
actinomycin	O
d	O
,	O
and	O
epirubicin	O
in	O
case	O
1	O
and	O
vincristine	O
and	O
actinomycin	O
d	O
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADR
developed	O
0	O
<EOS>	O
we	O
conclude	O
that	O
vincristine	O
and	O
actinomycin	B-Drug
d	I-Drug
were	O
the	O
cause	O
of	O
this	O
rare	O
from	O
of	O
hepatotoxicity	B-ADR
and	O
that	O
chemotherapy	O
for	O
the	O
underlying	O
malignant	O
disease	O
could	O
be	O
given	O
safely	O
after	O
clinical	O
recovery	O
0	O
<EOS>	O
we	O
conclude	O
that	O
vincristine	B-Drug
and	O
actinomycin	O
d	O
were	O
the	O
cause	O
of	O
this	O
rare	O
from	O
of	O
hepatotoxicity	B-ADR
and	O
that	O
chemotherapy	O
for	O
the	O
underlying	O
malignant	O
disease	O
could	O
be	O
given	O
safely	O
after	O
clinical	O
recovery	O
0	O
<EOS>	O
because	O
the	O
combination	O
of	O
bleomycin	B-Drug
and	O
vinca	O
alkaloid	O
is	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
aids-related	O
kaposi	O
sarcoma	O
,	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
provoking	O
acral	B-ADR
necrosis	I-ADR
in	O
patient	O
who	O
develop	O
raynaud	O
phenomenon	O
under	O
chemotherapy	O
0	O
<EOS>	O
because	O
the	O
combination	O
of	O
bleomycin	B-Drug
and	O
vinca	O
alkaloid	O
is	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
aids-related	O
kaposi	O
sarcoma	O
,	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
provoking	O
acral	O
necrosis	O
in	O
patient	O
who	O
develop	O
raynaud	B-ADR
phenomenon	I-ADR
under	O
chemotherapy	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	B-ADR
after	O
bleomycin	B-Drug
and	O
vincristine	O
/	O
vinblastine	O
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	O
raynaud	O
phenomenon	O
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	B-ADR
after	O
bleomycin	O
and	O
vincristine	O
/	O
vinblastine	B-Drug
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	O
raynaud	O
phenomenon	O
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	B-ADR
after	O
bleomycin	O
and	O
vincristine	B-Drug
/	O
vinblastine	O
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	O
raynaud	O
phenomenon	O
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	O
after	O
bleomycin	B-Drug
and	O
vincristine	O
/	O
vinblastine	O
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	B-ADR
raynaud	I-ADR
phenomenon	I-ADR
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	O
after	O
bleomycin	O
and	O
vincristine	O
/	O
vinblastine	B-Drug
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	B-ADR
raynaud	I-ADR
phenomenon	I-ADR
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
in	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	O
after	O
bleomycin	O
and	O
vincristine	B-Drug
/	O
vinblastine	O
chemotherapy	O
for	O
aids-related	O
kaposi	O
sarcoma	O
and	O
another	O
hiv-infected	O
patient	O
who	O
exhibited	O
symptom	O
of	O
severe	B-ADR
raynaud	I-ADR
phenomenon	I-ADR
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
0	O
<EOS>	O
development	O
of	O
essential	O
thrombocythemia	B-ADR
in	O
a	O
patient	O
treated	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
pentostatin	O
for	O
hairy	O
cell	O
leukemia	O
0	O
<EOS>	O
development	O
of	O
essential	O
thrombocythemia	B-ADR
in	O
a	O
patient	O
treated	O
with	O
interferon	O
alfa	O
and	O
pentostatin	B-Drug
for	O
hairy	O
cell	O
leukemia	O
0	O
<EOS>	O
second	O
cancer	O
including	O
various	O
type	O
of	O
hematological	B-ADR
malignancy	I-ADR
have	O
been	O
reported	O
in	O
patient	O
with	O
hairy	O
cell	O
leukemia	O
treated	O
with	O
chemotherapy	O
or	O
interferon	B-Drug
alfa	I-Drug
0	O
<EOS>	O
second	B-ADR
cancer	I-ADR
including	O
various	O
type	O
of	O
hematological	O
malignancy	O
have	O
been	O
reported	O
in	O
patient	O
with	O
hairy	O
cell	O
leukemia	O
treated	O
with	O
chemotherapy	O
or	O
interferon	B-Drug
alfa	I-Drug
0	O
<EOS>	O
effect	O
of	O
beta-blockade	O
on	O
symptomatic	O
dexamethasone-induced	B-Drug
hypertrophic	B-ADR
obstructive	I-ADR
cardiomyopathy	I-ADR
in	O
premature	O
infant	O
:	O
three	O
case	O
report	O
and	O
literature	O
review	O
0	O
<EOS>	O
one	O
patient	O
had	O
a	O
lower	B-ADR
average	I-ADR
heart	I-ADR
rate	I-ADR
and	O
two	O
patient	O
had	O
lower	O
average	O
mean	O
blood	O
pressure	O
value	O
during	O
propranolol	B-Drug
treatment	O
,	O
none	O
of	O
which	O
wa	O
clinically	O
significant	O
0	O
<EOS>	O
one	O
patient	O
had	O
a	O
lower	O
average	O
heart	O
rate	O
and	O
two	O
patient	O
had	O
lower	B-ADR
average	I-ADR
mean	I-ADR
blood	I-ADR
pressure	I-ADR
value	O
during	O
propranolol	B-Drug
treatment	O
,	O
none	O
of	O
which	O
wa	O
clinically	O
significant	O
0	O
<EOS>	O
study	O
design	O
:	O
case	O
report	O
are	O
presented	O
of	O
three	O
premature	O
infant	O
(	O
mean	O
gestational	O
age	O
27	O
week	O
)	O
cared	O
for	O
in	O
the	O
intensive	O
care	O
nursery	O
in	O
whom	O
clinically	O
significant	O
septal	O
hypertrophy	O
and	O
left	B-ADR
ventricular	I-ADR
outflow	I-ADR
tract	I-ADR
obstruction	I-ADR
developed	O
during	O
dexamethasone	B-Drug
treatment	O
for	O
bronchopulmonary	O
dysplasia	O
0	O
<EOS>	O
study	O
design	O
:	O
case	O
report	O
are	O
presented	O
of	O
three	O
premature	O
infant	O
(	O
mean	O
gestational	O
age	O
27	O
week	O
)	O
cared	O
for	O
in	O
the	O
intensive	O
care	O
nursery	O
in	O
whom	O
clinically	O
significant	O
septal	B-ADR
hypertrophy	I-ADR
and	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
developed	O
during	O
dexamethasone	B-Drug
treatment	O
for	O
bronchopulmonary	O
dysplasia	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
25-year-old	O
postpartum	O
white	O
woman	O
developed	O
multiple	O
watery	O
stool	O
and	O
abdominal	B-ADR
cramping	I-ADR
on	O
day	O
6	O
of	O
therapy	O
with	O
clindamycin	B-Drug
vaginal	O
cream	O
for	O
bacterial	O
vaginosis	O
0	O
<EOS>	O
case	O
summary	O
:	O
a	O
25-year-old	O
postpartum	O
white	O
woman	O
developed	O
multiple	B-ADR
watery	I-ADR
stool	I-ADR
and	O
abdominal	O
cramping	O
on	O
day	O
6	O
of	O
therapy	O
with	O
clindamycin	B-Drug
vaginal	O
cream	O
for	O
bacterial	O
vaginosis	O
0	O
<EOS>	O
clostridium	B-ADR
difficile	I-ADR
toxin-induced	I-ADR
colitis	I-ADR
after	O
use	O
of	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	O
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	B-ADR
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	O
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	O
difficile	O
toxin	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	B-ADR
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	O
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	O
difficile	O
toxin	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	O
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	O
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	O
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	B-ADR
difficile	I-ADR
toxin	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	O
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	O
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	B-ADR
difficile	I-ADR
toxin	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	O
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	O
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	B-ADR
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	O
difficile	O
toxin	O
0	O
<EOS>	O
conclusion	O
:	O
this	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
a	O
the	O
most	O
probable	O
cause	O
of	O
cdic	O
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	B-ADR
and	O
clindamycin	O
administration	O
,	O
lack	O
of	O
concomitant	O
medication	O
,	O
and	O
documentation	O
of	O
c.	O
difficile	O
toxin	O
0	O
<EOS>	O
discussion	O
:	O
no	O
published	O
clinical	O
study	O
in	O
patient	O
receiving	O
clindamycin	B-Drug
vaginal	O
cream	O
for	O
bacterial	O
vaginosis	O
have	O
documented	O
c.	B-ADR
difficile	I-ADR
toxin	I-ADR
in	I-ADR
stool	I-ADR
sample	O
of	O
patient	O
with	O
diarrhea	O
0	O
<EOS>	O
discussion	O
:	O
no	O
published	O
clinical	O
study	O
in	O
patient	O
receiving	O
clindamycin	B-Drug
vaginal	O
cream	O
for	O
bacterial	O
vaginosis	O
have	O
documented	O
c.	O
difficile	O
toxin	O
in	O
stool	O
sample	O
of	O
patient	O
with	O
diarrhea	B-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
toxin-positive	B-ADR
clostridium	I-ADR
difficile-induced	I-ADR
colitis	I-ADR
(	O
cdic	O
)	O
after	O
use	O
of	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
0	O
<EOS>	O
a	O
54-year-old	O
man	O
developed	O
ten	B-ADR
4	O
week	O
after	O
beginning	O
lamotrigine	B-Drug
for	O
complex	O
partial	O
seizure	O
related	O
to	O
a	O
glioblastoma	O
multiforme	O
brain	O
tumor	O
0	O
<EOS>	O
administration	O
of	O
lamotrigine	B-Drug
,	O
especially	O
in	O
combination	O
with	O
valproic	O
acid	O
,	O
may	O
lead	O
to	O
the	O
development	O
of	O
ten	B-ADR
0	O
<EOS>	O
administration	O
of	O
lamotrigine	O
,	O
especially	O
in	O
combination	O
with	O
valproic	B-Drug
acid	I-Drug
,	O
may	O
lead	O
to	O
the	O
development	O
of	O
ten	B-ADR
0	O
<EOS>	O
fatal	B-ADR
toxic	I-ADR
epidermal	I-ADR
necrolysis	I-ADR
related	O
to	O
lamotrigine	B-Drug
administration	O
0	O
<EOS>	O
it	O
wa	O
hypothesized	O
that	O
valproic	O
acid	O
may	O
interfere	O
with	O
glucuronidation	O
of	O
lamotrigine	B-Drug
,	O
leading	O
to	O
increased	O
serum	O
lamotrigine	O
level	O
,	O
or	O
perhaps	O
alter	O
the	O
drug	O
metabolism	O
,	O
resulting	O
in	O
accumulation	B-ADR
of	I-ADR
a	I-ADR
toxic	I-ADR
intermediate	I-ADR
metabolite	I-ADR
0	O
<EOS>	O
it	O
wa	O
hypothesized	O
that	O
valproic	B-Drug
acid	I-Drug
may	O
interfere	O
with	O
glucuronidation	O
of	O
lamotrigine	O
,	O
leading	O
to	O
increased	O
serum	O
lamotrigine	O
level	O
,	O
or	O
perhaps	O
alter	O
the	O
drug	O
metabolism	O
,	O
resulting	O
in	O
accumulation	B-ADR
of	I-ADR
a	I-ADR
toxic	I-ADR
intermediate	I-ADR
metabolite	I-ADR
0	O
<EOS>	O
it	O
wa	O
hypothesized	O
that	O
valproic	O
acid	O
may	O
interfere	O
with	O
glucuronidation	O
of	O
lamotrigine	B-Drug
,	O
leading	O
to	O
increased	B-ADR
serum	I-ADR
lamotrigine	I-ADR
level	I-ADR
,	O
or	O
perhaps	O
alter	O
the	O
drug	O
metabolism	O
,	O
resulting	O
in	O
accumulation	O
of	O
a	O
toxic	O
intermediate	O
metabolite	O
0	O
<EOS>	O
it	O
wa	O
hypothesized	O
that	O
valproic	B-Drug
acid	I-Drug
may	O
interfere	O
with	O
glucuronidation	O
of	O
lamotrigine	O
,	O
leading	O
to	O
increased	B-ADR
serum	I-ADR
lamotrigine	I-ADR
level	I-ADR
,	O
or	O
perhaps	O
alter	O
the	O
drug	O
metabolism	O
,	O
resulting	O
in	O
accumulation	O
of	O
a	O
toxic	O
intermediate	O
metabolite	O
0	O
<EOS>	O
to	O
date	O
,	O
eight	O
case	O
of	O
ten	O
and	O
one	O
of	O
sjs	B-ADR
related	O
to	O
lamotrigine	B-Drug
administration	O
have	O
been	O
reported	O
in	O
the	O
literature	O
0	O
<EOS>	O
to	O
date	O
,	O
eight	O
case	O
of	O
ten	B-ADR
and	O
one	O
of	O
sjs	O
related	O
to	O
lamotrigine	B-Drug
administration	O
have	O
been	O
reported	O
in	O
the	O
literature	O
0	O
<EOS>	O
a	O
syndrome	B-ADR
of	I-ADR
increased	I-ADR
affect	I-ADR
in	O
response	O
to	O
risperidone	B-Drug
among	O
patient	O
with	O
schizophrenia	O
0	O
<EOS>	O
six	O
of	O
13	O
outpatient	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten-week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	O
affect	O
,	O
including	O
feeling	O
of	O
agitation	O
and	O
depression	B-ADR
and	O
period	O
of	O
cry	O
and	O
insomnia	O
0	O
<EOS>	O
six	O
of	O
13	O
outpatient	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten-week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	O
affect	O
,	O
including	O
feeling	B-ADR
of	I-ADR
agitation	I-ADR
and	O
depression	O
and	O
period	O
of	O
cry	O
and	O
insomnia	O
0	O
<EOS>	O
six	O
of	O
13	O
outpatient	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten-week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	O
affect	O
,	O
including	O
feeling	O
of	O
agitation	O
and	O
depression	O
and	O
period	O
of	O
cry	O
and	O
insomnia	B-ADR
0	O
<EOS>	O
six	O
of	O
13	O
outpatient	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten-week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	B-ADR
affect	I-ADR
,	O
including	O
feeling	O
of	O
agitation	O
and	O
depression	O
and	O
period	O
of	O
cry	O
and	O
insomnia	O
0	O
<EOS>	O
six	O
of	O
13	O
outpatient	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten-week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	O
affect	O
,	O
including	O
feeling	O
of	O
agitation	O
and	O
depression	O
and	O
period	B-ADR
of	I-ADR
cry	I-ADR
and	O
insomnia	O
0	O
<EOS>	O
the	O
author	O
suggest	O
that	O
risperidone	B-Drug
may	O
increase	B-ADR
affect	I-ADR
in	O
patient	O
with	O
schizophrenia	O
and	O
that	O
some	O
patient	O
,	O
especially	O
those	O
with	O
anxiety	O
,	O
may	O
have	O
difficulty	O
managing	O
the	O
increase	O
0	O
<EOS>	O
methanol	B-Drug
toxicity	O
can	O
cause	O
severe	O
central	O
nervous	O
system	O
insult	O
in	O
which	O
a	O
characteristic	O
pattern	O
of	O
bilateral	B-ADR
putaminal	I-ADR
injury	I-ADR
is	O
noted	O
on	O
brain	O
imaging	O
study	O
0	O
<EOS>	O
methanol	B-Drug
toxicity	I-ADR
can	O
cause	O
severe	O
central	O
nervous	O
system	O
insult	O
in	O
which	O
a	O
characteristic	O
pattern	O
of	O
bilateral	O
putaminal	O
injury	O
is	O
noted	O
on	O
brain	O
imaging	O
study	O
0	O
<EOS>	O
methanol	B-Drug
toxicity	O
can	O
cause	O
severe	B-ADR
central	I-ADR
nervous	I-ADR
system	I-ADR
insult	I-ADR
in	O
which	O
a	O
characteristic	O
pattern	O
of	O
bilateral	O
putaminal	O
injury	O
is	O
noted	O
on	O
brain	O
imaging	O
study	O
0	O
<EOS>	O
putaminal	O
infarct	O
in	O
methanol	B-Drug
intoxication	I-ADR
:	O
case	O
report	O
and	O
role	O
of	O
brain	O
imaging	O
study	O
0	O
<EOS>	O
putaminal	B-ADR
infarct	I-ADR
in	O
methanol	B-Drug
intoxication	O
:	O
case	O
report	O
and	O
role	O
of	O
brain	O
imaging	O
study	O
0	O
<EOS>	O
theoretical	O
basal	O
ganglion	O
toxicologic	O
mechanism	O
of	O
methanol	B-Drug
poisoning	I-ADR
are	O
reviewed	O
,	O
and	O
the	O
role	O
of	O
brain	O
imaging	O
study	O
will	O
regard	O
to	O
diagnosis	O
,	O
prognosis	O
and	O
impact	O
on	O
management	O
is	O
discussed	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	O
with	O
associated	O
diffuse	O
brain	O
involvement	O
,	O
including	O
bilateral	B-ADR
putaminal	I-ADR
necrosis	I-ADR
and	O
cerebral	O
edema	O
with	O
ventricular	O
compression	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	O
with	O
associated	O
diffuse	O
brain	O
involvement	O
,	O
including	O
bilateral	O
putaminal	O
necrosis	O
and	O
cerebral	B-ADR
edema	I-ADR
with	O
ventricular	O
compression	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	O
with	O
associated	O
diffuse	B-ADR
brain	I-ADR
involvement	I-ADR
,	O
including	O
bilateral	O
putaminal	O
necrosis	O
and	O
cerebral	O
edema	O
with	O
ventricular	O
compression	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	B-ADR
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	O
with	O
associated	O
diffuse	O
brain	O
involvement	O
,	O
including	O
bilateral	O
putaminal	O
necrosis	O
and	O
cerebral	O
edema	O
with	O
ventricular	O
compression	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	I-ADR
with	O
associated	O
diffuse	O
brain	O
involvement	O
,	O
including	O
bilateral	O
putaminal	O
necrosis	O
and	O
cerebral	O
edema	O
with	O
ventricular	O
compression	O
0	O
<EOS>	O
we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	B-Drug
toxicity	O
with	O
associated	O
diffuse	O
brain	O
involvement	O
,	O
including	O
bilateral	O
putaminal	O
necrosis	O
and	O
cerebral	O
edema	O
with	O
ventricular	B-ADR
compression	I-ADR
0	O
<EOS>	O
a	O
28	O
year	O
old	O
white	O
schizophrenic	O
male	O
ha	O
been	O
under	O
risperidone	B-Drug
monotherapy	O
for	O
about	O
one	O
year	O
when	O
he	O
developed	O
dyskinetic	B-ADR
movement	I-ADR
0	O
<EOS>	O
risperidone-induced	B-Drug
tardive	B-ADR
dyskinesia	I-ADR
0	O
<EOS>	O
this	O
report	O
present	O
a	O
potential	O
case	O
of	O
risperidone-induced	B-Drug
tardive	B-ADR
dyskinesia	I-ADR
0	O
<EOS>	O
increased	B-ADR
ocular	I-ADR
pressure	I-ADR
in	O
two	O
patient	O
with	O
narrow	O
angle	O
glaucoma	O
treated	O
with	O
venlafaxine	B-Drug
0	O
<EOS>	O
a	O
61-year-old	O
man	O
developed	O
clinical	B-ADR
lupus	I-ADR
syndrome	I-ADR
with	O
positive	O
antinuclear	O
antibody	O
,	O
positive	O
lupus	O
erythematosus	O
(	O
le	O
)	O
cell	O
preparation	O
,	O
and	O
diffuse	O
proliferative	O
glomerulonephritis	O
following	O
26	O
month	O
of	O
procainamide	B-Drug
therapy	O
0	O
<EOS>	O
a	O
61-year-old	O
man	O
developed	O
clinical	O
lupus	O
syndrome	O
with	O
positive	O
antinuclear	O
antibody	O
,	O
positive	O
lupus	O
erythematosus	O
(	O
le	O
)	O
cell	O
preparation	O
,	O
and	O
diffuse	B-ADR
proliferative	I-ADR
glomerulonephritis	I-ADR
following	O
26	O
month	O
of	O
procainamide	B-Drug
therapy	O
0	O
<EOS>	O
a	O
61-year-old	O
man	O
developed	O
clinical	O
lupus	O
syndrome	O
with	O
positive	O
antinuclear	O
antibody	O
,	O
positive	O
lupus	B-ADR
erythematosus	I-ADR
(	O
le	O
)	O
cell	O
preparation	O
,	O
and	O
diffuse	O
proliferative	O
glomerulonephritis	O
following	O
26	O
month	O
of	O
procainamide	B-Drug
therapy	O
0	O
<EOS>	O
glomerulonephritis	B-ADR
in	O
procainamide	B-Drug
induced	O
lupus	O
erythematosus	O
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
glomerulonephritis	O
in	O
procainamide	B-Drug
induced	O
lupus	B-ADR
erythematosus	I-ADR
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
report	O
a	O
76-year-old	O
man	O
who	O
developed	O
an	O
acute	B-ADR
blistering	I-ADR
eruption	I-ADR
following	O
high-dose	O
penicillin	B-Drug
treatment	O
for	O
pneumococcal	O
septicaemia	O
0	O
<EOS>	O
a	O
case	O
of	O
prolonged	O
suxamethonium	B-Drug
apnoea	B-ADR
successfully	O
terminated	O
by	O
the	O
infusion	O
of	O
a	O
commercial	O
preparation	O
of	O
serumcholinesterase	O
is	O
reported	O
0	O
<EOS>	O
suxamethonium	B-Drug
apnoea	B-ADR
terminated	O
with	O
commercial	O
serumcholinesterase	O
0	O
<EOS>	O
cardiac	B-ADR
arrest	I-ADR
associated	O
with	O
sulprostone	B-Drug
use	O
during	O
caesarean	O
section	O
0	O
<EOS>	O
we	O
postulate	O
that	O
the	O
bolus	O
of	O
sulprostone	B-Drug
resulted	O
in	O
possible	O
coronary	O
spasm	O
that	O
resulted	O
in	O
cardiac	B-ADR
arrest	I-ADR
0	O
<EOS>	O
we	O
postulate	O
that	O
the	O
bolus	O
of	O
sulprostone	B-Drug
resulted	O
in	O
possible	O
coronary	B-ADR
spasm	I-ADR
that	O
resulted	O
in	O
cardiac	O
arrest	O
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	O
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	B-Drug
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	B-ADR
of	I-ADR
the	I-ADR
lamotrigine	I-ADR
blood	I-ADR
level	I-ADR
with	O
symptom	O
of	O
toxicity	O
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	O
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	B-ADR
of	I-ADR
the	I-ADR
lamotrigine	B-Drug
blood	I-ADR
level	I-ADR
with	O
symptom	O
of	O
toxicity	O
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	B-Drug
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	B-ADR
of	I-ADR
the	I-ADR
lamotrigine	I-ADR
blood	I-ADR
level	I-ADR
with	O
symptom	O
of	O
toxicity	O
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	B-Drug
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	B-ADR
of	I-ADR
the	I-ADR
lamotrigine	I-ADR
blood	I-ADR
level	I-ADR
with	O
symptom	O
of	O
toxicity	O
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	O
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	B-Drug
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
lamotrigine	O
blood	O
level	O
with	O
symptom	B-ADR
of	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	O
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
lamotrigine	B-Drug
blood	O
level	O
with	O
symptom	B-ADR
of	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	B-Drug
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
lamotrigine	O
blood	O
level	O
with	O
symptom	B-ADR
of	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
in	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	B-Drug
,	O
with	O
nondetectable	O
sertraline	O
and	O
desmethylsertraline	O
blood	O
level	O
,	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
lamotrigine	O
blood	O
level	O
with	O
symptom	B-ADR
of	I-ADR
toxicity	I-ADR
0	O
<EOS>	O
lamotrigine	B-Drug
toxicity	I-ADR
secondary	O
to	O
sertraline	O
0	O
<EOS>	O
lamotrigine	B-ADR
toxicity	I-ADR
secondary	O
to	O
sertraline	B-Drug
0	O
<EOS>	O
flutamide	B-Drug
withdrawal	O
syndrome	O
is	O
characterized	O
by	O
a	O
decrease	B-ADR
in	I-ADR
prostate-specific	I-ADR
antigen	I-ADR
(	O
psa	O
)	O
after	O
flutamide	O
withdrawal	O
in	O
a	O
subset	O
of	O
patient	O
with	O
progressing	O
metastatic	O
carcinoma	O
of	O
the	O
prostate	O
0	O
<EOS>	O
flutamide	B-Drug
withdrawal	O
syndrome	O
is	O
characterized	O
by	O
a	O
decrease	B-ADR
in	I-ADR
prostate-specific	I-ADR
antigen	I-ADR
(	O
psa	O
)	O
after	O
flutamide	O
withdrawal	O
in	O
a	O
subset	O
of	O
patient	O
with	O
progressing	O
metastatic	O
carcinoma	O
of	O
the	O
prostate	O
0	O
<EOS>	O
flutamide	B-Drug
withdrawal	I-ADR
syndrome	I-ADR
is	O
characterized	O
by	O
a	O
decrease	O
in	O
prostate-specific	O
antigen	O
(	O
psa	O
)	O
after	O
flutamide	O
withdrawal	O
in	O
a	O
subset	O
of	O
patient	O
with	O
progressing	O
metastatic	O
carcinoma	O
of	O
the	O
prostate	O
0	O
<EOS>	O
flutamide	B-Drug
withdrawal	I-ADR
syndrome	I-ADR
is	O
characterized	O
by	O
a	O
decrease	O
in	O
prostate-specific	O
antigen	O
(	O
psa	O
)	O
after	O
flutamide	O
withdrawal	O
in	O
a	O
subset	O
of	O
patient	O
with	O
progressing	O
metastatic	O
carcinoma	O
of	O
the	O
prostate	O
0	O
<EOS>	O
prolonged	O
prostate-specific	O
antigen	O
response	O
in	O
flutamide	B-Drug
withdrawal	I-ADR
syndrome	I-ADR
despite	O
disease	O
progression	O
0	O
<EOS>	O
prolonged	B-ADR
prostate-specific	I-ADR
antigen	I-ADR
response	I-ADR
in	O
flutamide	B-Drug
withdrawal	O
syndrome	O
despite	O
disease	O
progression	O
0	O
<EOS>	O
this	O
case	O
illustrates	O
the	O
potential	O
decoupling	B-ADR
of	I-ADR
psa	I-ADR
response	I-ADR
from	O
disease	O
status	O
in	O
flutamide	B-Drug
withdrawal	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
androgen-independent	O
prostate	O
cancer	O
in	O
whom	O
psa	B-ADR
continued	I-ADR
to	I-ADR
decrease	I-ADR
for	O
a	O
period	O
of	O
15	O
month	O
after	O
flutamide	B-Drug
withdrawal	O
0	O
<EOS>	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
oral	O
prednisone	B-Drug
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
0	O
<EOS>	O
we	O
describe	O
the	O
case	O
of	O
a	O
nonatopic	O
17-year-old	O
girl	O
with	O
bronchial	O
asthma	O
and	O
aspirin	O
intolerance	O
who	O
developed	O
a	O
dramatic	O
anaphylactic	B-ADR
reaction	I-ADR
to	O
oral	O
prednisone	B-Drug
0	O
<EOS>	O
animal	O
treated	O
with	O
hal	B-Drug
showed	O
a	O
highly	O
significant	B-ADR
32	I-ADR
%	I-ADR
-46	I-ADR
%	I-ADR
loss	I-ADR
of	I-ADR
tyrosine	I-ADR
hydroxylase	I-ADR
(	I-ADR
th	I-ADR
)	I-ADR
immunoreactive	I-ADR
neuron	I-ADR
in	O
the	O
substantia	O
nigra	O
,	O
and	O
20	O
%	O
contraction	O
of	O
the	O
th	O
stained	O
dendritic	O
arbour	O
0	O
<EOS>	O
method	O
:	O
double-blind	O
,	O
placebo-controlled	O
titrated	O
oral	O
challenge	O
with	O
pancreatic	O
enzyme	O
resulted	O
in	O
definite	O
vomiting	B-ADR
within	O
1	O
to	O
1.5	O
hour	O
after	O
challenge	O
with	O
viokase	O
and	O
pancrease	B-Drug
mt	I-Drug
16	I-Drug
,	O
but	O
not	O
with	O
placebo	O
0	O
<EOS>	O
method	O
:	O
double-blind	O
,	O
placebo-controlled	O
titrated	O
oral	O
challenge	O
with	O
pancreatic	O
enzyme	O
resulted	O
in	O
definite	O
vomiting	B-ADR
within	O
1	O
to	O
1.5	O
hour	O
after	O
challenge	O
with	O
viokase	B-Drug
and	O
pancrease	O
mt	O
16	O
,	O
but	O
not	O
with	O
placebo	O
0	O
<EOS>	O
she	O
wa	O
treated	O
with	O
pancrease	B-Drug
mt	I-Drug
16	I-Drug
,	O
but	O
had	O
consistent	O
vomiting	B-ADR
1	O
to	O
2	O
hour	O
after	O
administration	O
of	O
enzyme	O
0	O
<EOS>	O
the	O
vomiting	B-ADR
occurred	O
on	O
switching	O
to	O
different	O
pancreatic	O
enzyme	O
preparation	O
,	O
ie	O
,	O
creon	B-Drug
10	I-Drug
,	O
viokase	O
,	O
and	O
pancrease	O
mt	O
16	O
0	O
<EOS>	O
the	O
vomiting	B-ADR
occurred	O
on	O
switching	O
to	O
different	O
pancreatic	O
enzyme	O
preparation	O
,	O
ie	O
,	O
creon	O
10	O
,	O
viokase	O
,	O
and	O
pancrease	B-Drug
mt	I-Drug
16	I-Drug
0	O
<EOS>	O
the	O
vomiting	B-ADR
occurred	O
on	O
switching	O
to	O
different	O
pancreatic	O
enzyme	O
preparation	O
,	O
ie	O
,	O
creon	O
10	O
,	O
viokase	B-Drug
,	O
and	O
pancrease	O
mt	O
16	O
0	O
<EOS>	O
acute	O
valproate	B-Drug
ingestion	O
induces	O
symptomatic	B-ADR
methemoglobinemia	I-ADR
0	O
<EOS>	O
we	O
report	O
for	O
the	O
first	O
time	O
the	O
development	O
of	O
symptomatic	B-ADR
methemoglobinemia	I-ADR
after	O
an	O
acute	O
ingestion	O
of	O
divalproex	O
sodium	O
(	O
depakote	B-Drug
)	O
,	O
resulting	O
in	O
serum	O
concentration	O
10	O
time	O
greater	O
than	O
the	O
therapeutic	O
range	O
0	O
<EOS>	O
we	O
report	O
for	O
the	O
first	O
time	O
the	O
development	O
of	O
symptomatic	B-ADR
methemoglobinemia	I-ADR
after	O
an	O
acute	O
ingestion	O
of	O
divalproex	B-Drug
sodium	I-Drug
(	O
depakote	O
)	O
,	O
resulting	O
in	O
serum	O
concentration	O
10	O
time	O
greater	O
than	O
the	O
therapeutic	O
range	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	B-ADR
anemia	I-ADR
,	O
thrombocytopenia	O
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	B-ADR
anemia	I-ADR
,	O
thrombocytopenia	O
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
may	O
induce	O
cancer-associated	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	O
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
may	O
induce	O
cancer-associated	O
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	O
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	O
and	O
progressive	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	O
and	O
progressive	B-ADR
renal	I-ADR
failure	I-ADR
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	B-Drug
c	I-Drug
(	O
mmc	O
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	B-ADR
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
in	O
rare	O
case	O
mitomycin	O
c	O
(	O
mmc	B-Drug
)	O
may	O
induce	O
cancer-associated	O
hemolytic	O
uremic	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	B-ADR
and	O
progressive	O
renal	O
failure	O
0	O
<EOS>	O
mitomycin	B-Drug
c-related	I-Drug
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
in	O
cancer	O
patient	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
mmc-related	B-Drug
hemolytic	B-ADR
uremic	I-ADR
syndrome	I-ADR
,	O
and	O
discus	O
the	O
etiologic	O
parameter	O
,	O
clinical	O
aspect	O
,	O
prognosis	O
and	O
treatment	O
modality	O
of	O
this	O
severe	O
syndrome	O
0	O
<EOS>	O
cd4	B-ADR
t-lymphocyte	I-ADR
depletion	I-ADR
,	O
myelosuppression	O
,	O
and	O
subsequent	O
severe	O
infection	O
are	O
the	O
major	O
side	O
effect	O
of	O
fludarabine	B-Drug
phosphate	I-Drug
therapy	O
0	O
<EOS>	O
cd4	O
t-lymphocyte	O
depletion	O
,	O
myelosuppression	B-ADR
,	O
and	O
subsequent	O
severe	O
infection	O
are	O
the	O
major	O
side	O
effect	O
of	O
fludarabine	B-Drug
phosphate	I-Drug
therapy	O
0	O
<EOS>	O
cd4	O
t-lymphocyte	O
depletion	O
,	O
myelosuppression	O
,	O
and	O
subsequent	O
severe	B-ADR
infection	I-ADR
are	O
the	O
major	O
side	O
effect	O
of	O
fludarabine	B-Drug
phosphate	I-Drug
therapy	O
0	O
<EOS>	O
severe	B-ADR
respiratory	I-ADR
syncytial	I-ADR
virus	I-ADR
pulmonary	I-ADR
infection	I-ADR
in	O
a	O
patient	O
treated	O
with	O
fludarabine	B-Drug
for	O
chronic	O
lymphocytic	O
leukemia	O
0	O
<EOS>	O
we	O
report	O
here	O
on	O
a	O
heretofore	O
undescribed	O
respiratory	B-ADR
syncytial	I-ADR
virus	I-ADR
(	I-ADR
rsv	I-ADR
)	I-ADR
infection	I-ADR
in	O
a	O
patient	O
with	O
a	O
long-standing	O
history	O
of	O
refractory	O
cll	O
that	O
wa	O
treated	O
with	O
fludarabine	B-Drug
phosphate	I-Drug
0	O
<EOS>	O
serotonin	B-ADR
syndrome	I-ADR
induced	O
by	O
transitioning	O
from	O
phenelzine	B-Drug
to	O
venlafaxine	O
:	O
four	O
patient	O
report	O
0	O
<EOS>	O
serotonin	B-ADR
syndrome	I-ADR
induced	O
by	O
transitioning	O
from	O
phenelzine	O
to	O
venlafaxine	B-Drug
:	O
four	O
patient	O
report	O
0	O
<EOS>	O
although	O
this	O
g-csf-driven	B-Drug
leucocytosis	B-ADR
wa	O
alarming	O
it	O
did	O
not	O
appear	O
to	O
have	O
adversely	O
affected	O
the	O
patient	O
prognosis	O
0	O
<EOS>	O
leukaemoid	B-ADR
monocytosis	I-ADR
in	O
m4	O
aml	O
following	O
chemotherapy	O
and	O
g-csf	B-Drug
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
m4	O
aml	O
treated	O
with	O
standard	O
chemotherapy	O
followed	O
by	O
g-csf	B-Drug
who	O
developed	O
marked	O
monocytosis	B-ADR
on	O
day	O
8	O
of	O
g-csf	O
therapy	O
0	O
<EOS>	O
we	O
describe	O
a	O
patient	O
with	O
m4	O
aml	O
treated	O
with	O
standard	O
chemotherapy	O
followed	O
by	O
g-csf	B-Drug
who	O
developed	O
marked	O
monocytosis	B-ADR
on	O
day	O
8	O
of	O
g-csf	O
therapy	O
0	O
<EOS>	O
case	O
2	O
demonstrated	O
after	O
40	O
month	O
on	O
chlorambucil	B-Drug
the	O
presence	O
of	O
a	O
balanced	B-ADR
translocation	I-ADR
,	O
t	O
(	O
1	O
;	O
5	O
)	O
(	O
p36	O
;	O
q31	O
)	O
in	O
90	O
%	O
of	O
the	O
cell	O
0	O
<EOS>	O
chromosome	B-ADR
abnormality	I-ADR
after	O
chlorambucil	B-Drug
therapy	O
of	O
polycythaemia	O
vera	O
0	O
<EOS>	O
administration	O
of	O
steroid	O
and	O
decreasing	O
the	O
dose	O
of	O
ptu	B-Drug
produced	O
a	O
good	O
clinical	O
response	O
and	O
the	O
anca	B-ADR
disappeared	O
0	O
<EOS>	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody-positive	I-ADR
crescentic	I-ADR
glomerulonephritis	I-ADR
associated	O
with	O
propylthiouracil	B-Drug
therapy	O
0	O
<EOS>	O
a	O
teenage	O
girl	O
with	O
crescentic	O
glomerulonephritis	O
had	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody	I-ADR
(	O
anca	O
)	O
detected	O
after	O
she	O
had	O
received	O
propylthiouracil	B-Drug
(	O
ptu	O
)	O
for	O
hyperthyroidism	O
without	O
cutaneous	O
vasculitis	O
0	O
<EOS>	O
a	O
teenage	O
girl	O
with	O
crescentic	O
glomerulonephritis	O
had	O
antineutrophil	B-ADR
cytoplasmic	I-ADR
antibody	I-ADR
(	O
anca	O
)	O
detected	O
after	O
she	O
had	O
received	O
propylthiouracil	O
(	O
ptu	B-Drug
)	O
for	O
hyperthyroidism	O
without	O
cutaneous	O
vasculitis	O
0	O
<EOS>	O
it	O
wa	O
concluded	O
that	O
anca	B-ADR
is	O
closely	O
related	O
to	O
the	O
pathogenesis	O
of	O
crescentic	O
glomerulonephritis	O
and	O
that	O
treatment	O
with	O
ptu	B-Drug
appeared	O
to	O
induce	O
anca	O
0	O
<EOS>	O
it	O
wa	O
concluded	O
that	O
anca	B-ADR
is	O
closely	O
related	O
to	O
the	O
pathogenesis	O
of	O
crescentic	O
glomerulonephritis	O
and	O
that	O
treatment	O
with	O
ptu	B-Drug
appeared	O
to	O
induce	O
anca	O
0	O
<EOS>	O
a	O
drug	B-ADR
interaction	I-ADR
between	O
zafirlukast	O
and	O
theophylline	B-Drug
0	O
<EOS>	O
a	O
drug	B-ADR
interaction	I-ADR
between	O
zafirlukast	B-Drug
and	O
theophylline	O
0	O
<EOS>	O
attempt	O
were	O
made	O
to	O
stop	O
and	O
then	O
restart	O
the	O
theophylline	B-Drug
therapy	O
at	O
progressively	O
lower	O
dos	O
;	O
however	O
,	O
with	O
each	O
attempt	O
,	O
the	O
patient	O
reaction	B-ADR
to	I-ADR
the	I-ADR
drug	I-ADR
became	I-ADR
more	I-ADR
toxic	I-ADR
,	O
with	O
serum	O
theophylline	O
level	O
ranging	O
between	O
99.9	O
and	O
149.9	O
micromol	O
/	O
l	O
(	O
18	O
and	O
27	O
microg	O
/	O
ml	O
)	O
0	O
<EOS>	O
attempt	O
were	O
made	O
to	O
stop	O
and	O
then	O
restart	O
the	O
theophylline	B-Drug
therapy	O
at	O
progressively	O
lower	O
dos	O
;	O
however	O
,	O
with	O
each	O
attempt	O
,	O
the	O
patient	O
reaction	B-ADR
to	I-ADR
the	I-ADR
drug	I-ADR
became	I-ADR
more	I-ADR
toxic	I-ADR
,	O
with	O
serum	O
theophylline	O
level	O
ranging	O
between	O
99.9	O
and	O
149.9	O
micromol	O
/	O
l	O
(	O
18	O
and	O
27	O
microg	O
/	O
ml	O
)	O
0	O
<EOS>	O
one	O
explanation	O
for	O
the	O
noted	O
increase	B-ADR
in	I-ADR
the	I-ADR
theophylline	B-Drug
level	I-ADR
is	O
that	O
metabolism	O
occurs	O
mainly	O
by	O
cytochrome	O
p450	O
(	O
cyp	O
1a2	O
)	O
,	O
an	O
enzyme	O
that	O
is	O
known	O
to	O
be	O
inhibited	O
with	O
high	O
concentration	O
of	O
zafirlukast	O
0	O
<EOS>	O
one	O
explanation	O
for	O
the	O
noted	O
increase	B-ADR
in	I-ADR
the	I-ADR
theophylline	I-ADR
level	I-ADR
is	O
that	O
metabolism	O
occurs	O
mainly	O
by	O
cytochrome	O
p450	O
(	O
cyp	O
1a2	O
)	O
,	O
an	O
enzyme	O
that	O
is	O
known	O
to	O
be	O
inhibited	O
with	O
high	O
concentration	O
of	O
zafirlukast	B-Drug
0	O
<EOS>	O
recently	O
,	O
her	O
serum	O
theophylline	B-ADR
level	I-ADR
had	I-ADR
increased	I-ADR
to	I-ADR
the	I-ADR
toxic	I-ADR
range	I-ADR
(	O
133.2	O
micromol	O
/	O
l	O
[	O
24	O
microg	O
/	O
ml	O
]	O
)	O
shortly	O
after	O
the	O
addition	O
of	O
zafirlukast	O
(	O
accolate	B-Drug
,	O
zeneca	O
pharmaceutical	O
,	O
wilmington	O
,	O
del	O
)	O
to	O
her	O
regimen	O
0	O
<EOS>	O
recently	O
,	O
her	O
serum	O
theophylline	B-Drug
level	I-ADR
had	I-ADR
increased	I-ADR
to	I-ADR
the	I-ADR
toxic	I-ADR
range	I-ADR
(	O
133.2	O
micromol	O
/	O
l	O
[	O
24	O
microg	O
/	O
ml	O
]	O
)	O
shortly	O
after	O
the	O
addition	O
of	O
zafirlukast	O
(	O
accolate	O
,	O
zeneca	O
pharmaceutical	O
,	O
wilmington	O
,	O
del	O
)	O
to	O
her	O
regimen	O
0	O
<EOS>	O
recently	O
,	O
her	O
serum	O
theophylline	B-ADR
level	I-ADR
had	I-ADR
increased	I-ADR
to	I-ADR
the	I-ADR
toxic	I-ADR
range	I-ADR
(	O
133.2	O
micromol	O
/	O
l	O
[	O
24	O
microg	O
/	O
ml	O
]	O
)	O
shortly	O
after	O
the	O
addition	O
of	O
zafirlukast	B-Drug
(	O
accolate	O
,	O
zeneca	O
pharmaceutical	O
,	O
wilmington	O
,	O
del	O
)	O
to	O
her	O
regimen	O
0	O
<EOS>	O
the	O
noted	O
increase	B-ADR
in	I-ADR
the	I-ADR
theophylline	B-Drug
level	I-ADR
after	O
zafirlukast	O
administration	O
is	O
in	O
contrast	O
to	O
the	O
original	O
report	O
by	O
the	O
manufacturer	O
0	O
<EOS>	O
the	O
noted	O
increase	B-ADR
in	I-ADR
the	I-ADR
theophylline	I-ADR
level	I-ADR
after	O
zafirlukast	B-Drug
administration	O
is	O
in	O
contrast	O
to	O
the	O
original	O
report	O
by	O
the	O
manufacturer	O
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
(	O
to	O
our	O
knowledge	O
)	O
of	O
a	O
potentially	O
serious	O
drug-drug	B-ADR
interaction	I-ADR
between	O
zafirlukast	O
and	O
theophylline	B-Drug
0	O
<EOS>	O
we	O
present	O
the	O
first	O
case	O
(	O
to	O
our	O
knowledge	O
)	O
of	O
a	O
potentially	O
serious	O
drug-drug	B-ADR
interaction	I-ADR
between	O
zafirlukast	B-Drug
and	O
theophylline	O
0	O
<EOS>	O
a	O
21-year-old	O
patient	O
developed	O
rhabdomyolysis	B-ADR
during	O
his	O
nineteenth	O
week	O
of	O
treatment	O
with	O
clozapine	B-Drug
for	O
drug-resistant	O
schizophrenia	O
0	O
<EOS>	O
clozapine	B-Drug
is	O
speculated	O
to	O
cause	O
rhabdomyolysis	B-ADR
in	O
patient	O
with	O
defective	O
calcium-activated	O
k+	O
channel	O
0	O
<EOS>	O
rhabdomyolysis	B-ADR
associated	O
with	O
clozapine	B-Drug
treatment	O
in	O
a	O
patient	O
with	O
decreased	O
calcium-dependent	O
potassium	O
permeability	O
of	O
cell	O
membrane	O
0	O
<EOS>	O
we	O
describe	O
child	O
and	O
adolescent	O
with	O
chronic	O
hematologic	O
and	O
oncologic	O
disease	O
who	O
exhibited	O
drug-seeking	O
behavior	O
or	O
anticholinergic	B-ADR
symptom	I-ADR
with	O
the	O
use	O
of	O
diphenhydramine	B-Drug
0	O
<EOS>	O
we	O
describe	O
child	O
and	O
adolescent	O
with	O
chronic	O
hematologic	O
and	O
oncologic	O
disease	O
who	O
exhibited	O
drug-seeking	B-ADR
behavior	I-ADR
or	O
anticholinergic	O
symptom	O
with	O
the	O
use	O
of	O
diphenhydramine	B-Drug
0	O
<EOS>	O
excluding	O
other	O
cause	O
,	O
pentasa-associated	B-Drug
pancytopenia	B-ADR
wa	O
considered	O
0	O
<EOS>	O
he	O
developed	O
fever	O
,	O
nausea	O
,	O
diarrhea	B-ADR
,	O
and	O
malaise	O
and	O
stopped	O
taking	O
on	O
the	O
third	O
day	O
after	O
commencing	O
pentasa	B-Drug
0	O
<EOS>	O
he	O
developed	O
fever	B-ADR
,	O
nausea	O
,	O
diarrhea	O
,	O
and	O
malaise	O
and	O
stopped	O
taking	O
on	O
the	O
third	O
day	O
after	O
commencing	O
pentasa	B-Drug
0	O
<EOS>	O
he	O
developed	O
fever	O
,	O
nausea	O
,	O
diarrhea	O
,	O
and	O
malaise	B-ADR
and	O
stopped	O
taking	O
on	O
the	O
third	O
day	O
after	O
commencing	O
pentasa	B-Drug
0	O
<EOS>	O
he	O
developed	O
fever	O
,	O
nausea	B-ADR
,	O
diarrhea	O
,	O
and	O
malaise	O
and	O
stopped	O
taking	O
on	O
the	O
third	O
day	O
after	O
commencing	O
pentasa	B-Drug
0	O
<EOS>	O
pancytopenia	B-ADR
associated	O
with	O
5-aminosalicylic	B-Drug
acid	I-Drug
use	O
in	O
a	O
patient	O
with	O
crohn	O
disease	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
pancytopenia	B-ADR
in	O
a	O
23-year-old	O
man	O
with	O
crohn	O
disease	O
who	O
wa	O
treated	O
with	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
pentasa	O
;	O
nisshin	O
,	O
tokyo	O
,	O
japan	O
)	O
3	O
g	O
/	O
day	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
pancytopenia	B-ADR
in	O
a	O
23-year-old	O
man	O
with	O
crohn	O
disease	O
who	O
wa	O
treated	O
with	O
5-aminosalicylic	O
acid	O
(	O
pentasa	B-Drug
;	O
nisshin	O
,	O
tokyo	O
,	O
japan	O
)	O
3	O
g	O
/	O
day	O
0	O
<EOS>	O
1	O
change	B-ADR
in	I-ADR
the	I-ADR
plasma	I-ADR
cortisol	I-ADR
level	I-ADR
were	O
reported	O
in	O
a	O
male	O
patient	O
with	O
panic	O
disorder	O
during	O
the	O
period	O
of	O
low-dose	O
alprazolam	B-Drug
treatment	O
(	O
mean	O
0.62	O
+	O
/	O
-	O
0.15	O
mg	O
/	O
day	O
)	O
compared	O
with	O
during	O
the	O
period	O
of	O
high-dose	O
period	O
(	O
mean	O
1.08	O
+	O
/	O
-	O
0.28	O
mg	O
/	O
day	O
)	O
0	O
<EOS>	O
3	O
thus	O
,	O
the	O
decreased	B-ADR
plasma	I-ADR
cortisol	I-ADR
level	I-ADR
during	O
alprazolam	B-Drug
treatment	O
of	O
panic	O
disorder	O
wa	O
suggested	O
to	O
be	O
caused	O
not	O
by	O
symptom	O
alleviation	O
due	O
to	O
alprazolam	O
but	O
by	O
alprazolam	O
administration	O
itself	O
0	O
<EOS>	O
decreased	B-ADR
plasma	I-ADR
cortisol	I-ADR
level	I-ADR
during	O
alprazolam	B-Drug
treatment	O
of	O
panic	O
disorder	O
:	O
a	O
case	O
report	O
0	O
<EOS>	O
we	O
describe	O
a	O
renal	O
transplant	O
recipient	O
maintained	O
on	O
cyclosporine	B-Drug
and	O
prednisone	O
developing	O
nocardia	B-ADR
asteroides	I-ADR
brain	I-ADR
abscess	I-ADR
0	O
<EOS>	O
we	O
describe	O
a	O
renal	O
transplant	O
recipient	O
maintained	O
on	O
cyclosporine	O
and	O
prednisone	B-Drug
developing	O
nocardia	B-ADR
asteroides	I-ADR
brain	I-ADR
abscess	I-ADR
0	O
<EOS>	O
young	O
child	O
undergoing	O
cisplatin	B-Drug
chemotherapy	O
are	O
known	O
to	O
be	O
at	O
risk	O
for	O
progressive	B-ADR
sensorineural	I-ADR
hearing	I-ADR
loss	I-ADR
0	O
<EOS>	O
a	O
47	O
year-old	O
woman	O
who	O
had	O
a	O
4-year	O
history	O
of	O
intramuscular	O
pentazocine	B-Drug
injection	O
in	O
the	O
lower	O
extremity	O
,	O
developed	O
gradual	B-ADR
stiffness	I-ADR
and	O
weakness	O
of	O
the	O
lower	O
extremity	O
0	O
<EOS>	O
a	O
47	O
year-old	O
woman	O
who	O
had	O
a	O
4-year	O
history	O
of	O
intramuscular	O
pentazocine	B-Drug
injection	O
in	O
the	O
lower	O
extremity	O
,	O
developed	O
gradual	O
stiffness	O
and	O
weakness	B-ADR
of	I-ADR
the	I-ADR
lower	I-ADR
extremity	I-ADR
0	O
<EOS>	O
caution	O
in	O
longterm	O
usage	O
and	O
early	O
recognition	O
of	O
pentazocine	B-Drug
toxicity	O
a	O
a	O
neuromuscular	O
complication	O
are	O
important	O
in	O
order	O
to	O
prevent	O
irreversible	O
drug-induced	O
fibrous	B-ADR
myopathy	I-ADR
and	O
localized	O
neuropathy	O
0	O
<EOS>	O
caution	O
in	O
longterm	O
usage	O
and	O
early	O
recognition	O
of	O
pentazocine	B-Drug
toxicity	O
a	O
a	O
neuromuscular	B-ADR
complication	I-ADR
are	O
important	O
in	O
order	O
to	O
prevent	O
irreversible	O
drug-induced	O
fibrous	O
myopathy	O
and	O
localized	O
neuropathy	O
0	O
<EOS>	O
caution	O
in	O
longterm	O
usage	O
and	O
early	O
recognition	O
of	O
pentazocine	B-Drug
toxicity	O
a	O
a	O
neuromuscular	O
complication	O
are	O
important	O
in	O
order	O
to	O
prevent	O
irreversible	O
drug-induced	O
fibrous	O
myopathy	O
and	O
localized	O
neuropathy	B-ADR
0	O
<EOS>	O
caution	O
in	O
longterm	O
usage	O
and	O
early	O
recognition	O
of	O
pentazocine	B-Drug
toxicity	I-ADR
a	O
a	O
neuromuscular	O
complication	O
are	O
important	O
in	O
order	O
to	O
prevent	O
irreversible	O
drug-induced	O
fibrous	O
myopathy	O
and	O
localized	O
neuropathy	O
0	O
<EOS>	O
pentazocine-induced	B-Drug
fibrous	B-ADR
myopathy	I-ADR
and	O
localized	O
neuropathy	O
0	O
<EOS>	O
pentazocine-induced	B-Drug
fibrous	O
myopathy	O
and	O
localized	O
neuropathy	B-ADR
0	O
<EOS>	O
in	O
two	O
of	O
these	O
case	O
akathisia	B-ADR
resolved	O
after	O
withdrawal	O
of	O
olanzapine	B-Drug
and	O
substitution	O
by	O
a	O
classical	O
or	O
an	O
atypical	O
neuroleptic	O
agent	O
,	O
respectively	O
0	O
<EOS>	O
like	O
other	O
atypical	O
neuroleptic	O
olanzapine	B-Drug
is	O
considered	O
to	O
show	O
a	O
reduced	O
prevalence	O
of	O
extrapyramidal	B-ADR
side	I-ADR
effect	I-ADR
when	O
compared	O
to	O
classical	O
neuroleptic	O
drug	O
0	O
<EOS>	O
one	O
should	O
therefore	O
be	O
aware	O
of	O
possible	O
extrapyramidal	B-ADR
side	I-ADR
effect	I-ADR
with	O
olanzapine	B-Drug
that	O
are	O
reduced	O
compared	O
to	O
classical	O
neuroleptic	O
drug	O
but	O
not	O
completely	O
eliminated	O
0	O
<EOS>	O
severe	B-ADR
akathisia	I-ADR
during	O
olanzapine	B-Drug
treatment	O
of	O
acute	O
schizophrenia	O
0	O
<EOS>	O
we	O
report	O
on	O
three	O
patient	O
with	O
acute	O
schizophrenia	O
,	O
who	O
developed	O
severe	B-ADR
akathisia	I-ADR
during	O
treatment	O
with	O
olanzapine	B-Drug
(	O
20-25	O
mg	O
/	O
d	O
)	O
0	O
<EOS>	O
seizure	B-ADR
occurred	O
in	O
two	O
patient	O
with	O
probable	O
alzheimer	O
disease	O
who	O
were	O
receiving	O
long-term	O
treatment	O
with	O
metrifonate	B-Drug
,	O
an	O
irreversible	O
acetylcholinesterase	O
inhibitor	O
0	O
<EOS>	O
however	O
,	O
1	O
eye	O
had	O
vitreous	B-ADR
hemorrhage	I-ADR
after	O
repeated	O
injection	O
of	O
tpa	B-Drug
0	O
<EOS>	O
however	O
,	O
repeated	O
intracameral	O
tpa	B-Drug
injection	O
may	O
cause	O
unwanted	O
complication	O
such	O
a	O
vitreous	B-ADR
hemorrhage	I-ADR
0	O
<EOS>	O
although	O
praziquantel	B-Drug
administration	O
may	O
have	O
been	O
effective	O
in	O
killing	O
the	O
parasite	O
in	O
both	O
patient	O
,	O
we	O
are	O
concerned	O
about	O
the	O
production	O
of	O
marked	O
inflammation	B-ADR
a	O
a	O
result	O
of	O
treatment	O
0	O
<EOS>	O
nm	B-ADR
is	O
a	O
drug-related	O
response	O
to	O
various	O
medication	O
,	O
such	O
a	O
haloperidol	B-Drug
,	O
which	O
the	O
patient	O
wa	O
receiving	O
0	O
<EOS>	O
methimazole-induced	B-Drug
aplastic	B-ADR
anemia	I-ADR
in	O
third	O
exposure	O
:	O
successful	O
treatment	O
with	O
recombinant	O
human	O
granulocyte	O
colony-stimulating	O
factor	O
0	O
<EOS>	O
we	O
present	O
a	O
case	O
of	O
a	O
58-year-old	O
female	O
patient	O
with	O
graf	O
	O
disease	O
who	O
developed	O
aa	B-ADR
in	O
the	O
third	O
exposure	O
to	O
methimazole	B-Drug
(	O
mmi	O
)	O
0	O
<EOS>	O
fsgs	B-ADR
induced	O
by	O
adriamycin	B-Drug
(	O
pharmacia	O
&	O
upjohn	O
,	O
columbus	O
,	O
oh	O
)	O
ha	O
been	O
observed	O
experimentally	O
in	O
rat	O
0	O
<EOS>	O
the	O
case	O
demonstrates	O
that	O
hypersensitivity	O
reaction	O
to	O
pranlukast	B-Drug
and	O
resultant	O
atin	B-ADR
is	O
possible	O
,	O
and	O
that	O
periodic	O
urine	O
testing	O
in	O
patient	O
receiving	O
pranlukast	O
should	O
be	O
considered	O
0	O
<EOS>	O
the	O
case	O
demonstrates	O
that	O
hypersensitivity	O
reaction	O
to	O
pranlukast	B-Drug
and	O
resultant	O
atin	B-ADR
is	O
possible	O
,	O
and	O
that	O
periodic	O
urine	O
testing	O
in	O
patient	O
receiving	O
pranlukast	O
should	O
be	O
considered	O
0	O
<EOS>	O
the	O
case	O
demonstrates	O
that	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
pranlukast	B-Drug
and	O
resultant	O
atin	O
is	O
possible	O
,	O
and	O
that	O
periodic	O
urine	O
testing	O
in	O
patient	O
receiving	O
pranlukast	O
should	O
be	O
considered	O
0	O
<EOS>	O
the	O
case	O
demonstrates	O
that	O
hypersensitivity	B-ADR
reaction	I-ADR
to	O
pranlukast	B-Drug
and	O
resultant	O
atin	O
is	O
possible	O
,	O
and	O
that	O
periodic	O
urine	O
testing	O
in	O
patient	O
receiving	O
pranlukast	O
should	O
be	O
considered	O
0	O
<EOS>	O
tubulointerstitial	B-ADR
nephritis	I-ADR
induced	O
by	O
the	O
leukotriene	O
receptor	O
antagonist	O
pranlukast	B-Drug
0	O
<EOS>	O
within	O
6	O
month	O
of	O
pranlukast	B-Drug
withdrawal	O
,	O
anemia	B-ADR
resolved	O
and	O
urinary	O
sediment	O
and	O
renal	O
function	O
normalized	O
0	O
<EOS>	O
a	O
65-year-old	O
woman	O
with	O
angina	O
pectoris	O
presented	O
with	O
syncope	B-ADR
after	O
sublingual	O
ingestion	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
(	O
5	O
mg	O
)	O
0	O
<EOS>	O
elderly	O
patient	O
for	O
whom	O
nitrate	B-Drug
ha	O
been	O
prescribed	O
should	O
be	O
warned	O
of	O
the	O
occurrence	O
of	O
hypotension	B-ADR
,	O
leading	O
to	O
unconsciousness	O
0	O
<EOS>	O
elderly	O
patient	O
for	O
whom	O
nitrate	B-Drug
ha	O
been	O
prescribed	O
should	O
be	O
warned	O
of	O
the	O
occurrence	O
of	O
hypotension	O
,	O
leading	O
to	O
unconsciousness	B-ADR
0	O
<EOS>	O
in	O
a	O
postural	O
challenge	O
test	O
after	O
administration	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
(	O
5	O
mg	O
)	O
,	O
blood	B-ADR
pressure	I-ADR
decreased	I-ADR
from	O
120	O
/	O
67	O
to	O
65	O
/	O
35	O
mmhg	O
,	O
followed	O
by	O
syncope	O
with	O
a	O
sudden	O
decrease	O
in	O
pulse	O
rate	O
from	O
85	O
to	O
60	O
beat	O
/	O
min	O
0	O
<EOS>	O
in	O
a	O
postural	O
challenge	O
test	O
after	O
administration	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
(	O
5	O
mg	O
)	O
,	O
blood	O
pressure	O
decreased	O
from	O
120	O
/	O
67	O
to	O
65	O
/	O
35	O
mmhg	O
,	O
followed	O
by	O
syncope	O
with	O
a	O
sudden	B-ADR
decrease	I-ADR
in	I-ADR
pulse	I-ADR
rate	I-ADR
from	O
85	O
to	O
60	O
beat	O
/	O
min	O
0	O
<EOS>	O
in	O
a	O
postural	O
challenge	O
test	O
after	O
administration	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
(	O
5	O
mg	O
)	O
,	O
blood	O
pressure	O
decreased	O
from	O
120	O
/	O
67	O
to	O
65	O
/	O
35	O
mmhg	O
,	O
followed	O
by	O
syncope	B-ADR
with	O
a	O
sudden	O
decrease	O
in	O
pulse	O
rate	O
from	O
85	O
to	O
60	O
beat	O
/	O
min	O
0	O
<EOS>	O
syncope	B-ADR
in	O
a	O
65-year-old	O
woman	O
after	O
nitrate	B-Drug
ingestion	O
0	O
<EOS>	O
three	O
diabetic	O
case	O
of	O
acute	B-ADR
dizziness	I-ADR
due	O
to	O
initial	O
administration	O
of	O
voglibose	B-Drug
0	O
<EOS>	O
we	O
observed	O
3	O
diabetic	O
patient	O
with	O
intolerable	B-ADR
dizziness	I-ADR
followed	O
by	O
nausea	O
and	O
vomiting	O
immediately	O
after	O
an	O
initial	O
administration	O
of	O
the	O
alpha-glucosidase	O
inhibitor	O
,	O
voglibose	B-Drug
0	O
<EOS>	O
we	O
observed	O
3	O
diabetic	O
patient	O
with	O
intolerable	O
dizziness	O
followed	O
by	O
nausea	B-ADR
and	O
vomiting	O
immediately	O
after	O
an	O
initial	O
administration	O
of	O
the	O
alpha-glucosidase	O
inhibitor	O
,	O
voglibose	B-Drug
0	O
<EOS>	O
we	O
observed	O
3	O
diabetic	O
patient	O
with	O
intolerable	O
dizziness	O
followed	O
by	O
nausea	O
and	O
vomiting	B-ADR
immediately	O
after	O
an	O
initial	O
administration	O
of	O
the	O
alpha-glucosidase	O
inhibitor	O
,	O
voglibose	B-Drug
0	O
<EOS>	O
naproxen-associated	B-Drug
sudden	B-ADR
sensorineural	I-ADR
hearing	I-ADR
loss	I-ADR
0	O
<EOS>	O
naproxen	B-Drug
is	O
a	O
commonly	O
used	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
whose	O
side	O
effect	O
include	O
tinnitus	B-ADR
and	O
transient	O
hearing	O
loss	O
0	O
<EOS>	O
naproxen	B-Drug
is	O
a	O
commonly	O
used	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
nsaid	O
)	O
whose	O
side	O
effect	O
include	O
tinnitus	O
and	O
transient	B-ADR
hearing	I-ADR
loss	I-ADR
0	O
<EOS>	O
this	O
article	O
report	O
the	O
case	O
of	O
an	O
otherwise	O
healthy	O
patient	O
who	O
experienced	O
permanent	O
sensorineural	B-ADR
hearing	I-ADR
loss	I-ADR
after	O
a	O
brief	O
course	O
of	O
naproxen	B-Drug
and	O
review	O
the	O
literature	O
on	O
nsaid-related	O
permanent	O
sensorineural	O
hearing	O
loss	O
0	O
<EOS>	O
dental	B-ADR
and	I-ADR
gingival	I-ADR
pain	I-ADR
a	O
side	O
effect	O
of	O
niacin	B-Drug
therapy	O
0	O
<EOS>	O
the	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effect	O
of	O
niacin	B-Drug
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin-mediated	O
vasodilatation	O
,	O
hyperalgesia	B-ADR
of	I-ADR
sensory	I-ADR
nerve	I-ADR
receptor	I-ADR
,	O
and	O
potentiation	O
of	O
inflammation	O
in	O
the	O
gingiva	O
with	O
referral	O
of	O
pain	O
to	O
the	O
teeth	O
0	O
<EOS>	O
the	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effect	O
of	O
niacin	B-Drug
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin-mediated	O
vasodilatation	O
,	O
hyperalgesia	O
of	O
sensory	O
nerve	O
receptor	O
,	O
and	O
potentiation	O
of	O
inflammation	O
in	O
the	O
gingiva	O
with	O
referral	O
of	O
pain	B-ADR
to	I-ADR
the	I-ADR
teeth	I-ADR
0	O
<EOS>	O
the	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effect	O
of	O
niacin	B-Drug
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin-mediated	O
vasodilatation	O
,	O
hyperalgesia	O
of	O
sensory	O
nerve	O
receptor	O
,	O
and	O
potentiation	B-ADR
of	I-ADR
inflammation	I-ADR
in	I-ADR
the	I-ADR
gingiva	I-ADR
with	O
referral	O
of	O
pain	O
to	O
the	O
teeth	O
0	O
<EOS>	O
the	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effect	O
of	O
niacin	B-Drug
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin-mediated	B-ADR
vasodilatation	I-ADR
,	O
hyperalgesia	O
of	O
sensory	O
nerve	O
receptor	O
,	O
and	O
potentiation	O
of	O
inflammation	O
in	O
the	O
gingiva	O
with	O
referral	O
of	O
pain	O
to	O
the	O
teeth	O
0	O
<EOS>	O
two	O
65-year-old	O
white	O
men	O
with	O
coronary	O
heart	O
disease	O
,	O
given	O
niacin	B-Drug
therapy	O
for	O
dyslipidemia	O
for	O
5	O
month	O
,	O
developed	O
intense	B-ADR
dental	I-ADR
and	I-ADR
gingival	I-ADR
pain	I-ADR
that	O
wa	O
associated	O
with	O
increase	O
in	O
dose	O
and	O
that	O
wa	O
relieved	O
with	O
discontinuance	O
of	O
niacin	O
treatment	O
0	O
<EOS>	O
two	O
65-year-old	O
white	O
men	O
with	O
coronary	O
heart	O
disease	O
,	O
given	O
niacin	B-Drug
therapy	O
for	O
dyslipidemia	O
for	O
5	O
month	O
,	O
developed	O
intense	B-ADR
dental	I-ADR
and	I-ADR
gingival	I-ADR
pain	I-ADR
that	O
wa	O
associated	O
with	O
increase	O
in	O
dose	O
and	O
that	O
wa	O
relieved	O
with	O
discontinuance	O
of	O
niacin	O
treatment	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	O
and	O
calcitriol	B-Drug
are	O
secondary	O
hyperparathyroidism	O
and	O
vitamin	O
d	O
intoxication	O
,	O
potassium	B-ADR
loss	I-ADR
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	B-Drug
and	O
calcitriol	O
are	O
secondary	O
hyperparathyroidism	O
and	O
vitamin	O
d	O
intoxication	O
,	O
potassium	B-ADR
loss	I-ADR
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	O
and	O
calcitriol	B-Drug
are	O
secondary	B-ADR
hyperparathyroidism	I-ADR
and	O
vitamin	O
d	O
intoxication	O
,	O
potassium	O
loss	O
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	B-Drug
and	O
calcitriol	O
are	O
secondary	B-ADR
hyperparathyroidism	I-ADR
and	O
vitamin	O
d	O
intoxication	O
,	O
potassium	O
loss	O
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	O
and	O
calcitriol	B-Drug
are	O
secondary	O
hyperparathyroidism	O
and	O
vitamin	B-ADR
d	I-ADR
intoxication	I-ADR
,	O
potassium	O
loss	O
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
although	O
major	O
hazard	O
of	O
treatment	O
of	O
hypophosphatemic	O
osteomalacia	O
with	O
phosphate	B-Drug
and	O
calcitriol	O
are	O
secondary	O
hyperparathyroidism	O
and	O
vitamin	B-ADR
d	I-ADR
intoxication	I-ADR
,	O
potassium	O
loss	O
also	O
should	O
be	O
kept	O
in	O
mind	O
0	O
<EOS>	O
high-dose	O
phosphate	B-Drug
treatment	O
lead	O
to	O
hypokalemia	B-ADR
in	O
hypophosphatemic	O
osteomalacia	O
0	O
<EOS>	O
it	O
wa	O
concluded	O
that	O
potassium	O
loss	O
occurred	O
by	O
a	O
non-renal	O
(	O
intestinal	O
)	O
route	O
in	O
phosphate-induced	B-Drug
hypokalemia	B-ADR
0	O
<EOS>	O
it	O
wa	O
concluded	O
that	O
potassium	B-ADR
loss	I-ADR
occurred	O
by	O
a	O
non-renal	O
(	O
intestinal	O
)	O
route	O
in	O
phosphate-induced	B-Drug
hypokalemia	O
0	O
<EOS>	O
progressive	B-ADR
hypokalemia	I-ADR
developed	O
during	O
phosphate	B-Drug
treatment	O
0	O
<EOS>	O
the	O
mechanism	O
of	O
the	O
decrease	B-ADR
in	I-ADR
plasma	I-ADR
potassium	I-ADR
induced	O
by	O
phosphate	B-Drug
treatment	O
wa	O
investigated	O
in	O
a	O
24-year-old	O
hypertensive	O
patient	O
with	O
hypophosphatemic	O
osteomalacia	O
,	O
who	O
wa	O
the	O
youngest	O
of	O
four	O
patient	O
,	O
belonging	O
to	O
a	O
23	O
number	O
kindred	O
of	O
five	O
generation	O
0	O
<EOS>	O
transtubular	B-ADR
potassium	I-ADR
gradient	I-ADR
(	I-ADR
ttkg	I-ADR
)	I-ADR
also	I-ADR
decreased	I-ADR
and	O
an	O
inverse	O
correlation	O
wa	O
found	O
between	O
ttkg	O
and	O
dos	O
of	O
phosphate	B-Drug
(	O
r	O
=	O
-0.37	O
;	O
p	O
<	O
0.02	O
;	O
n	O
=	O
38	O
)	O
0	O
<EOS>	O
alveolar-interstitial	B-ADR
pneumopathy	I-ADR
after	O
gold-salts	B-Drug
compound	O
administration	O
,	O
requiring	O
mechanical	O
ventilation	O
0	O
<EOS>	O
the	O
pulmonary	B-ADR
toxicity	I-ADR
of	O
gold	B-Drug
salt	O
is	O
an	O
uncommon	O
cause	O
of	O
life-threatening	O
respiratory	O
failure	O
0	O
<EOS>	O
the	O
pulmonary	O
toxicity	O
of	O
gold	B-Drug
salt	O
is	O
an	O
uncommon	O
cause	O
of	O
life-threatening	O
respiratory	B-ADR
failure	I-ADR
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
severe	O
respiratory	B-ADR
failure	I-ADR
due	O
to	O
gold	B-Drug
salt	O
toxicity	O
in	O
a	O
patient	O
suffering	O
from	O
rheumatoid	O
arthritis	O
requiring	O
mechanical	O
ventilation	O
0	O
<EOS>	O
a	O
this	O
relapse	O
coincided	O
with	O
development	O
of	O
a	O
strong	O
delayed-type	O
hypersensitivity	B-ADR
response	I-ADR
to	O
tuberculin	B-Drug
and	O
improved	O
after	O
treatment	O
with	O
the	O
anti-inflammatory	O
agent	O
oxpentifylline	O
,	O
it	O
wa	O
probably	O
caused	O
by	O
restoration	O
of	O
pathogen-specific	O
cellular	O
immunity	O
0	O
<EOS>	O
a	O
patient	O
with	O
psoriasis	O
is	O
described	O
who	O
had	O
an	O
abnormal	O
response	O
to	O
the	O
glucose	O
tolerance	O
test	O
without	O
other	O
evidence	O
of	O
diabetes	O
and	O
then	O
developed	O
postprandial	O
hyperglycemia	O
and	O
glycosuria	B-ADR
during	O
a	O
period	O
of	O
topical	O
administration	O
of	O
a	O
corticosteroid	O
cream	O
,	O
halcinonide	B-Drug
cream	O
0.1	O
%	O
,	O
under	O
occlusion	O
0	O
<EOS>	O
a	O
patient	O
with	O
psoriasis	O
is	O
described	O
who	O
had	O
an	O
abnormal	O
response	O
to	O
the	O
glucose	O
tolerance	O
test	O
without	O
other	O
evidence	O
of	O
diabetes	O
and	O
then	O
developed	O
postprandial	B-ADR
hyperglycemia	I-ADR
and	O
glycosuria	O
during	O
a	O
period	O
of	O
topical	O
administration	O
of	O
a	O
corticosteroid	O
cream	O
,	O
halcinonide	B-Drug
cream	O
0.1	O
%	O
,	O
under	O
occlusion	O
0	O
<EOS>	O
a	O
second	O
patient	O
with	O
a	O
similar	O
glucose	O
tolerance	O
test	O
result	O
showed	O
postprandial	B-ADR
hyperglycemia	I-ADR
when	O
treated	O
similarly	O
with	O
betamethasone	B-Drug
valerate	I-Drug
cream	O
0.1	O
%	O
0	O
<EOS>	O
after	O
1	O
week	O
of	O
nefazodone	B-Drug
therapy	O
the	O
patient	O
experienced	O
headache	O
,	O
confusion	B-ADR
,	O
and	O
``	O
gray	O
area	O
'	O
in	O
her	O
vision	O
,	O
without	O
abnormal	O
ophthalmologic	O
finding	O
0	O
<EOS>	O
after	O
1	O
week	O
of	O
nefazodone	B-Drug
therapy	O
the	O
patient	O
experienced	O
headache	O
,	O
confusion	O
,	O
and	O
``	O
gray	B-ADR
area	I-ADR
'	O
in	O
her	O
vision	O
,	O
without	O
abnormal	O
ophthalmologic	O
finding	O
0	O
<EOS>	O
after	O
1	O
week	O
of	O
nefazodone	B-Drug
therapy	O
the	O
patient	O
experienced	O
headache	B-ADR
,	O
confusion	O
,	O
and	O
``	O
gray	O
area	O
'	O
in	O
her	O
vision	O
,	O
without	O
abnormal	O
ophthalmologic	O
finding	O
0	O
<EOS>	O
coadministration	O
of	O
antidepressant	O
agent	O
such	O
a	O
nefazodone	B-Drug
,	O
or	O
any	O
other	O
drug	O
that	O
inhibits	O
the	O
cyp3a4	O
isoenzyme	O
subfamily	O
,	O
should	O
be	O
anticipated	O
to	O
interfere	B-ADR
with	I-ADR
tacrolimus	I-ADR
metabolism	I-ADR
0	O
<EOS>	O
coadministration	O
of	O
antidepressant	O
agent	O
such	O
a	O
nefazodone	O
,	O
or	O
any	O
other	O
drug	O
that	O
inhibits	O
the	O
cyp3a4	O
isoenzyme	O
subfamily	O
,	O
should	O
be	O
anticipated	O
to	O
interfere	B-ADR
with	I-ADR
tacrolimus	B-Drug
metabolism	I-ADR
0	O
<EOS>	O
interaction	B-ADR
between	O
tacrolimus	O
and	O
nefazodone	B-Drug
in	O
a	O
stable	O
renal	O
transplant	O
recipient	O
0	O
<EOS>	O
interaction	B-ADR
between	O
tacrolimus	B-Drug
and	O
nefazodone	O
in	O
a	O
stable	O
renal	O
transplant	O
recipient	O
0	O
<EOS>	O
we	O
suspect	O
that	O
nefazodone	B-Drug
inhibits	B-ADR
metabolism	I-ADR
of	I-ADR
tacrolimus	I-ADR
0	O
<EOS>	O
we	O
suspect	O
that	O
nefazodone	O
inhibits	B-ADR
metabolism	I-ADR
of	I-ADR
tacrolimus	B-Drug
0	O
<EOS>	O
we	O
report	O
the	O
case	O
of	O
intoxication	B-ADR
of	O
a	O
41-year-old	O
female	O
patient	O
suffering	O
from	O
major	O
depression	O
with	O
mirtazapine	B-Drug
complicated	O
by	O
severe	O
hypothermia	O
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
a	O
case	O
of	O
the	O
use	O
of	O
pamidronate	O
for	O
significant	O
hypercalcemia	O
secondary	O
to	O
acute	B-ADR
vitamin	B-Drug
d	I-Drug
poisoning	I-ADR
0	O
<EOS>	O
conclusion	O
:	O
we	O
report	O
a	O
case	O
of	O
the	O
use	O
of	O
pamidronate	O
for	O
significant	O
hypercalcemia	B-ADR
secondary	O
to	O
acute	O
vitamin	B-Drug
d	I-Drug
poisoning	O
0	O
<EOS>	O
pamidronate	O
therapy	O
should	O
be	O
considered	O
in	O
patient	O
with	O
hypercalcemia	O
secondary	O
to	O
acute	B-ADR
vitamin	B-Drug
d	I-Drug
poisoning	I-ADR
0	O
<EOS>	O
pamidronate	O
therapy	O
should	O
be	O
considered	O
in	O
patient	O
with	O
hypercalcemia	B-ADR
secondary	O
to	O
acute	O
vitamin	B-Drug
d	I-Drug
poisoning	O
0	O
<EOS>	O
the	O
patient	O
wa	O
initially	O
treated	O
with	O
hydration	O
and	O
furosemide	B-Drug
but	O
developed	O
congestive	B-ADR
heart	I-ADR
failure	I-ADR
0	O
<EOS>	O
the	O
use	O
of	O
pamidronate	O
for	O
hypercalcemia	O
secondary	O
to	O
acute	O
vitamin	B-Drug
d	I-Drug
intoxication	I-ADR
0	O
<EOS>	O
we	O
report	O
the	O
use	O
of	O
pamidronate	O
for	O
acute	O
,	O
severe	B-ADR
hypercalcemia	I-ADR
secondary	O
to	O
iatrogenic	O
vitamin	B-Drug
d	I-Drug
poisoning	O
0	O
<EOS>	O
we	O
report	O
the	O
use	O
of	O
pamidronate	O
for	O
acute	O
,	O
severe	O
hypercalcemia	O
secondary	O
to	O
iatrogenic	O
vitamin	B-Drug
d	I-Drug
poisoning	I-ADR
0	O
<EOS>	O
a	O
40-year-old	O
man	O
with	O
a	O
long	O
standing	O
history	O
of	O
rheumatoid	O
arthritis	O
wa	O
treated	O
with	O
mtx	B-Drug
over	O
a	O
6	O
month	O
period	O
and	O
developed	O
an	O
overwhelming	B-ADR
hepatic	I-ADR
necrosis	I-ADR
0	O
<EOS>	O
methotrexate-induced	B-Drug
hepatic	B-ADR
necrosis	I-ADR
requiring	O
liver	O
transplantation	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
mtx-induced	B-Drug
hepatic	B-ADR
injury	I-ADR
and	O
liver	O
enzyme	O
elevation	O
have	O
been	O
demonstrated	O
after	O
treatment	O
of	O
leukemia	O
,	O
gestational	O
disease	O
and	O
during	O
treatment	O
of	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
mtx-induced	B-Drug
hepatic	O
injury	O
and	O
liver	B-ADR
enzyme	I-ADR
elevation	I-ADR
have	O
been	O
demonstrated	O
after	O
treatment	O
of	O
leukemia	O
,	O
gestational	O
disease	O
and	O
during	O
treatment	O
of	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
0	O
<EOS>	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
vinorelbine	B-Drug
may	O
cause	O
siadh	O
and	O
possibly	O
hypokalemia	B-ADR
0	O
<EOS>	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
vinorelbine	B-Drug
may	O
cause	O
siadh	B-ADR
and	O
possibly	O
hypokalemia	O
0	O
<EOS>	O
conclusion	O
:	O
because	O
of	O
it	O
structural	O
similarity	O
to	O
the	O
other	O
vinca	O
alkaloid	O
,	O
vinorelbine	B-Drug
is	O
believed	O
to	O
be	O
responsible	O
for	O
siadh	B-ADR
in	O
our	O
patient	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
onset	O
of	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
(	O
siadh	B-ADR
)	O
associated	O
with	O
vinorelbine	B-Drug
therapy	O
for	O
advanced	O
breast	O
cancer	O
0	O
<EOS>	O
objective	O
:	O
to	O
describe	O
onset	O
of	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
(	O
siadh	O
)	O
associated	O
with	O
vinorelbine	B-Drug
therapy	O
for	O
advanced	O
breast	O
cancer	O
0	O
<EOS>	O
syndrome	B-ADR
of	I-ADR
inappropriate	I-ADR
antidiuretic	I-ADR
hormone	I-ADR
associated	O
with	O
vinorelbine	B-Drug
therapy	O
0	O
<EOS>	O
pirmenol	B-Drug
hydrochloride-induced	I-Drug
qt	B-ADR
prolongation	I-ADR
and	O
t	O
wave	O
inversion	O
on	O
electrocardiogram	O
during	O
treatment	O
for	O
symptomatic	O
atrial	O
fibrillation	O
0	O
<EOS>	O
pirmenol	B-Drug
hydrochloride-induced	I-Drug
qt	O
prolongation	O
and	O
t	B-ADR
wave	I-ADR
inversion	I-ADR
on	O
electrocardiogram	O
during	O
treatment	O
for	O
symptomatic	O
atrial	O
fibrillation	O
0	O
<EOS>	O
thus	O
,	O
an	O
immunological	O
mechanism	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
pirmenol-induced	B-Drug
qt	B-ADR
prolongation	I-ADR
and	O
t	O
wave	O
inversion	O
on	O
the	O
electrocardiogram	O
0	O
<EOS>	O
thus	O
,	O
an	O
immunological	O
mechanism	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
pirmenol-induced	B-Drug
qt	O
prolongation	O
and	O
t	B-ADR
wave	I-ADR
inversion	I-ADR
on	O
the	O
electrocardiogram	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
56-year-old	O
female	O
who	O
exhibited	O
drug	O
refractory	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
in	O
which	O
marked	O
prolongation	B-ADR
of	I-ADR
the	I-ADR
qt	I-ADR
interval	I-ADR
and	O
t	O
wave	O
inversion	O
on	O
electrocardiogram	O
wa	O
demonstrated	O
reproducibly	O
shortly	O
after	O
the	O
administration	O
of	O
oral	O
pirmenol	B-Drug
therapy	O
0	O
<EOS>	O
we	O
report	O
on	O
a	O
56-year-old	O
female	O
who	O
exhibited	O
drug	O
refractory	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
in	O
which	O
marked	O
prolongation	O
of	O
the	O
qt	O
interval	O
and	O
t	B-ADR
wave	I-ADR
inversion	I-ADR
on	O
electrocardiogram	O
wa	O
demonstrated	O
reproducibly	O
shortly	O
after	O
the	O
administration	O
of	O
oral	O
pirmenol	B-Drug
therapy	O
0	O
<EOS>	O
disseminated	O
muscular	O
cysticercosis	O
with	O
myositis	B-ADR
induced	O
by	O
praziquantel	B-Drug
therapy	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	O
(	O
fever	O
,	O
diffuse	B-ADR
myalgia	I-ADR
,	O
weakness	O
of	O
the	O
lower	O
limb	O
,	O
and	O
inflammatory	O
reaction	O
around	O
dying	O
cysticerci	O
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	O
(	O
fever	B-ADR
,	O
diffuse	O
myalgia	O
,	O
weakness	O
of	O
the	O
lower	O
limb	O
,	O
and	O
inflammatory	O
reaction	O
around	O
dying	O
cysticerci	O
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	O
(	O
fever	O
,	O
diffuse	O
myalgia	O
,	O
weakness	O
of	O
the	O
lower	O
limb	O
,	O
and	O
inflammatory	B-ADR
reaction	I-ADR
around	I-ADR
dying	I-ADR
cysticerci	I-ADR
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	B-ADR
(	O
fever	O
,	O
diffuse	O
myalgia	O
,	O
weakness	O
of	O
the	O
lower	O
limb	O
,	O
and	O
inflammatory	O
reaction	O
around	O
dying	O
cysticerci	O
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
0	O
<EOS>	O
we	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	O
(	O
fever	O
,	O
diffuse	O
myalgia	O
,	O
weakness	B-ADR
of	I-ADR
the	I-ADR
lower	I-ADR
limb	I-ADR
,	O
and	O
inflammatory	O
reaction	O
around	O
dying	O
cysticerci	O
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
0	O
<EOS>	O
massive	B-ADR
subfascial	I-ADR
hematoma	I-ADR
after	O
alteplase	B-Drug
therapy	O
for	O
acute	O
myocardial	O
infarction	O
0	O
<EOS>	O
physician	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
between	O
the	O
use	O
of	O
alteplase	B-Drug
and	O
the	O
development	O
of	O
subfascial	B-ADR
hemorrhage	I-ADR
0	O
<EOS>	O
the	O
author	O
report	O
a	O
case	O
of	O
a	O
patient	O
who	O
received	O
alteplase	B-Drug
for	O
acute	O
myocardial	O
infarction	O
and	O
developed	O
spontaneous	O
subfascial	B-ADR
hematoma	I-ADR
without	O
any	O
evidence	O
of	O
direct	O
trauma	O
0	O
<EOS>	O
the	O
development	O
of	O
cutaneous	B-ADR
ecchymosis	I-ADR
associated	O
with	O
a	O
sudden	O
fall	O
in	O
hemoglobin	O
after	O
the	O
administration	O
of	O
alteplase	B-Drug
should	O
strongly	O
suggest	O
the	O
possibility	O
of	O
diffuse	O
subfascial	O
hematoma	O
0	O
<EOS>	O
the	O
development	O
of	O
cutaneous	O
ecchymosis	O
associated	O
with	O
a	O
sudden	O
fall	O
in	O
hemoglobin	O
after	O
the	O
administration	O
of	O
alteplase	B-Drug
should	O
strongly	O
suggest	O
the	O
possibility	O
of	O
diffuse	B-ADR
subfascial	I-ADR
hematoma	I-ADR
0	O
<EOS>	O
the	O
development	O
of	O
cutaneous	O
ecchymosis	O
associated	O
with	O
a	O
sudden	B-ADR
fall	I-ADR
in	I-ADR
hemoglobin	I-ADR
after	O
the	O
administration	O
of	O
alteplase	B-Drug
should	O
strongly	O
suggest	O
the	O
possibility	O
of	O
diffuse	O
subfascial	O
hematoma	O
0	O
<EOS>	O
a	O
fatal	B-ADR
case	I-ADR
of	I-ADR
pancytopenia	I-ADR
due	O
to	O
levomepromazine	B-Drug
0	O
<EOS>	O
a	O
fatal	B-ADR
pancytopenia	I-ADR
occurred	O
in	O
a	O
patient	O
with	O
an	O
history	O
of	O
depression	O
with	O
hypomanic	O
rebound	O
,	O
admitted	O
for	O
a	O
manic	O
episode	O
and	O
treated	O
with	O
levomepromazine	O
,	O
diazepam	B-Drug
and	O
lithium	O
carbonate	O
0	O
<EOS>	O
a	O
fatal	B-ADR
pancytopenia	I-ADR
occurred	O
in	O
a	O
patient	O
with	O
an	O
history	O
of	O
depression	O
with	O
hypomanic	O
rebound	O
,	O
admitted	O
for	O
a	O
manic	O
episode	O
and	O
treated	O
with	O
levomepromazine	B-Drug
,	O
diazepam	O
and	O
lithium	O
carbonate	O
0	O
<EOS>	O
a	O
fatal	B-ADR
pancytopenia	I-ADR
occurred	O
in	O
a	O
patient	O
with	O
an	O
history	O
of	O
depression	O
with	O
hypomanic	O
rebound	O
,	O
admitted	O
for	O
a	O
manic	O
episode	O
and	O
treated	O
with	O
levomepromazine	O
,	O
diazepam	O
and	O
lithium	B-Drug
carbonate	I-Drug
0	O
<EOS>	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
associated	O
with	O
thyrotropin	O
receptor	O
antibody	O
0	O
<EOS>	O
amiodarone-induced	B-Drug
thyrotoxicosis	O
associated	O
with	O
thyrotropin	B-ADR
receptor	I-ADR
antibody	I-ADR
0	O
<EOS>	O
among	O
12	O
thyrotoxic	O
patient	O
,	O
a	O
patient	O
with	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
,	O
who	O
had	O
been	O
taking	O
amiodarone	B-Drug
for	O
4	O
year	O
,	O
developed	O
thyrotoxicosis	B-ADR
with	O
subacute	O
onset	O
,	O
accompanied	O
by	O
transiently	O
positive	O
thyrotropin	O
(	O
tsh	O
)	O
receptor	O
antibody	O
(	O
trab	O
)	O
,	O
or	O
thyrotropin-binding	O
inhibiting	O
immunoglobulin	O
(	O
tbii	O
)	O
0	O
<EOS>	O
among	O
12	O
thyrotoxic	O
patient	O
,	O
a	O
patient	O
with	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
,	O
who	O
had	O
been	O
taking	O
amiodarone	B-Drug
for	O
4	O
year	O
,	O
developed	O
thyrotoxicosis	O
with	O
subacute	O
onset	O
,	O
accompanied	O
by	O
transiently	O
positive	O
thyrotropin	O
(	O
tsh	O
)	O
receptor	O
antibody	O
(	O
trab	O
)	O
,	O
or	O
thyrotropin-binding	B-ADR
inhibiting	I-ADR
immunoglobulin	I-ADR
(	O
tbii	O
)	O
0	O
<EOS>	O
among	O
12	O
thyrotoxic	O
patient	O
,	O
a	O
patient	O
with	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
,	O
who	O
had	O
been	O
taking	O
amiodarone	B-Drug
for	O
4	O
year	O
,	O
developed	O
thyrotoxicosis	O
with	O
subacute	O
onset	O
,	O
accompanied	O
by	O
transiently	B-ADR
positive	I-ADR
thyrotropin	I-ADR
(	I-ADR
tsh	I-ADR
)	I-ADR
receptor	I-ADR
antibody	I-ADR
(	O
trab	O
)	O
,	O
or	O
thyrotropin-binding	O
inhibiting	O
immunoglobulin	O
(	O
tbii	O
)	O
0	O
<EOS>	O
since	O
amiodarone	O
wa	O
first	O
marketed	O
in	O
1992	O
in	O
japan	O
,	O
the	O
incidence	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	O
(	O
ait	B-ADR
)	O
ha	O
been	O
increasing	O
0	O
<EOS>	O
since	O
amiodarone	O
wa	O
first	O
marketed	O
in	O
1992	O
in	O
japan	O
,	O
the	O
incidence	O
of	O
amiodarone-induced	B-Drug
thyrotoxicosis	B-ADR
(	O
ait	O
)	O
ha	O
been	O
increasing	O
0	O
<EOS>	O
these	O
in	O
vitro	O
finding	O
and	O
clinical	O
course	O
suggest	O
that	O
trab	O
/	O
tbii	O
without	O
thyroid-stimulating	O
activity	O
may	O
develop	O
in	O
patient	O
with	O
amiodarone-induced	B-Drug
destructive	B-ADR
thyroiditis	I-ADR
,	O
a	O
reported	O
in	O
patient	O
with	O
destructive	O
thyroiditis	O
,	O
such	O
a	O
subacute	O
and	O
silent	O
thyroiditis	O
0	O
<EOS>	O
these	O
in	O
vitro	O
finding	O
and	O
clinical	O
course	O
suggest	O
that	O
trab	O
/	O
tbii	O
without	O
thyroid-stimulating	O
activity	O
may	O
develop	O
in	O
patient	O
with	O
amiodarone-induced	B-Drug
destructive	B-ADR
thyroiditis	I-ADR
,	O
a	O
reported	O
in	O
patient	O
with	O
destructive	O
thyroiditis	O
,	O
such	O
a	O
subacute	O
and	O
silent	O
thyroiditis	O
0	O
<EOS>	O
these	O
in	O
vitro	O
finding	O
and	O
clinical	O
course	O
suggest	O
that	O
trab	O
/	O
tbii	O
without	O
thyroid-stimulating	O
activity	O
may	O
develop	O
in	O
patient	O
with	O
amiodarone-induced	B-Drug
destructive	O
thyroiditis	B-ADR
,	O
a	O
reported	O
in	O
patient	O
with	O
destructive	O
thyroiditis	O
,	O
such	O
a	O
subacute	O
and	O
silent	O
thyroiditis	O
0	O
<EOS>	O
these	O
in	O
vitro	O
finding	O
and	O
clinical	O
course	O
suggest	O
that	O
trab	B-ADR
/	I-ADR
tbii	I-ADR
without	I-ADR
thyroid-stimulating	I-ADR
activity	I-ADR
may	O
develop	O
in	O
patient	O
with	O
amiodarone-induced	B-Drug
destructive	O
thyroiditis	O
,	O
a	O
reported	O
in	O
patient	O
with	O
destructive	O
thyroiditis	O
,	O
such	O
a	O
subacute	O
and	O
silent	O
thyroiditis	O
0	O
<EOS>	O
conclusion	O
:	O
lipoid	B-ADR
pneumonia	I-ADR
a	O
a	O
result	O
of	O
mineral	B-Drug
oil	I-Drug
aspiration	O
still	O
occurs	O
in	O
the	O
pediatric	O
population	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	O
dysfunction	O
and	O
pneumonia	O
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	B-ADR
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	O
dysfunction	O
and	O
pneumonia	O
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	B-ADR
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	O
dysfunction	O
and	O
pneumonia	B-ADR
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	O
dysfunction	O
and	O
pneumonia	B-ADR
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	B-ADR
dysfunction	I-ADR
and	O
pneumonia	O
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
in	O
patient	O
with	O
swallowing	B-ADR
dysfunction	I-ADR
and	O
pneumonia	O
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
if	O
mineral	O
oil	O
use	O
ha	O
occurred	O
0	O
<EOS>	O
lipoid	B-ADR
pneumonia	I-ADR
:	O
a	O
silent	O
complication	O
of	O
mineral	B-Drug
oil	I-Drug
aspiration	O
0	O
<EOS>	O
mineral	B-Drug
oil	I-Drug
,	O
a	O
hydrocarbon	O
,	O
may	O
not	O
elicit	O
a	O
normal	O
protective	O
cough	O
reflex	O
and	O
may	O
impair	B-ADR
mucociliary	I-ADR
transport	I-ADR
0	O
<EOS>	O
our	O
case	O
point	O
to	O
the	O
need	O
for	O
increased	O
awareness	O
by	O
the	O
general	O
pediatrician	O
of	O
the	O
potential	B-ADR
hazard	I-ADR
of	O
mineral	B-Drug
oil	I-Drug
use	O
for	O
chronic	O
constipation	O
0	O
<EOS>	O
treatment	O
of	O
elp	B-ADR
in	O
child	O
is	O
generally	O
supportive	O
,	O
with	O
the	O
symptom	O
and	O
roentgenographic	O
abnormality	O
resolving	O
within	O
month	O
after	O
stopping	O
the	O
use	O
of	O
mineral	B-Drug
oil	I-Drug
0	O
<EOS>	O
treatment	O
of	O
elp	O
in	O
child	O
is	O
generally	O
supportive	O
,	O
with	O
the	O
symptom	O
and	O
roentgenographic	B-ADR
abnormality	I-ADR
resolving	O
within	O
month	O
after	O
stopping	O
the	O
use	O
of	O
mineral	B-Drug
oil	I-Drug
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
child	O
with	O
neurodevelopmental	O
delay	O
with	O
chronic	O
constipation	O
and	O
a	O
history	O
of	O
chronic	O
mineral	B-Drug
oil	I-Drug
ingestion	O
presenting	O
a	O
asymptomatic	O
exogenous	O
lipoid	O
pneumonia	O
(	O
elp	B-ADR
)	O
0	O
<EOS>	O
we	O
report	O
a	O
case	O
of	O
a	O
child	O
with	O
neurodevelopmental	O
delay	O
with	O
chronic	O
constipation	O
and	O
a	O
history	O
of	O
chronic	O
mineral	B-Drug
oil	I-Drug
ingestion	O
presenting	O
a	O
asymptomatic	O
exogenous	B-ADR
lipoid	I-ADR
pneumonia	I-ADR
(	O
elp	O
)	O
0	O
<EOS>	O
an	O
unusual	O
cause	O
of	O
burn	B-Drug
injury	I-Drug
:	O
unsupervised	O
use	O
of	O
drug	O
that	O
contain	O
psoralens	B-ADR
0	O
<EOS>	O
because	O
psoralens	B-Drug
sensitize	O
skin	O
to	O
ultraviolet	O
a	O
light	O
,	O
phototoxic	B-ADR
reaction	I-ADR
are	O
the	O
most	O
frequent	O
adverse	O
effect	O
of	O
this	O
treatment	O
0	O
<EOS>	O
in	O
this	O
article	O
,	O
we	O
present	O
the	O
case	O
of	O
a	O
vitiligo	O
patient	O
who	O
wa	O
admitted	O
to	O
our	O
facility	O
with	O
an	O
intense	B-ADR
burn	I-ADR
after	O
the	O
topical	O
use	O
of	O
8-methoxypsoralen	B-Drug
solution	O
a	O
a	O
suntanning	O
agent	O
0	O
<EOS>	O
sunburn	O
may	O
sometimes	O
be	O
a	O
major	O
injury	O
in	O
psoralen	B-Drug
user	O
because	O
high	O
dos	O
or	O
inappropriate	O
use	O
of	O
the	O
drug	O
may	O
render	O
the	O
skin	B-ADR
extremely	I-ADR
sensitive	I-ADR
0	O
<EOS>	O
sunburn	B-ADR
may	O
sometimes	O
be	O
a	O
major	O
injury	O
in	O
psoralen	B-Drug
user	O
because	O
high	O
dos	O
or	O
inappropriate	O
use	O
of	O
the	O
drug	O
may	O
render	O
the	O
skin	O
extremely	O
sensitive	O
0	O
<EOS>	O
conclusion	O
:	O
metoclopramide	B-Drug
may	O
cause	O
reversible	O
nonthrombocytopenic	B-ADR
vascular-type	I-ADR
palpable	I-ADR
purpura	I-ADR
0	O
<EOS>	O
objective	O
:	O
to	O
report	O
a	O
case	O
of	O
reversible	O
nonthrombocytopenic	B-ADR
palpable	I-ADR
purpura	I-ADR
associated	O
with	O
metoclopramide	B-Drug
0	O
<EOS>	O
reversible	O
nonthrombocytopenic	B-ADR
palpable	I-ADR
purpura	I-ADR
associated	O
with	O
metoclopramide	B-Drug
0	O
<EOS>	O
lithium	B-Drug
treatment	O
wa	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	O
intoxication	O
with	O
a	O
diabetes	B-ADR
insipidus-like	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
lithium	B-Drug
treatment	O
wa	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	O
intoxication	O
with	O
a	O
diabetes	B-ADR
insipidus-like	I-ADR
syndrome	I-ADR
0	O
<EOS>	O
lithium	B-Drug
treatment	O
wa	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	B-ADR
intoxication	I-ADR
with	O
a	O
diabetes	O
insipidus-like	O
syndrome	O
0	O
<EOS>	O
lithium	B-Drug
treatment	O
wa	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	B-ADR
intoxication	I-ADR
with	O
a	O
diabetes	O
insipidus-like	O
syndrome	O
0	O
<EOS>	O
eosinophilia	B-ADR
caused	O
by	O
clozapine	B-Drug
wa	O
observed	O
in	O
challenge	O
,	O
preceded	O
by	O
a	O
faster	O
neutrophil	O
production	O
and	O
consecutive	O
decrease	O
(	O
z	O
=	O
2.27	O
,	O
p	O
=	O
0.01	O
)	O
0	O
<EOS>	O
eosinophilia	B-ADR
ha	O
been	O
encountered	O
from	O
0.2	O
to	O
61.7	O
%	O
in	O
clozapine-treated	B-Drug
patient	O
,	O
mostly	O
with	O
a	O
transient	O
course	O
and	O
spontaneous	O
remission	O
0	O
<EOS>	O
successful	O
challenge	O
with	O
clozapine	B-Drug
in	O
a	O
history	O
of	O
eosinophilia	B-ADR
0	O
<EOS>	O
